| Title: | Transcriptomic Ovarian Cancer Datasets |
|---|---|
| Description: | A collection of Ovarian Cancer Transcriptomic Datasets that are part of the MetaGxData package compendium. |
| Authors: | Michael Zon [aut], Vandana Sandhu [aut], Christopher Eeles [ctb], Benjamin Haibe-Kains [aut, cre] |
| Maintainer: | Benjamin Haibe-Kains <[email protected]> |
| License: | Artistic-2.0 |
| Version: | 1.32.0 |
| Built: | 2026-10-10 11:11:52 UTC |
| Source: | https://github.com/bioc/MetaGxOvarian |
Ovarian cancer is the fifth leading cause of cancer death for women in the U.S. and the seventh most fatal worldwide. Although ovarian cancer is notable for its initial sensitivity to platinum-based therapies, the vast majority of patients eventually develop recurrent cancer and succumb to increasingly platinum-resistant disease. Modern, targeted cancer drugs intervene in cell signaling, and identifying key disease mechanisms and pathways would greatly advance our treatment abilities. In order to shed light on the molecular diversity of ovarian cancer, we performed comprehensive transcriptional profiling on 129 advanced stage, high grade serous ovarian cancers. We implemented a, re-sampling based version of the ISIS class discovery algorithm (rISIS: robust ISIS) and applied it to the entire set of ovarian cancer transcriptional profiles. rISIS identified a previously undescribed patient stratification, further supported by micro-RNA expression profiles, and gene set enrichment analysis found strong biological support for the stratification by extracellular matrix, cell adhesion, and angiogenesis genes. The corresponding "angiogenesis signature" was validated in ten published independent ovarian cancer gene expression datasets and is significantly associated with overall survival. The subtypes we have defined are of potential translational interest as they may be relevant for identifying patients who may benefit from the addition of anti-angiogenic therapies that are now being tested in clinical trials.
experimentData(eset):
Experiment data
Experimenter name: Bentink S, Haibe-Kains B, Risch T, Fan J-B, Hirsch MS, Holton K, Rubio R, April C, Chen J, Wickham-Garcia E, Liu J, Culhane A, Drapkin R, Quackenbush J, Matulonis UA: Angiogenic mRNA and microRNA gene expression signature predicts a novel subtype of serous ovarian cancer. PLoS ONE 2012, 7:e30269.
Laboratory: Bentink, Matulonis 2012
Contact information:
Title: Angiogenic mRNA and microRNA gene expression signature predicts a novel subtype of serous ovarian cancer.
URL:
PMIDs: 22348002
Abstract: A 212 word abstract is available. Use 'abstract' method.
Information is available on: preprocessing
notes:
platform_title:
Illumina humanRef-8 v2.0 expression beadchip
platform_shorttitle:
Illumina humanRef-8 v2.0
platform_summary:
illuminaHumanv2
platform_manufacturer:
Illumina
platform_distribution:
commercial
platform_accession:
GPL6104
version:
2015-09-22 19:06:44
featureData(eset):
An object of class 'AnnotatedDataFrame'
featureNames: ILMN_1343291 ILMN_1651228 ... ILMN_1815951 (12449
total)
varLabels: probeset gene EntrezGene.ID best_probe
varMetadata: labelDescription
assayData: 12449 features, 129 samples
Platform type:
Overall survival time-to-event summary (in years):
Call: survfit(formula = Surv(time, cens) ~ -1)
n events median 0.95LCL 0.95UCL
129.00 73.00 3.51 2.68 4.13
---------------------------
Available sample meta-data:
---------------------------
unique_patient_ID:
DFCI.1 DFCI.10 DFCI.100 DFCI.101 DFCI.102 DFCI.103 DFCI.104 DFCI.105
1 1 1 1 1 1 1 1
DFCI.106 DFCI.107 DFCI.108 DFCI.109 DFCI.11 DFCI.110 DFCI.111 DFCI.112
1 1 1 1 1 1 1 1
DFCI.113 DFCI.114 DFCI.115 DFCI.116 DFCI.117 DFCI.118 DFCI.119 DFCI.12
1 1 1 1 1 1 1 1
DFCI.120 DFCI.121 DFCI.122 DFCI.123 DFCI.124 DFCI.125 DFCI.126 DFCI.127
1 1 1 1 1 1 1 1
DFCI.128 DFCI.129 DFCI.13 DFCI.130 DFCI.131 DFCI.132 DFCI.14 DFCI.15
1 1 1 1 1 1 1 1
DFCI.16 DFCI.17 DFCI.18 DFCI.19 DFCI.2 DFCI.20 DFCI.21 DFCI.22
1 1 1 1 1 1 1 1
DFCI.23 DFCI.24 DFCI.25 DFCI.26 DFCI.27 DFCI.28 DFCI.29 DFCI.3
1 1 1 1 1 1 1 1
DFCI.30 DFCI.31 DFCI.32 DFCI.33 DFCI.34 DFCI.35 DFCI.36 DFCI.37
1 1 1 1 1 1 1 1
DFCI.38 DFCI.39 DFCI.4 DFCI.40 DFCI.41 DFCI.42 DFCI.44 DFCI.45
1 1 1 1 1 1 1 1
DFCI.46 DFCI.47 DFCI.48 DFCI.49 DFCI.50 DFCI.51 DFCI.52 DFCI.53
1 1 1 1 1 1 1 1
DFCI.54 DFCI.55 DFCI.56 DFCI.57 DFCI.58 DFCI.59 DFCI.6 DFCI.60
1 1 1 1 1 1 1 1
DFCI.61 DFCI.62 DFCI.63 DFCI.64 DFCI.65 DFCI.66 DFCI.67 DFCI.68
1 1 1 1 1 1 1 1
DFCI.69 DFCI.7 DFCI.70 (Other)
1 1 1 30
sample_type:
tumor
129
histological_type:
ser
129
primarysite:
ov
129
summarygrade:
high
129
summarystage:
early late
1 128
tumorstage:
2 3 4
1 109 19
substage:
a b c NA's
5 12 93 19
age_at_initial_pathologic_diagnosis:
Min. 1st Qu. Median Mean 3rd Qu. Max.
21.00 50.00 66.00 60.71 72.00 95.00
days_to_death:
Min. 1st Qu. Median Mean 3rd Qu. Max.
3.9 516.9 917.1 1007.0 1401.0 2724.0
vital_status:
deceased living
73 56
debulking:
optimal suboptimal NA's
98 28 3
uncurated_author_metadata:
Source.Name: DFCI-100///Characteristics.Age.: Age <has_measurement <Measurement <has_units <Unit <time unit <time unit=years>>>> <has_value <has_value=44.42>>>>///Characteristics.Channel.: Cy3///Characteristics.DiseaseStage.: IIIc///Characteristics.DiseaseState.: serous ovarian cancer///Term.Source.REF: SNOMED Clinical Terms///Characteristics.EventDeath.: 0///Characteristics.EventProgression.: 0///Characteristics.OptimalDebulking.: Yes///Characteristics.Organism.: Homo sapiens///Characteristics.Sex.: female///Term.Source.REF.1: EFO///Characteristics.SurvivalTime.: 33.77 months///Characteristics.TimeToProgression.: 15.87 months///Hybridization.Name: RNA-hyb-DFCI-100///Array.Design.REF: A-MEXP-931///Scan.Name: RNA-hyb-DFCI-100///Derived.Array.Data.Matrix.File: normalized.txt.proc///Comment..Derived.ArrayExpress.FTP.file.: ftp://ftp.ebi.ac.uk/pub/databases/microarray/data/experiment/MTAB/E-MTAB-386/E-MTAB-386.processed.1.zip
1
Source.Name: DFCI-101///Characteristics.Age.: Age <has_measurement <Measurement <has_units <Unit <time unit <time unit=years>>>> <has_value <has_value=40.9>>>>///Characteristics.Channel.: Cy3///Characteristics.DiseaseStage.: IV///Characteristics.DiseaseState.: serous ovarian cancer///Term.Source.REF: SNOMED Clinical Terms///Characteristics.EventDeath.: 1///Characteristics.EventProgression.: 1///Characteristics.OptimalDebulking.: Yes///Characteristics.Organism.: Homo sapiens///Characteristics.Sex.: female///Term.Source.REF.1: EFO///Characteristics.SurvivalTime.: 14.2 months///Characteristics.TimeToProgression.: 0 months///Hybridization.Name: RNA-hyb-DFCI-101///Array.Design.REF: A-MEXP-931///Scan.Name: RNA-hyb-DFCI-101///Derived.Array.Data.Matrix.File: normalized.txt.proc///Comment..Derived.ArrayExpress.FTP.file.: ftp://ftp.ebi.ac.uk/pub/databases/microarray/data/experiment/MTAB/E-MTAB-386/E-MTAB-386.processed.1.zip
1
Source.Name: DFCI-102///Characteristics.Age.: Age <has_measurement <Measurement <has_units <Unit <time unit <time unit=years>>>> <has_value <has_value=39.93>>>>///Characteristics.Channel.: Cy3///Characteristics.DiseaseStage.: IV///Characteristics.DiseaseState.: serous ovarian cancer///Term.Source.REF: SNOMED Clinical Terms///Characteristics.EventDeath.: 1///Characteristics.EventProgression.: 1///Characteristics.OptimalDebulking.: No///Characteristics.Organism.: Homo sapiens///Characteristics.Sex.: female///Term.Source.REF.1: EFO///Characteristics.SurvivalTime.: 21.87 months///Characteristics.TimeToProgression.: 0 months///Hybridization.Name: RNA-hyb-DFCI-102///Array.Design.REF: A-MEXP-931///Scan.Name: RNA-hyb-DFCI-102///Derived.Array.Data.Matrix.File: normalized.txt.proc///Comment..Derived.ArrayExpress.FTP.file.: ftp://ftp.ebi.ac.uk/pub/databases/microarray/data/experiment/MTAB/E-MTAB-386/E-MTAB-386.processed.1.zip
1
Source.Name: DFCI-103///Characteristics.Age.: Age <has_measurement <Measurement <has_units <Unit <time unit <time unit=years>>>> <has_value <has_value=45.24>>>>///Characteristics.Channel.: Cy3///Characteristics.DiseaseStage.: IIIc///Characteristics.DiseaseState.: serous ovarian cancer///Term.Source.REF: SNOMED Clinical Terms///Characteristics.EventDeath.: 1///Characteristics.EventProgression.: 1///Characteristics.OptimalDebulking.: Yes///Characteristics.Organism.: Homo sapiens///Characteristics.Sex.: female///Term.Source.REF.1: EFO///Characteristics.SurvivalTime.: 45.2 months///Characteristics.TimeToProgression.: 6.87 months///Hybridization.Name: RNA-hyb-DFCI-103///Array.Design.REF: A-MEXP-931///Scan.Name: RNA-hyb-DFCI-103///Derived.Array.Data.Matrix.File: normalized.txt.proc///Comment..Derived.ArrayExpress.FTP.file.: ftp://ftp.ebi.ac.uk/pub/databases/microarray/data/experiment/MTAB/E-MTAB-386/E-MTAB-386.processed.1.zip
1
Source.Name: DFCI-104///Characteristics.Age.: Age <has_measurement <Measurement <has_units <Unit <time unit <time unit=years>>>> <has_value <has_value=54.92>>>>///Characteristics.Channel.: Cy3///Characteristics.DiseaseStage.: IIIc///Characteristics.DiseaseState.: serous ovarian cancer///Term.Source.REF: SNOMED Clinical Terms///Characteristics.EventDeath.: 0///Characteristics.EventProgression.: 0///Characteristics.OptimalDebulking.: Yes///Characteristics.Organism.: Homo sapiens///Characteristics.Sex.: female///Term.Source.REF.1: EFO///Characteristics.SurvivalTime.: 53.67 months///Characteristics.TimeToProgression.: null months///Hybridization.Name: RNA-hyb-DFCI-104///Array.Design.REF: A-MEXP-931///Scan.Name: RNA-hyb-DFCI-104///Derived.Array.Data.Matrix.File: normalized.txt.proc///Comment..Derived.ArrayExpress.FTP.file.: ftp://ftp.ebi.ac.uk/pub/databases/microarray/data/experiment/MTAB/E-MTAB-386/E-MTAB-386.processed.1.zip
1
Source.Name: DFCI-105///Characteristics.Age.: Age <has_measurement <Measurement <has_units <Unit <time unit <time unit=years>>>> <has_value <has_value=39.47>>>>///Characteristics.Channel.: Cy3///Characteristics.DiseaseStage.: IIIa///Characteristics.DiseaseState.: serous ovarian cancer///Term.Source.REF: SNOMED Clinical Terms///Characteristics.EventDeath.: 0///Characteristics.EventProgression.: 0///Characteristics.OptimalDebulking.: Yes///Characteristics.Organism.: Homo sapiens///Characteristics.Sex.: female///Term.Source.REF.1: EFO///Characteristics.SurvivalTime.: 35.63 months///Characteristics.TimeToProgression.: 30.43 months///Hybridization.Name: RNA-hyb-DFCI-105///Array.Design.REF: A-MEXP-931///Scan.Name: RNA-hyb-DFCI-105///Derived.Array.Data.Matrix.File: normalized.txt.proc///Comment..Derived.ArrayExpress.FTP.file.: ftp://ftp.ebi.ac.uk/pub/databases/microarray/data/experiment/MTAB/E-MTAB-386/E-MTAB-386.processed.1.zip
1
Source.Name: DFCI-106///Characteristics.Age.: Age <has_measurement <Measurement <has_units <Unit <time unit <time unit=years>>>> <has_value <has_value=50.35>>>>///Characteristics.Channel.: Cy3///Characteristics.DiseaseStage.: IIIc///Characteristics.DiseaseState.: serous ovarian cancer///Term.Source.REF: SNOMED Clinical Terms///Characteristics.EventDeath.: 0///Characteristics.EventProgression.: 0///Characteristics.OptimalDebulking.: Yes///Characteristics.Organism.: Homo sapiens///Characteristics.Sex.: female///Term.Source.REF.1: EFO///Characteristics.SurvivalTime.: 40.73 months///Characteristics.TimeToProgression.: 2.77 months///Hybridization.Name: RNA-hyb-DFCI-106///Array.Design.REF: A-MEXP-931///Scan.Name: RNA-hyb-DFCI-106///Derived.Array.Data.Matrix.File: normalized.txt.proc///Comment..Derived.ArrayExpress.FTP.file.: ftp://ftp.ebi.ac.uk/pub/databases/microarray/data/experiment/MTAB/E-MTAB-386/E-MTAB-386.processed.1.zip
1
Source.Name: DFCI-107///Characteristics.Age.: Age <has_measurement <Measurement <has_units <Unit <time unit <time unit=years>>>> <has_value <has_value=43.63>>>>///Characteristics.Channel.: Cy3///Characteristics.DiseaseStage.: IIIc///Characteristics.DiseaseState.: serous ovarian cancer///Term.Source.REF: SNOMED Clinical Terms///Characteristics.EventDeath.: 0///Characteristics.EventProgression.: 0///Characteristics.OptimalDebulking.: Yes///Characteristics.Organism.: Homo sapiens///Characteristics.Sex.: female///Term.Source.REF.1: EFO///Characteristics.SurvivalTime.: 79.6 months///Characteristics.TimeToProgression.: 60.47 months///Hybridization.Name: RNA-hyb-DFCI-107///Array.Design.REF: A-MEXP-931///Scan.Name: RNA-hyb-DFCI-107///Derived.Array.Data.Matrix.File: normalized.txt.proc///Comment..Derived.ArrayExpress.FTP.file.: ftp://ftp.ebi.ac.uk/pub/databases/microarray/data/experiment/MTAB/E-MTAB-386/E-MTAB-386.processed.1.zip
1
Source.Name: DFCI-108///Characteristics.Age.: Age <has_measurement <Measurement <has_units <Unit <time unit <time unit=years>>>> <has_value <has_value=69.91>>>>///Characteristics.Channel.: Cy3///Characteristics.DiseaseStage.: IIIc///Characteristics.DiseaseState.: serous ovarian cancer///Term.Source.REF: SNOMED Clinical Terms///Characteristics.EventDeath.: 0///Characteristics.EventProgression.: 0///Characteristics.OptimalDebulking.: Yes///Characteristics.Organism.: Homo sapiens///Characteristics.Sex.: female///Term.Source.REF.1: EFO///Characteristics.SurvivalTime.: 14.93 months///Characteristics.TimeToProgression.: 4.7 months///Hybridization.Name: RNA-hyb-DFCI-108///Array.Design.REF: A-MEXP-931///Scan.Name: RNA-hyb-DFCI-108///Derived.Array.Data.Matrix.File: normalized.txt.proc///Comment..Derived.ArrayExpress.FTP.file.: ftp://ftp.ebi.ac.uk/pub/databases/microarray/data/experiment/MTAB/E-MTAB-386/E-MTAB-386.processed.1.zip
1
Source.Name: DFCI-109///Characteristics.Age.: Age <has_measurement <Measurement <has_units <Unit <time unit <time unit=years>>>> <has_value <has_value=79.12>>>>///Characteristics.Channel.: Cy3///Characteristics.DiseaseStage.: IIIc///Characteristics.DiseaseState.: serous ovarian cancer///Term.Source.REF: SNOMED Clinical Terms///Characteristics.EventDeath.: 0///Characteristics.EventProgression.: 0///Characteristics.OptimalDebulking.: Yes///Characteristics.Organism.: Homo sapiens///Characteristics.Sex.: female///Term.Source.REF.1: EFO///Characteristics.SurvivalTime.: 20.07 months///Characteristics.TimeToProgression.: 15.87 months///Hybridization.Name: RNA-hyb-DFCI-109///Array.Design.REF: A-MEXP-931///Scan.Name: RNA-hyb-DFCI-109///Derived.Array.Data.Matrix.File: normalized.txt.proc///Comment..Derived.ArrayExpress.FTP.file.: ftp://ftp.ebi.ac.uk/pub/databases/microarray/data/experiment/MTAB/E-MTAB-386/E-MTAB-386.processed.1.zip
1
Source.Name: DFCI-10///Characteristics.Age.: Age <has_measurement <Measurement <has_units <Unit <time unit <time unit=years>>>> <has_value <has_value=64.94>>>>///Characteristics.Channel.: Cy3///Characteristics.DiseaseStage.: IIIc///Characteristics.DiseaseState.: serous ovarian cancer///Term.Source.REF: SNOMED Clinical Terms///Characteristics.EventDeath.: 0///Characteristics.EventProgression.: 0///Characteristics.OptimalDebulking.: Yes///Characteristics.Organism.: Homo sapiens///Characteristics.Sex.: female///Term.Source.REF.1: EFO///Characteristics.SurvivalTime.: 1.53 months///Characteristics.TimeToProgression.: null months///Hybridization.Name: RNA-hyb-DFCI-10///Array.Design.REF: A-MEXP-931///Scan.Name: RNA-hyb-DFCI-10///Derived.Array.Data.Matrix.File: normalized.txt.proc///Comment..Derived.ArrayExpress.FTP.file.: ftp://ftp.ebi.ac.uk/pub/databases/microarray/data/experiment/MTAB/E-MTAB-386/E-MTAB-386.processed.1.zip
1
Source.Name: DFCI-110///Characteristics.Age.: Age <has_measurement <Measurement <has_units <Unit <time unit <time unit=years>>>> <has_value <has_value=77.76>>>>///Characteristics.Channel.: Cy3///Characteristics.DiseaseStage.: IIIc///Characteristics.DiseaseState.: serous ovarian cancer///Term.Source.REF: SNOMED Clinical Terms///Characteristics.EventDeath.: 0///Characteristics.EventProgression.: 0///Characteristics.OptimalDebulking.: No///Characteristics.Organism.: Homo sapiens///Characteristics.Sex.: female///Term.Source.REF.1: EFO///Characteristics.SurvivalTime.: 62.5 months///Characteristics.TimeToProgression.: 58.9 months///Hybridization.Name: RNA-hyb-DFCI-110///Array.Design.REF: A-MEXP-931///Scan.Name: RNA-hyb-DFCI-110///Derived.Array.Data.Matrix.File: normalized.txt.proc///Comment..Derived.ArrayExpress.FTP.file.: ftp://ftp.ebi.ac.uk/pub/databases/microarray/data/experiment/MTAB/E-MTAB-386/E-MTAB-386.processed.1.zip
1
Source.Name: DFCI-111///Characteristics.Age.: Age <has_measurement <Measurement <has_units <Unit <time unit <time unit=years>>>> <has_value <has_value=71.29>>>>///Characteristics.Channel.: Cy3///Characteristics.DiseaseStage.: IIIc///Characteristics.DiseaseState.: serous ovarian cancer///Term.Source.REF: SNOMED Clinical Terms///Characteristics.EventDeath.: 0///Characteristics.EventProgression.: 0///Characteristics.OptimalDebulking.: Yes///Characteristics.Organism.: Homo sapiens///Characteristics.Sex.: female///Term.Source.REF.1: EFO///Characteristics.SurvivalTime.: 30.67 months///Characteristics.TimeToProgression.: 24.17 months///Hybridization.Name: RNA-hyb-DFCI-111///Array.Design.REF: A-MEXP-931///Scan.Name: RNA-hyb-DFCI-111///Derived.Array.Data.Matrix.File: normalized.txt.proc///Comment..Derived.ArrayExpress.FTP.file.: ftp://ftp.ebi.ac.uk/pub/databases/microarray/data/experiment/MTAB/E-MTAB-386/E-MTAB-386.processed.1.zip
1
Source.Name: DFCI-112///Characteristics.Age.: Age <has_measurement <Measurement <has_units <Unit <time unit <time unit=years>>>> <has_value <has_value=73.54>>>>///Characteristics.Channel.: Cy3///Characteristics.DiseaseStage.: IIIc///Characteristics.DiseaseState.: serous ovarian cancer///Term.Source.REF: SNOMED Clinical Terms///Characteristics.EventDeath.: 1///Characteristics.EventProgression.: 1///Characteristics.OptimalDebulking.: Yes///Characteristics.Organism.: Homo sapiens///Characteristics.Sex.: female///Term.Source.REF.1: EFO///Characteristics.SurvivalTime.: 31.97 months///Characteristics.TimeToProgression.: 4.1 months///Hybridization.Name: RNA-hyb-DFCI-112///Array.Design.REF: A-MEXP-931///Scan.Name: RNA-hyb-DFCI-112///Derived.Array.Data.Matrix.File: normalized.txt.proc///Comment..Derived.ArrayExpress.FTP.file.: ftp://ftp.ebi.ac.uk/pub/databases/microarray/data/experiment/MTAB/E-MTAB-386/E-MTAB-386.processed.1.zip
1
Source.Name: DFCI-113///Characteristics.Age.: Age <has_measurement <Measurement <has_units <Unit <time unit <time unit=years>>>> <has_value <has_value=79.47>>>>///Characteristics.Channel.: Cy3///Characteristics.DiseaseStage.: IIIc///Characteristics.DiseaseState.: serous ovarian cancer///Term.Source.REF: SNOMED Clinical Terms///Characteristics.EventDeath.: 1///Characteristics.EventProgression.: 1///Characteristics.OptimalDebulking.: Yes///Characteristics.Organism.: Homo sapiens///Characteristics.Sex.: female///Term.Source.REF.1: EFO///Characteristics.SurvivalTime.: 23.6 months///Characteristics.TimeToProgression.: 5.97 months///Hybridization.Name: RNA-hyb-DFCI-113///Array.Design.REF: A-MEXP-931///Scan.Name: RNA-hyb-DFCI-113///Derived.Array.Data.Matrix.File: normalized.txt.proc///Comment..Derived.ArrayExpress.FTP.file.: ftp://ftp.ebi.ac.uk/pub/databases/microarray/data/experiment/MTAB/E-MTAB-386/E-MTAB-386.processed.1.zip
1
Source.Name: DFCI-114///Characteristics.Age.: Age <has_measurement <Measurement <has_units <Unit <time unit <time unit=years>>>> <has_value <has_value=80.91>>>>///Characteristics.Channel.: Cy3///Characteristics.DiseaseStage.: IIIc///Characteristics.DiseaseState.: serous ovarian cancer///Term.Source.REF: SNOMED Clinical Terms///Characteristics.EventDeath.: 1///Characteristics.EventProgression.: 1///Characteristics.OptimalDebulking.: No///Characteristics.Organism.: Homo sapiens///Characteristics.Sex.: female///Term.Source.REF.1: EFO///Characteristics.SurvivalTime.: 18.2 months///Characteristics.TimeToProgression.: 0 months///Hybridization.Name: RNA-hyb-DFCI-114///Array.Design.REF: A-MEXP-931///Scan.Name: RNA-hyb-DFCI-114///Derived.Array.Data.Matrix.File: normalized.txt.proc///Comment..Derived.ArrayExpress.FTP.file.: ftp://ftp.ebi.ac.uk/pub/databases/microarray/data/experiment/MTAB/E-MTAB-386/E-MTAB-386.processed.1.zip
1
Source.Name: DFCI-115///Characteristics.Age.: Age <has_measurement <Measurement <has_units <Unit <time unit <time unit=years>>>> <has_value <has_value=67.6>>>>///Characteristics.Channel.: Cy3///Characteristics.DiseaseStage.: IIIc///Characteristics.DiseaseState.: serous ovarian cancer///Term.Source.REF: SNOMED Clinical Terms///Characteristics.EventDeath.: 0///Characteristics.EventProgression.: 0///Characteristics.OptimalDebulking.: Yes///Characteristics.Organism.: Homo sapiens///Characteristics.Sex.: female///Term.Source.REF.1: EFO///Characteristics.SurvivalTime.: 41.83 months///Characteristics.TimeToProgression.: 32.67 months///Hybridization.Name: RNA-hyb-DFCI-115///Array.Design.REF: A-MEXP-931///Scan.Name: RNA-hyb-DFCI-115///Derived.Array.Data.Matrix.File: normalized.txt.proc///Comment..Derived.ArrayExpress.FTP.file.: ftp://ftp.ebi.ac.uk/pub/databases/microarray/data/experiment/MTAB/E-MTAB-386/E-MTAB-386.processed.1.zip
1
Source.Name: DFCI-116///Characteristics.Age.: Age <has_measurement <Measurement <has_units <Unit <time unit <time unit=years>>>> <has_value <has_value=72.33>>>>///Characteristics.Channel.: Cy3///Characteristics.DiseaseStage.: IIIc///Characteristics.DiseaseState.: serous ovarian cancer///Term.Source.REF: SNOMED Clinical Terms///Characteristics.EventDeath.: 0///Characteristics.EventProgression.: 0///Characteristics.OptimalDebulking.: Yes///Characteristics.Organism.: Homo sapiens///Characteristics.Sex.: female///Term.Source.REF.1: EFO///Characteristics.SurvivalTime.: 20.37 months///Characteristics.TimeToProgression.: 14.67 months///Hybridization.Name: RNA-hyb-DFCI-116///Array.Design.REF: A-MEXP-931///Scan.Name: RNA-hyb-DFCI-116///Derived.Array.Data.Matrix.File: normalized.txt.proc///Comment..Derived.ArrayExpress.FTP.file.: ftp://ftp.ebi.ac.uk/pub/databases/microarray/data/experiment/MTAB/E-MTAB-386/E-MTAB-386.processed.1.zip
1
Source.Name: DFCI-117///Characteristics.Age.: Age <has_measurement <Measurement <has_units <Unit <time unit <time unit=years>>>> <has_value <has_value=65.58>>>>///Characteristics.Channel.: Cy3///Characteristics.DiseaseStage.: IIIc///Characteristics.DiseaseState.: serous ovarian cancer///Term.Source.REF: SNOMED Clinical Terms///Characteristics.EventDeath.: 1///Characteristics.EventProgression.: 1///Characteristics.OptimalDebulking.: No///Characteristics.Organism.: Homo sapiens///Characteristics.Sex.: female///Term.Source.REF.1: EFO///Characteristics.SurvivalTime.: 43.93 months///Characteristics.TimeToProgression.: 9.9 months///Hybridization.Name: RNA-hyb-DFCI-117///Array.Design.REF: A-MEXP-931///Scan.Name: RNA-hyb-DFCI-117///Derived.Array.Data.Matrix.File: normalized.txt.proc///Comment..Derived.ArrayExpress.FTP.file.: ftp://ftp.ebi.ac.uk/pub/databases/microarray/data/experiment/MTAB/E-MTAB-386/E-MTAB-386.processed.1.zip
1
Source.Name: DFCI-118///Characteristics.Age.: Age <has_measurement <Measurement <has_units <Unit <time unit <time unit=years>>>> <has_value <has_value=69.39>>>>///Characteristics.Channel.: Cy3///Characteristics.DiseaseStage.: IIIc///Characteristics.DiseaseState.: serous ovarian cancer///Term.Source.REF: SNOMED Clinical Terms///Characteristics.EventDeath.: 1///Characteristics.EventProgression.: 1///Characteristics.OptimalDebulking.: Yes///Characteristics.Organism.: Homo sapiens///Characteristics.Sex.: female///Term.Source.REF.1: EFO///Characteristics.SurvivalTime.: 15.03 months///Characteristics.TimeToProgression.: 3.97 months///Hybridization.Name: RNA-hyb-DFCI-118 rep1 / RNA-hyb-DFCI-118 rep2///Array.Design.REF: A-MEXP-931///Scan.Name: RNA-hyb-DFCI-118 rep1 / RNA-hyb-DFCI-118 rep2///Derived.Array.Data.Matrix.File: normalized.txt.proc///Comment..Derived.ArrayExpress.FTP.file.: ftp://ftp.ebi.ac.uk/pub/databases/microarray/data/experiment/MTAB/E-MTAB-386/E-MTAB-386.processed.1.zip
1
Source.Name: DFCI-119///Characteristics.Age.: Age <has_measurement <Measurement <has_units <Unit <time unit <time unit=years>>>> <has_value <has_value=66.53>>>>///Characteristics.Channel.: Cy3///Characteristics.DiseaseStage.: IIIb///Characteristics.DiseaseState.: serous ovarian cancer///Term.Source.REF: SNOMED Clinical Terms///Characteristics.EventDeath.: 1///Characteristics.EventProgression.: 1///Characteristics.OptimalDebulking.: Yes///Characteristics.Organism.: Homo sapiens///Characteristics.Sex.: female///Term.Source.REF.1: EFO///Characteristics.SurvivalTime.: 63.3 months///Characteristics.TimeToProgression.: 39.6 months///Hybridization.Name: RNA-hyb-DFCI-119///Array.Design.REF: A-MEXP-931///Scan.Name: RNA-hyb-DFCI-119///Derived.Array.Data.Matrix.File: normalized.txt.proc///Comment..Derived.ArrayExpress.FTP.file.: ftp://ftp.ebi.ac.uk/pub/databases/microarray/data/experiment/MTAB/E-MTAB-386/E-MTAB-386.processed.1.zip
1
Source.Name: DFCI-11///Characteristics.Age.: Age <has_measurement <Measurement <has_units <Unit <time unit <time unit=years>>>> <has_value <has_value=68.58>>>>///Characteristics.Channel.: Cy3///Characteristics.DiseaseStage.: IIIc///Characteristics.DiseaseState.: serous ovarian cancer///Term.Source.REF: SNOMED Clinical Terms///Characteristics.EventDeath.: 0///Characteristics.EventProgression.: 0///Characteristics.OptimalDebulking.: Yes///Characteristics.Organism.: Homo sapiens///Characteristics.Sex.: female///Term.Source.REF.1: EFO///Characteristics.SurvivalTime.: 16.13 months///Characteristics.TimeToProgression.: 10.73 months///Hybridization.Name: RNA-hyb-DFCI-11///Array.Design.REF: A-MEXP-931///Scan.Name: RNA-hyb-DFCI-11///Derived.Array.Data.Matrix.File: normalized.txt.proc///Comment..Derived.ArrayExpress.FTP.file.: ftp://ftp.ebi.ac.uk/pub/databases/microarray/data/experiment/MTAB/E-MTAB-386/E-MTAB-386.processed.1.zip
1
Source.Name: DFCI-120///Characteristics.Age.: Age <has_measurement <Measurement <has_units <Unit <time unit <time unit=years>>>> <has_value <has_value=77.11>>>>///Characteristics.Channel.: Cy3///Characteristics.DiseaseStage.: IIIc///Characteristics.DiseaseState.: serous ovarian cancer///Term.Source.REF: SNOMED Clinical Terms///Characteristics.EventDeath.: 1///Characteristics.EventProgression.: 1///Characteristics.OptimalDebulking.: No///Characteristics.Organism.: Homo sapiens///Characteristics.Sex.: female///Term.Source.REF.1: EFO///Characteristics.SurvivalTime.: 46.63 months///Characteristics.TimeToProgression.: 11 months///Hybridization.Name: RNA-hyb-DFCI-120 rep1 / RNA-hyb-DFCI-120 rep2///Array.Design.REF: A-MEXP-931///Scan.Name: RNA-hyb-DFCI-120 rep1 / RNA-hyb-DFCI-120 rep2///Derived.Array.Data.Matrix.File: normalized.txt.proc///Comment..Derived.ArrayExpress.FTP.file.: ftp://ftp.ebi.ac.uk/pub/databases/microarray/data/experiment/MTAB/E-MTAB-386/E-MTAB-386.processed.1.zip
1
Source.Name: DFCI-121///Characteristics.Age.: Age <has_measurement <Measurement <has_units <Unit <time unit <time unit=years>>>> <has_value <has_value=71.53>>>>///Characteristics.Channel.: Cy3///Characteristics.DiseaseStage.: IIIa///Characteristics.DiseaseState.: serous ovarian cancer///Term.Source.REF: SNOMED Clinical Terms///Characteristics.EventDeath.: 1///Characteristics.EventProgression.: 1///Characteristics.OptimalDebulking.: Yes///Characteristics.Organism.: Homo sapiens///Characteristics.Sex.: female///Term.Source.REF.1: EFO///Characteristics.SurvivalTime.: 62.87 months///Characteristics.TimeToProgression.: 21 months///Hybridization.Name: RNA-hyb-DFCI-121///Array.Design.REF: A-MEXP-931///Scan.Name: RNA-hyb-DFCI-121///Derived.Array.Data.Matrix.File: normalized.txt.proc///Comment..Derived.ArrayExpress.FTP.file.: ftp://ftp.ebi.ac.uk/pub/databases/microarray/data/experiment/MTAB/E-MTAB-386/E-MTAB-386.processed.1.zip
1
Source.Name: DFCI-122///Characteristics.Age.: Age <has_measurement <Measurement <has_units <Unit <time unit <time unit=years>>>> <has_value <has_value=77.1>>>>///Characteristics.Channel.: Cy3///Characteristics.DiseaseStage.: IIIc///Characteristics.DiseaseState.: serous ovarian cancer///Term.Source.REF: SNOMED Clinical Terms///Characteristics.EventDeath.: 1///Characteristics.EventProgression.: 1///Characteristics.OptimalDebulking.: Yes///Characteristics.Organism.: Homo sapiens///Characteristics.Sex.: female///Term.Source.REF.1: EFO///Characteristics.SurvivalTime.: 21.4 months///Characteristics.TimeToProgression.: 0 months///Hybridization.Name: RNA-hyb-DFCI-122///Array.Design.REF: A-MEXP-931///Scan.Name: RNA-hyb-DFCI-122///Derived.Array.Data.Matrix.File: normalized.txt.proc///Comment..Derived.ArrayExpress.FTP.file.: ftp://ftp.ebi.ac.uk/pub/databases/microarray/data/experiment/MTAB/E-MTAB-386/E-MTAB-386.processed.1.zip
1
Source.Name: DFCI-123///Characteristics.Age.: Age <has_measurement <Measurement <has_units <Unit <time unit <time unit=years>>>> <has_value <has_value=67.59>>>>///Characteristics.Channel.: Cy3///Characteristics.DiseaseStage.: IIIc///Characteristics.DiseaseState.: serous ovarian cancer///Term.Source.REF: SNOMED Clinical Terms///Characteristics.EventDeath.: 1///Characteristics.EventProgression.: 1///Characteristics.OptimalDebulking.: Yes///Characteristics.Organism.: Homo sapiens///Characteristics.Sex.: female///Term.Source.REF.1: EFO///Characteristics.SurvivalTime.: 58.77 months///Characteristics.TimeToProgression.: 9.63 months///Hybridization.Name: RNA-hyb-DFCI-123///Array.Design.REF: A-MEXP-931///Scan.Name: RNA-hyb-DFCI-123///Derived.Array.Data.Matrix.File: normalized.txt.proc///Comment..Derived.ArrayExpress.FTP.file.: ftp://ftp.ebi.ac.uk/pub/databases/microarray/data/experiment/MTAB/E-MTAB-386/E-MTAB-386.processed.1.zip
1
Source.Name: DFCI-124///Characteristics.Age.: Age <has_measurement <Measurement <has_units <Unit <time unit <time unit=years>>>> <has_value <has_value=95.13>>>>///Characteristics.Channel.: Cy3///Characteristics.DiseaseStage.: IIIc///Characteristics.DiseaseState.: serous ovarian cancer///Term.Source.REF: SNOMED Clinical Terms///Characteristics.EventDeath.: 1///Characteristics.EventProgression.: 1///Characteristics.OptimalDebulking.: Yes///Characteristics.Organism.: Homo sapiens///Characteristics.Sex.: female///Term.Source.REF.1: EFO///Characteristics.SurvivalTime.: 9.2 months///Characteristics.TimeToProgression.: null months///Hybridization.Name: RNA-hyb-DFCI-124///Array.Design.REF: A-MEXP-931///Scan.Name: RNA-hyb-DFCI-124///Derived.Array.Data.Matrix.File: normalized.txt.proc///Comment..Derived.ArrayExpress.FTP.file.: ftp://ftp.ebi.ac.uk/pub/databases/microarray/data/experiment/MTAB/E-MTAB-386/E-MTAB-386.processed.1.zip
1
Source.Name: DFCI-125///Characteristics.Age.: Age <has_measurement <Measurement <has_units <Unit <time unit <time unit=years>>>> <has_value <has_value=69.1>>>>///Characteristics.Channel.: Cy3///Characteristics.DiseaseStage.: IIIc///Characteristics.DiseaseState.: serous ovarian cancer///Term.Source.REF: SNOMED Clinical Terms///Characteristics.EventDeath.: 0///Characteristics.EventProgression.: 0///Characteristics.OptimalDebulking.: No///Characteristics.Organism.: Homo sapiens///Characteristics.Sex.: female///Term.Source.REF.1: EFO///Characteristics.SurvivalTime.: 61.9 months///Characteristics.TimeToProgression.: 18.5 months///Hybridization.Name: RNA-hyb-DFCI-125///Array.Design.REF: A-MEXP-931///Scan.Name: RNA-hyb-DFCI-125///Derived.Array.Data.Matrix.File: normalized.txt.proc///Comment..Derived.ArrayExpress.FTP.file.: ftp://ftp.ebi.ac.uk/pub/databases/microarray/data/experiment/MTAB/E-MTAB-386/E-MTAB-386.processed.1.zip
1
Source.Name: DFCI-126///Characteristics.Age.: Age <has_measurement <Measurement <has_units <Unit <time unit <time unit=years>>>> <has_value <has_value=77.07>>>>///Characteristics.Channel.: Cy3///Characteristics.DiseaseStage.: IV///Characteristics.DiseaseState.: serous ovarian cancer///Term.Source.REF: SNOMED Clinical Terms///Characteristics.EventDeath.: 1///Characteristics.EventProgression.: 1///Characteristics.OptimalDebulking.: No///Characteristics.Organism.: Homo sapiens///Characteristics.Sex.: female///Term.Source.REF.1: EFO///Characteristics.SurvivalTime.: 18 months///Characteristics.TimeToProgression.: null months///Hybridization.Name: RNA-hyb-DFCI-126///Array.Design.REF: A-MEXP-931///Scan.Name: RNA-hyb-DFCI-126///Derived.Array.Data.Matrix.File: normalized.txt.proc///Comment..Derived.ArrayExpress.FTP.file.: ftp://ftp.ebi.ac.uk/pub/databases/microarray/data/experiment/MTAB/E-MTAB-386/E-MTAB-386.processed.1.zip
1
Source.Name: DFCI-127///Characteristics.Age.: Age <has_measurement <Measurement <has_units <Unit <time unit <time unit=years>>>> <has_value <has_value=67.86>>>>///Characteristics.Channel.: Cy3///Characteristics.DiseaseStage.: IV///Characteristics.DiseaseState.: serous ovarian cancer///Term.Source.REF: SNOMED Clinical Terms///Characteristics.EventDeath.: 1///Characteristics.EventProgression.: 1///Characteristics.OptimalDebulking.: No///Characteristics.Organism.: Homo sapiens///Characteristics.Sex.: female///Term.Source.REF.1: EFO///Characteristics.SurvivalTime.: 49.37 months///Characteristics.TimeToProgression.: 13 months///Hybridization.Name: RNA-hyb-DFCI-127 rep1 / RNA-hyb-DFCI-127 rep2///Array.Design.REF: A-MEXP-931///Scan.Name: RNA-hyb-DFCI-127 rep1 / RNA-hyb-DFCI-127 rep2///Derived.Array.Data.Matrix.File: normalized.txt.proc///Comment..Derived.ArrayExpress.FTP.file.: ftp://ftp.ebi.ac.uk/pub/databases/microarray/data/experiment/MTAB/E-MTAB-386/E-MTAB-386.processed.1.zip
1
Source.Name: DFCI-128///Characteristics.Age.: Age <has_measurement <Measurement <has_units <Unit <time unit <time unit=years>>>> <has_value <has_value=73.28>>>>///Characteristics.Channel.: Cy3///Characteristics.DiseaseStage.: IV///Characteristics.DiseaseState.: serous ovarian cancer///Term.Source.REF: SNOMED Clinical Terms///Characteristics.EventDeath.: 1///Characteristics.EventProgression.: 1///Characteristics.OptimalDebulking.: Yes///Characteristics.Organism.: Homo sapiens///Characteristics.Sex.: female///Term.Source.REF.1: EFO///Characteristics.SurvivalTime.: 28.43 months///Characteristics.TimeToProgression.: null months///Hybridization.Name: RNA-hyb-DFCI-128///Array.Design.REF: A-MEXP-931///Scan.Name: RNA-hyb-DFCI-128///Derived.Array.Data.Matrix.File: normalized.txt.proc///Comment..Derived.ArrayExpress.FTP.file.: ftp://ftp.ebi.ac.uk/pub/databases/microarray/data/experiment/MTAB/E-MTAB-386/E-MTAB-386.processed.1.zip
1
Source.Name: DFCI-129///Characteristics.Age.: Age <has_measurement <Measurement <has_units <Unit <time unit <time unit=years>>>> <has_value <has_value=68.33>>>>///Characteristics.Channel.: Cy3///Characteristics.DiseaseStage.: IV///Characteristics.DiseaseState.: serous ovarian cancer///Term.Source.REF: SNOMED Clinical Terms///Characteristics.EventDeath.: 0///Characteristics.EventProgression.: 0///Characteristics.OptimalDebulking.: Yes///Characteristics.Organism.: Homo sapiens///Characteristics.Sex.: female///Term.Source.REF.1: EFO///Characteristics.SurvivalTime.: 90.8 months///Characteristics.TimeToProgression.: 9.87 months///Hybridization.Name: RNA-hyb-DFCI-129 rep1 / RNA-hyb-DFCI-129 rep2///Array.Design.REF: A-MEXP-931///Scan.Name: RNA-hyb-DFCI-129 rep1 / RNA-hyb-DFCI-129 rep2///Derived.Array.Data.Matrix.File: normalized.txt.proc///Comment..Derived.ArrayExpress.FTP.file.: ftp://ftp.ebi.ac.uk/pub/databases/microarray/data/experiment/MTAB/E-MTAB-386/E-MTAB-386.processed.1.zip
1
Source.Name: DFCI-12///Characteristics.Age.: Age <has_measurement <Measurement <has_units <Unit <time unit <time unit=years>>>> <has_value <has_value=68.23>>>>///Characteristics.Channel.: Cy3///Characteristics.DiseaseStage.: IIIc///Characteristics.DiseaseState.: serous ovarian cancer///Term.Source.REF: SNOMED Clinical Terms///Characteristics.EventDeath.: 1///Characteristics.EventProgression.: 1///Characteristics.OptimalDebulking.: Yes///Characteristics.Organism.: Homo sapiens///Characteristics.Sex.: female///Term.Source.REF.1: EFO///Characteristics.SurvivalTime.: 30.57 months///Characteristics.TimeToProgression.: null months///Hybridization.Name: RNA-hyb-DFCI-12///Array.Design.REF: A-MEXP-931///Scan.Name: RNA-hyb-DFCI-12///Derived.Array.Data.Matrix.File: normalized.txt.proc///Comment..Derived.ArrayExpress.FTP.file.: ftp://ftp.ebi.ac.uk/pub/databases/microarray/data/experiment/MTAB/E-MTAB-386/E-MTAB-386.processed.1.zip
1
Source.Name: DFCI-130///Characteristics.Age.: Age <has_measurement <Measurement <has_units <Unit <time unit <time unit=years>>>> <has_value <has_value=67.97>>>>///Characteristics.Channel.: Cy3///Characteristics.DiseaseStage.: IIIc///Characteristics.DiseaseState.: serous ovarian cancer///Term.Source.REF: SNOMED Clinical Terms///Characteristics.EventDeath.: 1///Characteristics.EventProgression.: 1///Characteristics.OptimalDebulking.: Yes///Characteristics.Organism.: Homo sapiens///Characteristics.Sex.: female///Term.Source.REF.1: EFO///Characteristics.SurvivalTime.: 68.73 months///Characteristics.TimeToProgression.: 6.27 months///Hybridization.Name: RNA-hyb-DFCI-130 rep1 / RNA-hyb-DFCI-130 rep2///Array.Design.REF: A-MEXP-931///Scan.Name: RNA-hyb-DFCI-130 rep1 / RNA-hyb-DFCI-130 rep2///Derived.Array.Data.Matrix.File: normalized.txt.proc///Comment..Derived.ArrayExpress.FTP.file.: ftp://ftp.ebi.ac.uk/pub/databases/microarray/data/experiment/MTAB/E-MTAB-386/E-MTAB-386.processed.1.zip
1
Source.Name: DFCI-131///Characteristics.Age.: Age <has_measurement <Measurement <has_units <Unit <time unit <time unit=years>>>> <has_value <has_value=68.28>>>>///Characteristics.Channel.: Cy3///Characteristics.DiseaseStage.: IV///Characteristics.DiseaseState.: serous ovarian cancer///Term.Source.REF: SNOMED Clinical Terms///Characteristics.EventDeath.: 1///Characteristics.EventProgression.: 1///Characteristics.OptimalDebulking.: No///Characteristics.Organism.: Homo sapiens///Characteristics.Sex.: female///Term.Source.REF.1: EFO///Characteristics.SurvivalTime.: 21.73 months///Characteristics.TimeToProgression.: 0 months///Hybridization.Name: RNA-hyb-DFCI-131 rep1 / RNA-hyb-DFCI-131 rep2///Array.Design.REF: A-MEXP-931///Scan.Name: RNA-hyb-DFCI-131 rep1 / RNA-hyb-DFCI-131 rep2///Derived.Array.Data.Matrix.File: normalized.txt.proc///Comment..Derived.ArrayExpress.FTP.file.: ftp://ftp.ebi.ac.uk/pub/databases/microarray/data/experiment/MTAB/E-MTAB-386/E-MTAB-386.processed.1.zip
1
Source.Name: DFCI-132///Characteristics.Age.: Age <has_measurement <Measurement <has_units <Unit <time unit <time unit=years>>>> <has_value <has_value=75.63>>>>///Characteristics.Channel.: Cy3///Characteristics.DiseaseStage.: IIIc///Characteristics.DiseaseState.: serous ovarian cancer///Term.Source.REF: SNOMED Clinical Terms///Characteristics.EventDeath.: 0///Characteristics.EventProgression.: 0///Characteristics.OptimalDebulking.: No///Characteristics.Organism.: Homo sapiens///Characteristics.Sex.: female///Term.Source.REF.1: EFO///Characteristics.SurvivalTime.: 78.3 months///Characteristics.TimeToProgression.: 21.03 months///Hybridization.Name: RNA-hyb-DFCI-132 rep1 / RNA-hyb-DFCI-132 rep2///Array.Design.REF: A-MEXP-931///Scan.Name: RNA-hyb-DFCI-132 rep1 / RNA-hyb-DFCI-132 rep2///Derived.Array.Data.Matrix.File: normalized.txt.proc///Comment..Derived.ArrayExpress.FTP.file.: ftp://ftp.ebi.ac.uk/pub/databases/microarray/data/experiment/MTAB/E-MTAB-386/E-MTAB-386.processed.1.zip
1
Source.Name: DFCI-13///Characteristics.Age.: Age <has_measurement <Measurement <has_units <Unit <time unit <time unit=years>>>> <has_value <has_value=65.52>>>>///Characteristics.Channel.: Cy3///Characteristics.DiseaseStage.: IIIc///Characteristics.DiseaseState.: serous ovarian cancer///Term.Source.REF: SNOMED Clinical Terms///Characteristics.EventDeath.: 0///Characteristics.EventProgression.: 0///Characteristics.OptimalDebulking.: Yes///Characteristics.Organism.: Homo sapiens///Characteristics.Sex.: female///Term.Source.REF.1: EFO///Characteristics.SurvivalTime.: 33.77 months///Characteristics.TimeToProgression.: 9.43 months///Hybridization.Name: RNA-hyb-DFCI-13///Array.Design.REF: A-MEXP-931///Scan.Name: RNA-hyb-DFCI-13///Derived.Array.Data.Matrix.File: normalized.txt.proc///Comment..Derived.ArrayExpress.FTP.file.: ftp://ftp.ebi.ac.uk/pub/databases/microarray/data/experiment/MTAB/E-MTAB-386/E-MTAB-386.processed.1.zip
1
Source.Name: DFCI-14///Characteristics.Age.: Age <has_measurement <Measurement <has_units <Unit <time unit <time unit=years>>>> <has_value <has_value=81.56>>>>///Characteristics.Channel.: Cy3///Characteristics.DiseaseStage.: IIIc///Characteristics.DiseaseState.: serous ovarian cancer///Term.Source.REF: SNOMED Clinical Terms///Characteristics.EventDeath.: 1///Characteristics.EventProgression.: 1///Characteristics.OptimalDebulking.: Yes///Characteristics.Organism.: Homo sapiens///Characteristics.Sex.: female///Term.Source.REF.1: EFO///Characteristics.SurvivalTime.: 2.33 months///Characteristics.TimeToProgression.: null months///Hybridization.Name: RNA-hyb-DFCI-14///Array.Design.REF: A-MEXP-931///Scan.Name: RNA-hyb-DFCI-14///Derived.Array.Data.Matrix.File: normalized.txt.proc///Comment..Derived.ArrayExpress.FTP.file.: ftp://ftp.ebi.ac.uk/pub/databases/microarray/data/experiment/MTAB/E-MTAB-386/E-MTAB-386.processed.1.zip
1
Source.Name: DFCI-15///Characteristics.Age.: Age <has_measurement <Measurement <has_units <Unit <time unit <time unit=years>>>> <has_value <has_value=71.64>>>>///Characteristics.Channel.: Cy3///Characteristics.DiseaseStage.: IV///Characteristics.DiseaseState.: serous ovarian cancer///Term.Source.REF: SNOMED Clinical Terms///Characteristics.EventDeath.: 1///Characteristics.EventProgression.: 1///Characteristics.OptimalDebulking.: No///Characteristics.Organism.: Homo sapiens///Characteristics.Sex.: female///Term.Source.REF.1: EFO///Characteristics.SurvivalTime.: 16.2 months///Characteristics.TimeToProgression.: null months///Hybridization.Name: RNA-hyb-DFCI-15///Array.Design.REF: A-MEXP-931///Scan.Name: RNA-hyb-DFCI-15///Derived.Array.Data.Matrix.File: normalized.txt.proc///Comment..Derived.ArrayExpress.FTP.file.: ftp://ftp.ebi.ac.uk/pub/databases/microarray/data/experiment/MTAB/E-MTAB-386/E-MTAB-386.processed.1.zip
1
Source.Name: DFCI-16///Characteristics.Age.: Age <has_measurement <Measurement <has_units <Unit <time unit <time unit=years>>>> <has_value <has_value=69.08>>>>///Characteristics.Channel.: Cy3///Characteristics.DiseaseStage.: IV///Characteristics.DiseaseState.: serous ovarian cancer///Term.Source.REF: SNOMED Clinical Terms///Characteristics.EventDeath.: 1///Characteristics.EventProgression.: 1///Characteristics.OptimalDebulking.: Yes///Characteristics.Organism.: Homo sapiens///Characteristics.Sex.: female///Term.Source.REF.1: EFO///Characteristics.SurvivalTime.: 12.33 months///Characteristics.TimeToProgression.: 0 months///Hybridization.Name: RNA-hyb-DFCI-16///Array.Design.REF: A-MEXP-931///Scan.Name: RNA-hyb-DFCI-16///Derived.Array.Data.Matrix.File: normalized.txt.proc///Comment..Derived.ArrayExpress.FTP.file.: ftp://ftp.ebi.ac.uk/pub/databases/microarray/data/experiment/MTAB/E-MTAB-386/E-MTAB-386.processed.1.zip
1
Source.Name: DFCI-17///Characteristics.Age.: Age <has_measurement <Measurement <has_units <Unit <time unit <time unit=years>>>> <has_value <has_value=67.21>>>>///Characteristics.Channel.: Cy3///Characteristics.DiseaseStage.: IIIc///Characteristics.DiseaseState.: serous ovarian cancer///Term.Source.REF: SNOMED Clinical Terms///Characteristics.EventDeath.: 0///Characteristics.EventProgression.: 0///Characteristics.OptimalDebulking.: Yes///Characteristics.Organism.: Homo sapiens///Characteristics.Sex.: female///Term.Source.REF.1: EFO///Characteristics.SurvivalTime.: 86.17 months///Characteristics.TimeToProgression.: 81.4 months///Hybridization.Name: RNA-hyb-DFCI-17///Array.Design.REF: A-MEXP-931///Scan.Name: RNA-hyb-DFCI-17///Derived.Array.Data.Matrix.File: normalized.txt.proc///Comment..Derived.ArrayExpress.FTP.file.: ftp://ftp.ebi.ac.uk/pub/databases/microarray/data/experiment/MTAB/E-MTAB-386/E-MTAB-386.processed.1.zip
1
Source.Name: DFCI-18///Characteristics.Age.: Age <has_measurement <Measurement <has_units <Unit <time unit <time unit=years>>>> <has_value <has_value=70.94>>>>///Characteristics.Channel.: Cy3///Characteristics.DiseaseStage.: IIIc///Characteristics.DiseaseState.: serous ovarian cancer///Term.Source.REF: SNOMED Clinical Terms///Characteristics.EventDeath.: 1///Characteristics.EventProgression.: 1///Characteristics.OptimalDebulking.: Yes///Characteristics.Organism.: Homo sapiens///Characteristics.Sex.: female///Term.Source.REF.1: EFO///Characteristics.SurvivalTime.: 24.63 months///Characteristics.TimeToProgression.: 2.57 months///Hybridization.Name: RNA-hyb-DFCI-18///Array.Design.REF: A-MEXP-931///Scan.Name: RNA-hyb-DFCI-18///Derived.Array.Data.Matrix.File: normalized.txt.proc///Comment..Derived.ArrayExpress.FTP.file.: ftp://ftp.ebi.ac.uk/pub/databases/microarray/data/experiment/MTAB/E-MTAB-386/E-MTAB-386.processed.1.zip
1
Source.Name: DFCI-19///Characteristics.Age.: Age <has_measurement <Measurement <has_units <Unit <time unit <time unit=years>>>> <has_value <has_value=76.01>>>>///Characteristics.Channel.: Cy3///Characteristics.DiseaseStage.: IIIc///Characteristics.DiseaseState.: serous ovarian cancer///Term.Source.REF: SNOMED Clinical Terms///Characteristics.EventDeath.: 1///Characteristics.EventProgression.: 1///Characteristics.OptimalDebulking.: Yes///Characteristics.Organism.: Homo sapiens///Characteristics.Sex.: female///Term.Source.REF.1: EFO///Characteristics.SurvivalTime.: 12.07 months///Characteristics.TimeToProgression.: null months///Hybridization.Name: RNA-hyb-DFCI-19///Array.Design.REF: A-MEXP-931///Scan.Name: RNA-hyb-DFCI-19///Derived.Array.Data.Matrix.File: normalized.txt.proc///Comment..Derived.ArrayExpress.FTP.file.: ftp://ftp.ebi.ac.uk/pub/databases/microarray/data/experiment/MTAB/E-MTAB-386/E-MTAB-386.processed.1.zip
1
Source.Name: DFCI-1///Characteristics.Age.: Age <has_measurement <Measurement <has_units <Unit <time unit <time unit=years>>>> <has_value <has_value=77.74>>>>///Characteristics.Channel.: Cy3///Characteristics.DiseaseStage.: IIIc///Characteristics.DiseaseState.: serous ovarian cancer///Term.Source.REF: SNOMED Clinical Terms///Characteristics.EventDeath.: 0///Characteristics.EventProgression.: 0///Characteristics.OptimalDebulking.: No///Characteristics.Organism.: Homo sapiens///Characteristics.Sex.: female///Term.Source.REF.1: EFO///Characteristics.SurvivalTime.: 28.03 months///Characteristics.TimeToProgression.: 8 months///Hybridization.Name: RNA-hyb-DFCI-1///Array.Design.REF: A-MEXP-931///Scan.Name: RNA-hyb-DFCI-1///Derived.Array.Data.Matrix.File: normalized.txt.proc///Comment..Derived.ArrayExpress.FTP.file.: ftp://ftp.ebi.ac.uk/pub/databases/microarray/data/experiment/MTAB/E-MTAB-386/E-MTAB-386.processed.1.zip
1
Source.Name: DFCI-20///Characteristics.Age.: Age <has_measurement <Measurement <has_units <Unit <time unit <time unit=years>>>> <has_value <has_value=66.14>>>>///Characteristics.Channel.: Cy3///Characteristics.DiseaseStage.: IIIb///Characteristics.DiseaseState.: serous ovarian cancer///Term.Source.REF: SNOMED Clinical Terms///Characteristics.EventDeath.: 0///Characteristics.EventProgression.: 0///Characteristics.OptimalDebulking.: Yes///Characteristics.Organism.: Homo sapiens///Characteristics.Sex.: female///Term.Source.REF.1: EFO///Characteristics.SurvivalTime.: 67.73 months///Characteristics.TimeToProgression.: 60.3 months///Hybridization.Name: RNA-hyb-DFCI-20///Array.Design.REF: A-MEXP-931///Scan.Name: RNA-hyb-DFCI-20///Derived.Array.Data.Matrix.File: normalized.txt.proc///Comment..Derived.ArrayExpress.FTP.file.: ftp://ftp.ebi.ac.uk/pub/databases/microarray/data/experiment/MTAB/E-MTAB-386/E-MTAB-386.processed.1.zip
1
Source.Name: DFCI-21///Characteristics.Age.: Age <has_measurement <Measurement <has_units <Unit <time unit <time unit=years>>>> <has_value <has_value=71>>>>///Characteristics.Channel.: Cy3///Characteristics.DiseaseStage.: IIIc///Characteristics.DiseaseState.: serous ovarian cancer///Term.Source.REF: SNOMED Clinical Terms///Characteristics.EventDeath.: 1///Characteristics.EventProgression.: 1///Characteristics.OptimalDebulking.: Yes///Characteristics.Organism.: Homo sapiens///Characteristics.Sex.: female///Term.Source.REF.1: EFO///Characteristics.SurvivalTime.: 15.93 months///Characteristics.TimeToProgression.: 4.6 months///Hybridization.Name: RNA-hyb-DFCI-21///Array.Design.REF: A-MEXP-931///Scan.Name: RNA-hyb-DFCI-21///Derived.Array.Data.Matrix.File: normalized.txt.proc///Comment..Derived.ArrayExpress.FTP.file.: ftp://ftp.ebi.ac.uk/pub/databases/microarray/data/experiment/MTAB/E-MTAB-386/E-MTAB-386.processed.1.zip
1
Source.Name: DFCI-22///Characteristics.Age.: Age <has_measurement <Measurement <has_units <Unit <time unit <time unit=years>>>> <has_value <has_value=78.13>>>>///Characteristics.Channel.: Cy3///Characteristics.DiseaseStage.: IIIb///Characteristics.DiseaseState.: serous ovarian cancer///Term.Source.REF: SNOMED Clinical Terms///Characteristics.EventDeath.: 0///Characteristics.EventProgression.: 0///Characteristics.OptimalDebulking.: Yes///Characteristics.Organism.: Homo sapiens///Characteristics.Sex.: female///Term.Source.REF.1: EFO///Characteristics.SurvivalTime.: 16.6 months///Characteristics.TimeToProgression.: 10.37 months///Hybridization.Name: RNA-hyb-DFCI-22 rep1 / RNA-hyb-DFCI-22 rep2///Array.Design.REF: A-MEXP-931///Scan.Name: RNA-hyb-DFCI-22 rep1 / RNA-hyb-DFCI-22 rep2///Derived.Array.Data.Matrix.File: normalized.txt.proc///Comment..Derived.ArrayExpress.FTP.file.: ftp://ftp.ebi.ac.uk/pub/databases/microarray/data/experiment/MTAB/E-MTAB-386/E-MTAB-386.processed.1.zip
1
Source.Name: DFCI-23///Characteristics.Age.: Age <has_measurement <Measurement <has_units <Unit <time unit <time unit=years>>>> <has_value <has_value=76.71>>>>///Characteristics.Channel.: Cy3///Characteristics.DiseaseStage.: IIIc///Characteristics.DiseaseState.: serous ovarian cancer///Term.Source.REF: SNOMED Clinical Terms///Characteristics.EventDeath.: 0///Characteristics.EventProgression.: 0///Characteristics.OptimalDebulking.: Yes///Characteristics.Organism.: Homo sapiens///Characteristics.Sex.: female///Term.Source.REF.1: EFO///Characteristics.SurvivalTime.: 36.37 months///Characteristics.TimeToProgression.: 32.17 months///Hybridization.Name: RNA-hyb-DFCI-23///Array.Design.REF: A-MEXP-931///Scan.Name: RNA-hyb-DFCI-23///Derived.Array.Data.Matrix.File: normalized.txt.proc///Comment..Derived.ArrayExpress.FTP.file.: ftp://ftp.ebi.ac.uk/pub/databases/microarray/data/experiment/MTAB/E-MTAB-386/E-MTAB-386.processed.1.zip
1
Source.Name: DFCI-24///Characteristics.Age.: Age <has_measurement <Measurement <has_units <Unit <time unit <time unit=years>>>> <has_value <has_value=68.72>>>>///Characteristics.Channel.: Cy3///Characteristics.DiseaseStage.: IIIc///Characteristics.DiseaseState.: serous ovarian cancer///Term.Source.REF: SNOMED Clinical Terms///Characteristics.EventDeath.: 0///Characteristics.EventProgression.: 0///Characteristics.OptimalDebulking.: Unknown///Characteristics.Organism.: Homo sapiens///Characteristics.Sex.: female///Term.Source.REF.1: EFO///Characteristics.SurvivalTime.: 35.4 months///Characteristics.TimeToProgression.: 8.57 months///Hybridization.Name: RNA-hyb-DFCI-24///Array.Design.REF: A-MEXP-931///Scan.Name: RNA-hyb-DFCI-24///Derived.Array.Data.Matrix.File: normalized.txt.proc///Comment..Derived.ArrayExpress.FTP.file.: ftp://ftp.ebi.ac.uk/pub/databases/microarray/data/experiment/MTAB/E-MTAB-386/E-MTAB-386.processed.1.zip
1
Source.Name: DFCI-25///Characteristics.Age.: Age <has_measurement <Measurement <has_units <Unit <time unit <time unit=years>>>> <has_value <has_value=78.03>>>>///Characteristics.Channel.: Cy3///Characteristics.DiseaseStage.: IIIc///Characteristics.DiseaseState.: serous ovarian cancer///Term.Source.REF: SNOMED Clinical Terms///Characteristics.EventDeath.: 1///Characteristics.EventProgression.: 1///Characteristics.OptimalDebulking.: Unknown///Characteristics.Organism.: Homo sapiens///Characteristics.Sex.: female///Term.Source.REF.1: EFO///Characteristics.SurvivalTime.: 24.03 months///Characteristics.TimeToProgression.: 0 months///Hybridization.Name: RNA-hyb-DFCI-25///Array.Design.REF: A-MEXP-931///Scan.Name: RNA-hyb-DFCI-25///Derived.Array.Data.Matrix.File: normalized.txt.proc///Comment..Derived.ArrayExpress.FTP.file.: ftp://ftp.ebi.ac.uk/pub/databases/microarray/data/experiment/MTAB/E-MTAB-386/E-MTAB-386.processed.1.zip
1
Source.Name: DFCI-26///Characteristics.Age.: Age <has_measurement <Measurement <has_units <Unit <time unit <time unit=years>>>> <has_value <has_value=72.88>>>>///Characteristics.Channel.: Cy3///Characteristics.DiseaseStage.: IIIc///Characteristics.DiseaseState.: serous ovarian cancer///Term.Source.REF: SNOMED Clinical Terms///Characteristics.EventDeath.: 0///Characteristics.EventProgression.: 0///Characteristics.OptimalDebulking.: No///Characteristics.Organism.: Homo sapiens///Characteristics.Sex.: female///Term.Source.REF.1: EFO///Characteristics.SurvivalTime.: 40.03 months///Characteristics.TimeToProgression.: 6.1 months///Hybridization.Name: RNA-hyb-DFCI-26///Array.Design.REF: A-MEXP-931///Scan.Name: RNA-hyb-DFCI-26///Derived.Array.Data.Matrix.File: normalized.txt.proc///Comment..Derived.ArrayExpress.FTP.file.: ftp://ftp.ebi.ac.uk/pub/databases/microarray/data/experiment/MTAB/E-MTAB-386/E-MTAB-386.processed.1.zip
1
Source.Name: DFCI-27///Characteristics.Age.: Age <has_measurement <Measurement <has_units <Unit <time unit <time unit=years>>>> <has_value <has_value=72.39>>>>///Characteristics.Channel.: Cy3///Characteristics.DiseaseStage.: IIIa///Characteristics.DiseaseState.: serous ovarian cancer///Term.Source.REF: SNOMED Clinical Terms///Characteristics.EventDeath.: 1///Characteristics.EventProgression.: 1///Characteristics.OptimalDebulking.: Yes///Characteristics.Organism.: Homo sapiens///Characteristics.Sex.: female///Term.Source.REF.1: EFO///Characteristics.SurvivalTime.: 32.57 months///Characteristics.TimeToProgression.: 7.53 months///Hybridization.Name: RNA-hyb-DFCI-27///Array.Design.REF: A-MEXP-931///Scan.Name: RNA-hyb-DFCI-27///Derived.Array.Data.Matrix.File: normalized.txt.proc///Comment..Derived.ArrayExpress.FTP.file.: ftp://ftp.ebi.ac.uk/pub/databases/microarray/data/experiment/MTAB/E-MTAB-386/E-MTAB-386.processed.1.zip
1
Source.Name: DFCI-28///Characteristics.Age.: Age <has_measurement <Measurement <has_units <Unit <time unit <time unit=years>>>> <has_value <has_value=76.02>>>>///Characteristics.Channel.: Cy3///Characteristics.DiseaseStage.: IV///Characteristics.DiseaseState.: serous ovarian cancer///Term.Source.REF: SNOMED Clinical Terms///Characteristics.EventDeath.: 1///Characteristics.EventProgression.: 1///Characteristics.OptimalDebulking.: No///Characteristics.Organism.: Homo sapiens///Characteristics.Sex.: female///Term.Source.REF.1: EFO///Characteristics.SurvivalTime.: 17.93 months///Characteristics.TimeToProgression.: null months///Hybridization.Name: RNA-hyb-DFCI-28///Array.Design.REF: A-MEXP-931///Scan.Name: RNA-hyb-DFCI-28///Derived.Array.Data.Matrix.File: normalized.txt.proc///Comment..Derived.ArrayExpress.FTP.file.: ftp://ftp.ebi.ac.uk/pub/databases/microarray/data/experiment/MTAB/E-MTAB-386/E-MTAB-386.processed.1.zip
1
Source.Name: DFCI-29///Characteristics.Age.: Age <has_measurement <Measurement <has_units <Unit <time unit <time unit=years>>>> <has_value <has_value=68.68>>>>///Characteristics.Channel.: Cy3///Characteristics.DiseaseStage.: IIIc///Characteristics.DiseaseState.: serous ovarian cancer///Term.Source.REF: SNOMED Clinical Terms///Characteristics.EventDeath.: 1///Characteristics.EventProgression.: 1///Characteristics.OptimalDebulking.: Yes///Characteristics.Organism.: Homo sapiens///Characteristics.Sex.: female///Term.Source.REF.1: EFO///Characteristics.SurvivalTime.: 21.27 months///Characteristics.TimeToProgression.: 3.43 months///Hybridization.Name: RNA-hyb-DFCI-29///Array.Design.REF: A-MEXP-931///Scan.Name: RNA-hyb-DFCI-29///Derived.Array.Data.Matrix.File: normalized.txt.proc///Comment..Derived.ArrayExpress.FTP.file.: ftp://ftp.ebi.ac.uk/pub/databases/microarray/data/experiment/MTAB/E-MTAB-386/E-MTAB-386.processed.1.zip
1
Source.Name: DFCI-2///Characteristics.Age.: Age <has_measurement <Measurement <has_units <Unit <time unit <time unit=years>>>> <has_value <has_value=75.53>>>>///Characteristics.Channel.: Cy3///Characteristics.DiseaseStage.: IIIc///Characteristics.DiseaseState.: serous ovarian cancer///Term.Source.REF: SNOMED Clinical Terms///Characteristics.EventDeath.: 0///Characteristics.EventProgression.: 0///Characteristics.OptimalDebulking.: Yes///Characteristics.Organism.: Homo sapiens///Characteristics.Sex.: female///Term.Source.REF.1: EFO///Characteristics.SurvivalTime.: 13.33 months///Characteristics.TimeToProgression.: 8.27 months///Hybridization.Name: RNA-hyb-DFCI-2///Array.Design.REF: A-MEXP-931///Scan.Name: RNA-hyb-DFCI-2///Derived.Array.Data.Matrix.File: normalized.txt.proc///Comment..Derived.ArrayExpress.FTP.file.: ftp://ftp.ebi.ac.uk/pub/databases/microarray/data/experiment/MTAB/E-MTAB-386/E-MTAB-386.processed.1.zip
1
Source.Name: DFCI-30///Characteristics.Age.: Age <has_measurement <Measurement <has_units <Unit <time unit <time unit=years>>>> <has_value <has_value=74.96>>>>///Characteristics.Channel.: Cy3///Characteristics.DiseaseStage.: IIIc///Characteristics.DiseaseState.: serous ovarian cancer///Term.Source.REF: SNOMED Clinical Terms///Characteristics.EventDeath.: 1///Characteristics.EventProgression.: 1///Characteristics.OptimalDebulking.: No///Characteristics.Organism.: Homo sapiens///Characteristics.Sex.: female///Term.Source.REF.1: EFO///Characteristics.SurvivalTime.: 19.57 months///Characteristics.TimeToProgression.: 7.2 months///Hybridization.Name: RNA-hyb-DFCI-30///Array.Design.REF: A-MEXP-931///Scan.Name: RNA-hyb-DFCI-30///Derived.Array.Data.Matrix.File: normalized.txt.proc///Comment..Derived.ArrayExpress.FTP.file.: ftp://ftp.ebi.ac.uk/pub/databases/microarray/data/experiment/MTAB/E-MTAB-386/E-MTAB-386.processed.1.zip
1
Source.Name: DFCI-31///Characteristics.Age.: Age <has_measurement <Measurement <has_units <Unit <time unit <time unit=years>>>> <has_value <has_value=66.42>>>>///Characteristics.Channel.: Cy3///Characteristics.DiseaseStage.: IIIc///Characteristics.DiseaseState.: serous ovarian cancer///Term.Source.REF: SNOMED Clinical Terms///Characteristics.EventDeath.: 1///Characteristics.EventProgression.: 1///Characteristics.OptimalDebulking.: Yes///Characteristics.Organism.: Homo sapiens///Characteristics.Sex.: female///Term.Source.REF.1: EFO///Characteristics.SurvivalTime.: 50.3 months///Characteristics.TimeToProgression.: 33.77 months///Hybridization.Name: RNA-hyb-DFCI-31///Array.Design.REF: A-MEXP-931///Scan.Name: RNA-hyb-DFCI-31///Derived.Array.Data.Matrix.File: normalized.txt.proc///Comment..Derived.ArrayExpress.FTP.file.: ftp://ftp.ebi.ac.uk/pub/databases/microarray/data/experiment/MTAB/E-MTAB-386/E-MTAB-386.processed.1.zip
1
Source.Name: DFCI-32///Characteristics.Age.: Age <has_measurement <Measurement <has_units <Unit <time unit <time unit=years>>>> <has_value <has_value=67.68>>>>///Characteristics.Channel.: Cy3///Characteristics.DiseaseStage.: IV///Characteristics.DiseaseState.: serous ovarian cancer///Term.Source.REF: SNOMED Clinical Terms///Characteristics.EventDeath.: 0///Characteristics.EventProgression.: 0///Characteristics.OptimalDebulking.: No///Characteristics.Organism.: Homo sapiens///Characteristics.Sex.: female///Term.Source.REF.1: EFO///Characteristics.SurvivalTime.: 53.97 months///Characteristics.TimeToProgression.: 16.87 months///Hybridization.Name: RNA-hyb-DFCI-32///Array.Design.REF: A-MEXP-931///Scan.Name: RNA-hyb-DFCI-32///Derived.Array.Data.Matrix.File: normalized.txt.proc///Comment..Derived.ArrayExpress.FTP.file.: ftp://ftp.ebi.ac.uk/pub/databases/microarray/data/experiment/MTAB/E-MTAB-386/E-MTAB-386.processed.1.zip
1
Source.Name: DFCI-33///Characteristics.Age.: Age <has_measurement <Measurement <has_units <Unit <time unit <time unit=years>>>> <has_value <has_value=74.2>>>>///Characteristics.Channel.: Cy3///Characteristics.DiseaseStage.: IIIb///Characteristics.DiseaseState.: serous ovarian cancer///Term.Source.REF: SNOMED Clinical Terms///Characteristics.EventDeath.: 1///Characteristics.EventProgression.: 1///Characteristics.OptimalDebulking.: Yes///Characteristics.Organism.: Homo sapiens///Characteristics.Sex.: female///Term.Source.REF.1: EFO///Characteristics.SurvivalTime.: 34.77 months///Characteristics.TimeToProgression.: null months///Hybridization.Name: RNA-hyb-DFCI-33///Array.Design.REF: A-MEXP-931///Scan.Name: RNA-hyb-DFCI-33///Derived.Array.Data.Matrix.File: normalized.txt.proc///Comment..Derived.ArrayExpress.FTP.file.: ftp://ftp.ebi.ac.uk/pub/databases/microarray/data/experiment/MTAB/E-MTAB-386/E-MTAB-386.processed.1.zip
1
Source.Name: DFCI-34///Characteristics.Age.: Age <has_measurement <Measurement <has_units <Unit <time unit <time unit=years>>>> <has_value <has_value=89.36>>>>///Characteristics.Channel.: Cy3///Characteristics.DiseaseStage.: IIIc///Characteristics.DiseaseState.: serous ovarian cancer///Term.Source.REF: SNOMED Clinical Terms///Characteristics.EventDeath.: 1///Characteristics.EventProgression.: 1///Characteristics.OptimalDebulking.: Yes///Characteristics.Organism.: Homo sapiens///Characteristics.Sex.: female///Term.Source.REF.1: EFO///Characteristics.SurvivalTime.: 6.63 months///Characteristics.TimeToProgression.: null months///Hybridization.Name: RNA-hyb-DFCI-34///Array.Design.REF: A-MEXP-931///Scan.Name: RNA-hyb-DFCI-34///Derived.Array.Data.Matrix.File: normalized.txt.proc///Comment..Derived.ArrayExpress.FTP.file.: ftp://ftp.ebi.ac.uk/pub/databases/microarray/data/experiment/MTAB/E-MTAB-386/E-MTAB-386.processed.1.zip
1
Source.Name: DFCI-35///Characteristics.Age.: Age <has_measurement <Measurement <has_units <Unit <time unit <time unit=years>>>> <has_value <has_value=71.92>>>>///Characteristics.Channel.: Cy3///Characteristics.DiseaseStage.: IIIc///Characteristics.DiseaseState.: serous ovarian cancer///Term.Source.REF: SNOMED Clinical Terms///Characteristics.EventDeath.: 1///Characteristics.EventProgression.: 1///Characteristics.OptimalDebulking.: Yes///Characteristics.Organism.: Homo sapiens///Characteristics.Sex.: female///Term.Source.REF.1: EFO///Characteristics.SurvivalTime.: 50.67 months///Characteristics.TimeToProgression.: 6.93 months///Hybridization.Name: RNA-hyb-DFCI-35///Array.Design.REF: A-MEXP-931///Scan.Name: RNA-hyb-DFCI-35///Derived.Array.Data.Matrix.File: normalized.txt.proc///Comment..Derived.ArrayExpress.FTP.file.: ftp://ftp.ebi.ac.uk/pub/databases/microarray/data/experiment/MTAB/E-MTAB-386/E-MTAB-386.processed.1.zip
1
Source.Name: DFCI-36///Characteristics.Age.: Age <has_measurement <Measurement <has_units <Unit <time unit <time unit=years>>>> <has_value <has_value=65.01>>>>///Characteristics.Channel.: Cy3///Characteristics.DiseaseStage.: IIIc///Characteristics.DiseaseState.: serous ovarian cancer///Term.Source.REF: SNOMED Clinical Terms///Characteristics.EventDeath.: 1///Characteristics.EventProgression.: 1///Characteristics.OptimalDebulking.: No///Characteristics.Organism.: Homo sapiens///Characteristics.Sex.: female///Term.Source.REF.1: EFO///Characteristics.SurvivalTime.: 23.23 months///Characteristics.TimeToProgression.: 6 months///Hybridization.Name: RNA-hyb-DFCI-36///Array.Design.REF: A-MEXP-931///Scan.Name: RNA-hyb-DFCI-36///Derived.Array.Data.Matrix.File: normalized.txt.proc///Comment..Derived.ArrayExpress.FTP.file.: ftp://ftp.ebi.ac.uk/pub/databases/microarray/data/experiment/MTAB/E-MTAB-386/E-MTAB-386.processed.1.zip
1
Source.Name: DFCI-37///Characteristics.Age.: Age <has_measurement <Measurement <has_units <Unit <time unit <time unit=years>>>> <has_value <has_value=68.53>>>>///Characteristics.Channel.: Cy3///Characteristics.DiseaseStage.: IIIc///Characteristics.DiseaseState.: serous ovarian cancer///Term.Source.REF: SNOMED Clinical Terms///Characteristics.EventDeath.: 1///Characteristics.EventProgression.: 1///Characteristics.OptimalDebulking.: Yes///Characteristics.Organism.: Homo sapiens///Characteristics.Sex.: female///Term.Source.REF.1: EFO///Characteristics.SurvivalTime.: 38.03 months///Characteristics.TimeToProgression.: 4.07 months///Hybridization.Name: RNA-hyb-DFCI-37///Array.Design.REF: A-MEXP-931///Scan.Name: RNA-hyb-DFCI-37///Derived.Array.Data.Matrix.File: normalized.txt.proc///Comment..Derived.ArrayExpress.FTP.file.: ftp://ftp.ebi.ac.uk/pub/databases/microarray/data/experiment/MTAB/E-MTAB-386/E-MTAB-386.processed.1.zip
1
Source.Name: DFCI-38///Characteristics.Age.: Age <has_measurement <Measurement <has_units <Unit <time unit <time unit=years>>>> <has_value <has_value=65.95>>>>///Characteristics.Channel.: Cy3///Characteristics.DiseaseStage.: IIIc///Characteristics.DiseaseState.: serous ovarian cancer///Term.Source.REF: SNOMED Clinical Terms///Characteristics.EventDeath.: 0///Characteristics.EventProgression.: 0///Characteristics.OptimalDebulking.: Yes///Characteristics.Organism.: Homo sapiens///Characteristics.Sex.: female///Term.Source.REF.1: EFO///Characteristics.SurvivalTime.: 62.07 months///Characteristics.TimeToProgression.: 58.33 months///Hybridization.Name: RNA-hyb-DFCI-38///Array.Design.REF: A-MEXP-931///Scan.Name: RNA-hyb-DFCI-38///Derived.Array.Data.Matrix.File: normalized.txt.proc///Comment..Derived.ArrayExpress.FTP.file.: ftp://ftp.ebi.ac.uk/pub/databases/microarray/data/experiment/MTAB/E-MTAB-386/E-MTAB-386.processed.1.zip
1
Source.Name: DFCI-39///Characteristics.Age.: Age <has_measurement <Measurement <has_units <Unit <time unit <time unit=years>>>> <has_value <has_value=69.32>>>>///Characteristics.Channel.: Cy3///Characteristics.DiseaseStage.: IIIb///Characteristics.DiseaseState.: serous ovarian cancer///Term.Source.REF: SNOMED Clinical Terms///Characteristics.EventDeath.: 0///Characteristics.EventProgression.: 0///Characteristics.OptimalDebulking.: Unknown///Characteristics.Organism.: Homo sapiens///Characteristics.Sex.: female///Term.Source.REF.1: EFO///Characteristics.SurvivalTime.: 58.37 months///Characteristics.TimeToProgression.: 0 months///Hybridization.Name: RNA-hyb-DFCI-39///Array.Design.REF: A-MEXP-931///Scan.Name: RNA-hyb-DFCI-39///Derived.Array.Data.Matrix.File: normalized.txt.proc///Comment..Derived.ArrayExpress.FTP.file.: ftp://ftp.ebi.ac.uk/pub/databases/microarray/data/experiment/MTAB/E-MTAB-386/E-MTAB-386.processed.1.zip
1
Source.Name: DFCI-3///Characteristics.Age.: Age <has_measurement <Measurement <has_units <Unit <time unit <time unit=years>>>> <has_value <has_value=66.92>>>>///Characteristics.Channel.: Cy3///Characteristics.DiseaseStage.: IIIc///Characteristics.DiseaseState.: serous ovarian cancer///Term.Source.REF: SNOMED Clinical Terms///Characteristics.EventDeath.: 0///Characteristics.EventProgression.: 0///Characteristics.OptimalDebulking.: Yes///Characteristics.Organism.: Homo sapiens///Characteristics.Sex.: female///Term.Source.REF.1: EFO///Characteristics.SurvivalTime.: 17.47 months///Characteristics.TimeToProgression.: 7.5 months///Hybridization.Name: RNA-hyb-DFCI-3///Array.Design.REF: A-MEXP-931///Scan.Name: RNA-hyb-DFCI-3///Derived.Array.Data.Matrix.File: normalized.txt.proc///Comment..Derived.ArrayExpress.FTP.file.: ftp://ftp.ebi.ac.uk/pub/databases/microarray/data/experiment/MTAB/E-MTAB-386/E-MTAB-386.processed.1.zip
1
Source.Name: DFCI-40///Characteristics.Age.: Age <has_measurement <Measurement <has_units <Unit <time unit <time unit=years>>>> <has_value <has_value=74.03>>>>///Characteristics.Channel.: Cy3///Characteristics.DiseaseStage.: IIIb///Characteristics.DiseaseState.: serous ovarian cancer///Term.Source.REF: SNOMED Clinical Terms///Characteristics.EventDeath.: 0///Characteristics.EventProgression.: 0///Characteristics.OptimalDebulking.: Yes///Characteristics.Organism.: Homo sapiens///Characteristics.Sex.: female///Term.Source.REF.1: EFO///Characteristics.SurvivalTime.: 61.5 months///Characteristics.TimeToProgression.: 56.73 months///Hybridization.Name: RNA-hyb-DFCI-40///Array.Design.REF: A-MEXP-931///Scan.Name: RNA-hyb-DFCI-40///Derived.Array.Data.Matrix.File: normalized.txt.proc///Comment..Derived.ArrayExpress.FTP.file.: ftp://ftp.ebi.ac.uk/pub/databases/microarray/data/experiment/MTAB/E-MTAB-386/E-MTAB-386.processed.1.zip
1
Source.Name: DFCI-41///Characteristics.Age.: Age <has_measurement <Measurement <has_units <Unit <time unit <time unit=years>>>> <has_value <has_value=67.96>>>>///Characteristics.Channel.: Cy3///Characteristics.DiseaseStage.: IIIc///Characteristics.DiseaseState.: serous ovarian cancer///Term.Source.REF: SNOMED Clinical Terms///Characteristics.EventDeath.: 1///Characteristics.EventProgression.: 1///Characteristics.OptimalDebulking.: Yes///Characteristics.Organism.: Homo sapiens///Characteristics.Sex.: female///Term.Source.REF.1: EFO///Characteristics.SurvivalTime.: 39.9 months///Characteristics.TimeToProgression.: null months///Hybridization.Name: RNA-hyb-DFCI-41///Array.Design.REF: A-MEXP-931///Scan.Name: RNA-hyb-DFCI-41///Derived.Array.Data.Matrix.File: normalized.txt.proc///Comment..Derived.ArrayExpress.FTP.file.: ftp://ftp.ebi.ac.uk/pub/databases/microarray/data/experiment/MTAB/E-MTAB-386/E-MTAB-386.processed.1.zip
1
Source.Name: DFCI-42///Characteristics.Age.: Age <has_measurement <Measurement <has_units <Unit <time unit <time unit=years>>>> <has_value <has_value=72.09>>>>///Characteristics.Channel.: Cy3///Characteristics.DiseaseStage.: IIIb///Characteristics.DiseaseState.: serous ovarian cancer///Term.Source.REF: SNOMED Clinical Terms///Characteristics.EventDeath.: 1///Characteristics.EventProgression.: 1///Characteristics.OptimalDebulking.: Yes///Characteristics.Organism.: Homo sapiens///Characteristics.Sex.: female///Term.Source.REF.1: EFO///Characteristics.SurvivalTime.: 46.7 months///Characteristics.TimeToProgression.: null months///Hybridization.Name: RNA-hyb-DFCI-42///Array.Design.REF: A-MEXP-931///Scan.Name: RNA-hyb-DFCI-42///Derived.Array.Data.Matrix.File: normalized.txt.proc///Comment..Derived.ArrayExpress.FTP.file.: ftp://ftp.ebi.ac.uk/pub/databases/microarray/data/experiment/MTAB/E-MTAB-386/E-MTAB-386.processed.1.zip
1
Source.Name: DFCI-44///Characteristics.Age.: Age <has_measurement <Measurement <has_units <Unit <time unit <time unit=years>>>> <has_value <has_value=75.66>>>>///Characteristics.Channel.: Cy3///Characteristics.DiseaseStage.: IIIc///Characteristics.DiseaseState.: serous ovarian cancer///Term.Source.REF: SNOMED Clinical Terms///Characteristics.EventDeath.: 1///Characteristics.EventProgression.: 1///Characteristics.OptimalDebulking.: Yes///Characteristics.Organism.: Homo sapiens///Characteristics.Sex.: female///Term.Source.REF.1: EFO///Characteristics.SurvivalTime.: 13.3 months///Characteristics.TimeToProgression.: null months///Hybridization.Name: RNA-hyb-DFCI-44///Array.Design.REF: A-MEXP-931///Scan.Name: RNA-hyb-DFCI-44///Derived.Array.Data.Matrix.File: normalized.txt.proc///Comment..Derived.ArrayExpress.FTP.file.: ftp://ftp.ebi.ac.uk/pub/databases/microarray/data/experiment/MTAB/E-MTAB-386/E-MTAB-386.processed.1.zip
1
Source.Name: DFCI-45///Characteristics.Age.: Age <has_measurement <Measurement <has_units <Unit <time unit <time unit=years>>>> <has_value <has_value=75.15>>>>///Characteristics.Channel.: Cy3///Characteristics.DiseaseStage.: IIIc///Characteristics.DiseaseState.: serous ovarian cancer///Term.Source.REF: SNOMED Clinical Terms///Characteristics.EventDeath.: 1///Characteristics.EventProgression.: 1///Characteristics.OptimalDebulking.: No///Characteristics.Organism.: Homo sapiens///Characteristics.Sex.: female///Term.Source.REF.1: EFO///Characteristics.SurvivalTime.: 33.07 months///Characteristics.TimeToProgression.: 0 months///Hybridization.Name: RNA-hyb-DFCI-45///Array.Design.REF: A-MEXP-931///Scan.Name: RNA-hyb-DFCI-45///Derived.Array.Data.Matrix.File: normalized.txt.proc///Comment..Derived.ArrayExpress.FTP.file.: ftp://ftp.ebi.ac.uk/pub/databases/microarray/data/experiment/MTAB/E-MTAB-386/E-MTAB-386.processed.1.zip
1
Source.Name: DFCI-46///Characteristics.Age.: Age <has_measurement <Measurement <has_units <Unit <time unit <time unit=years>>>> <has_value <has_value=71.48>>>>///Characteristics.Channel.: Cy3///Characteristics.DiseaseStage.: IIIb///Characteristics.DiseaseState.: serous ovarian cancer///Term.Source.REF: SNOMED Clinical Terms///Characteristics.EventDeath.: 0///Characteristics.EventProgression.: 0///Characteristics.OptimalDebulking.: Yes///Characteristics.Organism.: Homo sapiens///Characteristics.Sex.: female///Term.Source.REF.1: EFO///Characteristics.SurvivalTime.: 30.93 months///Characteristics.TimeToProgression.: 12.6 months///Hybridization.Name: RNA-hyb-DFCI-46///Array.Design.REF: A-MEXP-931///Scan.Name: RNA-hyb-DFCI-46///Derived.Array.Data.Matrix.File: normalized.txt.proc///Comment..Derived.ArrayExpress.FTP.file.: ftp://ftp.ebi.ac.uk/pub/databases/microarray/data/experiment/MTAB/E-MTAB-386/E-MTAB-386.processed.1.zip
1
Source.Name: DFCI-47///Characteristics.Age.: Age <has_measurement <Measurement <has_units <Unit <time unit <time unit=years>>>> <has_value <has_value=21.95>>>>///Characteristics.Channel.: Cy3///Characteristics.DiseaseStage.: IIIc///Characteristics.DiseaseState.: serous ovarian cancer///Term.Source.REF: SNOMED Clinical Terms///Characteristics.EventDeath.: 1///Characteristics.EventProgression.: 1///Characteristics.OptimalDebulking.: Yes///Characteristics.Organism.: Homo sapiens///Characteristics.Sex.: female///Term.Source.REF.1: EFO///Characteristics.SurvivalTime.: 50.3 months///Characteristics.TimeToProgression.: 4.17 months///Hybridization.Name: RNA-hyb-DFCI-47///Array.Design.REF: A-MEXP-931///Scan.Name: RNA-hyb-DFCI-47///Derived.Array.Data.Matrix.File: normalized.txt.proc///Comment..Derived.ArrayExpress.FTP.file.: ftp://ftp.ebi.ac.uk/pub/databases/microarray/data/experiment/MTAB/E-MTAB-386/E-MTAB-386.processed.1.zip
1
Source.Name: DFCI-48///Characteristics.Age.: Age <has_measurement <Measurement <has_units <Unit <time unit <time unit=years>>>> <has_value <has_value=51.5>>>>///Characteristics.Channel.: Cy3///Characteristics.DiseaseStage.: IIIc///Characteristics.DiseaseState.: serous ovarian cancer///Term.Source.REF: SNOMED Clinical Terms///Characteristics.EventDeath.: 0///Characteristics.EventProgression.: 0///Characteristics.OptimalDebulking.: Yes///Characteristics.Organism.: Homo sapiens///Characteristics.Sex.: female///Term.Source.REF.1: EFO///Characteristics.SurvivalTime.: 63.8 months///Characteristics.TimeToProgression.: 60 months///Hybridization.Name: RNA-hyb-DFCI-48///Array.Design.REF: A-MEXP-931///Scan.Name: RNA-hyb-DFCI-48///Derived.Array.Data.Matrix.File: normalized.txt.proc///Comment..Derived.ArrayExpress.FTP.file.: ftp://ftp.ebi.ac.uk/pub/databases/microarray/data/experiment/MTAB/E-MTAB-386/E-MTAB-386.processed.1.zip
1
Source.Name: DFCI-49///Characteristics.Age.: Age <has_measurement <Measurement <has_units <Unit <time unit <time unit=years>>>> <has_value <has_value=46.2>>>>///Characteristics.Channel.: Cy3///Characteristics.DiseaseStage.: IIIc///Characteristics.DiseaseState.: serous ovarian cancer///Term.Source.REF: SNOMED Clinical Terms///Characteristics.EventDeath.: 1///Characteristics.EventProgression.: 1///Characteristics.OptimalDebulking.: No///Characteristics.Organism.: Homo sapiens///Characteristics.Sex.: female///Term.Source.REF.1: EFO///Characteristics.SurvivalTime.: 19.73 months///Characteristics.TimeToProgression.: 2.73 months///Hybridization.Name: RNA-hyb-DFCI-49///Array.Design.REF: A-MEXP-931///Scan.Name: RNA-hyb-DFCI-49///Derived.Array.Data.Matrix.File: normalized.txt.proc///Comment..Derived.ArrayExpress.FTP.file.: ftp://ftp.ebi.ac.uk/pub/databases/microarray/data/experiment/MTAB/E-MTAB-386/E-MTAB-386.processed.1.zip
1
Source.Name: DFCI-4///Characteristics.Age.: Age <has_measurement <Measurement <has_units <Unit <time unit <time unit=years>>>> <has_value <has_value=79.29>>>>///Characteristics.Channel.: Cy3///Characteristics.DiseaseStage.: IIIc///Characteristics.DiseaseState.: serous ovarian cancer///Term.Source.REF: SNOMED Clinical Terms///Characteristics.EventDeath.: 1///Characteristics.EventProgression.: 1///Characteristics.OptimalDebulking.: Yes///Characteristics.Organism.: Homo sapiens///Characteristics.Sex.: female///Term.Source.REF.1: EFO///Characteristics.SurvivalTime.: 49.2 months///Characteristics.TimeToProgression.: 11.1 months///Hybridization.Name: RNA-hyb-DFCI-4///Array.Design.REF: A-MEXP-931///Scan.Name: RNA-hyb-DFCI-4///Derived.Array.Data.Matrix.File: normalized.txt.proc///Comment..Derived.ArrayExpress.FTP.file.: ftp://ftp.ebi.ac.uk/pub/databases/microarray/data/experiment/MTAB/E-MTAB-386/E-MTAB-386.processed.1.zip
1
Source.Name: DFCI-50///Characteristics.Age.: Age <has_measurement <Measurement <has_units <Unit <time unit <time unit=years>>>> <has_value <has_value=49.15>>>>///Characteristics.Channel.: Cy3///Characteristics.DiseaseStage.: IIIc///Characteristics.DiseaseState.: serous ovarian cancer///Term.Source.REF: SNOMED Clinical Terms///Characteristics.EventDeath.: 1///Characteristics.EventProgression.: 1///Characteristics.OptimalDebulking.: Yes///Characteristics.Organism.: Homo sapiens///Characteristics.Sex.: female///Term.Source.REF.1: EFO///Characteristics.SurvivalTime.: 14.2 months///Characteristics.TimeToProgression.: 5.53 months///Hybridization.Name: RNA-hyb-DFCI-50///Array.Design.REF: A-MEXP-931///Scan.Name: RNA-hyb-DFCI-50///Derived.Array.Data.Matrix.File: normalized.txt.proc///Comment..Derived.ArrayExpress.FTP.file.: ftp://ftp.ebi.ac.uk/pub/databases/microarray/data/experiment/MTAB/E-MTAB-386/E-MTAB-386.processed.1.zip
1
Source.Name: DFCI-51///Characteristics.Age.: Age <has_measurement <Measurement <has_units <Unit <time unit <time unit=years>>>> <has_value <has_value=50.55>>>>///Characteristics.Channel.: Cy3///Characteristics.DiseaseStage.: IIIb///Characteristics.DiseaseState.: serous ovarian cancer///Term.Source.REF: SNOMED Clinical Terms///Characteristics.EventDeath.: 0///Characteristics.EventProgression.: 0///Characteristics.OptimalDebulking.: Yes///Characteristics.Organism.: Homo sapiens///Characteristics.Sex.: female///Term.Source.REF.1: EFO///Characteristics.SurvivalTime.: 45.83 months///Characteristics.TimeToProgression.: 10.87 months///Hybridization.Name: RNA-hyb-DFCI-51///Array.Design.REF: A-MEXP-931///Scan.Name: RNA-hyb-DFCI-51///Derived.Array.Data.Matrix.File: normalized.txt.proc///Comment..Derived.ArrayExpress.FTP.file.: ftp://ftp.ebi.ac.uk/pub/databases/microarray/data/experiment/MTAB/E-MTAB-386/E-MTAB-386.processed.1.zip
1
Source.Name: DFCI-52///Characteristics.Age.: Age <has_measurement <Measurement <has_units <Unit <time unit <time unit=years>>>> <has_value <has_value=50.97>>>>///Characteristics.Channel.: Cy3///Characteristics.DiseaseStage.: IIIc///Characteristics.DiseaseState.: serous ovarian cancer///Term.Source.REF: SNOMED Clinical Terms///Characteristics.EventDeath.: 1///Characteristics.EventProgression.: 1///Characteristics.OptimalDebulking.: Yes///Characteristics.Organism.: Homo sapiens///Characteristics.Sex.: female///Term.Source.REF.1: EFO///Characteristics.SurvivalTime.: 18.23 months///Characteristics.TimeToProgression.: 2.53 months///Hybridization.Name: RNA-hyb-DFCI-52///Array.Design.REF: A-MEXP-931///Scan.Name: RNA-hyb-DFCI-52///Derived.Array.Data.Matrix.File: normalized.txt.proc///Comment..Derived.ArrayExpress.FTP.file.: ftp://ftp.ebi.ac.uk/pub/databases/microarray/data/experiment/MTAB/E-MTAB-386/E-MTAB-386.processed.1.zip
1
Source.Name: DFCI-53///Characteristics.Age.: Age <has_measurement <Measurement <has_units <Unit <time unit <time unit=years>>>> <has_value <has_value=52.41>>>>///Characteristics.Channel.: Cy3///Characteristics.DiseaseStage.: IIIb///Characteristics.DiseaseState.: serous ovarian cancer///Term.Source.REF: SNOMED Clinical Terms///Characteristics.EventDeath.: 0///Characteristics.EventProgression.: 0///Characteristics.OptimalDebulking.: Yes///Characteristics.Organism.: Homo sapiens///Characteristics.Sex.: female///Term.Source.REF.1: EFO///Characteristics.SurvivalTime.: 26.97 months///Characteristics.TimeToProgression.: 22.53 months///Hybridization.Name: RNA-hyb-DFCI-53///Array.Design.REF: A-MEXP-931///Scan.Name: RNA-hyb-DFCI-53///Derived.Array.Data.Matrix.File: normalized.txt.proc///Comment..Derived.ArrayExpress.FTP.file.: ftp://ftp.ebi.ac.uk/pub/databases/microarray/data/experiment/MTAB/E-MTAB-386/E-MTAB-386.processed.1.zip
1
Source.Name: DFCI-54///Characteristics.Age.: Age <has_measurement <Measurement <has_units <Unit <time unit <time unit=years>>>> <has_value <has_value=50.96>>>>///Characteristics.Channel.: Cy3///Characteristics.DiseaseStage.: IIIc///Characteristics.DiseaseState.: serous ovarian cancer///Term.Source.REF: SNOMED Clinical Terms///Characteristics.EventDeath.: 0///Characteristics.EventProgression.: 0///Characteristics.OptimalDebulking.: Yes///Characteristics.Organism.: Homo sapiens///Characteristics.Sex.: female///Term.Source.REF.1: EFO///Characteristics.SurvivalTime.: 16.03 months///Characteristics.TimeToProgression.: 11.03 months///Hybridization.Name: RNA-hyb-DFCI-54///Array.Design.REF: A-MEXP-931///Scan.Name: RNA-hyb-DFCI-54///Derived.Array.Data.Matrix.File: normalized.txt.proc///Comment..Derived.ArrayExpress.FTP.file.: ftp://ftp.ebi.ac.uk/pub/databases/microarray/data/experiment/MTAB/E-MTAB-386/E-MTAB-386.processed.1.zip
1
Source.Name: DFCI-55///Characteristics.Age.: Age <has_measurement <Measurement <has_units <Unit <time unit <time unit=years>>>> <has_value <has_value=52.79>>>>///Characteristics.Channel.: Cy3///Characteristics.DiseaseStage.: IIIb///Characteristics.DiseaseState.: serous ovarian cancer///Term.Source.REF: SNOMED Clinical Terms///Characteristics.EventDeath.: 0///Characteristics.EventProgression.: 0///Characteristics.OptimalDebulking.: Yes///Characteristics.Organism.: Homo sapiens///Characteristics.Sex.: female///Term.Source.REF.1: EFO///Characteristics.SurvivalTime.: 16.2 months///Characteristics.TimeToProgression.: 3.87 months///Hybridization.Name: RNA-hyb-DFCI-55///Array.Design.REF: A-MEXP-931///Scan.Name: RNA-hyb-DFCI-55///Derived.Array.Data.Matrix.File: normalized.txt.proc///Comment..Derived.ArrayExpress.FTP.file.: ftp://ftp.ebi.ac.uk/pub/databases/microarray/data/experiment/MTAB/E-MTAB-386/E-MTAB-386.processed.1.zip
1
Source.Name: DFCI-56///Characteristics.Age.: Age <has_measurement <Measurement <has_units <Unit <time unit <time unit=years>>>> <has_value <has_value=47.06>>>>///Characteristics.Channel.: Cy3///Characteristics.DiseaseStage.: IIIc///Characteristics.DiseaseState.: serous ovarian cancer///Term.Source.REF: SNOMED Clinical Terms///Characteristics.EventDeath.: 0///Characteristics.EventProgression.: 0///Characteristics.OptimalDebulking.: Yes///Characteristics.Organism.: Homo sapiens///Characteristics.Sex.: female///Term.Source.REF.1: EFO///Characteristics.SurvivalTime.: 21.43 months///Characteristics.TimeToProgression.: 10.77 months///Hybridization.Name: RNA-hyb-DFCI-56///Array.Design.REF: A-MEXP-931///Scan.Name: RNA-hyb-DFCI-56///Derived.Array.Data.Matrix.File: normalized.txt.proc///Comment..Derived.ArrayExpress.FTP.file.: ftp://ftp.ebi.ac.uk/pub/databases/microarray/data/experiment/MTAB/E-MTAB-386/E-MTAB-386.processed.1.zip
1
Source.Name: DFCI-57///Characteristics.Age.: Age <has_measurement <Measurement <has_units <Unit <time unit <time unit=years>>>> <has_value <has_value=53.22>>>>///Characteristics.Channel.: Cy3///Characteristics.DiseaseStage.: IIIc///Characteristics.DiseaseState.: serous ovarian cancer///Term.Source.REF: SNOMED Clinical Terms///Characteristics.EventDeath.: 0///Characteristics.EventProgression.: 0///Characteristics.OptimalDebulking.: Yes///Characteristics.Organism.: Homo sapiens///Characteristics.Sex.: female///Term.Source.REF.1: EFO///Characteristics.SurvivalTime.: 18.03 months///Characteristics.TimeToProgression.: null months///Hybridization.Name: RNA-hyb-DFCI-57///Array.Design.REF: A-MEXP-931///Scan.Name: RNA-hyb-DFCI-57///Derived.Array.Data.Matrix.File: normalized.txt.proc///Comment..Derived.ArrayExpress.FTP.file.: ftp://ftp.ebi.ac.uk/pub/databases/microarray/data/experiment/MTAB/E-MTAB-386/E-MTAB-386.processed.1.zip
1
Source.Name: DFCI-58///Characteristics.Age.: Age <has_measurement <Measurement <has_units <Unit <time unit <time unit=years>>>> <has_value <has_value=52.88>>>>///Characteristics.Channel.: Cy3///Characteristics.DiseaseStage.: IIIc///Characteristics.DiseaseState.: serous ovarian cancer///Term.Source.REF: SNOMED Clinical Terms///Characteristics.EventDeath.: 1///Characteristics.EventProgression.: 1///Characteristics.OptimalDebulking.: Yes///Characteristics.Organism.: Homo sapiens///Characteristics.Sex.: female///Term.Source.REF.1: EFO///Characteristics.SurvivalTime.: 32.07 months///Characteristics.TimeToProgression.: 2.5 months///Hybridization.Name: RNA-hyb-DFCI-58///Array.Design.REF: A-MEXP-931///Scan.Name: RNA-hyb-DFCI-58///Derived.Array.Data.Matrix.File: normalized.txt.proc///Comment..Derived.ArrayExpress.FTP.file.: ftp://ftp.ebi.ac.uk/pub/databases/microarray/data/experiment/MTAB/E-MTAB-386/E-MTAB-386.processed.1.zip
1
Source.Name: DFCI-59///Characteristics.Age.: Age <has_measurement <Measurement <has_units <Unit <time unit <time unit=years>>>> <has_value <has_value=42.55>>>>///Characteristics.Channel.: Cy3///Characteristics.DiseaseStage.: IIIc///Characteristics.DiseaseState.: serous ovarian cancer///Term.Source.REF: SNOMED Clinical Terms///Characteristics.EventDeath.: 1///Characteristics.EventProgression.: 1///Characteristics.OptimalDebulking.: Yes///Characteristics.Organism.: Homo sapiens///Characteristics.Sex.: female///Term.Source.REF.1: EFO///Characteristics.SurvivalTime.: 67.5 months///Characteristics.TimeToProgression.: 8.3 months///Hybridization.Name: RNA-hyb-DFCI-59///Array.Design.REF: A-MEXP-931///Scan.Name: RNA-hyb-DFCI-59///Derived.Array.Data.Matrix.File: normalized.txt.proc///Comment..Derived.ArrayExpress.FTP.file.: ftp://ftp.ebi.ac.uk/pub/databases/microarray/data/experiment/MTAB/E-MTAB-386/E-MTAB-386.processed.1.zip
1
Source.Name: DFCI-60///Characteristics.Age.: Age <has_measurement <Measurement <has_units <Unit <time unit <time unit=years>>>> <has_value <has_value=51.73>>>>///Characteristics.Channel.: Cy3///Characteristics.DiseaseStage.: IV///Characteristics.DiseaseState.: serous ovarian cancer///Term.Source.REF: SNOMED Clinical Terms///Characteristics.EventDeath.: 1///Characteristics.EventProgression.: 1///Characteristics.OptimalDebulking.: Yes///Characteristics.Organism.: Homo sapiens///Characteristics.Sex.: female///Term.Source.REF.1: EFO///Characteristics.SurvivalTime.: 15.77 months///Characteristics.TimeToProgression.: 0.97 months///Hybridization.Name: RNA-hyb-DFCI-60///Array.Design.REF: A-MEXP-931///Scan.Name: RNA-hyb-DFCI-60///Derived.Array.Data.Matrix.File: normalized.txt.proc///Comment..Derived.ArrayExpress.FTP.file.: ftp://ftp.ebi.ac.uk/pub/databases/microarray/data/experiment/MTAB/E-MTAB-386/E-MTAB-386.processed.1.zip
1
Source.Name: DFCI-61///Characteristics.Age.: Age <has_measurement <Measurement <has_units <Unit <time unit <time unit=years>>>> <has_value <has_value=45.9>>>>///Characteristics.Channel.: Cy3///Characteristics.DiseaseStage.: IIIa///Characteristics.DiseaseState.: serous ovarian cancer///Term.Source.REF: SNOMED Clinical Terms///Characteristics.EventDeath.: 1///Characteristics.EventProgression.: 1///Characteristics.OptimalDebulking.: Yes///Characteristics.Organism.: Homo sapiens///Characteristics.Sex.: female///Term.Source.REF.1: EFO///Characteristics.SurvivalTime.: 38 months///Characteristics.TimeToProgression.: 13.33 months///Hybridization.Name: RNA-hyb-DFCI-61///Array.Design.REF: A-MEXP-931///Scan.Name: RNA-hyb-DFCI-61///Derived.Array.Data.Matrix.File: normalized.txt.proc///Comment..Derived.ArrayExpress.FTP.file.: ftp://ftp.ebi.ac.uk/pub/databases/microarray/data/experiment/MTAB/E-MTAB-386/E-MTAB-386.processed.1.zip
1
Source.Name: DFCI-62///Characteristics.Age.: Age <has_measurement <Measurement <has_units <Unit <time unit <time unit=years>>>> <has_value <has_value=51.13>>>>///Characteristics.Channel.: Cy3///Characteristics.DiseaseStage.: IIIc///Characteristics.DiseaseState.: serous ovarian cancer///Term.Source.REF: SNOMED Clinical Terms///Characteristics.EventDeath.: 0///Characteristics.EventProgression.: 0///Characteristics.OptimalDebulking.: Yes///Characteristics.Organism.: Homo sapiens///Characteristics.Sex.: female///Term.Source.REF.1: EFO///Characteristics.SurvivalTime.: 0.13 months///Characteristics.TimeToProgression.: null months///Hybridization.Name: RNA-hyb-DFCI-62 rep1 / RNA-hyb-DFCI-62 rep2///Array.Design.REF: A-MEXP-931///Scan.Name: RNA-hyb-DFCI-62 rep1 / RNA-hyb-DFCI-62 rep2///Derived.Array.Data.Matrix.File: normalized.txt.proc///Comment..Derived.ArrayExpress.FTP.file.: ftp://ftp.ebi.ac.uk/pub/databases/microarray/data/experiment/MTAB/E-MTAB-386/E-MTAB-386.processed.1.zip
1
Source.Name: DFCI-63///Characteristics.Age.: Age <has_measurement <Measurement <has_units <Unit <time unit <time unit=years>>>> <has_value <has_value=54.07>>>>///Characteristics.Channel.: Cy3///Characteristics.DiseaseStage.: IIIc///Characteristics.DiseaseState.: serous ovarian cancer///Term.Source.REF: SNOMED Clinical Terms///Characteristics.EventDeath.: 1///Characteristics.EventProgression.: 1///Characteristics.OptimalDebulking.: Yes///Characteristics.Organism.: Homo sapiens///Characteristics.Sex.: female///Term.Source.REF.1: EFO///Characteristics.SurvivalTime.: 17.07 months///Characteristics.TimeToProgression.: 0 months///Hybridization.Name: RNA-hyb-DFCI-63///Array.Design.REF: A-MEXP-931///Scan.Name: RNA-hyb-DFCI-63///Derived.Array.Data.Matrix.File: normalized.txt.proc///Comment..Derived.ArrayExpress.FTP.file.: ftp://ftp.ebi.ac.uk/pub/databases/microarray/data/experiment/MTAB/E-MTAB-386/E-MTAB-386.processed.1.zip
1
Source.Name: DFCI-64///Characteristics.Age.: Age <has_measurement <Measurement <has_units <Unit <time unit <time unit=years>>>> <has_value <has_value=45.35>>>>///Characteristics.Channel.: Cy3///Characteristics.DiseaseStage.: IV///Characteristics.DiseaseState.: serous ovarian cancer///Term.Source.REF: SNOMED Clinical Terms///Characteristics.EventDeath.: 0///Characteristics.EventProgression.: 0///Characteristics.OptimalDebulking.: Yes///Characteristics.Organism.: Homo sapiens///Characteristics.Sex.: female///Term.Source.REF.1: EFO///Characteristics.SurvivalTime.: 33.43 months///Characteristics.TimeToProgression.: 3.53 months///Hybridization.Name: RNA-hyb-DFCI-64///Array.Design.REF: A-MEXP-931///Scan.Name: RNA-hyb-DFCI-64///Derived.Array.Data.Matrix.File: normalized.txt.proc///Comment..Derived.ArrayExpress.FTP.file.: ftp://ftp.ebi.ac.uk/pub/databases/microarray/data/experiment/MTAB/E-MTAB-386/E-MTAB-386.processed.1.zip
1
Source.Name: DFCI-65///Characteristics.Age.: Age <has_measurement <Measurement <has_units <Unit <time unit <time unit=years>>>> <has_value <has_value=48.09>>>>///Characteristics.Channel.: Cy3///Characteristics.DiseaseStage.: IIIa///Characteristics.DiseaseState.: serous ovarian cancer///Term.Source.REF: SNOMED Clinical Terms///Characteristics.EventDeath.: 0///Characteristics.EventProgression.: 0///Characteristics.OptimalDebulking.: Yes///Characteristics.Organism.: Homo sapiens///Characteristics.Sex.: female///Term.Source.REF.1: EFO///Characteristics.SurvivalTime.: 57.73 months///Characteristics.TimeToProgression.: 18.87 months///Hybridization.Name: RNA-hyb-DFCI-65///Array.Design.REF: A-MEXP-931///Scan.Name: RNA-hyb-DFCI-65///Derived.Array.Data.Matrix.File: normalized.txt.proc///Comment..Derived.ArrayExpress.FTP.file.: ftp://ftp.ebi.ac.uk/pub/databases/microarray/data/experiment/MTAB/E-MTAB-386/E-MTAB-386.processed.1.zip
1
Source.Name: DFCI-66///Characteristics.Age.: Age <has_measurement <Measurement <has_units <Unit <time unit <time unit=years>>>> <has_value <has_value=49.65>>>>///Characteristics.Channel.: Cy3///Characteristics.DiseaseStage.: IIIc///Characteristics.DiseaseState.: serous ovarian cancer///Term.Source.REF: SNOMED Clinical Terms///Characteristics.EventDeath.: 1///Characteristics.EventProgression.: 1///Characteristics.OptimalDebulking.: Yes///Characteristics.Organism.: Homo sapiens///Characteristics.Sex.: female///Term.Source.REF.1: EFO///Characteristics.SurvivalTime.: 23 months///Characteristics.TimeToProgression.: 9.63 months///Hybridization.Name: RNA-hyb-DFCI-66///Array.Design.REF: A-MEXP-931///Scan.Name: RNA-hyb-DFCI-66///Derived.Array.Data.Matrix.File: normalized.txt.proc///Comment..Derived.ArrayExpress.FTP.file.: ftp://ftp.ebi.ac.uk/pub/databases/microarray/data/experiment/MTAB/E-MTAB-386/E-MTAB-386.processed.1.zip
1
Source.Name: DFCI-67///Characteristics.Age.: Age <has_measurement <Measurement <has_units <Unit <time unit <time unit=years>>>> <has_value <has_value=38.15>>>>///Characteristics.Channel.: Cy3///Characteristics.DiseaseStage.: IIIc///Characteristics.DiseaseState.: serous ovarian cancer///Term.Source.REF: SNOMED Clinical Terms///Characteristics.EventDeath.: 1///Characteristics.EventProgression.: 1///Characteristics.OptimalDebulking.: No///Characteristics.Organism.: Homo sapiens///Characteristics.Sex.: female///Term.Source.REF.1: EFO///Characteristics.SurvivalTime.: 31 months///Characteristics.TimeToProgression.: 1.13 months///Hybridization.Name: RNA-hyb-DFCI-67///Array.Design.REF: A-MEXP-931///Scan.Name: RNA-hyb-DFCI-67///Derived.Array.Data.Matrix.File: normalized.txt.proc///Comment..Derived.ArrayExpress.FTP.file.: ftp://ftp.ebi.ac.uk/pub/databases/microarray/data/experiment/MTAB/E-MTAB-386/E-MTAB-386.processed.1.zip
1
Source.Name: DFCI-68///Characteristics.Age.: Age <has_measurement <Measurement <has_units <Unit <time unit <time unit=years>>>> <has_value <has_value=51.23>>>>///Characteristics.Channel.: Cy3///Characteristics.DiseaseStage.: IIIc///Characteristics.DiseaseState.: serous ovarian cancer///Term.Source.REF: SNOMED Clinical Terms///Characteristics.EventDeath.: 1///Characteristics.EventProgression.: 1///Characteristics.OptimalDebulking.: Yes///Characteristics.Organism.: Homo sapiens///Characteristics.Sex.: female///Term.Source.REF.1: EFO///Characteristics.SurvivalTime.: 34.23 months///Characteristics.TimeToProgression.: 5.73 months///Hybridization.Name: RNA-hyb-DFCI-68///Array.Design.REF: A-MEXP-931///Scan.Name: RNA-hyb-DFCI-68///Derived.Array.Data.Matrix.File: normalized.txt.proc///Comment..Derived.ArrayExpress.FTP.file.: ftp://ftp.ebi.ac.uk/pub/databases/microarray/data/experiment/MTAB/E-MTAB-386/E-MTAB-386.processed.1.zip
1
Source.Name: DFCI-69///Characteristics.Age.: Age <has_measurement <Measurement <has_units <Unit <time unit <time unit=years>>>> <has_value <has_value=43.62>>>>///Characteristics.Channel.: Cy3///Characteristics.DiseaseStage.: IIIc///Characteristics.DiseaseState.: serous ovarian cancer///Term.Source.REF: SNOMED Clinical Terms///Characteristics.EventDeath.: 0///Characteristics.EventProgression.: 0///Characteristics.OptimalDebulking.: Yes///Characteristics.Organism.: Homo sapiens///Characteristics.Sex.: female///Term.Source.REF.1: EFO///Characteristics.SurvivalTime.: 39.77 months///Characteristics.TimeToProgression.: null months///Hybridization.Name: RNA-hyb-DFCI-69///Array.Design.REF: A-MEXP-931///Scan.Name: RNA-hyb-DFCI-69///Derived.Array.Data.Matrix.File: normalized.txt.proc///Comment..Derived.ArrayExpress.FTP.file.: ftp://ftp.ebi.ac.uk/pub/databases/microarray/data/experiment/MTAB/E-MTAB-386/E-MTAB-386.processed.1.zip
1
Source.Name: DFCI-6///Characteristics.Age.: Age <has_measurement <Measurement <has_units <Unit <time unit <time unit=years>>>> <has_value <has_value=67.63>>>>///Characteristics.Channel.: Cy3///Characteristics.DiseaseStage.: IIIc///Characteristics.DiseaseState.: serous ovarian cancer///Term.Source.REF: SNOMED Clinical Terms///Characteristics.EventDeath.: 1///Characteristics.EventProgression.: 1///Characteristics.OptimalDebulking.: No///Characteristics.Organism.: Homo sapiens///Characteristics.Sex.: female///Term.Source.REF.1: EFO///Characteristics.SurvivalTime.: 4.8 months///Characteristics.TimeToProgression.: null months///Hybridization.Name: RNA-hyb-DFCI-6///Array.Design.REF: A-MEXP-931///Scan.Name: RNA-hyb-DFCI-6///Derived.Array.Data.Matrix.File: normalized.txt.proc///Comment..Derived.ArrayExpress.FTP.file.: ftp://ftp.ebi.ac.uk/pub/databases/microarray/data/experiment/MTAB/E-MTAB-386/E-MTAB-386.processed.1.zip
1
Source.Name: DFCI-70///Characteristics.Age.: Age <has_measurement <Measurement <has_units <Unit <time unit <time unit=years>>>> <has_value <has_value=53.29>>>>///Characteristics.Channel.: Cy3///Characteristics.DiseaseStage.: IIIc///Characteristics.DiseaseState.: serous ovarian cancer///Term.Source.REF: SNOMED Clinical Terms///Characteristics.EventDeath.: 1///Characteristics.EventProgression.: 1///Characteristics.OptimalDebulking.: No///Characteristics.Organism.: Homo sapiens///Characteristics.Sex.: female///Term.Source.REF.1: EFO///Characteristics.SurvivalTime.: 24.03 months///Characteristics.TimeToProgression.: 9.17 months///Hybridization.Name: RNA-hyb-DFCI-70///Array.Design.REF: A-MEXP-931///Scan.Name: RNA-hyb-DFCI-70///Derived.Array.Data.Matrix.File: normalized.txt.proc///Comment..Derived.ArrayExpress.FTP.file.: ftp://ftp.ebi.ac.uk/pub/databases/microarray/data/experiment/MTAB/E-MTAB-386/E-MTAB-386.processed.1.zip
1
Source.Name: DFCI-71///Characteristics.Age.: Age <has_measurement <Measurement <has_units <Unit <time unit <time unit=years>>>> <has_value <has_value=45.5>>>>///Characteristics.Channel.: Cy3///Characteristics.DiseaseStage.: IIIc///Characteristics.DiseaseState.: serous ovarian cancer///Term.Source.REF: SNOMED Clinical Terms///Characteristics.EventDeath.: 1///Characteristics.EventProgression.: 1///Characteristics.OptimalDebulking.: Yes///Characteristics.Organism.: Homo sapiens///Characteristics.Sex.: female///Term.Source.REF.1: EFO///Characteristics.SurvivalTime.: 12.3 months///Characteristics.TimeToProgression.: 2.03 months///Hybridization.Name: RNA-hyb-DFCI-71///Array.Design.REF: A-MEXP-931///Scan.Name: RNA-hyb-DFCI-71///Derived.Array.Data.Matrix.File: normalized.txt.proc///Comment..Derived.ArrayExpress.FTP.file.: ftp://ftp.ebi.ac.uk/pub/databases/microarray/data/experiment/MTAB/E-MTAB-386/E-MTAB-386.processed.1.zip
1
(Other)
30
An expression set
It is difficult to predict the clinical outcome for patients with ovarian cancer. However, the use of biomarkers as additional prognostic factors may improve the outcome for these patients. In order to find novel candidate biomarkers, differences in gene expressions were analysed in 54 stage III serous ovarian adenocarcinomas with oligonucleotide microarrays containing 27,000 unique probes. The microarray data was verified with quantitative real-time polymerase chain reaction for the genes TACC1, MUC5B and PRAME. Using hierarchical cluster analysis we detected a sub-group that included 60% of the survivors. The gene expressions in tumours from patients in this sub-group of survivors were compared with the remaining tumours, and 204 genes were found to be differently expressed. We conclude that the sub-group of survivors might represent patients with favourable tumour biology and sensitivity to treatment. A selection of the 204 genes might be used as a predictive model to distinguish patients within and outside of this group. Alternative chemotherapy strategies could then be offered as first-line treatment, which may lead to improvements in the clinical outcome for these patients.
experimentData(eset):
Experiment data
Experimenter name: Partheen K, Levan K, Osterberg L, Horvath G.Expression analysis of stage III serous ovarian adenocarcinoma distinguishes a sub-group of survivors. Eur J Cancer. 2006 Nov; 42(16):2846-54.
Laboratory: Partheen, Horvath 2006
Contact information:
Title: Expression analysis of stage III serous ovarian adenocarcinoma distinguishes a sub-group of survivors.
URL:
PMIDs: 16996261
Abstract: A 177 word abstract is available. Use 'abstract' method.
Information is available on: preprocessing
notes:
platform_title:
SWEGENE H_v2.1.1_27k
platform_shorttitle:
SWEGENE H_v2.1.1_27k
platform_summary:
PartheenMetaData
platform_manufacturer:
other
platform_distribution:
non-commercial
platform_accession:
GPL5886
version:
2015-09-22 19:07:14
featureData(eset):
An object of class 'AnnotatedDataFrame'
featureNames: 28 29 ... 29999 (11304 total)
varLabels: probeset gene EntrezGene.ID best_probe
varMetadata: labelDescription
assayData: 11304 features, 54 samples
Platform type:
---------------------------
Available sample meta-data:
---------------------------
alt_sample_name:
1035LA0 1047LB 1059LB0 1177DB 1178LB0 1180DB 1186DB0 123DC 1242LC0 1274LC
1 1 1 1 1 1 1 1 1 1
134LC 1426LB 1487DB 1528DC 1538DC 1567DB 1568DC 1574LC0 164DC 1658DC
1 1 1 1 1 1 1 1 1 1
1760LB 1805DB 193DC 198DC 202DC 211DC 26DC 272DC 405LB 436DC
1 1 1 1 1 1 1 1 1 1
452DC 454LC 45LA0 462DB 46LB0 47DC 480DC0 489DC 505DB 541DC
1 1 1 1 1 1 1 1 1 1
559DC 563LA 626DC 662DC 719DC 742LC0 755LC 759DC 76DC 789DC
1 1 1 1 1 1 1 1 1 1
83LC 918DB0 988LC0 99LC0
1 1 1 1
sample_type:
tumor
54
histological_type:
ser
54
primarysite:
ov
54
summarystage:
late
54
tumorstage:
3
54
substage:
b c
19 35
age_at_initial_pathologic_diagnosis:
Min. 1st Qu. Median Mean 3rd Qu. Max.
35.00 51.25 59.50 59.56 69.75 84.00
pltx:
y
54
os_binary:
long short
20 34
debulking:
optimal suboptimal
13 41
uncurated_author_metadata:
title: 1035LA0///geo_accession: GSM311973///status: Public on Aug 12 2008///submission_date: Aug 12 2008///last_update_date: Aug 13 2008///type: RNA///channel_count: 2///source_name_ch1: serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: fresh frozen tumour///characteristics_ch1.1: 5 year survivor///characteristics_ch1.2: stage IIIab///characteristics_ch1.3: no macroscopic residual tumor///characteristics_ch1.4: age at diagnosis 36///characteristics_ch1.5: post surgical chemo therapy farmorubicine, carboplatin and cyclophosphamide///molecule_ch1: total RNA///extract_protocol_ch1: Homogenization with Trizol followed by total RNA extraction with Rneasy mini kit following manufacturer's instructions (Qiagen).///label_ch1: Cy3///label_protocol_ch1: Probes labelled with Cy3 were synthesized from 5 g of the total tumour RNA and reference labelled with Cy5 were synthesized from 5 g of commercial reference RNA by reverse transcription.///taxid_ch1: 9606///source_name_ch2: Universal Human Reference RNA purchased from Stratagene///organism_ch2: Homo sapiens///characteristics_ch2: Reference///molecule_ch2: total RNA///extract_protocol_ch2: Homogenization with Trizol followed by total RNA extraction with Rneasy mini kit following manufacturer's instructions (Qiagen).///label_ch2: Cy5///label_protocol_ch2: Probes labelled with Cy3 were synthesized from 5 g of the total tumour RNA and reference labelled with Cy5 were synthesized from 5 g of commercial reference RNA by reverse transcription.///taxid_ch2: 9606///hyb_protocol: The probes were purified using ChipShot labelling cleanup system (Promega). The hybridizations were carried out using Pronto! Micro Array reagent systems (Corning Inc.). For each sample, labelled tumour cDNA and reference cDNA were co-precipitated and hybridised to the oligoarray slide. After hybridization, slides were washed sequential.///scan_protocol: Scanned on an Agilent G2565AA scanner.///scan_protocol.1: Images were quantified using Genepix 6.0.0.74 (Axon Instruments).///description: Comparison of ovarian tumors of 5 year survivors to deceased patients///data_processing: Intensities were calculated by mean spot - median background. Flagged spots were removed as well as spots with intensities below 20 in both channels. Intensities below 20 in one channel were set to 20 to compensate for extreme quotients. Loess normalization was used///platform_id: GPL5886///contact_name: Karolina,,Partheen///contact_email: [email protected]///contact_phone: +46+31 342 78 55///contact_fax: +46 +31 41 72 05///contact_department: department of Oncology///contact_institute: University of Gothenburg///contact_address: Bl Strket 2///contact_city: Gothenburg///contact_zip.postal_code: 413 45///contact_country: Sweden///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM311nnn/GSM311973/GSM311973.gpr.gz///data_row_count: 30000
1
title: 1047LB///geo_accession: GSM311974///status: Public on Aug 12 2008///submission_date: Aug 12 2008///last_update_date: Aug 13 2008///type: RNA///channel_count: 2///source_name_ch1: serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: fresh frozen tumour///characteristics_ch1.1: 5 year survivor///characteristics_ch1.2: stage IIIab///characteristics_ch1.3: macroscopic residual tumor///characteristics_ch1.4: age at diagnosis 44///characteristics_ch1.5: post surgical chemo therapy farmorubicine, carboplatin and cyclophosphamide///molecule_ch1: total RNA///extract_protocol_ch1: Homogenization with Trizol followed by total RNA extraction with Rneasy mini kit following manufacturer's instructions (Qiagen).///label_ch1: Cy3///label_protocol_ch1: Probes labelled with Cy3 were synthesized from 5 g of the total tumour RNA and reference labelled with Cy5 were synthesized from 5 g of commercial reference RNA by reverse transcription.///taxid_ch1: 9606///source_name_ch2: Universal Human Reference RNA purchased from Stratagene///organism_ch2: Homo sapiens///characteristics_ch2: Reference///molecule_ch2: total RNA///extract_protocol_ch2: Homogenization with Trizol followed by total RNA extraction with Rneasy mini kit following manufacturer's instructions (Qiagen).///label_ch2: Cy5///label_protocol_ch2: Probes labelled with Cy3 were synthesized from 5 g of the total tumour RNA and reference labelled with Cy5 were synthesized from 5 g of commercial reference RNA by reverse transcription.///taxid_ch2: 9606///hyb_protocol: The probes were purified using ChipShot labelling cleanup system (Promega). The hybridizations were carried out using Pronto! Micro Array reagent systems (Corning Inc.). For each sample, labelled tumour cDNA and reference cDNA were co-precipitated and hybridised to the oligoarray slide. After hybridization, slides were washed sequential.///scan_protocol: Scanned on an Agilent G2565AA scanner.///scan_protocol.1: Images were quantified using Genepix 6.0.0.74 (Axon Instruments).///description: Comparison of ovarian tumors of 5 year survivors to deceased patients///data_processing: Intensities were calculated by mean spot - median background. Flagged spots were removed as well as spots with intensities below 20 in both channels. Intensities below 20 in one channel were set to 20 to compensate for extreme quotients. Loess normalization was used///platform_id: GPL5886///contact_name: Karolina,,Partheen///contact_email: [email protected]///contact_phone: +46+31 342 78 55///contact_fax: +46 +31 41 72 05///contact_department: department of Oncology///contact_institute: University of Gothenburg///contact_address: Bl Strket 2///contact_city: Gothenburg///contact_zip.postal_code: 413 45///contact_country: Sweden///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM311nnn/GSM311974/GSM311974.gpr.gz///data_row_count: 30000
1
title: 1059LB0///geo_accession: GSM311975///status: Public on Aug 12 2008///submission_date: Aug 12 2008///last_update_date: Aug 13 2008///type: RNA///channel_count: 2///source_name_ch1: serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: fresh frozen tumour///characteristics_ch1.1: 5 year survivor///characteristics_ch1.2: stage IIIab///characteristics_ch1.3: no macroscopic residual tumor///characteristics_ch1.4: age at diagnosis 84///characteristics_ch1.5: post surgical chemo therapy farmorubicine, carboplatin and cyclophosphamide///molecule_ch1: total RNA///extract_protocol_ch1: Homogenization with Trizol followed by total RNA extraction with Rneasy mini kit following manufacturer's instructions (Qiagen).///label_ch1: Cy3///label_protocol_ch1: Probes labelled with Cy3 were synthesized from 5 g of the total tumour RNA and reference labelled with Cy5 were synthesized from 5 g of commercial reference RNA by reverse transcription.///taxid_ch1: 9606///source_name_ch2: Universal Human Reference RNA purchased from Stratagene///organism_ch2: Homo sapiens///characteristics_ch2: Reference///molecule_ch2: total RNA///extract_protocol_ch2: Homogenization with Trizol followed by total RNA extraction with Rneasy mini kit following manufacturer's instructions (Qiagen).///label_ch2: Cy5///label_protocol_ch2: Probes labelled with Cy3 were synthesized from 5 g of the total tumour RNA and reference labelled with Cy5 were synthesized from 5 g of commercial reference RNA by reverse transcription.///taxid_ch2: 9606///hyb_protocol: The probes were purified using ChipShot labelling cleanup system (Promega). The hybridizations were carried out using Pronto! Micro Array reagent systems (Corning Inc.). For each sample, labelled tumour cDNA and reference cDNA were co-precipitated and hybridised to the oligoarray slide. After hybridization, slides were washed sequential.///scan_protocol: Scanned on an Agilent G2565AA scanner.///scan_protocol.1: Images were quantified using Genepix 6.0.0.74 (Axon Instruments).///description: Comparison of ovarian tumors of 5 year survivors to deceased patients///data_processing: Intensities were calculated by mean spot - median background. Flagged spots were removed as well as spots with intensities below 20 in both channels. Intensities below 20 in one channel were set to 20 to compensate for extreme quotients. Loess normalization was used///platform_id: GPL5886///contact_name: Karolina,,Partheen///contact_email: [email protected]///contact_phone: +46+31 342 78 55///contact_fax: +46 +31 41 72 05///contact_department: department of Oncology///contact_institute: University of Gothenburg///contact_address: Bl Strket 2///contact_city: Gothenburg///contact_zip.postal_code: 413 45///contact_country: Sweden///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM311nnn/GSM311975/GSM311975.gpr.gz///data_row_count: 30000
1
title: 1177DB///geo_accession: GSM311976///status: Public on Aug 12 2008///submission_date: Aug 12 2008///last_update_date: Aug 13 2008///type: RNA///channel_count: 2///source_name_ch1: serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: fresh frozen tumour///characteristics_ch1.1: deceased///characteristics_ch1.2: stage IIIab///characteristics_ch1.3: macroscopic residual tumor///characteristics_ch1.4: age at diagnosis 55///characteristics_ch1.5: post surgical chemo therapy farmorubicine, carboplatin and cyclophosphamide///molecule_ch1: total RNA///extract_protocol_ch1: Homogenization with Trizol followed by total RNA extraction with Rneasy mini kit following manufacturer's instructions (Qiagen).///label_ch1: Cy3///label_protocol_ch1: Probes labelled with Cy3 were synthesized from 5 g of the total tumour RNA and reference labelled with Cy5 were synthesized from 5 g of commercial reference RNA by reverse transcription.///taxid_ch1: 9606///source_name_ch2: Universal Human Reference RNA purchased from Stratagene///organism_ch2: Homo sapiens///characteristics_ch2: Reference///molecule_ch2: total RNA///extract_protocol_ch2: Homogenization with Trizol followed by total RNA extraction with Rneasy mini kit following manufacturer's instructions (Qiagen).///label_ch2: Cy5///label_protocol_ch2: Probes labelled with Cy3 were synthesized from 5 g of the total tumour RNA and reference labelled with Cy5 were synthesized from 5 g of commercial reference RNA by reverse transcription.///taxid_ch2: 9606///hyb_protocol: The probes were purified using ChipShot labelling cleanup system (Promega). The hybridizations were carried out using Pronto! Micro Array reagent systems (Corning Inc.). For each sample, labelled tumour cDNA and reference cDNA were co-precipitated and hybridised to the oligoarray slide. After hybridization, slides were washed sequential.///scan_protocol: Scanned on an Agilent G2565AA scanner.///scan_protocol.1: Images were quantified using Genepix 6.0.0.74 (Axon Instruments).///description: Comparison of ovarian tumors of 5 year survivors to deceased patients///data_processing: Intensities were calculated by mean spot - median background. Flagged spots were removed as well as spots with intensities below 20 in both channels. Intensities below 20 in one channel were set to 20 to compensate for extreme quotients. Loess normalization was used///platform_id: GPL5886///contact_name: Karolina,,Partheen///contact_email: [email protected]///contact_phone: +46+31 342 78 55///contact_fax: +46 +31 41 72 05///contact_department: department of Oncology///contact_institute: University of Gothenburg///contact_address: Bl Strket 2///contact_city: Gothenburg///contact_zip.postal_code: 413 45///contact_country: Sweden///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM311nnn/GSM311976/GSM311976.gpr.gz///data_row_count: 30000
1
title: 1178LB0///geo_accession: GSM311977///status: Public on Aug 12 2008///submission_date: Aug 12 2008///last_update_date: Aug 13 2008///type: RNA///channel_count: 2///source_name_ch1: serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: fresh frozen tumour///characteristics_ch1.1: 5 year survivor///characteristics_ch1.2: stage IIIab///characteristics_ch1.3: no macroscopic residual tumor///characteristics_ch1.4: age at diagnosis 60///characteristics_ch1.5: post surgical chemo therapy farmorubicine, carboplatin and cyclophosphamide///molecule_ch1: total RNA///extract_protocol_ch1: Homogenization with Trizol followed by total RNA extraction with Rneasy mini kit following manufacturer's instructions (Qiagen).///label_ch1: Cy3///label_protocol_ch1: Probes labelled with Cy3 were synthesized from 5 g of the total tumour RNA and reference labelled with Cy5 were synthesized from 5 g of commercial reference RNA by reverse transcription.///taxid_ch1: 9606///source_name_ch2: Universal Human Reference RNA purchased from Stratagene///organism_ch2: Homo sapiens///characteristics_ch2: Reference///molecule_ch2: total RNA///extract_protocol_ch2: Homogenization with Trizol followed by total RNA extraction with Rneasy mini kit following manufacturer's instructions (Qiagen).///label_ch2: Cy5///label_protocol_ch2: Probes labelled with Cy3 were synthesized from 5 g of the total tumour RNA and reference labelled with Cy5 were synthesized from 5 g of commercial reference RNA by reverse transcription.///taxid_ch2: 9606///hyb_protocol: The probes were purified using ChipShot labelling cleanup system (Promega). The hybridizations were carried out using Pronto! Micro Array reagent systems (Corning Inc.). For each sample, labelled tumour cDNA and reference cDNA were co-precipitated and hybridised to the oligoarray slide. After hybridization, slides were washed sequential.///scan_protocol: Scanned on an Agilent G2565AA scanner.///scan_protocol.1: Images were quantified using Genepix 6.0.0.74 (Axon Instruments).///description: Comparison of ovarian tumors of 5 year survivors to deceased patients///data_processing: Intensities were calculated by mean spot - median background. Flagged spots were removed as well as spots with intensities below 20 in both channels. Intensities below 20 in one channel were set to 20 to compensate for extreme quotients. Loess normalization was used///platform_id: GPL5886///contact_name: Karolina,,Partheen///contact_email: [email protected]///contact_phone: +46+31 342 78 55///contact_fax: +46 +31 41 72 05///contact_department: department of Oncology///contact_institute: University of Gothenburg///contact_address: Bl Strket 2///contact_city: Gothenburg///contact_zip.postal_code: 413 45///contact_country: Sweden///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM311nnn/GSM311977/GSM311977.gpr.gz///data_row_count: 30000
1
title: 1180DB///geo_accession: GSM311978///status: Public on Aug 12 2008///submission_date: Aug 12 2008///last_update_date: Aug 13 2008///type: RNA///channel_count: 2///source_name_ch1: serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: fresh frozen tumour///characteristics_ch1.1: deceased///characteristics_ch1.2: stage IIIab///characteristics_ch1.3: macroscopic residual tumor///characteristics_ch1.4: age at diagnosis 43///characteristics_ch1.5: post surgical chemo therapy farmorubicine, carboplatin and cyclophosphamide///molecule_ch1: total RNA///extract_protocol_ch1: Homogenization with Trizol followed by total RNA extraction with Rneasy mini kit following manufacturer's instructions (Qiagen).///label_ch1: Cy3///label_protocol_ch1: Probes labelled with Cy3 were synthesized from 5 g of the total tumour RNA and reference labelled with Cy5 were synthesized from 5 g of commercial reference RNA by reverse transcription.///taxid_ch1: 9606///source_name_ch2: Universal Human Reference RNA purchased from Stratagene///organism_ch2: Homo sapiens///characteristics_ch2: Reference///molecule_ch2: total RNA///extract_protocol_ch2: Homogenization with Trizol followed by total RNA extraction with Rneasy mini kit following manufacturer's instructions (Qiagen).///label_ch2: Cy5///label_protocol_ch2: Probes labelled with Cy3 were synthesized from 5 g of the total tumour RNA and reference labelled with Cy5 were synthesized from 5 g of commercial reference RNA by reverse transcription.///taxid_ch2: 9606///hyb_protocol: The probes were purified using ChipShot labelling cleanup system (Promega). The hybridizations were carried out using Pronto! Micro Array reagent systems (Corning Inc.). For each sample, labelled tumour cDNA and reference cDNA were co-precipitated and hybridised to the oligoarray slide. After hybridization, slides were washed sequential.///scan_protocol: Scanned on an Agilent G2565AA scanner.///scan_protocol.1: Images were quantified using Genepix 6.0.0.74 (Axon Instruments).///description: Comparison of ovarian tumors of 5 year survivors to deceased patients///data_processing: Intensities were calculated by mean spot - median background. Flagged spots were removed as well as spots with intensities below 20 in both channels. Intensities below 20 in one channel were set to 20 to compensate for extreme quotients. Loess normalization was used///platform_id: GPL5886///contact_name: Karolina,,Partheen///contact_email: [email protected]///contact_phone: +46+31 342 78 55///contact_fax: +46 +31 41 72 05///contact_department: department of Oncology///contact_institute: University of Gothenburg///contact_address: Bl Strket 2///contact_city: Gothenburg///contact_zip.postal_code: 413 45///contact_country: Sweden///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM311nnn/GSM311978/GSM311978.gpr.gz///data_row_count: 30000
1
title: 1186DB0///geo_accession: GSM311979///status: Public on Aug 12 2008///submission_date: Aug 12 2008///last_update_date: Aug 13 2008///type: RNA///channel_count: 2///source_name_ch1: serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: fresh frozen tumour///characteristics_ch1.1: deceased///characteristics_ch1.2: stage IIIab///characteristics_ch1.3: no macroscopic residual tumor///characteristics_ch1.4: age at diagnosis 65///characteristics_ch1.5: post surgical chemo therapy farmorubicine, carboplatin and cyclophosphamide///molecule_ch1: total RNA///extract_protocol_ch1: Homogenization with Trizol followed by total RNA extraction with Rneasy mini kit following manufacturer's instructions (Qiagen).///label_ch1: Cy3///label_protocol_ch1: Probes labelled with Cy3 were synthesized from 5 g of the total tumour RNA and reference labelled with Cy5 were synthesized from 5 g of commercial reference RNA by reverse transcription.///taxid_ch1: 9606///source_name_ch2: Universal Human Reference RNA purchased from Stratagene///organism_ch2: Homo sapiens///characteristics_ch2: Reference///molecule_ch2: total RNA///extract_protocol_ch2: Homogenization with Trizol followed by total RNA extraction with Rneasy mini kit following manufacturer's instructions (Qiagen).///label_ch2: Cy5///label_protocol_ch2: Probes labelled with Cy3 were synthesized from 5 g of the total tumour RNA and reference labelled with Cy5 were synthesized from 5 g of commercial reference RNA by reverse transcription.///taxid_ch2: 9606///hyb_protocol: The probes were purified using ChipShot labelling cleanup system (Promega). The hybridizations were carried out using Pronto! Micro Array reagent systems (Corning Inc.). For each sample, labelled tumour cDNA and reference cDNA were co-precipitated and hybridised to the oligoarray slide. After hybridization, slides were washed sequential.///scan_protocol: Scanned on an Agilent G2565AA scanner.///scan_protocol.1: Images were quantified using Genepix 6.0.0.74 (Axon Instruments).///description: Comparison of ovarian tumors of 5 year survivors to deceased patients///data_processing: Intensities were calculated by mean spot - median background. Flagged spots were removed as well as spots with intensities below 20 in both channels. Intensities below 20 in one channel were set to 20 to compensate for extreme quotients. Loess normalization was used///platform_id: GPL5886///contact_name: Karolina,,Partheen///contact_email: [email protected]///contact_phone: +46+31 342 78 55///contact_fax: +46 +31 41 72 05///contact_department: department of Oncology///contact_institute: University of Gothenburg///contact_address: Bl Strket 2///contact_city: Gothenburg///contact_zip.postal_code: 413 45///contact_country: Sweden///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM311nnn/GSM311979/GSM311979.gpr.gz///data_row_count: 30000
1
title: 123DC///geo_accession: GSM311945///status: Public on Aug 12 2008///submission_date: Aug 12 2008///last_update_date: Aug 13 2008///type: RNA///channel_count: 2///source_name_ch1: serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: fresh frozen tumour///characteristics_ch1.1: deceased///characteristics_ch1.2: stage IIIc///characteristics_ch1.3: macroscopic residual tumor///characteristics_ch1.4: age at diagnosis 56///characteristics_ch1.5: post surgical chemo therapy farmorubicine, carboplatin and cyclophosphamide///molecule_ch1: total RNA///extract_protocol_ch1: Homogenization with Trizol followed by total RNA extraction with Rneasy mini kit following manufacturer's instructions (Qiagen).///label_ch1: Cy3///label_protocol_ch1: Probes labelled with Cy3 were synthesized from 5 g of the total tumour RNA and reference labelled with Cy5 were synthesized from 5 g of commercial reference RNA by reverse transcription.///taxid_ch1: 9606///source_name_ch2: Universal Human Reference RNA purchased from Stratagene///organism_ch2: Homo sapiens///characteristics_ch2: Reference///molecule_ch2: total RNA///extract_protocol_ch2: Homogenization with Trizol followed by total RNA extraction with Rneasy mini kit following manufacturer's instructions (Qiagen).///label_ch2: Cy5///label_protocol_ch2: Probes labelled with Cy3 were synthesized from 5 g of the total tumour RNA and reference labelled with Cy5 were synthesized from 5 g of commercial reference RNA by reverse transcription.///taxid_ch2: 9606///hyb_protocol: The probes were purified using ChipShot labelling cleanup system (Promega). The hybridizations were carried out using Pronto! Micro Array reagent systems (Corning Inc.). For each sample, labelled tumour cDNA and reference cDNA were co-precipitated and hybridised to the oligoarray slide. After hybridization, slides were washed sequential.///scan_protocol: Scanned on an Agilent G2565AA scanner.///scan_protocol.1: Images were quantified using Genepix 6.0.0.74 (Axon Instruments).///description: Comparison of ovarian tumors of 5 year survivors to deceased patients///data_processing: Intensities were calculated by mean spot - median background. Flagged spots were removed as well as spots with intensities below 20 in both channels. Intensities below 20 in one channel were set to 20 to compensate for extreme quotients. Loess normalization was used///platform_id: GPL5886///contact_name: Karolina,,Partheen///contact_email: [email protected]///contact_phone: +46+31 342 78 55///contact_fax: +46 +31 41 72 05///contact_department: department of Oncology///contact_institute: University of Gothenburg///contact_address: Bl Strket 2///contact_city: Gothenburg///contact_zip.postal_code: 413 45///contact_country: Sweden///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM311nnn/GSM311945/GSM311945.gpr.gz///data_row_count: 30000
1
title: 1242LC0///geo_accession: GSM311980///status: Public on Aug 12 2008///submission_date: Aug 12 2008///last_update_date: Aug 13 2008///type: RNA///channel_count: 2///source_name_ch1: serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: fresh frozen tumour///characteristics_ch1.1: 5 year survivor///characteristics_ch1.2: stage IIIc///characteristics_ch1.3: no macroscopic residual tumor///characteristics_ch1.4: age at diagnosis 70///characteristics_ch1.5: post surgical chemo therapy farmorubicine, carboplatin and cyclophosphamide///molecule_ch1: total RNA///extract_protocol_ch1: Homogenization with Trizol followed by total RNA extraction with Rneasy mini kit following manufacturer's instructions (Qiagen).///label_ch1: Cy3///label_protocol_ch1: Probes labelled with Cy3 were synthesized from 5 g of the total tumour RNA and reference labelled with Cy5 were synthesized from 5 g of commercial reference RNA by reverse transcription.///taxid_ch1: 9606///source_name_ch2: Universal Human Reference RNA purchased from Stratagene///organism_ch2: Homo sapiens///characteristics_ch2: Reference///molecule_ch2: total RNA///extract_protocol_ch2: Homogenization with Trizol followed by total RNA extraction with Rneasy mini kit following manufacturer's instructions (Qiagen).///label_ch2: Cy5///label_protocol_ch2: Probes labelled with Cy3 were synthesized from 5 g of the total tumour RNA and reference labelled with Cy5 were synthesized from 5 g of commercial reference RNA by reverse transcription.///taxid_ch2: 9606///hyb_protocol: The probes were purified using ChipShot labelling cleanup system (Promega). The hybridizations were carried out using Pronto! Micro Array reagent systems (Corning Inc.). For each sample, labelled tumour cDNA and reference cDNA were co-precipitated and hybridised to the oligoarray slide. After hybridization, slides were washed sequential.///scan_protocol: Scanned on an Agilent G2565AA scanner.///scan_protocol.1: Images were quantified using Genepix 6.0.0.74 (Axon Instruments).///description: Comparison of ovarian tumors of 5 year survivors to deceased patients///data_processing: Intensities were calculated by mean spot - median background. Flagged spots were removed as well as spots with intensities below 20 in both channels. Intensities below 20 in one channel were set to 20 to compensate for extreme quotients. Loess normalization was used///platform_id: GPL5886///contact_name: Karolina,,Partheen///contact_email: [email protected]///contact_phone: +46+31 342 78 55///contact_fax: +46 +31 41 72 05///contact_department: department of Oncology///contact_institute: University of Gothenburg///contact_address: Bl Strket 2///contact_city: Gothenburg///contact_zip.postal_code: 413 45///contact_country: Sweden///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM311nnn/GSM311980/GSM311980.gpr.gz///data_row_count: 30000
1
title: 1274LC///geo_accession: GSM311981///status: Public on Aug 12 2008///submission_date: Aug 12 2008///last_update_date: Aug 13 2008///type: RNA///channel_count: 2///source_name_ch1: serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: fresh frozen tumour///characteristics_ch1.1: 5 year survivor///characteristics_ch1.2: stage IIIc///characteristics_ch1.3: macroscopic residual tumor///characteristics_ch1.4: age at diagnosis 65///characteristics_ch1.5: post surgical chemo therapy farmorubicine, carboplatin and cyclophosphamide///molecule_ch1: total RNA///extract_protocol_ch1: Homogenization with Trizol followed by total RNA extraction with Rneasy mini kit following manufacturer's instructions (Qiagen).///label_ch1: Cy3///label_protocol_ch1: Probes labelled with Cy3 were synthesized from 5 g of the total tumour RNA and reference labelled with Cy5 were synthesized from 5 g of commercial reference RNA by reverse transcription.///taxid_ch1: 9606///source_name_ch2: Universal Human Reference RNA purchased from Stratagene///organism_ch2: Homo sapiens///characteristics_ch2: Reference///molecule_ch2: total RNA///extract_protocol_ch2: Homogenization with Trizol followed by total RNA extraction with Rneasy mini kit following manufacturer's instructions (Qiagen).///label_ch2: Cy5///label_protocol_ch2: Probes labelled with Cy3 were synthesized from 5 g of the total tumour RNA and reference labelled with Cy5 were synthesized from 5 g of commercial reference RNA by reverse transcription.///taxid_ch2: 9606///hyb_protocol: The probes were purified using ChipShot labelling cleanup system (Promega). The hybridizations were carried out using Pronto! Micro Array reagent systems (Corning Inc.). For each sample, labelled tumour cDNA and reference cDNA were co-precipitated and hybridised to the oligoarray slide. After hybridization, slides were washed sequential.///scan_protocol: Scanned on an Agilent G2565AA scanner.///scan_protocol.1: Images were quantified using Genepix 6.0.0.74 (Axon Instruments).///description: Comparison of ovarian tumors of 5 year survivors to deceased patients///data_processing: Intensities were calculated by mean spot - median background. Flagged spots were removed as well as spots with intensities below 20 in both channels. Intensities below 20 in one channel were set to 20 to compensate for extreme quotients. Loess normalization was used///platform_id: GPL5886///contact_name: Karolina,,Partheen///contact_email: [email protected]///contact_phone: +46+31 342 78 55///contact_fax: +46 +31 41 72 05///contact_department: department of Oncology///contact_institute: University of Gothenburg///contact_address: Bl Strket 2///contact_city: Gothenburg///contact_zip.postal_code: 413 45///contact_country: Sweden///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM311nnn/GSM311981/GSM311981.gpr.gz///data_row_count: 30000
1
title: 134LC///geo_accession: GSM311946///status: Public on Aug 12 2008///submission_date: Aug 12 2008///last_update_date: Aug 13 2008///type: RNA///channel_count: 2///source_name_ch1: serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: fresh frozen tumour///characteristics_ch1.1: 5 year survivor///characteristics_ch1.2: stage IIIc///characteristics_ch1.3: macroscopic residual tumor///characteristics_ch1.4: age at diagnosis 60///characteristics_ch1.5: post surgical chemo therapy farmorubicine, carboplatin and cyclophosphamide///molecule_ch1: total RNA///extract_protocol_ch1: Homogenization with Trizol followed by total RNA extraction with Rneasy mini kit following manufacturer's instructions (Qiagen).///label_ch1: Cy3///label_protocol_ch1: Probes labelled with Cy3 were synthesized from 5 g of the total tumour RNA and reference labelled with Cy5 were synthesized from 5 g of commercial reference RNA by reverse transcription.///taxid_ch1: 9606///source_name_ch2: Universal Human Reference RNA purchased from Stratagene///organism_ch2: Homo sapiens///characteristics_ch2: Reference///molecule_ch2: total RNA///extract_protocol_ch2: Homogenization with Trizol followed by total RNA extraction with Rneasy mini kit following manufacturer's instructions (Qiagen).///label_ch2: Cy5///label_protocol_ch2: Probes labelled with Cy3 were synthesized from 5 g of the total tumour RNA and reference labelled with Cy5 were synthesized from 5 g of commercial reference RNA by reverse transcription.///taxid_ch2: 9606///hyb_protocol: The probes were purified using ChipShot labelling cleanup system (Promega). The hybridizations were carried out using Pronto! Micro Array reagent systems (Corning Inc.). For each sample, labelled tumour cDNA and reference cDNA were co-precipitated and hybridised to the oligoarray slide. After hybridization, slides were washed sequential.///scan_protocol: Scanned on an Agilent G2565AA scanner.///scan_protocol.1: Images were quantified using Genepix 6.0.0.74 (Axon Instruments).///description: Comparison of ovarian tumors of 5 year survivors to deceased patients///data_processing: Intensities were calculated by mean spot - median background. Flagged spots were removed as well as spots with intensities below 20 in both channels. Intensities below 20 in one channel were set to 20 to compensate for extreme quotients. Loess normalization was used///platform_id: GPL5886///contact_name: Karolina,,Partheen///contact_email: [email protected]///contact_phone: +46+31 342 78 55///contact_fax: +46 +31 41 72 05///contact_department: department of Oncology///contact_institute: University of Gothenburg///contact_address: Bl Strket 2///contact_city: Gothenburg///contact_zip.postal_code: 413 45///contact_country: Sweden///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM311nnn/GSM311946/GSM311946.gpr.gz///data_row_count: 30000
1
title: 1426LB///geo_accession: GSM311982///status: Public on Aug 12 2008///submission_date: Aug 12 2008///last_update_date: Aug 13 2008///type: RNA///channel_count: 2///source_name_ch1: serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: fresh frozen tumour///characteristics_ch1.1: 5 year survivor///characteristics_ch1.2: stage IIIab///characteristics_ch1.3: macroscopic residual tumor///characteristics_ch1.4: age at diagnosis 54///characteristics_ch1.5: post surgical chemo therapy farmorubicine, carboplatin and cyclophosphamide///molecule_ch1: total RNA///extract_protocol_ch1: Homogenization with Trizol followed by total RNA extraction with Rneasy mini kit following manufacturer's instructions (Qiagen).///label_ch1: Cy3///label_protocol_ch1: Probes labelled with Cy3 were synthesized from 5 g of the total tumour RNA and reference labelled with Cy5 were synthesized from 5 g of commercial reference RNA by reverse transcription.///taxid_ch1: 9606///source_name_ch2: Universal Human Reference RNA purchased from Stratagene///organism_ch2: Homo sapiens///characteristics_ch2: Reference///molecule_ch2: total RNA///extract_protocol_ch2: Homogenization with Trizol followed by total RNA extraction with Rneasy mini kit following manufacturer's instructions (Qiagen).///label_ch2: Cy5///label_protocol_ch2: Probes labelled with Cy3 were synthesized from 5 g of the total tumour RNA and reference labelled with Cy5 were synthesized from 5 g of commercial reference RNA by reverse transcription.///taxid_ch2: 9606///hyb_protocol: The probes were purified using ChipShot labelling cleanup system (Promega). The hybridizations were carried out using Pronto! Micro Array reagent systems (Corning Inc.). For each sample, labelled tumour cDNA and reference cDNA were co-precipitated and hybridised to the oligoarray slide. After hybridization, slides were washed sequential.///scan_protocol: Scanned on an Agilent G2565AA scanner.///scan_protocol.1: Images were quantified using Genepix 6.0.0.74 (Axon Instruments).///description: Comparison of ovarian tumors of 5 year survivors to deceased patients///data_processing: Intensities were calculated by mean spot - median background. Flagged spots were removed as well as spots with intensities below 20 in both channels. Intensities below 20 in one channel were set to 20 to compensate for extreme quotients. Loess normalization was used///platform_id: GPL5886///contact_name: Karolina,,Partheen///contact_email: [email protected]///contact_phone: +46+31 342 78 55///contact_fax: +46 +31 41 72 05///contact_department: department of Oncology///contact_institute: University of Gothenburg///contact_address: Bl Strket 2///contact_city: Gothenburg///contact_zip.postal_code: 413 45///contact_country: Sweden///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM311nnn/GSM311982/GSM311982.gpr.gz///data_row_count: 30000
1
title: 1487DB///geo_accession: GSM311983///status: Public on Aug 12 2008///submission_date: Aug 12 2008///last_update_date: Aug 13 2008///type: RNA///channel_count: 2///source_name_ch1: serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: fresh frozen tumour///characteristics_ch1.1: deceased///characteristics_ch1.2: stage IIIab///characteristics_ch1.3: macroscopic residual tumor///characteristics_ch1.4: age at diagnosis 47///characteristics_ch1.5: post surgical chemo therapy farmorubicine, carboplatin and cyclophosphamide///molecule_ch1: total RNA///extract_protocol_ch1: Homogenization with Trizol followed by total RNA extraction with Rneasy mini kit following manufacturer's instructions (Qiagen).///label_ch1: Cy3///label_protocol_ch1: Probes labelled with Cy3 were synthesized from 5 g of the total tumour RNA and reference labelled with Cy5 were synthesized from 5 g of commercial reference RNA by reverse transcription.///taxid_ch1: 9606///source_name_ch2: Universal Human Reference RNA purchased from Stratagene///organism_ch2: Homo sapiens///characteristics_ch2: Reference///molecule_ch2: total RNA///extract_protocol_ch2: Homogenization with Trizol followed by total RNA extraction with Rneasy mini kit following manufacturer's instructions (Qiagen).///label_ch2: Cy5///label_protocol_ch2: Probes labelled with Cy3 were synthesized from 5 g of the total tumour RNA and reference labelled with Cy5 were synthesized from 5 g of commercial reference RNA by reverse transcription.///taxid_ch2: 9606///hyb_protocol: The probes were purified using ChipShot labelling cleanup system (Promega). The hybridizations were carried out using Pronto! Micro Array reagent systems (Corning Inc.). For each sample, labelled tumour cDNA and reference cDNA were co-precipitated and hybridised to the oligoarray slide. After hybridization, slides were washed sequential.///scan_protocol: Scanned on an Agilent G2565AA scanner.///scan_protocol.1: Images were quantified using Genepix 6.0.0.74 (Axon Instruments).///description: Comparison of ovarian tumors of 5 year survivors to deceased patients///data_processing: Intensities were calculated by mean spot - median background. Flagged spots were removed as well as spots with intensities below 20 in both channels. Intensities below 20 in one channel were set to 20 to compensate for extreme quotients. Loess normalization was used///platform_id: GPL5886///contact_name: Karolina,,Partheen///contact_email: [email protected]///contact_phone: +46+31 342 78 55///contact_fax: +46 +31 41 72 05///contact_department: department of Oncology///contact_institute: University of Gothenburg///contact_address: Bl Strket 2///contact_city: Gothenburg///contact_zip.postal_code: 413 45///contact_country: Sweden///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM311nnn/GSM311983/GSM311983.gpr.gz///data_row_count: 30000
1
title: 1528DC///geo_accession: GSM311984///status: Public on Aug 12 2008///submission_date: Aug 12 2008///last_update_date: Aug 13 2008///type: RNA///channel_count: 2///source_name_ch1: serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: fresh frozen tumour///characteristics_ch1.1: deceased///characteristics_ch1.2: stage IIIc///characteristics_ch1.3: macroscopic residual tumor///characteristics_ch1.4: age at diagnosis 50///characteristics_ch1.5: post surgical chemo therapy farmorubicine, carboplatin and cyclophosphamide///molecule_ch1: total RNA///extract_protocol_ch1: Homogenization with Trizol followed by total RNA extraction with Rneasy mini kit following manufacturer's instructions (Qiagen).///label_ch1: Cy3///label_protocol_ch1: Probes labelled with Cy3 were synthesized from 5 g of the total tumour RNA and reference labelled with Cy5 were synthesized from 5 g of commercial reference RNA by reverse transcription.///taxid_ch1: 9606///source_name_ch2: Universal Human Reference RNA purchased from Stratagene///organism_ch2: Homo sapiens///characteristics_ch2: Reference///molecule_ch2: total RNA///extract_protocol_ch2: Homogenization with Trizol followed by total RNA extraction with Rneasy mini kit following manufacturer's instructions (Qiagen).///label_ch2: Cy5///label_protocol_ch2: Probes labelled with Cy3 were synthesized from 5 g of the total tumour RNA and reference labelled with Cy5 were synthesized from 5 g of commercial reference RNA by reverse transcription.///taxid_ch2: 9606///hyb_protocol: The probes were purified using ChipShot labelling cleanup system (Promega). The hybridizations were carried out using Pronto! Micro Array reagent systems (Corning Inc.). For each sample, labelled tumour cDNA and reference cDNA were co-precipitated and hybridised to the oligoarray slide. After hybridization, slides were washed sequential.///scan_protocol: Scanned on an Agilent G2565AA scanner.///scan_protocol.1: Images were quantified using Genepix 6.0.0.74 (Axon Instruments).///description: Comparison of ovarian tumors of 5 year survivors to deceased patients///data_processing: Intensities were calculated by mean spot - median background. Flagged spots were removed as well as spots with intensities below 20 in both channels. Intensities below 20 in one channel were set to 20 to compensate for extreme quotients. Loess normalization was used///platform_id: GPL5886///contact_name: Karolina,,Partheen///contact_email: [email protected]///contact_phone: +46+31 342 78 55///contact_fax: +46 +31 41 72 05///contact_department: department of Oncology///contact_institute: University of Gothenburg///contact_address: Bl Strket 2///contact_city: Gothenburg///contact_zip.postal_code: 413 45///contact_country: Sweden///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM311nnn/GSM311984/GSM311984.gpr.gz///data_row_count: 30000
1
title: 1538DC///geo_accession: GSM311985///status: Public on Aug 12 2008///submission_date: Aug 12 2008///last_update_date: Aug 13 2008///type: RNA///channel_count: 2///source_name_ch1: serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: fresh frozen tumour///characteristics_ch1.1: deceased///characteristics_ch1.2: stage IIIc///characteristics_ch1.3: macroscopic residual tumor///characteristics_ch1.4: age at diagnosis 62///characteristics_ch1.5: post surgical chemo therapy farmorubicine, carboplatin and cyclophosphamide///molecule_ch1: total RNA///extract_protocol_ch1: Homogenization with Trizol followed by total RNA extraction with Rneasy mini kit following manufacturer's instructions (Qiagen).///label_ch1: Cy3///label_protocol_ch1: Probes labelled with Cy3 were synthesized from 5 g of the total tumour RNA and reference labelled with Cy5 were synthesized from 5 g of commercial reference RNA by reverse transcription.///taxid_ch1: 9606///source_name_ch2: Universal Human Reference RNA purchased from Stratagene///organism_ch2: Homo sapiens///characteristics_ch2: Reference///molecule_ch2: total RNA///extract_protocol_ch2: Homogenization with Trizol followed by total RNA extraction with Rneasy mini kit following manufacturer's instructions (Qiagen).///label_ch2: Cy5///label_protocol_ch2: Probes labelled with Cy3 were synthesized from 5 g of the total tumour RNA and reference labelled with Cy5 were synthesized from 5 g of commercial reference RNA by reverse transcription.///taxid_ch2: 9606///hyb_protocol: The probes were purified using ChipShot labelling cleanup system (Promega). The hybridizations were carried out using Pronto! Micro Array reagent systems (Corning Inc.). For each sample, labelled tumour cDNA and reference cDNA were co-precipitated and hybridised to the oligoarray slide. After hybridization, slides were washed sequential.///scan_protocol: Scanned on an Agilent G2565AA scanner.///scan_protocol.1: Images were quantified using Genepix 6.0.0.74 (Axon Instruments).///description: Comparison of ovarian tumors of 5 year survivors to deceased patients///data_processing: Intensities were calculated by mean spot - median background. Flagged spots were removed as well as spots with intensities below 20 in both channels. Intensities below 20 in one channel were set to 20 to compensate for extreme quotients. Loess normalization was used///platform_id: GPL5886///contact_name: Karolina,,Partheen///contact_email: [email protected]///contact_phone: +46+31 342 78 55///contact_fax: +46 +31 41 72 05///contact_department: department of Oncology///contact_institute: University of Gothenburg///contact_address: Bl Strket 2///contact_city: Gothenburg///contact_zip.postal_code: 413 45///contact_country: Sweden///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM311nnn/GSM311985/GSM311985.gpr.gz///data_row_count: 30000
1
title: 1567DB///geo_accession: GSM311986///status: Public on Aug 12 2008///submission_date: Aug 12 2008///last_update_date: Aug 13 2008///type: RNA///channel_count: 2///source_name_ch1: serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: fresh frozen tumour///characteristics_ch1.1: deceased///characteristics_ch1.2: stage IIIab///characteristics_ch1.3: macroscopic residual tumor///characteristics_ch1.4: age at diagnosis 68///characteristics_ch1.5: post surgical chemo therapy farmorubicine, carboplatin and cyclophosphamide///molecule_ch1: total RNA///extract_protocol_ch1: Homogenization with Trizol followed by total RNA extraction with Rneasy mini kit following manufacturer's instructions (Qiagen).///label_ch1: Cy3///label_protocol_ch1: Probes labelled with Cy3 were synthesized from 5 g of the total tumour RNA and reference labelled with Cy5 were synthesized from 5 g of commercial reference RNA by reverse transcription.///taxid_ch1: 9606///source_name_ch2: Universal Human Reference RNA purchased from Stratagene///organism_ch2: Homo sapiens///characteristics_ch2: Reference///molecule_ch2: total RNA///extract_protocol_ch2: Homogenization with Trizol followed by total RNA extraction with Rneasy mini kit following manufacturer's instructions (Qiagen).///label_ch2: Cy5///label_protocol_ch2: Probes labelled with Cy3 were synthesized from 5 g of the total tumour RNA and reference labelled with Cy5 were synthesized from 5 g of commercial reference RNA by reverse transcription.///taxid_ch2: 9606///hyb_protocol: The probes were purified using ChipShot labelling cleanup system (Promega). The hybridizations were carried out using Pronto! Micro Array reagent systems (Corning Inc.). For each sample, labelled tumour cDNA and reference cDNA were co-precipitated and hybridised to the oligoarray slide. After hybridization, slides were washed sequential.///scan_protocol: Scanned on an Agilent G2565AA scanner.///scan_protocol.1: Images were quantified using Genepix 6.0.0.74 (Axon Instruments).///description: Comparison of ovarian tumors of 5 year survivors to deceased patients///data_processing: Intensities were calculated by mean spot - median background. Flagged spots were removed as well as spots with intensities below 20 in both channels. Intensities below 20 in one channel were set to 20 to compensate for extreme quotients. Loess normalization was used///platform_id: GPL5886///contact_name: Karolina,,Partheen///contact_email: [email protected]///contact_phone: +46+31 342 78 55///contact_fax: +46 +31 41 72 05///contact_department: department of Oncology///contact_institute: University of Gothenburg///contact_address: Bl Strket 2///contact_city: Gothenburg///contact_zip.postal_code: 413 45///contact_country: Sweden///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM311nnn/GSM311986/GSM311986.gpr.gz///data_row_count: 30000
1
title: 1568DC///geo_accession: GSM311987///status: Public on Aug 12 2008///submission_date: Aug 12 2008///last_update_date: Aug 13 2008///type: RNA///channel_count: 2///source_name_ch1: serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: fresh frozen tumour///characteristics_ch1.1: deceased///characteristics_ch1.2: stage IIIc///characteristics_ch1.3: macroscopic residual tumor///characteristics_ch1.4: age at diagnosis 51///characteristics_ch1.5: post surgical chemo therapy farmorubicine, carboplatin and cyclophosphamide///molecule_ch1: total RNA///extract_protocol_ch1: Homogenization with Trizol followed by total RNA extraction with Rneasy mini kit following manufacturer's instructions (Qiagen).///label_ch1: Cy3///label_protocol_ch1: Probes labelled with Cy3 were synthesized from 5 g of the total tumour RNA and reference labelled with Cy5 were synthesized from 5 g of commercial reference RNA by reverse transcription.///taxid_ch1: 9606///source_name_ch2: Universal Human Reference RNA purchased from Stratagene///organism_ch2: Homo sapiens///characteristics_ch2: Reference///molecule_ch2: total RNA///extract_protocol_ch2: Homogenization with Trizol followed by total RNA extraction with Rneasy mini kit following manufacturer's instructions (Qiagen).///label_ch2: Cy5///label_protocol_ch2: Probes labelled with Cy3 were synthesized from 5 g of the total tumour RNA and reference labelled with Cy5 were synthesized from 5 g of commercial reference RNA by reverse transcription.///taxid_ch2: 9606///hyb_protocol: The probes were purified using ChipShot labelling cleanup system (Promega). The hybridizations were carried out using Pronto! Micro Array reagent systems (Corning Inc.). For each sample, labelled tumour cDNA and reference cDNA were co-precipitated and hybridised to the oligoarray slide. After hybridization, slides were washed sequential.///scan_protocol: Scanned on an Agilent G2565AA scanner.///scan_protocol.1: Images were quantified using Genepix 6.0.0.74 (Axon Instruments).///description: Comparison of ovarian tumors of 5 year survivors to deceased patients///data_processing: Intensities were calculated by mean spot - median background. Flagged spots were removed as well as spots with intensities below 20 in both channels. Intensities below 20 in one channel were set to 20 to compensate for extreme quotients. Loess normalization was used///platform_id: GPL5886///contact_name: Karolina,,Partheen///contact_email: [email protected]///contact_phone: +46+31 342 78 55///contact_fax: +46 +31 41 72 05///contact_department: department of Oncology///contact_institute: University of Gothenburg///contact_address: Bl Strket 2///contact_city: Gothenburg///contact_zip.postal_code: 413 45///contact_country: Sweden///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM311nnn/GSM311987/GSM311987.gpr.gz///data_row_count: 30000
1
title: 1574LC0///geo_accession: GSM311988///status: Public on Aug 12 2008///submission_date: Aug 12 2008///last_update_date: Aug 13 2008///type: RNA///channel_count: 2///source_name_ch1: serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: fresh frozen tumour///characteristics_ch1.1: 5 year survivor///characteristics_ch1.2: stage IIIc///characteristics_ch1.3: no macroscopic residual tumor///characteristics_ch1.4: age at diagnosis 35///characteristics_ch1.5: post surgical chemo therapy farmorubicine, carboplatin and cyclophosphamide///molecule_ch1: total RNA///extract_protocol_ch1: Homogenization with Trizol followed by total RNA extraction with Rneasy mini kit following manufacturer's instructions (Qiagen).///label_ch1: Cy3///label_protocol_ch1: Probes labelled with Cy3 were synthesized from 5 g of the total tumour RNA and reference labelled with Cy5 were synthesized from 5 g of commercial reference RNA by reverse transcription.///taxid_ch1: 9606///source_name_ch2: Universal Human Reference RNA purchased from Stratagene///organism_ch2: Homo sapiens///characteristics_ch2: Reference///molecule_ch2: total RNA///extract_protocol_ch2: Homogenization with Trizol followed by total RNA extraction with Rneasy mini kit following manufacturer's instructions (Qiagen).///label_ch2: Cy5///label_protocol_ch2: Probes labelled with Cy3 were synthesized from 5 g of the total tumour RNA and reference labelled with Cy5 were synthesized from 5 g of commercial reference RNA by reverse transcription.///taxid_ch2: 9606///hyb_protocol: The probes were purified using ChipShot labelling cleanup system (Promega). The hybridizations were carried out using Pronto! Micro Array reagent systems (Corning Inc.). For each sample, labelled tumour cDNA and reference cDNA were co-precipitated and hybridised to the oligoarray slide. After hybridization, slides were washed sequential.///scan_protocol: Scanned on an Agilent G2565AA scanner.///scan_protocol.1: Images were quantified using Genepix 6.0.0.74 (Axon Instruments).///description: Comparison of ovarian tumors of 5 year survivors to deceased patients///data_processing: Intensities were calculated by mean spot - median background. Flagged spots were removed as well as spots with intensities below 20 in both channels. Intensities below 20 in one channel were set to 20 to compensate for extreme quotients. Loess normalization was used///platform_id: GPL5886///contact_name: Karolina,,Partheen///contact_email: [email protected]///contact_phone: +46+31 342 78 55///contact_fax: +46 +31 41 72 05///contact_department: department of Oncology///contact_institute: University of Gothenburg///contact_address: Bl Strket 2///contact_city: Gothenburg///contact_zip.postal_code: 413 45///contact_country: Sweden///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM311nnn/GSM311988/GSM311988.gpr.gz///data_row_count: 30000
1
title: 164DC///geo_accession: GSM311947///status: Public on Aug 12 2008///submission_date: Aug 12 2008///last_update_date: Aug 13 2008///type: RNA///channel_count: 2///source_name_ch1: serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: fresh frozen tumour///characteristics_ch1.1: deceased///characteristics_ch1.2: stage IIIc///characteristics_ch1.3: macroscopic residual tumor///characteristics_ch1.4: age at diagnosis 73///characteristics_ch1.5: post surgical chemo therapy farmorubicine, carboplatin and cyclophosphamide///molecule_ch1: total RNA///extract_protocol_ch1: Homogenization with Trizol followed by total RNA extraction with Rneasy mini kit following manufacturer's instructions (Qiagen).///label_ch1: Cy3///label_protocol_ch1: Probes labelled with Cy3 were synthesized from 5 g of the total tumour RNA and reference labelled with Cy5 were synthesized from 5 g of commercial reference RNA by reverse transcription.///taxid_ch1: 9606///source_name_ch2: Universal Human Reference RNA purchased from Stratagene///organism_ch2: Homo sapiens///characteristics_ch2: Reference///molecule_ch2: total RNA///extract_protocol_ch2: Homogenization with Trizol followed by total RNA extraction with Rneasy mini kit following manufacturer's instructions (Qiagen).///label_ch2: Cy5///label_protocol_ch2: Probes labelled with Cy3 were synthesized from 5 g of the total tumour RNA and reference labelled with Cy5 were synthesized from 5 g of commercial reference RNA by reverse transcription.///taxid_ch2: 9606///hyb_protocol: The probes were purified using ChipShot labelling cleanup system (Promega). The hybridizations were carried out using Pronto! Micro Array reagent systems (Corning Inc.). For each sample, labelled tumour cDNA and reference cDNA were co-precipitated and hybridised to the oligoarray slide. After hybridization, slides were washed sequential.///scan_protocol: Scanned on an Agilent G2565AA scanner.///scan_protocol.1: Images were quantified using Genepix 6.0.0.74 (Axon Instruments).///description: Comparison of ovarian tumors of 5 year survivors to deceased patients///data_processing: Intensities were calculated by mean spot - median background. Flagged spots were removed as well as spots with intensities below 20 in both channels. Intensities below 20 in one channel were set to 20 to compensate for extreme quotients. Loess normalization was used///platform_id: GPL5886///contact_name: Karolina,,Partheen///contact_email: [email protected]///contact_phone: +46+31 342 78 55///contact_fax: +46 +31 41 72 05///contact_department: department of Oncology///contact_institute: University of Gothenburg///contact_address: Bl Strket 2///contact_city: Gothenburg///contact_zip.postal_code: 413 45///contact_country: Sweden///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM311nnn/GSM311947/GSM311947.gpr.gz///data_row_count: 30000
1
title: 1658DC///geo_accession: GSM311989///status: Public on Aug 12 2008///submission_date: Aug 12 2008///last_update_date: Aug 13 2008///type: RNA///channel_count: 2///source_name_ch1: serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: fresh frozen tumour///characteristics_ch1.1: deceased///characteristics_ch1.2: stage IIIc///characteristics_ch1.3: macroscopic residual tumor///characteristics_ch1.4: age at diagnosis 70///characteristics_ch1.5: post surgical chemo therapy farmorubicine, carboplatin and cyclophosphamide///molecule_ch1: total RNA///extract_protocol_ch1: Homogenization with Trizol followed by total RNA extraction with Rneasy mini kit following manufacturer's instructions (Qiagen).///label_ch1: Cy3///label_protocol_ch1: Probes labelled with Cy3 were synthesized from 5 g of the total tumour RNA and reference labelled with Cy5 were synthesized from 5 g of commercial reference RNA by reverse transcription.///taxid_ch1: 9606///source_name_ch2: Universal Human Reference RNA purchased from Stratagene///organism_ch2: Homo sapiens///characteristics_ch2: Reference///molecule_ch2: total RNA///extract_protocol_ch2: Homogenization with Trizol followed by total RNA extraction with Rneasy mini kit following manufacturer's instructions (Qiagen).///label_ch2: Cy5///label_protocol_ch2: Probes labelled with Cy3 were synthesized from 5 g of the total tumour RNA and reference labelled with Cy5 were synthesized from 5 g of commercial reference RNA by reverse transcription.///taxid_ch2: 9606///hyb_protocol: The probes were purified using ChipShot labelling cleanup system (Promega). The hybridizations were carried out using Pronto! Micro Array reagent systems (Corning Inc.). For each sample, labelled tumour cDNA and reference cDNA were co-precipitated and hybridised to the oligoarray slide. After hybridization, slides were washed sequential.///scan_protocol: Scanned on an Agilent G2565AA scanner.///scan_protocol.1: Images were quantified using Genepix 6.0.0.74 (Axon Instruments).///description: Comparison of ovarian tumors of 5 year survivors to deceased patients///data_processing: Intensities were calculated by mean spot - median background. Flagged spots were removed as well as spots with intensities below 20 in both channels. Intensities below 20 in one channel were set to 20 to compensate for extreme quotients. Loess normalization was used///platform_id: GPL5886///contact_name: Karolina,,Partheen///contact_email: [email protected]///contact_phone: +46+31 342 78 55///contact_fax: +46 +31 41 72 05///contact_department: department of Oncology///contact_institute: University of Gothenburg///contact_address: Bl Strket 2///contact_city: Gothenburg///contact_zip.postal_code: 413 45///contact_country: Sweden///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM311nnn/GSM311989/GSM311989.gpr.gz///data_row_count: 30000
1
title: 1760LB///geo_accession: GSM311990///status: Public on Aug 12 2008///submission_date: Aug 12 2008///last_update_date: Aug 13 2008///type: RNA///channel_count: 2///source_name_ch1: serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: fresh frozen tumour///characteristics_ch1.1: 5 year survivor///characteristics_ch1.2: stage IIIab///characteristics_ch1.3: macroscopic residual tumor///characteristics_ch1.4: age at diagnosis 40///characteristics_ch1.5: post surgical chemo therapy farmorubicine, carboplatin and cyclophosphamide///molecule_ch1: total RNA///extract_protocol_ch1: Homogenization with Trizol followed by total RNA extraction with Rneasy mini kit following manufacturer's instructions (Qiagen).///label_ch1: Cy3///label_protocol_ch1: Probes labelled with Cy3 were synthesized from 5 g of the total tumour RNA and reference labelled with Cy5 were synthesized from 5 g of commercial reference RNA by reverse transcription.///taxid_ch1: 9606///source_name_ch2: Universal Human Reference RNA purchased from Stratagene///organism_ch2: Homo sapiens///characteristics_ch2: Reference///molecule_ch2: total RNA///extract_protocol_ch2: Homogenization with Trizol followed by total RNA extraction with Rneasy mini kit following manufacturer's instructions (Qiagen).///label_ch2: Cy5///label_protocol_ch2: Probes labelled with Cy3 were synthesized from 5 g of the total tumour RNA and reference labelled with Cy5 were synthesized from 5 g of commercial reference RNA by reverse transcription.///taxid_ch2: 9606///hyb_protocol: The probes were purified using ChipShot labelling cleanup system (Promega). The hybridizations were carried out using Pronto! Micro Array reagent systems (Corning Inc.). For each sample, labelled tumour cDNA and reference cDNA were co-precipitated and hybridised to the oligoarray slide. After hybridization, slides were washed sequential.///scan_protocol: Scanned on an Agilent G2565AA scanner.///scan_protocol.1: Images were quantified using Genepix 6.0.0.74 (Axon Instruments).///description: Comparison of ovarian tumors of 5 year survivors to deceased patients///data_processing: Intensities were calculated by mean spot - median background. Flagged spots were removed as well as spots with intensities below 20 in both channels. Intensities below 20 in one channel were set to 20 to compensate for extreme quotients. Loess normalization was used///platform_id: GPL5886///contact_name: Karolina,,Partheen///contact_email: [email protected]///contact_phone: +46+31 342 78 55///contact_fax: +46 +31 41 72 05///contact_department: department of Oncology///contact_institute: University of Gothenburg///contact_address: Bl Strket 2///contact_city: Gothenburg///contact_zip.postal_code: 413 45///contact_country: Sweden///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM311nnn/GSM311990/GSM311990.gpr.gz///data_row_count: 30000
1
title: 1805DB///geo_accession: GSM311991///status: Public on Aug 12 2008///submission_date: Aug 12 2008///last_update_date: Aug 13 2008///type: RNA///channel_count: 2///source_name_ch1: serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: fresh frozen tumour///characteristics_ch1.1: deceased///characteristics_ch1.2: stage IIIab///characteristics_ch1.3: macroscopic residual tumor///characteristics_ch1.4: age at diagnosis 82///characteristics_ch1.5: post surgical chemo therapy farmorubicine, carboplatin and cyclophosphamide///molecule_ch1: total RNA///extract_protocol_ch1: Homogenization with Trizol followed by total RNA extraction with Rneasy mini kit following manufacturer's instructions (Qiagen).///label_ch1: Cy3///label_protocol_ch1: Probes labelled with Cy3 were synthesized from 5 g of the total tumour RNA and reference labelled with Cy5 were synthesized from 5 g of commercial reference RNA by reverse transcription.///taxid_ch1: 9606///source_name_ch2: Universal Human Reference RNA purchased from Stratagene///organism_ch2: Homo sapiens///characteristics_ch2: Reference///molecule_ch2: total RNA///extract_protocol_ch2: Homogenization with Trizol followed by total RNA extraction with Rneasy mini kit following manufacturer's instructions (Qiagen).///label_ch2: Cy5///label_protocol_ch2: Probes labelled with Cy3 were synthesized from 5 g of the total tumour RNA and reference labelled with Cy5 were synthesized from 5 g of commercial reference RNA by reverse transcription.///taxid_ch2: 9606///hyb_protocol: The probes were purified using ChipShot labelling cleanup system (Promega). The hybridizations were carried out using Pronto! Micro Array reagent systems (Corning Inc.). For each sample, labelled tumour cDNA and reference cDNA were co-precipitated and hybridised to the oligoarray slide. After hybridization, slides were washed sequential.///scan_protocol: Scanned on an Agilent G2565AA scanner.///scan_protocol.1: Images were quantified using Genepix 6.0.0.74 (Axon Instruments).///description: Comparison of ovarian tumors of 5 year survivors to deceased patients///data_processing: Intensities were calculated by mean spot - median background. Flagged spots were removed as well as spots with intensities below 20 in both channels. Intensities below 20 in one channel were set to 20 to compensate for extreme quotients. Loess normalization was used///platform_id: GPL5886///contact_name: Karolina,,Partheen///contact_email: [email protected]///contact_phone: +46+31 342 78 55///contact_fax: +46 +31 41 72 05///contact_department: department of Oncology///contact_institute: University of Gothenburg///contact_address: Bl Strket 2///contact_city: Gothenburg///contact_zip.postal_code: 413 45///contact_country: Sweden///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM311nnn/GSM311991/GSM311991.gpr.gz///data_row_count: 30000
1
title: 193DC///geo_accession: GSM311948///status: Public on Aug 12 2008///submission_date: Aug 12 2008///last_update_date: Aug 13 2008///type: RNA///channel_count: 2///source_name_ch1: serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: fresh frozen tumour///characteristics_ch1.1: deceased///characteristics_ch1.2: stage IIIc///characteristics_ch1.3: macroscopic residual tumor///characteristics_ch1.4: age at diagnosis 59///characteristics_ch1.5: post surgical chemo therapy farmorubicine, carboplatin and cyclophosphamide///molecule_ch1: total RNA///extract_protocol_ch1: Homogenization with Trizol followed by total RNA extraction with Rneasy mini kit following manufacturer's instructions (Qiagen).///label_ch1: Cy3///label_protocol_ch1: Probes labelled with Cy3 were synthesized from 5 g of the total tumour RNA and reference labelled with Cy5 were synthesized from 5 g of commercial reference RNA by reverse transcription.///taxid_ch1: 9606///source_name_ch2: Universal Human Reference RNA purchased from Stratagene///organism_ch2: Homo sapiens///characteristics_ch2: Reference///molecule_ch2: total RNA///extract_protocol_ch2: Homogenization with Trizol followed by total RNA extraction with Rneasy mini kit following manufacturer's instructions (Qiagen).///label_ch2: Cy5///label_protocol_ch2: Probes labelled with Cy3 were synthesized from 5 g of the total tumour RNA and reference labelled with Cy5 were synthesized from 5 g of commercial reference RNA by reverse transcription.///taxid_ch2: 9606///hyb_protocol: The probes were purified using ChipShot labelling cleanup system (Promega). The hybridizations were carried out using Pronto! Micro Array reagent systems (Corning Inc.). For each sample, labelled tumour cDNA and reference cDNA were co-precipitated and hybridised to the oligoarray slide. After hybridization, slides were washed sequential.///scan_protocol: Scanned on an Agilent G2565AA scanner.///scan_protocol.1: Images were quantified using Genepix 6.0.0.74 (Axon Instruments).///description: Comparison of ovarian tumors of 5 year survivors to deceased patients///data_processing: Intensities were calculated by mean spot - median background. Flagged spots were removed as well as spots with intensities below 20 in both channels. Intensities below 20 in one channel were set to 20 to compensate for extreme quotients. Loess normalization was used///platform_id: GPL5886///contact_name: Karolina,,Partheen///contact_email: [email protected]///contact_phone: +46+31 342 78 55///contact_fax: +46 +31 41 72 05///contact_department: department of Oncology///contact_institute: University of Gothenburg///contact_address: Bl Strket 2///contact_city: Gothenburg///contact_zip.postal_code: 413 45///contact_country: Sweden///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM311nnn/GSM311948/GSM311948.gpr.gz///data_row_count: 30000
1
title: 198DC///geo_accession: GSM311949///status: Public on Aug 12 2008///submission_date: Aug 12 2008///last_update_date: Aug 13 2008///type: RNA///channel_count: 2///source_name_ch1: serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: fresh frozen tumour///characteristics_ch1.1: deceased///characteristics_ch1.2: stage IIIc///characteristics_ch1.3: macroscopic residual tumor///characteristics_ch1.4: age at diagnosis 67///characteristics_ch1.5: post surgical chemo therapy farmorubicine, carboplatin and cyclophosphamide///molecule_ch1: total RNA///extract_protocol_ch1: Homogenization with Trizol followed by total RNA extraction with Rneasy mini kit following manufacturer's instructions (Qiagen).///label_ch1: Cy3///label_protocol_ch1: Probes labelled with Cy3 were synthesized from 5 g of the total tumour RNA and reference labelled with Cy5 were synthesized from 5 g of commercial reference RNA by reverse transcription.///taxid_ch1: 9606///source_name_ch2: Universal Human Reference RNA purchased from Stratagene///organism_ch2: Homo sapiens///characteristics_ch2: Reference///molecule_ch2: total RNA///extract_protocol_ch2: Homogenization with Trizol followed by total RNA extraction with Rneasy mini kit following manufacturer's instructions (Qiagen).///label_ch2: Cy5///label_protocol_ch2: Probes labelled with Cy3 were synthesized from 5 g of the total tumour RNA and reference labelled with Cy5 were synthesized from 5 g of commercial reference RNA by reverse transcription.///taxid_ch2: 9606///hyb_protocol: The probes were purified using ChipShot labelling cleanup system (Promega). The hybridizations were carried out using Pronto! Micro Array reagent systems (Corning Inc.). For each sample, labelled tumour cDNA and reference cDNA were co-precipitated and hybridised to the oligoarray slide. After hybridization, slides were washed sequential.///scan_protocol: Scanned on an Agilent G2565AA scanner.///scan_protocol.1: Images were quantified using Genepix 6.0.0.74 (Axon Instruments).///description: Comparison of ovarian tumors of 5 year survivors to deceased patients///data_processing: Intensities were calculated by mean spot - median background. Flagged spots were removed as well as spots with intensities below 20 in both channels. Intensities below 20 in one channel were set to 20 to compensate for extreme quotients. Loess normalization was used///platform_id: GPL5886///contact_name: Karolina,,Partheen///contact_email: [email protected]///contact_phone: +46+31 342 78 55///contact_fax: +46 +31 41 72 05///contact_department: department of Oncology///contact_institute: University of Gothenburg///contact_address: Bl Strket 2///contact_city: Gothenburg///contact_zip.postal_code: 413 45///contact_country: Sweden///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM311nnn/GSM311949/GSM311949.gpr.gz///data_row_count: 30000
1
title: 202DC///geo_accession: GSM311950///status: Public on Aug 12 2008///submission_date: Aug 12 2008///last_update_date: Aug 13 2008///type: RNA///channel_count: 2///source_name_ch1: serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: fresh frozen tumour///characteristics_ch1.1: deceased///characteristics_ch1.2: stage IIIc///characteristics_ch1.3: macroscopic residual tumor///characteristics_ch1.4: age at diagnosis 59///characteristics_ch1.5: post surgical chemo therapy farmorubicine, carboplatin and cyclophosphamide///molecule_ch1: total RNA///extract_protocol_ch1: Homogenization with Trizol followed by total RNA extraction with Rneasy mini kit following manufacturer's instructions (Qiagen).///label_ch1: Cy3///label_protocol_ch1: Probes labelled with Cy3 were synthesized from 5 g of the total tumour RNA and reference labelled with Cy5 were synthesized from 5 g of commercial reference RNA by reverse transcription.///taxid_ch1: 9606///source_name_ch2: Universal Human Reference RNA purchased from Stratagene///organism_ch2: Homo sapiens///characteristics_ch2: Reference///molecule_ch2: total RNA///extract_protocol_ch2: Homogenization with Trizol followed by total RNA extraction with Rneasy mini kit following manufacturer's instructions (Qiagen).///label_ch2: Cy5///label_protocol_ch2: Probes labelled with Cy3 were synthesized from 5 g of the total tumour RNA and reference labelled with Cy5 were synthesized from 5 g of commercial reference RNA by reverse transcription.///taxid_ch2: 9606///hyb_protocol: The probes were purified using ChipShot labelling cleanup system (Promega). The hybridizations were carried out using Pronto! Micro Array reagent systems (Corning Inc.). For each sample, labelled tumour cDNA and reference cDNA were co-precipitated and hybridised to the oligoarray slide. After hybridization, slides were washed sequential.///scan_protocol: Scanned on an Agilent G2565AA scanner.///scan_protocol.1: Images were quantified using Genepix 6.0.0.74 (Axon Instruments).///description: Comparison of ovarian tumors of 5 year survivors to deceased patients///data_processing: Intensities were calculated by mean spot - median background. Flagged spots were removed as well as spots with intensities below 20 in both channels. Intensities below 20 in one channel were set to 20 to compensate for extreme quotients. Loess normalization was used///platform_id: GPL5886///contact_name: Karolina,,Partheen///contact_email: [email protected]///contact_phone: +46+31 342 78 55///contact_fax: +46 +31 41 72 05///contact_department: department of Oncology///contact_institute: University of Gothenburg///contact_address: Bl Strket 2///contact_city: Gothenburg///contact_zip.postal_code: 413 45///contact_country: Sweden///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM311nnn/GSM311950/GSM311950.gpr.gz///data_row_count: 30000
1
title: 211DC///geo_accession: GSM311951///status: Public on Aug 12 2008///submission_date: Aug 12 2008///last_update_date: Aug 13 2008///type: RNA///channel_count: 2///source_name_ch1: serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: fresh frozen tumour///characteristics_ch1.1: deceased///characteristics_ch1.2: stage IIIc///characteristics_ch1.3: macroscopic residual tumor///characteristics_ch1.4: age at diagnosis 70///characteristics_ch1.5: post surgical chemo therapy farmorubicine, carboplatin and cyclophosphamide///molecule_ch1: total RNA///extract_protocol_ch1: Homogenization with Trizol followed by total RNA extraction with Rneasy mini kit following manufacturer's instructions (Qiagen).///label_ch1: Cy3///label_protocol_ch1: Probes labelled with Cy3 were synthesized from 5 g of the total tumour RNA and reference labelled with Cy5 were synthesized from 5 g of commercial reference RNA by reverse transcription.///taxid_ch1: 9606///source_name_ch2: Universal Human Reference RNA purchased from Stratagene///organism_ch2: Homo sapiens///characteristics_ch2: Reference///molecule_ch2: total RNA///extract_protocol_ch2: Homogenization with Trizol followed by total RNA extraction with Rneasy mini kit following manufacturer's instructions (Qiagen).///label_ch2: Cy5///label_protocol_ch2: Probes labelled with Cy3 were synthesized from 5 g of the total tumour RNA and reference labelled with Cy5 were synthesized from 5 g of commercial reference RNA by reverse transcription.///taxid_ch2: 9606///hyb_protocol: The probes were purified using ChipShot labelling cleanup system (Promega). The hybridizations were carried out using Pronto! Micro Array reagent systems (Corning Inc.). For each sample, labelled tumour cDNA and reference cDNA were co-precipitated and hybridised to the oligoarray slide. After hybridization, slides were washed sequential.///scan_protocol: Scanned on an Agilent G2565AA scanner.///scan_protocol.1: Images were quantified using Genepix 6.0.0.74 (Axon Instruments).///description: Comparison of ovarian tumors of 5 year survivors to deceased patients///data_processing: Intensities were calculated by mean spot - median background. Flagged spots were removed as well as spots with intensities below 20 in both channels. Intensities below 20 in one channel were set to 20 to compensate for extreme quotients. Loess normalization was used///platform_id: GPL5886///contact_name: Karolina,,Partheen///contact_email: [email protected]///contact_phone: +46+31 342 78 55///contact_fax: +46 +31 41 72 05///contact_department: department of Oncology///contact_institute: University of Gothenburg///contact_address: Bl Strket 2///contact_city: Gothenburg///contact_zip.postal_code: 413 45///contact_country: Sweden///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM311nnn/GSM311951/GSM311951.gpr.gz///data_row_count: 30000
1
title: 26DC///geo_accession: GSM311938///status: Public on Aug 12 2008///submission_date: Aug 12 2008///last_update_date: Aug 13 2008///type: RNA///channel_count: 2///source_name_ch1: serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: fresh frozen tumour///characteristics_ch1.1: deceased///characteristics_ch1.2: stage IIIc///characteristics_ch1.3: macroscopic residual tumor///characteristics_ch1.4: age at diagnosis 41///characteristics_ch1.5: post surgical chemo therapy farmorubicine, carboplatin and cyclophosphamide///molecule_ch1: total RNA///extract_protocol_ch1: Homogenization with Trizol followed by total RNA extraction with Rneasy mini kit following manufacturer's instructions (Qiagen).///label_ch1: Cy3///label_protocol_ch1: Probes labelled with Cy3 were synthesized from 5 g of the total tumour RNA and reference labelled with Cy5 were synthesized from 5 g of commercial reference RNA by reverse transcription.///taxid_ch1: 9606///source_name_ch2: Universal Human Reference RNA purchased from Stratagene///organism_ch2: Homo sapiens///characteristics_ch2: Reference///molecule_ch2: total RNA///extract_protocol_ch2: Homogenization with Trizol followed by total RNA extraction with Rneasy mini kit following manufacturer's instructions (Qiagen).///label_ch2: Cy5///label_protocol_ch2: Probes labelled with Cy3 were synthesized from 5 g of the total tumour RNA and reference labelled with Cy5 were synthesized from 5 g of commercial reference RNA by reverse transcription.///taxid_ch2: 9606///hyb_protocol: The probes were purified using ChipShot labelling cleanup system (Promega). The hybridizations were carried out using Pronto! Micro Array reagent systems (Corning Inc.). For each sample, labelled tumour cDNA and reference cDNA were co-precipitated and hybridised to the oligoarray slide. After hybridization, slides were washed sequential.///scan_protocol: Scanned on an Agilent G2565AA scanner.///scan_protocol.1: Images were quantified using Genepix 6.0.0.74 (Axon Instruments).///description: Comparison of ovarian tumors of 5 year survivors to deceased patients///data_processing: Intensities were calculated by mean spot - median background. Flagged spots were removed as well as spots with intensities below 20 in both channels. Intensities below 20 in one channel were set to 20 to compensate for extreme quotients. Loess normalization was used///platform_id: GPL5886///contact_name: Karolina,,Partheen///contact_email: [email protected]///contact_phone: +46+31 342 78 55///contact_fax: +46 +31 41 72 05///contact_department: department of Oncology///contact_institute: University of Gothenburg///contact_address: Bl Strket 2///contact_city: Gothenburg///contact_zip.postal_code: 413 45///contact_country: Sweden///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM311nnn/GSM311938/GSM311938.gpr.gz///data_row_count: 30000
1
title: 272DC///geo_accession: GSM311952///status: Public on Aug 12 2008///submission_date: Aug 12 2008///last_update_date: Aug 13 2008///type: RNA///channel_count: 2///source_name_ch1: serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: fresh frozen tumour///characteristics_ch1.1: deceased///characteristics_ch1.2: stage IIIc///characteristics_ch1.3: macroscopic residual tumor///characteristics_ch1.4: age at diagnosis 54///characteristics_ch1.5: post surgical chemo therapy farmorubicine, carboplatin and cyclophosphamide///molecule_ch1: total RNA///extract_protocol_ch1: Homogenization with Trizol followed by total RNA extraction with Rneasy mini kit following manufacturer's instructions (Qiagen).///label_ch1: Cy3///label_protocol_ch1: Probes labelled with Cy3 were synthesized from 5 g of the total tumour RNA and reference labelled with Cy5 were synthesized from 5 g of commercial reference RNA by reverse transcription.///taxid_ch1: 9606///source_name_ch2: Universal Human Reference RNA purchased from Stratagene///organism_ch2: Homo sapiens///characteristics_ch2: Reference///molecule_ch2: total RNA///extract_protocol_ch2: Homogenization with Trizol followed by total RNA extraction with Rneasy mini kit following manufacturer's instructions (Qiagen).///label_ch2: Cy5///label_protocol_ch2: Probes labelled with Cy3 were synthesized from 5 g of the total tumour RNA and reference labelled with Cy5 were synthesized from 5 g of commercial reference RNA by reverse transcription.///taxid_ch2: 9606///hyb_protocol: The probes were purified using ChipShot labelling cleanup system (Promega). The hybridizations were carried out using Pronto! Micro Array reagent systems (Corning Inc.). For each sample, labelled tumour cDNA and reference cDNA were co-precipitated and hybridised to the oligoarray slide. After hybridization, slides were washed sequential.///scan_protocol: Scanned on an Agilent G2565AA scanner.///scan_protocol.1: Images were quantified using Genepix 6.0.0.74 (Axon Instruments).///description: Comparison of ovarian tumors of 5 year survivors to deceased patients///data_processing: Intensities were calculated by mean spot - median background. Flagged spots were removed as well as spots with intensities below 20 in both channels. Intensities below 20 in one channel were set to 20 to compensate for extreme quotients. Loess normalization was used///platform_id: GPL5886///contact_name: Karolina,,Partheen///contact_email: [email protected]///contact_phone: +46+31 342 78 55///contact_fax: +46 +31 41 72 05///contact_department: department of Oncology///contact_institute: University of Gothenburg///contact_address: Bl Strket 2///contact_city: Gothenburg///contact_zip.postal_code: 413 45///contact_country: Sweden///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM311nnn/GSM311952/GSM311952.gpr.gz///data_row_count: 30000
1
title: 405LB///geo_accession: GSM311953///status: Public on Aug 12 2008///submission_date: Aug 12 2008///last_update_date: Aug 13 2008///type: RNA///channel_count: 2///source_name_ch1: serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: fresh frozen tumour///characteristics_ch1.1: 5 year survivor///characteristics_ch1.2: stage IIIab///characteristics_ch1.3: macroscopic residual tumor///characteristics_ch1.4: age at diagnosis 50///characteristics_ch1.5: post surgical chemo therapy farmorubicine, carboplatin and cyclophosphamide///molecule_ch1: total RNA///extract_protocol_ch1: Homogenization with Trizol followed by total RNA extraction with Rneasy mini kit following manufacturer's instructions (Qiagen).///label_ch1: Cy3///label_protocol_ch1: Probes labelled with Cy3 were synthesized from 5 g of the total tumour RNA and reference labelled with Cy5 were synthesized from 5 g of commercial reference RNA by reverse transcription.///taxid_ch1: 9606///source_name_ch2: Universal Human Reference RNA purchased from Stratagene///organism_ch2: Homo sapiens///characteristics_ch2: Reference///molecule_ch2: total RNA///extract_protocol_ch2: Homogenization with Trizol followed by total RNA extraction with Rneasy mini kit following manufacturer's instructions (Qiagen).///label_ch2: Cy5///label_protocol_ch2: Probes labelled with Cy3 were synthesized from 5 g of the total tumour RNA and reference labelled with Cy5 were synthesized from 5 g of commercial reference RNA by reverse transcription.///taxid_ch2: 9606///hyb_protocol: The probes were purified using ChipShot labelling cleanup system (Promega). The hybridizations were carried out using Pronto! Micro Array reagent systems (Corning Inc.). For each sample, labelled tumour cDNA and reference cDNA were co-precipitated and hybridised to the oligoarray slide. After hybridization, slides were washed sequential.///scan_protocol: Scanned on an Agilent G2565AA scanner.///scan_protocol.1: Images were quantified using Genepix 6.0.0.74 (Axon Instruments).///description: Comparison of ovarian tumors of 5 year survivors to deceased patients///data_processing: Intensities were calculated by mean spot - median background. Flagged spots were removed as well as spots with intensities below 20 in both channels. Intensities below 20 in one channel were set to 20 to compensate for extreme quotients. Loess normalization was used///platform_id: GPL5886///contact_name: Karolina,,Partheen///contact_email: [email protected]///contact_phone: +46+31 342 78 55///contact_fax: +46 +31 41 72 05///contact_department: department of Oncology///contact_institute: University of Gothenburg///contact_address: Bl Strket 2///contact_city: Gothenburg///contact_zip.postal_code: 413 45///contact_country: Sweden///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM311nnn/GSM311953/GSM311953.gpr.gz///data_row_count: 30000
1
title: 436DC///geo_accession: GSM311954///status: Public on Aug 12 2008///submission_date: Aug 12 2008///last_update_date: Aug 13 2008///type: RNA///channel_count: 2///source_name_ch1: serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: fresh frozen tumour///characteristics_ch1.1: deceased///characteristics_ch1.2: stage IIIc///characteristics_ch1.3: macroscopic residual tumor///characteristics_ch1.4: age at diagnosis 56///characteristics_ch1.5: post surgical chemo therapy farmorubicine, carboplatin and cyclophosphamide///molecule_ch1: total RNA///extract_protocol_ch1: Homogenization with Trizol followed by total RNA extraction with Rneasy mini kit following manufacturer's instructions (Qiagen).///label_ch1: Cy3///label_protocol_ch1: Probes labelled with Cy3 were synthesized from 5 g of the total tumour RNA and reference labelled with Cy5 were synthesized from 5 g of commercial reference RNA by reverse transcription.///taxid_ch1: 9606///source_name_ch2: Universal Human Reference RNA purchased from Stratagene///organism_ch2: Homo sapiens///characteristics_ch2: Reference///molecule_ch2: total RNA///extract_protocol_ch2: Homogenization with Trizol followed by total RNA extraction with Rneasy mini kit following manufacturer's instructions (Qiagen).///label_ch2: Cy5///label_protocol_ch2: Probes labelled with Cy3 were synthesized from 5 g of the total tumour RNA and reference labelled with Cy5 were synthesized from 5 g of commercial reference RNA by reverse transcription.///taxid_ch2: 9606///hyb_protocol: The probes were purified using ChipShot labelling cleanup system (Promega). The hybridizations were carried out using Pronto! Micro Array reagent systems (Corning Inc.). For each sample, labelled tumour cDNA and reference cDNA were co-precipitated and hybridised to the oligoarray slide. After hybridization, slides were washed sequential.///scan_protocol: Scanned on an Agilent G2565AA scanner.///scan_protocol.1: Images were quantified using Genepix 6.0.0.74 (Axon Instruments).///description: Comparison of ovarian tumors of 5 year survivors to deceased patients///data_processing: Intensities were calculated by mean spot - median background. Flagged spots were removed as well as spots with intensities below 20 in both channels. Intensities below 20 in one channel were set to 20 to compensate for extreme quotients. Loess normalization was used///platform_id: GPL5886///contact_name: Karolina,,Partheen///contact_email: [email protected]///contact_phone: +46+31 342 78 55///contact_fax: +46 +31 41 72 05///contact_department: department of Oncology///contact_institute: University of Gothenburg///contact_address: Bl Strket 2///contact_city: Gothenburg///contact_zip.postal_code: 413 45///contact_country: Sweden///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM311nnn/GSM311954/GSM311954.gpr.gz///data_row_count: 30000
1
title: 452DC///geo_accession: GSM311955///status: Public on Aug 12 2008///submission_date: Aug 12 2008///last_update_date: Aug 13 2008///type: RNA///channel_count: 2///source_name_ch1: serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: fresh frozen tumour///characteristics_ch1.1: deceased///characteristics_ch1.2: stage IIIc///characteristics_ch1.3: macroscopic residual tumor///characteristics_ch1.4: age at diagnosis 69///characteristics_ch1.5: post surgical chemo therapy farmorubicine, carboplatin and cyclophosphamide///molecule_ch1: total RNA///extract_protocol_ch1: Homogenization with Trizol followed by total RNA extraction with Rneasy mini kit following manufacturer's instructions (Qiagen).///label_ch1: Cy3///label_protocol_ch1: Probes labelled with Cy3 were synthesized from 5 g of the total tumour RNA and reference labelled with Cy5 were synthesized from 5 g of commercial reference RNA by reverse transcription.///taxid_ch1: 9606///source_name_ch2: Universal Human Reference RNA purchased from Stratagene///organism_ch2: Homo sapiens///characteristics_ch2: Reference///molecule_ch2: total RNA///extract_protocol_ch2: Homogenization with Trizol followed by total RNA extraction with Rneasy mini kit following manufacturer's instructions (Qiagen).///label_ch2: Cy5///label_protocol_ch2: Probes labelled with Cy3 were synthesized from 5 g of the total tumour RNA and reference labelled with Cy5 were synthesized from 5 g of commercial reference RNA by reverse transcription.///taxid_ch2: 9606///hyb_protocol: The probes were purified using ChipShot labelling cleanup system (Promega). The hybridizations were carried out using Pronto! Micro Array reagent systems (Corning Inc.). For each sample, labelled tumour cDNA and reference cDNA were co-precipitated and hybridised to the oligoarray slide. After hybridization, slides were washed sequential.///scan_protocol: Scanned on an Agilent G2565AA scanner.///scan_protocol.1: Images were quantified using Genepix 6.0.0.74 (Axon Instruments).///description: Comparison of ovarian tumors of 5 year survivors to deceased patients///data_processing: Intensities were calculated by mean spot - median background. Flagged spots were removed as well as spots with intensities below 20 in both channels. Intensities below 20 in one channel were set to 20 to compensate for extreme quotients. Loess normalization was used///platform_id: GPL5886///contact_name: Karolina,,Partheen///contact_email: [email protected]///contact_phone: +46+31 342 78 55///contact_fax: +46 +31 41 72 05///contact_department: department of Oncology///contact_institute: University of Gothenburg///contact_address: Bl Strket 2///contact_city: Gothenburg///contact_zip.postal_code: 413 45///contact_country: Sweden///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM311nnn/GSM311955/GSM311955.gpr.gz///data_row_count: 30000
1
title: 454LC///geo_accession: GSM311956///status: Public on Aug 12 2008///submission_date: Aug 12 2008///last_update_date: Aug 13 2008///type: RNA///channel_count: 2///source_name_ch1: serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: fresh frozen tumour///characteristics_ch1.1: 5 year survivor///characteristics_ch1.2: stage IIIc///characteristics_ch1.3: macroscopic residual tumor///characteristics_ch1.4: age at diagnosis 43///characteristics_ch1.5: post surgical chemo therapy farmorubicine, carboplatin and cyclophosphamide///molecule_ch1: total RNA///extract_protocol_ch1: Homogenization with Trizol followed by total RNA extraction with Rneasy mini kit following manufacturer's instructions (Qiagen).///label_ch1: Cy3///label_protocol_ch1: Probes labelled with Cy3 were synthesized from 5 g of the total tumour RNA and reference labelled with Cy5 were synthesized from 5 g of commercial reference RNA by reverse transcription.///taxid_ch1: 9606///source_name_ch2: Universal Human Reference RNA purchased from Stratagene///organism_ch2: Homo sapiens///characteristics_ch2: Reference///molecule_ch2: total RNA///extract_protocol_ch2: Homogenization with Trizol followed by total RNA extraction with Rneasy mini kit following manufacturer's instructions (Qiagen).///label_ch2: Cy5///label_protocol_ch2: Probes labelled with Cy3 were synthesized from 5 g of the total tumour RNA and reference labelled with Cy5 were synthesized from 5 g of commercial reference RNA by reverse transcription.///taxid_ch2: 9606///hyb_protocol: The probes were purified using ChipShot labelling cleanup system (Promega). The hybridizations were carried out using Pronto! Micro Array reagent systems (Corning Inc.). For each sample, labelled tumour cDNA and reference cDNA were co-precipitated and hybridised to the oligoarray slide. After hybridization, slides were washed sequential.///scan_protocol: Scanned on an Agilent G2565AA scanner.///scan_protocol.1: Images were quantified using Genepix 6.0.0.74 (Axon Instruments).///description: Comparison of ovarian tumors of 5 year survivors to deceased patients///data_processing: Intensities were calculated by mean spot - median background. Flagged spots were removed as well as spots with intensities below 20 in both channels. Intensities below 20 in one channel were set to 20 to compensate for extreme quotients. Loess normalization was used///platform_id: GPL5886///contact_name: Karolina,,Partheen///contact_email: [email protected]///contact_phone: +46+31 342 78 55///contact_fax: +46 +31 41 72 05///contact_department: department of Oncology///contact_institute: University of Gothenburg///contact_address: Bl Strket 2///contact_city: Gothenburg///contact_zip.postal_code: 413 45///contact_country: Sweden///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM311nnn/GSM311956/GSM311956.gpr.gz///data_row_count: 30000
1
title: 45LA0///geo_accession: GSM311939///status: Public on Aug 12 2008///submission_date: Aug 12 2008///last_update_date: Aug 13 2008///type: RNA///channel_count: 2///source_name_ch1: serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: fresh frozen tumour///characteristics_ch1.1: 5 year survivor///characteristics_ch1.2: stage IIIab///characteristics_ch1.3: no macroscopic residual tumor///characteristics_ch1.4: age at diagnosis 43///characteristics_ch1.5: post surgical chemo therapy farmorubicine, carboplatin and cyclophosphamide///molecule_ch1: total RNA///extract_protocol_ch1: Homogenization with Trizol followed by total RNA extraction with Rneasy mini kit following manufacturer's instructions (Qiagen).///label_ch1: Cy3///label_protocol_ch1: Probes labelled with Cy3 were synthesized from 5 g of the total tumour RNA and reference labelled with Cy5 were synthesized from 5 g of commercial reference RNA by reverse transcription.///taxid_ch1: 9606///source_name_ch2: Universal Human Reference RNA purchased from Stratagene///organism_ch2: Homo sapiens///characteristics_ch2: Reference///molecule_ch2: total RNA///extract_protocol_ch2: Homogenization with Trizol followed by total RNA extraction with Rneasy mini kit following manufacturer's instructions (Qiagen).///label_ch2: Cy5///label_protocol_ch2: Probes labelled with Cy3 were synthesized from 5 g of the total tumour RNA and reference labelled with Cy5 were synthesized from 5 g of commercial reference RNA by reverse transcription.///taxid_ch2: 9606///hyb_protocol: The probes were purified using ChipShot labelling cleanup system (Promega). The hybridizations were carried out using Pronto! Micro Array reagent systems (Corning Inc.). For each sample, labelled tumour cDNA and reference cDNA were co-precipitated and hybridised to the oligoarray slide. After hybridization, slides were washed sequential.///scan_protocol: Scanned on an Agilent G2565AA scanner.///scan_protocol.1: Images were quantified using Genepix 6.0.0.74 (Axon Instruments).///description: Comparison of ovarian tumors of 5 year survivors to deceased patients///data_processing: Intensities were calculated by mean spot - median background. Flagged spots were removed as well as spots with intensities below 20 in both channels. Intensities below 20 in one channel were set to 20 to compensate for extreme quotients. Loess normalization was used///platform_id: GPL5886///contact_name: Karolina,,Partheen///contact_email: [email protected]///contact_phone: +46+31 342 78 55///contact_fax: +46 +31 41 72 05///contact_department: department of Oncology///contact_institute: University of Gothenburg///contact_address: Bl Strket 2///contact_city: Gothenburg///contact_zip.postal_code: 413 45///contact_country: Sweden///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM311nnn/GSM311939/GSM311939.gpr.gz///data_row_count: 30000
1
title: 462DB///geo_accession: GSM311957///status: Public on Aug 12 2008///submission_date: Aug 12 2008///last_update_date: Aug 13 2008///type: RNA///channel_count: 2///source_name_ch1: serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: fresh frozen tumour///characteristics_ch1.1: deceased///characteristics_ch1.2: stage IIIab///characteristics_ch1.3: macroscopic residual tumor///characteristics_ch1.4: age at diagnosis 59///characteristics_ch1.5: post surgical chemo therapy farmorubicine, carboplatin and cyclophosphamide///molecule_ch1: total RNA///extract_protocol_ch1: Homogenization with Trizol followed by total RNA extraction with Rneasy mini kit following manufacturer's instructions (Qiagen).///label_ch1: Cy3///label_protocol_ch1: Probes labelled with Cy3 were synthesized from 5 g of the total tumour RNA and reference labelled with Cy5 were synthesized from 5 g of commercial reference RNA by reverse transcription.///taxid_ch1: 9606///source_name_ch2: Universal Human Reference RNA purchased from Stratagene///organism_ch2: Homo sapiens///characteristics_ch2: Reference///molecule_ch2: total RNA///extract_protocol_ch2: Homogenization with Trizol followed by total RNA extraction with Rneasy mini kit following manufacturer's instructions (Qiagen).///label_ch2: Cy5///label_protocol_ch2: Probes labelled with Cy3 were synthesized from 5 g of the total tumour RNA and reference labelled with Cy5 were synthesized from 5 g of commercial reference RNA by reverse transcription.///taxid_ch2: 9606///hyb_protocol: The probes were purified using ChipShot labelling cleanup system (Promega). The hybridizations were carried out using Pronto! Micro Array reagent systems (Corning Inc.). For each sample, labelled tumour cDNA and reference cDNA were co-precipitated and hybridised to the oligoarray slide. After hybridization, slides were washed sequential.///scan_protocol: Scanned on an Agilent G2565AA scanner.///scan_protocol.1: Images were quantified using Genepix 6.0.0.74 (Axon Instruments).///description: Comparison of ovarian tumors of 5 year survivors to deceased patients///data_processing: Intensities were calculated by mean spot - median background. Flagged spots were removed as well as spots with intensities below 20 in both channels. Intensities below 20 in one channel were set to 20 to compensate for extreme quotients. Loess normalization was used///platform_id: GPL5886///contact_name: Karolina,,Partheen///contact_email: [email protected]///contact_phone: +46+31 342 78 55///contact_fax: +46 +31 41 72 05///contact_department: department of Oncology///contact_institute: University of Gothenburg///contact_address: Bl Strket 2///contact_city: Gothenburg///contact_zip.postal_code: 413 45///contact_country: Sweden///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM311nnn/GSM311957/GSM311957.gpr.gz///data_row_count: 30000
1
title: 46LB0///geo_accession: GSM311940///status: Public on Aug 12 2008///submission_date: Aug 12 2008///last_update_date: Aug 13 2008///type: RNA///channel_count: 2///source_name_ch1: serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: fresh frozen tumour///characteristics_ch1.1: 5 year survivor///characteristics_ch1.2: stage IIIab///characteristics_ch1.3: no macroscopic residual tumor///characteristics_ch1.4: age at diagnosis 43///characteristics_ch1.5: post surgical chemo therapy farmorubicine, carboplatin and cyclophosphamide///molecule_ch1: total RNA///extract_protocol_ch1: Homogenization with Trizol followed by total RNA extraction with Rneasy mini kit following manufacturer's instructions (Qiagen).///label_ch1: Cy3///label_protocol_ch1: Probes labelled with Cy3 were synthesized from 5 g of the total tumour RNA and reference labelled with Cy5 were synthesized from 5 g of commercial reference RNA by reverse transcription.///taxid_ch1: 9606///source_name_ch2: Universal Human Reference RNA purchased from Stratagene///organism_ch2: Homo sapiens///characteristics_ch2: Reference///molecule_ch2: total RNA///extract_protocol_ch2: Homogenization with Trizol followed by total RNA extraction with Rneasy mini kit following manufacturer's instructions (Qiagen).///label_ch2: Cy5///label_protocol_ch2: Probes labelled with Cy3 were synthesized from 5 g of the total tumour RNA and reference labelled with Cy5 were synthesized from 5 g of commercial reference RNA by reverse transcription.///taxid_ch2: 9606///hyb_protocol: The probes were purified using ChipShot labelling cleanup system (Promega). The hybridizations were carried out using Pronto! Micro Array reagent systems (Corning Inc.). For each sample, labelled tumour cDNA and reference cDNA were co-precipitated and hybridised to the oligoarray slide. After hybridization, slides were washed sequential.///scan_protocol: Scanned on an Agilent G2565AA scanner.///scan_protocol.1: Images were quantified using Genepix 6.0.0.74 (Axon Instruments).///description: Comparison of ovarian tumors of 5 year survivors to deceased patients///data_processing: Intensities were calculated by mean spot - median background. Flagged spots were removed as well as spots with intensities below 20 in both channels. Intensities below 20 in one channel were set to 20 to compensate for extreme quotients. Loess normalization was used///platform_id: GPL5886///contact_name: Karolina,,Partheen///contact_email: [email protected]///contact_phone: +46+31 342 78 55///contact_fax: +46 +31 41 72 05///contact_department: department of Oncology///contact_institute: University of Gothenburg///contact_address: Bl Strket 2///contact_city: Gothenburg///contact_zip.postal_code: 413 45///contact_country: Sweden///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM311nnn/GSM311940/GSM311940.gpr.gz///data_row_count: 30000
1
title: 47DC///geo_accession: GSM311941///status: Public on Aug 12 2008///submission_date: Aug 12 2008///last_update_date: Aug 13 2008///type: RNA///channel_count: 2///source_name_ch1: serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: fresh frozen tumour///characteristics_ch1.1: deceased///characteristics_ch1.2: stage IIIc///characteristics_ch1.3: macroscopic residual tumor///characteristics_ch1.4: age at diagnosis 56///characteristics_ch1.5: post surgical chemo therapy farmorubicine, carboplatin and cyclophosphamide///molecule_ch1: total RNA///extract_protocol_ch1: Homogenization with Trizol followed by total RNA extraction with Rneasy mini kit following manufacturer's instructions (Qiagen).///label_ch1: Cy3///label_protocol_ch1: Probes labelled with Cy3 were synthesized from 5 g of the total tumour RNA and reference labelled with Cy5 were synthesized from 5 g of commercial reference RNA by reverse transcription.///taxid_ch1: 9606///source_name_ch2: Universal Human Reference RNA purchased from Stratagene///organism_ch2: Homo sapiens///characteristics_ch2: Reference///molecule_ch2: total RNA///extract_protocol_ch2: Homogenization with Trizol followed by total RNA extraction with Rneasy mini kit following manufacturer's instructions (Qiagen).///label_ch2: Cy5///label_protocol_ch2: Probes labelled with Cy3 were synthesized from 5 g of the total tumour RNA and reference labelled with Cy5 were synthesized from 5 g of commercial reference RNA by reverse transcription.///taxid_ch2: 9606///hyb_protocol: The probes were purified using ChipShot labelling cleanup system (Promega). The hybridizations were carried out using Pronto! Micro Array reagent systems (Corning Inc.). For each sample, labelled tumour cDNA and reference cDNA were co-precipitated and hybridised to the oligoarray slide. After hybridization, slides were washed sequential.///scan_protocol: Scanned on an Agilent G2565AA scanner.///scan_protocol.1: Images were quantified using Genepix 6.0.0.74 (Axon Instruments).///description: Comparison of ovarian tumors of 5 year survivors to deceased patients///data_processing: Intensities were calculated by mean spot - median background. Flagged spots were removed as well as spots with intensities below 20 in both channels. Intensities below 20 in one channel were set to 20 to compensate for extreme quotients. Loess normalization was used///platform_id: GPL5886///contact_name: Karolina,,Partheen///contact_email: [email protected]///contact_phone: +46+31 342 78 55///contact_fax: +46 +31 41 72 05///contact_department: department of Oncology///contact_institute: University of Gothenburg///contact_address: Bl Strket 2///contact_city: Gothenburg///contact_zip.postal_code: 413 45///contact_country: Sweden///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM311nnn/GSM311941/GSM311941.gpr.gz///data_row_count: 30000
1
title: 480DC0///geo_accession: GSM311958///status: Public on Aug 12 2008///submission_date: Aug 12 2008///last_update_date: Aug 13 2008///type: RNA///channel_count: 2///source_name_ch1: serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: fresh frozen tumour///characteristics_ch1.1: deceased///characteristics_ch1.2: stage IIIc///characteristics_ch1.3: no macroscopic residual tumor///characteristics_ch1.4: age at diagnosis 73///characteristics_ch1.5: post surgical chemo therapy farmorubicine, carboplatin and cyclophosphamide///molecule_ch1: total RNA///extract_protocol_ch1: Homogenization with Trizol followed by total RNA extraction with Rneasy mini kit following manufacturer's instructions (Qiagen).///label_ch1: Cy3///label_protocol_ch1: Probes labelled with Cy3 were synthesized from 5 g of the total tumour RNA and reference labelled with Cy5 were synthesized from 5 g of commercial reference RNA by reverse transcription.///taxid_ch1: 9606///source_name_ch2: Universal Human Reference RNA purchased from Stratagene///organism_ch2: Homo sapiens///characteristics_ch2: Reference///molecule_ch2: total RNA///extract_protocol_ch2: Homogenization with Trizol followed by total RNA extraction with Rneasy mini kit following manufacturer's instructions (Qiagen).///label_ch2: Cy5///label_protocol_ch2: Probes labelled with Cy3 were synthesized from 5 g of the total tumour RNA and reference labelled with Cy5 were synthesized from 5 g of commercial reference RNA by reverse transcription.///taxid_ch2: 9606///hyb_protocol: The probes were purified using ChipShot labelling cleanup system (Promega). The hybridizations were carried out using Pronto! Micro Array reagent systems (Corning Inc.). For each sample, labelled tumour cDNA and reference cDNA were co-precipitated and hybridised to the oligoarray slide. After hybridization, slides were washed sequential.///scan_protocol: Scanned on an Agilent G2565AA scanner.///scan_protocol.1: Images were quantified using Genepix 6.0.0.74 (Axon Instruments).///description: Comparison of ovarian tumors of 5 year survivors to deceased patients///data_processing: Intensities were calculated by mean spot - median background. Flagged spots were removed as well as spots with intensities below 20 in both channels. Intensities below 20 in one channel were set to 20 to compensate for extreme quotients. Loess normalization was used///platform_id: GPL5886///contact_name: Karolina,,Partheen///contact_email: [email protected]///contact_phone: +46+31 342 78 55///contact_fax: +46 +31 41 72 05///contact_department: department of Oncology///contact_institute: University of Gothenburg///contact_address: Bl Strket 2///contact_city: Gothenburg///contact_zip.postal_code: 413 45///contact_country: Sweden///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM311nnn/GSM311958/GSM311958.gpr.gz///data_row_count: 30000
1
title: 489DC///geo_accession: GSM311959///status: Public on Aug 12 2008///submission_date: Aug 12 2008///last_update_date: Aug 13 2008///type: RNA///channel_count: 2///source_name_ch1: serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: fresh frozen tumour///characteristics_ch1.1: deceased///characteristics_ch1.2: stage IIIc///characteristics_ch1.3: macroscopic residual tumor///characteristics_ch1.4: age at diagnosis 64///characteristics_ch1.5: post surgical chemo therapy farmorubicine, carboplatin and cyclophosphamide///molecule_ch1: total RNA///extract_protocol_ch1: Homogenization with Trizol followed by total RNA extraction with Rneasy mini kit following manufacturer's instructions (Qiagen).///label_ch1: Cy3///label_protocol_ch1: Probes labelled with Cy3 were synthesized from 5 g of the total tumour RNA and reference labelled with Cy5 were synthesized from 5 g of commercial reference RNA by reverse transcription.///taxid_ch1: 9606///source_name_ch2: Universal Human Reference RNA purchased from Stratagene///organism_ch2: Homo sapiens///characteristics_ch2: Reference///molecule_ch2: total RNA///extract_protocol_ch2: Homogenization with Trizol followed by total RNA extraction with Rneasy mini kit following manufacturer's instructions (Qiagen).///label_ch2: Cy5///label_protocol_ch2: Probes labelled with Cy3 were synthesized from 5 g of the total tumour RNA and reference labelled with Cy5 were synthesized from 5 g of commercial reference RNA by reverse transcription.///taxid_ch2: 9606///hyb_protocol: The probes were purified using ChipShot labelling cleanup system (Promega). The hybridizations were carried out using Pronto! Micro Array reagent systems (Corning Inc.). For each sample, labelled tumour cDNA and reference cDNA were co-precipitated and hybridised to the oligoarray slide. After hybridization, slides were washed sequential.///scan_protocol: Scanned on an Agilent G2565AA scanner.///scan_protocol.1: Images were quantified using Genepix 6.0.0.74 (Axon Instruments).///description: Comparison of ovarian tumors of 5 year survivors to deceased patients///data_processing: Intensities were calculated by mean spot - median background. Flagged spots were removed as well as spots with intensities below 20 in both channels. Intensities below 20 in one channel were set to 20 to compensate for extreme quotients. Loess normalization was used///platform_id: GPL5886///contact_name: Karolina,,Partheen///contact_email: [email protected]///contact_phone: +46+31 342 78 55///contact_fax: +46 +31 41 72 05///contact_department: department of Oncology///contact_institute: University of Gothenburg///contact_address: Bl Strket 2///contact_city: Gothenburg///contact_zip.postal_code: 413 45///contact_country: Sweden///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM311nnn/GSM311959/GSM311959.gpr.gz///data_row_count: 30000
1
title: 505DB///geo_accession: GSM311960///status: Public on Aug 12 2008///submission_date: Aug 12 2008///last_update_date: Aug 13 2008///type: RNA///channel_count: 2///source_name_ch1: serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: fresh frozen tumour///characteristics_ch1.1: deceased///characteristics_ch1.2: stage IIIab///characteristics_ch1.3: macroscopic residual tumor///characteristics_ch1.4: age at diagnosis 74///characteristics_ch1.5: post surgical chemo therapy farmorubicine, carboplatin and cyclophosphamide///molecule_ch1: total RNA///extract_protocol_ch1: Homogenization with Trizol followed by total RNA extraction with Rneasy mini kit following manufacturer's instructions (Qiagen).///label_ch1: Cy3///label_protocol_ch1: Probes labelled with Cy3 were synthesized from 5 g of the total tumour RNA and reference labelled with Cy5 were synthesized from 5 g of commercial reference RNA by reverse transcription.///taxid_ch1: 9606///source_name_ch2: Universal Human Reference RNA purchased from Stratagene///organism_ch2: Homo sapiens///characteristics_ch2: Reference///molecule_ch2: total RNA///extract_protocol_ch2: Homogenization with Trizol followed by total RNA extraction with Rneasy mini kit following manufacturer's instructions (Qiagen).///label_ch2: Cy5///label_protocol_ch2: Probes labelled with Cy3 were synthesized from 5 g of the total tumour RNA and reference labelled with Cy5 were synthesized from 5 g of commercial reference RNA by reverse transcription.///taxid_ch2: 9606///hyb_protocol: The probes were purified using ChipShot labelling cleanup system (Promega). The hybridizations were carried out using Pronto! Micro Array reagent systems (Corning Inc.). For each sample, labelled tumour cDNA and reference cDNA were co-precipitated and hybridised to the oligoarray slide. After hybridization, slides were washed sequential.///scan_protocol: Scanned on an Agilent G2565AA scanner.///scan_protocol.1: Images were quantified using Genepix 6.0.0.74 (Axon Instruments).///description: Comparison of ovarian tumors of 5 year survivors to deceased patients///data_processing: Intensities were calculated by mean spot - median background. Flagged spots were removed as well as spots with intensities below 20 in both channels. Intensities below 20 in one channel were set to 20 to compensate for extreme quotients. Loess normalization was used///platform_id: GPL5886///contact_name: Karolina,,Partheen///contact_email: [email protected]///contact_phone: +46+31 342 78 55///contact_fax: +46 +31 41 72 05///contact_department: department of Oncology///contact_institute: University of Gothenburg///contact_address: Bl Strket 2///contact_city: Gothenburg///contact_zip.postal_code: 413 45///contact_country: Sweden///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM311nnn/GSM311960/GSM311960.gpr.gz///data_row_count: 30000
1
title: 541DC///geo_accession: GSM311961///status: Public on Aug 12 2008///submission_date: Aug 12 2008///last_update_date: Aug 13 2008///type: RNA///channel_count: 2///source_name_ch1: serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: fresh frozen tumour///characteristics_ch1.1: deceased///characteristics_ch1.2: stage IIIc///characteristics_ch1.3: macroscopic residual tumor///characteristics_ch1.4: age at diagnosis 64///characteristics_ch1.5: post surgical chemo therapy farmorubicine, carboplatin and cyclophosphamide///molecule_ch1: total RNA///extract_protocol_ch1: Homogenization with Trizol followed by total RNA extraction with Rneasy mini kit following manufacturer's instructions (Qiagen).///label_ch1: Cy3///label_protocol_ch1: Probes labelled with Cy3 were synthesized from 5 g of the total tumour RNA and reference labelled with Cy5 were synthesized from 5 g of commercial reference RNA by reverse transcription.///taxid_ch1: 9606///source_name_ch2: Universal Human Reference RNA purchased from Stratagene///organism_ch2: Homo sapiens///characteristics_ch2: Reference///molecule_ch2: total RNA///extract_protocol_ch2: Homogenization with Trizol followed by total RNA extraction with Rneasy mini kit following manufacturer's instructions (Qiagen).///label_ch2: Cy5///label_protocol_ch2: Probes labelled with Cy3 were synthesized from 5 g of the total tumour RNA and reference labelled with Cy5 were synthesized from 5 g of commercial reference RNA by reverse transcription.///taxid_ch2: 9606///hyb_protocol: The probes were purified using ChipShot labelling cleanup system (Promega). The hybridizations were carried out using Pronto! Micro Array reagent systems (Corning Inc.). For each sample, labelled tumour cDNA and reference cDNA were co-precipitated and hybridised to the oligoarray slide. After hybridization, slides were washed sequential.///scan_protocol: Scanned on an Agilent G2565AA scanner.///scan_protocol.1: Images were quantified using Genepix 6.0.0.74 (Axon Instruments).///description: Comparison of ovarian tumors of 5 year survivors to deceased patients///data_processing: Intensities were calculated by mean spot - median background. Flagged spots were removed as well as spots with intensities below 20 in both channels. Intensities below 20 in one channel were set to 20 to compensate for extreme quotients. Loess normalization was used///platform_id: GPL5886///contact_name: Karolina,,Partheen///contact_email: [email protected]///contact_phone: +46+31 342 78 55///contact_fax: +46 +31 41 72 05///contact_department: department of Oncology///contact_institute: University of Gothenburg///contact_address: Bl Strket 2///contact_city: Gothenburg///contact_zip.postal_code: 413 45///contact_country: Sweden///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM311nnn/GSM311961/GSM311961.gpr.gz///data_row_count: 30000
1
title: 559DC///geo_accession: GSM311962///status: Public on Aug 12 2008///submission_date: Aug 12 2008///last_update_date: Aug 13 2008///type: RNA///channel_count: 2///source_name_ch1: serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: fresh frozen tumour///characteristics_ch1.1: deceased///characteristics_ch1.2: stage IIIc///characteristics_ch1.3: macroscopic residual tumor///characteristics_ch1.4: age at diagnosis 75///characteristics_ch1.5: post surgical chemo therapy farmorubicine, carboplatin and cyclophosphamide///molecule_ch1: total RNA///extract_protocol_ch1: Homogenization with Trizol followed by total RNA extraction with Rneasy mini kit following manufacturer's instructions (Qiagen).///label_ch1: Cy3///label_protocol_ch1: Probes labelled with Cy3 were synthesized from 5 g of the total tumour RNA and reference labelled with Cy5 were synthesized from 5 g of commercial reference RNA by reverse transcription.///taxid_ch1: 9606///source_name_ch2: Universal Human Reference RNA purchased from Stratagene///organism_ch2: Homo sapiens///characteristics_ch2: Reference///molecule_ch2: total RNA///extract_protocol_ch2: Homogenization with Trizol followed by total RNA extraction with Rneasy mini kit following manufacturer's instructions (Qiagen).///label_ch2: Cy5///label_protocol_ch2: Probes labelled with Cy3 were synthesized from 5 g of the total tumour RNA and reference labelled with Cy5 were synthesized from 5 g of commercial reference RNA by reverse transcription.///taxid_ch2: 9606///hyb_protocol: The probes were purified using ChipShot labelling cleanup system (Promega). The hybridizations were carried out using Pronto! Micro Array reagent systems (Corning Inc.). For each sample, labelled tumour cDNA and reference cDNA were co-precipitated and hybridised to the oligoarray slide. After hybridization, slides were washed sequential.///scan_protocol: Scanned on an Agilent G2565AA scanner.///scan_protocol.1: Images were quantified using Genepix 6.0.0.74 (Axon Instruments).///description: Comparison of ovarian tumors of 5 year survivors to deceased patients///data_processing: Intensities were calculated by mean spot - median background. Flagged spots were removed as well as spots with intensities below 20 in both channels. Intensities below 20 in one channel were set to 20 to compensate for extreme quotients. Loess normalization was used///platform_id: GPL5886///contact_name: Karolina,,Partheen///contact_email: [email protected]///contact_phone: +46+31 342 78 55///contact_fax: +46 +31 41 72 05///contact_department: department of Oncology///contact_institute: University of Gothenburg///contact_address: Bl Strket 2///contact_city: Gothenburg///contact_zip.postal_code: 413 45///contact_country: Sweden///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM311nnn/GSM311962/GSM311962.gpr.gz///data_row_count: 30000
1
title: 563LA///geo_accession: GSM311963///status: Public on Aug 12 2008///submission_date: Aug 12 2008///last_update_date: Aug 13 2008///type: RNA///channel_count: 2///source_name_ch1: serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: fresh frozen tumour///characteristics_ch1.1: 5 year survivor///characteristics_ch1.2: stage IIIab///characteristics_ch1.3: macroscopic residual tumor///characteristics_ch1.4: age at diagnosis 62///characteristics_ch1.5: post surgical chemo therapy farmorubicine, carboplatin and cyclophosphamide///molecule_ch1: total RNA///extract_protocol_ch1: Homogenization with Trizol followed by total RNA extraction with Rneasy mini kit following manufacturer's instructions (Qiagen).///label_ch1: Cy3///label_protocol_ch1: Probes labelled with Cy3 were synthesized from 5 g of the total tumour RNA and reference labelled with Cy5 were synthesized from 5 g of commercial reference RNA by reverse transcription.///taxid_ch1: 9606///source_name_ch2: Universal Human Reference RNA purchased from Stratagene///organism_ch2: Homo sapiens///characteristics_ch2: Reference///molecule_ch2: total RNA///extract_protocol_ch2: Homogenization with Trizol followed by total RNA extraction with Rneasy mini kit following manufacturer's instructions (Qiagen).///label_ch2: Cy5///label_protocol_ch2: Probes labelled with Cy3 were synthesized from 5 g of the total tumour RNA and reference labelled with Cy5 were synthesized from 5 g of commercial reference RNA by reverse transcription.///taxid_ch2: 9606///hyb_protocol: The probes were purified using ChipShot labelling cleanup system (Promega). The hybridizations were carried out using Pronto! Micro Array reagent systems (Corning Inc.). For each sample, labelled tumour cDNA and reference cDNA were co-precipitated and hybridised to the oligoarray slide. After hybridization, slides were washed sequential.///scan_protocol: Scanned on an Agilent G2565AA scanner.///scan_protocol.1: Images were quantified using Genepix 6.0.0.74 (Axon Instruments).///description: Comparison of ovarian tumors of 5 year survivors to deceased patients///data_processing: Intensities were calculated by mean spot - median background. Flagged spots were removed as well as spots with intensities below 20 in both channels. Intensities below 20 in one channel were set to 20 to compensate for extreme quotients. Loess normalization was used///platform_id: GPL5886///contact_name: Karolina,,Partheen///contact_email: [email protected]///contact_phone: +46+31 342 78 55///contact_fax: +46 +31 41 72 05///contact_department: department of Oncology///contact_institute: University of Gothenburg///contact_address: Bl Strket 2///contact_city: Gothenburg///contact_zip.postal_code: 413 45///contact_country: Sweden///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM311nnn/GSM311963/GSM311963.gpr.gz///data_row_count: 30000
1
title: 626DC///geo_accession: GSM311964///status: Public on Aug 12 2008///submission_date: Aug 12 2008///last_update_date: Aug 13 2008///type: RNA///channel_count: 2///source_name_ch1: serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: fresh frozen tumour///characteristics_ch1.1: deceased///characteristics_ch1.2: stage IIIc///characteristics_ch1.3: macroscopic residual tumor///characteristics_ch1.4: age at diagnosis 54///characteristics_ch1.5: post surgical chemo therapy farmorubicine, carboplatin and cyclophosphamide///molecule_ch1: total RNA///extract_protocol_ch1: Homogenization with Trizol followed by total RNA extraction with Rneasy mini kit following manufacturer's instructions (Qiagen).///label_ch1: Cy3///label_protocol_ch1: Probes labelled with Cy3 were synthesized from 5 g of the total tumour RNA and reference labelled with Cy5 were synthesized from 5 g of commercial reference RNA by reverse transcription.///taxid_ch1: 9606///source_name_ch2: Universal Human Reference RNA purchased from Stratagene///organism_ch2: Homo sapiens///characteristics_ch2: Reference///molecule_ch2: total RNA///extract_protocol_ch2: Homogenization with Trizol followed by total RNA extraction with Rneasy mini kit following manufacturer's instructions (Qiagen).///label_ch2: Cy5///label_protocol_ch2: Probes labelled with Cy3 were synthesized from 5 g of the total tumour RNA and reference labelled with Cy5 were synthesized from 5 g of commercial reference RNA by reverse transcription.///taxid_ch2: 9606///hyb_protocol: The probes were purified using ChipShot labelling cleanup system (Promega). The hybridizations were carried out using Pronto! Micro Array reagent systems (Corning Inc.). For each sample, labelled tumour cDNA and reference cDNA were co-precipitated and hybridised to the oligoarray slide. After hybridization, slides were washed sequential.///scan_protocol: Scanned on an Agilent G2565AA scanner.///scan_protocol.1: Images were quantified using Genepix 6.0.0.74 (Axon Instruments).///description: Comparison of ovarian tumors of 5 year survivors to deceased patients///data_processing: Intensities were calculated by mean spot - median background. Flagged spots were removed as well as spots with intensities below 20 in both channels. Intensities below 20 in one channel were set to 20 to compensate for extreme quotients. Loess normalization was used///platform_id: GPL5886///contact_name: Karolina,,Partheen///contact_email: [email protected]///contact_phone: +46+31 342 78 55///contact_fax: +46 +31 41 72 05///contact_department: department of Oncology///contact_institute: University of Gothenburg///contact_address: Bl Strket 2///contact_city: Gothenburg///contact_zip.postal_code: 413 45///contact_country: Sweden///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM311nnn/GSM311964/GSM311964.gpr.gz///data_row_count: 30000
1
title: 662DC///geo_accession: GSM311965///status: Public on Aug 12 2008///submission_date: Aug 12 2008///last_update_date: Aug 13 2008///type: RNA///channel_count: 2///source_name_ch1: serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: fresh frozen tumour///characteristics_ch1.1: deceased///characteristics_ch1.2: stage IIIc///characteristics_ch1.3: macroscopic residual tumor///characteristics_ch1.4: age at diagnosis 65///characteristics_ch1.5: post surgical chemo therapy farmorubicine, carboplatin and cyclophosphamide///molecule_ch1: total RNA///extract_protocol_ch1: Homogenization with Trizol followed by total RNA extraction with Rneasy mini kit following manufacturer's instructions (Qiagen).///label_ch1: Cy3///label_protocol_ch1: Probes labelled with Cy3 were synthesized from 5 g of the total tumour RNA and reference labelled with Cy5 were synthesized from 5 g of commercial reference RNA by reverse transcription.///taxid_ch1: 9606///source_name_ch2: Universal Human Reference RNA purchased from Stratagene///organism_ch2: Homo sapiens///characteristics_ch2: Reference///molecule_ch2: total RNA///extract_protocol_ch2: Homogenization with Trizol followed by total RNA extraction with Rneasy mini kit following manufacturer's instructions (Qiagen).///label_ch2: Cy5///label_protocol_ch2: Probes labelled with Cy3 were synthesized from 5 g of the total tumour RNA and reference labelled with Cy5 were synthesized from 5 g of commercial reference RNA by reverse transcription.///taxid_ch2: 9606///hyb_protocol: The probes were purified using ChipShot labelling cleanup system (Promega). The hybridizations were carried out using Pronto! Micro Array reagent systems (Corning Inc.). For each sample, labelled tumour cDNA and reference cDNA were co-precipitated and hybridised to the oligoarray slide. After hybridization, slides were washed sequential.///scan_protocol: Scanned on an Agilent G2565AA scanner.///scan_protocol.1: Images were quantified using Genepix 6.0.0.74 (Axon Instruments).///description: Comparison of ovarian tumors of 5 year survivors to deceased patients///data_processing: Intensities were calculated by mean spot - median background. Flagged spots were removed as well as spots with intensities below 20 in both channels. Intensities below 20 in one channel were set to 20 to compensate for extreme quotients. Loess normalization was used///platform_id: GPL5886///contact_name: Karolina,,Partheen///contact_email: [email protected]///contact_phone: +46+31 342 78 55///contact_fax: +46 +31 41 72 05///contact_department: department of Oncology///contact_institute: University of Gothenburg///contact_address: Bl Strket 2///contact_city: Gothenburg///contact_zip.postal_code: 413 45///contact_country: Sweden///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM311nnn/GSM311965/GSM311965.gpr.gz///data_row_count: 30000
1
title: 719DC///geo_accession: GSM311966///status: Public on Aug 12 2008///submission_date: Aug 12 2008///last_update_date: Aug 13 2008///type: RNA///channel_count: 2///source_name_ch1: serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: fresh frozen tumour///characteristics_ch1.1: deceased///characteristics_ch1.2: stage IIIc///characteristics_ch1.3: macroscopic residual tumor///characteristics_ch1.4: age at diagnosis 77///characteristics_ch1.5: post surgical chemo therapy farmorubicine, carboplatin and cyclophosphamide///molecule_ch1: total RNA///extract_protocol_ch1: Homogenization with Trizol followed by total RNA extraction with Rneasy mini kit following manufacturer's instructions (Qiagen).///label_ch1: Cy3///label_protocol_ch1: Probes labelled with Cy3 were synthesized from 5 g of the total tumour RNA and reference labelled with Cy5 were synthesized from 5 g of commercial reference RNA by reverse transcription.///taxid_ch1: 9606///source_name_ch2: Universal Human Reference RNA purchased from Stratagene///organism_ch2: Homo sapiens///characteristics_ch2: Reference///molecule_ch2: total RNA///extract_protocol_ch2: Homogenization with Trizol followed by total RNA extraction with Rneasy mini kit following manufacturer's instructions (Qiagen).///label_ch2: Cy5///label_protocol_ch2: Probes labelled with Cy3 were synthesized from 5 g of the total tumour RNA and reference labelled with Cy5 were synthesized from 5 g of commercial reference RNA by reverse transcription.///taxid_ch2: 9606///hyb_protocol: The probes were purified using ChipShot labelling cleanup system (Promega). The hybridizations were carried out using Pronto! Micro Array reagent systems (Corning Inc.). For each sample, labelled tumour cDNA and reference cDNA were co-precipitated and hybridised to the oligoarray slide. After hybridization, slides were washed sequential.///scan_protocol: Scanned on an Agilent G2565AA scanner.///scan_protocol.1: Images were quantified using Genepix 6.0.0.74 (Axon Instruments).///description: Comparison of ovarian tumors of 5 year survivors to deceased patients///data_processing: Intensities were calculated by mean spot - median background. Flagged spots were removed as well as spots with intensities below 20 in both channels. Intensities below 20 in one channel were set to 20 to compensate for extreme quotients. Loess normalization was used///platform_id: GPL5886///contact_name: Karolina,,Partheen///contact_email: [email protected]///contact_phone: +46+31 342 78 55///contact_fax: +46 +31 41 72 05///contact_department: department of Oncology///contact_institute: University of Gothenburg///contact_address: Bl Strket 2///contact_city: Gothenburg///contact_zip.postal_code: 413 45///contact_country: Sweden///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM311nnn/GSM311966/GSM311966.gpr.gz///data_row_count: 30000
1
title: 742LC0///geo_accession: GSM311967///status: Public on Aug 12 2008///submission_date: Aug 12 2008///last_update_date: Aug 13 2008///type: RNA///channel_count: 2///source_name_ch1: serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: fresh frozen tumour///characteristics_ch1.1: 5 year survivor///characteristics_ch1.2: stage IIIc///characteristics_ch1.3: no macroscopic residual tumor///characteristics_ch1.4: age at diagnosis 49///characteristics_ch1.5: post surgical chemo therapy farmorubicine, carboplatin and cyclophosphamide///molecule_ch1: total RNA///extract_protocol_ch1: Homogenization with Trizol followed by total RNA extraction with Rneasy mini kit following manufacturer's instructions (Qiagen).///label_ch1: Cy3///label_protocol_ch1: Probes labelled with Cy3 were synthesized from 5 g of the total tumour RNA and reference labelled with Cy5 were synthesized from 5 g of commercial reference RNA by reverse transcription.///taxid_ch1: 9606///source_name_ch2: Universal Human Reference RNA purchased from Stratagene///organism_ch2: Homo sapiens///characteristics_ch2: Reference///molecule_ch2: total RNA///extract_protocol_ch2: Homogenization with Trizol followed by total RNA extraction with Rneasy mini kit following manufacturer's instructions (Qiagen).///label_ch2: Cy5///label_protocol_ch2: Probes labelled with Cy3 were synthesized from 5 g of the total tumour RNA and reference labelled with Cy5 were synthesized from 5 g of commercial reference RNA by reverse transcription.///taxid_ch2: 9606///hyb_protocol: The probes were purified using ChipShot labelling cleanup system (Promega). The hybridizations were carried out using Pronto! Micro Array reagent systems (Corning Inc.). For each sample, labelled tumour cDNA and reference cDNA were co-precipitated and hybridised to the oligoarray slide. After hybridization, slides were washed sequential.///scan_protocol: Scanned on an Agilent G2565AA scanner.///scan_protocol.1: Images were quantified using Genepix 6.0.0.74 (Axon Instruments).///description: Comparison of ovarian tumors of 5 year survivors to deceased patients///data_processing: Intensities were calculated by mean spot - median background. Flagged spots were removed as well as spots with intensities below 20 in both channels. Intensities below 20 in one channel were set to 20 to compensate for extreme quotients. Loess normalization was used///platform_id: GPL5886///contact_name: Karolina,,Partheen///contact_email: [email protected]///contact_phone: +46+31 342 78 55///contact_fax: +46 +31 41 72 05///contact_department: department of Oncology///contact_institute: University of Gothenburg///contact_address: Bl Strket 2///contact_city: Gothenburg///contact_zip.postal_code: 413 45///contact_country: Sweden///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM311nnn/GSM311967/GSM311967.gpr.gz///data_row_count: 30000
1
title: 755LC///geo_accession: GSM311968///status: Public on Aug 12 2008///submission_date: Aug 12 2008///last_update_date: Aug 13 2008///type: RNA///channel_count: 2///source_name_ch1: serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: fresh frozen tumour///characteristics_ch1.1: 5 year survivor///characteristics_ch1.2: stage IIIc///characteristics_ch1.3: macroscopic residual tumor///characteristics_ch1.4: age at diagnosis 77///characteristics_ch1.5: post surgical chemo therapy farmorubicine, carboplatin and cyclophosphamide///molecule_ch1: total RNA///extract_protocol_ch1: Homogenization with Trizol followed by total RNA extraction with Rneasy mini kit following manufacturer's instructions (Qiagen).///label_ch1: Cy3///label_protocol_ch1: Probes labelled with Cy3 were synthesized from 5 g of the total tumour RNA and reference labelled with Cy5 were synthesized from 5 g of commercial reference RNA by reverse transcription.///taxid_ch1: 9606///source_name_ch2: Universal Human Reference RNA purchased from Stratagene///organism_ch2: Homo sapiens///characteristics_ch2: Reference///molecule_ch2: total RNA///extract_protocol_ch2: Homogenization with Trizol followed by total RNA extraction with Rneasy mini kit following manufacturer's instructions (Qiagen).///label_ch2: Cy5///label_protocol_ch2: Probes labelled with Cy3 were synthesized from 5 g of the total tumour RNA and reference labelled with Cy5 were synthesized from 5 g of commercial reference RNA by reverse transcription.///taxid_ch2: 9606///hyb_protocol: The probes were purified using ChipShot labelling cleanup system (Promega). The hybridizations were carried out using Pronto! Micro Array reagent systems (Corning Inc.). For each sample, labelled tumour cDNA and reference cDNA were co-precipitated and hybridised to the oligoarray slide. After hybridization, slides were washed sequential.///scan_protocol: Scanned on an Agilent G2565AA scanner.///scan_protocol.1: Images were quantified using Genepix 6.0.0.74 (Axon Instruments).///description: Comparison of ovarian tumors of 5 year survivors to deceased patients///data_processing: Intensities were calculated by mean spot - median background. Flagged spots were removed as well as spots with intensities below 20 in both channels. Intensities below 20 in one channel were set to 20 to compensate for extreme quotients. Loess normalization was used///platform_id: GPL5886///contact_name: Karolina,,Partheen///contact_email: [email protected]///contact_phone: +46+31 342 78 55///contact_fax: +46 +31 41 72 05///contact_department: department of Oncology///contact_institute: University of Gothenburg///contact_address: Bl Strket 2///contact_city: Gothenburg///contact_zip.postal_code: 413 45///contact_country: Sweden///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM311nnn/GSM311968/GSM311968.gpr.gz///data_row_count: 30000
1
title: 759DC///geo_accession: GSM311969///status: Public on Aug 12 2008///submission_date: Aug 12 2008///last_update_date: Aug 13 2008///type: RNA///channel_count: 2///source_name_ch1: serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: fresh frozen tumour///characteristics_ch1.1: deceased///characteristics_ch1.2: stage IIIc///characteristics_ch1.3: macroscopic residual tumor///characteristics_ch1.4: age at diagnosis 52///characteristics_ch1.5: post surgical chemo therapy farmorubicine, carboplatin and cyclophosphamide///molecule_ch1: total RNA///extract_protocol_ch1: Homogenization with Trizol followed by total RNA extraction with Rneasy mini kit following manufacturer's instructions (Qiagen).///label_ch1: Cy3///label_protocol_ch1: Probes labelled with Cy3 were synthesized from 5 g of the total tumour RNA and reference labelled with Cy5 were synthesized from 5 g of commercial reference RNA by reverse transcription.///taxid_ch1: 9606///source_name_ch2: Universal Human Reference RNA purchased from Stratagene///organism_ch2: Homo sapiens///characteristics_ch2: Reference///molecule_ch2: total RNA///extract_protocol_ch2: Homogenization with Trizol followed by total RNA extraction with Rneasy mini kit following manufacturer's instructions (Qiagen).///label_ch2: Cy5///label_protocol_ch2: Probes labelled with Cy3 were synthesized from 5 g of the total tumour RNA and reference labelled with Cy5 were synthesized from 5 g of commercial reference RNA by reverse transcription.///taxid_ch2: 9606///hyb_protocol: The probes were purified using ChipShot labelling cleanup system (Promega). The hybridizations were carried out using Pronto! Micro Array reagent systems (Corning Inc.). For each sample, labelled tumour cDNA and reference cDNA were co-precipitated and hybridised to the oligoarray slide. After hybridization, slides were washed sequential.///scan_protocol: Scanned on an Agilent G2565AA scanner.///scan_protocol.1: Images were quantified using Genepix 6.0.0.74 (Axon Instruments).///description: Comparison of ovarian tumors of 5 year survivors to deceased patients///data_processing: Intensities were calculated by mean spot - median background. Flagged spots were removed as well as spots with intensities below 20 in both channels. Intensities below 20 in one channel were set to 20 to compensate for extreme quotients. Loess normalization was used///platform_id: GPL5886///contact_name: Karolina,,Partheen///contact_email: [email protected]///contact_phone: +46+31 342 78 55///contact_fax: +46 +31 41 72 05///contact_department: department of Oncology///contact_institute: University of Gothenburg///contact_address: Bl Strket 2///contact_city: Gothenburg///contact_zip.postal_code: 413 45///contact_country: Sweden///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM311nnn/GSM311969/GSM311969.gpr.gz///data_row_count: 30000
1
title: 76DC///geo_accession: GSM311942///status: Public on Aug 12 2008///submission_date: Aug 12 2008///last_update_date: Aug 13 2008///type: RNA///channel_count: 2///source_name_ch1: serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: fresh frozen tumour///characteristics_ch1.1: deceased///characteristics_ch1.2: stage IIIc///characteristics_ch1.3: macroscopic residual tumor///characteristics_ch1.4: age at diagnosis 76///characteristics_ch1.5: post surgical chemo therapy farmorubicine, carboplatin and cyclophosphamide///molecule_ch1: total RNA///extract_protocol_ch1: Homogenization with Trizol followed by total RNA extraction with Rneasy mini kit following manufacturer's instructions (Qiagen).///label_ch1: Cy3///label_protocol_ch1: Probes labelled with Cy3 were synthesized from 5 g of the total tumour RNA and reference labelled with Cy5 were synthesized from 5 g of commercial reference RNA by reverse transcription.///taxid_ch1: 9606///source_name_ch2: Universal Human Reference RNA purchased from Stratagene///organism_ch2: Homo sapiens///characteristics_ch2: Reference///molecule_ch2: total RNA///extract_protocol_ch2: Homogenization with Trizol followed by total RNA extraction with Rneasy mini kit following manufacturer's instructions (Qiagen).///label_ch2: Cy5///label_protocol_ch2: Probes labelled with Cy3 were synthesized from 5 g of the total tumour RNA and reference labelled with Cy5 were synthesized from 5 g of commercial reference RNA by reverse transcription.///taxid_ch2: 9606///hyb_protocol: The probes were purified using ChipShot labelling cleanup system (Promega). The hybridizations were carried out using Pronto! Micro Array reagent systems (Corning Inc.). For each sample, labelled tumour cDNA and reference cDNA were co-precipitated and hybridised to the oligoarray slide. After hybridization, slides were washed sequential.///scan_protocol: Scanned on an Agilent G2565AA scanner.///scan_protocol.1: Images were quantified using Genepix 6.0.0.74 (Axon Instruments).///description: Comparison of ovarian tumors of 5 year survivors to deceased patients///data_processing: Intensities were calculated by mean spot - median background. Flagged spots were removed as well as spots with intensities below 20 in both channels. Intensities below 20 in one channel were set to 20 to compensate for extreme quotients. Loess normalization was used///platform_id: GPL5886///contact_name: Karolina,,Partheen///contact_email: [email protected]///contact_phone: +46+31 342 78 55///contact_fax: +46 +31 41 72 05///contact_department: department of Oncology///contact_institute: University of Gothenburg///contact_address: Bl Strket 2///contact_city: Gothenburg///contact_zip.postal_code: 413 45///contact_country: Sweden///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM311nnn/GSM311942/GSM311942.gpr.gz///data_row_count: 30000
1
title: 789DC///geo_accession: GSM311970///status: Public on Aug 12 2008///submission_date: Aug 12 2008///last_update_date: Aug 13 2008///type: RNA///channel_count: 2///source_name_ch1: serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: fresh frozen tumour///characteristics_ch1.1: deceased///characteristics_ch1.2: stage IIIc///characteristics_ch1.3: macroscopic residual tumor///characteristics_ch1.4: age at diagnosis 63///characteristics_ch1.5: post surgical chemo therapy farmorubicine, carboplatin and cyclophosphamide///molecule_ch1: total RNA///extract_protocol_ch1: Homogenization with Trizol followed by total RNA extraction with Rneasy mini kit following manufacturer's instructions (Qiagen).///label_ch1: Cy3///label_protocol_ch1: Probes labelled with Cy3 were synthesized from 5 g of the total tumour RNA and reference labelled with Cy5 were synthesized from 5 g of commercial reference RNA by reverse transcription.///taxid_ch1: 9606///source_name_ch2: Universal Human Reference RNA purchased from Stratagene///organism_ch2: Homo sapiens///characteristics_ch2: Reference///molecule_ch2: total RNA///extract_protocol_ch2: Homogenization with Trizol followed by total RNA extraction with Rneasy mini kit following manufacturer's instructions (Qiagen).///label_ch2: Cy5///label_protocol_ch2: Probes labelled with Cy3 were synthesized from 5 g of the total tumour RNA and reference labelled with Cy5 were synthesized from 5 g of commercial reference RNA by reverse transcription.///taxid_ch2: 9606///hyb_protocol: The probes were purified using ChipShot labelling cleanup system (Promega). The hybridizations were carried out using Pronto! Micro Array reagent systems (Corning Inc.). For each sample, labelled tumour cDNA and reference cDNA were co-precipitated and hybridised to the oligoarray slide. After hybridization, slides were washed sequential.///scan_protocol: Scanned on an Agilent G2565AA scanner.///scan_protocol.1: Images were quantified using Genepix 6.0.0.74 (Axon Instruments).///description: Comparison of ovarian tumors of 5 year survivors to deceased patients///data_processing: Intensities were calculated by mean spot - median background. Flagged spots were removed as well as spots with intensities below 20 in both channels. Intensities below 20 in one channel were set to 20 to compensate for extreme quotients. Loess normalization was used///platform_id: GPL5886///contact_name: Karolina,,Partheen///contact_email: [email protected]///contact_phone: +46+31 342 78 55///contact_fax: +46 +31 41 72 05///contact_department: department of Oncology///contact_institute: University of Gothenburg///contact_address: Bl Strket 2///contact_city: Gothenburg///contact_zip.postal_code: 413 45///contact_country: Sweden///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM311nnn/GSM311970/GSM311970.gpr.gz///data_row_count: 30000
1
title: 83LC///geo_accession: GSM311943///status: Public on Aug 12 2008///submission_date: Aug 12 2008///last_update_date: Aug 13 2008///type: RNA///channel_count: 2///source_name_ch1: serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: fresh frozen tumour///characteristics_ch1.1: 5 year survivor///characteristics_ch1.2: stage IIIc///characteristics_ch1.3: macroscopic residual tumor///characteristics_ch1.4: age at diagnosis 58///characteristics_ch1.5: post surgical chemo therapy farmorubicine, carboplatin and cyclophosphamide///molecule_ch1: total RNA///extract_protocol_ch1: Homogenization with Trizol followed by total RNA extraction with Rneasy mini kit following manufacturer's instructions (Qiagen).///label_ch1: Cy3///label_protocol_ch1: Probes labelled with Cy3 were synthesized from 5 g of the total tumour RNA and reference labelled with Cy5 were synthesized from 5 g of commercial reference RNA by reverse transcription.///taxid_ch1: 9606///source_name_ch2: Universal Human Reference RNA purchased from Stratagene///organism_ch2: Homo sapiens///characteristics_ch2: Reference///molecule_ch2: total RNA///extract_protocol_ch2: Homogenization with Trizol followed by total RNA extraction with Rneasy mini kit following manufacturer's instructions (Qiagen).///label_ch2: Cy5///label_protocol_ch2: Probes labelled with Cy3 were synthesized from 5 g of the total tumour RNA and reference labelled with Cy5 were synthesized from 5 g of commercial reference RNA by reverse transcription.///taxid_ch2: 9606///hyb_protocol: The probes were purified using ChipShot labelling cleanup system (Promega). The hybridizations were carried out using Pronto! Micro Array reagent systems (Corning Inc.). For each sample, labelled tumour cDNA and reference cDNA were co-precipitated and hybridised to the oligoarray slide. After hybridization, slides were washed sequential.///scan_protocol: Scanned on an Agilent G2565AA scanner.///scan_protocol.1: Images were quantified using Genepix 6.0.0.74 (Axon Instruments).///description: Comparison of ovarian tumors of 5 year survivors to deceased patients///data_processing: Intensities were calculated by mean spot - median background. Flagged spots were removed as well as spots with intensities below 20 in both channels. Intensities below 20 in one channel were set to 20 to compensate for extreme quotients. Loess normalization was used///platform_id: GPL5886///contact_name: Karolina,,Partheen///contact_email: [email protected]///contact_phone: +46+31 342 78 55///contact_fax: +46 +31 41 72 05///contact_department: department of Oncology///contact_institute: University of Gothenburg///contact_address: Bl Strket 2///contact_city: Gothenburg///contact_zip.postal_code: 413 45///contact_country: Sweden///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM311nnn/GSM311943/GSM311943.gpr.gz///data_row_count: 30000
1
title: 918DB0///geo_accession: GSM311971///status: Public on Aug 12 2008///submission_date: Aug 12 2008///last_update_date: Aug 13 2008///type: RNA///channel_count: 2///source_name_ch1: serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: fresh frozen tumour///characteristics_ch1.1: deceased///characteristics_ch1.2: stage IIIab///characteristics_ch1.3: no macroscopic residual tumor///characteristics_ch1.4: age at diagnosis 70///characteristics_ch1.5: post surgical chemo therapy farmorubicine, carboplatin and cyclophosphamide///molecule_ch1: total RNA///extract_protocol_ch1: Homogenization with Trizol followed by total RNA extraction with Rneasy mini kit following manufacturer's instructions (Qiagen).///label_ch1: Cy3///label_protocol_ch1: Probes labelled with Cy3 were synthesized from 5 g of the total tumour RNA and reference labelled with Cy5 were synthesized from 5 g of commercial reference RNA by reverse transcription.///taxid_ch1: 9606///source_name_ch2: Universal Human Reference RNA purchased from Stratagene///organism_ch2: Homo sapiens///characteristics_ch2: Reference///molecule_ch2: total RNA///extract_protocol_ch2: Homogenization with Trizol followed by total RNA extraction with Rneasy mini kit following manufacturer's instructions (Qiagen).///label_ch2: Cy5///label_protocol_ch2: Probes labelled with Cy3 were synthesized from 5 g of the total tumour RNA and reference labelled with Cy5 were synthesized from 5 g of commercial reference RNA by reverse transcription.///taxid_ch2: 9606///hyb_protocol: The probes were purified using ChipShot labelling cleanup system (Promega). The hybridizations were carried out using Pronto! Micro Array reagent systems (Corning Inc.). For each sample, labelled tumour cDNA and reference cDNA were co-precipitated and hybridised to the oligoarray slide. After hybridization, slides were washed sequential.///scan_protocol: Scanned on an Agilent G2565AA scanner.///scan_protocol.1: Images were quantified using Genepix 6.0.0.74 (Axon Instruments).///description: Comparison of ovarian tumors of 5 year survivors to deceased patients///data_processing: Intensities were calculated by mean spot - median background. Flagged spots were removed as well as spots with intensities below 20 in both channels. Intensities below 20 in one channel were set to 20 to compensate for extreme quotients. Loess normalization was used///platform_id: GPL5886///contact_name: Karolina,,Partheen///contact_email: [email protected]///contact_phone: +46+31 342 78 55///contact_fax: +46 +31 41 72 05///contact_department: department of Oncology///contact_institute: University of Gothenburg///contact_address: Bl Strket 2///contact_city: Gothenburg///contact_zip.postal_code: 413 45///contact_country: Sweden///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM311nnn/GSM311971/GSM311971.gpr.gz///data_row_count: 30000
1
title: 988LC0///geo_accession: GSM311972///status: Public on Aug 12 2008///submission_date: Aug 12 2008///last_update_date: Aug 13 2008///type: RNA///channel_count: 2///source_name_ch1: serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: fresh frozen tumour///characteristics_ch1.1: 5 year survivor///characteristics_ch1.2: stage IIIc///characteristics_ch1.3: no macroscopic residual tumor///characteristics_ch1.4: age at diagnosis 52///characteristics_ch1.5: post surgical chemo therapy farmorubicine, carboplatin and cyclophosphamide///molecule_ch1: total RNA///extract_protocol_ch1: Homogenization with Trizol followed by total RNA extraction with Rneasy mini kit following manufacturer's instructions (Qiagen).///label_ch1: Cy3///label_protocol_ch1: Probes labelled with Cy3 were synthesized from 5 g of the total tumour RNA and reference labelled with Cy5 were synthesized from 5 g of commercial reference RNA by reverse transcription.///taxid_ch1: 9606///source_name_ch2: Universal Human Reference RNA purchased from Stratagene///organism_ch2: Homo sapiens///characteristics_ch2: Reference///molecule_ch2: total RNA///extract_protocol_ch2: Homogenization with Trizol followed by total RNA extraction with Rneasy mini kit following manufacturer's instructions (Qiagen).///label_ch2: Cy5///label_protocol_ch2: Probes labelled with Cy3 were synthesized from 5 g of the total tumour RNA and reference labelled with Cy5 were synthesized from 5 g of commercial reference RNA by reverse transcription.///taxid_ch2: 9606///hyb_protocol: The probes were purified using ChipShot labelling cleanup system (Promega). The hybridizations were carried out using Pronto! Micro Array reagent systems (Corning Inc.). For each sample, labelled tumour cDNA and reference cDNA were co-precipitated and hybridised to the oligoarray slide. After hybridization, slides were washed sequential.///scan_protocol: Scanned on an Agilent G2565AA scanner.///scan_protocol.1: Images were quantified using Genepix 6.0.0.74 (Axon Instruments).///description: Comparison of ovarian tumors of 5 year survivors to deceased patients///data_processing: Intensities were calculated by mean spot - median background. Flagged spots were removed as well as spots with intensities below 20 in both channels. Intensities below 20 in one channel were set to 20 to compensate for extreme quotients. Loess normalization was used///platform_id: GPL5886///contact_name: Karolina,,Partheen///contact_email: [email protected]///contact_phone: +46+31 342 78 55///contact_fax: +46 +31 41 72 05///contact_department: department of Oncology///contact_institute: University of Gothenburg///contact_address: Bl Strket 2///contact_city: Gothenburg///contact_zip.postal_code: 413 45///contact_country: Sweden///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM311nnn/GSM311972/GSM311972.gpr.gz///data_row_count: 30000
1
title: 99LC0///geo_accession: GSM311944///status: Public on Aug 12 2008///submission_date: Aug 12 2008///last_update_date: Aug 13 2008///type: RNA///channel_count: 2///source_name_ch1: serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: fresh frozen tumour///characteristics_ch1.1: 5 year survivor///characteristics_ch1.2: stage IIIc///characteristics_ch1.3: no macroscopic residual tumor///characteristics_ch1.4: age at diagnosis 72///characteristics_ch1.5: post surgical chemo therapy farmorubicine, carboplatin and cyclophosphamide///molecule_ch1: total RNA///extract_protocol_ch1: Homogenization with Trizol followed by total RNA extraction with Rneasy mini kit following manufacturer's instructions (Qiagen).///label_ch1: Cy3///label_protocol_ch1: Probes labelled with Cy3 were synthesized from 5 g of the total tumour RNA and reference labelled with Cy5 were synthesized from 5 g of commercial reference RNA by reverse transcription.///taxid_ch1: 9606///source_name_ch2: Universal Human Reference RNA purchased from Stratagene///organism_ch2: Homo sapiens///characteristics_ch2: Reference///molecule_ch2: total RNA///extract_protocol_ch2: Homogenization with Trizol followed by total RNA extraction with Rneasy mini kit following manufacturer's instructions (Qiagen).///label_ch2: Cy5///label_protocol_ch2: Probes labelled with Cy3 were synthesized from 5 g of the total tumour RNA and reference labelled with Cy5 were synthesized from 5 g of commercial reference RNA by reverse transcription.///taxid_ch2: 9606///hyb_protocol: The probes were purified using ChipShot labelling cleanup system (Promega). The hybridizations were carried out using Pronto! Micro Array reagent systems (Corning Inc.). For each sample, labelled tumour cDNA and reference cDNA were co-precipitated and hybridised to the oligoarray slide. After hybridization, slides were washed sequential.///scan_protocol: Scanned on an Agilent G2565AA scanner.///scan_protocol.1: Images were quantified using Genepix 6.0.0.74 (Axon Instruments).///description: Comparison of ovarian tumors of 5 year survivors to deceased patients///data_processing: Intensities were calculated by mean spot - median background. Flagged spots were removed as well as spots with intensities below 20 in both channels. Intensities below 20 in one channel were set to 20 to compensate for extreme quotients. Loess normalization was used///platform_id: GPL5886///contact_name: Karolina,,Partheen///contact_email: [email protected]///contact_phone: +46+31 342 78 55///contact_fax: +46 +31 41 72 05///contact_department: department of Oncology///contact_institute: University of Gothenburg///contact_address: Bl Strket 2///contact_city: Gothenburg///contact_zip.postal_code: 413 45///contact_country: Sweden///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM311nnn/GSM311944/GSM311944.gpr.gz///data_row_count: 30000
1
An expression set
To elucidate the mechanisms of rapid progression of serous ovarian cancer, gene expression profiles from 43 ovarian cancer tissues comprising eight early stage and 35 advanced stage tissues were carried out using oligonucleotide microarrays of 18,716 genes. By non-negative matrix factorization analysis using 178 genes, which were extracted as stage-specific genes, 35 advanced stage cases were classified into two subclasses with superior (n = 17) and poor (n = 18) outcome evaluated by progression-free survival (log rank test, P = 0.03). Of the 178 stage-specific genes, 112 genes were identified as showing different expression between the two subclasses. Of the 48 genes selected for biological function by gene ontology analysis or Ingenuity Pathway Analysis, five genes (ZEB2, CDH1, LTBP2, COL16A1, and ACTA2) were extracted as candidates for prognostic factors associated with progression-free survival. The relationship between high ZEB2 or low CDH1 expression and shorter progression-free survival was validated by real-time RT-PCR experiments of 37 independent advanced stage cancer samples. ZEB2 expression was negatively correlated with CDH1 expression in advanced stage samples, whereas ZEB2 knockdown in ovarian adenocarcinoma SKOV3 cells resulted in an increase in CDH1 expression. Multivariate analysis showed that high ZEB2 expression was independently associated with poor prognosis. Furthermore, the prognostic effect of E-cadherin encoded by CDH1 was verified using immunohistochemical analysis of an independent advanced stage cancer samples set (n = 74). These findings suggest that the expression of epithelial-mesenchymal transition-related genes such as ZEB2 and CDH1 may play important roles in the invasion process of advanced stage serous ovarian cancer.
experimentData(eset):
Experiment data
Experimenter name: Yoshihara K, Tajima A, Komata D, Yamamoto T, Kodama S, Fujiwara H, Suzuki M, Onishi Y, Hatae M, Sueyoshi K, Fujiwara H, Kudo Y, Inoue I, Tanaka K.Gene expression profiling of advanced-stage serous ovarian cancers distinguishes novel subclasses and implicates ZEB2 in tumor progression and prognosis. Cancer Sci. 2009 Aug; 100(8):1421-8.
Laboratory: Yoshihara, Tanaka 2009
Contact information:
Title: Gene expression profiling of advanced-stage serous ovarian cancers distinguishes novel subclasses and implicates ZEB2 in tumor progression and prognosis.
URL:
PMIDs: 19486012
Abstract: A 253 word abstract is available. Use 'abstract' method.
Information is available on: preprocessing
notes:
platform_title:
Agilent-012097 Human 1A Microarray (V2) G4110B (Feature Number version)
platform_shorttitle:
Agilent G4110B
platform_summary:
hgug4110b
platform_manufacturer:
Agilent
platform_distribution:
commercial
platform_accession:
GPL887
version:
2015-09-22 19:08:17
featureData(eset):
An object of class 'AnnotatedDataFrame'
featureNames: 3 5 ... 22571 (15999 total)
varLabels: probeset gene EntrezGene.ID best_probe
varMetadata: labelDescription
assayData: 15999 features, 53 samples
Platform type:
---------------------------
Available sample meta-data:
---------------------------
alt_sample_name:
Advanced serous ovarian cancer 10 Advanced serous ovarian cancer 11
1 1
Advanced serous ovarian cancer 15 Advanced serous ovarian cancer 17
1 1
Advanced serous ovarian cancer 18 Advanced serous ovarian cancer 2
1 1
Advanced serous ovarian cancer 20 Advanced serous ovarian cancer 23
1 1
Advanced serous ovarian cancer 24 Advanced serous ovarian cancer 25
1 1
Advanced serous ovarian cancer 27 Advanced serous ovarian cancer 36
1 1
Advanced serous ovarian cancer 37 Advanced serous ovarian cancer 38
1 1
Advanced serous ovarian cancer 39 Advanced serous ovarian cancer 42
1 1
Advanced serous ovarian cancer 43 Advanced serous ovarian cancer 45
1 1
Advanced serous ovarian cancer 46 Advanced serous ovarian cancer 49
1 1
Advanced serous ovarian cancer 50 Advanced serous ovarian cancer 51
1 1
Advanced serous ovarian cancer 52 Advanced serous ovarian cancer 53
1 1
Advanced serous ovarian cancer 54 Advanced serous ovarian cancer 55
1 1
Advanced serous ovarian cancer 56 Advanced serous ovarian cancer 57
1 1
Advanced serous ovarian cancer 58 Advanced serous ovarian cancer 6
1 1
Advanced serous ovarian cancer 60 Advanced serous ovarian cancer 61
1 1
Advanced serous ovarian cancer 62 Advanced serous ovarian cancer 64
1 1
Advanced serous ovarian cancer 7 Early serous ovarian cancer 28
1 1
Early serous ovarian cancer 32 Early serous ovarian cancer 33
1 1
Early serous ovarian cancer 35 Early serous ovarian cancer 5
1 1
Early serous ovarian cancer 65 Early serous ovarian cancer 8
1 1
Early serous ovarian cancer 9 Peritoneum normal 12
1 1
Peritoneum normal 15 Peritoneum normal 16
1 1
Peritoneum normal 18 Peritoneum normal 21
1 1
Peritoneum normal 23 Peritoneum normal 3
1 1
Peritoneum normal 30 Peritoneum normal 4
1 1
Peritoneum normal 7
1
sample_type:
healthy tumor
10 43
histological_type:
ser NA's
43 10
primarysite:
ov
53
summarystage:
early late NA's
8 35 10
tumorstage:
1 NA's
8 45
uncurated_author_metadata:
title: Advanced serous ovarian cancer 10///geo_accession: GSM312155///status: Public on Jul 19 2009///submission_date: Aug 13 2008///last_update_date: Jul 19 2009///type: RNA///channel_count: 1///source_name_ch1: ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: Gender: female///characteristics_ch1.1: Tissue: serous ovarian cancer///characteristics_ch1.2: Stage: advanced stage///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue sample using TRIzol reagent (Invitrogen, Carlsbad, CA, USA), and examined with 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Five hundred nanograms of total RNA were converted into labeled cRNA with nucleotides coupled to a cyanine 3-CTP (Cy3) (PerkinElmer, Boston, MA, USA) using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies). ///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.5 g) were hybridized for 17 hours at 65 degrees Celsius to an Agilent Human 1A (v2) Oligo Microarray.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: Serous ovarian cancer-10///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings.///platform_id: GPL887///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM312nnn/GSM312155/GSM312155_s10.txt.gz///data_row_count: 22153
1
title: Advanced serous ovarian cancer 11///geo_accession: GSM312141///status: Public on Jul 19 2009///submission_date: Aug 13 2008///last_update_date: Jul 19 2009///type: RNA///channel_count: 1///source_name_ch1: ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: Gender: female///characteristics_ch1.1: Tissue: serous ovarian cancer///characteristics_ch1.2: Stage: advanced stage///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue sample using TRIzol reagent (Invitrogen, Carlsbad, CA, USA), and examined with 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Five hundred nanograms of total RNA were converted into labeled cRNA with nucleotides coupled to a cyanine 3-CTP (Cy3) (PerkinElmer, Boston, MA, USA) using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies). ///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.5 g) were hybridized for 17 hours at 65 degrees Celsius to an Agilent Human 1A (v2) Oligo Microarray.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: Serous ovarian cancer-11///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings.///platform_id: GPL887///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM312nnn/GSM312141/GSM312141_s11.txt.gz///data_row_count: 22153
1
title: Advanced serous ovarian cancer 15///geo_accession: GSM312156///status: Public on Jul 19 2009///submission_date: Aug 13 2008///last_update_date: Jul 19 2009///type: RNA///channel_count: 1///source_name_ch1: ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: Gender: female///characteristics_ch1.1: Tissue: serous ovarian cancer///characteristics_ch1.2: Stage: advanced stage///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue sample using TRIzol reagent (Invitrogen, Carlsbad, CA, USA), and examined with 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Five hundred nanograms of total RNA were converted into labeled cRNA with nucleotides coupled to a cyanine 3-CTP (Cy3) (PerkinElmer, Boston, MA, USA) using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies). ///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.5 g) were hybridized for 17 hours at 65 degrees Celsius to an Agilent Human 1A (v2) Oligo Microarray.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: Serous ovarian cancer-15///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings.///platform_id: GPL887///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM312nnn/GSM312156/GSM312156_s15.txt.gz///data_row_count: 22153
1
title: Advanced serous ovarian cancer 17///geo_accession: GSM312142///status: Public on Jul 19 2009///submission_date: Aug 13 2008///last_update_date: Jul 19 2009///type: RNA///channel_count: 1///source_name_ch1: ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: Gender: female///characteristics_ch1.1: Tissue: serous ovarian cancer///characteristics_ch1.2: Stage: advanced stage///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue sample using TRIzol reagent (Invitrogen, Carlsbad, CA, USA), and examined with 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Five hundred nanograms of total RNA were converted into labeled cRNA with nucleotides coupled to a cyanine 3-CTP (Cy3) (PerkinElmer, Boston, MA, USA) using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies). ///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.5 g) were hybridized for 17 hours at 65 degrees Celsius to an Agilent Human 1A (v2) Oligo Microarray.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: Serous ovarian cancer-17///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings.///platform_id: GPL887///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM312nnn/GSM312142/GSM312142_s17.txt.gz///data_row_count: 22153
1
title: Advanced serous ovarian cancer 18///geo_accession: GSM312143///status: Public on Jul 19 2009///submission_date: Aug 13 2008///last_update_date: Jul 19 2009///type: RNA///channel_count: 1///source_name_ch1: ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: Gender: female///characteristics_ch1.1: Tissue: serous ovarian cancer///characteristics_ch1.2: Stage: advanced stage///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue sample using TRIzol reagent (Invitrogen, Carlsbad, CA, USA), and examined with 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Five hundred nanograms of total RNA were converted into labeled cRNA with nucleotides coupled to a cyanine 3-CTP (Cy3) (PerkinElmer, Boston, MA, USA) using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies). ///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.5 g) were hybridized for 17 hours at 65 degrees Celsius to an Agilent Human 1A (v2) Oligo Microarray.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: Serous ovarian cancer-18///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings.///platform_id: GPL887///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM312nnn/GSM312143/GSM312143_s18.txt.gz///data_row_count: 22153
1
title: Advanced serous ovarian cancer 20///geo_accession: GSM312144///status: Public on Jul 19 2009///submission_date: Aug 13 2008///last_update_date: Jul 19 2009///type: RNA///channel_count: 1///source_name_ch1: ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: Gender: female///characteristics_ch1.1: Tissue: serous ovarian cancer///characteristics_ch1.2: Stage: advanced stage///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue sample using TRIzol reagent (Invitrogen, Carlsbad, CA, USA), and examined with 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Five hundred nanograms of total RNA were converted into labeled cRNA with nucleotides coupled to a cyanine 3-CTP (Cy3) (PerkinElmer, Boston, MA, USA) using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies). ///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.5 g) were hybridized for 17 hours at 65 degrees Celsius to an Agilent Human 1A (v2) Oligo Microarray.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: Serous ovarian cancer-20///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings.///platform_id: GPL887///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM312nnn/GSM312144/GSM312144_s20.txt.gz///data_row_count: 22153
1
title: Advanced serous ovarian cancer 23///geo_accession: GSM312157///status: Public on Jul 19 2009///submission_date: Aug 13 2008///last_update_date: Jul 19 2009///type: RNA///channel_count: 1///source_name_ch1: ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: Gender: female///characteristics_ch1.1: Tissue: serous ovarian cancer///characteristics_ch1.2: Stage: advanced stage///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue sample using TRIzol reagent (Invitrogen, Carlsbad, CA, USA), and examined with 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Five hundred nanograms of total RNA were converted into labeled cRNA with nucleotides coupled to a cyanine 3-CTP (Cy3) (PerkinElmer, Boston, MA, USA) using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies). ///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.5 g) were hybridized for 17 hours at 65 degrees Celsius to an Agilent Human 1A (v2) Oligo Microarray.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: Serous ovarian cancer-23///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings.///platform_id: GPL887///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM312nnn/GSM312157/GSM312157_s23.txt.gz///data_row_count: 22153
1
title: Advanced serous ovarian cancer 24///geo_accession: GSM312145///status: Public on Jul 19 2009///submission_date: Aug 13 2008///last_update_date: Jul 19 2009///type: RNA///channel_count: 1///source_name_ch1: ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: Gender: female///characteristics_ch1.1: Tissue: serous ovarian cancer///characteristics_ch1.2: Stage: advanced stage///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue sample using TRIzol reagent (Invitrogen, Carlsbad, CA, USA), and examined with 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Five hundred nanograms of total RNA were converted into labeled cRNA with nucleotides coupled to a cyanine 3-CTP (Cy3) (PerkinElmer, Boston, MA, USA) using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies). ///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.5 g) were hybridized for 17 hours at 65 degrees Celsius to an Agilent Human 1A (v2) Oligo Microarray.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: Serous ovarian cancer-24///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings.///platform_id: GPL887///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM312nnn/GSM312145/GSM312145_s24.txt.gz///data_row_count: 22153
1
title: Advanced serous ovarian cancer 25///geo_accession: GSM312146///status: Public on Jul 19 2009///submission_date: Aug 13 2008///last_update_date: Jul 19 2009///type: RNA///channel_count: 1///source_name_ch1: ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: Gender: female///characteristics_ch1.1: Tissue: serous ovarian cancer///characteristics_ch1.2: Stage: advanced stage///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue sample using TRIzol reagent (Invitrogen, Carlsbad, CA, USA), and examined with 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Five hundred nanograms of total RNA were converted into labeled cRNA with nucleotides coupled to a cyanine 3-CTP (Cy3) (PerkinElmer, Boston, MA, USA) using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies). ///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.5 g) were hybridized for 17 hours at 65 degrees Celsius to an Agilent Human 1A (v2) Oligo Microarray.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: Serous ovarian cancer-25///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings.///platform_id: GPL887///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM312nnn/GSM312146/GSM312146_s25.txt.gz///data_row_count: 22153
1
title: Advanced serous ovarian cancer 27///geo_accession: GSM312158///status: Public on Jul 19 2009///submission_date: Aug 13 2008///last_update_date: Jul 19 2009///type: RNA///channel_count: 1///source_name_ch1: ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: Gender: female///characteristics_ch1.1: Tissue: serous ovarian cancer///characteristics_ch1.2: Stage: advanced stage///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue sample using TRIzol reagent (Invitrogen, Carlsbad, CA, USA), and examined with 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Five hundred nanograms of total RNA were converted into labeled cRNA with nucleotides coupled to a cyanine 3-CTP (Cy3) (PerkinElmer, Boston, MA, USA) using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies). ///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.5 g) were hybridized for 17 hours at 65 degrees Celsius to an Agilent Human 1A (v2) Oligo Microarray.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: Serous ovarian cancer-27///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings.///platform_id: GPL887///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM312nnn/GSM312158/GSM312158_s27.txt.gz///data_row_count: 22153
1
title: Advanced serous ovarian cancer 2///geo_accession: GSM312138///status: Public on Jul 19 2009///submission_date: Aug 13 2008///last_update_date: Jul 19 2009///type: RNA///channel_count: 1///source_name_ch1: ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: Gender: female///characteristics_ch1.1: Tissue: ovarian cancer///characteristics_ch1.2: Stage: advanced stage///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue sample using TRIzol reagent (Invitrogen, Carlsbad, CA, USA), and examined with 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Five hundred nanograms of total RNA were converted into labeled cRNA with nucleotides coupled to a cyanine 3-CTP (Cy3) (PerkinElmer, Boston, MA, USA) using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies). ///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.5 g) were hybridized for 17 hours at 65 degrees Celsius to an Agilent Human 1A (v2) Oligo Microarray.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: Serous ovarian cancer-2///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings.///platform_id: GPL887///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM312nnn/GSM312138/GSM312138_s2.txt.gz///data_row_count: 22153
1
title: Advanced serous ovarian cancer 36///geo_accession: GSM312147///status: Public on Jul 19 2009///submission_date: Aug 13 2008///last_update_date: Jul 19 2009///type: RNA///channel_count: 1///source_name_ch1: ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: Gender: female///characteristics_ch1.1: Tissue: serous ovarian cancer///characteristics_ch1.2: Stage: advanced stage///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue sample using TRIzol reagent (Invitrogen, Carlsbad, CA, USA), and examined with 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Five hundred nanograms of total RNA were converted into labeled cRNA with nucleotides coupled to a cyanine 3-CTP (Cy3) (PerkinElmer, Boston, MA, USA) using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies). ///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.5 g) were hybridized for 17 hours at 65 degrees Celsius to an Agilent Human 1A (v2) Oligo Microarray.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: Serous ovarian cancer-36///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings.///platform_id: GPL887///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM312nnn/GSM312147/GSM312147_s36.txt.gz///data_row_count: 22153
1
title: Advanced serous ovarian cancer 37///geo_accession: GSM312148///status: Public on Jul 19 2009///submission_date: Aug 13 2008///last_update_date: Jul 19 2009///type: RNA///channel_count: 1///source_name_ch1: ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: Gender: female///characteristics_ch1.1: Tissue: serous ovarian cancer///characteristics_ch1.2: Stage: advanced stage///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue sample using TRIzol reagent (Invitrogen, Carlsbad, CA, USA), and examined with 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Five hundred nanograms of total RNA were converted into labeled cRNA with nucleotides coupled to a cyanine 3-CTP (Cy3) (PerkinElmer, Boston, MA, USA) using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies). ///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.5 g) were hybridized for 17 hours at 65 degrees Celsius to an Agilent Human 1A (v2) Oligo Microarray.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: Serous ovarian cancer-37///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings.///platform_id: GPL887///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM312nnn/GSM312148/GSM312148_s37.txt.gz///data_row_count: 22153
1
title: Advanced serous ovarian cancer 38///geo_accession: GSM312149///status: Public on Jul 19 2009///submission_date: Aug 13 2008///last_update_date: Jul 19 2009///type: RNA///channel_count: 1///source_name_ch1: ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: Gender: female///characteristics_ch1.1: Tissue: serous ovarian cancer///characteristics_ch1.2: Stage: advanced stage///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue sample using TRIzol reagent (Invitrogen, Carlsbad, CA, USA), and examined with 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Five hundred nanograms of total RNA were converted into labeled cRNA with nucleotides coupled to a cyanine 3-CTP (Cy3) (PerkinElmer, Boston, MA, USA) using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies). ///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.5 g) were hybridized for 17 hours at 65 degrees Celsius to an Agilent Human 1A (v2) Oligo Microarray.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: Serous ovarian cancer-38///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings.///platform_id: GPL887///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM312nnn/GSM312149/GSM312149_s38.txt.gz///data_row_count: 22153
1
title: Advanced serous ovarian cancer 39///geo_accession: GSM312159///status: Public on Jul 19 2009///submission_date: Aug 13 2008///last_update_date: Jul 19 2009///type: RNA///channel_count: 1///source_name_ch1: ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: Gender: female///characteristics_ch1.1: Tissue: serous ovarian cancer///characteristics_ch1.2: Stage: advanced stage///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue sample using TRIzol reagent (Invitrogen, Carlsbad, CA, USA), and examined with 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Five hundred nanograms of total RNA were converted into labeled cRNA with nucleotides coupled to a cyanine 3-CTP (Cy3) (PerkinElmer, Boston, MA, USA) using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies). ///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.5 g) were hybridized for 17 hours at 65 degrees Celsius to an Agilent Human 1A (v2) Oligo Microarray.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: Serous ovarian cancer-39///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings.///platform_id: GPL887///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM312nnn/GSM312159/GSM312159_s39.txt.gz///data_row_count: 22153
1
title: Advanced serous ovarian cancer 42///geo_accession: GSM312160///status: Public on Jul 19 2009///submission_date: Aug 13 2008///last_update_date: Jul 19 2009///type: RNA///channel_count: 1///source_name_ch1: ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: Gender: female///characteristics_ch1.1: Tissue: serous ovarian cancer///characteristics_ch1.2: Stage: advanced stage///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue sample using TRIzol reagent (Invitrogen, Carlsbad, CA, USA), and examined with 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Five hundred nanograms of total RNA were converted into labeled cRNA with nucleotides coupled to a cyanine 3-CTP (Cy3) (PerkinElmer, Boston, MA, USA) using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies). ///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.5 g) were hybridized for 17 hours at 65 degrees Celsius to an Agilent Human 1A (v2) Oligo Microarray.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: Serous ovarian cancer-42///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings.///platform_id: GPL887///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM312nnn/GSM312160/GSM312160_s42.txt.gz///data_row_count: 22153
1
title: Advanced serous ovarian cancer 43///geo_accession: GSM312150///status: Public on Jul 19 2009///submission_date: Aug 13 2008///last_update_date: Jul 19 2009///type: RNA///channel_count: 1///source_name_ch1: ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: Gender: female///characteristics_ch1.1: Tissue: serous ovarian cancer///characteristics_ch1.2: Stage: advanced stage///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue sample using TRIzol reagent (Invitrogen, Carlsbad, CA, USA), and examined with 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Five hundred nanograms of total RNA were converted into labeled cRNA with nucleotides coupled to a cyanine 3-CTP (Cy3) (PerkinElmer, Boston, MA, USA) using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies). ///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.5 g) were hybridized for 17 hours at 65 degrees Celsius to an Agilent Human 1A (v2) Oligo Microarray.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: Serous ovarian cancer-43///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings.///platform_id: GPL887///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM312nnn/GSM312150/GSM312150_s43.txt.gz///data_row_count: 22153
1
title: Advanced serous ovarian cancer 45///geo_accession: GSM312161///status: Public on Jul 19 2009///submission_date: Aug 13 2008///last_update_date: Jul 19 2009///type: RNA///channel_count: 1///source_name_ch1: ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: Gender: female///characteristics_ch1.1: Tissue: serous ovarian cancer///characteristics_ch1.2: Stage: advanced stage///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue sample using TRIzol reagent (Invitrogen, Carlsbad, CA, USA), and examined with 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Five hundred nanograms of total RNA were converted into labeled cRNA with nucleotides coupled to a cyanine 3-CTP (Cy3) (PerkinElmer, Boston, MA, USA) using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies). ///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.5 g) were hybridized for 17 hours at 65 degrees Celsius to an Agilent Human 1A (v2) Oligo Microarray.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: Serous ovarian cancer-45///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings.///platform_id: GPL887///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM312nnn/GSM312161/GSM312161_s45.txt.gz///data_row_count: 22153
1
title: Advanced serous ovarian cancer 46///geo_accession: GSM312162///status: Public on Jul 19 2009///submission_date: Aug 13 2008///last_update_date: Jul 19 2009///type: RNA///channel_count: 1///source_name_ch1: ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: Gender: female///characteristics_ch1.1: Tissue: serous ovarian cancer///characteristics_ch1.2: Stage: advanced stage///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue sample using TRIzol reagent (Invitrogen, Carlsbad, CA, USA), and examined with 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Five hundred nanograms of total RNA were converted into labeled cRNA with nucleotides coupled to a cyanine 3-CTP (Cy3) (PerkinElmer, Boston, MA, USA) using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies). ///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.5 g) were hybridized for 17 hours at 65 degrees Celsius to an Agilent Human 1A (v2) Oligo Microarray.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: Serous ovarian cancer-46///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings.///platform_id: GPL887///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM312nnn/GSM312162/GSM312162_s46.txt.gz///data_row_count: 22153
1
title: Advanced serous ovarian cancer 49///geo_accession: GSM312151///status: Public on Jul 19 2009///submission_date: Aug 13 2008///last_update_date: Jul 19 2009///type: RNA///channel_count: 1///source_name_ch1: ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: Gender: female///characteristics_ch1.1: Tissue: serous ovarian cancer///characteristics_ch1.2: Stage: advanced stage///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue sample using TRIzol reagent (Invitrogen, Carlsbad, CA, USA), and examined with 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Five hundred nanograms of total RNA were converted into labeled cRNA with nucleotides coupled to a cyanine 3-CTP (Cy3) (PerkinElmer, Boston, MA, USA) using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies). ///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.5 g) were hybridized for 17 hours at 65 degrees Celsius to an Agilent Human 1A (v2) Oligo Microarray.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: Serous ovarian cancer-49///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings.///platform_id: GPL887///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM312nnn/GSM312151/GSM312151_s49.txt.gz///data_row_count: 22153
1
title: Advanced serous ovarian cancer 50///geo_accession: GSM312163///status: Public on Jul 19 2009///submission_date: Aug 13 2008///last_update_date: Jul 19 2009///type: RNA///channel_count: 1///source_name_ch1: ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: Gender: female///characteristics_ch1.1: Tissue: serous ovarian cancer///characteristics_ch1.2: Stage: advanced stage///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue sample using TRIzol reagent (Invitrogen, Carlsbad, CA, USA), and examined with 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Five hundred nanograms of total RNA were converted into labeled cRNA with nucleotides coupled to a cyanine 3-CTP (Cy3) (PerkinElmer, Boston, MA, USA) using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies). ///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.5 g) were hybridized for 17 hours at 65 degrees Celsius to an Agilent Human 1A (v2) Oligo Microarray.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: Serous ovarian cancer-50///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings.///platform_id: GPL887///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM312nnn/GSM312163/GSM312163_s50.txt.gz///data_row_count: 22153
1
title: Advanced serous ovarian cancer 51///geo_accession: GSM312165///status: Public on Jul 19 2009///submission_date: Aug 13 2008///last_update_date: Jul 19 2009///type: RNA///channel_count: 1///source_name_ch1: ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: Gender: female///characteristics_ch1.1: Tissue: serous ovarian cancer///characteristics_ch1.2: Stage: advanced stage///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue sample using TRIzol reagent (Invitrogen, Carlsbad, CA, USA), and examined with 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Five hundred nanograms of total RNA were converted into labeled cRNA with nucleotides coupled to a cyanine 3-CTP (Cy3) (PerkinElmer, Boston, MA, USA) using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies). ///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.5 g) were hybridized for 17 hours at 65 degrees Celsius to an Agilent Human 1A (v2) Oligo Microarray.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: Serous ovarian cancer-51///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings.///platform_id: GPL887///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM312nnn/GSM312165/GSM312165_s51.txt.gz///data_row_count: 22153
1
title: Advanced serous ovarian cancer 52///geo_accession: GSM312167///status: Public on Jul 19 2009///submission_date: Aug 13 2008///last_update_date: Jul 19 2009///type: RNA///channel_count: 1///source_name_ch1: ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: Gender: female///characteristics_ch1.1: Tissue: serous ovarian cancer///characteristics_ch1.2: Stage: advanced stage///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue sample using TRIzol reagent (Invitrogen, Carlsbad, CA, USA), and examined with 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Five hundred nanograms of total RNA were converted into labeled cRNA with nucleotides coupled to a cyanine 3-CTP (Cy3) (PerkinElmer, Boston, MA, USA) using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies). ///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.5 g) were hybridized for 17 hours at 65 degrees Celsius to an Agilent Human 1A (v2) Oligo Microarray.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: Serous ovarian cancer-52///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings.///platform_id: GPL887///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM312nnn/GSM312167/GSM312167_s52.txt.gz///data_row_count: 22153
1
title: Advanced serous ovarian cancer 53///geo_accession: GSM312168///status: Public on Jul 19 2009///submission_date: Aug 13 2008///last_update_date: Jul 19 2009///type: RNA///channel_count: 1///source_name_ch1: ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: Gender: female///characteristics_ch1.1: Tissue: serous ovarian cancer///characteristics_ch1.2: Stage: advanced stage///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue sample using TRIzol reagent (Invitrogen, Carlsbad, CA, USA), and examined with 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Five hundred nanograms of total RNA were converted into labeled cRNA with nucleotides coupled to a cyanine 3-CTP (Cy3) (PerkinElmer, Boston, MA, USA) using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies). ///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.5 g) were hybridized for 17 hours at 65 degrees Celsius to an Agilent Human 1A (v2) Oligo Microarray.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: Serous ovarian cancer-53///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings.///platform_id: GPL887///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM312nnn/GSM312168/GSM312168_s53.txt.gz///data_row_count: 22153
1
title: Advanced serous ovarian cancer 54///geo_accession: GSM312152///status: Public on Jul 19 2009///submission_date: Aug 13 2008///last_update_date: Jul 19 2009///type: RNA///channel_count: 1///source_name_ch1: ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: Gender: female///characteristics_ch1.1: Tissue: serous ovarian cancer///characteristics_ch1.2: Stage: advanced stage///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue sample using TRIzol reagent (Invitrogen, Carlsbad, CA, USA), and examined with 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Five hundred nanograms of total RNA were converted into labeled cRNA with nucleotides coupled to a cyanine 3-CTP (Cy3) (PerkinElmer, Boston, MA, USA) using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies). ///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.5 g) were hybridized for 17 hours at 65 degrees Celsius to an Agilent Human 1A (v2) Oligo Microarray.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: Serous ovarian cancer-54///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings.///platform_id: GPL887///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM312nnn/GSM312152/GSM312152_s54.txt.gz///data_row_count: 22153
1
title: Advanced serous ovarian cancer 55///geo_accession: GSM312170///status: Public on Jul 19 2009///submission_date: Aug 13 2008///last_update_date: Jul 19 2009///type: RNA///channel_count: 1///source_name_ch1: ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: Gender: female///characteristics_ch1.1: Tissue: serous ovarian cancer///characteristics_ch1.2: Stage: advanced stage///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue sample using TRIzol reagent (Invitrogen, Carlsbad, CA, USA), and examined with 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Five hundred nanograms of total RNA were converted into labeled cRNA with nucleotides coupled to a cyanine 3-CTP (Cy3) (PerkinElmer, Boston, MA, USA) using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies). ///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.5 g) were hybridized for 17 hours at 65 degrees Celsius to an Agilent Human 1A (v2) Oligo Microarray.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: Serous ovarian cancer-55///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings.///platform_id: GPL887///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM312nnn/GSM312170/GSM312170_1_s55.txt.gz///data_row_count: 22153
1
title: Advanced serous ovarian cancer 56///geo_accession: GSM312171///status: Public on Jul 19 2009///submission_date: Aug 13 2008///last_update_date: Jul 19 2009///type: RNA///channel_count: 1///source_name_ch1: ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: Gender: female///characteristics_ch1.1: Tissue: serous ovarian cancer///characteristics_ch1.2: Stage: advanced stage///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue sample using TRIzol reagent (Invitrogen, Carlsbad, CA, USA), and examined with 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Five hundred nanograms of total RNA were converted into labeled cRNA with nucleotides coupled to a cyanine 3-CTP (Cy3) (PerkinElmer, Boston, MA, USA) using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies). ///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.5 g) were hybridized for 17 hours at 65 degrees Celsius to an Agilent Human 1A (v2) Oligo Microarray.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: Serous ovarian cancer-56///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings.///platform_id: GPL887///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM312nnn/GSM312171/GSM312171_s56.txt.gz///data_row_count: 22153
1
title: Advanced serous ovarian cancer 57///geo_accession: GSM312153///status: Public on Jul 19 2009///submission_date: Aug 13 2008///last_update_date: Jul 19 2009///type: RNA///channel_count: 1///source_name_ch1: ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: Gender: female///characteristics_ch1.1: Tissue: serous ovarian cancer///characteristics_ch1.2: Stage: advanced stage///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue sample using TRIzol reagent (Invitrogen, Carlsbad, CA, USA), and examined with 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Five hundred nanograms of total RNA were converted into labeled cRNA with nucleotides coupled to a cyanine 3-CTP (Cy3) (PerkinElmer, Boston, MA, USA) using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies). ///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.5 g) were hybridized for 17 hours at 65 degrees Celsius to an Agilent Human 1A (v2) Oligo Microarray.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: Serous ovarian cancer-54///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings.///platform_id: GPL887///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM312nnn/GSM312153/GSM312153_s57.txt.gz///data_row_count: 22153
1
title: Advanced serous ovarian cancer 58///geo_accession: GSM312172///status: Public on Jul 19 2009///submission_date: Aug 13 2008///last_update_date: Jul 19 2009///type: RNA///channel_count: 1///source_name_ch1: ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: Gender: female///characteristics_ch1.1: Tissue: serous ovarian cancer///characteristics_ch1.2: Stage: advanced stage///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue sample using TRIzol reagent (Invitrogen, Carlsbad, CA, USA), and examined with 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Five hundred nanograms of total RNA were converted into labeled cRNA with nucleotides coupled to a cyanine 3-CTP (Cy3) (PerkinElmer, Boston, MA, USA) using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies). ///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.5 g) were hybridized for 17 hours at 65 degrees Celsius to an Agilent Human 1A (v2) Oligo Microarray.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: Serous ovarian cancer-58///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings.///platform_id: GPL887///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM312nnn/GSM312172/GSM312172_s58.txt.gz///data_row_count: 22153
1
title: Advanced serous ovarian cancer 60///geo_accession: GSM312173///status: Public on Jul 19 2009///submission_date: Aug 13 2008///last_update_date: Jul 19 2009///type: RNA///channel_count: 1///source_name_ch1: ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: Gender: female///characteristics_ch1.1: Tissue: serous ovarian cancer///characteristics_ch1.2: Stage: advanced stage///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue sample using TRIzol reagent (Invitrogen, Carlsbad, CA, USA), and examined with 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Five hundred nanograms of total RNA were converted into labeled cRNA with nucleotides coupled to a cyanine 3-CTP (Cy3) (PerkinElmer, Boston, MA, USA) using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies). ///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.5 g) were hybridized for 17 hours at 65 degrees Celsius to an Agilent Human 1A (v2) Oligo Microarray.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: Serous ovarian cancer-60///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings.///platform_id: GPL887///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM312nnn/GSM312173/GSM312173_s60.txt.gz///data_row_count: 22153
1
title: Advanced serous ovarian cancer 61///geo_accession: GSM312154///status: Public on Jul 19 2009///submission_date: Aug 13 2008///last_update_date: Jul 19 2009///type: RNA///channel_count: 1///source_name_ch1: ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: Gender: female///characteristics_ch1.1: Tissue: serous ovarian cancer///characteristics_ch1.2: Stage: advanced stage///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue sample using TRIzol reagent (Invitrogen, Carlsbad, CA, USA), and examined with 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Five hundred nanograms of total RNA were converted into labeled cRNA with nucleotides coupled to a cyanine 3-CTP (Cy3) (PerkinElmer, Boston, MA, USA) using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies). ///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.5 g) were hybridized for 17 hours at 65 degrees Celsius to an Agilent Human 1A (v2) Oligo Microarray.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: Serous ovarian cancer-61///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings.///platform_id: GPL887///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM312nnn/GSM312154/GSM312154_s61.txt.gz///data_row_count: 22153
1
title: Advanced serous ovarian cancer 62///geo_accession: GSM312174///status: Public on Jul 19 2009///submission_date: Aug 13 2008///last_update_date: Jul 19 2009///type: RNA///channel_count: 1///source_name_ch1: ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: Gender: female///characteristics_ch1.1: Tissue: serous ovarian cancer///characteristics_ch1.2: Stage: advanced stage///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue sample using TRIzol reagent (Invitrogen, Carlsbad, CA, USA), and examined with 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Five hundred nanograms of total RNA were converted into labeled cRNA with nucleotides coupled to a cyanine 3-CTP (Cy3) (PerkinElmer, Boston, MA, USA) using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies). ///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.5 g) were hybridized for 17 hours at 65 degrees Celsius to an Agilent Human 1A (v2) Oligo Microarray.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: Serous ovarian cancer-62///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings.///platform_id: GPL887///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM312nnn/GSM312174/GSM312174_s62.txt.gz///data_row_count: 22153
1
title: Advanced serous ovarian cancer 64///geo_accession: GSM312175///status: Public on Jul 19 2009///submission_date: Aug 13 2008///last_update_date: Jul 19 2009///type: RNA///channel_count: 1///source_name_ch1: ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: Gender: female///characteristics_ch1.1: Tissue: serous ovarian cancer///characteristics_ch1.2: Stage: advanced stage///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue sample using TRIzol reagent (Invitrogen, Carlsbad, CA, USA), and examined with 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Five hundred nanograms of total RNA were converted into labeled cRNA with nucleotides coupled to a cyanine 3-CTP (Cy3) (PerkinElmer, Boston, MA, USA) using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies). ///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.5 g) were hybridized for 17 hours at 65 degrees Celsius to an Agilent Human 1A (v2) Oligo Microarray.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: Serous ovarian cancer-64///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings.///platform_id: GPL887///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM312nnn/GSM312175/GSM312175_s64.txt.gz///data_row_count: 22153
1
title: Advanced serous ovarian cancer 6///geo_accession: GSM312139///status: Public on Jul 19 2009///submission_date: Aug 13 2008///last_update_date: Jul 19 2009///type: RNA///channel_count: 1///source_name_ch1: ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: Gender: female///characteristics_ch1.1: Tissue: serous ovarian cancer///characteristics_ch1.2: Stage: advanced stage///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue sample using TRIzol reagent (Invitrogen, Carlsbad, CA, USA), and examined with 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Five hundred nanograms of total RNA were converted into labeled cRNA with nucleotides coupled to a cyanine 3-CTP (Cy3) (PerkinElmer, Boston, MA, USA) using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies). ///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.5 g) were hybridized for 17 hours at 65 degrees Celsius to an Agilent Human 1A (v2) Oligo Microarray.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: Serous ovarian cancer-6///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings.///platform_id: GPL887///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM312nnn/GSM312139/GSM312139_s6.txt.gz///data_row_count: 22153
1
title: Advanced serous ovarian cancer 7///geo_accession: GSM312140///status: Public on Jul 19 2009///submission_date: Aug 13 2008///last_update_date: Jul 19 2009///type: RNA///channel_count: 1///source_name_ch1: ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: Gender: female///characteristics_ch1.1: Tissue: serous ovarian cancer///characteristics_ch1.2: Stage: advanced stage///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue sample using TRIzol reagent (Invitrogen, Carlsbad, CA, USA), and examined with 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Five hundred nanograms of total RNA were converted into labeled cRNA with nucleotides coupled to a cyanine 3-CTP (Cy3) (PerkinElmer, Boston, MA, USA) using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies). ///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.5 g) were hybridized for 17 hours at 65 degrees Celsius to an Agilent Human 1A (v2) Oligo Microarray.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: Serous ovarian cancer-7///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings.///platform_id: GPL887///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM312nnn/GSM312140/GSM312140_s7.txt.gz///data_row_count: 22153
1
title: Early serous ovarian cancer 28///geo_accession: GSM312180///status: Public on Jul 19 2009///submission_date: Aug 13 2008///last_update_date: Jul 19 2009///type: RNA///channel_count: 1///source_name_ch1: ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: Gender: female///characteristics_ch1.1: Tissue: serous ovarian cancer///characteristics_ch1.2: Stage: early stage///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue sample using TRIzol reagent (Invitrogen, Carlsbad, CA, USA), and examined with 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Five hundred nanograms of total RNA were converted into labeled cRNA with nucleotides coupled to a cyanine 3-CTP (Cy3) (PerkinElmer, Boston, MA, USA) using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies). ///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.5 g) were hybridized for 17 hours at 65 degrees Celsius to an Agilent Human 1A (v2) Oligo Microarray.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: Serous ovarian cancer-28///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings.///platform_id: GPL887///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM312nnn/GSM312180/GSM312180_s28.txt.gz///data_row_count: 22153
1
title: Early serous ovarian cancer 32///geo_accession: GSM312181///status: Public on Jul 19 2009///submission_date: Aug 13 2008///last_update_date: Jul 19 2009///type: RNA///channel_count: 1///source_name_ch1: ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: Gender: female///characteristics_ch1.1: Tissue: serous ovarian cancer///characteristics_ch1.2: Stage: early stage///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue sample using TRIzol reagent (Invitrogen, Carlsbad, CA, USA), and examined with 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Five hundred nanograms of total RNA were converted into labeled cRNA with nucleotides coupled to a cyanine 3-CTP (Cy3) (PerkinElmer, Boston, MA, USA) using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies). ///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.5 g) were hybridized for 17 hours at 65 degrees Celsius to an Agilent Human 1A (v2) Oligo Microarray.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: Serous ovarian cancer-32///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings.///platform_id: GPL887///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM312nnn/GSM312181/GSM312181_s32.txt.gz///data_row_count: 22153
1
title: Early serous ovarian cancer 33///geo_accession: GSM312182///status: Public on Jul 19 2009///submission_date: Aug 13 2008///last_update_date: Jul 19 2009///type: RNA///channel_count: 1///source_name_ch1: ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: Gender: female///characteristics_ch1.1: Tissue: serous ovarian cancer///characteristics_ch1.2: Stage: early stage///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue sample using TRIzol reagent (Invitrogen, Carlsbad, CA, USA), and examined with 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Five hundred nanograms of total RNA were converted into labeled cRNA with nucleotides coupled to a cyanine 3-CTP (Cy3) (PerkinElmer, Boston, MA, USA) using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies). ///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.5 g) were hybridized for 17 hours at 65 degrees Celsius to an Agilent Human 1A (v2) Oligo Microarray.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: Serous ovarian cancer-33///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings.///platform_id: GPL887///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM312nnn/GSM312182/GSM312182_s33.txt.gz///data_row_count: 22153
1
title: Early serous ovarian cancer 35///geo_accession: GSM312183///status: Public on Jul 19 2009///submission_date: Aug 13 2008///last_update_date: Jul 19 2009///type: RNA///channel_count: 1///source_name_ch1: ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: Gender: female///characteristics_ch1.1: Tissue: serous ovarian cancer///characteristics_ch1.2: Stage: early stage///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue sample using TRIzol reagent (Invitrogen, Carlsbad, CA, USA), and examined with 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Five hundred nanograms of total RNA were converted into labeled cRNA with nucleotides coupled to a cyanine 3-CTP (Cy3) (PerkinElmer, Boston, MA, USA) using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies). ///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.5 g) were hybridized for 17 hours at 65 degrees Celsius to an Agilent Human 1A (v2) Oligo Microarray.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: Serous ovarian cancer-35///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings.///platform_id: GPL887///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM312nnn/GSM312183/GSM312183_s35.txt.gz///data_row_count: 22153
1
title: Early serous ovarian cancer 5///geo_accession: GSM312176///status: Public on Jul 19 2009///submission_date: Aug 13 2008///last_update_date: Jul 19 2009///type: RNA///channel_count: 1///source_name_ch1: ovarian cacner///organism_ch1: Homo sapiens///characteristics_ch1: Gender: female///characteristics_ch1.1: Tissue: serous ovarian cancer///characteristics_ch1.2: Stage: early stage///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue sample using TRIzol reagent (Invitrogen, Carlsbad, CA, USA), and examined with 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Five hundred nanograms of total RNA were converted into labeled cRNA with nucleotides coupled to a cyanine 3-CTP (Cy3) (PerkinElmer, Boston, MA, USA) using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies). ///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.5 g) were hybridized for 17 hours at 65 degrees Celsius to an Agilent Human 1A (v2) Oligo Microarray.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: Serous ovarian cancer-5///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings.///platform_id: GPL887///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM312nnn/GSM312176/GSM312176_s5.txt.gz///data_row_count: 22153
1
title: Early serous ovarian cancer 65///geo_accession: GSM312185///status: Public on Jul 19 2009///submission_date: Aug 13 2008///last_update_date: Jul 19 2009///type: RNA///channel_count: 1///source_name_ch1: ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: Gender: female///characteristics_ch1.1: Tissue: serous ovarian cancer///characteristics_ch1.2: Stage: early stage///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue sample using TRIzol reagent (Invitrogen, Carlsbad, CA, USA), and examined with 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Five hundred nanograms of total RNA were converted into labeled cRNA with nucleotides coupled to a cyanine 3-CTP (Cy3) (PerkinElmer, Boston, MA, USA) using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies). ///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.5 g) were hybridized for 17 hours at 65 degrees Celsius to an Agilent Human 1A (v2) Oligo Microarray.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: Serous ovarian cancer-65///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings.///platform_id: GPL887///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM312nnn/GSM312185/GSM312185_s65.txt.gz///data_row_count: 22153
1
title: Early serous ovarian cancer 8///geo_accession: GSM312178///status: Public on Jul 19 2009///submission_date: Aug 13 2008///last_update_date: Jul 19 2009///type: RNA///channel_count: 1///source_name_ch1: ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: Gender: female///characteristics_ch1.1: Tissue: serous ovarian cancer///characteristics_ch1.2: Stage: early stage///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue sample using TRIzol reagent (Invitrogen, Carlsbad, CA, USA), and examined with 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Five hundred nanograms of total RNA were converted into labeled cRNA with nucleotides coupled to a cyanine 3-CTP (Cy3) (PerkinElmer, Boston, MA, USA) using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies). ///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.5 g) were hybridized for 17 hours at 65 degrees Celsius to an Agilent Human 1A (v2) Oligo Microarray.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: Serous ovarian cancer-8///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings.///platform_id: GPL887///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM312nnn/GSM312178/GSM312178_s8.txt.gz///data_row_count: 22153
1
title: Early serous ovarian cancer 9///geo_accession: GSM312179///status: Public on Jul 19 2009///submission_date: Aug 13 2008///last_update_date: Jul 19 2009///type: RNA///channel_count: 1///source_name_ch1: ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: Gender: female///characteristics_ch1.1: Tissue: serous ovarian cancer///characteristics_ch1.2: Stage: early stage///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue sample using TRIzol reagent (Invitrogen, Carlsbad, CA, USA), and examined with 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Five hundred nanograms of total RNA were converted into labeled cRNA with nucleotides coupled to a cyanine 3-CTP (Cy3) (PerkinElmer, Boston, MA, USA) using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies). ///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.5 g) were hybridized for 17 hours at 65 degrees Celsius to an Agilent Human 1A (v2) Oligo Microarray.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: Serous ovarian cancer-9///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings.///platform_id: GPL887///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM312nnn/GSM312179/GSM312179_s9.txt.gz///data_row_count: 22153
1
title: Peritoneum normal 12///geo_accession: GSM312131///status: Public on Jul 19 2009///submission_date: Aug 13 2008///last_update_date: Jul 19 2009///type: RNA///channel_count: 1///source_name_ch1: normal peritoneum///organism_ch1: Homo sapiens///characteristics_ch1: Gender: female///characteristics_ch1.1: Tissue: normal peritoneum///characteristics_ch1.2: ///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue sample using TRIzol reagent (Invitrogen, Carlsbad, CA, USA), and examined with 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Five hundred nanograms of total RNA were converted into labeled cRNA with nucleotides coupled to a cyanine 3-CTP (Cy3) (PerkinElmer, Boston, MA, USA) using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies). ///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.5 g) were hybridized for 17 hours at 65 degrees Celsius to an Agilent Human 1A (v2) Oligo Microarray.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: Peritoneum-Normal-12///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings.///platform_id: GPL887///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM312nnn/GSM312131/GSM312131_p12.txt.gz///data_row_count: 22153
1
title: Peritoneum normal 15///geo_accession: GSM312132///status: Public on Jul 19 2009///submission_date: Aug 13 2008///last_update_date: Jul 19 2009///type: RNA///channel_count: 1///source_name_ch1: normal peritoneum///organism_ch1: Homo sapiens///characteristics_ch1: Gender: female///characteristics_ch1.1: Tissue: normal peritoneum///characteristics_ch1.2: ///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue sample using TRIzol reagent (Invitrogen, Carlsbad, CA, USA), and examined with 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Five hundred nanograms of total RNA were converted into labeled cRNA with nucleotides coupled to a cyanine 3-CTP (Cy3) (PerkinElmer, Boston, MA, USA) using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies). ///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.5 g) were hybridized for 17 hours at 65 degrees Celsius to an Agilent Human 1A (v2) Oligo Microarray.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: Peritoneum-Normal-15///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings.///platform_id: GPL887///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM312nnn/GSM312132/GSM312132_p15.txt.gz///data_row_count: 22153
1
title: Peritoneum normal 16///geo_accession: GSM312133///status: Public on Jul 19 2009///submission_date: Aug 13 2008///last_update_date: Jul 19 2009///type: RNA///channel_count: 1///source_name_ch1: normal peritoneum///organism_ch1: Homo sapiens///characteristics_ch1: Gender: female///characteristics_ch1.1: Tissue: normal peritoneum///characteristics_ch1.2: ///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue sample using TRIzol reagent (Invitrogen, Carlsbad, CA, USA), and examined with 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Five hundred nanograms of total RNA were converted into labeled cRNA with nucleotides coupled to a cyanine 3-CTP (Cy3) (PerkinElmer, Boston, MA, USA) using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies). ///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.5 g) were hybridized for 17 hours at 65 degrees Celsius to an Agilent Human 1A (v2) Oligo Microarray.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: Peritoneum-Normal-16///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings.///platform_id: GPL887///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM312nnn/GSM312133/GSM312133_p16.txt.gz///data_row_count: 22153
1
title: Peritoneum normal 18///geo_accession: GSM312134///status: Public on Jul 19 2009///submission_date: Aug 13 2008///last_update_date: Jul 19 2009///type: RNA///channel_count: 1///source_name_ch1: normal peritoneum///organism_ch1: Homo sapiens///characteristics_ch1: Gender: female///characteristics_ch1.1: Tissue: normal peritoneum///characteristics_ch1.2: ///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue sample using TRIzol reagent (Invitrogen, Carlsbad, CA, USA), and examined with 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Five hundred nanograms of total RNA were converted into labeled cRNA with nucleotides coupled to a cyanine 3-CTP (Cy3) (PerkinElmer, Boston, MA, USA) using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies). ///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.5 g) were hybridized for 17 hours at 65 degrees Celsius to an Agilent Human 1A (v2) Oligo Microarray.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: Peritoneum-Normal-18///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings.///platform_id: GPL887///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM312nnn/GSM312134/GSM312134_p18.txt.gz///data_row_count: 22153
1
title: Peritoneum normal 21///geo_accession: GSM312135///status: Public on Jul 19 2009///submission_date: Aug 13 2008///last_update_date: Jul 19 2009///type: RNA///channel_count: 1///source_name_ch1: normal peritoneum///organism_ch1: Homo sapiens///characteristics_ch1: Gender: female///characteristics_ch1.1: Tissue: normal peritoneum///characteristics_ch1.2: ///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue sample using TRIzol reagent (Invitrogen, Carlsbad, CA, USA), and examined with 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Five hundred nanograms of total RNA were converted into labeled cRNA with nucleotides coupled to a cyanine 3-CTP (Cy3) (PerkinElmer, Boston, MA, USA) using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies). ///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.5 g) were hybridized for 17 hours at 65 degrees Celsius to an Agilent Human 1A (v2) Oligo Microarray.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: Peritoneum-Normal-21///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings.///platform_id: GPL887///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM312nnn/GSM312135/GSM312135_p21.txt.gz///data_row_count: 22153
1
title: Peritoneum normal 23///geo_accession: GSM312136///status: Public on Jul 19 2009///submission_date: Aug 13 2008///last_update_date: Jul 19 2009///type: RNA///channel_count: 1///source_name_ch1: normal peritoneum///organism_ch1: Homo sapiens///characteristics_ch1: Gender: female///characteristics_ch1.1: Tissue: normal peritoneum///characteristics_ch1.2: ///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue sample using TRIzol reagent (Invitrogen, Carlsbad, CA, USA), and examined with 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Five hundred nanograms of total RNA were converted into labeled cRNA with nucleotides coupled to a cyanine 3-CTP (Cy3) (PerkinElmer, Boston, MA, USA) using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies). ///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.5 g) were hybridized for 17 hours at 65 degrees Celsius to an Agilent Human 1A (v2) Oligo Microarray.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: Peritoneum-Normal-23///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings.///platform_id: GPL887///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM312nnn/GSM312136/GSM312136_1_p23.txt.gz///data_row_count: 22153
1
title: Peritoneum normal 30///geo_accession: GSM312137///status: Public on Jul 19 2009///submission_date: Aug 13 2008///last_update_date: Jul 19 2009///type: RNA///channel_count: 1///source_name_ch1: normal peritoneum///organism_ch1: Homo sapiens///characteristics_ch1: Gender: female///characteristics_ch1.1: Tissue: normal peritoneum///characteristics_ch1.2: ///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue sample using TRIzol reagent (Invitrogen, Carlsbad, CA, USA), and examined with 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Five hundred nanograms of total RNA were converted into labeled cRNA with nucleotides coupled to a cyanine 3-CTP (Cy3) (PerkinElmer, Boston, MA, USA) using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies). ///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.5 g) were hybridized for 17 hours at 65 degrees Celsius to an Agilent Human 1A (v2) Oligo Microarray.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: Peritoneum-Normal-30///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings.///platform_id: GPL887///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM312nnn/GSM312137/GSM312137_s30.txt.gz///data_row_count: 22153
1
title: Peritoneum normal 3///geo_accession: GSM311992///status: Public on Jul 19 2009///submission_date: Aug 12 2008///last_update_date: Jul 19 2009///type: RNA///channel_count: 1///source_name_ch1: normal peritoneum///organism_ch1: Homo sapiens///characteristics_ch1: Gender: female///characteristics_ch1.1: Tissue: normal peritoneum///characteristics_ch1.2: ///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue sample using TRIzol reagent (Invitrogen, Carlsbad, CA, USA), and examined with 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Five hundred nanograms of total RNA were converted into labeled cRNA with nucleotides coupled to a cyanine 3-CTP (Cy3) (PerkinElmer, Boston, MA, USA) using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies). ///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.5 g) were hybridized for 17 hours at 65 degrees Celsius to an Agilent Human 1A (v2) Oligo Microarray.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: Peritoneum-Normal-3///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings.///platform_id: GPL887///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM311nnn/GSM311992/GSM311992_p3.txt.gz///data_row_count: 22153
1
title: Peritoneum normal 4///geo_accession: GSM312129///status: Public on Jul 19 2009///submission_date: Aug 13 2008///last_update_date: Jul 19 2009///type: RNA///channel_count: 1///source_name_ch1: normal peritoneum///organism_ch1: Homo sapiens///characteristics_ch1: Gender: female///characteristics_ch1.1: Tissue: normal peritoneum///characteristics_ch1.2: ///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue sample using TRIzol reagent (Invitrogen, Carlsbad, CA, USA), and examined with 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Five hundred nanograms of total RNA were converted into labeled cRNA with nucleotides coupled to a cyanine 3-CTP (Cy3) (PerkinElmer, Boston, MA, USA) using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies). ///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.5 g) were hybridized for 17 hours at 65 degrees Celsius to an Agilent Human 1A (v2) Oligo Microarray.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: Peritoneum-Normal-4///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings.///platform_id: GPL887///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM312nnn/GSM312129/GSM312129_p4.txt.gz///data_row_count: 22153
1
title: Peritoneum normal 7///geo_accession: GSM312130///status: Public on Jul 19 2009///submission_date: Aug 13 2008///last_update_date: Jul 19 2009///type: RNA///channel_count: 1///source_name_ch1: normal peritoneum///organism_ch1: Homo sapiens///characteristics_ch1: Gender: female///characteristics_ch1.1: Tissue: normal peritoneum///characteristics_ch1.2: ///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue sample using TRIzol reagent (Invitrogen, Carlsbad, CA, USA), and examined with 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Five hundred nanograms of total RNA were converted into labeled cRNA with nucleotides coupled to a cyanine 3-CTP (Cy3) (PerkinElmer, Boston, MA, USA) using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies). ///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.5 g) were hybridized for 17 hours at 65 degrees Celsius to an Agilent Human 1A (v2) Oligo Microarray.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: Peritoneum-Normal-7///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings.///platform_id: GPL887///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM312nnn/GSM312130/GSM312130_p7.txt.gz///data_row_count: 22153
1
duplicates:
GSE12470.GSE12470_GSM312135 GSE12470.GSE12470_GSM312136
1 1
GSE12470.GSE12470_GSM312145 GSE12470.GSE12470_GSM312146
1 1
NA's
49
An expression set
Ovarian cancer has a poor prognosis due to advanced stage at presentation and either intrinsic or acquired resistance to classic cytotoxic drugs such as platinum and taxoids. Recent large clinical trials with different combinations and sequences of classic cytotoxic drugs indicate that further significant improvement in prognosis by this type of drugs is not to be expected. Currently a large number of drugs, targeting dysregulated molecular pathways in cancer cells have been developed and are introduced in the clinic. A major challenge is to identify those patients who will benefit from drugs targeting these specific dysregulated pathways.The aims of our study were (1) to develop a gene expression profile associated with overall survival in advanced stage serous ovarian cancer, (2) to assess the association of pathways and transcription factors with overall survival, and (3) to validate our identified profile and pathways/transcription factors in an independent set of ovarian cancers.According to a randomized design, profiling of 157 advanced stage serous ovarian cancers was performed in duplicate using approximately 35,000 70-mer oligonucleotide microarrays. A continuous predictor of overall survival was built taking into account well-known issues in microarray analysis, such as multiple testing and overfitting. A functional class scoring analysis was utilized to assess pathways/transcription factors for their association with overall survival. The prognostic value of genes that constitute our overall survival profile was validated on a fully independent, publicly available dataset of 118 well-defined primary serous ovarian cancers. Furthermore, functional class scoring analysis was also performed on this independent dataset to assess the similarities with results from our own dataset. An 86-gene overall survival profile discriminated between patients with unfavorable and favorable prognosis (median survival, 19 versus 41 mo, respectively; permutation p-value of log-rank statistic = 0.015) and maintained its independent prognostic value in multivariate analysis. Genes that composed the overall survival profile were also able to discriminate between the two risk groups in the independent dataset. In our dataset 17/167 pathways and 13/111 transcription factors were associated with overall survival, of which 16 and 12, respectively, were confirmed in the independent dataset.Our study provides new clues to genes, pathways, and transcription factors that contribute to the clinical outcome of serous ovarian cancer and might be exploited in designing new treatment strategies.
experimentData(eset):
Experiment data
Experimenter name: Crijns AP, Fehrmann RS, de Jong S, Gerbens F, Meersma GJ, Klip HG, Hollema H, Hofstra RM, te Meerman GJ, de Vries EG, van der Zee AG.Survival-related profile, pathways, and transcription factors in ovarian cancer. PLoS Med. 2009 Feb 3; 6(2):e24.
Laboratory: Crijns, van der Zee 2009
Contact information:
Title: Survival-related profile, pathways, and transcription factors in ovarian cancer.
URL:
PMIDs: 19192944
Abstract: A 371 word abstract is available. Use 'abstract' method.
Information is available on: preprocessing
notes:
platform_title:
Operon human v3 ~35K 70-mer two-color oligonucleotide microarrays
platform_shorttitle:
Operon v3 two-color
platform_summary:
OperonHumanV3
platform_manufacturer:
other
platform_distribution:
non-commercial
platform_accession:
GPL7759
version:
2015-09-22 19:11:43
featureData(eset):
An object of class 'AnnotatedDataFrame'
featureNames: 1 2 ... 37629 (20939 total)
varLabels: probeset gene EntrezGene.ID best_probe
varMetadata: labelDescription
assayData: 20939 features, 157 samples
Platform type:
Overall survival time-to-event summary (in years):
Call: survfit(formula = Surv(time, cens) ~ -1)
n events median 0.95LCL 0.95UCL
157.00 113.00 2.05 1.56 2.71
---------------------------
Available sample meta-data:
---------------------------
alt_sample_name:
151 NA's
1 156
unique_patient_ID:
Min. 1st Qu. Median Mean 3rd Qu. Max.
1 40 79 79 118 157
sample_type:
tumor
157
histological_type:
ser
157
primarysite:
ov
157
summarygrade:
high low NA's
85 59 13
summarystage:
late
157
grade:
1 2 3 4 NA's
14 45 82 3 13
age_at_initial_pathologic_diagnosis:
Min. 1st Qu. Median Mean 3rd Qu. Max.
21.00 50.00 60.00 57.95 67.00 84.00
days_to_death:
Min. 1st Qu. Median Mean 3rd Qu. Max.
30 360 630 1100 1470 7020
vital_status:
deceased living
113 44
uncurated_author_metadata:
title: Ovarian tumor sample 100 / Ovarian tumor sample 101///geo_accession: GSM405638 / GSM405874///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 41///characteristics_ch1.1: status: 0///characteristics_ch1.2: fumnd: 25///characteristics_ch1.3: age: 54///characteristics_ch1.4: sample nr: 197///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy3 / Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 2 in raw data file ; Characteristics / Channel 1 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: [email protected]///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405638/GSM405638.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405874/GSM405874.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 103 / Ovarian tumor sample 104///geo_accession: GSM405608 / GSM405784///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 42///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 2///characteristics_ch1.3: age: 57///characteristics_ch1.4: sample nr: 170///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy3 / Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 2 in raw data file ; Characteristics / Channel 1 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: [email protected]///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405608/GSM405608.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405784/GSM405784.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 105 / Ovarian tumor sample 106///geo_accession: GSM405628 / GSM405629///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 43///characteristics_ch1.1: status: 0///characteristics_ch1.2: fumnd: 59///characteristics_ch1.3: age: 63///characteristics_ch1.4: sample nr: 402///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ; 1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: [email protected]///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405628/GSM405628.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405629/GSM405629.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 108 / Ovarian tumor sample 109///geo_accession: GSM405700 / GSM405943///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 44///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 16///characteristics_ch1.3: age: 66///characteristics_ch1.4: sample nr: 5///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5 / Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics / Channel 2 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: [email protected]///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405700/GSM405700.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405943/GSM405943.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 10 / Ovarian tumor sample 11///geo_accession: GSM405902 / GSM405903///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 24///characteristics_ch1.1: status: 0///characteristics_ch1.2: fumnd: 5///characteristics_ch1.3: age: 52///characteristics_ch1.4: sample nr: 459///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ; 1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: [email protected]///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405902/GSM405902.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405903/GSM405903.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 111 / Ovarian tumor sample 112///geo_accession: GSM405598 / GSM405599///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 45///characteristics_ch1.1: status: 0///characteristics_ch1.2: fumnd: 64///characteristics_ch1.3: age: 66///characteristics_ch1.4: sample nr: 343///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ; 1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: [email protected]///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405598/GSM405598.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405599/GSM405599.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 115 / Ovarian tumor sample 117///geo_accession: GSM405774 / GSM405776///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 46///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 11///characteristics_ch1.3: age: 56///characteristics_ch1.4: sample nr: 345///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ; 1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: [email protected]///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405774/GSM405774.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405776/GSM405776.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 119 / Ovarian tumor sample 120///geo_accession: GSM405600 / GSM405805///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 47///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 33///characteristics_ch1.3: age: 43///characteristics_ch1.4: sample nr: 379///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5 / Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics / Channel 2 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: [email protected]///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405600/GSM405600.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405805/GSM405805.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 122 / Ovarian tumor sample 123///geo_accession: GSM405651 / GSM405794///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 48///characteristics_ch1.1: status: 0///characteristics_ch1.2: fumnd: 73///characteristics_ch1.3: age: 73///characteristics_ch1.4: sample nr: 211///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy3 / Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 2 in raw data file ; Characteristics / Channel 1 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: [email protected]///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405651/GSM405651.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405794/GSM405794.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 124 / Ovarian tumor sample 125///geo_accession: GSM405659 / GSM405787///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 49///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 30///characteristics_ch1.3: age: 54///characteristics_ch1.4: sample nr: 346///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5 / Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics / Channel 2 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: [email protected]///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405659/GSM405659.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405787/GSM405787.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 126 / Ovarian tumor sample 127///geo_accession: GSM405614 / GSM405615///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 50///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 18///characteristics_ch1.3: age: 48///characteristics_ch1.4: sample nr: 235///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ; 1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: [email protected]///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405614/GSM405614.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405615/GSM405615.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 129 / Ovarian tumor sample 130///geo_accession: GSM405641 / GSM405887///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 1///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 41///characteristics_ch1.3: age: 55///characteristics_ch1.4: sample nr: 200///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy3 / Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 2 in raw data file ; Characteristics / Channel 1 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: [email protected]///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405641/GSM405641.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405887/GSM405887.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 131 / Ovarian tumor sample 132///geo_accession: GSM405597 / GSM405684///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 51///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 8///characteristics_ch1.3: age: 57///characteristics_ch1.4: sample nr: 160///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy3 / Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 2 in raw data file ; Characteristics / Channel 1 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: [email protected]///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405597/GSM405597.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405684/GSM405684.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 133 / Ovarian tumor sample 134///geo_accession: GSM405756 / GSM405914///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 52///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 234///characteristics_ch1.3: age: 26///characteristics_ch1.4: sample nr: 468///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5 / Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics / Channel 2 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: [email protected]///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405756/GSM405756.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405914/GSM405914.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 135 / Ovarian tumor sample 136///geo_accession: GSM405658 / GSM405753///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 53///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 66///characteristics_ch1.3: age: 60///characteristics_ch1.4: sample nr: 219///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy3 / Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 2 in raw data file ; Characteristics / Channel 1 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: [email protected]///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405658/GSM405658.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405753/GSM405753.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 137 / Ovarian tumor sample 138///geo_accession: GSM405568 / GSM405946///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 100///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 18///characteristics_ch1.3: age: 62///characteristics_ch1.4: sample nr: 61///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5 / Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics / Channel 2 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: [email protected]///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405568/GSM405568.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405946/GSM405946.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 139 / Ovarian tumor sample 140///geo_accession: GSM405890 / GSM405937///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 101///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 42///characteristics_ch1.3: age: 57///characteristics_ch1.4: sample nr: 450///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy3 / Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 2 in raw data file ; Characteristics / Channel 1 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: [email protected]///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405890/GSM405890.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405937/GSM405937.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 13 / Ovarian tumor sample 14///geo_accession: GSM405578 / GSM405580///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 85///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 25///characteristics_ch1.3: age: 51///characteristics_ch1.4: sample nr: 248///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ; 1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: [email protected]///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405578/GSM405578.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405580/GSM405580.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 141 / Ovarian tumor sample 142///geo_accession: GSM405569 / GSM405601///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 102///characteristics_ch1.1: status: 0///characteristics_ch1.2: fumnd: 132///characteristics_ch1.3: age: 65///characteristics_ch1.4: sample nr: 117///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy3 / Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 2 in raw data file ; Characteristics / Channel 1 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: [email protected]///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405569/GSM405569.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405601/GSM405601.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 145 / Ovarian tumor sample 146///geo_accession: GSM405817 / GSM405819///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 54///characteristics_ch1.1: status: 0///characteristics_ch1.2: fumnd: 2///characteristics_ch1.3: age: 71///characteristics_ch1.4: sample nr: 385///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy3 / Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 2 in raw data file ; Characteristics / Channel 1 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: [email protected]///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405817/GSM405817.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405819/GSM405819.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 147 / Ovarian tumor sample 148///geo_accession: GSM405631 / GSM405904///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 55///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 12///characteristics_ch1.3: age: 65///characteristics_ch1.4: sample nr: 190///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy3 / Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 2 in raw data file ; Characteristics / Channel 1 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: [email protected]///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405631/GSM405631.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405904/GSM405904.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 149 / Ovarian tumor sample 150///geo_accession: GSM405716 / GSM405789///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 56///characteristics_ch1.1: status: 0///characteristics_ch1.2: fumnd: 133///characteristics_ch1.3: age: 49///characteristics_ch1.4: sample nr: 349///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5 / Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics / Channel 2 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: [email protected]///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405716/GSM405716.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405789/GSM405789.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 151///geo_accession: GSM405740///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 103///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 20///characteristics_ch1.3: age: 57///characteristics_ch1.4: sample nr: 305///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ; 1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: [email protected]///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405740/GSM405740.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 152 / Ovarian tumor sample 153///geo_accession: GSM405679 / GSM405822///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 57///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 20///characteristics_ch1.3: age: 71///characteristics_ch1.4: sample nr: 392///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5 / Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics / Channel 2 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: [email protected]///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405679/GSM405679.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405822/GSM405822.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 155 / Ovarian tumor sample 156///geo_accession: GSM405769 / GSM405898///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 58///characteristics_ch1.1: status: 0///characteristics_ch1.2: fumnd: 59///characteristics_ch1.3: age: 46///characteristics_ch1.4: sample nr: 455///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5 / Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics / Channel 2 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: [email protected]///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405769/GSM405769.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405898/GSM405898.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 157 / Ovarian tumor sample 158///geo_accession: GSM405701 / GSM405871///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 59///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 2///characteristics_ch1.3: age: 45///characteristics_ch1.4: sample nr: 263///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy3 / Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 2 in raw data file ; Characteristics / Channel 1 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: [email protected]///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405701/GSM405701.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405871/GSM405871.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 159 / Ovarian tumor sample 160///geo_accession: GSM405722 / GSM405809///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 104///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 49///characteristics_ch1.3: age: 37///characteristics_ch1.4: sample nr: 283///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy3 / Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 2 in raw data file ; Characteristics / Channel 1 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: [email protected]///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405722/GSM405722.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405809/GSM405809.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 161 / Ovarian tumor sample 162///geo_accession: GSM405826 / GSM405930///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 60///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 28///characteristics_ch1.3: age: 66///characteristics_ch1.4: sample nr: 393///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy3 / Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 2 in raw data file ; Characteristics / Channel 1 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: [email protected]///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405826/GSM405826.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405930/GSM405930.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 163 / Ovarian tumor sample 164///geo_accession: GSM405865 / GSM405916///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 105///characteristics_ch1.1: status: 0///characteristics_ch1.2: fumnd: 59///characteristics_ch1.3: age: 65///characteristics_ch1.4: sample nr: 471///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5 / Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics / Channel 2 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: [email protected]///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405865/GSM405865.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405916/GSM405916.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 165 / Ovarian tumor sample 166///geo_accession: GSM405634 / GSM405635///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 61///characteristics_ch1.1: status: 0///characteristics_ch1.2: fumnd: 67///characteristics_ch1.3: age: 72///characteristics_ch1.4: sample nr: 193///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ; 1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: [email protected]///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405634/GSM405634.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405635/GSM405635.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 169 / Ovarian tumor sample 170///geo_accession: GSM405556 / GSM405695///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 62///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 7///characteristics_ch1.3: age: 61///characteristics_ch1.4: sample nr: 258///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5 / Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics / Channel 2 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: [email protected]///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405556/GSM405556.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405695/GSM405695.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 171 / Ovarian tumor sample 172///geo_accession: GSM405559 / GSM405866///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 106///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 12///characteristics_ch1.3: age: 49///characteristics_ch1.4: sample nr: 429///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5 / Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics / Channel 2 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: [email protected]///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405559/GSM405559.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405866/GSM405866.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 173 / Ovarian tumor sample 174///geo_accession: GSM405652 / GSM405959///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 63///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 16///characteristics_ch1.3: age: 51///characteristics_ch1.4: sample nr: 213///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy3 / Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 2 in raw data file ; Characteristics / Channel 1 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: [email protected]///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405652/GSM405652.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405959/GSM405959.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 176 / Ovarian tumor sample 177///geo_accession: GSM405746 / GSM405864///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 64///characteristics_ch1.1: status: 0///characteristics_ch1.2: fumnd: 53///characteristics_ch1.3: age: 63///characteristics_ch1.4: sample nr: 427///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5 / Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics / Channel 2 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: [email protected]///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405746/GSM405746.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405864/GSM405864.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 178 / Ovarian tumor sample 179///geo_accession: GSM405882 / GSM405913///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 107///characteristics_ch1.1: status: 0///characteristics_ch1.2: fumnd: 119///characteristics_ch1.3: age: 21///characteristics_ch1.4: sample nr: 440///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy3 / Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 2 in raw data file ; Characteristics / Channel 1 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: [email protected]///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405882/GSM405882.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405913/GSM405913.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 180 / Ovarian tumor sample 181///geo_accession: GSM405591 / GSM405654///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 65///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 70///characteristics_ch1.3: age: 61///characteristics_ch1.4: sample nr: 214///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5 / Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics / Channel 2 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: [email protected]///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405591/GSM405591.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405654/GSM405654.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 185 / Ovarian tumor sample 186///geo_accession: GSM405613 / GSM405741///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 66///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 10///characteristics_ch1.3: age: 75///characteristics_ch1.4: sample nr: 179///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy3 / Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 2 in raw data file ; Characteristics / Channel 1 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: [email protected]///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405613/GSM405613.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405741/GSM405741.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 187 / Ovarian tumor sample 188///geo_accession: GSM405791 / GSM405878///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 67///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 4///characteristics_ch1.3: age: 22///characteristics_ch1.4: sample nr: 352///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy3 / Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 2 in raw data file ; Characteristics / Channel 1 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: [email protected]///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405791/GSM405791.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405878/GSM405878.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 189 / Ovarian tumor sample 190///geo_accession: GSM405626 / GSM405868///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 68///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 30///characteristics_ch1.3: age: 72///characteristics_ch1.4: sample nr: 431///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5 / Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics / Channel 2 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: [email protected]///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405626/GSM405626.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405868/GSM405868.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 18 / Ovarian tumor sample 19///geo_accession: GSM405612 / GSM405642///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 86///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 9///characteristics_ch1.3: age: 68///characteristics_ch1.4: sample nr: 177///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy3 / Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 2 in raw data file ; Characteristics / Channel 1 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: [email protected]///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405612/GSM405612.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405642/GSM405642.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 191 / Ovarian tumor sample 192///geo_accession: GSM405566 / GSM405610///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 69///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 8///characteristics_ch1.3: age: 54///characteristics_ch1.4: sample nr: 176///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5 / Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics / Channel 2 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: [email protected]///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405566/GSM405566.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405610/GSM405610.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 193 / Ovarian tumor sample 194///geo_accession: GSM405821 / GSM405823///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 70///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 17///characteristics_ch1.3: age: 62///characteristics_ch1.4: sample nr: 395///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ; 1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: [email protected]///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405821/GSM405821.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405823/GSM405823.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 196 / Ovarian tumor sample 197///geo_accession: GSM405603 / GSM405900///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 2///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 1///characteristics_ch1.3: age: 64///characteristics_ch1.4: sample nr: 457///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5 / Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics / Channel 2 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: [email protected]///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405603/GSM405603.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405900/GSM405900.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 198 / Ovarian tumor sample 199///geo_accession: GSM405562 / GSM405852///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 3///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 47///characteristics_ch1.3: age: 55///characteristics_ch1.4: sample nr: 413///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5 / Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics / Channel 2 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: [email protected]///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405562/GSM405562.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405852/GSM405852.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 1 / Ovarian tumor sample 2///geo_accession: GSM405750 / GSM405810///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 21///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 36///characteristics_ch1.3: age: 66///characteristics_ch1.4: sample nr: 383///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5 / Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics / Channel 2 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: [email protected]///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405750/GSM405750.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405810/GSM405810.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 200 / Ovarian tumor sample 201///geo_accession: GSM405583 / GSM405593///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 71///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 13///characteristics_ch1.3: age: 43///characteristics_ch1.4: sample nr: 133///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy3 / Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 2 in raw data file ; Characteristics / Channel 1 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: [email protected]///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405583/GSM405583.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405593/GSM405593.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 202 / Ovarian tumor sample 203///geo_accession: GSM405637 / GSM405655///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 4///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 22///characteristics_ch1.3: age: 72///characteristics_ch1.4: sample nr: 217///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5 / Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics / Channel 2 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: [email protected]///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405637/GSM405637.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405655/GSM405655.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 206 / Ovarian tumor sample 207///geo_accession: GSM405857 / GSM405901///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 5///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 7///characteristics_ch1.3: age: 40///characteristics_ch1.4: sample nr: 458///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5 / Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics / Channel 2 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: [email protected]///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405857/GSM405857.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405901/GSM405901.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 208 / Ovarian tumor sample 209///geo_accession: GSM405584 / GSM405661///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 72///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 18///characteristics_ch1.3: age: 53///characteristics_ch1.4: sample nr: 223///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5 / Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics / Channel 2 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: [email protected]///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405584/GSM405584.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405661/GSM405661.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 210 / Ovarian tumor sample 211///geo_accession: GSM405757 / GSM405800///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 6///characteristics_ch1.1: status: 0///characteristics_ch1.2: fumnd: 64///characteristics_ch1.3: age: 70///characteristics_ch1.4: sample nr: 376///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5 / Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics / Channel 2 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: [email protected]///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405757/GSM405757.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405800/GSM405800.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 212 / Ovarian tumor sample 213///geo_accession: GSM405699 / GSM405935///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 7///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 17///characteristics_ch1.3: age: 72///characteristics_ch1.4: sample nr: 262///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy3 / Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 2 in raw data file ; Characteristics / Channel 1 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: [email protected]///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405699/GSM405699.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405935/GSM405935.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 214 / Ovarian tumor sample 215///geo_accession: GSM405713 / GSM405872///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 73///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 5///characteristics_ch1.3: age: 65///characteristics_ch1.4: sample nr: 435///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5 / Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics / Channel 2 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: [email protected]///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405713/GSM405713.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405872/GSM405872.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 216 / Ovarian tumor sample 217///geo_accession: GSM405669 / GSM405754///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 8///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 12///characteristics_ch1.3: age: 71///characteristics_ch1.4: sample nr / sample nr///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5 / Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics / Channel 2 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: [email protected]///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405669/GSM405669.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405754/GSM405754.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 21 / Ovarian tumor sample 22///geo_accession: GSM405625 / GSM405644///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 25///characteristics_ch1.1: status: 0///characteristics_ch1.2: fumnd: 31///characteristics_ch1.3: age: 68///characteristics_ch1.4: sample nr: 186///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy3 / Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 2 in raw data file ; Characteristics / Channel 1 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: [email protected]///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405625/GSM405625.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405644/GSM405644.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 222 / Ovarian tumor sample 223///geo_accession: GSM405680 / GSM405856///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 108///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 22///characteristics_ch1.3: age: 61///characteristics_ch1.4: sample nr: 419///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5 / Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics / Channel 2 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: [email protected]///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405680/GSM405680.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405856/GSM405856.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 224 / Ovarian tumor sample 225///geo_accession: GSM405742 / GSM405747///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 109///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 12///characteristics_ch1.3: age: 53///characteristics_ch1.4: sample nr: 307///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy3 / Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 2 in raw data file ; Characteristics / Channel 1 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: [email protected]///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405742/GSM405742.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405747/GSM405747.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 228 / Ovarian tumor sample 229///geo_accession: GSM405665 / GSM405832///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 74///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 12///characteristics_ch1.3: age: 64///characteristics_ch1.4: sample nr: 396///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5 / Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics / Channel 2 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: [email protected]///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405665/GSM405665.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405832/GSM405832.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 230 / Ovarian tumor sample 231///geo_accession: GSM405570 / GSM405571///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 9///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 18///characteristics_ch1.3: age: 42///characteristics_ch1.4: sample nr: 336///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ; 1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: [email protected]///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405570/GSM405570.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405571/GSM405571.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 235 / Ovarian tumor sample 236///geo_accession: GSM405630 / GSM405668///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 10///characteristics_ch1.1: status: 0///characteristics_ch1.2: fumnd: 80///characteristics_ch1.3: age: 54///characteristics_ch1.4: sample nr: 232///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5 / Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics / Channel 2 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: [email protected]///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405630/GSM405630.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405668/GSM405668.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 237 / Ovarian tumor sample 238///geo_accession: GSM405807 / GSM405808///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 75///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 13///characteristics_ch1.3: age: 58///characteristics_ch1.4: sample nr: 438///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ; 1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: [email protected]///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405807/GSM405807.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405808/GSM405808.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 241 / Ovarian tumor sample 242///geo_accession: GSM405609 / GSM405928///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 11///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 5///characteristics_ch1.3: age: 48///characteristics_ch1.4: sample nr: 173///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy3 / Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 2 in raw data file ; Characteristics / Channel 1 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: [email protected]///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405609/GSM405609.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405928/GSM405928.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 244 / Ovarian tumor sample 245///geo_accession: GSM405624 / GSM405732///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 12///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 21///characteristics_ch1.3: age: 67///characteristics_ch1.4: sample nr: 185///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy3 / Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 2 in raw data file ; Characteristics / Channel 1 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: [email protected]///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405624/GSM405624.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405732/GSM405732.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 246 / Ovarian tumor sample 247///geo_accession: GSM405686 / GSM405708///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 76///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 2///characteristics_ch1.3: age: 78///characteristics_ch1.4: sample nr: 272///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5 / Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics / Channel 2 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: [email protected]///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405686/GSM405686.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405708/GSM405708.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 248 / Ovarian tumor sample 249///geo_accession: GSM405724 / GSM405853///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 110///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 41///characteristics_ch1.3: age: 73///characteristics_ch1.4: sample nr: 285///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy3 / Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 2 in raw data file ; Characteristics / Channel 1 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: [email protected]///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405724/GSM405724.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405853/GSM405853.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 24 / Ovarian tumor sample 25///geo_accession: GSM405707 / GSM405954///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 87///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 19///characteristics_ch1.3: age: 66///characteristics_ch1.4: sample nr: 67///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5 / Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics / Channel 2 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: [email protected]///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405707/GSM405707.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405954/GSM405954.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 250 / Ovarian tumor sample 251///geo_accession: GSM405899 / GSM405926///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 77///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 11///characteristics_ch1.3: age: 25///characteristics_ch1.4: sample nr / sample nr///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ; 1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: [email protected]///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405899/GSM405899.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405926/GSM405926.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 254 / Ovarian tumor sample 255///geo_accession: GSM405586 / GSM405633///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 78///characteristics_ch1.1: status: 0///characteristics_ch1.2: fumnd: 14///characteristics_ch1.3: age: 59///characteristics_ch1.4: sample nr: 191///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5 / Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics / Channel 2 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: [email protected]///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405586/GSM405586.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405633/GSM405633.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 256 / Ovarian tumor sample 257///geo_accession: GSM405561 / GSM405621///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 111///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 59///characteristics_ch1.3: age: 61///characteristics_ch1.4: sample nr: 111///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy3 / Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 2 in raw data file ; Characteristics / Channel 1 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: [email protected]///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405561/GSM405561.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405621/GSM405621.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 258 / Ovarian tumor sample 259///geo_accession: GSM405696 / GSM405697///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 13///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 19///characteristics_ch1.3: age: 41///characteristics_ch1.4: sample nr: 259///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ; 1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: [email protected]///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405696/GSM405696.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405697/GSM405697.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 261 / Ovarian tumor sample 262///geo_accession: GSM405678 / GSM405863///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 14///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 9///characteristics_ch1.3: age: 60///characteristics_ch1.4: sample nr: 239///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy3 / Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 2 in raw data file ; Characteristics / Channel 1 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: [email protected]///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405678/GSM405678.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405863/GSM405863.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 263 / Ovarian tumor sample 264///geo_accession: GSM405730 / GSM405798///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 15///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 6///characteristics_ch1.3: age: 68///characteristics_ch1.4: sample nr: 371///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5 / Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics / Channel 2 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: [email protected]///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405730/GSM405730.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405798/GSM405798.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 265 / Ovarian tumor sample 266///geo_accession: GSM405606 / GSM405951///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 112///characteristics_ch1.1: status: 0///characteristics_ch1.2: fumnd: 92///characteristics_ch1.3: age: 51///characteristics_ch1.4: sample nr: 168///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy3 / Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 2 in raw data file ; Characteristics / Channel 1 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: [email protected]///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405606/GSM405606.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405951/GSM405951.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 267 / Ovarian tumor sample 268///geo_accession: GSM405592 / GSM405703///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 113///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 31///characteristics_ch1.3: age: 62///characteristics_ch1.4: sample nr: 266///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5 / Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics / Channel 2 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: [email protected]///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405592/GSM405592.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405703/GSM405703.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 269 / Ovarian tumor sample 270///geo_accession: GSM405619 / GSM405650///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 114///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 24///characteristics_ch1.3: age: 74///characteristics_ch1.4: sample nr / sample nr///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5 / Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics / Channel 2 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: [email protected]///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405619/GSM405619.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405650/GSM405650.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 26 / Ovarian tumor sample 27///geo_accession: GSM405675 / GSM405758///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 26///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 61///characteristics_ch1.3: age: 71///characteristics_ch1.4: sample nr: 329///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5 / Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics / Channel 2 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: [email protected]///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405675/GSM405675.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405758/GSM405758.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 273 / Ovarian tumor sample 274///geo_accession: GSM405579 / GSM405581///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 115///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 14///characteristics_ch1.3: age: 60///characteristics_ch1.4: sample nr: 131///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ; 1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: [email protected]///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405579/GSM405579.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405581/GSM405581.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 278 / Ovarian tumor sample 279///geo_accession: GSM405683 / GSM405879///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 79///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 16///characteristics_ch1.3: age: 39///characteristics_ch1.4: sample nr: 439///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5 / Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics / Channel 2 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: [email protected]///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405683/GSM405683.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405879/GSM405879.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 280 / Ovarian tumor sample 281///geo_accession: GSM405859 / GSM405917///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 116///characteristics_ch1.1: status: 0///characteristics_ch1.2: fumnd: 117///characteristics_ch1.3: age: 52///characteristics_ch1.4: sample nr: 472///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5 / Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics / Channel 2 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: [email protected]///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405859/GSM405859.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405917/GSM405917.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 282 / Ovarian tumor sample 283///geo_accession: GSM405611 / GSM405704///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 117///characteristics_ch1.1: status: 0///characteristics_ch1.2: fumnd: 213///characteristics_ch1.3: age: 43///characteristics_ch1.4: sample nr: 267///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5 / Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics / Channel 2 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: [email protected]///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405611/GSM405611.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405704/GSM405704.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 284 / Ovarian tumor sample 285///geo_accession: GSM405645 / GSM405647///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 118///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 43///characteristics_ch1.3: age: 42///characteristics_ch1.4: sample nr: 202///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ; 1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: [email protected]///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405645/GSM405645.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405647/GSM405647.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 289 / Ovarian tumor sample 290///geo_accession: GSM405620 / GSM405910///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 119///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 12///characteristics_ch1.3: age: 57///characteristics_ch1.4: sample nr: 183///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy3 / Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 2 in raw data file ; Characteristics / Channel 1 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: [email protected]///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405620/GSM405620.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405910/GSM405910.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 291 / Ovarian tumor sample 292///geo_accession: GSM405653 / GSM405799///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 120///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 37///characteristics_ch1.3: age: 69///characteristics_ch1.4: sample nr: 374///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5 / Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics / Channel 2 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: [email protected]///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405653/GSM405653.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405799/GSM405799.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 293 / Ovarian tumor sample 294///geo_accession: GSM405770 / GSM405850///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 16///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 15///characteristics_ch1.3: age: 55///characteristics_ch1.4: sample nr: 338///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy3 / Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 2 in raw data file ; Characteristics / Channel 1 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: [email protected]///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405770/GSM405770.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405850/GSM405850.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 296 / Ovarian tumor sample 297///geo_accession: GSM405582 / GSM405692///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 121///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 16///characteristics_ch1.3: age: 48///characteristics_ch1.4: sample nr: 253///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5 / Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics / Channel 2 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: [email protected]///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405582/GSM405582.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405692/GSM405692.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 298 / Ovarian tumor sample 299///geo_accession: GSM405860 / GSM405921///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 17///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 2///characteristics_ch1.3: age: 70///characteristics_ch1.4: sample nr: 422///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy3 / Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 2 in raw data file ; Characteristics / Channel 1 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: [email protected]///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405860/GSM405860.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405921/GSM405921.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 300 / Ovarian tumor sample 301///geo_accession: GSM405563 / GSM405869///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 122///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 50///characteristics_ch1.3: age: 53///characteristics_ch1.4: sample nr / sample nr///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy3 / Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 2 in raw data file ; Characteristics / Channel 1 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: [email protected]///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405563/GSM405563.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405869/GSM405869.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 304 / Ovarian tumor sample 305///geo_accession: GSM405567 / GSM405834///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 123///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 59///characteristics_ch1.3: age: 42///characteristics_ch1.4: sample nr: 116///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy3 / Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 2 in raw data file ; Characteristics / Channel 1 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: [email protected]///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405567/GSM405567.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405834/GSM405834.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 306 / Ovarian tumor sample 307///geo_accession: GSM405949 / GSM405960///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 124///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 19///characteristics_ch1.3: age: 48///characteristics_ch1.4: sample nr: 7///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5 / Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics / Channel 2 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: [email protected]///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405949/GSM405949.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405960/GSM405960.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 309 / Ovarian tumor sample 310///geo_accession: GSM405605 / GSM405820///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 125///characteristics_ch1.1: status: 0///characteristics_ch1.2: fumnd: 71///characteristics_ch1.3: age: 66///characteristics_ch1.4: sample nr: 167///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy3 / Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 2 in raw data file ; Characteristics / Channel 1 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: [email protected]///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405605/GSM405605.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405820/GSM405820.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 311 / Ovarian tumor sample 312///geo_accession: GSM405677 / GSM405687///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 126///characteristics_ch1.1: status: 0///characteristics_ch1.2: fumnd: 29///characteristics_ch1.3: age: 42///characteristics_ch1.4: sample nr: 249///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5 / Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics / Channel 2 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: [email protected]///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405677/GSM405677.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405687/GSM405687.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 313 / Ovarian tumor sample 314///geo_accession: GSM405714 / GSM405715///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 127///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 37///characteristics_ch1.3: age: 44///characteristics_ch1.4: sample nr: 280///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ; 1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: [email protected]///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405714/GSM405714.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405715/GSM405715.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 316 / Ovarian tumor sample 317///geo_accession: GSM405772 / GSM405818///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 128///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 9///characteristics_ch1.3: age: 42///characteristics_ch1.4: sample nr: 33///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy3 / Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 2 in raw data file ; Characteristics / Channel 1 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: [email protected]///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405772/GSM405772.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405818/GSM405818.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 318 / Ovarian tumor sample 319///geo_accession: GSM405670 / GSM405811///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 80///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 47///characteristics_ch1.3: age: 50///characteristics_ch1.4: sample nr: 233///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy3 / Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 2 in raw data file ; Characteristics / Channel 1 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: [email protected]///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405670/GSM405670.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405811/GSM405811.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 322 / Ovarian tumor sample 323///geo_accession: GSM405738 / GSM405883///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 129///characteristics_ch1.1: status: 0///characteristics_ch1.2: fumnd: 130///characteristics_ch1.3: age: 69///characteristics_ch1.4: sample nr: 441///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5 / Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics / Channel 2 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: [email protected]///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405738/GSM405738.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405883/GSM405883.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 324 / Ovarian tumor sample 325///geo_accession: GSM405739 / GSM405858///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 130///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 16///characteristics_ch1.3: age: 60///characteristics_ch1.4: sample nr: 420///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5 / Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics / Channel 2 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: [email protected]///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405739/GSM405739.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405858/GSM405858.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 326 / Ovarian tumor sample 327///geo_accession: GSM405560 / GSM405737///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 131///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 33///characteristics_ch1.3: age: 58///characteristics_ch1.4: sample nr: 109///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy3 / Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 2 in raw data file ; Characteristics / Channel 1 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: [email protected]///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405560/GSM405560.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405737/GSM405737.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 328 / Ovarian tumor sample 329///geo_accession: GSM405693 / GSM405728///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 132///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 16///characteristics_ch1.3: age: 27///characteristics_ch1.4: sample nr: 292///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5 / Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics / Channel 2 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: [email protected]///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405693/GSM405693.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405728/GSM405728.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 32 / Ovarian tumor sample 33///geo_accession: GSM405694 / GSM405969///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 27///characteristics_ch1.1: status: 0///characteristics_ch1.2: fumnd: 29///characteristics_ch1.3: age: 43///characteristics_ch1.4: sample nr: 254///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy3 / Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 2 in raw data file ; Characteristics / Channel 1 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: [email protected]///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405694/GSM405694.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405969/GSM405969.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 331 / Ovarian tumor sample 332///geo_accession: GSM405752 / GSM405892///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 133///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 22///characteristics_ch1.3: age: 61///characteristics_ch1.4: sample nr / sample nr///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5 / Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics / Channel 2 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: [email protected]///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405752/GSM405752.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405892/GSM405892.xls.gz///data_row_count: 37632
1
(Other)
58
An expression set
Ovarian carcinoma has the highest mortality rate among gynaecological malignancies. In this project, we investigated the hypothesis that molecular markers are able to predict outcome of ovarian cancer independently of classical clinical predictors, and that these molecular markers can be validated using independent data sets. We applied a semi-supervised method for prediction of patient survival. Microarrays from a cohort of 80 ovarian carcinomas (TOC cohort) were used for the development of a predictive model, which was then evaluated in an entirely independent cohort of 118 carcinomas (Duke cohort). A 300-gene ovarian prognostic index (OPI) was generated and validated in a leave-one-out approach in the TOC cohort (Kaplan-Meier analysis, p = 0.0087). In a second validation step, the prognostic power of the OPI was confirmed in an independent data set (Duke cohort, p = 0.0063). In multivariate analysis, the OPI was independent of the post-operative residual tumour, the main clinico-pathological prognostic parameter with an adjusted hazard ratio of 6.4 (TOC cohort, CI 1.8-23.5, p = 0.0049) and 1.9 (Duke cohort, CI 1.2-3.0, p = 0.0068). We constructed a combined score of molecular data (OPI) and clinical parameters (residual tumour), which was able to define patient groups with highly significant differences in survival. The integrated analysis of gene expression data as well as residual tumour can be used for optimized assessment of the prognosis of platinum-taxol-treated ovarian cancer. As traditional treatment options are limited, this analysis may be able to optimize clinical management and to identify those patients who would be candidates for new therapeutic strategies.
experimentData(eset):
Experiment data
Experimenter name: Denkert C, Budczies J, Darb-Esfahani S, Gy??rffy B et al. A prognostic gene expression index in ovarian cancer - validation across different independent data sets. J Pathol 2009 Jun;218(2):273-80.
Laboratory: Denkert, Lage 2009
Contact information:
Title: A prognostic gene expression index in ovarian cancer - validation across different independent data sets.
URL:
PMIDs: 19294737
Abstract: A 254 word abstract is available. Use 'abstract' method.
Information is available on: preprocessing
notes:
platform_title:
[HG-U133A] Affymetrix Human Genome U133A Array
platform_shorttitle:
Affymetrix HG-U133A
platform_summary:
hgu133a
platform_manufacturer:
Affymetrix
platform_distribution:
commercial
platform_accession:
GPL96
version:
2015-09-22 19:13:08
featureData(eset):
An object of class 'AnnotatedDataFrame'
featureNames: 1007_s_at 1053_at ... AFFX-HUMISGF3A/M97935_MB_at
(20967 total)
varLabels: probeset gene EntrezGene.ID best_probe
varMetadata: labelDescription
assayData: 20967 features, 80 samples
Platform type:
Overall survival time-to-event summary (in years):
Call: survfit(formula = Surv(time, cens) ~ -1)
n events median 0.95LCL 0.95UCL
80.00 21.00 4.52 4.19 NA
---------------------------
Available sample meta-data:
---------------------------
alt_sample_name:
Min. 1st Qu. Median Mean 3rd Qu. Max.
1.00 20.75 40.50 40.50 60.25 80.00
sample_type:
tumor
80
histological_type:
clearcell endo mix other
2 6 1 2
ser undifferentiated
68 1
primarysite:
ov
80
summarygrade:
high low
54 26
summarystage:
early late
9 71
tumorstage:
1 2 3 4
8 1 69 2
substage:
a b c NA's
4 6 32 38
grade:
1 2 3
3 23 54
recurrence_status:
norecurrence recurrence NA's
50 26 4
days_to_death:
Min. 1st Qu. Median Mean 3rd Qu. Max.
210 660 1050 1011 1328 2190
vital_status:
deceased living
21 59
batch:
2004-09-29 2004-09-30 2004-10-01 2005-01-21 2005-01-25 2005-01-26 2005-01-28
1 2 6 4 7 8 10
2005-03-02 2006-07-26 2006-07-27 2006-07-28 2006-08-11 2006-08-18 2006-08-19
6 4 6 4 10 3 4
2006-08-21
5
uncurated_author_metadata:
title: ovarian cancer: O10///geo_accession: GSM368670///status: Public on Feb 09 2009///submission_date: Feb 09 2009///last_update_date: Aug 24 2010///type: RNA///channel_count: 1///source_name_ch1: ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: frozen tumor///characteristics_ch1.1: figo stage: 3c///characteristics_ch1.2: grade: III///characteristics_ch1.3: histological type: serous ovca///characteristics_ch1.4: residual tumor: 0///characteristics_ch1.5: overall survival time: 35///characteristics_ch1.6: overall survival event: 0///molecule_ch1: total RNA///extract_protocol_ch1: Total cellular RNA was isolated from tumor tissue, using the Qiagen Rneasy Mini Kit.///label_ch1: biotin///label_protocol_ch1: cDNA was synthesised from 5 g total RNA by reverse transcription, synthesis of biotin-labeled cRNA was performed using the BioArray High Yield RNA Transcription kit.///taxid_ch1: 9606///hyb_protocol: The fragmented cRNA was hybridised to HGU133 arrays at 45 C in a hybridization oven for 16 hr.///scan_protocol: Chip scanning was done with an Affymetrix Gene Array Scanner G2500A.///description: frozen tissue sample///data_processing: Signals and detection calls were calculated with the R package affy according to the standard MAS 5.0 protocol of the chip manufacturer.///platform_id: GPL96///contact_name: Jan,,Budczies///contact_email: [email protected]///contact_department: Institute of Pathology///contact_institute: Charite - Universitaetsmedizin Berlin///contact_address: Chariteplatz 2///contact_city: Berlin///contact_zip.postal_code: 10117///contact_country: Germany///contact_web_link: http://www.charite.de/ch/patho///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM368nnn/GSM368670/GSM368670.cel.gz///data_row_count: 22283
1
title: ovarian cancer: O11///geo_accession: GSM368671///status: Public on Feb 09 2009///submission_date: Feb 09 2009///last_update_date: Aug 24 2010///type: RNA///channel_count: 1///source_name_ch1: ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: frozen tumor///characteristics_ch1.1: figo stage: 3c///characteristics_ch1.2: grade: III///characteristics_ch1.3: histological type: serous ovca///characteristics_ch1.4: residual tumor: 1///characteristics_ch1.5: overall survival time: 54///characteristics_ch1.6: overall survival event: 0///molecule_ch1: total RNA///extract_protocol_ch1: Total cellular RNA was isolated from tumor tissue, using the Qiagen Rneasy Mini Kit.///label_ch1: biotin///label_protocol_ch1: cDNA was synthesised from 5 g total RNA by reverse transcription, synthesis of biotin-labeled cRNA was performed using the BioArray High Yield RNA Transcription kit.///taxid_ch1: 9606///hyb_protocol: The fragmented cRNA was hybridised to HGU133 arrays at 45 C in a hybridization oven for 16 hr.///scan_protocol: Chip scanning was done with an Affymetrix Gene Array Scanner G2500A.///description: frozen tissue sample///data_processing: Signals and detection calls were calculated with the R package affy according to the standard MAS 5.0 protocol of the chip manufacturer.///platform_id: GPL96///contact_name: Jan,,Budczies///contact_email: [email protected]///contact_department: Institute of Pathology///contact_institute: Charite - Universitaetsmedizin Berlin///contact_address: Chariteplatz 2///contact_city: Berlin///contact_zip.postal_code: 10117///contact_country: Germany///contact_web_link: http://www.charite.de/ch/patho///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM368nnn/GSM368671/GSM368671.cel.gz///data_row_count: 22283
1
title: ovarian cancer: O12///geo_accession: GSM368672///status: Public on Feb 09 2009///submission_date: Feb 09 2009///last_update_date: Aug 24 2010///type: RNA///channel_count: 1///source_name_ch1: ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: frozen tumor///characteristics_ch1.1: figo stage: 3c///characteristics_ch1.2: grade: III///characteristics_ch1.3: histological type: endometr ovca///characteristics_ch1.4: residual tumor: 0///characteristics_ch1.5: overall survival time: 68///characteristics_ch1.6: overall survival event: 0///molecule_ch1: total RNA///extract_protocol_ch1: Total cellular RNA was isolated from tumor tissue, using the Qiagen Rneasy Mini Kit.///label_ch1: biotin///label_protocol_ch1: cDNA was synthesised from 5 g total RNA by reverse transcription, synthesis of biotin-labeled cRNA was performed using the BioArray High Yield RNA Transcription kit.///taxid_ch1: 9606///hyb_protocol: The fragmented cRNA was hybridised to HGU133 arrays at 45 C in a hybridization oven for 16 hr.///scan_protocol: Chip scanning was done with an Affymetrix Gene Array Scanner G2500A.///description: frozen tissue sample///data_processing: Signals and detection calls were calculated with the R package affy according to the standard MAS 5.0 protocol of the chip manufacturer.///platform_id: GPL96///contact_name: Jan,,Budczies///contact_email: [email protected]///contact_department: Institute of Pathology///contact_institute: Charite - Universitaetsmedizin Berlin///contact_address: Chariteplatz 2///contact_city: Berlin///contact_zip.postal_code: 10117///contact_country: Germany///contact_web_link: http://www.charite.de/ch/patho///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM368nnn/GSM368672/GSM368672.cel.gz///data_row_count: 22283
1
title: ovarian cancer: O13///geo_accession: GSM368673///status: Public on Feb 09 2009///submission_date: Feb 09 2009///last_update_date: Aug 24 2010///type: RNA///channel_count: 1///source_name_ch1: ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: frozen tumor///characteristics_ch1.1: figo stage: 3c///characteristics_ch1.2: grade: III///characteristics_ch1.3: histological type: serous ovca///characteristics_ch1.4: residual tumor: 0///characteristics_ch1.5: overall survival time: 40///characteristics_ch1.6: overall survival event: 0///molecule_ch1: total RNA///extract_protocol_ch1: Total cellular RNA was isolated from tumor tissue, using the Qiagen Rneasy Mini Kit.///label_ch1: biotin///label_protocol_ch1: cDNA was synthesised from 5 g total RNA by reverse transcription, synthesis of biotin-labeled cRNA was performed using the BioArray High Yield RNA Transcription kit.///taxid_ch1: 9606///hyb_protocol: The fragmented cRNA was hybridised to HGU133 arrays at 45 C in a hybridization oven for 16 hr.///scan_protocol: Chip scanning was done with an Affymetrix Gene Array Scanner G2500A.///description: frozen tissue sample///data_processing: Signals and detection calls were calculated with the R package affy according to the standard MAS 5.0 protocol of the chip manufacturer.///platform_id: GPL96///contact_name: Jan,,Budczies///contact_email: [email protected]///contact_department: Institute of Pathology///contact_institute: Charite - Universitaetsmedizin Berlin///contact_address: Chariteplatz 2///contact_city: Berlin///contact_zip.postal_code: 10117///contact_country: Germany///contact_web_link: http://www.charite.de/ch/patho///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM368nnn/GSM368673/GSM368673.cel.gz///data_row_count: 22283
1
title: ovarian cancer: O14///geo_accession: GSM368674///status: Public on Feb 09 2009///submission_date: Feb 09 2009///last_update_date: Aug 24 2010///type: RNA///channel_count: 1///source_name_ch1: ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: frozen tumor///characteristics_ch1.1: figo stage: 3c///characteristics_ch1.2: grade: II///characteristics_ch1.3: histological type: serous ovca///characteristics_ch1.4: residual tumor: 0///characteristics_ch1.5: overall survival time: 18///characteristics_ch1.6: overall survival event: 1///molecule_ch1: total RNA///extract_protocol_ch1: Total cellular RNA was isolated from tumor tissue, using the Qiagen Rneasy Mini Kit.///label_ch1: biotin///label_protocol_ch1: cDNA was synthesised from 5 g total RNA by reverse transcription, synthesis of biotin-labeled cRNA was performed using the BioArray High Yield RNA Transcription kit.///taxid_ch1: 9606///hyb_protocol: The fragmented cRNA was hybridised to HGU133 arrays at 45 C in a hybridization oven for 16 hr.///scan_protocol: Chip scanning was done with an Affymetrix Gene Array Scanner G2500A.///description: frozen tissue sample///data_processing: Signals and detection calls were calculated with the R package affy according to the standard MAS 5.0 protocol of the chip manufacturer.///platform_id: GPL96///contact_name: Jan,,Budczies///contact_email: [email protected]///contact_department: Institute of Pathology///contact_institute: Charite - Universitaetsmedizin Berlin///contact_address: Chariteplatz 2///contact_city: Berlin///contact_zip.postal_code: 10117///contact_country: Germany///contact_web_link: http://www.charite.de/ch/patho///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM368nnn/GSM368674/GSM368674.cel.gz///data_row_count: 22283
1
title: ovarian cancer: O15///geo_accession: GSM368675///status: Public on Feb 09 2009///submission_date: Feb 09 2009///last_update_date: Aug 24 2010///type: RNA///channel_count: 1///source_name_ch1: ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: frozen tumor///characteristics_ch1.1: figo stage: 3c///characteristics_ch1.2: grade: III///characteristics_ch1.3: histological type: serous ovca///characteristics_ch1.4: residual tumor: NA///characteristics_ch1.5: overall survival time: 30///characteristics_ch1.6: overall survival event: 1///molecule_ch1: total RNA///extract_protocol_ch1: Total cellular RNA was isolated from tumor tissue, using the Qiagen Rneasy Mini Kit.///label_ch1: biotin///label_protocol_ch1: cDNA was synthesised from 5 g total RNA by reverse transcription, synthesis of biotin-labeled cRNA was performed using the BioArray High Yield RNA Transcription kit.///taxid_ch1: 9606///hyb_protocol: The fragmented cRNA was hybridised to HGU133 arrays at 45 C in a hybridization oven for 16 hr.///scan_protocol: Chip scanning was done with an Affymetrix Gene Array Scanner G2500A.///description: frozen tissue sample///data_processing: Signals and detection calls were calculated with the R package affy according to the standard MAS 5.0 protocol of the chip manufacturer.///platform_id: GPL96///contact_name: Jan,,Budczies///contact_email: [email protected]///contact_department: Institute of Pathology///contact_institute: Charite - Universitaetsmedizin Berlin///contact_address: Chariteplatz 2///contact_city: Berlin///contact_zip.postal_code: 10117///contact_country: Germany///contact_web_link: http://www.charite.de/ch/patho///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM368nnn/GSM368675/GSM368675.cel.gz///data_row_count: 22283
1
title: ovarian cancer: O16///geo_accession: GSM368676///status: Public on Feb 09 2009///submission_date: Feb 09 2009///last_update_date: Aug 24 2010///type: RNA///channel_count: 1///source_name_ch1: ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: frozen tumor///characteristics_ch1.1: figo stage: 1a///characteristics_ch1.2: grade: II///characteristics_ch1.3: histological type: clear cell ovca///characteristics_ch1.4: residual tumor: 0///characteristics_ch1.5: overall survival time: 45///characteristics_ch1.6: overall survival event: 0///molecule_ch1: total RNA///extract_protocol_ch1: Total cellular RNA was isolated from tumor tissue, using the Qiagen Rneasy Mini Kit.///label_ch1: biotin///label_protocol_ch1: cDNA was synthesised from 5 g total RNA by reverse transcription, synthesis of biotin-labeled cRNA was performed using the BioArray High Yield RNA Transcription kit.///taxid_ch1: 9606///hyb_protocol: The fragmented cRNA was hybridised to HGU133 arrays at 45 C in a hybridization oven for 16 hr.///scan_protocol: Chip scanning was done with an Affymetrix Gene Array Scanner G2500A.///description: frozen tissue sample///data_processing: Signals and detection calls were calculated with the R package affy according to the standard MAS 5.0 protocol of the chip manufacturer.///platform_id: GPL96///contact_name: Jan,,Budczies///contact_email: [email protected]///contact_department: Institute of Pathology///contact_institute: Charite - Universitaetsmedizin Berlin///contact_address: Chariteplatz 2///contact_city: Berlin///contact_zip.postal_code: 10117///contact_country: Germany///contact_web_link: http://www.charite.de/ch/patho///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM368nnn/GSM368676/GSM368676.cel.gz///data_row_count: 22283
1
title: ovarian cancer: O17///geo_accession: GSM368677///status: Public on Feb 09 2009///submission_date: Feb 09 2009///last_update_date: Aug 24 2010///type: RNA///channel_count: 1///source_name_ch1: ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: frozen tumor///characteristics_ch1.1: figo stage: 2b///characteristics_ch1.2: grade: III///characteristics_ch1.3: histological type: serous ovca///characteristics_ch1.4: residual tumor: 0///characteristics_ch1.5: overall survival time: 40///characteristics_ch1.6: overall survival event: 0///molecule_ch1: total RNA///extract_protocol_ch1: Total cellular RNA was isolated from tumor tissue, using the Qiagen Rneasy Mini Kit.///label_ch1: biotin///label_protocol_ch1: cDNA was synthesised from 5 g total RNA by reverse transcription, synthesis of biotin-labeled cRNA was performed using the BioArray High Yield RNA Transcription kit.///taxid_ch1: 9606///hyb_protocol: The fragmented cRNA was hybridised to HGU133 arrays at 45 C in a hybridization oven for 16 hr.///scan_protocol: Chip scanning was done with an Affymetrix Gene Array Scanner G2500A.///description: frozen tissue sample///data_processing: Signals and detection calls were calculated with the R package affy according to the standard MAS 5.0 protocol of the chip manufacturer.///platform_id: GPL96///contact_name: Jan,,Budczies///contact_email: [email protected]///contact_department: Institute of Pathology///contact_institute: Charite - Universitaetsmedizin Berlin///contact_address: Chariteplatz 2///contact_city: Berlin///contact_zip.postal_code: 10117///contact_country: Germany///contact_web_link: http://www.charite.de/ch/patho///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM368nnn/GSM368677/GSM368677.cel.gz///data_row_count: 22283
1
title: ovarian cancer: O18///geo_accession: GSM368678///status: Public on Feb 09 2009///submission_date: Feb 09 2009///last_update_date: Aug 24 2010///type: RNA///channel_count: 1///source_name_ch1: ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: frozen tumor///characteristics_ch1.1: figo stage: 3c///characteristics_ch1.2: grade: III///characteristics_ch1.3: histological type: serous ovca///characteristics_ch1.4: residual tumor: 0///characteristics_ch1.5: overall survival time: 67///characteristics_ch1.6: overall survival event: 0///molecule_ch1: total RNA///extract_protocol_ch1: Total cellular RNA was isolated from tumor tissue, using the Qiagen Rneasy Mini Kit.///label_ch1: biotin///label_protocol_ch1: cDNA was synthesised from 5 g total RNA by reverse transcription, synthesis of biotin-labeled cRNA was performed using the BioArray High Yield RNA Transcription kit.///taxid_ch1: 9606///hyb_protocol: The fragmented cRNA was hybridised to HGU133 arrays at 45 C in a hybridization oven for 16 hr.///scan_protocol: Chip scanning was done with an Affymetrix Gene Array Scanner G2500A.///description: frozen tissue sample///data_processing: Signals and detection calls were calculated with the R package affy according to the standard MAS 5.0 protocol of the chip manufacturer.///platform_id: GPL96///contact_name: Jan,,Budczies///contact_email: [email protected]///contact_department: Institute of Pathology///contact_institute: Charite - Universitaetsmedizin Berlin///contact_address: Chariteplatz 2///contact_city: Berlin///contact_zip.postal_code: 10117///contact_country: Germany///contact_web_link: http://www.charite.de/ch/patho///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM368nnn/GSM368678/GSM368678.cel.gz///data_row_count: 22283
1
title: ovarian cancer: O19///geo_accession: GSM368679///status: Public on Feb 09 2009///submission_date: Feb 09 2009///last_update_date: Aug 24 2010///type: RNA///channel_count: 1///source_name_ch1: ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: frozen tumor///characteristics_ch1.1: figo stage: 3c///characteristics_ch1.2: grade: III///characteristics_ch1.3: histological type: serous ovca///characteristics_ch1.4: residual tumor: 1///characteristics_ch1.5: overall survival time: 31///characteristics_ch1.6: overall survival event: 1///molecule_ch1: total RNA///extract_protocol_ch1: Total cellular RNA was isolated from tumor tissue, using the Qiagen Rneasy Mini Kit.///label_ch1: biotin///label_protocol_ch1: cDNA was synthesised from 5 g total RNA by reverse transcription, synthesis of biotin-labeled cRNA was performed using the BioArray High Yield RNA Transcription kit.///taxid_ch1: 9606///hyb_protocol: The fragmented cRNA was hybridised to HGU133 arrays at 45 C in a hybridization oven for 16 hr.///scan_protocol: Chip scanning was done with an Affymetrix Gene Array Scanner G2500A.///description: frozen tissue sample///data_processing: Signals and detection calls were calculated with the R package affy according to the standard MAS 5.0 protocol of the chip manufacturer.///platform_id: GPL96///contact_name: Jan,,Budczies///contact_email: [email protected]///contact_department: Institute of Pathology///contact_institute: Charite - Universitaetsmedizin Berlin///contact_address: Chariteplatz 2///contact_city: Berlin///contact_zip.postal_code: 10117///contact_country: Germany///contact_web_link: http://www.charite.de/ch/patho///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM368nnn/GSM368679/GSM368679.cel.gz///data_row_count: 22283
1
title: ovarian cancer: O1///geo_accession: GSM368661///status: Public on Feb 09 2009///submission_date: Feb 09 2009///last_update_date: Aug 24 2010///type: RNA///channel_count: 1///source_name_ch1: ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: frozen tumor///characteristics_ch1.1: figo stage: 4///characteristics_ch1.2: grade: III///characteristics_ch1.3: histological type: serous ovca///characteristics_ch1.4: residual tumor: 0///characteristics_ch1.5: overall survival time: 39///characteristics_ch1.6: overall survival event: 0///molecule_ch1: total RNA///extract_protocol_ch1: Total cellular RNA was isolated from tumor tissue, using the Qiagen Rneasy Mini Kit.///label_ch1: biotin///label_protocol_ch1: cDNA was synthesised from 5 g total RNA by reverse transcription, synthesis of biotin-labeled cRNA was performed using the BioArray High Yield RNA Transcription kit.///taxid_ch1: 9606///hyb_protocol: The fragmented cRNA was hybridised to HGU133 arrays at 45 C in a hybridization oven for 16 hr.///scan_protocol: Chip scanning was done with an Affymetrix Gene Array Scanner G2500A.///description: frozen tissue sample///data_processing: Signals and detection calls were calculated with the R package affy according to the standard MAS 5.0 protocol of the chip manufacturer.///platform_id: GPL96///contact_name: Jan,,Budczies///contact_email: [email protected]///contact_department: Institute of Pathology///contact_institute: Charite - Universitaetsmedizin Berlin///contact_address: Chariteplatz 2///contact_city: Berlin///contact_zip.postal_code: 10117///contact_country: Germany///contact_web_link: http://www.charite.de/ch/patho///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM368nnn/GSM368661/GSM368661.cel.gz///data_row_count: 22283
1
title: ovarian cancer: O20///geo_accession: GSM368680///status: Public on Feb 09 2009///submission_date: Feb 09 2009///last_update_date: Aug 24 2010///type: RNA///channel_count: 1///source_name_ch1: ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: frozen tumor///characteristics_ch1.1: figo stage: 3c///characteristics_ch1.2: grade: II///characteristics_ch1.3: histological type: serous ovca///characteristics_ch1.4: residual tumor: 0///characteristics_ch1.5: overall survival time: 38///characteristics_ch1.6: overall survival event: 0///molecule_ch1: total RNA///extract_protocol_ch1: Total cellular RNA was isolated from tumor tissue, using the Qiagen Rneasy Mini Kit.///label_ch1: biotin///label_protocol_ch1: cDNA was synthesised from 5 g total RNA by reverse transcription, synthesis of biotin-labeled cRNA was performed using the BioArray High Yield RNA Transcription kit.///taxid_ch1: 9606///hyb_protocol: The fragmented cRNA was hybridised to HGU133 arrays at 45 C in a hybridization oven for 16 hr.///scan_protocol: Chip scanning was done with an Affymetrix Gene Array Scanner G2500A.///description: frozen tissue sample///data_processing: Signals and detection calls were calculated with the R package affy according to the standard MAS 5.0 protocol of the chip manufacturer.///platform_id: GPL96///contact_name: Jan,,Budczies///contact_email: [email protected]///contact_department: Institute of Pathology///contact_institute: Charite - Universitaetsmedizin Berlin///contact_address: Chariteplatz 2///contact_city: Berlin///contact_zip.postal_code: 10117///contact_country: Germany///contact_web_link: http://www.charite.de/ch/patho///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM368nnn/GSM368680/GSM368680.cel.gz///data_row_count: 22283
1
title: ovarian cancer: O21///geo_accession: GSM368681///status: Public on Feb 09 2009///submission_date: Feb 09 2009///last_update_date: Aug 24 2010///type: RNA///channel_count: 1///source_name_ch1: ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: frozen tumor///characteristics_ch1.1: figo stage: 3c///characteristics_ch1.2: grade: III///characteristics_ch1.3: histological type: serous ovca///characteristics_ch1.4: residual tumor: 0///characteristics_ch1.5: overall survival time: 43///characteristics_ch1.6: overall survival event: 0///molecule_ch1: total RNA///extract_protocol_ch1: Total cellular RNA was isolated from tumor tissue, using the Qiagen Rneasy Mini Kit.///label_ch1: biotin///label_protocol_ch1: cDNA was synthesised from 5 g total RNA by reverse transcription, synthesis of biotin-labeled cRNA was performed using the BioArray High Yield RNA Transcription kit.///taxid_ch1: 9606///hyb_protocol: The fragmented cRNA was hybridised to HGU133 arrays at 45 C in a hybridization oven for 16 hr.///scan_protocol: Chip scanning was done with an Affymetrix Gene Array Scanner G2500A.///description: frozen tissue sample///data_processing: Signals and detection calls were calculated with the R package affy according to the standard MAS 5.0 protocol of the chip manufacturer.///platform_id: GPL96///contact_name: Jan,,Budczies///contact_email: [email protected]///contact_department: Institute of Pathology///contact_institute: Charite - Universitaetsmedizin Berlin///contact_address: Chariteplatz 2///contact_city: Berlin///contact_zip.postal_code: 10117///contact_country: Germany///contact_web_link: http://www.charite.de/ch/patho///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM368nnn/GSM368681/GSM368681.cel.gz///data_row_count: 22283
1
title: ovarian cancer: O22///geo_accession: GSM368682///status: Public on Feb 09 2009///submission_date: Feb 09 2009///last_update_date: Aug 24 2010///type: RNA///channel_count: 1///source_name_ch1: ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: frozen tumor///characteristics_ch1.1: figo stage: 1c///characteristics_ch1.2: grade: III///characteristics_ch1.3: histological type: serous ovca///characteristics_ch1.4: residual tumor: 0///characteristics_ch1.5: overall survival time: 29///characteristics_ch1.6: overall survival event: 0///molecule_ch1: total RNA///extract_protocol_ch1: Total cellular RNA was isolated from tumor tissue, using the Qiagen Rneasy Mini Kit.///label_ch1: biotin///label_protocol_ch1: cDNA was synthesised from 5 g total RNA by reverse transcription, synthesis of biotin-labeled cRNA was performed using the BioArray High Yield RNA Transcription kit.///taxid_ch1: 9606///hyb_protocol: The fragmented cRNA was hybridised to HGU133 arrays at 45 C in a hybridization oven for 16 hr.///scan_protocol: Chip scanning was done with an Affymetrix Gene Array Scanner G2500A.///description: frozen tissue sample///data_processing: Signals and detection calls were calculated with the R package affy according to the standard MAS 5.0 protocol of the chip manufacturer.///platform_id: GPL96///contact_name: Jan,,Budczies///contact_email: [email protected]///contact_department: Institute of Pathology///contact_institute: Charite - Universitaetsmedizin Berlin///contact_address: Chariteplatz 2///contact_city: Berlin///contact_zip.postal_code: 10117///contact_country: Germany///contact_web_link: http://www.charite.de/ch/patho///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM368nnn/GSM368682/GSM368682.cel.gz///data_row_count: 22283
1
title: ovarian cancer: O23///geo_accession: GSM368683///status: Public on Feb 09 2009///submission_date: Feb 09 2009///last_update_date: Aug 24 2010///type: RNA///channel_count: 1///source_name_ch1: ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: frozen tumor///characteristics_ch1.1: figo stage: 3c///characteristics_ch1.2: grade: III///characteristics_ch1.3: histological type: serous ovca///characteristics_ch1.4: residual tumor: 1///characteristics_ch1.5: overall survival time: 12///characteristics_ch1.6: overall survival event: 1///molecule_ch1: total RNA///extract_protocol_ch1: Total cellular RNA was isolated from tumor tissue, using the Qiagen Rneasy Mini Kit.///label_ch1: biotin///label_protocol_ch1: cDNA was synthesised from 5 g total RNA by reverse transcription, synthesis of biotin-labeled cRNA was performed using the BioArray High Yield RNA Transcription kit.///taxid_ch1: 9606///hyb_protocol: The fragmented cRNA was hybridised to HGU133 arrays at 45 C in a hybridization oven for 16 hr.///scan_protocol: Chip scanning was done with an Affymetrix Gene Array Scanner G2500A.///description: frozen tissue sample///data_processing: Signals and detection calls were calculated with the R package affy according to the standard MAS 5.0 protocol of the chip manufacturer.///platform_id: GPL96///contact_name: Jan,,Budczies///contact_email: [email protected]///contact_department: Institute of Pathology///contact_institute: Charite - Universitaetsmedizin Berlin///contact_address: Chariteplatz 2///contact_city: Berlin///contact_zip.postal_code: 10117///contact_country: Germany///contact_web_link: http://www.charite.de/ch/patho///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM368nnn/GSM368683/GSM368683.cel.gz///data_row_count: 22283
1
title: ovarian cancer: O24///geo_accession: GSM368684///status: Public on Feb 09 2009///submission_date: Feb 09 2009///last_update_date: Aug 24 2010///type: RNA///channel_count: 1///source_name_ch1: ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: frozen tumor///characteristics_ch1.1: figo stage: 1c///characteristics_ch1.2: grade: III///characteristics_ch1.3: histological type: clear cell ovca///characteristics_ch1.4: residual tumor: 0///characteristics_ch1.5: overall survival time: 51///characteristics_ch1.6: overall survival event: 1///molecule_ch1: total RNA///extract_protocol_ch1: Total cellular RNA was isolated from tumor tissue, using the Qiagen Rneasy Mini Kit.///label_ch1: biotin///label_protocol_ch1: cDNA was synthesised from 5 g total RNA by reverse transcription, synthesis of biotin-labeled cRNA was performed using the BioArray High Yield RNA Transcription kit.///taxid_ch1: 9606///hyb_protocol: The fragmented cRNA was hybridised to HGU133 arrays at 45 C in a hybridization oven for 16 hr.///scan_protocol: Chip scanning was done with an Affymetrix Gene Array Scanner G2500A.///description: frozen tissue sample///data_processing: Signals and detection calls were calculated with the R package affy according to the standard MAS 5.0 protocol of the chip manufacturer.///platform_id: GPL96///contact_name: Jan,,Budczies///contact_email: [email protected]///contact_department: Institute of Pathology///contact_institute: Charite - Universitaetsmedizin Berlin///contact_address: Chariteplatz 2///contact_city: Berlin///contact_zip.postal_code: 10117///contact_country: Germany///contact_web_link: http://www.charite.de/ch/patho///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM368nnn/GSM368684/GSM368684.cel.gz///data_row_count: 22283
1
title: ovarian cancer: O25///geo_accession: GSM368685///status: Public on Feb 09 2009///submission_date: Feb 09 2009///last_update_date: Aug 24 2010///type: RNA///channel_count: 1///source_name_ch1: ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: frozen tumor///characteristics_ch1.1: figo stage: 3c///characteristics_ch1.2: grade: III///characteristics_ch1.3: histological type: serous ovca///characteristics_ch1.4: residual tumor: 1///characteristics_ch1.5: overall survival time: 40///characteristics_ch1.6: overall survival event: 0///molecule_ch1: total RNA///extract_protocol_ch1: Total cellular RNA was isolated from tumor tissue, using the Qiagen Rneasy Mini Kit.///label_ch1: biotin///label_protocol_ch1: cDNA was synthesised from 5 g total RNA by reverse transcription, synthesis of biotin-labeled cRNA was performed using the BioArray High Yield RNA Transcription kit.///taxid_ch1: 9606///hyb_protocol: The fragmented cRNA was hybridised to HGU133 arrays at 45 C in a hybridization oven for 16 hr.///scan_protocol: Chip scanning was done with an Affymetrix Gene Array Scanner G2500A.///description: frozen tissue sample///data_processing: Signals and detection calls were calculated with the R package affy according to the standard MAS 5.0 protocol of the chip manufacturer.///platform_id: GPL96///contact_name: Jan,,Budczies///contact_email: [email protected]///contact_department: Institute of Pathology///contact_institute: Charite - Universitaetsmedizin Berlin///contact_address: Chariteplatz 2///contact_city: Berlin///contact_zip.postal_code: 10117///contact_country: Germany///contact_web_link: http://www.charite.de/ch/patho///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM368nnn/GSM368685/GSM368685.cel.gz///data_row_count: 22283
1
title: ovarian cancer: O26///geo_accession: GSM368686///status: Public on Feb 09 2009///submission_date: Feb 09 2009///last_update_date: Aug 24 2010///type: RNA///channel_count: 1///source_name_ch1: ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: frozen tumor///characteristics_ch1.1: figo stage: 1a///characteristics_ch1.2: grade: III///characteristics_ch1.3: histological type: endometr, clear cell ovca///characteristics_ch1.4: residual tumor: 0///characteristics_ch1.5: overall survival time: 37///characteristics_ch1.6: overall survival event: 0///molecule_ch1: total RNA///extract_protocol_ch1: Total cellular RNA was isolated from tumor tissue, using the Qiagen Rneasy Mini Kit.///label_ch1: biotin///label_protocol_ch1: cDNA was synthesised from 5 g total RNA by reverse transcription, synthesis of biotin-labeled cRNA was performed using the BioArray High Yield RNA Transcription kit.///taxid_ch1: 9606///hyb_protocol: The fragmented cRNA was hybridised to HGU133 arrays at 45 C in a hybridization oven for 16 hr.///scan_protocol: Chip scanning was done with an Affymetrix Gene Array Scanner G2500A.///description: frozen tissue sample///data_processing: Signals and detection calls were calculated with the R package affy according to the standard MAS 5.0 protocol of the chip manufacturer.///platform_id: GPL96///contact_name: Jan,,Budczies///contact_email: [email protected]///contact_department: Institute of Pathology///contact_institute: Charite - Universitaetsmedizin Berlin///contact_address: Chariteplatz 2///contact_city: Berlin///contact_zip.postal_code: 10117///contact_country: Germany///contact_web_link: http://www.charite.de/ch/patho///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM368nnn/GSM368686/GSM368686.cel.gz///data_row_count: 22283
1
title: ovarian cancer: O27///geo_accession: GSM368687///status: Public on Feb 09 2009///submission_date: Feb 09 2009///last_update_date: Aug 24 2010///type: RNA///channel_count: 1///source_name_ch1: ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: frozen tumor///characteristics_ch1.1: figo stage: 1b///characteristics_ch1.2: grade: III///characteristics_ch1.3: histological type: endometr ovca///characteristics_ch1.4: residual tumor: 0///characteristics_ch1.5: overall survival time: 49///characteristics_ch1.6: overall survival event: 0///molecule_ch1: total RNA///extract_protocol_ch1: Total cellular RNA was isolated from tumor tissue, using the Qiagen Rneasy Mini Kit.///label_ch1: biotin///label_protocol_ch1: cDNA was synthesised from 5 g total RNA by reverse transcription, synthesis of biotin-labeled cRNA was performed using the BioArray High Yield RNA Transcription kit.///taxid_ch1: 9606///hyb_protocol: The fragmented cRNA was hybridised to HGU133 arrays at 45 C in a hybridization oven for 16 hr.///scan_protocol: Chip scanning was done with an Affymetrix Gene Array Scanner G2500A.///description: frozen tissue sample///data_processing: Signals and detection calls were calculated with the R package affy according to the standard MAS 5.0 protocol of the chip manufacturer.///platform_id: GPL96///contact_name: Jan,,Budczies///contact_email: [email protected]///contact_department: Institute of Pathology///contact_institute: Charite - Universitaetsmedizin Berlin///contact_address: Chariteplatz 2///contact_city: Berlin///contact_zip.postal_code: 10117///contact_country: Germany///contact_web_link: http://www.charite.de/ch/patho///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM368nnn/GSM368687/GSM368687.cel.gz///data_row_count: 22283
1
title: ovarian cancer: O28///geo_accession: GSM368688///status: Public on Feb 09 2009///submission_date: Feb 09 2009///last_update_date: Aug 24 2010///type: RNA///channel_count: 1///source_name_ch1: ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: frozen tumor///characteristics_ch1.1: figo stage: 1c///characteristics_ch1.2: grade: III///characteristics_ch1.3: histological type: endometr ovca///characteristics_ch1.4: residual tumor: 0///characteristics_ch1.5: overall survival time: 36///characteristics_ch1.6: overall survival event: 0///molecule_ch1: total RNA///extract_protocol_ch1: Total cellular RNA was isolated from tumor tissue, using the Qiagen Rneasy Mini Kit.///label_ch1: biotin///label_protocol_ch1: cDNA was synthesised from 5 g total RNA by reverse transcription, synthesis of biotin-labeled cRNA was performed using the BioArray High Yield RNA Transcription kit.///taxid_ch1: 9606///hyb_protocol: The fragmented cRNA was hybridised to HGU133 arrays at 45 C in a hybridization oven for 16 hr.///scan_protocol: Chip scanning was done with an Affymetrix Gene Array Scanner G2500A.///description: frozen tissue sample///data_processing: Signals and detection calls were calculated with the R package affy according to the standard MAS 5.0 protocol of the chip manufacturer.///platform_id: GPL96///contact_name: Jan,,Budczies///contact_email: [email protected]///contact_department: Institute of Pathology///contact_institute: Charite - Universitaetsmedizin Berlin///contact_address: Chariteplatz 2///contact_city: Berlin///contact_zip.postal_code: 10117///contact_country: Germany///contact_web_link: http://www.charite.de/ch/patho///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM368nnn/GSM368688/GSM368688.cel.gz///data_row_count: 22283
1
title: ovarian cancer: O29///geo_accession: GSM368689///status: Public on Feb 09 2009///submission_date: Feb 09 2009///last_update_date: Aug 24 2010///type: RNA///channel_count: 1///source_name_ch1: ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: frozen tumor///characteristics_ch1.1: figo stage: 3c///characteristics_ch1.2: grade: III///characteristics_ch1.3: histological type: serous ovca///characteristics_ch1.4: residual tumor: NA///characteristics_ch1.5: overall survival time: 49///characteristics_ch1.6: overall survival event: 0///molecule_ch1: total RNA///extract_protocol_ch1: Total cellular RNA was isolated from tumor tissue, using the Qiagen Rneasy Mini Kit.///label_ch1: biotin///label_protocol_ch1: cDNA was synthesised from 5 g total RNA by reverse transcription, synthesis of biotin-labeled cRNA was performed using the BioArray High Yield RNA Transcription kit.///taxid_ch1: 9606///hyb_protocol: The fragmented cRNA was hybridised to HGU133 arrays at 45 C in a hybridization oven for 16 hr.///scan_protocol: Chip scanning was done with an Affymetrix Gene Array Scanner G2500A.///description: frozen tissue sample///data_processing: Signals and detection calls were calculated with the R package affy according to the standard MAS 5.0 protocol of the chip manufacturer.///platform_id: GPL96///contact_name: Jan,,Budczies///contact_email: [email protected]///contact_department: Institute of Pathology///contact_institute: Charite - Universitaetsmedizin Berlin///contact_address: Chariteplatz 2///contact_city: Berlin///contact_zip.postal_code: 10117///contact_country: Germany///contact_web_link: http://www.charite.de/ch/patho///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM368nnn/GSM368689/GSM368689.cel.gz///data_row_count: 22283
1
title: ovarian cancer: O2///geo_accession: GSM368662///status: Public on Feb 09 2009///submission_date: Feb 09 2009///last_update_date: Aug 24 2010///type: RNA///channel_count: 1///source_name_ch1: ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: frozen tumor///characteristics_ch1.1: figo stage: 3c///characteristics_ch1.2: grade: III///characteristics_ch1.3: histological type: serous ovca///characteristics_ch1.4: residual tumor: 1///characteristics_ch1.5: overall survival time: 35///characteristics_ch1.6: overall survival event: 0///molecule_ch1: total RNA///extract_protocol_ch1: Total cellular RNA was isolated from tumor tissue, using the Qiagen Rneasy Mini Kit.///label_ch1: biotin///label_protocol_ch1: cDNA was synthesised from 5 g total RNA by reverse transcription, synthesis of biotin-labeled cRNA was performed using the BioArray High Yield RNA Transcription kit.///taxid_ch1: 9606///hyb_protocol: The fragmented cRNA was hybridised to HGU133 arrays at 45 C in a hybridization oven for 16 hr.///scan_protocol: Chip scanning was done with an Affymetrix Gene Array Scanner G2500A.///description: frozen tissue sample///data_processing: Signals and detection calls were calculated with the R package affy according to the standard MAS 5.0 protocol of the chip manufacturer.///platform_id: GPL96///contact_name: Jan,,Budczies///contact_email: [email protected]///contact_department: Institute of Pathology///contact_institute: Charite - Universitaetsmedizin Berlin///contact_address: Chariteplatz 2///contact_city: Berlin///contact_zip.postal_code: 10117///contact_country: Germany///contact_web_link: http://www.charite.de/ch/patho///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM368nnn/GSM368662/GSM368662.cel.gz///data_row_count: 22283
1
title: ovarian cancer: O30///geo_accession: GSM368690///status: Public on Feb 09 2009///submission_date: Feb 09 2009///last_update_date: Aug 24 2010///type: RNA///channel_count: 1///source_name_ch1: ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: frozen tumor///characteristics_ch1.1: figo stage: 3c///characteristics_ch1.2: grade: II///characteristics_ch1.3: histological type: serous ovca///characteristics_ch1.4: residual tumor: NA///characteristics_ch1.5: overall survival time: 46///characteristics_ch1.6: overall survival event: 1///molecule_ch1: total RNA///extract_protocol_ch1: Total cellular RNA was isolated from tumor tissue, using the Qiagen Rneasy Mini Kit.///label_ch1: biotin///label_protocol_ch1: cDNA was synthesised from 5 g total RNA by reverse transcription, synthesis of biotin-labeled cRNA was performed using the BioArray High Yield RNA Transcription kit.///taxid_ch1: 9606///hyb_protocol: The fragmented cRNA was hybridised to HGU133 arrays at 45 C in a hybridization oven for 16 hr.///scan_protocol: Chip scanning was done with an Affymetrix Gene Array Scanner G2500A.///description: frozen tissue sample///data_processing: Signals and detection calls were calculated with the R package affy according to the standard MAS 5.0 protocol of the chip manufacturer.///platform_id: GPL96///contact_name: Jan,,Budczies///contact_email: [email protected]///contact_department: Institute of Pathology///contact_institute: Charite - Universitaetsmedizin Berlin///contact_address: Chariteplatz 2///contact_city: Berlin///contact_zip.postal_code: 10117///contact_country: Germany///contact_web_link: http://www.charite.de/ch/patho///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM368nnn/GSM368690/GSM368690.cel.gz///data_row_count: 22283
1
title: ovarian cancer: O31///geo_accession: GSM368691///status: Public on Feb 09 2009///submission_date: Feb 09 2009///last_update_date: Aug 24 2010///type: RNA///channel_count: 1///source_name_ch1: ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: frozen tumor///characteristics_ch1.1: figo stage: 3c///characteristics_ch1.2: grade: III///characteristics_ch1.3: histological type: serous ovca///characteristics_ch1.4: residual tumor: 1///characteristics_ch1.5: overall survival time: 20///characteristics_ch1.6: overall survival event: 0///molecule_ch1: total RNA///extract_protocol_ch1: Total cellular RNA was isolated from tumor tissue, using the Qiagen Rneasy Mini Kit.///label_ch1: biotin///label_protocol_ch1: cDNA was synthesised from 5 g total RNA by reverse transcription, synthesis of biotin-labeled cRNA was performed using the BioArray High Yield RNA Transcription kit.///taxid_ch1: 9606///hyb_protocol: The fragmented cRNA was hybridised to HGU133 arrays at 45 C in a hybridization oven for 16 hr.///scan_protocol: Chip scanning was done with an Affymetrix Gene Array Scanner G2500A.///description: frozen tissue sample///data_processing: Signals and detection calls were calculated with the R package affy according to the standard MAS 5.0 protocol of the chip manufacturer.///platform_id: GPL96///contact_name: Jan,,Budczies///contact_email: [email protected]///contact_department: Institute of Pathology///contact_institute: Charite - Universitaetsmedizin Berlin///contact_address: Chariteplatz 2///contact_city: Berlin///contact_zip.postal_code: 10117///contact_country: Germany///contact_web_link: http://www.charite.de/ch/patho///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM368nnn/GSM368691/GSM368691.cel.gz///data_row_count: 22283
1
title: ovarian cancer: O32///geo_accession: GSM368692///status: Public on Feb 09 2009///submission_date: Feb 09 2009///last_update_date: Aug 24 2010///type: RNA///channel_count: 1///source_name_ch1: ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: frozen tumor///characteristics_ch1.1: figo stage: 3c///characteristics_ch1.2: grade: III///characteristics_ch1.3: histological type: serous ovca///characteristics_ch1.4: residual tumor: 0///characteristics_ch1.5: overall survival time: 37///characteristics_ch1.6: overall survival event: 0///molecule_ch1: total RNA///extract_protocol_ch1: Total cellular RNA was isolated from tumor tissue, using the Qiagen Rneasy Mini Kit.///label_ch1: biotin///label_protocol_ch1: cDNA was synthesised from 5 g total RNA by reverse transcription, synthesis of biotin-labeled cRNA was performed using the BioArray High Yield RNA Transcription kit.///taxid_ch1: 9606///hyb_protocol: The fragmented cRNA was hybridised to HGU133 arrays at 45 C in a hybridization oven for 16 hr.///scan_protocol: Chip scanning was done with an Affymetrix Gene Array Scanner G2500A.///description: frozen tissue sample///data_processing: Signals and detection calls were calculated with the R package affy according to the standard MAS 5.0 protocol of the chip manufacturer.///platform_id: GPL96///contact_name: Jan,,Budczies///contact_email: [email protected]///contact_department: Institute of Pathology///contact_institute: Charite - Universitaetsmedizin Berlin///contact_address: Chariteplatz 2///contact_city: Berlin///contact_zip.postal_code: 10117///contact_country: Germany///contact_web_link: http://www.charite.de/ch/patho///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM368nnn/GSM368692/GSM368692.cel.gz///data_row_count: 22283
1
title: ovarian cancer: O33///geo_accession: GSM368693///status: Public on Feb 09 2009///submission_date: Feb 09 2009///last_update_date: Aug 24 2010///type: RNA///channel_count: 1///source_name_ch1: ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: frozen tumor///characteristics_ch1.1: figo stage: 3b///characteristics_ch1.2: grade: II///characteristics_ch1.3: histological type: serous ovca///characteristics_ch1.4: residual tumor: 0///characteristics_ch1.5: overall survival time: 37///characteristics_ch1.6: overall survival event: 0///molecule_ch1: total RNA///extract_protocol_ch1: Total cellular RNA was isolated from tumor tissue, using the Qiagen Rneasy Mini Kit.///label_ch1: biotin///label_protocol_ch1: cDNA was synthesised from 5 g total RNA by reverse transcription, synthesis of biotin-labeled cRNA was performed using the BioArray High Yield RNA Transcription kit.///taxid_ch1: 9606///hyb_protocol: The fragmented cRNA was hybridised to HGU133 arrays at 45 C in a hybridization oven for 16 hr.///scan_protocol: Chip scanning was done with an Affymetrix Gene Array Scanner G2500A.///description: frozen tissue sample///data_processing: Signals and detection calls were calculated with the R package affy according to the standard MAS 5.0 protocol of the chip manufacturer.///platform_id: GPL96///contact_name: Jan,,Budczies///contact_email: [email protected]///contact_department: Institute of Pathology///contact_institute: Charite - Universitaetsmedizin Berlin///contact_address: Chariteplatz 2///contact_city: Berlin///contact_zip.postal_code: 10117///contact_country: Germany///contact_web_link: http://www.charite.de/ch/patho///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM368nnn/GSM368693/GSM368693.cel.gz///data_row_count: 22283
1
title: ovarian cancer: O34///geo_accession: GSM368694///status: Public on Feb 09 2009///submission_date: Feb 09 2009///last_update_date: Aug 24 2010///type: RNA///channel_count: 1///source_name_ch1: ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: frozen tumor///characteristics_ch1.1: figo stage: 3b///characteristics_ch1.2: grade: III///characteristics_ch1.3: histological type: serous ovca///characteristics_ch1.4: residual tumor: 0///characteristics_ch1.5: overall survival time: 40///characteristics_ch1.6: overall survival event: 1///molecule_ch1: total RNA///extract_protocol_ch1: Total cellular RNA was isolated from tumor tissue, using the Qiagen Rneasy Mini Kit.///label_ch1: biotin///label_protocol_ch1: cDNA was synthesised from 5 g total RNA by reverse transcription, synthesis of biotin-labeled cRNA was performed using the BioArray High Yield RNA Transcription kit.///taxid_ch1: 9606///hyb_protocol: The fragmented cRNA was hybridised to HGU133 arrays at 45 C in a hybridization oven for 16 hr.///scan_protocol: Chip scanning was done with an Affymetrix Gene Array Scanner G2500A.///description: frozen tissue sample///data_processing: Signals and detection calls were calculated with the R package affy according to the standard MAS 5.0 protocol of the chip manufacturer.///platform_id: GPL96///contact_name: Jan,,Budczies///contact_email: [email protected]///contact_department: Institute of Pathology///contact_institute: Charite - Universitaetsmedizin Berlin///contact_address: Chariteplatz 2///contact_city: Berlin///contact_zip.postal_code: 10117///contact_country: Germany///contact_web_link: http://www.charite.de/ch/patho///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM368nnn/GSM368694/GSM368694.cel.gz///data_row_count: 22283
1
title: ovarian cancer: O35///geo_accession: GSM368695///status: Public on Feb 09 2009///submission_date: Feb 09 2009///last_update_date: Aug 24 2010///type: RNA///channel_count: 1///source_name_ch1: ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: frozen tumor///characteristics_ch1.1: figo stage: 3c///characteristics_ch1.2: grade: III///characteristics_ch1.3: histological type: serous ovca///characteristics_ch1.4: residual tumor: 1///characteristics_ch1.5: overall survival time: 47///characteristics_ch1.6: overall survival event: 0///molecule_ch1: total RNA///extract_protocol_ch1: Total cellular RNA was isolated from tumor tissue, using the Qiagen Rneasy Mini Kit.///label_ch1: biotin///label_protocol_ch1: cDNA was synthesised from 5 g total RNA by reverse transcription, synthesis of biotin-labeled cRNA was performed using the BioArray High Yield RNA Transcription kit.///taxid_ch1: 9606///hyb_protocol: The fragmented cRNA was hybridised to HGU133 arrays at 45 C in a hybridization oven for 16 hr.///scan_protocol: Chip scanning was done with an Affymetrix Gene Array Scanner G2500A.///description: frozen tissue sample///data_processing: Signals and detection calls were calculated with the R package affy according to the standard MAS 5.0 protocol of the chip manufacturer.///platform_id: GPL96///contact_name: Jan,,Budczies///contact_email: [email protected]///contact_department: Institute of Pathology///contact_institute: Charite - Universitaetsmedizin Berlin///contact_address: Chariteplatz 2///contact_city: Berlin///contact_zip.postal_code: 10117///contact_country: Germany///contact_web_link: http://www.charite.de/ch/patho///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM368nnn/GSM368695/GSM368695.cel.gz///data_row_count: 22283
1
title: ovarian cancer: O36///geo_accession: GSM368696///status: Public on Feb 09 2009///submission_date: Feb 09 2009///last_update_date: Aug 24 2010///type: RNA///channel_count: 1///source_name_ch1: ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: frozen tumor///characteristics_ch1.1: figo stage: 3b///characteristics_ch1.2: grade: II///characteristics_ch1.3: histological type: serous ovca///characteristics_ch1.4: residual tumor: 1///characteristics_ch1.5: overall survival time: 42///characteristics_ch1.6: overall survival event: 0///molecule_ch1: total RNA///extract_protocol_ch1: Total cellular RNA was isolated from tumor tissue, using the Qiagen Rneasy Mini Kit.///label_ch1: biotin///label_protocol_ch1: cDNA was synthesised from 5 g total RNA by reverse transcription, synthesis of biotin-labeled cRNA was performed using the BioArray High Yield RNA Transcription kit.///taxid_ch1: 9606///hyb_protocol: The fragmented cRNA was hybridised to HGU133 arrays at 45 C in a hybridization oven for 16 hr.///scan_protocol: Chip scanning was done with an Affymetrix Gene Array Scanner G2500A.///description: frozen tissue sample///data_processing: Signals and detection calls were calculated with the R package affy according to the standard MAS 5.0 protocol of the chip manufacturer.///platform_id: GPL96///contact_name: Jan,,Budczies///contact_email: [email protected]///contact_department: Institute of Pathology///contact_institute: Charite - Universitaetsmedizin Berlin///contact_address: Chariteplatz 2///contact_city: Berlin///contact_zip.postal_code: 10117///contact_country: Germany///contact_web_link: http://www.charite.de/ch/patho///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM368nnn/GSM368696/GSM368696.cel.gz///data_row_count: 22283
1
title: ovarian cancer: O37///geo_accession: GSM368697///status: Public on Feb 09 2009///submission_date: Feb 09 2009///last_update_date: Aug 24 2010///type: RNA///channel_count: 1///source_name_ch1: ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: frozen tumor///characteristics_ch1.1: figo stage: 3c///characteristics_ch1.2: grade: II///characteristics_ch1.3: histological type: serous ovca///characteristics_ch1.4: residual tumor: 0///characteristics_ch1.5: overall survival time: 52///characteristics_ch1.6: overall survival event: 0///molecule_ch1: total RNA///extract_protocol_ch1: Total cellular RNA was isolated from tumor tissue, using the Qiagen Rneasy Mini Kit.///label_ch1: biotin///label_protocol_ch1: cDNA was synthesised from 5 g total RNA by reverse transcription, synthesis of biotin-labeled cRNA was performed using the BioArray High Yield RNA Transcription kit.///taxid_ch1: 9606///hyb_protocol: The fragmented cRNA was hybridised to HGU133 arrays at 45 C in a hybridization oven for 16 hr.///scan_protocol: Chip scanning was done with an Affymetrix Gene Array Scanner G2500A.///description: frozen tissue sample///data_processing: Signals and detection calls were calculated with the R package affy according to the standard MAS 5.0 protocol of the chip manufacturer.///platform_id: GPL96///contact_name: Jan,,Budczies///contact_email: [email protected]///contact_department: Institute of Pathology///contact_institute: Charite - Universitaetsmedizin Berlin///contact_address: Chariteplatz 2///contact_city: Berlin///contact_zip.postal_code: 10117///contact_country: Germany///contact_web_link: http://www.charite.de/ch/patho///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM368nnn/GSM368697/GSM368697.cel.gz///data_row_count: 22283
1
title: ovarian cancer: O38///geo_accession: GSM368698///status: Public on Feb 09 2009///submission_date: Feb 09 2009///last_update_date: Aug 24 2010///type: RNA///channel_count: 1///source_name_ch1: ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: frozen tumor///characteristics_ch1.1: figo stage: 3c///characteristics_ch1.2: grade: III///characteristics_ch1.3: histological type: serous ovca///characteristics_ch1.4: residual tumor: NA///characteristics_ch1.5: overall survival time: 22///characteristics_ch1.6: overall survival event: 0///molecule_ch1: total RNA///extract_protocol_ch1: Total cellular RNA was isolated from tumor tissue, using the Qiagen Rneasy Mini Kit.///label_ch1: biotin///label_protocol_ch1: cDNA was synthesised from 5 g total RNA by reverse transcription, synthesis of biotin-labeled cRNA was performed using the BioArray High Yield RNA Transcription kit.///taxid_ch1: 9606///hyb_protocol: The fragmented cRNA was hybridised to HGU133 arrays at 45 C in a hybridization oven for 16 hr.///scan_protocol: Chip scanning was done with an Affymetrix Gene Array Scanner G2500A.///description: frozen tissue sample///data_processing: Signals and detection calls were calculated with the R package affy according to the standard MAS 5.0 protocol of the chip manufacturer.///platform_id: GPL96///contact_name: Jan,,Budczies///contact_email: [email protected]///contact_department: Institute of Pathology///contact_institute: Charite - Universitaetsmedizin Berlin///contact_address: Chariteplatz 2///contact_city: Berlin///contact_zip.postal_code: 10117///contact_country: Germany///contact_web_link: http://www.charite.de/ch/patho///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM368nnn/GSM368698/GSM368698.cel.gz///data_row_count: 22283
1
title: ovarian cancer: O39///geo_accession: GSM368699///status: Public on Feb 09 2009///submission_date: Feb 09 2009///last_update_date: Aug 24 2010///type: RNA///channel_count: 1///source_name_ch1: ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: frozen tumor///characteristics_ch1.1: figo stage: 3c///characteristics_ch1.2: grade: III///characteristics_ch1.3: histological type: serous ovca///characteristics_ch1.4: residual tumor: 0///characteristics_ch1.5: overall survival time: 45///characteristics_ch1.6: overall survival event: 1///molecule_ch1: total RNA///extract_protocol_ch1: Total cellular RNA was isolated from tumor tissue, using the Qiagen Rneasy Mini Kit.///label_ch1: biotin///label_protocol_ch1: cDNA was synthesised from 5 g total RNA by reverse transcription, synthesis of biotin-labeled cRNA was performed using the BioArray High Yield RNA Transcription kit.///taxid_ch1: 9606///hyb_protocol: The fragmented cRNA was hybridised to HGU133 arrays at 45 C in a hybridization oven for 16 hr.///scan_protocol: Chip scanning was done with an Affymetrix Gene Array Scanner G2500A.///description: frozen tissue sample///data_processing: Signals and detection calls were calculated with the R package affy according to the standard MAS 5.0 protocol of the chip manufacturer.///platform_id: GPL96///contact_name: Jan,,Budczies///contact_email: [email protected]///contact_department: Institute of Pathology///contact_institute: Charite - Universitaetsmedizin Berlin///contact_address: Chariteplatz 2///contact_city: Berlin///contact_zip.postal_code: 10117///contact_country: Germany///contact_web_link: http://www.charite.de/ch/patho///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM368nnn/GSM368699/GSM368699.cel.gz///data_row_count: 22283
1
title: ovarian cancer: O3///geo_accession: GSM368663///status: Public on Feb 09 2009///submission_date: Feb 09 2009///last_update_date: Aug 24 2010///type: RNA///channel_count: 1///source_name_ch1: ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: frozen tumor///characteristics_ch1.1: figo stage: 3b///characteristics_ch1.2: grade: III///characteristics_ch1.3: histological type: transitional cell ca///characteristics_ch1.4: residual tumor: 1///characteristics_ch1.5: overall survival time: 27///characteristics_ch1.6: overall survival event: 0///molecule_ch1: total RNA///extract_protocol_ch1: Total cellular RNA was isolated from tumor tissue, using the Qiagen Rneasy Mini Kit.///label_ch1: biotin///label_protocol_ch1: cDNA was synthesised from 5 g total RNA by reverse transcription, synthesis of biotin-labeled cRNA was performed using the BioArray High Yield RNA Transcription kit.///taxid_ch1: 9606///hyb_protocol: The fragmented cRNA was hybridised to HGU133 arrays at 45 C in a hybridization oven for 16 hr.///scan_protocol: Chip scanning was done with an Affymetrix Gene Array Scanner G2500A.///description: frozen tissue sample///data_processing: Signals and detection calls were calculated with the R package affy according to the standard MAS 5.0 protocol of the chip manufacturer.///platform_id: GPL96///contact_name: Jan,,Budczies///contact_email: [email protected]///contact_department: Institute of Pathology///contact_institute: Charite - Universitaetsmedizin Berlin///contact_address: Chariteplatz 2///contact_city: Berlin///contact_zip.postal_code: 10117///contact_country: Germany///contact_web_link: http://www.charite.de/ch/patho///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM368nnn/GSM368663/GSM368663.cel.gz///data_row_count: 22283
1
title: ovarian cancer: O40///geo_accession: GSM368700///status: Public on Feb 09 2009///submission_date: Feb 09 2009///last_update_date: Aug 24 2010///type: RNA///channel_count: 1///source_name_ch1: ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: frozen tumor///characteristics_ch1.1: figo stage: 3c///characteristics_ch1.2: grade: III///characteristics_ch1.3: histological type: serous ovca///characteristics_ch1.4: residual tumor: 1///characteristics_ch1.5: overall survival time: 20///characteristics_ch1.6: overall survival event: 1///molecule_ch1: total RNA///extract_protocol_ch1: Total cellular RNA was isolated from tumor tissue, using the Qiagen Rneasy Mini Kit.///label_ch1: biotin///label_protocol_ch1: cDNA was synthesised from 5 g total RNA by reverse transcription, synthesis of biotin-labeled cRNA was performed using the BioArray High Yield RNA Transcription kit.///taxid_ch1: 9606///hyb_protocol: The fragmented cRNA was hybridised to HGU133 arrays at 45 C in a hybridization oven for 16 hr.///scan_protocol: Chip scanning was done with an Affymetrix Gene Array Scanner G2500A.///description: frozen tissue sample///data_processing: Signals and detection calls were calculated with the R package affy according to the standard MAS 5.0 protocol of the chip manufacturer.///platform_id: GPL96///contact_name: Jan,,Budczies///contact_email: [email protected]///contact_department: Institute of Pathology///contact_institute: Charite - Universitaetsmedizin Berlin///contact_address: Chariteplatz 2///contact_city: Berlin///contact_zip.postal_code: 10117///contact_country: Germany///contact_web_link: http://www.charite.de/ch/patho///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM368nnn/GSM368700/GSM368700.cel.gz///data_row_count: 22283
1
title: ovarian cancer: O41///geo_accession: GSM368701///status: Public on Feb 09 2009///submission_date: Feb 09 2009///last_update_date: Aug 24 2010///type: RNA///channel_count: 1///source_name_ch1: ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: frozen tumor///characteristics_ch1.1: figo stage: 3c///characteristics_ch1.2: grade: II///characteristics_ch1.3: histological type: serous ovca///characteristics_ch1.4: residual tumor: 0///characteristics_ch1.5: overall survival time: 45///characteristics_ch1.6: overall survival event: 0///molecule_ch1: total RNA///extract_protocol_ch1: Total cellular RNA was isolated from tumor tissue, using the Qiagen Rneasy Mini Kit.///label_ch1: biotin///label_protocol_ch1: cDNA was synthesised from 5 g total RNA by reverse transcription, synthesis of biotin-labeled cRNA was performed using the BioArray High Yield RNA Transcription kit.///taxid_ch1: 9606///hyb_protocol: The fragmented cRNA was hybridised to HGU133 arrays at 45 C in a hybridization oven for 16 hr.///scan_protocol: Chip scanning was done with an Affymetrix Gene Array Scanner G2500A.///description: frozen tissue sample///data_processing: Signals and detection calls were calculated with the R package affy according to the standard MAS 5.0 protocol of the chip manufacturer.///platform_id: GPL96///contact_name: Jan,,Budczies///contact_email: [email protected]///contact_department: Institute of Pathology///contact_institute: Charite - Universitaetsmedizin Berlin///contact_address: Chariteplatz 2///contact_city: Berlin///contact_zip.postal_code: 10117///contact_country: Germany///contact_web_link: http://www.charite.de/ch/patho///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM368nnn/GSM368701/GSM368701.cel.gz///data_row_count: 22283
1
title: ovarian cancer: O42///geo_accession: GSM368702///status: Public on Feb 09 2009///submission_date: Feb 09 2009///last_update_date: Aug 24 2010///type: RNA///channel_count: 1///source_name_ch1: ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: frozen tumor///characteristics_ch1.1: figo stage: 4///characteristics_ch1.2: grade: III///characteristics_ch1.3: histological type: endometr ovca///characteristics_ch1.4: residual tumor: 0///characteristics_ch1.5: overall survival time: 32///characteristics_ch1.6: overall survival event: 0///molecule_ch1: total RNA///extract_protocol_ch1: Total cellular RNA was isolated from tumor tissue, using the Qiagen Rneasy Mini Kit.///label_ch1: biotin///label_protocol_ch1: cDNA was synthesised from 5 g total RNA by reverse transcription, synthesis of biotin-labeled cRNA was performed using the BioArray High Yield RNA Transcription kit.///taxid_ch1: 9606///hyb_protocol: The fragmented cRNA was hybridised to HGU133 arrays at 45 C in a hybridization oven for 16 hr.///scan_protocol: Chip scanning was done with an Affymetrix Gene Array Scanner G2500A.///description: frozen tissue sample///data_processing: Signals and detection calls were calculated with the R package affy according to the standard MAS 5.0 protocol of the chip manufacturer.///platform_id: GPL96///contact_name: Jan,,Budczies///contact_email: [email protected]///contact_department: Institute of Pathology///contact_institute: Charite - Universitaetsmedizin Berlin///contact_address: Chariteplatz 2///contact_city: Berlin///contact_zip.postal_code: 10117///contact_country: Germany///contact_web_link: http://www.charite.de/ch/patho///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM368nnn/GSM368702/GSM368702.cel.gz///data_row_count: 22283
1
title: ovarian cancer: O43///geo_accession: GSM368703///status: Public on Feb 09 2009///submission_date: Feb 09 2009///last_update_date: Aug 24 2010///type: RNA///channel_count: 1///source_name_ch1: ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: frozen tumor///characteristics_ch1.1: figo stage: 3c///characteristics_ch1.2: grade: III///characteristics_ch1.3: histological type: serous ovca///characteristics_ch1.4: residual tumor: 0///characteristics_ch1.5: overall survival time: 49///characteristics_ch1.6: overall survival event: 0///molecule_ch1: total RNA///extract_protocol_ch1: Total cellular RNA was isolated from tumor tissue, using the Qiagen Rneasy Mini Kit.///label_ch1: biotin///label_protocol_ch1: cDNA was synthesised from 5 g total RNA by reverse transcription, synthesis of biotin-labeled cRNA was performed using the BioArray High Yield RNA Transcription kit.///taxid_ch1: 9606///hyb_protocol: The fragmented cRNA was hybridised to HGU133 arrays at 45 C in a hybridization oven for 16 hr.///scan_protocol: Chip scanning was done with an Affymetrix Gene Array Scanner G2500A.///description: frozen tissue sample///data_processing: Signals and detection calls were calculated with the R package affy according to the standard MAS 5.0 protocol of the chip manufacturer.///platform_id: GPL96///contact_name: Jan,,Budczies///contact_email: [email protected]///contact_department: Institute of Pathology///contact_institute: Charite - Universitaetsmedizin Berlin///contact_address: Chariteplatz 2///contact_city: Berlin///contact_zip.postal_code: 10117///contact_country: Germany///contact_web_link: http://www.charite.de/ch/patho///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM368nnn/GSM368703/GSM368703.cel.gz///data_row_count: 22283
1
title: ovarian cancer: O44///geo_accession: GSM368704///status: Public on Feb 09 2009///submission_date: Feb 09 2009///last_update_date: Aug 24 2010///type: RNA///channel_count: 1///source_name_ch1: ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: frozen tumor///characteristics_ch1.1: figo stage: 3c///characteristics_ch1.2: grade: II///characteristics_ch1.3: histological type: serous ovca///characteristics_ch1.4: residual tumor: 1///characteristics_ch1.5: overall survival time: 15///characteristics_ch1.6: overall survival event: 0///molecule_ch1: total RNA///extract_protocol_ch1: Total cellular RNA was isolated from tumor tissue, using the Qiagen Rneasy Mini Kit.///label_ch1: biotin///label_protocol_ch1: cDNA was synthesised from 5 g total RNA by reverse transcription, synthesis of biotin-labeled cRNA was performed using the BioArray High Yield RNA Transcription kit.///taxid_ch1: 9606///hyb_protocol: The fragmented cRNA was hybridised to HGU133 arrays at 45 C in a hybridization oven for 16 hr.///scan_protocol: Chip scanning was done with an Affymetrix Gene Array Scanner G2500A.///description: frozen tissue sample///data_processing: Signals and detection calls were calculated with the R package affy according to the standard MAS 5.0 protocol of the chip manufacturer.///platform_id: GPL96///contact_name: Jan,,Budczies///contact_email: [email protected]///contact_department: Institute of Pathology///contact_institute: Charite - Universitaetsmedizin Berlin///contact_address: Chariteplatz 2///contact_city: Berlin///contact_zip.postal_code: 10117///contact_country: Germany///contact_web_link: http://www.charite.de/ch/patho///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM368nnn/GSM368704/GSM368704.cel.gz///data_row_count: 22283
1
title: ovarian cancer: O45///geo_accession: GSM368705///status: Public on Feb 09 2009///submission_date: Feb 09 2009///last_update_date: Aug 24 2010///type: RNA///channel_count: 1///source_name_ch1: ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: frozen tumor///characteristics_ch1.1: figo stage: 3///characteristics_ch1.2: grade: II///characteristics_ch1.3: histological type: serous ovca///characteristics_ch1.4: residual tumor: 1///characteristics_ch1.5: overall survival time: 43///characteristics_ch1.6: overall survival event: 1///molecule_ch1: total RNA///extract_protocol_ch1: Total cellular RNA was isolated from tumor tissue, using the Qiagen Rneasy Mini Kit.///label_ch1: biotin///label_protocol_ch1: cDNA was synthesised from 5 g total RNA by reverse transcription, synthesis of biotin-labeled cRNA was performed using the BioArray High Yield RNA Transcription kit.///taxid_ch1: 9606///hyb_protocol: The fragmented cRNA was hybridised to HGU133 arrays at 45 C in a hybridization oven for 16 hr.///scan_protocol: Chip scanning was done with an Affymetrix Gene Array Scanner G2500A.///description: frozen tissue sample///data_processing: Signals and detection calls were calculated with the R package affy according to the standard MAS 5.0 protocol of the chip manufacturer.///platform_id: GPL96///contact_name: Jan,,Budczies///contact_email: [email protected]///contact_department: Institute of Pathology///contact_institute: Charite - Universitaetsmedizin Berlin///contact_address: Chariteplatz 2///contact_city: Berlin///contact_zip.postal_code: 10117///contact_country: Germany///contact_web_link: http://www.charite.de/ch/patho///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM368nnn/GSM368705/GSM368705.cel.gz///data_row_count: 22283
1
title: ovarian cancer: O46///geo_accession: GSM368706///status: Public on Feb 09 2009///submission_date: Feb 09 2009///last_update_date: Aug 24 2010///type: RNA///channel_count: 1///source_name_ch1: ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: frozen tumor///characteristics_ch1.1: figo stage: 3///characteristics_ch1.2: grade: I///characteristics_ch1.3: histological type: serous ovca///characteristics_ch1.4: residual tumor: 0///characteristics_ch1.5: overall survival time: 73///characteristics_ch1.6: overall survival event: 0///molecule_ch1: total RNA///extract_protocol_ch1: Total cellular RNA was isolated from tumor tissue, using the Qiagen Rneasy Mini Kit.///label_ch1: biotin///label_protocol_ch1: cDNA was synthesised from 5 g total RNA by reverse transcription, synthesis of biotin-labeled cRNA was performed using the BioArray High Yield RNA Transcription kit.///taxid_ch1: 9606///hyb_protocol: The fragmented cRNA was hybridised to HGU133 arrays at 45 C in a hybridization oven for 16 hr.///scan_protocol: Chip scanning was done with an Affymetrix Gene Array Scanner G2500A.///description: frozen tissue sample///data_processing: Signals and detection calls were calculated with the R package affy according to the standard MAS 5.0 protocol of the chip manufacturer.///platform_id: GPL96///contact_name: Jan,,Budczies///contact_email: [email protected]///contact_department: Institute of Pathology///contact_institute: Charite - Universitaetsmedizin Berlin///contact_address: Chariteplatz 2///contact_city: Berlin///contact_zip.postal_code: 10117///contact_country: Germany///contact_web_link: http://www.charite.de/ch/patho///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM368nnn/GSM368706/GSM368706.cel.gz///data_row_count: 22283
1
title: ovarian cancer: O47///geo_accession: GSM368707///status: Public on Feb 09 2009///submission_date: Feb 09 2009///last_update_date: Aug 24 2010///type: RNA///channel_count: 1///source_name_ch1: ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: frozen tumor///characteristics_ch1.1: figo stage: 3///characteristics_ch1.2: grade: III///characteristics_ch1.3: histological type: serous ovca///characteristics_ch1.4: residual tumor: 0///characteristics_ch1.5: overall survival time: 53///characteristics_ch1.6: overall survival event: 1///molecule_ch1: total RNA///extract_protocol_ch1: Total cellular RNA was isolated from tumor tissue, using the Qiagen Rneasy Mini Kit.///label_ch1: biotin///label_protocol_ch1: cDNA was synthesised from 5 g total RNA by reverse transcription, synthesis of biotin-labeled cRNA was performed using the BioArray High Yield RNA Transcription kit.///taxid_ch1: 9606///hyb_protocol: The fragmented cRNA was hybridised to HGU133 arrays at 45 C in a hybridization oven for 16 hr.///scan_protocol: Chip scanning was done with an Affymetrix Gene Array Scanner G2500A.///description: frozen tissue sample///data_processing: Signals and detection calls were calculated with the R package affy according to the standard MAS 5.0 protocol of the chip manufacturer.///platform_id: GPL96///contact_name: Jan,,Budczies///contact_email: [email protected]///contact_department: Institute of Pathology///contact_institute: Charite - Universitaetsmedizin Berlin///contact_address: Chariteplatz 2///contact_city: Berlin///contact_zip.postal_code: 10117///contact_country: Germany///contact_web_link: http://www.charite.de/ch/patho///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM368nnn/GSM368707/GSM368707.cel.gz///data_row_count: 22283
1
title: ovarian cancer: O48///geo_accession: GSM368708///status: Public on Feb 09 2009///submission_date: Feb 09 2009///last_update_date: Aug 24 2010///type: RNA///channel_count: 1///source_name_ch1: ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: frozen tumor///characteristics_ch1.1: figo stage: 3///characteristics_ch1.2: grade: I///characteristics_ch1.3: histological type: serous ovca///characteristics_ch1.4: residual tumor: 1///characteristics_ch1.5: overall survival time: 38///characteristics_ch1.6: overall survival event: 1///molecule_ch1: total RNA///extract_protocol_ch1: Total cellular RNA was isolated from tumor tissue, using the Qiagen Rneasy Mini Kit.///label_ch1: biotin///label_protocol_ch1: cDNA was synthesised from 5 g total RNA by reverse transcription, synthesis of biotin-labeled cRNA was performed using the BioArray High Yield RNA Transcription kit.///taxid_ch1: 9606///hyb_protocol: The fragmented cRNA was hybridised to HGU133 arrays at 45 C in a hybridization oven for 16 hr.///scan_protocol: Chip scanning was done with an Affymetrix Gene Array Scanner G2500A.///description: frozen tissue sample///data_processing: Signals and detection calls were calculated with the R package affy according to the standard MAS 5.0 protocol of the chip manufacturer.///platform_id: GPL96///contact_name: Jan,,Budczies///contact_email: [email protected]///contact_department: Institute of Pathology///contact_institute: Charite - Universitaetsmedizin Berlin///contact_address: Chariteplatz 2///contact_city: Berlin///contact_zip.postal_code: 10117///contact_country: Germany///contact_web_link: http://www.charite.de/ch/patho///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM368nnn/GSM368708/GSM368708.cel.gz///data_row_count: 22283
1
title: ovarian cancer: O49///geo_accession: GSM368709///status: Public on Feb 09 2009///submission_date: Feb 09 2009///last_update_date: Aug 24 2010///type: RNA///channel_count: 1///source_name_ch1: ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: frozen tumor///characteristics_ch1.1: figo stage: 3///characteristics_ch1.2: grade: III///characteristics_ch1.3: histological type: serous ovca///characteristics_ch1.4: residual tumor: 0///characteristics_ch1.5: overall survival time: 51///characteristics_ch1.6: overall survival event: 0///molecule_ch1: total RNA///extract_protocol_ch1: Total cellular RNA was isolated from tumor tissue, using the Qiagen Rneasy Mini Kit.///label_ch1: biotin///label_protocol_ch1: cDNA was synthesised from 5 g total RNA by reverse transcription, synthesis of biotin-labeled cRNA was performed using the BioArray High Yield RNA Transcription kit.///taxid_ch1: 9606///hyb_protocol: The fragmented cRNA was hybridised to HGU133 arrays at 45 C in a hybridization oven for 16 hr.///scan_protocol: Chip scanning was done with an Affymetrix Gene Array Scanner G2500A.///description: frozen tissue sample///data_processing: Signals and detection calls were calculated with the R package affy according to the standard MAS 5.0 protocol of the chip manufacturer.///platform_id: GPL96///contact_name: Jan,,Budczies///contact_email: [email protected]///contact_department: Institute of Pathology///contact_institute: Charite - Universitaetsmedizin Berlin///contact_address: Chariteplatz 2///contact_city: Berlin///contact_zip.postal_code: 10117///contact_country: Germany///contact_web_link: http://www.charite.de/ch/patho///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM368nnn/GSM368709/GSM368709.cel.gz///data_row_count: 22283
1
title: ovarian cancer: O4///geo_accession: GSM368664///status: Public on Feb 09 2009///submission_date: Feb 09 2009///last_update_date: Aug 24 2010///type: RNA///channel_count: 1///source_name_ch1: ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: frozen tumor///characteristics_ch1.1: figo stage: 3c///characteristics_ch1.2: grade: III///characteristics_ch1.3: histological type: serous ovca///characteristics_ch1.4: residual tumor: 0///characteristics_ch1.5: overall survival time: 14///characteristics_ch1.6: overall survival event: 0///molecule_ch1: total RNA///extract_protocol_ch1: Total cellular RNA was isolated from tumor tissue, using the Qiagen Rneasy Mini Kit.///label_ch1: biotin///label_protocol_ch1: cDNA was synthesised from 5 g total RNA by reverse transcription, synthesis of biotin-labeled cRNA was performed using the BioArray High Yield RNA Transcription kit.///taxid_ch1: 9606///hyb_protocol: The fragmented cRNA was hybridised to HGU133 arrays at 45 C in a hybridization oven for 16 hr.///scan_protocol: Chip scanning was done with an Affymetrix Gene Array Scanner G2500A.///description: frozen tissue sample///data_processing: Signals and detection calls were calculated with the R package affy according to the standard MAS 5.0 protocol of the chip manufacturer.///platform_id: GPL96///contact_name: Jan,,Budczies///contact_email: [email protected]///contact_department: Institute of Pathology///contact_institute: Charite - Universitaetsmedizin Berlin///contact_address: Chariteplatz 2///contact_city: Berlin///contact_zip.postal_code: 10117///contact_country: Germany///contact_web_link: http://www.charite.de/ch/patho///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM368nnn/GSM368664/GSM368664.cel.gz///data_row_count: 22283
1
title: ovarian cancer: O50///geo_accession: GSM368710///status: Public on Feb 09 2009///submission_date: Feb 09 2009///last_update_date: Aug 24 2010///type: RNA///channel_count: 1///source_name_ch1: ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: frozen tumor///characteristics_ch1.1: figo stage: 3///characteristics_ch1.2: grade: III///characteristics_ch1.3: histological type: serous ovca///characteristics_ch1.4: residual tumor: 1///characteristics_ch1.5: overall survival time: 55///characteristics_ch1.6: overall survival event: 1///molecule_ch1: total RNA///extract_protocol_ch1: Total cellular RNA was isolated from tumor tissue, using the Qiagen Rneasy Mini Kit.///label_ch1: biotin///label_protocol_ch1: cDNA was synthesised from 5 g total RNA by reverse transcription, synthesis of biotin-labeled cRNA was performed using the BioArray High Yield RNA Transcription kit.///taxid_ch1: 9606///hyb_protocol: The fragmented cRNA was hybridised to HGU133 arrays at 45 C in a hybridization oven for 16 hr.///scan_protocol: Chip scanning was done with an Affymetrix Gene Array Scanner G2500A.///description: frozen tissue sample///data_processing: Signals and detection calls were calculated with the R package affy according to the standard MAS 5.0 protocol of the chip manufacturer.///platform_id: GPL96///contact_name: Jan,,Budczies///contact_email: [email protected]///contact_department: Institute of Pathology///contact_institute: Charite - Universitaetsmedizin Berlin///contact_address: Chariteplatz 2///contact_city: Berlin///contact_zip.postal_code: 10117///contact_country: Germany///contact_web_link: http://www.charite.de/ch/patho///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM368nnn/GSM368710/GSM368710.cel.gz///data_row_count: 22283
1
title: ovarian cancer: O51///geo_accession: GSM368711///status: Public on Feb 09 2009///submission_date: Feb 09 2009///last_update_date: Aug 24 2010///type: RNA///channel_count: 1///source_name_ch1: ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: frozen tumor///characteristics_ch1.1: figo stage: 3///characteristics_ch1.2: grade: II///characteristics_ch1.3: histological type: serous ovca///characteristics_ch1.4: residual tumor: 0///characteristics_ch1.5: overall survival time: 27///characteristics_ch1.6: overall survival event: 1///molecule_ch1: total RNA///extract_protocol_ch1: Total cellular RNA was isolated from tumor tissue, using the Qiagen Rneasy Mini Kit.///label_ch1: biotin///label_protocol_ch1: cDNA was synthesised from 5 g total RNA by reverse transcription, synthesis of biotin-labeled cRNA was performed using the BioArray High Yield RNA Transcription kit.///taxid_ch1: 9606///hyb_protocol: The fragmented cRNA was hybridised to HGU133 arrays at 45 C in a hybridization oven for 16 hr.///scan_protocol: Chip scanning was done with an Affymetrix Gene Array Scanner G2500A.///description: frozen tissue sample///data_processing: Signals and detection calls were calculated with the R package affy according to the standard MAS 5.0 protocol of the chip manufacturer.///platform_id: GPL96///contact_name: Jan,,Budczies///contact_email: [email protected]///contact_department: Institute of Pathology///contact_institute: Charite - Universitaetsmedizin Berlin///contact_address: Chariteplatz 2///contact_city: Berlin///contact_zip.postal_code: 10117///contact_country: Germany///contact_web_link: http://www.charite.de/ch/patho///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM368nnn/GSM368711/GSM368711.cel.gz///data_row_count: 22283
1
title: ovarian cancer: O52///geo_accession: GSM368712///status: Public on Feb 09 2009///submission_date: Feb 09 2009///last_update_date: Aug 24 2010///type: RNA///channel_count: 1///source_name_ch1: ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: frozen tumor///characteristics_ch1.1: figo stage: 3///characteristics_ch1.2: grade: III///characteristics_ch1.3: histological type: endometr ovca///characteristics_ch1.4: residual tumor: 1///characteristics_ch1.5: overall survival time: 7///characteristics_ch1.6: overall survival event: 1///molecule_ch1: total RNA///extract_protocol_ch1: Total cellular RNA was isolated from tumor tissue, using the Qiagen Rneasy Mini Kit.///label_ch1: biotin///label_protocol_ch1: cDNA was synthesised from 5 g total RNA by reverse transcription, synthesis of biotin-labeled cRNA was performed using the BioArray High Yield RNA Transcription kit.///taxid_ch1: 9606///hyb_protocol: The fragmented cRNA was hybridised to HGU133 arrays at 45 C in a hybridization oven for 16 hr.///scan_protocol: Chip scanning was done with an Affymetrix Gene Array Scanner G2500A.///description: frozen tissue sample///data_processing: Signals and detection calls were calculated with the R package affy according to the standard MAS 5.0 protocol of the chip manufacturer.///platform_id: GPL96///contact_name: Jan,,Budczies///contact_email: [email protected]///contact_department: Institute of Pathology///contact_institute: Charite - Universitaetsmedizin Berlin///contact_address: Chariteplatz 2///contact_city: Berlin///contact_zip.postal_code: 10117///contact_country: Germany///contact_web_link: http://www.charite.de/ch/patho///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM368nnn/GSM368712/GSM368712.cel.gz///data_row_count: 22283
1
title: ovarian cancer: O53///geo_accession: GSM368713///status: Public on Feb 09 2009///submission_date: Feb 09 2009///last_update_date: Aug 24 2010///type: RNA///channel_count: 1///source_name_ch1: ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: frozen tumor///characteristics_ch1.1: figo stage: 3///characteristics_ch1.2: grade: II///characteristics_ch1.3: histological type: serous ovca///characteristics_ch1.4: residual tumor: 0///characteristics_ch1.5: overall survival time: 44///characteristics_ch1.6: overall survival event: 0///molecule_ch1: total RNA///extract_protocol_ch1: Total cellular RNA was isolated from tumor tissue, using the Qiagen Rneasy Mini Kit.///label_ch1: biotin///label_protocol_ch1: cDNA was synthesised from 5 g total RNA by reverse transcription, synthesis of biotin-labeled cRNA was performed using the BioArray High Yield RNA Transcription kit.///taxid_ch1: 9606///hyb_protocol: The fragmented cRNA was hybridised to HGU133 arrays at 45 C in a hybridization oven for 16 hr.///scan_protocol: Chip scanning was done with an Affymetrix Gene Array Scanner G2500A.///description: frozen tissue sample///data_processing: Signals and detection calls were calculated with the R package affy according to the standard MAS 5.0 protocol of the chip manufacturer.///platform_id: GPL96///contact_name: Jan,,Budczies///contact_email: [email protected]///contact_department: Institute of Pathology///contact_institute: Charite - Universitaetsmedizin Berlin///contact_address: Chariteplatz 2///contact_city: Berlin///contact_zip.postal_code: 10117///contact_country: Germany///contact_web_link: http://www.charite.de/ch/patho///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM368nnn/GSM368713/GSM368713.cel.gz///data_row_count: 22283
1
title: ovarian cancer: O54///geo_accession: GSM368714///status: Public on Feb 09 2009///submission_date: Feb 09 2009///last_update_date: Aug 24 2010///type: RNA///channel_count: 1///source_name_ch1: ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: frozen tumor///characteristics_ch1.1: figo stage: 3///characteristics_ch1.2: grade: III///characteristics_ch1.3: histological type: serous ovca///characteristics_ch1.4: residual tumor: 0///characteristics_ch1.5: overall survival time: 22///characteristics_ch1.6: overall survival event: 0///molecule_ch1: total RNA///extract_protocol_ch1: Total cellular RNA was isolated from tumor tissue, using the Qiagen Rneasy Mini Kit.///label_ch1: biotin///label_protocol_ch1: cDNA was synthesised from 5 g total RNA by reverse transcription, synthesis of biotin-labeled cRNA was performed using the BioArray High Yield RNA Transcription kit.///taxid_ch1: 9606///hyb_protocol: The fragmented cRNA was hybridised to HGU133 arrays at 45 C in a hybridization oven for 16 hr.///scan_protocol: Chip scanning was done with an Affymetrix Gene Array Scanner G2500A.///description: frozen tissue sample///data_processing: Signals and detection calls were calculated with the R package affy according to the standard MAS 5.0 protocol of the chip manufacturer.///platform_id: GPL96///contact_name: Jan,,Budczies///contact_email: [email protected]///contact_department: Institute of Pathology///contact_institute: Charite - Universitaetsmedizin Berlin///contact_address: Chariteplatz 2///contact_city: Berlin///contact_zip.postal_code: 10117///contact_country: Germany///contact_web_link: http://www.charite.de/ch/patho///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM368nnn/GSM368714/GSM368714.cel.gz///data_row_count: 22283
1
title: ovarian cancer: O55///geo_accession: GSM368715///status: Public on Feb 09 2009///submission_date: Feb 09 2009///last_update_date: Aug 24 2010///type: RNA///channel_count: 1///source_name_ch1: ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: frozen tumor///characteristics_ch1.1: figo stage: 3///characteristics_ch1.2: grade: III///characteristics_ch1.3: histological type: serous ovca///characteristics_ch1.4: residual tumor: 1///characteristics_ch1.5: overall survival time: 36///characteristics_ch1.6: overall survival event: 0///molecule_ch1: total RNA///extract_protocol_ch1: Total cellular RNA was isolated from tumor tissue, using the Qiagen Rneasy Mini Kit.///label_ch1: biotin///label_protocol_ch1: cDNA was synthesised from 5 g total RNA by reverse transcription, synthesis of biotin-labeled cRNA was performed using the BioArray High Yield RNA Transcription kit.///taxid_ch1: 9606///hyb_protocol: The fragmented cRNA was hybridised to HGU133 arrays at 45 C in a hybridization oven for 16 hr.///scan_protocol: Chip scanning was done with an Affymetrix Gene Array Scanner G2500A.///description: frozen tissue sample///data_processing: Signals and detection calls were calculated with the R package affy according to the standard MAS 5.0 protocol of the chip manufacturer.///platform_id: GPL96///contact_name: Jan,,Budczies///contact_email: [email protected]///contact_department: Institute of Pathology///contact_institute: Charite - Universitaetsmedizin Berlin///contact_address: Chariteplatz 2///contact_city: Berlin///contact_zip.postal_code: 10117///contact_country: Germany///contact_web_link: http://www.charite.de/ch/patho///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM368nnn/GSM368715/GSM368715.cel.gz///data_row_count: 22283
1
title: ovarian cancer: O56///geo_accession: GSM368716///status: Public on Feb 09 2009///submission_date: Feb 09 2009///last_update_date: Aug 24 2010///type: RNA///channel_count: 1///source_name_ch1: ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: frozen tumor///characteristics_ch1.1: figo stage: 3///characteristics_ch1.2: grade: II///characteristics_ch1.3: histological type: serous ovca///characteristics_ch1.4: residual tumor: 0///characteristics_ch1.5: overall survival time: 35///characteristics_ch1.6: overall survival event: 0///molecule_ch1: total RNA///extract_protocol_ch1: Total cellular RNA was isolated from tumor tissue, using the Qiagen Rneasy Mini Kit.///label_ch1: biotin///label_protocol_ch1: cDNA was synthesised from 5 g total RNA by reverse transcription, synthesis of biotin-labeled cRNA was performed using the BioArray High Yield RNA Transcription kit.///taxid_ch1: 9606///hyb_protocol: The fragmented cRNA was hybridised to HGU133 arrays at 45 C in a hybridization oven for 16 hr.///scan_protocol: Chip scanning was done with an Affymetrix Gene Array Scanner G2500A.///description: frozen tissue sample///data_processing: Signals and detection calls were calculated with the R package affy according to the standard MAS 5.0 protocol of the chip manufacturer.///platform_id: GPL96///contact_name: Jan,,Budczies///contact_email: [email protected]///contact_department: Institute of Pathology///contact_institute: Charite - Universitaetsmedizin Berlin///contact_address: Chariteplatz 2///contact_city: Berlin///contact_zip.postal_code: 10117///contact_country: Germany///contact_web_link: http://www.charite.de/ch/patho///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM368nnn/GSM368716/GSM368716.cel.gz///data_row_count: 22283
1
title: ovarian cancer: O57///geo_accession: GSM368717///status: Public on Feb 09 2009///submission_date: Feb 09 2009///last_update_date: Aug 24 2010///type: RNA///channel_count: 1///source_name_ch1: ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: frozen tumor///characteristics_ch1.1: figo stage: 3///characteristics_ch1.2: grade: II///characteristics_ch1.3: histological type: serous ovca///characteristics_ch1.4: residual tumor: 0///characteristics_ch1.5: overall survival time: 34///characteristics_ch1.6: overall survival event: 0///molecule_ch1: total RNA///extract_protocol_ch1: Total cellular RNA was isolated from tumor tissue, using the Qiagen Rneasy Mini Kit.///label_ch1: biotin///label_protocol_ch1: cDNA was synthesised from 5 g total RNA by reverse transcription, synthesis of biotin-labeled cRNA was performed using the BioArray High Yield RNA Transcription kit.///taxid_ch1: 9606///hyb_protocol: The fragmented cRNA was hybridised to HGU133 arrays at 45 C in a hybridization oven for 16 hr.///scan_protocol: Chip scanning was done with an Affymetrix Gene Array Scanner G2500A.///description: frozen tissue sample///data_processing: Signals and detection calls were calculated with the R package affy according to the standard MAS 5.0 protocol of the chip manufacturer.///platform_id: GPL96///contact_name: Jan,,Budczies///contact_email: [email protected]///contact_department: Institute of Pathology///contact_institute: Charite - Universitaetsmedizin Berlin///contact_address: Chariteplatz 2///contact_city: Berlin///contact_zip.postal_code: 10117///contact_country: Germany///contact_web_link: http://www.charite.de/ch/patho///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM368nnn/GSM368717/GSM368717.cel.gz///data_row_count: 22283
1
title: ovarian cancer: O58///geo_accession: GSM368718///status: Public on Feb 09 2009///submission_date: Feb 09 2009///last_update_date: Aug 24 2010///type: RNA///channel_count: 1///source_name_ch1: ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: frozen tumor///characteristics_ch1.1: figo stage: 3///characteristics_ch1.2: grade: III///characteristics_ch1.3: histological type: sarcomatoid///characteristics_ch1.4: residual tumor: 1///characteristics_ch1.5: overall survival time: 34///characteristics_ch1.6: overall survival event: 0///molecule_ch1: total RNA///extract_protocol_ch1: Total cellular RNA was isolated from tumor tissue, using the Qiagen Rneasy Mini Kit.///label_ch1: biotin///label_protocol_ch1: cDNA was synthesised from 5 g total RNA by reverse transcription, synthesis of biotin-labeled cRNA was performed using the BioArray High Yield RNA Transcription kit.///taxid_ch1: 9606///hyb_protocol: The fragmented cRNA was hybridised to HGU133 arrays at 45 C in a hybridization oven for 16 hr.///scan_protocol: Chip scanning was done with an Affymetrix Gene Array Scanner G2500A.///description: frozen tissue sample///data_processing: Signals and detection calls were calculated with the R package affy according to the standard MAS 5.0 protocol of the chip manufacturer.///platform_id: GPL96///contact_name: Jan,,Budczies///contact_email: [email protected]///contact_department: Institute of Pathology///contact_institute: Charite - Universitaetsmedizin Berlin///contact_address: Chariteplatz 2///contact_city: Berlin///contact_zip.postal_code: 10117///contact_country: Germany///contact_web_link: http://www.charite.de/ch/patho///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM368nnn/GSM368718/GSM368718.cel.gz///data_row_count: 22283
1
title: ovarian cancer: O59///geo_accession: GSM368719///status: Public on Feb 09 2009///submission_date: Feb 09 2009///last_update_date: Aug 24 2010///type: RNA///channel_count: 1///source_name_ch1: ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: frozen tumor///characteristics_ch1.1: figo stage: 3///characteristics_ch1.2: grade: II///characteristics_ch1.3: histological type: serous ovca///characteristics_ch1.4: residual tumor: 0///characteristics_ch1.5: overall survival time: 23///characteristics_ch1.6: overall survival event: 0///molecule_ch1: total RNA///extract_protocol_ch1: Total cellular RNA was isolated from tumor tissue, using the Qiagen Rneasy Mini Kit.///label_ch1: biotin///label_protocol_ch1: cDNA was synthesised from 5 g total RNA by reverse transcription, synthesis of biotin-labeled cRNA was performed using the BioArray High Yield RNA Transcription kit.///taxid_ch1: 9606///hyb_protocol: The fragmented cRNA was hybridised to HGU133 arrays at 45 C in a hybridization oven for 16 hr.///scan_protocol: Chip scanning was done with an Affymetrix Gene Array Scanner G2500A.///description: frozen tissue sample///data_processing: Signals and detection calls were calculated with the R package affy according to the standard MAS 5.0 protocol of the chip manufacturer.///platform_id: GPL96///contact_name: Jan,,Budczies///contact_email: [email protected]///contact_department: Institute of Pathology///contact_institute: Charite - Universitaetsmedizin Berlin///contact_address: Chariteplatz 2///contact_city: Berlin///contact_zip.postal_code: 10117///contact_country: Germany///contact_web_link: http://www.charite.de/ch/patho///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM368nnn/GSM368719/GSM368719.cel.gz///data_row_count: 22283
1
title: ovarian cancer: O5///geo_accession: GSM368665///status: Public on Feb 09 2009///submission_date: Feb 09 2009///last_update_date: Aug 24 2010///type: RNA///channel_count: 1///source_name_ch1: ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: frozen tumor///characteristics_ch1.1: figo stage: 3c///characteristics_ch1.2: grade: III///characteristics_ch1.3: histological type: serous ovca///characteristics_ch1.4: residual tumor: 1///characteristics_ch1.5: overall survival time: 46///characteristics_ch1.6: overall survival event: 0///molecule_ch1: total RNA///extract_protocol_ch1: Total cellular RNA was isolated from tumor tissue, using the Qiagen Rneasy Mini Kit.///label_ch1: biotin///label_protocol_ch1: cDNA was synthesised from 5 g total RNA by reverse transcription, synthesis of biotin-labeled cRNA was performed using the BioArray High Yield RNA Transcription kit.///taxid_ch1: 9606///hyb_protocol: The fragmented cRNA was hybridised to HGU133 arrays at 45 C in a hybridization oven for 16 hr.///scan_protocol: Chip scanning was done with an Affymetrix Gene Array Scanner G2500A.///description: frozen tissue sample///data_processing: Signals and detection calls were calculated with the R package affy according to the standard MAS 5.0 protocol of the chip manufacturer.///platform_id: GPL96///contact_name: Jan,,Budczies///contact_email: [email protected]///contact_department: Institute of Pathology///contact_institute: Charite - Universitaetsmedizin Berlin///contact_address: Chariteplatz 2///contact_city: Berlin///contact_zip.postal_code: 10117///contact_country: Germany///contact_web_link: http://www.charite.de/ch/patho///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM368nnn/GSM368665/GSM368665.cel.gz///data_row_count: 22283
1
title: ovarian cancer: O60///geo_accession: GSM368720///status: Public on Feb 09 2009///submission_date: Feb 09 2009///last_update_date: Aug 24 2010///type: RNA///channel_count: 1///source_name_ch1: ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: frozen tumor///characteristics_ch1.1: figo stage: 3///characteristics_ch1.2: grade: III///characteristics_ch1.3: histological type: serous ovca///characteristics_ch1.4: residual tumor: 0///characteristics_ch1.5: overall survival time: 24///characteristics_ch1.6: overall survival event: 0///molecule_ch1: total RNA///extract_protocol_ch1: Total cellular RNA was isolated from tumor tissue, using the Qiagen Rneasy Mini Kit.///label_ch1: biotin///label_protocol_ch1: cDNA was synthesised from 5 g total RNA by reverse transcription, synthesis of biotin-labeled cRNA was performed using the BioArray High Yield RNA Transcription kit.///taxid_ch1: 9606///hyb_protocol: The fragmented cRNA was hybridised to HGU133 arrays at 45 C in a hybridization oven for 16 hr.///scan_protocol: Chip scanning was done with an Affymetrix Gene Array Scanner G2500A.///description: frozen tissue sample///data_processing: Signals and detection calls were calculated with the R package affy according to the standard MAS 5.0 protocol of the chip manufacturer.///platform_id: GPL96///contact_name: Jan,,Budczies///contact_email: [email protected]///contact_department: Institute of Pathology///contact_institute: Charite - Universitaetsmedizin Berlin///contact_address: Chariteplatz 2///contact_city: Berlin///contact_zip.postal_code: 10117///contact_country: Germany///contact_web_link: http://www.charite.de/ch/patho///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM368nnn/GSM368720/GSM368720.cel.gz///data_row_count: 22283
1
title: ovarian cancer: O61///geo_accession: GSM368721///status: Public on Feb 09 2009///submission_date: Feb 09 2009///last_update_date: Aug 24 2010///type: RNA///channel_count: 1///source_name_ch1: ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: frozen tumor///characteristics_ch1.1: figo stage: 3///characteristics_ch1.2: grade: III///characteristics_ch1.3: histological type: serous ovca///characteristics_ch1.4: residual tumor: 0///characteristics_ch1.5: overall survival time: 25///characteristics_ch1.6: overall survival event: 0///molecule_ch1: total RNA///extract_protocol_ch1: Total cellular RNA was isolated from tumor tissue, using the Qiagen Rneasy Mini Kit.///label_ch1: biotin///label_protocol_ch1: cDNA was synthesised from 5 g total RNA by reverse transcription, synthesis of biotin-labeled cRNA was performed using the BioArray High Yield RNA Transcription kit.///taxid_ch1: 9606///hyb_protocol: The fragmented cRNA was hybridised to HGU133 arrays at 45 C in a hybridization oven for 16 hr.///scan_protocol: Chip scanning was done with an Affymetrix Gene Array Scanner G2500A.///description: frozen tissue sample///data_processing: Signals and detection calls were calculated with the R package affy according to the standard MAS 5.0 protocol of the chip manufacturer.///platform_id: GPL96///contact_name: Jan,,Budczies///contact_email: [email protected]///contact_department: Institute of Pathology///contact_institute: Charite - Universitaetsmedizin Berlin///contact_address: Chariteplatz 2///contact_city: Berlin///contact_zip.postal_code: 10117///contact_country: Germany///contact_web_link: http://www.charite.de/ch/patho///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM368nnn/GSM368721/GSM368721.cel.gz///data_row_count: 22283
1
title: ovarian cancer: O62///geo_accession: GSM368722///status: Public on Feb 09 2009///submission_date: Feb 09 2009///last_update_date: Aug 24 2010///type: RNA///channel_count: 1///source_name_ch1: ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: frozen tumor///characteristics_ch1.1: figo stage: 3///characteristics_ch1.2: grade: III///characteristics_ch1.3: histological type: serous ovca///characteristics_ch1.4: residual tumor: 0///characteristics_ch1.5: overall survival time: 25///characteristics_ch1.6: overall survival event: 0///molecule_ch1: total RNA///extract_protocol_ch1: Total cellular RNA was isolated from tumor tissue, using the Qiagen Rneasy Mini Kit.///label_ch1: biotin///label_protocol_ch1: cDNA was synthesised from 5 g total RNA by reverse transcription, synthesis of biotin-labeled cRNA was performed using the BioArray High Yield RNA Transcription kit.///taxid_ch1: 9606///hyb_protocol: The fragmented cRNA was hybridised to HGU133 arrays at 45 C in a hybridization oven for 16 hr.///scan_protocol: Chip scanning was done with an Affymetrix Gene Array Scanner G2500A.///description: frozen tissue sample///data_processing: Signals and detection calls were calculated with the R package affy according to the standard MAS 5.0 protocol of the chip manufacturer.///platform_id: GPL96///contact_name: Jan,,Budczies///contact_email: [email protected]///contact_department: Institute of Pathology///contact_institute: Charite - Universitaetsmedizin Berlin///contact_address: Chariteplatz 2///contact_city: Berlin///contact_zip.postal_code: 10117///contact_country: Germany///contact_web_link: http://www.charite.de/ch/patho///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM368nnn/GSM368722/GSM368722.cel.gz///data_row_count: 22283
1
title: ovarian cancer: O63///geo_accession: GSM368723///status: Public on Feb 09 2009///submission_date: Feb 09 2009///last_update_date: Aug 24 2010///type: RNA///channel_count: 1///source_name_ch1: ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: frozen tumor///characteristics_ch1.1: figo stage: 3///characteristics_ch1.2: grade: III///characteristics_ch1.3: histological type: serous ovca///characteristics_ch1.4: residual tumor: 0///characteristics_ch1.5: overall survival time: 21///characteristics_ch1.6: overall survival event: 0///molecule_ch1: total RNA///extract_protocol_ch1: Total cellular RNA was isolated from tumor tissue, using the Qiagen Rneasy Mini Kit.///label_ch1: biotin///label_protocol_ch1: cDNA was synthesised from 5 g total RNA by reverse transcription, synthesis of biotin-labeled cRNA was performed using the BioArray High Yield RNA Transcription kit.///taxid_ch1: 9606///hyb_protocol: The fragmented cRNA was hybridised to HGU133 arrays at 45 C in a hybridization oven for 16 hr.///scan_protocol: Chip scanning was done with an Affymetrix Gene Array Scanner G2500A.///description: frozen tissue sample///data_processing: Signals and detection calls were calculated with the R package affy according to the standard MAS 5.0 protocol of the chip manufacturer.///platform_id: GPL96///contact_name: Jan,,Budczies///contact_email: [email protected]///contact_department: Institute of Pathology///contact_institute: Charite - Universitaetsmedizin Berlin///contact_address: Chariteplatz 2///contact_city: Berlin///contact_zip.postal_code: 10117///contact_country: Germany///contact_web_link: http://www.charite.de/ch/patho///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM368nnn/GSM368723/GSM368723.cel.gz///data_row_count: 22283
1
title: ovarian cancer: O64///geo_accession: GSM368724///status: Public on Feb 09 2009///submission_date: Feb 09 2009///last_update_date: Aug 24 2010///type: RNA///channel_count: 1///source_name_ch1: ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: frozen tumor///characteristics_ch1.1: figo stage: 3///characteristics_ch1.2: grade: III///characteristics_ch1.3: histological type: serous ovca///characteristics_ch1.4: residual tumor: 1///characteristics_ch1.5: overall survival time: 12///characteristics_ch1.6: overall survival event: 1///molecule_ch1: total RNA///extract_protocol_ch1: Total cellular RNA was isolated from tumor tissue, using the Qiagen Rneasy Mini Kit.///label_ch1: biotin///label_protocol_ch1: cDNA was synthesised from 5 g total RNA by reverse transcription, synthesis of biotin-labeled cRNA was performed using the BioArray High Yield RNA Transcription kit.///taxid_ch1: 9606///hyb_protocol: The fragmented cRNA was hybridised to HGU133 arrays at 45 C in a hybridization oven for 16 hr.///scan_protocol: Chip scanning was done with an Affymetrix Gene Array Scanner G2500A.///description: frozen tissue sample///data_processing: Signals and detection calls were calculated with the R package affy according to the standard MAS 5.0 protocol of the chip manufacturer.///platform_id: GPL96///contact_name: Jan,,Budczies///contact_email: [email protected]///contact_department: Institute of Pathology///contact_institute: Charite - Universitaetsmedizin Berlin///contact_address: Chariteplatz 2///contact_city: Berlin///contact_zip.postal_code: 10117///contact_country: Germany///contact_web_link: http://www.charite.de/ch/patho///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM368nnn/GSM368724/GSM368724.cel.gz///data_row_count: 22283
1
title: ovarian cancer: O65///geo_accession: GSM368725///status: Public on Feb 09 2009///submission_date: Feb 09 2009///last_update_date: Aug 24 2010///type: RNA///channel_count: 1///source_name_ch1: ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: frozen tumor///characteristics_ch1.1: figo stage: 3///characteristics_ch1.2: grade: III///characteristics_ch1.3: histological type: serous ovca///characteristics_ch1.4: residual tumor: 0///characteristics_ch1.5: overall survival time: 13///characteristics_ch1.6: overall survival event: 1///molecule_ch1: total RNA///extract_protocol_ch1: Total cellular RNA was isolated from tumor tissue, using the Qiagen Rneasy Mini Kit.///label_ch1: biotin///label_protocol_ch1: cDNA was synthesised from 5 g total RNA by reverse transcription, synthesis of biotin-labeled cRNA was performed using the BioArray High Yield RNA Transcription kit.///taxid_ch1: 9606///hyb_protocol: The fragmented cRNA was hybridised to HGU133 arrays at 45 C in a hybridization oven for 16 hr.///scan_protocol: Chip scanning was done with an Affymetrix Gene Array Scanner G2500A.///description: frozen tissue sample///data_processing: Signals and detection calls were calculated with the R package affy according to the standard MAS 5.0 protocol of the chip manufacturer.///platform_id: GPL96///contact_name: Jan,,Budczies///contact_email: [email protected]///contact_department: Institute of Pathology///contact_institute: Charite - Universitaetsmedizin Berlin///contact_address: Chariteplatz 2///contact_city: Berlin///contact_zip.postal_code: 10117///contact_country: Germany///contact_web_link: http://www.charite.de/ch/patho///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM368nnn/GSM368725/GSM368725.cel.gz///data_row_count: 22283
1
title: ovarian cancer: O66///geo_accession: GSM368726///status: Public on Feb 09 2009///submission_date: Feb 09 2009///last_update_date: Aug 24 2010///type: RNA///channel_count: 1///source_name_ch1: ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: frozen tumor///characteristics_ch1.1: figo stage: 3///characteristics_ch1.2: grade: III///characteristics_ch1.3: histological type: serous ovca///characteristics_ch1.4: residual tumor: 0///characteristics_ch1.5: overall survival time: 7///characteristics_ch1.6: overall survival event: 0///molecule_ch1: total RNA///extract_protocol_ch1: Total cellular RNA was isolated from tumor tissue, using the Qiagen Rneasy Mini Kit.///label_ch1: biotin///label_protocol_ch1: cDNA was synthesised from 5 g total RNA by reverse transcription, synthesis of biotin-labeled cRNA was performed using the BioArray High Yield RNA Transcription kit.///taxid_ch1: 9606///hyb_protocol: The fragmented cRNA was hybridised to HGU133 arrays at 45 C in a hybridization oven for 16 hr.///scan_protocol: Chip scanning was done with an Affymetrix Gene Array Scanner G2500A.///description: frozen tissue sample///data_processing: Signals and detection calls were calculated with the R package affy according to the standard MAS 5.0 protocol of the chip manufacturer.///platform_id: GPL96///contact_name: Jan,,Budczies///contact_email: [email protected]///contact_department: Institute of Pathology///contact_institute: Charite - Universitaetsmedizin Berlin///contact_address: Chariteplatz 2///contact_city: Berlin///contact_zip.postal_code: 10117///contact_country: Germany///contact_web_link: http://www.charite.de/ch/patho///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM368nnn/GSM368726/GSM368726.cel.gz///data_row_count: 22283
1
title: ovarian cancer: O67///geo_accession: GSM368727///status: Public on Feb 09 2009///submission_date: Feb 09 2009///last_update_date: Aug 24 2010///type: RNA///channel_count: 1///source_name_ch1: ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: frozen tumor///characteristics_ch1.1: figo stage: 3///characteristics_ch1.2: grade: II///characteristics_ch1.3: histological type: serous ovca///characteristics_ch1.4: residual tumor: 0///characteristics_ch1.5: overall survival time: 10///characteristics_ch1.6: overall survival event: 0///molecule_ch1: total RNA///extract_protocol_ch1: Total cellular RNA was isolated from tumor tissue, using the Qiagen Rneasy Mini Kit.///label_ch1: biotin///label_protocol_ch1: cDNA was synthesised from 5 g total RNA by reverse transcription, synthesis of biotin-labeled cRNA was performed using the BioArray High Yield RNA Transcription kit.///taxid_ch1: 9606///hyb_protocol: The fragmented cRNA was hybridised to HGU133 arrays at 45 C in a hybridization oven for 16 hr.///scan_protocol: Chip scanning was done with an Affymetrix Gene Array Scanner G2500A.///description: frozen tissue sample///data_processing: Signals and detection calls were calculated with the R package affy according to the standard MAS 5.0 protocol of the chip manufacturer.///platform_id: GPL96///contact_name: Jan,,Budczies///contact_email: [email protected]///contact_department: Institute of Pathology///contact_institute: Charite - Universitaetsmedizin Berlin///contact_address: Chariteplatz 2///contact_city: Berlin///contact_zip.postal_code: 10117///contact_country: Germany///contact_web_link: http://www.charite.de/ch/patho///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM368nnn/GSM368727/GSM368727.cel.gz///data_row_count: 22283
1
title: ovarian cancer: O68///geo_accession: GSM368728///status: Public on Feb 09 2009///submission_date: Feb 09 2009///last_update_date: Aug 24 2010///type: RNA///channel_count: 1///source_name_ch1: ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: frozen tumor///characteristics_ch1.1: figo stage: 3///characteristics_ch1.2: grade: III///characteristics_ch1.3: histological type: serous ovca///characteristics_ch1.4: residual tumor: 1///characteristics_ch1.5: overall survival time: 20///characteristics_ch1.6: overall survival event: 1///molecule_ch1: total RNA///extract_protocol_ch1: Total cellular RNA was isolated from tumor tissue, using the Qiagen Rneasy Mini Kit.///label_ch1: biotin///label_protocol_ch1: cDNA was synthesised from 5 g total RNA by reverse transcription, synthesis of biotin-labeled cRNA was performed using the BioArray High Yield RNA Transcription kit.///taxid_ch1: 9606///hyb_protocol: The fragmented cRNA was hybridised to HGU133 arrays at 45 C in a hybridization oven for 16 hr.///scan_protocol: Chip scanning was done with an Affymetrix Gene Array Scanner G2500A.///description: frozen tissue sample///data_processing: Signals and detection calls were calculated with the R package affy according to the standard MAS 5.0 protocol of the chip manufacturer.///platform_id: GPL96///contact_name: Jan,,Budczies///contact_email: [email protected]///contact_department: Institute of Pathology///contact_institute: Charite - Universitaetsmedizin Berlin///contact_address: Chariteplatz 2///contact_city: Berlin///contact_zip.postal_code: 10117///contact_country: Germany///contact_web_link: http://www.charite.de/ch/patho///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM368nnn/GSM368728/GSM368728.cel.gz///data_row_count: 22283
1
title: ovarian cancer: O69///geo_accession: GSM368729///status: Public on Feb 09 2009///submission_date: Feb 09 2009///last_update_date: Aug 24 2010///type: RNA///channel_count: 1///source_name_ch1: ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: frozen tumor///characteristics_ch1.1: figo stage: 3///characteristics_ch1.2: grade: II///characteristics_ch1.3: histological type: serous ovca///characteristics_ch1.4: residual tumor: 0///characteristics_ch1.5: overall survival time: 58///characteristics_ch1.6: overall survival event: 0///molecule_ch1: total RNA///extract_protocol_ch1: Total cellular RNA was isolated from tumor tissue, using the Qiagen Rneasy Mini Kit.///label_ch1: biotin///label_protocol_ch1: cDNA was synthesised from 5 g total RNA by reverse transcription, synthesis of biotin-labeled cRNA was performed using the BioArray High Yield RNA Transcription kit.///taxid_ch1: 9606///hyb_protocol: The fragmented cRNA was hybridised to HGU133 arrays at 45 C in a hybridization oven for 16 hr.///scan_protocol: Chip scanning was done with an Affymetrix Gene Array Scanner G2500A.///description: frozen tissue sample///data_processing: Signals and detection calls were calculated with the R package affy according to the standard MAS 5.0 protocol of the chip manufacturer.///platform_id: GPL96///contact_name: Jan,,Budczies///contact_email: [email protected]///contact_department: Institute of Pathology///contact_institute: Charite - Universitaetsmedizin Berlin///contact_address: Chariteplatz 2///contact_city: Berlin///contact_zip.postal_code: 10117///contact_country: Germany///contact_web_link: http://www.charite.de/ch/patho///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM368nnn/GSM368729/GSM368729.cel.gz///data_row_count: 22283
1
title: ovarian cancer: O6///geo_accession: GSM368666///status: Public on Feb 09 2009///submission_date: Feb 09 2009///last_update_date: Aug 24 2010///type: RNA///channel_count: 1///source_name_ch1: ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: frozen tumor///characteristics_ch1.1: figo stage: 3c///characteristics_ch1.2: grade: II///characteristics_ch1.3: histological type: serous ovca///characteristics_ch1.4: residual tumor: 0///characteristics_ch1.5: overall survival time: 37///characteristics_ch1.6: overall survival event: 0///molecule_ch1: total RNA///extract_protocol_ch1: Total cellular RNA was isolated from tumor tissue, using the Qiagen Rneasy Mini Kit.///label_ch1: biotin///label_protocol_ch1: cDNA was synthesised from 5 g total RNA by reverse transcription, synthesis of biotin-labeled cRNA was performed using the BioArray High Yield RNA Transcription kit.///taxid_ch1: 9606///hyb_protocol: The fragmented cRNA was hybridised to HGU133 arrays at 45 C in a hybridization oven for 16 hr.///scan_protocol: Chip scanning was done with an Affymetrix Gene Array Scanner G2500A.///description: frozen tissue sample///data_processing: Signals and detection calls were calculated with the R package affy according to the standard MAS 5.0 protocol of the chip manufacturer.///platform_id: GPL96///contact_name: Jan,,Budczies///contact_email: [email protected]///contact_department: Institute of Pathology///contact_institute: Charite - Universitaetsmedizin Berlin///contact_address: Chariteplatz 2///contact_city: Berlin///contact_zip.postal_code: 10117///contact_country: Germany///contact_web_link: http://www.charite.de/ch/patho///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM368nnn/GSM368666/GSM368666.cel.gz///data_row_count: 22283
1
title: ovarian cancer: O70///geo_accession: GSM368730///status: Public on Feb 09 2009///submission_date: Feb 09 2009///last_update_date: Aug 24 2010///type: RNA///channel_count: 1///source_name_ch1: ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: frozen tumor///characteristics_ch1.1: figo stage: 3///characteristics_ch1.2: grade: II///characteristics_ch1.3: histological type: serous ovca///characteristics_ch1.4: residual tumor: 1///characteristics_ch1.5: overall survival time: 13///characteristics_ch1.6: overall survival event: 1///molecule_ch1: total RNA///extract_protocol_ch1: Total cellular RNA was isolated from tumor tissue, using the Qiagen Rneasy Mini Kit.///label_ch1: biotin///label_protocol_ch1: cDNA was synthesised from 5 g total RNA by reverse transcription, synthesis of biotin-labeled cRNA was performed using the BioArray High Yield RNA Transcription kit.///taxid_ch1: 9606///hyb_protocol: The fragmented cRNA was hybridised to HGU133 arrays at 45 C in a hybridization oven for 16 hr.///scan_protocol: Chip scanning was done with an Affymetrix Gene Array Scanner G2500A.///description: frozen tissue sample///data_processing: Signals and detection calls were calculated with the R package affy according to the standard MAS 5.0 protocol of the chip manufacturer.///platform_id: GPL96///contact_name: Jan,,Budczies///contact_email: [email protected]///contact_department: Institute of Pathology///contact_institute: Charite - Universitaetsmedizin Berlin///contact_address: Chariteplatz 2///contact_city: Berlin///contact_zip.postal_code: 10117///contact_country: Germany///contact_web_link: http://www.charite.de/ch/patho///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM368nnn/GSM368730/GSM368730.cel.gz///data_row_count: 22283
1
title: ovarian cancer: O71///geo_accession: GSM368731///status: Public on Feb 09 2009///submission_date: Feb 09 2009///last_update_date: Aug 24 2010///type: RNA///channel_count: 1///source_name_ch1: ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: frozen tumor///characteristics_ch1.1: figo stage: 3///characteristics_ch1.2: grade: III///characteristics_ch1.3: histological type: serous ovca///characteristics_ch1.4: residual tumor: 1///characteristics_ch1.5: overall survival time: 8///characteristics_ch1.6: overall survival event: 1///molecule_ch1: total RNA///extract_protocol_ch1: Total cellular RNA was isolated from tumor tissue, using the Qiagen Rneasy Mini Kit.///label_ch1: biotin///label_protocol_ch1: cDNA was synthesised from 5 g total RNA by reverse transcription, synthesis of biotin-labeled cRNA was performed using the BioArray High Yield RNA Transcription kit.///taxid_ch1: 9606///hyb_protocol: The fragmented cRNA was hybridised to HGU133 arrays at 45 C in a hybridization oven for 16 hr.///scan_protocol: Chip scanning was done with an Affymetrix Gene Array Scanner G2500A.///description: frozen tissue sample///data_processing: Signals and detection calls were calculated with the R package affy according to the standard MAS 5.0 protocol of the chip manufacturer.///platform_id: GPL96///contact_name: Jan,,Budczies///contact_email: [email protected]///contact_department: Institute of Pathology///contact_institute: Charite - Universitaetsmedizin Berlin///contact_address: Chariteplatz 2///contact_city: Berlin///contact_zip.postal_code: 10117///contact_country: Germany///contact_web_link: http://www.charite.de/ch/patho///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM368nnn/GSM368731/GSM368731.cel.gz///data_row_count: 22283
1
title: ovarian cancer: O72///geo_accession: GSM368732///status: Public on Feb 09 2009///submission_date: Feb 09 2009///last_update_date: Aug 24 2010///type: RNA///channel_count: 1///source_name_ch1: ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: frozen tumor///characteristics_ch1.1: figo stage: 3///characteristics_ch1.2: grade: III///characteristics_ch1.3: histological type: serous ovca///characteristics_ch1.4: residual tumor: 0///characteristics_ch1.5: overall survival time: 15///characteristics_ch1.6: overall survival event: 1///molecule_ch1: total RNA///extract_protocol_ch1: Total cellular RNA was isolated from tumor tissue, using the Qiagen Rneasy Mini Kit.///label_ch1: biotin///label_protocol_ch1: cDNA was synthesised from 5 g total RNA by reverse transcription, synthesis of biotin-labeled cRNA was performed using the BioArray High Yield RNA Transcription kit.///taxid_ch1: 9606///hyb_protocol: The fragmented cRNA was hybridised to HGU133 arrays at 45 C in a hybridization oven for 16 hr.///scan_protocol: Chip scanning was done with an Affymetrix Gene Array Scanner G2500A.///description: frozen tissue sample///data_processing: Signals and detection calls were calculated with the R package affy according to the standard MAS 5.0 protocol of the chip manufacturer.///platform_id: GPL96///contact_name: Jan,,Budczies///contact_email: [email protected]///contact_department: Institute of Pathology///contact_institute: Charite - Universitaetsmedizin Berlin///contact_address: Chariteplatz 2///contact_city: Berlin///contact_zip.postal_code: 10117///contact_country: Germany///contact_web_link: http://www.charite.de/ch/patho///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM368nnn/GSM368732/GSM368732.cel.gz///data_row_count: 22283
1
title: ovarian cancer: O73///geo_accession: GSM368733///status: Public on Feb 09 2009///submission_date: Feb 09 2009///last_update_date: Aug 24 2010///type: RNA///channel_count: 1///source_name_ch1: ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: frozen tumor///characteristics_ch1.1: figo stage: 3///characteristics_ch1.2: grade: III///characteristics_ch1.3: histological type: undifferentiated ovca///characteristics_ch1.4: residual tumor: 1///characteristics_ch1.5: overall survival time: 27///characteristics_ch1.6: overall survival event: 0///molecule_ch1: total RNA///extract_protocol_ch1: Total cellular RNA was isolated from tumor tissue, using the Qiagen Rneasy Mini Kit.///label_ch1: biotin///label_protocol_ch1: cDNA was synthesised from 5 g total RNA by reverse transcription, synthesis of biotin-labeled cRNA was performed using the BioArray High Yield RNA Transcription kit.///taxid_ch1: 9606///hyb_protocol: The fragmented cRNA was hybridised to HGU133 arrays at 45 C in a hybridization oven for 16 hr.///scan_protocol: Chip scanning was done with an Affymetrix Gene Array Scanner G2500A.///description: frozen tissue sample///data_processing: Signals and detection calls were calculated with the R package affy according to the standard MAS 5.0 protocol of the chip manufacturer.///platform_id: GPL96///contact_name: Jan,,Budczies///contact_email: [email protected]///contact_department: Institute of Pathology///contact_institute: Charite - Universitaetsmedizin Berlin///contact_address: Chariteplatz 2///contact_city: Berlin///contact_zip.postal_code: 10117///contact_country: Germany///contact_web_link: http://www.charite.de/ch/patho///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM368nnn/GSM368733/GSM368733.cel.gz///data_row_count: 22283
1
title: ovarian cancer: O74///geo_accession: GSM368734///status: Public on Feb 09 2009///submission_date: Feb 09 2009///last_update_date: Aug 24 2010///type: RNA///channel_count: 1///source_name_ch1: ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: frozen tumor///characteristics_ch1.1: figo stage: 3///characteristics_ch1.2: grade: III///characteristics_ch1.3: histological type: serous ovca///characteristics_ch1.4: residual tumor: 0///characteristics_ch1.5: overall survival time: 23///characteristics_ch1.6: overall survival event: 0///molecule_ch1: total RNA///extract_protocol_ch1: Total cellular RNA was isolated from tumor tissue, using the Qiagen Rneasy Mini Kit.///label_ch1: biotin///label_protocol_ch1: cDNA was synthesised from 5 g total RNA by reverse transcription, synthesis of biotin-labeled cRNA was performed using the BioArray High Yield RNA Transcription kit.///taxid_ch1: 9606///hyb_protocol: The fragmented cRNA was hybridised to HGU133 arrays at 45 C in a hybridization oven for 16 hr.///scan_protocol: Chip scanning was done with an Affymetrix Gene Array Scanner G2500A.///description: frozen tissue sample///data_processing: Signals and detection calls were calculated with the R package affy according to the standard MAS 5.0 protocol of the chip manufacturer.///platform_id: GPL96///contact_name: Jan,,Budczies///contact_email: [email protected]///contact_department: Institute of Pathology///contact_institute: Charite - Universitaetsmedizin Berlin///contact_address: Chariteplatz 2///contact_city: Berlin///contact_zip.postal_code: 10117///contact_country: Germany///contact_web_link: http://www.charite.de/ch/patho///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM368nnn/GSM368734/GSM368734.cel.gz///data_row_count: 22283
1
title: ovarian cancer: O75///geo_accession: GSM368735///status: Public on Feb 09 2009///submission_date: Feb 09 2009///last_update_date: Aug 24 2010///type: RNA///channel_count: 1///source_name_ch1: ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: frozen tumor///characteristics_ch1.1: figo stage: 3///characteristics_ch1.2: grade: II///characteristics_ch1.3: histological type: serous ovca///characteristics_ch1.4: residual tumor: 0///characteristics_ch1.5: overall survival time: 29///characteristics_ch1.6: overall survival event: 0///molecule_ch1: total RNA///extract_protocol_ch1: Total cellular RNA was isolated from tumor tissue, using the Qiagen Rneasy Mini Kit.///label_ch1: biotin///label_protocol_ch1: cDNA was synthesised from 5 g total RNA by reverse transcription, synthesis of biotin-labeled cRNA was performed using the BioArray High Yield RNA Transcription kit.///taxid_ch1: 9606///hyb_protocol: The fragmented cRNA was hybridised to HGU133 arrays at 45 C in a hybridization oven for 16 hr.///scan_protocol: Chip scanning was done with an Affymetrix Gene Array Scanner G2500A.///description: frozen tissue sample///data_processing: Signals and detection calls were calculated with the R package affy according to the standard MAS 5.0 protocol of the chip manufacturer.///platform_id: GPL96///contact_name: Jan,,Budczies///contact_email: [email protected]///contact_department: Institute of Pathology///contact_institute: Charite - Universitaetsmedizin Berlin///contact_address: Chariteplatz 2///contact_city: Berlin///contact_zip.postal_code: 10117///contact_country: Germany///contact_web_link: http://www.charite.de/ch/patho///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM368nnn/GSM368735/GSM368735.cel.gz///data_row_count: 22283
1
title: ovarian cancer: O76///geo_accession: GSM368736///status: Public on Feb 09 2009///submission_date: Feb 09 2009///last_update_date: Aug 24 2010///type: RNA///channel_count: 1///source_name_ch1: ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: frozen tumor///characteristics_ch1.1: figo stage: 3///characteristics_ch1.2: grade: III///characteristics_ch1.3: histological type: serous ovca///characteristics_ch1.4: residual tumor: 0///characteristics_ch1.5: overall survival time: 25///characteristics_ch1.6: overall survival event: 0///molecule_ch1: total RNA///extract_protocol_ch1: Total cellular RNA was isolated from tumor tissue, using the Qiagen Rneasy Mini Kit.///label_ch1: biotin///label_protocol_ch1: cDNA was synthesised from 5 g total RNA by reverse transcription, synthesis of biotin-labeled cRNA was performed using the BioArray High Yield RNA Transcription kit.///taxid_ch1: 9606///hyb_protocol: The fragmented cRNA was hybridised to HGU133 arrays at 45 C in a hybridization oven for 16 hr.///scan_protocol: Chip scanning was done with an Affymetrix Gene Array Scanner G2500A.///description: frozen tissue sample///data_processing: Signals and detection calls were calculated with the R package affy according to the standard MAS 5.0 protocol of the chip manufacturer.///platform_id: GPL96///contact_name: Jan,,Budczies///contact_email: [email protected]///contact_department: Institute of Pathology///contact_institute: Charite - Universitaetsmedizin Berlin///contact_address: Chariteplatz 2///contact_city: Berlin///contact_zip.postal_code: 10117///contact_country: Germany///contact_web_link: http://www.charite.de/ch/patho///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM368nnn/GSM368736/GSM368736.cel.gz///data_row_count: 22283
1
title: ovarian cancer: O77///geo_accession: GSM368737///status: Public on Feb 09 2009///submission_date: Feb 09 2009///last_update_date: Aug 24 2010///type: RNA///channel_count: 1///source_name_ch1: ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: frozen tumor///characteristics_ch1.1: figo stage: 3///characteristics_ch1.2: grade: III///characteristics_ch1.3: histological type: serous ovca///characteristics_ch1.4: residual tumor: 1///characteristics_ch1.5: overall survival time: 20///characteristics_ch1.6: overall survival event: 0///molecule_ch1: total RNA///extract_protocol_ch1: Total cellular RNA was isolated from tumor tissue, using the Qiagen Rneasy Mini Kit.///label_ch1: biotin///label_protocol_ch1: cDNA was synthesised from 5 g total RNA by reverse transcription, synthesis of biotin-labeled cRNA was performed using the BioArray High Yield RNA Transcription kit.///taxid_ch1: 9606///hyb_protocol: The fragmented cRNA was hybridised to HGU133 arrays at 45 C in a hybridization oven for 16 hr.///scan_protocol: Chip scanning was done with an Affymetrix Gene Array Scanner G2500A.///description: frozen tissue sample///data_processing: Signals and detection calls were calculated with the R package affy according to the standard MAS 5.0 protocol of the chip manufacturer.///platform_id: GPL96///contact_name: Jan,,Budczies///contact_email: [email protected]///contact_department: Institute of Pathology///contact_institute: Charite - Universitaetsmedizin Berlin///contact_address: Chariteplatz 2///contact_city: Berlin///contact_zip.postal_code: 10117///contact_country: Germany///contact_web_link: http://www.charite.de/ch/patho///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM368nnn/GSM368737/GSM368737.cel.gz///data_row_count: 22283
1
title: ovarian cancer: O78///geo_accession: GSM368738///status: Public on Feb 09 2009///submission_date: Feb 09 2009///last_update_date: Aug 24 2010///type: RNA///channel_count: 1///source_name_ch1: ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: frozen tumor///characteristics_ch1.1: figo stage: 3///characteristics_ch1.2: grade: II///characteristics_ch1.3: histological type: serous ovca///characteristics_ch1.4: residual tumor: 1///characteristics_ch1.5: overall survival time: 23///characteristics_ch1.6: overall survival event: 0///molecule_ch1: total RNA///extract_protocol_ch1: Total cellular RNA was isolated from tumor tissue, using the Qiagen Rneasy Mini Kit.///label_ch1: biotin///label_protocol_ch1: cDNA was synthesised from 5 g total RNA by reverse transcription, synthesis of biotin-labeled cRNA was performed using the BioArray High Yield RNA Transcription kit.///taxid_ch1: 9606///hyb_protocol: The fragmented cRNA was hybridised to HGU133 arrays at 45 C in a hybridization oven for 16 hr.///scan_protocol: Chip scanning was done with an Affymetrix Gene Array Scanner G2500A.///description: frozen tissue sample///data_processing: Signals and detection calls were calculated with the R package affy according to the standard MAS 5.0 protocol of the chip manufacturer.///platform_id: GPL96///contact_name: Jan,,Budczies///contact_email: [email protected]///contact_department: Institute of Pathology///contact_institute: Charite - Universitaetsmedizin Berlin///contact_address: Chariteplatz 2///contact_city: Berlin///contact_zip.postal_code: 10117///contact_country: Germany///contact_web_link: http://www.charite.de/ch/patho///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM368nnn/GSM368738/GSM368738.cel.gz///data_row_count: 22283
1
title: ovarian cancer: O79///geo_accession: GSM368739///status: Public on Feb 09 2009///submission_date: Feb 09 2009///last_update_date: Aug 24 2010///type: RNA///channel_count: 1///source_name_ch1: ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: frozen tumor///characteristics_ch1.1: figo stage: 3///characteristics_ch1.2: grade: II///characteristics_ch1.3: histological type: serous ovca///characteristics_ch1.4: residual tumor: 0///characteristics_ch1.5: overall survival time: 24///characteristics_ch1.6: overall survival event: 0///molecule_ch1: total RNA///extract_protocol_ch1: Total cellular RNA was isolated from tumor tissue, using the Qiagen Rneasy Mini Kit.///label_ch1: biotin///label_protocol_ch1: cDNA was synthesised from 5 g total RNA by reverse transcription, synthesis of biotin-labeled cRNA was performed using the BioArray High Yield RNA Transcription kit.///taxid_ch1: 9606///hyb_protocol: The fragmented cRNA was hybridised to HGU133 arrays at 45 C in a hybridization oven for 16 hr.///scan_protocol: Chip scanning was done with an Affymetrix Gene Array Scanner G2500A.///description: frozen tissue sample///data_processing: Signals and detection calls were calculated with the R package affy according to the standard MAS 5.0 protocol of the chip manufacturer.///platform_id: GPL96///contact_name: Jan,,Budczies///contact_email: [email protected]///contact_department: Institute of Pathology///contact_institute: Charite - Universitaetsmedizin Berlin///contact_address: Chariteplatz 2///contact_city: Berlin///contact_zip.postal_code: 10117///contact_country: Germany///contact_web_link: http://www.charite.de/ch/patho///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM368nnn/GSM368739/GSM368739.cel.gz///data_row_count: 22283
1
title: ovarian cancer: O7///geo_accession: GSM368667///status: Public on Feb 09 2009///submission_date: Feb 09 2009///last_update_date: Aug 24 2010///type: RNA///channel_count: 1///source_name_ch1: ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: frozen tumor///characteristics_ch1.1: figo stage: 1a///characteristics_ch1.2: grade: III///characteristics_ch1.3: histological type: serous ovca///characteristics_ch1.4: residual tumor: 0///characteristics_ch1.5: overall survival time: 36///characteristics_ch1.6: overall survival event: 0///molecule_ch1: total RNA///extract_protocol_ch1: Total cellular RNA was isolated from tumor tissue, using the Qiagen Rneasy Mini Kit.///label_ch1: biotin///label_protocol_ch1: cDNA was synthesised from 5 g total RNA by reverse transcription, synthesis of biotin-labeled cRNA was performed using the BioArray High Yield RNA Transcription kit.///taxid_ch1: 9606///hyb_protocol: The fragmented cRNA was hybridised to HGU133 arrays at 45 C in a hybridization oven for 16 hr.///scan_protocol: Chip scanning was done with an Affymetrix Gene Array Scanner G2500A.///description: frozen tissue sample///data_processing: Signals and detection calls were calculated with the R package affy according to the standard MAS 5.0 protocol of the chip manufacturer.///platform_id: GPL96///contact_name: Jan,,Budczies///contact_email: [email protected]///contact_department: Institute of Pathology///contact_institute: Charite - Universitaetsmedizin Berlin///contact_address: Chariteplatz 2///contact_city: Berlin///contact_zip.postal_code: 10117///contact_country: Germany///contact_web_link: http://www.charite.de/ch/patho///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM368nnn/GSM368667/GSM368667.cel.gz///data_row_count: 22283
1
title: ovarian cancer: O80///geo_accession: GSM368740///status: Public on Feb 09 2009///submission_date: Feb 09 2009///last_update_date: Aug 24 2010///type: RNA///channel_count: 1///source_name_ch1: ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: frozen tumor///characteristics_ch1.1: figo stage: 3///characteristics_ch1.2: grade: II///characteristics_ch1.3: histological type: serous ovca///characteristics_ch1.4: residual tumor: 1///characteristics_ch1.5: overall survival time: 21///characteristics_ch1.6: overall survival event: 0///molecule_ch1: total RNA///extract_protocol_ch1: Total cellular RNA was isolated from tumor tissue, using the Qiagen Rneasy Mini Kit.///label_ch1: biotin///label_protocol_ch1: cDNA was synthesised from 5 g total RNA by reverse transcription, synthesis of biotin-labeled cRNA was performed using the BioArray High Yield RNA Transcription kit.///taxid_ch1: 9606///hyb_protocol: The fragmented cRNA was hybridised to HGU133 arrays at 45 C in a hybridization oven for 16 hr.///scan_protocol: Chip scanning was done with an Affymetrix Gene Array Scanner G2500A.///description: frozen tissue sample///data_processing: Signals and detection calls were calculated with the R package affy according to the standard MAS 5.0 protocol of the chip manufacturer.///platform_id: GPL96///contact_name: Jan,,Budczies///contact_email: [email protected]///contact_department: Institute of Pathology///contact_institute: Charite - Universitaetsmedizin Berlin///contact_address: Chariteplatz 2///contact_city: Berlin///contact_zip.postal_code: 10117///contact_country: Germany///contact_web_link: http://www.charite.de/ch/patho///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM368nnn/GSM368740/GSM368740.cel.gz///data_row_count: 22283
1
title: ovarian cancer: O8///geo_accession: GSM368668///status: Public on Feb 09 2009///submission_date: Feb 09 2009///last_update_date: Aug 24 2010///type: RNA///channel_count: 1///source_name_ch1: ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: frozen tumor///characteristics_ch1.1: figo stage: 3c///characteristics_ch1.2: grade: III///characteristics_ch1.3: histological type: serous ovca///characteristics_ch1.4: residual tumor: 0///characteristics_ch1.5: overall survival time: 12///characteristics_ch1.6: overall survival event: 0///molecule_ch1: total RNA///extract_protocol_ch1: Total cellular RNA was isolated from tumor tissue, using the Qiagen Rneasy Mini Kit.///label_ch1: biotin///label_protocol_ch1: cDNA was synthesised from 5 g total RNA by reverse transcription, synthesis of biotin-labeled cRNA was performed using the BioArray High Yield RNA Transcription kit.///taxid_ch1: 9606///hyb_protocol: The fragmented cRNA was hybridised to HGU133 arrays at 45 C in a hybridization oven for 16 hr.///scan_protocol: Chip scanning was done with an Affymetrix Gene Array Scanner G2500A.///description: frozen tissue sample///data_processing: Signals and detection calls were calculated with the R package affy according to the standard MAS 5.0 protocol of the chip manufacturer.///platform_id: GPL96///contact_name: Jan,,Budczies///contact_email: [email protected]///contact_department: Institute of Pathology///contact_institute: Charite - Universitaetsmedizin Berlin///contact_address: Chariteplatz 2///contact_city: Berlin///contact_zip.postal_code: 10117///contact_country: Germany///contact_web_link: http://www.charite.de/ch/patho///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM368nnn/GSM368668/GSM368668.cel.gz///data_row_count: 22283
1
title: ovarian cancer: O9///geo_accession: GSM368669///status: Public on Feb 09 2009///submission_date: Feb 09 2009///last_update_date: Aug 24 2010///type: RNA///channel_count: 1///source_name_ch1: ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: frozen tumor///characteristics_ch1.1: figo stage: 1a///characteristics_ch1.2: grade: I///characteristics_ch1.3: histological type: endometr ovca///characteristics_ch1.4: residual tumor: 0///characteristics_ch1.5: overall survival time: 70///characteristics_ch1.6: overall survival event: 0///molecule_ch1: total RNA///extract_protocol_ch1: Total cellular RNA was isolated from tumor tissue, using the Qiagen Rneasy Mini Kit.///label_ch1: biotin///label_protocol_ch1: cDNA was synthesised from 5 g total RNA by reverse transcription, synthesis of biotin-labeled cRNA was performed using the BioArray High Yield RNA Transcription kit.///taxid_ch1: 9606///hyb_protocol: The fragmented cRNA was hybridised to HGU133 arrays at 45 C in a hybridization oven for 16 hr.///scan_protocol: Chip scanning was done with an Affymetrix Gene Array Scanner G2500A.///description: frozen tissue sample///data_processing: Signals and detection calls were calculated with the R package affy according to the standard MAS 5.0 protocol of the chip manufacturer.///platform_id: GPL96///contact_name: Jan,,Budczies///contact_email: [email protected]///contact_department: Institute of Pathology///contact_institute: Charite - Universitaetsmedizin Berlin///contact_address: Chariteplatz 2///contact_city: Berlin///contact_zip.postal_code: 10117///contact_country: Germany///contact_web_link: http://www.charite.de/ch/patho///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM368nnn/GSM368669/GSM368669.cel.gz///data_row_count: 22283
1
duplicates:
GSE14764.GSE14764_GSM368667 GSE14764.GSE14764_GSM368668
1 1
NA's
78
An expression set
Advanced-stage ovarian cancer patients are generally treated with platinum/taxane-based chemotherapy after primary debulking surgery. However, there is a wide range of outcomes for individual patients. Therefore, the clinicopathological factors alone are insufficient for predicting prognosis. Our aim is to identify a progression-free survival (PFS)-related molecular profile for predicting survival of patients with advanced-stage serous ovarian cancer.Advanced-stage serous ovarian cancer tissues from 110 Japanese patients who underwent primary surgery and platinum/taxane-based chemotherapy were profiled using oligonucleotide microarrays. We selected 88 PFS-related genes by a univariate Cox model (p<0.01) and generated the prognostic index based on 88 PFS-related genes after adjustment of regression coefficients of the respective genes by ridge regression Cox model using 10-fold cross-validation. The prognostic index was independently associated with PFS time compared to other clinical factors in multivariate analysis [hazard ratio (HR), 3.72; 95% confidence interval (CI), 2.66-5.43; p<0.0001]. In an external dataset, multivariate analysis revealed that this prognostic index was significantly correlated with PFS time (HR, 1.54; 95% CI, 1.20-1.98; p = 0.0008). Furthermore, the correlation between the prognostic index and overall survival time was confirmed in the two independent external datasets (log rank test, p = 0.0010 and 0.0008).The prognostic ability of our index based on the 88-gene expression profile in ridge regression Cox hazard model was shown to be independent of other clinical factors in predicting cancer prognosis across two distinct datasets. Further study will be necessary to improve predictive accuracy of the prognostic index toward clinical application for evaluation of the risk of recurrence in patients with advanced-stage serous ovarian cancer.
experimentData(eset):
Experiment data
Experimenter name: Yoshihara K, Tajima A, Yahata T, Kodama S, Fujiwara H, Suzuki M, Onishi Y, Hatae M, Sueyoshi K, Fujiwara H, Kudo Y, Kotera K, Masuzaki H, Tashiro H, Katabuchi H, Inoue I, Tanaka K.Gene expression profile for predicting survival in advanced-stage serous ovarian cancer across two independent datasets. PLoS One. 2010 Mar 12; 5(3):e9615.
Laboratory: Yoshihara, Tanaka 2010
Contact information:
Title: Gene expression profile for predicting survival in advanced-stage serous ovarian cancer across two independent datasets.
URL:
PMIDs: 20300634
Abstract: A 257 word abstract is available. Use 'abstract' method.
Information is available on: preprocessing
notes:
platform_title:
Agilent-012391 Whole Human Genome Oligo Microarray G4112A
platform_shorttitle:
Agilent G4112A
platform_summary:
hgug4112a
platform_manufacturer:
Agilent
platform_distribution:
commercial
platform_accession:
GPL6848
version:
2015-09-22 19:16:49
featureData(eset):
An object of class 'AnnotatedDataFrame'
featureNames: A_23_P100001 A_23_P100011 ... A_32_P99902 (30936 total)
varLabels: probeset gene EntrezGene.ID best_probe
varMetadata: labelDescription
assayData: 30936 features, 110 samples
Platform type:
Overall survival time-to-event summary (in years):
Call: survfit(formula = Surv(time, cens) ~ -1)
n events median 0.95LCL 0.95UCL
110.00 46.00 4.44 4.03 NA
---------------------------
Available sample meta-data:
---------------------------
alt_sample_name:
Serous ovarian cancer 10 Serous ovarian cancer 100 Serous ovarian cancer 104
1 1 1
Serous ovarian cancer 106 Serous ovarian cancer 107 Serous ovarian cancer 108
1 1 1
Serous ovarian cancer 109 Serous ovarian cancer 11 Serous ovarian cancer 110
1 1 1
Serous ovarian cancer 111 Serous ovarian cancer 112 Serous ovarian cancer 113
1 1 1
Serous ovarian cancer 114 Serous ovarian cancer 115 Serous ovarian cancer 116
1 1 1
Serous ovarian cancer 117 Serous ovarian cancer 118 Serous ovarian cancer 119
1 1 1
Serous ovarian cancer 12 Serous ovarian cancer 120 Serous ovarian cancer 122
1 1 1
Serous ovarian cancer 123 Serous ovarian cancer 127 Serous ovarian cancer 129
1 1 1
Serous ovarian cancer 130 Serous ovarian cancer 131 Serous ovarian cancer 132
1 1 1
Serous ovarian cancer 134 Serous ovarian cancer 136 Serous ovarian cancer 137
1 1 1
Serous ovarian cancer 139 Serous ovarian cancer 140 Serous ovarian cancer 143
1 1 1
Serous ovarian cancer 144 Serous ovarian cancer 145 Serous ovarian cancer 146
1 1 1
Serous ovarian cancer 148 Serous ovarian cancer 149 Serous ovarian cancer 15
1 1 1
Serous ovarian cancer 150 Serous ovarian cancer 151 Serous ovarian cancer 154
1 1 1
Serous ovarian cancer 156 Serous ovarian cancer 157 Serous ovarian cancer 16
1 1 1
Serous ovarian cancer 160 Serous ovarian cancer 17 Serous ovarian cancer 171
1 1 1
Serous ovarian cancer 172 Serous ovarian cancer 173 Serous ovarian cancer 174
1 1 1
Serous ovarian cancer 176 Serous ovarian cancer 178 Serous ovarian cancer 18
1 1 1
Serous ovarian cancer 182 Serous ovarian cancer 183 Serous ovarian cancer 184
1 1 1
Serous ovarian cancer 185 Serous ovarian cancer 186 Serous ovarian cancer 2
1 1 1
Serous ovarian cancer 20 Serous ovarian cancer 22 Serous ovarian cancer 23
1 1 1
Serous ovarian cancer 25 Serous ovarian cancer 27 Serous ovarian cancer 31
1 1 1
Serous ovarian cancer 36 Serous ovarian cancer 37 Serous ovarian cancer 38
1 1 1
Serous ovarian cancer 4 Serous ovarian cancer 41 Serous ovarian cancer 42
1 1 1
Serous ovarian cancer 43 Serous ovarian cancer 44 Serous ovarian cancer 45
1 1 1
Serous ovarian cancer 49 Serous ovarian cancer 50 Serous ovarian cancer 51
1 1 1
Serous ovarian cancer 52 Serous ovarian cancer 53 Serous ovarian cancer 54
1 1 1
Serous ovarian cancer 55 Serous ovarian cancer 56 Serous ovarian cancer 57
1 1 1
Serous ovarian cancer 58 Serous ovarian cancer 6 Serous ovarian cancer 60
1 1 1
Serous ovarian cancer 61 Serous ovarian cancer 62 Serous ovarian cancer 64
1 1 1
Serous ovarian cancer 66 Serous ovarian cancer 67 Serous ovarian cancer 68
1 1 1
Serous ovarian cancer 69 Serous ovarian cancer 7 Serous ovarian cancer 72
1 1 1
Serous ovarian cancer 77 Serous ovarian cancer 79 Serous ovarian cancer 80
1 1 1
(Other)
11
sample_type:
tumor
110
histological_type:
ser
110
primarysite:
ov
110
summarygrade:
high low
43 67
summarystage:
late
110
tumorstage:
3 4
93 17
substage:
a b c NA's
6 18 69 17
grade:
1 2 3
26 41 43
pltx:
y
110
tax:
y
110
days_to_tumor_recurrence:
Min. 1st Qu. Median Mean 3rd Qu. Max.
30.0 285.0 510.0 673.9 870.0 2250.0
recurrence_status:
norecurrence recurrence
34 76
days_to_death:
Min. 1st Qu. Median Mean 3rd Qu. Max.
30 660 915 1086 1530 2430
vital_status:
deceased living
46 64
debulking:
optimal suboptimal
57 53
uncurated_author_metadata:
title: Serous ovarian cancer 100///geo_accession: GSM432221///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 3///characteristics_ch1.1: Stage: IV///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 1///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 1///characteristics_ch1.6: death (1): 1///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432221/GSM432221.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 104///geo_accession: GSM432222///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 3///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 24///characteristics_ch1.4: recurrence (1): 0///characteristics_ch1.5: overall survival (m): 24///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432222/GSM432222.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 106///geo_accession: GSM432223///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 15 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 3///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 15///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 26///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432223/GSM432223.txt.gz///data_row_count: 41000///relation: Reanalyzed by: GSM795125
1
title: Serous ovarian cancer 107///geo_accession: GSM432224///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 3///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 17///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 33///characteristics_ch1.6: death (1): 1///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432224/GSM432224.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 108///geo_accession: GSM432225///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 15 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 1///characteristics_ch1.1: Stage: IIIb///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 37///characteristics_ch1.4: recurrence (1): 0///characteristics_ch1.5: overall survival (m): 37///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432225/GSM432225.txt.gz///data_row_count: 41000///relation: Reanalyzed by: GSM795126
1
title: Serous ovarian cancer 109///geo_accession: GSM432226///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 15 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 3///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 7///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 20///characteristics_ch1.6: death (1): 1///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432226/GSM432226.txt.gz///data_row_count: 41000///relation: Reanalyzed by: GSM795127
1
title: Serous ovarian cancer 10///geo_accession: GSM432220///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 3///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 55///characteristics_ch1.4: recurrence (1): 0///characteristics_ch1.5: overall survival (m): 55///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432220/GSM432220.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 110///geo_accession: GSM432228///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 15 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 3///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 60///characteristics_ch1.4: recurrence (1): 0///characteristics_ch1.5: overall survival (m): 60///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432228/GSM432228.txt.gz///data_row_count: 41000///relation: Reanalyzed by: GSM795128
1
title: Serous ovarian cancer 111///geo_accession: GSM432229///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 15 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 2///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 18///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 57///characteristics_ch1.6: death (1): 1///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432229/GSM432229.txt.gz///data_row_count: 41000///relation: Reanalyzed by: GSM795129
1
title: Serous ovarian cancer 112///geo_accession: GSM432230///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 2///characteristics_ch1.1: Stage: IIIa///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 48///characteristics_ch1.4: recurrence (1): 0///characteristics_ch1.5: overall survival (m): 48///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432230/GSM432230.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 113///geo_accession: GSM432231///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 1///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 43///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 69///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432231/GSM432231.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 114///geo_accession: GSM432232///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 1///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 8///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 27///characteristics_ch1.6: death (1): 1///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432232/GSM432232.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 115///geo_accession: GSM432233///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 3///characteristics_ch1.1: Stage: IIIb///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 12///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 69///characteristics_ch1.6: death (1): 1///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432233/GSM432233.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 116///geo_accession: GSM432234///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 1///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 14///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 51///characteristics_ch1.6: death (1): 1///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432234/GSM432234.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 117///geo_accession: GSM432235///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 2///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 17///characteristics_ch1.4: recurrence (1): 0///characteristics_ch1.5: overall survival (m): 17///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432235/GSM432235.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 118///geo_accession: GSM432236///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 2///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 8///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 17///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432236/GSM432236.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 119///geo_accession: GSM432237///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 3///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 17///characteristics_ch1.4: recurrence (1): 0///characteristics_ch1.5: overall survival (m): 17///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432237/GSM432237.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 11///geo_accession: GSM432227///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 2///characteristics_ch1.1: Stage: IIIb///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 46///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 47///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432227/GSM432227.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 120///geo_accession: GSM432239///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 2///characteristics_ch1.1: Stage: IV///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 6///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 52///characteristics_ch1.6: death (1): 1///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432239/GSM432239.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 122///geo_accession: GSM432240///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 2///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 8///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 25///characteristics_ch1.6: death (1): 1///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432240/GSM432240.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 123///geo_accession: GSM432242///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 2///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 15///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 22///characteristics_ch1.6: death (1): 1///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432242/GSM432242.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 127///geo_accession: GSM432243///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 3///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 23///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 53///characteristics_ch1.6: death (1): 1///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432243/GSM432243.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 129///geo_accession: GSM432244///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 3///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 12///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 13///characteristics_ch1.6: death (1): 1///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432244/GSM432244.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 12///geo_accession: GSM432238///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 3///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 8///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 24///characteristics_ch1.6: death (1): 1///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432238/GSM432238.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 130///geo_accession: GSM432245///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 3///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 25///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 79///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432245/GSM432245.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 131///geo_accession: GSM432246///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 1///characteristics_ch1.1: Stage: IIIa///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 74///characteristics_ch1.4: recurrence (1): 0///characteristics_ch1.5: overall survival (m): 74///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432246/GSM432246.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 132///geo_accession: GSM432247///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 3///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 75///characteristics_ch1.4: recurrence (1): 0///characteristics_ch1.5: overall survival (m): 75///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432247/GSM432247.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 134///geo_accession: GSM432248///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 2///characteristics_ch1.1: Stage: IIIa///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 30///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 62///characteristics_ch1.6: death (1): 1///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432248/GSM432248.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 136///geo_accession: GSM432249///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 2///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 64///characteristics_ch1.4: recurrence (1): 0///characteristics_ch1.5: overall survival (m): 64///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432249/GSM432249.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 137///geo_accession: GSM432250///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 3///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 46///characteristics_ch1.4: recurrence (1): 0///characteristics_ch1.5: overall survival (m): 46///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432250/GSM432250.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 139///geo_accession: GSM432251///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 3///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 35///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 44///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432251/GSM432251.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 140///geo_accession: GSM432252///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 3///characteristics_ch1.1: Stage: IV///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 14///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 28///characteristics_ch1.6: death (1): 1///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432252/GSM432252.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 143///geo_accession: GSM432253///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 2///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 6///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 33///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432253/GSM432253.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 144///geo_accession: GSM432254///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 3///characteristics_ch1.1: Stage: IV///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 26///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 31///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432254/GSM432254.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 145///geo_accession: GSM432255///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 3///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 24///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 28///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432255/GSM432255.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 146///geo_accession: GSM432256///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 3///characteristics_ch1.1: Stage: IIIb///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 24///characteristics_ch1.4: recurrence (1): 0///characteristics_ch1.5: overall survival (m): 24///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432256/GSM432256.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 148///geo_accession: GSM432257///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 3///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 15///characteristics_ch1.4: recurrence (1): 0///characteristics_ch1.5: overall survival (m): 15///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432257/GSM432257.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 149///geo_accession: GSM432258///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 2///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 15///characteristics_ch1.4: recurrence (1): 0///characteristics_ch1.5: overall survival (m): 15///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432258/GSM432258.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 150///geo_accession: GSM432260///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 2///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 14///characteristics_ch1.4: recurrence (1): 0///characteristics_ch1.5: overall survival (m): 14///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432260/GSM432260.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 151///geo_accession: GSM432261///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 1///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 13///characteristics_ch1.4: recurrence (1): 0///characteristics_ch1.5: overall survival (m): 13///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432261/GSM432261.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 154///geo_accession: GSM432262///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 2///characteristics_ch1.1: Stage: IIIb///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 9///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 9///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432262/GSM432262.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 156///geo_accession: GSM432263///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 3///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 29///characteristics_ch1.4: recurrence (1): 0///characteristics_ch1.5: overall survival (m): 29///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432263/GSM432263.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 157///geo_accession: GSM432264///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 2///characteristics_ch1.1: Stage: IIIb///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 26///characteristics_ch1.4: recurrence (1): 0///characteristics_ch1.5: overall survival (m): 26///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432264/GSM432264.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 15///geo_accession: GSM432259///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 2///characteristics_ch1.1: Stage: IIIb///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 18///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 49///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432259/GSM432259.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 160///geo_accession: GSM432266///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 2///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 16///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 20///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432266/GSM432266.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 16///geo_accession: GSM432265///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 1///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 13///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 49///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432265/GSM432265.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 171///geo_accession: GSM432268///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 3///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 3///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 15///characteristics_ch1.6: death (1): 1///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432268/GSM432268.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 172///geo_accession: GSM432269///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 3///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 2///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 12///characteristics_ch1.6: death (1): 1///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432269/GSM432269.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 173///geo_accession: GSM432270///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 2///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 5///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 26///characteristics_ch1.6: death (1): 1///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432270/GSM432270.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 174///geo_accession: GSM432271///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 3///characteristics_ch1.1: Stage: IV///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 23///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 41///characteristics_ch1.6: death (1): 1///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432271/GSM432271.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 176///geo_accession: GSM432272///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 3///characteristics_ch1.1: Stage: IV///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 1///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 11///characteristics_ch1.6: death (1): 1///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432272/GSM432272.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 178///geo_accession: GSM432273///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 3///characteristics_ch1.1: Stage: IV///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 17///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 47///characteristics_ch1.6: death (1): 1///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432273/GSM432273.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 17///geo_accession: GSM432267///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 2///characteristics_ch1.1: Stage: IIIb///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 47///characteristics_ch1.4: recurrence (1): 0///characteristics_ch1.5: overall survival (m): 47///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432267/GSM432267.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 182///geo_accession: GSM432275///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 2///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 1///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 1///characteristics_ch1.6: death (1): 1///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432275/GSM432275.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 183///geo_accession: GSM432276///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 2///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 72///characteristics_ch1.4: recurrence (1): 0///characteristics_ch1.5: overall survival (m): 72///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432276/GSM432276.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 184///geo_accession: GSM432277///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 2///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 65///characteristics_ch1.4: recurrence (1): 0///characteristics_ch1.5: overall survival (m): 65///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432277/GSM432277.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 185///geo_accession: GSM432278///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 3///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 20///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 33///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432278/GSM432278.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 186///geo_accession: GSM432279///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 3///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 12///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 29///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432279/GSM432279.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 18///geo_accession: GSM432274///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 1///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 50///characteristics_ch1.4: recurrence (1): 0///characteristics_ch1.5: overall survival (m): 50///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432274/GSM432274.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 20///geo_accession: GSM432281///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 2///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 70///characteristics_ch1.4: recurrence (1): 0///characteristics_ch1.5: overall survival (m): 70///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432281/GSM432281.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 22///geo_accession: GSM432282///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 2///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 15///characteristics_ch1.4: recurrence (1): 0///characteristics_ch1.5: overall survival (m): 15///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432282/GSM432282.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 23///geo_accession: GSM432283///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 2///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 2///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 8///characteristics_ch1.6: death (1): 1///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432283/GSM432283.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 25///geo_accession: GSM432284///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 1///characteristics_ch1.1: Stage: IIIb///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 29///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 80///characteristics_ch1.6: death (1): 1///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432284/GSM432284.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 27///geo_accession: GSM432285///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 1///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 8///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 11///characteristics_ch1.6: death (1): 1///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432285/GSM432285.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 2///geo_accession: GSM432280///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 2///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 18///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 49///characteristics_ch1.6: death (1): 1///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432280/GSM432280.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 31///geo_accession: GSM432286///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 3///characteristics_ch1.1: Stage: IIIb///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 2///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 5///characteristics_ch1.6: death (1): 1///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432286/GSM432286.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 36///geo_accession: GSM432287///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 1///characteristics_ch1.1: Stage: IV///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 23///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 28///characteristics_ch1.6: death (1): 1///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432287/GSM432287.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 37///geo_accession: GSM432288///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 2///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 21///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 25///characteristics_ch1.6: death (1): 1///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432288/GSM432288.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 38///geo_accession: GSM432289///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 2///characteristics_ch1.1: Stage: IIIb///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 15///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 64///characteristics_ch1.6: death (1): 1///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432289/GSM432289.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 41///geo_accession: GSM432291///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 1///characteristics_ch1.1: Stage: IIIb///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 61///characteristics_ch1.4: recurrence (1): 0///characteristics_ch1.5: overall survival (m): 61///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432291/GSM432291.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 42///geo_accession: GSM432292///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 3///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 17///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 46///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432292/GSM432292.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 43///geo_accession: GSM432293///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 2///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 7///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 34///characteristics_ch1.6: death (1): 1///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432293/GSM432293.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 44///geo_accession: GSM432294///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 3///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 4///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 17///characteristics_ch1.6: death (1): 1///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432294/GSM432294.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 45///geo_accession: GSM432295///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 1///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 35///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 39///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432295/GSM432295.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 49///geo_accession: GSM432296///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 2///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 33///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 37///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432296/GSM432296.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 4///geo_accession: GSM432290///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 2///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 2///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 41///characteristics_ch1.6: death (1): 1///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432290/GSM432290.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 50///geo_accession: GSM432297///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 3///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 8///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 33///characteristics_ch1.6: death (1): 1///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432297/GSM432297.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 51///geo_accession: GSM432298///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 2///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 14///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 25///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432298/GSM432298.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 52///geo_accession: GSM432299///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 3///characteristics_ch1.1: Stage: IV///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 4///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 24///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432299/GSM432299.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 53///geo_accession: GSM432300///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 3///characteristics_ch1.1: Stage: IV///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 9///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 23///characteristics_ch1.6: death (1): 1///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432300/GSM432300.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 54///geo_accession: GSM432301///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 1///characteristics_ch1.1: Stage: IIIb///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 30///characteristics_ch1.4: recurrence (1): 0///characteristics_ch1.5: overall survival (m): 30///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432301/GSM432301.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 55///geo_accession: GSM432302///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 3///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 30///characteristics_ch1.4: recurrence (1): 0///characteristics_ch1.5: overall survival (m): 30///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432302/GSM432302.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 56///geo_accession: GSM432303///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 1///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 14///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 29///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432303/GSM432303.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 57///geo_accession: GSM432304///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 3///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 12///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 23///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432304/GSM432304.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 58///geo_accession: GSM432305///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 1///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 13///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 20///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432305/GSM432305.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 60///geo_accession: GSM432307///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 2///characteristics_ch1.1: Stage: IV///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 47///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 81///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432307/GSM432307.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 61///geo_accession: GSM432308///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 1///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 26///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 74///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432308/GSM432308.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 62///geo_accession: GSM432309///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 2///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 11///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 26///characteristics_ch1.6: death (1): 1///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432309/GSM432309.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 64///geo_accession: GSM432310///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 2///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 26///characteristics_ch1.4: recurrence (1): 0///characteristics_ch1.5: overall survival (m): 26///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432310/GSM432310.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 66///geo_accession: GSM432311///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 1///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 19///characteristics_ch1.4: recurrence (1): 0///characteristics_ch1.5: overall survival (m): 19///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432311/GSM432311.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 67///geo_accession: GSM432312///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 1///characteristics_ch1.1: Stage: IIIb///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 22///characteristics_ch1.4: recurrence (1): 0///characteristics_ch1.5: overall survival (m): 22///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432312/GSM432312.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 68///geo_accession: GSM432313///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 1///characteristics_ch1.1: Stage: IIIa///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 22///characteristics_ch1.4: recurrence (1): 0///characteristics_ch1.5: overall survival (m): 22///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432313/GSM432313.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 69///geo_accession: GSM432314///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 1///characteristics_ch1.1: Stage: IIIb///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 21///characteristics_ch1.4: recurrence (1): 0///characteristics_ch1.5: overall survival (m): 21///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432314/GSM432314.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 6///geo_accession: GSM432306///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 3///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 12///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 32///characteristics_ch1.6: death (1): 1///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432306/GSM432306.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 72///geo_accession: GSM432316///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 2///characteristics_ch1.1: Stage: IIIb///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 13///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 26///characteristics_ch1.6: death (1): 1///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432316/GSM432316.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 77///geo_accession: GSM432317///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 3///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 1///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 1///characteristics_ch1.6: death (1): 1///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432317/GSM432317.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 79///geo_accession: GSM432318///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 1///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 16///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 27///characteristics_ch1.6: death (1): 1///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432318/GSM432318.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 7///geo_accession: GSM432315///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 1///characteristics_ch1.1: Stage: IIIa///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 19///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 42///characteristics_ch1.6: death (1): 1///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432315/GSM432315.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 80///geo_accession: GSM432319///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 2///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 12///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 68///characteristics_ch1.6: death (1): 1///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432319/GSM432319.txt.gz///data_row_count: 41000///relation:
1
(Other)
11
An expression set
Advanced stage papillary serous tumors of the ovary are responsible for the majority of ovarian cancer deaths, yet the molecular determinants modulating patient survival are poorly characterized. Here, we identify and validate a prognostic gene expression signature correlating with survival in a series of microdissected serous ovarian tumors. Independent evaluation confirmed the association of a prognostic gene microfibril-associated glycoprotein 2 (MAGP2) with poor prognosis, whereas in vitro mechanistic analyses demonstrated its ability to prolong tumor cell survival and stimulate endothelial cell motility and survival via the alpha(V)beta(3) integrin receptor. Increased MAGP2 expression correlated with microvessel density suggesting a proangiogenic role in vivo. Thus, MAGP2 may serve as a survival-associated target.
experimentData(eset):
Experiment data
Experimenter name: Mok SC, Bonome T, Vathipadiekal V, Bell A, Johnson ME, Wong KK, Park DC, Hao K, Yip DK, Donninger H, Ozbun L, Samimi G, Brady J, Randonovich M, Pise-Masison CA, Barrett JC, Wong WH, Welch WR, Berkowitz RS, Birrer MJ.A gene signature predictive for outcome in advanced ovarian cancer identifies a survival factor: microfibril-associated glycoprotein 2. Cancer Cell. 2009 Dec 8; 16(6):521-32.
Laboratory: Mok, Birrer 2009
Contact information:
Title: A gene signature predictive for outcome in advanced ovarian cancer identifies a survival factor: microfibril-associated glycoprotein 2.
URL:
PMIDs: 19962670
Abstract: A 110 word abstract is available. Use 'abstract' method.
Information is available on: preprocessing
notes:
platform_title:
[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array
platform_shorttitle:
Affymetrix HG-U133Plus2
platform_summary:
hgu133plus2
platform_manufacturer:
Affymetrix|Operon
platform_distribution:
commercial|non-commercial
platform_accession:
GPL570|GPL9216
version:
2015-09-22 19:21:25
featureData(eset):
An object of class 'AnnotatedDataFrame'
featureNames: 1007_s_at 1053_at ... AFFX-HUMISGF3A/M97935_MB_at
(42447 total)
varLabels: probeset gene EntrezGene.ID best_probe
varMetadata: labelDescription
assayData: 42447 features, 63 samples
Platform type:
Overall survival time-to-event summary (in years):
Call: survfit(formula = Surv(time, cens) ~ -1)
10 observations deleted due to missingness
n events median 0.95LCL 0.95UCL
53.00 41.00 2.05 1.48 3.70
---------------------------
Available sample meta-data:
---------------------------
alt_sample_name:
Min. 1st Qu. Median Mean 3rd Qu. Max.
312.0 395.0 694.0 893.3 1040.0 2237.0
sample_type:
healthy tumor
10 53
histological_type:
ser NA's
53 10
primarysite:
ov
63
summarygrade:
high NA's
53 10
summarystage:
late NA's
53 10
tumorstage:
3 NA's
53 10
grade:
3 NA's
53 10
days_to_death:
Min. 1st Qu. Median Mean 3rd Qu. Max. NA's
150 450 630 1212 1440 4500 10
vital_status:
deceased living NA's
41 12 10
debulking:
optimal
63
percent_normal_cells:
0
63
percent_stromal_cells:
0
63
percent_tumor_cells:
100
63
batch:
2004-03-12 2004-04-08 2004-04-09 2004-07-20 2004-08-12 2004-08-13 2004-09-30
20 6 9 11 10 1 6
uncurated_author_metadata:
title: Normal Ovary, 2008///geo_accession: GSM462643///status: Public on Oct 17 2009///submission_date: Oct 16 2009///last_update_date: Jan 19 2011///type: RNA///channel_count: 1///source_name_ch1: normal ovarian surface epithelium (OSE)///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian surface epithelium (OSE)///characteristics_ch1.1: ///characteristics_ch1.2: ///characteristics_ch1.3: ///treatment_protocol_ch1: All specimens were subjected to laser-based microdissection and analyzed as pure, microdissected epithelial cell populations.///molecule_ch1: total RNA///extract_protocol_ch1: RNeasy Micro Kit according to the manufacturers protocol (Qiagen Inc., Valencia, CA).///label_ch1: biotin///label_protocol_ch1: Two rounds of amplification were completed according to standard Affymetrix Two-Cycle Amplification protocol using 25ng of total RNA.///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Arrays were scanned using the laser confocal GeneChip Scanner 3000 (Affymetrix).///description: Gene expression data from normal ovary.///description.1: HOSE2008///data_processing: Low-level analysis included array normalization and estimation of expression level using an invariant set of probe sets to adjust the overall signal level of the arrays to the same level. Next, a model-based PM-only approach established gene expression levels using dChip software. A modified semi-supervised method was applied in two stages: (1) supervised dimension reduction by fitting a univariate Cox model that included a jackknifing step to each gene, so only those genes with a consistently large Cox score were included in the signature. Among 200, 100, or 300 probe sets, 200 yielded an optimally sized predictor; (2) In stage 2, the dimensions of the data set were reduced from 200 to 5 by PC analysis. The number of PCs was set at 5 capturing 90
1
title: Normal Ovary, 2061///geo_accession: GSM462644///status: Public on Oct 17 2009///submission_date: Oct 16 2009///last_update_date: Jan 19 2011///type: RNA///channel_count: 1///source_name_ch1: normal ovarian surface epithelium (OSE)///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian surface epithelium (OSE)///characteristics_ch1.1: ///characteristics_ch1.2: ///characteristics_ch1.3: ///treatment_protocol_ch1: All specimens were subjected to laser-based microdissection and analyzed as pure, microdissected epithelial cell populations.///molecule_ch1: total RNA///extract_protocol_ch1: RNeasy Micro Kit according to the manufacturers protocol (Qiagen Inc., Valencia, CA).///label_ch1: biotin///label_protocol_ch1: Two rounds of amplification were completed according to standard Affymetrix Two-Cycle Amplification protocol using 25ng of total RNA.///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Arrays were scanned using the laser confocal GeneChip Scanner 3000 (Affymetrix).///description: Gene expression data from normal ovary.///description.1: HOSE2061///data_processing: Low-level analysis included array normalization and estimation of expression level using an invariant set of probe sets to adjust the overall signal level of the arrays to the same level. Next, a model-based PM-only approach established gene expression levels using dChip software. A modified semi-supervised method was applied in two stages: (1) supervised dimension reduction by fitting a univariate Cox model that included a jackknifing step to each gene, so only those genes with a consistently large Cox score were included in the signature. Among 200, 100, or 300 probe sets, 200 yielded an optimally sized predictor; (2) In stage 2, the dimensions of the data set were reduced from 200 to 5 by PC analysis. The number of PCs was set at 5 capturing 90
1
title: Normal Ovary, 2064///geo_accession: GSM462645///status: Public on Oct 17 2009///submission_date: Oct 16 2009///last_update_date: Jan 19 2011///type: RNA///channel_count: 1///source_name_ch1: normal ovarian surface epithelium (OSE)///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian surface epithelium (OSE)///characteristics_ch1.1: ///characteristics_ch1.2: ///characteristics_ch1.3: ///treatment_protocol_ch1: All specimens were subjected to laser-based microdissection and analyzed as pure, microdissected epithelial cell populations.///molecule_ch1: total RNA///extract_protocol_ch1: RNeasy Micro Kit according to the manufacturers protocol (Qiagen Inc., Valencia, CA).///label_ch1: biotin///label_protocol_ch1: Two rounds of amplification were completed according to standard Affymetrix Two-Cycle Amplification protocol using 25ng of total RNA.///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Arrays were scanned using the laser confocal GeneChip Scanner 3000 (Affymetrix).///description: Gene expression data from normal ovary.///description.1: HOSE2064///data_processing: Low-level analysis included array normalization and estimation of expression level using an invariant set of probe sets to adjust the overall signal level of the arrays to the same level. Next, a model-based PM-only approach established gene expression levels using dChip software. A modified semi-supervised method was applied in two stages: (1) supervised dimension reduction by fitting a univariate Cox model that included a jackknifing step to each gene, so only those genes with a consistently large Cox score were included in the signature. Among 200, 100, or 300 probe sets, 200 yielded an optimally sized predictor; (2) In stage 2, the dimensions of the data set were reduced from 200 to 5 by PC analysis. The number of PCs was set at 5 capturing 90
1
title: Normal Ovary, 2085///geo_accession: GSM462646///status: Public on Oct 17 2009///submission_date: Oct 16 2009///last_update_date: Jan 19 2011///type: RNA///channel_count: 1///source_name_ch1: normal ovarian surface epithelium (OSE)///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian surface epithelium (OSE)///characteristics_ch1.1: ///characteristics_ch1.2: ///characteristics_ch1.3: ///treatment_protocol_ch1: All specimens were subjected to laser-based microdissection and analyzed as pure, microdissected epithelial cell populations.///molecule_ch1: total RNA///extract_protocol_ch1: RNeasy Micro Kit according to the manufacturers protocol (Qiagen Inc., Valencia, CA).///label_ch1: biotin///label_protocol_ch1: Two rounds of amplification were completed according to standard Affymetrix Two-Cycle Amplification protocol using 25ng of total RNA.///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Arrays were scanned using the laser confocal GeneChip Scanner 3000 (Affymetrix).///description: Gene expression data from normal ovary.///description.1: HOSE2085///data_processing: Low-level analysis included array normalization and estimation of expression level using an invariant set of probe sets to adjust the overall signal level of the arrays to the same level. Next, a model-based PM-only approach established gene expression levels using dChip software. A modified semi-supervised method was applied in two stages: (1) supervised dimension reduction by fitting a univariate Cox model that included a jackknifing step to each gene, so only those genes with a consistently large Cox score were included in the signature. Among 200, 100, or 300 probe sets, 200 yielded an optimally sized predictor; (2) In stage 2, the dimensions of the data set were reduced from 200 to 5 by PC analysis. The number of PCs was set at 5 capturing 90
1
title: Normal Ovary, 2225///geo_accession: GSM462647///status: Public on Oct 17 2009///submission_date: Oct 16 2009///last_update_date: Jan 19 2011///type: RNA///channel_count: 1///source_name_ch1: normal ovarian surface epithelium (OSE)///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian surface epithelium (OSE)///characteristics_ch1.1: ///characteristics_ch1.2: ///characteristics_ch1.3: ///treatment_protocol_ch1: All specimens were subjected to laser-based microdissection and analyzed as pure, microdissected epithelial cell populations.///molecule_ch1: total RNA///extract_protocol_ch1: RNeasy Micro Kit according to the manufacturers protocol (Qiagen Inc., Valencia, CA).///label_ch1: biotin///label_protocol_ch1: Two rounds of amplification were completed according to standard Affymetrix Two-Cycle Amplification protocol using 25ng of total RNA.///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Arrays were scanned using the laser confocal GeneChip Scanner 3000 (Affymetrix).///description: Gene expression data from normal ovary.///description.1: HOSE2225///data_processing: Low-level analysis included array normalization and estimation of expression level using an invariant set of probe sets to adjust the overall signal level of the arrays to the same level. Next, a model-based PM-only approach established gene expression levels using dChip software. A modified semi-supervised method was applied in two stages: (1) supervised dimension reduction by fitting a univariate Cox model that included a jackknifing step to each gene, so only those genes with a consistently large Cox score were included in the signature. Among 200, 100, or 300 probe sets, 200 yielded an optimally sized predictor; (2) In stage 2, the dimensions of the data set were reduced from 200 to 5 by PC analysis. The number of PCs was set at 5 capturing 90
1
title: Normal Ovary, 2226///geo_accession: GSM462648///status: Public on Oct 17 2009///submission_date: Oct 16 2009///last_update_date: Jan 19 2011///type: RNA///channel_count: 1///source_name_ch1: normal ovarian surface epithelium (OSE)///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian surface epithelium (OSE)///characteristics_ch1.1: ///characteristics_ch1.2: ///characteristics_ch1.3: ///treatment_protocol_ch1: All specimens were subjected to laser-based microdissection and analyzed as pure, microdissected epithelial cell populations.///molecule_ch1: total RNA///extract_protocol_ch1: RNeasy Micro Kit according to the manufacturers protocol (Qiagen Inc., Valencia, CA).///label_ch1: biotin///label_protocol_ch1: Two rounds of amplification were completed according to standard Affymetrix Two-Cycle Amplification protocol using 25ng of total RNA.///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Arrays were scanned using the laser confocal GeneChip Scanner 3000 (Affymetrix).///description: Gene expression data from normal ovary.///description.1: HOSE2226///data_processing: Low-level analysis included array normalization and estimation of expression level using an invariant set of probe sets to adjust the overall signal level of the arrays to the same level. Next, a model-based PM-only approach established gene expression levels using dChip software. A modified semi-supervised method was applied in two stages: (1) supervised dimension reduction by fitting a univariate Cox model that included a jackknifing step to each gene, so only those genes with a consistently large Cox score were included in the signature. Among 200, 100, or 300 probe sets, 200 yielded an optimally sized predictor; (2) In stage 2, the dimensions of the data set were reduced from 200 to 5 by PC analysis. The number of PCs was set at 5 capturing 90
1
title: Normal Ovary, 2228///geo_accession: GSM462649///status: Public on Oct 17 2009///submission_date: Oct 16 2009///last_update_date: Jan 19 2011///type: RNA///channel_count: 1///source_name_ch1: normal ovarian surface epithelium (OSE)///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian surface epithelium (OSE)///characteristics_ch1.1: ///characteristics_ch1.2: ///characteristics_ch1.3: ///treatment_protocol_ch1: All specimens were subjected to laser-based microdissection and analyzed as pure, microdissected epithelial cell populations.///molecule_ch1: total RNA///extract_protocol_ch1: RNeasy Micro Kit according to the manufacturers protocol (Qiagen Inc., Valencia, CA).///label_ch1: biotin///label_protocol_ch1: Two rounds of amplification were completed according to standard Affymetrix Two-Cycle Amplification protocol using 25ng of total RNA.///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Arrays were scanned using the laser confocal GeneChip Scanner 3000 (Affymetrix).///description: Gene expression data from normal ovary.///description.1: HOSE2228///data_processing: Low-level analysis included array normalization and estimation of expression level using an invariant set of probe sets to adjust the overall signal level of the arrays to the same level. Next, a model-based PM-only approach established gene expression levels using dChip software. A modified semi-supervised method was applied in two stages: (1) supervised dimension reduction by fitting a univariate Cox model that included a jackknifing step to each gene, so only those genes with a consistently large Cox score were included in the signature. Among 200, 100, or 300 probe sets, 200 yielded an optimally sized predictor; (2) In stage 2, the dimensions of the data set were reduced from 200 to 5 by PC analysis. The number of PCs was set at 5 capturing 90
1
title: Normal Ovary, 2230///geo_accession: GSM462650///status: Public on Oct 17 2009///submission_date: Oct 16 2009///last_update_date: Jan 19 2011///type: RNA///channel_count: 1///source_name_ch1: normal ovarian surface epithelium (OSE)///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian surface epithelium (OSE)///characteristics_ch1.1: ///characteristics_ch1.2: ///characteristics_ch1.3: ///treatment_protocol_ch1: All specimens were subjected to laser-based microdissection and analyzed as pure, microdissected epithelial cell populations.///molecule_ch1: total RNA///extract_protocol_ch1: RNeasy Micro Kit according to the manufacturers protocol (Qiagen Inc., Valencia, CA).///label_ch1: biotin///label_protocol_ch1: Two rounds of amplification were completed according to standard Affymetrix Two-Cycle Amplification protocol using 25ng of total RNA.///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Arrays were scanned using the laser confocal GeneChip Scanner 3000 (Affymetrix).///description: Gene expression data from normal ovary.///description.1: HOSE2230///data_processing: Low-level analysis included array normalization and estimation of expression level using an invariant set of probe sets to adjust the overall signal level of the arrays to the same level. Next, a model-based PM-only approach established gene expression levels using dChip software. A modified semi-supervised method was applied in two stages: (1) supervised dimension reduction by fitting a univariate Cox model that included a jackknifing step to each gene, so only those genes with a consistently large Cox score were included in the signature. Among 200, 100, or 300 probe sets, 200 yielded an optimally sized predictor; (2) In stage 2, the dimensions of the data set were reduced from 200 to 5 by PC analysis. The number of PCs was set at 5 capturing 90
1
title: Normal Ovary, 2234///geo_accession: GSM462651///status: Public on Oct 17 2009///submission_date: Oct 16 2009///last_update_date: Jan 19 2011///type: RNA///channel_count: 1///source_name_ch1: normal ovarian surface epithelium (OSE)///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian surface epithelium (OSE)///characteristics_ch1.1: ///characteristics_ch1.2: ///characteristics_ch1.3: ///treatment_protocol_ch1: All specimens were subjected to laser-based microdissection and analyzed as pure, microdissected epithelial cell populations.///molecule_ch1: total RNA///extract_protocol_ch1: RNeasy Micro Kit according to the manufacturers protocol (Qiagen Inc., Valencia, CA).///label_ch1: biotin///label_protocol_ch1: Two rounds of amplification were completed according to standard Affymetrix Two-Cycle Amplification protocol using 25ng of total RNA.///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Arrays were scanned using the laser confocal GeneChip Scanner 3000 (Affymetrix).///description: Gene expression data from normal ovary.///description.1: HOSE2234///data_processing: Low-level analysis included array normalization and estimation of expression level using an invariant set of probe sets to adjust the overall signal level of the arrays to the same level. Next, a model-based PM-only approach established gene expression levels using dChip software. A modified semi-supervised method was applied in two stages: (1) supervised dimension reduction by fitting a univariate Cox model that included a jackknifing step to each gene, so only those genes with a consistently large Cox score were included in the signature. Among 200, 100, or 300 probe sets, 200 yielded an optimally sized predictor; (2) In stage 2, the dimensions of the data set were reduced from 200 to 5 by PC analysis. The number of PCs was set at 5 capturing 90
1
title: Normal Ovary, 2237///geo_accession: GSM462652///status: Public on Oct 17 2009///submission_date: Oct 16 2009///last_update_date: Jan 19 2011///type: RNA///channel_count: 1///source_name_ch1: normal ovarian surface epithelium (OSE)///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian surface epithelium (OSE)///characteristics_ch1.1: ///characteristics_ch1.2: ///characteristics_ch1.3: ///treatment_protocol_ch1: All specimens were subjected to laser-based microdissection and analyzed as pure, microdissected epithelial cell populations.///molecule_ch1: total RNA///extract_protocol_ch1: RNeasy Micro Kit according to the manufacturers protocol (Qiagen Inc., Valencia, CA).///label_ch1: biotin///label_protocol_ch1: Two rounds of amplification were completed according to standard Affymetrix Two-Cycle Amplification protocol using 25ng of total RNA.///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Arrays were scanned using the laser confocal GeneChip Scanner 3000 (Affymetrix).///description: Gene expression data from normal ovary.///description.1: HOSE2237///data_processing: Low-level analysis included array normalization and estimation of expression level using an invariant set of probe sets to adjust the overall signal level of the arrays to the same level. Next, a model-based PM-only approach established gene expression levels using dChip software. A modified semi-supervised method was applied in two stages: (1) supervised dimension reduction by fitting a univariate Cox model that included a jackknifing step to each gene, so only those genes with a consistently large Cox score were included in the signature. Among 200, 100, or 300 probe sets, 200 yielded an optimally sized predictor; (2) In stage 2, the dimensions of the data set were reduced from 200 to 5 by PC analysis. The number of PCs was set at 5 capturing 90
1
title: Ovarian Tumor, 1109///geo_accession: GSM461390///status: Public on Oct 17 2009///submission_date: Oct 11 2009///last_update_date: Jan 19 2011///type: RNA///channel_count: 1///source_name_ch1: papillary serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: papillary serous ovarian adenocarcinoma///characteristics_ch1.1: tumor stage: late///characteristics_ch1.2: tumor grade: high///characteristics_ch1.3: surv data: 34 (A)///treatment_protocol_ch1: All specimens were subjected to laser-based microdissection and analyzed as pure, microdissected epithelial cell populations.///molecule_ch1: total RNA///extract_protocol_ch1: RNeasy Micro Kit according to the manufacturers protocol (Qiagen Inc., Valencia, CA).///label_ch1: biotin///label_protocol_ch1: Two rounds of amplification were completed according to standard Affymetrix Two-Cycle Amplification protocol using 25ng of total RNA.///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Arrays were scanned using the laser confocal GeneChip Scanner 3000 (Affymetrix).///description: Gene expression data from tumor.///description.1: 1109///data_processing: Low-level analysis included array normalization and estimation of expression level using an invariant set of probe sets to adjust the overall signal level of the arrays to the same level. Next, a model-based PM-only approach established gene expression levels using dChip software. A modified semi-supervised method was applied in two stages: (1) supervised dimension reduction by fitting a univariate Cox model that included a jackknifing step to each gene, so only those genes with a consistently large Cox score were included in the signature. Among 200, 100, or 300 probe sets, 200 yielded an optimally sized predictor; (2) In stage 2, the dimensions of the data set were reduced from 200 to 5 by PC analysis. The number of PCs was set at 5 capturing 90
1
title: Ovarian Tumor, 1214///geo_accession: GSM461391///status: Public on Oct 17 2009///submission_date: Oct 11 2009///last_update_date: Jan 19 2011///type: RNA///channel_count: 1///source_name_ch1: papillary serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: papillary serous ovarian adenocarcinoma///characteristics_ch1.1: tumor stage: late///characteristics_ch1.2: tumor grade: high///characteristics_ch1.3: surv data: 17///treatment_protocol_ch1: All specimens were subjected to laser-based microdissection and analyzed as pure, microdissected epithelial cell populations.///molecule_ch1: total RNA///extract_protocol_ch1: RNeasy Micro Kit according to the manufacturers protocol (Qiagen Inc., Valencia, CA).///label_ch1: biotin///label_protocol_ch1: Two rounds of amplification were completed according to standard Affymetrix Two-Cycle Amplification protocol using 25ng of total RNA.///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Arrays were scanned using the laser confocal GeneChip Scanner 3000 (Affymetrix).///description: Gene expression data from tumor.///description.1: 1214///data_processing: Low-level analysis included array normalization and estimation of expression level using an invariant set of probe sets to adjust the overall signal level of the arrays to the same level. Next, a model-based PM-only approach established gene expression levels using dChip software. A modified semi-supervised method was applied in two stages: (1) supervised dimension reduction by fitting a univariate Cox model that included a jackknifing step to each gene, so only those genes with a consistently large Cox score were included in the signature. Among 200, 100, or 300 probe sets, 200 yielded an optimally sized predictor; (2) In stage 2, the dimensions of the data set were reduced from 200 to 5 by PC analysis. The number of PCs was set at 5 capturing 90
1
title: Ovarian Tumor, 1231///geo_accession: GSM461367///status: Public on Oct 17 2009///submission_date: Oct 11 2009///last_update_date: Jan 19 2011///type: RNA///channel_count: 1///source_name_ch1: papillary serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: papillary serous ovarian adenocarcinoma///characteristics_ch1.1: tumor stage: late///characteristics_ch1.2: tumor grade: high///characteristics_ch1.3: surv data: 15///treatment_protocol_ch1: All specimens were subjected to laser-based microdissection and analyzed as pure, microdissected epithelial cell populations.///molecule_ch1: total RNA///extract_protocol_ch1: RNeasy Micro Kit according to the manufacturers protocol (Qiagen Inc., Valencia, CA).///label_ch1: biotin///label_protocol_ch1: Two rounds of amplification were completed according to standard Affymetrix Two-Cycle Amplification protocol using 25ng of total RNA.///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Arrays were scanned using the laser confocal GeneChip Scanner 3000 (Affymetrix).///description: Gene expression data from tumor.///description.1: 1231///data_processing: Low-level analysis included array normalization and estimation of expression level using an invariant set of probe sets to adjust the overall signal level of the arrays to the same level. Next, a model-based PM-only approach established gene expression levels using dChip software. A modified semi-supervised method was applied in two stages: (1) supervised dimension reduction by fitting a univariate Cox model that included a jackknifing step to each gene, so only those genes with a consistently large Cox score were included in the signature. Among 200, 100, or 300 probe sets, 200 yielded an optimally sized predictor; (2) In stage 2, the dimensions of the data set were reduced from 200 to 5 by PC analysis. The number of PCs was set at 5 capturing 90
1
title: Ovarian Tumor, 1562///geo_accession: GSM461368///status: Public on Oct 17 2009///submission_date: Oct 11 2009///last_update_date: Jan 19 2011///type: RNA///channel_count: 1///source_name_ch1: papillary serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: papillary serous ovarian adenocarcinoma///characteristics_ch1.1: tumor stage: late///characteristics_ch1.2: tumor grade: high///characteristics_ch1.3: surv data: 19 (A)///treatment_protocol_ch1: All specimens were subjected to laser-based microdissection and analyzed as pure, microdissected epithelial cell populations.///molecule_ch1: total RNA///extract_protocol_ch1: RNeasy Micro Kit according to the manufacturers protocol (Qiagen Inc., Valencia, CA).///label_ch1: biotin///label_protocol_ch1: Two rounds of amplification were completed according to standard Affymetrix Two-Cycle Amplification protocol using 25ng of total RNA.///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Arrays were scanned using the laser confocal GeneChip Scanner 3000 (Affymetrix).///description: Gene expression data from tumor.///description.1: 1562///data_processing: Low-level analysis included array normalization and estimation of expression level using an invariant set of probe sets to adjust the overall signal level of the arrays to the same level. Next, a model-based PM-only approach established gene expression levels using dChip software. A modified semi-supervised method was applied in two stages: (1) supervised dimension reduction by fitting a univariate Cox model that included a jackknifing step to each gene, so only those genes with a consistently large Cox score were included in the signature. Among 200, 100, or 300 probe sets, 200 yielded an optimally sized predictor; (2) In stage 2, the dimensions of the data set were reduced from 200 to 5 by PC analysis. The number of PCs was set at 5 capturing 90
1
title: Ovarian Tumor, 1660///geo_accession: GSM461369///status: Public on Oct 17 2009///submission_date: Oct 11 2009///last_update_date: Jan 19 2011///type: RNA///channel_count: 1///source_name_ch1: papillary serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: papillary serous ovarian adenocarcinoma///characteristics_ch1.1: tumor stage: late///characteristics_ch1.2: tumor grade: high///characteristics_ch1.3: surv data: 15 (A)///treatment_protocol_ch1: All specimens were subjected to laser-based microdissection and analyzed as pure, microdissected epithelial cell populations.///molecule_ch1: total RNA///extract_protocol_ch1: RNeasy Micro Kit according to the manufacturers protocol (Qiagen Inc., Valencia, CA).///label_ch1: biotin///label_protocol_ch1: Two rounds of amplification were completed according to standard Affymetrix Two-Cycle Amplification protocol using 25ng of total RNA.///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Arrays were scanned using the laser confocal GeneChip Scanner 3000 (Affymetrix).///description: Gene expression data from tumor.///description.1: 1660///data_processing: Low-level analysis included array normalization and estimation of expression level using an invariant set of probe sets to adjust the overall signal level of the arrays to the same level. Next, a model-based PM-only approach established gene expression levels using dChip software. A modified semi-supervised method was applied in two stages: (1) supervised dimension reduction by fitting a univariate Cox model that included a jackknifing step to each gene, so only those genes with a consistently large Cox score were included in the signature. Among 200, 100, or 300 probe sets, 200 yielded an optimally sized predictor; (2) In stage 2, the dimensions of the data set were reduced from 200 to 5 by PC analysis. The number of PCs was set at 5 capturing 90
1
title: Ovarian Tumor, 1993///geo_accession: GSM461400///status: Public on Oct 17 2009///submission_date: Oct 11 2009///last_update_date: Jan 19 2011///type: RNA///channel_count: 1///source_name_ch1: papillary serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: papillary serous ovarian adenocarcinoma///characteristics_ch1.1: tumor stage: late///characteristics_ch1.2: tumor grade: high///characteristics_ch1.3: surv data: 11 (A)///treatment_protocol_ch1: All specimens were subjected to laser-based microdissection and analyzed as pure, microdissected epithelial cell populations.///molecule_ch1: total RNA///extract_protocol_ch1: RNeasy Micro Kit according to the manufacturers protocol (Qiagen Inc., Valencia, CA).///label_ch1: biotin///label_protocol_ch1: Two rounds of amplification were completed according to standard Affymetrix Two-Cycle Amplification protocol using 25ng of total RNA.///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Arrays were scanned using the laser confocal GeneChip Scanner 3000 (Affymetrix).///description: Gene expression data from tumor.///description.1: 1993///data_processing: Low-level analysis included array normalization and estimation of expression level using an invariant set of probe sets to adjust the overall signal level of the arrays to the same level. Next, a model-based PM-only approach established gene expression levels using dChip software. A modified semi-supervised method was applied in two stages: (1) supervised dimension reduction by fitting a univariate Cox model that included a jackknifing step to each gene, so only those genes with a consistently large Cox score were included in the signature. Among 200, 100, or 300 probe sets, 200 yielded an optimally sized predictor; (2) In stage 2, the dimensions of the data set were reduced from 200 to 5 by PC analysis. The number of PCs was set at 5 capturing 90
1
title: Ovarian Tumor, 312///geo_accession: GSM461379///status: Public on Oct 17 2009///submission_date: Oct 11 2009///last_update_date: Jan 19 2011///type: RNA///channel_count: 1///source_name_ch1: papillary serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: papillary serous ovarian adenocarcinoma///characteristics_ch1.1: tumor stage: late///characteristics_ch1.2: tumor grade: high///characteristics_ch1.3: surv data: 48///treatment_protocol_ch1: All specimens were subjected to laser-based microdissection and analyzed as pure, microdissected epithelial cell populations.///molecule_ch1: total RNA///extract_protocol_ch1: RNeasy Micro Kit according to the manufacturers protocol (Qiagen Inc., Valencia, CA).///label_ch1: biotin///label_protocol_ch1: Two rounds of amplification were completed according to standard Affymetrix Two-Cycle Amplification protocol using 25ng of total RNA.///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Arrays were scanned using the laser confocal GeneChip Scanner 3000 (Affymetrix).///description: Gene expression data from tumor.///description.1: 312///data_processing: Low-level analysis included array normalization and estimation of expression level using an invariant set of probe sets to adjust the overall signal level of the arrays to the same level. Next, a model-based PM-only approach established gene expression levels using dChip software. A modified semi-supervised method was applied in two stages: (1) supervised dimension reduction by fitting a univariate Cox model that included a jackknifing step to each gene, so only those genes with a consistently large Cox score were included in the signature. Among 200, 100, or 300 probe sets, 200 yielded an optimally sized predictor; (2) In stage 2, the dimensions of the data set were reduced from 200 to 5 by PC analysis. The number of PCs was set at 5 capturing 90
1
title: Ovarian Tumor, 317///geo_accession: GSM461348///status: Public on Oct 17 2009///submission_date: Oct 11 2009///last_update_date: Jan 19 2011///type: RNA///channel_count: 1///source_name_ch1: papillary serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: papillary serous ovarian adenocarcinoma///characteristics_ch1.1: tumor stage: late///characteristics_ch1.2: tumor grade: high///characteristics_ch1.3: surv data: 150 (A)///treatment_protocol_ch1: All specimens were subjected to laser-based microdissection and analyzed as pure, microdissected epithelial cell populations.///molecule_ch1: total RNA///extract_protocol_ch1: RNeasy Micro Kit according to the manufacturers protocol (Qiagen Inc., Valencia, CA).///label_ch1: biotin///label_protocol_ch1: Two rounds of amplification were completed according to standard Affymetrix Two-Cycle Amplification protocol using 25ng of total RNA.///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Arrays were scanned using the laser confocal GeneChip Scanner 3000 (Affymetrix).///description: Gene expression data from tumor.///description.1: 317///data_processing: Low-level analysis included array normalization and estimation of expression level using an invariant set of probe sets to adjust the overall signal level of the arrays to the same level. Next, a model-based PM-only approach established gene expression levels using dChip software. A modified semi-supervised method was applied in two stages: (1) supervised dimension reduction by fitting a univariate Cox model that included a jackknifing step to each gene, so only those genes with a consistently large Cox score were included in the signature. Among 200, 100, or 300 probe sets, 200 yielded an optimally sized predictor; (2) In stage 2, the dimensions of the data set were reduced from 200 to 5 by PC analysis. The number of PCs was set at 5 capturing 90
1
title: Ovarian Tumor, 321///geo_accession: GSM461380///status: Public on Oct 17 2009///submission_date: Oct 11 2009///last_update_date: Jan 19 2011///type: RNA///channel_count: 1///source_name_ch1: papillary serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: papillary serous ovarian adenocarcinoma///characteristics_ch1.1: tumor stage: late///characteristics_ch1.2: tumor grade: high///characteristics_ch1.3: surv data: 45///treatment_protocol_ch1: All specimens were subjected to laser-based microdissection and analyzed as pure, microdissected epithelial cell populations.///molecule_ch1: total RNA///extract_protocol_ch1: RNeasy Micro Kit according to the manufacturers protocol (Qiagen Inc., Valencia, CA).///label_ch1: biotin///label_protocol_ch1: Two rounds of amplification were completed according to standard Affymetrix Two-Cycle Amplification protocol using 25ng of total RNA.///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Arrays were scanned using the laser confocal GeneChip Scanner 3000 (Affymetrix).///description: Gene expression data from tumor.///description.1: 321///data_processing: Low-level analysis included array normalization and estimation of expression level using an invariant set of probe sets to adjust the overall signal level of the arrays to the same level. Next, a model-based PM-only approach established gene expression levels using dChip software. A modified semi-supervised method was applied in two stages: (1) supervised dimension reduction by fitting a univariate Cox model that included a jackknifing step to each gene, so only those genes with a consistently large Cox score were included in the signature. Among 200, 100, or 300 probe sets, 200 yielded an optimally sized predictor; (2) In stage 2, the dimensions of the data set were reduced from 200 to 5 by PC analysis. The number of PCs was set at 5 capturing 90
1
title: Ovarian Tumor, 324///geo_accession: GSM461373///status: Public on Oct 17 2009///submission_date: Oct 11 2009///last_update_date: Jan 19 2011///type: RNA///channel_count: 1///source_name_ch1: papillary serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: papillary serous ovarian adenocarcinoma///characteristics_ch1.1: tumor stage: late///characteristics_ch1.2: tumor grade: high///characteristics_ch1.3: surv data: 59///treatment_protocol_ch1: All specimens were subjected to laser-based microdissection and analyzed as pure, microdissected epithelial cell populations.///molecule_ch1: total RNA///extract_protocol_ch1: RNeasy Micro Kit according to the manufacturers protocol (Qiagen Inc., Valencia, CA).///label_ch1: biotin///label_protocol_ch1: Two rounds of amplification were completed according to standard Affymetrix Two-Cycle Amplification protocol using 25ng of total RNA.///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Arrays were scanned using the laser confocal GeneChip Scanner 3000 (Affymetrix).///description: Gene expression data from tumor.///description.1: 324///data_processing: Low-level analysis included array normalization and estimation of expression level using an invariant set of probe sets to adjust the overall signal level of the arrays to the same level. Next, a model-based PM-only approach established gene expression levels using dChip software. A modified semi-supervised method was applied in two stages: (1) supervised dimension reduction by fitting a univariate Cox model that included a jackknifing step to each gene, so only those genes with a consistently large Cox score were included in the signature. Among 200, 100, or 300 probe sets, 200 yielded an optimally sized predictor; (2) In stage 2, the dimensions of the data set were reduced from 200 to 5 by PC analysis. The number of PCs was set at 5 capturing 90
1
title: Ovarian Tumor, 332///geo_accession: GSM461349///status: Public on Oct 17 2009///submission_date: Oct 11 2009///last_update_date: Jan 19 2011///type: RNA///channel_count: 1///source_name_ch1: papillary serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: papillary serous ovarian adenocarcinoma///characteristics_ch1.1: tumor stage: late///characteristics_ch1.2: tumor grade: high///characteristics_ch1.3: surv data: 7///treatment_protocol_ch1: All specimens were subjected to laser-based microdissection and analyzed as pure, microdissected epithelial cell populations.///molecule_ch1: total RNA///extract_protocol_ch1: RNeasy Micro Kit according to the manufacturers protocol (Qiagen Inc., Valencia, CA).///label_ch1: biotin///label_protocol_ch1: Two rounds of amplification were completed according to standard Affymetrix Two-Cycle Amplification protocol using 25ng of total RNA.///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Arrays were scanned using the laser confocal GeneChip Scanner 3000 (Affymetrix).///description: Gene expression data from tumor.///description.1: 332///data_processing: Low-level analysis included array normalization and estimation of expression level using an invariant set of probe sets to adjust the overall signal level of the arrays to the same level. Next, a model-based PM-only approach established gene expression levels using dChip software. A modified semi-supervised method was applied in two stages: (1) supervised dimension reduction by fitting a univariate Cox model that included a jackknifing step to each gene, so only those genes with a consistently large Cox score were included in the signature. Among 200, 100, or 300 probe sets, 200 yielded an optimally sized predictor; (2) In stage 2, the dimensions of the data set were reduced from 200 to 5 by PC analysis. The number of PCs was set at 5 capturing 90
1
title: Ovarian Tumor, 345///geo_accession: GSM461392///status: Public on Oct 17 2009///submission_date: Oct 11 2009///last_update_date: Jan 19 2011///type: RNA///channel_count: 1///source_name_ch1: papillary serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: papillary serous ovarian adenocarcinoma///characteristics_ch1.1: tumor stage: late///characteristics_ch1.2: tumor grade: high///characteristics_ch1.3: surv data: 18///treatment_protocol_ch1: All specimens were subjected to laser-based microdissection and analyzed as pure, microdissected epithelial cell populations.///molecule_ch1: total RNA///extract_protocol_ch1: RNeasy Micro Kit according to the manufacturers protocol (Qiagen Inc., Valencia, CA).///label_ch1: biotin///label_protocol_ch1: Two rounds of amplification were completed according to standard Affymetrix Two-Cycle Amplification protocol using 25ng of total RNA.///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Arrays were scanned using the laser confocal GeneChip Scanner 3000 (Affymetrix).///description: Gene expression data from tumor.///description.1: 345///data_processing: Low-level analysis included array normalization and estimation of expression level using an invariant set of probe sets to adjust the overall signal level of the arrays to the same level. Next, a model-based PM-only approach established gene expression levels using dChip software. A modified semi-supervised method was applied in two stages: (1) supervised dimension reduction by fitting a univariate Cox model that included a jackknifing step to each gene, so only those genes with a consistently large Cox score were included in the signature. Among 200, 100, or 300 probe sets, 200 yielded an optimally sized predictor; (2) In stage 2, the dimensions of the data set were reduced from 200 to 5 by PC analysis. The number of PCs was set at 5 capturing 90
1
title: Ovarian Tumor, 349///geo_accession: GSM461350///status: Public on Oct 17 2009///submission_date: Oct 11 2009///last_update_date: Jan 19 2011///type: RNA///channel_count: 1///source_name_ch1: papillary serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: papillary serous ovarian adenocarcinoma///characteristics_ch1.1: tumor stage: late///characteristics_ch1.2: tumor grade: high///characteristics_ch1.3: surv data: 144 (A)///treatment_protocol_ch1: All specimens were subjected to laser-based microdissection and analyzed as pure, microdissected epithelial cell populations.///molecule_ch1: total RNA///extract_protocol_ch1: RNeasy Micro Kit according to the manufacturers protocol (Qiagen Inc., Valencia, CA).///label_ch1: biotin///label_protocol_ch1: Two rounds of amplification were completed according to standard Affymetrix Two-Cycle Amplification protocol using 25ng of total RNA.///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Arrays were scanned using the laser confocal GeneChip Scanner 3000 (Affymetrix).///description: Gene expression data from tumor.///description.1: 349///data_processing: Low-level analysis included array normalization and estimation of expression level using an invariant set of probe sets to adjust the overall signal level of the arrays to the same level. Next, a model-based PM-only approach established gene expression levels using dChip software. A modified semi-supervised method was applied in two stages: (1) supervised dimension reduction by fitting a univariate Cox model that included a jackknifing step to each gene, so only those genes with a consistently large Cox score were included in the signature. Among 200, 100, or 300 probe sets, 200 yielded an optimally sized predictor; (2) In stage 2, the dimensions of the data set were reduced from 200 to 5 by PC analysis. The number of PCs was set at 5 capturing 90
1
title: Ovarian Tumor, 351///geo_accession: GSM461351///status: Public on Oct 17 2009///submission_date: Oct 11 2009///last_update_date: Jan 19 2011///type: RNA///channel_count: 1///source_name_ch1: papillary serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: papillary serous ovarian adenocarcinoma///characteristics_ch1.1: tumor stage: late///characteristics_ch1.2: tumor grade: high///characteristics_ch1.3: surv data: 142 (A)///treatment_protocol_ch1: All specimens were subjected to laser-based microdissection and analyzed as pure, microdissected epithelial cell populations.///molecule_ch1: total RNA///extract_protocol_ch1: RNeasy Micro Kit according to the manufacturers protocol (Qiagen Inc., Valencia, CA).///label_ch1: biotin///label_protocol_ch1: Two rounds of amplification were completed according to standard Affymetrix Two-Cycle Amplification protocol using 25ng of total RNA.///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Arrays were scanned using the laser confocal GeneChip Scanner 3000 (Affymetrix).///description: Gene expression data from tumor.///description.1: 351///data_processing: Low-level analysis included array normalization and estimation of expression level using an invariant set of probe sets to adjust the overall signal level of the arrays to the same level. Next, a model-based PM-only approach established gene expression levels using dChip software. A modified semi-supervised method was applied in two stages: (1) supervised dimension reduction by fitting a univariate Cox model that included a jackknifing step to each gene, so only those genes with a consistently large Cox score were included in the signature. Among 200, 100, or 300 probe sets, 200 yielded an optimally sized predictor; (2) In stage 2, the dimensions of the data set were reduced from 200 to 5 by PC analysis. The number of PCs was set at 5 capturing 90
1
title: Ovarian Tumor, 358///geo_accession: GSM461393///status: Public on Oct 17 2009///submission_date: Oct 11 2009///last_update_date: Jan 19 2011///type: RNA///channel_count: 1///source_name_ch1: papillary serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: papillary serous ovarian adenocarcinoma///characteristics_ch1.1: tumor stage: late///characteristics_ch1.2: tumor grade: high///characteristics_ch1.3: surv data: 21///treatment_protocol_ch1: All specimens were subjected to laser-based microdissection and analyzed as pure, microdissected epithelial cell populations.///molecule_ch1: total RNA///extract_protocol_ch1: RNeasy Micro Kit according to the manufacturers protocol (Qiagen Inc., Valencia, CA).///label_ch1: biotin///label_protocol_ch1: Two rounds of amplification were completed according to standard Affymetrix Two-Cycle Amplification protocol using 25ng of total RNA.///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Arrays were scanned using the laser confocal GeneChip Scanner 3000 (Affymetrix).///description: Gene expression data from tumor.///description.1: 358///data_processing: Low-level analysis included array normalization and estimation of expression level using an invariant set of probe sets to adjust the overall signal level of the arrays to the same level. Next, a model-based PM-only approach established gene expression levels using dChip software. A modified semi-supervised method was applied in two stages: (1) supervised dimension reduction by fitting a univariate Cox model that included a jackknifing step to each gene, so only those genes with a consistently large Cox score were included in the signature. Among 200, 100, or 300 probe sets, 200 yielded an optimally sized predictor; (2) In stage 2, the dimensions of the data set were reduced from 200 to 5 by PC analysis. The number of PCs was set at 5 capturing 90
1
title: Ovarian Tumor, 367///geo_accession: GSM461381///status: Public on Oct 17 2009///submission_date: Oct 11 2009///last_update_date: Jan 19 2011///type: RNA///channel_count: 1///source_name_ch1: papillary serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: papillary serous ovarian adenocarcinoma///characteristics_ch1.1: tumor stage: late///characteristics_ch1.2: tumor grade: high///characteristics_ch1.3: surv data: 16///treatment_protocol_ch1: All specimens were subjected to laser-based microdissection and analyzed as pure, microdissected epithelial cell populations.///molecule_ch1: total RNA///extract_protocol_ch1: RNeasy Micro Kit according to the manufacturers protocol (Qiagen Inc., Valencia, CA).///label_ch1: biotin///label_protocol_ch1: Two rounds of amplification were completed according to standard Affymetrix Two-Cycle Amplification protocol using 25ng of total RNA.///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Arrays were scanned using the laser confocal GeneChip Scanner 3000 (Affymetrix).///description: Gene expression data from tumor.///description.1: 367///data_processing: Low-level analysis included array normalization and estimation of expression level using an invariant set of probe sets to adjust the overall signal level of the arrays to the same level. Next, a model-based PM-only approach established gene expression levels using dChip software. A modified semi-supervised method was applied in two stages: (1) supervised dimension reduction by fitting a univariate Cox model that included a jackknifing step to each gene, so only those genes with a consistently large Cox score were included in the signature. Among 200, 100, or 300 probe sets, 200 yielded an optimally sized predictor; (2) In stage 2, the dimensions of the data set were reduced from 200 to 5 by PC analysis. The number of PCs was set at 5 capturing 90
1
title: Ovarian Tumor, 377///geo_accession: GSM461374///status: Public on Oct 17 2009///submission_date: Oct 11 2009///last_update_date: Jan 19 2011///type: RNA///channel_count: 1///source_name_ch1: papillary serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: papillary serous ovarian adenocarcinoma///characteristics_ch1.1: tumor stage: late///characteristics_ch1.2: tumor grade: high///characteristics_ch1.3: surv data: 12///treatment_protocol_ch1: All specimens were subjected to laser-based microdissection and analyzed as pure, microdissected epithelial cell populations.///molecule_ch1: total RNA///extract_protocol_ch1: RNeasy Micro Kit according to the manufacturers protocol (Qiagen Inc., Valencia, CA).///label_ch1: biotin///label_protocol_ch1: Two rounds of amplification were completed according to standard Affymetrix Two-Cycle Amplification protocol using 25ng of total RNA.///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Arrays were scanned using the laser confocal GeneChip Scanner 3000 (Affymetrix).///description: Gene expression data from tumor.///description.1: 377///data_processing: Low-level analysis included array normalization and estimation of expression level using an invariant set of probe sets to adjust the overall signal level of the arrays to the same level. Next, a model-based PM-only approach established gene expression levels using dChip software. A modified semi-supervised method was applied in two stages: (1) supervised dimension reduction by fitting a univariate Cox model that included a jackknifing step to each gene, so only those genes with a consistently large Cox score were included in the signature. Among 200, 100, or 300 probe sets, 200 yielded an optimally sized predictor; (2) In stage 2, the dimensions of the data set were reduced from 200 to 5 by PC analysis. The number of PCs was set at 5 capturing 90
1
title: Ovarian Tumor, 380///geo_accession: GSM461375///status: Public on Oct 17 2009///submission_date: Oct 11 2009///last_update_date: Jan 19 2011///type: RNA///channel_count: 1///source_name_ch1: papillary serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: papillary serous ovarian adenocarcinoma///characteristics_ch1.1: tumor stage: late///characteristics_ch1.2: tumor grade: high///characteristics_ch1.3: surv data: 57///treatment_protocol_ch1: All specimens were subjected to laser-based microdissection and analyzed as pure, microdissected epithelial cell populations.///molecule_ch1: total RNA///extract_protocol_ch1: RNeasy Micro Kit according to the manufacturers protocol (Qiagen Inc., Valencia, CA).///label_ch1: biotin///label_protocol_ch1: Two rounds of amplification were completed according to standard Affymetrix Two-Cycle Amplification protocol using 25ng of total RNA.///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Arrays were scanned using the laser confocal GeneChip Scanner 3000 (Affymetrix).///description: Gene expression data from tumor.///description.1: 380///data_processing: Low-level analysis included array normalization and estimation of expression level using an invariant set of probe sets to adjust the overall signal level of the arrays to the same level. Next, a model-based PM-only approach established gene expression levels using dChip software. A modified semi-supervised method was applied in two stages: (1) supervised dimension reduction by fitting a univariate Cox model that included a jackknifing step to each gene, so only those genes with a consistently large Cox score were included in the signature. Among 200, 100, or 300 probe sets, 200 yielded an optimally sized predictor; (2) In stage 2, the dimensions of the data set were reduced from 200 to 5 by PC analysis. The number of PCs was set at 5 capturing 90
1
title: Ovarian Tumor, 386///geo_accession: GSM461352///status: Public on Oct 17 2009///submission_date: Oct 11 2009///last_update_date: Jan 19 2011///type: RNA///channel_count: 1///source_name_ch1: papillary serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: papillary serous ovarian adenocarcinoma///characteristics_ch1.1: tumor stage: late///characteristics_ch1.2: tumor grade: high///characteristics_ch1.3: surv data: 95///treatment_protocol_ch1: All specimens were subjected to laser-based microdissection and analyzed as pure, microdissected epithelial cell populations.///molecule_ch1: total RNA///extract_protocol_ch1: RNeasy Micro Kit according to the manufacturers protocol (Qiagen Inc., Valencia, CA).///label_ch1: biotin///label_protocol_ch1: Two rounds of amplification were completed according to standard Affymetrix Two-Cycle Amplification protocol using 25ng of total RNA.///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Arrays were scanned using the laser confocal GeneChip Scanner 3000 (Affymetrix).///description: Gene expression data from tumor.///description.1: 386///data_processing: Low-level analysis included array normalization and estimation of expression level using an invariant set of probe sets to adjust the overall signal level of the arrays to the same level. Next, a model-based PM-only approach established gene expression levels using dChip software. A modified semi-supervised method was applied in two stages: (1) supervised dimension reduction by fitting a univariate Cox model that included a jackknifing step to each gene, so only those genes with a consistently large Cox score were included in the signature. Among 200, 100, or 300 probe sets, 200 yielded an optimally sized predictor; (2) In stage 2, the dimensions of the data set were reduced from 200 to 5 by PC analysis. The number of PCs was set at 5 capturing 90
1
title: Ovarian Tumor, 388///geo_accession: GSM461353///status: Public on Oct 17 2009///submission_date: Oct 11 2009///last_update_date: Jan 19 2011///type: RNA///channel_count: 1///source_name_ch1: papillary serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: papillary serous ovarian adenocarcinoma///characteristics_ch1.1: tumor stage: late///characteristics_ch1.2: tumor grade: high///characteristics_ch1.3: surv data: 132 (A)///treatment_protocol_ch1: All specimens were subjected to laser-based microdissection and analyzed as pure, microdissected epithelial cell populations.///molecule_ch1: total RNA///extract_protocol_ch1: RNeasy Micro Kit according to the manufacturers protocol (Qiagen Inc., Valencia, CA).///label_ch1: biotin///label_protocol_ch1: Two rounds of amplification were completed according to standard Affymetrix Two-Cycle Amplification protocol using 25ng of total RNA.///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Arrays were scanned using the laser confocal GeneChip Scanner 3000 (Affymetrix).///description: Gene expression data from tumor.///description.1: 388///data_processing: Low-level analysis included array normalization and estimation of expression level using an invariant set of probe sets to adjust the overall signal level of the arrays to the same level. Next, a model-based PM-only approach established gene expression levels using dChip software. A modified semi-supervised method was applied in two stages: (1) supervised dimension reduction by fitting a univariate Cox model that included a jackknifing step to each gene, so only those genes with a consistently large Cox score were included in the signature. Among 200, 100, or 300 probe sets, 200 yielded an optimally sized predictor; (2) In stage 2, the dimensions of the data set were reduced from 200 to 5 by PC analysis. The number of PCs was set at 5 capturing 90
1
title: Ovarian Tumor, 389///geo_accession: GSM461354///status: Public on Oct 17 2009///submission_date: Oct 11 2009///last_update_date: Jan 19 2011///type: RNA///channel_count: 1///source_name_ch1: papillary serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: papillary serous ovarian adenocarcinoma///characteristics_ch1.1: tumor stage: late///characteristics_ch1.2: tumor grade: high///characteristics_ch1.3: surv data: 13///treatment_protocol_ch1: All specimens were subjected to laser-based microdissection and analyzed as pure, microdissected epithelial cell populations.///molecule_ch1: total RNA///extract_protocol_ch1: RNeasy Micro Kit according to the manufacturers protocol (Qiagen Inc., Valencia, CA).///label_ch1: biotin///label_protocol_ch1: Two rounds of amplification were completed according to standard Affymetrix Two-Cycle Amplification protocol using 25ng of total RNA.///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Arrays were scanned using the laser confocal GeneChip Scanner 3000 (Affymetrix).///description: Gene expression data from tumor.///description.1: 389///data_processing: Low-level analysis included array normalization and estimation of expression level using an invariant set of probe sets to adjust the overall signal level of the arrays to the same level. Next, a model-based PM-only approach established gene expression levels using dChip software. A modified semi-supervised method was applied in two stages: (1) supervised dimension reduction by fitting a univariate Cox model that included a jackknifing step to each gene, so only those genes with a consistently large Cox score were included in the signature. Among 200, 100, or 300 probe sets, 200 yielded an optimally sized predictor; (2) In stage 2, the dimensions of the data set were reduced from 200 to 5 by PC analysis. The number of PCs was set at 5 capturing 90
1
title: Ovarian Tumor, 394///geo_accession: GSM461382///status: Public on Oct 17 2009///submission_date: Oct 11 2009///last_update_date: Jan 19 2011///type: RNA///channel_count: 1///source_name_ch1: papillary serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: papillary serous ovarian adenocarcinoma///characteristics_ch1.1: tumor stage: late///characteristics_ch1.2: tumor grade: high///characteristics_ch1.3: surv data: 16///treatment_protocol_ch1: All specimens were subjected to laser-based microdissection and analyzed as pure, microdissected epithelial cell populations.///molecule_ch1: total RNA///extract_protocol_ch1: RNeasy Micro Kit according to the manufacturers protocol (Qiagen Inc., Valencia, CA).///label_ch1: biotin///label_protocol_ch1: Two rounds of amplification were completed according to standard Affymetrix Two-Cycle Amplification protocol using 25ng of total RNA.///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Arrays were scanned using the laser confocal GeneChip Scanner 3000 (Affymetrix).///description: Gene expression data from tumor.///description.1: 394///data_processing: Low-level analysis included array normalization and estimation of expression level using an invariant set of probe sets to adjust the overall signal level of the arrays to the same level. Next, a model-based PM-only approach established gene expression levels using dChip software. A modified semi-supervised method was applied in two stages: (1) supervised dimension reduction by fitting a univariate Cox model that included a jackknifing step to each gene, so only those genes with a consistently large Cox score were included in the signature. Among 200, 100, or 300 probe sets, 200 yielded an optimally sized predictor; (2) In stage 2, the dimensions of the data set were reduced from 200 to 5 by PC analysis. The number of PCs was set at 5 capturing 90
1
title: Ovarian Tumor, 396///geo_accession: GSM461376///status: Public on Oct 17 2009///submission_date: Oct 11 2009///last_update_date: Jan 19 2011///type: RNA///channel_count: 1///source_name_ch1: papillary serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: papillary serous ovarian adenocarcinoma///characteristics_ch1.1: tumor stage: late///characteristics_ch1.2: tumor grade: high///characteristics_ch1.3: surv data: 21///treatment_protocol_ch1: All specimens were subjected to laser-based microdissection and analyzed as pure, microdissected epithelial cell populations.///molecule_ch1: total RNA///extract_protocol_ch1: RNeasy Micro Kit according to the manufacturers protocol (Qiagen Inc., Valencia, CA).///label_ch1: biotin///label_protocol_ch1: Two rounds of amplification were completed according to standard Affymetrix Two-Cycle Amplification protocol using 25ng of total RNA.///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Arrays were scanned using the laser confocal GeneChip Scanner 3000 (Affymetrix).///description: Gene expression data from tumor.///description.1: 396///data_processing: Low-level analysis included array normalization and estimation of expression level using an invariant set of probe sets to adjust the overall signal level of the arrays to the same level. Next, a model-based PM-only approach established gene expression levels using dChip software. A modified semi-supervised method was applied in two stages: (1) supervised dimension reduction by fitting a univariate Cox model that included a jackknifing step to each gene, so only those genes with a consistently large Cox score were included in the signature. Among 200, 100, or 300 probe sets, 200 yielded an optimally sized predictor; (2) In stage 2, the dimensions of the data set were reduced from 200 to 5 by PC analysis. The number of PCs was set at 5 capturing 90
1
title: Ovarian Tumor, 402///geo_accession: GSM461355///status: Public on Oct 17 2009///submission_date: Oct 11 2009///last_update_date: Jan 19 2011///type: RNA///channel_count: 1///source_name_ch1: papillary serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: papillary serous ovarian adenocarcinoma///characteristics_ch1.1: tumor stage: late///characteristics_ch1.2: tumor grade: high///characteristics_ch1.3: surv data: 8///treatment_protocol_ch1: All specimens were subjected to laser-based microdissection and analyzed as pure, microdissected epithelial cell populations.///molecule_ch1: total RNA///extract_protocol_ch1: RNeasy Micro Kit according to the manufacturers protocol (Qiagen Inc., Valencia, CA).///label_ch1: biotin///label_protocol_ch1: Two rounds of amplification were completed according to standard Affymetrix Two-Cycle Amplification protocol using 25ng of total RNA.///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Arrays were scanned using the laser confocal GeneChip Scanner 3000 (Affymetrix).///description: Gene expression data from tumor.///description.1: 402///data_processing: Low-level analysis included array normalization and estimation of expression level using an invariant set of probe sets to adjust the overall signal level of the arrays to the same level. Next, a model-based PM-only approach established gene expression levels using dChip software. A modified semi-supervised method was applied in two stages: (1) supervised dimension reduction by fitting a univariate Cox model that included a jackknifing step to each gene, so only those genes with a consistently large Cox score were included in the signature. Among 200, 100, or 300 probe sets, 200 yielded an optimally sized predictor; (2) In stage 2, the dimensions of the data set were reduced from 200 to 5 by PC analysis. The number of PCs was set at 5 capturing 90
1
title: Ovarian Tumor, 410///geo_accession: GSM461356///status: Public on Oct 17 2009///submission_date: Oct 11 2009///last_update_date: Jan 19 2011///type: RNA///channel_count: 1///source_name_ch1: papillary serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: papillary serous ovarian adenocarcinoma///characteristics_ch1.1: tumor stage: late///characteristics_ch1.2: tumor grade: high///characteristics_ch1.3: surv data: 150 (A)///treatment_protocol_ch1: All specimens were subjected to laser-based microdissection and analyzed as pure, microdissected epithelial cell populations.///molecule_ch1: total RNA///extract_protocol_ch1: RNeasy Micro Kit according to the manufacturers protocol (Qiagen Inc., Valencia, CA).///label_ch1: biotin///label_protocol_ch1: Two rounds of amplification were completed according to standard Affymetrix Two-Cycle Amplification protocol using 25ng of total RNA.///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Arrays were scanned using the laser confocal GeneChip Scanner 3000 (Affymetrix).///description: Gene expression data from tumor.///description.1: 410///data_processing: Low-level analysis included array normalization and estimation of expression level using an invariant set of probe sets to adjust the overall signal level of the arrays to the same level. Next, a model-based PM-only approach established gene expression levels using dChip software. A modified semi-supervised method was applied in two stages: (1) supervised dimension reduction by fitting a univariate Cox model that included a jackknifing step to each gene, so only those genes with a consistently large Cox score were included in the signature. Among 200, 100, or 300 probe sets, 200 yielded an optimally sized predictor; (2) In stage 2, the dimensions of the data set were reduced from 200 to 5 by PC analysis. The number of PCs was set at 5 capturing 90
1
title: Ovarian Tumor, 412///geo_accession: GSM461357///status: Public on Oct 17 2009///submission_date: Oct 11 2009///last_update_date: Jan 19 2011///type: RNA///channel_count: 1///source_name_ch1: papillary serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: papillary serous ovarian adenocarcinoma///characteristics_ch1.1: tumor stage: late///characteristics_ch1.2: tumor grade: high///characteristics_ch1.3: surv data: 113///treatment_protocol_ch1: All specimens were subjected to laser-based microdissection and analyzed as pure, microdissected epithelial cell populations.///molecule_ch1: total RNA///extract_protocol_ch1: RNeasy Micro Kit according to the manufacturers protocol (Qiagen Inc., Valencia, CA).///label_ch1: biotin///label_protocol_ch1: Two rounds of amplification were completed according to standard Affymetrix Two-Cycle Amplification protocol using 25ng of total RNA.///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Arrays were scanned using the laser confocal GeneChip Scanner 3000 (Affymetrix).///description: Gene expression data from tumor.///description.1: 412///data_processing: Low-level analysis included array normalization and estimation of expression level using an invariant set of probe sets to adjust the overall signal level of the arrays to the same level. Next, a model-based PM-only approach established gene expression levels using dChip software. A modified semi-supervised method was applied in two stages: (1) supervised dimension reduction by fitting a univariate Cox model that included a jackknifing step to each gene, so only those genes with a consistently large Cox score were included in the signature. Among 200, 100, or 300 probe sets, 200 yielded an optimally sized predictor; (2) In stage 2, the dimensions of the data set were reduced from 200 to 5 by PC analysis. The number of PCs was set at 5 capturing 90
1
title: Ovarian Tumor, 434///geo_accession: GSM461358///status: Public on Oct 17 2009///submission_date: Oct 11 2009///last_update_date: Jan 19 2011///type: RNA///channel_count: 1///source_name_ch1: papillary serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: papillary serous ovarian adenocarcinoma///characteristics_ch1.1: tumor stage: late///characteristics_ch1.2: tumor grade: high///characteristics_ch1.3: surv data: 72///treatment_protocol_ch1: All specimens were subjected to laser-based microdissection and analyzed as pure, microdissected epithelial cell populations.///molecule_ch1: total RNA///extract_protocol_ch1: RNeasy Micro Kit according to the manufacturers protocol (Qiagen Inc., Valencia, CA).///label_ch1: biotin///label_protocol_ch1: Two rounds of amplification were completed according to standard Affymetrix Two-Cycle Amplification protocol using 25ng of total RNA.///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Arrays were scanned using the laser confocal GeneChip Scanner 3000 (Affymetrix).///description: Gene expression data from tumor.///description.1: 434///data_processing: Low-level analysis included array normalization and estimation of expression level using an invariant set of probe sets to adjust the overall signal level of the arrays to the same level. Next, a model-based PM-only approach established gene expression levels using dChip software. A modified semi-supervised method was applied in two stages: (1) supervised dimension reduction by fitting a univariate Cox model that included a jackknifing step to each gene, so only those genes with a consistently large Cox score were included in the signature. Among 200, 100, or 300 probe sets, 200 yielded an optimally sized predictor; (2) In stage 2, the dimensions of the data set were reduced from 200 to 5 by PC analysis. The number of PCs was set at 5 capturing 90
1
title: Ovarian Tumor, 443///geo_accession: GSM461377///status: Public on Oct 17 2009///submission_date: Oct 11 2009///last_update_date: Jan 19 2011///type: RNA///channel_count: 1///source_name_ch1: papillary serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: papillary serous ovarian adenocarcinoma///characteristics_ch1.1: tumor stage: late///characteristics_ch1.2: tumor grade: high///characteristics_ch1.3: surv data: 111///treatment_protocol_ch1: All specimens were subjected to laser-based microdissection and analyzed as pure, microdissected epithelial cell populations.///molecule_ch1: total RNA///extract_protocol_ch1: RNeasy Micro Kit according to the manufacturers protocol (Qiagen Inc., Valencia, CA).///label_ch1: biotin///label_protocol_ch1: Two rounds of amplification were completed according to standard Affymetrix Two-Cycle Amplification protocol using 25ng of total RNA.///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Arrays were scanned using the laser confocal GeneChip Scanner 3000 (Affymetrix).///description: Gene expression data from tumor.///description.1: 443///data_processing: Low-level analysis included array normalization and estimation of expression level using an invariant set of probe sets to adjust the overall signal level of the arrays to the same level. Next, a model-based PM-only approach established gene expression levels using dChip software. A modified semi-supervised method was applied in two stages: (1) supervised dimension reduction by fitting a univariate Cox model that included a jackknifing step to each gene, so only those genes with a consistently large Cox score were included in the signature. Among 200, 100, or 300 probe sets, 200 yielded an optimally sized predictor; (2) In stage 2, the dimensions of the data set were reduced from 200 to 5 by PC analysis. The number of PCs was set at 5 capturing 90
1
title: Ovarian Tumor, 461///geo_accession: GSM461394///status: Public on Oct 17 2009///submission_date: Oct 11 2009///last_update_date: Jan 19 2011///type: RNA///channel_count: 1///source_name_ch1: papillary serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: papillary serous ovarian adenocarcinoma///characteristics_ch1.1: tumor stage: late///characteristics_ch1.2: tumor grade: high///characteristics_ch1.3: surv data: 32///treatment_protocol_ch1: All specimens were subjected to laser-based microdissection and analyzed as pure, microdissected epithelial cell populations.///molecule_ch1: total RNA///extract_protocol_ch1: RNeasy Micro Kit according to the manufacturers protocol (Qiagen Inc., Valencia, CA).///label_ch1: biotin///label_protocol_ch1: Two rounds of amplification were completed according to standard Affymetrix Two-Cycle Amplification protocol using 25ng of total RNA.///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Arrays were scanned using the laser confocal GeneChip Scanner 3000 (Affymetrix).///description: Gene expression data from tumor.///description.1: 461///data_processing: Low-level analysis included array normalization and estimation of expression level using an invariant set of probe sets to adjust the overall signal level of the arrays to the same level. Next, a model-based PM-only approach established gene expression levels using dChip software. A modified semi-supervised method was applied in two stages: (1) supervised dimension reduction by fitting a univariate Cox model that included a jackknifing step to each gene, so only those genes with a consistently large Cox score were included in the signature. Among 200, 100, or 300 probe sets, 200 yielded an optimally sized predictor; (2) In stage 2, the dimensions of the data set were reduced from 200 to 5 by PC analysis. The number of PCs was set at 5 capturing 90
1
title: Ovarian Tumor, 467///geo_accession: GSM461359///status: Public on Oct 17 2009///submission_date: Oct 11 2009///last_update_date: Jan 19 2011///type: RNA///channel_count: 1///source_name_ch1: papillary serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: papillary serous ovarian adenocarcinoma///characteristics_ch1.1: tumor stage: late///characteristics_ch1.2: tumor grade: high///characteristics_ch1.3: surv data: 11///treatment_protocol_ch1: All specimens were subjected to laser-based microdissection and analyzed as pure, microdissected epithelial cell populations.///molecule_ch1: total RNA///extract_protocol_ch1: RNeasy Micro Kit according to the manufacturers protocol (Qiagen Inc., Valencia, CA).///label_ch1: biotin///label_protocol_ch1: Two rounds of amplification were completed according to standard Affymetrix Two-Cycle Amplification protocol using 25ng of total RNA.///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Arrays were scanned using the laser confocal GeneChip Scanner 3000 (Affymetrix).///description: Gene expression data from tumor.///description.1: 467///data_processing: Low-level analysis included array normalization and estimation of expression level using an invariant set of probe sets to adjust the overall signal level of the arrays to the same level. Next, a model-based PM-only approach established gene expression levels using dChip software. A modified semi-supervised method was applied in two stages: (1) supervised dimension reduction by fitting a univariate Cox model that included a jackknifing step to each gene, so only those genes with a consistently large Cox score were included in the signature. Among 200, 100, or 300 probe sets, 200 yielded an optimally sized predictor; (2) In stage 2, the dimensions of the data set were reduced from 200 to 5 by PC analysis. The number of PCs was set at 5 capturing 90
1
title: Ovarian Tumor, 477///geo_accession: GSM461383///status: Public on Oct 17 2009///submission_date: Oct 11 2009///last_update_date: Jan 19 2011///type: RNA///channel_count: 1///source_name_ch1: papillary serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: papillary serous ovarian adenocarcinoma///characteristics_ch1.1: tumor stage: late///characteristics_ch1.2: tumor grade: high///characteristics_ch1.3: surv data: 21///treatment_protocol_ch1: All specimens were subjected to laser-based microdissection and analyzed as pure, microdissected epithelial cell populations.///molecule_ch1: total RNA///extract_protocol_ch1: RNeasy Micro Kit according to the manufacturers protocol (Qiagen Inc., Valencia, CA).///label_ch1: biotin///label_protocol_ch1: Two rounds of amplification were completed according to standard Affymetrix Two-Cycle Amplification protocol using 25ng of total RNA.///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Arrays were scanned using the laser confocal GeneChip Scanner 3000 (Affymetrix).///description: Gene expression data from tumor.///description.1: 477///data_processing: Low-level analysis included array normalization and estimation of expression level using an invariant set of probe sets to adjust the overall signal level of the arrays to the same level. Next, a model-based PM-only approach established gene expression levels using dChip software. A modified semi-supervised method was applied in two stages: (1) supervised dimension reduction by fitting a univariate Cox model that included a jackknifing step to each gene, so only those genes with a consistently large Cox score were included in the signature. Among 200, 100, or 300 probe sets, 200 yielded an optimally sized predictor; (2) In stage 2, the dimensions of the data set were reduced from 200 to 5 by PC analysis. The number of PCs was set at 5 capturing 90
1
title: Ovarian Tumor, 486///geo_accession: GSM461395///status: Public on Oct 17 2009///submission_date: Oct 11 2009///last_update_date: Jan 19 2011///type: RNA///channel_count: 1///source_name_ch1: papillary serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: papillary serous ovarian adenocarcinoma///characteristics_ch1.1: tumor stage: late///characteristics_ch1.2: tumor grade: high///characteristics_ch1.3: surv data: 21///treatment_protocol_ch1: All specimens were subjected to laser-based microdissection and analyzed as pure, microdissected epithelial cell populations.///molecule_ch1: total RNA///extract_protocol_ch1: RNeasy Micro Kit according to the manufacturers protocol (Qiagen Inc., Valencia, CA).///label_ch1: biotin///label_protocol_ch1: Two rounds of amplification were completed according to standard Affymetrix Two-Cycle Amplification protocol using 25ng of total RNA.///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Arrays were scanned using the laser confocal GeneChip Scanner 3000 (Affymetrix).///description: Gene expression data from tumor.///description.1: 486///data_processing: Low-level analysis included array normalization and estimation of expression level using an invariant set of probe sets to adjust the overall signal level of the arrays to the same level. Next, a model-based PM-only approach established gene expression levels using dChip software. A modified semi-supervised method was applied in two stages: (1) supervised dimension reduction by fitting a univariate Cox model that included a jackknifing step to each gene, so only those genes with a consistently large Cox score were included in the signature. Among 200, 100, or 300 probe sets, 200 yielded an optimally sized predictor; (2) In stage 2, the dimensions of the data set were reduced from 200 to 5 by PC analysis. The number of PCs was set at 5 capturing 90
1
title: Ovarian Tumor, 629///geo_accession: GSM461360///status: Public on Oct 17 2009///submission_date: Oct 11 2009///last_update_date: Jan 19 2011///type: RNA///channel_count: 1///source_name_ch1: papillary serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: papillary serous ovarian adenocarcinoma///characteristics_ch1.1: tumor stage: late///characteristics_ch1.2: tumor grade: high///characteristics_ch1.3: surv data: 50 (A)///treatment_protocol_ch1: All specimens were subjected to laser-based microdissection and analyzed as pure, microdissected epithelial cell populations.///molecule_ch1: total RNA///extract_protocol_ch1: RNeasy Micro Kit according to the manufacturers protocol (Qiagen Inc., Valencia, CA).///label_ch1: biotin///label_protocol_ch1: Two rounds of amplification were completed according to standard Affymetrix Two-Cycle Amplification protocol using 25ng of total RNA.///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Arrays were scanned using the laser confocal GeneChip Scanner 3000 (Affymetrix).///description: Gene expression data from tumor.///description.1: 629///data_processing: Low-level analysis included array normalization and estimation of expression level using an invariant set of probe sets to adjust the overall signal level of the arrays to the same level. Next, a model-based PM-only approach established gene expression levels using dChip software. A modified semi-supervised method was applied in two stages: (1) supervised dimension reduction by fitting a univariate Cox model that included a jackknifing step to each gene, so only those genes with a consistently large Cox score were included in the signature. Among 200, 100, or 300 probe sets, 200 yielded an optimally sized predictor; (2) In stage 2, the dimensions of the data set were reduced from 200 to 5 by PC analysis. The number of PCs was set at 5 capturing 90
1
title: Ovarian Tumor, 631///geo_accession: GSM461396///status: Public on Oct 17 2009///submission_date: Oct 11 2009///last_update_date: Jan 19 2011///type: RNA///channel_count: 1///source_name_ch1: papillary serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: papillary serous ovarian adenocarcinoma///characteristics_ch1.1: tumor stage: late///characteristics_ch1.2: tumor grade: high///characteristics_ch1.3: surv data: 30///treatment_protocol_ch1: All specimens were subjected to laser-based microdissection and analyzed as pure, microdissected epithelial cell populations.///molecule_ch1: total RNA///extract_protocol_ch1: RNeasy Micro Kit according to the manufacturers protocol (Qiagen Inc., Valencia, CA).///label_ch1: biotin///label_protocol_ch1: Two rounds of amplification were completed according to standard Affymetrix Two-Cycle Amplification protocol using 25ng of total RNA.///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Arrays were scanned using the laser confocal GeneChip Scanner 3000 (Affymetrix).///description: Gene expression data from tumor.///description.1: 631///data_processing: Low-level analysis included array normalization and estimation of expression level using an invariant set of probe sets to adjust the overall signal level of the arrays to the same level. Next, a model-based PM-only approach established gene expression levels using dChip software. A modified semi-supervised method was applied in two stages: (1) supervised dimension reduction by fitting a univariate Cox model that included a jackknifing step to each gene, so only those genes with a consistently large Cox score were included in the signature. Among 200, 100, or 300 probe sets, 200 yielded an optimally sized predictor; (2) In stage 2, the dimensions of the data set were reduced from 200 to 5 by PC analysis. The number of PCs was set at 5 capturing 90
1
title: Ovarian Tumor, 656///geo_accession: GSM461384///status: Public on Oct 17 2009///submission_date: Oct 11 2009///last_update_date: Jan 19 2011///type: RNA///channel_count: 1///source_name_ch1: papillary serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: papillary serous ovarian adenocarcinoma///characteristics_ch1.1: tumor stage: late///characteristics_ch1.2: tumor grade: high///characteristics_ch1.3: surv data: 25///treatment_protocol_ch1: All specimens were subjected to laser-based microdissection and analyzed as pure, microdissected epithelial cell populations.///molecule_ch1: total RNA///extract_protocol_ch1: RNeasy Micro Kit according to the manufacturers protocol (Qiagen Inc., Valencia, CA).///label_ch1: biotin///label_protocol_ch1: Two rounds of amplification were completed according to standard Affymetrix Two-Cycle Amplification protocol using 25ng of total RNA.///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Arrays were scanned using the laser confocal GeneChip Scanner 3000 (Affymetrix).///description: Gene expression data from tumor.///description.1: 656///data_processing: Low-level analysis included array normalization and estimation of expression level using an invariant set of probe sets to adjust the overall signal level of the arrays to the same level. Next, a model-based PM-only approach established gene expression levels using dChip software. A modified semi-supervised method was applied in two stages: (1) supervised dimension reduction by fitting a univariate Cox model that included a jackknifing step to each gene, so only those genes with a consistently large Cox score were included in the signature. Among 200, 100, or 300 probe sets, 200 yielded an optimally sized predictor; (2) In stage 2, the dimensions of the data set were reduced from 200 to 5 by PC analysis. The number of PCs was set at 5 capturing 90
1
title: Ovarian Tumor, 662///geo_accession: GSM461370///status: Public on Oct 17 2009///submission_date: Oct 11 2009///last_update_date: Jan 19 2011///type: RNA///channel_count: 1///source_name_ch1: papillary serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: papillary serous ovarian adenocarcinoma///characteristics_ch1.1: tumor stage: late///characteristics_ch1.2: tumor grade: high///characteristics_ch1.3: surv data: 23///treatment_protocol_ch1: All specimens were subjected to laser-based microdissection and analyzed as pure, microdissected epithelial cell populations.///molecule_ch1: total RNA///extract_protocol_ch1: RNeasy Micro Kit according to the manufacturers protocol (Qiagen Inc., Valencia, CA).///label_ch1: biotin///label_protocol_ch1: Two rounds of amplification were completed according to standard Affymetrix Two-Cycle Amplification protocol using 25ng of total RNA.///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Arrays were scanned using the laser confocal GeneChip Scanner 3000 (Affymetrix).///description: Gene expression data from tumor.///description.1: 662///data_processing: Low-level analysis included array normalization and estimation of expression level using an invariant set of probe sets to adjust the overall signal level of the arrays to the same level. Next, a model-based PM-only approach established gene expression levels using dChip software. A modified semi-supervised method was applied in two stages: (1) supervised dimension reduction by fitting a univariate Cox model that included a jackknifing step to each gene, so only those genes with a consistently large Cox score were included in the signature. Among 200, 100, or 300 probe sets, 200 yielded an optimally sized predictor; (2) In stage 2, the dimensions of the data set were reduced from 200 to 5 by PC analysis. The number of PCs was set at 5 capturing 90
1
title: Ovarian Tumor, 692///geo_accession: GSM461397///status: Public on Oct 17 2009///submission_date: Oct 11 2009///last_update_date: Jan 19 2011///type: RNA///channel_count: 1///source_name_ch1: papillary serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: papillary serous ovarian adenocarcinoma///characteristics_ch1.1: tumor stage: late///characteristics_ch1.2: tumor grade: high///characteristics_ch1.3: surv data: 35///treatment_protocol_ch1: All specimens were subjected to laser-based microdissection and analyzed as pure, microdissected epithelial cell populations.///molecule_ch1: total RNA///extract_protocol_ch1: RNeasy Micro Kit according to the manufacturers protocol (Qiagen Inc., Valencia, CA).///label_ch1: biotin///label_protocol_ch1: Two rounds of amplification were completed according to standard Affymetrix Two-Cycle Amplification protocol using 25ng of total RNA.///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Arrays were scanned using the laser confocal GeneChip Scanner 3000 (Affymetrix).///description: Gene expression data from tumor.///description.1: 692///data_processing: Low-level analysis included array normalization and estimation of expression level using an invariant set of probe sets to adjust the overall signal level of the arrays to the same level. Next, a model-based PM-only approach established gene expression levels using dChip software. A modified semi-supervised method was applied in two stages: (1) supervised dimension reduction by fitting a univariate Cox model that included a jackknifing step to each gene, so only those genes with a consistently large Cox score were included in the signature. Among 200, 100, or 300 probe sets, 200 yielded an optimally sized predictor; (2) In stage 2, the dimensions of the data set were reduced from 200 to 5 by PC analysis. The number of PCs was set at 5 capturing 90
1
title: Ovarian Tumor, 694///geo_accession: GSM461385///status: Public on Oct 17 2009///submission_date: Oct 11 2009///last_update_date: Jan 19 2011///type: RNA///channel_count: 1///source_name_ch1: papillary serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: papillary serous ovarian adenocarcinoma///characteristics_ch1.1: tumor stage: late///characteristics_ch1.2: tumor grade: high///characteristics_ch1.3: surv data: 33///treatment_protocol_ch1: All specimens were subjected to laser-based microdissection and analyzed as pure, microdissected epithelial cell populations.///molecule_ch1: total RNA///extract_protocol_ch1: RNeasy Micro Kit according to the manufacturers protocol (Qiagen Inc., Valencia, CA).///label_ch1: biotin///label_protocol_ch1: Two rounds of amplification were completed according to standard Affymetrix Two-Cycle Amplification protocol using 25ng of total RNA.///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Arrays were scanned using the laser confocal GeneChip Scanner 3000 (Affymetrix).///description: Gene expression data from tumor.///description.1: 694///data_processing: Low-level analysis included array normalization and estimation of expression level using an invariant set of probe sets to adjust the overall signal level of the arrays to the same level. Next, a model-based PM-only approach established gene expression levels using dChip software. A modified semi-supervised method was applied in two stages: (1) supervised dimension reduction by fitting a univariate Cox model that included a jackknifing step to each gene, so only those genes with a consistently large Cox score were included in the signature. Among 200, 100, or 300 probe sets, 200 yielded an optimally sized predictor; (2) In stage 2, the dimensions of the data set were reduced from 200 to 5 by PC analysis. The number of PCs was set at 5 capturing 90
1
title: Ovarian Tumor, 702///geo_accession: GSM461361///status: Public on Oct 17 2009///submission_date: Oct 11 2009///last_update_date: Jan 19 2011///type: RNA///channel_count: 1///source_name_ch1: papillary serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: papillary serous ovarian adenocarcinoma///characteristics_ch1.1: tumor stage: late///characteristics_ch1.2: tumor grade: high///characteristics_ch1.3: surv data: 13///treatment_protocol_ch1: All specimens were subjected to laser-based microdissection and analyzed as pure, microdissected epithelial cell populations.///molecule_ch1: total RNA///extract_protocol_ch1: RNeasy Micro Kit according to the manufacturers protocol (Qiagen Inc., Valencia, CA).///label_ch1: biotin///label_protocol_ch1: Two rounds of amplification were completed according to standard Affymetrix Two-Cycle Amplification protocol using 25ng of total RNA.///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Arrays were scanned using the laser confocal GeneChip Scanner 3000 (Affymetrix).///description: Gene expression data from tumor.///description.1: 702///data_processing: Low-level analysis included array normalization and estimation of expression level using an invariant set of probe sets to adjust the overall signal level of the arrays to the same level. Next, a model-based PM-only approach established gene expression levels using dChip software. A modified semi-supervised method was applied in two stages: (1) supervised dimension reduction by fitting a univariate Cox model that included a jackknifing step to each gene, so only those genes with a consistently large Cox score were included in the signature. Among 200, 100, or 300 probe sets, 200 yielded an optimally sized predictor; (2) In stage 2, the dimensions of the data set were reduced from 200 to 5 by PC analysis. The number of PCs was set at 5 capturing 90
1
title: Ovarian Tumor, 714///geo_accession: GSM461362///status: Public on Oct 17 2009///submission_date: Oct 11 2009///last_update_date: Jan 19 2011///type: RNA///channel_count: 1///source_name_ch1: papillary serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: papillary serous ovarian adenocarcinoma///characteristics_ch1.1: tumor stage: late///characteristics_ch1.2: tumor grade: high///characteristics_ch1.3: surv data: 8///treatment_protocol_ch1: All specimens were subjected to laser-based microdissection and analyzed as pure, microdissected epithelial cell populations.///molecule_ch1: total RNA///extract_protocol_ch1: RNeasy Micro Kit according to the manufacturers protocol (Qiagen Inc., Valencia, CA).///label_ch1: biotin///label_protocol_ch1: Two rounds of amplification were completed according to standard Affymetrix Two-Cycle Amplification protocol using 25ng of total RNA.///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Arrays were scanned using the laser confocal GeneChip Scanner 3000 (Affymetrix).///description: Gene expression data from tumor.///description.1: 714///data_processing: Low-level analysis included array normalization and estimation of expression level using an invariant set of probe sets to adjust the overall signal level of the arrays to the same level. Next, a model-based PM-only approach established gene expression levels using dChip software. A modified semi-supervised method was applied in two stages: (1) supervised dimension reduction by fitting a univariate Cox model that included a jackknifing step to each gene, so only those genes with a consistently large Cox score were included in the signature. Among 200, 100, or 300 probe sets, 200 yielded an optimally sized predictor; (2) In stage 2, the dimensions of the data set were reduced from 200 to 5 by PC analysis. The number of PCs was set at 5 capturing 90
1
title: Ovarian Tumor, 715///geo_accession: GSM461386///status: Public on Oct 17 2009///submission_date: Oct 11 2009///last_update_date: Jan 19 2011///type: RNA///channel_count: 1///source_name_ch1: papillary serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: papillary serous ovarian adenocarcinoma///characteristics_ch1.1: tumor stage: late///characteristics_ch1.2: tumor grade: high///characteristics_ch1.3: surv data: 33///treatment_protocol_ch1: All specimens were subjected to laser-based microdissection and analyzed as pure, microdissected epithelial cell populations.///molecule_ch1: total RNA///extract_protocol_ch1: RNeasy Micro Kit according to the manufacturers protocol (Qiagen Inc., Valencia, CA).///label_ch1: biotin///label_protocol_ch1: Two rounds of amplification were completed according to standard Affymetrix Two-Cycle Amplification protocol using 25ng of total RNA.///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Arrays were scanned using the laser confocal GeneChip Scanner 3000 (Affymetrix).///description: Gene expression data from tumor.///description.1: 715///data_processing: Low-level analysis included array normalization and estimation of expression level using an invariant set of probe sets to adjust the overall signal level of the arrays to the same level. Next, a model-based PM-only approach established gene expression levels using dChip software. A modified semi-supervised method was applied in two stages: (1) supervised dimension reduction by fitting a univariate Cox model that included a jackknifing step to each gene, so only those genes with a consistently large Cox score were included in the signature. Among 200, 100, or 300 probe sets, 200 yielded an optimally sized predictor; (2) In stage 2, the dimensions of the data set were reduced from 200 to 5 by PC analysis. The number of PCs was set at 5 capturing 90
1
title: Ovarian Tumor, 718///geo_accession: GSM461398///status: Public on Oct 17 2009///submission_date: Oct 11 2009///last_update_date: Jan 19 2011///type: RNA///channel_count: 1///source_name_ch1: papillary serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: papillary serous ovarian adenocarcinoma///characteristics_ch1.1: tumor stage: late///characteristics_ch1.2: tumor grade: high///characteristics_ch1.3: surv data: 26///treatment_protocol_ch1: All specimens were subjected to laser-based microdissection and analyzed as pure, microdissected epithelial cell populations.///molecule_ch1: total RNA///extract_protocol_ch1: RNeasy Micro Kit according to the manufacturers protocol (Qiagen Inc., Valencia, CA).///label_ch1: biotin///label_protocol_ch1: Two rounds of amplification were completed according to standard Affymetrix Two-Cycle Amplification protocol using 25ng of total RNA.///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Arrays were scanned using the laser confocal GeneChip Scanner 3000 (Affymetrix).///description: Gene expression data from tumor.///description.1: 718///data_processing: Low-level analysis included array normalization and estimation of expression level using an invariant set of probe sets to adjust the overall signal level of the arrays to the same level. Next, a model-based PM-only approach established gene expression levels using dChip software. A modified semi-supervised method was applied in two stages: (1) supervised dimension reduction by fitting a univariate Cox model that included a jackknifing step to each gene, so only those genes with a consistently large Cox score were included in the signature. Among 200, 100, or 300 probe sets, 200 yielded an optimally sized predictor; (2) In stage 2, the dimensions of the data set were reduced from 200 to 5 by PC analysis. The number of PCs was set at 5 capturing 90
1
title: Ovarian Tumor, 744///geo_accession: GSM461378///status: Public on Oct 17 2009///submission_date: Oct 11 2009///last_update_date: Jan 19 2011///type: RNA///channel_count: 1///source_name_ch1: papillary serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: papillary serous ovarian adenocarcinoma///characteristics_ch1.1: tumor stage: late///characteristics_ch1.2: tumor grade: high///characteristics_ch1.3: surv data: 14///treatment_protocol_ch1: All specimens were subjected to laser-based microdissection and analyzed as pure, microdissected epithelial cell populations.///molecule_ch1: total RNA///extract_protocol_ch1: RNeasy Micro Kit according to the manufacturers protocol (Qiagen Inc., Valencia, CA).///label_ch1: biotin///label_protocol_ch1: Two rounds of amplification were completed according to standard Affymetrix Two-Cycle Amplification protocol using 25ng of total RNA.///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Arrays were scanned using the laser confocal GeneChip Scanner 3000 (Affymetrix).///description: Gene expression data from tumor.///description.1: 744///data_processing: Low-level analysis included array normalization and estimation of expression level using an invariant set of probe sets to adjust the overall signal level of the arrays to the same level. Next, a model-based PM-only approach established gene expression levels using dChip software. A modified semi-supervised method was applied in two stages: (1) supervised dimension reduction by fitting a univariate Cox model that included a jackknifing step to each gene, so only those genes with a consistently large Cox score were included in the signature. Among 200, 100, or 300 probe sets, 200 yielded an optimally sized predictor; (2) In stage 2, the dimensions of the data set were reduced from 200 to 5 by PC analysis. The number of PCs was set at 5 capturing 90
1
title: Ovarian Tumor, 765///geo_accession: GSM461363///status: Public on Oct 17 2009///submission_date: Oct 11 2009///last_update_date: Jan 19 2011///type: RNA///channel_count: 1///source_name_ch1: papillary serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: papillary serous ovarian adenocarcinoma///characteristics_ch1.1: tumor stage: late///characteristics_ch1.2: tumor grade: high///characteristics_ch1.3: surv data: 12///treatment_protocol_ch1: All specimens were subjected to laser-based microdissection and analyzed as pure, microdissected epithelial cell populations.///molecule_ch1: total RNA///extract_protocol_ch1: RNeasy Micro Kit according to the manufacturers protocol (Qiagen Inc., Valencia, CA).///label_ch1: biotin///label_protocol_ch1: Two rounds of amplification were completed according to standard Affymetrix Two-Cycle Amplification protocol using 25ng of total RNA.///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Arrays were scanned using the laser confocal GeneChip Scanner 3000 (Affymetrix).///description: Gene expression data from tumor.///description.1: 765///data_processing: Low-level analysis included array normalization and estimation of expression level using an invariant set of probe sets to adjust the overall signal level of the arrays to the same level. Next, a model-based PM-only approach established gene expression levels using dChip software. A modified semi-supervised method was applied in two stages: (1) supervised dimension reduction by fitting a univariate Cox model that included a jackknifing step to each gene, so only those genes with a consistently large Cox score were included in the signature. Among 200, 100, or 300 probe sets, 200 yielded an optimally sized predictor; (2) In stage 2, the dimensions of the data set were reduced from 200 to 5 by PC analysis. The number of PCs was set at 5 capturing 90
1
title: Ovarian Tumor, 778///geo_accession: GSM461399///status: Public on Oct 17 2009///submission_date: Oct 11 2009///last_update_date: Jan 19 2011///type: RNA///channel_count: 1///source_name_ch1: papillary serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: papillary serous ovarian adenocarcinoma///characteristics_ch1.1: tumor stage: late///characteristics_ch1.2: tumor grade: high///characteristics_ch1.3: surv data: 16///treatment_protocol_ch1: All specimens were subjected to laser-based microdissection and analyzed as pure, microdissected epithelial cell populations.///molecule_ch1: total RNA///extract_protocol_ch1: RNeasy Micro Kit according to the manufacturers protocol (Qiagen Inc., Valencia, CA).///label_ch1: biotin///label_protocol_ch1: Two rounds of amplification were completed according to standard Affymetrix Two-Cycle Amplification protocol using 25ng of total RNA.///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Arrays were scanned using the laser confocal GeneChip Scanner 3000 (Affymetrix).///description: Gene expression data from tumor.///description.1: 778///data_processing: Low-level analysis included array normalization and estimation of expression level using an invariant set of probe sets to adjust the overall signal level of the arrays to the same level. Next, a model-based PM-only approach established gene expression levels using dChip software. A modified semi-supervised method was applied in two stages: (1) supervised dimension reduction by fitting a univariate Cox model that included a jackknifing step to each gene, so only those genes with a consistently large Cox score were included in the signature. Among 200, 100, or 300 probe sets, 200 yielded an optimally sized predictor; (2) In stage 2, the dimensions of the data set were reduced from 200 to 5 by PC analysis. The number of PCs was set at 5 capturing 90
1
title: Ovarian Tumor, 780///geo_accession: GSM461364///status: Public on Oct 17 2009///submission_date: Oct 11 2009///last_update_date: Jan 19 2011///type: RNA///channel_count: 1///source_name_ch1: papillary serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: papillary serous ovarian adenocarcinoma///characteristics_ch1.1: tumor stage: late///characteristics_ch1.2: tumor grade: high///characteristics_ch1.3: surv data: 11///treatment_protocol_ch1: All specimens were subjected to laser-based microdissection and analyzed as pure, microdissected epithelial cell populations.///molecule_ch1: total RNA///extract_protocol_ch1: RNeasy Micro Kit according to the manufacturers protocol (Qiagen Inc., Valencia, CA).///label_ch1: biotin///label_protocol_ch1: Two rounds of amplification were completed according to standard Affymetrix Two-Cycle Amplification protocol using 25ng of total RNA.///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Arrays were scanned using the laser confocal GeneChip Scanner 3000 (Affymetrix).///description: Gene expression data from tumor.///description.1: 780///data_processing: Low-level analysis included array normalization and estimation of expression level using an invariant set of probe sets to adjust the overall signal level of the arrays to the same level. Next, a model-based PM-only approach established gene expression levels using dChip software. A modified semi-supervised method was applied in two stages: (1) supervised dimension reduction by fitting a univariate Cox model that included a jackknifing step to each gene, so only those genes with a consistently large Cox score were included in the signature. Among 200, 100, or 300 probe sets, 200 yielded an optimally sized predictor; (2) In stage 2, the dimensions of the data set were reduced from 200 to 5 by PC analysis. The number of PCs was set at 5 capturing 90
1
title: Ovarian Tumor, 786///geo_accession: GSM461387///status: Public on Oct 17 2009///submission_date: Oct 11 2009///last_update_date: Jan 19 2011///type: RNA///channel_count: 1///source_name_ch1: papillary serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: papillary serous ovarian adenocarcinoma///characteristics_ch1.1: tumor stage: late///characteristics_ch1.2: tumor grade: high///characteristics_ch1.3: surv data: 48 (A)///treatment_protocol_ch1: All specimens were subjected to laser-based microdissection and analyzed as pure, microdissected epithelial cell populations.///molecule_ch1: total RNA///extract_protocol_ch1: RNeasy Micro Kit according to the manufacturers protocol (Qiagen Inc., Valencia, CA).///label_ch1: biotin///label_protocol_ch1: Two rounds of amplification were completed according to standard Affymetrix Two-Cycle Amplification protocol using 25ng of total RNA.///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Arrays were scanned using the laser confocal GeneChip Scanner 3000 (Affymetrix).///description: Gene expression data from tumor.///description.1: 786///data_processing: Low-level analysis included array normalization and estimation of expression level using an invariant set of probe sets to adjust the overall signal level of the arrays to the same level. Next, a model-based PM-only approach established gene expression levels using dChip software. A modified semi-supervised method was applied in two stages: (1) supervised dimension reduction by fitting a univariate Cox model that included a jackknifing step to each gene, so only those genes with a consistently large Cox score were included in the signature. Among 200, 100, or 300 probe sets, 200 yielded an optimally sized predictor; (2) In stage 2, the dimensions of the data set were reduced from 200 to 5 by PC analysis. The number of PCs was set at 5 capturing 90
1
title: Ovarian Tumor, 794///geo_accession: GSM461388///status: Public on Oct 17 2009///submission_date: Oct 11 2009///last_update_date: Jan 19 2011///type: RNA///channel_count: 1///source_name_ch1: papillary serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: papillary serous ovarian adenocarcinoma///characteristics_ch1.1: tumor stage: late///characteristics_ch1.2: tumor grade: high///characteristics_ch1.3: surv data: 15///treatment_protocol_ch1: All specimens were subjected to laser-based microdissection and analyzed as pure, microdissected epithelial cell populations.///molecule_ch1: total RNA///extract_protocol_ch1: RNeasy Micro Kit according to the manufacturers protocol (Qiagen Inc., Valencia, CA).///label_ch1: biotin///label_protocol_ch1: Two rounds of amplification were completed according to standard Affymetrix Two-Cycle Amplification protocol using 25ng of total RNA.///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Arrays were scanned using the laser confocal GeneChip Scanner 3000 (Affymetrix).///description: Gene expression data from tumor.///description.1: 794///data_processing: Low-level analysis included array normalization and estimation of expression level using an invariant set of probe sets to adjust the overall signal level of the arrays to the same level. Next, a model-based PM-only approach established gene expression levels using dChip software. A modified semi-supervised method was applied in two stages: (1) supervised dimension reduction by fitting a univariate Cox model that included a jackknifing step to each gene, so only those genes with a consistently large Cox score were included in the signature. Among 200, 100, or 300 probe sets, 200 yielded an optimally sized predictor; (2) In stage 2, the dimensions of the data set were reduced from 200 to 5 by PC analysis. The number of PCs was set at 5 capturing 90
1
title: Ovarian Tumor, 799///geo_accession: GSM461365///status: Public on Oct 17 2009///submission_date: Oct 11 2009///last_update_date: Jan 19 2011///type: RNA///channel_count: 1///source_name_ch1: papillary serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: papillary serous ovarian adenocarcinoma///characteristics_ch1.1: tumor stage: late///characteristics_ch1.2: tumor grade: high///characteristics_ch1.3: surv data: 5///treatment_protocol_ch1: All specimens were subjected to laser-based microdissection and analyzed as pure, microdissected epithelial cell populations.///molecule_ch1: total RNA///extract_protocol_ch1: RNeasy Micro Kit according to the manufacturers protocol (Qiagen Inc., Valencia, CA).///label_ch1: biotin///label_protocol_ch1: Two rounds of amplification were completed according to standard Affymetrix Two-Cycle Amplification protocol using 25ng of total RNA.///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Arrays were scanned using the laser confocal GeneChip Scanner 3000 (Affymetrix).///description: Gene expression data from tumor.///description.1: 799///data_processing: Low-level analysis included array normalization and estimation of expression level using an invariant set of probe sets to adjust the overall signal level of the arrays to the same level. Next, a model-based PM-only approach established gene expression levels using dChip software. A modified semi-supervised method was applied in two stages: (1) supervised dimension reduction by fitting a univariate Cox model that included a jackknifing step to each gene, so only those genes with a consistently large Cox score were included in the signature. Among 200, 100, or 300 probe sets, 200 yielded an optimally sized predictor; (2) In stage 2, the dimensions of the data set were reduced from 200 to 5 by PC analysis. The number of PCs was set at 5 capturing 90
1
title: Ovarian Tumor, 800///geo_accession: GSM461371///status: Public on Oct 17 2009///submission_date: Oct 11 2009///last_update_date: Jan 19 2011///type: RNA///channel_count: 1///source_name_ch1: papillary serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: papillary serous ovarian adenocarcinoma///characteristics_ch1.1: tumor stage: late///characteristics_ch1.2: tumor grade: high///characteristics_ch1.3: surv data: 36///treatment_protocol_ch1: All specimens were subjected to laser-based microdissection and analyzed as pure, microdissected epithelial cell populations.///molecule_ch1: total RNA///extract_protocol_ch1: RNeasy Micro Kit according to the manufacturers protocol (Qiagen Inc., Valencia, CA).///label_ch1: biotin///label_protocol_ch1: Two rounds of amplification were completed according to standard Affymetrix Two-Cycle Amplification protocol using 25ng of total RNA.///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Arrays were scanned using the laser confocal GeneChip Scanner 3000 (Affymetrix).///description: Gene expression data from tumor.///description.1: 800///data_processing: Low-level analysis included array normalization and estimation of expression level using an invariant set of probe sets to adjust the overall signal level of the arrays to the same level. Next, a model-based PM-only approach established gene expression levels using dChip software. A modified semi-supervised method was applied in two stages: (1) supervised dimension reduction by fitting a univariate Cox model that included a jackknifing step to each gene, so only those genes with a consistently large Cox score were included in the signature. Among 200, 100, or 300 probe sets, 200 yielded an optimally sized predictor; (2) In stage 2, the dimensions of the data set were reduced from 200 to 5 by PC analysis. The number of PCs was set at 5 capturing 90
1
title: Ovarian Tumor, 872///geo_accession: GSM461366///status: Public on Oct 17 2009///submission_date: Oct 11 2009///last_update_date: Jan 19 2011///type: RNA///channel_count: 1///source_name_ch1: papillary serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: papillary serous ovarian adenocarcinoma///characteristics_ch1.1: tumor stage: late///characteristics_ch1.2: tumor grade: high///characteristics_ch1.3: surv data: 9///treatment_protocol_ch1: All specimens were subjected to laser-based microdissection and analyzed as pure, microdissected epithelial cell populations.///molecule_ch1: total RNA///extract_protocol_ch1: RNeasy Micro Kit according to the manufacturers protocol (Qiagen Inc., Valencia, CA).///label_ch1: biotin///label_protocol_ch1: Two rounds of amplification were completed according to standard Affymetrix Two-Cycle Amplification protocol using 25ng of total RNA.///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Arrays were scanned using the laser confocal GeneChip Scanner 3000 (Affymetrix).///description: Gene expression data from tumor.///description.1: 872///data_processing: Low-level analysis included array normalization and estimation of expression level using an invariant set of probe sets to adjust the overall signal level of the arrays to the same level. Next, a model-based PM-only approach established gene expression levels using dChip software. A modified semi-supervised method was applied in two stages: (1) supervised dimension reduction by fitting a univariate Cox model that included a jackknifing step to each gene, so only those genes with a consistently large Cox score were included in the signature. Among 200, 100, or 300 probe sets, 200 yielded an optimally sized predictor; (2) In stage 2, the dimensions of the data set were reduced from 200 to 5 by PC analysis. The number of PCs was set at 5 capturing 90
1
title: Ovarian Tumor, 934///geo_accession: GSM461372///status: Public on Oct 17 2009///submission_date: Oct 11 2009///last_update_date: Jan 19 2011///type: RNA///channel_count: 1///source_name_ch1: papillary serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: papillary serous ovarian adenocarcinoma///characteristics_ch1.1: tumor stage: late///characteristics_ch1.2: tumor grade: high///characteristics_ch1.3: surv data: 36 (A)///treatment_protocol_ch1: All specimens were subjected to laser-based microdissection and analyzed as pure, microdissected epithelial cell populations.///molecule_ch1: total RNA///extract_protocol_ch1: RNeasy Micro Kit according to the manufacturers protocol (Qiagen Inc., Valencia, CA).///label_ch1: biotin///label_protocol_ch1: Two rounds of amplification were completed according to standard Affymetrix Two-Cycle Amplification protocol using 25ng of total RNA.///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Arrays were scanned using the laser confocal GeneChip Scanner 3000 (Affymetrix).///description: Gene expression data from tumor.///description.1: 934///data_processing: Low-level analysis included array normalization and estimation of expression level using an invariant set of probe sets to adjust the overall signal level of the arrays to the same level. Next, a model-based PM-only approach established gene expression levels using dChip software. A modified semi-supervised method was applied in two stages: (1) supervised dimension reduction by fitting a univariate Cox model that included a jackknifing step to each gene, so only those genes with a consistently large Cox score were included in the signature. Among 200, 100, or 300 probe sets, 200 yielded an optimally sized predictor; (2) In stage 2, the dimensions of the data set were reduced from 200 to 5 by PC analysis. The number of PCs was set at 5 capturing 90
1
title: Ovarian Tumor, 970///geo_accession: GSM461389///status: Public on Oct 17 2009///submission_date: Oct 11 2009///last_update_date: Jan 19 2011///type: RNA///channel_count: 1///source_name_ch1: papillary serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: papillary serous ovarian adenocarcinoma///characteristics_ch1.1: tumor stage: late///characteristics_ch1.2: tumor grade: high///characteristics_ch1.3: surv data: 18///treatment_protocol_ch1: All specimens were subjected to laser-based microdissection and analyzed as pure, microdissected epithelial cell populations.///molecule_ch1: total RNA///extract_protocol_ch1: RNeasy Micro Kit according to the manufacturers protocol (Qiagen Inc., Valencia, CA).///label_ch1: biotin///label_protocol_ch1: Two rounds of amplification were completed according to standard Affymetrix Two-Cycle Amplification protocol using 25ng of total RNA.///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Arrays were scanned using the laser confocal GeneChip Scanner 3000 (Affymetrix).///description: Gene expression data from tumor.///description.1: 970///data_processing: Low-level analysis included array normalization and estimation of expression level using an invariant set of probe sets to adjust the overall signal level of the arrays to the same level. Next, a model-based PM-only approach established gene expression levels using dChip software. A modified semi-supervised method was applied in two stages: (1) supervised dimension reduction by fitting a univariate Cox model that included a jackknifing step to each gene, so only those genes with a consistently large Cox score were included in the signature. Among 200, 100, or 300 probe sets, 200 yielded an optimally sized predictor; (2) In stage 2, the dimensions of the data set were reduced from 200 to 5 by PC analysis. The number of PCs was set at 5 capturing 90
1
duplicates:
GSE18520.GSE18520_GSM462649
1
GSE18520.GSE18520_GSM462649///GSE18520.GSE18520_GSM462650
1
GSE18520.GSE18520_GSM462650
1
NA's
60
An expression set
To define a gene expression profile of BRCAness that correlates with chemotherapy response and outcome in epithelial ovarian cancer (EOC).A publicly available microarray data set including 61 patients with EOC with either sporadic disease or BRCA(1/2) germline mutations was used for development of the BRCAness profile. Correlation with platinum responsiveness was assessed in platinum-sensitive and platinum-resistant tumor biopsy specimens from six patients with BRCA germline mutations. Association with poly-ADP ribose polymerase (PARP) inhibitor responsiveness and with radiation-induced RAD51 foci formation (a surrogate of homologous recombination) was assessed in Capan-1 cell line clones. The BRCAness profile was validated in 70 patients enriched for sporadic disease to assess its association with outcome.The BRCAness profile accurately predicted platinum responsiveness in eight out of 10 patient-derived tumor specimens, and between PARP-inhibitor sensitivity and resistance in four out of four Capan-1 clones. [corrected] When applied to the 70 patients with sporadic disease, patients with the BRCA-like (BL) profile had improved disease-free survival (34 months v 15 months; log-rank P = .013) and overall survival (72 months v 41 months; log-rank P = .006) compared with patients with a non-BRCA-like (NBL) profile, respectively. The BRCAness profile maintained independent prognostic value in multivariate analysis, which controlled for other known clinical prognostic factors.The BRCAness profile correlates with responsiveness to platinum and PARP inhibitors and identifies a subset of sporadic patients with improved outcome. Additional evaluation of this profile as a predictive tool in patients with sporadic EOC is warranted.
experimentData(eset):
Experiment data
Experimenter name: Konstantinopoulos PA, Spentzos D, Karlan BY, Taniguchi T et al. Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer. J Clin Oncol 2010 Aug 1;28(22):3555-61.
Laboratory: Konstantinopoulos, Cannistra 2010 hgu95
Contact information:
Title: Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer.
URL:
PMIDs: 20547991
Abstract: A 241 word abstract is available. Use 'abstract' method.
Information is available on: preprocessing
notes:
platform_title:
[HG_U95Av2] Affymetrix Human Genome U95 Version 2 Array
platform_shorttitle:
Affymetrix HG_U95Av2
platform_summary:
hgu95av2
platform_manufacturer:
Affymetrix
platform_distribution:
commercial
platform_accession:
GPL570|GPL8300
version:
2015-09-22 19:26:29
featureData(eset):
An object of class 'AnnotatedDataFrame'
featureNames: 1007_s_at 1053_at ... AFFX-MurIL4_at (54253 total)
varLabels: probeset gene EntrezGene.ID best_probe
varMetadata: labelDescription
assayData: 54253 features, 70 samples
Platform type:
Overall survival time-to-event summary (in years):
Call: survfit(formula = Surv(time, cens) ~ -1)
n events median 0.95LCL 0.95UCL
70.00 40.00 3.78 2.96 5.92
---------------------------
Available sample meta-data:
---------------------------
alt_sample_name:
Ovarian cancer_sample 1 Ovarian cancer_sample 10 Ovarian cancer_sample 11
1 1 1
Ovarian cancer_sample 12 Ovarian cancer_sample 13 Ovarian cancer_sample 14
1 1 1
Ovarian cancer_sample 15 Ovarian cancer_sample 16 Ovarian cancer_sample 17
1 1 1
Ovarian cancer_sample 18 Ovarian cancer_sample 19 Ovarian cancer_sample 2
1 1 1
Ovarian cancer_sample 20 Ovarian cancer_sample 21 Ovarian cancer_sample 22
1 1 1
Ovarian cancer_sample 23 Ovarian cancer_sample 24 Ovarian cancer_sample 25
1 1 1
Ovarian cancer_sample 26 Ovarian cancer_sample 27 Ovarian cancer_sample 28
1 1 1
Ovarian cancer_sample 29 Ovarian cancer_sample 3 Ovarian cancer_sample 30
1 1 1
Ovarian cancer_sample 31 Ovarian cancer_sample 32 Ovarian cancer_sample 33
1 1 1
Ovarian cancer_sample 34 Ovarian cancer_sample 35 Ovarian cancer_sample 36
1 1 1
Ovarian cancer_sample 37 Ovarian cancer_sample 38 Ovarian cancer_sample 39
1 1 1
Ovarian cancer_sample 4 Ovarian cancer_sample 40 Ovarian cancer_sample 41
1 1 1
Ovarian cancer_sample 42 Ovarian cancer_sample 43 Ovarian cancer_sample 44
1 1 1
Ovarian cancer_sample 45 Ovarian cancer_sample 46 Ovarian cancer_sample 47
1 1 1
Ovarian cancer_sample 48 Ovarian cancer_sample 49 Ovarian cancer_sample 5
1 1 1
Ovarian cancer_sample 50 Ovarian cancer_sample 51 Ovarian cancer_sample 52
1 1 1
Ovarian cancer_sample 53 Ovarian cancer_sample 54 Ovarian cancer_sample 55
1 1 1
Ovarian cancer_sample 56 Ovarian cancer_sample 57 Ovarian cancer_sample 58
1 1 1
Ovarian cancer_sample 59 Ovarian cancer_sample 6 Ovarian cancer_sample 60
1 1 1
Ovarian cancer_sample 61 Ovarian cancer_sample 62 Ovarian cancer_sample 63
1 1 1
Ovarian cancer_sample 64 Ovarian cancer_sample 65 Ovarian cancer_sample 66
1 1 1
Ovarian cancer_sample 67 Ovarian cancer_sample 68 Ovarian cancer_sample 69
1 1 1
Ovarian cancer_sample 7 Ovarian cancer_sample 70 Ovarian cancer_sample 8
1 1 1
Ovarian cancer_sample 9
1
batch:
2001-09-14 2001-12-14 2002-08-20 2003-09-09 2003-09-18 2009-08-14
7 4 14 13 4 28
days_to_death:
Min. 1st Qu. Median Mean 3rd Qu. Max.
30.0 667.5 1125.0 1170.0 1522.0 3450.0
primarysite:
ov
70
sample_type:
tumor
70
uncurated_author_metadata:
title: Ovarian cancer_sample 10///geo_accession: GSM495148///status: Public on Jul 11 2010///submission_date: Jan 11 2010///last_update_date: Jul 11 2010///type: RNA///channel_count: 1///source_name_ch1: Ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: overall survival (months): 37///characteristics_ch1.1: overall survival (censored): 1 [event (death)]///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated using the trizol protocol///label_ch1: biotin///label_protocol_ch1: RNA is converted into cDNA using a T7 promoter-tailed oligo-dT primer in the synthesis of the first cDNA strand; second strand cDNA synthesis is then carried out.///label_protocol_ch1.1: The double-stranded cDNA is used as the template in an in vitro transcription (IVT) reaction catalyzed by T7 polymerase and containing biotinylated CTP and UTP in addition to the four unmodified ribonucleoside triphosphates///taxid_ch1: 9606///hyb_protocol: Standard Affymetrix protocol.///scan_protocol: Standard Affymetrix protocol. Each cRNA bound at its complementary oligonucleotide is excited using a confocal laser scanner, and the positions and intensities of the fluorescent emissions are captured.///description: PK2009081437///data_processing: RMA///platform_id: GPL570///contact_name: panagiotis,,konstantinopoulos///contact_email: [email protected]///contact_department: hem/onc///contact_institute: bidmc///contact_address: 330 brookline av///contact_city: boston///contact_state: MA///contact_zip.postal_code: 2215///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM495nnn/GSM495148/GSM495148.CEL.gz///data_row_count: 54675
1
title: Ovarian cancer_sample 11///geo_accession: GSM495149///status: Public on Jul 11 2010///submission_date: Jan 11 2010///last_update_date: Jul 11 2010///type: RNA///channel_count: 1///source_name_ch1: Ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: overall survival (months): 54///characteristics_ch1.1: overall survival (censored): 1 [event (death)]///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated using the trizol protocol///label_ch1: biotin///label_protocol_ch1: RNA is converted into cDNA using a T7 promoter-tailed oligo-dT primer in the synthesis of the first cDNA strand; second strand cDNA synthesis is then carried out.///label_protocol_ch1.1: The double-stranded cDNA is used as the template in an in vitro transcription (IVT) reaction catalyzed by T7 polymerase and containing biotinylated CTP and UTP in addition to the four unmodified ribonucleoside triphosphates///taxid_ch1: 9606///hyb_protocol: Standard Affymetrix protocol.///scan_protocol: Standard Affymetrix protocol. Each cRNA bound at its complementary oligonucleotide is excited using a confocal laser scanner, and the positions and intensities of the fluorescent emissions are captured.///description: PK2009081438///data_processing: RMA///platform_id: GPL570///contact_name: panagiotis,,konstantinopoulos///contact_email: [email protected]///contact_department: hem/onc///contact_institute: bidmc///contact_address: 330 brookline av///contact_city: boston///contact_state: MA///contact_zip.postal_code: 2215///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM495nnn/GSM495149/GSM495149.CEL.gz///data_row_count: 54675
1
title: Ovarian cancer_sample 12///geo_accession: GSM495150///status: Public on Jul 11 2010///submission_date: Jan 11 2010///last_update_date: Jul 11 2010///type: RNA///channel_count: 1///source_name_ch1: Ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: overall survival (months): 63///characteristics_ch1.1: overall survival (censored): 0 [censored]///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated using the trizol protocol///label_ch1: biotin///label_protocol_ch1: RNA is converted into cDNA using a T7 promoter-tailed oligo-dT primer in the synthesis of the first cDNA strand; second strand cDNA synthesis is then carried out.///label_protocol_ch1.1: The double-stranded cDNA is used as the template in an in vitro transcription (IVT) reaction catalyzed by T7 polymerase and containing biotinylated CTP and UTP in addition to the four unmodified ribonucleoside triphosphates///taxid_ch1: 9606///hyb_protocol: Standard Affymetrix protocol.///scan_protocol: Standard Affymetrix protocol. Each cRNA bound at its complementary oligonucleotide is excited using a confocal laser scanner, and the positions and intensities of the fluorescent emissions are captured.///description: PK2009081439///data_processing: RMA///platform_id: GPL570///contact_name: panagiotis,,konstantinopoulos///contact_email: [email protected]///contact_department: hem/onc///contact_institute: bidmc///contact_address: 330 brookline av///contact_city: boston///contact_state: MA///contact_zip.postal_code: 2215///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM495nnn/GSM495150/GSM495150.CEL.gz///data_row_count: 54675
1
title: Ovarian cancer_sample 13///geo_accession: GSM495151///status: Public on Jul 11 2010///submission_date: Jan 11 2010///last_update_date: Jul 11 2010///type: RNA///channel_count: 1///source_name_ch1: Ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: overall survival (months): 18///characteristics_ch1.1: overall survival (censored): 1 [event (death)]///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated using the trizol protocol///label_ch1: biotin///label_protocol_ch1: RNA is converted into cDNA using a T7 promoter-tailed oligo-dT primer in the synthesis of the first cDNA strand; second strand cDNA synthesis is then carried out.///label_protocol_ch1.1: The double-stranded cDNA is used as the template in an in vitro transcription (IVT) reaction catalyzed by T7 polymerase and containing biotinylated CTP and UTP in addition to the four unmodified ribonucleoside triphosphates///taxid_ch1: 9606///hyb_protocol: Standard Affymetrix protocol.///scan_protocol: Standard Affymetrix protocol. Each cRNA bound at its complementary oligonucleotide is excited using a confocal laser scanner, and the positions and intensities of the fluorescent emissions are captured.///description: PK2009081440///data_processing: RMA///platform_id: GPL570///contact_name: panagiotis,,konstantinopoulos///contact_email: [email protected]///contact_department: hem/onc///contact_institute: bidmc///contact_address: 330 brookline av///contact_city: boston///contact_state: MA///contact_zip.postal_code: 2215///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM495nnn/GSM495151/GSM495151.CEL.gz///data_row_count: 54675
1
title: Ovarian cancer_sample 14///geo_accession: GSM495152///status: Public on Jul 11 2010///submission_date: Jan 11 2010///last_update_date: Jul 11 2010///type: RNA///channel_count: 1///source_name_ch1: Ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: overall survival (months): 72///characteristics_ch1.1: overall survival (censored): 1 [event (death)]///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated using the trizol protocol///label_ch1: biotin///label_protocol_ch1: RNA is converted into cDNA using a T7 promoter-tailed oligo-dT primer in the synthesis of the first cDNA strand; second strand cDNA synthesis is then carried out.///label_protocol_ch1.1: The double-stranded cDNA is used as the template in an in vitro transcription (IVT) reaction catalyzed by T7 polymerase and containing biotinylated CTP and UTP in addition to the four unmodified ribonucleoside triphosphates///taxid_ch1: 9606///hyb_protocol: Standard Affymetrix protocol.///scan_protocol: Standard Affymetrix protocol. Each cRNA bound at its complementary oligonucleotide is excited using a confocal laser scanner, and the positions and intensities of the fluorescent emissions are captured.///description: PK2009081441///data_processing: RMA///platform_id: GPL570///contact_name: panagiotis,,konstantinopoulos///contact_email: [email protected]///contact_department: hem/onc///contact_institute: bidmc///contact_address: 330 brookline av///contact_city: boston///contact_state: MA///contact_zip.postal_code: 2215///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM495nnn/GSM495152/GSM495152.CEL.gz///data_row_count: 54675
1
title: Ovarian cancer_sample 15///geo_accession: GSM495153///status: Public on Jul 11 2010///submission_date: Jan 11 2010///last_update_date: Jul 11 2010///type: RNA///channel_count: 1///source_name_ch1: Ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: overall survival (months): 72///characteristics_ch1.1: overall survival (censored): 1 [event (death)]///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated using the trizol protocol///label_ch1: biotin///label_protocol_ch1: RNA is converted into cDNA using a T7 promoter-tailed oligo-dT primer in the synthesis of the first cDNA strand; second strand cDNA synthesis is then carried out.///label_protocol_ch1.1: The double-stranded cDNA is used as the template in an in vitro transcription (IVT) reaction catalyzed by T7 polymerase and containing biotinylated CTP and UTP in addition to the four unmodified ribonucleoside triphosphates///taxid_ch1: 9606///hyb_protocol: Standard Affymetrix protocol.///scan_protocol: Standard Affymetrix protocol. Each cRNA bound at its complementary oligonucleotide is excited using a confocal laser scanner, and the positions and intensities of the fluorescent emissions are captured.///description: PK2009081442///data_processing: RMA///platform_id: GPL570///contact_name: panagiotis,,konstantinopoulos///contact_email: [email protected]///contact_department: hem/onc///contact_institute: bidmc///contact_address: 330 brookline av///contact_city: boston///contact_state: MA///contact_zip.postal_code: 2215///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM495nnn/GSM495153/GSM495153.CEL.gz///data_row_count: 54675
1
title: Ovarian cancer_sample 16///geo_accession: GSM495154///status: Public on Jul 11 2010///submission_date: Jan 11 2010///last_update_date: Jul 11 2010///type: RNA///channel_count: 1///source_name_ch1: Ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: overall survival (months): 10///characteristics_ch1.1: overall survival (censored): 1 [event (death)]///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated using the trizol protocol///label_ch1: biotin///label_protocol_ch1: RNA is converted into cDNA using a T7 promoter-tailed oligo-dT primer in the synthesis of the first cDNA strand; second strand cDNA synthesis is then carried out.///label_protocol_ch1.1: The double-stranded cDNA is used as the template in an in vitro transcription (IVT) reaction catalyzed by T7 polymerase and containing biotinylated CTP and UTP in addition to the four unmodified ribonucleoside triphosphates///taxid_ch1: 9606///hyb_protocol: Standard Affymetrix protocol.///scan_protocol: Standard Affymetrix protocol. Each cRNA bound at its complementary oligonucleotide is excited using a confocal laser scanner, and the positions and intensities of the fluorescent emissions are captured.///description: PK2009081443///data_processing: RMA///platform_id: GPL570///contact_name: panagiotis,,konstantinopoulos///contact_email: [email protected]///contact_department: hem/onc///contact_institute: bidmc///contact_address: 330 brookline av///contact_city: boston///contact_state: MA///contact_zip.postal_code: 2215///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM495nnn/GSM495154/GSM495154.CEL.gz///data_row_count: 54675
1
title: Ovarian cancer_sample 17///geo_accession: GSM495155///status: Public on Jul 11 2010///submission_date: Jan 11 2010///last_update_date: Jul 11 2010///type: RNA///channel_count: 1///source_name_ch1: Ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: overall survival (months): 32///characteristics_ch1.1: overall survival (censored): 1 [event (death)]///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated using the trizol protocol///label_ch1: biotin///label_protocol_ch1: RNA is converted into cDNA using a T7 promoter-tailed oligo-dT primer in the synthesis of the first cDNA strand; second strand cDNA synthesis is then carried out.///label_protocol_ch1.1: The double-stranded cDNA is used as the template in an in vitro transcription (IVT) reaction catalyzed by T7 polymerase and containing biotinylated CTP and UTP in addition to the four unmodified ribonucleoside triphosphates///taxid_ch1: 9606///hyb_protocol: Standard Affymetrix protocol.///scan_protocol: Standard Affymetrix protocol. Each cRNA bound at its complementary oligonucleotide is excited using a confocal laser scanner, and the positions and intensities of the fluorescent emissions are captured.///description: PK2009081444///data_processing: RMA///platform_id: GPL570///contact_name: panagiotis,,konstantinopoulos///contact_email: [email protected]///contact_department: hem/onc///contact_institute: bidmc///contact_address: 330 brookline av///contact_city: boston///contact_state: MA///contact_zip.postal_code: 2215///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM495nnn/GSM495155/GSM495155.CEL.gz///data_row_count: 54675
1
title: Ovarian cancer_sample 18///geo_accession: GSM495156///status: Public on Jul 11 2010///submission_date: Jan 11 2010///last_update_date: Jul 11 2010///type: RNA///channel_count: 1///source_name_ch1: Ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: overall survival (months): 48///characteristics_ch1.1: overall survival (censored): 1 [event (death)]///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated using the trizol protocol///label_ch1: biotin///label_protocol_ch1: RNA is converted into cDNA using a T7 promoter-tailed oligo-dT primer in the synthesis of the first cDNA strand; second strand cDNA synthesis is then carried out.///label_protocol_ch1.1: The double-stranded cDNA is used as the template in an in vitro transcription (IVT) reaction catalyzed by T7 polymerase and containing biotinylated CTP and UTP in addition to the four unmodified ribonucleoside triphosphates///taxid_ch1: 9606///hyb_protocol: Standard Affymetrix protocol.///scan_protocol: Standard Affymetrix protocol. Each cRNA bound at its complementary oligonucleotide is excited using a confocal laser scanner, and the positions and intensities of the fluorescent emissions are captured.///description: PK2009081445///data_processing: RMA///platform_id: GPL570///contact_name: panagiotis,,konstantinopoulos///contact_email: [email protected]///contact_department: hem/onc///contact_institute: bidmc///contact_address: 330 brookline av///contact_city: boston///contact_state: MA///contact_zip.postal_code: 2215///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM495nnn/GSM495156/GSM495156.CEL.gz///data_row_count: 54675
1
title: Ovarian cancer_sample 19///geo_accession: GSM495157///status: Public on Jul 11 2010///submission_date: Jan 11 2010///last_update_date: Jul 11 2010///type: RNA///channel_count: 1///source_name_ch1: Ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: overall survival (months): 63///characteristics_ch1.1: overall survival (censored): 0 [censored]///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated using the trizol protocol///label_ch1: biotin///label_protocol_ch1: RNA is converted into cDNA using a T7 promoter-tailed oligo-dT primer in the synthesis of the first cDNA strand; second strand cDNA synthesis is then carried out.///label_protocol_ch1.1: The double-stranded cDNA is used as the template in an in vitro transcription (IVT) reaction catalyzed by T7 polymerase and containing biotinylated CTP and UTP in addition to the four unmodified ribonucleoside triphosphates///taxid_ch1: 9606///hyb_protocol: Standard Affymetrix protocol.///scan_protocol: Standard Affymetrix protocol. Each cRNA bound at its complementary oligonucleotide is excited using a confocal laser scanner, and the positions and intensities of the fluorescent emissions are captured.///description: PK2009081446///data_processing: RMA///platform_id: GPL570///contact_name: panagiotis,,konstantinopoulos///contact_email: [email protected]///contact_department: hem/onc///contact_institute: bidmc///contact_address: 330 brookline av///contact_city: boston///contact_state: MA///contact_zip.postal_code: 2215///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM495nnn/GSM495157/GSM495157.CEL.gz///data_row_count: 54675
1
title: Ovarian cancer_sample 1///geo_accession: GSM495139///status: Public on Jul 11 2010///submission_date: Jan 11 2010///last_update_date: Jul 11 2010///type: RNA///channel_count: 1///source_name_ch1: Ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: overall survival (months): 18///characteristics_ch1.1: overall survival (censored): 1 [event (death)]///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated using the trizol protocol///label_ch1: biotin///label_protocol_ch1: RNA is converted into cDNA using a T7 promoter-tailed oligo-dT primer in the synthesis of the first cDNA strand; second strand cDNA synthesis is then carried out.///label_protocol_ch1.1: The double-stranded cDNA is used as the template in an in vitro transcription (IVT) reaction catalyzed by T7 polymerase and containing biotinylated CTP and UTP in addition to the four unmodified ribonucleoside triphosphates///taxid_ch1: 9606///hyb_protocol: Standard Affymetrix protocol.///scan_protocol: Standard Affymetrix protocol. Each cRNA bound at its complementary oligonucleotide is excited using a confocal laser scanner, and the positions and intensities of the fluorescent emissions are captured.///description: PK2009081427///data_processing: RMA///platform_id: GPL570///contact_name: panagiotis,,konstantinopoulos///contact_email: [email protected]///contact_department: hem/onc///contact_institute: bidmc///contact_address: 330 brookline av///contact_city: boston///contact_state: MA///contact_zip.postal_code: 2215///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM495nnn/GSM495139/GSM495139.CEL.gz///data_row_count: 54675
1
title: Ovarian cancer_sample 20///geo_accession: GSM495158///status: Public on Jul 11 2010///submission_date: Jan 11 2010///last_update_date: Jul 11 2010///type: RNA///channel_count: 1///source_name_ch1: Ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: overall survival (months): 41///characteristics_ch1.1: overall survival (censored): 1 [event (death)]///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated using the trizol protocol///label_ch1: biotin///label_protocol_ch1: RNA is converted into cDNA using a T7 promoter-tailed oligo-dT primer in the synthesis of the first cDNA strand; second strand cDNA synthesis is then carried out.///label_protocol_ch1.1: The double-stranded cDNA is used as the template in an in vitro transcription (IVT) reaction catalyzed by T7 polymerase and containing biotinylated CTP and UTP in addition to the four unmodified ribonucleoside triphosphates///taxid_ch1: 9606///hyb_protocol: Standard Affymetrix protocol.///scan_protocol: Standard Affymetrix protocol. Each cRNA bound at its complementary oligonucleotide is excited using a confocal laser scanner, and the positions and intensities of the fluorescent emissions are captured.///description: PK2009081447///data_processing: RMA///platform_id: GPL570///contact_name: panagiotis,,konstantinopoulos///contact_email: [email protected]///contact_department: hem/onc///contact_institute: bidmc///contact_address: 330 brookline av///contact_city: boston///contact_state: MA///contact_zip.postal_code: 2215///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM495nnn/GSM495158/GSM495158.CEL.gz///data_row_count: 54675
1
title: Ovarian cancer_sample 21///geo_accession: GSM495159///status: Public on Jul 11 2010///submission_date: Jan 11 2010///last_update_date: Jul 11 2010///type: RNA///channel_count: 1///source_name_ch1: Ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: overall survival (months): 45///characteristics_ch1.1: overall survival (censored): 1 [event (death)]///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated using the trizol protocol///label_ch1: biotin///label_protocol_ch1: RNA is converted into cDNA using a T7 promoter-tailed oligo-dT primer in the synthesis of the first cDNA strand; second strand cDNA synthesis is then carried out.///label_protocol_ch1.1: The double-stranded cDNA is used as the template in an in vitro transcription (IVT) reaction catalyzed by T7 polymerase and containing biotinylated CTP and UTP in addition to the four unmodified ribonucleoside triphosphates///taxid_ch1: 9606///hyb_protocol: Standard Affymetrix protocol.///scan_protocol: Standard Affymetrix protocol. Each cRNA bound at its complementary oligonucleotide is excited using a confocal laser scanner, and the positions and intensities of the fluorescent emissions are captured.///description: PK2009081448///data_processing: RMA///platform_id: GPL570///contact_name: panagiotis,,konstantinopoulos///contact_email: [email protected]///contact_department: hem/onc///contact_institute: bidmc///contact_address: 330 brookline av///contact_city: boston///contact_state: MA///contact_zip.postal_code: 2215///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM495nnn/GSM495159/GSM495159.CEL.gz///data_row_count: 54675
1
title: Ovarian cancer_sample 22///geo_accession: GSM495160///status: Public on Jul 11 2010///submission_date: Jan 11 2010///last_update_date: Jul 11 2010///type: RNA///channel_count: 1///source_name_ch1: Ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: overall survival (months): 29///characteristics_ch1.1: overall survival (censored): 0 [censored]///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated using the trizol protocol///label_ch1: biotin///label_protocol_ch1: RNA is converted into cDNA using a T7 promoter-tailed oligo-dT primer in the synthesis of the first cDNA strand; second strand cDNA synthesis is then carried out.///label_protocol_ch1.1: The double-stranded cDNA is used as the template in an in vitro transcription (IVT) reaction catalyzed by T7 polymerase and containing biotinylated CTP and UTP in addition to the four unmodified ribonucleoside triphosphates///taxid_ch1: 9606///hyb_protocol: Standard Affymetrix protocol.///scan_protocol: Standard Affymetrix protocol. Each cRNA bound at its complementary oligonucleotide is excited using a confocal laser scanner, and the positions and intensities of the fluorescent emissions are captured.///description: PK2009081449///data_processing: RMA///platform_id: GPL570///contact_name: panagiotis,,konstantinopoulos///contact_email: [email protected]///contact_department: hem/onc///contact_institute: bidmc///contact_address: 330 brookline av///contact_city: boston///contact_state: MA///contact_zip.postal_code: 2215///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM495nnn/GSM495160/GSM495160.CEL.gz///data_row_count: 54675
1
title: Ovarian cancer_sample 23///geo_accession: GSM495161///status: Public on Jul 11 2010///submission_date: Jan 11 2010///last_update_date: Jul 11 2010///type: RNA///channel_count: 1///source_name_ch1: Ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: overall survival (months): 20///characteristics_ch1.1: overall survival (censored): 0 [censored]///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated using the trizol protocol///label_ch1: biotin///label_protocol_ch1: RNA is converted into cDNA using a T7 promoter-tailed oligo-dT primer in the synthesis of the first cDNA strand; second strand cDNA synthesis is then carried out.///label_protocol_ch1.1: The double-stranded cDNA is used as the template in an in vitro transcription (IVT) reaction catalyzed by T7 polymerase and containing biotinylated CTP and UTP in addition to the four unmodified ribonucleoside triphosphates///taxid_ch1: 9606///hyb_protocol: Standard Affymetrix protocol.///scan_protocol: Standard Affymetrix protocol. Each cRNA bound at its complementary oligonucleotide is excited using a confocal laser scanner, and the positions and intensities of the fluorescent emissions are captured.///description: PK2009081450///data_processing: RMA///platform_id: GPL570///contact_name: panagiotis,,konstantinopoulos///contact_email: [email protected]///contact_department: hem/onc///contact_institute: bidmc///contact_address: 330 brookline av///contact_city: boston///contact_state: MA///contact_zip.postal_code: 2215///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM495nnn/GSM495161/GSM495161.CEL.gz///data_row_count: 54675
1
title: Ovarian cancer_sample 24///geo_accession: GSM495162///status: Public on Jul 11 2010///submission_date: Jan 11 2010///last_update_date: Jul 11 2010///type: RNA///channel_count: 1///source_name_ch1: Ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: overall survival (months): 14///characteristics_ch1.1: overall survival (censored): 0 [censored]///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated using the trizol protocol///label_ch1: biotin///label_protocol_ch1: RNA is converted into cDNA using a T7 promoter-tailed oligo-dT primer in the synthesis of the first cDNA strand; second strand cDNA synthesis is then carried out.///label_protocol_ch1.1: The double-stranded cDNA is used as the template in an in vitro transcription (IVT) reaction catalyzed by T7 polymerase and containing biotinylated CTP and UTP in addition to the four unmodified ribonucleoside triphosphates///taxid_ch1: 9606///hyb_protocol: Standard Affymetrix protocol.///scan_protocol: Standard Affymetrix protocol. Each cRNA bound at its complementary oligonucleotide is excited using a confocal laser scanner, and the positions and intensities of the fluorescent emissions are captured.///description: PK2009081451///data_processing: RMA///platform_id: GPL570///contact_name: panagiotis,,konstantinopoulos///contact_email: [email protected]///contact_department: hem/onc///contact_institute: bidmc///contact_address: 330 brookline av///contact_city: boston///contact_state: MA///contact_zip.postal_code: 2215///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM495nnn/GSM495162/GSM495162.CEL.gz///data_row_count: 54675
1
title: Ovarian cancer_sample 25///geo_accession: GSM495163///status: Public on Jul 11 2010///submission_date: Jan 11 2010///last_update_date: Jul 11 2010///type: RNA///channel_count: 1///source_name_ch1: Ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: overall survival (months): 33///characteristics_ch1.1: overall survival (censored): 0 [censored]///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated using the trizol protocol///label_ch1: biotin///label_protocol_ch1: RNA is converted into cDNA using a T7 promoter-tailed oligo-dT primer in the synthesis of the first cDNA strand; second strand cDNA synthesis is then carried out.///label_protocol_ch1.1: The double-stranded cDNA is used as the template in an in vitro transcription (IVT) reaction catalyzed by T7 polymerase and containing biotinylated CTP and UTP in addition to the four unmodified ribonucleoside triphosphates///taxid_ch1: 9606///hyb_protocol: Standard Affymetrix protocol.///scan_protocol: Standard Affymetrix protocol. Each cRNA bound at its complementary oligonucleotide is excited using a confocal laser scanner, and the positions and intensities of the fluorescent emissions are captured.///description: PK2009081453///data_processing: RMA///platform_id: GPL570///contact_name: panagiotis,,konstantinopoulos///contact_email: [email protected]///contact_department: hem/onc///contact_institute: bidmc///contact_address: 330 brookline av///contact_city: boston///contact_state: MA///contact_zip.postal_code: 2215///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM495nnn/GSM495163/GSM495163.CEL.gz///data_row_count: 54675
1
title: Ovarian cancer_sample 26///geo_accession: GSM495164///status: Public on Jul 11 2010///submission_date: Jan 11 2010///last_update_date: Jul 11 2010///type: RNA///channel_count: 1///source_name_ch1: Ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: overall survival (months): 114///characteristics_ch1.1: overall survival (censored): 0 [censored]///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated using the trizol protocol///label_ch1: biotin///label_protocol_ch1: RNA is converted into cDNA using a T7 promoter-tailed oligo-dT primer in the synthesis of the first cDNA strand; second strand cDNA synthesis is then carried out.///label_protocol_ch1.1: The double-stranded cDNA is used as the template in an in vitro transcription (IVT) reaction catalyzed by T7 polymerase and containing biotinylated CTP and UTP in addition to the four unmodified ribonucleoside triphosphates///taxid_ch1: 9606///hyb_protocol: Standard Affymetrix protocol.///scan_protocol: Standard Affymetrix protocol. Each cRNA bound at its complementary oligonucleotide is excited using a confocal laser scanner, and the positions and intensities of the fluorescent emissions are captured.///description: PK2009081455///data_processing: RMA///platform_id: GPL570///contact_name: panagiotis,,konstantinopoulos///contact_email: [email protected]///contact_department: hem/onc///contact_institute: bidmc///contact_address: 330 brookline av///contact_city: boston///contact_state: MA///contact_zip.postal_code: 2215///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM495nnn/GSM495164/GSM495164.CEL.gz///data_row_count: 54675
1
title: Ovarian cancer_sample 27///geo_accession: GSM495165///status: Public on Jul 11 2010///submission_date: Jan 11 2010///last_update_date: Jul 11 2010///type: RNA///channel_count: 1///source_name_ch1: Ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: overall survival (months): 32///characteristics_ch1.1: overall survival (censored): 1 [event (death)]///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated using the trizol protocol///label_ch1: biotin///label_protocol_ch1: RNA is converted into cDNA using a T7 promoter-tailed oligo-dT primer in the synthesis of the first cDNA strand; second strand cDNA synthesis is then carried out.///label_protocol_ch1.1: The double-stranded cDNA is used as the template in an in vitro transcription (IVT) reaction catalyzed by T7 polymerase and containing biotinylated CTP and UTP in addition to the four unmodified ribonucleoside triphosphates///taxid_ch1: 9606///hyb_protocol: Standard Affymetrix protocol.///scan_protocol: Standard Affymetrix protocol. Each cRNA bound at its complementary oligonucleotide is excited using a confocal laser scanner, and the positions and intensities of the fluorescent emissions are captured.///description: PK2009081457///data_processing: RMA///platform_id: GPL570///contact_name: panagiotis,,konstantinopoulos///contact_email: [email protected]///contact_department: hem/onc///contact_institute: bidmc///contact_address: 330 brookline av///contact_city: boston///contact_state: MA///contact_zip.postal_code: 2215///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM495nnn/GSM495165/GSM495165.CEL.gz///data_row_count: 54675
1
title: Ovarian cancer_sample 28///geo_accession: GSM495166///status: Public on Jul 11 2010///submission_date: Jan 11 2010///last_update_date: Jul 11 2010///type: RNA///channel_count: 1///source_name_ch1: Ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: overall survival (months): 9///characteristics_ch1.1: overall survival (censored): 0 [censored]///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated using the trizol protocol///label_ch1: biotin///label_protocol_ch1: RNA is converted into cDNA using a T7 promoter-tailed oligo-dT primer in the synthesis of the first cDNA strand; second strand cDNA synthesis is then carried out.///label_protocol_ch1.1: The double-stranded cDNA is used as the template in an in vitro transcription (IVT) reaction catalyzed by T7 polymerase and containing biotinylated CTP and UTP in addition to the four unmodified ribonucleoside triphosphates///taxid_ch1: 9606///hyb_protocol: Standard Affymetrix protocol.///scan_protocol: Standard Affymetrix protocol. Each cRNA bound at its complementary oligonucleotide is excited using a confocal laser scanner, and the positions and intensities of the fluorescent emissions are captured.///description: PK2009081458///data_processing: RMA///platform_id: GPL570///contact_name: panagiotis,,konstantinopoulos///contact_email: [email protected]///contact_department: hem/onc///contact_institute: bidmc///contact_address: 330 brookline av///contact_city: boston///contact_state: MA///contact_zip.postal_code: 2215///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM495nnn/GSM495166/GSM495166.CEL.gz///data_row_count: 54675
1
title: Ovarian cancer_sample 29///geo_accession: GSM495167///status: Public on Jul 11 2010///submission_date: Jan 11 2010///last_update_date: Jul 11 2010///type: RNA///channel_count: 1///source_name_ch1: Ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: overall survival (months): 36///characteristics_ch1.1: overall survival (censored): 1 [event (death)]///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated using the trizol protocol///label_ch1: biotin///label_protocol_ch1: RNA is converted into cDNA using a T7 promoter-tailed oligo-dT primer in the synthesis of the first cDNA strand; second strand cDNA synthesis is then carried out.///label_protocol_ch1.1: The double-stranded cDNA is used as the template in an in vitro transcription (IVT) reaction catalyzed by T7 polymerase and containing biotinylated CTP and UTP in addition to the four unmodified ribonucleoside triphosphates///taxid_ch1: 9606///hyb_protocol: Standard Affymetrix protocol.///scan_protocol: Standard Affymetrix protocol. Each cRNA bound at its complementary oligonucleotide is excited using a confocal laser scanner, and the positions and intensities of the fluorescent emissions are captured.///description: 082002 HGU95Av2 DS 7A3///data_processing: RMA///platform_id: GPL8300///contact_name: panagiotis,,konstantinopoulos///contact_email: [email protected]///contact_department: hem/onc///contact_institute: bidmc///contact_address: 330 brookline av///contact_city: boston///contact_state: MA///contact_zip.postal_code: 2215///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM495nnn/GSM495167/GSM495167.CEL.gz///data_row_count: 12558
1
title: Ovarian cancer_sample 2///geo_accession: GSM495140///status: Public on Jul 11 2010///submission_date: Jan 11 2010///last_update_date: Jul 11 2010///type: RNA///channel_count: 1///source_name_ch1: Ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: overall survival (months): 48///characteristics_ch1.1: overall survival (censored): 1 [event (death)]///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated using the trizol protocol///label_ch1: biotin///label_protocol_ch1: RNA is converted into cDNA using a T7 promoter-tailed oligo-dT primer in the synthesis of the first cDNA strand; second strand cDNA synthesis is then carried out.///label_protocol_ch1.1: The double-stranded cDNA is used as the template in an in vitro transcription (IVT) reaction catalyzed by T7 polymerase and containing biotinylated CTP and UTP in addition to the four unmodified ribonucleoside triphosphates///taxid_ch1: 9606///hyb_protocol: Standard Affymetrix protocol.///scan_protocol: Standard Affymetrix protocol. Each cRNA bound at its complementary oligonucleotide is excited using a confocal laser scanner, and the positions and intensities of the fluorescent emissions are captured.///description: PK2009081428///data_processing: RMA///platform_id: GPL570///contact_name: panagiotis,,konstantinopoulos///contact_email: [email protected]///contact_department: hem/onc///contact_institute: bidmc///contact_address: 330 brookline av///contact_city: boston///contact_state: MA///contact_zip.postal_code: 2215///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM495nnn/GSM495140/GSM495140.CEL.gz///data_row_count: 54675
1
title: Ovarian cancer_sample 30///geo_accession: GSM495168///status: Public on Jul 11 2010///submission_date: Jan 11 2010///last_update_date: Jul 11 2010///type: RNA///channel_count: 1///source_name_ch1: Ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: overall survival (months): 35///characteristics_ch1.1: overall survival (censored): 0 [censored]///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated using the trizol protocol///label_ch1: biotin///label_protocol_ch1: RNA is converted into cDNA using a T7 promoter-tailed oligo-dT primer in the synthesis of the first cDNA strand; second strand cDNA synthesis is then carried out.///label_protocol_ch1.1: The double-stranded cDNA is used as the template in an in vitro transcription (IVT) reaction catalyzed by T7 polymerase and containing biotinylated CTP and UTP in addition to the four unmodified ribonucleoside triphosphates///taxid_ch1: 9606///hyb_protocol: Standard Affymetrix protocol.///scan_protocol: Standard Affymetrix protocol. Each cRNA bound at its complementary oligonucleotide is excited using a confocal laser scanner, and the positions and intensities of the fluorescent emissions are captured.///description: 082002 HGU95Av2 DS 7A4///data_processing: RMA///platform_id: GPL8300///contact_name: panagiotis,,konstantinopoulos///contact_email: [email protected]///contact_department: hem/onc///contact_institute: bidmc///contact_address: 330 brookline av///contact_city: boston///contact_state: MA///contact_zip.postal_code: 2215///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM495nnn/GSM495168/GSM495168.CEL.gz///data_row_count: 12558
1
title: Ovarian cancer_sample 31///geo_accession: GSM495169///status: Public on Jul 11 2010///submission_date: Jan 11 2010///last_update_date: Jul 11 2010///type: RNA///channel_count: 1///source_name_ch1: Ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: overall survival (months): 41///characteristics_ch1.1: overall survival (censored): 0 [censored]///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated using the trizol protocol///label_ch1: biotin///label_protocol_ch1: RNA is converted into cDNA using a T7 promoter-tailed oligo-dT primer in the synthesis of the first cDNA strand; second strand cDNA synthesis is then carried out.///label_protocol_ch1.1: The double-stranded cDNA is used as the template in an in vitro transcription (IVT) reaction catalyzed by T7 polymerase and containing biotinylated CTP and UTP in addition to the four unmodified ribonucleoside triphosphates///taxid_ch1: 9606///hyb_protocol: Standard Affymetrix protocol.///scan_protocol: Standard Affymetrix protocol. Each cRNA bound at its complementary oligonucleotide is excited using a confocal laser scanner, and the positions and intensities of the fluorescent emissions are captured.///description: 082002 HGU95Av2 DS 7A5///data_processing: RMA///platform_id: GPL8300///contact_name: panagiotis,,konstantinopoulos///contact_email: [email protected]///contact_department: hem/onc///contact_institute: bidmc///contact_address: 330 brookline av///contact_city: boston///contact_state: MA///contact_zip.postal_code: 2215///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM495nnn/GSM495169/GSM495169.CEL.gz///data_row_count: 12558
1
title: Ovarian cancer_sample 32///geo_accession: GSM495170///status: Public on Jul 11 2010///submission_date: Jan 11 2010///last_update_date: Jul 11 2010///type: RNA///channel_count: 1///source_name_ch1: Ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: overall survival (months): 1///characteristics_ch1.1: overall survival (censored): 1 [event (death)]///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated using the trizol protocol///label_ch1: biotin///label_protocol_ch1: RNA is converted into cDNA using a T7 promoter-tailed oligo-dT primer in the synthesis of the first cDNA strand; second strand cDNA synthesis is then carried out.///label_protocol_ch1.1: The double-stranded cDNA is used as the template in an in vitro transcription (IVT) reaction catalyzed by T7 polymerase and containing biotinylated CTP and UTP in addition to the four unmodified ribonucleoside triphosphates///taxid_ch1: 9606///hyb_protocol: Standard Affymetrix protocol.///scan_protocol: Standard Affymetrix protocol. Each cRNA bound at its complementary oligonucleotide is excited using a confocal laser scanner, and the positions and intensities of the fluorescent emissions are captured.///description: 082002 HGU95Av2 DS 7A6///data_processing: RMA///platform_id: GPL8300///contact_name: panagiotis,,konstantinopoulos///contact_email: [email protected]///contact_department: hem/onc///contact_institute: bidmc///contact_address: 330 brookline av///contact_city: boston///contact_state: MA///contact_zip.postal_code: 2215///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM495nnn/GSM495170/GSM495170.CEL.gz///data_row_count: 12558
1
title: Ovarian cancer_sample 33///geo_accession: GSM495171///status: Public on Jul 11 2010///submission_date: Jan 11 2010///last_update_date: Jul 11 2010///type: RNA///channel_count: 1///source_name_ch1: Ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: overall survival (months): 28///characteristics_ch1.1: overall survival (censored): 1 [event (death)]///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated using the trizol protocol///label_ch1: biotin///label_protocol_ch1: RNA is converted into cDNA using a T7 promoter-tailed oligo-dT primer in the synthesis of the first cDNA strand; second strand cDNA synthesis is then carried out.///label_protocol_ch1.1: The double-stranded cDNA is used as the template in an in vitro transcription (IVT) reaction catalyzed by T7 polymerase and containing biotinylated CTP and UTP in addition to the four unmodified ribonucleoside triphosphates///taxid_ch1: 9606///hyb_protocol: Standard Affymetrix protocol.///scan_protocol: Standard Affymetrix protocol. Each cRNA bound at its complementary oligonucleotide is excited using a confocal laser scanner, and the positions and intensities of the fluorescent emissions are captured.///description: 082002 HGU95Av2 DS 7A7///data_processing: RMA///platform_id: GPL8300///contact_name: panagiotis,,konstantinopoulos///contact_email: [email protected]///contact_department: hem/onc///contact_institute: bidmc///contact_address: 330 brookline av///contact_city: boston///contact_state: MA///contact_zip.postal_code: 2215///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM495nnn/GSM495171/GSM495171.CEL.gz///data_row_count: 12558
1
title: Ovarian cancer_sample 34///geo_accession: GSM495172///status: Public on Jul 11 2010///submission_date: Jan 11 2010///last_update_date: Jul 11 2010///type: RNA///channel_count: 1///source_name_ch1: Ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: overall survival (months): 66///characteristics_ch1.1: overall survival (censored): 0 [censored]///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated using the trizol protocol///label_ch1: biotin///label_protocol_ch1: RNA is converted into cDNA using a T7 promoter-tailed oligo-dT primer in the synthesis of the first cDNA strand; second strand cDNA synthesis is then carried out.///label_protocol_ch1.1: The double-stranded cDNA is used as the template in an in vitro transcription (IVT) reaction catalyzed by T7 polymerase and containing biotinylated CTP and UTP in addition to the four unmodified ribonucleoside triphosphates///taxid_ch1: 9606///hyb_protocol: Standard Affymetrix protocol.///scan_protocol: Standard Affymetrix protocol. Each cRNA bound at its complementary oligonucleotide is excited using a confocal laser scanner, and the positions and intensities of the fluorescent emissions are captured.///description: 082002 HGU95AV2 DS 7A9///data_processing: RMA///platform_id: GPL8300///contact_name: panagiotis,,konstantinopoulos///contact_email: [email protected]///contact_department: hem/onc///contact_institute: bidmc///contact_address: 330 brookline av///contact_city: boston///contact_state: MA///contact_zip.postal_code: 2215///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM495nnn/GSM495172/GSM495172.CEL.gz///data_row_count: 12558
1
title: Ovarian cancer_sample 35///geo_accession: GSM495173///status: Public on Jul 11 2010///submission_date: Jan 11 2010///last_update_date: Jul 11 2010///type: RNA///channel_count: 1///source_name_ch1: Ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: overall survival (months): 48///characteristics_ch1.1: overall survival (censored): 1 [event (death)]///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated using the trizol protocol///label_ch1: biotin///label_protocol_ch1: RNA is converted into cDNA using a T7 promoter-tailed oligo-dT primer in the synthesis of the first cDNA strand; second strand cDNA synthesis is then carried out.///label_protocol_ch1.1: The double-stranded cDNA is used as the template in an in vitro transcription (IVT) reaction catalyzed by T7 polymerase and containing biotinylated CTP and UTP in addition to the four unmodified ribonucleoside triphosphates///taxid_ch1: 9606///hyb_protocol: Standard Affymetrix protocol.///scan_protocol: Standard Affymetrix protocol. Each cRNA bound at its complementary oligonucleotide is excited using a confocal laser scanner, and the positions and intensities of the fluorescent emissions are captured.///description: 082002 HGU95Av2 DS 7B2///data_processing: RMA///platform_id: GPL8300///contact_name: panagiotis,,konstantinopoulos///contact_email: [email protected]///contact_department: hem/onc///contact_institute: bidmc///contact_address: 330 brookline av///contact_city: boston///contact_state: MA///contact_zip.postal_code: 2215///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM495nnn/GSM495173/GSM495173.CEL.gz///data_row_count: 12558
1
title: Ovarian cancer_sample 36///geo_accession: GSM495174///status: Public on Jul 11 2010///submission_date: Jan 11 2010///last_update_date: Jul 11 2010///type: RNA///channel_count: 1///source_name_ch1: Ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: overall survival (months): 12///characteristics_ch1.1: overall survival (censored): 1 [event (death)]///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated using the trizol protocol///label_ch1: biotin///label_protocol_ch1: RNA is converted into cDNA using a T7 promoter-tailed oligo-dT primer in the synthesis of the first cDNA strand; second strand cDNA synthesis is then carried out.///label_protocol_ch1.1: The double-stranded cDNA is used as the template in an in vitro transcription (IVT) reaction catalyzed by T7 polymerase and containing biotinylated CTP and UTP in addition to the four unmodified ribonucleoside triphosphates///taxid_ch1: 9606///hyb_protocol: Standard Affymetrix protocol.///scan_protocol: Standard Affymetrix protocol. Each cRNA bound at its complementary oligonucleotide is excited using a confocal laser scanner, and the positions and intensities of the fluorescent emissions are captured.///description: 082002 HGU95Av2 DS 7B3///data_processing: RMA///platform_id: GPL8300///contact_name: panagiotis,,konstantinopoulos///contact_email: [email protected]///contact_department: hem/onc///contact_institute: bidmc///contact_address: 330 brookline av///contact_city: boston///contact_state: MA///contact_zip.postal_code: 2215///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM495nnn/GSM495174/GSM495174.CEL.gz///data_row_count: 12558
1
title: Ovarian cancer_sample 37///geo_accession: GSM495175///status: Public on Jul 11 2010///submission_date: Jan 11 2010///last_update_date: Jul 11 2010///type: RNA///channel_count: 1///source_name_ch1: Ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: overall survival (months): 41///characteristics_ch1.1: overall survival (censored): 1 [event (death)]///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated using the trizol protocol///label_ch1: biotin///label_protocol_ch1: RNA is converted into cDNA using a T7 promoter-tailed oligo-dT primer in the synthesis of the first cDNA strand; second strand cDNA synthesis is then carried out.///label_protocol_ch1.1: The double-stranded cDNA is used as the template in an in vitro transcription (IVT) reaction catalyzed by T7 polymerase and containing biotinylated CTP and UTP in addition to the four unmodified ribonucleoside triphosphates///taxid_ch1: 9606///hyb_protocol: Standard Affymetrix protocol.///scan_protocol: Standard Affymetrix protocol. Each cRNA bound at its complementary oligonucleotide is excited using a confocal laser scanner, and the positions and intensities of the fluorescent emissions are captured.///description: 082002 HGU95Av2 DS 7B5///data_processing: RMA///platform_id: GPL8300///contact_name: panagiotis,,konstantinopoulos///contact_email: [email protected]///contact_department: hem/onc///contact_institute: bidmc///contact_address: 330 brookline av///contact_city: boston///contact_state: MA///contact_zip.postal_code: 2215///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM495nnn/GSM495175/GSM495175.CEL.gz///data_row_count: 12558
1
title: Ovarian cancer_sample 38///geo_accession: GSM495176///status: Public on Jul 11 2010///submission_date: Jan 11 2010///last_update_date: Jul 11 2010///type: RNA///channel_count: 1///source_name_ch1: Ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: overall survival (months): 19///characteristics_ch1.1: overall survival (censored): 1 [event (death)]///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated using the trizol protocol///label_ch1: biotin///label_protocol_ch1: RNA is converted into cDNA using a T7 promoter-tailed oligo-dT primer in the synthesis of the first cDNA strand; second strand cDNA synthesis is then carried out.///label_protocol_ch1.1: The double-stranded cDNA is used as the template in an in vitro transcription (IVT) reaction catalyzed by T7 polymerase and containing biotinylated CTP and UTP in addition to the four unmodified ribonucleoside triphosphates///taxid_ch1: 9606///hyb_protocol: Standard Affymetrix protocol.///scan_protocol: Standard Affymetrix protocol. Each cRNA bound at its complementary oligonucleotide is excited using a confocal laser scanner, and the positions and intensities of the fluorescent emissions are captured.///description: 082002 HGU95Av2 DS 7B8///data_processing: RMA///platform_id: GPL8300///contact_name: panagiotis,,konstantinopoulos///contact_email: [email protected]///contact_department: hem/onc///contact_institute: bidmc///contact_address: 330 brookline av///contact_city: boston///contact_state: MA///contact_zip.postal_code: 2215///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM495nnn/GSM495176/GSM495176.CEL.gz///data_row_count: 12558
1
title: Ovarian cancer_sample 39///geo_accession: GSM495177///status: Public on Jul 11 2010///submission_date: Jan 11 2010///last_update_date: Jul 11 2010///type: RNA///channel_count: 1///source_name_ch1: Ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: overall survival (months): 25///characteristics_ch1.1: overall survival (censored): 1 [event (death)]///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated using the trizol protocol///label_ch1: biotin///label_protocol_ch1: RNA is converted into cDNA using a T7 promoter-tailed oligo-dT primer in the synthesis of the first cDNA strand; second strand cDNA synthesis is then carried out.///label_protocol_ch1.1: The double-stranded cDNA is used as the template in an in vitro transcription (IVT) reaction catalyzed by T7 polymerase and containing biotinylated CTP and UTP in addition to the four unmodified ribonucleoside triphosphates///taxid_ch1: 9606///hyb_protocol: Standard Affymetrix protocol.///scan_protocol: Standard Affymetrix protocol. Each cRNA bound at its complementary oligonucleotide is excited using a confocal laser scanner, and the positions and intensities of the fluorescent emissions are captured.///description: 082002 HGU95Av2 DS 7B9///data_processing: RMA///platform_id: GPL8300///contact_name: panagiotis,,konstantinopoulos///contact_email: [email protected]///contact_department: hem/onc///contact_institute: bidmc///contact_address: 330 brookline av///contact_city: boston///contact_state: MA///contact_zip.postal_code: 2215///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM495nnn/GSM495177/GSM495177.CEL.gz///data_row_count: 12558
1
title: Ovarian cancer_sample 3///geo_accession: GSM495141///status: Public on Jul 11 2010///submission_date: Jan 11 2010///last_update_date: Jul 11 2010///type: RNA///channel_count: 1///source_name_ch1: Ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: overall survival (months): 115///characteristics_ch1.1: overall survival (censored): 0 [censored]///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated using the trizol protocol///label_ch1: biotin///label_protocol_ch1: RNA is converted into cDNA using a T7 promoter-tailed oligo-dT primer in the synthesis of the first cDNA strand; second strand cDNA synthesis is then carried out.///label_protocol_ch1.1: The double-stranded cDNA is used as the template in an in vitro transcription (IVT) reaction catalyzed by T7 polymerase and containing biotinylated CTP and UTP in addition to the four unmodified ribonucleoside triphosphates///taxid_ch1: 9606///hyb_protocol: Standard Affymetrix protocol.///scan_protocol: Standard Affymetrix protocol. Each cRNA bound at its complementary oligonucleotide is excited using a confocal laser scanner, and the positions and intensities of the fluorescent emissions are captured.///description: PK2009081429///data_processing: RMA///platform_id: GPL570///contact_name: panagiotis,,konstantinopoulos///contact_email: [email protected]///contact_department: hem/onc///contact_institute: bidmc///contact_address: 330 brookline av///contact_city: boston///contact_state: MA///contact_zip.postal_code: 2215///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM495nnn/GSM495141/GSM495141.CEL.gz///data_row_count: 54675
1
title: Ovarian cancer_sample 40///geo_accession: GSM495178///status: Public on Jul 11 2010///submission_date: Jan 11 2010///last_update_date: Jul 11 2010///type: RNA///channel_count: 1///source_name_ch1: Ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: overall survival (months): 23///characteristics_ch1.1: overall survival (censored): 0 [censored]///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated using the trizol protocol///label_ch1: biotin///label_protocol_ch1: RNA is converted into cDNA using a T7 promoter-tailed oligo-dT primer in the synthesis of the first cDNA strand; second strand cDNA synthesis is then carried out.///label_protocol_ch1.1: The double-stranded cDNA is used as the template in an in vitro transcription (IVT) reaction catalyzed by T7 polymerase and containing biotinylated CTP and UTP in addition to the four unmodified ribonucleoside triphosphates///taxid_ch1: 9606///hyb_protocol: Standard Affymetrix protocol.///scan_protocol: Standard Affymetrix protocol. Each cRNA bound at its complementary oligonucleotide is excited using a confocal laser scanner, and the positions and intensities of the fluorescent emissions are captured.///description: 082002 HGU95Av2 DS 7C2///data_processing: RMA///platform_id: GPL8300///contact_name: panagiotis,,konstantinopoulos///contact_email: [email protected]///contact_department: hem/onc///contact_institute: bidmc///contact_address: 330 brookline av///contact_city: boston///contact_state: MA///contact_zip.postal_code: 2215///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM495nnn/GSM495178/GSM495178.CEL.gz///data_row_count: 12558
1
title: Ovarian cancer_sample 41///geo_accession: GSM495179///status: Public on Jul 11 2010///submission_date: Jan 11 2010///last_update_date: Jul 11 2010///type: RNA///channel_count: 1///source_name_ch1: Ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: overall survival (months): 16///characteristics_ch1.1: overall survival (censored): 1 [event (death)]///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated using the trizol protocol///label_ch1: biotin///label_protocol_ch1: RNA is converted into cDNA using a T7 promoter-tailed oligo-dT primer in the synthesis of the first cDNA strand; second strand cDNA synthesis is then carried out.///label_protocol_ch1.1: The double-stranded cDNA is used as the template in an in vitro transcription (IVT) reaction catalyzed by T7 polymerase and containing biotinylated CTP and UTP in addition to the four unmodified ribonucleoside triphosphates///taxid_ch1: 9606///hyb_protocol: Standard Affymetrix protocol.///scan_protocol: Standard Affymetrix protocol. Each cRNA bound at its complementary oligonucleotide is excited using a confocal laser scanner, and the positions and intensities of the fluorescent emissions are captured.///description: 082002 HGU95Av2 DS 7C3///data_processing: RMA///platform_id: GPL8300///contact_name: panagiotis,,konstantinopoulos///contact_email: [email protected]///contact_department: hem/onc///contact_institute: bidmc///contact_address: 330 brookline av///contact_city: boston///contact_state: MA///contact_zip.postal_code: 2215///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM495nnn/GSM495179/GSM495179.CEL.gz///data_row_count: 12558
1
title: Ovarian cancer_sample 42///geo_accession: GSM495180///status: Public on Jul 11 2010///submission_date: Jan 11 2010///last_update_date: Jul 11 2010///type: RNA///channel_count: 1///source_name_ch1: Ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: overall survival (months): 22///characteristics_ch1.1: overall survival (censored): 0 [censored]///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated using the trizol protocol///label_ch1: biotin///label_protocol_ch1: RNA is converted into cDNA using a T7 promoter-tailed oligo-dT primer in the synthesis of the first cDNA strand; second strand cDNA synthesis is then carried out.///label_protocol_ch1.1: The double-stranded cDNA is used as the template in an in vitro transcription (IVT) reaction catalyzed by T7 polymerase and containing biotinylated CTP and UTP in addition to the four unmodified ribonucleoside triphosphates///taxid_ch1: 9606///hyb_protocol: Standard Affymetrix protocol.///scan_protocol: Standard Affymetrix protocol. Each cRNA bound at its complementary oligonucleotide is excited using a confocal laser scanner, and the positions and intensities of the fluorescent emissions are captured.///description: 082002 HGU95Av2 DS 7C4///data_processing: RMA///platform_id: GPL8300///contact_name: panagiotis,,konstantinopoulos///contact_email: [email protected]///contact_department: hem/onc///contact_institute: bidmc///contact_address: 330 brookline av///contact_city: boston///contact_state: MA///contact_zip.postal_code: 2215///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM495nnn/GSM495180/GSM495180.CEL.gz///data_row_count: 12558
1
title: Ovarian cancer_sample 43///geo_accession: GSM495181///status: Public on Jul 11 2010///submission_date: Jan 11 2010///last_update_date: Jul 11 2010///type: RNA///channel_count: 1///source_name_ch1: Ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: overall survival (months): 42///characteristics_ch1.1: overall survival (censored): 1 [event (death)]///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated using the trizol protocol///label_ch1: biotin///label_protocol_ch1: RNA is converted into cDNA using a T7 promoter-tailed oligo-dT primer in the synthesis of the first cDNA strand; second strand cDNA synthesis is then carried out.///label_protocol_ch1.1: The double-stranded cDNA is used as the template in an in vitro transcription (IVT) reaction catalyzed by T7 polymerase and containing biotinylated CTP and UTP in addition to the four unmodified ribonucleoside triphosphates///taxid_ch1: 9606///hyb_protocol: Standard Affymetrix protocol.///scan_protocol: Standard Affymetrix protocol. Each cRNA bound at its complementary oligonucleotide is excited using a confocal laser scanner, and the positions and intensities of the fluorescent emissions are captured.///description: 090903 HGU95AV2 TL 14B2///data_processing: RMA///platform_id: GPL8300///contact_name: panagiotis,,konstantinopoulos///contact_email: [email protected]///contact_department: hem/onc///contact_institute: bidmc///contact_address: 330 brookline av///contact_city: boston///contact_state: MA///contact_zip.postal_code: 2215///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM495nnn/GSM495181/GSM495181.CEL.gz///data_row_count: 12558
1
title: Ovarian cancer_sample 44///geo_accession: GSM495182///status: Public on Jul 11 2010///submission_date: Jan 11 2010///last_update_date: Jul 11 2010///type: RNA///channel_count: 1///source_name_ch1: Ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: overall survival (months): 58///characteristics_ch1.1: overall survival (censored): 0 [censored]///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated using the trizol protocol///label_ch1: biotin///label_protocol_ch1: RNA is converted into cDNA using a T7 promoter-tailed oligo-dT primer in the synthesis of the first cDNA strand; second strand cDNA synthesis is then carried out.///label_protocol_ch1.1: The double-stranded cDNA is used as the template in an in vitro transcription (IVT) reaction catalyzed by T7 polymerase and containing biotinylated CTP and UTP in addition to the four unmodified ribonucleoside triphosphates///taxid_ch1: 9606///hyb_protocol: Standard Affymetrix protocol.///scan_protocol: Standard Affymetrix protocol. Each cRNA bound at its complementary oligonucleotide is excited using a confocal laser scanner, and the positions and intensities of the fluorescent emissions are captured.///description: 090903 HGU95AV2 TL 14B3///data_processing: RMA///platform_id: GPL8300///contact_name: panagiotis,,konstantinopoulos///contact_email: [email protected]///contact_department: hem/onc///contact_institute: bidmc///contact_address: 330 brookline av///contact_city: boston///contact_state: MA///contact_zip.postal_code: 2215///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM495nnn/GSM495182/GSM495182.CEL.gz///data_row_count: 12558
1
title: Ovarian cancer_sample 45///geo_accession: GSM495183///status: Public on Jul 11 2010///submission_date: Jan 11 2010///last_update_date: Jul 11 2010///type: RNA///channel_count: 1///source_name_ch1: Ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: overall survival (months): 59///characteristics_ch1.1: overall survival (censored): 0 [censored]///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated using the trizol protocol///label_ch1: biotin///label_protocol_ch1: RNA is converted into cDNA using a T7 promoter-tailed oligo-dT primer in the synthesis of the first cDNA strand; second strand cDNA synthesis is then carried out.///label_protocol_ch1.1: The double-stranded cDNA is used as the template in an in vitro transcription (IVT) reaction catalyzed by T7 polymerase and containing biotinylated CTP and UTP in addition to the four unmodified ribonucleoside triphosphates///taxid_ch1: 9606///hyb_protocol: Standard Affymetrix protocol.///scan_protocol: Standard Affymetrix protocol. Each cRNA bound at its complementary oligonucleotide is excited using a confocal laser scanner, and the positions and intensities of the fluorescent emissions are captured.///description: 090903 HGU95AV2 TL 14B5///data_processing: RMA///platform_id: GPL8300///contact_name: panagiotis,,konstantinopoulos///contact_email: [email protected]///contact_department: hem/onc///contact_institute: bidmc///contact_address: 330 brookline av///contact_city: boston///contact_state: MA///contact_zip.postal_code: 2215///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM495nnn/GSM495183/GSM495183.CEL.gz///data_row_count: 12558
1
title: Ovarian cancer_sample 46///geo_accession: GSM495184///status: Public on Jul 11 2010///submission_date: Jan 11 2010///last_update_date: Jul 11 2010///type: RNA///channel_count: 1///source_name_ch1: Ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: overall survival (months): 33///characteristics_ch1.1: overall survival (censored): 1 [event (death)]///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated using the trizol protocol///label_ch1: biotin///label_protocol_ch1: RNA is converted into cDNA using a T7 promoter-tailed oligo-dT primer in the synthesis of the first cDNA strand; second strand cDNA synthesis is then carried out.///label_protocol_ch1.1: The double-stranded cDNA is used as the template in an in vitro transcription (IVT) reaction catalyzed by T7 polymerase and containing biotinylated CTP and UTP in addition to the four unmodified ribonucleoside triphosphates///taxid_ch1: 9606///hyb_protocol: Standard Affymetrix protocol.///scan_protocol: Standard Affymetrix protocol. Each cRNA bound at its complementary oligonucleotide is excited using a confocal laser scanner, and the positions and intensities of the fluorescent emissions are captured.///description: 090903 HGU95AV2 TL 14B6///data_processing: RMA///platform_id: GPL8300///contact_name: panagiotis,,konstantinopoulos///contact_email: [email protected]///contact_department: hem/onc///contact_institute: bidmc///contact_address: 330 brookline av///contact_city: boston///contact_state: MA///contact_zip.postal_code: 2215///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM495nnn/GSM495184/GSM495184.CEL.gz///data_row_count: 12558
1
title: Ovarian cancer_sample 47///geo_accession: GSM495185///status: Public on Jul 11 2010///submission_date: Jan 11 2010///last_update_date: Jul 11 2010///type: RNA///channel_count: 1///source_name_ch1: Ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: overall survival (months): 65///characteristics_ch1.1: overall survival (censored): 0 [censored]///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated using the trizol protocol///label_ch1: biotin///label_protocol_ch1: RNA is converted into cDNA using a T7 promoter-tailed oligo-dT primer in the synthesis of the first cDNA strand; second strand cDNA synthesis is then carried out.///label_protocol_ch1.1: The double-stranded cDNA is used as the template in an in vitro transcription (IVT) reaction catalyzed by T7 polymerase and containing biotinylated CTP and UTP in addition to the four unmodified ribonucleoside triphosphates///taxid_ch1: 9606///hyb_protocol: Standard Affymetrix protocol.///scan_protocol: Standard Affymetrix protocol. Each cRNA bound at its complementary oligonucleotide is excited using a confocal laser scanner, and the positions and intensities of the fluorescent emissions are captured.///description: 090903 HGU95AV2 TL 14C2///data_processing: RMA///platform_id: GPL8300///contact_name: panagiotis,,konstantinopoulos///contact_email: [email protected]///contact_department: hem/onc///contact_institute: bidmc///contact_address: 330 brookline av///contact_city: boston///contact_state: MA///contact_zip.postal_code: 2215///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM495nnn/GSM495185/GSM495185.CEL.gz///data_row_count: 12558
1
title: Ovarian cancer_sample 48///geo_accession: GSM495186///status: Public on Jul 11 2010///submission_date: Jan 11 2010///last_update_date: Jul 11 2010///type: RNA///channel_count: 1///source_name_ch1: Ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: overall survival (months): 46///characteristics_ch1.1: overall survival (censored): 1 [event (death)]///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated using the trizol protocol///label_ch1: biotin///label_protocol_ch1: RNA is converted into cDNA using a T7 promoter-tailed oligo-dT primer in the synthesis of the first cDNA strand; second strand cDNA synthesis is then carried out.///label_protocol_ch1.1: The double-stranded cDNA is used as the template in an in vitro transcription (IVT) reaction catalyzed by T7 polymerase and containing biotinylated CTP and UTP in addition to the four unmodified ribonucleoside triphosphates///taxid_ch1: 9606///hyb_protocol: Standard Affymetrix protocol.///scan_protocol: Standard Affymetrix protocol. Each cRNA bound at its complementary oligonucleotide is excited using a confocal laser scanner, and the positions and intensities of the fluorescent emissions are captured.///description: 090903 HGU95AV2 TL 14C3///data_processing: RMA///platform_id: GPL8300///contact_name: panagiotis,,konstantinopoulos///contact_email: [email protected]///contact_department: hem/onc///contact_institute: bidmc///contact_address: 330 brookline av///contact_city: boston///contact_state: MA///contact_zip.postal_code: 2215///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM495nnn/GSM495186/GSM495186.CEL.gz///data_row_count: 12558
1
title: Ovarian cancer_sample 49///geo_accession: GSM495187///status: Public on Jul 11 2010///submission_date: Jan 11 2010///last_update_date: Jul 11 2010///type: RNA///channel_count: 1///source_name_ch1: Ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: overall survival (months): 51///characteristics_ch1.1: overall survival (censored): 0 [censored]///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated using the trizol protocol///label_ch1: biotin///label_protocol_ch1: RNA is converted into cDNA using a T7 promoter-tailed oligo-dT primer in the synthesis of the first cDNA strand; second strand cDNA synthesis is then carried out.///label_protocol_ch1.1: The double-stranded cDNA is used as the template in an in vitro transcription (IVT) reaction catalyzed by T7 polymerase and containing biotinylated CTP and UTP in addition to the four unmodified ribonucleoside triphosphates///taxid_ch1: 9606///hyb_protocol: Standard Affymetrix protocol.///scan_protocol: Standard Affymetrix protocol. Each cRNA bound at its complementary oligonucleotide is excited using a confocal laser scanner, and the positions and intensities of the fluorescent emissions are captured.///description: 090903 HGU95AV2 TL 14C6///data_processing: RMA///platform_id: GPL8300///contact_name: panagiotis,,konstantinopoulos///contact_email: [email protected]///contact_department: hem/onc///contact_institute: bidmc///contact_address: 330 brookline av///contact_city: boston///contact_state: MA///contact_zip.postal_code: 2215///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM495nnn/GSM495187/GSM495187.CEL.gz///data_row_count: 12558
1
title: Ovarian cancer_sample 4///geo_accession: GSM495142///status: Public on Jul 11 2010///submission_date: Jan 11 2010///last_update_date: Jul 11 2010///type: RNA///channel_count: 1///source_name_ch1: Ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: overall survival (months): 100///characteristics_ch1.1: overall survival (censored): 0 [censored]///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated using the trizol protocol///label_ch1: biotin///label_protocol_ch1: RNA is converted into cDNA using a T7 promoter-tailed oligo-dT primer in the synthesis of the first cDNA strand; second strand cDNA synthesis is then carried out.///label_protocol_ch1.1: The double-stranded cDNA is used as the template in an in vitro transcription (IVT) reaction catalyzed by T7 polymerase and containing biotinylated CTP and UTP in addition to the four unmodified ribonucleoside triphosphates///taxid_ch1: 9606///hyb_protocol: Standard Affymetrix protocol.///scan_protocol: Standard Affymetrix protocol. Each cRNA bound at its complementary oligonucleotide is excited using a confocal laser scanner, and the positions and intensities of the fluorescent emissions are captured.///description: PK2009081430///data_processing: RMA///platform_id: GPL570///contact_name: panagiotis,,konstantinopoulos///contact_email: [email protected]///contact_department: hem/onc///contact_institute: bidmc///contact_address: 330 brookline av///contact_city: boston///contact_state: MA///contact_zip.postal_code: 2215///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM495nnn/GSM495142/GSM495142.CEL.gz///data_row_count: 54675
1
title: Ovarian cancer_sample 50///geo_accession: GSM495188///status: Public on Jul 11 2010///submission_date: Jan 11 2010///last_update_date: Jul 11 2010///type: RNA///channel_count: 1///source_name_ch1: Ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: overall survival (months): 33///characteristics_ch1.1: overall survival (censored): 1 [event (death)]///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated using the trizol protocol///label_ch1: biotin///label_protocol_ch1: RNA is converted into cDNA using a T7 promoter-tailed oligo-dT primer in the synthesis of the first cDNA strand; second strand cDNA synthesis is then carried out.///label_protocol_ch1.1: The double-stranded cDNA is used as the template in an in vitro transcription (IVT) reaction catalyzed by T7 polymerase and containing biotinylated CTP and UTP in addition to the four unmodified ribonucleoside triphosphates///taxid_ch1: 9606///hyb_protocol: Standard Affymetrix protocol.///scan_protocol: Standard Affymetrix protocol. Each cRNA bound at its complementary oligonucleotide is excited using a confocal laser scanner, and the positions and intensities of the fluorescent emissions are captured.///description: 090903 HGU95AV2 TL 14C8///data_processing: RMA///platform_id: GPL8300///contact_name: panagiotis,,konstantinopoulos///contact_email: [email protected]///contact_department: hem/onc///contact_institute: bidmc///contact_address: 330 brookline av///contact_city: boston///contact_state: MA///contact_zip.postal_code: 2215///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM495nnn/GSM495188/GSM495188.CEL.gz///data_row_count: 12558
1
title: Ovarian cancer_sample 51///geo_accession: GSM495189///status: Public on Jul 11 2010///submission_date: Jan 11 2010///last_update_date: Jul 11 2010///type: RNA///channel_count: 1///source_name_ch1: Ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: overall survival (months): 51///characteristics_ch1.1: overall survival (censored): 0 [censored]///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated using the trizol protocol///label_ch1: biotin///label_protocol_ch1: RNA is converted into cDNA using a T7 promoter-tailed oligo-dT primer in the synthesis of the first cDNA strand; second strand cDNA synthesis is then carried out.///label_protocol_ch1.1: The double-stranded cDNA is used as the template in an in vitro transcription (IVT) reaction catalyzed by T7 polymerase and containing biotinylated CTP and UTP in addition to the four unmodified ribonucleoside triphosphates///taxid_ch1: 9606///hyb_protocol: Standard Affymetrix protocol.///scan_protocol: Standard Affymetrix protocol. Each cRNA bound at its complementary oligonucleotide is excited using a confocal laser scanner, and the positions and intensities of the fluorescent emissions are captured.///description: 090903 HGU95AV2 TL 14C9///data_processing: RMA///platform_id: GPL8300///contact_name: panagiotis,,konstantinopoulos///contact_email: [email protected]///contact_department: hem/onc///contact_institute: bidmc///contact_address: 330 brookline av///contact_city: boston///contact_state: MA///contact_zip.postal_code: 2215///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM495nnn/GSM495189/GSM495189.CEL.gz///data_row_count: 12558
1
title: Ovarian cancer_sample 52///geo_accession: GSM495190///status: Public on Jul 11 2010///submission_date: Jan 11 2010///last_update_date: Jul 11 2010///type: RNA///channel_count: 1///source_name_ch1: Ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: overall survival (months): 52///characteristics_ch1.1: overall survival (censored): 0 [censored]///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated using the trizol protocol///label_ch1: biotin///label_protocol_ch1: RNA is converted into cDNA using a T7 promoter-tailed oligo-dT primer in the synthesis of the first cDNA strand; second strand cDNA synthesis is then carried out.///label_protocol_ch1.1: The double-stranded cDNA is used as the template in an in vitro transcription (IVT) reaction catalyzed by T7 polymerase and containing biotinylated CTP and UTP in addition to the four unmodified ribonucleoside triphosphates///taxid_ch1: 9606///hyb_protocol: Standard Affymetrix protocol.///scan_protocol: Standard Affymetrix protocol. Each cRNA bound at its complementary oligonucleotide is excited using a confocal laser scanner, and the positions and intensities of the fluorescent emissions are captured.///description: 090903 HGU95AV2 TL 14D1///data_processing: RMA///platform_id: GPL8300///contact_name: panagiotis,,konstantinopoulos///contact_email: [email protected]///contact_department: hem/onc///contact_institute: bidmc///contact_address: 330 brookline av///contact_city: boston///contact_state: MA///contact_zip.postal_code: 2215///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM495nnn/GSM495190/GSM495190.CEL.gz///data_row_count: 12558
1
title: Ovarian cancer_sample 53///geo_accession: GSM495191///status: Public on Jul 11 2010///submission_date: Jan 11 2010///last_update_date: Jul 11 2010///type: RNA///channel_count: 1///source_name_ch1: Ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: overall survival (months): 50///characteristics_ch1.1: overall survival (censored): 0 [censored]///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated using the trizol protocol///label_ch1: biotin///label_protocol_ch1: RNA is converted into cDNA using a T7 promoter-tailed oligo-dT primer in the synthesis of the first cDNA strand; second strand cDNA synthesis is then carried out.///label_protocol_ch1.1: The double-stranded cDNA is used as the template in an in vitro transcription (IVT) reaction catalyzed by T7 polymerase and containing biotinylated CTP and UTP in addition to the four unmodified ribonucleoside triphosphates///taxid_ch1: 9606///hyb_protocol: Standard Affymetrix protocol.///scan_protocol: Standard Affymetrix protocol. Each cRNA bound at its complementary oligonucleotide is excited using a confocal laser scanner, and the positions and intensities of the fluorescent emissions are captured.///description: 090903 HGU95AV2 TL 14D3///data_processing: RMA///platform_id: GPL8300///contact_name: panagiotis,,konstantinopoulos///contact_email: [email protected]///contact_department: hem/onc///contact_institute: bidmc///contact_address: 330 brookline av///contact_city: boston///contact_state: MA///contact_zip.postal_code: 2215///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM495nnn/GSM495191/GSM495191.CEL.gz///data_row_count: 12558
1
title: Ovarian cancer_sample 54///geo_accession: GSM495192///status: Public on Jul 11 2010///submission_date: Jan 11 2010///last_update_date: Jul 11 2010///type: RNA///channel_count: 1///source_name_ch1: Ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: overall survival (months): 44///characteristics_ch1.1: overall survival (censored): 0 [censored]///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated using the trizol protocol///label_ch1: biotin///label_protocol_ch1: RNA is converted into cDNA using a T7 promoter-tailed oligo-dT primer in the synthesis of the first cDNA strand; second strand cDNA synthesis is then carried out.///label_protocol_ch1.1: The double-stranded cDNA is used as the template in an in vitro transcription (IVT) reaction catalyzed by T7 polymerase and containing biotinylated CTP and UTP in addition to the four unmodified ribonucleoside triphosphates///taxid_ch1: 9606///hyb_protocol: Standard Affymetrix protocol.///scan_protocol: Standard Affymetrix protocol. Each cRNA bound at its complementary oligonucleotide is excited using a confocal laser scanner, and the positions and intensities of the fluorescent emissions are captured.///description: 090903 HGU95AV2 TL 14D5///data_processing: RMA///platform_id: GPL8300///contact_name: panagiotis,,konstantinopoulos///contact_email: [email protected]///contact_department: hem/onc///contact_institute: bidmc///contact_address: 330 brookline av///contact_city: boston///contact_state: MA///contact_zip.postal_code: 2215///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM495nnn/GSM495192/GSM495192.CEL.gz///data_row_count: 12558
1
title: Ovarian cancer_sample 55///geo_accession: GSM495193///status: Public on Jul 11 2010///submission_date: Jan 11 2010///last_update_date: Jul 11 2010///type: RNA///channel_count: 1///source_name_ch1: Ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: overall survival (months): 10///characteristics_ch1.1: overall survival (censored): 1 [event (death)]///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated using the trizol protocol///label_ch1: biotin///label_protocol_ch1: RNA is converted into cDNA using a T7 promoter-tailed oligo-dT primer in the synthesis of the first cDNA strand; second strand cDNA synthesis is then carried out.///label_protocol_ch1.1: The double-stranded cDNA is used as the template in an in vitro transcription (IVT) reaction catalyzed by T7 polymerase and containing biotinylated CTP and UTP in addition to the four unmodified ribonucleoside triphosphates///taxid_ch1: 9606///hyb_protocol: Standard Affymetrix protocol.///scan_protocol: Standard Affymetrix protocol. Each cRNA bound at its complementary oligonucleotide is excited using a confocal laser scanner, and the positions and intensities of the fluorescent emissions are captured.///description: 090903 HGU95AV2 TL 14D6///data_processing: RMA///platform_id: GPL8300///contact_name: panagiotis,,konstantinopoulos///contact_email: [email protected]///contact_department: hem/onc///contact_institute: bidmc///contact_address: 330 brookline av///contact_city: boston///contact_state: MA///contact_zip.postal_code: 2215///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM495nnn/GSM495193/GSM495193.CEL.gz///data_row_count: 12558
1
title: Ovarian cancer_sample 56///geo_accession: GSM495194///status: Public on Jul 11 2010///submission_date: Jan 11 2010///last_update_date: Jul 11 2010///type: RNA///channel_count: 1///source_name_ch1: Ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: overall survival (months): 8///characteristics_ch1.1: overall survival (censored): 1 [event (death)]///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated using the trizol protocol///label_ch1: biotin///label_protocol_ch1: RNA is converted into cDNA using a T7 promoter-tailed oligo-dT primer in the synthesis of the first cDNA strand; second strand cDNA synthesis is then carried out.///label_protocol_ch1.1: The double-stranded cDNA is used as the template in an in vitro transcription (IVT) reaction catalyzed by T7 polymerase and containing biotinylated CTP and UTP in addition to the four unmodified ribonucleoside triphosphates///taxid_ch1: 9606///hyb_protocol: Standard Affymetrix protocol.///scan_protocol: Standard Affymetrix protocol. Each cRNA bound at its complementary oligonucleotide is excited using a confocal laser scanner, and the positions and intensities of the fluorescent emissions are captured.///description: 091301 HGU95Av2 SC G4///data_processing: RMA///platform_id: GPL8300///contact_name: panagiotis,,konstantinopoulos///contact_email: [email protected]///contact_department: hem/onc///contact_institute: bidmc///contact_address: 330 brookline av///contact_city: boston///contact_state: MA///contact_zip.postal_code: 2215///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM495nnn/GSM495194/GSM495194.CEL.gz///data_row_count: 12558
1
title: Ovarian cancer_sample 57///geo_accession: GSM495195///status: Public on Jul 11 2010///submission_date: Jan 11 2010///last_update_date: Jul 11 2010///type: RNA///channel_count: 1///source_name_ch1: Ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: overall survival (months): 4///characteristics_ch1.1: overall survival (censored): 1 [event (death)]///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated using the trizol protocol///label_ch1: biotin///label_protocol_ch1: RNA is converted into cDNA using a T7 promoter-tailed oligo-dT primer in the synthesis of the first cDNA strand; second strand cDNA synthesis is then carried out.///label_protocol_ch1.1: The double-stranded cDNA is used as the template in an in vitro transcription (IVT) reaction catalyzed by T7 polymerase and containing biotinylated CTP and UTP in addition to the four unmodified ribonucleoside triphosphates///taxid_ch1: 9606///hyb_protocol: Standard Affymetrix protocol.///scan_protocol: Standard Affymetrix protocol. Each cRNA bound at its complementary oligonucleotide is excited using a confocal laser scanner, and the positions and intensities of the fluorescent emissions are captured.///description: 091301 HGU95Av2 SC G5///data_processing: RMA///platform_id: GPL8300///contact_name: panagiotis,,konstantinopoulos///contact_email: [email protected]///contact_department: hem/onc///contact_institute: bidmc///contact_address: 330 brookline av///contact_city: boston///contact_state: MA///contact_zip.postal_code: 2215///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM495nnn/GSM495195/GSM495195.CEL.gz///data_row_count: 12558
1
title: Ovarian cancer_sample 58///geo_accession: GSM495196///status: Public on Jul 11 2010///submission_date: Jan 11 2010///last_update_date: Jul 11 2010///type: RNA///channel_count: 1///source_name_ch1: Ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: overall survival (months): 30///characteristics_ch1.1: overall survival (censored): 1 [event (death)]///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated using the trizol protocol///label_ch1: biotin///label_protocol_ch1: RNA is converted into cDNA using a T7 promoter-tailed oligo-dT primer in the synthesis of the first cDNA strand; second strand cDNA synthesis is then carried out.///label_protocol_ch1.1: The double-stranded cDNA is used as the template in an in vitro transcription (IVT) reaction catalyzed by T7 polymerase and containing biotinylated CTP and UTP in addition to the four unmodified ribonucleoside triphosphates///taxid_ch1: 9606///hyb_protocol: Standard Affymetrix protocol.///scan_protocol: Standard Affymetrix protocol. Each cRNA bound at its complementary oligonucleotide is excited using a confocal laser scanner, and the positions and intensities of the fluorescent emissions are captured.///description: 091301 HGU95Av2 SC G6///data_processing: RMA///platform_id: GPL8300///contact_name: panagiotis,,konstantinopoulos///contact_email: [email protected]///contact_department: hem/onc///contact_institute: bidmc///contact_address: 330 brookline av///contact_city: boston///contact_state: MA///contact_zip.postal_code: 2215///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM495nnn/GSM495196/GSM495196.CEL.gz///data_row_count: 12558
1
title: Ovarian cancer_sample 59///geo_accession: GSM495197///status: Public on Jul 11 2010///submission_date: Jan 11 2010///last_update_date: Jul 11 2010///type: RNA///channel_count: 1///source_name_ch1: Ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: overall survival (months): 52///characteristics_ch1.1: overall survival (censored): 0 [censored]///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated using the trizol protocol///label_ch1: biotin///label_protocol_ch1: RNA is converted into cDNA using a T7 promoter-tailed oligo-dT primer in the synthesis of the first cDNA strand; second strand cDNA synthesis is then carried out.///label_protocol_ch1.1: The double-stranded cDNA is used as the template in an in vitro transcription (IVT) reaction catalyzed by T7 polymerase and containing biotinylated CTP and UTP in addition to the four unmodified ribonucleoside triphosphates///taxid_ch1: 9606///hyb_protocol: Standard Affymetrix protocol.///scan_protocol: Standard Affymetrix protocol. Each cRNA bound at its complementary oligonucleotide is excited using a confocal laser scanner, and the positions and intensities of the fluorescent emissions are captured.///description: 091301 HGU95Av2 SC G7///data_processing: RMA///platform_id: GPL8300///contact_name: panagiotis,,konstantinopoulos///contact_email: [email protected]///contact_department: hem/onc///contact_institute: bidmc///contact_address: 330 brookline av///contact_city: boston///contact_state: MA///contact_zip.postal_code: 2215///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM495nnn/GSM495197/GSM495197.CEL.gz///data_row_count: 12558
1
title: Ovarian cancer_sample 5///geo_accession: GSM495143///status: Public on Jul 11 2010///submission_date: Jan 11 2010///last_update_date: Jul 11 2010///type: RNA///channel_count: 1///source_name_ch1: Ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: overall survival (months): 15///characteristics_ch1.1: overall survival (censored): 1 [event (death)]///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated using the trizol protocol///label_ch1: biotin///label_protocol_ch1: RNA is converted into cDNA using a T7 promoter-tailed oligo-dT primer in the synthesis of the first cDNA strand; second strand cDNA synthesis is then carried out.///label_protocol_ch1.1: The double-stranded cDNA is used as the template in an in vitro transcription (IVT) reaction catalyzed by T7 polymerase and containing biotinylated CTP and UTP in addition to the four unmodified ribonucleoside triphosphates///taxid_ch1: 9606///hyb_protocol: Standard Affymetrix protocol.///scan_protocol: Standard Affymetrix protocol. Each cRNA bound at its complementary oligonucleotide is excited using a confocal laser scanner, and the positions and intensities of the fluorescent emissions are captured.///description: PK2009081431///data_processing: RMA///platform_id: GPL570///contact_name: panagiotis,,konstantinopoulos///contact_email: [email protected]///contact_department: hem/onc///contact_institute: bidmc///contact_address: 330 brookline av///contact_city: boston///contact_state: MA///contact_zip.postal_code: 2215///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM495nnn/GSM495143/GSM495143.CEL.gz///data_row_count: 54675
1
title: Ovarian cancer_sample 60///geo_accession: GSM495198///status: Public on Jul 11 2010///submission_date: Jan 11 2010///last_update_date: Jul 11 2010///type: RNA///channel_count: 1///source_name_ch1: Ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: overall survival (months): 50///characteristics_ch1.1: overall survival (censored): 1 [event (death)]///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated using the trizol protocol///label_ch1: biotin///label_protocol_ch1: RNA is converted into cDNA using a T7 promoter-tailed oligo-dT primer in the synthesis of the first cDNA strand; second strand cDNA synthesis is then carried out.///label_protocol_ch1.1: The double-stranded cDNA is used as the template in an in vitro transcription (IVT) reaction catalyzed by T7 polymerase and containing biotinylated CTP and UTP in addition to the four unmodified ribonucleoside triphosphates///taxid_ch1: 9606///hyb_protocol: Standard Affymetrix protocol.///scan_protocol: Standard Affymetrix protocol. Each cRNA bound at its complementary oligonucleotide is excited using a confocal laser scanner, and the positions and intensities of the fluorescent emissions are captured.///description: 091301 HGU95Av2 SC G9///data_processing: RMA///platform_id: GPL8300///contact_name: panagiotis,,konstantinopoulos///contact_email: [email protected]///contact_department: hem/onc///contact_institute: bidmc///contact_address: 330 brookline av///contact_city: boston///contact_state: MA///contact_zip.postal_code: 2215///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM495nnn/GSM495198/GSM495198.CEL.gz///data_row_count: 12558
1
title: Ovarian cancer_sample 61///geo_accession: GSM495199///status: Public on Jul 11 2010///submission_date: Jan 11 2010///last_update_date: Jul 11 2010///type: RNA///channel_count: 1///source_name_ch1: Ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: overall survival (months): 68///characteristics_ch1.1: overall survival (censored): 0 [censored]///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated using the trizol protocol///label_ch1: biotin///label_protocol_ch1: RNA is converted into cDNA using a T7 promoter-tailed oligo-dT primer in the synthesis of the first cDNA strand; second strand cDNA synthesis is then carried out.///label_protocol_ch1.1: The double-stranded cDNA is used as the template in an in vitro transcription (IVT) reaction catalyzed by T7 polymerase and containing biotinylated CTP and UTP in addition to the four unmodified ribonucleoside triphosphates///taxid_ch1: 9606///hyb_protocol: Standard Affymetrix protocol.///scan_protocol: Standard Affymetrix protocol. Each cRNA bound at its complementary oligonucleotide is excited using a confocal laser scanner, and the positions and intensities of the fluorescent emissions are captured.///description: 091301 HGU95Av2 SC H1///data_processing: RMA///platform_id: GPL8300///contact_name: panagiotis,,konstantinopoulos///contact_email: [email protected]///contact_department: hem/onc///contact_institute: bidmc///contact_address: 330 brookline av///contact_city: boston///contact_state: MA///contact_zip.postal_code: 2215///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM495nnn/GSM495199/GSM495199.CEL.gz///data_row_count: 12558
1
title: Ovarian cancer_sample 62///geo_accession: GSM495200///status: Public on Jul 11 2010///submission_date: Jan 11 2010///last_update_date: Jul 11 2010///type: RNA///channel_count: 1///source_name_ch1: Ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: overall survival (months): 46///characteristics_ch1.1: overall survival (censored): 1 [event (death)]///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated using the trizol protocol///label_ch1: biotin///label_protocol_ch1: RNA is converted into cDNA using a T7 promoter-tailed oligo-dT primer in the synthesis of the first cDNA strand; second strand cDNA synthesis is then carried out.///label_protocol_ch1.1: The double-stranded cDNA is used as the template in an in vitro transcription (IVT) reaction catalyzed by T7 polymerase and containing biotinylated CTP and UTP in addition to the four unmodified ribonucleoside triphosphates///taxid_ch1: 9606///hyb_protocol: Standard Affymetrix protocol.///scan_protocol: Standard Affymetrix protocol. Each cRNA bound at its complementary oligonucleotide is excited using a confocal laser scanner, and the positions and intensities of the fluorescent emissions are captured.///description: 091301 HGU95Av2 SC H2///data_processing: RMA///platform_id: GPL8300///contact_name: panagiotis,,konstantinopoulos///contact_email: [email protected]///contact_department: hem/onc///contact_institute: bidmc///contact_address: 330 brookline av///contact_city: boston///contact_state: MA///contact_zip.postal_code: 2215///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM495nnn/GSM495200/GSM495200.CEL.gz///data_row_count: 12558
1
title: Ovarian cancer_sample 63///geo_accession: GSM495201///status: Public on Jul 11 2010///submission_date: Jan 11 2010///last_update_date: Jul 11 2010///type: RNA///channel_count: 1///source_name_ch1: Ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: overall survival (months): 44///characteristics_ch1.1: overall survival (censored): 0 [censored]///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated using the trizol protocol///label_ch1: biotin///label_protocol_ch1: RNA is converted into cDNA using a T7 promoter-tailed oligo-dT primer in the synthesis of the first cDNA strand; second strand cDNA synthesis is then carried out.///label_protocol_ch1.1: The double-stranded cDNA is used as the template in an in vitro transcription (IVT) reaction catalyzed by T7 polymerase and containing biotinylated CTP and UTP in addition to the four unmodified ribonucleoside triphosphates///taxid_ch1: 9606///hyb_protocol: Standard Affymetrix protocol.///scan_protocol: Standard Affymetrix protocol. Each cRNA bound at its complementary oligonucleotide is excited using a confocal laser scanner, and the positions and intensities of the fluorescent emissions are captured.///description: 091803 HU95AV2 TL 15D4///data_processing: RMA///platform_id: GPL8300///contact_name: panagiotis,,konstantinopoulos///contact_email: [email protected]///contact_department: hem/onc///contact_institute: bidmc///contact_address: 330 brookline av///contact_city: boston///contact_state: MA///contact_zip.postal_code: 2215///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM495nnn/GSM495201/GSM495201.CEL.gz///data_row_count: 12558
1
title: Ovarian cancer_sample 64///geo_accession: GSM495202///status: Public on Jul 11 2010///submission_date: Jan 11 2010///last_update_date: Jul 11 2010///type: RNA///channel_count: 1///source_name_ch1: Ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: overall survival (months): 12///characteristics_ch1.1: overall survival (censored): 1 [event (death)]///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated using the trizol protocol///label_ch1: biotin///label_protocol_ch1: RNA is converted into cDNA using a T7 promoter-tailed oligo-dT primer in the synthesis of the first cDNA strand; second strand cDNA synthesis is then carried out.///label_protocol_ch1.1: The double-stranded cDNA is used as the template in an in vitro transcription (IVT) reaction catalyzed by T7 polymerase and containing biotinylated CTP and UTP in addition to the four unmodified ribonucleoside triphosphates///taxid_ch1: 9606///hyb_protocol: Standard Affymetrix protocol.///scan_protocol: Standard Affymetrix protocol. Each cRNA bound at its complementary oligonucleotide is excited using a confocal laser scanner, and the positions and intensities of the fluorescent emissions are captured.///description: 091803 HU95AV2 TL 15D6///data_processing: RMA///platform_id: GPL8300///contact_name: panagiotis,,konstantinopoulos///contact_email: [email protected]///contact_department: hem/onc///contact_institute: bidmc///contact_address: 330 brookline av///contact_city: boston///contact_state: MA///contact_zip.postal_code: 2215///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM495nnn/GSM495202/GSM495202.CEL.gz///data_row_count: 12558
1
title: Ovarian cancer_sample 65///geo_accession: GSM495203///status: Public on Jul 11 2010///submission_date: Jan 11 2010///last_update_date: Jul 11 2010///type: RNA///channel_count: 1///source_name_ch1: Ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: overall survival (months): 39///characteristics_ch1.1: overall survival (censored): 0 [censored]///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated using the trizol protocol///label_ch1: biotin///label_protocol_ch1: RNA is converted into cDNA using a T7 promoter-tailed oligo-dT primer in the synthesis of the first cDNA strand; second strand cDNA synthesis is then carried out.///label_protocol_ch1.1: The double-stranded cDNA is used as the template in an in vitro transcription (IVT) reaction catalyzed by T7 polymerase and containing biotinylated CTP and UTP in addition to the four unmodified ribonucleoside triphosphates///taxid_ch1: 9606///hyb_protocol: Standard Affymetrix protocol.///scan_protocol: Standard Affymetrix protocol. Each cRNA bound at its complementary oligonucleotide is excited using a confocal laser scanner, and the positions and intensities of the fluorescent emissions are captured.///description: 091803 HU95AV2 TL 15D7///data_processing: RMA///platform_id: GPL8300///contact_name: panagiotis,,konstantinopoulos///contact_email: [email protected]///contact_department: hem/onc///contact_institute: bidmc///contact_address: 330 brookline av///contact_city: boston///contact_state: MA///contact_zip.postal_code: 2215///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM495nnn/GSM495203/GSM495203.CEL.gz///data_row_count: 12558
1
title: Ovarian cancer_sample 66///geo_accession: GSM495204///status: Public on Jul 11 2010///submission_date: Jan 11 2010///last_update_date: Jul 11 2010///type: RNA///channel_count: 1///source_name_ch1: Ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: overall survival (months): 38///characteristics_ch1.1: overall survival (censored): 0 [censored]///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated using the trizol protocol///label_ch1: biotin///label_protocol_ch1: RNA is converted into cDNA using a T7 promoter-tailed oligo-dT primer in the synthesis of the first cDNA strand; second strand cDNA synthesis is then carried out.///label_protocol_ch1.1: The double-stranded cDNA is used as the template in an in vitro transcription (IVT) reaction catalyzed by T7 polymerase and containing biotinylated CTP and UTP in addition to the four unmodified ribonucleoside triphosphates///taxid_ch1: 9606///hyb_protocol: Standard Affymetrix protocol.///scan_protocol: Standard Affymetrix protocol. Each cRNA bound at its complementary oligonucleotide is excited using a confocal laser scanner, and the positions and intensities of the fluorescent emissions are captured.///description: 091803 HU95AV2 TL 15D9///data_processing: RMA///platform_id: GPL8300///contact_name: panagiotis,,konstantinopoulos///contact_email: [email protected]///contact_department: hem/onc///contact_institute: bidmc///contact_address: 330 brookline av///contact_city: boston///contact_state: MA///contact_zip.postal_code: 2215///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM495nnn/GSM495204/GSM495204.CEL.gz///data_row_count: 12558
1
title: Ovarian cancer_sample 67///geo_accession: GSM495205///status: Public on Jul 11 2010///submission_date: Jan 11 2010///last_update_date: Jul 11 2010///type: RNA///channel_count: 1///source_name_ch1: Ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: overall survival (months): 30///characteristics_ch1.1: overall survival (censored): 1 [event (death)]///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated using the trizol protocol///label_ch1: biotin///label_protocol_ch1: RNA is converted into cDNA using a T7 promoter-tailed oligo-dT primer in the synthesis of the first cDNA strand; second strand cDNA synthesis is then carried out.///label_protocol_ch1.1: The double-stranded cDNA is used as the template in an in vitro transcription (IVT) reaction catalyzed by T7 polymerase and containing biotinylated CTP and UTP in addition to the four unmodified ribonucleoside triphosphates///taxid_ch1: 9606///hyb_protocol: Standard Affymetrix protocol.///scan_protocol: Standard Affymetrix protocol. Each cRNA bound at its complementary oligonucleotide is excited using a confocal laser scanner, and the positions and intensities of the fluorescent emissions are captured.///description: 121401 HGU95Av2 SC R5///data_processing: RMA///platform_id: GPL8300///contact_name: panagiotis,,konstantinopoulos///contact_email: [email protected]///contact_department: hem/onc///contact_institute: bidmc///contact_address: 330 brookline av///contact_city: boston///contact_state: MA///contact_zip.postal_code: 2215///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM495nnn/GSM495205/GSM495205.CEL.gz///data_row_count: 12558
1
title: Ovarian cancer_sample 68///geo_accession: GSM495206///status: Public on Jul 11 2010///submission_date: Jan 11 2010///last_update_date: Jul 11 2010///type: RNA///channel_count: 1///source_name_ch1: Ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: overall survival (months): 34///characteristics_ch1.1: overall survival (censored): 1 [event (death)]///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated using the trizol protocol///label_ch1: biotin///label_protocol_ch1: RNA is converted into cDNA using a T7 promoter-tailed oligo-dT primer in the synthesis of the first cDNA strand; second strand cDNA synthesis is then carried out.///label_protocol_ch1.1: The double-stranded cDNA is used as the template in an in vitro transcription (IVT) reaction catalyzed by T7 polymerase and containing biotinylated CTP and UTP in addition to the four unmodified ribonucleoside triphosphates///taxid_ch1: 9606///hyb_protocol: Standard Affymetrix protocol.///scan_protocol: Standard Affymetrix protocol. Each cRNA bound at its complementary oligonucleotide is excited using a confocal laser scanner, and the positions and intensities of the fluorescent emissions are captured.///description: 121401 HGU95Av2 SC R6///data_processing: RMA///platform_id: GPL8300///contact_name: panagiotis,,konstantinopoulos///contact_email: [email protected]///contact_department: hem/onc///contact_institute: bidmc///contact_address: 330 brookline av///contact_city: boston///contact_state: MA///contact_zip.postal_code: 2215///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM495nnn/GSM495206/GSM495206.CEL.gz///data_row_count: 12558
1
title: Ovarian cancer_sample 69///geo_accession: GSM495207///status: Public on Jul 11 2010///submission_date: Jan 11 2010///last_update_date: Jul 11 2010///type: RNA///channel_count: 1///source_name_ch1: Ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: overall survival (months): 24///characteristics_ch1.1: overall survival (censored): 1 [event (death)]///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated using the trizol protocol///label_ch1: biotin///label_protocol_ch1: RNA is converted into cDNA using a T7 promoter-tailed oligo-dT primer in the synthesis of the first cDNA strand; second strand cDNA synthesis is then carried out.///label_protocol_ch1.1: The double-stranded cDNA is used as the template in an in vitro transcription (IVT) reaction catalyzed by T7 polymerase and containing biotinylated CTP and UTP in addition to the four unmodified ribonucleoside triphosphates///taxid_ch1: 9606///hyb_protocol: Standard Affymetrix protocol.///scan_protocol: Standard Affymetrix protocol. Each cRNA bound at its complementary oligonucleotide is excited using a confocal laser scanner, and the positions and intensities of the fluorescent emissions are captured.///description: 121401 HGU95Av2 SC R7///data_processing: RMA///platform_id: GPL8300///contact_name: panagiotis,,konstantinopoulos///contact_email: [email protected]///contact_department: hem/onc///contact_institute: bidmc///contact_address: 330 brookline av///contact_city: boston///contact_state: MA///contact_zip.postal_code: 2215///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM495nnn/GSM495207/GSM495207.CEL.gz///data_row_count: 12558
1
title: Ovarian cancer_sample 6///geo_accession: GSM495144///status: Public on Jul 11 2010///submission_date: Jan 11 2010///last_update_date: Jul 11 2010///type: RNA///channel_count: 1///source_name_ch1: Ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: overall survival (months): 11///characteristics_ch1.1: overall survival (censored): 1 [event (death)]///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated using the trizol protocol///label_ch1: biotin///label_protocol_ch1: RNA is converted into cDNA using a T7 promoter-tailed oligo-dT primer in the synthesis of the first cDNA strand; second strand cDNA synthesis is then carried out.///label_protocol_ch1.1: The double-stranded cDNA is used as the template in an in vitro transcription (IVT) reaction catalyzed by T7 polymerase and containing biotinylated CTP and UTP in addition to the four unmodified ribonucleoside triphosphates///taxid_ch1: 9606///hyb_protocol: Standard Affymetrix protocol.///scan_protocol: Standard Affymetrix protocol. Each cRNA bound at its complementary oligonucleotide is excited using a confocal laser scanner, and the positions and intensities of the fluorescent emissions are captured.///description: PK2009081432///data_processing: RMA///platform_id: GPL570///contact_name: panagiotis,,konstantinopoulos///contact_email: [email protected]///contact_department: hem/onc///contact_institute: bidmc///contact_address: 330 brookline av///contact_city: boston///contact_state: MA///contact_zip.postal_code: 2215///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM495nnn/GSM495144/GSM495144.CEL.gz///data_row_count: 54675
1
title: Ovarian cancer_sample 70///geo_accession: GSM495208///status: Public on Jul 11 2010///submission_date: Jan 11 2010///last_update_date: Jul 11 2010///type: RNA///channel_count: 1///source_name_ch1: Ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: overall survival (months): 39///characteristics_ch1.1: overall survival (censored): 0 [censored]///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated using the trizol protocol///label_ch1: biotin///label_protocol_ch1: RNA is converted into cDNA using a T7 promoter-tailed oligo-dT primer in the synthesis of the first cDNA strand; second strand cDNA synthesis is then carried out.///label_protocol_ch1.1: The double-stranded cDNA is used as the template in an in vitro transcription (IVT) reaction catalyzed by T7 polymerase and containing biotinylated CTP and UTP in addition to the four unmodified ribonucleoside triphosphates///taxid_ch1: 9606///hyb_protocol: Standard Affymetrix protocol.///scan_protocol: Standard Affymetrix protocol. Each cRNA bound at its complementary oligonucleotide is excited using a confocal laser scanner, and the positions and intensities of the fluorescent emissions are captured.///description: 121401 HGU95Av2 SC R8///data_processing: RMA///platform_id: GPL8300///contact_name: panagiotis,,konstantinopoulos///contact_email: [email protected]///contact_department: hem/onc///contact_institute: bidmc///contact_address: 330 brookline av///contact_city: boston///contact_state: MA///contact_zip.postal_code: 2215///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM495nnn/GSM495208/GSM495208.CEL.gz///data_row_count: 12558
1
title: Ovarian cancer_sample 7///geo_accession: GSM495145///status: Public on Jul 11 2010///submission_date: Jan 11 2010///last_update_date: Jul 11 2010///type: RNA///channel_count: 1///source_name_ch1: Ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: overall survival (months): 54///characteristics_ch1.1: overall survival (censored): 0 [censored]///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated using the trizol protocol///label_ch1: biotin///label_protocol_ch1: RNA is converted into cDNA using a T7 promoter-tailed oligo-dT primer in the synthesis of the first cDNA strand; second strand cDNA synthesis is then carried out.///label_protocol_ch1.1: The double-stranded cDNA is used as the template in an in vitro transcription (IVT) reaction catalyzed by T7 polymerase and containing biotinylated CTP and UTP in addition to the four unmodified ribonucleoside triphosphates///taxid_ch1: 9606///hyb_protocol: Standard Affymetrix protocol.///scan_protocol: Standard Affymetrix protocol. Each cRNA bound at its complementary oligonucleotide is excited using a confocal laser scanner, and the positions and intensities of the fluorescent emissions are captured.///description: PK2009081434///data_processing: RMA///platform_id: GPL570///contact_name: panagiotis,,konstantinopoulos///contact_email: [email protected]///contact_department: hem/onc///contact_institute: bidmc///contact_address: 330 brookline av///contact_city: boston///contact_state: MA///contact_zip.postal_code: 2215///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM495nnn/GSM495145/GSM495145.CEL.gz///data_row_count: 54675
1
title: Ovarian cancer_sample 8///geo_accession: GSM495146///status: Public on Jul 11 2010///submission_date: Jan 11 2010///last_update_date: Jul 11 2010///type: RNA///channel_count: 1///source_name_ch1: Ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: overall survival (months): 33///characteristics_ch1.1: overall survival (censored): 1 [event (death)]///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated using the trizol protocol///label_ch1: biotin///label_protocol_ch1: RNA is converted into cDNA using a T7 promoter-tailed oligo-dT primer in the synthesis of the first cDNA strand; second strand cDNA synthesis is then carried out.///label_protocol_ch1.1: The double-stranded cDNA is used as the template in an in vitro transcription (IVT) reaction catalyzed by T7 polymerase and containing biotinylated CTP and UTP in addition to the four unmodified ribonucleoside triphosphates///taxid_ch1: 9606///hyb_protocol: Standard Affymetrix protocol.///scan_protocol: Standard Affymetrix protocol. Each cRNA bound at its complementary oligonucleotide is excited using a confocal laser scanner, and the positions and intensities of the fluorescent emissions are captured.///description: PK2009081435///data_processing: RMA///platform_id: GPL570///contact_name: panagiotis,,konstantinopoulos///contact_email: [email protected]///contact_department: hem/onc///contact_institute: bidmc///contact_address: 330 brookline av///contact_city: boston///contact_state: MA///contact_zip.postal_code: 2215///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM495nnn/GSM495146/GSM495146.CEL.gz///data_row_count: 54675
1
title: Ovarian cancer_sample 9///geo_accession: GSM495147///status: Public on Jul 11 2010///submission_date: Jan 11 2010///last_update_date: Jul 11 2010///type: RNA///channel_count: 1///source_name_ch1: Ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: overall survival (months): 5///characteristics_ch1.1: overall survival (censored): 1 [event (death)]///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated using the trizol protocol///label_ch1: biotin///label_protocol_ch1: RNA is converted into cDNA using a T7 promoter-tailed oligo-dT primer in the synthesis of the first cDNA strand; second strand cDNA synthesis is then carried out.///label_protocol_ch1.1: The double-stranded cDNA is used as the template in an in vitro transcription (IVT) reaction catalyzed by T7 polymerase and containing biotinylated CTP and UTP in addition to the four unmodified ribonucleoside triphosphates///taxid_ch1: 9606///hyb_protocol: Standard Affymetrix protocol.///scan_protocol: Standard Affymetrix protocol. Each cRNA bound at its complementary oligonucleotide is excited using a confocal laser scanner, and the positions and intensities of the fluorescent emissions are captured.///description: PK2009081436///data_processing: RMA///platform_id: GPL570///contact_name: panagiotis,,konstantinopoulos///contact_email: [email protected]///contact_department: hem/onc///contact_institute: bidmc///contact_address: 330 brookline av///contact_city: boston///contact_state: MA///contact_zip.postal_code: 2215///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM495nnn/GSM495147/GSM495147.CEL.gz///data_row_count: 54675
1
vital_status:
deceased living
40 30
An expression set
The distinction between primary and secondary ovarian tumors may be challenging for pathologists. The purpose of the present work was to develop genomic and transcriptomic tools to further refine the pathological diagnosis of ovarian tumors after a previous history of breast cancer.Sixteen paired breast-ovary tumors from patients with a former diagnosis of breast cancer were collected. The genomic profiles of paired tumors were analyzed using the Affymetrix GeneChip Mapping 50 K Xba Array or Genome-Wide Human SNP Array 6.0 (for one pair), and the data were normalized with ITALICS (ITerative and Alternative normaLIzation and Copy number calling for affymetrix Snp arrays) algorithm or Partek Genomic Suite, respectively. The transcriptome of paired samples was analyzed using Affymetrix GeneChip Human Genome U133 Plus 2.0 Arrays, and the data were normalized with gc-Robust Multi-array Average (gcRMA) algorithm. A hierarchical clustering of these samples was performed, combined with a dataset of well-identified primary and secondary ovarian tumors.In 12 of the 16 paired tumors analyzed, the comparison of genomic profiles confirmed the pathological diagnosis of primary ovarian tumor (n = 5) or metastasis of breast cancer (n = 7). Among four cases with uncertain pathological diagnosis, genomic profiles were clearly distinct between the ovarian and breast tumors in two pairs, thus indicating primary ovarian carcinomas, and showed common patterns in the two others, indicating metastases from breast cancer. In all pairs, the result of the transcriptomic analysis was concordant with that of the genomic analysis.In patients with ovarian carcinoma and a previous history of breast cancer, SNP array analysis can be used to distinguish primary and secondary ovarian tumors. Transcriptomic analysis may be used when primary breast tissue specimen is not available.
experimentData(eset):
Experiment data
Experimenter name: Meyniel JP, Cottu PH, Decraene C, Stern MH, Couturier J, Lebigot I, Nicolas A, Weber N, Fourchotte V, Alran S, Rapinat A, Gentien D, Roman-Roman S, Mignot L, Sastre-Garau X.A genomic and transcriptomic approach for a differential diagnosis between primary and secondary ovarian carcinomas in patients with a previous history of breast cancer. BMC Cancer. 2010 May 21; 10:222.
Laboratory: Meyniel, Sastre-Garau 2010
Contact information:
Title: A genomic and transcriptomic approach for a differential diagnosis between primary and secondary ovarian carcinomas in patients with a previous history of breast cancer.
URL:
PMIDs: 20492709
Abstract: A 277 word abstract is available. Use 'abstract' method.
Information is available on: preprocessing
notes:
platform_title:
[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array
platform_shorttitle:
Affymetrix HG-U133Plus2
platform_summary:
hgu133plus2
platform_manufacturer:
Affymetrix
platform_distribution:
commercial
platform_accession:
GPL570|GPL2005|GPL6801
version:
2015-09-22 19:33:01
featureData(eset):
An object of class 'AnnotatedDataFrame'
featureNames: 1007_s_at 1053_at ... AFFX-HUMISGF3A/M97935_MB_at
(42447 total)
varLabels: probeset gene EntrezGene.ID best_probe
varMetadata: labelDescription
assayData: 42447 features, 140 samples
Platform type:
---------------------------
Available sample meta-data:
---------------------------
alt_sample_name:
Breast metastasis in the ovary_OC01_ARN0016 [HG-U133_Plus_2]
1
Breast metastasis in the ovary_OC01_ARN0017 [HG-U133_Plus_2]
1
Breast metastasis in the ovary_OC01_ARN0020 [HG-U133_Plus_2]
1
Breast metastasis in the ovary_OC01_ARN0029 [HG-U133_Plus_2]
1
Breast metastasis in the ovary_OC01_ARN0035 [HG-U133_Plus_2]
1
Breast metastasis in the ovary_OC01_ARN0046 [HG-U133_Plus_2]
1
Breast metastasis in the ovary_OC01_ARN0051 [HG-U133_Plus_2]
1
Breast metastasis in the ovary_OC01_ARN0053 [HG-U133_Plus_2]
1
Breast metastasis in the ovary_OC01_ARN0055 [HG-U133_Plus_2]
1
Breast metastasis in the ovary_OC01_ARN0060 [HG-U133_Plus_2]
1
Breast metastasis in the ovary_OC01_ARN0069 [HG-U133_Plus_2]
1
Breast metastasis in the ovary_OC01_ARN0073 [HG-U133_Plus_2]
1
Breast metastasis in the ovary_OC01_ARN0077 [HG-U133_Plus_2]
1
Breast metastasis in the ovary_OC01_ARN0079 [HG-U133_Plus_2]
1
Breast metastasis in the ovary_OC01_ARN0081 [HG-U133_Plus_2]
1
Breast metastasis in the ovary_OC01_ARN0083 [HG-U133_Plus_2]
1
Breast metastasis in the ovary_OC01_ARN0092 [HG-U133_Plus_2]
1
Breast metastasis in the ovary_OC01_ARN0097 [HG-U133_Plus_2]
1
Breast metastasis in the ovary_OC01_ARN0098 [HG-U133_Plus_2]
1
Breast metastasis in the ovary_OC01_ARN0099 [HG-U133_Plus_2]
1
Breast metastasis in the ovary_OC01_ARN0102 [HG-U133_Plus_2]
1
Breast metastasis in the ovary_OC01_ARN0104 [HG-U133_Plus_2]
1
Breast metastasis in the ovary_OC01_ARN0112 [HG-U133_Plus_2]
1
Breast metastasis in the ovary_OC01_ARN0120 [HG-U133_Plus_2]
1
Breast metastasis in the ovary_OC01_ARN0121 [HG-U133_Plus_2]
1
Breast metastasis in the ovary_OC01_ARN0123 [HG-U133_Plus_2]
1
Breast metastasis in the ovary_OC01_ARN0126 [HG-U133_Plus_2]
1
Breast metastasis in the ovary_OC01_ARN0141 [HG-U133_Plus_2]
1
Breast metastasis in the ovary_OC01_ARN0142 [HG-U133_Plus_2]
1
Breast metastasis in the ovary_OC01_ARN0143 [HG-U133_Plus_2]
1
Breast metastasis in the ovary_OC01_ARN0145 [HG-U133_Plus_2]
1
Breast metastasis in the ovary_OC01_ARN0146 [HG-U133_Plus_2]
1
Breast metastasis in the ovary_OC01_ARN0153 [HG-U133_Plus_2]
1
Breast metastasis in the ovary_OC01_ARN0162 [HG-U133_Plus_2]
1
Breast metastasis in the ovary_OC01_ARN0201 [HG-U133_Plus_2]
1
Ovarian carcinoma_OC01_ARN0001 [HG-U133_Plus_2]
1
Ovarian carcinoma_OC01_ARN0002 [HG-U133_Plus_2]
1
Ovarian carcinoma_OC01_ARN0004 [HG-U133_Plus_2]
1
Ovarian carcinoma_OC01_ARN0005 [HG-U133_Plus_2]
1
Ovarian carcinoma_OC01_ARN0007 [HG-U133_Plus_2]
1
Ovarian carcinoma_OC01_ARN0008 [HG-U133_Plus_2]
1
Ovarian carcinoma_OC01_ARN0009 [HG-U133_Plus_2]
1
Ovarian carcinoma_OC01_ARN0010 [HG-U133_Plus_2]
1
Ovarian carcinoma_OC01_ARN0011 [HG-U133_Plus_2]
1
Ovarian carcinoma_OC01_ARN0012 [HG-U133_Plus_2]
1
Ovarian carcinoma_OC01_ARN0013 [HG-U133_Plus_2]
1
Ovarian carcinoma_OC01_ARN0015 [HG-U133_Plus_2]
1
Ovarian carcinoma_OC01_ARN0022 [HG-U133_Plus_2]
1
Ovarian carcinoma_OC01_ARN0023 [HG-U133_Plus_2]
1
Ovarian carcinoma_OC01_ARN0025 [HG-U133_Plus_2]
1
Ovarian carcinoma_OC01_ARN0028 [HG-U133_Plus_2]
1
Ovarian carcinoma_OC01_ARN0030 [HG-U133_Plus_2]
1
Ovarian carcinoma_OC01_ARN0032 [HG-U133_Plus_2]
1
Ovarian carcinoma_OC01_ARN0034 [HG-U133_Plus_2]
1
Ovarian carcinoma_OC01_ARN0036 [HG-U133_Plus_2]
1
Ovarian carcinoma_OC01_ARN0037 [HG-U133_Plus_2]
1
Ovarian carcinoma_OC01_ARN0038 [HG-U133_Plus_2]
1
Ovarian carcinoma_OC01_ARN0039 [HG-U133_Plus_2]
1
Ovarian carcinoma_OC01_ARN0041 [HG-U133_Plus_2]
1
Ovarian carcinoma_OC01_ARN0042 [HG-U133_Plus_2]
1
Ovarian carcinoma_OC01_ARN0045 [HG-U133_Plus_2]
1
Ovarian carcinoma_OC01_ARN0049 [HG-U133_Plus_2]
1
Ovarian carcinoma_OC01_ARN0057 [HG-U133_Plus_2]
1
Ovarian carcinoma_OC01_ARN0058 [HG-U133_Plus_2]
1
Ovarian carcinoma_OC01_ARN0061 [HG-U133_Plus_2]
1
Ovarian carcinoma_OC01_ARN0062 [HG-U133_Plus_2]
1
Ovarian carcinoma_OC01_ARN0063 [HG-U133_Plus_2]
1
Ovarian carcinoma_OC01_ARN0064 [HG-U133_Plus_2]
1
Ovarian carcinoma_OC01_ARN0066 [HG-U133_Plus_2]
1
Ovarian carcinoma_OC01_ARN0067 [HG-U133_Plus_2]
1
Ovarian carcinoma_OC01_ARN0070 [HG-U133_Plus_2]
1
Ovarian carcinoma_OC01_ARN0072 [HG-U133_Plus_2]
1
Ovarian carcinoma_OC01_ARN0075 [HG-U133_Plus_2]
1
Ovarian carcinoma_OC01_ARN0076 [HG-U133_Plus_2]
1
Ovarian carcinoma_OC01_ARN0080 [HG-U133_Plus_2]
1
Ovarian carcinoma_OC01_ARN0084 [HG-U133_Plus_2]
1
Ovarian carcinoma_OC01_ARN0085 [HG-U133_Plus_2]
1
Ovarian carcinoma_OC01_ARN0089 [HG-U133_Plus_2]
1
Ovarian carcinoma_OC01_ARN0091 [HG-U133_Plus_2]
1
Ovarian carcinoma_OC01_ARN0093 [HG-U133_Plus_2]
1
Ovarian carcinoma_OC01_ARN0095 [HG-U133_Plus_2]
1
Ovarian carcinoma_OC01_ARN0096 [HG-U133_Plus_2]
1
Ovarian carcinoma_OC01_ARN0100 [HG-U133_Plus_2]
1
Ovarian carcinoma_OC01_ARN0101 [HG-U133_Plus_2]
1
Ovarian carcinoma_OC01_ARN0103 [HG-U133_Plus_2]
1
Ovarian carcinoma_OC01_ARN0105 [HG-U133_Plus_2]
1
Ovarian carcinoma_OC01_ARN0106 [HG-U133_Plus_2]
1
Ovarian carcinoma_OC01_ARN0107 [HG-U133_Plus_2]
1
Ovarian carcinoma_OC01_ARN0108 [HG-U133_Plus_2]
1
Ovarian carcinoma_OC01_ARN0109 [HG-U133_Plus_2]
1
Ovarian carcinoma_OC01_ARN0111 [HG-U133_Plus_2]
1
Ovarian carcinoma_OC01_ARN0113 [HG-U133_Plus_2]
1
Ovarian carcinoma_OC01_ARN0114 [HG-U133_Plus_2]
1
Ovarian carcinoma_OC01_ARN0115 [HG-U133_Plus_2]
1
Ovarian carcinoma_OC01_ARN0116 [HG-U133_Plus_2]
1
Ovarian carcinoma_OC01_ARN0118 [HG-U133_Plus_2]
1
Ovarian carcinoma_OC01_ARN0119 [HG-U133_Plus_2]
1
Ovarian carcinoma_OC01_ARN0124 [HG-U133_Plus_2]
1
Ovarian carcinoma_OC01_ARN0125 [HG-U133_Plus_2]
1
(Other)
41
sample_type:
tumor
140
histological_type:
clearcell endo mucinous other ser NA's
6 6 7 6 71 44
primarysite:
other ov
44 96
summarygrade:
high low NA's
63 33 44
summarystage:
early late NA's
27 67 46
tumorstage:
1 2 3 4 NA's
18 9 52 15 46
substage:
a b c NA's
14 10 55 61
grade:
1 2 3 NA's
6 27 63 44
batch:
2006-06-01 2006-06-27 2006-06-28 2006-06-29 2006-06-30 2006-07-20 2008-03-06
21 18 37 20 36 7 1
uncurated_author_metadata:
title: Breast metastasis in the ovary_OC01_ARN0016 [HG-U133_Plus_2]///geo_accession: GSM516692///status: Public on Apr 14 2010///submission_date: Mar 01 2010///last_update_date: Apr 14 2010///type: RNA///channel_count: 1///source_name_ch1: Breast metastasis in the ovary///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Ovary///characteristics_ch1.1: histology (disease state): Breast metastasis in the ovary///characteristics_ch1.2: identifier: OC01_ARN0016///characteristics_ch1.3: histotype: N/A///characteristics_ch1.4: tumor/metastasis: M///characteristics_ch1.5: grade: N/A///characteristics_ch1.6: stade: N/A///treatment_protocol_ch1: N/A///growth_protocol_ch1: N/A///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix)_mRNA.///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from breast metastasis in the ovary///data_processing: The data were processed/analyzed with gc-RMA (Partek Genomic Suite 6.09.1008).///platform_id: GPL570///contact_name: Jean-Philippe,,MEYNIEL///contact_email: [email protected]///contact_phone: 33153194126///contact_fax: 33153194130///contact_department: Translational Research Dept///contact_institute: Institut Curie///contact_address: 26, rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM516nnn/GSM516692/GSM516692.CEL.gz///data_row_count: 54675
1
title: Breast metastasis in the ovary_OC01_ARN0017 [HG-U133_Plus_2]///geo_accession: GSM516693///status: Public on Apr 14 2010///submission_date: Mar 01 2010///last_update_date: Apr 14 2010///type: RNA///channel_count: 1///source_name_ch1: Breast metastasis in the ovary///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Ovary///characteristics_ch1.1: histology (disease state): Breast metastasis in the ovary///characteristics_ch1.2: identifier: OC01_ARN0017///characteristics_ch1.3: histotype: N/A///characteristics_ch1.4: tumor/metastasis: M///characteristics_ch1.5: grade: N/A///characteristics_ch1.6: stade: N/A///treatment_protocol_ch1: N/A///growth_protocol_ch1: N/A///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix)_mRNA.///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from breast metastasis in the ovary///data_processing: The data were processed/analyzed with gc-RMA (Partek Genomic Suite 6.09.1008).///platform_id: GPL570///contact_name: Jean-Philippe,,MEYNIEL///contact_email: [email protected]///contact_phone: 33153194126///contact_fax: 33153194130///contact_department: Translational Research Dept///contact_institute: Institut Curie///contact_address: 26, rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM516nnn/GSM516693/GSM516693.CEL.gz///data_row_count: 54675
1
title: Breast metastasis in the ovary_OC01_ARN0020 [HG-U133_Plus_2]///geo_accession: GSM516695///status: Public on Apr 14 2010///submission_date: Mar 01 2010///last_update_date: Apr 14 2010///type: RNA///channel_count: 1///source_name_ch1: Breast metastasis in the ovary///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Ovary///characteristics_ch1.1: histology (disease state): Breast metastasis in the ovary///characteristics_ch1.2: identifier: OC01_ARN0020///characteristics_ch1.3: histotype: N/A///characteristics_ch1.4: tumor/metastasis: M///characteristics_ch1.5: grade: N/A///characteristics_ch1.6: stade: N/A///treatment_protocol_ch1: N/A///growth_protocol_ch1: N/A///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix)_mRNA.///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from breast metastasis in the ovary///data_processing: The data were processed/analyzed with gc-RMA (Partek Genomic Suite 6.09.1008).///platform_id: GPL570///contact_name: Jean-Philippe,,MEYNIEL///contact_email: [email protected]///contact_phone: 33153194126///contact_fax: 33153194130///contact_department: Translational Research Dept///contact_institute: Institut Curie///contact_address: 26, rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM516nnn/GSM516695/GSM516695.CEL.gz///data_row_count: 54675
1
title: Breast metastasis in the ovary_OC01_ARN0029 [HG-U133_Plus_2]///geo_accession: GSM516701///status: Public on Apr 14 2010///submission_date: Mar 01 2010///last_update_date: Apr 14 2010///type: RNA///channel_count: 1///source_name_ch1: Breast metastasis in the ovary///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Ovary///characteristics_ch1.1: histology (disease state): Breast metastasis in the ovary///characteristics_ch1.2: identifier: OC01_ARN0029///characteristics_ch1.3: histotype: N/A///characteristics_ch1.4: tumor/metastasis: M///characteristics_ch1.5: grade: N/A///characteristics_ch1.6: stade: N/A///treatment_protocol_ch1: N/A///growth_protocol_ch1: N/A///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix)_mRNA.///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from breast metastasis in the ovary///data_processing: The data were processed/analyzed with gc-RMA (Partek Genomic Suite 6.09.1008).///platform_id: GPL570///contact_name: Jean-Philippe,,MEYNIEL///contact_email: [email protected]///contact_phone: 33153194126///contact_fax: 33153194130///contact_department: Translational Research Dept///contact_institute: Institut Curie///contact_address: 26, rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM516nnn/GSM516701/GSM516701.CEL.gz///data_row_count: 54675
1
title: Breast metastasis in the ovary_OC01_ARN0035 [HG-U133_Plus_2]///geo_accession: GSM516705///status: Public on Apr 14 2010///submission_date: Mar 01 2010///last_update_date: Apr 14 2010///type: RNA///channel_count: 1///source_name_ch1: Breast metastasis in the ovary///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Ovary///characteristics_ch1.1: histology (disease state): Breast metastasis in the ovary///characteristics_ch1.2: identifier: OC01_ARN0035///characteristics_ch1.3: histotype: N/A///characteristics_ch1.4: tumor/metastasis: M///characteristics_ch1.5: grade: N/A///characteristics_ch1.6: stade: N/A///treatment_protocol_ch1: N/A///growth_protocol_ch1: N/A///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix)_mRNA.///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from breast metastasis in the ovary///data_processing: The data were processed/analyzed with gc-RMA (Partek Genomic Suite 6.09.1008).///platform_id: GPL570///contact_name: Jean-Philippe,,MEYNIEL///contact_email: [email protected]///contact_phone: 33153194126///contact_fax: 33153194130///contact_department: Translational Research Dept///contact_institute: Institut Curie///contact_address: 26, rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM516nnn/GSM516705/GSM516705.CEL.gz///data_row_count: 54675
1
title: Breast metastasis in the ovary_OC01_ARN0046 [HG-U133_Plus_2]///geo_accession: GSM516714///status: Public on Apr 14 2010///submission_date: Mar 01 2010///last_update_date: Apr 14 2010///type: RNA///channel_count: 1///source_name_ch1: Breast metastasis in the ovary///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Ovary///characteristics_ch1.1: histology (disease state): Breast metastasis in the ovary///characteristics_ch1.2: identifier: OC01_ARN0046///characteristics_ch1.3: histotype: N/A///characteristics_ch1.4: tumor/metastasis: M///characteristics_ch1.5: grade: N/A///characteristics_ch1.6: stade: N/A///treatment_protocol_ch1: N/A///growth_protocol_ch1: N/A///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix)_mRNA.///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from breast metastasis in the ovary///data_processing: The data were processed/analyzed with gc-RMA (Partek Genomic Suite 6.09.1008).///platform_id: GPL570///contact_name: Jean-Philippe,,MEYNIEL///contact_email: [email protected]///contact_phone: 33153194126///contact_fax: 33153194130///contact_department: Translational Research Dept///contact_institute: Institut Curie///contact_address: 26, rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM516nnn/GSM516714/GSM516714.CEL.gz///data_row_count: 54675
1
title: Breast metastasis in the ovary_OC01_ARN0051 [HG-U133_Plus_2]///geo_accession: GSM516716///status: Public on Apr 14 2010///submission_date: Mar 01 2010///last_update_date: Apr 14 2010///type: RNA///channel_count: 1///source_name_ch1: Breast metastasis in the ovary///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Ovary///characteristics_ch1.1: histology (disease state): Breast metastasis in the ovary///characteristics_ch1.2: identifier: OC01_ARN0051///characteristics_ch1.3: histotype: N/A///characteristics_ch1.4: tumor/metastasis: M///characteristics_ch1.5: grade: N/A///characteristics_ch1.6: stade: N/A///treatment_protocol_ch1: N/A///growth_protocol_ch1: N/A///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix)_mRNA.///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from breast metastasis in the ovary///data_processing: The data were processed/analyzed with gc-RMA (Partek Genomic Suite 6.09.1008).///platform_id: GPL570///contact_name: Jean-Philippe,,MEYNIEL///contact_email: [email protected]///contact_phone: 33153194126///contact_fax: 33153194130///contact_department: Translational Research Dept///contact_institute: Institut Curie///contact_address: 26, rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM516nnn/GSM516716/GSM516716.CEL.gz///data_row_count: 54675
1
title: Breast metastasis in the ovary_OC01_ARN0053 [HG-U133_Plus_2]///geo_accession: GSM516717///status: Public on Apr 14 2010///submission_date: Mar 01 2010///last_update_date: Apr 14 2010///type: RNA///channel_count: 1///source_name_ch1: Breast metastasis in the ovary///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Ovary///characteristics_ch1.1: histology (disease state): Breast metastasis in the ovary///characteristics_ch1.2: identifier: OC01_ARN0053///characteristics_ch1.3: histotype: N/A///characteristics_ch1.4: tumor/metastasis: M///characteristics_ch1.5: grade: N/A///characteristics_ch1.6: stade: N/A///treatment_protocol_ch1: N/A///growth_protocol_ch1: N/A///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix)_mRNA.///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from breast metastasis in the ovary///data_processing: The data were processed/analyzed with gc-RMA (Partek Genomic Suite 6.09.1008).///platform_id: GPL570///contact_name: Jean-Philippe,,MEYNIEL///contact_email: [email protected]///contact_phone: 33153194126///contact_fax: 33153194130///contact_department: Translational Research Dept///contact_institute: Institut Curie///contact_address: 26, rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM516nnn/GSM516717/GSM516717.CEL.gz///data_row_count: 54675
1
title: Breast metastasis in the ovary_OC01_ARN0055 [HG-U133_Plus_2]///geo_accession: GSM516718///status: Public on Apr 14 2010///submission_date: Mar 01 2010///last_update_date: Apr 14 2010///type: RNA///channel_count: 1///source_name_ch1: Breast metastasis in the ovary///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Ovary///characteristics_ch1.1: histology (disease state): Breast metastasis in the ovary///characteristics_ch1.2: identifier: OC01_ARN0055///characteristics_ch1.3: histotype: N/A///characteristics_ch1.4: tumor/metastasis: M///characteristics_ch1.5: grade: N/A///characteristics_ch1.6: stade: N/A///treatment_protocol_ch1: N/A///growth_protocol_ch1: N/A///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix)_mRNA.///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from breast metastasis in the ovary///data_processing: The data were processed/analyzed with gc-RMA (Partek Genomic Suite 6.09.1008).///platform_id: GPL570///contact_name: Jean-Philippe,,MEYNIEL///contact_email: [email protected]///contact_phone: 33153194126///contact_fax: 33153194130///contact_department: Translational Research Dept///contact_institute: Institut Curie///contact_address: 26, rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM516nnn/GSM516718/GSM516718.CEL.gz///data_row_count: 54675
1
title: Breast metastasis in the ovary_OC01_ARN0060 [HG-U133_Plus_2]///geo_accession: GSM516722///status: Public on Apr 14 2010///submission_date: Mar 01 2010///last_update_date: Apr 14 2010///type: RNA///channel_count: 1///source_name_ch1: Breast metastasis in the ovary///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Ovary///characteristics_ch1.1: histology (disease state): Breast metastasis in the ovary///characteristics_ch1.2: identifier: OC01_ARN0060///characteristics_ch1.3: histotype: N/A///characteristics_ch1.4: tumor/metastasis: M///characteristics_ch1.5: grade: N/A///characteristics_ch1.6: stade: N/A///treatment_protocol_ch1: N/A///growth_protocol_ch1: N/A///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix)_mRNA.///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from breast metastasis in the ovary///data_processing: The data were processed/analyzed with gc-RMA (Partek Genomic Suite 6.09.1008).///platform_id: GPL570///contact_name: Jean-Philippe,,MEYNIEL///contact_email: [email protected]///contact_phone: 33153194126///contact_fax: 33153194130///contact_department: Translational Research Dept///contact_institute: Institut Curie///contact_address: 26, rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM516nnn/GSM516722/GSM516722.CEL.gz///data_row_count: 54675
1
title: Breast metastasis in the ovary_OC01_ARN0069 [HG-U133_Plus_2]///geo_accession: GSM516729///status: Public on Apr 14 2010///submission_date: Mar 01 2010///last_update_date: Apr 14 2010///type: RNA///channel_count: 1///source_name_ch1: Breast metastasis in the ovary///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Ovary///characteristics_ch1.1: histology (disease state): Breast metastasis in the ovary///characteristics_ch1.2: identifier: OC01_ARN0069///characteristics_ch1.3: histotype: N/A///characteristics_ch1.4: tumor/metastasis: M///characteristics_ch1.5: grade: N/A///characteristics_ch1.6: stade: N/A///treatment_protocol_ch1: N/A///growth_protocol_ch1: N/A///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix)_mRNA.///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from breast metastasis in the ovary///data_processing: The data were processed/analyzed with gc-RMA (Partek Genomic Suite 6.09.1008).///platform_id: GPL570///contact_name: Jean-Philippe,,MEYNIEL///contact_email: [email protected]///contact_phone: 33153194126///contact_fax: 33153194130///contact_department: Translational Research Dept///contact_institute: Institut Curie///contact_address: 26, rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM516nnn/GSM516729/GSM516729.CEL.gz///data_row_count: 54675
1
title: Breast metastasis in the ovary_OC01_ARN0073 [HG-U133_Plus_2]///geo_accession: GSM516732///status: Public on Apr 14 2010///submission_date: Mar 01 2010///last_update_date: Apr 14 2010///type: RNA///channel_count: 1///source_name_ch1: Breast metastasis in the ovary///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Ovary///characteristics_ch1.1: histology (disease state): Breast metastasis in the ovary///characteristics_ch1.2: identifier: OC01_ARN0073///characteristics_ch1.3: histotype: N/A///characteristics_ch1.4: tumor/metastasis: M///characteristics_ch1.5: grade: N/A///characteristics_ch1.6: stade: N/A///treatment_protocol_ch1: N/A///growth_protocol_ch1: N/A///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix)_mRNA.///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from breast metastasis in the ovary///data_processing: The data were processed/analyzed with gc-RMA (Partek Genomic Suite 6.09.1008).///platform_id: GPL570///contact_name: Jean-Philippe,,MEYNIEL///contact_email: [email protected]///contact_phone: 33153194126///contact_fax: 33153194130///contact_department: Translational Research Dept///contact_institute: Institut Curie///contact_address: 26, rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM516nnn/GSM516732/GSM516732.CEL.gz///data_row_count: 54675
1
title: Breast metastasis in the ovary_OC01_ARN0077 [HG-U133_Plus_2]///geo_accession: GSM516736///status: Public on Apr 14 2010///submission_date: Mar 01 2010///last_update_date: Apr 14 2010///type: RNA///channel_count: 1///source_name_ch1: Breast metastasis in the ovary///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Ovary///characteristics_ch1.1: histology (disease state): Breast metastasis in the ovary///characteristics_ch1.2: identifier: OC01_ARN0077///characteristics_ch1.3: histotype: N/A///characteristics_ch1.4: tumor/metastasis: M///characteristics_ch1.5: grade: N/A///characteristics_ch1.6: stade: N/A///treatment_protocol_ch1: N/A///growth_protocol_ch1: N/A///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix)_mRNA.///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from breast metastasis in the ovary///data_processing: The data were processed/analyzed with gc-RMA (Partek Genomic Suite 6.09.1008).///platform_id: GPL570///contact_name: Jean-Philippe,,MEYNIEL///contact_email: [email protected]///contact_phone: 33153194126///contact_fax: 33153194130///contact_department: Translational Research Dept///contact_institute: Institut Curie///contact_address: 26, rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM516nnn/GSM516736/GSM516736.CEL.gz///data_row_count: 54675
1
title: Breast metastasis in the ovary_OC01_ARN0079 [HG-U133_Plus_2]///geo_accession: GSM516738///status: Public on Apr 14 2010///submission_date: Mar 01 2010///last_update_date: Apr 14 2010///type: RNA///channel_count: 1///source_name_ch1: Breast metastasis in the ovary///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Ovary///characteristics_ch1.1: histology (disease state): Breast metastasis in the ovary///characteristics_ch1.2: identifier: OC01_ARN0079///characteristics_ch1.3: histotype: N/A///characteristics_ch1.4: tumor/metastasis: M///characteristics_ch1.5: grade: N/A///characteristics_ch1.6: stade: N/A///treatment_protocol_ch1: N/A///growth_protocol_ch1: N/A///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix)_mRNA.///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from breast metastasis in the ovary///data_processing: The data were processed/analyzed with gc-RMA (Partek Genomic Suite 6.09.1008).///platform_id: GPL570///contact_name: Jean-Philippe,,MEYNIEL///contact_email: [email protected]///contact_phone: 33153194126///contact_fax: 33153194130///contact_department: Translational Research Dept///contact_institute: Institut Curie///contact_address: 26, rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM516nnn/GSM516738/GSM516738.CEL.gz///data_row_count: 54675
1
title: Breast metastasis in the ovary_OC01_ARN0081 [HG-U133_Plus_2]///geo_accession: GSM516740///status: Public on Apr 14 2010///submission_date: Mar 01 2010///last_update_date: Apr 14 2010///type: RNA///channel_count: 1///source_name_ch1: Breast metastasis in the ovary///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Ovary///characteristics_ch1.1: histology (disease state): Breast metastasis in the ovary///characteristics_ch1.2: identifier: OC01_ARN0081///characteristics_ch1.3: histotype: N/A///characteristics_ch1.4: tumor/metastasis: M///characteristics_ch1.5: grade: N/A///characteristics_ch1.6: stade: N/A///treatment_protocol_ch1: N/A///growth_protocol_ch1: N/A///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix)_mRNA.///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from breast metastasis in the ovary///data_processing: The data were processed/analyzed with gc-RMA (Partek Genomic Suite 6.09.1008).///platform_id: GPL570///contact_name: Jean-Philippe,,MEYNIEL///contact_email: [email protected]///contact_phone: 33153194126///contact_fax: 33153194130///contact_department: Translational Research Dept///contact_institute: Institut Curie///contact_address: 26, rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM516nnn/GSM516740/GSM516740.CEL.gz///data_row_count: 54675
1
title: Breast metastasis in the ovary_OC01_ARN0083 [HG-U133_Plus_2]///geo_accession: GSM516741///status: Public on Apr 14 2010///submission_date: Mar 01 2010///last_update_date: Apr 14 2010///type: RNA///channel_count: 1///source_name_ch1: Breast metastasis in the ovary///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Ovary///characteristics_ch1.1: histology (disease state): Breast metastasis in the ovary///characteristics_ch1.2: identifier: OC01_ARN0083///characteristics_ch1.3: histotype: N/A///characteristics_ch1.4: tumor/metastasis: M///characteristics_ch1.5: grade: N/A///characteristics_ch1.6: stade: N/A///treatment_protocol_ch1: N/A///growth_protocol_ch1: N/A///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix)_mRNA.///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from breast metastasis in the ovary///data_processing: The data were processed/analyzed with gc-RMA (Partek Genomic Suite 6.09.1008).///platform_id: GPL570///contact_name: Jean-Philippe,,MEYNIEL///contact_email: [email protected]///contact_phone: 33153194126///contact_fax: 33153194130///contact_department: Translational Research Dept///contact_institute: Institut Curie///contact_address: 26, rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM516nnn/GSM516741/GSM516741.CEL.gz///data_row_count: 54675
1
title: Breast metastasis in the ovary_OC01_ARN0092 [HG-U133_Plus_2]///geo_accession: GSM516748///status: Public on Apr 14 2010///submission_date: Mar 01 2010///last_update_date: Apr 14 2010///type: RNA///channel_count: 1///source_name_ch1: Breast metastasis in the ovary///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Ovary///characteristics_ch1.1: histology (disease state): Breast metastasis in the ovary///characteristics_ch1.2: identifier: OC01_ARN0092///characteristics_ch1.3: histotype: N/A///characteristics_ch1.4: tumor/metastasis: M///characteristics_ch1.5: grade: N/A///characteristics_ch1.6: stade: N/A///treatment_protocol_ch1: N/A///growth_protocol_ch1: N/A///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix)_mRNA.///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from breast metastasis in the ovary///data_processing: The data were processed/analyzed with gc-RMA (Partek Genomic Suite 6.09.1008).///platform_id: GPL570///contact_name: Jean-Philippe,,MEYNIEL///contact_email: [email protected]///contact_phone: 33153194126///contact_fax: 33153194130///contact_department: Translational Research Dept///contact_institute: Institut Curie///contact_address: 26, rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM516nnn/GSM516748/GSM516748.CEL.gz///data_row_count: 54675
1
title: Breast metastasis in the ovary_OC01_ARN0097 [HG-U133_Plus_2]///geo_accession: GSM516752///status: Public on Apr 14 2010///submission_date: Mar 01 2010///last_update_date: Apr 14 2010///type: RNA///channel_count: 1///source_name_ch1: Breast metastasis in the ovary///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Ovary///characteristics_ch1.1: histology (disease state): Breast metastasis in the ovary///characteristics_ch1.2: identifier: OC01_ARN0097///characteristics_ch1.3: histotype: N/A///characteristics_ch1.4: tumor/metastasis: M///characteristics_ch1.5: grade: N/A///characteristics_ch1.6: stade: N/A///treatment_protocol_ch1: N/A///growth_protocol_ch1: N/A///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix)_mRNA.///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from breast metastasis in the ovary///data_processing: The data were processed/analyzed with gc-RMA (Partek Genomic Suite 6.09.1008).///platform_id: GPL570///contact_name: Jean-Philippe,,MEYNIEL///contact_email: [email protected]///contact_phone: 33153194126///contact_fax: 33153194130///contact_department: Translational Research Dept///contact_institute: Institut Curie///contact_address: 26, rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM516nnn/GSM516752/GSM516752.CEL.gz///data_row_count: 54675
1
title: Breast metastasis in the ovary_OC01_ARN0098 [HG-U133_Plus_2]///geo_accession: GSM516753///status: Public on Apr 14 2010///submission_date: Mar 01 2010///last_update_date: Apr 14 2010///type: RNA///channel_count: 1///source_name_ch1: Breast metastasis in the ovary///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Ovary///characteristics_ch1.1: histology (disease state): Breast metastasis in the ovary///characteristics_ch1.2: identifier: OC01_ARN0098///characteristics_ch1.3: histotype: N/A///characteristics_ch1.4: tumor/metastasis: M///characteristics_ch1.5: grade: N/A///characteristics_ch1.6: stade: N/A///treatment_protocol_ch1: N/A///growth_protocol_ch1: N/A///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix)_mRNA.///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from breast metastasis in the ovary///data_processing: The data were processed/analyzed with gc-RMA (Partek Genomic Suite 6.09.1008).///platform_id: GPL570///contact_name: Jean-Philippe,,MEYNIEL///contact_email: [email protected]///contact_phone: 33153194126///contact_fax: 33153194130///contact_department: Translational Research Dept///contact_institute: Institut Curie///contact_address: 26, rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM516nnn/GSM516753/GSM516753.CEL.gz///data_row_count: 54675
1
title: Breast metastasis in the ovary_OC01_ARN0099 [HG-U133_Plus_2]///geo_accession: GSM516754///status: Public on Apr 14 2010///submission_date: Mar 01 2010///last_update_date: Apr 14 2010///type: RNA///channel_count: 1///source_name_ch1: Breast metastasis in the ovary///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Ovary///characteristics_ch1.1: histology (disease state): Breast metastasis in the ovary///characteristics_ch1.2: identifier: OC01_ARN0099///characteristics_ch1.3: histotype: N/A///characteristics_ch1.4: tumor/metastasis: M///characteristics_ch1.5: grade: N/A///characteristics_ch1.6: stade: N/A///treatment_protocol_ch1: N/A///growth_protocol_ch1: N/A///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix)_mRNA.///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from breast metastasis in the ovary///data_processing: The data were processed/analyzed with gc-RMA (Partek Genomic Suite 6.09.1008).///platform_id: GPL570///contact_name: Jean-Philippe,,MEYNIEL///contact_email: [email protected]///contact_phone: 33153194126///contact_fax: 33153194130///contact_department: Translational Research Dept///contact_institute: Institut Curie///contact_address: 26, rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM516nnn/GSM516754/GSM516754.CEL.gz///data_row_count: 54675
1
title: Breast metastasis in the ovary_OC01_ARN0102 [HG-U133_Plus_2]///geo_accession: GSM516757///status: Public on Apr 14 2010///submission_date: Mar 01 2010///last_update_date: Apr 14 2010///type: RNA///channel_count: 1///source_name_ch1: Breast metastasis in the ovary///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Ovary///characteristics_ch1.1: histology (disease state): Breast metastasis in the ovary///characteristics_ch1.2: identifier: OC01_ARN0102///characteristics_ch1.3: histotype: N/A///characteristics_ch1.4: tumor/metastasis: M///characteristics_ch1.5: grade: N/A///characteristics_ch1.6: stade: N/A///treatment_protocol_ch1: N/A///growth_protocol_ch1: N/A///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix)_mRNA.///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from breast metastasis in the ovary///data_processing: The data were processed/analyzed with gc-RMA (Partek Genomic Suite 6.09.1008).///platform_id: GPL570///contact_name: Jean-Philippe,,MEYNIEL///contact_email: [email protected]///contact_phone: 33153194126///contact_fax: 33153194130///contact_department: Translational Research Dept///contact_institute: Institut Curie///contact_address: 26, rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM516nnn/GSM516757/GSM516757.CEL.gz///data_row_count: 54675
1
title: Breast metastasis in the ovary_OC01_ARN0104 [HG-U133_Plus_2]///geo_accession: GSM516759///status: Public on Apr 14 2010///submission_date: Mar 01 2010///last_update_date: Apr 14 2010///type: RNA///channel_count: 1///source_name_ch1: Breast metastasis in the ovary///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Ovary///characteristics_ch1.1: histology (disease state): Breast metastasis in the ovary///characteristics_ch1.2: identifier: OC01_ARN0104///characteristics_ch1.3: histotype: N/A///characteristics_ch1.4: tumor/metastasis: M///characteristics_ch1.5: grade: N/A///characteristics_ch1.6: stade: N/A///treatment_protocol_ch1: N/A///growth_protocol_ch1: N/A///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix)_mRNA.///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from breast metastasis in the ovary///data_processing: The data were processed/analyzed with gc-RMA (Partek Genomic Suite 6.09.1008).///platform_id: GPL570///contact_name: Jean-Philippe,,MEYNIEL///contact_email: [email protected]///contact_phone: 33153194126///contact_fax: 33153194130///contact_department: Translational Research Dept///contact_institute: Institut Curie///contact_address: 26, rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM516nnn/GSM516759/GSM516759.CEL.gz///data_row_count: 54675
1
title: Breast metastasis in the ovary_OC01_ARN0112 [HG-U133_Plus_2]///geo_accession: GSM516766///status: Public on Apr 14 2010///submission_date: Mar 01 2010///last_update_date: Apr 14 2010///type: RNA///channel_count: 1///source_name_ch1: Breast metastasis in the ovary///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Ovary///characteristics_ch1.1: histology (disease state): Breast metastasis in the ovary///characteristics_ch1.2: identifier: OC01_ARN0112///characteristics_ch1.3: histotype: N/A///characteristics_ch1.4: tumor/metastasis: M///characteristics_ch1.5: grade: N/A///characteristics_ch1.6: stade: N/A///treatment_protocol_ch1: N/A///growth_protocol_ch1: N/A///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix)_mRNA.///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from breast metastasis in the ovary///data_processing: The data were processed/analyzed with gc-RMA (Partek Genomic Suite 6.09.1008).///platform_id: GPL570///contact_name: Jean-Philippe,,MEYNIEL///contact_email: [email protected]///contact_phone: 33153194126///contact_fax: 33153194130///contact_department: Translational Research Dept///contact_institute: Institut Curie///contact_address: 26, rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM516nnn/GSM516766/GSM516766.CEL.gz///data_row_count: 54675
1
title: Breast metastasis in the ovary_OC01_ARN0120 [HG-U133_Plus_2]///geo_accession: GSM516773///status: Public on Apr 14 2010///submission_date: Mar 01 2010///last_update_date: Apr 14 2010///type: RNA///channel_count: 1///source_name_ch1: Breast metastasis in the ovary///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Ovary///characteristics_ch1.1: histology (disease state): Breast metastasis in the ovary///characteristics_ch1.2: identifier: OC01_ARN0120///characteristics_ch1.3: histotype: N/A///characteristics_ch1.4: tumor/metastasis: M///characteristics_ch1.5: grade: N/A///characteristics_ch1.6: stade: N/A///treatment_protocol_ch1: N/A///growth_protocol_ch1: N/A///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix)_mRNA.///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from breast metastasis in the ovary///data_processing: The data were processed/analyzed with gc-RMA (Partek Genomic Suite 6.09.1008).///platform_id: GPL570///contact_name: Jean-Philippe,,MEYNIEL///contact_email: [email protected]///contact_phone: 33153194126///contact_fax: 33153194130///contact_department: Translational Research Dept///contact_institute: Institut Curie///contact_address: 26, rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM516nnn/GSM516773/GSM516773.CEL.gz///data_row_count: 54675
1
title: Breast metastasis in the ovary_OC01_ARN0121 [HG-U133_Plus_2]///geo_accession: GSM516774///status: Public on Apr 14 2010///submission_date: Mar 01 2010///last_update_date: Apr 14 2010///type: RNA///channel_count: 1///source_name_ch1: Breast metastasis in the ovary///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Ovary///characteristics_ch1.1: histology (disease state): Breast metastasis in the ovary///characteristics_ch1.2: identifier: OC01_ARN0121///characteristics_ch1.3: histotype: N/A///characteristics_ch1.4: tumor/metastasis: M///characteristics_ch1.5: grade: N/A///characteristics_ch1.6: stade: N/A///treatment_protocol_ch1: N/A///growth_protocol_ch1: N/A///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix)_mRNA.///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from breast metastasis in the ovary///data_processing: The data were processed/analyzed with gc-RMA (Partek Genomic Suite 6.09.1008).///platform_id: GPL570///contact_name: Jean-Philippe,,MEYNIEL///contact_email: [email protected]///contact_phone: 33153194126///contact_fax: 33153194130///contact_department: Translational Research Dept///contact_institute: Institut Curie///contact_address: 26, rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM516nnn/GSM516774/GSM516774.CEL.gz///data_row_count: 54675
1
title: Breast metastasis in the ovary_OC01_ARN0123 [HG-U133_Plus_2]///geo_accession: GSM516775///status: Public on Apr 14 2010///submission_date: Mar 01 2010///last_update_date: Apr 14 2010///type: RNA///channel_count: 1///source_name_ch1: Breast metastasis in the ovary///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Ovary///characteristics_ch1.1: histology (disease state): Breast metastasis in the ovary///characteristics_ch1.2: identifier: OC01_ARN0123///characteristics_ch1.3: histotype: N/A///characteristics_ch1.4: tumor/metastasis: M///characteristics_ch1.5: grade: N/A///characteristics_ch1.6: stade: N/A///treatment_protocol_ch1: N/A///growth_protocol_ch1: N/A///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix)_mRNA.///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from breast metastasis in the ovary///data_processing: The data were processed/analyzed with gc-RMA (Partek Genomic Suite 6.09.1008).///platform_id: GPL570///contact_name: Jean-Philippe,,MEYNIEL///contact_email: [email protected]///contact_phone: 33153194126///contact_fax: 33153194130///contact_department: Translational Research Dept///contact_institute: Institut Curie///contact_address: 26, rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM516nnn/GSM516775/GSM516775.CEL.gz///data_row_count: 54675
1
title: Breast metastasis in the ovary_OC01_ARN0126 [HG-U133_Plus_2]///geo_accession: GSM516778///status: Public on Apr 14 2010///submission_date: Mar 01 2010///last_update_date: Apr 14 2010///type: RNA///channel_count: 1///source_name_ch1: Breast metastasis in the ovary///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Ovary///characteristics_ch1.1: histology (disease state): Breast metastasis in the ovary///characteristics_ch1.2: identifier: OC01_ARN0126///characteristics_ch1.3: histotype: N/A///characteristics_ch1.4: tumor/metastasis: M///characteristics_ch1.5: grade: N/A///characteristics_ch1.6: stade: N/A///treatment_protocol_ch1: N/A///growth_protocol_ch1: N/A///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix)_mRNA.///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from breast metastasis in the ovary///data_processing: The data were processed/analyzed with gc-RMA (Partek Genomic Suite 6.09.1008).///platform_id: GPL570///contact_name: Jean-Philippe,,MEYNIEL///contact_email: [email protected]///contact_phone: 33153194126///contact_fax: 33153194130///contact_department: Translational Research Dept///contact_institute: Institut Curie///contact_address: 26, rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM516nnn/GSM516778/GSM516778.CEL.gz///data_row_count: 54675
1
title: Breast metastasis in the ovary_OC01_ARN0141 [HG-U133_Plus_2]///geo_accession: GSM516790///status: Public on Apr 14 2010///submission_date: Mar 01 2010///last_update_date: Apr 14 2010///type: RNA///channel_count: 1///source_name_ch1: Breast metastasis in the ovary///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Ovary///characteristics_ch1.1: histology (disease state): Breast metastasis in the ovary///characteristics_ch1.2: identifier: OC01_ARN0141///characteristics_ch1.3: histotype: N/A///characteristics_ch1.4: tumor/metastasis: M///characteristics_ch1.5: grade: N/A///characteristics_ch1.6: stade: N/A///treatment_protocol_ch1: N/A///growth_protocol_ch1: N/A///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix)_mRNA.///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from breast metastasis in the ovary///data_processing: The data were processed/analyzed with gc-RMA (Partek Genomic Suite 6.09.1008).///platform_id: GPL570///contact_name: Jean-Philippe,,MEYNIEL///contact_email: [email protected]///contact_phone: 33153194126///contact_fax: 33153194130///contact_department: Translational Research Dept///contact_institute: Institut Curie///contact_address: 26, rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM516nnn/GSM516790/GSM516790.CEL.gz///data_row_count: 54675
1
title: Breast metastasis in the ovary_OC01_ARN0142 [HG-U133_Plus_2]///geo_accession: GSM516791///status: Public on Apr 14 2010///submission_date: Mar 01 2010///last_update_date: Apr 14 2010///type: RNA///channel_count: 1///source_name_ch1: Breast metastasis in the ovary///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Ovary///characteristics_ch1.1: histology (disease state): Breast metastasis in the ovary///characteristics_ch1.2: identifier: OC01_ARN0142///characteristics_ch1.3: histotype: N/A///characteristics_ch1.4: tumor/metastasis: M///characteristics_ch1.5: grade: N/A///characteristics_ch1.6: stade: N/A///treatment_protocol_ch1: N/A///growth_protocol_ch1: N/A///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix)_mRNA.///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from breast metastasis in the ovary///data_processing: The data were processed/analyzed with gc-RMA (Partek Genomic Suite 6.09.1008).///platform_id: GPL570///contact_name: Jean-Philippe,,MEYNIEL///contact_email: [email protected]///contact_phone: 33153194126///contact_fax: 33153194130///contact_department: Translational Research Dept///contact_institute: Institut Curie///contact_address: 26, rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM516nnn/GSM516791/GSM516791.CEL.gz///data_row_count: 54675
1
title: Breast metastasis in the ovary_OC01_ARN0143 [HG-U133_Plus_2]///geo_accession: GSM516792///status: Public on Apr 14 2010///submission_date: Mar 01 2010///last_update_date: Apr 14 2010///type: RNA///channel_count: 1///source_name_ch1: Breast metastasis in the ovary///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Ovary///characteristics_ch1.1: histology (disease state): Breast metastasis in the ovary///characteristics_ch1.2: identifier: OC01_ARN0143///characteristics_ch1.3: histotype: N/A///characteristics_ch1.4: tumor/metastasis: M///characteristics_ch1.5: grade: N/A///characteristics_ch1.6: stade: N/A///treatment_protocol_ch1: N/A///growth_protocol_ch1: N/A///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix)_mRNA.///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from breast metastasis in the ovary///data_processing: The data were processed/analyzed with gc-RMA (Partek Genomic Suite 6.09.1008).///platform_id: GPL570///contact_name: Jean-Philippe,,MEYNIEL///contact_email: [email protected]///contact_phone: 33153194126///contact_fax: 33153194130///contact_department: Translational Research Dept///contact_institute: Institut Curie///contact_address: 26, rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM516nnn/GSM516792/GSM516792.CEL.gz///data_row_count: 54675
1
title: Breast metastasis in the ovary_OC01_ARN0145 [HG-U133_Plus_2]///geo_accession: GSM516793///status: Public on Apr 14 2010///submission_date: Mar 01 2010///last_update_date: Apr 14 2010///type: RNA///channel_count: 1///source_name_ch1: Breast metastasis in the ovary///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Ovary///characteristics_ch1.1: histology (disease state): Breast metastasis in the ovary///characteristics_ch1.2: identifier: OC01_ARN0145///characteristics_ch1.3: histotype: N/A///characteristics_ch1.4: tumor/metastasis: M///characteristics_ch1.5: grade: N/A///characteristics_ch1.6: stade: N/A///treatment_protocol_ch1: N/A///growth_protocol_ch1: N/A///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix)_mRNA.///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from breast metastasis in the ovary///data_processing: The data were processed/analyzed with gc-RMA (Partek Genomic Suite 6.09.1008).///platform_id: GPL570///contact_name: Jean-Philippe,,MEYNIEL///contact_email: [email protected]///contact_phone: 33153194126///contact_fax: 33153194130///contact_department: Translational Research Dept///contact_institute: Institut Curie///contact_address: 26, rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM516nnn/GSM516793/GSM516793.CEL.gz///data_row_count: 54675
1
title: Breast metastasis in the ovary_OC01_ARN0146 [HG-U133_Plus_2]///geo_accession: GSM516794///status: Public on Apr 14 2010///submission_date: Mar 01 2010///last_update_date: Apr 14 2010///type: RNA///channel_count: 1///source_name_ch1: Breast metastasis in the ovary///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Ovary///characteristics_ch1.1: histology (disease state): Breast metastasis in the ovary///characteristics_ch1.2: identifier: OC01_ARN0146///characteristics_ch1.3: histotype: N/A///characteristics_ch1.4: tumor/metastasis: M///characteristics_ch1.5: grade: N/A///characteristics_ch1.6: stade: N/A///treatment_protocol_ch1: N/A///growth_protocol_ch1: N/A///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix)_mRNA.///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from breast metastasis in the ovary///data_processing: The data were processed/analyzed with gc-RMA (Partek Genomic Suite 6.09.1008).///platform_id: GPL570///contact_name: Jean-Philippe,,MEYNIEL///contact_email: [email protected]///contact_phone: 33153194126///contact_fax: 33153194130///contact_department: Translational Research Dept///contact_institute: Institut Curie///contact_address: 26, rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM516nnn/GSM516794/GSM516794.CEL.gz///data_row_count: 54675
1
title: Breast metastasis in the ovary_OC01_ARN0153 [HG-U133_Plus_2]///geo_accession: GSM516800///status: Public on Apr 14 2010///submission_date: Mar 01 2010///last_update_date: Apr 14 2010///type: RNA///channel_count: 1///source_name_ch1: Breast metastasis in the ovary///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Ovary///characteristics_ch1.1: histology (disease state): Breast metastasis in the ovary///characteristics_ch1.2: identifier: OC01_ARN0153///characteristics_ch1.3: histotype: N/A///characteristics_ch1.4: tumor/metastasis: M///characteristics_ch1.5: grade: N/A///characteristics_ch1.6: stade: N/A///treatment_protocol_ch1: N/A///growth_protocol_ch1: N/A///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix)_mRNA.///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from breast metastasis in the ovary///data_processing: The data were processed/analyzed with gc-RMA (Partek Genomic Suite 6.09.1008).///platform_id: GPL570///contact_name: Jean-Philippe,,MEYNIEL///contact_email: [email protected]///contact_phone: 33153194126///contact_fax: 33153194130///contact_department: Translational Research Dept///contact_institute: Institut Curie///contact_address: 26, rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM516nnn/GSM516800/GSM516800.CEL.gz///data_row_count: 54675
1
title: Breast metastasis in the ovary_OC01_ARN0162 [HG-U133_Plus_2]///geo_accession: GSM516809///status: Public on Apr 14 2010///submission_date: Mar 01 2010///last_update_date: Apr 14 2010///type: RNA///channel_count: 1///source_name_ch1: Breast metastasis in the ovary///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Ovary///characteristics_ch1.1: histology (disease state): Breast metastasis in the ovary///characteristics_ch1.2: identifier: OC01_ARN0162///characteristics_ch1.3: histotype: N/A///characteristics_ch1.4: tumor/metastasis: M///characteristics_ch1.5: grade: N/A///characteristics_ch1.6: stade: N/A///treatment_protocol_ch1: N/A///growth_protocol_ch1: N/A///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix)_mRNA.///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from breast metastasis in the ovary///data_processing: The data were processed/analyzed with gc-RMA (Partek Genomic Suite 6.09.1008).///platform_id: GPL570///contact_name: Jean-Philippe,,MEYNIEL///contact_email: [email protected]///contact_phone: 33153194126///contact_fax: 33153194130///contact_department: Translational Research Dept///contact_institute: Institut Curie///contact_address: 26, rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM516nnn/GSM516809/GSM516809.CEL.gz///data_row_count: 54675
1
title: Breast metastasis in the ovary_OC01_ARN0201 [HG-U133_Plus_2]///geo_accession: GSM516810///status: Public on Apr 14 2010///submission_date: Mar 01 2010///last_update_date: Apr 14 2010///type: RNA///channel_count: 1///source_name_ch1: Breast metastasis in the ovary///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Ovary///characteristics_ch1.1: histology (disease state): Breast metastasis in the ovary///characteristics_ch1.2: identifier: OC01_ARN0201///characteristics_ch1.3: histotype: N/A///characteristics_ch1.4: tumor/metastasis: M///characteristics_ch1.5: grade: N/A///characteristics_ch1.6: stade: N/A///treatment_protocol_ch1: N/A///growth_protocol_ch1: N/A///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix)_mRNA.///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from breast metastasis in the ovary///data_processing: The data were processed/analyzed with gc-RMA (Partek Genomic Suite 6.09.1008).///platform_id: GPL570///contact_name: Jean-Philippe,,MEYNIEL///contact_email: [email protected]///contact_phone: 33153194126///contact_fax: 33153194130///contact_department: Translational Research Dept///contact_institute: Institut Curie///contact_address: 26, rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM516nnn/GSM516810/GSM516810.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma_OC01_ARN0001 [HG-U133_Plus_2]///geo_accession: GSM516678///status: Public on Apr 14 2010///submission_date: Mar 01 2010///last_update_date: Apr 14 2010///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Ovary///characteristics_ch1.1: histology (disease state): Ovarian carcinoma///characteristics_ch1.2: identifier: OC01_ARN0001///characteristics_ch1.3: histotype: Serous///characteristics_ch1.4: tumor/metastasis: T///characteristics_ch1.5: grade: 3///characteristics_ch1.6: stade: Ib///treatment_protocol_ch1: N/A///growth_protocol_ch1: N/A///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix)_mRNA.///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were processed/analyzed with gc-RMA (Partek Genomic Suite 6.09.1008).///platform_id: GPL570///contact_name: Jean-Philippe,,MEYNIEL///contact_email: [email protected]///contact_phone: 33153194126///contact_fax: 33153194130///contact_department: Translational Research Dept///contact_institute: Institut Curie///contact_address: 26, rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM516nnn/GSM516678/GSM516678.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma_OC01_ARN0002 [HG-U133_Plus_2]///geo_accession: GSM516679///status: Public on Apr 14 2010///submission_date: Mar 01 2010///last_update_date: Apr 14 2010///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Ovary///characteristics_ch1.1: histology (disease state): Ovarian carcinoma///characteristics_ch1.2: identifier: OC01_ARN0002///characteristics_ch1.3: histotype: Endometrioid///characteristics_ch1.4: tumor/metastasis: T///characteristics_ch1.5: grade: 2///characteristics_ch1.6: stade: IIb///treatment_protocol_ch1: N/A///growth_protocol_ch1: N/A///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix)_mRNA.///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were processed/analyzed with gc-RMA (Partek Genomic Suite 6.09.1008).///platform_id: GPL570///contact_name: Jean-Philippe,,MEYNIEL///contact_email: [email protected]///contact_phone: 33153194126///contact_fax: 33153194130///contact_department: Translational Research Dept///contact_institute: Institut Curie///contact_address: 26, rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM516nnn/GSM516679/GSM516679.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma_OC01_ARN0004 [HG-U133_Plus_2]///geo_accession: GSM516680///status: Public on Apr 14 2010///submission_date: Mar 01 2010///last_update_date: Apr 14 2010///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Ovary///characteristics_ch1.1: histology (disease state): Ovarian carcinoma///characteristics_ch1.2: identifier: OC01_ARN0004///characteristics_ch1.3: histotype: Serous///characteristics_ch1.4: tumor/metastasis: T///characteristics_ch1.5: grade: 3///characteristics_ch1.6: stade: IIIc///treatment_protocol_ch1: N/A///growth_protocol_ch1: N/A///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix)_mRNA.///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were processed/analyzed with gc-RMA (Partek Genomic Suite 6.09.1008).///platform_id: GPL570///contact_name: Jean-Philippe,,MEYNIEL///contact_email: [email protected]///contact_phone: 33153194126///contact_fax: 33153194130///contact_department: Translational Research Dept///contact_institute: Institut Curie///contact_address: 26, rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM516nnn/GSM516680/GSM516680.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma_OC01_ARN0005 [HG-U133_Plus_2]///geo_accession: GSM516681///status: Public on Apr 14 2010///submission_date: Mar 01 2010///last_update_date: Apr 14 2010///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Ovary///characteristics_ch1.1: histology (disease state): Ovarian carcinoma///characteristics_ch1.2: identifier: OC01_ARN0005///characteristics_ch1.3: histotype: Serous///characteristics_ch1.4: tumor/metastasis: T///characteristics_ch1.5: grade: 3///characteristics_ch1.6: stade: IV///treatment_protocol_ch1: N/A///growth_protocol_ch1: N/A///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix)_mRNA.///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were processed/analyzed with gc-RMA (Partek Genomic Suite 6.09.1008).///platform_id: GPL570///contact_name: Jean-Philippe,,MEYNIEL///contact_email: [email protected]///contact_phone: 33153194126///contact_fax: 33153194130///contact_department: Translational Research Dept///contact_institute: Institut Curie///contact_address: 26, rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM516nnn/GSM516681/GSM516681.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma_OC01_ARN0007 [HG-U133_Plus_2]///geo_accession: GSM516683///status: Public on Apr 14 2010///submission_date: Mar 01 2010///last_update_date: Apr 14 2010///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Ovary///characteristics_ch1.1: histology (disease state): Ovarian carcinoma///characteristics_ch1.2: identifier: OC01_ARN0007///characteristics_ch1.3: histotype: Serous///characteristics_ch1.4: tumor/metastasis: T///characteristics_ch1.5: grade: 3///characteristics_ch1.6: stade: IIIc///treatment_protocol_ch1: N/A///growth_protocol_ch1: N/A///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix)_mRNA.///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were processed/analyzed with gc-RMA (Partek Genomic Suite 6.09.1008).///platform_id: GPL570///contact_name: Jean-Philippe,,MEYNIEL///contact_email: [email protected]///contact_phone: 33153194126///contact_fax: 33153194130///contact_department: Translational Research Dept///contact_institute: Institut Curie///contact_address: 26, rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM516nnn/GSM516683/GSM516683.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma_OC01_ARN0008 [HG-U133_Plus_2]///geo_accession: GSM516684///status: Public on Apr 14 2010///submission_date: Mar 01 2010///last_update_date: Apr 14 2010///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Ovary///characteristics_ch1.1: histology (disease state): Ovarian carcinoma///characteristics_ch1.2: identifier: OC01_ARN0008///characteristics_ch1.3: histotype: Serous///characteristics_ch1.4: tumor/metastasis: T///characteristics_ch1.5: grade: 3///characteristics_ch1.6: stade: IIIc///treatment_protocol_ch1: N/A///growth_protocol_ch1: N/A///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix)_mRNA.///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were processed/analyzed with gc-RMA (Partek Genomic Suite 6.09.1008).///platform_id: GPL570///contact_name: Jean-Philippe,,MEYNIEL///contact_email: [email protected]///contact_phone: 33153194126///contact_fax: 33153194130///contact_department: Translational Research Dept///contact_institute: Institut Curie///contact_address: 26, rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM516nnn/GSM516684/GSM516684.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma_OC01_ARN0009 [HG-U133_Plus_2]///geo_accession: GSM516685///status: Public on Apr 14 2010///submission_date: Mar 01 2010///last_update_date: Apr 14 2010///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Ovary///characteristics_ch1.1: histology (disease state): Ovarian carcinoma///characteristics_ch1.2: identifier: OC01_ARN0009///characteristics_ch1.3: histotype: Serous///characteristics_ch1.4: tumor/metastasis: T///characteristics_ch1.5: grade: 2///characteristics_ch1.6: stade: IIIc///treatment_protocol_ch1: N/A///growth_protocol_ch1: N/A///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix)_mRNA.///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were processed/analyzed with gc-RMA (Partek Genomic Suite 6.09.1008).///platform_id: GPL570///contact_name: Jean-Philippe,,MEYNIEL///contact_email: [email protected]///contact_phone: 33153194126///contact_fax: 33153194130///contact_department: Translational Research Dept///contact_institute: Institut Curie///contact_address: 26, rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM516nnn/GSM516685/GSM516685.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma_OC01_ARN0010 [HG-U133_Plus_2]///geo_accession: GSM516686///status: Public on Apr 14 2010///submission_date: Mar 01 2010///last_update_date: Apr 14 2010///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Ovary///characteristics_ch1.1: histology (disease state): Ovarian carcinoma///characteristics_ch1.2: identifier: OC01_ARN0010///characteristics_ch1.3: histotype: Serous///characteristics_ch1.4: tumor/metastasis: T///characteristics_ch1.5: grade: 3///characteristics_ch1.6: stade: N/A///treatment_protocol_ch1: N/A///growth_protocol_ch1: N/A///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix)_mRNA.///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were processed/analyzed with gc-RMA (Partek Genomic Suite 6.09.1008).///platform_id: GPL570///contact_name: Jean-Philippe,,MEYNIEL///contact_email: [email protected]///contact_phone: 33153194126///contact_fax: 33153194130///contact_department: Translational Research Dept///contact_institute: Institut Curie///contact_address: 26, rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM516nnn/GSM516686/GSM516686.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma_OC01_ARN0011 [HG-U133_Plus_2]///geo_accession: GSM516687///status: Public on Apr 14 2010///submission_date: Mar 01 2010///last_update_date: Apr 14 2010///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Ovary///characteristics_ch1.1: histology (disease state): Ovarian carcinoma///characteristics_ch1.2: identifier: OC01_ARN0011///characteristics_ch1.3: histotype: Serous///characteristics_ch1.4: tumor/metastasis: T///characteristics_ch1.5: grade: 2///characteristics_ch1.6: stade: Ib///treatment_protocol_ch1: N/A///growth_protocol_ch1: N/A///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix)_mRNA.///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were processed/analyzed with gc-RMA (Partek Genomic Suite 6.09.1008).///platform_id: GPL570///contact_name: Jean-Philippe,,MEYNIEL///contact_email: [email protected]///contact_phone: 33153194126///contact_fax: 33153194130///contact_department: Translational Research Dept///contact_institute: Institut Curie///contact_address: 26, rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM516nnn/GSM516687/GSM516687.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma_OC01_ARN0012 [HG-U133_Plus_2]///geo_accession: GSM516688///status: Public on Apr 14 2010///submission_date: Mar 01 2010///last_update_date: Apr 14 2010///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Ovary///characteristics_ch1.1: histology (disease state): Ovarian carcinoma///characteristics_ch1.2: identifier: OC01_ARN0012///characteristics_ch1.3: histotype: Serous///characteristics_ch1.4: tumor/metastasis: T///characteristics_ch1.5: grade: 1///characteristics_ch1.6: stade: Ib///treatment_protocol_ch1: N/A///growth_protocol_ch1: N/A///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix)_mRNA.///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were processed/analyzed with gc-RMA (Partek Genomic Suite 6.09.1008).///platform_id: GPL570///contact_name: Jean-Philippe,,MEYNIEL///contact_email: [email protected]///contact_phone: 33153194126///contact_fax: 33153194130///contact_department: Translational Research Dept///contact_institute: Institut Curie///contact_address: 26, rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM516nnn/GSM516688/GSM516688.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma_OC01_ARN0013 [HG-U133_Plus_2]///geo_accession: GSM516689///status: Public on Apr 14 2010///submission_date: Mar 01 2010///last_update_date: Apr 14 2010///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Ovary///characteristics_ch1.1: histology (disease state): Ovarian carcinoma///characteristics_ch1.2: identifier: OC01_ARN0013///characteristics_ch1.3: histotype: Mucinous///characteristics_ch1.4: tumor/metastasis: T///characteristics_ch1.5: grade: 3///characteristics_ch1.6: stade: IIIc///treatment_protocol_ch1: N/A///growth_protocol_ch1: N/A///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix)_mRNA.///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were processed/analyzed with gc-RMA (Partek Genomic Suite 6.09.1008).///platform_id: GPL570///contact_name: Jean-Philippe,,MEYNIEL///contact_email: [email protected]///contact_phone: 33153194126///contact_fax: 33153194130///contact_department: Translational Research Dept///contact_institute: Institut Curie///contact_address: 26, rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM516nnn/GSM516689/GSM516689.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma_OC01_ARN0015 [HG-U133_Plus_2]///geo_accession: GSM516691///status: Public on Apr 14 2010///submission_date: Mar 01 2010///last_update_date: Apr 14 2010///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Ovary///characteristics_ch1.1: histology (disease state): Ovarian carcinoma///characteristics_ch1.2: identifier: OC01_ARN0015///characteristics_ch1.3: histotype: Serous///characteristics_ch1.4: tumor/metastasis: T///characteristics_ch1.5: grade: 3///characteristics_ch1.6: stade: IV///treatment_protocol_ch1: N/A///growth_protocol_ch1: N/A///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix)_mRNA.///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were processed/analyzed with gc-RMA (Partek Genomic Suite 6.09.1008).///platform_id: GPL570///contact_name: Jean-Philippe,,MEYNIEL///contact_email: [email protected]///contact_phone: 33153194126///contact_fax: 33153194130///contact_department: Translational Research Dept///contact_institute: Institut Curie///contact_address: 26, rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM516nnn/GSM516691/GSM516691.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma_OC01_ARN0022 [HG-U133_Plus_2]///geo_accession: GSM516697///status: Public on Apr 14 2010///submission_date: Mar 01 2010///last_update_date: Apr 14 2010///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Ovary///characteristics_ch1.1: histology (disease state): Ovarian carcinoma///characteristics_ch1.2: identifier: OC01_ARN0022///characteristics_ch1.3: histotype: Serous///characteristics_ch1.4: tumor/metastasis: T///characteristics_ch1.5: grade: 2///characteristics_ch1.6: stade: Ia///treatment_protocol_ch1: N/A///growth_protocol_ch1: N/A///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix)_mRNA.///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were processed/analyzed with gc-RMA (Partek Genomic Suite 6.09.1008).///platform_id: GPL570///contact_name: Jean-Philippe,,MEYNIEL///contact_email: [email protected]///contact_phone: 33153194126///contact_fax: 33153194130///contact_department: Translational Research Dept///contact_institute: Institut Curie///contact_address: 26, rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM516nnn/GSM516697/GSM516697.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma_OC01_ARN0023 [HG-U133_Plus_2]///geo_accession: GSM516698///status: Public on Apr 14 2010///submission_date: Mar 01 2010///last_update_date: Apr 14 2010///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Ovary///characteristics_ch1.1: histology (disease state): Ovarian carcinoma///characteristics_ch1.2: identifier: OC01_ARN0023///characteristics_ch1.3: histotype: Serous///characteristics_ch1.4: tumor/metastasis: T///characteristics_ch1.5: grade: 3///characteristics_ch1.6: stade: IV///treatment_protocol_ch1: N/A///growth_protocol_ch1: N/A///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix)_mRNA.///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were processed/analyzed with gc-RMA (Partek Genomic Suite 6.09.1008).///platform_id: GPL570///contact_name: Jean-Philippe,,MEYNIEL///contact_email: [email protected]///contact_phone: 33153194126///contact_fax: 33153194130///contact_department: Translational Research Dept///contact_institute: Institut Curie///contact_address: 26, rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM516nnn/GSM516698/GSM516698.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma_OC01_ARN0025 [HG-U133_Plus_2]///geo_accession: GSM516699///status: Public on Apr 14 2010///submission_date: Mar 01 2010///last_update_date: Apr 14 2010///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Ovary///characteristics_ch1.1: histology (disease state): Ovarian carcinoma///characteristics_ch1.2: identifier: OC01_ARN0025///characteristics_ch1.3: histotype: Serous///characteristics_ch1.4: tumor/metastasis: T///characteristics_ch1.5: grade: 3///characteristics_ch1.6: stade: IV///treatment_protocol_ch1: N/A///growth_protocol_ch1: N/A///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix)_mRNA.///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were processed/analyzed with gc-RMA (Partek Genomic Suite 6.09.1008).///platform_id: GPL570///contact_name: Jean-Philippe,,MEYNIEL///contact_email: [email protected]///contact_phone: 33153194126///contact_fax: 33153194130///contact_department: Translational Research Dept///contact_institute: Institut Curie///contact_address: 26, rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM516nnn/GSM516699/GSM516699.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma_OC01_ARN0028 [HG-U133_Plus_2]///geo_accession: GSM516700///status: Public on Apr 14 2010///submission_date: Mar 01 2010///last_update_date: Apr 14 2010///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Ovary///characteristics_ch1.1: histology (disease state): Ovarian carcinoma///characteristics_ch1.2: identifier: OC01_ARN0028///characteristics_ch1.3: histotype: Serous///characteristics_ch1.4: tumor/metastasis: T///characteristics_ch1.5: grade: 1///characteristics_ch1.6: stade: IV///treatment_protocol_ch1: N/A///growth_protocol_ch1: N/A///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix)_mRNA.///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were processed/analyzed with gc-RMA (Partek Genomic Suite 6.09.1008).///platform_id: GPL570///contact_name: Jean-Philippe,,MEYNIEL///contact_email: [email protected]///contact_phone: 33153194126///contact_fax: 33153194130///contact_department: Translational Research Dept///contact_institute: Institut Curie///contact_address: 26, rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM516nnn/GSM516700/GSM516700.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma_OC01_ARN0030 [HG-U133_Plus_2]///geo_accession: GSM516702///status: Public on Apr 14 2010///submission_date: Mar 01 2010///last_update_date: Apr 14 2010///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Ovary///characteristics_ch1.1: histology (disease state): Ovarian carcinoma///characteristics_ch1.2: identifier: OC01_ARN0030///characteristics_ch1.3: histotype: Endometrioid///characteristics_ch1.4: tumor/metastasis: T///characteristics_ch1.5: grade: 3///characteristics_ch1.6: stade: IIIc///treatment_protocol_ch1: N/A///growth_protocol_ch1: N/A///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix)_mRNA.///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were processed/analyzed with gc-RMA (Partek Genomic Suite 6.09.1008).///platform_id: GPL570///contact_name: Jean-Philippe,,MEYNIEL///contact_email: [email protected]///contact_phone: 33153194126///contact_fax: 33153194130///contact_department: Translational Research Dept///contact_institute: Institut Curie///contact_address: 26, rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM516nnn/GSM516702/GSM516702.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma_OC01_ARN0032 [HG-U133_Plus_2]///geo_accession: GSM516703///status: Public on Apr 14 2010///submission_date: Mar 01 2010///last_update_date: Apr 14 2010///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Ovary///characteristics_ch1.1: histology (disease state): Ovarian carcinoma///characteristics_ch1.2: identifier: OC01_ARN0032///characteristics_ch1.3: histotype: Mucinous///characteristics_ch1.4: tumor/metastasis: T///characteristics_ch1.5: grade: 2///characteristics_ch1.6: stade: Ia///treatment_protocol_ch1: N/A///growth_protocol_ch1: N/A///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix)_mRNA.///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were processed/analyzed with gc-RMA (Partek Genomic Suite 6.09.1008).///platform_id: GPL570///contact_name: Jean-Philippe,,MEYNIEL///contact_email: [email protected]///contact_phone: 33153194126///contact_fax: 33153194130///contact_department: Translational Research Dept///contact_institute: Institut Curie///contact_address: 26, rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM516nnn/GSM516703/GSM516703.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma_OC01_ARN0034 [HG-U133_Plus_2]///geo_accession: GSM516704///status: Public on Apr 14 2010///submission_date: Mar 01 2010///last_update_date: Apr 14 2010///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Ovary///characteristics_ch1.1: histology (disease state): Ovarian carcinoma///characteristics_ch1.2: identifier: OC01_ARN0034///characteristics_ch1.3: histotype: Serous///characteristics_ch1.4: tumor/metastasis: T///characteristics_ch1.5: grade: 3///characteristics_ch1.6: stade: IIIc///treatment_protocol_ch1: N/A///growth_protocol_ch1: N/A///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix)_mRNA.///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were processed/analyzed with gc-RMA (Partek Genomic Suite 6.09.1008).///platform_id: GPL570///contact_name: Jean-Philippe,,MEYNIEL///contact_email: [email protected]///contact_phone: 33153194126///contact_fax: 33153194130///contact_department: Translational Research Dept///contact_institute: Institut Curie///contact_address: 26, rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM516nnn/GSM516704/GSM516704.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma_OC01_ARN0036 [HG-U133_Plus_2]///geo_accession: GSM516706///status: Public on Apr 14 2010///submission_date: Mar 01 2010///last_update_date: Apr 14 2010///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Ovary///characteristics_ch1.1: histology (disease state): Ovarian carcinoma///characteristics_ch1.2: identifier: OC01_ARN0036///characteristics_ch1.3: histotype: Serous///characteristics_ch1.4: tumor/metastasis: T///characteristics_ch1.5: grade: 2///characteristics_ch1.6: stade: Ic///treatment_protocol_ch1: N/A///growth_protocol_ch1: N/A///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix)_mRNA.///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were processed/analyzed with gc-RMA (Partek Genomic Suite 6.09.1008).///platform_id: GPL570///contact_name: Jean-Philippe,,MEYNIEL///contact_email: [email protected]///contact_phone: 33153194126///contact_fax: 33153194130///contact_department: Translational Research Dept///contact_institute: Institut Curie///contact_address: 26, rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM516nnn/GSM516706/GSM516706.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma_OC01_ARN0037 [HG-U133_Plus_2]///geo_accession: GSM516707///status: Public on Apr 14 2010///submission_date: Mar 01 2010///last_update_date: Apr 14 2010///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Ovary///characteristics_ch1.1: histology (disease state): Ovarian carcinoma///characteristics_ch1.2: identifier: OC01_ARN0037///characteristics_ch1.3: histotype: Serous///characteristics_ch1.4: tumor/metastasis: T///characteristics_ch1.5: grade: 2///characteristics_ch1.6: stade: IIIc///treatment_protocol_ch1: N/A///growth_protocol_ch1: N/A///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix)_mRNA.///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were processed/analyzed with gc-RMA (Partek Genomic Suite 6.09.1008).///platform_id: GPL570///contact_name: Jean-Philippe,,MEYNIEL///contact_email: [email protected]///contact_phone: 33153194126///contact_fax: 33153194130///contact_department: Translational Research Dept///contact_institute: Institut Curie///contact_address: 26, rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM516nnn/GSM516707/GSM516707.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma_OC01_ARN0038 [HG-U133_Plus_2]///geo_accession: GSM516708///status: Public on Apr 14 2010///submission_date: Mar 01 2010///last_update_date: Apr 14 2010///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Ovary///characteristics_ch1.1: histology (disease state): Ovarian carcinoma///characteristics_ch1.2: identifier: OC01_ARN0038///characteristics_ch1.3: histotype: Serous///characteristics_ch1.4: tumor/metastasis: T///characteristics_ch1.5: grade: 3///characteristics_ch1.6: stade: IIIc///treatment_protocol_ch1: N/A///growth_protocol_ch1: N/A///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix)_mRNA.///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were processed/analyzed with gc-RMA (Partek Genomic Suite 6.09.1008).///platform_id: GPL570///contact_name: Jean-Philippe,,MEYNIEL///contact_email: [email protected]///contact_phone: 33153194126///contact_fax: 33153194130///contact_department: Translational Research Dept///contact_institute: Institut Curie///contact_address: 26, rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM516nnn/GSM516708/GSM516708.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma_OC01_ARN0039 [HG-U133_Plus_2]///geo_accession: GSM516709///status: Public on Apr 14 2010///submission_date: Mar 01 2010///last_update_date: Apr 14 2010///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Ovary///characteristics_ch1.1: histology (disease state): Ovarian carcinoma///characteristics_ch1.2: identifier: OC01_ARN0039///characteristics_ch1.3: histotype: Serous///characteristics_ch1.4: tumor/metastasis: T///characteristics_ch1.5: grade: 3///characteristics_ch1.6: stade: IIIc///treatment_protocol_ch1: N/A///growth_protocol_ch1: N/A///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix)_mRNA.///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were processed/analyzed with gc-RMA (Partek Genomic Suite 6.09.1008).///platform_id: GPL570///contact_name: Jean-Philippe,,MEYNIEL///contact_email: [email protected]///contact_phone: 33153194126///contact_fax: 33153194130///contact_department: Translational Research Dept///contact_institute: Institut Curie///contact_address: 26, rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM516nnn/GSM516709/GSM516709.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma_OC01_ARN0041 [HG-U133_Plus_2]///geo_accession: GSM516711///status: Public on Apr 14 2010///submission_date: Mar 01 2010///last_update_date: Apr 14 2010///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Ovary///characteristics_ch1.1: histology (disease state): Ovarian carcinoma///characteristics_ch1.2: identifier: OC01_ARN0041///characteristics_ch1.3: histotype: Clear Cells///characteristics_ch1.4: tumor/metastasis: T///characteristics_ch1.5: grade: 2///characteristics_ch1.6: stade: IIIb///treatment_protocol_ch1: N/A///growth_protocol_ch1: N/A///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix)_mRNA.///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were processed/analyzed with gc-RMA (Partek Genomic Suite 6.09.1008).///platform_id: GPL570///contact_name: Jean-Philippe,,MEYNIEL///contact_email: [email protected]///contact_phone: 33153194126///contact_fax: 33153194130///contact_department: Translational Research Dept///contact_institute: Institut Curie///contact_address: 26, rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM516nnn/GSM516711/GSM516711.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma_OC01_ARN0042 [HG-U133_Plus_2]///geo_accession: GSM516712///status: Public on Apr 14 2010///submission_date: Mar 01 2010///last_update_date: Apr 14 2010///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Ovary///characteristics_ch1.1: histology (disease state): Ovarian carcinoma///characteristics_ch1.2: identifier: OC01_ARN0042///characteristics_ch1.3: histotype: Mucinous///characteristics_ch1.4: tumor/metastasis: T///characteristics_ch1.5: grade: 1///characteristics_ch1.6: stade: Ia///treatment_protocol_ch1: N/A///growth_protocol_ch1: N/A///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix)_mRNA.///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were processed/analyzed with gc-RMA (Partek Genomic Suite 6.09.1008).///platform_id: GPL570///contact_name: Jean-Philippe,,MEYNIEL///contact_email: [email protected]///contact_phone: 33153194126///contact_fax: 33153194130///contact_department: Translational Research Dept///contact_institute: Institut Curie///contact_address: 26, rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM516nnn/GSM516712/GSM516712.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma_OC01_ARN0045 [HG-U133_Plus_2]///geo_accession: GSM516713///status: Public on Apr 14 2010///submission_date: Mar 01 2010///last_update_date: Apr 14 2010///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Ovary///characteristics_ch1.1: histology (disease state): Ovarian carcinoma///characteristics_ch1.2: identifier: OC01_ARN0045///characteristics_ch1.3: histotype: Adenocarcinoma///characteristics_ch1.4: tumor/metastasis: T///characteristics_ch1.5: grade: 3///characteristics_ch1.6: stade: IV///treatment_protocol_ch1: N/A///growth_protocol_ch1: N/A///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix)_mRNA.///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were processed/analyzed with gc-RMA (Partek Genomic Suite 6.09.1008).///platform_id: GPL570///contact_name: Jean-Philippe,,MEYNIEL///contact_email: [email protected]///contact_phone: 33153194126///contact_fax: 33153194130///contact_department: Translational Research Dept///contact_institute: Institut Curie///contact_address: 26, rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM516nnn/GSM516713/GSM516713.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma_OC01_ARN0049 [HG-U133_Plus_2]///geo_accession: GSM516715///status: Public on Apr 14 2010///submission_date: Mar 01 2010///last_update_date: Apr 14 2010///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Ovary///characteristics_ch1.1: histology (disease state): Ovarian carcinoma///characteristics_ch1.2: identifier: OC01_ARN0049///characteristics_ch1.3: histotype: Serous///characteristics_ch1.4: tumor/metastasis: T///characteristics_ch1.5: grade: 3///characteristics_ch1.6: stade: IIIc///treatment_protocol_ch1: N/A///growth_protocol_ch1: N/A///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix)_mRNA.///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were processed/analyzed with gc-RMA (Partek Genomic Suite 6.09.1008).///platform_id: GPL570///contact_name: Jean-Philippe,,MEYNIEL///contact_email: [email protected]///contact_phone: 33153194126///contact_fax: 33153194130///contact_department: Translational Research Dept///contact_institute: Institut Curie///contact_address: 26, rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM516nnn/GSM516715/GSM516715.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma_OC01_ARN0057 [HG-U133_Plus_2]///geo_accession: GSM516720///status: Public on Apr 14 2010///submission_date: Mar 01 2010///last_update_date: Apr 14 2010///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Ovary///characteristics_ch1.1: histology (disease state): Ovarian carcinoma///characteristics_ch1.2: identifier: OC01_ARN0057///characteristics_ch1.3: histotype: Mucinous///characteristics_ch1.4: tumor/metastasis: T///characteristics_ch1.5: grade: 2///characteristics_ch1.6: stade: Ic///treatment_protocol_ch1: N/A///growth_protocol_ch1: N/A///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix)_mRNA.///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were processed/analyzed with gc-RMA (Partek Genomic Suite 6.09.1008).///platform_id: GPL570///contact_name: Jean-Philippe,,MEYNIEL///contact_email: [email protected]///contact_phone: 33153194126///contact_fax: 33153194130///contact_department: Translational Research Dept///contact_institute: Institut Curie///contact_address: 26, rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM516nnn/GSM516720/GSM516720.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma_OC01_ARN0058 [HG-U133_Plus_2]///geo_accession: GSM516721///status: Public on Apr 14 2010///submission_date: Mar 01 2010///last_update_date: Apr 14 2010///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Ovary///characteristics_ch1.1: histology (disease state): Ovarian carcinoma///characteristics_ch1.2: identifier: OC01_ARN0058///characteristics_ch1.3: histotype: Clear Cells///characteristics_ch1.4: tumor/metastasis: T///characteristics_ch1.5: grade: 3///characteristics_ch1.6: stade: Ic///treatment_protocol_ch1: N/A///growth_protocol_ch1: N/A///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix)_mRNA.///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were processed/analyzed with gc-RMA (Partek Genomic Suite 6.09.1008).///platform_id: GPL570///contact_name: Jean-Philippe,,MEYNIEL///contact_email: [email protected]///contact_phone: 33153194126///contact_fax: 33153194130///contact_department: Translational Research Dept///contact_institute: Institut Curie///contact_address: 26, rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM516nnn/GSM516721/GSM516721.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma_OC01_ARN0061 [HG-U133_Plus_2]///geo_accession: GSM516723///status: Public on Apr 14 2010///submission_date: Mar 01 2010///last_update_date: Apr 14 2010///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Ovary///characteristics_ch1.1: histology (disease state): Ovarian carcinoma///characteristics_ch1.2: identifier: OC01_ARN0061///characteristics_ch1.3: histotype: Serous///characteristics_ch1.4: tumor/metastasis: T///characteristics_ch1.5: grade: 3///characteristics_ch1.6: stade: IIIc///treatment_protocol_ch1: N/A///growth_protocol_ch1: N/A///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix)_mRNA.///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were processed/analyzed with gc-RMA (Partek Genomic Suite 6.09.1008).///platform_id: GPL570///contact_name: Jean-Philippe,,MEYNIEL///contact_email: [email protected]///contact_phone: 33153194126///contact_fax: 33153194130///contact_department: Translational Research Dept///contact_institute: Institut Curie///contact_address: 26, rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM516nnn/GSM516723/GSM516723.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma_OC01_ARN0062 [HG-U133_Plus_2]///geo_accession: GSM516724///status: Public on Apr 14 2010///submission_date: Mar 01 2010///last_update_date: Apr 14 2010///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Ovary///characteristics_ch1.1: histology (disease state): Ovarian carcinoma///characteristics_ch1.2: identifier: OC01_ARN0062///characteristics_ch1.3: histotype: Serous///characteristics_ch1.4: tumor/metastasis: T///characteristics_ch1.5: grade: 3///characteristics_ch1.6: stade: IIIc///treatment_protocol_ch1: N/A///growth_protocol_ch1: N/A///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix)_mRNA.///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were processed/analyzed with gc-RMA (Partek Genomic Suite 6.09.1008).///platform_id: GPL570///contact_name: Jean-Philippe,,MEYNIEL///contact_email: [email protected]///contact_phone: 33153194126///contact_fax: 33153194130///contact_department: Translational Research Dept///contact_institute: Institut Curie///contact_address: 26, rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM516nnn/GSM516724/GSM516724.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma_OC01_ARN0063 [HG-U133_Plus_2]///geo_accession: GSM516725///status: Public on Apr 14 2010///submission_date: Mar 01 2010///last_update_date: Apr 14 2010///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Ovary///characteristics_ch1.1: histology (disease state): Ovarian carcinoma///characteristics_ch1.2: identifier: OC01_ARN0063///characteristics_ch1.3: histotype: Serous///characteristics_ch1.4: tumor/metastasis: T///characteristics_ch1.5: grade: 2///characteristics_ch1.6: stade: IIIc///treatment_protocol_ch1: N/A///growth_protocol_ch1: N/A///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix)_mRNA.///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were processed/analyzed with gc-RMA (Partek Genomic Suite 6.09.1008).///platform_id: GPL570///contact_name: Jean-Philippe,,MEYNIEL///contact_email: [email protected]///contact_phone: 33153194126///contact_fax: 33153194130///contact_department: Translational Research Dept///contact_institute: Institut Curie///contact_address: 26, rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM516nnn/GSM516725/GSM516725.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma_OC01_ARN0064 [HG-U133_Plus_2]///geo_accession: GSM516726///status: Public on Apr 14 2010///submission_date: Mar 01 2010///last_update_date: Apr 14 2010///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Ovary///characteristics_ch1.1: histology (disease state): Ovarian carcinoma///characteristics_ch1.2: identifier: OC01_ARN0064///characteristics_ch1.3: histotype: Serous///characteristics_ch1.4: tumor/metastasis: T///characteristics_ch1.5: grade: 3///characteristics_ch1.6: stade: IV///treatment_protocol_ch1: N/A///growth_protocol_ch1: N/A///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix)_mRNA.///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were processed/analyzed with gc-RMA (Partek Genomic Suite 6.09.1008).///platform_id: GPL570///contact_name: Jean-Philippe,,MEYNIEL///contact_email: [email protected]///contact_phone: 33153194126///contact_fax: 33153194130///contact_department: Translational Research Dept///contact_institute: Institut Curie///contact_address: 26, rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM516nnn/GSM516726/GSM516726.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma_OC01_ARN0066 [HG-U133_Plus_2]///geo_accession: GSM516727///status: Public on Apr 14 2010///submission_date: Mar 01 2010///last_update_date: Apr 14 2010///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Ovary///characteristics_ch1.1: histology (disease state): Ovarian carcinoma///characteristics_ch1.2: identifier: OC01_ARN0066///characteristics_ch1.3: histotype: Serous///characteristics_ch1.4: tumor/metastasis: T///characteristics_ch1.5: grade: 3///characteristics_ch1.6: stade: IIIc///treatment_protocol_ch1: N/A///growth_protocol_ch1: N/A///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix)_mRNA.///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were processed/analyzed with gc-RMA (Partek Genomic Suite 6.09.1008).///platform_id: GPL570///contact_name: Jean-Philippe,,MEYNIEL///contact_email: [email protected]///contact_phone: 33153194126///contact_fax: 33153194130///contact_department: Translational Research Dept///contact_institute: Institut Curie///contact_address: 26, rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM516nnn/GSM516727/GSM516727.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma_OC01_ARN0067 [HG-U133_Plus_2]///geo_accession: GSM516728///status: Public on Apr 14 2010///submission_date: Mar 01 2010///last_update_date: Apr 14 2010///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Ovary///characteristics_ch1.1: histology (disease state): Ovarian carcinoma///characteristics_ch1.2: identifier: OC01_ARN0067///characteristics_ch1.3: histotype: Mucinous///characteristics_ch1.4: tumor/metastasis: T///characteristics_ch1.5: grade: 2///characteristics_ch1.6: stade: Ic///treatment_protocol_ch1: N/A///growth_protocol_ch1: N/A///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix)_mRNA.///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were processed/analyzed with gc-RMA (Partek Genomic Suite 6.09.1008).///platform_id: GPL570///contact_name: Jean-Philippe,,MEYNIEL///contact_email: [email protected]///contact_phone: 33153194126///contact_fax: 33153194130///contact_department: Translational Research Dept///contact_institute: Institut Curie///contact_address: 26, rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM516nnn/GSM516728/GSM516728.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma_OC01_ARN0070 [HG-U133_Plus_2]///geo_accession: GSM516730///status: Public on Apr 14 2010///submission_date: Mar 01 2010///last_update_date: Apr 14 2010///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Ovary///characteristics_ch1.1: histology (disease state): Ovarian carcinoma///characteristics_ch1.2: identifier: OC01_ARN0070///characteristics_ch1.3: histotype: Serous///characteristics_ch1.4: tumor/metastasis: T///characteristics_ch1.5: grade: 3///characteristics_ch1.6: stade: IIIc///treatment_protocol_ch1: N/A///growth_protocol_ch1: N/A///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix)_mRNA.///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were processed/analyzed with gc-RMA (Partek Genomic Suite 6.09.1008).///platform_id: GPL570///contact_name: Jean-Philippe,,MEYNIEL///contact_email: [email protected]///contact_phone: 33153194126///contact_fax: 33153194130///contact_department: Translational Research Dept///contact_institute: Institut Curie///contact_address: 26, rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM516nnn/GSM516730/GSM516730.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma_OC01_ARN0072 [HG-U133_Plus_2]///geo_accession: GSM516731///status: Public on Apr 14 2010///submission_date: Mar 01 2010///last_update_date: Apr 14 2010///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Ovary///characteristics_ch1.1: histology (disease state): Ovarian carcinoma///characteristics_ch1.2: identifier: OC01_ARN0072///characteristics_ch1.3: histotype: Serous///characteristics_ch1.4: tumor/metastasis: T///characteristics_ch1.5: grade: 2///characteristics_ch1.6: stade: IIb///treatment_protocol_ch1: N/A///growth_protocol_ch1: N/A///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix)_mRNA.///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were processed/analyzed with gc-RMA (Partek Genomic Suite 6.09.1008).///platform_id: GPL570///contact_name: Jean-Philippe,,MEYNIEL///contact_email: [email protected]///contact_phone: 33153194126///contact_fax: 33153194130///contact_department: Translational Research Dept///contact_institute: Institut Curie///contact_address: 26, rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM516nnn/GSM516731/GSM516731.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma_OC01_ARN0075 [HG-U133_Plus_2]///geo_accession: GSM516734///status: Public on Apr 14 2010///submission_date: Mar 01 2010///last_update_date: Apr 14 2010///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Ovary///characteristics_ch1.1: histology (disease state): Ovarian carcinoma///characteristics_ch1.2: identifier: OC01_ARN0075///characteristics_ch1.3: histotype: Serous///characteristics_ch1.4: tumor/metastasis: T///characteristics_ch1.5: grade: 2///characteristics_ch1.6: stade: IIIc///treatment_protocol_ch1: N/A///growth_protocol_ch1: N/A///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix)_mRNA.///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were processed/analyzed with gc-RMA (Partek Genomic Suite 6.09.1008).///platform_id: GPL570///contact_name: Jean-Philippe,,MEYNIEL///contact_email: [email protected]///contact_phone: 33153194126///contact_fax: 33153194130///contact_department: Translational Research Dept///contact_institute: Institut Curie///contact_address: 26, rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM516nnn/GSM516734/GSM516734.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma_OC01_ARN0076 [HG-U133_Plus_2]///geo_accession: GSM516735///status: Public on Apr 14 2010///submission_date: Mar 01 2010///last_update_date: Apr 14 2010///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Ovary///characteristics_ch1.1: histology (disease state): Ovarian carcinoma///characteristics_ch1.2: identifier: OC01_ARN0076///characteristics_ch1.3: histotype: Brenner Tumor///characteristics_ch1.4: tumor/metastasis: T///characteristics_ch1.5: grade: 3///characteristics_ch1.6: stade: IIIc///treatment_protocol_ch1: N/A///growth_protocol_ch1: N/A///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix)_mRNA.///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were processed/analyzed with gc-RMA (Partek Genomic Suite 6.09.1008).///platform_id: GPL570///contact_name: Jean-Philippe,,MEYNIEL///contact_email: [email protected]///contact_phone: 33153194126///contact_fax: 33153194130///contact_department: Translational Research Dept///contact_institute: Institut Curie///contact_address: 26, rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM516nnn/GSM516735/GSM516735.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma_OC01_ARN0080 [HG-U133_Plus_2]///geo_accession: GSM516739///status: Public on Apr 14 2010///submission_date: Mar 01 2010///last_update_date: Apr 14 2010///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Ovary///characteristics_ch1.1: histology (disease state): Ovarian carcinoma///characteristics_ch1.2: identifier: OC01_ARN0080///characteristics_ch1.3: histotype: Serous///characteristics_ch1.4: tumor/metastasis: T///characteristics_ch1.5: grade: 2///characteristics_ch1.6: stade: IIIc///treatment_protocol_ch1: N/A///growth_protocol_ch1: N/A///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix)_mRNA.///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were processed/analyzed with gc-RMA (Partek Genomic Suite 6.09.1008).///platform_id: GPL570///contact_name: Jean-Philippe,,MEYNIEL///contact_email: [email protected]///contact_phone: 33153194126///contact_fax: 33153194130///contact_department: Translational Research Dept///contact_institute: Institut Curie///contact_address: 26, rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM516nnn/GSM516739/GSM516739.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma_OC01_ARN0084 [HG-U133_Plus_2]///geo_accession: GSM516742///status: Public on Apr 14 2010///submission_date: Mar 01 2010///last_update_date: Apr 14 2010///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Ovary///characteristics_ch1.1: histology (disease state): Ovarian carcinoma///characteristics_ch1.2: identifier: OC01_ARN0084///characteristics_ch1.3: histotype: Serous///characteristics_ch1.4: tumor/metastasis: T///characteristics_ch1.5: grade: 2///characteristics_ch1.6: stade: IIIc///treatment_protocol_ch1: N/A///growth_protocol_ch1: N/A///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix)_mRNA.///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were processed/analyzed with gc-RMA (Partek Genomic Suite 6.09.1008).///platform_id: GPL570///contact_name: Jean-Philippe,,MEYNIEL///contact_email: [email protected]///contact_phone: 33153194126///contact_fax: 33153194130///contact_department: Translational Research Dept///contact_institute: Institut Curie///contact_address: 26, rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM516nnn/GSM516742/GSM516742.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma_OC01_ARN0085 [HG-U133_Plus_2]///geo_accession: GSM516743///status: Public on Apr 14 2010///submission_date: Mar 01 2010///last_update_date: Apr 14 2010///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Ovary///characteristics_ch1.1: histology (disease state): Ovarian carcinoma///characteristics_ch1.2: identifier: OC01_ARN0085///characteristics_ch1.3: histotype: Clear Cells///characteristics_ch1.4: tumor/metastasis: T///characteristics_ch1.5: grade: 2///characteristics_ch1.6: stade: Ia///treatment_protocol_ch1: N/A///growth_protocol_ch1: N/A///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix)_mRNA.///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were processed/analyzed with gc-RMA (Partek Genomic Suite 6.09.1008).///platform_id: GPL570///contact_name: Jean-Philippe,,MEYNIEL///contact_email: [email protected]///contact_phone: 33153194126///contact_fax: 33153194130///contact_department: Translational Research Dept///contact_institute: Institut Curie///contact_address: 26, rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM516nnn/GSM516743/GSM516743.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma_OC01_ARN0089 [HG-U133_Plus_2]///geo_accession: GSM516745///status: Public on Apr 14 2010///submission_date: Mar 01 2010///last_update_date: Apr 14 2010///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Ovary///characteristics_ch1.1: histology (disease state): Ovarian carcinoma///characteristics_ch1.2: identifier: OC01_ARN0089///characteristics_ch1.3: histotype: Serous///characteristics_ch1.4: tumor/metastasis: T///characteristics_ch1.5: grade: 3///characteristics_ch1.6: stade: IIIc///treatment_protocol_ch1: N/A///growth_protocol_ch1: N/A///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix)_mRNA.///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were processed/analyzed with gc-RMA (Partek Genomic Suite 6.09.1008).///platform_id: GPL570///contact_name: Jean-Philippe,,MEYNIEL///contact_email: [email protected]///contact_phone: 33153194126///contact_fax: 33153194130///contact_department: Translational Research Dept///contact_institute: Institut Curie///contact_address: 26, rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM516nnn/GSM516745/GSM516745.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma_OC01_ARN0091 [HG-U133_Plus_2]///geo_accession: GSM516747///status: Public on Apr 14 2010///submission_date: Mar 01 2010///last_update_date: Apr 14 2010///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Ovary///characteristics_ch1.1: histology (disease state): Ovarian carcinoma///characteristics_ch1.2: identifier: OC01_ARN0091///characteristics_ch1.3: histotype: Adenocarcinoma///characteristics_ch1.4: tumor/metastasis: T///characteristics_ch1.5: grade: 3///characteristics_ch1.6: stade: IIa///treatment_protocol_ch1: N/A///growth_protocol_ch1: N/A///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix)_mRNA.///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were processed/analyzed with gc-RMA (Partek Genomic Suite 6.09.1008).///platform_id: GPL570///contact_name: Jean-Philippe,,MEYNIEL///contact_email: [email protected]///contact_phone: 33153194126///contact_fax: 33153194130///contact_department: Translational Research Dept///contact_institute: Institut Curie///contact_address: 26, rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM516nnn/GSM516747/GSM516747.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma_OC01_ARN0093 [HG-U133_Plus_2]///geo_accession: GSM516749///status: Public on Apr 14 2010///submission_date: Mar 01 2010///last_update_date: Apr 14 2010///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Ovary///characteristics_ch1.1: histology (disease state): Ovarian carcinoma///characteristics_ch1.2: identifier: OC01_ARN0093///characteristics_ch1.3: histotype: Serous///characteristics_ch1.4: tumor/metastasis: T///characteristics_ch1.5: grade: 3///characteristics_ch1.6: stade: IIIc///treatment_protocol_ch1: N/A///growth_protocol_ch1: N/A///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix)_mRNA.///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were processed/analyzed with gc-RMA (Partek Genomic Suite 6.09.1008).///platform_id: GPL570///contact_name: Jean-Philippe,,MEYNIEL///contact_email: [email protected]///contact_phone: 33153194126///contact_fax: 33153194130///contact_department: Translational Research Dept///contact_institute: Institut Curie///contact_address: 26, rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM516nnn/GSM516749/GSM516749.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma_OC01_ARN0095 [HG-U133_Plus_2]///geo_accession: GSM516750///status: Public on Apr 14 2010///submission_date: Mar 01 2010///last_update_date: Apr 14 2010///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Ovary///characteristics_ch1.1: histology (disease state): Ovarian carcinoma///characteristics_ch1.2: identifier: OC01_ARN0095///characteristics_ch1.3: histotype: Serous///characteristics_ch1.4: tumor/metastasis: T///characteristics_ch1.5: grade: 2///characteristics_ch1.6: stade: IIIb///treatment_protocol_ch1: N/A///growth_protocol_ch1: N/A///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix)_mRNA.///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were processed/analyzed with gc-RMA (Partek Genomic Suite 6.09.1008).///platform_id: GPL570///contact_name: Jean-Philippe,,MEYNIEL///contact_email: [email protected]///contact_phone: 33153194126///contact_fax: 33153194130///contact_department: Translational Research Dept///contact_institute: Institut Curie///contact_address: 26, rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM516nnn/GSM516750/GSM516750.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma_OC01_ARN0096 [HG-U133_Plus_2]///geo_accession: GSM516751///status: Public on Apr 14 2010///submission_date: Mar 01 2010///last_update_date: Apr 14 2010///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Ovary///characteristics_ch1.1: histology (disease state): Ovarian carcinoma///characteristics_ch1.2: identifier: OC01_ARN0096///characteristics_ch1.3: histotype: Mucinous///characteristics_ch1.4: tumor/metastasis: T///characteristics_ch1.5: grade: 1///characteristics_ch1.6: stade: IIIc///treatment_protocol_ch1: N/A///growth_protocol_ch1: N/A///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix)_mRNA.///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were processed/analyzed with gc-RMA (Partek Genomic Suite 6.09.1008).///platform_id: GPL570///contact_name: Jean-Philippe,,MEYNIEL///contact_email: [email protected]///contact_phone: 33153194126///contact_fax: 33153194130///contact_department: Translational Research Dept///contact_institute: Institut Curie///contact_address: 26, rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM516nnn/GSM516751/GSM516751.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma_OC01_ARN0100 [HG-U133_Plus_2]///geo_accession: GSM516755///status: Public on Apr 14 2010///submission_date: Mar 01 2010///last_update_date: Apr 14 2010///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Ovary///characteristics_ch1.1: histology (disease state): Ovarian carcinoma///characteristics_ch1.2: identifier: OC01_ARN0100///characteristics_ch1.3: histotype: Serous///characteristics_ch1.4: tumor/metastasis: T///characteristics_ch1.5: grade: 3///characteristics_ch1.6: stade: IIb///treatment_protocol_ch1: N/A///growth_protocol_ch1: N/A///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix)_mRNA.///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were processed/analyzed with gc-RMA (Partek Genomic Suite 6.09.1008).///platform_id: GPL570///contact_name: Jean-Philippe,,MEYNIEL///contact_email: [email protected]///contact_phone: 33153194126///contact_fax: 33153194130///contact_department: Translational Research Dept///contact_institute: Institut Curie///contact_address: 26, rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM516nnn/GSM516755/GSM516755.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma_OC01_ARN0101 [HG-U133_Plus_2]///geo_accession: GSM516756///status: Public on Apr 14 2010///submission_date: Mar 01 2010///last_update_date: Apr 14 2010///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Ovary///characteristics_ch1.1: histology (disease state): Ovarian carcinoma///characteristics_ch1.2: identifier: OC01_ARN0101///characteristics_ch1.3: histotype: Clear Cells///characteristics_ch1.4: tumor/metastasis: T///characteristics_ch1.5: grade: 3///characteristics_ch1.6: stade: IV///treatment_protocol_ch1: N/A///growth_protocol_ch1: N/A///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix)_mRNA.///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were processed/analyzed with gc-RMA (Partek Genomic Suite 6.09.1008).///platform_id: GPL570///contact_name: Jean-Philippe,,MEYNIEL///contact_email: [email protected]///contact_phone: 33153194126///contact_fax: 33153194130///contact_department: Translational Research Dept///contact_institute: Institut Curie///contact_address: 26, rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM516nnn/GSM516756/GSM516756.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma_OC01_ARN0103 [HG-U133_Plus_2]///geo_accession: GSM516758///status: Public on Apr 14 2010///submission_date: Mar 01 2010///last_update_date: Apr 14 2010///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Ovary///characteristics_ch1.1: histology (disease state): Ovarian carcinoma///characteristics_ch1.2: identifier: OC01_ARN0103///characteristics_ch1.3: histotype: Serous///characteristics_ch1.4: tumor/metastasis: T///characteristics_ch1.5: grade: 3///characteristics_ch1.6: stade: IIIc///treatment_protocol_ch1: N/A///growth_protocol_ch1: N/A///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix)_mRNA.///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were processed/analyzed with gc-RMA (Partek Genomic Suite 6.09.1008).///platform_id: GPL570///contact_name: Jean-Philippe,,MEYNIEL///contact_email: [email protected]///contact_phone: 33153194126///contact_fax: 33153194130///contact_department: Translational Research Dept///contact_institute: Institut Curie///contact_address: 26, rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM516nnn/GSM516758/GSM516758.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma_OC01_ARN0105 [HG-U133_Plus_2]///geo_accession: GSM516760///status: Public on Apr 14 2010///submission_date: Mar 01 2010///last_update_date: Apr 14 2010///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Ovary///characteristics_ch1.1: histology (disease state): Ovarian carcinoma///characteristics_ch1.2: identifier: OC01_ARN0105///characteristics_ch1.3: histotype: Serous///characteristics_ch1.4: tumor/metastasis: T///characteristics_ch1.5: grade: 3///characteristics_ch1.6: stade: IIIc///treatment_protocol_ch1: N/A///growth_protocol_ch1: N/A///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix)_mRNA.///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were processed/analyzed with gc-RMA (Partek Genomic Suite 6.09.1008).///platform_id: GPL570///contact_name: Jean-Philippe,,MEYNIEL///contact_email: [email protected]///contact_phone: 33153194126///contact_fax: 33153194130///contact_department: Translational Research Dept///contact_institute: Institut Curie///contact_address: 26, rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM516nnn/GSM516760/GSM516760.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma_OC01_ARN0106 [HG-U133_Plus_2]///geo_accession: GSM516761///status: Public on Apr 14 2010///submission_date: Mar 01 2010///last_update_date: Apr 14 2010///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Ovary///characteristics_ch1.1: histology (disease state): Ovarian carcinoma///characteristics_ch1.2: identifier: OC01_ARN0106///characteristics_ch1.3: histotype: Serous///characteristics_ch1.4: tumor/metastasis: T///characteristics_ch1.5: grade: 3///characteristics_ch1.6: stade: IIIc///treatment_protocol_ch1: N/A///growth_protocol_ch1: N/A///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix)_mRNA.///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were processed/analyzed with gc-RMA (Partek Genomic Suite 6.09.1008).///platform_id: GPL570///contact_name: Jean-Philippe,,MEYNIEL///contact_email: [email protected]///contact_phone: 33153194126///contact_fax: 33153194130///contact_department: Translational Research Dept///contact_institute: Institut Curie///contact_address: 26, rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM516nnn/GSM516761/GSM516761.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma_OC01_ARN0107 [HG-U133_Plus_2]///geo_accession: GSM516762///status: Public on Apr 14 2010///submission_date: Mar 01 2010///last_update_date: Apr 14 2010///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Ovary///characteristics_ch1.1: histology (disease state): Ovarian carcinoma///characteristics_ch1.2: identifier: OC01_ARN0107///characteristics_ch1.3: histotype: Serous///characteristics_ch1.4: tumor/metastasis: T///characteristics_ch1.5: grade: 2///characteristics_ch1.6: stade: IIIc///treatment_protocol_ch1: N/A///growth_protocol_ch1: N/A///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix)_mRNA.///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were processed/analyzed with gc-RMA (Partek Genomic Suite 6.09.1008).///platform_id: GPL570///contact_name: Jean-Philippe,,MEYNIEL///contact_email: [email protected]///contact_phone: 33153194126///contact_fax: 33153194130///contact_department: Translational Research Dept///contact_institute: Institut Curie///contact_address: 26, rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM516nnn/GSM516762/GSM516762.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma_OC01_ARN0108 [HG-U133_Plus_2]///geo_accession: GSM516763///status: Public on Apr 14 2010///submission_date: Mar 01 2010///last_update_date: Apr 14 2010///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Ovary///characteristics_ch1.1: histology (disease state): Ovarian carcinoma///characteristics_ch1.2: identifier: OC01_ARN0108///characteristics_ch1.3: histotype: Serous///characteristics_ch1.4: tumor/metastasis: T///characteristics_ch1.5: grade: 3///characteristics_ch1.6: stade: IIIc///treatment_protocol_ch1: N/A///growth_protocol_ch1: N/A///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix)_mRNA.///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were processed/analyzed with gc-RMA (Partek Genomic Suite 6.09.1008).///platform_id: GPL570///contact_name: Jean-Philippe,,MEYNIEL///contact_email: [email protected]///contact_phone: 33153194126///contact_fax: 33153194130///contact_department: Translational Research Dept///contact_institute: Institut Curie///contact_address: 26, rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM516nnn/GSM516763/GSM516763.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma_OC01_ARN0109 [HG-U133_Plus_2]///geo_accession: GSM516764///status: Public on Apr 14 2010///submission_date: Mar 01 2010///last_update_date: Apr 14 2010///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Ovary///characteristics_ch1.1: histology (disease state): Ovarian carcinoma///characteristics_ch1.2: identifier: OC01_ARN0109///characteristics_ch1.3: histotype: Clear Cells///characteristics_ch1.4: tumor/metastasis: T///characteristics_ch1.5: grade: 2///characteristics_ch1.6: stade: IIa///treatment_protocol_ch1: N/A///growth_protocol_ch1: N/A///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix)_mRNA.///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were processed/analyzed with gc-RMA (Partek Genomic Suite 6.09.1008).///platform_id: GPL570///contact_name: Jean-Philippe,,MEYNIEL///contact_email: [email protected]///contact_phone: 33153194126///contact_fax: 33153194130///contact_department: Translational Research Dept///contact_institute: Institut Curie///contact_address: 26, rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM516nnn/GSM516764/GSM516764.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma_OC01_ARN0111 [HG-U133_Plus_2]///geo_accession: GSM516765///status: Public on Apr 14 2010///submission_date: Mar 01 2010///last_update_date: Apr 14 2010///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Ovary///characteristics_ch1.1: histology (disease state): Ovarian carcinoma///characteristics_ch1.2: identifier: OC01_ARN0111///characteristics_ch1.3: histotype: Serous///characteristics_ch1.4: tumor/metastasis: T///characteristics_ch1.5: grade: 3///characteristics_ch1.6: stade: IIIc///treatment_protocol_ch1: N/A///growth_protocol_ch1: N/A///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix)_mRNA.///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were processed/analyzed with gc-RMA (Partek Genomic Suite 6.09.1008).///platform_id: GPL570///contact_name: Jean-Philippe,,MEYNIEL///contact_email: [email protected]///contact_phone: 33153194126///contact_fax: 33153194130///contact_department: Translational Research Dept///contact_institute: Institut Curie///contact_address: 26, rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM516nnn/GSM516765/GSM516765.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma_OC01_ARN0113 [HG-U133_Plus_2]///geo_accession: GSM516767///status: Public on Apr 14 2010///submission_date: Mar 01 2010///last_update_date: Apr 14 2010///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Ovary///characteristics_ch1.1: histology (disease state): Ovarian carcinoma///characteristics_ch1.2: identifier: OC01_ARN0113///characteristics_ch1.3: histotype: Endometrioid///characteristics_ch1.4: tumor/metastasis: T///characteristics_ch1.5: grade: 1///characteristics_ch1.6: stade: IIa///treatment_protocol_ch1: N/A///growth_protocol_ch1: N/A///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix)_mRNA.///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were processed/analyzed with gc-RMA (Partek Genomic Suite 6.09.1008).///platform_id: GPL570///contact_name: Jean-Philippe,,MEYNIEL///contact_email: [email protected]///contact_phone: 33153194126///contact_fax: 33153194130///contact_department: Translational Research Dept///contact_institute: Institut Curie///contact_address: 26, rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM516nnn/GSM516767/GSM516767.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma_OC01_ARN0114 [HG-U133_Plus_2]///geo_accession: GSM516768///status: Public on Apr 14 2010///submission_date: Mar 01 2010///last_update_date: Apr 14 2010///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Ovary///characteristics_ch1.1: histology (disease state): Ovarian carcinoma///characteristics_ch1.2: identifier: OC01_ARN0114///characteristics_ch1.3: histotype: Carcinosarcoma///characteristics_ch1.4: tumor/metastasis: T///characteristics_ch1.5: grade: 3///characteristics_ch1.6: stade: IIIc///treatment_protocol_ch1: N/A///growth_protocol_ch1: N/A///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix)_mRNA.///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were processed/analyzed with gc-RMA (Partek Genomic Suite 6.09.1008).///platform_id: GPL570///contact_name: Jean-Philippe,,MEYNIEL///contact_email: [email protected]///contact_phone: 33153194126///contact_fax: 33153194130///contact_department: Translational Research Dept///contact_institute: Institut Curie///contact_address: 26, rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM516nnn/GSM516768/GSM516768.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma_OC01_ARN0115 [HG-U133_Plus_2]///geo_accession: GSM516769///status: Public on Apr 14 2010///submission_date: Mar 01 2010///last_update_date: Apr 14 2010///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Ovary///characteristics_ch1.1: histology (disease state): Ovarian carcinoma///characteristics_ch1.2: identifier: OC01_ARN0115///characteristics_ch1.3: histotype: Endometrioid///characteristics_ch1.4: tumor/metastasis: T///characteristics_ch1.5: grade: 2///characteristics_ch1.6: stade: Ia///treatment_protocol_ch1: N/A///growth_protocol_ch1: N/A///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix)_mRNA.///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were processed/analyzed with gc-RMA (Partek Genomic Suite 6.09.1008).///platform_id: GPL570///contact_name: Jean-Philippe,,MEYNIEL///contact_email: [email protected]///contact_phone: 33153194126///contact_fax: 33153194130///contact_department: Translational Research Dept///contact_institute: Institut Curie///contact_address: 26, rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM516nnn/GSM516769/GSM516769.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma_OC01_ARN0116 [HG-U133_Plus_2]///geo_accession: GSM516770///status: Public on Apr 14 2010///submission_date: Mar 01 2010///last_update_date: Apr 14 2010///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Ovary///characteristics_ch1.1: histology (disease state): Ovarian carcinoma///characteristics_ch1.2: identifier: OC01_ARN0116///characteristics_ch1.3: histotype: Serous///characteristics_ch1.4: tumor/metastasis: T///characteristics_ch1.5: grade: 2///characteristics_ch1.6: stade: IV///treatment_protocol_ch1: N/A///growth_protocol_ch1: N/A///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix)_mRNA.///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were processed/analyzed with gc-RMA (Partek Genomic Suite 6.09.1008).///platform_id: GPL570///contact_name: Jean-Philippe,,MEYNIEL///contact_email: [email protected]///contact_phone: 33153194126///contact_fax: 33153194130///contact_department: Translational Research Dept///contact_institute: Institut Curie///contact_address: 26, rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM516nnn/GSM516770/GSM516770.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma_OC01_ARN0118 [HG-U133_Plus_2]///geo_accession: GSM516771///status: Public on Apr 14 2010///submission_date: Mar 01 2010///last_update_date: Apr 14 2010///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Ovary///characteristics_ch1.1: histology (disease state): Ovarian carcinoma///characteristics_ch1.2: identifier: OC01_ARN0118///characteristics_ch1.3: histotype: Serous///characteristics_ch1.4: tumor/metastasis: T///characteristics_ch1.5: grade: 2///characteristics_ch1.6: stade: IIIa///treatment_protocol_ch1: N/A///growth_protocol_ch1: N/A///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix)_mRNA.///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were processed/analyzed with gc-RMA (Partek Genomic Suite 6.09.1008).///platform_id: GPL570///contact_name: Jean-Philippe,,MEYNIEL///contact_email: [email protected]///contact_phone: 33153194126///contact_fax: 33153194130///contact_department: Translational Research Dept///contact_institute: Institut Curie///contact_address: 26, rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM516nnn/GSM516771/GSM516771.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma_OC01_ARN0119 [HG-U133_Plus_2]///geo_accession: GSM516772///status: Public on Apr 14 2010///submission_date: Mar 01 2010///last_update_date: Apr 14 2010///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Ovary///characteristics_ch1.1: histology (disease state): Ovarian carcinoma///characteristics_ch1.2: identifier: OC01_ARN0119///characteristics_ch1.3: histotype: Serous///characteristics_ch1.4: tumor/metastasis: T///characteristics_ch1.5: grade: 3///characteristics_ch1.6: stade: IIIc///treatment_protocol_ch1: N/A///growth_protocol_ch1: N/A///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix)_mRNA.///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were processed/analyzed with gc-RMA (Partek Genomic Suite 6.09.1008).///platform_id: GPL570///contact_name: Jean-Philippe,,MEYNIEL///contact_email: [email protected]///contact_phone: 33153194126///contact_fax: 33153194130///contact_department: Translational Research Dept///contact_institute: Institut Curie///contact_address: 26, rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM516nnn/GSM516772/GSM516772.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma_OC01_ARN0124 [HG-U133_Plus_2]///geo_accession: GSM516776///status: Public on Apr 14 2010///submission_date: Mar 01 2010///last_update_date: Apr 14 2010///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Ovary///characteristics_ch1.1: histology (disease state): Ovarian carcinoma///characteristics_ch1.2: identifier: OC01_ARN0124///characteristics_ch1.3: histotype: Serous///characteristics_ch1.4: tumor/metastasis: T///characteristics_ch1.5: grade: 3///characteristics_ch1.6: stade: IIIc///treatment_protocol_ch1: N/A///growth_protocol_ch1: N/A///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix)_mRNA.///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were processed/analyzed with gc-RMA (Partek Genomic Suite 6.09.1008).///platform_id: GPL570///contact_name: Jean-Philippe,,MEYNIEL///contact_email: [email protected]///contact_phone: 33153194126///contact_fax: 33153194130///contact_department: Translational Research Dept///contact_institute: Institut Curie///contact_address: 26, rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM516nnn/GSM516776/GSM516776.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma_OC01_ARN0125 [HG-U133_Plus_2]///geo_accession: GSM516777///status: Public on Apr 14 2010///submission_date: Mar 01 2010///last_update_date: Apr 14 2010///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Ovary///characteristics_ch1.1: histology (disease state): Ovarian carcinoma///characteristics_ch1.2: identifier: OC01_ARN0125///characteristics_ch1.3: histotype: Serous///characteristics_ch1.4: tumor/metastasis: T///characteristics_ch1.5: grade: 3///characteristics_ch1.6: stade: IIIc///treatment_protocol_ch1: N/A///growth_protocol_ch1: N/A///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix)_mRNA.///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were processed/analyzed with gc-RMA (Partek Genomic Suite 6.09.1008).///platform_id: GPL570///contact_name: Jean-Philippe,,MEYNIEL///contact_email: [email protected]///contact_phone: 33153194126///contact_fax: 33153194130///contact_department: Translational Research Dept///contact_institute: Institut Curie///contact_address: 26, rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM516nnn/GSM516777/GSM516777.CEL.gz///data_row_count: 54675
1
(Other)
41
duplicates:
GSE20565.GSE20565_GSM516722 GSE20565.GSE20565_GSM516741
1 1
NA's
138
An expression set
EXpression Project for Oncology, International Genomics Consortium, www.intgen.org
experimentData(eset):
Experiment data
Experimenter name: EXpression Project for Oncology, International Genomics Consortium, www.intgen.org
Laboratory: expO, IGC 2005
Contact information:
Title: IGC EXpression Project for Oncology
URL:
PMIDs: PMID unknown
Abstract: A 8 word abstract is available. Use 'abstract' method.
Information is available on: preprocessing
notes:
platform_title:
[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array
platform_shorttitle:
Affymetrix HG-U133Plus2
platform_summary:
hgu133plus2
platform_manufacturer:
Affymetrix
platform_distribution:
commercial
platform_accession:
GPL570
version:
2015-09-22 19:40:35
featureData(eset):
An object of class 'AnnotatedDataFrame'
featureNames: 1007_s_at 1053_at ... AFFX-HUMISGF3A/M97935_MB_at
(42447 total)
varLabels: probeset gene EntrezGene.ID best_probe
varMetadata: labelDescription
assayData: 42447 features, 204 samples
Platform type:
---------------------------
Available sample meta-data:
---------------------------
alt_sample_name:
Abdominal wall mass - 8176 Omentum - 1006
1 1
Omentum - 8174 Omentum - 8186
1 1
Omentum - 8240 Ovary - 101094
1 1
Ovary - 101109 Ovary - 101120
1 1
Ovary - 101150 Ovary - 1018
1 1
Ovary - 1040 Ovary - 1057
1 1
Ovary - 112866 Ovary - 112867
1 1
Ovary - 118662 Ovary - 118671
1 1
Ovary - 1241 Ovary - 1270
1 1
Ovary - 129660 Ovary - 129669
1 1
Ovary - 1311 Ovary - 1313
1 1
Ovary - 1323 Ovary - 133643
1 1
Ovary - 133651 Ovary - 1351
1 1
Ovary - 151614 Ovary - 151622
1 1
Ovary - 161465 Ovary - 161524
1 1
Ovary - 161525 Ovary - 161534
1 1
Ovary - 1636 Ovary - 1639
1 1
Ovary - 1643 Ovary - 170809
1 1
Ovary - 174931 Ovary - 174936
1 1
Ovary - 180953 Ovary - 184837
1 1
Ovary - 187243 Ovary - 187246
1 1
Ovary - 187251 Ovary - 187253
1 1
Ovary - 191413 Ovary - 191424
1 1
Ovary - 195198 Ovary - 199399
1 1
Ovary - 199400 Ovary - 202030
1 1
Ovary - 202041 Ovary - 20284
1 1
Ovary - 20285 Ovary - 20296
1 1
Ovary - 20307 Ovary - 20315
1 1
Ovary - 20323 Ovary - 20325
1 1
Ovary - 20326 Ovary - 20329
1 1
Ovary - 207532 Ovary - 209699
1 1
Ovary - 209709 Ovary - 209714
1 1
Ovary - 209718 Ovary - 211371
1 1
Ovary - 211372 Ovary - 211395
1 1
Ovary - 211409 Ovary - 21758
1 1
Ovary - 219571 Ovary - 219581
1 1
Ovary - 219590 Ovary - 219604
1 1
Ovary - 21981 Ovary - 22218
1 1
Ovary - 226414 Ovary - 226423
1 1
Ovary - 228537 Ovary - 228549
1 1
Ovary - 231863 Ovary - 234328
1 1
Ovary - 234329 Ovary - 235691
1 1
Ovary - 235692 Ovary - 235695
1 1
Ovary - 23862 Ovary - 23884
1 1
Ovary - 23904 Ovary - 23930
1 1
Ovary - 23934 Ovary - 23936
1 1
Ovary - 23938 Ovary - 241181
1 1
Ovary - 241187 Ovary - 241196
1 1
Ovary - 241198 Ovary - 241199
1 1
Ovary - 242929 (Other)
1 105
sample_type:
tumor
204
histological_type:
clearcell endo mucinous other
9 28 11 59
ser undifferentiated NA's
85 2 10
primarysite:
other ov NA's
23 178 3
summarygrade:
high low NA's
91 31 82
summarystage:
early late NA's
37 87 80
tumorstage:
1 2 3 4 NA's
20 14 58 18 94
substage:
a b c NA's
17 22 79 86
grade:
1 2 3 4 NA's
11 20 83 8 82
age_at_initial_pathologic_diagnosis:
Min. 1st Qu. Median Mean 3rd Qu. Max.
25.00 45.00 55.00 58.82 65.00 85.00
batch:
2004-12-03 2004-12-04 2004-12-07 2005-02-11 2005-03-03 2005-03-10 2005-03-11
3 3 1 1 1 1 1
2005-03-15 2005-03-16 2005-03-17 2005-03-19 2005-03-22 2005-04-13 2005-04-26
3 1 2 4 2 1 5
2005-04-29 2005-05-10 2005-06-01 2005-06-03 2005-06-08 2005-06-17 2005-08-05
2 2 5 3 3 6 3
2005-08-09 2005-08-11 2005-09-07 2005-09-09 2005-09-13 2005-11-02 2005-11-04
1 6 1 3 3 6 3
2005-11-15 2005-11-18 2005-12-02 2006-01-24 2006-01-26 2006-02-07 2006-02-28
3 1 4 2 1 1 1
2006-03-06 2006-03-14 2006-04-18 2006-04-20 2006-05-16 2006-06-08 2006-07-26
2 2 1 2 3 1 2
2006-07-28 2006-09-12 2006-09-14 2006-10-10 2006-10-24 2006-10-31 2006-11-09
1 2 1 1 9 5 10
2006-11-21 2006-11-30 2006-12-07 2007-01-12 2007-02-09 2007-03-07 2007-03-09
1 6 3 1 1 8 1
2007-03-15 2007-05-01 2007-05-03 2007-05-15 2007-05-18 2007-05-30 2007-06-12
4 2 3 4 2 2 1
2007-07-27 2007-09-05 2007-09-07 2007-09-11 2007-09-12 2008-02-15 2008-02-21
2 3 1 4 4 1 3
2008-02-27 2008-03-04 2008-05-13 2008-05-16 2008-05-23
2 1 4 4 5
uncurated_author_metadata:
title: Abdominal wall mass - 8176///geo_accession: GSM38066///status: Public on Jan 15 2005///submission_date: Dec 23 2004///last_update_date: Oct 09 2007///type: RNA///channel_count: 1///source_name_ch1: Ovary///organism_ch1: Homo sapiens///molecule_ch1: total RNA///taxid_ch1: 9606///description: Quality metric = 28S to 18S: 1.5///description.1: Patient Age: 50-60///description.2: Gender: Female///description.3: Ethnic Background: Caucasian///description.4: Tobacco Use : No///description.5: Alcohol Consumption?: Yes///description.6: Family History of Cancer?: No///description.7: Prior Therapy: Chemotherapy///description.8: Prior Therapy: Surgical///description.9: Relapse Since Primary Treatment: Yes///description.10: Number of Years Until Relapse: 0-5///description.11: Presenting Symptoms: Bloating///description.12: Retreatment T: 3c///description.13: Retreatment N: X///description.14: Retreatment M: 1///description.15: Retreatment Metastatic Sites: Other///description.16: Retreatment Stage: 4///description.17: Retreatment Grade: X///description.18: Primary Site: Ovary///description.19: Histology: Metastatic Papillary Serous Carcinoma///description.20: ///description.21: ///description.22: ///description.23: ///description.24: ///description.25: ///description.26: ///description.27: ///description.28: ///description.29: NA///description.30: NA///description.31: NA///platform_id: GPL570///contact_name: Michael,,Bittner///contact_email: [email protected]///contact_phone: 602-343-8808///contact_fax: 602-343-8440///contact_laboratory: expO///contact_department: NA///contact_institute: IGC///contact_address: 445 N. 5th Street///contact_city: Phoenix///contact_state: AZ///contact_zip.postal_code: 85004///contact_country: USA///contact_web_link: www.intgen.org///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM38nnn/GSM38066/GSM38066.CEL.gz///data_row_count: 54675
1
title: Omentum - 1006///geo_accession: GSM46815///status: Public on Mar 31 2005///submission_date: Mar 31 2005///last_update_date: Oct 09 2007///type: RNA///channel_count: 1///source_name_ch1: Ovary///organism_ch1: Homo sapiens///molecule_ch1: total RNA///taxid_ch1: 9606///description: Quality metric = 28S to 18S: 1.3///description.1: Patient Age: 60-70///description.2: Gender: Female///description.3: Ethnic Background: Caucasian///description.4: Tobacco Use : No///description.5: Alcohol Consumption?: No///description.6: Family History of Cancer?: Yes///description.7: Presenting Symptoms: Abdominal pain///description.8: Presenting Symptoms: Bloating///description.9: Pathological T: 3c///description.10: Pathological N: 1///description.11: Pathological M: 1///description.12: Pathological Metastatic Sites: Hepatic///description.13: Pathological Stage: 4///description.14: Pathological Grade: 3///description.15: Primary Site: Ovary///description.16: Histology: Metastatic Papillary Serous Adenocarcinoma///description.17: ///description.18: ///description.19: ///description.20: ///description.21: ///description.22: ///description.23: ///description.24: ///description.25: ///description.26: ///description.27: ///description.28: ///description.29: NA///description.30: NA///description.31: NA///platform_id: GPL570///contact_name: Michael,,Bittner///contact_email: [email protected]///contact_phone: 602-343-8808///contact_fax: 602-343-8440///contact_laboratory: expO///contact_department: NA///contact_institute: IGC///contact_address: 445 N. 5th Street///contact_city: Phoenix///contact_state: AZ///contact_zip.postal_code: 85004///contact_country: USA///contact_web_link: www.intgen.org///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM46nnn/GSM46815/GSM46815.CEL.gz///data_row_count: 54675
1
title: Omentum - 8174///geo_accession: GSM38065///status: Public on Jan 15 2005///submission_date: Dec 23 2004///last_update_date: Oct 09 2007///type: RNA///channel_count: 1///source_name_ch1: Ovary///organism_ch1: Homo sapiens///molecule_ch1: total RNA///taxid_ch1: 9606///description: Quality metric = 28S to 18S: 1.6///description.1: Patient Age: 80-90///description.2: Gender: Female///description.3: Ethnic Background: Caucasian///description.4: Tobacco Use : Yes///description.5: Years of Tobacco Use: 26-30///description.6: Type of Tobacco Use: Cigarettes///description.7: Alcohol Consumption?: Yes///description.8: Family History of Cancer?: Yes///description.9: Days from Patient Diagnosis to Excision: 142///description.10: Prior Therapy: Chemotherapy///description.11: Primary Site: Ovary///description.12: Histology: Metastatic Papillary Serous Carcinoma///description.13: ///description.14: ///description.15: ///description.16: ///description.17: ///description.18: ///description.19: ///description.20: ///description.21: ///description.22: ///description.23: ///description.24: ///description.25: ///description.26: ///description.27: ///description.28: ///description.29: ///description.30: ///description.31: ///platform_id: GPL570///contact_name: Michael,,Bittner///contact_email: [email protected]///contact_phone: 602-343-8808///contact_fax: 602-343-8440///contact_laboratory: expO///contact_department: NA///contact_institute: IGC///contact_address: 445 N. 5th Street///contact_city: Phoenix///contact_state: AZ///contact_zip.postal_code: 85004///contact_country: USA///contact_web_link: www.intgen.org///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM38nnn/GSM38065/GSM38065.CEL.gz///data_row_count: 54675
1
title: Omentum - 8186///geo_accession: GSM38070///status: Public on Jan 15 2005///submission_date: Dec 23 2004///last_update_date: Oct 09 2007///type: RNA///channel_count: 1///source_name_ch1: Ovary///organism_ch1: Homo sapiens///molecule_ch1: total RNA///taxid_ch1: 9606///description: Quality metric = 28S to 18S: 1.4///description.1: Patient Age: 60-70///description.2: Gender: Female///description.3: Ethnic Background: Caucasian///description.4: Tobacco Use : Yes///description.5: Years of Tobacco Use: 46-50///description.6: Type of Tobacco Use: Cigarettes///description.7: Alcohol Consumption?: No///description.8: Family History of Cancer?: Yes///description.9: Days from Patient Diagnosis to Excision: 105///description.10: Prior Therapy: Chemotherapy///description.11: Presenting Symptoms: Bloating///description.12: Pathological T: 3c///description.13: Pathological N: X///description.14: Pathological M: X///description.15: Pathological Stage: Unknown///description.16: Pathological Grade: 4///description.17: Pathological Stage During or Following Multimodality Therapy: Yes///description.18: Primary Site: Ovary vs Peritoneum///description.19: Histology: Metastatic Papillary Serous Carcinoma///description.20: ///description.21: ///description.22: ///description.23: ///description.24: ///description.25: ///description.26: ///description.27: ///description.28: NA///description.29: NA///description.30: NA///description.31: NA///platform_id: GPL570///contact_name: Michael,,Bittner///contact_email: [email protected]///contact_phone: 602-343-8808///contact_fax: 602-343-8440///contact_laboratory: expO///contact_department: NA///contact_institute: IGC///contact_address: 445 N. 5th Street///contact_city: Phoenix///contact_state: AZ///contact_zip.postal_code: 85004///contact_country: USA///contact_web_link: www.intgen.org///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM38nnn/GSM38070/GSM38070.CEL.gz///data_row_count: 54675
1
title: Omentum - 8240///geo_accession: GSM38095///status: Public on Jan 15 2005///submission_date: Dec 23 2004///last_update_date: Oct 09 2007///type: RNA///channel_count: 1///source_name_ch1: Ovary///organism_ch1: Homo sapiens///molecule_ch1: total RNA///taxid_ch1: 9606///description: Quality metric = 28S to 18S: 1.3///description.1: Patient Age: 60-70///description.2: Gender: Female///description.3: Ethnic Background: Caucasian///description.4: Tobacco Use : No///description.5: Alcohol Consumption?: No///description.6: Family History of Cancer?: Yes///description.7: Prior Therapy: Chemotherapy///description.8: Prior Therapy: Hormonal Treatment///description.9: Prior Therapy: Radiation///description.10: Prior Therapy: Surgical///description.11: Relapse Since Primary Treatment: Yes///description.12: Number of Years Until Relapse: 11-15///description.13: Mammogram: Yes///description.14: Number of years in which a mammogram was obtained?: 11-15///description.15: Oophorectomy?: No///description.16: Fibrocystic disease?: No///description.17: Mammogram calcifications?: No///description.18: Retreatment T: X///description.19: Retreatment N: X///description.20: Retreatment M: 1///description.21: Retreatment Metastatic Sites: Peritoneum///description.22: Retreatment Stage: 4///description.23: Retreatment Grade: 3///description.24: Retreatment ER: Positive///description.25: Retreatment PR: Positive///description.26: Primary Site: Breast///description.27: Histology: Metastatic Lobular Carcinoma///description.28: ///description.29: ///description.30: NA///description.31: NA///platform_id: GPL570///contact_name: Michael,,Bittner///contact_email: [email protected]///contact_phone: 602-343-8808///contact_fax: 602-343-8440///contact_laboratory: expO///contact_department: NA///contact_institute: IGC///contact_address: 445 N. 5th Street///contact_city: Phoenix///contact_state: AZ///contact_zip.postal_code: 85004///contact_country: USA///contact_web_link: www.intgen.org///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM38nnn/GSM38095/GSM38095.CEL.gz///data_row_count: 54675
1
title: Ovary - 101094///geo_accession: GSM102426///status: Public on Mar 30 2006///submission_date: Mar 30 2006///last_update_date: Mar 30 2006///type: RNA///channel_count: 1///source_name_ch1: Ovary///organism_ch1: Homo sapiens///molecule_ch1: total RNA///taxid_ch1: 9606///description: Quality metric = 28S to 18S: 1.1///description.1: Patient Age: 70-80///description.2: Gender: Female///description.3: Ethnic Background: Caucasian///description.4: Tobacco Use : Yes///description.5: Years of Tobacco Use: 6-10///description.6: Type of Tobacco Use: Cigarettes///description.7: Alcohol Consumption?: Yes///description.8: Family History of Cancer?: No///description.9: Presenting Symptoms: Abdominal pain///description.10: Pathological Grade: 2///description.11: Pathological Multiple Tumors: No///description.12: Pathological Stage During or Following Multimodality Therapy: No///description.13: Primary Site: Ovary///description.14: Histology: Endometrioid adenocarcinoma, secretory variant///description.15: ///description.16: ///description.17: ///description.18: ///description.19: ///description.20: ///description.21: ///description.22: ///description.23: ///description.24: ///description.25: ///description.26: ///description.27: ///description.28: ///description.29: ///description.30: NA///description.31: NA///platform_id: GPL570///contact_name: Michael,,Bittner///contact_email: [email protected]///contact_phone: 602-343-8808///contact_fax: 602-343-8440///contact_laboratory: expO///contact_department: NA///contact_institute: IGC///contact_address: 445 N. 5th Street///contact_city: Phoenix///contact_state: AZ///contact_zip.postal_code: 85004///contact_country: USA///contact_web_link: www.intgen.org///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM102nnn/GSM102426/GSM102426.CEL.gz///data_row_count: 54675
1
title: Ovary - 101109///geo_accession: GSM203626///status: Public on Jun 25 2007///submission_date: Jun 22 2007///last_update_date: Jun 25 2007///type: RNA///channel_count: 1///source_name_ch1: Ovary///organism_ch1: Homo sapiens///molecule_ch1: total RNA///taxid_ch1: 9606///description: Quality metric = 28S to 18S: 1.1///description.1: Patient Age: 60-70///description.2: Gender: Female///description.3: Ethnic Background: Caucasian///description.4: Tobacco Use : No///description.5: Alcohol Consumption?: No///description.6: Family History of Cancer?: No///description.7: Presenting Symptoms: Abdominal pain///description.8: Presenting Symptoms: Bloating///description.9: Pathological T: 3c///description.10: Pathological N: X///description.11: Pathological M: X///description.12: Pathological Stage: Unknown///description.13: Pathological Grade: 2///description.14: Primary Site: Ovary///description.15: Histology: Papillary Serous Carcinoma///description.16: ///description.17: ///description.18: ///description.19: ///description.20: ///description.21: ///description.22: ///description.23: ///description.24: ///description.25: ///description.26: ///description.27: ///description.28: NA///description.29: NA///description.30: NA///description.31: NA///platform_id: GPL570///contact_name: Michael,,Bittner///contact_email: [email protected]///contact_phone: 602-343-8808///contact_fax: 602-343-8440///contact_laboratory: expO///contact_department: NA///contact_institute: IGC///contact_address: 445 N. 5th Street///contact_city: Phoenix///contact_state: AZ///contact_zip.postal_code: 85004///contact_country: USA///contact_web_link: www.intgen.org///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM203nnn/GSM203626/GSM203626.CEL.gz///data_row_count: 54675
1
title: Ovary - 101120///geo_accession: GSM88956///status: Public on Dec 22 2005///submission_date: Dec 22 2005///last_update_date: Dec 22 2005///type: RNA///channel_count: 1///source_name_ch1: Ovary///organism_ch1: Homo sapiens///molecule_ch1: total RNA///taxid_ch1: 9606///description: Quality metric = 28S to 18S: 1.0///description.1: Patient Age: 60-70///description.2: Gender: Female///description.3: Ethnic Background: Caucasian///description.4: Tobacco Use : No///description.5: Alcohol Consumption?: No///description.6: Family History of Cancer?: Yes///description.7: Days from Patient Diagnosis to Excision: 45///description.8: Presenting Symptoms: Vaginal bleeding///description.9: Pathological Grade: 3///description.10: Primary Site: Ovary///description.11: Histology: Endometrioid adenocarcinoma///description.12: ///description.13: ///description.14: ///description.15: ///description.16: ///description.17: ///description.18: ///description.19: ///description.20: ///description.21: ///description.22: ///description.23: ///description.24: ///description.25: ///description.26: ///description.27: ///description.28: ///description.29: NA///description.30: NA///description.31: NA///platform_id: GPL570///contact_name: Michael,,Bittner///contact_email: [email protected]///contact_phone: 602-343-8808///contact_fax: 602-343-8440///contact_laboratory: expO///contact_department: NA///contact_institute: IGC///contact_address: 445 N. 5th Street///contact_city: Phoenix///contact_state: AZ///contact_zip.postal_code: 85004///contact_country: USA///contact_web_link: www.intgen.org///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM88nnn/GSM88956/GSM88956.CEL.gz///data_row_count: 54675
1
title: Ovary - 101150///geo_accession: GSM102445///status: Public on Mar 30 2006///submission_date: Mar 30 2006///last_update_date: Mar 30 2006///type: RNA///channel_count: 1///source_name_ch1: Ovary///organism_ch1: Homo sapiens///molecule_ch1: total RNA///taxid_ch1: 9606///description: Quality metric = 28S to 18S: 1.3///description.1: Patient Age: 60-70///description.2: Gender: Female///description.3: Ethnic Background: Caucasian///description.4: Tobacco Use : Yes///description.5: Years of Tobacco Use: 36-40///description.6: Type of Tobacco Use: Cigarettes///description.7: Alcohol Consumption?: Yes///description.8: Family History of Cancer?: No///description.9: Days from Patient Diagnosis to Excision: 15///description.10: Presenting Symptoms: Abdominal mass///description.11: Presenting Symptoms: Abdominal pain///description.12: Presenting Symptoms: Bloating///description.13: Pathological T: 3c///description.14: Pathological N: 0///description.15: Pathological M: 0///description.16: Pathological Stage: 3C///description.17: Pathological Grade: 3///description.18: Pathological Multiple Tumors: No///description.19: Pathological Stage During or Following Multimodality Therapy: No///description.20: Primary Site: Ovary///description.21: Histology: Papillary Serous Carcinoma///description.22: ///description.23: ///description.24: ///description.25: ///description.26: ///description.27: ///description.28: ///description.29: NA///description.30: NA///description.31: NA///platform_id: GPL570///contact_name: Michael,,Bittner///contact_email: [email protected]///contact_phone: 602-343-8808///contact_fax: 602-343-8440///contact_laboratory: expO///contact_department: NA///contact_institute: IGC///contact_address: 445 N. 5th Street///contact_city: Phoenix///contact_state: AZ///contact_zip.postal_code: 85004///contact_country: USA///contact_web_link: www.intgen.org///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM102nnn/GSM102445/GSM102445.CEL.gz///data_row_count: 54675
1
title: Ovary - 1018///geo_accession: GSM53029///status: Public on Jul 01 2005///submission_date: Jun 30 2005///last_update_date: Jun 30 2005///type: RNA///channel_count: 1///source_name_ch1: Ovary///organism_ch1: Homo sapiens///molecule_ch1: total RNA///taxid_ch1: 9606///description: Quality metric = 28S to 18S: 1.4///description.1: Patient Age: 40-50///description.2: Gender: Female///description.3: Ethnic Background: Caucasian///description.4: Tobacco Use : Yes///description.5: Years of Tobacco Use: 11-15///description.6: Type of Tobacco Use: Cigarettes///description.7: Alcohol Consumption?: Yes///description.8: Family History of Cancer?: No///description.9: Days from Patient Diagnosis to Excision: 1///description.10: Presenting Symptoms: Abdominal mass///description.11: Presenting Symptoms: Abdominal pain///description.12: Presenting Symptoms: Bloating///description.13: Primary Site: Ovary///description.14: Histology: Endometrioid Carcinoma///description.15: ///description.16: ///description.17: ///description.18: ///description.19: ///description.20: ///description.21: ///description.22: ///description.23: ///description.24: ///description.25: ///description.26: ///description.27: ///description.28: ///description.29: ///description.30: NA///description.31: NA///platform_id: GPL570///contact_name: Michael,,Bittner///contact_email: [email protected]///contact_phone: 602-343-8808///contact_fax: 602-343-8440///contact_laboratory: expO///contact_department: NA///contact_institute: IGC///contact_address: 445 N. 5th Street///contact_city: Phoenix///contact_state: AZ///contact_zip.postal_code: 85004///contact_country: USA///contact_web_link: www.intgen.org///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM53nnn/GSM53029/GSM53029.CEL.gz///data_row_count: 54675
1
title: Ovary - 1040///geo_accession: GSM53036///status: Public on Jul 01 2005///submission_date: Jun 30 2005///last_update_date: Jun 30 2005///type: RNA///channel_count: 1///source_name_ch1: Ovary///organism_ch1: Homo sapiens///molecule_ch1: total RNA///taxid_ch1: 9606///description: Quality metric = 28S to 18S: 1.4///description.1: Patient Age: 50-60///description.2: Gender: Female///description.3: Ethnic Background: Caucasian///description.4: Tobacco Use : Yes///description.5: Years of Tobacco Use: 26-30///description.6: Type of Tobacco Use: Cigarettes///description.7: Alcohol Consumption?: Yes///description.8: Family History of Cancer?: No///description.9: Days from Patient Diagnosis to Excision: 13///description.10: Presenting Symptoms: Abdominal pain///description.11: Presenting Symptoms: Bloating///description.12: Primary Site: Ovary///description.13: Histology: Serous Adenocarinoma///description.14: ///description.15: ///description.16: ///description.17: ///description.18: ///description.19: ///description.20: ///description.21: ///description.22: ///description.23: ///description.24: ///description.25: ///description.26: ///description.27: ///description.28: ///description.29: NA///description.30: NA///description.31: NA///platform_id: GPL570///contact_name: Michael,,Bittner///contact_email: [email protected]///contact_phone: 602-343-8808///contact_fax: 602-343-8440///contact_laboratory: expO///contact_department: NA///contact_institute: IGC///contact_address: 445 N. 5th Street///contact_city: Phoenix///contact_state: AZ///contact_zip.postal_code: 85004///contact_country: USA///contact_web_link: www.intgen.org///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM53nnn/GSM53036/GSM53036.CEL.gz///data_row_count: 54675
1
title: Ovary - 1057///geo_accession: GSM46821///status: Public on Mar 31 2005///submission_date: Mar 31 2005///last_update_date: Oct 09 2007///type: RNA///channel_count: 1///source_name_ch1: Ovary///organism_ch1: Homo sapiens///molecule_ch1: total RNA///taxid_ch1: 9606///description: Quality metric = 28S to 18S: 1.2///description.1: Patient Age: 60-70///description.2: Gender: Female///description.3: Ethnic Background: Caucasian///description.4: Tobacco Use : No///description.5: Alcohol Consumption?: Yes///description.6: Family History of Cancer?: Yes///description.7: Days from Patient Diagnosis to Excision: 30///description.8: Clinical Question: Stage///description.9: Clinical Value: No AJCC Staging Scheme for Unknown Primary///description.10: Primary Site: Unknown///description.11: Clinical Question: Histology///description.12: Clinical Value: Metastatic Adenocarcinoma///description.13: ///description.14: ///description.15: ///description.16: ///description.17: ///description.18: ///description.19: ///description.20: ///description.21: ///description.22: ///description.23: ///description.24: ///description.25: ///description.26: ///description.27: ///description.28: ///description.29: NA///description.30: NA///description.31: NA///platform_id: GPL570///contact_name: Michael,,Bittner///contact_email: [email protected]///contact_phone: 602-343-8808///contact_fax: 602-343-8440///contact_laboratory: expO///contact_department: NA///contact_institute: IGC///contact_address: 445 N. 5th Street///contact_city: Phoenix///contact_state: AZ///contact_zip.postal_code: 85004///contact_country: USA///contact_web_link: www.intgen.org///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM46nnn/GSM46821/GSM46821.CEL.gz///data_row_count: 54675
1
title: Ovary - 112866///geo_accession: GSM88973///status: Public on Dec 22 2005///submission_date: Dec 22 2005///last_update_date: Dec 22 2005///type: RNA///channel_count: 1///source_name_ch1: Ovary///organism_ch1: Homo sapiens///molecule_ch1: total RNA///taxid_ch1: 9606///description: Quality metric = 28S to 18S: 1.1///description.1: Patient Age: 60-70///description.2: Gender: Female///description.3: Ethnic Background: Caucasian///description.4: Tobacco Use : Yes///description.5: Years of Tobacco Use: 21-25///description.6: Type of Tobacco Use: Cigarettes///description.7: Alcohol Consumption?: Yes///description.8: Family History of Cancer?: No///description.9: Presenting Symptoms: Abdominal pain///description.10: Presenting Symptoms: Bloating///description.11: Pathological Grade: 3///description.12: Pathological Multiple Tumors: No///description.13: Pathological Stage During or Following Multimodality Therapy: No///description.14: Primary Site: Ovary///description.15: Histology: Serous Adenocarinoma///description.16: ///description.17: ///description.18: ///description.19: ///description.20: ///description.21: ///description.22: ///description.23: ///description.24: ///description.25: ///description.26: ///description.27: ///description.28: NA///description.29: NA///description.30: NA///description.31: NA///platform_id: GPL570///contact_name: Michael,,Bittner///contact_email: [email protected]///contact_phone: 602-343-8808///contact_fax: 602-343-8440///contact_laboratory: expO///contact_department: NA///contact_institute: IGC///contact_address: 445 N. 5th Street///contact_city: Phoenix///contact_state: AZ///contact_zip.postal_code: 85004///contact_country: USA///contact_web_link: www.intgen.org///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM88nnn/GSM88973/GSM88973.CEL.gz///data_row_count: 54675
1
title: Ovary - 112867///geo_accession: GSM88974///status: Public on Dec 22 2005///submission_date: Dec 22 2005///last_update_date: Dec 22 2005///type: RNA///channel_count: 1///source_name_ch1: Ovary///organism_ch1: Homo sapiens///molecule_ch1: total RNA///taxid_ch1: 9606///description: Quality metric = 28S to 18S: 1.3///description.1: Patient Age: 60-70///description.2: Gender: Female///description.3: Ethnic Background: Caucasian///description.4: Tobacco Use : Yes///description.5: Years of Tobacco Use: 16-20///description.6: Type of Tobacco Use: Cigarettes///description.7: Alcohol Consumption?: Yes///description.8: Family History of Cancer?: Yes///description.9: Presenting Symptoms: Abdominal pain///description.10: Presenting Symptoms: Bloating///description.11: Pathological T: 3a///description.12: Pathological N: 0///description.13: Pathological Grade: 2///description.14: Pathological Multiple Tumors: No///description.15: Pathological Stage During or Following Multimodality Therapy: No///description.16: Primary Site: Ovary///description.17: Histology: Papillary Serous Carcinoma///description.18: ///description.19: ///description.20: ///description.21: ///description.22: ///description.23: ///description.24: ///description.25: ///description.26: ///description.27: ///description.28: ///description.29: ///description.30: ///description.31: ///platform_id: GPL570///contact_name: Michael,,Bittner///contact_email: [email protected]///contact_phone: 602-343-8808///contact_fax: 602-343-8440///contact_laboratory: expO///contact_department: NA///contact_institute: IGC///contact_address: 445 N. 5th Street///contact_city: Phoenix///contact_state: AZ///contact_zip.postal_code: 85004///contact_country: USA///contact_web_link: www.intgen.org///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM88nnn/GSM88974/GSM88974.CEL.gz///data_row_count: 54675
1
title: Ovary - 118662///geo_accession: GSM102478///status: Public on Mar 30 2006///submission_date: Mar 30 2006///last_update_date: Mar 30 2006///type: RNA///channel_count: 1///source_name_ch1: Ovary///organism_ch1: Homo sapiens///molecule_ch1: total RNA///taxid_ch1: 9606///description: Quality metric = 28S to 18S: 1.5///description.1: Patient Age: 50-60///description.2: Gender: Female///description.3: Ethnic Background: Caucasian///description.4: Tobacco Use : No///description.5: Alcohol Consumption?: No///description.6: Family History of Cancer?: Yes///description.7: Presenting Symptoms: Abdominal pain///description.8: Pathological T: 3c///description.9: Pathological N: 1///description.10: Pathological M: 0///description.11: Pathological Stage: 3C///description.12: Pathological Grade: 3///description.13: Pathological Multiple Tumors: No///description.14: Pathological Stage During or Following Multimodality Therapy: No///description.15: Primary Site: Ovary///description.16: Histology: Adenocarcinoma, endometrioid and papillary serous///description.17: ///description.18: ///description.19: ///description.20: ///description.21: ///description.22: ///description.23: ///description.24: ///description.25: ///description.26: ///description.27: ///description.28: ///description.29: NA///description.30: NA///description.31: NA///platform_id: GPL570///contact_name: Michael,,Bittner///contact_email: [email protected]///contact_phone: 602-343-8808///contact_fax: 602-343-8440///contact_laboratory: expO///contact_department: NA///contact_institute: IGC///contact_address: 445 N. 5th Street///contact_city: Phoenix///contact_state: AZ///contact_zip.postal_code: 85004///contact_country: USA///contact_web_link: www.intgen.org///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM102nnn/GSM102478/GSM102478.CEL.gz///data_row_count: 54675
1
title: Ovary - 118671///geo_accession: GSM102483///status: Public on Mar 30 2006///submission_date: Mar 30 2006///last_update_date: Mar 30 2006///type: RNA///channel_count: 1///source_name_ch1: Ovary///organism_ch1: Homo sapiens///molecule_ch1: total RNA///taxid_ch1: 9606///description: Quality metric = 28S to 18S: 1.6///description.1: Patient Age: 40-50///description.2: Gender: Female///description.3: Ethnic Background: Caucasian///description.4: Tobacco Use : No///description.5: Alcohol Consumption?: Yes///description.6: Family History of Cancer?: Yes///description.7: Days from Patient Diagnosis to Excision: 14///description.8: Presenting Symptoms: Bloating///description.9: Presenting Symptoms: Vaginal bleeding///description.10: Clinical Question: Stage///description.11: Clinical Value: No AJCC Scheme for this site/histology///description.12: Primary Site: Ovary///description.13: Clinical Question: Histology///description.14: Clinical Value: Adult Granulosa Cell Tumor///description.15: ///description.16: ///description.17: ///description.18: ///description.19: ///description.20: ///description.21: ///description.22: ///description.23: ///description.24: ///description.25: ///description.26: ///description.27: ///description.28: ///description.29: ///description.30: NA///description.31: NA///platform_id: GPL570///contact_name: Michael,,Bittner///contact_email: [email protected]///contact_phone: 602-343-8808///contact_fax: 602-343-8440///contact_laboratory: expO///contact_department: NA///contact_institute: IGC///contact_address: 445 N. 5th Street///contact_city: Phoenix///contact_state: AZ///contact_zip.postal_code: 85004///contact_country: USA///contact_web_link: www.intgen.org///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM102nnn/GSM102483/GSM102483.CEL.gz///data_row_count: 54675
1
title: Ovary - 1241///geo_accession: GSM53054///status: Public on Jul 01 2005///submission_date: Jun 30 2005///last_update_date: Jun 30 2005///type: RNA///channel_count: 1///source_name_ch1: Ovary///organism_ch1: Homo sapiens///molecule_ch1: total RNA///taxid_ch1: 9606///description: Quality metric = 28S to 18S: 1.4///description.1: Patient Age: 50-60///description.2: Gender: Female///description.3: Ethnic Background: Caucasian///description.4: Tobacco Use : Yes///description.5: Years of Tobacco Use: 26-30///description.6: Type of Tobacco Use: Cigarettes///description.7: Alcohol Consumption?: No///description.8: Family History of Cancer?: No///description.9: Days from Patient Diagnosis to Excision: 7///description.10: Presenting Symptoms: Abdominal pain///description.11: Primary Site: Ovary///description.12: Histology: Papillary Serous Adenocarcinoma///description.13: ///description.14: ///description.15: ///description.16: ///description.17: ///description.18: ///description.19: ///description.20: ///description.21: ///description.22: ///description.23: ///description.24: ///description.25: ///description.26: ///description.27: ///description.28: ///description.29: NA///description.30: NA///description.31: NA///platform_id: GPL570///contact_name: Michael,,Bittner///contact_email: [email protected]///contact_phone: 602-343-8808///contact_fax: 602-343-8440///contact_laboratory: expO///contact_department: NA///contact_institute: IGC///contact_address: 445 N. 5th Street///contact_city: Phoenix///contact_state: AZ///contact_zip.postal_code: 85004///contact_country: USA///contact_web_link: www.intgen.org///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM53nnn/GSM53054/GSM53054.CEL.gz///data_row_count: 54675
1
title: Ovary - 1270///geo_accession: GSM53056///status: Public on Jul 01 2005///submission_date: Jun 30 2005///last_update_date: Jun 30 2005///type: RNA///channel_count: 1///source_name_ch1: Ovary///organism_ch1: Homo sapiens///molecule_ch1: total RNA///taxid_ch1: 9606///description: Quality metric = 28S to 18S: 1.3///description.1: Patient Age: 40-50///description.2: Gender: Female///description.3: Ethnic Background: Caucasian///description.4: Tobacco Use : No///description.5: Alcohol Consumption?: No///description.6: Family History of Cancer?: Yes///description.7: Days from Patient Diagnosis to Excision: 5///description.8: Presenting Symptoms: Abdominal Pain///description.9: Presenting Symptoms: Diarrhea///description.10: Presenting Symptoms: Nausea///description.11: Presenting Symptoms: Vomiting///description.12: Screening studies performed?: No///description.13: Primary Site: Colon///description.14: Histology: Metastatic Adenocarcinoma///description.15: ///description.16: ///description.17: ///description.18: ///description.19: ///description.20: ///description.21: ///description.22: ///description.23: ///description.24: ///description.25: ///description.26: ///description.27: ///description.28: ///description.29: NA///description.30: NA///description.31: NA///platform_id: GPL570///contact_name: Michael,,Bittner///contact_email: [email protected]///contact_phone: 602-343-8808///contact_fax: 602-343-8440///contact_laboratory: expO///contact_department: NA///contact_institute: IGC///contact_address: 445 N. 5th Street///contact_city: Phoenix///contact_state: AZ///contact_zip.postal_code: 85004///contact_country: USA///contact_web_link: www.intgen.org///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM53nnn/GSM53056/GSM53056.CEL.gz///data_row_count: 54675
1
title: Ovary - 129660///geo_accession: GSM152577///status: Public on Jan 03 2007///submission_date: Dec 22 2006///last_update_date: Jan 03 2007///type: RNA///channel_count: 1///source_name_ch1: Ovary///organism_ch1: Homo sapiens///molecule_ch1: total RNA///taxid_ch1: 9606///description: Quality metric = 28S to 18S: 1.7///description.1: Patient Age: 70-80///description.2: Gender: Female///description.3: Ethnic Background: Caucasian///description.4: Tobacco Use : Yes///description.5: Years of Tobacco Use: 16-20///description.6: Type of Tobacco Use: Cigarettes///description.7: Alcohol Consumption?: No///description.8: Family History of Cancer?: Yes///description.9: Prior Therapy: Chemotherapy///description.10: Presenting Symptoms: Bloating///description.11: Pathological T: 3b///description.12: Pathological N: X///description.13: Pathological M: 0///description.14: Pathological Stage: Unknown///description.15: Pathological Grade: 3///description.16: Pathological Multiple Tumors: No///description.17: Pathological Stage During or Following Multimodality Therapy: Yes///description.18: Primary Site: Ovary///description.19: Histology: Serous Adenocarinoma///description.20: ///description.21: ///description.22: ///description.23: ///description.24: ///description.25: ///description.26: ///description.27: ///description.28: ///description.29: NA///description.30: NA///description.31: NA///platform_id: GPL570///contact_name: Michael,,Bittner///contact_email: [email protected]///contact_phone: 602-343-8808///contact_fax: 602-343-8440///contact_laboratory: expO///contact_department: NA///contact_institute: IGC///contact_address: 445 N. 5th Street///contact_city: Phoenix///contact_state: AZ///contact_zip.postal_code: 85004///contact_country: USA///contact_web_link: www.intgen.org///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM152nnn/GSM152577/GSM152577.CEL.gz///data_row_count: 54675
1
title: Ovary - 129669///geo_accession: GSM152581///status: Public on Jan 03 2007///submission_date: Dec 22 2006///last_update_date: Jan 03 2007///type: RNA///channel_count: 1///source_name_ch1: Ovary///organism_ch1: Homo sapiens///molecule_ch1: total RNA///taxid_ch1: 9606///description: Quality metric = 28S to 18S: 1.3///description.1: Patient Age: 50-60///description.2: Gender: Female///description.3: Ethnic Background: Caucasian///description.4: Tobacco Use : Yes///description.5: Years of Tobacco Use: 36-40///description.6: Type of Tobacco Use: Cigarettes///description.7: Alcohol Consumption?: No///description.8: Family History of Cancer?: No///description.9: Presenting Symptoms: Abdominal mass///description.10: Presenting Symptoms: Bloating///description.11: Pathological T: 1c///description.12: Pathological N: 0///description.13: Pathological M: 0///description.14: Pathological Stage: 1C///description.15: Pathological Grade: 3///description.16: Pathological Multiple Tumors: No///description.17: Pathological Stage During or Following Multimodality Therapy: No///description.18: Primary Site: Ovary///description.19: Histology: Papillary Serous Adenocarcinoma///description.20: ///description.21: ///description.22: ///description.23: ///description.24: ///description.25: ///description.26: ///description.27: ///description.28: ///description.29: NA///description.30: NA///description.31: NA///platform_id: GPL570///contact_name: Michael,,Bittner///contact_email: [email protected]///contact_phone: 602-343-8808///contact_fax: 602-343-8440///contact_laboratory: expO///contact_department: NA///contact_institute: IGC///contact_address: 445 N. 5th Street///contact_city: Phoenix///contact_state: AZ///contact_zip.postal_code: 85004///contact_country: USA///contact_web_link: www.intgen.org///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM152nnn/GSM152581/GSM152581.CEL.gz///data_row_count: 54675
1
title: Ovary - 1311///geo_accession: GSM46830///status: Public on Mar 31 2005///submission_date: Mar 31 2005///last_update_date: Oct 09 2007///type: RNA///channel_count: 1///source_name_ch1: Ovary///organism_ch1: Homo sapiens///molecule_ch1: total RNA///taxid_ch1: 9606///description: Quality metric = 28S to 18S: 1.7///description.1: Patient Age: 60-70///description.2: Gender: Female///description.3: Ethnic Background: Caucasian///description.4: Tobacco Use : No///description.5: Alcohol Consumption?: No///description.6: Family History of Cancer?: No///description.7: Days from Patient Diagnosis to Excision: 18///description.8: Presenting Symptoms: Abdominal mass///description.9: Presenting Symptoms: Bloating///description.10: Primary Site: Ovary///description.11: Histology: Endometrioid Carcinoma///description.12: ///description.13: ///description.14: ///description.15: ///description.16: ///description.17: ///description.18: ///description.19: ///description.20: ///description.21: ///description.22: ///description.23: ///description.24: ///description.25: ///description.26: ///description.27: ///description.28: ///description.29: NA///description.30: NA///description.31: NA///platform_id: GPL570///contact_name: Michael,,Bittner///contact_email: [email protected]///contact_phone: 602-343-8808///contact_fax: 602-343-8440///contact_laboratory: expO///contact_department: NA///contact_institute: IGC///contact_address: 445 N. 5th Street///contact_city: Phoenix///contact_state: AZ///contact_zip.postal_code: 85004///contact_country: USA///contact_web_link: www.intgen.org///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM46nnn/GSM46830/GSM46830.CEL.gz///data_row_count: 54675
1
title: Ovary - 1313///geo_accession: GSM46831///status: Public on Mar 31 2005///submission_date: Mar 31 2005///last_update_date: Oct 09 2007///type: RNA///channel_count: 1///source_name_ch1: Ovary///organism_ch1: Homo sapiens///molecule_ch1: total RNA///taxid_ch1: 9606///description: Quality metric = 28S to 18S: 1.4///description.1: Patient Age: 70-80///description.2: Gender: Female///description.3: Ethnic Background: Caucasian///description.4: Tobacco Use : Yes///description.5: Years of Tobacco Use: 6-10///description.6: Type of Tobacco Use: Cigarettes///description.7: Alcohol Consumption?: No///description.8: Family History of Cancer?: Yes///description.9: Days from Patient Diagnosis to Excision: 4///description.10: Presenting Symptoms: Abdominal mass///description.11: Presenting Symptoms: Abdominal pain///description.12: Presenting Symptoms: Bloating///description.13: Pathological T: 3c///description.14: Pathological N: X///description.15: Pathological M: 1///description.16: Pathological Metastatic Sites: Pleura///description.17: Pathological Stage: 4///description.18: Pathological Grade: 3///description.19: Primary Site: Ovary///description.20: Histology: Papillary Serous Carcinoma///description.21: ///description.22: ///description.23: ///description.24: ///description.25: ///description.26: ///description.27: ///description.28: ///description.29: NA///description.30: NA///description.31: NA///platform_id: GPL570///contact_name: Michael,,Bittner///contact_email: [email protected]///contact_phone: 602-343-8808///contact_fax: 602-343-8440///contact_laboratory: expO///contact_department: NA///contact_institute: IGC///contact_address: 445 N. 5th Street///contact_city: Phoenix///contact_state: AZ///contact_zip.postal_code: 85004///contact_country: USA///contact_web_link: www.intgen.org///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM46nnn/GSM46831/GSM46831.CEL.gz///data_row_count: 54675
1
title: Ovary - 1323///geo_accession: GSM53063///status: Public on Jul 01 2005///submission_date: Jun 30 2005///last_update_date: Jun 30 2005///type: RNA///channel_count: 1///source_name_ch1: Ovary///organism_ch1: Homo sapiens///molecule_ch1: total RNA///taxid_ch1: 9606///description: Quality metric = 28S to 18S: 1.5///description.1: Patient Age: 80-90///description.2: Gender: Female///description.3: Ethnic Background: Caucasian///description.4: Tobacco Use : No///description.5: Alcohol Consumption?: No///description.6: Family History of Cancer?: No///description.7: Days from Patient Diagnosis to Excision: 8///description.8: Primary Site: Ovary///description.9: Histology: Endometrioid Carcinoma///description.10: ///description.11: ///description.12: ///description.13: ///description.14: ///description.15: ///description.16: ///description.17: ///description.18: ///description.19: ///description.20: ///description.21: ///description.22: ///description.23: ///description.24: ///description.25: ///description.26: ///description.27: ///description.28: ///description.29: ///description.30: NA///description.31: NA///platform_id: GPL570///contact_name: Michael,,Bittner///contact_email: [email protected]///contact_phone: 602-343-8808///contact_fax: 602-343-8440///contact_laboratory: expO///contact_department: NA///contact_institute: IGC///contact_address: 445 N. 5th Street///contact_city: Phoenix///contact_state: AZ///contact_zip.postal_code: 85004///contact_country: USA///contact_web_link: www.intgen.org///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM53nnn/GSM53063/GSM53063.CEL.gz///data_row_count: 54675
1
title: Ovary - 133643///geo_accession: GSM137904///status: Public on Sep 28 2006///submission_date: Sep 28 2006///last_update_date: Sep 28 2006///type: RNA///channel_count: 1///source_name_ch1: Ovary///organism_ch1: Homo sapiens///molecule_ch1: total RNA///taxid_ch1: 9606///description: Quality metric = 28S to 18S: 1.1///description.1: Patient Age: 60-70///description.2: Gender: Female///description.3: Ethnic Background: Caucasian///description.4: Tobacco Use : Yes///description.5: Years of Tobacco Use: 51-55///description.6: Type of Tobacco Use: Cigarettes///description.7: Alcohol Consumption?: Yes///description.8: Family History of Cancer?: Yes///description.9: Presenting Symptoms: Abdominal pain///description.10: Pathological T: 3c///description.11: Pathological N: 1///description.12: Pathological M: 0///description.13: Pathological Stage: 3C///description.14: Pathological Grade: 4///description.15: Pathological Multiple Tumors: Yes///description.16: Pathological Stage During or Following Multimodality Therapy: No///description.17: Primary Site: Ovary///description.18: Histology: Serous Adenocarinoma///description.19: ///description.20: ///description.21: ///description.22: ///description.23: ///description.24: ///description.25: ///description.26: ///description.27: ///description.28: ///description.29: NA///description.30: NA///description.31: NA///platform_id: GPL570///contact_name: Michael,,Bittner///contact_email: [email protected]///contact_phone: 602-343-8808///contact_fax: 602-343-8440///contact_laboratory: expO///contact_department: NA///contact_institute: IGC///contact_address: 445 N. 5th Street///contact_city: Phoenix///contact_state: AZ///contact_zip.postal_code: 85004///contact_country: USA///contact_web_link: www.intgen.org///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM137nnn/GSM137904/GSM137904.CEL.gz///data_row_count: 54675
1
title: Ovary - 133651///geo_accession: GSM137905///status: Public on Sep 28 2006///submission_date: Sep 28 2006///last_update_date: Sep 28 2006///type: RNA///channel_count: 1///source_name_ch1: Ovary///organism_ch1: Homo sapiens///molecule_ch1: total RNA///taxid_ch1: 9606///description: Quality metric = 28S to 18S: 1.3///description.1: Patient Age: 40-50///description.2: Gender: Female///description.3: Ethnic Background: Caucasian///description.4: Tobacco Use : Yes///description.5: Years of Tobacco Use: 6-10///description.6: Type of Tobacco Use: Cigarettes///description.7: Alcohol Consumption?: Yes///description.8: Family History of Cancer?: Yes///description.9: Days from Patient Diagnosis to Excision: 10///description.10: Presenting Symptoms: Abdominal mass///description.11: Presenting Symptoms: Abdominal pain///description.12: Presenting Symptoms: Bloating///description.13: Pathological T: 1c///description.14: Pathological N: 0///description.15: Pathological M: 0///description.16: Pathological Stage: 1C///description.17: Pathological Grade: 3///description.18: Pathological Multiple Tumors: No///description.19: Pathological Stage During or Following Multimodality Therapy: No///description.20: Primary Site: Ovary///description.21: Histology: Papillary Serous Carcinoma///description.22: ///description.23: ///description.24: ///description.25: ///description.26: ///description.27: ///description.28: ///description.29: ///description.30: ///description.31: ///platform_id: GPL570///contact_name: Michael,,Bittner///contact_email: [email protected]///contact_phone: 602-343-8808///contact_fax: 602-343-8440///contact_laboratory: expO///contact_department: NA///contact_institute: IGC///contact_address: 445 N. 5th Street///contact_city: Phoenix///contact_state: AZ///contact_zip.postal_code: 85004///contact_country: USA///contact_web_link: www.intgen.org///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM137nnn/GSM137905/GSM137905.CEL.gz///data_row_count: 54675
1
title: Ovary - 1351///geo_accession: GSM46839///status: Public on Mar 31 2005///submission_date: Mar 31 2005///last_update_date: Oct 09 2007///type: RNA///channel_count: 1///source_name_ch1: Ovary///organism_ch1: Homo sapiens///molecule_ch1: total RNA///taxid_ch1: 9606///description: Quality metric = 28S to 18S: 1.5///description.1: Patient Age: 60-70///description.2: Gender: Female///description.3: Ethnic Background: Caucasian///description.4: Tobacco Use : No///description.5: Alcohol Consumption?: Yes///description.6: Family History of Cancer?: Yes///description.7: Days from Patient Diagnosis to Excision: 4///description.8: Presenting Symptoms: Abdominal pain///description.9: Presenting Symptoms: Bloating///description.10: Pathological T: 3c///description.11: Pathological N: X///description.12: Pathological M: 0///description.13: Pathological Stage: 3C///description.14: Pathological Grade: 3///description.15: Primary Site: Ovary///description.16: Histology: Papillary Serous Carcinoma///description.17: ///description.18: ///description.19: ///description.20: ///description.21: ///description.22: ///description.23: ///description.24: ///description.25: ///description.26: ///description.27: ///description.28: ///description.29: ///description.30: ///description.31: ///platform_id: GPL570///contact_name: Michael,,Bittner///contact_email: [email protected]///contact_phone: 602-343-8808///contact_fax: 602-343-8440///contact_laboratory: expO///contact_department: NA///contact_institute: IGC///contact_address: 445 N. 5th Street///contact_city: Phoenix///contact_state: AZ///contact_zip.postal_code: 85004///contact_country: USA///contact_web_link: www.intgen.org///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM46nnn/GSM46839/GSM46839.CEL.gz///data_row_count: 54675
1
title: Ovary - 151614///geo_accession: GSM117668///status: Public on Jul 07 2006///submission_date: Jun 30 2006///last_update_date: Jul 07 2006///type: RNA///channel_count: 1///source_name_ch1: Ovary///organism_ch1: Homo sapiens///molecule_ch1: total RNA///taxid_ch1: 9606///description: Quality metric = 28S to 18S: 1.1///description.1: Patient Age: 50-60///description.2: Gender: Female///description.3: Ethnic Background: Caucasian///description.4: Tobacco Use : Yes///description.5: Years of Tobacco Use: 16-20///description.6: Type of Tobacco Use: Cigarettes///description.7: Alcohol Consumption?: No///description.8: Family History of Cancer?: No///description.9: Days from Patient Diagnosis to Excision: 21///description.10: Clinical Question: Stage///description.11: Clinical Value: No AJCC Scheme for this Site/Histology///description.12: Primary Site: Gastrointestinal Tract, NOS///description.13: Clinical Question: Histology///description.14: Clinical Value: Metastatic Signet ring cell adenocarcinoma///description.15: ///description.16: ///description.17: ///description.18: ///description.19: ///description.20: ///description.21: ///description.22: ///description.23: ///description.24: ///description.25: ///description.26: ///description.27: ///description.28: ///description.29: NA///description.30: NA///description.31: NA///platform_id: GPL570///contact_name: Michael,,Bittner///contact_email: [email protected]///contact_phone: 602-343-8808///contact_fax: 602-343-8440///contact_laboratory: expO///contact_department: NA///contact_institute: IGC///contact_address: 445 N. 5th Street///contact_city: Phoenix///contact_state: AZ///contact_zip.postal_code: 85004///contact_country: USA///contact_web_link: www.intgen.org///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM117nnn/GSM117668/GSM117668.CEL.gz///data_row_count: 54675
1
title: Ovary - 151622///geo_accession: GSM117670///status: Public on Jul 07 2006///submission_date: Jun 30 2006///last_update_date: Jul 07 2006///type: RNA///channel_count: 1///source_name_ch1: Ovary///organism_ch1: Homo sapiens///molecule_ch1: total RNA///taxid_ch1: 9606///description: Quality metric = 28S to 18S: 1.1///description.1: Patient Age: 80-90///description.2: Gender: Female///description.3: Ethnic Background: Caucasian///description.4: Tobacco Use : No///description.5: Alcohol Consumption?: No///description.6: Family History of Cancer?: No///description.7: Days from Patient Diagnosis to Excision: 21///description.8: Presenting Symptoms: Abdominal pain///description.9: Presenting Symptoms: Bloating///description.10: Presenting Symptoms: Vaginal bleeding///description.11: Pathological Question: Stage///description.12: Pathological Value: No AJCC Staging Scheme for this Site/Histology///description.13: Primary Site: Ovary///description.14: Pathological Question: Histology///description.15: Pathological Value: Borderline tumor of ovary, mixed epithelial type///description.16: ///description.17: ///description.18: ///description.19: ///description.20: ///description.21: ///description.22: ///description.23: ///description.24: ///description.25: ///description.26: ///description.27: ///description.28: ///description.29: ///description.30: ///description.31: ///platform_id: GPL570///contact_name: Michael,,Bittner///contact_email: [email protected]///contact_phone: 602-343-8808///contact_fax: 602-343-8440///contact_laboratory: expO///contact_department: NA///contact_institute: IGC///contact_address: 445 N. 5th Street///contact_city: Phoenix///contact_state: AZ///contact_zip.postal_code: 85004///contact_country: USA///contact_web_link: www.intgen.org///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM117nnn/GSM117670/GSM117670.CEL.gz///data_row_count: 54675
1
title: Ovary - 161465///geo_accession: GSM102538///status: Public on Mar 30 2006///submission_date: Mar 30 2006///last_update_date: Mar 30 2006///type: RNA///channel_count: 1///source_name_ch1: Ovary///organism_ch1: Homo sapiens///molecule_ch1: total RNA///taxid_ch1: 9606///description: Quality metric = 28S to 18S: 1.5///description.1: Patient Age: 70-80///description.2: Gender: Female///description.3: Ethnic Background: Caucasian///description.4: Tobacco Use : No///description.5: Alcohol Consumption?: No///description.6: Family History of Cancer?: No///description.7: Presenting Symptoms: Abdominal mass///description.8: Presenting Symptoms: Abdominal pain///description.9: Clinical T: 3c///description.10: Clinical N: X///description.11: Clinical M: 0///description.12: Clinical Stage: 3C///description.13: Clinical Grade: 3///description.14: Clinical Multiple Tumors: No///description.15: Clinical Stage During or Following Multimodality Therapy: No///description.16: Primary Site: Ovary///description.17: Histology: Malignant mixed muellerian tumor///description.18: ///description.19: ///description.20: ///description.21: ///description.22: ///description.23: ///description.24: ///description.25: ///description.26: ///description.27: ///description.28: ///description.29: ///description.30: NA///description.31: NA///platform_id: GPL570///contact_name: Michael,,Bittner///contact_email: [email protected]///contact_phone: 602-343-8808///contact_fax: 602-343-8440///contact_laboratory: expO///contact_department: NA///contact_institute: IGC///contact_address: 445 N. 5th Street///contact_city: Phoenix///contact_state: AZ///contact_zip.postal_code: 85004///contact_country: USA///contact_web_link: www.intgen.org///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM102nnn/GSM102538/GSM102538.CEL.gz///data_row_count: 54675
1
title: Ovary - 161524///geo_accession: GSM117696///status: Public on Jul 07 2006///submission_date: Jun 30 2006///last_update_date: Jul 07 2006///type: RNA///channel_count: 1///source_name_ch1: Ovary///organism_ch1: Homo sapiens///molecule_ch1: total RNA///taxid_ch1: 9606///description: Quality metric = 28S to 18S: 1.1///description.1: Patient Age: 60-70///description.2: Gender: Female///description.3: Ethnic Background: Caucasian///description.4: Tobacco Use : No///description.5: Alcohol Consumption?: No///description.6: Family History of Cancer?: No///description.7: Days from Patient Diagnosis to Excision: 30///description.8: Presenting Symptoms: Abdominal pain///description.9: Presenting Symptoms: Bloating///description.10: Pathological T: 3c///description.11: Pathological N: 1///description.12: Pathological Grade: 3///description.13: Pathological Multiple Tumors: No///description.14: Pathological Stage During or Following Multimodality Therapy: No///description.15: Primary Site: Ovary///description.16: Histology: Papillary Serous Adenocarcinoma///description.17: ///description.18: ///description.19: ///description.20: ///description.21: ///description.22: ///description.23: ///description.24: ///description.25: ///description.26: ///description.27: ///description.28: ///description.29: ///description.30: ///description.31: ///platform_id: GPL570///contact_name: Michael,,Bittner///contact_email: [email protected]///contact_phone: 602-343-8808///contact_fax: 602-343-8440///contact_laboratory: expO///contact_department: NA///contact_institute: IGC///contact_address: 445 N. 5th Street///contact_city: Phoenix///contact_state: AZ///contact_zip.postal_code: 85004///contact_country: USA///contact_web_link: www.intgen.org///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM117nnn/GSM117696/GSM117696.CEL.gz///data_row_count: 54675
1
title: Ovary - 161525///geo_accession: GSM152596///status: Public on Jan 03 2007///submission_date: Dec 22 2006///last_update_date: Jan 03 2007///type: RNA///channel_count: 1///source_name_ch1: Ovary///organism_ch1: Homo sapiens///molecule_ch1: total RNA///taxid_ch1: 9606///description: Quality metric = 28S to 18S: 1.4///description.1: Patient Age: 70-80///description.2: Gender: Female///description.3: Ethnic Background: Caucasian///description.4: Tobacco Use : Yes///description.5: Years of Tobacco Use: 51-55///description.6: Type of Tobacco Use: Cigarettes///description.7: Alcohol Consumption?: No///description.8: Family History of Cancer?: Yes///description.9: Days from Patient Diagnosis to Excision: 7///description.10: Presenting Symptoms: Abdominal pain///description.11: Clinical T: 2b///description.12: Clinical N: 0///description.13: Clinical M: 0///description.14: Clinical Stage: 2B///description.15: Clinical Grade: 3///description.16: Clinical Multiple Tumors: No///description.17: Clinical Stage During or Following Multimodality Therapy: No///description.18: Primary Site: Ovary///description.19: Histology: Papillary Serous Carcinoma///description.20: ///description.21: ///description.22: ///description.23: ///description.24: ///description.25: ///description.26: ///description.27: ///description.28: ///description.29: NA///description.30: NA///description.31: NA///platform_id: GPL570///contact_name: Michael,,Bittner///contact_email: [email protected]///contact_phone: 602-343-8808///contact_fax: 602-343-8440///contact_laboratory: expO///contact_department: NA///contact_institute: IGC///contact_address: 445 N. 5th Street///contact_city: Phoenix///contact_state: AZ///contact_zip.postal_code: 85004///contact_country: USA///contact_web_link: www.intgen.org///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM152nnn/GSM152596/GSM152596.CEL.gz///data_row_count: 54675
1
title: Ovary - 161534///geo_accession: GSM152599///status: Public on Jan 03 2007///submission_date: Dec 22 2006///last_update_date: Jan 03 2007///type: RNA///channel_count: 1///source_name_ch1: Ovary///organism_ch1: Homo sapiens///molecule_ch1: total RNA///taxid_ch1: 9606///description: Quality metric = 28S to 18S: 1.5///description.1: Patient Age: 40-50///description.2: Gender: Female///description.3: Ethnic Background: Caucasian///description.4: Tobacco Use : Yes///description.5: Years of Tobacco Use: 6-10///description.6: Type of Tobacco Use: Cigarettes///description.7: Alcohol Consumption?: No///description.8: Family History of Cancer?: Yes///description.9: Days from Patient Diagnosis to Excision: 7///description.10: Pathological T: 1c///description.11: Pathological N: 0///description.12: Pathological M: 0///description.13: Pathological Stage: 1C///description.14: Pathological Grade: 1///description.15: Pathological Multiple Tumors: No///description.16: Pathological Stage During or Following Multimodality Therapy: No///description.17: Primary Site: Ovary///description.18: Histology: Endometrioid Carcinoma///description.19: ///description.20: ///description.21: ///description.22: ///description.23: ///description.24: ///description.25: ///description.26: ///description.27: ///description.28: ///description.29: ///description.30: NA///description.31: NA///platform_id: GPL570///contact_name: Michael,,Bittner///contact_email: [email protected]///contact_phone: 602-343-8808///contact_fax: 602-343-8440///contact_laboratory: expO///contact_department: NA///contact_institute: IGC///contact_address: 445 N. 5th Street///contact_city: Phoenix///contact_state: AZ///contact_zip.postal_code: 85004///contact_country: USA///contact_web_link: www.intgen.org///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM152nnn/GSM152599/GSM152599.CEL.gz///data_row_count: 54675
1
title: Ovary - 1636///geo_accession: GSM53066///status: Public on Jul 01 2005///submission_date: Jun 30 2005///last_update_date: Jun 30 2005///type: RNA///channel_count: 1///source_name_ch1: Ovary///organism_ch1: Homo sapiens///molecule_ch1: total RNA///taxid_ch1: 9606///description: Quality metric = 28S to 18S: 1.3///description.1: Patient Age: 60-70///description.2: Gender: Female///description.3: Ethnic Background: Caucasian///description.4: Tobacco Use : Yes///description.5: Years of Tobacco Use: 6-10///description.6: Type of Tobacco Use: Cigarettes///description.7: Alcohol Consumption?: No///description.8: Family History of Cancer?: No///description.9: Days from Patient Diagnosis to Excision: 18///description.10: Presenting Symptoms: Bloating///description.11: Presenting Symptoms: Vaginal bleeding///description.12: Primary Site: Unknown///description.13: Histology: Metastatic Malignant Neoplasm, NOS///description.14: ///description.15: ///description.16: ///description.17: ///description.18: ///description.19: ///description.20: ///description.21: ///description.22: ///description.23: ///description.24: ///description.25: ///description.26: ///description.27: ///description.28: ///description.29: ///description.30: NA///description.31: NA///platform_id: GPL570///contact_name: Michael,,Bittner///contact_email: [email protected]///contact_phone: 602-343-8808///contact_fax: 602-343-8440///contact_laboratory: expO///contact_department: NA///contact_institute: IGC///contact_address: 445 N. 5th Street///contact_city: Phoenix///contact_state: AZ///contact_zip.postal_code: 85004///contact_country: USA///contact_web_link: www.intgen.org///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM53nnn/GSM53066/GSM53066.CEL.gz///data_row_count: 54675
1
title: Ovary - 1639///geo_accession: GSM53068///status: Public on Jul 01 2005///submission_date: Jun 30 2005///last_update_date: Jun 30 2005///type: RNA///channel_count: 1///source_name_ch1: Ovary///organism_ch1: Homo sapiens///molecule_ch1: total RNA///taxid_ch1: 9606///description: Quality metric = 28S to 18S: 1.3///description.1: Patient Age: 40-50///description.2: Gender: Female///description.3: Ethnic Background: Caucasian///description.4: Tobacco Use : Yes///description.5: Years of Tobacco Use: 6-10///description.6: Type of Tobacco Use: Cigarettes///description.7: Alcohol Consumption?: Yes///description.8: Family History of Cancer?: Yes///description.9: Days from Patient Diagnosis to Excision: 45///description.10: Presenting Symptoms: Abdominal pain///description.11: Presenting Symptoms: Bloating///description.12: Primary Site: Ovary///description.13: Histology: Papillary Serous Carcinoma///description.14: ///description.15: ///description.16: ///description.17: ///description.18: ///description.19: ///description.20: ///description.21: ///description.22: ///description.23: ///description.24: ///description.25: ///description.26: ///description.27: ///description.28: ///description.29: NA///description.30: NA///description.31: NA///platform_id: GPL570///contact_name: Michael,,Bittner///contact_email: [email protected]///contact_phone: 602-343-8808///contact_fax: 602-343-8440///contact_laboratory: expO///contact_department: NA///contact_institute: IGC///contact_address: 445 N. 5th Street///contact_city: Phoenix///contact_state: AZ///contact_zip.postal_code: 85004///contact_country: USA///contact_web_link: www.intgen.org///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM53nnn/GSM53068/GSM53068.CEL.gz///data_row_count: 54675
1
title: Ovary - 1643///geo_accession: GSM53069///status: Public on Jul 01 2005///submission_date: Jun 30 2005///last_update_date: Jun 30 2005///type: RNA///channel_count: 1///source_name_ch1: Ovary///organism_ch1: Homo sapiens///molecule_ch1: total RNA///taxid_ch1: 9606///description: Quality metric = 28S to 18S: 1.2///description.1: Patient Age: 60-70///description.2: Gender: Female///description.3: Ethnic Background: Caucasian///description.4: Tobacco Use : Yes///description.5: Years of Tobacco Use: 11-15///description.6: Type of Tobacco Use: Cigarettes///description.7: Alcohol Consumption?: Yes///description.8: Family History of Cancer?: No///description.9: Days from Patient Diagnosis to Excision: 1///description.10: Primary Site: Ovary///description.11: Histology: Serous Adenocarinoma///description.12: ///description.13: ///description.14: ///description.15: ///description.16: ///description.17: ///description.18: ///description.19: ///description.20: ///description.21: ///description.22: ///description.23: ///description.24: ///description.25: ///description.26: ///description.27: ///description.28: ///description.29: ///description.30: NA///description.31: NA///platform_id: GPL570///contact_name: Michael,,Bittner///contact_email: [email protected]///contact_phone: 602-343-8808///contact_fax: 602-343-8440///contact_laboratory: expO///contact_department: NA///contact_institute: IGC///contact_address: 445 N. 5th Street///contact_city: Phoenix///contact_state: AZ///contact_zip.postal_code: 85004///contact_country: USA///contact_web_link: www.intgen.org///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM53nnn/GSM53069/GSM53069.CEL.gz///data_row_count: 54675
1
title: Ovary - 170809///geo_accession: GSM137917///status: Public on Sep 28 2006///submission_date: Sep 28 2006///last_update_date: Sep 28 2006///type: RNA///channel_count: 1///source_name_ch1: Ovary///organism_ch1: Homo sapiens///molecule_ch1: total RNA///taxid_ch1: 9606///description: Quality metric = 28S to 18S: 1.3///description.1: Patient Age: 60-70///description.2: Gender: Female///description.3: Ethnic Background: African-American///description.4: Tobacco Use : No///description.5: Alcohol Consumption?: No///description.6: Family History of Cancer?: Yes///description.7: Days from Patient Diagnosis to Excision: 15///description.8: Pathological Question: T///description.9: Pathological Value: X///description.10: Pathological Question: N///description.11: Pathological Value: X///description.12: Pathological Question: M///description.13: Pathological Value: 1///description.14: Pathological Question: Metastatic Sites///description.15: Pathological Value: Ovary, omentum///description.16: Pathological Question: Stage///description.17: Pathological Value: 4///description.18: Pathological Question: Grade///description.19: Pathological Value: X///description.20: Pathological Question: Multiple Tumors///description.21: Pathological Value: No///description.22: Pathological Question: Stage During or Following Multimodality Therapy///description.23: Pathological Value: No///description.24: Primary Site: Exocrine pancreas///description.25: Pathological Question: Histology///description.26: Pathological Value: Metastatic Adenocarcinoma///description.27: ///description.28: ///description.29: NA///description.30: NA///description.31: NA///platform_id: GPL570///contact_name: Michael,,Bittner///contact_email: [email protected]///contact_phone: 602-343-8808///contact_fax: 602-343-8440///contact_laboratory: expO///contact_department: NA///contact_institute: IGC///contact_address: 445 N. 5th Street///contact_city: Phoenix///contact_state: AZ///contact_zip.postal_code: 85004///contact_country: USA///contact_web_link: www.intgen.org///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM137nnn/GSM137917/GSM137917.CEL.gz///data_row_count: 54675
1
title: Ovary - 174931///geo_accession: GSM117716///status: Public on Jul 07 2006///submission_date: Jun 30 2006///last_update_date: Jul 07 2006///type: RNA///channel_count: 1///source_name_ch1: Ovary///organism_ch1: Homo sapiens///molecule_ch1: total RNA///taxid_ch1: 9606///description: Quality metric = 28S to 18S: 1.2///description.1: Patient Age: 60-70///description.2: Gender: Female///description.3: Ethnic Background: Caucasian///description.4: Tobacco Use : Yes///description.5: Years of Tobacco Use: 11-15///description.6: Type of Tobacco Use: Cigarettes///description.7: Alcohol Consumption?: No///description.8: Family History of Cancer?: Yes///description.9: Days from Patient Diagnosis to Excision: 14///description.10: Presenting Symptoms: Bloating///description.11: Pathological T: 3c///description.12: Pathological N: 1///description.13: Pathological M: 0///description.14: Pathological Stage: 3C///description.15: Pathological Grade: 4///description.16: Pathological Multiple Tumors: No///description.17: Pathological Stage During or Following Multimodality Therapy: No///description.18: Primary Site: Ovary///description.19: Histology: Clear cell adenocarcinoma///description.20: ///description.21: ///description.22: ///description.23: ///description.24: ///description.25: ///description.26: ///description.27: ///description.28: ///description.29: ///description.30: ///description.31: ///platform_id: GPL570///contact_name: Michael,,Bittner///contact_email: [email protected]///contact_phone: 602-343-8808///contact_fax: 602-343-8440///contact_laboratory: expO///contact_department: NA///contact_institute: IGC///contact_address: 445 N. 5th Street///contact_city: Phoenix///contact_state: AZ///contact_zip.postal_code: 85004///contact_country: USA///contact_web_link: www.intgen.org///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM117nnn/GSM117716/GSM117716.CEL.gz///data_row_count: 54675
1
title: Ovary - 174936///geo_accession: GSM117718///status: Public on Jul 07 2006///submission_date: Jun 30 2006///last_update_date: Jul 07 2006///type: RNA///channel_count: 1///source_name_ch1: Ovary///organism_ch1: Homo sapiens///molecule_ch1: total RNA///taxid_ch1: 9606///description: Quality metric = 28S to 18S: 1.1///description.1: Patient Age: 50-60///description.2: Gender: Female///description.3: Ethnic Background: Caucasian///description.4: Tobacco Use : No///description.5: Alcohol Consumption?: No///description.6: Family History of Cancer?: No///description.7: Days from Patient Diagnosis to Excision: 120///description.8: Prior Therapy: Chemotherapy///description.9: Presenting Symptoms: Abdominal mass///description.10: Presenting Symptoms: Abdominal pain///description.11: Presenting Symptoms: Bloating///description.12: Pathological T: 3c///description.13: Pathological N: 1///description.14: Pathological M: 0///description.15: Pathological Stage: 3C///description.16: Pathological Grade: 4///description.17: Pathological Multiple Tumors: No///description.18: Pathological Stage During or Following Multimodality Therapy: Yes///description.19: Primary Site: Ovary///description.20: Histology: Clear cell adenocarcinoma///description.21: ///description.22: ///description.23: ///description.24: ///description.25: ///description.26: ///description.27: ///description.28: ///description.29: ///description.30: NA///description.31: NA///platform_id: GPL570///contact_name: Michael,,Bittner///contact_email: [email protected]///contact_phone: 602-343-8808///contact_fax: 602-343-8440///contact_laboratory: expO///contact_department: NA///contact_institute: IGC///contact_address: 445 N. 5th Street///contact_city: Phoenix///contact_state: AZ///contact_zip.postal_code: 85004///contact_country: USA///contact_web_link: www.intgen.org///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM117nnn/GSM117718/GSM117718.CEL.gz///data_row_count: 54675
1
title: Ovary - 180953///geo_accession: GSM152603///status: Public on Jan 03 2007///submission_date: Dec 22 2006///last_update_date: Jan 03 2007///type: RNA///channel_count: 1///source_name_ch1: Ovary///organism_ch1: Homo sapiens///molecule_ch1: total RNA///taxid_ch1: 9606///description: Quality metric = 28S to 18S: 1.3///description.1: Patient Age: 50-60///description.2: Gender: Female///description.3: Ethnic Background: Caucasian///description.4: Tobacco Use : No///description.5: Alcohol Consumption?: No///description.6: Family History of Cancer?: Yes///description.7: Presenting Symptoms: Abdominal pain///description.8: Presenting Symptoms: Bloating///description.9: Pathological T: 2c///description.10: Pathological N: 0///description.11: Pathological M: 0///description.12: Pathological Stage: 2C///description.13: Pathological Grade: 2///description.14: Pathological Multiple Tumors: No///description.15: Pathological Stage During or Following Multimodality Therapy: No///description.16: Primary Site: Ovary///description.17: Histology: Endometrioid Carcinoma///description.18: ///description.19: ///description.20: ///description.21: ///description.22: ///description.23: ///description.24: ///description.25: ///description.26: ///description.27: ///description.28: NA///description.29: NA///description.30: NA///description.31: NA///platform_id: GPL570///contact_name: Michael,,Bittner///contact_email: [email protected]///contact_phone: 602-343-8808///contact_fax: 602-343-8440///contact_laboratory: expO///contact_department: NA///contact_institute: IGC///contact_address: 445 N. 5th Street///contact_city: Phoenix///contact_state: AZ///contact_zip.postal_code: 85004///contact_country: USA///contact_web_link: www.intgen.org///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM152nnn/GSM152603/GSM152603.CEL.gz///data_row_count: 54675
1
title: Ovary - 184837///geo_accession: GSM117744///status: Public on Jul 07 2006///submission_date: Jun 30 2006///last_update_date: Jul 07 2006///type: RNA///channel_count: 1///source_name_ch1: Ovary///organism_ch1: Homo sapiens///molecule_ch1: total RNA///taxid_ch1: 9606///description: Quality metric = 28S to 18S: 1.1///description.1: Patient Age: 50-60///description.2: Gender: Female///description.3: Ethnic Background: Caucasian///description.4: Tobacco Use : Yes///description.5: Years of Tobacco Use: 26-30///description.6: Type of Tobacco Use: Cigarettes///description.7: Alcohol Consumption?: Yes///description.8: Family History of Cancer?: Yes///description.9: Days from Patient Diagnosis to Excision: 5///description.10: Presenting Symptoms: Abdominal mass///description.11: Presenting Symptoms: Abdominal pain///description.12: Presenting Symptoms: Bloating///description.13: Pathological T: 3c///description.14: Pathological N: X///description.15: Pathological M: 0///description.16: Pathological Stage: 3C///description.17: Pathological Grade: 3///description.18: Pathological Multiple Tumors: No///description.19: Pathological Stage During or Following Multimodality Therapy: No///description.20: Primary Site: Ovary///description.21: Histology: Serous Adenocarinoma///description.22: ///description.23: ///description.24: ///description.25: ///description.26: ///description.27: ///description.28: NA///description.29: NA///description.30: NA///description.31: NA///platform_id: GPL570///contact_name: Michael,,Bittner///contact_email: [email protected]///contact_phone: 602-343-8808///contact_fax: 602-343-8440///contact_laboratory: expO///contact_department: NA///contact_institute: IGC///contact_address: 445 N. 5th Street///contact_city: Phoenix///contact_state: AZ///contact_zip.postal_code: 85004///contact_country: USA///contact_web_link: www.intgen.org///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM117nnn/GSM117744/GSM117744.CEL.gz///data_row_count: 54675
1
title: Ovary - 187243///geo_accession: GSM203635///status: Public on Jun 25 2007///submission_date: Jun 22 2007///last_update_date: Jun 25 2007///type: RNA///channel_count: 1///source_name_ch1: Ovary///organism_ch1: Homo sapiens///molecule_ch1: total RNA///taxid_ch1: 9606///description: Quality metric = 28S to 18S: 1.4///description.1: Patient Age: 70-80///description.2: Gender: Female///description.3: Ethnic Background: Caucasian///description.4: Tobacco Use : Yes///description.5: Years of Tobacco Use: 26-30///description.6: Type of Tobacco Use: Cigarettes///description.7: Alcohol Consumption?: Yes///description.8: Family History of Cancer?: Yes///description.9: Presenting Symptoms: Abdominal mass///description.10: Presenting Symptoms: Bloating///description.11: Pathological T: 3c///description.12: Pathological N: X///description.13: Pathological M: 0///description.14: Pathological Stage: 3C///description.15: Pathological Grade: 3///description.16: Primary Site: Ovary///description.17: Histology: Papillary Serous Carcinoma///description.18: ///description.19: ///description.20: ///description.21: ///description.22: ///description.23: ///description.24: ///description.25: ///description.26: ///description.27: ///description.28: ///description.29: ///description.30: ///description.31: ///platform_id: GPL570///contact_name: Michael,,Bittner///contact_email: [email protected]///contact_phone: 602-343-8808///contact_fax: 602-343-8440///contact_laboratory: expO///contact_department: NA///contact_institute: IGC///contact_address: 445 N. 5th Street///contact_city: Phoenix///contact_state: AZ///contact_zip.postal_code: 85004///contact_country: USA///contact_web_link: www.intgen.org///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM203nnn/GSM203635/GSM203635.CEL.gz///data_row_count: 54675
1
title: Ovary - 187246///geo_accession: GSM203637///status: Public on Jun 25 2007///submission_date: Jun 22 2007///last_update_date: Jun 25 2007///type: RNA///channel_count: 1///source_name_ch1: Ovary///organism_ch1: Homo sapiens///molecule_ch1: total RNA///taxid_ch1: 9606///description: Quality metric = 28S to 18S: 1.4///description.1: Patient Age: 70-80///description.2: Gender: Female///description.3: Ethnic Background: African-American///description.4: Tobacco Use : No///description.5: Alcohol Consumption?: Yes///description.6: Family History of Cancer?: Yes///description.7: Prior Therapy: Chemotherapy///description.8: Presenting Symptoms: Abdominal pain///description.9: Presenting Symptoms: Bloating///description.10: Pathological T: 3b///description.11: Pathological N: X///description.12: Pathological M: 1///description.13: Pathological Metastatic Sites: Pleura///description.14: Pathological Stage: 4///description.15: Pathological Grade: 3///description.16: Pathological Stage During or Following Multimodality Therapy: Yes///description.17: Primary Site: Ovary///description.18: Histology: Papillary Serous Carcinoma///description.19: ///description.20: ///description.21: ///description.22: ///description.23: ///description.24: ///description.25: ///description.26: ///description.27: ///description.28: ///description.29: NA///description.30: NA///description.31: NA///platform_id: GPL570///contact_name: Michael,,Bittner///contact_email: [email protected]///contact_phone: 602-343-8808///contact_fax: 602-343-8440///contact_laboratory: expO///contact_department: NA///contact_institute: IGC///contact_address: 445 N. 5th Street///contact_city: Phoenix///contact_state: AZ///contact_zip.postal_code: 85004///contact_country: USA///contact_web_link: www.intgen.org///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM203nnn/GSM203637/GSM203637.CEL.gz///data_row_count: 54675
1
title: Ovary - 187251///geo_accession: GSM203638///status: Public on Jun 25 2007///submission_date: Jun 22 2007///last_update_date: Jun 25 2007///type: RNA///channel_count: 1///source_name_ch1: Ovary///organism_ch1: Homo sapiens///molecule_ch1: total RNA///taxid_ch1: 9606///description: Quality metric = 28S to 18S: 1.4///description.1: Patient Age: 70-80///description.2: Gender: Female///description.3: Ethnic Background: Caucasian///description.4: Tobacco Use : Yes///description.5: Years of Tobacco Use: 6-10///description.6: Type of Tobacco Use: Cigarettes///description.7: Alcohol Consumption?: Yes///description.8: Family History of Cancer?: No///description.9: Days from Patient Diagnosis to Excision: 45///description.10: Presenting Symptoms: Abdominal pain///description.11: Pathological T: 1b///description.12: Pathological N: 0///description.13: Pathological M: X///description.14: Pathological Stage: Unknown///description.15: Primary Site: Ovary///description.16: Histology: Mucinous cystic tumor of low malignant potential///description.17: ///description.18: ///description.19: ///description.20: ///description.21: ///description.22: ///description.23: ///description.24: ///description.25: ///description.26: ///description.27: ///description.28: ///description.29: NA///description.30: NA///description.31: NA///platform_id: GPL570///contact_name: Michael,,Bittner///contact_email: [email protected]///contact_phone: 602-343-8808///contact_fax: 602-343-8440///contact_laboratory: expO///contact_department: NA///contact_institute: IGC///contact_address: 445 N. 5th Street///contact_city: Phoenix///contact_state: AZ///contact_zip.postal_code: 85004///contact_country: USA///contact_web_link: www.intgen.org///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM203nnn/GSM203638/GSM203638.CEL.gz///data_row_count: 54675
1
title: Ovary - 187253///geo_accession: GSM179787///status: Public on Apr 06 2007///submission_date: Apr 02 2007///last_update_date: Apr 06 2007///type: RNA///channel_count: 1///source_name_ch1: Ovary///organism_ch1: Homo sapiens///molecule_ch1: total RNA///taxid_ch1: 9606///description: Quality metric = 28S to 18S: 2.0///description.1: Patient Age: 40-50///description.2: Gender: Female///description.3: Ethnic Background: Asian///description.4: Tobacco Use : Yes///description.5: Years of Tobacco Use: 16-20///description.6: Type of Tobacco Use: Cigarettes///description.7: Alcohol Consumption?: Yes///description.8: Family History of Cancer?: Yes///description.9: Presenting Symptoms: Abdominal pain///description.10: Presenting Symptoms: Vaginal bleeding///description.11: Pathological T: 3c///description.12: Pathological N: 1///description.13: Pathological M: 0///description.14: Pathological Stage: 3C///description.15: Pathological Grade: 3///description.16: Primary Site: Ovary///description.17: Histology: Clear cell adenocarcinoma///description.18: ///description.19: ///description.20: ///description.21: ///description.22: ///description.23: ///description.24: ///description.25: ///description.26: ///description.27: ///description.28: ///description.29: NA///description.30: NA///description.31: NA///platform_id: GPL570///contact_name: Michael,,Bittner///contact_email: [email protected]///contact_phone: 602-343-8808///contact_fax: 602-343-8440///contact_laboratory: expO///contact_department: NA///contact_institute: IGC///contact_address: 445 N. 5th Street///contact_city: Phoenix///contact_state: AZ///contact_zip.postal_code: 85004///contact_country: USA///contact_web_link: www.intgen.org///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM179nnn/GSM179787/GSM179787.CEL.gz///data_row_count: 54675
1
title: Ovary - 191413///geo_accession: GSM137957///status: Public on Sep 28 2006///submission_date: Sep 28 2006///last_update_date: Sep 28 2006///type: RNA///channel_count: 1///source_name_ch1: Ovary///organism_ch1: Homo sapiens///molecule_ch1: total RNA///taxid_ch1: 9606///description: Quality metric = 28S to 18S: 1.6///description.1: Patient Age: 40-50///description.2: Gender: Female///description.3: Ethnic Background: Caucasian///description.4: Tobacco Use : No///description.5: Alcohol Consumption?: No///description.6: Family History of Cancer?: No///description.7: Days from Patient Diagnosis to Excision: 1///description.8: Presenting Symptoms: Abdominal pain///description.9: Presenting Symptoms: Bloating///description.10: Clinical Question: Stage///description.11: Clinical Value: No AJCC Scheme for this site and histology///description.12: Primary Site: Ovary///description.13: Clinical Question: Histology///description.14: Clinical Value: Endometrioid tumor of low malignant potential///description.15: ///description.16: ///description.17: ///description.18: ///description.19: ///description.20: ///description.21: ///description.22: ///description.23: ///description.24: ///description.25: ///description.26: ///description.27: ///description.28: ///description.29: NA///description.30: NA///description.31: NA///platform_id: GPL570///contact_name: Michael,,Bittner///contact_email: [email protected]///contact_phone: 602-343-8808///contact_fax: 602-343-8440///contact_laboratory: expO///contact_department: NA///contact_institute: IGC///contact_address: 445 N. 5th Street///contact_city: Phoenix///contact_state: AZ///contact_zip.postal_code: 85004///contact_country: USA///contact_web_link: www.intgen.org///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM137nnn/GSM137957/GSM137957.CEL.gz///data_row_count: 54675
1
title: Ovary - 191424///geo_accession: GSM137965///status: Public on Sep 28 2006///submission_date: Sep 28 2006///last_update_date: Sep 28 2006///type: RNA///channel_count: 1///source_name_ch1: Ovary///organism_ch1: Homo sapiens///molecule_ch1: total RNA///taxid_ch1: 9606///description: Quality metric = 28S to 18S: 1.4///description.1: Patient Age: 60-70///description.2: Gender: Female///description.3: Ethnic Background: Caucasian///description.4: Tobacco Use : No///description.5: Alcohol Consumption?: No///description.6: Family History of Cancer?: Yes///description.7: Days from Patient Diagnosis to Excision: 1///description.8: Presenting Symptoms: Abdominal mass///description.9: Pathological T: 2c///description.10: Pathological N: 0///description.11: Pathological M: X///description.12: Pathological Stage: Unknown///description.13: Pathological Grade: 2///description.14: Pathological Stage During or Following Multimodality Therapy: No///description.15: Primary Site: Ovary///description.16: Histology: Endometrioid Carcinoma///description.17: ///description.18: ///description.19: ///description.20: ///description.21: ///description.22: ///description.23: ///description.24: ///description.25: ///description.26: ///description.27: ///description.28: ///description.29: NA///description.30: NA///description.31: NA///platform_id: GPL570///contact_name: Michael,,Bittner///contact_email: [email protected]///contact_phone: 602-343-8808///contact_fax: 602-343-8440///contact_laboratory: expO///contact_department: NA///contact_institute: IGC///contact_address: 445 N. 5th Street///contact_city: Phoenix///contact_state: AZ///contact_zip.postal_code: 85004///contact_country: USA///contact_web_link: www.intgen.org///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM137nnn/GSM137965/GSM137965.CEL.gz///data_row_count: 54675
1
title: Ovary - 195198///geo_accession: GSM137983///status: Public on Sep 28 2006///submission_date: Sep 28 2006///last_update_date: Sep 28 2006///type: RNA///channel_count: 1///source_name_ch1: Ovary///organism_ch1: Homo sapiens///molecule_ch1: total RNA///taxid_ch1: 9606///description: Quality metric = 28S to 18S: 1.2///description.1: Patient Age: 60-70///description.2: Gender: Female///description.3: Ethnic Background: Caucasian///description.4: Tobacco Use : No///description.5: Alcohol Consumption?: No///description.6: Family History of Cancer?: No///description.7: Prior Therapy: Chemotherapy///description.8: Relapse Since Primary Treatment: Yes///description.9: Number of Years Until Relapse: 0-5///description.10: Retreatment T: 3c///description.11: Retreatment N: X///description.12: Retreatment M: 0///description.13: Retreatment Stage: 3C///description.14: Retreatment Grade: 3///description.15: Primary Site: Ovary///description.16: Histology: Papillary Serous Carcinoma///description.17: ///description.18: ///description.19: ///description.20: ///description.21: ///description.22: ///description.23: ///description.24: ///description.25: ///description.26: ///description.27: ///description.28: ///description.29: NA///description.30: NA///description.31: NA///platform_id: GPL570///contact_name: Michael,,Bittner///contact_email: [email protected]///contact_phone: 602-343-8808///contact_fax: 602-343-8440///contact_laboratory: expO///contact_department: NA///contact_institute: IGC///contact_address: 445 N. 5th Street///contact_city: Phoenix///contact_state: AZ///contact_zip.postal_code: 85004///contact_country: USA///contact_web_link: www.intgen.org///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM137nnn/GSM137983/GSM137983.CEL.gz///data_row_count: 54675
1
title: Ovary - 199399///geo_accession: GSM179798///status: Public on Apr 06 2007///submission_date: Apr 02 2007///last_update_date: Apr 06 2007///type: RNA///channel_count: 1///source_name_ch1: Ovary///organism_ch1: Homo sapiens///molecule_ch1: total RNA///taxid_ch1: 9606///description: Quality metric = 28S to 18S: 1.0///description.1: Patient Age: 50-60///description.2: Gender: Female///description.3: Ethnic Background: Caucasian///description.4: Tobacco Use : No///description.5: Alcohol Consumption?: No///description.6: Family History of Cancer?: Yes///description.7: Days from Patient Diagnosis to Excision: 30///description.8: Prior Therapy: Chemotherapy///description.9: Clinical T: 3b///description.10: Clinical N: 0///description.11: Clinical M: 0///description.12: Clinical Stage: 3B///description.13: Clinical Grade: 3///description.14: Primary Site: Ovary///description.15: Histology: Carcinoma, NOS///description.16: ///description.17: ///description.18: ///description.19: ///description.20: ///description.21: ///description.22: ///description.23: ///description.24: ///description.25: ///description.26: ///description.27: ///description.28: ///description.29: ///description.30: NA///description.31: NA///platform_id: GPL570///contact_name: Michael,,Bittner///contact_email: [email protected]///contact_phone: 602-343-8808///contact_fax: 602-343-8440///contact_laboratory: expO///contact_department: NA///contact_institute: IGC///contact_address: 445 N. 5th Street///contact_city: Phoenix///contact_state: AZ///contact_zip.postal_code: 85004///contact_country: USA///contact_web_link: www.intgen.org///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM179nnn/GSM179798/GSM179798.CEL.gz///data_row_count: 54675
1
title: Ovary - 199400///geo_accession: GSM179799///status: Public on Apr 06 2007///submission_date: Apr 02 2007///last_update_date: Apr 06 2007///type: RNA///channel_count: 1///source_name_ch1: Ovary///organism_ch1: Homo sapiens///molecule_ch1: total RNA///taxid_ch1: 9606///description: Quality metric = 28S to 18S: 1.6///description.1: Patient Age: 60-70///description.2: Gender: Female///description.3: Ethnic Background: Caucasian///description.4: Tobacco Use : No///description.5: Alcohol Consumption?: No///description.6: Family History of Cancer?: Yes///description.7: Days from Patient Diagnosis to Excision: 13///description.8: Pathological T: 1c///description.9: Pathological N: 0///description.10: Pathological M: 0///description.11: Pathological Stage: 1C///description.12: Pathological Grade: 3///description.13: Pathological Multiple Tumors: No///description.14: Pathological Stage During or Following Multimodality Therapy: No///description.15: Primary Site: Ovary///description.16: Histology: Adenocarcinoma with mixed subtypes///description.17: ///description.18: ///description.19: ///description.20: ///description.21: ///description.22: ///description.23: ///description.24: ///description.25: ///description.26: ///description.27: ///description.28: ///description.29: NA///description.30: NA///description.31: NA///platform_id: GPL570///contact_name: Michael,,Bittner///contact_email: [email protected]///contact_phone: 602-343-8808///contact_fax: 602-343-8440///contact_laboratory: expO///contact_department: NA///contact_institute: IGC///contact_address: 445 N. 5th Street///contact_city: Phoenix///contact_state: AZ///contact_zip.postal_code: 85004///contact_country: USA///contact_web_link: www.intgen.org///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM179nnn/GSM179799/GSM179799.CEL.gz///data_row_count: 54675
1
title: Ovary - 202030///geo_accession: GSM152634///status: Public on Jan 03 2007///submission_date: Dec 22 2006///last_update_date: Jan 03 2007///type: RNA///channel_count: 1///source_name_ch1: Ovary///organism_ch1: Homo sapiens///molecule_ch1: total RNA///taxid_ch1: 9606///description: Quality metric = 28S to 18S: 1.4///description.1: Patient Age: 40-50///description.2: Gender: Female///description.3: Ethnic Background: Caucasian///description.4: Tobacco Use : Yes///description.5: Years of Tobacco Use: 21-25///description.6: Type of Tobacco Use: Cigarettes///description.7: Alcohol Consumption?: Yes///description.8: Family History of Cancer?: No///description.9: Days from Patient Diagnosis to Excision: 7///description.10: Presenting Symptoms: Abdominal pain///description.11: Presenting Symptoms: Bloating///description.12: Pathological T: 1c///description.13: Pathological N: 0///description.14: Pathological M: 0///description.15: Pathological Stage: 1C///description.16: Pathological Grade: 3///description.17: Pathological Multiple Tumors: No///description.18: Pathological Stage During or Following Multimodality Therapy: No///description.19: Primary Site: Ovary///description.20: Histology: Clear cell adenocarcinoma///description.21: ///description.22: ///description.23: ///description.24: ///description.25: ///description.26: ///description.27: ///description.28: ///description.29: ///description.30: NA///description.31: NA///platform_id: GPL570///contact_name: Michael,,Bittner///contact_email: [email protected]///contact_phone: 602-343-8808///contact_fax: 602-343-8440///contact_laboratory: expO///contact_department: NA///contact_institute: IGC///contact_address: 445 N. 5th Street///contact_city: Phoenix///contact_state: AZ///contact_zip.postal_code: 85004///contact_country: USA///contact_web_link: www.intgen.org///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM152nnn/GSM152634/GSM152634.CEL.gz///data_row_count: 54675
1
title: Ovary - 202041///geo_accession: GSM152639///status: Public on Jan 03 2007///submission_date: Dec 22 2006///last_update_date: Jan 03 2007///type: RNA///channel_count: 1///source_name_ch1: Ovary///organism_ch1: Homo sapiens///molecule_ch1: total RNA///taxid_ch1: 9606///description: Quality metric = 28S to 18S: 1.9///description.1: Patient Age: 60-70///description.2: Gender: Female///description.3: Ethnic Background: Caucasian///description.4: Tobacco Use : Yes///description.5: Years of Tobacco Use: 0-5///description.6: Type of Tobacco Use: Cigarettes///description.7: Alcohol Consumption?: No///description.8: Family History of Cancer?: No///description.9: Days from Patient Diagnosis to Excision: 28///description.10: Clinical Stage: 2///description.11: Clinical Symptoms: A///description.12: Primary Site: Small intestine///description.13: Histology: Diffuse large B-cell lymphoma///description.14: ///description.15: ///description.16: ///description.17: ///description.18: ///description.19: ///description.20: ///description.21: ///description.22: ///description.23: ///description.24: ///description.25: ///description.26: ///description.27: ///description.28: ///description.29: ///description.30: NA///description.31: NA///platform_id: GPL570///contact_name: Michael,,Bittner///contact_email: [email protected]///contact_phone: 602-343-8808///contact_fax: 602-343-8440///contact_laboratory: expO///contact_department: NA///contact_institute: IGC///contact_address: 445 N. 5th Street///contact_city: Phoenix///contact_state: AZ///contact_zip.postal_code: 85004///contact_country: USA///contact_web_link: www.intgen.org///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM152nnn/GSM152639/GSM152639.CEL.gz///data_row_count: 54675
1
title: Ovary - 20284///geo_accession: GSM76489///status: Public on Sep 30 2005///submission_date: Sep 30 2005///last_update_date: Sep 30 2005///type: RNA///channel_count: 1///source_name_ch1: Ovary///organism_ch1: Homo sapiens///molecule_ch1: total RNA///taxid_ch1: 9606///description: Quality metric = 28S to 18S: 1.4///description.1: Patient Age: 70-80///description.2: Gender: Female///description.3: Ethnic Background: Caucasian///description.4: Tobacco Use : No///description.5: Alcohol Consumption?: Yes///description.6: Family History of Cancer?: Yes///description.7: Days from Patient Diagnosis to Excision: 30///description.8: Primary Site: Ovary///description.9: Histology: Serous Adenocarinoma///description.10: ///description.11: ///description.12: ///description.13: ///description.14: ///description.15: ///description.16: ///description.17: ///description.18: ///description.19: ///description.20: ///description.21: ///description.22: ///description.23: ///description.24: ///description.25: ///description.26: ///description.27: ///description.28: ///description.29: NA///description.30: NA///description.31: NA///platform_id: GPL570///contact_name: Michael,,Bittner///contact_email: [email protected]///contact_phone: 602-343-8808///contact_fax: 602-343-8440///contact_laboratory: expO///contact_department: NA///contact_institute: IGC///contact_address: 445 N. 5th Street///contact_city: Phoenix///contact_state: AZ///contact_zip.postal_code: 85004///contact_country: USA///contact_web_link: www.intgen.org///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM76nnn/GSM76489/GSM76489.CEL.gz///data_row_count: 54675
1
title: Ovary - 20285///geo_accession: GSM88984///status: Public on Dec 22 2005///submission_date: Dec 22 2005///last_update_date: Dec 22 2005///type: RNA///channel_count: 1///source_name_ch1: Ovary///organism_ch1: Homo sapiens///molecule_ch1: total RNA///taxid_ch1: 9606///description: Quality metric = 28S to 18S: 1.3///description.1: Patient Age: 50-60///description.2: Gender: Female///description.3: Ethnic Background: Caucasian///description.4: Tobacco Use : No///description.5: Alcohol Consumption?: Yes///description.6: Family History of Cancer?: Yes///description.7: Days from Patient Diagnosis to Excision: 47///description.8: Presenting Symptoms: Vaginal bleeding///description.9: Pathological Grade: 3///description.10: Pathological Multiple Tumors: No///description.11: Pathological Stage During or Following Multimodality Therapy: No///description.12: Primary Site: Ovary///description.13: Histology: Clear cell adenocarcinoma///description.14: ///description.15: ///description.16: ///description.17: ///description.18: ///description.19: ///description.20: ///description.21: ///description.22: ///description.23: ///description.24: ///description.25: ///description.26: ///description.27: ///description.28: ///description.29: NA///description.30: NA///description.31: NA///platform_id: GPL570///contact_name: Michael,,Bittner///contact_email: [email protected]///contact_phone: 602-343-8808///contact_fax: 602-343-8440///contact_laboratory: expO///contact_department: NA///contact_institute: IGC///contact_address: 445 N. 5th Street///contact_city: Phoenix///contact_state: AZ///contact_zip.postal_code: 85004///contact_country: USA///contact_web_link: www.intgen.org///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM88nnn/GSM88984/GSM88984.CEL.gz///data_row_count: 54675
1
title: Ovary - 20296///geo_accession: GSM53077///status: Public on Jul 01 2005///submission_date: Jun 30 2005///last_update_date: Jun 30 2005///type: RNA///channel_count: 1///source_name_ch1: Ovary///organism_ch1: Homo sapiens///molecule_ch1: total RNA///taxid_ch1: 9606///description: Quality metric = 28S to 18S: 1.4///description.1: Patient Age: 60-70///description.2: Gender: Female///description.3: Ethnic Background: Caucasian///description.4: Tobacco Use : No///description.5: Alcohol Consumption?: No///description.6: Family History of Cancer?: Yes///description.7: Days from Patient Diagnosis to Excision: 1///description.8: Presenting Symptoms: Abdominal mass///description.9: Presenting Symptoms: Abdominal pain///description.10: Presenting Symptoms: Bloating///description.11: Primary Site: Ovary///description.12: Histology: Endometrioid Carcinoma///description.13: ///description.14: ///description.15: ///description.16: ///description.17: ///description.18: ///description.19: ///description.20: ///description.21: ///description.22: ///description.23: ///description.24: ///description.25: ///description.26: ///description.27: ///description.28: ///description.29: NA///description.30: NA///description.31: NA///platform_id: GPL570///contact_name: Michael,,Bittner///contact_email: [email protected]///contact_phone: 602-343-8808///contact_fax: 602-343-8440///contact_laboratory: expO///contact_department: NA///contact_institute: IGC///contact_address: 445 N. 5th Street///contact_city: Phoenix///contact_state: AZ///contact_zip.postal_code: 85004///contact_country: USA///contact_web_link: www.intgen.org///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM53nnn/GSM53077/GSM53077.CEL.gz///data_row_count: 54675
1
title: Ovary - 20307///geo_accession: GSM76500///status: Public on Sep 30 2005///submission_date: Sep 30 2005///last_update_date: Sep 30 2005///type: RNA///channel_count: 1///source_name_ch1: Ovary///organism_ch1: Homo sapiens///molecule_ch1: total RNA///taxid_ch1: 9606///description: Quality metric = 28S to 18S: 1.1///description.1: Patient Age: 60-70///description.2: Gender: Female///description.3: Ethnic Background: Caucasian///description.4: Tobacco Use : No///description.5: Alcohol Consumption?: No///description.6: Family History of Cancer?: No///description.7: Days from Patient Diagnosis to Excision: 75///description.8: Prior Therapy: Chemotherapy///description.9: Presenting Symptoms: Abdominal pain///description.10: Pathological T: 3c///description.11: Pathological N: 0///description.12: Pathological M: 1///description.13: Pathological Metastatic Sites: Pleura///description.14: Pathological Stage: 4///description.15: Pathological Grade: 3///description.16: Pathological Stage During or Following Multimodality Therapy: Yes///description.17: Primary Site: Ovary///description.18: Histology: Adenocarcinoma///description.19: ///description.20: ///description.21: ///description.22: ///description.23: ///description.24: ///description.25: ///description.26: ///description.27: ///description.28: ///description.29: NA///description.30: NA///description.31: NA///platform_id: GPL570///contact_name: Michael,,Bittner///contact_email: [email protected]///contact_phone: 602-343-8808///contact_fax: 602-343-8440///contact_laboratory: expO///contact_department: NA///contact_institute: IGC///contact_address: 445 N. 5th Street///contact_city: Phoenix///contact_state: AZ///contact_zip.postal_code: 85004///contact_country: USA///contact_web_link: www.intgen.org///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM76nnn/GSM76500/GSM76500.CEL.gz///data_row_count: 54675
1
title: Ovary - 20315///geo_accession: GSM76504///status: Public on Sep 30 2005///submission_date: Sep 30 2005///last_update_date: Sep 30 2005///type: RNA///channel_count: 1///source_name_ch1: Ovary///organism_ch1: Homo sapiens///molecule_ch1: total RNA///taxid_ch1: 9606///description: Quality metric = 28S to 18S: 1.2///description.1: Patient Age: 70-80///description.2: Gender: Female///description.3: Ethnic Background: Caucasian///description.4: Tobacco Use : No///description.5: Alcohol Consumption?: Yes///description.6: Family History of Cancer?: Yes///description.7: Days from Patient Diagnosis to Excision: 45///description.8: Presenting Symptoms: Bloating///description.9: Pathological T: 3c///description.10: Pathological N: 0///description.11: Pathological M: 0///description.12: Pathological Stage: 3C///description.13: Pathological Grade: 3///description.14: Pathological Multiple Tumors: No///description.15: Pathological Stage During or Following Multimodality Therapy: No///description.16: Primary Site: Ovary///description.17: Histology: Adenocarcinoma, endometrioid and papillary serous///description.18: ///description.19: ///description.20: ///description.21: ///description.22: ///description.23: ///description.24: ///description.25: ///description.26: ///description.27: ///description.28: ///description.29: NA///description.30: NA///description.31: NA///platform_id: GPL570///contact_name: Michael,,Bittner///contact_email: [email protected]///contact_phone: 602-343-8808///contact_fax: 602-343-8440///contact_laboratory: expO///contact_department: NA///contact_institute: IGC///contact_address: 445 N. 5th Street///contact_city: Phoenix///contact_state: AZ///contact_zip.postal_code: 85004///contact_country: USA///contact_web_link: www.intgen.org///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM76nnn/GSM76504/GSM76504.CEL.gz///data_row_count: 54675
1
title: Ovary - 20323///geo_accession: GSM76509///status: Public on Sep 30 2005///submission_date: Sep 30 2005///last_update_date: Sep 30 2005///type: RNA///channel_count: 1///source_name_ch1: Ovary///organism_ch1: Homo sapiens///molecule_ch1: total RNA///taxid_ch1: 9606///description: Quality metric = 28S to 18S: 1.2///description.1: Patient Age: 70-80///description.2: Gender: Female///description.3: Ethnic Background: Caucasian///description.4: Tobacco Use : No///description.5: Alcohol Consumption?: No///description.6: Family History of Cancer?: Yes///description.7: Prior Therapy: Chemotherapy///description.8: Prior Therapy: Surgical///description.9: Relapse Since Primary Treatment: Yes///description.10: Number of Years Until Relapse: 0-5///description.11: Retreatment T: X///description.12: Retreatment N: 2///description.13: Retreatment M: 1///description.14: Retreatment Metastatic Sites: Other///description.15: Retreatment Stage: 4///description.16: Retreatment Grade: 2///description.17: Primary Site: Colon///description.18: Histology: Metastatic Adenocarcinoma///description.19: ///description.20: ///description.21: ///description.22: ///description.23: ///description.24: ///description.25: ///description.26: ///description.27: ///description.28: ///description.29: NA///description.30: NA///description.31: NA///platform_id: GPL570///contact_name: Michael,,Bittner///contact_email: [email protected]///contact_phone: 602-343-8808///contact_fax: 602-343-8440///contact_laboratory: expO///contact_department: NA///contact_institute: IGC///contact_address: 445 N. 5th Street///contact_city: Phoenix///contact_state: AZ///contact_zip.postal_code: 85004///contact_country: USA///contact_web_link: www.intgen.org///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM76nnn/GSM76509/GSM76509.CEL.gz///data_row_count: 54675
1
title: Ovary - 20325///geo_accession: GSM76510///status: Public on Sep 30 2005///submission_date: Sep 30 2005///last_update_date: Sep 30 2005///type: RNA///channel_count: 1///source_name_ch1: Ovary///organism_ch1: Homo sapiens///molecule_ch1: total RNA///taxid_ch1: 9606///description: Quality metric = 28S to 18S: 1.1///description.1: Patient Age: 50-60///description.2: Gender: Female///description.3: Ethnic Background: Caucasian///description.4: Tobacco Use : No///description.5: Alcohol Consumption?: No///description.6: Family History of Cancer?: Yes///description.7: Days from Patient Diagnosis to Excision: 17///description.8: Presenting Symptoms: Abdominal mass///description.9: Pathological T: 3c///description.10: Pathological N: X///description.11: Pathological M: 1///description.12: Pathological Metastatic Sites: Pleura///description.13: Pathological Stage: 4///description.14: Pathological Grade: 3///description.15: Pathological Multiple Tumors: No///description.16: Pathological Stage During or Following Multimodality Therapy: No///description.17: Primary Site: Ovary///description.18: Histology: Serous Adenocarinoma///description.19: ///description.20: ///description.21: ///description.22: ///description.23: ///description.24: ///description.25: ///description.26: ///description.27: ///description.28: ///description.29: ///description.30: NA///description.31: NA///platform_id: GPL570///contact_name: Michael,,Bittner///contact_email: [email protected]///contact_phone: 602-343-8808///contact_fax: 602-343-8440///contact_laboratory: expO///contact_department: NA///contact_institute: IGC///contact_address: 445 N. 5th Street///contact_city: Phoenix///contact_state: AZ///contact_zip.postal_code: 85004///contact_country: USA///contact_web_link: www.intgen.org///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM76nnn/GSM76510/GSM76510.CEL.gz///data_row_count: 54675
1
title: Ovary - 20326///geo_accession: GSM76511///status: Public on Sep 30 2005///submission_date: Sep 30 2005///last_update_date: Sep 30 2005///type: RNA///channel_count: 1///source_name_ch1: Ovary///organism_ch1: Homo sapiens///molecule_ch1: total RNA///taxid_ch1: 9606///description: Quality metric = 28S to 18S: 1.5///description.1: Patient Age: 40-50///description.2: Gender: Female///description.3: Ethnic Background: Caucasian///description.4: Tobacco Use : Yes///description.5: Years of Tobacco Use: 6-10///description.6: Type of Tobacco Use: Cigarettes///description.7: Alcohol Consumption?: No///description.8: Family History of Cancer?: No///description.9: Days from Patient Diagnosis to Excision: 1///description.10: Primary Site: Ovary///description.11: Histology: Papillary Serous Carcinoma///description.12: ///description.13: ///description.14: ///description.15: ///description.16: ///description.17: ///description.18: ///description.19: ///description.20: ///description.21: ///description.22: ///description.23: ///description.24: ///description.25: ///description.26: ///description.27: ///description.28: ///description.29: NA///description.30: NA///description.31: NA///platform_id: GPL570///contact_name: Michael,,Bittner///contact_email: [email protected]///contact_phone: 602-343-8808///contact_fax: 602-343-8440///contact_laboratory: expO///contact_department: NA///contact_institute: IGC///contact_address: 445 N. 5th Street///contact_city: Phoenix///contact_state: AZ///contact_zip.postal_code: 85004///contact_country: USA///contact_web_link: www.intgen.org///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM76nnn/GSM76511/GSM76511.CEL.gz///data_row_count: 54675
1
title: Ovary - 20329///geo_accession: GSM102546///status: Public on Mar 30 2006///submission_date: Mar 30 2006///last_update_date: Mar 30 2006///type: RNA///channel_count: 1///source_name_ch1: Ovary///organism_ch1: Homo sapiens///molecule_ch1: total RNA///taxid_ch1: 9606///description: Quality metric = 28S to 18S: 1.1///description.1: Patient Age: 60-70///description.2: Gender: Female///description.3: Ethnic Background: Caucasian///description.4: Tobacco Use : Yes///description.5: Years of Tobacco Use: 36-40///description.6: Type of Tobacco Use: Cigarettes///description.7: Alcohol Consumption?: No///description.8: Family History of Cancer?: Yes///description.9: Days from Patient Diagnosis to Excision: 7///description.10: Presenting Symptoms: Abdominal mass///description.11: Presenting Symptoms: Abdominal pain///description.12: Presenting Symptoms: Bloating///description.13: Pathological T: 3c///description.14: Pathological N: 1///description.15: Pathological M: 0///description.16: Pathological Stage: 3C///description.17: Pathological Grade: 3///description.18: Pathological Multiple Tumors: No///description.19: Pathological Stage During or Following Multimodality Therapy: No///description.20: Primary Site: Ovary///description.21: Histology: Serous Adenocarinoma///description.22: ///description.23: ///description.24: ///description.25: ///description.26: ///description.27: ///description.28: ///description.29: ///description.30: NA///description.31: NA///platform_id: GPL570///contact_name: Michael,,Bittner///contact_email: [email protected]///contact_phone: 602-343-8808///contact_fax: 602-343-8440///contact_laboratory: expO///contact_department: NA///contact_institute: IGC///contact_address: 445 N. 5th Street///contact_city: Phoenix///contact_state: AZ///contact_zip.postal_code: 85004///contact_country: USA///contact_web_link: www.intgen.org///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM102nnn/GSM102546/GSM102546.CEL.gz///data_row_count: 54675
1
title: Ovary - 207532///geo_accession: GSM152646///status: Public on Jan 03 2007///submission_date: Dec 22 2006///last_update_date: Jan 03 2007///type: RNA///channel_count: 1///source_name_ch1: Ovary///organism_ch1: Homo sapiens///molecule_ch1: total RNA///taxid_ch1: 9606///description: Quality metric = 28S to 18S: 1.2///description.1: Patient Age: 60-70///description.2: Gender: Female///description.3: Ethnic Background: Caucasian///description.4: Tobacco Use : Yes///description.5: Years of Tobacco Use: 11-15///description.6: Type of Tobacco Use: Cigarettes///description.7: Alcohol Consumption?: No///description.8: Family History of Cancer?: Yes///description.9: Days from Patient Diagnosis to Excision: 21///description.10: Presenting Symptoms: Abdominal mass///description.11: Pathological T: 2c///description.12: Pathological N: 0///description.13: Pathological M: 0///description.14: Pathological Stage: 2C///description.15: Pathological Grade: 3///description.16: Pathological Multiple Tumors: No///description.17: Pathological Stage During or Following Multimodality Therapy: No///description.18: Primary Site: Ovary///description.19: Histology: Papillary Serous Adenocarcinoma///description.20: ///description.21: ///description.22: ///description.23: ///description.24: ///description.25: ///description.26: ///description.27: ///description.28: ///description.29: NA///description.30: NA///description.31: NA///platform_id: GPL570///contact_name: Michael,,Bittner///contact_email: [email protected]///contact_phone: 602-343-8808///contact_fax: 602-343-8440///contact_laboratory: expO///contact_department: NA///contact_institute: IGC///contact_address: 445 N. 5th Street///contact_city: Phoenix///contact_state: AZ///contact_zip.postal_code: 85004///contact_country: USA///contact_web_link: www.intgen.org///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM152nnn/GSM152646/GSM152646.CEL.gz///data_row_count: 54675
1
title: Ovary - 209699///geo_accession: GSM152653///status: Public on Jan 03 2007///submission_date: Dec 22 2006///last_update_date: Jan 03 2007///type: RNA///channel_count: 1///source_name_ch1: Ovary///organism_ch1: Homo sapiens///molecule_ch1: total RNA///taxid_ch1: 9606///description: Quality metric = 28S to 18S: 1.2///description.1: Patient Age: 50-60///description.2: Gender: Female///description.3: Ethnic Background: Caucasian///description.4: Tobacco Use : Yes///description.5: Years of Tobacco Use: 21-25///description.6: Type of Tobacco Use: Cigarettes///description.7: Alcohol Consumption?: Yes///description.8: Family History of Cancer?: No///description.9: Days from Patient Diagnosis to Excision: 21///description.10: Presenting Symptoms: Abdominal pain///description.11: Presenting Symptoms: Bloating///description.12: Pathological T: 2b///description.13: Pathological N: 0///description.14: Pathological M: 0///description.15: Pathological Stage: 2B///description.16: Pathological Grade: 2///description.17: Pathological Multiple Tumors: No///description.18: Pathological Stage During or Following Multimodality Therapy: No///description.19: Primary Site: Ovary///description.20: Histology: Papillary serous cystadenocarcinoma///description.21: ///description.22: ///description.23: ///description.24: ///description.25: ///description.26: ///description.27: ///description.28: ///description.29: NA///description.30: NA///description.31: NA///platform_id: GPL570///contact_name: Michael,,Bittner///contact_email: [email protected]///contact_phone: 602-343-8808///contact_fax: 602-343-8440///contact_laboratory: expO///contact_department: NA///contact_institute: IGC///contact_address: 445 N. 5th Street///contact_city: Phoenix///contact_state: AZ///contact_zip.postal_code: 85004///contact_country: USA///contact_web_link: www.intgen.org///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM152nnn/GSM152653/GSM152653.CEL.gz///data_row_count: 54675
1
title: Ovary - 209709///geo_accession: GSM152654///status: Public on Jan 03 2007///submission_date: Dec 22 2006///last_update_date: Jan 03 2007///type: RNA///channel_count: 1///source_name_ch1: Ovary///organism_ch1: Homo sapiens///molecule_ch1: total RNA///taxid_ch1: 9606///description: Quality metric = 28S to 18S: 1.6///description.1: Patient Age: 80-90///description.2: Gender: Female///description.3: Ethnic Background: Caucasian///description.4: Tobacco Use : Yes///description.5: Years of Tobacco Use: 0-5///description.6: Type of Tobacco Use: Cigarettes///description.7: Alcohol Consumption?: No///description.8: Family History of Cancer?: Yes///description.9: Days from Patient Diagnosis to Excision: 26///description.10: Presenting Symptoms: Abdominal pain///description.11: Presenting Symptoms: Bloating///description.12: Pathological T: 3c///description.13: Pathological N: 1///description.14: Pathological M: 0///description.15: Pathological Stage: 3C///description.16: Pathological Grade: 3///description.17: Pathological Multiple Tumors: No///description.18: Pathological Stage During or Following Multimodality Therapy: No///description.19: Primary Site: Ovary///description.20: Histology: Papillary Serous Adenocarcinoma///description.21: ///description.22: ///description.23: ///description.24: ///description.25: ///description.26: ///description.27: ///description.28: ///description.29: NA///description.30: NA///description.31: NA///platform_id: GPL570///contact_name: Michael,,Bittner///contact_email: [email protected]///contact_phone: 602-343-8808///contact_fax: 602-343-8440///contact_laboratory: expO///contact_department: NA///contact_institute: IGC///contact_address: 445 N. 5th Street///contact_city: Phoenix///contact_state: AZ///contact_zip.postal_code: 85004///contact_country: USA///contact_web_link: www.intgen.org///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM152nnn/GSM152654/GSM152654.CEL.gz///data_row_count: 54675
1
title: Ovary - 209714///geo_accession: GSM152657///status: Public on Jan 03 2007///submission_date: Dec 22 2006///last_update_date: Jan 03 2007///type: RNA///channel_count: 1///source_name_ch1: Ovary///organism_ch1: Homo sapiens///molecule_ch1: total RNA///taxid_ch1: 9606///description: Quality metric = 28S to 18S: 1.8///description.1: Patient Age: 50-60///description.2: Gender: Female///description.3: Ethnic Background: Caucasian///description.4: Tobacco Use : No///description.5: Alcohol Consumption?: No///description.6: Family History of Cancer?: Yes///description.7: Days from Patient Diagnosis to Excision: 30///description.8: Presenting Symptoms: Abdominal pain///description.9: Presenting Symptoms: Bloating///description.10: Clinical T: 1b///description.11: Clinical N: 0///description.12: Clinical M: 0///description.13: Clinical Stage: 1B///description.14: Primary Site: Ovary///description.15: Histology: Benign serous cystadenoma of borderline malignancy///description.16: ///description.17: ///description.18: ///description.19: ///description.20: ///description.21: ///description.22: ///description.23: ///description.24: ///description.25: ///description.26: ///description.27: ///description.28: ///description.29: NA///description.30: NA///description.31: NA///platform_id: GPL570///contact_name: Michael,,Bittner///contact_email: [email protected]///contact_phone: 602-343-8808///contact_fax: 602-343-8440///contact_laboratory: expO///contact_department: NA///contact_institute: IGC///contact_address: 445 N. 5th Street///contact_city: Phoenix///contact_state: AZ///contact_zip.postal_code: 85004///contact_country: USA///contact_web_link: www.intgen.org///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM152nnn/GSM152657/GSM152657.CEL.gz///data_row_count: 54675
1
title: Ovary - 209718///geo_accession: GSM152659///status: Public on Jan 03 2007///submission_date: Dec 22 2006///last_update_date: Jan 03 2007///type: RNA///channel_count: 1///source_name_ch1: Ovary///organism_ch1: Homo sapiens///molecule_ch1: total RNA///taxid_ch1: 9606///description: Quality metric = 28S to 18S: 1.0///description.1: Patient Age: 40-50///description.2: Gender: Female///description.3: Ethnic Background: Caucasian///description.4: Tobacco Use : Yes///description.5: Years of Tobacco Use: 21-25///description.6: Type of Tobacco Use: Cigarettes///description.7: Alcohol Consumption?: No///description.8: Family History of Cancer?: Yes///description.9: Days from Patient Diagnosis to Excision: 26///description.10: Presenting Symptoms: Abdominal pain///description.11: Presenting Symptoms: Vaginal bleeding///description.12: Pathological T: 3b///description.13: Pathological N: 0///description.14: Pathological M: 0///description.15: Pathological Stage: 3B///description.16: Pathological Grade: 3///description.17: Pathological Multiple Tumors: Yes///description.18: Pathological Stage During or Following Multimodality Therapy: No///description.19: Primary Site: Ovary///description.20: Histology: Papillary Serous Adenocarcinoma///description.21: ///description.22: ///description.23: ///description.24: ///description.25: ///description.26: ///description.27: ///description.28: ///description.29: ///description.30: NA///description.31: NA///platform_id: GPL570///contact_name: Michael,,Bittner///contact_email: [email protected]///contact_phone: 602-343-8808///contact_fax: 602-343-8440///contact_laboratory: expO///contact_department: NA///contact_institute: IGC///contact_address: 445 N. 5th Street///contact_city: Phoenix///contact_state: AZ///contact_zip.postal_code: 85004///contact_country: USA///contact_web_link: www.intgen.org///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM152nnn/GSM152659/GSM152659.CEL.gz///data_row_count: 54675
1
title: Ovary - 211371///geo_accession: GSM179807///status: Public on Apr 06 2007///submission_date: Apr 02 2007///last_update_date: Apr 06 2007///type: RNA///channel_count: 1///source_name_ch1: Ovary///organism_ch1: Homo sapiens///molecule_ch1: total RNA///taxid_ch1: 9606///description: Quality metric = 28S to 18S: 1.5///description.1: Patient Age: 50-60///description.2: Gender: Female///description.3: Ethnic Background: Caucasian///description.4: Tobacco Use : Yes///description.5: Years of Tobacco Use: 26-30///description.6: Type of Tobacco Use: Cigarettes///description.7: Alcohol Consumption?: Yes///description.8: Family History of Cancer?: No///description.9: Presenting Symptoms: Abdominal mass///description.10: Presenting Symptoms: Bloating///description.11: Pathological T: 1b///description.12: Pathological N: 0///description.13: Pathological M: 0///description.14: Pathological Stage: 1B///description.15: Pathological Grade: 3///description.16: Primary Site: Ovary///description.17: Histology: Papillary Serous Carcinoma///description.18: ///description.19: ///description.20: ///description.21: ///description.22: ///description.23: ///description.24: ///description.25: ///description.26: ///description.27: ///description.28: ///description.29: ///description.30: NA///description.31: NA///platform_id: GPL570///contact_name: Michael,,Bittner///contact_email: [email protected]///contact_phone: 602-343-8808///contact_fax: 602-343-8440///contact_laboratory: expO///contact_department: NA///contact_institute: IGC///contact_address: 445 N. 5th Street///contact_city: Phoenix///contact_state: AZ///contact_zip.postal_code: 85004///contact_country: USA///contact_web_link: www.intgen.org///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM179nnn/GSM179807/GSM179807.CEL.gz///data_row_count: 54675
1
title: Ovary - 211372///geo_accession: GSM179808///status: Public on Apr 06 2007///submission_date: Apr 02 2007///last_update_date: Apr 06 2007///type: RNA///channel_count: 1///source_name_ch1: Ovary///organism_ch1: Homo sapiens///molecule_ch1: total RNA///taxid_ch1: 9606///description: Quality metric = 28S to 18S: 1.5///description.1: Patient Age: 60-70///description.2: Gender: Female///description.3: Ethnic Background: Caucasian///description.4: Tobacco Use : No///description.5: Alcohol Consumption?: Yes///description.6: Family History of Cancer?: Yes///description.7: Days from Patient Diagnosis to Excision: 21///description.8: Presenting Symptoms: Abdominal mass///description.9: Presenting Symptoms: Abdominal pain///description.10: Presenting Symptoms: Bloating///description.11: Pathological T: 3c///description.12: Pathological N: 1///description.13: Pathological M: X///description.14: Pathological Stage: 3C///description.15: Pathological Grade: 2///description.16: Pathological Stage During or Following Multimodality Therapy: No///description.17: Primary Site: Ovary///description.18: Histology: Adenocarcinoma, endometrioid and papillary serous///description.19: ///description.20: ///description.21: ///description.22: ///description.23: ///description.24: ///description.25: ///description.26: ///description.27: ///description.28: ///description.29: ///description.30: ///description.31: ///platform_id: GPL570///contact_name: Michael,,Bittner///contact_email: [email protected]///contact_phone: 602-343-8808///contact_fax: 602-343-8440///contact_laboratory: expO///contact_department: NA///contact_institute: IGC///contact_address: 445 N. 5th Street///contact_city: Phoenix///contact_state: AZ///contact_zip.postal_code: 85004///contact_country: USA///contact_web_link: www.intgen.org///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM179nnn/GSM179808/GSM179808.CEL.gz///data_row_count: 54675
1
title: Ovary - 211395///geo_accession: GSM152662///status: Public on Jan 03 2007///submission_date: Dec 22 2006///last_update_date: Jan 03 2007///type: RNA///channel_count: 1///source_name_ch1: Ovary///organism_ch1: Homo sapiens///molecule_ch1: total RNA///taxid_ch1: 9606///description: Quality metric = 28S to 18S: 1.3///description.1: Patient Age: 40-50///description.2: Gender: Female///description.3: Ethnic Background: Caucasian///description.4: Tobacco Use : Yes///description.5: Years of Tobacco Use: 16-20///description.6: Type of Tobacco Use: Cigarettes///description.7: Alcohol Consumption?: No///description.8: Family History of Cancer?: No///description.9: Days from Patient Diagnosis to Excision: 14///description.10: Presenting Symptoms: Abdominal pain///description.11: Presenting Symptoms: Bloating///description.12: Clinical T: 2a///description.13: Clinical N: 1///description.14: Clinical M: 0///description.15: Clinical Stage: 3C///description.16: Clinical Grade: 3///description.17: Clinical Multiple Tumors: Yes///description.18: Clinical Stage During or Following Multimodality Therapy: No///description.19: Primary Site: Ovary///description.20: Histology: Serous Adenocarinoma///description.21: ///description.22: ///description.23: ///description.24: ///description.25: ///description.26: ///description.27: ///description.28: ///description.29: ///description.30: NA///description.31: NA///platform_id: GPL570///contact_name: Michael,,Bittner///contact_email: [email protected]///contact_phone: 602-343-8808///contact_fax: 602-343-8440///contact_laboratory: expO///contact_department: NA///contact_institute: IGC///contact_address: 445 N. 5th Street///contact_city: Phoenix///contact_state: AZ///contact_zip.postal_code: 85004///contact_country: USA///contact_web_link: www.intgen.org///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM152nnn/GSM152662/GSM152662.CEL.gz///data_row_count: 54675
1
title: Ovary - 211409///geo_accession: GSM152668///status: Public on Jan 03 2007///submission_date: Dec 22 2006///last_update_date: Jan 03 2007///type: RNA///channel_count: 1///source_name_ch1: Ovary///organism_ch1: Homo sapiens///molecule_ch1: total RNA///taxid_ch1: 9606///description: Quality metric = 28S to 18S: 1.5///description.1: Patient Age: 50-60///description.2: Gender: Female///description.3: Ethnic Background: Caucasian///description.4: Tobacco Use : No///description.5: Alcohol Consumption?: Yes///description.6: Family History of Cancer?: Yes///description.7: Days from Patient Diagnosis to Excision: 21///description.8: Presenting Symptoms: Abdominal pain///description.9: Presenting Symptoms: Bloating///description.10: Pathological T: 3b///description.11: Pathological N: 0///description.12: Pathological M: X///description.13: Pathological Stage: 3B///description.14: Pathological Grade: 3///description.15: Pathological Multiple Tumors: No///description.16: Pathological Stage During or Following Multimodality Therapy: No///description.17: Primary Site: Ovary///description.18: Histology: Transitional cell carcinoma///description.19: ///description.20: ///description.21: ///description.22: ///description.23: ///description.24: ///description.25: ///description.26: ///description.27: ///description.28: ///description.29: ///description.30: NA///description.31: NA///platform_id: GPL570///contact_name: Michael,,Bittner///contact_email: [email protected]///contact_phone: 602-343-8808///contact_fax: 602-343-8440///contact_laboratory: expO///contact_department: NA///contact_institute: IGC///contact_address: 445 N. 5th Street///contact_city: Phoenix///contact_state: AZ///contact_zip.postal_code: 85004///contact_country: USA///contact_web_link: www.intgen.org///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM152nnn/GSM152668/GSM152668.CEL.gz///data_row_count: 54675
1
title: Ovary - 21758///geo_accession: GSM76533///status: Public on Sep 30 2005///submission_date: Sep 30 2005///last_update_date: Sep 30 2005///type: RNA///channel_count: 1///source_name_ch1: Ovary///organism_ch1: Homo sapiens///molecule_ch1: total RNA///taxid_ch1: 9606///description: Quality metric = 28S to 18S: 1.3///description.1: Patient Age: 70-80///description.2: Gender: Female///description.3: Ethnic Background: Caucasian///description.4: Tobacco Use : No///description.5: Alcohol Consumption?: No///description.6: Family History of Cancer?: Yes///description.7: Days from Patient Diagnosis to Excision: 30///description.8: Presenting Symptoms: Bloating///description.9: Primary Site: Ovary///description.10: Histology: Mucinous Adenocarinoma///description.11: ///description.12: ///description.13: ///description.14: ///description.15: ///description.16: ///description.17: ///description.18: ///description.19: ///description.20: ///description.21: ///description.22: ///description.23: ///description.24: ///description.25: ///description.26: ///description.27: ///description.28: ///description.29: NA///description.30: NA///description.31: NA///platform_id: GPL570///contact_name: Michael,,Bittner///contact_email: [email protected]///contact_phone: 602-343-8808///contact_fax: 602-343-8440///contact_laboratory: expO///contact_department: NA///contact_institute: IGC///contact_address: 445 N. 5th Street///contact_city: Phoenix///contact_state: AZ///contact_zip.postal_code: 85004///contact_country: USA///contact_web_link: www.intgen.org///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM76nnn/GSM76533/GSM76533.CEL.gz///data_row_count: 54675
1
title: Ovary - 219571///geo_accession: GSM152672///status: Public on Jan 03 2007///submission_date: Dec 22 2006///last_update_date: Jan 03 2007///type: RNA///channel_count: 1///source_name_ch1: Ovary///organism_ch1: Homo sapiens///molecule_ch1: total RNA///taxid_ch1: 9606///description: Quality metric = 28S to 18S: 1.9///description.1: Patient Age: 30-40///description.2: Gender: Female///description.3: Ethnic Background: Caucasian///description.4: Tobacco Use : No///description.5: Alcohol Consumption?: No///description.6: Family History of Cancer?: No///description.7: Presenting Symptoms: Abdominal pain///description.8: Presenting Symptoms: Bloating///description.9: Pathological T: 1c///description.10: Pathological N: 0///description.11: Pathological M: 0///description.12: Pathological Stage: 1C///description.13: Pathological Grade: 3///description.14: Pathological Multiple Tumors: No///description.15: Pathological Stage During or Following Multimodality Therapy: No///description.16: Primary Site: Ovary///description.17: Histology: Malignant teratoma///description.18: ///description.19: ///description.20: ///description.21: ///description.22: ///description.23: ///description.24: ///description.25: ///description.26: ///description.27: ///description.28: ///description.29: NA///description.30: NA///description.31: NA///platform_id: GPL570///contact_name: Michael,,Bittner///contact_email: [email protected]///contact_phone: 602-343-8808///contact_fax: 602-343-8440///contact_laboratory: expO///contact_department: NA///contact_institute: IGC///contact_address: 445 N. 5th Street///contact_city: Phoenix///contact_state: AZ///contact_zip.postal_code: 85004///contact_country: USA///contact_web_link: www.intgen.org///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM152nnn/GSM152672/GSM152672.CEL.gz///data_row_count: 54675
1
title: Ovary - 219581///geo_accession: GSM152676///status: Public on Jan 03 2007///submission_date: Dec 22 2006///last_update_date: Jan 03 2007///type: RNA///channel_count: 1///source_name_ch1: Ovary///organism_ch1: Homo sapiens///molecule_ch1: total RNA///taxid_ch1: 9606///description: Quality metric = 28S to 18S: 1.4///description.1: Patient Age: 50-60///description.2: Gender: Female///description.3: Ethnic Background: Caucasian///description.4: Tobacco Use : Yes///description.5: Years of Tobacco Use: 21-25///description.6: Type of Tobacco Use: Cigarettes///description.7: Alcohol Consumption?: Yes///description.8: Family History of Cancer?: Yes///description.9: Days from Patient Diagnosis to Excision: 30///description.10: Presenting Symptoms: Abdominal pain///description.11: Presenting Symptoms: Bloating///description.12: Pathological T: 3b///description.13: Pathological N: 1///description.14: Pathological M: 0///description.15: Pathological Stage: 3C///description.16: Pathological Grade: 3///description.17: Pathological Multiple Tumors: No///description.18: Pathological Stage During or Following Multimodality Therapy: No///description.19: Primary Site: Ovary///description.20: Histology: Adenocarcinoma with mixed subtypes///description.21: ///description.22: ///description.23: ///description.24: ///description.25: ///description.26: ///description.27: ///description.28: ///description.29: NA///description.30: NA///description.31: NA///platform_id: GPL570///contact_name: Michael,,Bittner///contact_email: [email protected]///contact_phone: 602-343-8808///contact_fax: 602-343-8440///contact_laboratory: expO///contact_department: NA///contact_institute: IGC///contact_address: 445 N. 5th Street///contact_city: Phoenix///contact_state: AZ///contact_zip.postal_code: 85004///contact_country: USA///contact_web_link: www.intgen.org///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM152nnn/GSM152676/GSM152676.CEL.gz///data_row_count: 54675
1
title: Ovary - 219590///geo_accession: GSM152679///status: Public on Jan 03 2007///submission_date: Dec 22 2006///last_update_date: Jan 03 2007///type: RNA///channel_count: 1///source_name_ch1: Ovary///organism_ch1: Homo sapiens///molecule_ch1: total RNA///taxid_ch1: 9606///description: Quality metric = 28S to 18S: 1.2///description.1: Patient Age: 40-50///description.2: Gender: Female///description.3: Ethnic Background: Caucasian///description.4: Tobacco Use : Yes///description.5: Years of Tobacco Use: 16-20///description.6: Type of Tobacco Use: Cigarettes///description.7: Alcohol Consumption?: Yes///description.8: Family History of Cancer?: Yes///description.9: Days from Patient Diagnosis to Excision: 21///description.10: Pathological T: 3c///description.11: Pathological N: 0///description.12: Pathological M: 0///description.13: Pathological Stage: 3C///description.14: Pathological Grade: 3///description.15: Pathological Multiple Tumors: No///description.16: Pathological Stage During or Following Multimodality Therapy: No///description.17: Primary Site: Ovary///description.18: Histology: Adenocarcinoma with mixed subtypes///description.19: ///description.20: ///description.21: ///description.22: ///description.23: ///description.24: ///description.25: ///description.26: ///description.27: ///description.28: ///description.29: ///description.30: NA///description.31: NA///platform_id: GPL570///contact_name: Michael,,Bittner///contact_email: [email protected]///contact_phone: 602-343-8808///contact_fax: 602-343-8440///contact_laboratory: expO///contact_department: NA///contact_institute: IGC///contact_address: 445 N. 5th Street///contact_city: Phoenix///contact_state: AZ///contact_zip.postal_code: 85004///contact_country: USA///contact_web_link: www.intgen.org///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM152nnn/GSM152679/GSM152679.CEL.gz///data_row_count: 54675
1
title: Ovary - 219604///geo_accession: GSM152683///status: Public on Jan 03 2007///submission_date: Dec 22 2006///last_update_date: Jan 03 2007///type: RNA///channel_count: 1///source_name_ch1: Ovary///organism_ch1: Homo sapiens///molecule_ch1: total RNA///taxid_ch1: 9606///description: Quality metric = 28S to 18S: 1.4///description.1: Patient Age: 60-70///description.2: Gender: Female///description.3: Ethnic Background: Caucasian///description.4: Tobacco Use : Yes///description.5: Years of Tobacco Use: 6-10///description.6: Type of Tobacco Use: Cigarettes///description.7: Alcohol Consumption?: Yes///description.8: Family History of Cancer?: Yes///description.9: Days from Patient Diagnosis to Excision: 30///description.10: Presenting Symptoms: Abdominal mass///description.11: Pathological T: 2c///description.12: Pathological N: 0///description.13: Pathological M: 0///description.14: Pathological Stage: 2C///description.15: Pathological Grade: 3///description.16: Pathological Stage During or Following Multimodality Therapy: No///description.17: Primary Site: Ovary///description.18: Histology: Papillary Serous Carcinoma///description.19: ///description.20: ///description.21: ///description.22: ///description.23: ///description.24: ///description.25: ///description.26: ///description.27: ///description.28: ///description.29: NA///description.30: NA///description.31: NA///platform_id: GPL570///contact_name: Michael,,Bittner///contact_email: [email protected]///contact_phone: 602-343-8808///contact_fax: 602-343-8440///contact_laboratory: expO///contact_department: NA///contact_institute: IGC///contact_address: 445 N. 5th Street///contact_city: Phoenix///contact_state: AZ///contact_zip.postal_code: 85004///contact_country: USA///contact_web_link: www.intgen.org///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM152nnn/GSM152683/GSM152683.CEL.gz///data_row_count: 54675
1
title: Ovary - 21981///geo_accession: GSM88992///status: Public on Dec 22 2005///submission_date: Dec 22 2005///last_update_date: Dec 22 2005///type: RNA///channel_count: 1///source_name_ch1: Ovary///organism_ch1: Homo sapiens///molecule_ch1: total RNA///taxid_ch1: 9606///description: Quality metric = 28S to 18S: 1.3///description.1: Patient Age: 30-40///description.2: Gender: Female///description.3: Ethnic Background: Hispanic///description.4: Tobacco Use : No///description.5: Family History of Cancer?: No///description.6: Days from Patient Diagnosis to Excision: 12///description.7: Presenting Symptoms: Abdominal pain///description.8: Pathological Grade: 2///description.9: Pathological Multiple Tumors: No///description.10: Pathological Stage During or Following Multimodality Therapy: No///description.11: Primary Site: Ovary///description.12: Histology: Endometrioid Carcinoma///description.13: ///description.14: ///description.15: ///description.16: ///description.17: ///description.18: ///description.19: ///description.20: ///description.21: ///description.22: ///description.23: ///description.24: ///description.25: ///description.26: ///description.27: ///description.28: ///description.29: NA///description.30: NA///description.31: NA///platform_id: GPL570///contact_name: Michael,,Bittner///contact_email: [email protected]///contact_phone: 602-343-8808///contact_fax: 602-343-8440///contact_laboratory: expO///contact_department: NA///contact_institute: IGC///contact_address: 445 N. 5th Street///contact_city: Phoenix///contact_state: AZ///contact_zip.postal_code: 85004///contact_country: USA///contact_web_link: www.intgen.org///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM88nnn/GSM88992/GSM88992.CEL.gz///data_row_count: 54675
1
title: Ovary - 22218///geo_accession: GSM46853///status: Public on Mar 31 2005///submission_date: Mar 31 2005///last_update_date: Oct 09 2007///type: RNA///channel_count: 1///source_name_ch1: Ovary///organism_ch1: Homo sapiens///molecule_ch1: total RNA///taxid_ch1: 9606///description: Quality metric = 28S to 18S: 1.3///description.1: Patient Age: 50-60///description.2: Gender: Female///description.3: Ethnic Background: Caucasian///description.4: Tobacco Use : Yes///description.5: Years of Tobacco Use: 16-20///description.6: Type of Tobacco Use: Cigarettes///description.7: Alcohol Consumption?: Yes///description.8: Family History of Cancer?: No///description.9: Days from Patient Diagnosis to Excision: 1///description.10: Presenting Symptoms: Abdominal mass///description.11: Primary Site: Ovary///description.12: Histology: Endometrioid Carcinoma///description.13: ///description.14: ///description.15: ///description.16: ///description.17: ///description.18: ///description.19: ///description.20: ///description.21: ///description.22: ///description.23: ///description.24: ///description.25: ///description.26: ///description.27: ///description.28: ///description.29: NA///description.30: NA///description.31: NA///platform_id: GPL570///contact_name: Michael,,Bittner///contact_email: [email protected]///contact_phone: 602-343-8808///contact_fax: 602-343-8440///contact_laboratory: expO///contact_department: NA///contact_institute: IGC///contact_address: 445 N. 5th Street///contact_city: Phoenix///contact_state: AZ///contact_zip.postal_code: 85004///contact_country: USA///contact_web_link: www.intgen.org///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM46nnn/GSM46853/GSM46853.CEL.gz///data_row_count: 54675
1
title: Ovary - 226414///geo_accession: GSM152688///status: Public on Jan 03 2007///submission_date: Dec 22 2006///last_update_date: Jan 03 2007///type: RNA///channel_count: 1///source_name_ch1: Ovary///organism_ch1: Homo sapiens///molecule_ch1: total RNA///taxid_ch1: 9606///description: Quality metric = 28S to 18S: 1.6///description.1: Patient Age: 60-70///description.2: Gender: Female///description.3: Ethnic Background: Caucasian///description.4: Tobacco Use : No///description.5: Alcohol Consumption?: No///description.6: Family History of Cancer?: Yes///description.7: Presenting Symptoms: Abdominal mass///description.8: Presenting Symptoms: Abdominal pain///description.9: Clinical T: 1a///description.10: Clinical N: 0///description.11: Clinical M: 0///description.12: Clinical Stage: 1A///description.13: Clinical Grade: 3///description.14: Clinical Multiple Tumors: No///description.15: Clinical Stage During or Following Multimodality Therapy: No///description.16: Primary Site: Ovary///description.17: Histology: Endometrioid adenocarcinoma///description.18: ///description.19: ///description.20: ///description.21: ///description.22: ///description.23: ///description.24: ///description.25: ///description.26: ///description.27: ///description.28: ///description.29: NA///description.30: NA///description.31: NA///platform_id: GPL570///contact_name: Michael,,Bittner///contact_email: [email protected]///contact_phone: 602-343-8808///contact_fax: 602-343-8440///contact_laboratory: expO///contact_department: NA///contact_institute: IGC///contact_address: 445 N. 5th Street///contact_city: Phoenix///contact_state: AZ///contact_zip.postal_code: 85004///contact_country: USA///contact_web_link: www.intgen.org///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM152nnn/GSM152688/GSM152688.CEL.gz///data_row_count: 54675
1
title: Ovary - 226423///geo_accession: GSM152693///status: Public on Jan 03 2007///submission_date: Dec 22 2006///last_update_date: Jan 03 2007///type: RNA///channel_count: 1///source_name_ch1: Ovary///organism_ch1: Homo sapiens///molecule_ch1: total RNA///taxid_ch1: 9606///description: Quality metric = 28S to 18S: 1.2///description.1: Patient Age: 60-70///description.2: Gender: Female///description.3: Ethnic Background: Caucasian///description.4: Tobacco Use : Yes///description.5: Years of Tobacco Use: 6-10///description.6: Type of Tobacco Use: Cigarettes///description.7: Alcohol Consumption?: No///description.8: Family History of Cancer?: No///description.9: Presenting Symptoms: Abdominal mass///description.10: Presenting Symptoms: Bloating///description.11: Pathological T: 3c///description.12: Pathological N: X///description.13: Pathological M: 0///description.14: Pathological Stage: 3C///description.15: Pathological Grade: 3///description.16: Pathological Stage During or Following Multimodality Therapy: No///description.17: Primary Site: Ovary///description.18: Histology: Serous Adenocarinoma///description.19: ///description.20: ///description.21: ///description.22: ///description.23: ///description.24: ///description.25: ///description.26: ///description.27: ///description.28: ///description.29: NA///description.30: NA///description.31: NA///platform_id: GPL570///contact_name: Michael,,Bittner///contact_email: [email protected]///contact_phone: 602-343-8808///contact_fax: 602-343-8440///contact_laboratory: expO///contact_department: NA///contact_institute: IGC///contact_address: 445 N. 5th Street///contact_city: Phoenix///contact_state: AZ///contact_zip.postal_code: 85004///contact_country: USA///contact_web_link: www.intgen.org///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM152nnn/GSM152693/GSM152693.CEL.gz///data_row_count: 54675
1
title: Ovary - 228537///geo_accession: GSM152700///status: Public on Jan 03 2007///submission_date: Dec 22 2006///last_update_date: Jan 03 2007///type: RNA///channel_count: 1///source_name_ch1: Ovary///organism_ch1: Homo sapiens///molecule_ch1: total RNA///taxid_ch1: 9606///description: Quality metric = 28S to 18S: 1.6///description.1: Patient Age: 60-70///description.2: Gender: Female///description.3: Ethnic Background: Caucasian///description.4: Tobacco Use : No///description.5: Alcohol Consumption?: No///description.6: Family History of Cancer?: Yes///description.7: Days from Patient Diagnosis to Excision: 26///description.8: Presenting Symptoms: Abdominal pain///description.9: Presenting Symptoms: Bloating///description.10: Presenting Symptoms: Vaginal bleeding///description.11: Pathological T: 2b///description.12: Pathological N: 0///description.13: Pathological M: 0///description.14: Pathological Stage: 2B///description.15: Pathological Grade: 1///description.16: Pathological Multiple Tumors: No///description.17: Pathological Stage During or Following Multimodality Therapy: No///description.18: Primary Site: Ovary///description.19: Histology: Mucinous Adenocarinoma///description.20: ///description.21: ///description.22: ///description.23: ///description.24: ///description.25: ///description.26: ///description.27: ///description.28: ///description.29: NA///description.30: NA///description.31: NA///platform_id: GPL570///contact_name: Michael,,Bittner///contact_email: [email protected]///contact_phone: 602-343-8808///contact_fax: 602-343-8440///contact_laboratory: expO///contact_department: NA///contact_institute: IGC///contact_address: 445 N. 5th Street///contact_city: Phoenix///contact_state: AZ///contact_zip.postal_code: 85004///contact_country: USA///contact_web_link: www.intgen.org///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM152nnn/GSM152700/GSM152700.CEL.gz///data_row_count: 54675
1
title: Ovary - 228549///geo_accession: GSM152706///status: Public on Jan 03 2007///submission_date: Dec 22 2006///last_update_date: Jan 03 2007///type: RNA///channel_count: 1///source_name_ch1: Ovary///organism_ch1: Homo sapiens///molecule_ch1: total RNA///taxid_ch1: 9606///description: Quality metric = 28S to 18S: 1.4///description.1: Patient Age: 70-80///description.2: Gender: Female///description.3: Ethnic Background: African-American///description.4: Tobacco Use : No///description.5: Alcohol Consumption?: No///description.6: Family History of Cancer?: No///description.7: Days from Patient Diagnosis to Excision: 80///description.8: Prior Therapy: Chemotherapy///description.9: Presenting Symptoms: Abdominal pain///description.10: Pathological T: 3c///description.11: Pathological N: 1///description.12: Pathological M: 1///description.13: Pathological Metastatic Sites: Hepatic///description.14: Pathological Stage: 4///description.15: Pathological Grade: 3///description.16: Pathological Multiple Tumors: No///description.17: Pathological Stage During or Following Multimodality Therapy: Yes///description.18: Primary Site: Ovary///description.19: Histology: Papillary cystadenocarcinoma///description.20: ///description.21: ///description.22: ///description.23: ///description.24: ///description.25: ///description.26: ///description.27: ///description.28: ///description.29: NA///description.30: NA///description.31: NA///platform_id: GPL570///contact_name: Michael,,Bittner///contact_email: [email protected]///contact_phone: 602-343-8808///contact_fax: 602-343-8440///contact_laboratory: expO///contact_department: NA///contact_institute: IGC///contact_address: 445 N. 5th Street///contact_city: Phoenix///contact_state: AZ///contact_zip.postal_code: 85004///contact_country: USA///contact_web_link: www.intgen.org///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM152nnn/GSM152706/GSM152706.CEL.gz///data_row_count: 54675
1
title: Ovary - 231863///geo_accession: GSM152709///status: Public on Jan 03 2007///submission_date: Dec 22 2006///last_update_date: Jan 03 2007///type: RNA///channel_count: 1///source_name_ch1: Ovary///organism_ch1: Homo sapiens///molecule_ch1: total RNA///taxid_ch1: 9606///description: Quality metric = 28S to 18S: 1.3///description.1: Patient Age: 50-60///description.2: Gender: Female///description.3: Ethnic Background: Caucasian///description.4: Tobacco Use : No///description.5: Alcohol Consumption?: Yes///description.6: Family History of Cancer?: No///description.7: Days from Patient Diagnosis to Excision: 5///description.8: Presenting Symptoms: Abdominal Pain///description.9: Screening studies performed?: No///description.10: Pathological T: 3///description.11: Pathological N: 2///description.12: Pathological M: 1///description.13: Pathological Metastatic Sites: Other///description.14: Pathological Stage: 4///description.15: Pathological Grade: 2///description.16: Pathological Multiple Tumors: No///description.17: Pathological Stage During or Following Multimodality Therapy: No///description.18: Primary Site: Colon///description.19: Histology: Metastatic Mucinous Carcinoma///description.20: ///description.21: ///description.22: ///description.23: ///description.24: ///description.25: ///description.26: ///description.27: ///description.28: ///description.29: NA///description.30: NA///description.31: NA///platform_id: GPL570///contact_name: Michael,,Bittner///contact_email: [email protected]///contact_phone: 602-343-8808///contact_fax: 602-343-8440///contact_laboratory: expO///contact_department: NA///contact_institute: IGC///contact_address: 445 N. 5th Street///contact_city: Phoenix///contact_state: AZ///contact_zip.postal_code: 85004///contact_country: USA///contact_web_link: www.intgen.org///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM152nnn/GSM152709/GSM152709.CEL.gz///data_row_count: 54675
1
title: Ovary - 234328///geo_accession: GSM203661///status: Public on Jun 25 2007///submission_date: Jun 22 2007///last_update_date: Jun 25 2007///type: RNA///channel_count: 1///source_name_ch1: Ovary///organism_ch1: Homo sapiens///molecule_ch1: total RNA///taxid_ch1: 9606///description: Quality metric = 28S to 18S: 1.2///description.1: Patient Age: 20-30///description.2: Gender: Female///description.3: Ethnic Background: Asian///description.4: Tobacco Use : No///description.5: Alcohol Consumption?: No///description.6: Family History of Cancer?: No///description.7: Days from Patient Diagnosis to Excision: 19///description.8: Pathological T: 3b///description.9: Pathological N: 0///description.10: Pathological M: 0///description.11: Pathological Stage: 3B///description.12: Primary Site: Ovary///description.13: Histology: Papillary serous tumor of low malignant potential///description.14: ///description.15: ///description.16: ///description.17: ///description.18: ///description.19: ///description.20: ///description.21: ///description.22: ///description.23: ///description.24: ///description.25: ///description.26: ///description.27: ///description.28: ///description.29: NA///description.30: NA///description.31: NA///platform_id: GPL570///contact_name: Michael,,Bittner///contact_email: [email protected]///contact_phone: 602-343-8808///contact_fax: 602-343-8440///contact_laboratory: expO///contact_department: NA///contact_institute: IGC///contact_address: 445 N. 5th Street///contact_city: Phoenix///contact_state: AZ///contact_zip.postal_code: 85004///contact_country: USA///contact_web_link: www.intgen.org///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM203nnn/GSM203661/GSM203661.CEL.gz///data_row_count: 54675
1
title: Ovary - 234329///geo_accession: GSM179813///status: Public on Apr 06 2007///submission_date: Apr 02 2007///last_update_date: Apr 06 2007///type: RNA///channel_count: 1///source_name_ch1: Ovary///organism_ch1: Homo sapiens///molecule_ch1: total RNA///taxid_ch1: 9606///description: Quality metric = 28S to 18S: 1.3///description.1: Patient Age: 60-70///description.2: Gender: Female///description.3: Ethnic Background: Caucasian///description.4: Tobacco Use : Yes///description.5: Years of Tobacco Use: 16-20///description.6: Type of Tobacco Use: Cigarettes///description.7: Alcohol Consumption?: No///description.8: Family History of Cancer?: No///description.9: Days from Patient Diagnosis to Excision: 20///description.10: Clinical T: 3c///description.11: Clinical N: 0///description.12: Clinical M: 0///description.13: Clinical Stage: 3C///description.14: Clinical Grade: 3///description.15: Primary Site: Ovary///description.16: Histology: Papillary Serous Carcinoma///description.17: ///description.18: ///description.19: ///description.20: ///description.21: ///description.22: ///description.23: ///description.24: ///description.25: ///description.26: ///description.27: ///description.28: ///description.29: NA///description.30: NA///description.31: NA///platform_id: GPL570///contact_name: Michael,,Bittner///contact_email: [email protected]///contact_phone: 602-343-8808///contact_fax: 602-343-8440///contact_laboratory: expO///contact_department: NA///contact_institute: IGC///contact_address: 445 N. 5th Street///contact_city: Phoenix///contact_state: AZ///contact_zip.postal_code: 85004///contact_country: USA///contact_web_link: www.intgen.org///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM179nnn/GSM179813/GSM179813.CEL.gz///data_row_count: 54675
1
title: Ovary - 235691///geo_accession: GSM152721///status: Public on Jan 03 2007///submission_date: Dec 22 2006///last_update_date: Jan 03 2007///type: RNA///channel_count: 1///source_name_ch1: Ovary///organism_ch1: Homo sapiens///molecule_ch1: total RNA///taxid_ch1: 9606///description: Quality metric = 28S to 18S: 1.2///description.1: Patient Age: 50-60///description.2: Gender: Female///description.3: Ethnic Background: Caucasian///description.4: Tobacco Use : No///description.5: Alcohol Consumption?: No///description.6: Family History of Cancer?: No///description.7: Days from Patient Diagnosis to Excision: 7///description.8: Presenting Symptoms: Abdominal Pain///description.9: Presenting Symptoms: Nausea///description.10: Presenting Symptoms: Vomiting///description.11: Screening studies performed?: No///description.12: Pathological T: 3///description.13: Pathological N: 1///description.14: Pathological M: 1///description.15: Pathological Metastatic Sites: Other///description.16: Pathological Stage: 4///description.17: Pathological Grade: 3///description.18: Pathological Multiple Tumors: No///description.19: Pathological Stage During or Following Multimodality Therapy: No///description.20: Primary Site: Colon///description.21: Histology: Mucinous Carcinoma///description.22: ///description.23: ///description.24: ///description.25: ///description.26: ///description.27: ///description.28: ///description.29: NA///description.30: NA///description.31: NA///platform_id: GPL570///contact_name: Michael,,Bittner///contact_email: [email protected]///contact_phone: 602-343-8808///contact_fax: 602-343-8440///contact_laboratory: expO///contact_department: NA///contact_institute: IGC///contact_address: 445 N. 5th Street///contact_city: Phoenix///contact_state: AZ///contact_zip.postal_code: 85004///contact_country: USA///contact_web_link: www.intgen.org///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM152nnn/GSM152721/GSM152721.CEL.gz///data_row_count: 54675
1
title: Ovary - 235692///geo_accession: GSM152722///status: Public on Jan 03 2007///submission_date: Dec 22 2006///last_update_date: Jan 03 2007///type: RNA///channel_count: 1///source_name_ch1: Ovary///organism_ch1: Homo sapiens///molecule_ch1: total RNA///taxid_ch1: 9606///description: Quality metric = 28S to 18S: 1.6///description.1: Patient Age: 50-60///description.2: Gender: Female///description.3: Ethnic Background: Caucasian///description.4: Tobacco Use : Yes///description.5: Years of Tobacco Use: 21-25///description.6: Type of Tobacco Use: Cigarettes///description.7: Alcohol Consumption?: No///description.8: Family History of Cancer?: Yes///description.9: Days from Patient Diagnosis to Excision: 30///description.10: Presenting Symptoms: Bloating///description.11: Clinical T: 1a///description.12: Clinical N: 0///description.13: Clinical M: 0///description.14: Clinical Stage: 1A///description.15: Clinical Grade: 3///description.16: Clinical Multiple Tumors: No///description.17: Clinical Stage During or Following Multimodality Therapy: No///description.18: Primary Site: Ovary///description.19: Histology: Clear cell adenocarcinoma///description.20: ///description.21: ///description.22: ///description.23: ///description.24: ///description.25: ///description.26: ///description.27: ///description.28: ///description.29: NA///description.30: NA///description.31: NA///platform_id: GPL570///contact_name: Michael,,Bittner///contact_email: [email protected]///contact_phone: 602-343-8808///contact_fax: 602-343-8440///contact_laboratory: expO///contact_department: NA///contact_institute: IGC///contact_address: 445 N. 5th Street///contact_city: Phoenix///contact_state: AZ///contact_zip.postal_code: 85004///contact_country: USA///contact_web_link: www.intgen.org///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM152nnn/GSM152722/GSM152722.CEL.gz///data_row_count: 54675
1
title: Ovary - 235695///geo_accession: GSM152724///status: Public on Jan 03 2007///submission_date: Dec 22 2006///last_update_date: Jan 03 2007///type: RNA///channel_count: 1///source_name_ch1: Ovary///organism_ch1: Homo sapiens///molecule_ch1: total RNA///taxid_ch1: 9606///description: Quality metric = 28S to 18S: 1.7///description.1: Patient Age: 40-50///description.2: Gender: Female///description.3: Ethnic Background: Caucasian///description.4: Tobacco Use : No///description.5: Alcohol Consumption?: No///description.6: Family History of Cancer?: No///description.7: Days from Patient Diagnosis to Excision: 23///description.8: Presenting Symptoms: Abdominal pain///description.9: Presenting Symptoms: Bloating///description.10: Pathological T: 3c///description.11: Pathological N: 1///description.12: Pathological M: 0///description.13: Pathological Stage: 3C///description.14: Pathological Grade: 3///description.15: Pathological Multiple Tumors: No///description.16: Pathological Stage During or Following Multimodality Therapy: No///description.17: Primary Site: Ovary///description.18: Histology: Papillary Serous Adenocarcinoma///description.19: ///description.20: ///description.21: ///description.22: ///description.23: ///description.24: ///description.25: ///description.26: ///description.27: ///description.28: ///description.29: NA///description.30: NA///description.31: NA///platform_id: GPL570///contact_name: Michael,,Bittner///contact_email: [email protected]///contact_phone: 602-343-8808///contact_fax: 602-343-8440///contact_laboratory: expO///contact_department: NA///contact_institute: IGC///contact_address: 445 N. 5th Street///contact_city: Phoenix///contact_state: AZ///contact_zip.postal_code: 85004///contact_country: USA///contact_web_link: www.intgen.org///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM152nnn/GSM152724/GSM152724.CEL.gz///data_row_count: 54675
1
title: Ovary - 23862///geo_accession: GSM53098///status: Public on Jul 01 2005///submission_date: Jun 30 2005///last_update_date: Jun 30 2005///type: RNA///channel_count: 1///source_name_ch1: Ovary///organism_ch1: Homo sapiens///molecule_ch1: total RNA///taxid_ch1: 9606///description: Quality metric = 28S to 18S: 1.3///description.1: Patient Age: 60-70///description.2: Gender: Female///description.3: Ethnic Background: Caucasian///description.4: Tobacco Use : Yes///description.5: Years of Tobacco Use: 6-10///description.6: Type of Tobacco Use: Cigarettes///description.7: Alcohol Consumption?: Yes///description.8: Family History of Cancer?: No///description.9: Presenting Symptoms: Abdominal mass///description.10: Presenting Symptoms: Abdominal pain///description.11: Presenting Symptoms: Bloating///description.12: Primary Site: Ovary///description.13: Histology: Mucinous Adenocarinoma///description.14: ///description.15: ///description.16: ///description.17: ///description.18: ///description.19: ///description.20: ///description.21: ///description.22: ///description.23: ///description.24: ///description.25: ///description.26: ///description.27: ///description.28: ///description.29: NA///description.30: NA///description.31: NA///platform_id: GPL570///contact_name: Michael,,Bittner///contact_email: [email protected]///contact_phone: 602-343-8808///contact_fax: 602-343-8440///contact_laboratory: expO///contact_department: NA///contact_institute: IGC///contact_address: 445 N. 5th Street///contact_city: Phoenix///contact_state: AZ///contact_zip.postal_code: 85004///contact_country: USA///contact_web_link: www.intgen.org///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM53nnn/GSM53098/GSM53098.CEL.gz///data_row_count: 54675
1
title: Ovary - 23884///geo_accession: GSM53100///status: Public on Jul 01 2005///submission_date: Jun 30 2005///last_update_date: Oct 09 2007///type: RNA///channel_count: 1///source_name_ch1: Ovary///organism_ch1: Homo sapiens///molecule_ch1: total RNA///taxid_ch1: 9606///description: Quality metric = 28S to 18S: 1.3///description.1: Patient Age: 60-70///description.2: Gender: Female///description.3: Ethnic Background: Caucasian///description.4: Tobacco Use : No///description.5: Alcohol Consumption?: No///description.6: Family History of Cancer?: No///description.7: Days from Patient Diagnosis to Excision: 1///description.8: Pathological T: 2b///description.9: Pathological N: 0///description.10: Pathological M: 0///description.11: Pathological Stage: 2B///description.12: Pathological Grade: 4///description.13: Primary Site: Ovary///description.14: Histology: Serous Adenocarinoma///description.15: ///description.16: ///description.17: ///description.18: ///description.19: ///description.20: ///description.21: ///description.22: ///description.23: ///description.24: ///description.25: ///description.26: ///description.27: ///description.28: ///description.29: ///description.30: NA///description.31: NA///platform_id: GPL570///contact_name: Michael,,Bittner///contact_email: [email protected]///contact_phone: 602-343-8808///contact_fax: 602-343-8440///contact_laboratory: expO///contact_department: NA///contact_institute: IGC///contact_address: 445 N. 5th Street///contact_city: Phoenix///contact_state: AZ///contact_zip.postal_code: 85004///contact_country: USA///contact_web_link: www.intgen.org///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM53nnn/GSM53100/GSM53100.CEL.gz///data_row_count: 54675
1
title: Ovary - 23904///geo_accession: GSM46886///status: Public on Mar 31 2005///submission_date: Mar 31 2005///last_update_date: Oct 09 2007///type: RNA///channel_count: 1///source_name_ch1: Ovary///organism_ch1: Homo sapiens///molecule_ch1: total RNA///taxid_ch1: 9606///description: Quality metric = 28S to 18S: 1.5///description.1: Patient Age: 50-60///description.2: Gender: Female///description.3: Ethnic Background: Caucasian///description.4: Tobacco Use : Yes///description.5: Years of Tobacco Use: 6-10///description.6: Type of Tobacco Use: Cigarettes///description.7: Alcohol Consumption?: No///description.8: Family History of Cancer?: Yes///description.9: Days from Patient Diagnosis to Excision: 1///description.10: Presenting Symptoms: Abdominal mass///description.11: Presenting Symptoms: Abdominal pain///description.12: Pathological T: 3a///description.13: Pathological N: 1///description.14: Pathological M: 0///description.15: Pathological Stage: 3C///description.16: Pathological Grade: 1///description.17: Primary Site: Ovary///description.18: Histology: Benign serous cystadenoma of borderline malignancy///description.19: ///description.20: ///description.21: ///description.22: ///description.23: ///description.24: ///description.25: ///description.26: ///description.27: ///description.28: ///description.29: ///description.30: NA///description.31: NA///platform_id: GPL570///contact_name: Michael,,Bittner///contact_email: [email protected]///contact_phone: 602-343-8808///contact_fax: 602-343-8440///contact_laboratory: expO///contact_department: NA///contact_institute: IGC///contact_address: 445 N. 5th Street///contact_city: Phoenix///contact_state: AZ///contact_zip.postal_code: 85004///contact_country: USA///contact_web_link: www.intgen.org///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM46nnn/GSM46886/GSM46886.CEL.gz///data_row_count: 54675
1
title: Ovary - 23930///geo_accession: GSM53104///status: Public on Jul 01 2005///submission_date: Jun 30 2005///last_update_date: Jun 30 2005///type: RNA///channel_count: 1///source_name_ch1: Ovary///organism_ch1: Homo sapiens///molecule_ch1: total RNA///taxid_ch1: 9606///description: Quality metric = 28S to 18S: 1.3///description.1: Patient Age: 40-50///description.2: Gender: Female///description.3: Ethnic Background: Caucasian///description.4: Tobacco Use : No///description.5: Alcohol Consumption?: No///description.6: Family History of Cancer?: No///description.7: Days from Patient Diagnosis to Excision: 1///description.8: Presenting Symptoms: Abdominal mass///description.9: Primary Site: Ovary///description.10: Histology: Mucinous cystic tumor of low malignant potential///description.11: ///description.12: ///description.13: ///description.14: ///description.15: ///description.16: ///description.17: ///description.18: ///description.19: ///description.20: ///description.21: ///description.22: ///description.23: ///description.24: ///description.25: ///description.26: ///description.27: ///description.28: ///description.29: NA///description.30: NA///description.31: NA///platform_id: GPL570///contact_name: Michael,,Bittner///contact_email: [email protected]///contact_phone: 602-343-8808///contact_fax: 602-343-8440///contact_laboratory: expO///contact_department: NA///contact_institute: IGC///contact_address: 445 N. 5th Street///contact_city: Phoenix///contact_state: AZ///contact_zip.postal_code: 85004///contact_country: USA///contact_web_link: www.intgen.org///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM53nnn/GSM53104/GSM53104.CEL.gz///data_row_count: 54675
1
title: Ovary - 23934///geo_accession: GSM53105///status: Public on Jul 01 2005///submission_date: Jun 30 2005///last_update_date: Jun 30 2005///type: RNA///channel_count: 1///source_name_ch1: Ovary///organism_ch1: Homo sapiens///molecule_ch1: total RNA///taxid_ch1: 9606///description: Quality metric = 28S to 18S: 1.5///description.1: Patient Age: 20-30///description.2: Gender: Female///description.3: Ethnic Background: Caucasian///description.4: Tobacco Use : Yes///description.5: Years of Tobacco Use: 11-15///description.6: Type of Tobacco Use: Cigarettes///description.7: Alcohol Consumption?: No///description.8: Family History of Cancer?: No///description.9: Presenting Symptoms: Abdominal pain///description.10: Primary Site: Ovary///description.11: Histology: Clear cell adenocarcinoma///description.12: ///description.13: ///description.14: ///description.15: ///description.16: ///description.17: ///description.18: ///description.19: ///description.20: ///description.21: ///description.22: ///description.23: ///description.24: ///description.25: ///description.26: ///description.27: ///description.28: ///description.29: NA///description.30: NA///description.31: NA///platform_id: GPL570///contact_name: Michael,,Bittner///contact_email: [email protected]///contact_phone: 602-343-8808///contact_fax: 602-343-8440///contact_laboratory: expO///contact_department: NA///contact_institute: IGC///contact_address: 445 N. 5th Street///contact_city: Phoenix///contact_state: AZ///contact_zip.postal_code: 85004///contact_country: USA///contact_web_link: www.intgen.org///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM53nnn/GSM53105/GSM53105.CEL.gz///data_row_count: 54675
1
title: Ovary - 23936///geo_accession: GSM46897///status: Public on Mar 31 2005///submission_date: Mar 31 2005///last_update_date: Oct 09 2007///type: RNA///channel_count: 1///source_name_ch1: Ovary///organism_ch1: Homo sapiens///molecule_ch1: total RNA///taxid_ch1: 9606///description: Quality metric = 28S to 18S: 1.3///description.1: Patient Age: 40-50///description.2: Gender: Female///description.3: Ethnic Background: Caucasian///description.4: Tobacco Use : Yes///description.5: Years of Tobacco Use: 16-20///description.6: Type of Tobacco Use: Cigarettes///description.7: Alcohol Consumption?: Yes///description.8: Family History of Cancer?: No///description.9: Presenting Symptoms: Vaginal bleeding///description.10: Pathological T: 2b///description.11: Pathological N: 0///description.12: Pathological M: X///description.13: Pathological Stage: Unknown///description.14: Pathological Grade: 1///description.15: Primary Site: Endometrium///description.16: Histology: Endometrioid adenocarcinoma with sguamous metaplasia///description.17: ///description.18: ///description.19: ///description.20: ///description.21: ///description.22: ///description.23: ///description.24: ///description.25: ///description.26: ///description.27: ///description.28: ///description.29: NA///description.30: NA///description.31: NA///platform_id: GPL570///contact_name: Michael,,Bittner///contact_email: [email protected]///contact_phone: 602-343-8808///contact_fax: 602-343-8440///contact_laboratory: expO///contact_department: NA///contact_institute: IGC///contact_address: 445 N. 5th Street///contact_city: Phoenix///contact_state: AZ///contact_zip.postal_code: 85004///contact_country: USA///contact_web_link: www.intgen.org///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM46nnn/GSM46897/GSM46897.CEL.gz///data_row_count: 54675
1
title: Ovary - 23938///geo_accession: GSM46898///status: Public on Mar 31 2005///submission_date: Mar 31 2005///last_update_date: Oct 09 2007///type: RNA///channel_count: 1///source_name_ch1: Ovary///organism_ch1: Homo sapiens///molecule_ch1: total RNA///taxid_ch1: 9606///description: Quality metric = 28S to 18S: 1.4///description.1: Patient Age: 60-70///description.2: Gender: Female///description.3: Ethnic Background: Caucasian///description.4: Tobacco Use : No///description.5: Alcohol Consumption?: No///description.6: Family History of Cancer?: Yes///description.7: Presenting Symptoms: Abdominal mass///description.8: Presenting Symptoms: Abdominal pain///description.9: Pathological T: 3c///description.10: Pathological N: 0///description.11: Pathological M: 0///description.12: Pathological Stage: 3C///description.13: Pathological Grade: 3///description.14: Primary Site: Ovary///description.15: Histology: Papillary Serous Adenocarcinoma///description.16: ///description.17: ///description.18: ///description.19: ///description.20: ///description.21: ///description.22: ///description.23: ///description.24: ///description.25: ///description.26: ///description.27: ///description.28: NA///description.29: NA///description.30: NA///description.31: NA///platform_id: GPL570///contact_name: Michael,,Bittner///contact_email: [email protected]///contact_phone: 602-343-8808///contact_fax: 602-343-8440///contact_laboratory: expO///contact_department: NA///contact_institute: IGC///contact_address: 445 N. 5th Street///contact_city: Phoenix///contact_state: AZ///contact_zip.postal_code: 85004///contact_country: USA///contact_web_link: www.intgen.org///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM46nnn/GSM46898/GSM46898.CEL.gz///data_row_count: 54675
1
title: Ovary - 241181///geo_accession: GSM152733///status: Public on Jan 03 2007///submission_date: Dec 22 2006///last_update_date: Jan 03 2007///type: RNA///channel_count: 1///source_name_ch1: Ovary///organism_ch1: Homo sapiens///molecule_ch1: total RNA///taxid_ch1: 9606///description: Quality metric = 28S to 18S: 1.6///description.1: Patient Age: 60-70///description.2: Gender: Female///description.3: Ethnic Background: Caucasian///description.4: Tobacco Use : No///description.5: Alcohol Consumption?: No///description.6: Family History of Cancer?: Yes///description.7: Presenting Symptoms: Bloating///description.8: Pathological T: 1a///description.9: Pathological N: 0///description.10: Pathological M: 0///description.11: Pathological Stage: 1A///description.12: Pathological Grade: 1///description.13: Pathological Multiple Tumors: No///description.14: Pathological Stage During or Following Multimodality Therapy: No///description.15: Primary Site: Ovary///description.16: Histology: Endometrioid Carcinoma///description.17: ///description.18: ///description.19: ///description.20: ///description.21: ///description.22: ///description.23: ///description.24: ///description.25: ///description.26: ///description.27: ///description.28: ///description.29: NA///description.30: NA///description.31: NA///platform_id: GPL570///contact_name: Michael,,Bittner///contact_email: [email protected]///contact_phone: 602-343-8808///contact_fax: 602-343-8440///contact_laboratory: expO///contact_department: NA///contact_institute: IGC///contact_address: 445 N. 5th Street///contact_city: Phoenix///contact_state: AZ///contact_zip.postal_code: 85004///contact_country: USA///contact_web_link: www.intgen.org///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM152nnn/GSM152733/GSM152733.CEL.gz///data_row_count: 54675
1
title: Ovary - 241187///geo_accession: GSM152735///status: Public on Jan 03 2007///submission_date: Dec 22 2006///last_update_date: Jan 03 2007///type: RNA///channel_count: 1///source_name_ch1: Ovary///organism_ch1: Homo sapiens///molecule_ch1: total RNA///taxid_ch1: 9606///description: Quality metric = 28S to 18S: 1.1///description.1: Patient Age: 80-90///description.2: Gender: Female///description.3: Ethnic Background: Caucasian///description.4: Tobacco Use : Yes///description.5: Years of Tobacco Use: 0-5///description.6: Type of Tobacco Use: Cigarettes///description.7: Alcohol Consumption?: No///description.8: Family History of Cancer?: Yes///description.9: Days from Patient Diagnosis to Excision: 20///description.10: Presenting Symptoms: Abdominal pain///description.11: Presenting Symptoms: Bloating///description.12: Pathological T: 3c///description.13: Pathological N: 0///description.14: Pathological M: 0///description.15: Pathological Stage: 3C///description.16: Pathological Grade: 1///description.17: Pathological Stage During or Following Multimodality Therapy: No///description.18: Primary Site: Ovary///description.19: Histology: Papillary mucinous cystadenocarcinoma///description.20: ///description.21: ///description.22: ///description.23: ///description.24: ///description.25: ///description.26: ///description.27: ///description.28: ///description.29: NA///description.30: NA///description.31: NA///platform_id: GPL570///contact_name: Michael,,Bittner///contact_email: [email protected]///contact_phone: 602-343-8808///contact_fax: 602-343-8440///contact_laboratory: expO///contact_department: NA///contact_institute: IGC///contact_address: 445 N. 5th Street///contact_city: Phoenix///contact_state: AZ///contact_zip.postal_code: 85004///contact_country: USA///contact_web_link: www.intgen.org///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM152nnn/GSM152735/GSM152735.CEL.gz///data_row_count: 54675
1
title: Ovary - 241196///geo_accession: GSM179822///status: Public on Apr 06 2007///submission_date: Apr 02 2007///last_update_date: Apr 06 2007///type: RNA///channel_count: 1///source_name_ch1: Ovary///organism_ch1: Homo sapiens///molecule_ch1: total RNA///taxid_ch1: 9606///description: Quality metric = 28S to 18S: 1.5///description.1: Patient Age: 40-50///description.2: Gender: Female///description.3: Ethnic Background: Caucasian///description.4: Tobacco Use : Yes///description.5: Years of Tobacco Use: 31-35///description.6: Type of Tobacco Use: Cigarettes///description.7: Alcohol Consumption?: No///description.8: Family History of Cancer?: Yes///description.9: Days from Patient Diagnosis to Excision: 16///description.10: Pathological T: 3c///description.11: Pathological N: 1///description.12: Pathological M: 0///description.13: Pathological Stage: 3C///description.14: Pathological Grade: 3///description.15: Primary Site: Ovary///description.16: Histology: Papillary Serous Adenocarcinoma///description.17: ///description.18: ///description.19: ///description.20: ///description.21: ///description.22: ///description.23: ///description.24: ///description.25: ///description.26: ///description.27: ///description.28: NA///description.29: NA///description.30: NA///description.31: NA///platform_id: GPL570///contact_name: Michael,,Bittner///contact_email: [email protected]///contact_phone: 602-343-8808///contact_fax: 602-343-8440///contact_laboratory: expO///contact_department: NA///contact_institute: IGC///contact_address: 445 N. 5th Street///contact_city: Phoenix///contact_state: AZ///contact_zip.postal_code: 85004///contact_country: USA///contact_web_link: www.intgen.org///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM179nnn/GSM179822/GSM179822.CEL.gz///data_row_count: 54675
1
title: Ovary - 241198///geo_accession: GSM152739///status: Public on Jan 03 2007///submission_date: Dec 22 2006///last_update_date: Jan 03 2007///type: RNA///channel_count: 1///source_name_ch1: Ovary///organism_ch1: Homo sapiens///molecule_ch1: total RNA///taxid_ch1: 9606///description: Quality metric = 28S to 18S: 1.0///description.1: Patient Age: 50-60///description.2: Gender: Female///description.3: Ethnic Background: Caucasian///description.4: Tobacco Use : No///description.5: Alcohol Consumption?: No///description.6: Family History of Cancer?: Yes///description.7: Days from Patient Diagnosis to Excision: 60///description.8: Pathological Question: Stage///description.9: Pathological Value: No AJCC scheme for this site and histology///description.10: Pathological Question: Grade///description.11: Pathological Value: X///description.12: Pathological Question: Multiple Tumors///description.13: Pathological Value: Yes///description.14: Primary Site: Endometrium///description.15: Pathological Question: Histology///description.16: Pathological Value: Metastatic Leiomyosarcoma///description.17: ///description.18: ///description.19: ///description.20: ///description.21: ///description.22: ///description.23: ///description.24: ///description.25: ///description.26: ///description.27: ///description.28: ///description.29: NA///description.30: NA///description.31: NA///platform_id: GPL570///contact_name: Michael,,Bittner///contact_email: [email protected]///contact_phone: 602-343-8808///contact_fax: 602-343-8440///contact_laboratory: expO///contact_department: NA///contact_institute: IGC///contact_address: 445 N. 5th Street///contact_city: Phoenix///contact_state: AZ///contact_zip.postal_code: 85004///contact_country: USA///contact_web_link: www.intgen.org///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM152nnn/GSM152739/GSM152739.CEL.gz///data_row_count: 54675
1
title: Ovary - 241199///geo_accession: GSM179823///status: Public on Apr 06 2007///submission_date: Apr 02 2007///last_update_date: Apr 06 2007///type: RNA///channel_count: 1///source_name_ch1: Ovary///organism_ch1: Homo sapiens///molecule_ch1: total RNA///taxid_ch1: 9606///description: Quality metric = 28S to 18S: 1.3///description.1: Patient Age: 50-60///description.2: Gender: Female///description.3: Ethnic Background: Caucasian///description.4: Tobacco Use : No///description.5: Alcohol Consumption?: Yes///description.6: Family History of Cancer?: Yes///description.7: Days from Patient Diagnosis to Excision: 13///description.8: Presenting Symptoms: Abdominal mass///description.9: Pathological T: 3c///description.10: Pathological N: 1///description.11: Pathological M: 0///description.12: Pathological Stage: 3C///description.13: Pathological Grade: 3///description.14: Primary Site: Ovary///description.15: Histology: Papillary serous cystadenocarcinoma///description.16: ///description.17: ///description.18: ///description.19: ///description.20: ///description.21: ///description.22: ///description.23: ///description.24: ///description.25: ///description.26: ///description.27: ///description.28: ///description.29: NA///description.30: NA///description.31: NA///platform_id: GPL570///contact_name: Michael,,Bittner///contact_email: [email protected]///contact_phone: 602-343-8808///contact_fax: 602-343-8440///contact_laboratory: expO///contact_department: NA///contact_institute: IGC///contact_address: 445 N. 5th Street///contact_city: Phoenix///contact_state: AZ///contact_zip.postal_code: 85004///contact_country: USA///contact_web_link: www.intgen.org///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM179nnn/GSM179823/GSM179823.CEL.gz///data_row_count: 54675
1
title: Ovary - 242929///geo_accession: GSM179830///status: Public on Apr 06 2007///submission_date: Apr 02 2007///last_update_date: Apr 06 2007///type: RNA///channel_count: 1///source_name_ch1: Ovary///organism_ch1: Homo sapiens///molecule_ch1: total RNA///taxid_ch1: 9606///description: Quality metric = 28S to 18S: 1.6///description.1: Patient Age: 60-70///description.2: Gender: Female///description.3: Ethnic Background: Caucasian///description.4: Tobacco Use : Yes///description.5: Years of Tobacco Use: 6-10///description.6: Type of Tobacco Use: Cigarettes///description.7: Alcohol Consumption?: Yes///description.8: Family History of Cancer?: No///description.9: Days from Patient Diagnosis to Excision: 13///description.10: Presenting Symptoms: Abdominal pain///description.11: Presenting Symptoms: Bloating///description.12: Pathological T: 1c///description.13: Pathological N: 0///description.14: Pathological M: 0///description.15: Pathological Stage: 1C///description.16: Pathological Grade: 1///description.17: Pathological Multiple Tumors: No///description.18: Pathological Stage During or Following Multimodality Therapy: No///description.19: Primary Site: Ovary///description.20: Histology: Endometrioid adenocarcinoma///description.21: ///description.22: ///description.23: ///description.24: ///description.25: ///description.26: ///description.27: ///description.28: ///description.29: NA///description.30: NA///description.31: NA///platform_id: GPL570///contact_name: Michael,,Bittner///contact_email: [email protected]///contact_phone: 602-343-8808///contact_fax: 602-343-8440///contact_laboratory: expO///contact_department: NA///contact_institute: IGC///contact_address: 445 N. 5th Street///contact_city: Phoenix///contact_state: AZ///contact_zip.postal_code: 85004///contact_country: USA///contact_web_link: www.intgen.org///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM179nnn/GSM179830/GSM179830.CEL.gz///data_row_count: 54675
1
(Other)
105
duplicates:
GSE2109.GSE2109_GSM76554 GSE2109.GSE2109_GSM76567 NA's
1 1 202
An expression set
Although there is evidence that redox regulation has an essential role in malignancies, its impact on tumor prognosis remains unclear. Here we show crosstalk between oxidative stress and the miR-200 family of microRNAs that affects tumorigenesis and chemosensitivity. miR-141 and miR-200a target p38?? and modulate the oxidative stress response. Enhanced expression of these microRNAs mimics p38?? deficiency and increases tumor growth in mouse models, but it also improves the response to chemotherapeutic agents. High-grade human ovarian adenocarcinomas that accumulate miR-200a have low concentrations of p38?? and an associated oxidative stress signature. The miR200a-dependent stress signature correlates with improved survival of patients in response to treatment. Therefore, the role of miR-200a in stress could be a predictive marker for clinical outcome in ovarian cancer. In addition, although oxidative stress promotes tumor growth, it also sensitizes tumors to treatment, which could account for the limited success of antioxidants in clinical trials.
experimentData(eset):
Experiment data
Experimenter name: Mateescu B, Batista L, Mariani O, Meyniel J, Cottu PH, Sastre-Garau X, Mechta-Grigoriou F
Laboratory: Mateescu, Mechta-Grigoriou 2011
Contact information:
Title: miR-141 and miR-200a act on ovarian tumorigenesis by controlling oxidative stress response.
URL:
PMIDs: 22101765
Abstract: A 149 word abstract is available. Use 'abstract' method.
Information is available on: preprocessing
notes:
platform_title:
[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array
platform_shorttitle:
Affymetrix HG-U133Plus2
platform_summary:
hgu133plus2
platform_manufacturer:
Affymetrix
platform_distribution:
commercial
platform_accession:
GPL570
platform_technology:
in situ oligonucleotide
version:
2015-09-22 19:44:56
featureData(eset):
An object of class 'AnnotatedDataFrame'
featureNames: 1007_s_at 1053_at ... AFFX-HUMISGF3A/M97935_MB_at
(42447 total)
varLabels: probeset gene EntrezGene.ID best_probe
varMetadata: labelDescription
assayData: 42447 features, 107 samples
Platform type:
Overall survival time-to-event summary (in years):
Call: survfit(formula = Surv(time, cens) ~ -1)
n events median 0.95LCL 0.95UCL
107.00 76.00 3.05 2.50 4.56
---------------------------
Available sample meta-data:
---------------------------
alt_sample_name:
Ovarian carcinoma 1 Ovarian carcinoma 10 Ovarian carcinoma 100
1 1 1
Ovarian carcinoma 101 Ovarian carcinoma 102 Ovarian carcinoma 103
1 1 1
Ovarian carcinoma 104 Ovarian carcinoma 105 Ovarian carcinoma 106
1 1 1
Ovarian carcinoma 107 Ovarian carcinoma 11 Ovarian carcinoma 12
1 1 1
Ovarian carcinoma 13 Ovarian carcinoma 14 Ovarian carcinoma 15
1 1 1
Ovarian carcinoma 16 Ovarian carcinoma 17 Ovarian carcinoma 18
1 1 1
Ovarian carcinoma 19 Ovarian carcinoma 2 Ovarian carcinoma 20
1 1 1
Ovarian carcinoma 21 Ovarian carcinoma 22 Ovarian carcinoma 23
1 1 1
Ovarian carcinoma 24 Ovarian carcinoma 25 Ovarian carcinoma 26
1 1 1
Ovarian carcinoma 27 Ovarian carcinoma 28 Ovarian carcinoma 29
1 1 1
Ovarian carcinoma 3 Ovarian carcinoma 30 Ovarian carcinoma 31
1 1 1
Ovarian carcinoma 32 Ovarian carcinoma 33 Ovarian carcinoma 34
1 1 1
Ovarian carcinoma 35 Ovarian carcinoma 36 Ovarian carcinoma 37
1 1 1
Ovarian carcinoma 38 Ovarian carcinoma 39 Ovarian carcinoma 4
1 1 1
Ovarian carcinoma 40 Ovarian carcinoma 41 Ovarian carcinoma 42
1 1 1
Ovarian carcinoma 43 Ovarian carcinoma 44 Ovarian carcinoma 45
1 1 1
Ovarian carcinoma 46 Ovarian carcinoma 47 Ovarian carcinoma 48
1 1 1
Ovarian carcinoma 49 Ovarian carcinoma 5 Ovarian carcinoma 50
1 1 1
Ovarian carcinoma 51 Ovarian carcinoma 52 Ovarian carcinoma 53
1 1 1
Ovarian carcinoma 54 Ovarian carcinoma 55 Ovarian carcinoma 56
1 1 1
Ovarian carcinoma 57 Ovarian carcinoma 58 Ovarian carcinoma 59
1 1 1
Ovarian carcinoma 6 Ovarian carcinoma 60 Ovarian carcinoma 61
1 1 1
Ovarian carcinoma 62 Ovarian carcinoma 63 Ovarian carcinoma 64
1 1 1
Ovarian carcinoma 65 Ovarian carcinoma 66 Ovarian carcinoma 67
1 1 1
Ovarian carcinoma 68 Ovarian carcinoma 69 Ovarian carcinoma 7
1 1 1
Ovarian carcinoma 70 Ovarian carcinoma 71 Ovarian carcinoma 72
1 1 1
Ovarian carcinoma 73 Ovarian carcinoma 74 Ovarian carcinoma 75
1 1 1
Ovarian carcinoma 76 Ovarian carcinoma 77 Ovarian carcinoma 78
1 1 1
Ovarian carcinoma 79 Ovarian carcinoma 8 Ovarian carcinoma 80
1 1 1
Ovarian carcinoma 81 Ovarian carcinoma 82 Ovarian carcinoma 83
1 1 1
Ovarian carcinoma 84 Ovarian carcinoma 85 Ovarian carcinoma 86
1 1 1
Ovarian carcinoma 87 Ovarian carcinoma 88 Ovarian carcinoma 89
1 1 1
Ovarian carcinoma 9 Ovarian carcinoma 90 Ovarian carcinoma 91
1 1 1
(Other)
8
sample_type:
tumor
107
histological_type:
clearcell endo mucinous other ser
6 8 8 6 79
summarygrade:
high low
67 40
summarystage:
early late
31 76
tumorstage:
1 2 3 4
20 11 59 17
substage:
a b c NA's
16 12 62 17
grade:
1 2 3
7 33 67
days_to_tumor_recurrence:
Min. 1st Qu. Median Mean 3rd Qu. Max.
3.0 340.5 584.0 1108.0 1525.0 7386.0
recurrence_status:
norecurrence recurrence
27 80
days_to_death:
Min. 1st Qu. Median Mean 3rd Qu. Max.
3 668 1096 1520 2220 7386
vital_status:
deceased living
76 31
batch:
2006-06-01 2006-06-27 2006-06-28 2006-06-29 2006-06-30 2006-07-20 2008-03-06
15 14 23 16 21 3 1
2009-03-18 2009-03-19
4 10
uncurated_author_metadata:
title: Ovarian carcinoma 100///geo_accession: GSM643032///status: Public on Nov 01 2011///submission_date: Dec 20 2010///last_update_date: Aug 19 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma 100///organism_ch1: Homo sapiens///characteristics_ch1: histological type: Serous///characteristics_ch1.1: grade: 3///characteristics_ch1.2: Stage: IV///characteristics_ch1.3: tissue: ovarian carcinoma tumor///characteristics_ch1.4: os event: 1///characteristics_ch1.5: os time (years): 0.0520192///characteristics_ch1.6: pfs event: 1///characteristics_ch1.7: pfs time (years): 0.0520192///characteristics_ch1.8: signature: FIBROSIS///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were analyzed with Partek software (6.10.0915 version)///platform_id: GPL570///contact_name: Fatima,,Mechta-Grigoriou///contact_email: [email protected]///contact_phone: 33156246653///contact_fax: 33156246650///contact_laboratory: \Stress and Cancer\ Lab.///contact_department: INSERM U830///contact_institute: Institut Curie///contact_address: 26 rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM643nnn/GSM643032/GSM643032_OC01_ARN0157_s1h1s1_U133p2.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma 101///geo_accession: GSM643033///status: Public on Nov 01 2011///submission_date: Dec 20 2010///last_update_date: Aug 19 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma 101///organism_ch1: Homo sapiens///characteristics_ch1: histological type: Serous///characteristics_ch1.1: grade: 1///characteristics_ch1.2: Stage: Ia///characteristics_ch1.3: tissue: ovarian carcinoma tumor///characteristics_ch1.4: os event: 0///characteristics_ch1.5: os time (years): 5.60712///characteristics_ch1.6: pfs event: 0///characteristics_ch1.7: pfs time (years): 5.60712///characteristics_ch1.8: signature: STRESS///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were analyzed with Partek software (6.10.0915 version)///platform_id: GPL570///contact_name: Fatima,,Mechta-Grigoriou///contact_email: [email protected]///contact_phone: 33156246653///contact_fax: 33156246650///contact_laboratory: \Stress and Cancer\ Lab.///contact_department: INSERM U830///contact_institute: Institut Curie///contact_address: 26 rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM643nnn/GSM643033/GSM643033_OC01_ARN0158_s1h1s1_U133p2.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma 102///geo_accession: GSM643034///status: Public on Nov 01 2011///submission_date: Dec 20 2010///last_update_date: Aug 19 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma 102///organism_ch1: Homo sapiens///characteristics_ch1: histological type: Endometrioid///characteristics_ch1.1: grade: 2///characteristics_ch1.2: Stage: Ia///characteristics_ch1.3: tissue: ovarian carcinoma tumor///characteristics_ch1.4: os event: 0///characteristics_ch1.5: os time (years): 6.61191///characteristics_ch1.6: pfs event: 0///characteristics_ch1.7: pfs time (years): 6.61191///characteristics_ch1.8: signature: STRESS///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were analyzed with Partek software (6.10.0915 version)///platform_id: GPL570///contact_name: Fatima,,Mechta-Grigoriou///contact_email: [email protected]///contact_phone: 33156246653///contact_fax: 33156246650///contact_laboratory: \Stress and Cancer\ Lab.///contact_department: INSERM U830///contact_institute: Institut Curie///contact_address: 26 rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM643nnn/GSM643034/GSM643034_OC01_ARN0159_s1h1s1_U133p2.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma 103///geo_accession: GSM643035///status: Public on Nov 01 2011///submission_date: Dec 20 2010///last_update_date: Aug 19 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma 103///organism_ch1: Homo sapiens///characteristics_ch1: histological type: Serous///characteristics_ch1.1: grade: 3///characteristics_ch1.2: Stage: IV///characteristics_ch1.3: tissue: ovarian carcinoma tumor///characteristics_ch1.4: os event: 1///characteristics_ch1.5: os time (years): 2.65845///characteristics_ch1.6: pfs event: 1///characteristics_ch1.7: pfs time (years): 1.88364///characteristics_ch1.8: signature: FIBROSIS///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were analyzed with Partek software (6.10.0915 version)///platform_id: GPL570///contact_name: Fatima,,Mechta-Grigoriou///contact_email: [email protected]///contact_phone: 33156246653///contact_fax: 33156246650///contact_laboratory: \Stress and Cancer\ Lab.///contact_department: INSERM U830///contact_institute: Institut Curie///contact_address: 26 rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM643nnn/GSM643035/GSM643035_OC01_ARN0161_s1h1s1_U133p2.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma 104///geo_accession: GSM643036///status: Public on Nov 01 2011///submission_date: Dec 20 2010///last_update_date: Aug 19 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma 104///organism_ch1: Homo sapiens///characteristics_ch1: histological type: Serous///characteristics_ch1.1: grade: 3///characteristics_ch1.2: Stage: IIa///characteristics_ch1.3: tissue: ovarian carcinoma tumor///characteristics_ch1.4: os event: 1///characteristics_ch1.5: os time (years): 2.17112///characteristics_ch1.6: pfs event: 1///characteristics_ch1.7: pfs time (years): 0.774812///characteristics_ch1.8: signature: STRESS///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were analyzed with Partek software (6.10.0915 version)///platform_id: GPL570///contact_name: Fatima,,Mechta-Grigoriou///contact_email: [email protected]///contact_phone: 33156246653///contact_fax: 33156246650///contact_laboratory: \Stress and Cancer\ Lab.///contact_department: INSERM U830///contact_institute: Institut Curie///contact_address: 26 rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM643nnn/GSM643036/GSM643036_OC01_ARN0204_s1h1s1_U133p2.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma 105///geo_accession: GSM643037///status: Public on Nov 01 2011///submission_date: Dec 20 2010///last_update_date: Aug 19 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma 105///organism_ch1: Homo sapiens///characteristics_ch1: histological type: Serous///characteristics_ch1.1: grade: 3///characteristics_ch1.2: Stage: Ic///characteristics_ch1.3: tissue: ovarian carcinoma tumor///characteristics_ch1.4: os event: 0///characteristics_ch1.5: os time (years): 5.82615///characteristics_ch1.6: pfs event: 0///characteristics_ch1.7: pfs time (years): 5.82615///characteristics_ch1.8: signature: FIBROSIS///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were analyzed with Partek software (6.10.0915 version)///platform_id: GPL570///contact_name: Fatima,,Mechta-Grigoriou///contact_email: [email protected]///contact_phone: 33156246653///contact_fax: 33156246650///contact_laboratory: \Stress and Cancer\ Lab.///contact_department: INSERM U830///contact_institute: Institut Curie///contact_address: 26 rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM643nnn/GSM643037/GSM643037_OC01_ARN0206_s1h1s1_U133p2.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma 106///geo_accession: GSM643038///status: Public on Nov 01 2011///submission_date: Dec 20 2010///last_update_date: Aug 19 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma 106///organism_ch1: Homo sapiens///characteristics_ch1: histological type: Serous///characteristics_ch1.1: grade: 3///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: tissue: ovarian carcinoma tumor///characteristics_ch1.4: os event: 1///characteristics_ch1.5: os time (years): 3.81383///characteristics_ch1.6: pfs event: 1///characteristics_ch1.7: pfs time (years): 1.98494///characteristics_ch1.8: signature: FIBROSIS///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were analyzed with Partek software (6.10.0915 version)///platform_id: GPL570///contact_name: Fatima,,Mechta-Grigoriou///contact_email: [email protected]///contact_phone: 33156246653///contact_fax: 33156246650///contact_laboratory: \Stress and Cancer\ Lab.///contact_department: INSERM U830///contact_institute: Institut Curie///contact_address: 26 rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM643nnn/GSM643038/GSM643038_OC01_ARN0207_s1h1s1_U133p2.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma 107///geo_accession: GSM643039///status: Public on Nov 01 2011///submission_date: Dec 20 2010///last_update_date: Aug 19 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma 107///organism_ch1: Homo sapiens///characteristics_ch1: histological type: Adenocarcinoma///characteristics_ch1.1: grade: 3///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: tissue: ovarian carcinoma tumor///characteristics_ch1.4: os event: 1///characteristics_ch1.5: os time (years): 0.405202///characteristics_ch1.6: pfs event: 1///characteristics_ch1.7: pfs time (years): 0.202601///characteristics_ch1.8: signature: STRESS///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were analyzed with Partek software (6.10.0915 version)///platform_id: GPL570///contact_name: Fatima,,Mechta-Grigoriou///contact_email: [email protected]///contact_phone: 33156246653///contact_fax: 33156246650///contact_laboratory: \Stress and Cancer\ Lab.///contact_department: INSERM U830///contact_institute: Institut Curie///contact_address: 26 rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM643nnn/GSM643039/GSM643039_OC01_ARN0210_s1h1s1_U133p2.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma 10///geo_accession: GSM642942///status: Public on Nov 01 2011///submission_date: Dec 20 2010///last_update_date: Aug 19 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma 10///organism_ch1: Homo sapiens///characteristics_ch1: histological type: Mucinous///characteristics_ch1.1: grade: 3///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: tissue: ovarian carcinoma tumor///characteristics_ch1.4: os event: 1///characteristics_ch1.5: os time (years): 2.95962///characteristics_ch1.6: pfs event: 1///characteristics_ch1.7: pfs time (years): 1.77413///characteristics_ch1.8: signature: FIBROSIS///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were analyzed with Partek software (6.10.0915 version)///platform_id: GPL570///contact_name: Fatima,,Mechta-Grigoriou///contact_email: [email protected]///contact_phone: 33156246653///contact_fax: 33156246650///contact_laboratory: \Stress and Cancer\ Lab.///contact_department: INSERM U830///contact_institute: Institut Curie///contact_address: 26 rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM642nnn/GSM642942/GSM642942_OC01_ARN0013_s1h1s1_U133p2.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma 11///geo_accession: GSM642943///status: Public on Nov 01 2011///submission_date: Dec 20 2010///last_update_date: Aug 19 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma 11///organism_ch1: Homo sapiens///characteristics_ch1: histological type: Serous///characteristics_ch1.1: grade: 3///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: tissue: ovarian carcinoma tumor///characteristics_ch1.4: os event: 1///characteristics_ch1.5: os time (years): 2.71595///characteristics_ch1.6: pfs event: 1///characteristics_ch1.7: pfs time (years): 1.05407///characteristics_ch1.8: signature: STRESS///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were analyzed with Partek software (6.10.0915 version)///platform_id: GPL570///contact_name: Fatima,,Mechta-Grigoriou///contact_email: [email protected]///contact_phone: 33156246653///contact_fax: 33156246650///contact_laboratory: \Stress and Cancer\ Lab.///contact_department: INSERM U830///contact_institute: Institut Curie///contact_address: 26 rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM642nnn/GSM642943/GSM642943_OC01_ARN0014_s1h1s1_U133p2.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma 12///geo_accession: GSM642944///status: Public on Nov 01 2011///submission_date: Dec 20 2010///last_update_date: Aug 19 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma 12///organism_ch1: Homo sapiens///characteristics_ch1: histological type: Serous///characteristics_ch1.1: grade: 3///characteristics_ch1.2: Stage: IV///characteristics_ch1.3: tissue: ovarian carcinoma tumor///characteristics_ch1.4: os event: 1///characteristics_ch1.5: os time (years): 4.62149///characteristics_ch1.6: pfs event: 1///characteristics_ch1.7: pfs time (years): 2.80903///characteristics_ch1.8: signature: FIBROSIS///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were analyzed with Partek software (6.10.0915 version)///platform_id: GPL570///contact_name: Fatima,,Mechta-Grigoriou///contact_email: [email protected]///contact_phone: 33156246653///contact_fax: 33156246650///contact_laboratory: \Stress and Cancer\ Lab.///contact_department: INSERM U830///contact_institute: Institut Curie///contact_address: 26 rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM642nnn/GSM642944/GSM642944_OC01_ARN0015_s1h1s1_U133p2.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma 13///geo_accession: GSM642945///status: Public on Nov 01 2011///submission_date: Dec 20 2010///last_update_date: Aug 19 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma 13///organism_ch1: Homo sapiens///characteristics_ch1: histological type: Serous///characteristics_ch1.1: grade: 3///characteristics_ch1.2: Stage: IIb///characteristics_ch1.3: tissue: ovarian carcinoma tumor///characteristics_ch1.4: os event: 0///characteristics_ch1.5: os time (years): 4.09856///characteristics_ch1.6: pfs event: 1///characteristics_ch1.7: pfs time (years): 2.93224///characteristics_ch1.8: signature: STRESS///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were analyzed with Partek software (6.10.0915 version)///platform_id: GPL570///contact_name: Fatima,,Mechta-Grigoriou///contact_email: [email protected]///contact_phone: 33156246653///contact_fax: 33156246650///contact_laboratory: \Stress and Cancer\ Lab.///contact_department: INSERM U830///contact_institute: Institut Curie///contact_address: 26 rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM642nnn/GSM642945/GSM642945_OC01_ARN0019_s1h1s1_U133p2.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma 14///geo_accession: GSM642946///status: Public on Nov 01 2011///submission_date: Dec 20 2010///last_update_date: Aug 19 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma 14///organism_ch1: Homo sapiens///characteristics_ch1: histological type: Serous///characteristics_ch1.1: grade: 2///characteristics_ch1.2: Stage: Ia///characteristics_ch1.3: tissue: ovarian carcinoma tumor///characteristics_ch1.4: os event: 1///characteristics_ch1.5: os time (years): 1.47844///characteristics_ch1.6: pfs event: 1///characteristics_ch1.7: pfs time (years): 0.922656///characteristics_ch1.8: signature: FIBROSIS///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were analyzed with Partek software (6.10.0915 version)///platform_id: GPL570///contact_name: Fatima,,Mechta-Grigoriou///contact_email: [email protected]///contact_phone: 33156246653///contact_fax: 33156246650///contact_laboratory: \Stress and Cancer\ Lab.///contact_department: INSERM U830///contact_institute: Institut Curie///contact_address: 26 rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM642nnn/GSM642946/GSM642946_OC01_ARN0022_s1h1s1_U133p2.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma 15///geo_accession: GSM642947///status: Public on Nov 01 2011///submission_date: Dec 20 2010///last_update_date: Aug 19 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma 15///organism_ch1: Homo sapiens///characteristics_ch1: histological type: Serous///characteristics_ch1.1: grade: 3///characteristics_ch1.2: Stage: IV///characteristics_ch1.3: tissue: ovarian carcinoma tumor///characteristics_ch1.4: os event: 0///characteristics_ch1.5: os time (years): 4.62423///characteristics_ch1.6: pfs event: 0///characteristics_ch1.7: pfs time (years): 4.62423///characteristics_ch1.8: signature: FIBROSIS///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were analyzed with Partek software (6.10.0915 version)///platform_id: GPL570///contact_name: Fatima,,Mechta-Grigoriou///contact_email: [email protected]///contact_phone: 33156246653///contact_fax: 33156246650///contact_laboratory: \Stress and Cancer\ Lab.///contact_department: INSERM U830///contact_institute: Institut Curie///contact_address: 26 rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM642nnn/GSM642947/GSM642947_OC01_ARN0023_s1h1s1_U133p2.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma 16///geo_accession: GSM642948///status: Public on Nov 01 2011///submission_date: Dec 20 2010///last_update_date: Aug 19 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma 16///organism_ch1: Homo sapiens///characteristics_ch1: histological type: Serous///characteristics_ch1.1: grade: 3///characteristics_ch1.2: Stage: IV///characteristics_ch1.3: tissue: ovarian carcinoma tumor///characteristics_ch1.4: os event: 1///characteristics_ch1.5: os time (years): 5.02396///characteristics_ch1.6: pfs event: 1///characteristics_ch1.7: pfs time (years): 4.29295///characteristics_ch1.8: signature: FIBROSIS///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were analyzed with Partek software (6.10.0915 version)///platform_id: GPL570///contact_name: Fatima,,Mechta-Grigoriou///contact_email: [email protected]///contact_phone: 33156246653///contact_fax: 33156246650///contact_laboratory: \Stress and Cancer\ Lab.///contact_department: INSERM U830///contact_institute: Institut Curie///contact_address: 26 rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM642nnn/GSM642948/GSM642948_OC01_ARN0025_s1h1s1_U133p2.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma 17///geo_accession: GSM642949///status: Public on Nov 01 2011///submission_date: Dec 20 2010///last_update_date: Aug 19 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma 17///organism_ch1: Homo sapiens///characteristics_ch1: histological type: Serous///characteristics_ch1.1: grade: 2///characteristics_ch1.2: Stage: IV///characteristics_ch1.3: tissue: ovarian carcinoma tumor///characteristics_ch1.4: os event: 0///characteristics_ch1.5: os time (years): 0.744695///characteristics_ch1.6: pfs event: 0///characteristics_ch1.7: pfs time (years): 0.744695///characteristics_ch1.8: signature: FIBROSIS///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were analyzed with Partek software (6.10.0915 version)///platform_id: GPL570///contact_name: Fatima,,Mechta-Grigoriou///contact_email: [email protected]///contact_phone: 33156246653///contact_fax: 33156246650///contact_laboratory: \Stress and Cancer\ Lab.///contact_department: INSERM U830///contact_institute: Institut Curie///contact_address: 26 rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM642nnn/GSM642949/GSM642949_OC01_ARN0026_s2h1s1_U133p2.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma 18///geo_accession: GSM642950///status: Public on Nov 01 2011///submission_date: Dec 20 2010///last_update_date: Aug 19 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma 18///organism_ch1: Homo sapiens///characteristics_ch1: histological type: Endometrioid///characteristics_ch1.1: grade: 3///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: tissue: ovarian carcinoma tumor///characteristics_ch1.4: os event: 1///characteristics_ch1.5: os time (years): 1.84531///characteristics_ch1.6: pfs event: 1///characteristics_ch1.7: pfs time (years): 1.45106///characteristics_ch1.8: signature: STRESS///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were analyzed with Partek software (6.10.0915 version)///platform_id: GPL570///contact_name: Fatima,,Mechta-Grigoriou///contact_email: [email protected]///contact_phone: 33156246653///contact_fax: 33156246650///contact_laboratory: \Stress and Cancer\ Lab.///contact_department: INSERM U830///contact_institute: Institut Curie///contact_address: 26 rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM642nnn/GSM642950/GSM642950_OC01_ARN0027_s2h1s1_U133p2.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma 19///geo_accession: GSM642951///status: Public on Nov 01 2011///submission_date: Dec 20 2010///last_update_date: Aug 19 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma 19///organism_ch1: Homo sapiens///characteristics_ch1: histological type: Serous///characteristics_ch1.1: grade: 1///characteristics_ch1.2: Stage: IV///characteristics_ch1.3: tissue: ovarian carcinoma tumor///characteristics_ch1.4: os event: 1///characteristics_ch1.5: os time (years): 1.68652///characteristics_ch1.6: pfs event: 1///characteristics_ch1.7: pfs time (years): 0.824093///characteristics_ch1.8: signature: FIBROSIS///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were analyzed with Partek software (6.10.0915 version)///platform_id: GPL570///contact_name: Fatima,,Mechta-Grigoriou///contact_email: [email protected]///contact_phone: 33156246653///contact_fax: 33156246650///contact_laboratory: \Stress and Cancer\ Lab.///contact_department: INSERM U830///contact_institute: Institut Curie///contact_address: 26 rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM642nnn/GSM642951/GSM642951_OC01_ARN0028_s1h1s1_U133p2.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma 1///geo_accession: GSM642933///status: Public on Nov 01 2011///submission_date: Dec 20 2010///last_update_date: Aug 19 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma 1///organism_ch1: Homo sapiens///characteristics_ch1: histological type: Serous///characteristics_ch1.1: grade: 3///characteristics_ch1.2: Stage: Ib///characteristics_ch1.3: tissue: ovarian carcinoma tumor///characteristics_ch1.4: os event: 0///characteristics_ch1.5: os time (years): 20.2218///characteristics_ch1.6: pfs event: 0///characteristics_ch1.7: pfs time (years): 20.2218///characteristics_ch1.8: signature: STRESS///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were analyzed with Partek software (6.10.0915 version)///platform_id: GPL570///contact_name: Fatima,,Mechta-Grigoriou///contact_email: [email protected]///contact_phone: 33156246653///contact_fax: 33156246650///contact_laboratory: \Stress and Cancer\ Lab.///contact_department: INSERM U830///contact_institute: Institut Curie///contact_address: 26 rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM642nnn/GSM642933/GSM642933_OC01_ARN0001_s1h1s1_U133p2.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma 20///geo_accession: GSM642952///status: Public on Nov 01 2011///submission_date: Dec 20 2010///last_update_date: Aug 19 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma 20///organism_ch1: Homo sapiens///characteristics_ch1: histological type: Endometrioid///characteristics_ch1.1: grade: 3///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: tissue: ovarian carcinoma tumor///characteristics_ch1.4: os event: 1///characteristics_ch1.5: os time (years): 1.09514///characteristics_ch1.6: pfs event: 1///characteristics_ch1.7: pfs time (years): 0.887064///characteristics_ch1.8: signature: FIBROSIS///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were analyzed with Partek software (6.10.0915 version)///platform_id: GPL570///contact_name: Fatima,,Mechta-Grigoriou///contact_email: [email protected]///contact_phone: 33156246653///contact_fax: 33156246650///contact_laboratory: \Stress and Cancer\ Lab.///contact_department: INSERM U830///contact_institute: Institut Curie///contact_address: 26 rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM642nnn/GSM642952/GSM642952_OC01_ARN0030_s1h1s1_U133p2.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma 21///geo_accession: GSM642953///status: Public on Nov 01 2011///submission_date: Dec 20 2010///last_update_date: Aug 19 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma 21///organism_ch1: Homo sapiens///characteristics_ch1: histological type: Serous///characteristics_ch1.1: grade: 2///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: tissue: ovarian carcinoma tumor///characteristics_ch1.4: os event: 1///characteristics_ch1.5: os time (years): 2.423///characteristics_ch1.6: pfs event: 1///characteristics_ch1.7: pfs time (years): 1.11431///characteristics_ch1.8: signature: FIBROSIS///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were analyzed with Partek software (6.10.0915 version)///platform_id: GPL570///contact_name: Fatima,,Mechta-Grigoriou///contact_email: [email protected]///contact_phone: 33156246653///contact_fax: 33156246650///contact_laboratory: \Stress and Cancer\ Lab.///contact_department: INSERM U830///contact_institute: Institut Curie///contact_address: 26 rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM642nnn/GSM642953/GSM642953_OC01_ARN0031_s2h1s1_U133p2.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma 22///geo_accession: GSM642954///status: Public on Nov 01 2011///submission_date: Dec 20 2010///last_update_date: Aug 19 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma 22///organism_ch1: Homo sapiens///characteristics_ch1: histological type: Mucinous///characteristics_ch1.1: grade: 2///characteristics_ch1.2: Stage: Ia///characteristics_ch1.3: tissue: ovarian carcinoma tumor///characteristics_ch1.4: os event: 0///characteristics_ch1.5: os time (years): 12.2163///characteristics_ch1.6: pfs event: 0///characteristics_ch1.7: pfs time (years): 12.2163///characteristics_ch1.8: signature: STRESS///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were analyzed with Partek software (6.10.0915 version)///platform_id: GPL570///contact_name: Fatima,,Mechta-Grigoriou///contact_email: [email protected]///contact_phone: 33156246653///contact_fax: 33156246650///contact_laboratory: \Stress and Cancer\ Lab.///contact_department: INSERM U830///contact_institute: Institut Curie///contact_address: 26 rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM642nnn/GSM642954/GSM642954_OC01_ARN0032_s1h1s1_U133p2.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma 23///geo_accession: GSM642955///status: Public on Nov 01 2011///submission_date: Dec 20 2010///last_update_date: Aug 19 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma 23///organism_ch1: Homo sapiens///characteristics_ch1: histological type: Serous///characteristics_ch1.1: grade: 3///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: tissue: ovarian carcinoma tumor///characteristics_ch1.4: os event: 1///characteristics_ch1.5: os time (years): 1.81246///characteristics_ch1.6: pfs event: 1///characteristics_ch1.7: pfs time (years): 0.900753///characteristics_ch1.8: signature: STRESS///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were analyzed with Partek software (6.10.0915 version)///platform_id: GPL570///contact_name: Fatima,,Mechta-Grigoriou///contact_email: [email protected]///contact_phone: 33156246653///contact_fax: 33156246650///contact_laboratory: \Stress and Cancer\ Lab.///contact_department: INSERM U830///contact_institute: Institut Curie///contact_address: 26 rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM642nnn/GSM642955/GSM642955_OC01_ARN0033_s2h1s1_U133p2.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma 24///geo_accession: GSM642956///status: Public on Nov 01 2011///submission_date: Dec 20 2010///last_update_date: Aug 19 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma 24///organism_ch1: Homo sapiens///characteristics_ch1: histological type: Serous///characteristics_ch1.1: grade: 3///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: tissue: ovarian carcinoma tumor///characteristics_ch1.4: os event: 0///characteristics_ch1.5: os time (years): 11.1431///characteristics_ch1.6: pfs event: 1///characteristics_ch1.7: pfs time (years): 3.91239///characteristics_ch1.8: signature: FIBROSIS///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were analyzed with Partek software (6.10.0915 version)///platform_id: GPL570///contact_name: Fatima,,Mechta-Grigoriou///contact_email: [email protected]///contact_phone: 33156246653///contact_fax: 33156246650///contact_laboratory: \Stress and Cancer\ Lab.///contact_department: INSERM U830///contact_institute: Institut Curie///contact_address: 26 rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM642nnn/GSM642956/GSM642956_OC01_ARN0034_s1h1s1_U133p2.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma 25///geo_accession: GSM642957///status: Public on Nov 01 2011///submission_date: Dec 20 2010///last_update_date: Aug 19 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma 25///organism_ch1: Homo sapiens///characteristics_ch1: histological type: Serous///characteristics_ch1.1: grade: 2///characteristics_ch1.2: Stage: Ic///characteristics_ch1.3: tissue: ovarian carcinoma tumor///characteristics_ch1.4: os event: 1///characteristics_ch1.5: os time (years): 0.689938///characteristics_ch1.6: pfs event: 0///characteristics_ch1.7: pfs time (years): 0.689938///characteristics_ch1.8: signature: FIBROSIS///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were analyzed with Partek software (6.10.0915 version)///platform_id: GPL570///contact_name: Fatima,,Mechta-Grigoriou///contact_email: [email protected]///contact_phone: 33156246653///contact_fax: 33156246650///contact_laboratory: \Stress and Cancer\ Lab.///contact_department: INSERM U830///contact_institute: Institut Curie///contact_address: 26 rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM642nnn/GSM642957/GSM642957_OC01_ARN0036_s1h1s1_U133p2.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma 26///geo_accession: GSM642958///status: Public on Nov 01 2011///submission_date: Dec 20 2010///last_update_date: Aug 19 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma 26///organism_ch1: Homo sapiens///characteristics_ch1: histological type: Serous///characteristics_ch1.1: grade: 2///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: tissue: ovarian carcinoma tumor///characteristics_ch1.4: os event: 1///characteristics_ch1.5: os time (years): 1.84805///characteristics_ch1.6: pfs event: 1///characteristics_ch1.7: pfs time (years): 1.66461///characteristics_ch1.8: signature: FIBROSIS///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were analyzed with Partek software (6.10.0915 version)///platform_id: GPL570///contact_name: Fatima,,Mechta-Grigoriou///contact_email: [email protected]///contact_phone: 33156246653///contact_fax: 33156246650///contact_laboratory: \Stress and Cancer\ Lab.///contact_department: INSERM U830///contact_institute: Institut Curie///contact_address: 26 rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM642nnn/GSM642958/GSM642958_OC01_ARN0037_s1h1s1_U133p2.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma 27///geo_accession: GSM642959///status: Public on Nov 01 2011///submission_date: Dec 20 2010///last_update_date: Aug 19 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma 27///organism_ch1: Homo sapiens///characteristics_ch1: histological type: Serous///characteristics_ch1.1: grade: 3///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: tissue: ovarian carcinoma tumor///characteristics_ch1.4: os event: 1///characteristics_ch1.5: os time (years): 2.97878///characteristics_ch1.6: pfs event: 1///characteristics_ch1.7: pfs time (years): 1.27036///characteristics_ch1.8: signature: STRESS///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were analyzed with Partek software (6.10.0915 version)///platform_id: GPL570///contact_name: Fatima,,Mechta-Grigoriou///contact_email: [email protected]///contact_phone: 33156246653///contact_fax: 33156246650///contact_laboratory: \Stress and Cancer\ Lab.///contact_department: INSERM U830///contact_institute: Institut Curie///contact_address: 26 rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM642nnn/GSM642959/GSM642959_OC01_ARN0038_s1h1s1_U133p2.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma 28///geo_accession: GSM642960///status: Public on Nov 01 2011///submission_date: Dec 20 2010///last_update_date: Aug 19 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma 28///organism_ch1: Homo sapiens///characteristics_ch1: histological type: Serous///characteristics_ch1.1: grade: 3///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: tissue: ovarian carcinoma tumor///characteristics_ch1.4: os event: 1///characteristics_ch1.5: os time (years): 1.90007///characteristics_ch1.6: pfs event: 1///characteristics_ch1.7: pfs time (years): 1.52225///characteristics_ch1.8: signature: FIBROSIS///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were analyzed with Partek software (6.10.0915 version)///platform_id: GPL570///contact_name: Fatima,,Mechta-Grigoriou///contact_email: [email protected]///contact_phone: 33156246653///contact_fax: 33156246650///contact_laboratory: \Stress and Cancer\ Lab.///contact_department: INSERM U830///contact_institute: Institut Curie///contact_address: 26 rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM642nnn/GSM642960/GSM642960_OC01_ARN0039_s1h1s1_U133p2.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma 29///geo_accession: GSM642961///status: Public on Nov 01 2011///submission_date: Dec 20 2010///last_update_date: Aug 19 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma 29///organism_ch1: Homo sapiens///characteristics_ch1: histological type: Serous///characteristics_ch1.1: grade: 3///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: tissue: ovarian carcinoma tumor///characteristics_ch1.4: os event: 0///characteristics_ch1.5: os time (years): 8.19439///characteristics_ch1.6: pfs event: 1///characteristics_ch1.7: pfs time (years): 1.85352///characteristics_ch1.8: signature: FIBROSIS///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were analyzed with Partek software (6.10.0915 version)///platform_id: GPL570///contact_name: Fatima,,Mechta-Grigoriou///contact_email: [email protected]///contact_phone: 33156246653///contact_fax: 33156246650///contact_laboratory: \Stress and Cancer\ Lab.///contact_department: INSERM U830///contact_institute: Institut Curie///contact_address: 26 rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM642nnn/GSM642961/GSM642961_OC01_ARN0040_s1h1s1_U133p2.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma 2///geo_accession: GSM642934///status: Public on Nov 01 2011///submission_date: Dec 20 2010///last_update_date: Aug 19 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma 2///organism_ch1: Homo sapiens///characteristics_ch1: histological type: Endometrioid///characteristics_ch1.1: grade: 2///characteristics_ch1.2: Stage: IIb///characteristics_ch1.3: tissue: ovarian carcinoma tumor///characteristics_ch1.4: os event: 0///characteristics_ch1.5: os time (years): 9.71663///characteristics_ch1.6: pfs event: 0///characteristics_ch1.7: pfs time (years): 9.71663///characteristics_ch1.8: signature: STRESS///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were analyzed with Partek software (6.10.0915 version)///platform_id: GPL570///contact_name: Fatima,,Mechta-Grigoriou///contact_email: [email protected]///contact_phone: 33156246653///contact_fax: 33156246650///contact_laboratory: \Stress and Cancer\ Lab.///contact_department: INSERM U830///contact_institute: Institut Curie///contact_address: 26 rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM642nnn/GSM642934/GSM642934_OC01_ARN0002_s1h1s1_U133p2.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma 30///geo_accession: GSM642962///status: Public on Nov 01 2011///submission_date: Dec 20 2010///last_update_date: Aug 19 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma 30///organism_ch1: Homo sapiens///characteristics_ch1: histological type: Clear Cells///characteristics_ch1.1: grade: 2///characteristics_ch1.2: Stage: IIIb///characteristics_ch1.3: tissue: ovarian carcinoma tumor///characteristics_ch1.4: os event: 1///characteristics_ch1.5: os time (years): 2.17385///characteristics_ch1.6: pfs event: 1///characteristics_ch1.7: pfs time (years): 0.843258///characteristics_ch1.8: signature: STRESS///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were analyzed with Partek software (6.10.0915 version)///platform_id: GPL570///contact_name: Fatima,,Mechta-Grigoriou///contact_email: [email protected]///contact_phone: 33156246653///contact_fax: 33156246650///contact_laboratory: \Stress and Cancer\ Lab.///contact_department: INSERM U830///contact_institute: Institut Curie///contact_address: 26 rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM642nnn/GSM642962/GSM642962_OC01_ARN0041_s1h1s1_U133p2.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma 31///geo_accession: GSM642963///status: Public on Nov 01 2011///submission_date: Dec 20 2010///last_update_date: Aug 19 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma 31///organism_ch1: Homo sapiens///characteristics_ch1: histological type: Mucinous///characteristics_ch1.1: grade: 1///characteristics_ch1.2: Stage: Ia///characteristics_ch1.3: tissue: ovarian carcinoma tumor///characteristics_ch1.4: os event: 0///characteristics_ch1.5: os time (years): 6.51061///characteristics_ch1.6: pfs event: 0///characteristics_ch1.7: pfs time (years): 6.51061///characteristics_ch1.8: signature: STRESS///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were analyzed with Partek software (6.10.0915 version)///platform_id: GPL570///contact_name: Fatima,,Mechta-Grigoriou///contact_email: [email protected]///contact_phone: 33156246653///contact_fax: 33156246650///contact_laboratory: \Stress and Cancer\ Lab.///contact_department: INSERM U830///contact_institute: Institut Curie///contact_address: 26 rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM642nnn/GSM642963/GSM642963_OC01_ARN0042_s1h1s1_U133p2.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma 32///geo_accession: GSM642964///status: Public on Nov 01 2011///submission_date: Dec 20 2010///last_update_date: Aug 19 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma 32///organism_ch1: Homo sapiens///characteristics_ch1: histological type: Serous///characteristics_ch1.1: grade: 3///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: tissue: ovarian carcinoma tumor///characteristics_ch1.4: os event: 1///characteristics_ch1.5: os time (years): 6.25873///characteristics_ch1.6: pfs event: 1///characteristics_ch1.7: pfs time (years): 1.51677///characteristics_ch1.8: signature: FIBROSIS///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were analyzed with Partek software (6.10.0915 version)///platform_id: GPL570///contact_name: Fatima,,Mechta-Grigoriou///contact_email: [email protected]///contact_phone: 33156246653///contact_fax: 33156246650///contact_laboratory: \Stress and Cancer\ Lab.///contact_department: INSERM U830///contact_institute: Institut Curie///contact_address: 26 rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM642nnn/GSM642964/GSM642964_OC01_ARN0043_s2h1s1_U133p2.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma 33///geo_accession: GSM642965///status: Public on Nov 01 2011///submission_date: Dec 20 2010///last_update_date: Aug 19 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma 33///organism_ch1: Homo sapiens///characteristics_ch1: histological type: Adenocarcinoma///characteristics_ch1.1: grade: 3///characteristics_ch1.2: Stage: IV///characteristics_ch1.3: tissue: ovarian carcinoma tumor///characteristics_ch1.4: os event: 1///characteristics_ch1.5: os time (years): 3.90144///characteristics_ch1.6: pfs event: 1///characteristics_ch1.7: pfs time (years): 1.94661///characteristics_ch1.8: signature: FIBROSIS///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were analyzed with Partek software (6.10.0915 version)///platform_id: GPL570///contact_name: Fatima,,Mechta-Grigoriou///contact_email: [email protected]///contact_phone: 33156246653///contact_fax: 33156246650///contact_laboratory: \Stress and Cancer\ Lab.///contact_department: INSERM U830///contact_institute: Institut Curie///contact_address: 26 rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM642nnn/GSM642965/GSM642965_OC01_ARN0045_s1h1s1_U133p2.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma 34///geo_accession: GSM642966///status: Public on Nov 01 2011///submission_date: Dec 20 2010///last_update_date: Aug 19 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma 34///organism_ch1: Homo sapiens///characteristics_ch1: histological type: Serous///characteristics_ch1.1: grade: 3///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: tissue: ovarian carcinoma tumor///characteristics_ch1.4: os event: 1///characteristics_ch1.5: os time (years): 1.42916///characteristics_ch1.6: pfs event: 0///characteristics_ch1.7: pfs time (years): 1.42916///characteristics_ch1.8: signature: STRESS///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were analyzed with Partek software (6.10.0915 version)///platform_id: GPL570///contact_name: Fatima,,Mechta-Grigoriou///contact_email: [email protected]///contact_phone: 33156246653///contact_fax: 33156246650///contact_laboratory: \Stress and Cancer\ Lab.///contact_department: INSERM U830///contact_institute: Institut Curie///contact_address: 26 rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM642nnn/GSM642966/GSM642966_OC01_ARN0049_s2h1s1_U133p2.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma 35///geo_accession: GSM642967///status: Public on Nov 01 2011///submission_date: Dec 20 2010///last_update_date: Aug 19 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma 35///organism_ch1: Homo sapiens///characteristics_ch1: histological type: Serous///characteristics_ch1.1: grade: 2///characteristics_ch1.2: Stage: Ia///characteristics_ch1.3: tissue: ovarian carcinoma tumor///characteristics_ch1.4: os event: 1///characteristics_ch1.5: os time (years): 5.32512///characteristics_ch1.6: pfs event: 1///characteristics_ch1.7: pfs time (years): 2.84736///characteristics_ch1.8: signature: STRESS///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were analyzed with Partek software (6.10.0915 version)///platform_id: GPL570///contact_name: Fatima,,Mechta-Grigoriou///contact_email: [email protected]///contact_phone: 33156246653///contact_fax: 33156246650///contact_laboratory: \Stress and Cancer\ Lab.///contact_department: INSERM U830///contact_institute: Institut Curie///contact_address: 26 rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM642nnn/GSM642967/GSM642967_OC01_ARN0050_s2h1s1_U133p2.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma 36///geo_accession: GSM642968///status: Public on Nov 01 2011///submission_date: Dec 20 2010///last_update_date: Aug 19 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma 36///organism_ch1: Homo sapiens///characteristics_ch1: histological type: Serous///characteristics_ch1.1: grade: 3///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: tissue: ovarian carcinoma tumor///characteristics_ch1.4: os event: 0///characteristics_ch1.5: os time (years): 10.0616///characteristics_ch1.6: pfs event: 0///characteristics_ch1.7: pfs time (years): 10.0616///characteristics_ch1.8: signature: STRESS///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were analyzed with Partek software (6.10.0915 version)///platform_id: GPL570///contact_name: Fatima,,Mechta-Grigoriou///contact_email: [email protected]///contact_phone: 33156246653///contact_fax: 33156246650///contact_laboratory: \Stress and Cancer\ Lab.///contact_department: INSERM U830///contact_institute: Institut Curie///contact_address: 26 rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM642nnn/GSM642968/GSM642968_OC01_ARN0052_s2h1s1_U133p2.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma 37///geo_accession: GSM642969///status: Public on Nov 01 2011///submission_date: Dec 20 2010///last_update_date: Aug 19 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma 37///organism_ch1: Homo sapiens///characteristics_ch1: histological type: Serous///characteristics_ch1.1: grade: 2///characteristics_ch1.2: Stage: IV///characteristics_ch1.3: tissue: ovarian carcinoma tumor///characteristics_ch1.4: os event: 1///characteristics_ch1.5: os time (years): 2.18207///characteristics_ch1.6: pfs event: 1///characteristics_ch1.7: pfs time (years): 1.14442///characteristics_ch1.8: signature: FIBROSIS///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were analyzed with Partek software (6.10.0915 version)///platform_id: GPL570///contact_name: Fatima,,Mechta-Grigoriou///contact_email: [email protected]///contact_phone: 33156246653///contact_fax: 33156246650///contact_laboratory: \Stress and Cancer\ Lab.///contact_department: INSERM U830///contact_institute: Institut Curie///contact_address: 26 rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM642nnn/GSM642969/GSM642969_OC01_ARN0054_s2h1s1_U133p2.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma 38///geo_accession: GSM642970///status: Public on Nov 01 2011///submission_date: Dec 20 2010///last_update_date: Aug 19 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma 38///organism_ch1: Homo sapiens///characteristics_ch1: histological type: Mucinous///characteristics_ch1.1: grade: 2///characteristics_ch1.2: Stage: Ic///characteristics_ch1.3: tissue: ovarian carcinoma tumor///characteristics_ch1.4: os event: 1///characteristics_ch1.5: os time (years): 2.46133///characteristics_ch1.6: pfs event: 1///characteristics_ch1.7: pfs time (years): 1.95209///characteristics_ch1.8: signature: STRESS///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were analyzed with Partek software (6.10.0915 version)///platform_id: GPL570///contact_name: Fatima,,Mechta-Grigoriou///contact_email: [email protected]///contact_phone: 33156246653///contact_fax: 33156246650///contact_laboratory: \Stress and Cancer\ Lab.///contact_department: INSERM U830///contact_institute: Institut Curie///contact_address: 26 rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM642nnn/GSM642970/GSM642970_OC01_ARN0057_s2h1s1_U133p2.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma 39///geo_accession: GSM642971///status: Public on Nov 01 2011///submission_date: Dec 20 2010///last_update_date: Aug 19 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma 39///organism_ch1: Homo sapiens///characteristics_ch1: histological type: Clear Cells///characteristics_ch1.1: grade: 3///characteristics_ch1.2: Stage: Ic///characteristics_ch1.3: tissue: ovarian carcinoma tumor///characteristics_ch1.4: os event: 0///characteristics_ch1.5: os time (years): 9.99042///characteristics_ch1.6: pfs event: 0///characteristics_ch1.7: pfs time (years): 9.99042///characteristics_ch1.8: signature: STRESS///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were analyzed with Partek software (6.10.0915 version)///platform_id: GPL570///contact_name: Fatima,,Mechta-Grigoriou///contact_email: [email protected]///contact_phone: 33156246653///contact_fax: 33156246650///contact_laboratory: \Stress and Cancer\ Lab.///contact_department: INSERM U830///contact_institute: Institut Curie///contact_address: 26 rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM642nnn/GSM642971/GSM642971_OC01_ARN0058_s2h1s1_U133p2.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma 3///geo_accession: GSM642935///status: Public on Nov 01 2011///submission_date: Dec 20 2010///last_update_date: Aug 19 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma 3///organism_ch1: Homo sapiens///characteristics_ch1: histological type: Serous///characteristics_ch1.1: grade: 3///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: tissue: ovarian carcinoma tumor///characteristics_ch1.4: os event: 1///characteristics_ch1.5: os time (years): 6.04517///characteristics_ch1.6: pfs event: 1///characteristics_ch1.7: pfs time (years): 3.08556///characteristics_ch1.8: signature: FIBROSIS///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were analyzed with Partek software (6.10.0915 version)///platform_id: GPL570///contact_name: Fatima,,Mechta-Grigoriou///contact_email: [email protected]///contact_phone: 33156246653///contact_fax: 33156246650///contact_laboratory: \Stress and Cancer\ Lab.///contact_department: INSERM U830///contact_institute: Institut Curie///contact_address: 26 rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM642nnn/GSM642935/GSM642935_OC01_ARN0004_s1h1s1_U133p2.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma 40///geo_accession: GSM642972///status: Public on Nov 01 2011///submission_date: Dec 20 2010///last_update_date: Aug 19 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma 40///organism_ch1: Homo sapiens///characteristics_ch1: histological type: Serous///characteristics_ch1.1: grade: 3///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: tissue: ovarian carcinoma tumor///characteristics_ch1.4: os event: 1///characteristics_ch1.5: os time (years): 6.79535///characteristics_ch1.6: pfs event: 1///characteristics_ch1.7: pfs time (years): 3.96715///characteristics_ch1.8: signature: STRESS///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were analyzed with Partek software (6.10.0915 version)///platform_id: GPL570///contact_name: Fatima,,Mechta-Grigoriou///contact_email: [email protected]///contact_phone: 33156246653///contact_fax: 33156246650///contact_laboratory: \Stress and Cancer\ Lab.///contact_department: INSERM U830///contact_institute: Institut Curie///contact_address: 26 rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM642nnn/GSM642972/GSM642972_OC01_ARN0062_s2h1s1_U133p2.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma 41///geo_accession: GSM642973///status: Public on Nov 01 2011///submission_date: Dec 20 2010///last_update_date: Aug 19 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma 41///organism_ch1: Homo sapiens///characteristics_ch1: histological type: Serous///characteristics_ch1.1: grade: 2///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: tissue: ovarian carcinoma tumor///characteristics_ch1.4: os event: 1///characteristics_ch1.5: os time (years): 4.55578///characteristics_ch1.6: pfs event: 1///characteristics_ch1.7: pfs time (years): 1.79877///characteristics_ch1.8: signature: STRESS///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were analyzed with Partek software (6.10.0915 version)///platform_id: GPL570///contact_name: Fatima,,Mechta-Grigoriou///contact_email: [email protected]///contact_phone: 33156246653///contact_fax: 33156246650///contact_laboratory: \Stress and Cancer\ Lab.///contact_department: INSERM U830///contact_institute: Institut Curie///contact_address: 26 rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM642nnn/GSM642973/GSM642973_OC01_ARN0063_s2h1s1_U133p2.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma 42///geo_accession: GSM642974///status: Public on Nov 01 2011///submission_date: Dec 20 2010///last_update_date: Aug 19 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma 42///organism_ch1: Homo sapiens///characteristics_ch1: histological type: Serous///characteristics_ch1.1: grade: 3///characteristics_ch1.2: Stage: IV///characteristics_ch1.3: tissue: ovarian carcinoma tumor///characteristics_ch1.4: os event: 1///characteristics_ch1.5: os time (years): 0.837782///characteristics_ch1.6: pfs event: 1///characteristics_ch1.7: pfs time (years): 0.479124///characteristics_ch1.8: signature: FIBROSIS///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were analyzed with Partek software (6.10.0915 version)///platform_id: GPL570///contact_name: Fatima,,Mechta-Grigoriou///contact_email: [email protected]///contact_phone: 33156246653///contact_fax: 33156246650///contact_laboratory: \Stress and Cancer\ Lab.///contact_department: INSERM U830///contact_institute: Institut Curie///contact_address: 26 rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM642nnn/GSM642974/GSM642974_OC01_ARN0064_s2h1s1_U133p2.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma 43///geo_accession: GSM642975///status: Public on Nov 01 2011///submission_date: Dec 20 2010///last_update_date: Aug 19 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma 43///organism_ch1: Homo sapiens///characteristics_ch1: histological type: Mucinous///characteristics_ch1.1: grade: 2///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: tissue: ovarian carcinoma tumor///characteristics_ch1.4: os event: 1///characteristics_ch1.5: os time (years): 0.25462///characteristics_ch1.6: pfs event: 1///characteristics_ch1.7: pfs time (years): 0.172485///characteristics_ch1.8: signature: STRESS///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were analyzed with Partek software (6.10.0915 version)///platform_id: GPL570///contact_name: Fatima,,Mechta-Grigoriou///contact_email: [email protected]///contact_phone: 33156246653///contact_fax: 33156246650///contact_laboratory: \Stress and Cancer\ Lab.///contact_department: INSERM U830///contact_institute: Institut Curie///contact_address: 26 rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM642nnn/GSM642975/GSM642975_OC01_ARN0065_s2h1s1_U133p2.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma 44///geo_accession: GSM642976///status: Public on Nov 01 2011///submission_date: Dec 20 2010///last_update_date: Aug 19 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma 44///organism_ch1: Homo sapiens///characteristics_ch1: histological type: Serous///characteristics_ch1.1: grade: 3///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: tissue: ovarian carcinoma tumor///characteristics_ch1.4: os event: 1///characteristics_ch1.5: os time (years): 2.48049///characteristics_ch1.6: pfs event: 1///characteristics_ch1.7: pfs time (years): 0.780287///characteristics_ch1.8: signature: STRESS///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were analyzed with Partek software (6.10.0915 version)///platform_id: GPL570///contact_name: Fatima,,Mechta-Grigoriou///contact_email: [email protected]///contact_phone: 33156246653///contact_fax: 33156246650///contact_laboratory: \Stress and Cancer\ Lab.///contact_department: INSERM U830///contact_institute: Institut Curie///contact_address: 26 rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM642nnn/GSM642976/GSM642976_OC01_ARN0066_s2h1s1_U133p2.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma 45///geo_accession: GSM642977///status: Public on Nov 01 2011///submission_date: Dec 20 2010///last_update_date: Aug 19 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma 45///organism_ch1: Homo sapiens///characteristics_ch1: histological type: Mucinous///characteristics_ch1.1: grade: 2///characteristics_ch1.2: Stage: Ic///characteristics_ch1.3: tissue: ovarian carcinoma tumor///characteristics_ch1.4: os event: 0///characteristics_ch1.5: os time (years): 6.67214///characteristics_ch1.6: pfs event: 0///characteristics_ch1.7: pfs time (years): 6.67214///characteristics_ch1.8: signature: STRESS///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were analyzed with Partek software (6.10.0915 version)///platform_id: GPL570///contact_name: Fatima,,Mechta-Grigoriou///contact_email: [email protected]///contact_phone: 33156246653///contact_fax: 33156246650///contact_laboratory: \Stress and Cancer\ Lab.///contact_department: INSERM U830///contact_institute: Institut Curie///contact_address: 26 rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM642nnn/GSM642977/GSM642977_OC01_ARN0067_s2h1s1_U133p2.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma 46///geo_accession: GSM642978///status: Public on Nov 01 2011///submission_date: Dec 20 2010///last_update_date: Aug 19 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma 46///organism_ch1: Homo sapiens///characteristics_ch1: histological type: Serous///characteristics_ch1.1: grade: 3///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: tissue: ovarian carcinoma tumor///characteristics_ch1.4: os event: 0///characteristics_ch1.5: os time (years): 4.69268///characteristics_ch1.6: pfs event: 0///characteristics_ch1.7: pfs time (years): 4.69268///characteristics_ch1.8: signature: STRESS///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were analyzed with Partek software (6.10.0915 version)///platform_id: GPL570///contact_name: Fatima,,Mechta-Grigoriou///contact_email: [email protected]///contact_phone: 33156246653///contact_fax: 33156246650///contact_laboratory: \Stress and Cancer\ Lab.///contact_department: INSERM U830///contact_institute: Institut Curie///contact_address: 26 rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM642nnn/GSM642978/GSM642978_OC01_ARN0070_s2h1s1_U133p2.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma 47///geo_accession: GSM642979///status: Public on Nov 01 2011///submission_date: Dec 20 2010///last_update_date: Aug 19 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma 47///organism_ch1: Homo sapiens///characteristics_ch1: histological type: Serous///characteristics_ch1.1: grade: 2///characteristics_ch1.2: Stage: IIb///characteristics_ch1.3: tissue: ovarian carcinoma tumor///characteristics_ch1.4: os event: 1///characteristics_ch1.5: os time (years): 1.55236///characteristics_ch1.6: pfs event: 0///characteristics_ch1.7: pfs time (years): 1.55236///characteristics_ch1.8: signature: FIBROSIS///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were analyzed with Partek software (6.10.0915 version)///platform_id: GPL570///contact_name: Fatima,,Mechta-Grigoriou///contact_email: [email protected]///contact_phone: 33156246653///contact_fax: 33156246650///contact_laboratory: \Stress and Cancer\ Lab.///contact_department: INSERM U830///contact_institute: Institut Curie///contact_address: 26 rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM642nnn/GSM642979/GSM642979_OC01_ARN0072_s1h1s1_U133p2.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma 48///geo_accession: GSM642980///status: Public on Nov 01 2011///submission_date: Dec 20 2010///last_update_date: Aug 19 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma 48///organism_ch1: Homo sapiens///characteristics_ch1: histological type: Serous///characteristics_ch1.1: grade: 3///characteristics_ch1.2: Stage: Ib///characteristics_ch1.3: tissue: ovarian carcinoma tumor///characteristics_ch1.4: os event: 1///characteristics_ch1.5: os time (years): 3.80287///characteristics_ch1.6: pfs event: 1///characteristics_ch1.7: pfs time (years): 1.14168///characteristics_ch1.8: signature: STRESS///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were analyzed with Partek software (6.10.0915 version)///platform_id: GPL570///contact_name: Fatima,,Mechta-Grigoriou///contact_email: [email protected]///contact_phone: 33156246653///contact_fax: 33156246650///contact_laboratory: \Stress and Cancer\ Lab.///contact_department: INSERM U830///contact_institute: Institut Curie///contact_address: 26 rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM642nnn/GSM642980/GSM642980_OC01_ARN0074_s1h1s1_U133p2.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma 49///geo_accession: GSM642981///status: Public on Nov 01 2011///submission_date: Dec 20 2010///last_update_date: Aug 19 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma 49///organism_ch1: Homo sapiens///characteristics_ch1: histological type: Serous///characteristics_ch1.1: grade: 2///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: tissue: ovarian carcinoma tumor///characteristics_ch1.4: os event: 1///characteristics_ch1.5: os time (years): 3.8768///characteristics_ch1.6: pfs event: 1///characteristics_ch1.7: pfs time (years): 2.32991///characteristics_ch1.8: signature: FIBROSIS///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were analyzed with Partek software (6.10.0915 version)///platform_id: GPL570///contact_name: Fatima,,Mechta-Grigoriou///contact_email: [email protected]///contact_phone: 33156246653///contact_fax: 33156246650///contact_laboratory: \Stress and Cancer\ Lab.///contact_department: INSERM U830///contact_institute: Institut Curie///contact_address: 26 rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM642nnn/GSM642981/GSM642981_OC01_ARN0075_s1h1s1_U133p2.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma 4///geo_accession: GSM642936///status: Public on Nov 01 2011///submission_date: Dec 20 2010///last_update_date: Aug 19 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma 4///organism_ch1: Homo sapiens///characteristics_ch1: histological type: Serous///characteristics_ch1.1: grade: 3///characteristics_ch1.2: Stage: IV///characteristics_ch1.3: tissue: ovarian carcinoma tumor///characteristics_ch1.4: os event: 1///characteristics_ch1.5: os time (years): 2.47502///characteristics_ch1.6: pfs event: 1///characteristics_ch1.7: pfs time (years): 1.79603///characteristics_ch1.8: signature: STRESS///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were analyzed with Partek software (6.10.0915 version)///platform_id: GPL570///contact_name: Fatima,,Mechta-Grigoriou///contact_email: [email protected]///contact_phone: 33156246653///contact_fax: 33156246650///contact_laboratory: \Stress and Cancer\ Lab.///contact_department: INSERM U830///contact_institute: Institut Curie///contact_address: 26 rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM642nnn/GSM642936/GSM642936_OC01_ARN0005_s1h1s1_U133p2.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma 50///geo_accession: GSM642982///status: Public on Nov 01 2011///submission_date: Dec 20 2010///last_update_date: Aug 19 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma 50///organism_ch1: Homo sapiens///characteristics_ch1: histological type: Brenner Tumor///characteristics_ch1.1: grade: 3///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: tissue: ovarian carcinoma tumor///characteristics_ch1.4: os event: 1///characteristics_ch1.5: os time (years): 1.14442///characteristics_ch1.6: pfs event: 1///characteristics_ch1.7: pfs time (years): 0.416153///characteristics_ch1.8: signature: STRESS///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were analyzed with Partek software (6.10.0915 version)///platform_id: GPL570///contact_name: Fatima,,Mechta-Grigoriou///contact_email: [email protected]///contact_phone: 33156246653///contact_fax: 33156246650///contact_laboratory: \Stress and Cancer\ Lab.///contact_department: INSERM U830///contact_institute: Institut Curie///contact_address: 26 rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM642nnn/GSM642982/GSM642982_OC01_ARN0076_s1h1s1_U133p2.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma 51///geo_accession: GSM642983///status: Public on Nov 01 2011///submission_date: Dec 20 2010///last_update_date: Aug 19 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma 51///organism_ch1: Homo sapiens///characteristics_ch1: histological type: Serous///characteristics_ch1.1: grade: 2///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: tissue: ovarian carcinoma tumor///characteristics_ch1.4: os event: 1///characteristics_ch1.5: os time (years): 2.01506///characteristics_ch1.6: pfs event: 1///characteristics_ch1.7: pfs time (years): 1.21287///characteristics_ch1.8: signature: FIBROSIS///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were analyzed with Partek software (6.10.0915 version)///platform_id: GPL570///contact_name: Fatima,,Mechta-Grigoriou///contact_email: [email protected]///contact_phone: 33156246653///contact_fax: 33156246650///contact_laboratory: \Stress and Cancer\ Lab.///contact_department: INSERM U830///contact_institute: Institut Curie///contact_address: 26 rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM642nnn/GSM642983/GSM642983_OC01_ARN0080_s1h1s1_U133p2.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma 52///geo_accession: GSM642984///status: Public on Nov 01 2011///submission_date: Dec 20 2010///last_update_date: Aug 19 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma 52///organism_ch1: Homo sapiens///characteristics_ch1: histological type: Serous///characteristics_ch1.1: grade: 1///characteristics_ch1.2: Stage: Ib///characteristics_ch1.3: tissue: ovarian carcinoma tumor///characteristics_ch1.4: os event: 0///characteristics_ch1.5: os time (years): 10.2916///characteristics_ch1.6: pfs event: 0///characteristics_ch1.7: pfs time (years): 10.2916///characteristics_ch1.8: signature: STRESS///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were analyzed with Partek software (6.10.0915 version)///platform_id: GPL570///contact_name: Fatima,,Mechta-Grigoriou///contact_email: [email protected]///contact_phone: 33156246653///contact_fax: 33156246650///contact_laboratory: \Stress and Cancer\ Lab.///contact_department: INSERM U830///contact_institute: Institut Curie///contact_address: 26 rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM642nnn/GSM642984/GSM642984_OC01_ARN0082_s2h1s1_U133p2.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma 53///geo_accession: GSM642985///status: Public on Nov 01 2011///submission_date: Dec 20 2010///last_update_date: Aug 19 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma 53///organism_ch1: Homo sapiens///characteristics_ch1: histological type: Serous///characteristics_ch1.1: grade: 2///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: tissue: ovarian carcinoma tumor///characteristics_ch1.4: os event: 0///characteristics_ch1.5: os time (years): 8.57769///characteristics_ch1.6: pfs event: 1///characteristics_ch1.7: pfs time (years): 8.45722///characteristics_ch1.8: signature: STRESS///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were analyzed with Partek software (6.10.0915 version)///platform_id: GPL570///contact_name: Fatima,,Mechta-Grigoriou///contact_email: [email protected]///contact_phone: 33156246653///contact_fax: 33156246650///contact_laboratory: \Stress and Cancer\ Lab.///contact_department: INSERM U830///contact_institute: Institut Curie///contact_address: 26 rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM642nnn/GSM642985/GSM642985_OC01_ARN0084_s1h1s1_U133p2.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma 54///geo_accession: GSM642986///status: Public on Nov 01 2011///submission_date: Dec 20 2010///last_update_date: Aug 19 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma 54///organism_ch1: Homo sapiens///characteristics_ch1: histological type: Clear Cells///characteristics_ch1.1: grade: 2///characteristics_ch1.2: Stage: Ia///characteristics_ch1.3: tissue: ovarian carcinoma tumor///characteristics_ch1.4: os event: 0///characteristics_ch1.5: os time (years): 8.01369///characteristics_ch1.6: pfs event: 1///characteristics_ch1.7: pfs time (years): 1.30048///characteristics_ch1.8: signature: FIBROSIS///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were analyzed with Partek software (6.10.0915 version)///platform_id: GPL570///contact_name: Fatima,,Mechta-Grigoriou///contact_email: [email protected]///contact_phone: 33156246653///contact_fax: 33156246650///contact_laboratory: \Stress and Cancer\ Lab.///contact_department: INSERM U830///contact_institute: Institut Curie///contact_address: 26 rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM642nnn/GSM642986/GSM642986_OC01_ARN0085_s1h1s1_U133p2.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma 55///geo_accession: GSM642987///status: Public on Nov 01 2011///submission_date: Dec 20 2010///last_update_date: Aug 19 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma 55///organism_ch1: Homo sapiens///characteristics_ch1: histological type: Serous///characteristics_ch1.1: grade: 3///characteristics_ch1.2: Stage: 1Ia///characteristics_ch1.3: tissue: ovarian carcinoma tumor///characteristics_ch1.4: os event: 0///characteristics_ch1.5: os time (years): 8.33676///characteristics_ch1.6: pfs event: 1///characteristics_ch1.7: pfs time (years): 6.8282///characteristics_ch1.8: signature: FIBROSIS///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were analyzed with Partek software (6.10.0915 version)///platform_id: GPL570///contact_name: Fatima,,Mechta-Grigoriou///contact_email: [email protected]///contact_phone: 33156246653///contact_fax: 33156246650///contact_laboratory: \Stress and Cancer\ Lab.///contact_department: INSERM U830///contact_institute: Institut Curie///contact_address: 26 rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM642nnn/GSM642987/GSM642987_OC01_ARN0086_s2h1s1_U133p2.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma 56///geo_accession: GSM642988///status: Public on Nov 01 2011///submission_date: Dec 20 2010///last_update_date: Aug 19 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma 56///organism_ch1: Homo sapiens///characteristics_ch1: histological type: Serous///characteristics_ch1.1: grade: 3///characteristics_ch1.2: Stage: IIIb///characteristics_ch1.3: tissue: ovarian carcinoma tumor///characteristics_ch1.4: os event: 1///characteristics_ch1.5: os time (years): 7.62765///characteristics_ch1.6: pfs event: 1///characteristics_ch1.7: pfs time (years): 2.04244///characteristics_ch1.8: signature: STRESS///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were analyzed with Partek software (6.10.0915 version)///platform_id: GPL570///contact_name: Fatima,,Mechta-Grigoriou///contact_email: [email protected]///contact_phone: 33156246653///contact_fax: 33156246650///contact_laboratory: \Stress and Cancer\ Lab.///contact_department: INSERM U830///contact_institute: Institut Curie///contact_address: 26 rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM642nnn/GSM642988/GSM642988_OC01_ARN0087_s2h1s1_U133p2.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma 57///geo_accession: GSM642989///status: Public on Nov 01 2011///submission_date: Dec 20 2010///last_update_date: Aug 19 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma 57///organism_ch1: Homo sapiens///characteristics_ch1: histological type: Serous///characteristics_ch1.1: grade: 3///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: tissue: ovarian carcinoma tumor///characteristics_ch1.4: os event: 1///characteristics_ch1.5: os time (years): 3.37851///characteristics_ch1.6: pfs event: 1///characteristics_ch1.7: pfs time (years): 1.2512///characteristics_ch1.8: signature: FIBROSIS///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were analyzed with Partek software (6.10.0915 version)///platform_id: GPL570///contact_name: Fatima,,Mechta-Grigoriou///contact_email: [email protected]///contact_phone: 33156246653///contact_fax: 33156246650///contact_laboratory: \Stress and Cancer\ Lab.///contact_department: INSERM U830///contact_institute: Institut Curie///contact_address: 26 rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM642nnn/GSM642989/GSM642989_OC01_ARN0089_s1h1s1_U133p2.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma 58///geo_accession: GSM642990///status: Public on Nov 01 2011///submission_date: Dec 20 2010///last_update_date: Aug 19 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma 58///organism_ch1: Homo sapiens///characteristics_ch1: histological type: Adenocarcinoma///characteristics_ch1.1: grade: 3///characteristics_ch1.2: Stage: IIa///characteristics_ch1.3: tissue: ovarian carcinoma tumor///characteristics_ch1.4: os event: 0///characteristics_ch1.5: os time (years): 6.20397///characteristics_ch1.6: pfs event: 0///characteristics_ch1.7: pfs time (years): 6.20397///characteristics_ch1.8: signature: STRESS///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were analyzed with Partek software (6.10.0915 version)///platform_id: GPL570///contact_name: Fatima,,Mechta-Grigoriou///contact_email: [email protected]///contact_phone: 33156246653///contact_fax: 33156246650///contact_laboratory: \Stress and Cancer\ Lab.///contact_department: INSERM U830///contact_institute: Institut Curie///contact_address: 26 rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM642nnn/GSM642990/GSM642990_OC01_ARN0091_s1h1s1_U133p2.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma 59///geo_accession: GSM642991///status: Public on Nov 01 2011///submission_date: Dec 20 2010///last_update_date: Aug 19 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma 59///organism_ch1: Homo sapiens///characteristics_ch1: histological type: Serous///characteristics_ch1.1: grade: 3///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: tissue: ovarian carcinoma tumor///characteristics_ch1.4: os event: 0///characteristics_ch1.5: os time (years): 5.02122///characteristics_ch1.6: pfs event: 1///characteristics_ch1.7: pfs time (years): 2.87474///characteristics_ch1.8: signature: FIBROSIS///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were analyzed with Partek software (6.10.0915 version)///platform_id: GPL570///contact_name: Fatima,,Mechta-Grigoriou///contact_email: [email protected]///contact_phone: 33156246653///contact_fax: 33156246650///contact_laboratory: \Stress and Cancer\ Lab.///contact_department: INSERM U830///contact_institute: Institut Curie///contact_address: 26 rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM642nnn/GSM642991/GSM642991_OC01_ARN0093_s1h1s1_U133p2.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma 5///geo_accession: GSM642937///status: Public on Nov 01 2011///submission_date: Dec 20 2010///last_update_date: Aug 19 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma 5///organism_ch1: Homo sapiens///characteristics_ch1: histological type: Serous///characteristics_ch1.1: grade: 3///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: tissue: ovarian carcinoma tumor///characteristics_ch1.4: os event: 1///characteristics_ch1.5: os time (years): 4.2245///characteristics_ch1.6: pfs event: 1///characteristics_ch1.7: pfs time (years): 1.56605///characteristics_ch1.8: signature: FIBROSIS///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were analyzed with Partek software (6.10.0915 version)///platform_id: GPL570///contact_name: Fatima,,Mechta-Grigoriou///contact_email: [email protected]///contact_phone: 33156246653///contact_fax: 33156246650///contact_laboratory: \Stress and Cancer\ Lab.///contact_department: INSERM U830///contact_institute: Institut Curie///contact_address: 26 rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM642nnn/GSM642937/GSM642937_OC01_ARN0007_s1h1s1_U133p2.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma 60///geo_accession: GSM642992///status: Public on Nov 01 2011///submission_date: Dec 20 2010///last_update_date: Aug 19 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma 60///organism_ch1: Homo sapiens///characteristics_ch1: histological type: Serous///characteristics_ch1.1: grade: 2///characteristics_ch1.2: Stage: IIIb///characteristics_ch1.3: tissue: ovarian carcinoma tumor///characteristics_ch1.4: os event: 1///characteristics_ch1.5: os time (years): 2.83368///characteristics_ch1.6: pfs event: 1///characteristics_ch1.7: pfs time (years): 1.96304///characteristics_ch1.8: signature: STRESS///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were analyzed with Partek software (6.10.0915 version)///platform_id: GPL570///contact_name: Fatima,,Mechta-Grigoriou///contact_email: [email protected]///contact_phone: 33156246653///contact_fax: 33156246650///contact_laboratory: \Stress and Cancer\ Lab.///contact_department: INSERM U830///contact_institute: Institut Curie///contact_address: 26 rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM642nnn/GSM642992/GSM642992_OC01_ARN0095_s1h1s1_U133p2.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma 61///geo_accession: GSM642993///status: Public on Nov 01 2011///submission_date: Dec 20 2010///last_update_date: Aug 19 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma 61///organism_ch1: Homo sapiens///characteristics_ch1: histological type: Mucinous///characteristics_ch1.1: grade: 1///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: tissue: ovarian carcinoma tumor///characteristics_ch1.4: os event: 1///characteristics_ch1.5: os time (years): 1.72758///characteristics_ch1.6: pfs event: 1///characteristics_ch1.7: pfs time (years): 0.591376///characteristics_ch1.8: signature: FIBROSIS///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were analyzed with Partek software (6.10.0915 version)///platform_id: GPL570///contact_name: Fatima,,Mechta-Grigoriou///contact_email: [email protected]///contact_phone: 33156246653///contact_fax: 33156246650///contact_laboratory: \Stress and Cancer\ Lab.///contact_department: INSERM U830///contact_institute: Institut Curie///contact_address: 26 rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM642nnn/GSM642993/GSM642993_OC01_ARN0096_s1h1s1_U133p2.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma 62///geo_accession: GSM642994///status: Public on Nov 01 2011///submission_date: Dec 20 2010///last_update_date: Aug 19 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma 62///organism_ch1: Homo sapiens///characteristics_ch1: histological type: Serous///characteristics_ch1.1: grade: 3///characteristics_ch1.2: Stage: IIb///characteristics_ch1.3: tissue: ovarian carcinoma tumor///characteristics_ch1.4: os event: 1///characteristics_ch1.5: os time (years): 9.29227///characteristics_ch1.6: pfs event: 1///characteristics_ch1.7: pfs time (years): 6.30253///characteristics_ch1.8: signature: STRESS///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were analyzed with Partek software (6.10.0915 version)///platform_id: GPL570///contact_name: Fatima,,Mechta-Grigoriou///contact_email: [email protected]///contact_phone: 33156246653///contact_fax: 33156246650///contact_laboratory: \Stress and Cancer\ Lab.///contact_department: INSERM U830///contact_institute: Institut Curie///contact_address: 26 rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM642nnn/GSM642994/GSM642994_OC01_ARN0100_s1h1s1_U133p2.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma 63///geo_accession: GSM642995///status: Public on Nov 01 2011///submission_date: Dec 20 2010///last_update_date: Aug 19 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma 63///organism_ch1: Homo sapiens///characteristics_ch1: histological type: Clear Cells///characteristics_ch1.1: grade: 3///characteristics_ch1.2: Stage: IV///characteristics_ch1.3: tissue: ovarian carcinoma tumor///characteristics_ch1.4: os event: 1///characteristics_ch1.5: os time (years): 1.3963///characteristics_ch1.6: pfs event: 1///characteristics_ch1.7: pfs time (years): 1.33881///characteristics_ch1.8: signature: STRESS///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were analyzed with Partek software (6.10.0915 version)///platform_id: GPL570///contact_name: Fatima,,Mechta-Grigoriou///contact_email: [email protected]///contact_phone: 33156246653///contact_fax: 33156246650///contact_laboratory: \Stress and Cancer\ Lab.///contact_department: INSERM U830///contact_institute: Institut Curie///contact_address: 26 rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM642nnn/GSM642995/GSM642995_OC01_ARN0101_s1h1s1_U133p2.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma 64///geo_accession: GSM642996///status: Public on Nov 01 2011///submission_date: Dec 20 2010///last_update_date: Aug 19 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma 64///organism_ch1: Homo sapiens///characteristics_ch1: histological type: Serous///characteristics_ch1.1: grade: 3///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: tissue: ovarian carcinoma tumor///characteristics_ch1.4: os event: 1///characteristics_ch1.5: os time (years): 1.58522///characteristics_ch1.6: pfs event: 1///characteristics_ch1.7: pfs time (years): 0.810404///characteristics_ch1.8: signature: FIBROSIS///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were analyzed with Partek software (6.10.0915 version)///platform_id: GPL570///contact_name: Fatima,,Mechta-Grigoriou///contact_email: [email protected]///contact_phone: 33156246653///contact_fax: 33156246650///contact_laboratory: \Stress and Cancer\ Lab.///contact_department: INSERM U830///contact_institute: Institut Curie///contact_address: 26 rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM642nnn/GSM642996/GSM642996_OC01_ARN0103_s1h1s1_U133p2.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma 65///geo_accession: GSM642997///status: Public on Nov 01 2011///submission_date: Dec 20 2010///last_update_date: Aug 19 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma 65///organism_ch1: Homo sapiens///characteristics_ch1: histological type: Serous///characteristics_ch1.1: grade: 3///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: tissue: ovarian carcinoma tumor///characteristics_ch1.4: os event: 1///characteristics_ch1.5: os time (years): 0.783025///characteristics_ch1.6: pfs event: 1///characteristics_ch1.7: pfs time (years): 0.613279///characteristics_ch1.8: signature: FIBROSIS///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were analyzed with Partek software (6.10.0915 version)///platform_id: GPL570///contact_name: Fatima,,Mechta-Grigoriou///contact_email: [email protected]///contact_phone: 33156246653///contact_fax: 33156246650///contact_laboratory: \Stress and Cancer\ Lab.///contact_department: INSERM U830///contact_institute: Institut Curie///contact_address: 26 rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM642nnn/GSM642997/GSM642997_OC01_ARN0105_s1h1s1_U133p2.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma 66///geo_accession: GSM642998///status: Public on Nov 01 2011///submission_date: Dec 20 2010///last_update_date: Aug 19 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma 66///organism_ch1: Homo sapiens///characteristics_ch1: histological type: Serous///characteristics_ch1.1: grade: 3///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: tissue: ovarian carcinoma tumor///characteristics_ch1.4: os event: 1///characteristics_ch1.5: os time (years): 2.15743///characteristics_ch1.6: pfs event: 1///characteristics_ch1.7: pfs time (years): 1.15537///characteristics_ch1.8: signature: FIBROSIS///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were analyzed with Partek software (6.10.0915 version)///platform_id: GPL570///contact_name: Fatima,,Mechta-Grigoriou///contact_email: [email protected]///contact_phone: 33156246653///contact_fax: 33156246650///contact_laboratory: \Stress and Cancer\ Lab.///contact_department: INSERM U830///contact_institute: Institut Curie///contact_address: 26 rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM642nnn/GSM642998/GSM642998_OC01_ARN0106_s1h1s1_U133p2.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma 67///geo_accession: GSM642999///status: Public on Nov 01 2011///submission_date: Dec 20 2010///last_update_date: Aug 19 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma 67///organism_ch1: Homo sapiens///characteristics_ch1: histological type: Serous///characteristics_ch1.1: grade: 2///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: tissue: ovarian carcinoma tumor///characteristics_ch1.4: os event: 1///characteristics_ch1.5: os time (years): 7.35661///characteristics_ch1.6: pfs event: 1///characteristics_ch1.7: pfs time (years): 1.9165///characteristics_ch1.8: signature: FIBROSIS///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were analyzed with Partek software (6.10.0915 version)///platform_id: GPL570///contact_name: Fatima,,Mechta-Grigoriou///contact_email: [email protected]///contact_phone: 33156246653///contact_fax: 33156246650///contact_laboratory: \Stress and Cancer\ Lab.///contact_department: INSERM U830///contact_institute: Institut Curie///contact_address: 26 rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM642nnn/GSM642999/GSM642999_OC01_ARN0107_s1h1s1_U133p2.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma 68///geo_accession: GSM643000///status: Public on Nov 01 2011///submission_date: Dec 20 2010///last_update_date: Aug 19 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma 68///organism_ch1: Homo sapiens///characteristics_ch1: histological type: Serous///characteristics_ch1.1: grade: 3///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: tissue: ovarian carcinoma tumor///characteristics_ch1.4: os event: 1///characteristics_ch1.5: os time (years): 3.49076///characteristics_ch1.6: pfs event: 1///characteristics_ch1.7: pfs time (years): 1.59069///characteristics_ch1.8: signature: STRESS///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were analyzed with Partek software (6.10.0915 version)///platform_id: GPL570///contact_name: Fatima,,Mechta-Grigoriou///contact_email: [email protected]///contact_phone: 33156246653///contact_fax: 33156246650///contact_laboratory: \Stress and Cancer\ Lab.///contact_department: INSERM U830///contact_institute: Institut Curie///contact_address: 26 rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM643nnn/GSM643000/GSM643000_OC01_ARN0108_s1h1s1_U133p2.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma 69///geo_accession: GSM643001///status: Public on Nov 01 2011///submission_date: Dec 20 2010///last_update_date: Aug 19 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma 69///organism_ch1: Homo sapiens///characteristics_ch1: histological type: Clear Cells///characteristics_ch1.1: grade: 2///characteristics_ch1.2: Stage: IIa///characteristics_ch1.3: tissue: ovarian carcinoma tumor///characteristics_ch1.4: os event: 1///characteristics_ch1.5: os time (years): 1.26215///characteristics_ch1.6: pfs event: 1///characteristics_ch1.7: pfs time (years): 0.47091///characteristics_ch1.8: signature: FIBROSIS///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were analyzed with Partek software (6.10.0915 version)///platform_id: GPL570///contact_name: Fatima,,Mechta-Grigoriou///contact_email: [email protected]///contact_phone: 33156246653///contact_fax: 33156246650///contact_laboratory: \Stress and Cancer\ Lab.///contact_department: INSERM U830///contact_institute: Institut Curie///contact_address: 26 rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM643nnn/GSM643001/GSM643001_OC01_ARN0109_s1h1s1_U133p2.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma 6///geo_accession: GSM642938///status: Public on Nov 01 2011///submission_date: Dec 20 2010///last_update_date: Aug 19 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma 6///organism_ch1: Homo sapiens///characteristics_ch1: histological type: Serous///characteristics_ch1.1: grade: 3///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: tissue: ovarian carcinoma tumor///characteristics_ch1.4: os event: 1///characteristics_ch1.5: os time (years): 2.35455///characteristics_ch1.6: pfs event: 1///characteristics_ch1.7: pfs time (years): 1.33881///characteristics_ch1.8: signature: FIBROSIS///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were analyzed with Partek software (6.10.0915 version)///platform_id: GPL570///contact_name: Fatima,,Mechta-Grigoriou///contact_email: [email protected]///contact_phone: 33156246653///contact_fax: 33156246650///contact_laboratory: \Stress and Cancer\ Lab.///contact_department: INSERM U830///contact_institute: Institut Curie///contact_address: 26 rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM642nnn/GSM642938/GSM642938_OC01_ARN0008_s1h1s1_U133p2.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma 70///geo_accession: GSM643002///status: Public on Nov 01 2011///submission_date: Dec 20 2010///last_update_date: Aug 19 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma 70///organism_ch1: Homo sapiens///characteristics_ch1: histological type: Serous///characteristics_ch1.1: grade: 3///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: tissue: ovarian carcinoma tumor///characteristics_ch1.4: os event: 1///characteristics_ch1.5: os time (years): 2.29979///characteristics_ch1.6: pfs event: 1///characteristics_ch1.7: pfs time (years): 1.40452///characteristics_ch1.8: signature: STRESS///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were analyzed with Partek software (6.10.0915 version)///platform_id: GPL570///contact_name: Fatima,,Mechta-Grigoriou///contact_email: [email protected]///contact_phone: 33156246653///contact_fax: 33156246650///contact_laboratory: \Stress and Cancer\ Lab.///contact_department: INSERM U830///contact_institute: Institut Curie///contact_address: 26 rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM643nnn/GSM643002/GSM643002_OC01_ARN0111_s1h1s1_U133p2.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma 71///geo_accession: GSM643003///status: Public on Nov 01 2011///submission_date: Dec 20 2010///last_update_date: Aug 19 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma 71///organism_ch1: Homo sapiens///characteristics_ch1: histological type: Endometrioid///characteristics_ch1.1: grade: 1///characteristics_ch1.2: Stage: IIa///characteristics_ch1.3: tissue: ovarian carcinoma tumor///characteristics_ch1.4: os event: 0///characteristics_ch1.5: os time (years): 4.75565///characteristics_ch1.6: pfs event: 0///characteristics_ch1.7: pfs time (years): 4.75565///characteristics_ch1.8: signature: FIBROSIS///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were analyzed with Partek software (6.10.0915 version)///platform_id: GPL570///contact_name: Fatima,,Mechta-Grigoriou///contact_email: [email protected]///contact_phone: 33156246653///contact_fax: 33156246650///contact_laboratory: \Stress and Cancer\ Lab.///contact_department: INSERM U830///contact_institute: Institut Curie///contact_address: 26 rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM643nnn/GSM643003/GSM643003_OC01_ARN0113_s1h1s1_U133p2.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma 72///geo_accession: GSM643004///status: Public on Nov 01 2011///submission_date: Dec 20 2010///last_update_date: Aug 19 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma 72///organism_ch1: Homo sapiens///characteristics_ch1: histological type: Carcinosarcoma///characteristics_ch1.1: grade: 3///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: tissue: ovarian carcinoma tumor///characteristics_ch1.4: os event: 1///characteristics_ch1.5: os time (years): 0.922656///characteristics_ch1.6: pfs event: 1///characteristics_ch1.7: pfs time (years): 0.837782///characteristics_ch1.8: signature: FIBROSIS///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were analyzed with Partek software (6.10.0915 version)///platform_id: GPL570///contact_name: Fatima,,Mechta-Grigoriou///contact_email: [email protected]///contact_phone: 33156246653///contact_fax: 33156246650///contact_laboratory: \Stress and Cancer\ Lab.///contact_department: INSERM U830///contact_institute: Institut Curie///contact_address: 26 rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM643nnn/GSM643004/GSM643004_OC01_ARN0114_s1h1s1_U133p2.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma 73///geo_accession: GSM643005///status: Public on Nov 01 2011///submission_date: Dec 20 2010///last_update_date: Aug 19 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma 73///organism_ch1: Homo sapiens///characteristics_ch1: histological type: Endometrioid///characteristics_ch1.1: grade: 2///characteristics_ch1.2: Stage: Ia///characteristics_ch1.3: tissue: ovarian carcinoma tumor///characteristics_ch1.4: os event: 0///characteristics_ch1.5: os time (years): 5.24025///characteristics_ch1.6: pfs event: 0///characteristics_ch1.7: pfs time (years): 5.24025///characteristics_ch1.8: signature: FIBROSIS///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were analyzed with Partek software (6.10.0915 version)///platform_id: GPL570///contact_name: Fatima,,Mechta-Grigoriou///contact_email: [email protected]///contact_phone: 33156246653///contact_fax: 33156246650///contact_laboratory: \Stress and Cancer\ Lab.///contact_department: INSERM U830///contact_institute: Institut Curie///contact_address: 26 rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM643nnn/GSM643005/GSM643005_OC01_ARN0115_s1h1s1_U133p2.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma 74///geo_accession: GSM643006///status: Public on Nov 01 2011///submission_date: Dec 20 2010///last_update_date: Aug 19 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma 74///organism_ch1: Homo sapiens///characteristics_ch1: histological type: Serous///characteristics_ch1.1: grade: 2///characteristics_ch1.2: Stage: IV///characteristics_ch1.3: tissue: ovarian carcinoma tumor///characteristics_ch1.4: os event: 1///characteristics_ch1.5: os time (years): 1.56605///characteristics_ch1.6: pfs event: 1///characteristics_ch1.7: pfs time (years): 0.80219///characteristics_ch1.8: signature: FIBROSIS///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were analyzed with Partek software (6.10.0915 version)///platform_id: GPL570///contact_name: Fatima,,Mechta-Grigoriou///contact_email: [email protected]///contact_phone: 33156246653///contact_fax: 33156246650///contact_laboratory: \Stress and Cancer\ Lab.///contact_department: INSERM U830///contact_institute: Institut Curie///contact_address: 26 rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM643nnn/GSM643006/GSM643006_OC01_ARN0116_s1h1s1_U133p2.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma 75///geo_accession: GSM643007///status: Public on Nov 01 2011///submission_date: Dec 20 2010///last_update_date: Aug 19 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma 75///organism_ch1: Homo sapiens///characteristics_ch1: histological type: Serous///characteristics_ch1.1: grade: 2///characteristics_ch1.2: Stage: IIIa///characteristics_ch1.3: tissue: ovarian carcinoma tumor///characteristics_ch1.4: os event: 1///characteristics_ch1.5: os time (years): 0.774812///characteristics_ch1.6: pfs event: 1///characteristics_ch1.7: pfs time (years): 0.33128///characteristics_ch1.8: signature: STRESS///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were analyzed with Partek software (6.10.0915 version)///platform_id: GPL570///contact_name: Fatima,,Mechta-Grigoriou///contact_email: [email protected]///contact_phone: 33156246653///contact_fax: 33156246650///contact_laboratory: \Stress and Cancer\ Lab.///contact_department: INSERM U830///contact_institute: Institut Curie///contact_address: 26 rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM643nnn/GSM643007/GSM643007_OC01_ARN0118_s1h1s1_U133p2.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma 76///geo_accession: GSM643008///status: Public on Nov 01 2011///submission_date: Dec 20 2010///last_update_date: Aug 19 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma 76///organism_ch1: Homo sapiens///characteristics_ch1: histological type: Serous///characteristics_ch1.1: grade: 3///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: tissue: ovarian carcinoma tumor///characteristics_ch1.4: os event: 1///characteristics_ch1.5: os time (years): 6.11362///characteristics_ch1.6: pfs event: 1///characteristics_ch1.7: pfs time (years): 3.96715///characteristics_ch1.8: signature: FIBROSIS///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were analyzed with Partek software (6.10.0915 version)///platform_id: GPL570///contact_name: Fatima,,Mechta-Grigoriou///contact_email: [email protected]///contact_phone: 33156246653///contact_fax: 33156246650///contact_laboratory: \Stress and Cancer\ Lab.///contact_department: INSERM U830///contact_institute: Institut Curie///contact_address: 26 rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM643nnn/GSM643008/GSM643008_OC01_ARN0119_s1h1s1_U133p2.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma 77///geo_accession: GSM643009///status: Public on Nov 01 2011///submission_date: Dec 20 2010///last_update_date: Aug 19 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma 77///organism_ch1: Homo sapiens///characteristics_ch1: histological type: Serous///characteristics_ch1.1: grade: 3///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: tissue: ovarian carcinoma tumor///characteristics_ch1.4: os event: 1///characteristics_ch1.5: os time (years): 1.87817///characteristics_ch1.6: pfs event: 1///characteristics_ch1.7: pfs time (years): 1.62902///characteristics_ch1.8: signature: FIBROSIS///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were analyzed with Partek software (6.10.0915 version)///platform_id: GPL570///contact_name: Fatima,,Mechta-Grigoriou///contact_email: [email protected]///contact_phone: 33156246653///contact_fax: 33156246650///contact_laboratory: \Stress and Cancer\ Lab.///contact_department: INSERM U830///contact_institute: Institut Curie///contact_address: 26 rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM643nnn/GSM643009/GSM643009_OC01_ARN0124_s1h1s1_U133p2.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma 78///geo_accession: GSM643010///status: Public on Nov 01 2011///submission_date: Dec 20 2010///last_update_date: Aug 19 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma 78///organism_ch1: Homo sapiens///characteristics_ch1: histological type: Serous///characteristics_ch1.1: grade: 3///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: tissue: ovarian carcinoma tumor///characteristics_ch1.4: os event: 1///characteristics_ch1.5: os time (years): 0.531143///characteristics_ch1.6: pfs event: 0///characteristics_ch1.7: pfs time (years): 0.531143///characteristics_ch1.8: signature: FIBROSIS///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were analyzed with Partek software (6.10.0915 version)///platform_id: GPL570///contact_name: Fatima,,Mechta-Grigoriou///contact_email: [email protected]///contact_phone: 33156246653///contact_fax: 33156246650///contact_laboratory: \Stress and Cancer\ Lab.///contact_department: INSERM U830///contact_institute: Institut Curie///contact_address: 26 rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM643nnn/GSM643010/GSM643010_OC01_ARN0125_s1h1s1_U133p2.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma 79///geo_accession: GSM643011///status: Public on Nov 01 2011///submission_date: Dec 20 2010///last_update_date: Aug 19 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma 79///organism_ch1: Homo sapiens///characteristics_ch1: histological type: Serous///characteristics_ch1.1: grade: 3///characteristics_ch1.2: Stage: IV///characteristics_ch1.3: tissue: ovarian carcinoma tumor///characteristics_ch1.4: os event: 1///characteristics_ch1.5: os time (years): 0.00821355///characteristics_ch1.6: pfs event: 1///characteristics_ch1.7: pfs time (years): 0.00821355///characteristics_ch1.8: signature: FIBROSIS///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were analyzed with Partek software (6.10.0915 version)///platform_id: GPL570///contact_name: Fatima,,Mechta-Grigoriou///contact_email: [email protected]///contact_phone: 33156246653///contact_fax: 33156246650///contact_laboratory: \Stress and Cancer\ Lab.///contact_department: INSERM U830///contact_institute: Institut Curie///contact_address: 26 rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM643nnn/GSM643011/GSM643011_OC01_ARN0127_s1h1s1_U133p2.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma 7///geo_accession: GSM642939///status: Public on Nov 01 2011///submission_date: Dec 20 2010///last_update_date: Aug 19 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma 7///organism_ch1: Homo sapiens///characteristics_ch1: histological type: Serous///characteristics_ch1.1: grade: 2///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: tissue: ovarian carcinoma tumor///characteristics_ch1.4: os event: 1///characteristics_ch1.5: os time (years): 2.12731///characteristics_ch1.6: pfs event: 1///characteristics_ch1.7: pfs time (years): 0.941821///characteristics_ch1.8: signature: STRESS///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were analyzed with Partek software (6.10.0915 version)///platform_id: GPL570///contact_name: Fatima,,Mechta-Grigoriou///contact_email: [email protected]///contact_phone: 33156246653///contact_fax: 33156246650///contact_laboratory: \Stress and Cancer\ Lab.///contact_department: INSERM U830///contact_institute: Institut Curie///contact_address: 26 rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM642nnn/GSM642939/GSM642939_OC01_ARN0009_s1h1s1_U133p2.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma 80///geo_accession: GSM643012///status: Public on Nov 01 2011///submission_date: Dec 20 2010///last_update_date: Aug 19 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma 80///organism_ch1: Homo sapiens///characteristics_ch1: histological type: Serous///characteristics_ch1.1: grade: 3///characteristics_ch1.2: Stage: Ic///characteristics_ch1.3: tissue: ovarian carcinoma tumor///characteristics_ch1.4: os event: 0///characteristics_ch1.5: os time (years): 9.60986///characteristics_ch1.6: pfs event: 1///characteristics_ch1.7: pfs time (years): 8.06571///characteristics_ch1.8: signature: STRESS///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were analyzed with Partek software (6.10.0915 version)///platform_id: GPL570///contact_name: Fatima,,Mechta-Grigoriou///contact_email: [email protected]///contact_phone: 33156246653///contact_fax: 33156246650///contact_laboratory: \Stress and Cancer\ Lab.///contact_department: INSERM U830///contact_institute: Institut Curie///contact_address: 26 rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM643nnn/GSM643012/GSM643012_OC01_ARN0128_s1h1s1_U133p2.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma 81///geo_accession: GSM643013///status: Public on Nov 01 2011///submission_date: Dec 20 2010///last_update_date: Aug 19 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma 81///organism_ch1: Homo sapiens///characteristics_ch1: histological type: Endometrioid///characteristics_ch1.1: grade: 3///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: tissue: ovarian carcinoma tumor///characteristics_ch1.4: os event: 0///characteristics_ch1.5: os time (years): 9.27858///characteristics_ch1.6: pfs event: 0///characteristics_ch1.7: pfs time (years): 9.27858///characteristics_ch1.8: signature: STRESS///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were analyzed with Partek software (6.10.0915 version)///platform_id: GPL570///contact_name: Fatima,,Mechta-Grigoriou///contact_email: [email protected]///contact_phone: 33156246653///contact_fax: 33156246650///contact_laboratory: \Stress and Cancer\ Lab.///contact_department: INSERM U830///contact_institute: Institut Curie///contact_address: 26 rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM643nnn/GSM643013/GSM643013_OC01_ARN0129_s1h1s1_U133p2.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma 82///geo_accession: GSM643014///status: Public on Nov 01 2011///submission_date: Dec 20 2010///last_update_date: Aug 19 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma 82///organism_ch1: Homo sapiens///characteristics_ch1: histological type: Serous///characteristics_ch1.1: grade: 3///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: tissue: ovarian carcinoma tumor///characteristics_ch1.4: os event: 1///characteristics_ch1.5: os time (years): 2.49418///characteristics_ch1.6: pfs event: 1///characteristics_ch1.7: pfs time (years): 1.58522///characteristics_ch1.8: signature: STRESS///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were analyzed with Partek software (6.10.0915 version)///platform_id: GPL570///contact_name: Fatima,,Mechta-Grigoriou///contact_email: [email protected]///contact_phone: 33156246653///contact_fax: 33156246650///contact_laboratory: \Stress and Cancer\ Lab.///contact_department: INSERM U830///contact_institute: Institut Curie///contact_address: 26 rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM643nnn/GSM643014/GSM643014_OC01_ARN0130_s1h1s1_U133p2.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma 83///geo_accession: GSM643015///status: Public on Nov 01 2011///submission_date: Dec 20 2010///last_update_date: Aug 19 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma 83///organism_ch1: Homo sapiens///characteristics_ch1: histological type: Serous///characteristics_ch1.1: grade: 3///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: tissue: ovarian carcinoma tumor///characteristics_ch1.4: os event: 1///characteristics_ch1.5: os time (years): 3.81109///characteristics_ch1.6: pfs event: 1///characteristics_ch1.7: pfs time (years): 1.44832///characteristics_ch1.8: signature: FIBROSIS///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were analyzed with Partek software (6.10.0915 version)///platform_id: GPL570///contact_name: Fatima,,Mechta-Grigoriou///contact_email: [email protected]///contact_phone: 33156246653///contact_fax: 33156246650///contact_laboratory: \Stress and Cancer\ Lab.///contact_department: INSERM U830///contact_institute: Institut Curie///contact_address: 26 rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM643nnn/GSM643015/GSM643015_OC01_ARN0131_s2h1s1_U133p2.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma 84///geo_accession: GSM643016///status: Public on Nov 01 2011///submission_date: Dec 20 2010///last_update_date: Aug 19 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma 84///organism_ch1: Homo sapiens///characteristics_ch1: histological type: Serous///characteristics_ch1.1: grade: 3///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: tissue: ovarian carcinoma tumor///characteristics_ch1.4: os event: 1///characteristics_ch1.5: os time (years): 3.00068///characteristics_ch1.6: pfs event: 1///characteristics_ch1.7: pfs time (years): 2.45311///characteristics_ch1.8: signature: FIBROSIS///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were analyzed with Partek software (6.10.0915 version)///platform_id: GPL570///contact_name: Fatima,,Mechta-Grigoriou///contact_email: [email protected]///contact_phone: 33156246653///contact_fax: 33156246650///contact_laboratory: \Stress and Cancer\ Lab.///contact_department: INSERM U830///contact_institute: Institut Curie///contact_address: 26 rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM643nnn/GSM643016/GSM643016_OC01_ARN0132_s1h1s1_U133p2.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma 85///geo_accession: GSM643017///status: Public on Nov 01 2011///submission_date: Dec 20 2010///last_update_date: Aug 19 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma 85///organism_ch1: Homo sapiens///characteristics_ch1: histological type: Serous///characteristics_ch1.1: grade: 3///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: tissue: ovarian carcinoma tumor///characteristics_ch1.4: os event: 0///characteristics_ch1.5: os time (years): 7.75907///characteristics_ch1.6: pfs event: 0///characteristics_ch1.7: pfs time (years): 7.75907///characteristics_ch1.8: signature: FIBROSIS///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were analyzed with Partek software (6.10.0915 version)///platform_id: GPL570///contact_name: Fatima,,Mechta-Grigoriou///contact_email: [email protected]///contact_phone: 33156246653///contact_fax: 33156246650///contact_laboratory: \Stress and Cancer\ Lab.///contact_department: INSERM U830///contact_institute: Institut Curie///contact_address: 26 rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM643nnn/GSM643017/GSM643017_OC01_ARN0133_s1h1s1_U133p2.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma 86///geo_accession: GSM643018///status: Public on Nov 01 2011///submission_date: Dec 20 2010///last_update_date: Aug 19 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma 86///organism_ch1: Homo sapiens///characteristics_ch1: histological type: Clear Cells///characteristics_ch1.1: grade: 2///characteristics_ch1.2: Stage: Ia///characteristics_ch1.3: tissue: ovarian carcinoma tumor///characteristics_ch1.4: os event: 0///characteristics_ch1.5: os time (years): 7.72348///characteristics_ch1.6: pfs event: 0///characteristics_ch1.7: pfs time (years): 7.72348///characteristics_ch1.8: signature: STRESS///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were analyzed with Partek software (6.10.0915 version)///platform_id: GPL570///contact_name: Fatima,,Mechta-Grigoriou///contact_email: [email protected]///contact_phone: 33156246653///contact_fax: 33156246650///contact_laboratory: \Stress and Cancer\ Lab.///contact_department: INSERM U830///contact_institute: Institut Curie///contact_address: 26 rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM643nnn/GSM643018/GSM643018_OC01_ARN0134_s1h1s1_U133p2.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma 87///geo_accession: GSM643019///status: Public on Nov 01 2011///submission_date: Dec 20 2010///last_update_date: Aug 19 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma 87///organism_ch1: Homo sapiens///characteristics_ch1: histological type: Serous///characteristics_ch1.1: grade: 3///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: tissue: ovarian carcinoma tumor///characteristics_ch1.4: os event: 1///characteristics_ch1.5: os time (years): 2.8063///characteristics_ch1.6: pfs event: 1///characteristics_ch1.7: pfs time (years): 1.5989///characteristics_ch1.8: signature: FIBROSIS///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were analyzed with Partek software (6.10.0915 version)///platform_id: GPL570///contact_name: Fatima,,Mechta-Grigoriou///contact_email: [email protected]///contact_phone: 33156246653///contact_fax: 33156246650///contact_laboratory: \Stress and Cancer\ Lab.///contact_department: INSERM U830///contact_institute: Institut Curie///contact_address: 26 rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM643nnn/GSM643019/GSM643019_OC01_ARN0135_s1h1s1_U133p2.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma 88///geo_accession: GSM643020///status: Public on Nov 01 2011///submission_date: Dec 20 2010///last_update_date: Aug 19 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma 88///organism_ch1: Homo sapiens///characteristics_ch1: histological type: Serous///characteristics_ch1.1: grade: 3///characteristics_ch1.2: Stage: IIIa///characteristics_ch1.3: tissue: ovarian carcinoma tumor///characteristics_ch1.4: os event: 0///characteristics_ch1.5: os time (years): 6.45585///characteristics_ch1.6: pfs event: 0///characteristics_ch1.7: pfs time (years): 6.45585///characteristics_ch1.8: signature: FIBROSIS///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were analyzed with Partek software (6.10.0915 version)///platform_id: GPL570///contact_name: Fatima,,Mechta-Grigoriou///contact_email: [email protected]///contact_phone: 33156246653///contact_fax: 33156246650///contact_laboratory: \Stress and Cancer\ Lab.///contact_department: INSERM U830///contact_institute: Institut Curie///contact_address: 26 rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM643nnn/GSM643020/GSM643020_OC01_ARN0136_s1h1s1_U133p2.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma 89///geo_accession: GSM643021///status: Public on Nov 01 2011///submission_date: Dec 20 2010///last_update_date: Aug 19 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma 89///organism_ch1: Homo sapiens///characteristics_ch1: histological type: Mucinous///characteristics_ch1.1: grade: 2///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: tissue: ovarian carcinoma tumor///characteristics_ch1.4: os event: 1///characteristics_ch1.5: os time (years): 0.506502///characteristics_ch1.6: pfs event: 1///characteristics_ch1.7: pfs time (years): 0.347707///characteristics_ch1.8: signature: STRESS///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were analyzed with Partek software (6.10.0915 version)///platform_id: GPL570///contact_name: Fatima,,Mechta-Grigoriou///contact_email: [email protected]///contact_phone: 33156246653///contact_fax: 33156246650///contact_laboratory: \Stress and Cancer\ Lab.///contact_department: INSERM U830///contact_institute: Institut Curie///contact_address: 26 rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM643nnn/GSM643021/GSM643021_OC01_ARN0137_s1h1s1_U133p2.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma 8///geo_accession: GSM642940///status: Public on Nov 01 2011///submission_date: Dec 20 2010///last_update_date: Aug 19 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma 8///organism_ch1: Homo sapiens///characteristics_ch1: histological type: Serous///characteristics_ch1.1: grade: 2///characteristics_ch1.2: Stage: Ib///characteristics_ch1.3: tissue: ovarian carcinoma tumor///characteristics_ch1.4: os event: 1///characteristics_ch1.5: os time (years): 4.75838///characteristics_ch1.6: pfs event: 0///characteristics_ch1.7: pfs time (years): 4.75838///characteristics_ch1.8: signature: STRESS///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were analyzed with Partek software (6.10.0915 version)///platform_id: GPL570///contact_name: Fatima,,Mechta-Grigoriou///contact_email: [email protected]///contact_phone: 33156246653///contact_fax: 33156246650///contact_laboratory: \Stress and Cancer\ Lab.///contact_department: INSERM U830///contact_institute: Institut Curie///contact_address: 26 rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM642nnn/GSM642940/GSM642940_OC01_ARN0011_s1h1s1_U133p2.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma 90///geo_accession: GSM643022///status: Public on Nov 01 2011///submission_date: Dec 20 2010///last_update_date: Aug 19 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma 90///organism_ch1: Homo sapiens///characteristics_ch1: histological type: Serous///characteristics_ch1.1: grade: 3///characteristics_ch1.2: Stage: IIc///characteristics_ch1.3: tissue: ovarian carcinoma tumor///characteristics_ch1.4: os event: 0///characteristics_ch1.5: os time (years): 5.859///characteristics_ch1.6: pfs event: 1///characteristics_ch1.7: pfs time (years): 4.06023///characteristics_ch1.8: signature: STRESS///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were analyzed with Partek software (6.10.0915 version)///platform_id: GPL570///contact_name: Fatima,,Mechta-Grigoriou///contact_email: [email protected]///contact_phone: 33156246653///contact_fax: 33156246650///contact_laboratory: \Stress and Cancer\ Lab.///contact_department: INSERM U830///contact_institute: Institut Curie///contact_address: 26 rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM643nnn/GSM643022/GSM643022_OC01_ARN0138_s1h1s1_U133p2.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma 91///geo_accession: GSM643023///status: Public on Nov 01 2011///submission_date: Dec 20 2010///last_update_date: Aug 19 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma 91///organism_ch1: Homo sapiens///characteristics_ch1: histological type: Endometrioid///characteristics_ch1.1: grade: 2///characteristics_ch1.2: Stage: IIc///characteristics_ch1.3: tissue: ovarian carcinoma tumor///characteristics_ch1.4: os event: 1///characteristics_ch1.5: os time (years): 0.676249///characteristics_ch1.6: pfs event: 1///characteristics_ch1.7: pfs time (years): 0.574949///characteristics_ch1.8: signature: STRESS///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were analyzed with Partek software (6.10.0915 version)///platform_id: GPL570///contact_name: Fatima,,Mechta-Grigoriou///contact_email: [email protected]///contact_phone: 33156246653///contact_fax: 33156246650///contact_laboratory: \Stress and Cancer\ Lab.///contact_department: INSERM U830///contact_institute: Institut Curie///contact_address: 26 rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM643nnn/GSM643023/GSM643023_OC01_ARN0144_s2h1s1_U133p2.CEL.gz///data_row_count: 54675
1
title: Ovarian carcinoma 92///geo_accession: GSM643024///status: Public on Nov 01 2011///submission_date: Dec 20 2010///last_update_date: Aug 19 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian carcinoma 92///organism_ch1: Homo sapiens///characteristics_ch1: histological type: Serous///characteristics_ch1.1: grade: 3///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: tissue: ovarian carcinoma tumor///characteristics_ch1.4: os event: 1///characteristics_ch1.5: os time (years): 3.04723///characteristics_ch1.6: pfs event: 1///characteristics_ch1.7: pfs time (years): 2.65845///characteristics_ch1.8: signature: FIBROSIS///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification was conducted using miRNeasy kit///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2,0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.///scan_protocol: GeneChips were scanned using the Affymetrix 7G Scanner GCS3000///description: Gene expression data from ovarian carcinoma///data_processing: The data were analyzed with Partek software (6.10.0915 version)///platform_id: GPL570///contact_name: Fatima,,Mechta-Grigoriou///contact_email: [email protected]///contact_phone: 33156246653///contact_fax: 33156246650///contact_laboratory: \Stress and Cancer\ Lab.///contact_department: INSERM U830///contact_institute: Institut Curie///contact_address: 26 rue d'Ulm///contact_city: PARIS///contact_zip.postal_code: 75248///contact_country: France///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM643nnn/GSM643024/GSM643024_OC01_ARN0147_s1h1s1_U133p2.CEL.gz///data_row_count: 54675
1
(Other)
8
An expression set
Despite the existence of morphologically indistinguishable disease, patients with advanced ovarian tumors display a broad range of survival end points. We hypothesize that gene expression profiling can identify a prognostic signature accounting for these distinct clinical outcomes. To resolve survival-associated loci, gene expression profiling was completed for an extensive set of 185 (90 optimal/95 suboptimal) primary ovarian tumors using the Affymetrix human U133A microarray. Cox regression analysis identified probe sets associated with survival in optimally and suboptimally debulked tumor sets at a P value of <0.01. Leave-one-out cross-validation was applied to each tumor cohort and confirmed by a permutation test. External validation was conducted by applying the gene signature to a publicly available array database of expression profiles of advanced stage suboptimally debulked tumors. The prognostic signature successfully classified the tumors according to survival for suboptimally (P = 0.0179) but not optimally debulked (P = 0.144) patients. The suboptimal gene signature was validated using the independent set of tumors (odds ratio, 8.75; P = 0.0146). To elucidate signaling events amenable to therapeutic intervention in suboptimally debulked patients, pathway analysis was completed for the top 57 survival-associated probe sets. For suboptimally debulked patients, confirmation of the predictive gene signature supports the existence of a clinically relevant predictor, as well as the possibility of novel therapeutic opportunities. Ultimately, the prognostic classifier defined for suboptimally debulked tumors may aid in the classification and enhancement of patient outcome for this high-risk population.
experimentData(eset):
Experiment data
Experimenter name: Bonome T, Levine DA, Shih J, Randonovich M, Pise-Masison CA, Bogomolniy F, Ozbun L, Brady J, Barrett JC, Boyd J, Birrer MJ: A Gene Signature Predicting for Survival in Suboptimally Debulked Patients with Ovarian Cancer. Cancer Research 2008, 68:5478 -5486.
Laboratory: Bonome, Birrer 2008
Contact information:
Title: A gene signature predicting for survival in suboptimally debulked patients with ovarian cancer.
URL:
PMIDs: 18593951
Abstract: A 238 word abstract is available. Use 'abstract' method.
Information is available on: preprocessing
notes:
platform_title:
[HG-U133A] Affymetrix Human Genome U133A Array
platform_shorttitle:
Affymetrix HG-U133A
platform_summary:
hgu133a
platform_manufacturer:
Affymetrix
platform_distribution:
commercial
platform_accession:
GPL96
version:
2015-09-22 19:46:24
featureData(eset):
An object of class 'AnnotatedDataFrame'
featureNames: 1007_s_at 1053_at ... AFFX-HUMISGF3A/M97935_MB_at
(20967 total)
varLabels: probeset gene EntrezGene.ID best_probe
varMetadata: labelDescription
assayData: 20967 features, 195 samples
Platform type:
Overall survival time-to-event summary (in years):
Call: survfit(formula = Surv(time, cens) ~ -1)
10 observations deleted due to missingness
n events median 0.95LCL 0.95UCL
185.00 129.00 3.83 3.24 4.83
---------------------------
Available sample meta-data:
---------------------------
alt_sample_name:
Normal HOSE2008 Normal HOSE2061 Normal HOSE2064
1 1 1
Normal HOSE2085 Normal HOSE2225 Normal HOSE2226
1 1 1
Normal HOSE2228 Normal HOSE2230 Normal HOSE2234
1 1 1
Normal HOSE2237 Ovarian Cancer SO10 Ovarian Cancer SO100
1 1 1
Ovarian Cancer SO103 Ovarian Cancer SO106 Ovarian Cancer SO108
1 1 1
Ovarian Cancer SO11 Ovarian Cancer SO113 Ovarian Cancer SO115
1 1 1
Ovarian Cancer SO116 Ovarian Cancer SO117 Ovarian Cancer SO118
1 1 1
Ovarian Cancer SO12 Ovarian Cancer SO121 Ovarian Cancer SO122
1 1 1
Ovarian Cancer SO124 Ovarian Cancer SO129 Ovarian Cancer SO13
1 1 1
Ovarian Cancer SO131 Ovarian Cancer SO134 Ovarian Cancer SO135
1 1 1
Ovarian Cancer SO137 Ovarian Cancer SO141 Ovarian Cancer SO143
1 1 1
Ovarian Cancer SO148 Ovarian Cancer SO154 Ovarian Cancer SO16
1 1 1
Ovarian Cancer SO166 Ovarian Cancer SO17 Ovarian Cancer SO173
1 1 1
Ovarian Cancer SO174 Ovarian Cancer SO18 Ovarian Cancer SO181
1 1 1
Ovarian Cancer SO184 Ovarian Cancer SO185 Ovarian Cancer SO187
1 1 1
Ovarian Cancer SO189 Ovarian Cancer SO190 Ovarian Cancer SO193
1 1 1
Ovarian Cancer SO194 Ovarian Cancer SO196 Ovarian Cancer SO197
1 1 1
Ovarian Cancer SO2 Ovarian Cancer SO200 Ovarian Cancer SO201
1 1 1
Ovarian Cancer SO203 Ovarian Cancer SO205 Ovarian Cancer SO21
1 1 1
Ovarian Cancer SO211 Ovarian Cancer SO214 Ovarian Cancer SO216
1 1 1
Ovarian Cancer SO217 Ovarian Cancer SO218 Ovarian Cancer SO224
1 1 1
Ovarian Cancer SO225 Ovarian Cancer SO227 Ovarian Cancer SO228
1 1 1
Ovarian Cancer SO229 Ovarian Cancer SO23 Ovarian Cancer SO230
1 1 1
Ovarian Cancer SO231 Ovarian Cancer SO235 Ovarian Cancer SO236
1 1 1
Ovarian Cancer SO237 Ovarian Cancer SO241 Ovarian Cancer SO242
1 1 1
Ovarian Cancer SO243 Ovarian Cancer SO244 Ovarian Cancer SO246
1 1 1
Ovarian Cancer SO247 Ovarian Cancer SO249 Ovarian Cancer SO25
1 1 1
Ovarian Cancer SO250 Ovarian Cancer SO256 Ovarian Cancer SO257
1 1 1
Ovarian Cancer SO258 Ovarian Cancer SO261 Ovarian Cancer SO262
1 1 1
Ovarian Cancer SO263 Ovarian Cancer SO265 Ovarian Cancer SO267
1 1 1
Ovarian Cancer SO268 Ovarian Cancer SO272 Ovarian Cancer SO273
1 1 1
Ovarian Cancer SO278 Ovarian Cancer SO279 Ovarian Cancer SO282
1 1 1
Ovarian Cancer SO283 Ovarian Cancer SO285 Ovarian Cancer SO290
1 1 1
(Other)
96
sample_type:
healthy tumor
10 185
histological_type:
ser NA's
185 10
primarysite:
ov
195
summarygrade:
high NA's
185 10
summarystage:
late NA's
185 10
tumorstage:
3 4 NA's
146 36 13
substage:
b c NA's
9 137 49
age_at_initial_pathologic_diagnosis:
Min. 1st Qu. Median Mean 3rd Qu. Max. NA's
26.00 52.00 63.00 61.54 70.00 84.00 13
recurrence_status:
norecurrence recurrence
42 153
days_to_death:
Min. 1st Qu. Median Mean 3rd Qu. Max. NA's
21.9 660.6 1164.0 1429.0 1880.0 4982.0 10
vital_status:
deceased living NA's
129 56 10
debulking:
optimal suboptimal NA's
90 95 10
percent_normal_cells:
20-
195
percent_stromal_cells:
20-
195
percent_tumor_cells:
80+
195
batch:
2003-11-04 2003-11-05 2003-11-06 2003-11-07 2003-11-20 2003-11-21 2003-12-16
14 16 9 6 10 15 17
2003-12-23 2003-12-24 2004-04-20 2004-04-21 2004-04-27 2004-09-28 2005-07-27
12 11 20 17 9 14 15
2006-11-09
10
uncurated_author_metadata:
title: Normal HOSE2008///geo_accession: GSM657520///status: Public on Jan 20 2011///submission_date: Jan 19 2011///last_update_date: Jan 20 2011///type: RNA///channel_count: 1///source_name_ch1: Ovarian surface epithelial cells///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Normal ovarian surface epithelium///characteristics_ch1.1: ///characteristics_ch1.2: ///characteristics_ch1.3: ///treatment_protocol_ch1: Tumor specimens were obtained from 185 previously untreated late-stage (IIIIV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using the RNeasy Micro kit (Qiagen)///label_ch1: Biotin///label_protocol_ch1: Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)///description: Gene expression data from ovarian surface epithelial cells///data_processing: Robust Multi-Array Analysis was performed///platform_id: GPL96///contact_name: Michael,,Birrer///contact_email: [email protected]///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657520/GSM657520_HOSE2008.CEL.gz///data_row_count: 22283
1
title: Normal HOSE2061///geo_accession: GSM657521///status: Public on Jan 20 2011///submission_date: Jan 19 2011///last_update_date: Jan 20 2011///type: RNA///channel_count: 1///source_name_ch1: Ovarian surface epithelial cells///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Normal ovarian surface epithelium///characteristics_ch1.1: ///characteristics_ch1.2: ///characteristics_ch1.3: ///treatment_protocol_ch1: Tumor specimens were obtained from 185 previously untreated late-stage (IIIIV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using the RNeasy Micro kit (Qiagen)///label_ch1: Biotin///label_protocol_ch1: Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)///description: Gene expression data from ovarian surface epithelial cells///data_processing: Robust Multi-Array Analysis was performed///platform_id: GPL96///contact_name: Michael,,Birrer///contact_email: [email protected]///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657521/GSM657521_HOSE2061.CEL.gz///data_row_count: 22283
1
title: Normal HOSE2064///geo_accession: GSM657522///status: Public on Jan 20 2011///submission_date: Jan 19 2011///last_update_date: Jan 20 2011///type: RNA///channel_count: 1///source_name_ch1: Ovarian surface epithelial cells///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Normal ovarian surface epithelium///characteristics_ch1.1: ///characteristics_ch1.2: ///characteristics_ch1.3: ///treatment_protocol_ch1: Tumor specimens were obtained from 185 previously untreated late-stage (IIIIV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using the RNeasy Micro kit (Qiagen)///label_ch1: Biotin///label_protocol_ch1: Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)///description: Gene expression data from ovarian surface epithelial cells///data_processing: Robust Multi-Array Analysis was performed///platform_id: GPL96///contact_name: Michael,,Birrer///contact_email: [email protected]///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657522/GSM657522_HOSE2064.CEL.gz///data_row_count: 22283
1
title: Normal HOSE2085///geo_accession: GSM657523///status: Public on Jan 20 2011///submission_date: Jan 19 2011///last_update_date: Jan 20 2011///type: RNA///channel_count: 1///source_name_ch1: Ovarian surface epithelial cells///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Normal ovarian surface epithelium///characteristics_ch1.1: ///characteristics_ch1.2: ///characteristics_ch1.3: ///treatment_protocol_ch1: Tumor specimens were obtained from 185 previously untreated late-stage (IIIIV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using the RNeasy Micro kit (Qiagen)///label_ch1: Biotin///label_protocol_ch1: Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)///description: Gene expression data from ovarian surface epithelial cells///data_processing: Robust Multi-Array Analysis was performed///platform_id: GPL96///contact_name: Michael,,Birrer///contact_email: [email protected]///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657523/GSM657523_HOSE2085.CEL.gz///data_row_count: 22283
1
title: Normal HOSE2225///geo_accession: GSM657524///status: Public on Jan 20 2011///submission_date: Jan 19 2011///last_update_date: Jan 20 2011///type: RNA///channel_count: 1///source_name_ch1: Ovarian surface epithelial cells///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Normal ovarian surface epithelium///characteristics_ch1.1: ///characteristics_ch1.2: ///characteristics_ch1.3: ///treatment_protocol_ch1: Tumor specimens were obtained from 185 previously untreated late-stage (IIIIV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using the RNeasy Micro kit (Qiagen)///label_ch1: Biotin///label_protocol_ch1: Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)///description: Gene expression data from ovarian surface epithelial cells///data_processing: Robust Multi-Array Analysis was performed///platform_id: GPL96///contact_name: Michael,,Birrer///contact_email: [email protected]///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657524/GSM657524_HOSE2225.CEL.gz///data_row_count: 22283
1
title: Normal HOSE2226///geo_accession: GSM657525///status: Public on Jan 20 2011///submission_date: Jan 19 2011///last_update_date: Jan 20 2011///type: RNA///channel_count: 1///source_name_ch1: Ovarian surface epithelial cells///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Normal ovarian surface epithelium///characteristics_ch1.1: ///characteristics_ch1.2: ///characteristics_ch1.3: ///treatment_protocol_ch1: Tumor specimens were obtained from 185 previously untreated late-stage (IIIIV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using the RNeasy Micro kit (Qiagen)///label_ch1: Biotin///label_protocol_ch1: Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)///description: Gene expression data from ovarian surface epithelial cells///data_processing: Robust Multi-Array Analysis was performed///platform_id: GPL96///contact_name: Michael,,Birrer///contact_email: [email protected]///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657525/GSM657525_HOSE2226.CEL.gz///data_row_count: 22283
1
title: Normal HOSE2228///geo_accession: GSM657526///status: Public on Jan 20 2011///submission_date: Jan 19 2011///last_update_date: Jan 20 2011///type: RNA///channel_count: 1///source_name_ch1: Ovarian surface epithelial cells///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Normal ovarian surface epithelium///characteristics_ch1.1: ///characteristics_ch1.2: ///characteristics_ch1.3: ///treatment_protocol_ch1: Tumor specimens were obtained from 185 previously untreated late-stage (IIIIV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using the RNeasy Micro kit (Qiagen)///label_ch1: Biotin///label_protocol_ch1: Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)///description: Gene expression data from ovarian surface epithelial cells///data_processing: Robust Multi-Array Analysis was performed///platform_id: GPL96///contact_name: Michael,,Birrer///contact_email: [email protected]///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657526/GSM657526_HOSE2228.CEL.gz///data_row_count: 22283
1
title: Normal HOSE2230///geo_accession: GSM657527///status: Public on Jan 20 2011///submission_date: Jan 19 2011///last_update_date: Jan 20 2011///type: RNA///channel_count: 1///source_name_ch1: Ovarian surface epithelial cells///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Normal ovarian surface epithelium///characteristics_ch1.1: ///characteristics_ch1.2: ///characteristics_ch1.3: ///treatment_protocol_ch1: Tumor specimens were obtained from 185 previously untreated late-stage (IIIIV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using the RNeasy Micro kit (Qiagen)///label_ch1: Biotin///label_protocol_ch1: Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)///description: Gene expression data from ovarian surface epithelial cells///data_processing: Robust Multi-Array Analysis was performed///platform_id: GPL96///contact_name: Michael,,Birrer///contact_email: [email protected]///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657527/GSM657527_HOSE2230.CEL.gz///data_row_count: 22283
1
title: Normal HOSE2234///geo_accession: GSM657528///status: Public on Jan 20 2011///submission_date: Jan 19 2011///last_update_date: Jan 20 2011///type: RNA///channel_count: 1///source_name_ch1: Ovarian surface epithelial cells///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Normal ovarian surface epithelium///characteristics_ch1.1: ///characteristics_ch1.2: ///characteristics_ch1.3: ///treatment_protocol_ch1: Tumor specimens were obtained from 185 previously untreated late-stage (IIIIV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using the RNeasy Micro kit (Qiagen)///label_ch1: Biotin///label_protocol_ch1: Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)///description: Gene expression data from ovarian surface epithelial cells///data_processing: Robust Multi-Array Analysis was performed///platform_id: GPL96///contact_name: Michael,,Birrer///contact_email: [email protected]///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657528/GSM657528_HOSE2234.CEL.gz///data_row_count: 22283
1
title: Normal HOSE2237///geo_accession: GSM657519///status: Public on Jan 20 2011///submission_date: Jan 19 2011///last_update_date: Jan 20 2011///type: RNA///channel_count: 1///source_name_ch1: Ovarian surface epithelial cells///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Normal ovarian surface epithelium///characteristics_ch1.1: ///characteristics_ch1.2: ///characteristics_ch1.3: ///treatment_protocol_ch1: Tumor specimens were obtained from 185 previously untreated late-stage (IIIIV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using the RNeasy Micro kit (Qiagen)///label_ch1: Biotin///label_protocol_ch1: Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)///description: Gene expression data from ovarian surface epithelial cells///data_processing: Robust Multi-Array Analysis was performed///platform_id: GPL96///contact_name: Michael,,Birrer///contact_email: [email protected]///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657519/GSM657519_HOSE2237.CEL.gz///data_row_count: 22283
1
title: Ovarian Cancer SO100///geo_accession: GSM657530///status: Public on Jan 20 2011///submission_date: Jan 19 2011///last_update_date: Jan 20 2011///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Late-stage high-grade ovarian cancer///characteristics_ch1.1: surgery outcome: Optimal///characteristics_ch1.2: status: NED (no evidence of disease)///characteristics_ch1.3: survival years: 4.51///treatment_protocol_ch1: Tumor specimens were obtained from 185 previously untreated late-stage (IIIIV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using the RNeasy Micro kit (Qiagen)///label_ch1: Biotin///label_protocol_ch1: Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)///description: Gene expression data from late-stage high-grade ovarian cancer///data_processing: Robust Multi-Array Analysis was performed///platform_id: GPL96///contact_name: Michael,,Birrer///contact_email: [email protected]///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657530/GSM657530_SO100.CEL.gz///data_row_count: 22283
1
title: Ovarian Cancer SO103///geo_accession: GSM657531///status: Public on Jan 20 2011///submission_date: Jan 19 2011///last_update_date: Jan 20 2011///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Late-stage high-grade ovarian cancer///characteristics_ch1.1: surgery outcome: Optimal///characteristics_ch1.2: status: NED (no evidence of disease)///characteristics_ch1.3: survival years: 4.38///treatment_protocol_ch1: Tumor specimens were obtained from 185 previously untreated late-stage (IIIIV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using the RNeasy Micro kit (Qiagen)///label_ch1: Biotin///label_protocol_ch1: Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)///description: Gene expression data from late-stage high-grade ovarian cancer///data_processing: Robust Multi-Array Analysis was performed///platform_id: GPL96///contact_name: Michael,,Birrer///contact_email: [email protected]///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657531/GSM657531_SO103.CEL.gz///data_row_count: 22283
1
title: Ovarian Cancer SO106///geo_accession: GSM657532///status: Public on Jan 20 2011///submission_date: Jan 19 2011///last_update_date: Jan 20 2011///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Late-stage high-grade ovarian cancer///characteristics_ch1.1: surgery outcome: Optimal///characteristics_ch1.2: status: DOD (dead of disease)///characteristics_ch1.3: survival years: 1.72///treatment_protocol_ch1: Tumor specimens were obtained from 185 previously untreated late-stage (IIIIV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using the RNeasy Micro kit (Qiagen)///label_ch1: Biotin///label_protocol_ch1: Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)///description: Gene expression data from late-stage high-grade ovarian cancer///data_processing: Robust Multi-Array Analysis was performed///platform_id: GPL96///contact_name: Michael,,Birrer///contact_email: [email protected]///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657532/GSM657532_SO106.CEL.gz///data_row_count: 22283
1
title: Ovarian Cancer SO108///geo_accession: GSM657533///status: Public on Jan 20 2011///submission_date: Jan 19 2011///last_update_date: Jan 20 2011///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Late-stage high-grade ovarian cancer///characteristics_ch1.1: surgery outcome: Optimal///characteristics_ch1.2: status: AWD (alive with disease)///characteristics_ch1.3: survival years: 3.99///treatment_protocol_ch1: Tumor specimens were obtained from 185 previously untreated late-stage (IIIIV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using the RNeasy Micro kit (Qiagen)///label_ch1: Biotin///label_protocol_ch1: Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)///description: Gene expression data from late-stage high-grade ovarian cancer///data_processing: Robust Multi-Array Analysis was performed///platform_id: GPL96///contact_name: Michael,,Birrer///contact_email: [email protected]///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657533/GSM657533_SO108.CEL.gz///data_row_count: 22283
1
title: Ovarian Cancer SO10///geo_accession: GSM657529///status: Public on Jan 20 2011///submission_date: Jan 19 2011///last_update_date: Jan 20 2011///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Late-stage high-grade ovarian cancer///characteristics_ch1.1: surgery outcome: Optimal///characteristics_ch1.2: status: AWD (alive with disease)///characteristics_ch1.3: survival years: 7.48///treatment_protocol_ch1: Tumor specimens were obtained from 185 previously untreated late-stage (IIIIV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using the RNeasy Micro kit (Qiagen)///label_ch1: Biotin///label_protocol_ch1: Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)///description: Gene expression data from late-stage high-grade ovarian cancer///data_processing: Robust Multi-Array Analysis was performed///platform_id: GPL96///contact_name: Michael,,Birrer///contact_email: [email protected]///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657529/GSM657529_SO10.CEL.gz///data_row_count: 22283
1
title: Ovarian Cancer SO113///geo_accession: GSM657535///status: Public on Jan 20 2011///submission_date: Jan 19 2011///last_update_date: Jan 20 2011///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Late-stage high-grade ovarian cancer///characteristics_ch1.1: surgery outcome: Optimal///characteristics_ch1.2: status: NED (no evidence of disease)///characteristics_ch1.3: survival years: 3.77///treatment_protocol_ch1: Tumor specimens were obtained from 185 previously untreated late-stage (IIIIV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using the RNeasy Micro kit (Qiagen)///label_ch1: Biotin///label_protocol_ch1: Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)///description: Gene expression data from late-stage high-grade ovarian cancer///data_processing: Robust Multi-Array Analysis was performed///platform_id: GPL96///contact_name: Michael,,Birrer///contact_email: [email protected]///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657535/GSM657535_SO113.CEL.gz///data_row_count: 22283
1
title: Ovarian Cancer SO115///geo_accession: GSM657536///status: Public on Jan 20 2011///submission_date: Jan 19 2011///last_update_date: Jan 20 2011///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Late-stage high-grade ovarian cancer///characteristics_ch1.1: surgery outcome: Optimal///characteristics_ch1.2: status: DOD (dead of disease)///characteristics_ch1.3: survival years: 2.45///treatment_protocol_ch1: Tumor specimens were obtained from 185 previously untreated late-stage (IIIIV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using the RNeasy Micro kit (Qiagen)///label_ch1: Biotin///label_protocol_ch1: Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)///description: Gene expression data from late-stage high-grade ovarian cancer///data_processing: Robust Multi-Array Analysis was performed///platform_id: GPL96///contact_name: Michael,,Birrer///contact_email: [email protected]///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657536/GSM657536_SO115.CEL.gz///data_row_count: 22283
1
title: Ovarian Cancer SO116///geo_accession: GSM657537///status: Public on Jan 20 2011///submission_date: Jan 19 2011///last_update_date: Jan 20 2011///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Late-stage high-grade ovarian cancer///characteristics_ch1.1: surgery outcome: Optimal///characteristics_ch1.2: status: AWD (alive with disease)///characteristics_ch1.3: survival years: 3.58///treatment_protocol_ch1: Tumor specimens were obtained from 185 previously untreated late-stage (IIIIV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using the RNeasy Micro kit (Qiagen)///label_ch1: Biotin///label_protocol_ch1: Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)///description: Gene expression data from late-stage high-grade ovarian cancer///data_processing: Robust Multi-Array Analysis was performed///platform_id: GPL96///contact_name: Michael,,Birrer///contact_email: [email protected]///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657537/GSM657537_SO116.CEL.gz///data_row_count: 22283
1
title: Ovarian Cancer SO117///geo_accession: GSM657538///status: Public on Jan 20 2011///submission_date: Jan 19 2011///last_update_date: Jan 20 2011///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Late-stage high-grade ovarian cancer///characteristics_ch1.1: surgery outcome: Optimal///characteristics_ch1.2: status: AWD (alive with disease)///characteristics_ch1.3: survival years: 3.53///treatment_protocol_ch1: Tumor specimens were obtained from 185 previously untreated late-stage (IIIIV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using the RNeasy Micro kit (Qiagen)///label_ch1: Biotin///label_protocol_ch1: Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)///description: Gene expression data from late-stage high-grade ovarian cancer///data_processing: Robust Multi-Array Analysis was performed///platform_id: GPL96///contact_name: Michael,,Birrer///contact_email: [email protected]///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657538/GSM657538_SO117.CEL.gz///data_row_count: 22283
1
title: Ovarian Cancer SO118///geo_accession: GSM657539///status: Public on Jan 20 2011///submission_date: Jan 19 2011///last_update_date: Jan 20 2011///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Late-stage high-grade ovarian cancer///characteristics_ch1.1: surgery outcome: Suboptimal///characteristics_ch1.2: status: AWD (alive with disease)///characteristics_ch1.3: survival years: 3.49///treatment_protocol_ch1: Tumor specimens were obtained from 185 previously untreated late-stage (IIIIV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using the RNeasy Micro kit (Qiagen)///label_ch1: Biotin///label_protocol_ch1: Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)///description: Gene expression data from late-stage high-grade ovarian cancer///data_processing: Robust Multi-Array Analysis was performed///platform_id: GPL96///contact_name: Michael,,Birrer///contact_email: [email protected]///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657539/GSM657539_SO118.CEL.gz///data_row_count: 22283
1
title: Ovarian Cancer SO11///geo_accession: GSM657534///status: Public on Jan 20 2011///submission_date: Jan 19 2011///last_update_date: Jan 20 2011///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Late-stage high-grade ovarian cancer///characteristics_ch1.1: surgery outcome: Optimal///characteristics_ch1.2: status: DOD (dead of disease)///characteristics_ch1.3: survival years: 2.51///treatment_protocol_ch1: Tumor specimens were obtained from 185 previously untreated late-stage (IIIIV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using the RNeasy Micro kit (Qiagen)///label_ch1: Biotin///label_protocol_ch1: Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)///description: Gene expression data from late-stage high-grade ovarian cancer///data_processing: Robust Multi-Array Analysis was performed///platform_id: GPL96///contact_name: Michael,,Birrer///contact_email: [email protected]///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657534/GSM657534_SO11.CEL.gz///data_row_count: 22283
1
title: Ovarian Cancer SO121///geo_accession: GSM657541///status: Public on Jan 20 2011///submission_date: Jan 19 2011///last_update_date: Jan 20 2011///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Late-stage high-grade ovarian cancer///characteristics_ch1.1: surgery outcome: Optimal///characteristics_ch1.2: status: NED (no evidence of disease)///characteristics_ch1.3: survival years: 3.3///treatment_protocol_ch1: Tumor specimens were obtained from 185 previously untreated late-stage (IIIIV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using the RNeasy Micro kit (Qiagen)///label_ch1: Biotin///label_protocol_ch1: Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)///description: Gene expression data from late-stage high-grade ovarian cancer///data_processing: Robust Multi-Array Analysis was performed///platform_id: GPL96///contact_name: Michael,,Birrer///contact_email: [email protected]///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657541/GSM657541_SO121.CEL.gz///data_row_count: 22283
1
title: Ovarian Cancer SO122///geo_accession: GSM657542///status: Public on Jan 20 2011///submission_date: Jan 19 2011///last_update_date: Jan 20 2011///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Late-stage high-grade ovarian cancer///characteristics_ch1.1: surgery outcome: Optimal///characteristics_ch1.2: status: DOD (dead of disease)///characteristics_ch1.3: survival years: 2.3///treatment_protocol_ch1: Tumor specimens were obtained from 185 previously untreated late-stage (IIIIV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using the RNeasy Micro kit (Qiagen)///label_ch1: Biotin///label_protocol_ch1: Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)///description: Gene expression data from late-stage high-grade ovarian cancer///data_processing: Robust Multi-Array Analysis was performed///platform_id: GPL96///contact_name: Michael,,Birrer///contact_email: [email protected]///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657542/GSM657542_SO122.CEL.gz///data_row_count: 22283
1
title: Ovarian Cancer SO124///geo_accession: GSM657543///status: Public on Jan 20 2011///submission_date: Jan 19 2011///last_update_date: Jan 20 2011///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Late-stage high-grade ovarian cancer///characteristics_ch1.1: surgery outcome: Optimal///characteristics_ch1.2: status: NED (no evidence of disease)///characteristics_ch1.3: survival years: 3.26///treatment_protocol_ch1: Tumor specimens were obtained from 185 previously untreated late-stage (IIIIV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using the RNeasy Micro kit (Qiagen)///label_ch1: Biotin///label_protocol_ch1: Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)///description: Gene expression data from late-stage high-grade ovarian cancer///data_processing: Robust Multi-Array Analysis was performed///platform_id: GPL96///contact_name: Michael,,Birrer///contact_email: [email protected]///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657543/GSM657543_SO124.CEL.gz///data_row_count: 22283
1
title: Ovarian Cancer SO129///geo_accession: GSM657544///status: Public on Jan 20 2011///submission_date: Jan 19 2011///last_update_date: Jan 20 2011///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Late-stage high-grade ovarian cancer///characteristics_ch1.1: surgery outcome: Optimal///characteristics_ch1.2: status: NED (no evidence of disease)///characteristics_ch1.3: survival years: 2.82///treatment_protocol_ch1: Tumor specimens were obtained from 185 previously untreated late-stage (IIIIV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using the RNeasy Micro kit (Qiagen)///label_ch1: Biotin///label_protocol_ch1: Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)///description: Gene expression data from late-stage high-grade ovarian cancer///data_processing: Robust Multi-Array Analysis was performed///platform_id: GPL96///contact_name: Michael,,Birrer///contact_email: [email protected]///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657544/GSM657544_SO129.CEL.gz///data_row_count: 22283
1
title: Ovarian Cancer SO12///geo_accession: GSM657540///status: Public on Jan 20 2011///submission_date: Jan 19 2011///last_update_date: Jan 20 2011///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Late-stage high-grade ovarian cancer///characteristics_ch1.1: surgery outcome: Optimal///characteristics_ch1.2: status: DOD (dead of disease)///characteristics_ch1.3: survival years: 0.71///treatment_protocol_ch1: Tumor specimens were obtained from 185 previously untreated late-stage (IIIIV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using the RNeasy Micro kit (Qiagen)///label_ch1: Biotin///label_protocol_ch1: Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)///description: Gene expression data from late-stage high-grade ovarian cancer///data_processing: Robust Multi-Array Analysis was performed///platform_id: GPL96///contact_name: Michael,,Birrer///contact_email: [email protected]///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657540/GSM657540_SO12.CEL.gz///data_row_count: 22283
1
title: Ovarian Cancer SO131///geo_accession: GSM657546///status: Public on Jan 20 2011///submission_date: Jan 19 2011///last_update_date: Jan 20 2011///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Late-stage high-grade ovarian cancer///characteristics_ch1.1: surgery outcome: Optimal///characteristics_ch1.2: status: NED (no evidence of disease)///characteristics_ch1.3: survival years: 2.94///treatment_protocol_ch1: Tumor specimens were obtained from 185 previously untreated late-stage (IIIIV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using the RNeasy Micro kit (Qiagen)///label_ch1: Biotin///label_protocol_ch1: Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)///description: Gene expression data from late-stage high-grade ovarian cancer///data_processing: Robust Multi-Array Analysis was performed///platform_id: GPL96///contact_name: Michael,,Birrer///contact_email: [email protected]///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657546/GSM657546_SO131.CEL.gz///data_row_count: 22283
1
title: Ovarian Cancer SO134///geo_accession: GSM657547///status: Public on Jan 20 2011///submission_date: Jan 19 2011///last_update_date: Jan 20 2011///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Late-stage high-grade ovarian cancer///characteristics_ch1.1: surgery outcome: Optimal///characteristics_ch1.2: status: DOD (dead of disease)///characteristics_ch1.3: survival years: 1.03///treatment_protocol_ch1: Tumor specimens were obtained from 185 previously untreated late-stage (IIIIV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using the RNeasy Micro kit (Qiagen)///label_ch1: Biotin///label_protocol_ch1: Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)///description: Gene expression data from late-stage high-grade ovarian cancer///data_processing: Robust Multi-Array Analysis was performed///platform_id: GPL96///contact_name: Michael,,Birrer///contact_email: [email protected]///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657547/GSM657547_SO134.CEL.gz///data_row_count: 22283
1
title: Ovarian Cancer SO135///geo_accession: GSM657548///status: Public on Jan 20 2011///submission_date: Jan 19 2011///last_update_date: Jan 20 2011///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Late-stage high-grade ovarian cancer///characteristics_ch1.1: surgery outcome: Optimal///characteristics_ch1.2: status: DOD (dead of disease)///characteristics_ch1.3: survival years: 3.55///treatment_protocol_ch1: Tumor specimens were obtained from 185 previously untreated late-stage (IIIIV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using the RNeasy Micro kit (Qiagen)///label_ch1: Biotin///label_protocol_ch1: Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)///description: Gene expression data from late-stage high-grade ovarian cancer///data_processing: Robust Multi-Array Analysis was performed///platform_id: GPL96///contact_name: Michael,,Birrer///contact_email: [email protected]///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657548/GSM657548_SO135.CEL.gz///data_row_count: 22283
1
title: Ovarian Cancer SO137///geo_accession: GSM657549///status: Public on Jan 20 2011///submission_date: Jan 19 2011///last_update_date: Jan 20 2011///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Late-stage high-grade ovarian cancer///characteristics_ch1.1: surgery outcome: Suboptimal///characteristics_ch1.2: status: DOD (dead of disease)///characteristics_ch1.3: survival years: 0.17///treatment_protocol_ch1: Tumor specimens were obtained from 185 previously untreated late-stage (IIIIV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using the RNeasy Micro kit (Qiagen)///label_ch1: Biotin///label_protocol_ch1: Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)///description: Gene expression data from late-stage high-grade ovarian cancer///data_processing: Robust Multi-Array Analysis was performed///platform_id: GPL96///contact_name: Michael,,Birrer///contact_email: [email protected]///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657549/GSM657549_SO137.CEL.gz///data_row_count: 22283
1
title: Ovarian Cancer SO13///geo_accession: GSM657545///status: Public on Jan 20 2011///submission_date: Jan 19 2011///last_update_date: Jan 20 2011///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Late-stage high-grade ovarian cancer///characteristics_ch1.1: surgery outcome: Suboptimal///characteristics_ch1.2: status: NED (no evidence of disease)///characteristics_ch1.3: survival years: 7.33///treatment_protocol_ch1: Tumor specimens were obtained from 185 previously untreated late-stage (IIIIV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using the RNeasy Micro kit (Qiagen)///label_ch1: Biotin///label_protocol_ch1: Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)///description: Gene expression data from late-stage high-grade ovarian cancer///data_processing: Robust Multi-Array Analysis was performed///platform_id: GPL96///contact_name: Michael,,Birrer///contact_email: [email protected]///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657545/GSM657545_SO13.CEL.gz///data_row_count: 22283
1
title: Ovarian Cancer SO141///geo_accession: GSM657550///status: Public on Jan 20 2011///submission_date: Jan 19 2011///last_update_date: Jan 20 2011///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Late-stage high-grade ovarian cancer///characteristics_ch1.1: surgery outcome: Suboptimal///characteristics_ch1.2: status: DOD (dead of disease)///characteristics_ch1.3: survival years: 1.47///treatment_protocol_ch1: Tumor specimens were obtained from 185 previously untreated late-stage (IIIIV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using the RNeasy Micro kit (Qiagen)///label_ch1: Biotin///label_protocol_ch1: Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)///description: Gene expression data from late-stage high-grade ovarian cancer///data_processing: Robust Multi-Array Analysis was performed///platform_id: GPL96///contact_name: Michael,,Birrer///contact_email: [email protected]///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657550/GSM657550_SO141.CEL.gz///data_row_count: 22283
1
title: Ovarian Cancer SO143///geo_accession: GSM657551///status: Public on Jan 20 2011///submission_date: Jan 19 2011///last_update_date: Jan 20 2011///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Late-stage high-grade ovarian cancer///characteristics_ch1.1: surgery outcome: Optimal///characteristics_ch1.2: status: AWD (alive with disease)///characteristics_ch1.3: survival years: 6.86///treatment_protocol_ch1: Tumor specimens were obtained from 185 previously untreated late-stage (IIIIV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using the RNeasy Micro kit (Qiagen)///label_ch1: Biotin///label_protocol_ch1: Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)///description: Gene expression data from late-stage high-grade ovarian cancer///data_processing: Robust Multi-Array Analysis was performed///platform_id: GPL96///contact_name: Michael,,Birrer///contact_email: [email protected]///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657551/GSM657551_SO143.CEL.gz///data_row_count: 22283
1
title: Ovarian Cancer SO148///geo_accession: GSM657552///status: Public on Jan 20 2011///submission_date: Jan 19 2011///last_update_date: Jan 20 2011///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Late-stage high-grade ovarian cancer///characteristics_ch1.1: surgery outcome: Suboptimal///characteristics_ch1.2: status: DOD (dead of disease)///characteristics_ch1.3: survival years: 2.37///treatment_protocol_ch1: Tumor specimens were obtained from 185 previously untreated late-stage (IIIIV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using the RNeasy Micro kit (Qiagen)///label_ch1: Biotin///label_protocol_ch1: Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)///description: Gene expression data from late-stage high-grade ovarian cancer///data_processing: Robust Multi-Array Analysis was performed///platform_id: GPL96///contact_name: Michael,,Birrer///contact_email: [email protected]///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657552/GSM657552_SO148.CEL.gz///data_row_count: 22283
1
title: Ovarian Cancer SO154///geo_accession: GSM657553///status: Public on Jan 20 2011///submission_date: Jan 19 2011///last_update_date: Jan 20 2011///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Late-stage high-grade ovarian cancer///characteristics_ch1.1: surgery outcome: Suboptimal///characteristics_ch1.2: status: AWD (alive with disease)///characteristics_ch1.3: survival years: 3.7///treatment_protocol_ch1: Tumor specimens were obtained from 185 previously untreated late-stage (IIIIV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using the RNeasy Micro kit (Qiagen)///label_ch1: Biotin///label_protocol_ch1: Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)///description: Gene expression data from late-stage high-grade ovarian cancer///data_processing: Robust Multi-Array Analysis was performed///platform_id: GPL96///contact_name: Michael,,Birrer///contact_email: [email protected]///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657553/GSM657553_SO154.CEL.gz///data_row_count: 22283
1
title: Ovarian Cancer SO166///geo_accession: GSM657555///status: Public on Jan 20 2011///submission_date: Jan 19 2011///last_update_date: Jan 20 2011///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Late-stage high-grade ovarian cancer///characteristics_ch1.1: surgery outcome: Optimal///characteristics_ch1.2: status: NED (no evidence of disease)///characteristics_ch1.3: survival years: 2.93///treatment_protocol_ch1: Tumor specimens were obtained from 185 previously untreated late-stage (IIIIV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using the RNeasy Micro kit (Qiagen)///label_ch1: Biotin///label_protocol_ch1: Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)///description: Gene expression data from late-stage high-grade ovarian cancer///data_processing: Robust Multi-Array Analysis was performed///platform_id: GPL96///contact_name: Michael,,Birrer///contact_email: [email protected]///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657555/GSM657555_SO166.CEL.gz///data_row_count: 22283
1
title: Ovarian Cancer SO16///geo_accession: GSM657554///status: Public on Jan 20 2011///submission_date: Jan 19 2011///last_update_date: Jan 20 2011///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Late-stage high-grade ovarian cancer///characteristics_ch1.1: surgery outcome: Suboptimal///characteristics_ch1.2: status: DOD (dead of disease)///characteristics_ch1.3: survival years: 6.29///treatment_protocol_ch1: Tumor specimens were obtained from 185 previously untreated late-stage (IIIIV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using the RNeasy Micro kit (Qiagen)///label_ch1: Biotin///label_protocol_ch1: Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)///description: Gene expression data from late-stage high-grade ovarian cancer///data_processing: Robust Multi-Array Analysis was performed///platform_id: GPL96///contact_name: Michael,,Birrer///contact_email: [email protected]///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657554/GSM657554_SO16.CEL.gz///data_row_count: 22283
1
title: Ovarian Cancer SO173///geo_accession: GSM657557///status: Public on Jan 20 2011///submission_date: Jan 19 2011///last_update_date: Jan 20 2011///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Late-stage high-grade ovarian cancer///characteristics_ch1.1: surgery outcome: Optimal///characteristics_ch1.2: status: AWD (alive with disease)///characteristics_ch1.3: survival years: 2.71///treatment_protocol_ch1: Tumor specimens were obtained from 185 previously untreated late-stage (IIIIV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using the RNeasy Micro kit (Qiagen)///label_ch1: Biotin///label_protocol_ch1: Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)///description: Gene expression data from late-stage high-grade ovarian cancer///data_processing: Robust Multi-Array Analysis was performed///platform_id: GPL96///contact_name: Michael,,Birrer///contact_email: [email protected]///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657557/GSM657557_SO173.CEL.gz///data_row_count: 22283
1
title: Ovarian Cancer SO174///geo_accession: GSM657558///status: Public on Jan 20 2011///submission_date: Jan 19 2011///last_update_date: Jan 20 2011///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Late-stage high-grade ovarian cancer///characteristics_ch1.1: surgery outcome: Suboptimal///characteristics_ch1.2: status: DOD (dead of disease)///characteristics_ch1.3: survival years: 2.84///treatment_protocol_ch1: Tumor specimens were obtained from 185 previously untreated late-stage (IIIIV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using the RNeasy Micro kit (Qiagen)///label_ch1: Biotin///label_protocol_ch1: Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)///description: Gene expression data from late-stage high-grade ovarian cancer///data_processing: Robust Multi-Array Analysis was performed///platform_id: GPL96///contact_name: Michael,,Birrer///contact_email: [email protected]///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657558/GSM657558_SO174.CEL.gz///data_row_count: 22283
1
title: Ovarian Cancer SO17///geo_accession: GSM657556///status: Public on Jan 20 2011///submission_date: Jan 19 2011///last_update_date: Jan 20 2011///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Late-stage high-grade ovarian cancer///characteristics_ch1.1: surgery outcome: Suboptimal///characteristics_ch1.2: status: DOD (dead of disease)///characteristics_ch1.3: survival years: 3.83///treatment_protocol_ch1: Tumor specimens were obtained from 185 previously untreated late-stage (IIIIV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using the RNeasy Micro kit (Qiagen)///label_ch1: Biotin///label_protocol_ch1: Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)///description: Gene expression data from late-stage high-grade ovarian cancer///data_processing: Robust Multi-Array Analysis was performed///platform_id: GPL96///contact_name: Michael,,Birrer///contact_email: [email protected]///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657556/GSM657556_SO17.CEL.gz///data_row_count: 22283
1
title: Ovarian Cancer SO181///geo_accession: GSM657560///status: Public on Jan 20 2011///submission_date: Jan 19 2011///last_update_date: Jan 20 2011///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Late-stage high-grade ovarian cancer///characteristics_ch1.1: surgery outcome: Optimal///characteristics_ch1.2: status: NED (no evidence of disease)///characteristics_ch1.3: survival years: 2.1///treatment_protocol_ch1: Tumor specimens were obtained from 185 previously untreated late-stage (IIIIV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using the RNeasy Micro kit (Qiagen)///label_ch1: Biotin///label_protocol_ch1: Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)///description: Gene expression data from late-stage high-grade ovarian cancer///data_processing: Robust Multi-Array Analysis was performed///platform_id: GPL96///contact_name: Michael,,Birrer///contact_email: [email protected]///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657560/GSM657560_SO181.CEL.gz///data_row_count: 22283
1
title: Ovarian Cancer SO184///geo_accession: GSM657561///status: Public on Jan 20 2011///submission_date: Jan 19 2011///last_update_date: Jan 20 2011///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Late-stage high-grade ovarian cancer///characteristics_ch1.1: surgery outcome: Optimal///characteristics_ch1.2: status: NED (no evidence of disease)///characteristics_ch1.3: survival years: 2.43///treatment_protocol_ch1: Tumor specimens were obtained from 185 previously untreated late-stage (IIIIV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using the RNeasy Micro kit (Qiagen)///label_ch1: Biotin///label_protocol_ch1: Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)///description: Gene expression data from late-stage high-grade ovarian cancer///data_processing: Robust Multi-Array Analysis was performed///platform_id: GPL96///contact_name: Michael,,Birrer///contact_email: [email protected]///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657561/GSM657561_SO184.CEL.gz///data_row_count: 22283
1
title: Ovarian Cancer SO185///geo_accession: GSM657562///status: Public on Jan 20 2011///submission_date: Jan 19 2011///last_update_date: Jan 20 2011///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Late-stage high-grade ovarian cancer///characteristics_ch1.1: surgery outcome: Optimal///characteristics_ch1.2: status: NED (no evidence of disease)///characteristics_ch1.3: survival years: 2.37///treatment_protocol_ch1: Tumor specimens were obtained from 185 previously untreated late-stage (IIIIV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using the RNeasy Micro kit (Qiagen)///label_ch1: Biotin///label_protocol_ch1: Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)///description: Gene expression data from late-stage high-grade ovarian cancer///data_processing: Robust Multi-Array Analysis was performed///platform_id: GPL96///contact_name: Michael,,Birrer///contact_email: [email protected]///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657562/GSM657562_SO185.CEL.gz///data_row_count: 22283
1
title: Ovarian Cancer SO187///geo_accession: GSM657563///status: Public on Jan 20 2011///submission_date: Jan 19 2011///last_update_date: Jan 20 2011///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Late-stage high-grade ovarian cancer///characteristics_ch1.1: surgery outcome: Optimal///characteristics_ch1.2: status: AWD (alive with disease)///characteristics_ch1.3: survival years: 2.48///treatment_protocol_ch1: Tumor specimens were obtained from 185 previously untreated late-stage (IIIIV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using the RNeasy Micro kit (Qiagen)///label_ch1: Biotin///label_protocol_ch1: Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)///description: Gene expression data from late-stage high-grade ovarian cancer///data_processing: Robust Multi-Array Analysis was performed///platform_id: GPL96///contact_name: Michael,,Birrer///contact_email: [email protected]///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657563/GSM657563_SO187.CEL.gz///data_row_count: 22283
1
title: Ovarian Cancer SO189///geo_accession: GSM657564///status: Public on Jan 20 2011///submission_date: Jan 19 2011///last_update_date: Jan 20 2011///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Late-stage high-grade ovarian cancer///characteristics_ch1.1: surgery outcome: Optimal///characteristics_ch1.2: status: NED (no evidence of disease)///characteristics_ch1.3: survival years: 2.3///treatment_protocol_ch1: Tumor specimens were obtained from 185 previously untreated late-stage (IIIIV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using the RNeasy Micro kit (Qiagen)///label_ch1: Biotin///label_protocol_ch1: Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)///description: Gene expression data from late-stage high-grade ovarian cancer///data_processing: Robust Multi-Array Analysis was performed///platform_id: GPL96///contact_name: Michael,,Birrer///contact_email: [email protected]///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657564/GSM657564_SO189.CEL.gz///data_row_count: 22283
1
title: Ovarian Cancer SO18///geo_accession: GSM657559///status: Public on Jan 20 2011///submission_date: Jan 19 2011///last_update_date: Jan 20 2011///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Late-stage high-grade ovarian cancer///characteristics_ch1.1: surgery outcome: Optimal///characteristics_ch1.2: status: DOD (dead of disease)///characteristics_ch1.3: survival years: 6.3///treatment_protocol_ch1: Tumor specimens were obtained from 185 previously untreated late-stage (IIIIV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using the RNeasy Micro kit (Qiagen)///label_ch1: Biotin///label_protocol_ch1: Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)///description: Gene expression data from late-stage high-grade ovarian cancer///data_processing: Robust Multi-Array Analysis was performed///platform_id: GPL96///contact_name: Michael,,Birrer///contact_email: [email protected]///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657559/GSM657559_SO18.CEL.gz///data_row_count: 22283
1
title: Ovarian Cancer SO190///geo_accession: GSM657565///status: Public on Jan 20 2011///submission_date: Jan 19 2011///last_update_date: Jan 20 2011///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Late-stage high-grade ovarian cancer///characteristics_ch1.1: surgery outcome: Optimal///characteristics_ch1.2: status: DOD (dead of disease)///characteristics_ch1.3: survival years: 2.16///treatment_protocol_ch1: Tumor specimens were obtained from 185 previously untreated late-stage (IIIIV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using the RNeasy Micro kit (Qiagen)///label_ch1: Biotin///label_protocol_ch1: Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)///description: Gene expression data from late-stage high-grade ovarian cancer///data_processing: Robust Multi-Array Analysis was performed///platform_id: GPL96///contact_name: Michael,,Birrer///contact_email: [email protected]///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657565/GSM657565_SO190.CEL.gz///data_row_count: 22283
1
title: Ovarian Cancer SO193///geo_accession: GSM657566///status: Public on Jan 20 2011///submission_date: Jan 19 2011///last_update_date: Jan 20 2011///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Late-stage high-grade ovarian cancer///characteristics_ch1.1: surgery outcome: Optimal///characteristics_ch1.2: status: AWD (alive with disease)///characteristics_ch1.3: survival years: 2.27///treatment_protocol_ch1: Tumor specimens were obtained from 185 previously untreated late-stage (IIIIV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using the RNeasy Micro kit (Qiagen)///label_ch1: Biotin///label_protocol_ch1: Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)///description: Gene expression data from late-stage high-grade ovarian cancer///data_processing: Robust Multi-Array Analysis was performed///platform_id: GPL96///contact_name: Michael,,Birrer///contact_email: [email protected]///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657566/GSM657566_SO193.CEL.gz///data_row_count: 22283
1
title: Ovarian Cancer SO194///geo_accession: GSM657567///status: Public on Jan 20 2011///submission_date: Jan 19 2011///last_update_date: Jan 20 2011///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Late-stage high-grade ovarian cancer///characteristics_ch1.1: surgery outcome: Optimal///characteristics_ch1.2: status: AWD (alive with disease)///characteristics_ch1.3: survival years: 2.23///treatment_protocol_ch1: Tumor specimens were obtained from 185 previously untreated late-stage (IIIIV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using the RNeasy Micro kit (Qiagen)///label_ch1: Biotin///label_protocol_ch1: Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)///description: Gene expression data from late-stage high-grade ovarian cancer///data_processing: Robust Multi-Array Analysis was performed///platform_id: GPL96///contact_name: Michael,,Birrer///contact_email: [email protected]///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657567/GSM657567_SO194.CEL.gz///data_row_count: 22283
1
title: Ovarian Cancer SO196///geo_accession: GSM657568///status: Public on Jan 20 2011///submission_date: Jan 19 2011///last_update_date: Jan 20 2011///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Late-stage high-grade ovarian cancer///characteristics_ch1.1: surgery outcome: Optimal///characteristics_ch1.2: status: DOD (dead of disease)///characteristics_ch1.3: survival years: 1.28///treatment_protocol_ch1: Tumor specimens were obtained from 185 previously untreated late-stage (IIIIV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using the RNeasy Micro kit (Qiagen)///label_ch1: Biotin///label_protocol_ch1: Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)///description: Gene expression data from late-stage high-grade ovarian cancer///data_processing: Robust Multi-Array Analysis was performed///platform_id: GPL96///contact_name: Michael,,Birrer///contact_email: [email protected]///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657568/GSM657568_SO196.CEL.gz///data_row_count: 22283
1
title: Ovarian Cancer SO197///geo_accession: GSM657569///status: Public on Jan 20 2011///submission_date: Jan 19 2011///last_update_date: Jan 20 2011///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Late-stage high-grade ovarian cancer///characteristics_ch1.1: surgery outcome: Optimal///characteristics_ch1.2: status: AWD (alive with disease)///characteristics_ch1.3: survival years: 2.16///treatment_protocol_ch1: Tumor specimens were obtained from 185 previously untreated late-stage (IIIIV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using the RNeasy Micro kit (Qiagen)///label_ch1: Biotin///label_protocol_ch1: Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)///description: Gene expression data from late-stage high-grade ovarian cancer///data_processing: Robust Multi-Array Analysis was performed///platform_id: GPL96///contact_name: Michael,,Birrer///contact_email: [email protected]///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657569/GSM657569_SO197.CEL.gz///data_row_count: 22283
1
title: Ovarian Cancer SO200///geo_accession: GSM657571///status: Public on Jan 20 2011///submission_date: Jan 19 2011///last_update_date: Jan 20 2011///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Late-stage high-grade ovarian cancer///characteristics_ch1.1: surgery outcome: Optimal///characteristics_ch1.2: status: AWD (alive with disease)///characteristics_ch1.3: survival years: 2.15///treatment_protocol_ch1: Tumor specimens were obtained from 185 previously untreated late-stage (IIIIV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using the RNeasy Micro kit (Qiagen)///label_ch1: Biotin///label_protocol_ch1: Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)///description: Gene expression data from late-stage high-grade ovarian cancer///data_processing: Robust Multi-Array Analysis was performed///platform_id: GPL96///contact_name: Michael,,Birrer///contact_email: [email protected]///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657571/GSM657571_SO200.CEL.gz///data_row_count: 22283
1
title: Ovarian Cancer SO201///geo_accession: GSM657572///status: Public on Jan 20 2011///submission_date: Jan 19 2011///last_update_date: Jan 20 2011///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Late-stage high-grade ovarian cancer///characteristics_ch1.1: surgery outcome: Optimal///characteristics_ch1.2: status: AWD (alive with disease)///characteristics_ch1.3: survival years: 2.06///treatment_protocol_ch1: Tumor specimens were obtained from 185 previously untreated late-stage (IIIIV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using the RNeasy Micro kit (Qiagen)///label_ch1: Biotin///label_protocol_ch1: Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)///description: Gene expression data from late-stage high-grade ovarian cancer///data_processing: Robust Multi-Array Analysis was performed///platform_id: GPL96///contact_name: Michael,,Birrer///contact_email: [email protected]///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657572/GSM657572_SO201.CEL.gz///data_row_count: 22283
1
title: Ovarian Cancer SO203///geo_accession: GSM657573///status: Public on Jan 20 2011///submission_date: Jan 19 2011///last_update_date: Jan 20 2011///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Late-stage high-grade ovarian cancer///characteristics_ch1.1: surgery outcome: Optimal///characteristics_ch1.2: status: DOD (dead of disease)///characteristics_ch1.3: survival years: 1.59///treatment_protocol_ch1: Tumor specimens were obtained from 185 previously untreated late-stage (IIIIV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using the RNeasy Micro kit (Qiagen)///label_ch1: Biotin///label_protocol_ch1: Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)///description: Gene expression data from late-stage high-grade ovarian cancer///data_processing: Robust Multi-Array Analysis was performed///platform_id: GPL96///contact_name: Michael,,Birrer///contact_email: [email protected]///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657573/GSM657573_SO203.CEL.gz///data_row_count: 22283
1
title: Ovarian Cancer SO205///geo_accession: GSM657574///status: Public on Jan 20 2011///submission_date: Jan 19 2011///last_update_date: Jan 20 2011///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Late-stage high-grade ovarian cancer///characteristics_ch1.1: surgery outcome: Optimal///characteristics_ch1.2: status: NED (no evidence of disease)///characteristics_ch1.3: survival years: 1.89///treatment_protocol_ch1: Tumor specimens were obtained from 185 previously untreated late-stage (IIIIV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using the RNeasy Micro kit (Qiagen)///label_ch1: Biotin///label_protocol_ch1: Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)///description: Gene expression data from late-stage high-grade ovarian cancer///data_processing: Robust Multi-Array Analysis was performed///platform_id: GPL96///contact_name: Michael,,Birrer///contact_email: [email protected]///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657574/GSM657574_SO205.CEL.gz///data_row_count: 22283
1
title: Ovarian Cancer SO211///geo_accession: GSM657576///status: Public on Jan 20 2011///submission_date: Jan 19 2011///last_update_date: Jan 20 2011///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Late-stage high-grade ovarian cancer///characteristics_ch1.1: surgery outcome: Suboptimal///characteristics_ch1.2: status: DOD (dead of disease)///characteristics_ch1.3: survival years: 4.94///treatment_protocol_ch1: Tumor specimens were obtained from 185 previously untreated late-stage (IIIIV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using the RNeasy Micro kit (Qiagen)///label_ch1: Biotin///label_protocol_ch1: Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)///description: Gene expression data from late-stage high-grade ovarian cancer///data_processing: Robust Multi-Array Analysis was performed///platform_id: GPL96///contact_name: Michael,,Birrer///contact_email: [email protected]///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657576/GSM657576_SO211.CEL.gz///data_row_count: 22283
1
title: Ovarian Cancer SO214///geo_accession: GSM657577///status: Public on Jan 20 2011///submission_date: Jan 19 2011///last_update_date: Jan 20 2011///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Late-stage high-grade ovarian cancer///characteristics_ch1.1: surgery outcome: Suboptimal///characteristics_ch1.2: status: DOD (dead of disease)///characteristics_ch1.3: survival years: 2.96///treatment_protocol_ch1: Tumor specimens were obtained from 185 previously untreated late-stage (IIIIV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using the RNeasy Micro kit (Qiagen)///label_ch1: Biotin///label_protocol_ch1: Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)///description: Gene expression data from late-stage high-grade ovarian cancer///data_processing: Robust Multi-Array Analysis was performed///platform_id: GPL96///contact_name: Michael,,Birrer///contact_email: [email protected]///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657577/GSM657577_SO214.CEL.gz///data_row_count: 22283
1
title: Ovarian Cancer SO216///geo_accession: GSM657578///status: Public on Jan 20 2011///submission_date: Jan 19 2011///last_update_date: Jan 20 2011///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Late-stage high-grade ovarian cancer///characteristics_ch1.1: surgery outcome: Suboptimal///characteristics_ch1.2: status: DOD (dead of disease)///characteristics_ch1.3: survival years: 1.75///treatment_protocol_ch1: Tumor specimens were obtained from 185 previously untreated late-stage (IIIIV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using the RNeasy Micro kit (Qiagen)///label_ch1: Biotin///label_protocol_ch1: Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)///description: Gene expression data from late-stage high-grade ovarian cancer///data_processing: Robust Multi-Array Analysis was performed///platform_id: GPL96///contact_name: Michael,,Birrer///contact_email: [email protected]///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657578/GSM657578_SO216.CEL.gz///data_row_count: 22283
1
title: Ovarian Cancer SO217///geo_accession: GSM657579///status: Public on Jan 20 2011///submission_date: Jan 19 2011///last_update_date: Jan 20 2011///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Late-stage high-grade ovarian cancer///characteristics_ch1.1: surgery outcome: Suboptimal///characteristics_ch1.2: status: DOD (dead of disease)///characteristics_ch1.3: survival years: 1.91///treatment_protocol_ch1: Tumor specimens were obtained from 185 previously untreated late-stage (IIIIV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using the RNeasy Micro kit (Qiagen)///label_ch1: Biotin///label_protocol_ch1: Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)///description: Gene expression data from late-stage high-grade ovarian cancer///data_processing: Robust Multi-Array Analysis was performed///platform_id: GPL96///contact_name: Michael,,Birrer///contact_email: [email protected]///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657579/GSM657579_SO217.CEL.gz///data_row_count: 22283
1
title: Ovarian Cancer SO218///geo_accession: GSM657580///status: Public on Jan 20 2011///submission_date: Jan 19 2011///last_update_date: Jan 20 2011///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Late-stage high-grade ovarian cancer///characteristics_ch1.1: surgery outcome: Optimal///characteristics_ch1.2: status: DOD (dead of disease)///characteristics_ch1.3: survival years: 4.6///treatment_protocol_ch1: Tumor specimens were obtained from 185 previously untreated late-stage (IIIIV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using the RNeasy Micro kit (Qiagen)///label_ch1: Biotin///label_protocol_ch1: Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)///description: Gene expression data from late-stage high-grade ovarian cancer///data_processing: Robust Multi-Array Analysis was performed///platform_id: GPL96///contact_name: Michael,,Birrer///contact_email: [email protected]///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657580/GSM657580_SO218.CEL.gz///data_row_count: 22283
1
title: Ovarian Cancer SO21///geo_accession: GSM657575///status: Public on Jan 20 2011///submission_date: Jan 19 2011///last_update_date: Jan 20 2011///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Late-stage high-grade ovarian cancer///characteristics_ch1.1: surgery outcome: Optimal///characteristics_ch1.2: status: DOD (dead of disease)///characteristics_ch1.3: survival years: 0.56///treatment_protocol_ch1: Tumor specimens were obtained from 185 previously untreated late-stage (IIIIV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using the RNeasy Micro kit (Qiagen)///label_ch1: Biotin///label_protocol_ch1: Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)///description: Gene expression data from late-stage high-grade ovarian cancer///data_processing: Robust Multi-Array Analysis was performed///platform_id: GPL96///contact_name: Michael,,Birrer///contact_email: [email protected]///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657575/GSM657575_SO21.CEL.gz///data_row_count: 22283
1
title: Ovarian Cancer SO224///geo_accession: GSM657581///status: Public on Jan 20 2011///submission_date: Jan 19 2011///last_update_date: Jan 20 2011///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Late-stage high-grade ovarian cancer///characteristics_ch1.1: surgery outcome: Suboptimal///characteristics_ch1.2: status: DOD (dead of disease)///characteristics_ch1.3: survival years: 3.18///treatment_protocol_ch1: Tumor specimens were obtained from 185 previously untreated late-stage (IIIIV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using the RNeasy Micro kit (Qiagen)///label_ch1: Biotin///label_protocol_ch1: Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)///description: Gene expression data from late-stage high-grade ovarian cancer///data_processing: Robust Multi-Array Analysis was performed///platform_id: GPL96///contact_name: Michael,,Birrer///contact_email: [email protected]///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657581/GSM657581_SO224.CEL.gz///data_row_count: 22283
1
title: Ovarian Cancer SO225///geo_accession: GSM657582///status: Public on Jan 20 2011///submission_date: Jan 19 2011///last_update_date: Jan 20 2011///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Late-stage high-grade ovarian cancer///characteristics_ch1.1: surgery outcome: Optimal///characteristics_ch1.2: status: DOD (dead of disease)///characteristics_ch1.3: survival years: 8.8///treatment_protocol_ch1: Tumor specimens were obtained from 185 previously untreated late-stage (IIIIV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using the RNeasy Micro kit (Qiagen)///label_ch1: Biotin///label_protocol_ch1: Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)///description: Gene expression data from late-stage high-grade ovarian cancer///data_processing: Robust Multi-Array Analysis was performed///platform_id: GPL96///contact_name: Michael,,Birrer///contact_email: [email protected]///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657582/GSM657582_SO225.CEL.gz///data_row_count: 22283
1
title: Ovarian Cancer SO227///geo_accession: GSM657583///status: Public on Jan 20 2011///submission_date: Jan 19 2011///last_update_date: Jan 20 2011///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Late-stage high-grade ovarian cancer///characteristics_ch1.1: surgery outcome: Suboptimal///characteristics_ch1.2: status: DOD (dead of disease)///characteristics_ch1.3: survival years: 5.68///treatment_protocol_ch1: Tumor specimens were obtained from 185 previously untreated late-stage (IIIIV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using the RNeasy Micro kit (Qiagen)///label_ch1: Biotin///label_protocol_ch1: Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)///description: Gene expression data from late-stage high-grade ovarian cancer///data_processing: Robust Multi-Array Analysis was performed///platform_id: GPL96///contact_name: Michael,,Birrer///contact_email: [email protected]///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657583/GSM657583_SO227.CEL.gz///data_row_count: 22283
1
title: Ovarian Cancer SO228///geo_accession: GSM657584///status: Public on Jan 20 2011///submission_date: Jan 19 2011///last_update_date: Jan 20 2011///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Late-stage high-grade ovarian cancer///characteristics_ch1.1: surgery outcome: Optimal///characteristics_ch1.2: status: DOD (dead of disease)///characteristics_ch1.3: survival years: 6.75///treatment_protocol_ch1: Tumor specimens were obtained from 185 previously untreated late-stage (IIIIV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using the RNeasy Micro kit (Qiagen)///label_ch1: Biotin///label_protocol_ch1: Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)///description: Gene expression data from late-stage high-grade ovarian cancer///data_processing: Robust Multi-Array Analysis was performed///platform_id: GPL96///contact_name: Michael,,Birrer///contact_email: [email protected]///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657584/GSM657584_SO228.CEL.gz///data_row_count: 22283
1
title: Ovarian Cancer SO229///geo_accession: GSM657585///status: Public on Jan 20 2011///submission_date: Jan 19 2011///last_update_date: Jan 20 2011///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Late-stage high-grade ovarian cancer///characteristics_ch1.1: surgery outcome: Suboptimal///characteristics_ch1.2: status: DOD (dead of disease)///characteristics_ch1.3: survival years: 0.86///treatment_protocol_ch1: Tumor specimens were obtained from 185 previously untreated late-stage (IIIIV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using the RNeasy Micro kit (Qiagen)///label_ch1: Biotin///label_protocol_ch1: Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)///description: Gene expression data from late-stage high-grade ovarian cancer///data_processing: Robust Multi-Array Analysis was performed///platform_id: GPL96///contact_name: Michael,,Birrer///contact_email: [email protected]///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657585/GSM657585_SO229.CEL.gz///data_row_count: 22283
1
title: Ovarian Cancer SO230///geo_accession: GSM657587///status: Public on Jan 20 2011///submission_date: Jan 19 2011///last_update_date: Jan 20 2011///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Late-stage high-grade ovarian cancer///characteristics_ch1.1: surgery outcome: Optimal///characteristics_ch1.2: status: DOD (dead of disease)///characteristics_ch1.3: survival years: 3.64///treatment_protocol_ch1: Tumor specimens were obtained from 185 previously untreated late-stage (IIIIV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using the RNeasy Micro kit (Qiagen)///label_ch1: Biotin///label_protocol_ch1: Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)///description: Gene expression data from late-stage high-grade ovarian cancer///data_processing: Robust Multi-Array Analysis was performed///platform_id: GPL96///contact_name: Michael,,Birrer///contact_email: [email protected]///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657587/GSM657587_SO230.CEL.gz///data_row_count: 22283
1
title: Ovarian Cancer SO231///geo_accession: GSM657588///status: Public on Jan 20 2011///submission_date: Jan 19 2011///last_update_date: Jan 20 2011///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Late-stage high-grade ovarian cancer///characteristics_ch1.1: surgery outcome: Optimal///characteristics_ch1.2: status: DOD (dead of disease)///characteristics_ch1.3: survival years: 5.15///treatment_protocol_ch1: Tumor specimens were obtained from 185 previously untreated late-stage (IIIIV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using the RNeasy Micro kit (Qiagen)///label_ch1: Biotin///label_protocol_ch1: Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)///description: Gene expression data from late-stage high-grade ovarian cancer///data_processing: Robust Multi-Array Analysis was performed///platform_id: GPL96///contact_name: Michael,,Birrer///contact_email: [email protected]///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657588/GSM657588_SO231.CEL.gz///data_row_count: 22283
1
title: Ovarian Cancer SO235///geo_accession: GSM657589///status: Public on Jan 20 2011///submission_date: Jan 19 2011///last_update_date: Jan 20 2011///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Late-stage high-grade ovarian cancer///characteristics_ch1.1: surgery outcome: Suboptimal///characteristics_ch1.2: status: DOD (dead of disease)///characteristics_ch1.3: survival years: 0.62///treatment_protocol_ch1: Tumor specimens were obtained from 185 previously untreated late-stage (IIIIV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using the RNeasy Micro kit (Qiagen)///label_ch1: Biotin///label_protocol_ch1: Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)///description: Gene expression data from late-stage high-grade ovarian cancer///data_processing: Robust Multi-Array Analysis was performed///platform_id: GPL96///contact_name: Michael,,Birrer///contact_email: [email protected]///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657589/GSM657589_SO235.CEL.gz///data_row_count: 22283
1
title: Ovarian Cancer SO236///geo_accession: GSM657590///status: Public on Jan 20 2011///submission_date: Jan 19 2011///last_update_date: Jan 20 2011///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Late-stage high-grade ovarian cancer///characteristics_ch1.1: surgery outcome: Optimal///characteristics_ch1.2: status: NED (no evidence of disease)///characteristics_ch1.3: survival years: 13.5///treatment_protocol_ch1: Tumor specimens were obtained from 185 previously untreated late-stage (IIIIV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using the RNeasy Micro kit (Qiagen)///label_ch1: Biotin///label_protocol_ch1: Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)///description: Gene expression data from late-stage high-grade ovarian cancer///data_processing: Robust Multi-Array Analysis was performed///platform_id: GPL96///contact_name: Michael,,Birrer///contact_email: [email protected]///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657590/GSM657590_SO236.CEL.gz///data_row_count: 22283
1
title: Ovarian Cancer SO237///geo_accession: GSM657591///status: Public on Jan 20 2011///submission_date: Jan 19 2011///last_update_date: Jan 20 2011///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Late-stage high-grade ovarian cancer///characteristics_ch1.1: surgery outcome: Suboptimal///characteristics_ch1.2: status: DOD (dead of disease)///characteristics_ch1.3: survival years: 0.59///treatment_protocol_ch1: Tumor specimens were obtained from 185 previously untreated late-stage (IIIIV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using the RNeasy Micro kit (Qiagen)///label_ch1: Biotin///label_protocol_ch1: Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)///description: Gene expression data from late-stage high-grade ovarian cancer///data_processing: Robust Multi-Array Analysis was performed///platform_id: GPL96///contact_name: Michael,,Birrer///contact_email: [email protected]///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657591/GSM657591_SO237.CEL.gz///data_row_count: 22283
1
title: Ovarian Cancer SO23///geo_accession: GSM657586///status: Public on Jan 20 2011///submission_date: Jan 19 2011///last_update_date: Jan 20 2011///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Late-stage high-grade ovarian cancer///characteristics_ch1.1: surgery outcome: Optimal///characteristics_ch1.2: status: NED (no evidence of disease)///characteristics_ch1.3: survival years: 6.91///treatment_protocol_ch1: Tumor specimens were obtained from 185 previously untreated late-stage (IIIIV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using the RNeasy Micro kit (Qiagen)///label_ch1: Biotin///label_protocol_ch1: Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)///description: Gene expression data from late-stage high-grade ovarian cancer///data_processing: Robust Multi-Array Analysis was performed///platform_id: GPL96///contact_name: Michael,,Birrer///contact_email: [email protected]///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657586/GSM657586_SO23.CEL.gz///data_row_count: 22283
1
title: Ovarian Cancer SO241///geo_accession: GSM657592///status: Public on Jan 20 2011///submission_date: Jan 19 2011///last_update_date: Jan 20 2011///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Late-stage high-grade ovarian cancer///characteristics_ch1.1: surgery outcome: Suboptimal///characteristics_ch1.2: status: DOD (dead of disease)///characteristics_ch1.3: survival years: 3.12///treatment_protocol_ch1: Tumor specimens were obtained from 185 previously untreated late-stage (IIIIV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using the RNeasy Micro kit (Qiagen)///label_ch1: Biotin///label_protocol_ch1: Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)///description: Gene expression data from late-stage high-grade ovarian cancer///data_processing: Robust Multi-Array Analysis was performed///platform_id: GPL96///contact_name: Michael,,Birrer///contact_email: [email protected]///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657592/GSM657592_SO241.CEL.gz///data_row_count: 22283
1
title: Ovarian Cancer SO242///geo_accession: GSM657593///status: Public on Jan 20 2011///submission_date: Jan 19 2011///last_update_date: Jan 20 2011///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Late-stage high-grade ovarian cancer///characteristics_ch1.1: surgery outcome: Suboptimal///characteristics_ch1.2: status: DOD (dead of disease)///characteristics_ch1.3: survival years: 0.21///treatment_protocol_ch1: Tumor specimens were obtained from 185 previously untreated late-stage (IIIIV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using the RNeasy Micro kit (Qiagen)///label_ch1: Biotin///label_protocol_ch1: Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)///description: Gene expression data from late-stage high-grade ovarian cancer///data_processing: Robust Multi-Array Analysis was performed///platform_id: GPL96///contact_name: Michael,,Birrer///contact_email: [email protected]///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657593/GSM657593_SO242.CEL.gz///data_row_count: 22283
1
title: Ovarian Cancer SO243///geo_accession: GSM657594///status: Public on Jan 20 2011///submission_date: Jan 19 2011///last_update_date: Jan 20 2011///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Late-stage high-grade ovarian cancer///characteristics_ch1.1: surgery outcome: Optimal///characteristics_ch1.2: status: NED (no evidence of disease)///characteristics_ch1.3: survival years: 13.1///treatment_protocol_ch1: Tumor specimens were obtained from 185 previously untreated late-stage (IIIIV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using the RNeasy Micro kit (Qiagen)///label_ch1: Biotin///label_protocol_ch1: Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)///description: Gene expression data from late-stage high-grade ovarian cancer///data_processing: Robust Multi-Array Analysis was performed///platform_id: GPL96///contact_name: Michael,,Birrer///contact_email: [email protected]///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657594/GSM657594_SO243.CEL.gz///data_row_count: 22283
1
title: Ovarian Cancer SO244///geo_accession: GSM657595///status: Public on Jan 20 2011///submission_date: Jan 19 2011///last_update_date: Jan 20 2011///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Late-stage high-grade ovarian cancer///characteristics_ch1.1: surgery outcome: Suboptimal///characteristics_ch1.2: status: DOD (dead of disease)///characteristics_ch1.3: survival years: 0.99///treatment_protocol_ch1: Tumor specimens were obtained from 185 previously untreated late-stage (IIIIV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using the RNeasy Micro kit (Qiagen)///label_ch1: Biotin///label_protocol_ch1: Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)///description: Gene expression data from late-stage high-grade ovarian cancer///data_processing: Robust Multi-Array Analysis was performed///platform_id: GPL96///contact_name: Michael,,Birrer///contact_email: [email protected]///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657595/GSM657595_SO244.CEL.gz///data_row_count: 22283
1
title: Ovarian Cancer SO246///geo_accession: GSM657596///status: Public on Jan 20 2011///submission_date: Jan 19 2011///last_update_date: Jan 20 2011///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Late-stage high-grade ovarian cancer///characteristics_ch1.1: surgery outcome: Optimal///characteristics_ch1.2: status: DOD (dead of disease)///characteristics_ch1.3: survival years: 3.95///treatment_protocol_ch1: Tumor specimens were obtained from 185 previously untreated late-stage (IIIIV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using the RNeasy Micro kit (Qiagen)///label_ch1: Biotin///label_protocol_ch1: Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)///description: Gene expression data from late-stage high-grade ovarian cancer///data_processing: Robust Multi-Array Analysis was performed///platform_id: GPL96///contact_name: Michael,,Birrer///contact_email: [email protected]///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657596/GSM657596_SO246.CEL.gz///data_row_count: 22283
1
title: Ovarian Cancer SO247///geo_accession: GSM657597///status: Public on Jan 20 2011///submission_date: Jan 19 2011///last_update_date: Jan 20 2011///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Late-stage high-grade ovarian cancer///characteristics_ch1.1: surgery outcome: Suboptimal///characteristics_ch1.2: status: DOD (dead of disease)///characteristics_ch1.3: survival years: 5.34///treatment_protocol_ch1: Tumor specimens were obtained from 185 previously untreated late-stage (IIIIV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using the RNeasy Micro kit (Qiagen)///label_ch1: Biotin///label_protocol_ch1: Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)///description: Gene expression data from late-stage high-grade ovarian cancer///data_processing: Robust Multi-Array Analysis was performed///platform_id: GPL96///contact_name: Michael,,Birrer///contact_email: [email protected]///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657597/GSM657597_SO247.CEL.gz///data_row_count: 22283
1
title: Ovarian Cancer SO249///geo_accession: GSM657598///status: Public on Jan 20 2011///submission_date: Jan 19 2011///last_update_date: Jan 20 2011///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Late-stage high-grade ovarian cancer///characteristics_ch1.1: surgery outcome: Suboptimal///characteristics_ch1.2: status: DOD (dead of disease)///characteristics_ch1.3: survival years: 6.83///treatment_protocol_ch1: Tumor specimens were obtained from 185 previously untreated late-stage (IIIIV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using the RNeasy Micro kit (Qiagen)///label_ch1: Biotin///label_protocol_ch1: Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)///description: Gene expression data from late-stage high-grade ovarian cancer///data_processing: Robust Multi-Array Analysis was performed///platform_id: GPL96///contact_name: Michael,,Birrer///contact_email: [email protected]///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657598/GSM657598_SO249.CEL.gz///data_row_count: 22283
1
title: Ovarian Cancer SO250///geo_accession: GSM657600///status: Public on Jan 20 2011///submission_date: Jan 19 2011///last_update_date: Jan 20 2011///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Late-stage high-grade ovarian cancer///characteristics_ch1.1: surgery outcome: Suboptimal///characteristics_ch1.2: status: DOD (dead of disease)///characteristics_ch1.3: survival years: 8.64///treatment_protocol_ch1: Tumor specimens were obtained from 185 previously untreated late-stage (IIIIV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using the RNeasy Micro kit (Qiagen)///label_ch1: Biotin///label_protocol_ch1: Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)///description: Gene expression data from late-stage high-grade ovarian cancer///data_processing: Robust Multi-Array Analysis was performed///platform_id: GPL96///contact_name: Michael,,Birrer///contact_email: [email protected]///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657600/GSM657600_SO250.CEL.gz///data_row_count: 22283
1
title: Ovarian Cancer SO256///geo_accession: GSM657601///status: Public on Jan 20 2011///submission_date: Jan 19 2011///last_update_date: Jan 20 2011///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Late-stage high-grade ovarian cancer///characteristics_ch1.1: surgery outcome: Suboptimal///characteristics_ch1.2: status: DOD (dead of disease)///characteristics_ch1.3: survival years: 1.94///treatment_protocol_ch1: Tumor specimens were obtained from 185 previously untreated late-stage (IIIIV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using the RNeasy Micro kit (Qiagen)///label_ch1: Biotin///label_protocol_ch1: Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)///description: Gene expression data from late-stage high-grade ovarian cancer///data_processing: Robust Multi-Array Analysis was performed///platform_id: GPL96///contact_name: Michael,,Birrer///contact_email: [email protected]///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657601/GSM657601_SO256.CEL.gz///data_row_count: 22283
1
title: Ovarian Cancer SO257///geo_accession: GSM657602///status: Public on Jan 20 2011///submission_date: Jan 19 2011///last_update_date: Jan 20 2011///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Late-stage high-grade ovarian cancer///characteristics_ch1.1: surgery outcome: Suboptimal///characteristics_ch1.2: status: DOD (dead of disease)///characteristics_ch1.3: survival years: 2.2///treatment_protocol_ch1: Tumor specimens were obtained from 185 previously untreated late-stage (IIIIV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using the RNeasy Micro kit (Qiagen)///label_ch1: Biotin///label_protocol_ch1: Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)///description: Gene expression data from late-stage high-grade ovarian cancer///data_processing: Robust Multi-Array Analysis was performed///platform_id: GPL96///contact_name: Michael,,Birrer///contact_email: [email protected]///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657602/GSM657602_SO257.CEL.gz///data_row_count: 22283
1
title: Ovarian Cancer SO258///geo_accession: GSM657603///status: Public on Jan 20 2011///submission_date: Jan 19 2011///last_update_date: Jan 20 2011///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Late-stage high-grade ovarian cancer///characteristics_ch1.1: surgery outcome: Suboptimal///characteristics_ch1.2: status: DOD (dead of disease)///characteristics_ch1.3: survival years: 1.72///treatment_protocol_ch1: Tumor specimens were obtained from 185 previously untreated late-stage (IIIIV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using the RNeasy Micro kit (Qiagen)///label_ch1: Biotin///label_protocol_ch1: Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)///description: Gene expression data from late-stage high-grade ovarian cancer///data_processing: Robust Multi-Array Analysis was performed///platform_id: GPL96///contact_name: Michael,,Birrer///contact_email: [email protected]///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657603/GSM657603_SO258.CEL.gz///data_row_count: 22283
1
title: Ovarian Cancer SO25///geo_accession: GSM657599///status: Public on Jan 20 2011///submission_date: Jan 19 2011///last_update_date: Jan 20 2011///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Late-stage high-grade ovarian cancer///characteristics_ch1.1: surgery outcome: Optimal///characteristics_ch1.2: status: DOD (dead of disease)///characteristics_ch1.3: survival years: 3.5///treatment_protocol_ch1: Tumor specimens were obtained from 185 previously untreated late-stage (IIIIV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using the RNeasy Micro kit (Qiagen)///label_ch1: Biotin///label_protocol_ch1: Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)///description: Gene expression data from late-stage high-grade ovarian cancer///data_processing: Robust Multi-Array Analysis was performed///platform_id: GPL96///contact_name: Michael,,Birrer///contact_email: [email protected]///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657599/GSM657599_SO25.CEL.gz///data_row_count: 22283
1
title: Ovarian Cancer SO261///geo_accession: GSM657604///status: Public on Jan 20 2011///submission_date: Jan 19 2011///last_update_date: Jan 20 2011///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Late-stage high-grade ovarian cancer///characteristics_ch1.1: surgery outcome: Suboptimal///characteristics_ch1.2: status: DOD (dead of disease)///characteristics_ch1.3: survival years: 0.98///treatment_protocol_ch1: Tumor specimens were obtained from 185 previously untreated late-stage (IIIIV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using the RNeasy Micro kit (Qiagen)///label_ch1: Biotin///label_protocol_ch1: Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)///description: Gene expression data from late-stage high-grade ovarian cancer///data_processing: Robust Multi-Array Analysis was performed///platform_id: GPL96///contact_name: Michael,,Birrer///contact_email: [email protected]///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657604/GSM657604_SO261.CEL.gz///data_row_count: 22283
1
title: Ovarian Cancer SO262///geo_accession: GSM657605///status: Public on Jan 20 2011///submission_date: Jan 19 2011///last_update_date: Jan 20 2011///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Late-stage high-grade ovarian cancer///characteristics_ch1.1: surgery outcome: Suboptimal///characteristics_ch1.2: status: DOD (dead of disease)///characteristics_ch1.3: survival years: 7.88///treatment_protocol_ch1: Tumor specimens were obtained from 185 previously untreated late-stage (IIIIV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using the RNeasy Micro kit (Qiagen)///label_ch1: Biotin///label_protocol_ch1: Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)///description: Gene expression data from late-stage high-grade ovarian cancer///data_processing: Robust Multi-Array Analysis was performed///platform_id: GPL96///contact_name: Michael,,Birrer///contact_email: [email protected]///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657605/GSM657605_SO262.CEL.gz///data_row_count: 22283
1
title: Ovarian Cancer SO263///geo_accession: GSM657606///status: Public on Jan 20 2011///submission_date: Jan 19 2011///last_update_date: Jan 20 2011///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Late-stage high-grade ovarian cancer///characteristics_ch1.1: surgery outcome: Suboptimal///characteristics_ch1.2: status: DOD (dead of disease)///characteristics_ch1.3: survival years: 3.93///treatment_protocol_ch1: Tumor specimens were obtained from 185 previously untreated late-stage (IIIIV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using the RNeasy Micro kit (Qiagen)///label_ch1: Biotin///label_protocol_ch1: Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)///description: Gene expression data from late-stage high-grade ovarian cancer///data_processing: Robust Multi-Array Analysis was performed///platform_id: GPL96///contact_name: Michael,,Birrer///contact_email: [email protected]///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657606/GSM657606_SO263.CEL.gz///data_row_count: 22283
1
title: Ovarian Cancer SO265///geo_accession: GSM657607///status: Public on Jan 20 2011///submission_date: Jan 19 2011///last_update_date: Jan 20 2011///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Late-stage high-grade ovarian cancer///characteristics_ch1.1: surgery outcome: Suboptimal///characteristics_ch1.2: status: DOD (dead of disease)///characteristics_ch1.3: survival years: 0.33///treatment_protocol_ch1: Tumor specimens were obtained from 185 previously untreated late-stage (IIIIV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using the RNeasy Micro kit (Qiagen)///label_ch1: Biotin///label_protocol_ch1: Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)///description: Gene expression data from late-stage high-grade ovarian cancer///data_processing: Robust Multi-Array Analysis was performed///platform_id: GPL96///contact_name: Michael,,Birrer///contact_email: [email protected]///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657607/GSM657607_SO265.CEL.gz///data_row_count: 22283
1
title: Ovarian Cancer SO267///geo_accession: GSM657608///status: Public on Jan 20 2011///submission_date: Jan 19 2011///last_update_date: Jan 20 2011///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Late-stage high-grade ovarian cancer///characteristics_ch1.1: surgery outcome: Suboptimal///characteristics_ch1.2: status: DOD (dead of disease)///characteristics_ch1.3: survival years: 1.3///treatment_protocol_ch1: Tumor specimens were obtained from 185 previously untreated late-stage (IIIIV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using the RNeasy Micro kit (Qiagen)///label_ch1: Biotin///label_protocol_ch1: Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)///description: Gene expression data from late-stage high-grade ovarian cancer///data_processing: Robust Multi-Array Analysis was performed///platform_id: GPL96///contact_name: Michael,,Birrer///contact_email: [email protected]///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657608/GSM657608_SO267.CEL.gz///data_row_count: 22283
1
title: Ovarian Cancer SO268///geo_accession: GSM657609///status: Public on Jan 20 2011///submission_date: Jan 19 2011///last_update_date: Jan 20 2011///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Late-stage high-grade ovarian cancer///characteristics_ch1.1: surgery outcome: Optimal///characteristics_ch1.2: status: DOD (dead of disease)///characteristics_ch1.3: survival years: 9.22///treatment_protocol_ch1: Tumor specimens were obtained from 185 previously untreated late-stage (IIIIV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using the RNeasy Micro kit (Qiagen)///label_ch1: Biotin///label_protocol_ch1: Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)///description: Gene expression data from late-stage high-grade ovarian cancer///data_processing: Robust Multi-Array Analysis was performed///platform_id: GPL96///contact_name: Michael,,Birrer///contact_email: [email protected]///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657609/GSM657609_SO268.CEL.gz///data_row_count: 22283
1
title: Ovarian Cancer SO272///geo_accession: GSM657610///status: Public on Jan 20 2011///submission_date: Jan 19 2011///last_update_date: Jan 20 2011///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Late-stage high-grade ovarian cancer///characteristics_ch1.1: surgery outcome: Suboptimal///characteristics_ch1.2: status: DOD (dead of disease)///characteristics_ch1.3: survival years: 3.75///treatment_protocol_ch1: Tumor specimens were obtained from 185 previously untreated late-stage (IIIIV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using the RNeasy Micro kit (Qiagen)///label_ch1: Biotin///label_protocol_ch1: Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)///description: Gene expression data from late-stage high-grade ovarian cancer///data_processing: Robust Multi-Array Analysis was performed///platform_id: GPL96///contact_name: Michael,,Birrer///contact_email: [email protected]///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657610/GSM657610_SO272.CEL.gz///data_row_count: 22283
1
title: Ovarian Cancer SO273///geo_accession: GSM657611///status: Public on Jan 20 2011///submission_date: Jan 19 2011///last_update_date: Jan 20 2011///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Late-stage high-grade ovarian cancer///characteristics_ch1.1: surgery outcome: Optimal///characteristics_ch1.2: status: DOD (dead of disease)///characteristics_ch1.3: survival years: 2.52///treatment_protocol_ch1: Tumor specimens were obtained from 185 previously untreated late-stage (IIIIV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using the RNeasy Micro kit (Qiagen)///label_ch1: Biotin///label_protocol_ch1: Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)///description: Gene expression data from late-stage high-grade ovarian cancer///data_processing: Robust Multi-Array Analysis was performed///platform_id: GPL96///contact_name: Michael,,Birrer///contact_email: [email protected]///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657611/GSM657611_SO273.CEL.gz///data_row_count: 22283
1
title: Ovarian Cancer SO278///geo_accession: GSM657612///status: Public on Jan 20 2011///submission_date: Jan 19 2011///last_update_date: Jan 20 2011///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Late-stage high-grade ovarian cancer///characteristics_ch1.1: surgery outcome: Optimal///characteristics_ch1.2: status: DOD (dead of disease)///characteristics_ch1.3: survival years: 4.53///treatment_protocol_ch1: Tumor specimens were obtained from 185 previously untreated late-stage (IIIIV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using the RNeasy Micro kit (Qiagen)///label_ch1: Biotin///label_protocol_ch1: Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)///description: Gene expression data from late-stage high-grade ovarian cancer///data_processing: Robust Multi-Array Analysis was performed///platform_id: GPL96///contact_name: Michael,,Birrer///contact_email: [email protected]///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657612/GSM657612_SO278.CEL.gz///data_row_count: 22283
1
title: Ovarian Cancer SO279///geo_accession: GSM657613///status: Public on Jan 20 2011///submission_date: Jan 19 2011///last_update_date: Jan 20 2011///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Late-stage high-grade ovarian cancer///characteristics_ch1.1: surgery outcome: Suboptimal///characteristics_ch1.2: status: DOD (dead of disease)///characteristics_ch1.3: survival years: 0.92///treatment_protocol_ch1: Tumor specimens were obtained from 185 previously untreated late-stage (IIIIV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using the RNeasy Micro kit (Qiagen)///label_ch1: Biotin///label_protocol_ch1: Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)///description: Gene expression data from late-stage high-grade ovarian cancer///data_processing: Robust Multi-Array Analysis was performed///platform_id: GPL96///contact_name: Michael,,Birrer///contact_email: [email protected]///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657613/GSM657613_SO279.CEL.gz///data_row_count: 22283
1
title: Ovarian Cancer SO282///geo_accession: GSM657614///status: Public on Jan 20 2011///submission_date: Jan 19 2011///last_update_date: Jan 20 2011///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Late-stage high-grade ovarian cancer///characteristics_ch1.1: surgery outcome: Suboptimal///characteristics_ch1.2: status: DOD (dead of disease)///characteristics_ch1.3: survival years: 2.4///treatment_protocol_ch1: Tumor specimens were obtained from 185 previously untreated late-stage (IIIIV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using the RNeasy Micro kit (Qiagen)///label_ch1: Biotin///label_protocol_ch1: Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)///description: Gene expression data from late-stage high-grade ovarian cancer///data_processing: Robust Multi-Array Analysis was performed///platform_id: GPL96///contact_name: Michael,,Birrer///contact_email: [email protected]///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657614/GSM657614_SO282.CEL.gz///data_row_count: 22283
1
title: Ovarian Cancer SO283///geo_accession: GSM657615///status: Public on Jan 20 2011///submission_date: Jan 19 2011///last_update_date: Jan 20 2011///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Late-stage high-grade ovarian cancer///characteristics_ch1.1: surgery outcome: Suboptimal///characteristics_ch1.2: status: DOD (dead of disease)///characteristics_ch1.3: survival years: 0.66///treatment_protocol_ch1: Tumor specimens were obtained from 185 previously untreated late-stage (IIIIV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using the RNeasy Micro kit (Qiagen)///label_ch1: Biotin///label_protocol_ch1: Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)///description: Gene expression data from late-stage high-grade ovarian cancer///data_processing: Robust Multi-Array Analysis was performed///platform_id: GPL96///contact_name: Michael,,Birrer///contact_email: [email protected]///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657615/GSM657615_SO283.CEL.gz///data_row_count: 22283
1
title: Ovarian Cancer SO285///geo_accession: GSM657616///status: Public on Jan 20 2011///submission_date: Jan 19 2011///last_update_date: Jan 20 2011///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Late-stage high-grade ovarian cancer///characteristics_ch1.1: surgery outcome: Suboptimal///characteristics_ch1.2: status: DOD (dead of disease)///characteristics_ch1.3: survival years: 2.32///treatment_protocol_ch1: Tumor specimens were obtained from 185 previously untreated late-stage (IIIIV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using the RNeasy Micro kit (Qiagen)///label_ch1: Biotin///label_protocol_ch1: Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)///description: Gene expression data from late-stage high-grade ovarian cancer///data_processing: Robust Multi-Array Analysis was performed///platform_id: GPL96///contact_name: Michael,,Birrer///contact_email: [email protected]///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657616/GSM657616_SO285.CEL.gz///data_row_count: 22283
1
title: Ovarian Cancer SO290///geo_accession: GSM657617///status: Public on Jan 20 2011///submission_date: Jan 19 2011///last_update_date: Jan 20 2011///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Late-stage high-grade ovarian cancer///characteristics_ch1.1: surgery outcome: Optimal///characteristics_ch1.2: status: DOD (dead of disease)///characteristics_ch1.3: survival years: 3.5///treatment_protocol_ch1: Tumor specimens were obtained from 185 previously untreated late-stage (IIIIV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using the RNeasy Micro kit (Qiagen)///label_ch1: Biotin///label_protocol_ch1: Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)///description: Gene expression data from late-stage high-grade ovarian cancer///data_processing: Robust Multi-Array Analysis was performed///platform_id: GPL96///contact_name: Michael,,Birrer///contact_email: [email protected]///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657617/GSM657617_SO290.CEL.gz///data_row_count: 22283
1
title: Ovarian Cancer SO295///geo_accession: GSM657618///status: Public on Jan 20 2011///submission_date: Jan 19 2011///last_update_date: Jan 20 2011///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: tissue: Late-stage high-grade ovarian cancer///characteristics_ch1.1: surgery outcome: Suboptimal///characteristics_ch1.2: status: DOD (dead of disease)///characteristics_ch1.3: survival years: 3.24///treatment_protocol_ch1: Tumor specimens were obtained from 185 previously untreated late-stage (IIIIV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using the RNeasy Micro kit (Qiagen)///label_ch1: Biotin///label_protocol_ch1: Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)///description: Gene expression data from late-stage high-grade ovarian cancer///data_processing: Robust Multi-Array Analysis was performed///platform_id: GPL96///contact_name: Michael,,Birrer///contact_email: [email protected]///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657618/GSM657618_SO295.CEL.gz///data_row_count: 22283
1
(Other)
96
duplicates:
GSE26712.GSE26712_GSM657526
1
GSE26712.GSE26712_GSM657526///GSE26712.GSE26712_GSM657527
1
GSE26712.GSE26712_GSM657527
1
NA's
192
An expression set
This study assesses the ability of multidrug resistance (MDR)-associated gene expression patterns to predict survival in patients with newly diagnosed carcinoma of the ovary. The scope of this research differs substantially from that of previous reports, as a very large set of genes was evaluated whose expression has been shown to affect response to chemotherapy.We applied a customized TaqMan low density array, a highly sensitive and specific assay, to study the expression profiles of 380 MDR-linked genes in 80 tumor specimens collected at initial surgery to debulk primary serous carcinoma. The RNA expression profiles of these drug resistance genes were correlated with clinical outcomes.Leave-one-out cross-validation was used to estimate the ability of MDR gene expression to predict survival. Although gene expression alone does not predict overall survival (OS; P = 0.06), four covariates (age, stage, CA125 level, and surgical debulking) do (P = 0.03). When gene expression was added to the covariates, we found an 11-gene signature that provides a major improvement in OS prediction (log-rank statistic P < 0.003). The predictive power of this 11-gene signature was confirmed by dividing high- and low-risk patient groups, as defined by their clinical covariates, into four specific risk groups on the basis of expression levels.This study reveals an 11-gene signature that allows a more precise prognosis for patients with serous cancer of the ovary treated with carboplatin- and paclitaxel-based therapy. These 11 new targets offer opportunities for new therapies to improve clinical outcome in ovarian cancer.
experimentData(eset):
Experiment data
Experimenter name: Gillet JP, Calcagno AM, Varma S, Davidson B et al. Multidrug resistance-linked gene signature predicts overall survival of patients with primary ovarian serous carcinoma. Clin Cancer Res 2012 Jun 1;18(11):3197-206.
Laboratory: Gillet, Gottesman 2012
Contact information:
Title: Multidrug resistance-linked gene signature predicts overall survival of patients with primary ovarian serous carcinoma.
URL:
PMIDs: 22492981
Abstract: A 244 word abstract is available. Use 'abstract' method.
Information is available on: preprocessing
notes:
platform_title:
TaqMan qRT-PCR Homo sapiens Low-Density Array 380
platform_shorttitle:
TaqMan qRT-PCR
platform_summary:
NA
platform_manufacturer:
TaqMan
platform_distribution:
custom
platform_accession:
GPL13728
version:
2015-09-22 19:46:26
featureData(eset):
An object of class 'AnnotatedDataFrame'
featureNames: 5 6 ... 380 (363 total)
varLabels: probeset gene EntrezGene.ID best_probe
varMetadata: labelDescription
assayData: 363 features, 103 samples
Platform type:
Overall survival time-to-event summary (in years):
Call: survfit(formula = Surv(time, cens) ~ -1)
n events median 0.95LCL 0.95UCL
103.00 57.00 3.42 2.92 5.34
---------------------------
Available sample meta-data:
---------------------------
alt_sample_name:
Norwegian patient 1 Norwegian patient 10 Norwegian patient 11
1 1 1
Norwegian patient 12 Norwegian patient 13 Norwegian patient 14
1 1 1
Norwegian patient 15 Norwegian patient 16 Norwegian patient 17
1 1 1
Norwegian patient 18 Norwegian patient 19 Norwegian patient 2
1 1 1
Norwegian patient 20 Norwegian patient 21 Norwegian patient 22
1 1 1
Norwegian patient 23 Norwegian patient 3 Norwegian patient 4
1 1 1
Norwegian patient 5 Norwegian patient 6 Norwegian patient 7
1 1 1
Norwegian patient 8 Norwegian patient 9 US Patient 1
1 1 1
US Patient 10 US Patient 11 US Patient 12
1 1 1
US Patient 13 US Patient 14 US Patient 15
1 1 1
US Patient 16 US Patient 17 US Patient 18
1 1 1
US Patient 19 US Patient 2 US Patient 20
1 1 1
US Patient 21 US Patient 22 US Patient 23
1 1 1
US Patient 24 US Patient 25 US Patient 26
1 1 1
US Patient 27 US Patient 28 US Patient 29
1 1 1
US Patient 3 US Patient 30 US Patient 31
1 1 1
US Patient 32 US Patient 33 US Patient 34
1 1 1
US Patient 35 US Patient 36 US Patient 37
1 1 1
US Patient 38 US Patient 39 US Patient 4
1 1 1
US Patient 40 US Patient 41 US Patient 42
1 1 1
US Patient 43 US Patient 44 US Patient 45
1 1 1
US Patient 46 US Patient 47 US Patient 48
1 1 1
US Patient 49 US Patient 5 US Patient 50
1 1 1
US Patient 51 US Patient 52 US Patient 53
1 1 1
US Patient 54 US Patient 55 US Patient 56
1 1 1
US Patient 57 US Patient 58 US Patient 59
1 1 1
US Patient 6 US Patient 60 US Patient 61
1 1 1
US Patient 62 US Patient 63 US Patient 64
1 1 1
US Patient 65 US Patient 66 US Patient 67
1 1 1
US Patient 68 US Patient 69 US Patient 7
1 1 1
US Patient 70 US Patient 71 US Patient 72
1 1 1
US Patient 73 US Patient 74 US Patient 75
1 1 1
US Patient 76 US Patient 77 US Patient 78
1 1 1
(Other)
4
sample_type:
tumor
103
histological_type:
clearcell ser
1 102
summarygrade:
high low NA's
92 9 2
summarystage:
late
103
tumorstage:
3 4
82 21
substage:
b c NA's
2 60 41
grade:
1 2 3 NA's
4 5 92 2
age_at_initial_pathologic_diagnosis:
Min. 1st Qu. Median Mean 3rd Qu. Max.
30.00 56.00 61.00 62.45 71.50 87.00
days_to_death:
Min. 1st Qu. Median Mean 3rd Qu. Max.
24 598 1053 1156 1568 4748
vital_status:
deceased living
57 46
debulking:
optimal suboptimal
81 22
uncurated_author_metadata:
title: Norwegian patient 10///geo_accession: GSM742654///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 60///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 1903///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: carbo+taxol///characteristics_ch1.9: surgical debulking or residual disease (cm): >1///characteristics_ch1.10: progression-free survival (pfs; months): 6///characteristics_ch1.11: overall survival (os; months): 26///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: Dec-02///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: NPT10///description.1: Norwegian Radium Hospital///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: [email protected]///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
1
title: Norwegian patient 11///geo_accession: GSM742655///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 30///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3///characteristics_ch1.4: tumor grade: 1///characteristics_ch1.5: preop. ca125: 933///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: carbo+taxol///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 52///characteristics_ch1.11: overall survival (os; months): 57///characteristics_ch1.12: status: no evidence of disease (NED)///characteristics_ch1.13: platinum sensitivity: sensitive///characteristics_ch1.14: diagnostic date: Mar-04///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: NPT11///description.1: Norwegian Radium Hospital///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: [email protected]///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
1
title: Norwegian patient 12///geo_accession: GSM742656///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 42///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3///characteristics_ch1.4: tumor grade: 1///characteristics_ch1.5: preop. ca125: 99///characteristics_ch1.6: preop. ca125 defined as high or low: LOW///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: carbo+taxol///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 52///characteristics_ch1.11: overall survival (os; months): 56///characteristics_ch1.12: status: no evidence of disease (NED)///characteristics_ch1.13: platinum sensitivity: sensitive///characteristics_ch1.14: diagnostic date: Apr-04///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: NPT12///description.1: Norwegian Radium Hospital///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: [email protected]///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
1
title: Norwegian patient 13///geo_accession: GSM742657///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 58///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3///characteristics_ch1.4: tumor grade: 1///characteristics_ch1.5: preop. ca125: 241///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: carbo+taxol///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 25///characteristics_ch1.11: overall survival (os; months): 50///characteristics_ch1.12: status: alive with disease (AWD)///characteristics_ch1.13: platinum sensitivity: sensitive///characteristics_ch1.14: diagnostic date: Oct-04///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: NPT13///description.1: Norwegian Radium Hospital///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: [email protected]///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
1
title: Norwegian patient 14///geo_accession: GSM742658///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 59///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 4///characteristics_ch1.4: tumor grade: 2///characteristics_ch1.5: preop. ca125: 2966///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: PR///characteristics_ch1.8: chemotherapy: carbo+taxol///characteristics_ch1.9: surgical debulking or residual disease (cm): >1///characteristics_ch1.10: progression-free survival (pfs; months): 0///characteristics_ch1.11: overall survival (os; months): 52///characteristics_ch1.12: status: alive with disease (AWD)///characteristics_ch1.13: platinum sensitivity: resistant///characteristics_ch1.14: diagnostic date: Aug-04///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: NPT14///description.1: Norwegian Radium Hospital///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: [email protected]///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
1
title: Norwegian patient 15///geo_accession: GSM742659///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 50///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 637///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: carbo+taxol///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 36///characteristics_ch1.11: overall survival (os; months): 47///characteristics_ch1.12: status: alive with disease (AWD)///characteristics_ch1.13: platinum sensitivity: sensitive///characteristics_ch1.14: diagnostic date: Dec-04///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: NPT15///description.1: Norwegian Radium Hospital///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: [email protected]///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
1
title: Norwegian patient 16///geo_accession: GSM742660///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 50///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 4///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 492///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: carbo+taxol///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 42///characteristics_ch1.11: overall survival (os; months): 47///characteristics_ch1.12: status: no evidence of disease (NED)///characteristics_ch1.13: platinum sensitivity: sensitive///characteristics_ch1.14: diagnostic date: Jan-05///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: NPT16///description.1: Norwegian Radium Hospital///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: [email protected]///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
1
title: Norwegian patient 17///geo_accession: GSM742661///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 79///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 230///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: Unknown///characteristics_ch1.8: chemotherapy: carbo///characteristics_ch1.9: surgical debulking or residual disease (cm): >1///characteristics_ch1.10: progression-free survival (pfs; months): 0///characteristics_ch1.11: overall survival (os; months): 5///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: Feb-05///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: NPT17///description.1: Norwegian Radium Hospital///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: [email protected]///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
1
title: Norwegian patient 18///geo_accession: GSM742662///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 53///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 1354///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: PR///characteristics_ch1.8: chemotherapy: carbo+taxol///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 0///characteristics_ch1.11: overall survival (os; months): 33///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: resistant///characteristics_ch1.14: diagnostic date: Jan-05///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: NPT18///description.1: Norwegian Radium Hospital///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: [email protected]///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
1
title: Norwegian patient 19///geo_accession: GSM742663///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 62///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 4///characteristics_ch1.4: tumor grade: 2///characteristics_ch1.5: preop. ca125: 1145///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: PR///characteristics_ch1.8: chemotherapy: carbo+taxol///characteristics_ch1.9: surgical debulking or residual disease (cm): >1///characteristics_ch1.10: progression-free survival (pfs; months): 0///characteristics_ch1.11: overall survival (os; months): 41///characteristics_ch1.12: status: alive with disease (AWD)///characteristics_ch1.13: platinum sensitivity: resistant///characteristics_ch1.14: diagnostic date: Jum-05///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: NPT19///description.1: Norwegian Radium Hospital///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: [email protected]///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
1
title: Norwegian patient 1///geo_accession: GSM742645///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 67///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 1100///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: PD///characteristics_ch1.8: chemotherapy: carbo+taxol///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 0///characteristics_ch1.11: overall survival (os; months): 5///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: resistant///characteristics_ch1.14: diagnostic date: Mar-01///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: NPT1///description.1: Norwegian Radium Hospital///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: [email protected]///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
1
title: Norwegian patient 20///geo_accession: GSM742664///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 56///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 305///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: carbo+taxol///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 9///characteristics_ch1.11: overall survival (os; months): 29///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: Oct-05///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: NPT20///description.1: Norwegian Radium Hospital///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: [email protected]///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
1
title: Norwegian patient 21///geo_accession: GSM742665///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 71///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 937///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: carbo+taxol///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 7///characteristics_ch1.11: overall survival (os; months): 15///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: Sep-05///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: NPT21///description.1: Norwegian Radium Hospital///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: [email protected]///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
1
title: Norwegian patient 22///geo_accession: GSM742666///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 56///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 2359///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: carbo+taxol///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 31///characteristics_ch1.11: overall survival (os; months): 36///characteristics_ch1.12: status: no evidence of disease (NED)///characteristics_ch1.13: platinum sensitivity: sensitive///characteristics_ch1.14: diagnostic date: Nov-05///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: NPT22///description.1: Norwegian Radium Hospital///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: [email protected]///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
1
title: Norwegian patient 23///geo_accession: GSM742667///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 76///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 4///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 1400///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: carbo///characteristics_ch1.9: surgical debulking or residual disease (cm): >1///characteristics_ch1.10: progression-free survival (pfs; months): 7///characteristics_ch1.11: overall survival (os; months): 17///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: Apr-1999///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: NPT23///description.1: Norwegian Radium Hospital///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: [email protected]///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
1
title: Norwegian patient 2///geo_accession: GSM742646///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 61///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 700///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: carbo+taxol///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 9///characteristics_ch1.11: overall survival (os; months): 31///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: Sep-01///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: NPT2///description.1: Norwegian Radium Hospital///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: [email protected]///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
1
title: Norwegian patient 3///geo_accession: GSM742647///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 75///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 1965///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: carbo+taxol///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 77///characteristics_ch1.11: overall survival (os; months): 83///characteristics_ch1.12: status: no evidence of disease (NED)///characteristics_ch1.13: platinum sensitivity: sensitive///characteristics_ch1.14: diagnostic date: Jan-02///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: NPT3///description.1: Norwegian Radium Hospital///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: [email protected]///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
1
title: Norwegian patient 4///geo_accession: GSM742648///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 52///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 761///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: carbo+taxol///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 42///characteristics_ch1.11: overall survival (os; months): 64///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: sensitive///characteristics_ch1.14: diagnostic date: 2002 jan///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: NPT4///description.1: Norwegian Radium Hospital///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: [email protected]///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
1
title: Norwegian patient 5///geo_accession: GSM742649///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 51///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 4///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 24290///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: PR///characteristics_ch1.8: chemotherapy: carbo+taxol///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 4///characteristics_ch1.11: overall survival (os; months): 34///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: resistant///characteristics_ch1.14: diagnostic date: Mar-02///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: NPT5///description.1: Norwegian Radium Hospital///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: [email protected]///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
1
title: Norwegian patient 6///geo_accession: GSM742650///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 66///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 4///characteristics_ch1.4: tumor grade: 2///characteristics_ch1.5: preop. ca125: 1331///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: carbo+taxol///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 9///characteristics_ch1.11: overall survival (os; months): 53///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: May-02///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: NPT6///description.1: Norwegian Radium Hospital///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: [email protected]///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
1
title: Norwegian patient 7///geo_accession: GSM742651///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 60///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 375///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: carbo+taxol///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 7///characteristics_ch1.11: overall survival (os; months): 27///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: Jul-02///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: NPT7///description.1: Norwegian Radium Hospital///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: [email protected]///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
1
title: Norwegian patient 8///geo_accession: GSM742652///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 48///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 4///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 40790///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: PD///characteristics_ch1.8: chemotherapy: carbo+taxol///characteristics_ch1.9: surgical debulking or residual disease (cm): >1///characteristics_ch1.10: progression-free survival (pfs; months): 0///characteristics_ch1.11: overall survival (os; months): 10///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: resistant///characteristics_ch1.14: diagnostic date: Jul-02///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: NPT8///description.1: Norwegian Radium Hospital///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: [email protected]///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
1
title: Norwegian patient 9///geo_accession: GSM742653///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 74///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 1395///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: carbo///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 65///characteristics_ch1.11: overall survival (os; months): 72///characteristics_ch1.12: status: no evidence of disease (NED)///characteristics_ch1.13: platinum sensitivity: sensitive///characteristics_ch1.14: diagnostic date: Nov-02///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: NPT9///description.1: Norwegian Radium Hospital///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: [email protected]///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
1
title: US Patient 10///geo_accession: GSM742574///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 69///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 306///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: PD///characteristics_ch1.8: chemotherapy: carbo/taxol///characteristics_ch1.9: surgical debulking or residual disease (cm): >1///characteristics_ch1.10: progression-free survival (pfs; months): 0///characteristics_ch1.11: overall survival (os; months): 15///characteristics_ch1.12: status: alive with disease (AWD)///characteristics_ch1.13: platinum sensitivity: resistant///characteristics_ch1.14: diagnostic date: accrued from Apr-01 to Aug-05///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT10///description.1: Cleveland Clinic///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: [email protected]///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
1
title: US Patient 11///geo_accession: GSM742575///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 52///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 536///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: carbo/cc2103///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 14///characteristics_ch1.11: overall survival (os; months): 14///characteristics_ch1.12: status: no evidence of disease (NED)///characteristics_ch1.13: platinum sensitivity: sensitive///characteristics_ch1.14: diagnostic date: accrued from Apr-01 to Aug-05///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT11///description.1: Cleveland Clinic///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: [email protected]///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
1
title: US Patient 12///geo_accession: GSM742576///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 49///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 293///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: PR///characteristics_ch1.8: chemotherapy: modifed triple doublets///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 37.8///characteristics_ch1.11: overall survival (os; months): 68.9///characteristics_ch1.12: status: alive with disease (AWD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: Jul-03///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT12///description.1: MGH (Boston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: [email protected]///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
1
title: US Patient 13///geo_accession: GSM742577///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 82///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 4///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 3000///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: PR///characteristics_ch1.8: chemotherapy: carboplatin///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): unknown///characteristics_ch1.11: overall survival (os; months): 26.1///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: Sep-03///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT13///description.1: MGH (Boston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: [email protected]///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
1
title: US Patient 14///geo_accession: GSM742578///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 52///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 793///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: taxol/carboplatin///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 64.8///characteristics_ch1.11: overall survival (os; months): 64.8///characteristics_ch1.12: status: no evidence of disease (NED)///characteristics_ch1.13: platinum sensitivity: sensitive///characteristics_ch1.14: diagnostic date: Nov-03///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT14///description.1: MGH (Boston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: [email protected]///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
1
title: US Patient 15///geo_accession: GSM742579///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 71///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 2792///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: taxol/carboplatin///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 9.2///characteristics_ch1.11: overall survival (os; months): 23.8///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: Aug-04///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT15///description.1: MGH (Boston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: [email protected]///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
1
title: US Patient 16///geo_accession: GSM742580///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 63///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 2983///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: taxol/carboplatin///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 9.6///characteristics_ch1.11: overall survival (os; months): 34.6///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: Aug-04///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT16///description.1: MGH (Boston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: [email protected]///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
1
title: US Patient 17///geo_accession: GSM742581///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 48///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 3723///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: taxol/carboplatin///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 18.2///characteristics_ch1.11: overall survival (os; months): 33///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: sensitive///characteristics_ch1.14: diagnostic date: Aug-04///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT17///description.1: MGH (Boston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: [email protected]///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
1
title: US Patient 18///geo_accession: GSM742582///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 63///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: Unknown///characteristics_ch1.5: preop. ca125: 3078///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: taxol/carboplatin///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 21.2///characteristics_ch1.11: overall survival (os; months): 52.4///characteristics_ch1.12: status: alive with disease (AWD)///characteristics_ch1.13: platinum sensitivity: sensitive///characteristics_ch1.14: diagnostic date: Dec-04///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT18///description.1: MGH (Boston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: [email protected]///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
1
title: US Patient 19///geo_accession: GSM742583///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 55///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous, transitional///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 8942///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: PD///characteristics_ch1.8: chemotherapy: taxol/carboplatin///characteristics_ch1.9: surgical debulking or residual disease (cm): >1///characteristics_ch1.10: progression-free survival (pfs; months): 2.7///characteristics_ch1.11: overall survival (os; months): 6.3///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: resistant///characteristics_ch1.14: diagnostic date: Mar-06///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT19///description.1: MGH (Boston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: [email protected]///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
1
title: US Patient 1///geo_accession: GSM742565///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 87///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 1584///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: carbo/taxol/gem/toxo/doxil///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 17.5///characteristics_ch1.11: overall survival (os; months): 50///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: sensitive///characteristics_ch1.14: diagnostic date: accrued from Apr-01 to Aug-05///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT1///description.1: Cleveland Clinic///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: [email protected]///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
1
title: US Patient 20///geo_accession: GSM742584///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 66///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 4///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 9603///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: tcA///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 37.6///characteristics_ch1.11: overall survival (os; months): 37.6///characteristics_ch1.12: status: no evidence of disease (NED)///characteristics_ch1.13: platinum sensitivity: sensitive///characteristics_ch1.14: diagnostic date: Mar-06///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT20///description.1: MGH (Boston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: [email protected]///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
1
title: US Patient 21///geo_accession: GSM742585///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 60///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 4///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 210///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: PD///characteristics_ch1.8: chemotherapy: taxotere/carboplatin///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 2.6///characteristics_ch1.11: overall survival (os; months): 36.9///characteristics_ch1.12: status: alive with disease (AWD) ?///characteristics_ch1.13: platinum sensitivity: resistant///characteristics_ch1.14: diagnostic date: Mar-06///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT21///description.1: MGH (Boston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: [email protected]///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
1
title: US Patient 22///geo_accession: GSM742586///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 60///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 1103///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: IP/IV platinum/taxol///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 13.6///characteristics_ch1.11: overall survival (os; months): 31///characteristics_ch1.12: status: alive with disease (AWD)///characteristics_ch1.13: platinum sensitivity: sensitive///characteristics_ch1.14: diagnostic date: Sep-06///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT22///description.1: MGH (Boston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: [email protected]///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
1
title: US Patient 23///geo_accession: GSM742587///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 60///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous, transitional///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 20000///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: PR///characteristics_ch1.8: chemotherapy: taxol/carboplatin/Avastin///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 9.9///characteristics_ch1.11: overall survival (os; months): 46.9///characteristics_ch1.12: status: alive with disease (AWD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: May-05///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT23///description.1: MGH (Boston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: [email protected]///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
1
title: US Patient 24///geo_accession: GSM742588///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 62///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous, transitional///characteristics_ch1.3: figo stage: 4///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 696///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: taxol/carboplatin/Avastin///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 48.3///characteristics_ch1.11: overall survival (os; months): 48.3///characteristics_ch1.12: status: no evidence of disease (NED)///characteristics_ch1.13: platinum sensitivity: sensitive///characteristics_ch1.14: diagnostic date: Apr-05///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT24///description.1: MGH (Boston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: [email protected]///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
1
title: US Patient 25///geo_accession: GSM742589///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 84///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 103///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: taxol/carboplatin///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 33.1///characteristics_ch1.11: overall survival (os; months): 33.1///characteristics_ch1.12: status: no evidence of disease (NED) ?///characteristics_ch1.13: platinum sensitivity: sensitive///characteristics_ch1.14: diagnostic date: Jul-06///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT25///description.1: MGH (Boston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: [email protected]///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
1
title: US Patient 26///geo_accession: GSM742590///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 73///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous, transitional///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 789///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: carbo/taxane///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 12///characteristics_ch1.11: overall survival (os; months): 47.3///characteristics_ch1.12: status: alive with disease (AWD) ?///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: May-05///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT26///description.1: MGH (Boston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: [email protected]///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
1
title: US Patient 27///geo_accession: GSM742591///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 62///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 802///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: IP taxol/carbo///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 9.5///characteristics_ch1.11: overall survival (os; months): 31.2///characteristics_ch1.12: status: alive with disease (AWD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: Sep-06///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT27///description.1: MGH (Boston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: [email protected]///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
1
title: US Patient 28///geo_accession: GSM742592///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 64///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 4///characteristics_ch1.4: tumor grade: 2///characteristics_ch1.5: preop. ca125: 988///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: tcA///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 17///characteristics_ch1.11: overall survival (os; months): 44.2///characteristics_ch1.12: status: alive with disease (AWD)///characteristics_ch1.13: platinum sensitivity: sensitive///characteristics_ch1.14: diagnostic date: Aug-05///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT28///description.1: MGH (Boston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: [email protected]///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
1
title: US Patient 29///geo_accession: GSM742593///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 51///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous, transitional///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 1139///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: tcA///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 5.5///characteristics_ch1.11: overall survival (os; months): 15.1///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: Mar-05///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT29///description.1: MGH (Boston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: [email protected]///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
1
title: US Patient 2///geo_accession: GSM742566///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 43///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 564///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: carbo/taxol/gem/toxo/doxil///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 16///characteristics_ch1.11: overall survival (os; months): 75///characteristics_ch1.12: status: alive with disease (AWD)///characteristics_ch1.13: platinum sensitivity: sensitive///characteristics_ch1.14: diagnostic date: accrued from Apr-01 to Aug-05///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT2///description.1: Cleveland Clinic///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: [email protected]///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
1
title: US Patient 30///geo_accession: GSM742594///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 61///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 4///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 450///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: PR///characteristics_ch1.8: chemotherapy: t/c, carbo///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 10.2///characteristics_ch1.11: overall survival (os; months): 40.1///characteristics_ch1.12: status: alive with disease (AWD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: Dec-05///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT30///description.1: MGH (Boston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: [email protected]///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
1
title: US Patient 31///geo_accession: GSM742595///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 74///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 2301///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: taxol/carboplatin///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 12.2///characteristics_ch1.11: overall survival (os; months): 31.3///characteristics_ch1.12: status: alive with disease (AWD)///characteristics_ch1.13: platinum sensitivity: sensitive///characteristics_ch1.14: diagnostic date: Sep-06///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT31///description.1: MGH (Boston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: [email protected]///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
1
title: US Patient 32///geo_accession: GSM742596///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 72///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 4///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 1684///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: taxol/carboplatin///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): unknown///characteristics_ch1.11: overall survival (os; months): 8.7///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: Jan-05///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT32///description.1: MGH (Boston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: [email protected]///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
1
title: US Patient 33///geo_accession: GSM742597///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 67///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 2106///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: Unknown///characteristics_ch1.8: chemotherapy: none///characteristics_ch1.9: surgical debulking or residual disease (cm): >1///characteristics_ch1.10: progression-free survival (pfs; months): 0///characteristics_ch1.11: overall survival (os; months): 0.8///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: Oct-05///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT33///description.1: MGH (Boston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: [email protected]///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
1
title: US Patient 34///geo_accession: GSM742598///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 66///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 2///characteristics_ch1.5: preop. ca125: 990///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: taxol/carboplatin///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 10.1///characteristics_ch1.11: overall survival (os; months): 18.2///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: Oct-02///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT34///description.1: MGH (Boston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: [email protected]///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
1
title: US Patient 35///geo_accession: GSM742599///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 66///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 281///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: Unknown///characteristics_ch1.8: chemotherapy: taxol/carbo///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 0///characteristics_ch1.11: overall survival (os; months): 27.8///characteristics_ch1.12: status: no evidence of disease (NED) ?///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: Dec-06///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT35///description.1: MGH (Boston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: [email protected]///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
1
title: US Patient 36///geo_accession: GSM742600///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 67///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 206///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: taxol/carboplatin///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 20.2///characteristics_ch1.11: overall survival (os; months): 51///characteristics_ch1.12: status: alive with disease (AWD)///characteristics_ch1.13: platinum sensitivity: sensitive///characteristics_ch1.14: diagnostic date: Jan-05///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT36///description.1: MGH (Boston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: [email protected]///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
1
title: US Patient 37///geo_accession: GSM742601///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 44///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 3738///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: taxol/carbo///characteristics_ch1.9: surgical debulking or residual disease (cm): >1///characteristics_ch1.10: progression-free survival (pfs; months): 10.4///characteristics_ch1.11: overall survival (os; months): 24.6///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: Oct-04///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT37///description.1: MGH (Boston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: [email protected]///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
1
title: US Patient 38///geo_accession: GSM742602///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 76///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 4///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 2389///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: Unknown///characteristics_ch1.8: chemotherapy: Unknown///characteristics_ch1.9: surgical debulking or residual disease (cm): >1///characteristics_ch1.10: progression-free survival (pfs; months): unknown///characteristics_ch1.11: overall survival (os; months): 9.3///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: Aug-02///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT38///description.1: MGH (Boston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: [email protected]///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
1
title: US Patient 39///geo_accession: GSM742603///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 65///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 104///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: IP taxol/carboplatin///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 32.7///characteristics_ch1.11: overall survival (os; months): 32.7///characteristics_ch1.12: status: no evidence of disease (NED)///characteristics_ch1.13: platinum sensitivity: sensitive///characteristics_ch1.14: diagnostic date: Jul-06///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT39///description.1: MGH (Boston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: [email protected]///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
1
title: US Patient 3///geo_accession: GSM742567///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 61///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 404///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: PD///characteristics_ch1.8: chemotherapy: carbo/taxol///characteristics_ch1.9: surgical debulking or residual disease (cm): >1///characteristics_ch1.10: progression-free survival (pfs; months): 0///characteristics_ch1.11: overall survival (os; months): 12///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: resistant///characteristics_ch1.14: diagnostic date: accrued from Apr-01 to Aug-05///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT3///description.1: Cleveland Clinic///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: [email protected]///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
1
title: US Patient 40///geo_accession: GSM742604///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 56///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous, transitional///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 1591///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: IP taxol/carboplatin///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 54///characteristics_ch1.11: overall survival (os; months): 54///characteristics_ch1.12: status: no evidence of disease (NED)///characteristics_ch1.13: platinum sensitivity: sensitive///characteristics_ch1.14: diagnostic date: Oct-04///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT40///description.1: MGH (Boston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: [email protected]///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
1
title: US Patient 41///geo_accession: GSM742605///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 71///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 1072///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: PD///characteristics_ch1.8: chemotherapy: taxol/carboplatin///characteristics_ch1.9: surgical debulking or residual disease (cm): >1///characteristics_ch1.10: progression-free survival (pfs; months): 1.4///characteristics_ch1.11: overall survival (os; months): 9.4///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: resistant///characteristics_ch1.14: diagnostic date: Feb-06///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT41///description.1: MGH (Boston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: [email protected]///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
1
title: US Patient 42///geo_accession: GSM742606///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 61///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 146///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: carboplatin/Gemcitabine, carboplatin/taxol, adriamycin/topotecan///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 19.8///characteristics_ch1.11: overall survival (os; months): 41.2///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: sensitive///characteristics_ch1.14: diagnostic date: Mar-04///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT42///description.1: MGH (Boston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: [email protected]///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
1
title: US Patient 43///geo_accession: GSM742607///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 59///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 26///characteristics_ch1.6: preop. ca125 defined as high or low: LOW///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: taxol/carboplatin///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 25.7///characteristics_ch1.11: overall survival (os; months): 53///characteristics_ch1.12: status: alive with disease (AWD)///characteristics_ch1.13: platinum sensitivity: sensitive///characteristics_ch1.14: diagnostic date: Nov-04///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT43///description.1: MGH (Boston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: [email protected]///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
1
title: US Patient 44///geo_accession: GSM742608///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 56///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 4///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 534///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: taxol/carboplatin///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 8.1///characteristics_ch1.11: overall survival (os; months): 36.6///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: Dec-04///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT44///description.1: MGH (Boston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: [email protected]///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
1
title: US Patient 45///geo_accession: GSM742609///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 58///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 334///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: IP taxol/carbo///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 8.6///characteristics_ch1.11: overall survival (os; months): 10.6///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: May-05///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT45///description.1: MGH (Boston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: [email protected]///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
1
title: US Patient 46///geo_accession: GSM742610///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 56///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 4///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 600///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: t/c///characteristics_ch1.9: surgical debulking or residual disease (cm): >1///characteristics_ch1.10: progression-free survival (pfs; months): 6.7///characteristics_ch1.11: overall survival (os; months): 18.3///characteristics_ch1.12: status: alive with disease (AWD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: Jun-07///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT46///description.1: MGH (Boston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: [email protected]///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
1
title: US Patient 47///geo_accession: GSM742611///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 55///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: Carcinoma arising in borderline///characteristics_ch1.5: preop. ca125: 619///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: t/c///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 16.8///characteristics_ch1.11: overall survival (os; months): 16.8///characteristics_ch1.12: status: no evidence of disease (NED)///characteristics_ch1.13: platinum sensitivity: sensitive///characteristics_ch1.14: diagnostic date: Aug-07///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT47///description.1: MGH (Boston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: [email protected]///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
1
title: US Patient 48///geo_accession: GSM742612///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 56///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 229///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: t/c///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 14///characteristics_ch1.11: overall survival (os; months): 14///characteristics_ch1.12: status: no evidence of disease (NED)///characteristics_ch1.13: platinum sensitivity: sensitive///characteristics_ch1.14: diagnostic date: Oct-07///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT48///description.1: MGH (Boston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: [email protected]///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
1
title: US Patient 49///geo_accession: GSM742613///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 59///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 3252///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: PD///characteristics_ch1.8: chemotherapy: taxol/ cisplatin (6X), carboplatin (15X), tamoxifen, taxol (2X)///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 15///characteristics_ch1.11: overall survival (os; months): 36///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: Jul-95///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT49///description.1: MDA (Houston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: [email protected]///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
1
title: US Patient 4///geo_accession: GSM742568///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 82///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3B///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 12033///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: Unknown///characteristics_ch1.8: chemotherapy: none///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 1///characteristics_ch1.11: overall survival (os; months): 1///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: accrued from Apr-01 to Aug-05///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT4///description.1: Cleveland Clinic///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: [email protected]///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
1
title: US Patient 50///geo_accession: GSM742614///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 78///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 862.5///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: PD///characteristics_ch1.8: chemotherapy: carboplatin (6X) then surgery and then taxol (6X), carboplatin (6x)///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): unknown///characteristics_ch1.11: overall survival (os; months): 32///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: Aug-97///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT50///description.1: MDA (Houston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: [email protected]///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
1
title: US Patient 51///geo_accession: GSM742615///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 76///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 4///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 3000///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: Unknown///characteristics_ch1.8: chemotherapy: taxol/ cisplatin (6X), carboplatin (6X),carbo (5x), topotecan (23x), gemcitabine (12x), tamoxifen, doxil (18x), xeloda (15x), arimidex///characteristics_ch1.9: surgical debulking or residual disease (cm): >1///characteristics_ch1.10: progression-free survival (pfs; months): 5///characteristics_ch1.11: overall survival (os; months): 90///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: Jul-95///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT51///description.1: MDA (Houston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: [email protected]///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
1
title: US Patient 52///geo_accession: GSM742616///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 78///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: Elevated///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: Unknown///characteristics_ch1.8: chemotherapy: none///characteristics_ch1.9: surgical debulking or residual disease (cm): >1///characteristics_ch1.10: progression-free survival (pfs; months): unknown///characteristics_ch1.11: overall survival (os; months): 1///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: Apr-97///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT52///description.1: MDA (Houston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: [email protected]///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
1
title: US Patient 53///geo_accession: GSM742617///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 53///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: Elevated///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: Unknown///characteristics_ch1.8: chemotherapy: taxol/carbo (1x)///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): unknown///characteristics_ch1.11: overall survival (os; months): 17///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: Feb-96///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT53///description.1: MDA (Houston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: [email protected]///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
1
title: US Patient 54///geo_accession: GSM742618///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 73///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 11.7///characteristics_ch1.6: preop. ca125 defined as high or low: LOW///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: carboplatin (9x), taxol (12x), tamoxifen, XRt, xeloda (4x), doxil (9x), carboplatin (7x), arimidex///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 18///characteristics_ch1.11: overall survival (os; months): 60///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: sensitive///characteristics_ch1.14: diagnostic date: May-98///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT54///description.1: MDA (Houston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: [email protected]///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
1
title: US Patient 55///geo_accession: GSM742619///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 78///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 338.3///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: Unknown///characteristics_ch1.8: chemotherapy: taxol/carboplatin (6x), carboplatin (4x), tamoxifen///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 19///characteristics_ch1.11: overall survival (os; months): 38///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: May-98///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT55///description.1: MDA (Houston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: [email protected]///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
1
title: US Patient 56///geo_accession: GSM742620///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 51///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 5140///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: cisplatin/taxol (6X)///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 151///characteristics_ch1.11: overall survival (os; months): 156///characteristics_ch1.12: status: no evidence of disease (NED)///characteristics_ch1.13: platinum sensitivity: sensitive///characteristics_ch1.14: diagnostic date: Mar-95///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT56///description.1: MDA (Houston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: [email protected]///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
1
title: US Patient 57///geo_accession: GSM742621///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 57///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 4///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 3398///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: taxol/cisplatin (7x), taxol/carboplatin (3x), carbo (6x), whole brain XRt, intra-thecal topotecan and iv topotecan (1x)///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 16///characteristics_ch1.11: overall survival (os; months): 22///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: sensitive///characteristics_ch1.14: diagnostic date: Oct-97///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT57///description.1: MDA (Houston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: [email protected]///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
1
title: US Patient 58///geo_accession: GSM742622///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 77///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 548///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: Unknown///characteristics_ch1.8: chemotherapy: carboplatin/cytoxan (3x)///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): unknown///characteristics_ch1.11: overall survival (os; months): 37///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: Aug-96///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT58///description.1: MDA (Houston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: [email protected]///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
1
title: US Patient 59///geo_accession: GSM742623///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 66///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 298///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: PD///characteristics_ch1.8: chemotherapy: carboplatin (6X), subopt tRS, interferon (2x), carboplatin (12x), tamoxifen, doxorubicin (9x), taxol (3x), topotecan///characteristics_ch1.9: surgical debulking or residual disease (cm): >1///characteristics_ch1.10: progression-free survival (pfs; months): unknown///characteristics_ch1.11: overall survival (os; months): 68///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: Jul-98///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT59///description.1: MDA (Houston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: [email protected]///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
1
title: US Patient 5///geo_accession: GSM742569///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 57///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 1130///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: carbo/taxol/cpt11/tam/topo///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 15///characteristics_ch1.11: overall survival (os; months): 24///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: sensitive///characteristics_ch1.14: diagnostic date: accrued from Apr-01 to Aug-05///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT5///description.1: Cleveland Clinic///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: [email protected]///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
1
title: US Patient 60///geo_accession: GSM742624///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 61///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: Elevated///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: carboplatin/cytoxan (8X)///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 156///characteristics_ch1.11: overall survival (os; months): 156///characteristics_ch1.12: status: no evidence of disease (NED)///characteristics_ch1.13: platinum sensitivity: sensitive///characteristics_ch1.14: diagnostic date: Jun-95///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT60///description.1: MDA (Houston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: [email protected]///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
1
title: US Patient 61///geo_accession: GSM742625///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 82///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous, endometrioid///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 981///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: Unknown///characteristics_ch1.8: chemotherapy: taxol/carboplatin (6X)///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 17///characteristics_ch1.11: overall survival (os; months): 24///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: Nov-03///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT61///description.1: MDA (Houston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: [email protected]///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
1
title: US Patient 62///geo_accession: GSM742626///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 68///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 2373.4///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: Unknown///characteristics_ch1.8: chemotherapy: carboplatin (2X)///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): unknown///characteristics_ch1.11: overall survival (os; months): 35///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: Nov-03///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT62///description.1: MDA (Houston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: [email protected]///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
1
title: US Patient 63///geo_accession: GSM742627///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 56///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 382///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: PD///characteristics_ch1.8: chemotherapy: taxol/carboplatin (6X),carboplatin(3X), doxil(12X), taxol/ avastin(5X), topotecan(3X)///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): unknown///characteristics_ch1.11: overall survival (os; months): 60///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: Aug-03///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT63///description.1: MDA (Houston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: [email protected]///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
1
title: US Patient 64///geo_accession: GSM742628///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 59///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 144///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: Unknown///characteristics_ch1.8: chemotherapy: taxol/carboplatin (6X)///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 66///characteristics_ch1.11: overall survival (os; months): 66///characteristics_ch1.12: status: no evidence of disease (NED)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: Jun-03///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT64///description.1: MDA (Houston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: [email protected]///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
1
title: US Patient 65///geo_accession: GSM742629///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 67///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 11713///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: PD///characteristics_ch1.8: chemotherapy: taxol/carboplatin (6X), caboplatin (11X), taxotere (6X), doxil (24X)///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 16///characteristics_ch1.11: overall survival (os; months): 63///characteristics_ch1.12: status: alive with disease (AWD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: May-03///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT65///description.1: MDA (Houston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: [email protected]///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
1
title: US Patient 66///geo_accession: GSM742630///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 72///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 3705.6///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: PD///characteristics_ch1.8: chemotherapy: carboplatin/topotecan(4X), carbo/taxol(4X), doxil(4X), topotecan(2X), taxotere (3X), Xelado (3X), taxol (4X)///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 13///characteristics_ch1.11: overall survival (os; months): 41///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: Feb-03///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT66///description.1: MDA (Houston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: [email protected]///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
1
title: US Patient 67///geo_accession: GSM742631///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 71///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 4///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 2353///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: Unknown///characteristics_ch1.8: chemotherapy: none///characteristics_ch1.9: surgical debulking or residual disease (cm): >1///characteristics_ch1.10: progression-free survival (pfs; months): unknown///characteristics_ch1.11: overall survival (os; months): 2///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: Jan-03///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT67///description.1: MDA (Houston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: [email protected]///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
1
title: US Patient 68///geo_accession: GSM742632///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 74///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 715///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: taxol/carboplatin (6X), taxol (2x), letrozole///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 28///characteristics_ch1.11: overall survival (os; months): 64///characteristics_ch1.12: status: alive with disease (AWD)///characteristics_ch1.13: platinum sensitivity: sensitive///characteristics_ch1.14: diagnostic date: Jan-03///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT68///description.1: MDA (Houston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: [email protected]///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
1
title: US Patient 69///geo_accession: GSM742633///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 73///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 89.1///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: Unknown///characteristics_ch1.8: chemotherapy: taxol/carboplatin (6X), carboplatin (6x), tamoxifen///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 17///characteristics_ch1.11: overall survival (os; months): 36///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: Jan-03///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT69///description.1: MDA (Houston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: [email protected]///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
1
title: US Patient 6///geo_accession: GSM742570///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 40///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3B///characteristics_ch1.4: tumor grade: 1///characteristics_ch1.5: preop. ca125: 523///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: carbo/taxol///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 23///characteristics_ch1.11: overall survival (os; months): 46///characteristics_ch1.12: status: alive with disease (AWD)///characteristics_ch1.13: platinum sensitivity: sensitive///characteristics_ch1.14: diagnostic date: accrued from Apr-01 to Aug-05///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT6///description.1: Cleveland Clinic///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: [email protected]///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
1
title: US Patient 70///geo_accession: GSM742634///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 49///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 3444.5///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: Unknown///characteristics_ch1.8: chemotherapy: taxol (5X)/carboplatin (6X), taxol (9x), carboplatin (4x), doxil (4x), topotecan (3x), navelbine (2x), gemcitabine (2x)///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): unknown///characteristics_ch1.11: overall survival (os; months): 32///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: Feb-03///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT70///description.1: MDA (Houston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: [email protected]///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
1
title: US Patient 71///geo_accession: GSM742635///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 78///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 311///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: PR///characteristics_ch1.8: chemotherapy: taxol/carboplatin (6X), tamoxifen, femara///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 17///characteristics_ch1.11: overall survival (os; months): 47///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: Aug-02///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT71///description.1: MDA (Houston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: [email protected]///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
1
title: US Patient 72///geo_accession: GSM742636///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 45///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 8.8///characteristics_ch1.6: preop. ca125 defined as high or low: LOW///characteristics_ch1.7: response: PD///characteristics_ch1.8: chemotherapy: taxol/carboplatin (6X), taxol (6X), carboplatin (2X)///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): unknown///characteristics_ch1.11: overall survival (os; months): 28///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: Nov-01///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT72///description.1: MDA (Houston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: [email protected]///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
1
title: US Patient 73///geo_accession: GSM742637///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 59///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 156///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: PD///characteristics_ch1.8: chemotherapy: taxol/carboplatin (8X), carboplatin (3X)///characteristics_ch1.9: surgical debulking or residual disease (cm): >1///characteristics_ch1.10: progression-free survival (pfs; months): unknown///characteristics_ch1.11: overall survival (os; months): 37///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: Oct-03///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT73///description.1: MDA (Houston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: [email protected]///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
1
title: US Patient 74///geo_accession: GSM742638///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 52///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 165///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: PD///characteristics_ch1.8: chemotherapy: taxol/carboplatin & doxil (6X), taxol/ carboplatin (6X), carboplatin///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 23///characteristics_ch1.11: overall survival (os; months): 57///characteristics_ch1.12: status: alive with disease (AWD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: Aug-03///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT74///description.1: MDA (Houston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: [email protected]///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
1
title: US Patient 75///geo_accession: GSM742639///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 73///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 176///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: Unknown///characteristics_ch1.8: chemotherapy: patient decided to have chemo elsewhere (standard treatment recommendation is carbo/taxol 6X)///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 60///characteristics_ch1.11: overall survival (os; months): 60///characteristics_ch1.12: status: alive with disease (AWD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: May-03///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT75///description.1: MDA (Houston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: [email protected]///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
1
title: US Patient 76///geo_accession: GSM742640///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 45///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 4///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 2215///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: Unknown///characteristics_ch1.8: chemotherapy: taxol/ carboplatin (6X), topotecan (4X), carboplatin (4X)///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 10///characteristics_ch1.11: overall survival (os; months): 21///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: Mar-03///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT76///description.1: MDA (Houston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: [email protected]///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
1
title: US Patient 77///geo_accession: GSM742641///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 58///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 1693///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: Unknown///characteristics_ch1.8: chemotherapy: taxol (9X), then taxol/carboplatin (one dose only due to severe neuropathy)///characteristics_ch1.9: surgical debulking or residual disease (cm): >1///characteristics_ch1.10: progression-free survival (pfs; months): 49///characteristics_ch1.11: overall survival (os; months): 65///characteristics_ch1.12: status: alive with disease (AWD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: Dec-02///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT77///description.1: MDA (Houston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: [email protected]///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
1
title: US Patient 78///geo_accession: GSM742642///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 60///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 10.8///characteristics_ch1.6: preop. ca125 defined as high or low: LOW///characteristics_ch1.7: response: PD///characteristics_ch1.8: chemotherapy: taxol/carboplatin (6X) given prior to surgery, then 3 more cycle of taxol/carbo///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 10///characteristics_ch1.11: overall survival (os; months): 14///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: Mar-04///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT78///description.1: MDA (Houston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: [email protected]///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
1
title: US Patient 79///geo_accession: GSM742643///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 60///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 1920///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: PD///characteristics_ch1.8: chemotherapy: taxol/carboplatin (6X) given prior to surgery, then 3 more cycle of taxol/carbo///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 10///characteristics_ch1.11: overall survival (os; months): 14///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: Mar-04///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT79///description.1: MDA (Houston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: [email protected]///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
1
(Other)
4
An expression set
Despite advances in radical surgery and chemotherapy delivery, ovarian cancer is the most lethal gynecologic malignancy. Standard therapy includes treatment with platinum-based combination chemotherapies yet there is no biomarker model to predict their responses to these agents. We here have developed and independently tested our multi-gene molecular predictors for forecasting patients' responses to individual drugs on a cohort of 55 ovarian cancer patients. To independently validate these molecular predictors, we performed microarray profiling on FFPE tumor samples of 55 ovarian cancer patients (UVA-55) treated with platinum-based adjuvant chemotherapy. Genome-wide chemosensitivity biomarkers were initially discovered from the in vitro drug activities and genomic expression data for carboplatin and paclitaxel, respectively. Multivariate predictors were trained with the cell line data and then evaluated with a historical patient cohort. For the UVA-55 cohort, the carboplatin, taxol, and combination predictors significantly stratified responder patients and non-responder patients (p = 0.019, 0.04, 0.014) with sensitivity = 91%, 96%, 93 and NPV = 57%, 67%, 67% in pathologic clinical response. The combination predictor also demonstrated a significant survival difference between predicted responders and non-responders with a median survival of 55.4 months vs. 32.1 months. Thus, COXEN single- and combination-drug predictors successfully stratified platinum resistance and taxane response in an independent cohort of ovarian cancer patients based on their FFPE tumor samples.
experimentData(eset):
Experiment data
Experimenter name: Ferriss JS, Kim Y, Duska L, Birrer M, Levine DA, Moskaluk C,Theodorescu D, Lee JK
Laboratory: Ferriss, Lee 2012
Contact information:
Title: Multi-gene expression predictors of single drug responses to adjuvant chemotherapy in ovarian carcinoma: predicting platinum resistance.
URL:
PMIDs: 22348014
Abstract: A 215 word abstract is available. Use 'abstract' method.
Information is available on: preprocessing
notes:
platform_title:
[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array
platform_shorttitle:
Affymetrix HG-U133Plus2
platform_summary:
hgu133plus2
platform_manufacturer:
Affymetrix
platform_distribution:
commercial
platform_accession:
GPL570
version:
2015-09-22 19:50:24
featureData(eset):
An object of class 'AnnotatedDataFrame'
featureNames: 1007_s_at 1053_at ... AFFX-HUMISGF3A/M97935_MB_at
(42447 total)
varLabels: probeset gene EntrezGene.ID best_probe
varMetadata: labelDescription
assayData: 42447 features, 58 samples
Platform type:
Overall survival time-to-event summary (in years):
Call: survfit(formula = Surv(time, cens) ~ -1)
n events median 0.95LCL 0.95UCL
58.00 36.00 4.19 2.70 6.17
---------------------------
Available sample meta-data:
---------------------------
alt_sample_name:
OV_FFPE_1 OV_FFPE_10 OV_FFPE_11 OV_FFPE_12 OV_FFPE_13 OV_FFPE_14 OV_FFPE_15
1 1 1 1 1 1 1
OV_FFPE_16 OV_FFPE_17 OV_FFPE_18 OV_FFPE_19 OV_FFPE_2 OV_FFPE_20 OV_FFPE_21
1 1 1 1 1 1 1
OV_FFPE_22 OV_FFPE_23 OV_FFPE_24 OV_FFPE_25 OV_FFPE_26 OV_FFPE_27 OV_FFPE_28
1 1 1 1 1 1 1
OV_FFPE_29 OV_FFPE_3 OV_FFPE_30 OV_FFPE_31 OV_FFPE_32 OV_FFPE_33 OV_FFPE_34
1 1 1 1 1 1 1
OV_FFPE_35 OV_FFPE_36 OV_FFPE_37 OV_FFPE_38 OV_FFPE_39 OV_FFPE_4 OV_FFPE_40
1 1 1 1 1 1 1
OV_FFPE_41 OV_FFPE_42 OV_FFPE_43 OV_FFPE_44 OV_FFPE_45 OV_FFPE_46 OV_FFPE_47
1 1 1 1 1 1 1
OV_FFPE_48 OV_FFPE_49 OV_FFPE_5 OV_FFPE_50 OV_FFPE_51 OV_FFPE_52 OV_FFPE_53
1 1 1 1 1 1 1
OV_FFPE_54 OV_FFPE_55 OV_FFPE_56 OV_FFPE_57 OV_FFPE_58 OV_FFPE_6 OV_FFPE_7
1 1 1 1 1 1 1
OV_FFPE_8 OV_FFPE_9
1 1
sample_type:
tumor
58
histological_type:
clearcell endo mucinous other
5 1 1 1
ser undifferentiated NA's
47 1 2
summarygrade:
high low NA's
33 21 4
summarystage:
late
58
tumorstage:
3 4
53 5
substage:
a b c
9 11 38
grade:
1 2 3 NA's
2 19 33 4
age_at_initial_pathologic_diagnosis:
Min. 1st Qu. Median Mean 3rd Qu. Max.
38.00 53.50 62.00 62.57 72.00 85.00
pltx:
y
58
tax:
n y
4 54
neo:
n
58
days_to_tumor_recurrence:
Min. 1st Qu. Median Mean 3rd Qu. Max.
12.0 255.2 386.0 742.1 768.2 4208.0
recurrence_status:
norecurrence recurrence NA's
6 48 4
days_to_death:
Min. 1st Qu. Median Mean 3rd Qu. Max.
49.0 585.2 1010.0 1375.0 2131.0 4208.0
vital_status:
deceased living
36 22
debulking:
optimal suboptimal NA's
26 30 2
batch:
2009-10-07 2009-10-08 2009-10-09 2009-10-20
28 18 8 4
uncurated_author_metadata:
title: OV_FFPE_10///geo_accession: GSM746870///status: Public on Aug 21 2012///submission_date: Jun 22 2011///last_update_date: Aug 21 2012///type: RNA///channel_count: 1///source_name_ch1: formalin-fixed paraffin embedded (FFPE) tissue, ovarian cancer cells///organism_ch1: Homo sapiens///characteristics_ch1: cell type: ovarian cancer cell///characteristics_ch1.1: age: 76///characteristics_ch1.2: dob: 1921-11-18///characteristics_ch1.3: race: White///characteristics_ch1.4: histo: Clear///characteristics_ch1.5: grade: Poor///characteristics_ch1.6: Stage: IIIC///characteristics_ch1.7: surgtype: Primary Surgery///characteristics_ch1.8: datedx: 1998-11-01///characteristics_ch1.9: surgdate: 1998-11-01///characteristics_ch1.10: optimal: Optimal///characteristics_ch1.11: chemtype: Adjuvant///characteristics_ch1.12: chemoresponse: PR (partial response)///characteristics_ch1.13: chemo agent: Carboplatin/Taxol///characteristics_ch1.14: date.of.relapse: 1998-12-01///characteristics_ch1.15: date.last.follow.up: 1998-12-20///characteristics_ch1.16: st.categ: 4///characteristics_ch1.17: pfi days: 30///characteristics_ch1.18: relapse(1=yes, 0=no): 1///characteristics_ch1.19: overall survival days: 49///characteristics_ch1.20: censoring(dead=1,alive=0): 1///molecule_ch1: total RNA///extract_protocol_ch1: RNA extraction and amplification was performed with the NuGen WT-Ovation FFPE RNA Amplification kit.///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Punches of FFPE tumor tissue blocks and gene expression profiling were performed in a standard procedure by Almac Dignostics, Inc. (Durham, NC).///scan_protocol: GeneChips were scanned using the Hewlett-Packard GeneArray Scanner G2500A.///description: S0456F021.CEL///description.1: Gene expression data from stage III-IV ovarian cancer patients///data_processing: Data normalization and quality control assessment of the hybridization results were performed with the RMA Bioconductor package (http://www.bioconductor.org)///platform_id: GPL570///contact_name: Youngchul,,Kim///contact_department: Public Health Sciences///contact_institute: University of Virginia///contact_address: University street///contact_city: Charlottesville///contact_state: VA///contact_zip.postal_code: 22903///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM746nnn/GSM746870/GSM746870.CEL.gz///data_row_count: 54675
1
title: OV_FFPE_11///geo_accession: GSM746871///status: Public on Aug 21 2012///submission_date: Jun 22 2011///last_update_date: Aug 21 2012///type: RNA///channel_count: 1///source_name_ch1: formalin-fixed paraffin embedded (FFPE) tissue, ovarian cancer cells///organism_ch1: Homo sapiens///characteristics_ch1: cell type: ovarian cancer cell///characteristics_ch1.1: age: 75///characteristics_ch1.2: dob: 1918-12-09///characteristics_ch1.3: race: White///characteristics_ch1.4: histo: Serous///characteristics_ch1.5: grade: Poor///characteristics_ch1.6: Stage: IIIC///characteristics_ch1.7: surgtype: Primary Surgery///characteristics_ch1.8: datedx: 1995-03-07///characteristics_ch1.9: surgdate: 1995-03-07///characteristics_ch1.10: optimal: Sub-optimal///characteristics_ch1.11: chemtype: Adjuvant///characteristics_ch1.12: chemoresponse: CR (completely response)///characteristics_ch1.13: chemo agent: Carboplatin/Taxol///characteristics_ch1.14: date.of.relapse: 1996-04-11///characteristics_ch1.15: date.last.follow.up: 1996-06-19///characteristics_ch1.16: st.categ: 4///characteristics_ch1.17: pfi days: 401///characteristics_ch1.18: relapse(1=yes, 0=no): 1///characteristics_ch1.19: overall survival days: 470///characteristics_ch1.20: censoring(dead=1,alive=0): 1///molecule_ch1: total RNA///extract_protocol_ch1: RNA extraction and amplification was performed with the NuGen WT-Ovation FFPE RNA Amplification kit.///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Punches of FFPE tumor tissue blocks and gene expression profiling were performed in a standard procedure by Almac Dignostics, Inc. (Durham, NC).///scan_protocol: GeneChips were scanned using the Hewlett-Packard GeneArray Scanner G2500A.///description: S0456F022.CEL///description.1: Gene expression data from stage III-IV ovarian cancer patients///data_processing: Data normalization and quality control assessment of the hybridization results were performed with the RMA Bioconductor package (http://www.bioconductor.org)///platform_id: GPL570///contact_name: Youngchul,,Kim///contact_department: Public Health Sciences///contact_institute: University of Virginia///contact_address: University street///contact_city: Charlottesville///contact_state: VA///contact_zip.postal_code: 22903///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM746nnn/GSM746871/GSM746871.CEL.gz///data_row_count: 54675
1
title: OV_FFPE_12///geo_accession: GSM746872///status: Public on Aug 21 2012///submission_date: Jun 22 2011///last_update_date: Aug 21 2012///type: RNA///channel_count: 1///source_name_ch1: formalin-fixed paraffin embedded (FFPE) tissue, ovarian cancer cells///organism_ch1: Homo sapiens///characteristics_ch1: cell type: ovarian cancer cell///characteristics_ch1.1: age: 78///characteristics_ch1.2: dob: 1925-03-13///characteristics_ch1.3: race: White///characteristics_ch1.4: histo: Serous///characteristics_ch1.5: grade: Poor///characteristics_ch1.6: Stage: IIIC///characteristics_ch1.7: surgtype: Primary Surgery///characteristics_ch1.8: datedx: 1996-11-12///characteristics_ch1.9: surgdate: 1996-11-12///characteristics_ch1.10: optimal: Sub-optimal///characteristics_ch1.11: chemtype: Adjuvant///characteristics_ch1.12: chemoresponse: PR (partial response)///characteristics_ch1.13: chemo agent: Carboplatin/Taxol///characteristics_ch1.14: date.of.relapse: 1998-04-01///characteristics_ch1.15: date.last.follow.up: 2004-11-13///characteristics_ch1.16: st.categ: 4///characteristics_ch1.17: pfi days: 505///characteristics_ch1.18: relapse(1=yes, 0=no): 1///characteristics_ch1.19: overall survival days: 2923///characteristics_ch1.20: censoring(dead=1,alive=0): 1///molecule_ch1: total RNA///extract_protocol_ch1: RNA extraction and amplification was performed with the NuGen WT-Ovation FFPE RNA Amplification kit.///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Punches of FFPE tumor tissue blocks and gene expression profiling were performed in a standard procedure by Almac Dignostics, Inc. (Durham, NC).///scan_protocol: GeneChips were scanned using the Hewlett-Packard GeneArray Scanner G2500A.///description: S0456F025.CEL///description.1: Gene expression data from stage III-IV ovarian cancer patients///data_processing: Data normalization and quality control assessment of the hybridization results were performed with the RMA Bioconductor package (http://www.bioconductor.org)///platform_id: GPL570///contact_name: Youngchul,,Kim///contact_department: Public Health Sciences///contact_institute: University of Virginia///contact_address: University street///contact_city: Charlottesville///contact_state: VA///contact_zip.postal_code: 22903///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM746nnn/GSM746872/GSM746872.CEL.gz///data_row_count: 54675
1
title: OV_FFPE_13///geo_accession: GSM746873///status: Public on Aug 21 2012///submission_date: Jun 22 2011///last_update_date: Aug 21 2012///type: RNA///channel_count: 1///source_name_ch1: formalin-fixed paraffin embedded (FFPE) tissue, ovarian cancer cells///organism_ch1: Homo sapiens///characteristics_ch1: cell type: ovarian cancer cell///characteristics_ch1.1: age: 58///characteristics_ch1.2: dob: 1938-05-02///characteristics_ch1.3: race: White///characteristics_ch1.4: histo: Serous///characteristics_ch1.5: grade: Poor///characteristics_ch1.6: Stage: IIIC///characteristics_ch1.7: surgtype: Primary Surgery///characteristics_ch1.8: datedx: 1997-02-05///characteristics_ch1.9: surgdate: 1997-02-05///characteristics_ch1.10: optimal: Sub-optimal///characteristics_ch1.11: chemtype: Adjuvant///characteristics_ch1.12: chemoresponse: PR (partial response)///characteristics_ch1.13: chemo agent: Carboplatin/Taxol///characteristics_ch1.14: date.of.relapse: 1998-07-01///characteristics_ch1.15: date.last.follow.up: 2002-07-22///characteristics_ch1.16: st.categ: 2///characteristics_ch1.17: pfi days: 511///characteristics_ch1.18: relapse(1=yes, 0=no): 1///characteristics_ch1.19: overall survival days: 1993///characteristics_ch1.20: censoring(dead=1,alive=0): 0///molecule_ch1: total RNA///extract_protocol_ch1: RNA extraction and amplification was performed with the NuGen WT-Ovation FFPE RNA Amplification kit.///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Punches of FFPE tumor tissue blocks and gene expression profiling were performed in a standard procedure by Almac Dignostics, Inc. (Durham, NC).///scan_protocol: GeneChips were scanned using the Hewlett-Packard GeneArray Scanner G2500A.///description: S0456F027.CEL///description.1: Gene expression data from stage III-IV ovarian cancer patients///data_processing: Data normalization and quality control assessment of the hybridization results were performed with the RMA Bioconductor package (http://www.bioconductor.org)///platform_id: GPL570///contact_name: Youngchul,,Kim///contact_department: Public Health Sciences///contact_institute: University of Virginia///contact_address: University street///contact_city: Charlottesville///contact_state: VA///contact_zip.postal_code: 22903///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM746nnn/GSM746873/GSM746873.CEL.gz///data_row_count: 54675
1
title: OV_FFPE_14///geo_accession: GSM746874///status: Public on Aug 21 2012///submission_date: Jun 22 2011///last_update_date: Aug 21 2012///type: RNA///channel_count: 1///source_name_ch1: formalin-fixed paraffin embedded (FFPE) tissue, ovarian cancer cells///organism_ch1: Homo sapiens///characteristics_ch1: cell type: ovarian cancer cell///characteristics_ch1.1: age: 50///characteristics_ch1.2: dob: 1953-04-09///characteristics_ch1.3: race: White///characteristics_ch1.4: histo: Clear///characteristics_ch1.5: grade: Unk///characteristics_ch1.6: Stage: IIIB///characteristics_ch1.7: surgtype: Primary Surgery///characteristics_ch1.8: datedx: 2002-06-06///characteristics_ch1.9: surgdate: 2002-06-06///characteristics_ch1.10: optimal: Sub-optimal///characteristics_ch1.11: chemtype: Adjuvant///characteristics_ch1.12: chemoresponse: CR (completely response)///characteristics_ch1.13: chemo agent: Carboplatin/Taxol///characteristics_ch1.14: date.of.relapse: 2003-10-13///characteristics_ch1.15: date.last.follow.up: 2005-10-24///characteristics_ch1.16: st.categ: 2///characteristics_ch1.17: pfi days: 494///characteristics_ch1.18: relapse(1=yes, 0=no): 1///characteristics_ch1.19: overall survival days: 1236///characteristics_ch1.20: censoring(dead=1,alive=0): 0///molecule_ch1: total RNA///extract_protocol_ch1: RNA extraction and amplification was performed with the NuGen WT-Ovation FFPE RNA Amplification kit.///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Punches of FFPE tumor tissue blocks and gene expression profiling were performed in a standard procedure by Almac Dignostics, Inc. (Durham, NC).///scan_protocol: GeneChips were scanned using the Hewlett-Packard GeneArray Scanner G2500A.///description: S0456F028.CEL///description.1: Gene expression data from stage III-IV ovarian cancer patients///data_processing: Data normalization and quality control assessment of the hybridization results were performed with the RMA Bioconductor package (http://www.bioconductor.org)///platform_id: GPL570///contact_name: Youngchul,,Kim///contact_department: Public Health Sciences///contact_institute: University of Virginia///contact_address: University street///contact_city: Charlottesville///contact_state: VA///contact_zip.postal_code: 22903///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM746nnn/GSM746874/GSM746874.CEL.gz///data_row_count: 54675
1
title: OV_FFPE_15///geo_accession: GSM746875///status: Public on Aug 21 2012///submission_date: Jun 22 2011///last_update_date: Aug 21 2012///type: RNA///channel_count: 1///source_name_ch1: formalin-fixed paraffin embedded (FFPE) tissue, ovarian cancer cells///organism_ch1: Homo sapiens///characteristics_ch1: cell type: ovarian cancer cell///characteristics_ch1.1: age: 61///characteristics_ch1.2: dob: 1941-12-01///characteristics_ch1.3: race: White///characteristics_ch1.4: histo: Serous///characteristics_ch1.5: grade: Poor///characteristics_ch1.6: Stage: IIIC///characteristics_ch1.7: surgtype: Primary Surgery///characteristics_ch1.8: datedx: 2002-04-23///characteristics_ch1.9: surgdate: 2002-04-23///characteristics_ch1.10: optimal: Sub-optimal///characteristics_ch1.11: chemtype: Adjuvant///characteristics_ch1.12: chemoresponse: PR (partial response)///characteristics_ch1.13: chemo agent: Carboplatin/Taxol///characteristics_ch1.14: date.last.follow.up: 2002-11-04///characteristics_ch1.15: st.categ: 2///characteristics_ch1.16: pfi days: 195///characteristics_ch1.17: relapse(1=yes, 0=no): UNKnown///characteristics_ch1.18: overall survival days: 195///characteristics_ch1.19: censoring(dead=1,alive=0): 0///characteristics_ch1.20: ///molecule_ch1: total RNA///extract_protocol_ch1: RNA extraction and amplification was performed with the NuGen WT-Ovation FFPE RNA Amplification kit.///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Punches of FFPE tumor tissue blocks and gene expression profiling were performed in a standard procedure by Almac Dignostics, Inc. (Durham, NC).///scan_protocol: GeneChips were scanned using the Hewlett-Packard GeneArray Scanner G2500A.///description: S0456F030.CEL///description.1: Gene expression data from stage III-IV ovarian cancer patients///data_processing: Data normalization and quality control assessment of the hybridization results were performed with the RMA Bioconductor package (http://www.bioconductor.org)///platform_id: GPL570///contact_name: Youngchul,,Kim///contact_department: Public Health Sciences///contact_institute: University of Virginia///contact_address: University street///contact_city: Charlottesville///contact_state: VA///contact_zip.postal_code: 22903///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM746nnn/GSM746875/GSM746875.CEL.gz///data_row_count: 54675
1
title: OV_FFPE_16///geo_accession: GSM746876///status: Public on Aug 21 2012///submission_date: Jun 22 2011///last_update_date: Aug 21 2012///type: RNA///channel_count: 1///source_name_ch1: formalin-fixed paraffin embedded (FFPE) tissue, ovarian cancer cells///organism_ch1: Homo sapiens///characteristics_ch1: cell type: ovarian cancer cell///characteristics_ch1.1: age: 53///characteristics_ch1.2: dob: 1943-07-22///characteristics_ch1.3: race: White///characteristics_ch1.4: histo: Serous///characteristics_ch1.5: grade: Mod///characteristics_ch1.6: Stage: IIIC///characteristics_ch1.7: surgtype: Primary Surgery///characteristics_ch1.8: datedx: 1997-01-01///characteristics_ch1.9: surgdate: 1997-01-01///characteristics_ch1.10: optimal: Sub-optimal///characteristics_ch1.11: chemtype: Adjuvant///characteristics_ch1.12: chemoresponse: PR (partial response)///characteristics_ch1.13: chemo agent: Carboplatin/Taxol///characteristics_ch1.14: date.of.relapse: 1997-02-01///characteristics_ch1.15: date.last.follow.up: 2000-04-27///characteristics_ch1.16: st.categ: 4///characteristics_ch1.17: pfi days: 31///characteristics_ch1.18: relapse(1=yes, 0=no): 1///characteristics_ch1.19: overall survival days: 1212///characteristics_ch1.20: censoring(dead=1,alive=0): 1///molecule_ch1: total RNA///extract_protocol_ch1: RNA extraction and amplification was performed with the NuGen WT-Ovation FFPE RNA Amplification kit.///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Punches of FFPE tumor tissue blocks and gene expression profiling were performed in a standard procedure by Almac Dignostics, Inc. (Durham, NC).///scan_protocol: GeneChips were scanned using the Hewlett-Packard GeneArray Scanner G2500A.///description: S0456F032.CEL///description.1: Gene expression data from stage III-IV ovarian cancer patients///data_processing: Data normalization and quality control assessment of the hybridization results were performed with the RMA Bioconductor package (http://www.bioconductor.org)///platform_id: GPL570///contact_name: Youngchul,,Kim///contact_department: Public Health Sciences///contact_institute: University of Virginia///contact_address: University street///contact_city: Charlottesville///contact_state: VA///contact_zip.postal_code: 22903///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM746nnn/GSM746876/GSM746876.CEL.gz///data_row_count: 54675
1
title: OV_FFPE_17///geo_accession: GSM746877///status: Public on Aug 21 2012///submission_date: Jun 22 2011///last_update_date: Aug 21 2012///type: RNA///channel_count: 1///source_name_ch1: formalin-fixed paraffin embedded (FFPE) tissue, ovarian cancer cells///organism_ch1: Homo sapiens///characteristics_ch1: cell type: ovarian cancer cell///characteristics_ch1.1: age: 73///characteristics_ch1.2: dob: 1923-05-23///characteristics_ch1.3: race: White///characteristics_ch1.4: histo: Serous///characteristics_ch1.5: grade: Mod///characteristics_ch1.6: Stage: IVA///characteristics_ch1.7: surgtype: Primary Surgery///characteristics_ch1.8: datedx: 1996-07-30///characteristics_ch1.9: surgdate: 1996-07-30///characteristics_ch1.10: optimal: Sub-optimal///characteristics_ch1.11: chemtype: Adjuvant///characteristics_ch1.12: chemoresponse: PR (partial response)///characteristics_ch1.13: chemo agent: Carboplatin/Taxol///characteristics_ch1.14: date.of.relapse: 1997-04-01///characteristics_ch1.15: date.last.follow.up: 1997-03-29///characteristics_ch1.16: st.categ: 4///characteristics_ch1.17: pfi days: 245///characteristics_ch1.18: relapse(1=yes, 0=no): 1///characteristics_ch1.19: overall survival days: 242///characteristics_ch1.20: censoring(dead=1,alive=0): 1///molecule_ch1: total RNA///extract_protocol_ch1: RNA extraction and amplification was performed with the NuGen WT-Ovation FFPE RNA Amplification kit.///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Punches of FFPE tumor tissue blocks and gene expression profiling were performed in a standard procedure by Almac Dignostics, Inc. (Durham, NC).///scan_protocol: GeneChips were scanned using the Hewlett-Packard GeneArray Scanner G2500A.///description: S0456F033.CEL///description.1: Gene expression data from stage III-IV ovarian cancer patients///data_processing: Data normalization and quality control assessment of the hybridization results were performed with the RMA Bioconductor package (http://www.bioconductor.org)///platform_id: GPL570///contact_name: Youngchul,,Kim///contact_department: Public Health Sciences///contact_institute: University of Virginia///contact_address: University street///contact_city: Charlottesville///contact_state: VA///contact_zip.postal_code: 22903///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM746nnn/GSM746877/GSM746877.CEL.gz///data_row_count: 54675
1
title: OV_FFPE_18///geo_accession: GSM746878///status: Public on Aug 21 2012///submission_date: Jun 22 2011///last_update_date: Aug 21 2012///type: RNA///channel_count: 1///source_name_ch1: formalin-fixed paraffin embedded (FFPE) tissue, ovarian cancer cells///organism_ch1: Homo sapiens///characteristics_ch1: cell type: ovarian cancer cell///characteristics_ch1.1: age: 85///characteristics_ch1.2: dob: 1910-04-01///characteristics_ch1.3: race: White///characteristics_ch1.4: histo: Serous///characteristics_ch1.5: grade: Poor///characteristics_ch1.6: Stage: IIIC///characteristics_ch1.7: surgtype: Primary Surgery///characteristics_ch1.8: datedx: 1996-01-04///characteristics_ch1.9: surgdate: 1996-01-04///characteristics_ch1.10: optimal: Optimal///characteristics_ch1.11: chemtype: Adjuvant///characteristics_ch1.12: chemoresponse: unknown///characteristics_ch1.13: chemo agent: Carboplatin/Taxol///characteristics_ch1.14: date.last.follow.up: 2002-01-07///characteristics_ch1.15: st.categ: 6///characteristics_ch1.16: pfi days: 2195///characteristics_ch1.17: relapse(1=yes, 0=no): UNKnown///characteristics_ch1.18: overall survival days: 2195///characteristics_ch1.19: censoring(dead=1,alive=0): 1///characteristics_ch1.20: ///molecule_ch1: total RNA///extract_protocol_ch1: RNA extraction and amplification was performed with the NuGen WT-Ovation FFPE RNA Amplification kit.///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Punches of FFPE tumor tissue blocks and gene expression profiling were performed in a standard procedure by Almac Dignostics, Inc. (Durham, NC).///scan_protocol: GeneChips were scanned using the Hewlett-Packard GeneArray Scanner G2500A.///description: S0456F034.CEL///description.1: Gene expression data from stage III-IV ovarian cancer patients///data_processing: Data normalization and quality control assessment of the hybridization results were performed with the RMA Bioconductor package (http://www.bioconductor.org)///platform_id: GPL570///contact_name: Youngchul,,Kim///contact_department: Public Health Sciences///contact_institute: University of Virginia///contact_address: University street///contact_city: Charlottesville///contact_state: VA///contact_zip.postal_code: 22903///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM746nnn/GSM746878/GSM746878.CEL.gz///data_row_count: 54675
1
title: OV_FFPE_19///geo_accession: GSM746879///status: Public on Aug 21 2012///submission_date: Jun 22 2011///last_update_date: Aug 21 2012///type: RNA///channel_count: 1///source_name_ch1: formalin-fixed paraffin embedded (FFPE) tissue, ovarian cancer cells///organism_ch1: Homo sapiens///characteristics_ch1: cell type: ovarian cancer cell///characteristics_ch1.1: age: 68///characteristics_ch1.2: dob: 1930-02-21///characteristics_ch1.3: race: White///characteristics_ch1.4: histo: Serous///characteristics_ch1.5: grade: Mod///characteristics_ch1.6: Stage: IIIA///characteristics_ch1.7: datedx: 1998-06-18///characteristics_ch1.8: surgdate: 1998-06-18///characteristics_ch1.9: optimal: Optimal///characteristics_ch1.10: chemtype: Adjuvant///characteristics_ch1.11: chemoresponse: CR (completely response)///characteristics_ch1.12: chemo agent: Cisplatin/Taxol///characteristics_ch1.13: date.last.follow.up: 2004-09-16///characteristics_ch1.14: st.categ: 1///characteristics_ch1.15: pfi days: 2282///characteristics_ch1.16: relapse(1=yes, 0=no): 0///characteristics_ch1.17: overall survival days: 2282///characteristics_ch1.18: censoring(dead=1,alive=0): 0///characteristics_ch1.19: ///characteristics_ch1.20: ///molecule_ch1: total RNA///extract_protocol_ch1: RNA extraction and amplification was performed with the NuGen WT-Ovation FFPE RNA Amplification kit.///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Punches of FFPE tumor tissue blocks and gene expression profiling were performed in a standard procedure by Almac Dignostics, Inc. (Durham, NC).///scan_protocol: GeneChips were scanned using the Hewlett-Packard GeneArray Scanner G2500A.///description: S0456F036.CEL///description.1: Gene expression data from stage III-IV ovarian cancer patients///data_processing: Data normalization and quality control assessment of the hybridization results were performed with the RMA Bioconductor package (http://www.bioconductor.org)///platform_id: GPL570///contact_name: Youngchul,,Kim///contact_department: Public Health Sciences///contact_institute: University of Virginia///contact_address: University street///contact_city: Charlottesville///contact_state: VA///contact_zip.postal_code: 22903///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM746nnn/GSM746879/GSM746879.CEL.gz///data_row_count: 54675
1
title: OV_FFPE_1///geo_accession: GSM746861///status: Public on Aug 21 2012///submission_date: Jun 22 2011///last_update_date: Aug 21 2012///type: RNA///channel_count: 1///source_name_ch1: formalin-fixed paraffin embedded (FFPE) tissue, ovarian cancer cells///organism_ch1: Homo sapiens///characteristics_ch1: cell type: ovarian cancer cell///characteristics_ch1.1: age: 68///characteristics_ch1.2: dob: 1930-03-16///characteristics_ch1.3: race: White///characteristics_ch1.4: histo: Serous///characteristics_ch1.5: grade: Poor///characteristics_ch1.6: Stage: IVA///characteristics_ch1.7: surgtype: Primary Surgery///characteristics_ch1.8: datedx: 1998-05-12///characteristics_ch1.9: surgdate: 1998-05-12///characteristics_ch1.10: optimal: Sub-optimal///characteristics_ch1.11: chemtype: Adjuvant///characteristics_ch1.12: chemoresponse: PR (partial response)///characteristics_ch1.13: chemo agent: Carboplatin/Taxol///characteristics_ch1.14: date.of.relapse: 1999-06-01///characteristics_ch1.15: date.last.follow.up: 2000-03-28///characteristics_ch1.16: st.categ: 4///characteristics_ch1.17: pfi days: 385///characteristics_ch1.18: relapse(1=yes, 0=no): 1///characteristics_ch1.19: overall survival days: 686///characteristics_ch1.20: censoring(dead=1,alive=0): 1///molecule_ch1: total RNA///extract_protocol_ch1: RNA extraction and amplification was performed with the NuGen WT-Ovation FFPE RNA Amplification kit.///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Punches of FFPE tumor tissue blocks and gene expression profiling were performed in a standard procedure by Almac Dignostics, Inc. (Durham, NC).///scan_protocol: GeneChips were scanned using the Hewlett-Packard GeneArray Scanner G2500A.///description: S0456F001.CEL///description.1: Gene expression data from stage III-IV ovarian cancer patients///data_processing: Data normalization and quality control assessment of the hybridization results were performed with the RMA Bioconductor package (http://www.bioconductor.org)///platform_id: GPL570///contact_name: Youngchul,,Kim///contact_department: Public Health Sciences///contact_institute: University of Virginia///contact_address: University street///contact_city: Charlottesville///contact_state: VA///contact_zip.postal_code: 22903///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM746nnn/GSM746861/GSM746861.CEL.gz///data_row_count: 54675
1
title: OV_FFPE_20///geo_accession: GSM746880///status: Public on Aug 21 2012///submission_date: Jun 22 2011///last_update_date: Aug 21 2012///type: RNA///channel_count: 1///source_name_ch1: formalin-fixed paraffin embedded (FFPE) tissue, ovarian cancer cells///organism_ch1: Homo sapiens///characteristics_ch1: cell type: ovarian cancer cell///characteristics_ch1.1: age: 56///characteristics_ch1.2: dob: 1938-10-21///characteristics_ch1.3: race: White///characteristics_ch1.4: histo: Serous///characteristics_ch1.5: grade: Poor///characteristics_ch1.6: Stage: IIIC///characteristics_ch1.7: surgtype: Primary Surgery///characteristics_ch1.8: datedx: 1995-10-04///characteristics_ch1.9: surgdate: 1995-10-12///characteristics_ch1.10: optimal: Sub-optimal///characteristics_ch1.11: chemtype: Adjuvant///characteristics_ch1.12: chemoresponse: CR (completely response)///characteristics_ch1.13: chemo agent: Carboplatin/Taxol///characteristics_ch1.14: date.of.relapse: 1996-08-08///characteristics_ch1.15: date.last.follow.up: 1997-12-30///characteristics_ch1.16: st.categ: 4///characteristics_ch1.17: pfi days: 309///characteristics_ch1.18: relapse(1=yes, 0=no): 1///characteristics_ch1.19: overall survival days: 818///characteristics_ch1.20: censoring(dead=1,alive=0): 1///molecule_ch1: total RNA///extract_protocol_ch1: RNA extraction and amplification was performed with the NuGen WT-Ovation FFPE RNA Amplification kit.///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Punches of FFPE tumor tissue blocks and gene expression profiling were performed in a standard procedure by Almac Dignostics, Inc. (Durham, NC).///scan_protocol: GeneChips were scanned using the Hewlett-Packard GeneArray Scanner G2500A.///description: S0456F037.CEL///description.1: Gene expression data from stage III-IV ovarian cancer patients///data_processing: Data normalization and quality control assessment of the hybridization results were performed with the RMA Bioconductor package (http://www.bioconductor.org)///platform_id: GPL570///contact_name: Youngchul,,Kim///contact_department: Public Health Sciences///contact_institute: University of Virginia///contact_address: University street///contact_city: Charlottesville///contact_state: VA///contact_zip.postal_code: 22903///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM746nnn/GSM746880/GSM746880.CEL.gz///data_row_count: 54675
1
title: OV_FFPE_21///geo_accession: GSM746881///status: Public on Aug 21 2012///submission_date: Jun 22 2011///last_update_date: Aug 21 2012///type: RNA///channel_count: 1///source_name_ch1: formalin-fixed paraffin embedded (FFPE) tissue, ovarian cancer cells///organism_ch1: Homo sapiens///characteristics_ch1: cell type: ovarian cancer cell///characteristics_ch1.1: age: 66///characteristics_ch1.2: dob: 1930-07-05///characteristics_ch1.3: race: White///characteristics_ch1.4: histo: Transitional///characteristics_ch1.5: grade: Poor///characteristics_ch1.6: Stage: IVA///characteristics_ch1.7: surgtype: Primary Surgery///characteristics_ch1.8: datedx: 1996-09-24///characteristics_ch1.9: surgdate: 1996-09-24///characteristics_ch1.10: optimal: Sub-optimal///characteristics_ch1.11: chemtype: Adjuvant///characteristics_ch1.12: chemoresponse: CR (completely response)///characteristics_ch1.13: chemo agent: Carboplatin/Taxol///characteristics_ch1.14: date.last.follow.up: 2005-10-22///characteristics_ch1.15: st.categ: 1///characteristics_ch1.16: pfi days: 3315///characteristics_ch1.17: relapse(1=yes, 0=no): 0///characteristics_ch1.18: overall survival days: 3315///characteristics_ch1.19: censoring(dead=1,alive=0): 0///characteristics_ch1.20: ///molecule_ch1: total RNA///extract_protocol_ch1: RNA extraction and amplification was performed with the NuGen WT-Ovation FFPE RNA Amplification kit.///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Punches of FFPE tumor tissue blocks and gene expression profiling were performed in a standard procedure by Almac Dignostics, Inc. (Durham, NC).///scan_protocol: GeneChips were scanned using the Hewlett-Packard GeneArray Scanner G2500A.///description: S0456F039.CEL///description.1: Gene expression data from stage III-IV ovarian cancer patients///data_processing: Data normalization and quality control assessment of the hybridization results were performed with the RMA Bioconductor package (http://www.bioconductor.org)///platform_id: GPL570///contact_name: Youngchul,,Kim///contact_department: Public Health Sciences///contact_institute: University of Virginia///contact_address: University street///contact_city: Charlottesville///contact_state: VA///contact_zip.postal_code: 22903///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM746nnn/GSM746881/GSM746881.CEL.gz///data_row_count: 54675
1
title: OV_FFPE_22///geo_accession: GSM746882///status: Public on Aug 21 2012///submission_date: Jun 22 2011///last_update_date: Aug 21 2012///type: RNA///channel_count: 1///source_name_ch1: formalin-fixed paraffin embedded (FFPE) tissue, ovarian cancer cells///organism_ch1: Homo sapiens///characteristics_ch1: cell type: ovarian cancer cell///characteristics_ch1.1: age: 71///characteristics_ch1.2: dob: 1926-11-13///characteristics_ch1.3: race: White///characteristics_ch1.4: histo: Serous///characteristics_ch1.5: grade: Poor///characteristics_ch1.6: Stage: IIIB///characteristics_ch1.7: surgtype: Primary Surgery///characteristics_ch1.8: datedx: 1997-09-09///characteristics_ch1.9: surgdate: 1997-09-09///characteristics_ch1.10: optimal: Optimal///characteristics_ch1.11: chemtype: Adjuvant///characteristics_ch1.12: chemoresponse: unknown///characteristics_ch1.13: chemo agent: Carboplatin/Taxol///characteristics_ch1.14: date.last.follow.up: 1998-10-01///characteristics_ch1.15: st.categ: 4///characteristics_ch1.16: pfi days: 387///characteristics_ch1.17: relapse(1=yes, 0=no): UNKnown///characteristics_ch1.18: overall survival days: 387///characteristics_ch1.19: censoring(dead=1,alive=0): 1///characteristics_ch1.20: ///molecule_ch1: total RNA///extract_protocol_ch1: RNA extraction and amplification was performed with the NuGen WT-Ovation FFPE RNA Amplification kit.///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Punches of FFPE tumor tissue blocks and gene expression profiling were performed in a standard procedure by Almac Dignostics, Inc. (Durham, NC).///scan_protocol: GeneChips were scanned using the Hewlett-Packard GeneArray Scanner G2500A.///description: S0456F044.CEL///description.1: Gene expression data from stage III-IV ovarian cancer patients///data_processing: Data normalization and quality control assessment of the hybridization results were performed with the RMA Bioconductor package (http://www.bioconductor.org)///platform_id: GPL570///contact_name: Youngchul,,Kim///contact_department: Public Health Sciences///contact_institute: University of Virginia///contact_address: University street///contact_city: Charlottesville///contact_state: VA///contact_zip.postal_code: 22903///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM746nnn/GSM746882/GSM746882.CEL.gz///data_row_count: 54675
1
title: OV_FFPE_23///geo_accession: GSM746883///status: Public on Aug 21 2012///submission_date: Jun 22 2011///last_update_date: Aug 21 2012///type: RNA///channel_count: 1///source_name_ch1: formalin-fixed paraffin embedded (FFPE) tissue, ovarian cancer cells///organism_ch1: Homo sapiens///characteristics_ch1: cell type: ovarian cancer cell///characteristics_ch1.1: age: 57///characteristics_ch1.2: dob: 1946-10-13///characteristics_ch1.3: race: White///characteristics_ch1.4: histo: Clear///characteristics_ch1.5: grade: Unk///characteristics_ch1.6: Stage: IIIC///characteristics_ch1.7: surgtype: Primary Surgery///characteristics_ch1.8: datedx: 2002-07-18///characteristics_ch1.9: surgdate: 2002-07-18///characteristics_ch1.10: optimal: Optimal///characteristics_ch1.11: chemtype: Adjuvant///characteristics_ch1.12: chemoresponse: PR (partial response)///characteristics_ch1.13: chemo agent: Carboplatin/Taxol///characteristics_ch1.14: date.of.relapse: 2003-05-01///characteristics_ch1.15: date.last.follow.up: 2004-05-07///characteristics_ch1.16: st.categ: 2///characteristics_ch1.17: pfi days: 287///characteristics_ch1.18: relapse(1=yes, 0=no): 1///characteristics_ch1.19: overall survival days: 659///characteristics_ch1.20: censoring(dead=1,alive=0): 0///molecule_ch1: total RNA///extract_protocol_ch1: RNA extraction and amplification was performed with the NuGen WT-Ovation FFPE RNA Amplification kit.///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Punches of FFPE tumor tissue blocks and gene expression profiling were performed in a standard procedure by Almac Dignostics, Inc. (Durham, NC).///scan_protocol: GeneChips were scanned using the Hewlett-Packard GeneArray Scanner G2500A.///description: S0456F045a.CEL///description.1: Gene expression data from stage III-IV ovarian cancer patients///data_processing: Data normalization and quality control assessment of the hybridization results were performed with the RMA Bioconductor package (http://www.bioconductor.org)///platform_id: GPL570///contact_name: Youngchul,,Kim///contact_department: Public Health Sciences///contact_institute: University of Virginia///contact_address: University street///contact_city: Charlottesville///contact_state: VA///contact_zip.postal_code: 22903///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM746nnn/GSM746883/GSM746883.CEL.gz///data_row_count: 54675
1
title: OV_FFPE_24///geo_accession: GSM746884///status: Public on Aug 21 2012///submission_date: Jun 22 2011///last_update_date: Aug 21 2012///type: RNA///channel_count: 1///source_name_ch1: formalin-fixed paraffin embedded (FFPE) tissue, ovarian cancer cells///organism_ch1: Homo sapiens///characteristics_ch1: cell type: ovarian cancer cell///characteristics_ch1.1: age: 55///characteristics_ch1.2: dob: 1948-10-12///characteristics_ch1.3: race: White///characteristics_ch1.4: histo: Serous///characteristics_ch1.5: grade: Well///characteristics_ch1.6: Stage: IIIC///characteristics_ch1.7: surgtype: Primary Surgery///characteristics_ch1.8: datedx: 2002-04-29///characteristics_ch1.9: surgdate: 2002-04-29///characteristics_ch1.10: optimal: Optimal///characteristics_ch1.11: chemtype: Adjuvant///characteristics_ch1.12: chemoresponse: PR (partial response)///characteristics_ch1.13: chemo agent: Carboplatin/Taxol///characteristics_ch1.14: date.of.relapse: 2003-05-01///characteristics_ch1.15: date.last.follow.up: 2006-08-25///characteristics_ch1.16: st.categ: 4///characteristics_ch1.17: pfi days: 367///characteristics_ch1.18: relapse(1=yes, 0=no): 1///characteristics_ch1.19: overall survival days: 1579///characteristics_ch1.20: censoring(dead=1,alive=0): 1///molecule_ch1: total RNA///extract_protocol_ch1: RNA extraction and amplification was performed with the NuGen WT-Ovation FFPE RNA Amplification kit.///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Punches of FFPE tumor tissue blocks and gene expression profiling were performed in a standard procedure by Almac Dignostics, Inc. (Durham, NC).///scan_protocol: GeneChips were scanned using the Hewlett-Packard GeneArray Scanner G2500A.///description: S0456F047.CEL///description.1: Gene expression data from stage III-IV ovarian cancer patients///data_processing: Data normalization and quality control assessment of the hybridization results were performed with the RMA Bioconductor package (http://www.bioconductor.org)///platform_id: GPL570///contact_name: Youngchul,,Kim///contact_department: Public Health Sciences///contact_institute: University of Virginia///contact_address: University street///contact_city: Charlottesville///contact_state: VA///contact_zip.postal_code: 22903///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM746nnn/GSM746884/GSM746884.CEL.gz///data_row_count: 54675
1
title: OV_FFPE_25///geo_accession: GSM746885///status: Public on Aug 21 2012///submission_date: Jun 22 2011///last_update_date: Aug 21 2012///type: RNA///channel_count: 1///source_name_ch1: formalin-fixed paraffin embedded (FFPE) tissue, ovarian cancer cells///organism_ch1: Homo sapiens///characteristics_ch1: cell type: ovarian cancer cell///characteristics_ch1.1: age: 74///characteristics_ch1.2: dob: 1922-02-09///characteristics_ch1.3: race: White///characteristics_ch1.4: histo: Serous///characteristics_ch1.5: grade: Mod///characteristics_ch1.6: Stage: IIIB///characteristics_ch1.7: surgtype: Primary Surgery///characteristics_ch1.8: datedx: 1997-02-04///characteristics_ch1.9: surgdate: 1997-02-04///characteristics_ch1.10: optimal: Optimal///characteristics_ch1.11: chemtype: Adjuvant///characteristics_ch1.12: chemoresponse: CR (completely response)///characteristics_ch1.13: chemo agent: Cisplatin/Cytoxan///characteristics_ch1.14: date.of.relapse: 1998-07-31///characteristics_ch1.15: date.last.follow.up: 1999-10-17///characteristics_ch1.16: st.categ: 6///characteristics_ch1.17: pfi days: 542///characteristics_ch1.18: relapse(1=yes, 0=no): 1///characteristics_ch1.19: overall survival days: 985///characteristics_ch1.20: censoring(dead=1,alive=0): 1///molecule_ch1: total RNA///extract_protocol_ch1: RNA extraction and amplification was performed with the NuGen WT-Ovation FFPE RNA Amplification kit.///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Punches of FFPE tumor tissue blocks and gene expression profiling were performed in a standard procedure by Almac Dignostics, Inc. (Durham, NC).///scan_protocol: GeneChips were scanned using the Hewlett-Packard GeneArray Scanner G2500A.///description: S0456F048.CEL///description.1: Gene expression data from stage III-IV ovarian cancer patients///data_processing: Data normalization and quality control assessment of the hybridization results were performed with the RMA Bioconductor package (http://www.bioconductor.org)///platform_id: GPL570///contact_name: Youngchul,,Kim///contact_department: Public Health Sciences///contact_institute: University of Virginia///contact_address: University street///contact_city: Charlottesville///contact_state: VA///contact_zip.postal_code: 22903///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM746nnn/GSM746885/GSM746885.CEL.gz///data_row_count: 54675
1
title: OV_FFPE_26///geo_accession: GSM746886///status: Public on Aug 21 2012///submission_date: Jun 22 2011///last_update_date: Aug 21 2012///type: RNA///channel_count: 1///source_name_ch1: formalin-fixed paraffin embedded (FFPE) tissue, ovarian cancer cells///organism_ch1: Homo sapiens///characteristics_ch1: cell type: ovarian cancer cell///characteristics_ch1.1: age: 72///characteristics_ch1.2: dob: 1924-01-11///characteristics_ch1.3: race: Black///characteristics_ch1.4: histo: Serous///characteristics_ch1.5: grade: Poor///characteristics_ch1.6: Stage: IIIC///characteristics_ch1.7: surgtype: Primary Surgery///characteristics_ch1.8: datedx: 1996-08-20///characteristics_ch1.9: surgdate: 1996-08-20///characteristics_ch1.10: optimal: Sub-optimal///characteristics_ch1.11: chemtype: Adjuvant///characteristics_ch1.12: chemoresponse: PR (partial response)///characteristics_ch1.13: chemo agent: Carboplatin/Taxol///characteristics_ch1.14: date.of.relapse: 1997-02-01///characteristics_ch1.15: date.last.follow.up: 1997-04-14///characteristics_ch1.16: st.categ: 4///characteristics_ch1.17: pfi days: 165///characteristics_ch1.18: relapse(1=yes, 0=no): 1///characteristics_ch1.19: overall survival days: 237///characteristics_ch1.20: censoring(dead=1,alive=0): 1///molecule_ch1: total RNA///extract_protocol_ch1: RNA extraction and amplification was performed with the NuGen WT-Ovation FFPE RNA Amplification kit.///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Punches of FFPE tumor tissue blocks and gene expression profiling were performed in a standard procedure by Almac Dignostics, Inc. (Durham, NC).///scan_protocol: GeneChips were scanned using the Hewlett-Packard GeneArray Scanner G2500A.///description: S0456F049.CEL///description.1: Gene expression data from stage III-IV ovarian cancer patients///data_processing: Data normalization and quality control assessment of the hybridization results were performed with the RMA Bioconductor package (http://www.bioconductor.org)///platform_id: GPL570///contact_name: Youngchul,,Kim///contact_department: Public Health Sciences///contact_institute: University of Virginia///contact_address: University street///contact_city: Charlottesville///contact_state: VA///contact_zip.postal_code: 22903///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM746nnn/GSM746886/GSM746886.CEL.gz///data_row_count: 54675
1
title: OV_FFPE_27///geo_accession: GSM746887///status: Public on Aug 21 2012///submission_date: Jun 22 2011///last_update_date: Aug 21 2012///type: RNA///channel_count: 1///source_name_ch1: formalin-fixed paraffin embedded (FFPE) tissue, ovarian cancer cells///organism_ch1: Homo sapiens///characteristics_ch1: cell type: ovarian cancer cell///characteristics_ch1.1: age: 72///characteristics_ch1.2: dob: 1931-09-07///characteristics_ch1.3: race: White///characteristics_ch1.4: histo: Serous///characteristics_ch1.5: grade: Poor///characteristics_ch1.6: Stage: IIIC///characteristics_ch1.7: surgtype: Primary Surgery///characteristics_ch1.8: datedx: 2002-08-01///characteristics_ch1.9: surgdate: 2002-08-27///characteristics_ch1.10: optimal: Sub-optimal///characteristics_ch1.11: chemtype: Adjuvant///characteristics_ch1.12: chemoresponse: PD (progress of disease)///characteristics_ch1.13: chemo agent: Carboplatin/Taxol///characteristics_ch1.14: date.of.relapse: 2002-09-01///characteristics_ch1.15: date.last.follow.up: 2002-12-16///characteristics_ch1.16: st.categ: 4///characteristics_ch1.17: pfi days: 31///characteristics_ch1.18: relapse(1=yes, 0=no): 1///characteristics_ch1.19: overall survival days: 137///characteristics_ch1.20: censoring(dead=1,alive=0): 1///molecule_ch1: total RNA///extract_protocol_ch1: RNA extraction and amplification was performed with the NuGen WT-Ovation FFPE RNA Amplification kit.///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Punches of FFPE tumor tissue blocks and gene expression profiling were performed in a standard procedure by Almac Dignostics, Inc. (Durham, NC).///scan_protocol: GeneChips were scanned using the Hewlett-Packard GeneArray Scanner G2500A.///description: S0456F050.CEL///description.1: Gene expression data from stage III-IV ovarian cancer patients///data_processing: Data normalization and quality control assessment of the hybridization results were performed with the RMA Bioconductor package (http://www.bioconductor.org)///platform_id: GPL570///contact_name: Youngchul,,Kim///contact_department: Public Health Sciences///contact_institute: University of Virginia///contact_address: University street///contact_city: Charlottesville///contact_state: VA///contact_zip.postal_code: 22903///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM746nnn/GSM746887/GSM746887.CEL.gz///data_row_count: 54675
1
title: OV_FFPE_28///geo_accession: GSM746888///status: Public on Aug 21 2012///submission_date: Jun 22 2011///last_update_date: Aug 21 2012///type: RNA///channel_count: 1///source_name_ch1: formalin-fixed paraffin embedded (FFPE) tissue, ovarian cancer cells///organism_ch1: Homo sapiens///characteristics_ch1: cell type: ovarian cancer cell///characteristics_ch1.1: age: 74///characteristics_ch1.2: dob: 1927-01-10///characteristics_ch1.3: race: White///characteristics_ch1.4: histo: Undiff///characteristics_ch1.5: grade: Mod///characteristics_ch1.6: Stage: IIIB///characteristics_ch1.7: surgtype: Primary Surgery///characteristics_ch1.8: datedx: 2001-07-17///characteristics_ch1.9: surgdate: 2001-07-17///characteristics_ch1.10: optimal: Optimal///characteristics_ch1.11: chemtype: Adjuvant///characteristics_ch1.12: chemoresponse: CR (completely response)///characteristics_ch1.13: chemo agent: Carboplatin/Taxol///characteristics_ch1.14: date.last.follow.up: 2007-09-10///characteristics_ch1.15: st.categ: 1///characteristics_ch1.16: pfi days: 2246///characteristics_ch1.17: relapse(1=yes, 0=no): 0///characteristics_ch1.18: overall survival days: 2246///characteristics_ch1.19: censoring(dead=1,alive=0): 0///characteristics_ch1.20: ///molecule_ch1: total RNA///extract_protocol_ch1: RNA extraction and amplification was performed with the NuGen WT-Ovation FFPE RNA Amplification kit.///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Punches of FFPE tumor tissue blocks and gene expression profiling were performed in a standard procedure by Almac Dignostics, Inc. (Durham, NC).///scan_protocol: GeneChips were scanned using the Hewlett-Packard GeneArray Scanner G2500A.///description: S0456F051.CEL///description.1: Gene expression data from stage III-IV ovarian cancer patients///data_processing: Data normalization and quality control assessment of the hybridization results were performed with the RMA Bioconductor package (http://www.bioconductor.org)///platform_id: GPL570///contact_name: Youngchul,,Kim///contact_department: Public Health Sciences///contact_institute: University of Virginia///contact_address: University street///contact_city: Charlottesville///contact_state: VA///contact_zip.postal_code: 22903///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM746nnn/GSM746888/GSM746888.CEL.gz///data_row_count: 54675
1
title: OV_FFPE_29///geo_accession: GSM746889///status: Public on Aug 21 2012///submission_date: Jun 22 2011///last_update_date: Aug 21 2012///type: RNA///channel_count: 1///source_name_ch1: formalin-fixed paraffin embedded (FFPE) tissue, ovarian cancer cells///organism_ch1: Homo sapiens///characteristics_ch1: cell type: ovarian cancer cell///characteristics_ch1.1: age: 66///characteristics_ch1.2: dob: 1935-06-11///characteristics_ch1.3: race: White///characteristics_ch1.4: histo: Serous///characteristics_ch1.5: grade: Poor///characteristics_ch1.6: Stage: IIIC///characteristics_ch1.7: surgtype: Primary Surgery///characteristics_ch1.8: datedx: 2001-10-08///characteristics_ch1.9: surgdate: 2001-10-08///characteristics_ch1.10: optimal: Optimal///characteristics_ch1.11: chemtype: Adjuvant///characteristics_ch1.12: chemoresponse: CR (completely response)///characteristics_ch1.13: chemo agent: Carboplatin/Taxol///characteristics_ch1.14: date.of.relapse: 2003-02-01///characteristics_ch1.15: date.last.follow.up: 2003-09-05///characteristics_ch1.16: st.categ: 2///characteristics_ch1.17: pfi days: 481///characteristics_ch1.18: relapse(1=yes, 0=no): 1///characteristics_ch1.19: overall survival days: 697///characteristics_ch1.20: censoring(dead=1,alive=0): 0///molecule_ch1: total RNA///extract_protocol_ch1: RNA extraction and amplification was performed with the NuGen WT-Ovation FFPE RNA Amplification kit.///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Punches of FFPE tumor tissue blocks and gene expression profiling were performed in a standard procedure by Almac Dignostics, Inc. (Durham, NC).///scan_protocol: GeneChips were scanned using the Hewlett-Packard GeneArray Scanner G2500A.///description: S0456F053.CEL///description.1: Gene expression data from stage III-IV ovarian cancer patients///data_processing: Data normalization and quality control assessment of the hybridization results were performed with the RMA Bioconductor package (http://www.bioconductor.org)///platform_id: GPL570///contact_name: Youngchul,,Kim///contact_department: Public Health Sciences///contact_institute: University of Virginia///contact_address: University street///contact_city: Charlottesville///contact_state: VA///contact_zip.postal_code: 22903///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM746nnn/GSM746889/GSM746889.CEL.gz///data_row_count: 54675
1
title: OV_FFPE_2///geo_accession: GSM746862///status: Public on Aug 21 2012///submission_date: Jun 22 2011///last_update_date: Aug 21 2012///type: RNA///channel_count: 1///source_name_ch1: formalin-fixed paraffin embedded (FFPE) tissue, ovarian cancer cells///organism_ch1: Homo sapiens///characteristics_ch1: cell type: ovarian cancer cell///characteristics_ch1.1: age: 75///characteristics_ch1.2: dob: 1921-11-24///characteristics_ch1.3: race: White///characteristics_ch1.4: histo: Serous///characteristics_ch1.5: grade: Mod///characteristics_ch1.6: Stage: IIIC///characteristics_ch1.7: surgtype: Primary Surgery///characteristics_ch1.8: datedx: 1997-05-14///characteristics_ch1.9: surgdate: 1997-05-14///characteristics_ch1.10: optimal: Optimal///characteristics_ch1.11: chemtype: Adjuvant///characteristics_ch1.12: chemoresponse: CR (completely response)///characteristics_ch1.13: chemo agent: Carboplatin/Taxol///characteristics_ch1.14: date.of.relapse: 2004-06-08///characteristics_ch1.15: date.last.follow.up: 2004-06-08///characteristics_ch1.16: st.categ: 2///characteristics_ch1.17: pfi days: 2582///characteristics_ch1.18: relapse(1=yes, 0=no): 1///characteristics_ch1.19: overall survival days: 2582///characteristics_ch1.20: censoring(dead=1,alive=0): 0///molecule_ch1: total RNA///extract_protocol_ch1: RNA extraction and amplification was performed with the NuGen WT-Ovation FFPE RNA Amplification kit.///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Punches of FFPE tumor tissue blocks and gene expression profiling were performed in a standard procedure by Almac Dignostics, Inc. (Durham, NC).///scan_protocol: GeneChips were scanned using the Hewlett-Packard GeneArray Scanner G2500A.///description: S0456F005.CEL///description.1: Gene expression data from stage III-IV ovarian cancer patients///data_processing: Data normalization and quality control assessment of the hybridization results were performed with the RMA Bioconductor package (http://www.bioconductor.org)///platform_id: GPL570///contact_name: Youngchul,,Kim///contact_department: Public Health Sciences///contact_institute: University of Virginia///contact_address: University street///contact_city: Charlottesville///contact_state: VA///contact_zip.postal_code: 22903///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM746nnn/GSM746862/GSM746862.CEL.gz///data_row_count: 54675
1
title: OV_FFPE_30///geo_accession: GSM746890///status: Public on Aug 21 2012///submission_date: Jun 22 2011///last_update_date: Aug 21 2012///type: RNA///channel_count: 1///source_name_ch1: formalin-fixed paraffin embedded (FFPE) tissue, ovarian cancer cells///organism_ch1: Homo sapiens///characteristics_ch1: cell type: ovarian cancer cell///characteristics_ch1.1: age: 56///characteristics_ch1.2: dob: 1946-06-06///characteristics_ch1.3: race: White///characteristics_ch1.4: histo: Serous///characteristics_ch1.5: grade: Mod///characteristics_ch1.6: Stage: IIIA///characteristics_ch1.7: surgtype: Primary Surgery///characteristics_ch1.8: datedx: 2003-01-07///characteristics_ch1.9: surgdate: 2003-01-07///characteristics_ch1.10: optimal: Optimal///characteristics_ch1.11: chemtype: Adjuvant///characteristics_ch1.12: chemoresponse: CR (completely response)///characteristics_ch1.13: chemo agent: Carboplatin///characteristics_ch1.14: date.of.relapse: 2005-10-06///characteristics_ch1.15: date.last.follow.up: 2008-11-19///characteristics_ch1.16: st.categ: 2///characteristics_ch1.17: pfi days: 1003///characteristics_ch1.18: relapse(1=yes, 0=no): 1///characteristics_ch1.19: overall survival days: 2143///characteristics_ch1.20: censoring(dead=1,alive=0): 0///molecule_ch1: total RNA///extract_protocol_ch1: RNA extraction and amplification was performed with the NuGen WT-Ovation FFPE RNA Amplification kit.///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Punches of FFPE tumor tissue blocks and gene expression profiling were performed in a standard procedure by Almac Dignostics, Inc. (Durham, NC).///scan_protocol: GeneChips were scanned using the Hewlett-Packard GeneArray Scanner G2500A.///description: S0456F054.CEL///description.1: Gene expression data from stage III-IV ovarian cancer patients///data_processing: Data normalization and quality control assessment of the hybridization results were performed with the RMA Bioconductor package (http://www.bioconductor.org)///platform_id: GPL570///contact_name: Youngchul,,Kim///contact_department: Public Health Sciences///contact_institute: University of Virginia///contact_address: University street///contact_city: Charlottesville///contact_state: VA///contact_zip.postal_code: 22903///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM746nnn/GSM746890/GSM746890.CEL.gz///data_row_count: 54675
1
title: OV_FFPE_31///geo_accession: GSM746891///status: Public on Aug 21 2012///submission_date: Jun 22 2011///last_update_date: Aug 21 2012///type: RNA///channel_count: 1///source_name_ch1: formalin-fixed paraffin embedded (FFPE) tissue, ovarian cancer cells///organism_ch1: Homo sapiens///characteristics_ch1: cell type: ovarian cancer cell///characteristics_ch1.1: age: 64///characteristics_ch1.2: dob: 1931-07-12///characteristics_ch1.3: race: White///characteristics_ch1.4: histo: Serous///characteristics_ch1.5: grade: Mod///characteristics_ch1.6: Stage: IIIB///characteristics_ch1.7: surgtype: Primary Surgery///characteristics_ch1.8: datedx: 1996-02-15///characteristics_ch1.9: surgdate: 1996-02-15///characteristics_ch1.10: optimal: Optimal///characteristics_ch1.11: chemtype: Adjuvant///characteristics_ch1.12: chemoresponse: CR (completely response)///characteristics_ch1.13: chemo agent: Carboplatin/Taxol///characteristics_ch1.14: date.of.relapse: 1997-03-01///characteristics_ch1.15: date.last.follow.up: 1998-01-19///characteristics_ch1.16: st.categ: 4///characteristics_ch1.17: pfi days: 380///characteristics_ch1.18: relapse(1=yes, 0=no): 1///characteristics_ch1.19: overall survival days: 704///characteristics_ch1.20: censoring(dead=1,alive=0): 1///molecule_ch1: total RNA///extract_protocol_ch1: RNA extraction and amplification was performed with the NuGen WT-Ovation FFPE RNA Amplification kit.///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Punches of FFPE tumor tissue blocks and gene expression profiling were performed in a standard procedure by Almac Dignostics, Inc. (Durham, NC).///scan_protocol: GeneChips were scanned using the Hewlett-Packard GeneArray Scanner G2500A.///description: S0456F056.CEL///description.1: Gene expression data from stage III-IV ovarian cancer patients///data_processing: Data normalization and quality control assessment of the hybridization results were performed with the RMA Bioconductor package (http://www.bioconductor.org)///platform_id: GPL570///contact_name: Youngchul,,Kim///contact_department: Public Health Sciences///contact_institute: University of Virginia///contact_address: University street///contact_city: Charlottesville///contact_state: VA///contact_zip.postal_code: 22903///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM746nnn/GSM746891/GSM746891.CEL.gz///data_row_count: 54675
1
title: OV_FFPE_32///geo_accession: GSM746892///status: Public on Aug 21 2012///submission_date: Jun 22 2011///last_update_date: Aug 21 2012///type: RNA///channel_count: 1///source_name_ch1: formalin-fixed paraffin embedded (FFPE) tissue, ovarian cancer cells///organism_ch1: Homo sapiens///characteristics_ch1: cell type: ovarian cancer cell///characteristics_ch1.1: age: 53///characteristics_ch1.2: dob: 1945-06-08///characteristics_ch1.3: race: Black///characteristics_ch1.4: histo: Serous///characteristics_ch1.5: grade: Poor///characteristics_ch1.6: Stage: IIIC///characteristics_ch1.7: surgtype: Primary Surgery///characteristics_ch1.8: datedx: 1998-06-02///characteristics_ch1.9: surgdate: 1998-06-02///characteristics_ch1.10: optimal: Sub-optimal///characteristics_ch1.11: chemtype: Adjuvant///characteristics_ch1.12: chemoresponse: CR (completely response)///characteristics_ch1.13: chemo agent: Carboplatin/Taxol///characteristics_ch1.14: date.of.relapse: 1999-06-04///characteristics_ch1.15: date.last.follow.up: 2002-09-10///characteristics_ch1.16: st.categ: 4///characteristics_ch1.17: pfi days: 367///characteristics_ch1.18: relapse(1=yes, 0=no): 1///characteristics_ch1.19: overall survival days: 1561///characteristics_ch1.20: censoring(dead=1,alive=0): 1///molecule_ch1: total RNA///extract_protocol_ch1: RNA extraction and amplification was performed with the NuGen WT-Ovation FFPE RNA Amplification kit.///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Punches of FFPE tumor tissue blocks and gene expression profiling were performed in a standard procedure by Almac Dignostics, Inc. (Durham, NC).///scan_protocol: GeneChips were scanned using the Hewlett-Packard GeneArray Scanner G2500A.///description: S0456F057.CEL///description.1: Gene expression data from stage III-IV ovarian cancer patients///data_processing: Data normalization and quality control assessment of the hybridization results were performed with the RMA Bioconductor package (http://www.bioconductor.org)///platform_id: GPL570///contact_name: Youngchul,,Kim///contact_department: Public Health Sciences///contact_institute: University of Virginia///contact_address: University street///contact_city: Charlottesville///contact_state: VA///contact_zip.postal_code: 22903///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM746nnn/GSM746892/GSM746892.CEL.gz///data_row_count: 54675
1
title: OV_FFPE_33///geo_accession: GSM746893///status: Public on Aug 21 2012///submission_date: Jun 22 2011///last_update_date: Aug 21 2012///type: RNA///channel_count: 1///source_name_ch1: formalin-fixed paraffin embedded (FFPE) tissue, ovarian cancer cells///organism_ch1: Homo sapiens///characteristics_ch1: cell type: ovarian cancer cell///characteristics_ch1.1: age: 76///characteristics_ch1.2: dob: 1918-12-23///characteristics_ch1.3: race: White///characteristics_ch1.4: histo: Serous///characteristics_ch1.5: grade: Poor///characteristics_ch1.6: Stage: IIIC///characteristics_ch1.7: surgtype: Primary Surgery///characteristics_ch1.8: datedx: 1995-10-05///characteristics_ch1.9: surgdate: 1995-10-12///characteristics_ch1.10: optimal: Sub-optimal///characteristics_ch1.11: chemtype: Adjuvant///characteristics_ch1.12: chemoresponse: CR (completely response)///characteristics_ch1.13: chemo agent: Carboplatin/Taxol///characteristics_ch1.14: date.of.relapse: 1996-09-11///characteristics_ch1.15: date.last.follow.up: 1998-08-13///characteristics_ch1.16: st.categ: 4///characteristics_ch1.17: pfi days: 342///characteristics_ch1.18: relapse(1=yes, 0=no): 1///characteristics_ch1.19: overall survival days: 1043///characteristics_ch1.20: censoring(dead=1,alive=0): 1///molecule_ch1: total RNA///extract_protocol_ch1: RNA extraction and amplification was performed with the NuGen WT-Ovation FFPE RNA Amplification kit.///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Punches of FFPE tumor tissue blocks and gene expression profiling were performed in a standard procedure by Almac Dignostics, Inc. (Durham, NC).///scan_protocol: GeneChips were scanned using the Hewlett-Packard GeneArray Scanner G2500A.///description: S0456F058d.CEL///description.1: Gene expression data from stage III-IV ovarian cancer patients///data_processing: Data normalization and quality control assessment of the hybridization results were performed with the RMA Bioconductor package (http://www.bioconductor.org)///platform_id: GPL570///contact_name: Youngchul,,Kim///contact_department: Public Health Sciences///contact_institute: University of Virginia///contact_address: University street///contact_city: Charlottesville///contact_state: VA///contact_zip.postal_code: 22903///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM746nnn/GSM746893/GSM746893.CEL.gz///data_row_count: 54675
1
title: OV_FFPE_34///geo_accession: GSM746894///status: Public on Aug 21 2012///submission_date: Jun 22 2011///last_update_date: Aug 21 2012///type: RNA///channel_count: 1///source_name_ch1: formalin-fixed paraffin embedded (FFPE) tissue, ovarian cancer cells///organism_ch1: Homo sapiens///characteristics_ch1: cell type: ovarian cancer cell///characteristics_ch1.1: age: 84///characteristics_ch1.2: dob: 1918-11-04///characteristics_ch1.3: race: White///characteristics_ch1.4: histo: Clear///characteristics_ch1.5: grade: Unk///characteristics_ch1.6: Stage: IIIC///characteristics_ch1.7: surgtype: Primary Surgery///characteristics_ch1.8: datedx: 2002-02-19///characteristics_ch1.9: surgdate: 2002-02-19///characteristics_ch1.10: optimal: Optimal///characteristics_ch1.11: chemtype: Adjuvant///characteristics_ch1.12: chemoresponse: PR (partial response)///characteristics_ch1.13: chemo agent: Carboplatin/Taxol///characteristics_ch1.14: date.of.relapse: 2002-11-11///characteristics_ch1.15: date.last.follow.up: 2006-10-23///characteristics_ch1.16: st.categ: 2///characteristics_ch1.17: pfi days: 265///characteristics_ch1.18: relapse(1=yes, 0=no): 1///characteristics_ch1.19: overall survival days: 1707///characteristics_ch1.20: censoring(dead=1,alive=0): 0///molecule_ch1: total RNA///extract_protocol_ch1: RNA extraction and amplification was performed with the NuGen WT-Ovation FFPE RNA Amplification kit.///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Punches of FFPE tumor tissue blocks and gene expression profiling were performed in a standard procedure by Almac Dignostics, Inc. (Durham, NC).///scan_protocol: GeneChips were scanned using the Hewlett-Packard GeneArray Scanner G2500A.///description: S0456F059.CEL///description.1: Gene expression data from stage III-IV ovarian cancer patients///data_processing: Data normalization and quality control assessment of the hybridization results were performed with the RMA Bioconductor package (http://www.bioconductor.org)///platform_id: GPL570///contact_name: Youngchul,,Kim///contact_department: Public Health Sciences///contact_institute: University of Virginia///contact_address: University street///contact_city: Charlottesville///contact_state: VA///contact_zip.postal_code: 22903///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM746nnn/GSM746894/GSM746894.CEL.gz///data_row_count: 54675
1
title: OV_FFPE_35///geo_accession: GSM746895///status: Public on Aug 21 2012///submission_date: Jun 22 2011///last_update_date: Aug 21 2012///type: RNA///channel_count: 1///source_name_ch1: formalin-fixed paraffin embedded (FFPE) tissue, ovarian cancer cells///organism_ch1: Homo sapiens///characteristics_ch1: cell type: ovarian cancer cell///characteristics_ch1.1: age: 73///characteristics_ch1.2: dob: 1924-01-17///characteristics_ch1.3: race: Black///characteristics_ch1.4: histo: Serous///characteristics_ch1.5: grade: Poor///characteristics_ch1.6: Stage: IVA///characteristics_ch1.7: surgtype: Primary Surgery///characteristics_ch1.8: datedx: 1998-01-06///characteristics_ch1.9: surgdate: 1998-01-06///characteristics_ch1.10: optimal: Sub-optimal///characteristics_ch1.11: chemtype: Adjuvant///characteristics_ch1.12: chemoresponse: CR (completely response)///characteristics_ch1.13: chemo agent: Carboplatin/Taxol///characteristics_ch1.14: date.of.relapse: 1999-05-01///characteristics_ch1.15: date.last.follow.up: 2001-03-03///characteristics_ch1.16: st.categ: 4///characteristics_ch1.17: pfi days: 480///characteristics_ch1.18: relapse(1=yes, 0=no): 1///characteristics_ch1.19: overall survival days: 1152///characteristics_ch1.20: censoring(dead=1,alive=0): 1///molecule_ch1: total RNA///extract_protocol_ch1: RNA extraction and amplification was performed with the NuGen WT-Ovation FFPE RNA Amplification kit.///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Punches of FFPE tumor tissue blocks and gene expression profiling were performed in a standard procedure by Almac Dignostics, Inc. (Durham, NC).///scan_protocol: GeneChips were scanned using the Hewlett-Packard GeneArray Scanner G2500A.///description: S0456F060.CEL///description.1: Gene expression data from stage III-IV ovarian cancer patients///data_processing: Data normalization and quality control assessment of the hybridization results were performed with the RMA Bioconductor package (http://www.bioconductor.org)///platform_id: GPL570///contact_name: Youngchul,,Kim///contact_department: Public Health Sciences///contact_institute: University of Virginia///contact_address: University street///contact_city: Charlottesville///contact_state: VA///contact_zip.postal_code: 22903///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM746nnn/GSM746895/GSM746895.CEL.gz///data_row_count: 54675
1
title: OV_FFPE_36///geo_accession: GSM746896///status: Public on Aug 21 2012///submission_date: Jun 22 2011///last_update_date: Aug 21 2012///type: RNA///channel_count: 1///source_name_ch1: formalin-fixed paraffin embedded (FFPE) tissue, ovarian cancer cells///organism_ch1: Homo sapiens///characteristics_ch1: cell type: ovarian cancer cell///characteristics_ch1.1: age: 62///characteristics_ch1.2: dob: 1935-02-10///characteristics_ch1.3: race: White///characteristics_ch1.4: histo: Unknown///characteristics_ch1.5: grade: Poor///characteristics_ch1.6: Stage: IIIC///characteristics_ch1.7: surgtype: Primary Surgery///characteristics_ch1.8: datedx: 1997-04-08///characteristics_ch1.9: surgdate: 1997-04-08///characteristics_ch1.10: optimal: Sub-optimal///characteristics_ch1.11: chemtype: Adjuvant///characteristics_ch1.12: chemoresponse: CR (completely response)///characteristics_ch1.13: chemo agent: Carboplatin///characteristics_ch1.14: date.of.relapse: 1999-02-01///characteristics_ch1.15: date.last.follow.up: 2001-06-15///characteristics_ch1.16: st.categ: 4///characteristics_ch1.17: pfi days: 664///characteristics_ch1.18: relapse(1=yes, 0=no): 1///characteristics_ch1.19: overall survival days: 1529///characteristics_ch1.20: censoring(dead=1,alive=0): 1///molecule_ch1: total RNA///extract_protocol_ch1: RNA extraction and amplification was performed with the NuGen WT-Ovation FFPE RNA Amplification kit.///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Punches of FFPE tumor tissue blocks and gene expression profiling were performed in a standard procedure by Almac Dignostics, Inc. (Durham, NC).///scan_protocol: GeneChips were scanned using the Hewlett-Packard GeneArray Scanner G2500A.///description: S0456F061.CEL///description.1: Gene expression data from stage III-IV ovarian cancer patients///data_processing: Data normalization and quality control assessment of the hybridization results were performed with the RMA Bioconductor package (http://www.bioconductor.org)///platform_id: GPL570///contact_name: Youngchul,,Kim///contact_department: Public Health Sciences///contact_institute: University of Virginia///contact_address: University street///contact_city: Charlottesville///contact_state: VA///contact_zip.postal_code: 22903///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM746nnn/GSM746896/GSM746896.CEL.gz///data_row_count: 54675
1
title: OV_FFPE_37///geo_accession: GSM746897///status: Public on Aug 21 2012///submission_date: Jun 22 2011///last_update_date: Aug 21 2012///type: RNA///channel_count: 1///source_name_ch1: formalin-fixed paraffin embedded (FFPE) tissue, ovarian cancer cells///organism_ch1: Homo sapiens///characteristics_ch1: cell type: ovarian cancer cell///characteristics_ch1.1: age: 51///characteristics_ch1.2: dob: 1945-01-31///characteristics_ch1.3: race: White///characteristics_ch1.4: histo: Serous///characteristics_ch1.5: grade: Mod///characteristics_ch1.6: Stage: IIIB///characteristics_ch1.7: surgtype: Primary Surgery///characteristics_ch1.8: datedx: 1996-09-24///characteristics_ch1.9: surgdate: 1996-09-24///characteristics_ch1.10: optimal: Optimal///characteristics_ch1.11: chemtype: Adjuvant///characteristics_ch1.12: chemoresponse: CR (completely response)///characteristics_ch1.13: chemo agent: Cisplatin/Taxol///characteristics_ch1.14: date.last.follow.up: 2008-04-02///characteristics_ch1.15: st.categ: 1///characteristics_ch1.16: pfi days: 4208///characteristics_ch1.17: relapse(1=yes, 0=no): 0///characteristics_ch1.18: overall survival days: 4208///characteristics_ch1.19: censoring(dead=1,alive=0): 0///characteristics_ch1.20: ///molecule_ch1: total RNA///extract_protocol_ch1: RNA extraction and amplification was performed with the NuGen WT-Ovation FFPE RNA Amplification kit.///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Punches of FFPE tumor tissue blocks and gene expression profiling were performed in a standard procedure by Almac Dignostics, Inc. (Durham, NC).///scan_protocol: GeneChips were scanned using the Hewlett-Packard GeneArray Scanner G2500A.///description: S0456F062.CEL///description.1: Gene expression data from stage III-IV ovarian cancer patients///data_processing: Data normalization and quality control assessment of the hybridization results were performed with the RMA Bioconductor package (http://www.bioconductor.org)///platform_id: GPL570///contact_name: Youngchul,,Kim///contact_department: Public Health Sciences///contact_institute: University of Virginia///contact_address: University street///contact_city: Charlottesville///contact_state: VA///contact_zip.postal_code: 22903///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM746nnn/GSM746897/GSM746897.CEL.gz///data_row_count: 54675
1
title: OV_FFPE_38///geo_accession: GSM746898///status: Public on Aug 21 2012///submission_date: Jun 22 2011///last_update_date: Aug 21 2012///type: RNA///channel_count: 1///source_name_ch1: formalin-fixed paraffin embedded (FFPE) tissue, ovarian cancer cells///organism_ch1: Homo sapiens///characteristics_ch1: cell type: ovarian cancer cell///characteristics_ch1.1: age: 38///characteristics_ch1.2: dob: 1958-02-02///characteristics_ch1.3: race: White///characteristics_ch1.4: histo: Serous///characteristics_ch1.5: grade: Mod///characteristics_ch1.6: Stage: IIIC///characteristics_ch1.7: surgtype: Primary Surgery///characteristics_ch1.8: datedx: 1997-05-27///characteristics_ch1.9: surgdate: 1997-05-27///characteristics_ch1.10: optimal: Sub-optimal///characteristics_ch1.11: chemtype: Adjuvant///characteristics_ch1.12: chemoresponse: CR (completely response)///characteristics_ch1.13: chemo agent: Carboplatin/Cytoxan///characteristics_ch1.14: date.of.relapse: 1998-04-13///characteristics_ch1.15: date.last.follow.up: 1998-08-04///characteristics_ch1.16: st.categ: 4///characteristics_ch1.17: pfi days: 321///characteristics_ch1.18: relapse(1=yes, 0=no): 1///characteristics_ch1.19: overall survival days: 434///characteristics_ch1.20: censoring(dead=1,alive=0): 1///molecule_ch1: total RNA///extract_protocol_ch1: RNA extraction and amplification was performed with the NuGen WT-Ovation FFPE RNA Amplification kit.///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Punches of FFPE tumor tissue blocks and gene expression profiling were performed in a standard procedure by Almac Dignostics, Inc. (Durham, NC).///scan_protocol: GeneChips were scanned using the Hewlett-Packard GeneArray Scanner G2500A.///description: S0456F063.CEL///description.1: Gene expression data from stage III-IV ovarian cancer patients///data_processing: Data normalization and quality control assessment of the hybridization results were performed with the RMA Bioconductor package (http://www.bioconductor.org)///platform_id: GPL570///contact_name: Youngchul,,Kim///contact_department: Public Health Sciences///contact_institute: University of Virginia///contact_address: University street///contact_city: Charlottesville///contact_state: VA///contact_zip.postal_code: 22903///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM746nnn/GSM746898/GSM746898.CEL.gz///data_row_count: 54675
1
title: OV_FFPE_39///geo_accession: GSM746899///status: Public on Aug 21 2012///submission_date: Jun 22 2011///last_update_date: Aug 21 2012///type: RNA///channel_count: 1///source_name_ch1: formalin-fixed paraffin embedded (FFPE) tissue, ovarian cancer cells///organism_ch1: Homo sapiens///characteristics_ch1: cell type: ovarian cancer cell///characteristics_ch1.1: age: 49///characteristics_ch1.2: dob: 1948-09-09///characteristics_ch1.3: race: White///characteristics_ch1.4: histo: Serous///characteristics_ch1.5: grade: Poor///characteristics_ch1.6: Stage: IIIC///characteristics_ch1.7: surgtype: Primary Surgery///characteristics_ch1.8: datedx: 1998-01-27///characteristics_ch1.9: surgdate: 1998-01-27///characteristics_ch1.10: optimal: Optimal///characteristics_ch1.11: chemtype: Adjuvant///characteristics_ch1.12: chemoresponse: CR (completely response)///characteristics_ch1.13: chemo agent: Carboplatin/Taxol///characteristics_ch1.14: date.of.relapse: 1999-04-03///characteristics_ch1.15: date.last.follow.up: 2005-06-29///characteristics_ch1.16: st.categ: 2///characteristics_ch1.17: pfi days: 431///characteristics_ch1.18: relapse(1=yes, 0=no): 1///characteristics_ch1.19: overall survival days: 2710///characteristics_ch1.20: censoring(dead=1,alive=0): 0///molecule_ch1: total RNA///extract_protocol_ch1: RNA extraction and amplification was performed with the NuGen WT-Ovation FFPE RNA Amplification kit.///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Punches of FFPE tumor tissue blocks and gene expression profiling were performed in a standard procedure by Almac Dignostics, Inc. (Durham, NC).///scan_protocol: GeneChips were scanned using the Hewlett-Packard GeneArray Scanner G2500A.///description: S0456F064.CEL///description.1: Gene expression data from stage III-IV ovarian cancer patients///data_processing: Data normalization and quality control assessment of the hybridization results were performed with the RMA Bioconductor package (http://www.bioconductor.org)///platform_id: GPL570///contact_name: Youngchul,,Kim///contact_department: Public Health Sciences///contact_institute: University of Virginia///contact_address: University street///contact_city: Charlottesville///contact_state: VA///contact_zip.postal_code: 22903///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM746nnn/GSM746899/GSM746899.CEL.gz///data_row_count: 54675
1
title: OV_FFPE_3///geo_accession: GSM746863///status: Public on Aug 21 2012///submission_date: Jun 22 2011///last_update_date: Aug 21 2012///type: RNA///channel_count: 1///source_name_ch1: formalin-fixed paraffin embedded (FFPE) tissue, ovarian cancer cells///organism_ch1: Homo sapiens///characteristics_ch1: cell type: ovarian cancer cell///characteristics_ch1.1: age: 52///characteristics_ch1.2: dob: 1944-10-28///characteristics_ch1.3: race: White///characteristics_ch1.4: histo: Serous///characteristics_ch1.5: grade: Poor///characteristics_ch1.6: Stage: IIIC///characteristics_ch1.7: surgtype: Primary Surgery///characteristics_ch1.8: datedx: 1997-03-25///characteristics_ch1.9: surgdate: 1997-04-17///characteristics_ch1.10: optimal: Sub-optimal///characteristics_ch1.11: chemtype: Adjuvant///characteristics_ch1.12: chemoresponse: PR (partial response)///characteristics_ch1.13: chemo agent: Carboplatin/Taxol///characteristics_ch1.14: date.of.relapse: 1997-09-16///characteristics_ch1.15: date.last.follow.up: 1998-11-10///characteristics_ch1.16: st.categ: 4///characteristics_ch1.17: pfi days: 175///characteristics_ch1.18: relapse(1=yes, 0=no): 1///characteristics_ch1.19: overall survival days: 595///characteristics_ch1.20: censoring(dead=1,alive=0): 1///molecule_ch1: total RNA///extract_protocol_ch1: RNA extraction and amplification was performed with the NuGen WT-Ovation FFPE RNA Amplification kit.///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Punches of FFPE tumor tissue blocks and gene expression profiling were performed in a standard procedure by Almac Dignostics, Inc. (Durham, NC).///scan_protocol: GeneChips were scanned using the Hewlett-Packard GeneArray Scanner G2500A.///description: S0456F008.CEL///description.1: Gene expression data from stage III-IV ovarian cancer patients///data_processing: Data normalization and quality control assessment of the hybridization results were performed with the RMA Bioconductor package (http://www.bioconductor.org)///platform_id: GPL570///contact_name: Youngchul,,Kim///contact_department: Public Health Sciences///contact_institute: University of Virginia///contact_address: University street///contact_city: Charlottesville///contact_state: VA///contact_zip.postal_code: 22903///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM746nnn/GSM746863/GSM746863.CEL.gz///data_row_count: 54675
1
title: OV_FFPE_40///geo_accession: GSM746900///status: Public on Aug 21 2012///submission_date: Jun 22 2011///last_update_date: Aug 21 2012///type: RNA///channel_count: 1///source_name_ch1: formalin-fixed paraffin embedded (FFPE) tissue, ovarian cancer cells///organism_ch1: Homo sapiens///characteristics_ch1: cell type: ovarian cancer cell///characteristics_ch1.1: age: 55///characteristics_ch1.2: dob: 1943-11-30///characteristics_ch1.3: race: White///characteristics_ch1.4: histo: Serous///characteristics_ch1.5: grade: Poor///characteristics_ch1.6: Stage: IIIC///characteristics_ch1.7: surgtype: Primary Surgery///characteristics_ch1.8: datedx: 1998-04-23///characteristics_ch1.9: surgdate: 1998-04-23///characteristics_ch1.10: optimal: Optimal///characteristics_ch1.11: chemtype: Adjuvant///characteristics_ch1.12: chemoresponse: CR (completely response)///characteristics_ch1.13: chemo agent: Carboplatin/Taxol///characteristics_ch1.14: date.of.relapse: 2000-11-07///characteristics_ch1.15: date.last.follow.up: 2004-01-17///characteristics_ch1.16: st.categ: 3///characteristics_ch1.17: pfi days: 929///characteristics_ch1.18: relapse(1=yes, 0=no): 1///characteristics_ch1.19: overall survival days: 2095///characteristics_ch1.20: censoring(dead=1,alive=0): 1///molecule_ch1: total RNA///extract_protocol_ch1: RNA extraction and amplification was performed with the NuGen WT-Ovation FFPE RNA Amplification kit.///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Punches of FFPE tumor tissue blocks and gene expression profiling were performed in a standard procedure by Almac Dignostics, Inc. (Durham, NC).///scan_protocol: GeneChips were scanned using the Hewlett-Packard GeneArray Scanner G2500A.///description: S0456F065.CEL///description.1: Gene expression data from stage III-IV ovarian cancer patients///data_processing: Data normalization and quality control assessment of the hybridization results were performed with the RMA Bioconductor package (http://www.bioconductor.org)///platform_id: GPL570///contact_name: Youngchul,,Kim///contact_department: Public Health Sciences///contact_institute: University of Virginia///contact_address: University street///contact_city: Charlottesville///contact_state: VA///contact_zip.postal_code: 22903///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM746nnn/GSM746900/GSM746900.CEL.gz///data_row_count: 54675
1
title: OV_FFPE_41///geo_accession: GSM746901///status: Public on Aug 21 2012///submission_date: Jun 22 2011///last_update_date: Aug 21 2012///type: RNA///channel_count: 1///source_name_ch1: formalin-fixed paraffin embedded (FFPE) tissue, ovarian cancer cells///organism_ch1: Homo sapiens///characteristics_ch1: cell type: ovarian cancer cell///characteristics_ch1.1: age: 74///characteristics_ch1.2: dob: 1929-07-21///characteristics_ch1.3: race: White///characteristics_ch1.4: histo: Endometrioid///characteristics_ch1.5: grade: Poor///characteristics_ch1.6: Stage: IIIB///characteristics_ch1.7: surgtype: Primary Surgery///characteristics_ch1.8: datedx: 2002-01-10///characteristics_ch1.9: surgdate: 2002-01-10///characteristics_ch1.10: chemtype: Adjuvant///characteristics_ch1.11: chemoresponse: CR (completely response)///characteristics_ch1.12: chemo agent: Carboplatin/Taxol///characteristics_ch1.13: date.last.follow.up: 2002-05-15///characteristics_ch1.14: st.categ: 1///characteristics_ch1.15: pfi days: 125///characteristics_ch1.16: relapse(1=yes, 0=no): 0///characteristics_ch1.17: overall survival days: 125///characteristics_ch1.18: censoring(dead=1,alive=0): 0///characteristics_ch1.19: ///characteristics_ch1.20: ///molecule_ch1: total RNA///extract_protocol_ch1: RNA extraction and amplification was performed with the NuGen WT-Ovation FFPE RNA Amplification kit.///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Punches of FFPE tumor tissue blocks and gene expression profiling were performed in a standard procedure by Almac Dignostics, Inc. (Durham, NC).///scan_protocol: GeneChips were scanned using the Hewlett-Packard GeneArray Scanner G2500A.///description: S0456F069.CEL///description.1: Gene expression data from stage III-IV ovarian cancer patients///data_processing: Data normalization and quality control assessment of the hybridization results were performed with the RMA Bioconductor package (http://www.bioconductor.org)///platform_id: GPL570///contact_name: Youngchul,,Kim///contact_department: Public Health Sciences///contact_institute: University of Virginia///contact_address: University street///contact_city: Charlottesville///contact_state: VA///contact_zip.postal_code: 22903///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM746nnn/GSM746901/GSM746901.CEL.gz///data_row_count: 54675
1
title: OV_FFPE_42///geo_accession: GSM746902///status: Public on Aug 21 2012///submission_date: Jun 22 2011///last_update_date: Aug 21 2012///type: RNA///channel_count: 1///source_name_ch1: formalin-fixed paraffin embedded (FFPE) tissue, ovarian cancer cells///organism_ch1: Homo sapiens///characteristics_ch1: cell type: ovarian cancer cell///characteristics_ch1.1: age: 66///characteristics_ch1.2: dob: 1936-08-14///characteristics_ch1.3: race: White///characteristics_ch1.4: histo: Serous///characteristics_ch1.5: grade: Poor///characteristics_ch1.6: Stage: IIIC///characteristics_ch1.7: surgtype: Primary Surgery///characteristics_ch1.8: datedx: 2001-09-07///characteristics_ch1.9: surgdate: 2001-09-18///characteristics_ch1.10: optimal: Sub-optimal///characteristics_ch1.11: chemtype: Adjuvant///characteristics_ch1.12: chemoresponse: CR (completely response)///characteristics_ch1.13: chemo agent: Carboplatin/Taxol///characteristics_ch1.14: date.of.relapse: 2002-08-01///characteristics_ch1.15: date.last.follow.up: 2004-05-22///characteristics_ch1.16: st.categ: 2///characteristics_ch1.17: pfi days: 328///characteristics_ch1.18: relapse(1=yes, 0=no): 1///characteristics_ch1.19: overall survival days: 988///characteristics_ch1.20: censoring(dead=1,alive=0): 0///molecule_ch1: total RNA///extract_protocol_ch1: RNA extraction and amplification was performed with the NuGen WT-Ovation FFPE RNA Amplification kit.///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Punches of FFPE tumor tissue blocks and gene expression profiling were performed in a standard procedure by Almac Dignostics, Inc. (Durham, NC).///scan_protocol: GeneChips were scanned using the Hewlett-Packard GeneArray Scanner G2500A.///description: S0456F070.CEL///description.1: Gene expression data from stage III-IV ovarian cancer patients///data_processing: Data normalization and quality control assessment of the hybridization results were performed with the RMA Bioconductor package (http://www.bioconductor.org)///platform_id: GPL570///contact_name: Youngchul,,Kim///contact_department: Public Health Sciences///contact_institute: University of Virginia///contact_address: University street///contact_city: Charlottesville///contact_state: VA///contact_zip.postal_code: 22903///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM746nnn/GSM746902/GSM746902.CEL.gz///data_row_count: 54675
1
title: OV_FFPE_43///geo_accession: GSM746903///status: Public on Aug 21 2012///submission_date: Jun 22 2011///last_update_date: Aug 21 2012///type: RNA///channel_count: 1///source_name_ch1: formalin-fixed paraffin embedded (FFPE) tissue, ovarian cancer cells///organism_ch1: Homo sapiens///characteristics_ch1: cell type: ovarian cancer cell///characteristics_ch1.1: age: 53///characteristics_ch1.2: dob: 1943-05-10///characteristics_ch1.3: race: White///characteristics_ch1.4: histo: Serous///characteristics_ch1.5: grade: Well///characteristics_ch1.6: Stage: IIIA///characteristics_ch1.7: surgtype: Primary Surgery///characteristics_ch1.8: datedx: 1997-04-17///characteristics_ch1.9: surgdate: 1997-04-17///characteristics_ch1.10: optimal: Optimal///characteristics_ch1.11: chemtype: Adjuvant///characteristics_ch1.12: chemoresponse: CR (completely response)///characteristics_ch1.13: chemo agent: Carboplatin/Taxol///characteristics_ch1.14: date.last.follow.up: 2007-04-09///characteristics_ch1.15: st.categ: 1///characteristics_ch1.16: pfi days: 3644///characteristics_ch1.17: relapse(1=yes, 0=no): 0///characteristics_ch1.18: overall survival days: 3644///characteristics_ch1.19: censoring(dead=1,alive=0): 0///characteristics_ch1.20: ///molecule_ch1: total RNA///extract_protocol_ch1: RNA extraction and amplification was performed with the NuGen WT-Ovation FFPE RNA Amplification kit.///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Punches of FFPE tumor tissue blocks and gene expression profiling were performed in a standard procedure by Almac Dignostics, Inc. (Durham, NC).///scan_protocol: GeneChips were scanned using the Hewlett-Packard GeneArray Scanner G2500A.///description: S0456F072.CEL///description.1: Gene expression data from stage III-IV ovarian cancer patients///data_processing: Data normalization and quality control assessment of the hybridization results were performed with the RMA Bioconductor package (http://www.bioconductor.org)///platform_id: GPL570///contact_name: Youngchul,,Kim///contact_department: Public Health Sciences///contact_institute: University of Virginia///contact_address: University street///contact_city: Charlottesville///contact_state: VA///contact_zip.postal_code: 22903///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM746nnn/GSM746903/GSM746903.CEL.gz///data_row_count: 54675
1
title: OV_FFPE_44///geo_accession: GSM746904///status: Public on Aug 21 2012///submission_date: Jun 22 2011///last_update_date: Aug 21 2012///type: RNA///channel_count: 1///source_name_ch1: formalin-fixed paraffin embedded (FFPE) tissue, ovarian cancer cells///organism_ch1: Homo sapiens///characteristics_ch1: cell type: ovarian cancer cell///characteristics_ch1.1: age: 61///characteristics_ch1.2: dob: 1942-07-17///characteristics_ch1.3: race: White///characteristics_ch1.4: histo: Serous///characteristics_ch1.5: grade: Poor///characteristics_ch1.6: Stage: IIIC///characteristics_ch1.7: surgtype: Primary Surgery///characteristics_ch1.8: datedx: 2002-02-22///characteristics_ch1.9: surgdate: 2002-02-22///characteristics_ch1.10: optimal: Sub-optimal///characteristics_ch1.11: chemtype: Adjuvant///characteristics_ch1.12: chemoresponse: CR (completely response)///characteristics_ch1.13: chemo agent: Carboplatin/Taxol///characteristics_ch1.14: date.of.relapse: 2004-05-13///characteristics_ch1.15: date.last.follow.up: 2009-01-09///characteristics_ch1.16: st.categ: 2///characteristics_ch1.17: pfi days: 811///characteristics_ch1.18: relapse(1=yes, 0=no): 1///characteristics_ch1.19: overall survival days: 2513///characteristics_ch1.20: censoring(dead=1,alive=0): 0///molecule_ch1: total RNA///extract_protocol_ch1: RNA extraction and amplification was performed with the NuGen WT-Ovation FFPE RNA Amplification kit.///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Punches of FFPE tumor tissue blocks and gene expression profiling were performed in a standard procedure by Almac Dignostics, Inc. (Durham, NC).///scan_protocol: GeneChips were scanned using the Hewlett-Packard GeneArray Scanner G2500A.///description: S0456F074.CEL///description.1: Gene expression data from stage III-IV ovarian cancer patients///data_processing: Data normalization and quality control assessment of the hybridization results were performed with the RMA Bioconductor package (http://www.bioconductor.org)///platform_id: GPL570///contact_name: Youngchul,,Kim///contact_department: Public Health Sciences///contact_institute: University of Virginia///contact_address: University street///contact_city: Charlottesville///contact_state: VA///contact_zip.postal_code: 22903///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM746nnn/GSM746904/GSM746904.CEL.gz///data_row_count: 54675
1
title: OV_FFPE_45///geo_accession: GSM746905///status: Public on Aug 21 2012///submission_date: Jun 22 2011///last_update_date: Aug 21 2012///type: RNA///channel_count: 1///source_name_ch1: formalin-fixed paraffin embedded (FFPE) tissue, ovarian cancer cells///organism_ch1: Homo sapiens///characteristics_ch1: cell type: ovarian cancer cell///characteristics_ch1.1: age: 62///characteristics_ch1.2: dob: 1941-10-29///characteristics_ch1.3: race: White///characteristics_ch1.4: histo: Serous///characteristics_ch1.5: grade: Poor///characteristics_ch1.6: Stage: IIIC///characteristics_ch1.7: surgtype: Primary Surgery///characteristics_ch1.8: datedx: 1996-10-10///characteristics_ch1.9: surgdate: 1996-10-10///characteristics_ch1.10: optimal: Sub-optimal///characteristics_ch1.11: chemtype: Adjuvant///characteristics_ch1.12: chemoresponse: CR (completely response)///characteristics_ch1.13: chemo agent: Carboplatin/Taxol///characteristics_ch1.14: date.of.relapse: 1999-03-01///characteristics_ch1.15: date.last.follow.up: 2007-06-04///characteristics_ch1.16: st.categ: 2///characteristics_ch1.17: pfi days: 872///characteristics_ch1.18: relapse(1=yes, 0=no): 1///characteristics_ch1.19: overall survival days: 3889///characteristics_ch1.20: censoring(dead=1,alive=0): 0///molecule_ch1: total RNA///extract_protocol_ch1: RNA extraction and amplification was performed with the NuGen WT-Ovation FFPE RNA Amplification kit.///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Punches of FFPE tumor tissue blocks and gene expression profiling were performed in a standard procedure by Almac Dignostics, Inc. (Durham, NC).///scan_protocol: GeneChips were scanned using the Hewlett-Packard GeneArray Scanner G2500A.///description: S0456F076.CEL///description.1: Gene expression data from stage III-IV ovarian cancer patients///data_processing: Data normalization and quality control assessment of the hybridization results were performed with the RMA Bioconductor package (http://www.bioconductor.org)///platform_id: GPL570///contact_name: Youngchul,,Kim///contact_department: Public Health Sciences///contact_institute: University of Virginia///contact_address: University street///contact_city: Charlottesville///contact_state: VA///contact_zip.postal_code: 22903///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM746nnn/GSM746905/GSM746905.CEL.gz///data_row_count: 54675
1
title: OV_FFPE_46///geo_accession: GSM746906///status: Public on Aug 21 2012///submission_date: Jun 22 2011///last_update_date: Aug 21 2012///type: RNA///channel_count: 1///source_name_ch1: formalin-fixed paraffin embedded (FFPE) tissue, ovarian cancer cells///organism_ch1: Homo sapiens///characteristics_ch1: cell type: ovarian cancer cell///characteristics_ch1.1: age: 69///characteristics_ch1.2: dob: 1925-11-13///characteristics_ch1.3: race: White///characteristics_ch1.4: histo: Serous///characteristics_ch1.5: grade: Mod///characteristics_ch1.6: Stage: IIIC///characteristics_ch1.7: surgtype: Primary Surgery///characteristics_ch1.8: datedx: 1995-09-19///characteristics_ch1.9: surgdate: 1995-09-26///characteristics_ch1.10: optimal: Sub-optimal///characteristics_ch1.11: chemtype: Adjuvant///characteristics_ch1.12: chemoresponse: PR (partial response)///characteristics_ch1.13: chemo agent: Carboplatin/Taxol///characteristics_ch1.14: date.of.relapse: 1997-12-01///characteristics_ch1.15: date.last.follow.up: 2001-11-17///characteristics_ch1.16: st.categ: 4///characteristics_ch1.17: pfi days: 804///characteristics_ch1.18: relapse(1=yes, 0=no): 1///characteristics_ch1.19: overall survival days: 2251///characteristics_ch1.20: censoring(dead=1,alive=0): 1///molecule_ch1: total RNA///extract_protocol_ch1: RNA extraction and amplification was performed with the NuGen WT-Ovation FFPE RNA Amplification kit.///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Punches of FFPE tumor tissue blocks and gene expression profiling were performed in a standard procedure by Almac Dignostics, Inc. (Durham, NC).///scan_protocol: GeneChips were scanned using the Hewlett-Packard GeneArray Scanner G2500A.///description: S0456F081.CEL///description.1: Gene expression data from stage III-IV ovarian cancer patients///data_processing: Data normalization and quality control assessment of the hybridization results were performed with the RMA Bioconductor package (http://www.bioconductor.org)///platform_id: GPL570///contact_name: Youngchul,,Kim///contact_department: Public Health Sciences///contact_institute: University of Virginia///contact_address: University street///contact_city: Charlottesville///contact_state: VA///contact_zip.postal_code: 22903///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM746nnn/GSM746906/GSM746906.CEL.gz///data_row_count: 54675
1
title: OV_FFPE_47///geo_accession: GSM746907///status: Public on Aug 21 2012///submission_date: Jun 22 2011///last_update_date: Aug 21 2012///type: RNA///channel_count: 1///source_name_ch1: formalin-fixed paraffin embedded (FFPE) tissue, ovarian cancer cells///organism_ch1: Homo sapiens///characteristics_ch1: cell type: ovarian cancer cell///characteristics_ch1.1: age: 70///characteristics_ch1.2: dob: 1925-04-20///characteristics_ch1.3: race: White///characteristics_ch1.4: histo: Serous///characteristics_ch1.5: grade: Mod///characteristics_ch1.6: Stage: IIIB///characteristics_ch1.7: surgtype: Primary Surgery///characteristics_ch1.8: datedx: 1995-08-08///characteristics_ch1.9: surgdate: 1995-08-08///characteristics_ch1.10: optimal: Sub-optimal///characteristics_ch1.11: chemtype: Adjuvant///characteristics_ch1.12: chemoresponse: PR (partial response)///characteristics_ch1.13: chemo agent: Carboplatin/Taxol///characteristics_ch1.14: date.of.relapse: 1997-03-10///characteristics_ch1.15: date.last.follow.up: 2003-04-03///characteristics_ch1.16: st.categ: 6///characteristics_ch1.17: pfi days: 580///characteristics_ch1.18: relapse(1=yes, 0=no): 1///characteristics_ch1.19: overall survival days: 2795///characteristics_ch1.20: censoring(dead=1,alive=0): 1///molecule_ch1: total RNA///extract_protocol_ch1: RNA extraction and amplification was performed with the NuGen WT-Ovation FFPE RNA Amplification kit.///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Punches of FFPE tumor tissue blocks and gene expression profiling were performed in a standard procedure by Almac Dignostics, Inc. (Durham, NC).///scan_protocol: GeneChips were scanned using the Hewlett-Packard GeneArray Scanner G2500A.///description: S0456F082.CEL///description.1: Gene expression data from stage III-IV ovarian cancer patients///data_processing: Data normalization and quality control assessment of the hybridization results were performed with the RMA Bioconductor package (http://www.bioconductor.org)///platform_id: GPL570///contact_name: Youngchul,,Kim///contact_department: Public Health Sciences///contact_institute: University of Virginia///contact_address: University street///contact_city: Charlottesville///contact_state: VA///contact_zip.postal_code: 22903///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM746nnn/GSM746907/GSM746907.CEL.gz///data_row_count: 54675
1
title: OV_FFPE_48///geo_accession: GSM746908///status: Public on Aug 21 2012///submission_date: Jun 22 2011///last_update_date: Aug 21 2012///type: RNA///channel_count: 1///source_name_ch1: formalin-fixed paraffin embedded (FFPE) tissue, ovarian cancer cells///organism_ch1: Homo sapiens///characteristics_ch1: cell type: ovarian cancer cell///characteristics_ch1.1: age: 64///characteristics_ch1.2: dob: 1939-04-18///characteristics_ch1.3: race: Black///characteristics_ch1.4: histo: Serous///characteristics_ch1.5: grade: Poor///characteristics_ch1.6: Stage: IVA///characteristics_ch1.7: surgtype: Primary Surgery///characteristics_ch1.8: datedx: 2002-04-09///characteristics_ch1.9: surgdate: 2002-04-09///characteristics_ch1.10: chemtype: Adjuvant///characteristics_ch1.11: chemoresponse: PR (partial response)///characteristics_ch1.12: chemo agent: Carboplatin/Taxol///characteristics_ch1.13: date.of.relapse: 2003-02-01///characteristics_ch1.14: date.last.follow.up: 2004-04-20///characteristics_ch1.15: st.categ: 4///characteristics_ch1.16: pfi days: 298///characteristics_ch1.17: relapse(1=yes, 0=no): 1///characteristics_ch1.18: overall survival days: 742///characteristics_ch1.19: censoring(dead=1,alive=0): 1///characteristics_ch1.20: ///molecule_ch1: total RNA///extract_protocol_ch1: RNA extraction and amplification was performed with the NuGen WT-Ovation FFPE RNA Amplification kit.///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Punches of FFPE tumor tissue blocks and gene expression profiling were performed in a standard procedure by Almac Dignostics, Inc. (Durham, NC).///scan_protocol: GeneChips were scanned using the Hewlett-Packard GeneArray Scanner G2500A.///description: S0456F083.CEL///description.1: Gene expression data from stage III-IV ovarian cancer patients///data_processing: Data normalization and quality control assessment of the hybridization results were performed with the RMA Bioconductor package (http://www.bioconductor.org)///platform_id: GPL570///contact_name: Youngchul,,Kim///contact_department: Public Health Sciences///contact_institute: University of Virginia///contact_address: University street///contact_city: Charlottesville///contact_state: VA///contact_zip.postal_code: 22903///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM746nnn/GSM746908/GSM746908.CEL.gz///data_row_count: 54675
1
title: OV_FFPE_49///geo_accession: GSM746909///status: Public on Aug 21 2012///submission_date: Jun 22 2011///last_update_date: Aug 21 2012///type: RNA///channel_count: 1///source_name_ch1: formalin-fixed paraffin embedded (FFPE) tissue, ovarian cancer cells///organism_ch1: Homo sapiens///characteristics_ch1: cell type: ovarian cancer cell///characteristics_ch1.1: age: 66///characteristics_ch1.2: dob: 1932-01-12///characteristics_ch1.3: race: White///characteristics_ch1.4: histo: Mucinous///characteristics_ch1.5: grade: Mod///characteristics_ch1.6: Stage: IIIC///characteristics_ch1.7: surgtype: Primary Surgery///characteristics_ch1.8: datedx: 1998-01-20///characteristics_ch1.9: surgdate: 1998-01-20///characteristics_ch1.10: optimal: Sub-optimal///characteristics_ch1.11: chemtype: Adjuvant///characteristics_ch1.12: chemoresponse: PR (partial response)///characteristics_ch1.13: chemo agent: Carboplatin/Taxol///characteristics_ch1.14: date.of.relapse: 1998-02-01///characteristics_ch1.15: date.last.follow.up: 1998-04-24///characteristics_ch1.16: st.categ: 4///characteristics_ch1.17: pfi days: 12///characteristics_ch1.18: relapse(1=yes, 0=no): 1///characteristics_ch1.19: overall survival days: 94///characteristics_ch1.20: censoring(dead=1,alive=0): 1///molecule_ch1: total RNA///extract_protocol_ch1: RNA extraction and amplification was performed with the NuGen WT-Ovation FFPE RNA Amplification kit.///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Punches of FFPE tumor tissue blocks and gene expression profiling were performed in a standard procedure by Almac Dignostics, Inc. (Durham, NC).///scan_protocol: GeneChips were scanned using the Hewlett-Packard GeneArray Scanner G2500A.///description: S0456F087.CEL///description.1: Gene expression data from stage III-IV ovarian cancer patients///data_processing: Data normalization and quality control assessment of the hybridization results were performed with the RMA Bioconductor package (http://www.bioconductor.org)///platform_id: GPL570///contact_name: Youngchul,,Kim///contact_department: Public Health Sciences///contact_institute: University of Virginia///contact_address: University street///contact_city: Charlottesville///contact_state: VA///contact_zip.postal_code: 22903///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM746nnn/GSM746909/GSM746909.CEL.gz///data_row_count: 54675
1
title: OV_FFPE_4///geo_accession: GSM746864///status: Public on Aug 21 2012///submission_date: Jun 22 2011///last_update_date: Aug 21 2012///type: RNA///channel_count: 1///source_name_ch1: formalin-fixed paraffin embedded (FFPE) tissue, ovarian cancer cells///organism_ch1: Homo sapiens///characteristics_ch1: cell type: ovarian cancer cell///characteristics_ch1.1: age: 47///characteristics_ch1.2: dob: 1950-05-11///characteristics_ch1.3: race: White///characteristics_ch1.4: histo: Serous///characteristics_ch1.5: grade: Mod///characteristics_ch1.6: Stage: IIIC///characteristics_ch1.7: surgtype: Primary Surgery///characteristics_ch1.8: datedx: 1997-10-21///characteristics_ch1.9: surgdate: 1997-10-21///characteristics_ch1.10: optimal: Optimal///characteristics_ch1.11: chemtype: Adjuvant///characteristics_ch1.12: chemoresponse: PR (partial response)///characteristics_ch1.13: chemo agent: Carboplatin/Taxol///characteristics_ch1.14: date.of.relapse: 1998-04-01///characteristics_ch1.15: date.last.follow.up: 1998-11-02///characteristics_ch1.16: st.categ: 4///characteristics_ch1.17: pfi days: 162///characteristics_ch1.18: relapse(1=yes, 0=no): 1///characteristics_ch1.19: overall survival days: 377///characteristics_ch1.20: censoring(dead=1,alive=0): 1///molecule_ch1: total RNA///extract_protocol_ch1: RNA extraction and amplification was performed with the NuGen WT-Ovation FFPE RNA Amplification kit.///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Punches of FFPE tumor tissue blocks and gene expression profiling were performed in a standard procedure by Almac Dignostics, Inc. (Durham, NC).///scan_protocol: GeneChips were scanned using the Hewlett-Packard GeneArray Scanner G2500A.///description: S0456F009.CEL///description.1: Gene expression data from stage III-IV ovarian cancer patients///data_processing: Data normalization and quality control assessment of the hybridization results were performed with the RMA Bioconductor package (http://www.bioconductor.org)///platform_id: GPL570///contact_name: Youngchul,,Kim///contact_department: Public Health Sciences///contact_institute: University of Virginia///contact_address: University street///contact_city: Charlottesville///contact_state: VA///contact_zip.postal_code: 22903///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM746nnn/GSM746864/GSM746864.CEL.gz///data_row_count: 54675
1
title: OV_FFPE_50///geo_accession: GSM746910///status: Public on Aug 21 2012///submission_date: Jun 22 2011///last_update_date: Aug 21 2012///type: RNA///channel_count: 1///source_name_ch1: formalin-fixed paraffin embedded (FFPE) tissue, ovarian cancer cells///organism_ch1: Homo sapiens///characteristics_ch1: cell type: ovarian cancer cell///characteristics_ch1.1: age: 60///characteristics_ch1.2: dob: 1938-05-27///characteristics_ch1.3: race: White///characteristics_ch1.4: histo: Serous///characteristics_ch1.5: grade: Unk///characteristics_ch1.6: Stage: IIIB///characteristics_ch1.7: surgtype: Primary Surgery///characteristics_ch1.8: datedx: 1998-11-18///characteristics_ch1.9: surgdate: 1998-11-18///characteristics_ch1.10: optimal: Sub-optimal///characteristics_ch1.11: chemtype: Adjuvant///characteristics_ch1.12: chemoresponse: PR (partial response)///characteristics_ch1.13: chemo agent: Carboplatin/Taxol///characteristics_ch1.14: date.of.relapse: 1999-08-27///characteristics_ch1.15: date.last.follow.up: 2000-08-06///characteristics_ch1.16: st.categ: 4///characteristics_ch1.17: pfi days: 282///characteristics_ch1.18: relapse(1=yes, 0=no): 1///characteristics_ch1.19: overall survival days: 627///characteristics_ch1.20: censoring(dead=1,alive=0): 1///molecule_ch1: total RNA///extract_protocol_ch1: RNA extraction and amplification was performed with the NuGen WT-Ovation FFPE RNA Amplification kit.///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Punches of FFPE tumor tissue blocks and gene expression profiling were performed in a standard procedure by Almac Dignostics, Inc. (Durham, NC).///scan_protocol: GeneChips were scanned using the Hewlett-Packard GeneArray Scanner G2500A.///description: S0456F088.CEL///description.1: Gene expression data from stage III-IV ovarian cancer patients///data_processing: Data normalization and quality control assessment of the hybridization results were performed with the RMA Bioconductor package (http://www.bioconductor.org)///platform_id: GPL570///contact_name: Youngchul,,Kim///contact_department: Public Health Sciences///contact_institute: University of Virginia///contact_address: University street///contact_city: Charlottesville///contact_state: VA///contact_zip.postal_code: 22903///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM746nnn/GSM746910/GSM746910.CEL.gz///data_row_count: 54675
1
title: OV_FFPE_51///geo_accession: GSM746911///status: Public on Aug 21 2012///submission_date: Jun 22 2011///last_update_date: Aug 21 2012///type: RNA///channel_count: 1///source_name_ch1: formalin-fixed paraffin embedded (FFPE) tissue, ovarian cancer cells///organism_ch1: Homo sapiens///characteristics_ch1: cell type: ovarian cancer cell///characteristics_ch1.1: age: 59///characteristics_ch1.2: dob: 1936-04-23///characteristics_ch1.3: race: White///characteristics_ch1.4: histo: Serous///characteristics_ch1.5: grade: Mod///characteristics_ch1.6: Stage: IIIC///characteristics_ch1.7: surgtype: Primary Surgery///characteristics_ch1.8: datedx: 1996-01-25///characteristics_ch1.9: surgdate: 1996-01-30///characteristics_ch1.10: optimal: Sub-optimal///characteristics_ch1.11: chemtype: Adjuvant///characteristics_ch1.12: chemoresponse: PR (partial response)///characteristics_ch1.13: chemo agent: Cisplatin/Taxol///characteristics_ch1.14: date.of.relapse: 1996-08-30///characteristics_ch1.15: date.last.follow.up: 1996-12-08///characteristics_ch1.16: st.categ: 4///characteristics_ch1.17: pfi days: 218///characteristics_ch1.18: relapse(1=yes, 0=no): 1///characteristics_ch1.19: overall survival days: 318///characteristics_ch1.20: censoring(dead=1,alive=0): 1///molecule_ch1: total RNA///extract_protocol_ch1: RNA extraction and amplification was performed with the NuGen WT-Ovation FFPE RNA Amplification kit.///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Punches of FFPE tumor tissue blocks and gene expression profiling were performed in a standard procedure by Almac Dignostics, Inc. (Durham, NC).///scan_protocol: GeneChips were scanned using the Hewlett-Packard GeneArray Scanner G2500A.///description: S0456F090.CEL///description.1: Gene expression data from stage III-IV ovarian cancer patients///data_processing: Data normalization and quality control assessment of the hybridization results were performed with the RMA Bioconductor package (http://www.bioconductor.org)///platform_id: GPL570///contact_name: Youngchul,,Kim///contact_department: Public Health Sciences///contact_institute: University of Virginia///contact_address: University street///contact_city: Charlottesville///contact_state: VA///contact_zip.postal_code: 22903///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM746nnn/GSM746911/GSM746911.CEL.gz///data_row_count: 54675
1
title: OV_FFPE_52///geo_accession: GSM746912///status: Public on Aug 21 2012///submission_date: Jun 22 2011///last_update_date: Aug 21 2012///type: RNA///channel_count: 1///source_name_ch1: formalin-fixed paraffin embedded (FFPE) tissue, ovarian cancer cells///organism_ch1: Homo sapiens///characteristics_ch1: cell type: ovarian cancer cell///characteristics_ch1.1: age: 72///characteristics_ch1.2: dob: 1925-12-29///characteristics_ch1.3: race: White///characteristics_ch1.4: histo: Serous///characteristics_ch1.5: grade: Mod///characteristics_ch1.6: Stage: IIIC///characteristics_ch1.7: surgtype: Primary Surgery///characteristics_ch1.8: datedx: 1998-10-21///characteristics_ch1.9: surgdate: 1998-10-21///characteristics_ch1.10: optimal: Sub-optimal///characteristics_ch1.11: chemtype: Adjuvant///characteristics_ch1.12: chemoresponse: PR (partial response)///characteristics_ch1.13: chemo agent: Cisplatin/Taxol///characteristics_ch1.14: date.of.relapse: 1999-02-12///characteristics_ch1.15: date.last.follow.up: 2001-06-20///characteristics_ch1.16: st.categ: 2///characteristics_ch1.17: pfi days: 114///characteristics_ch1.18: relapse(1=yes, 0=no): 1///characteristics_ch1.19: overall survival days: 973///characteristics_ch1.20: censoring(dead=1,alive=0): 0///molecule_ch1: total RNA///extract_protocol_ch1: RNA extraction and amplification was performed with the NuGen WT-Ovation FFPE RNA Amplification kit.///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Punches of FFPE tumor tissue blocks and gene expression profiling were performed in a standard procedure by Almac Dignostics, Inc. (Durham, NC).///scan_protocol: GeneChips were scanned using the Hewlett-Packard GeneArray Scanner G2500A.///description: S0456F092.CEL///description.1: Gene expression data from stage III-IV ovarian cancer patients///data_processing: Data normalization and quality control assessment of the hybridization results were performed with the RMA Bioconductor package (http://www.bioconductor.org)///platform_id: GPL570///contact_name: Youngchul,,Kim///contact_department: Public Health Sciences///contact_institute: University of Virginia///contact_address: University street///contact_city: Charlottesville///contact_state: VA///contact_zip.postal_code: 22903///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM746nnn/GSM746912/GSM746912.CEL.gz///data_row_count: 54675
1
title: OV_FFPE_53///geo_accession: GSM746913///status: Public on Aug 21 2012///submission_date: Jun 22 2011///last_update_date: Aug 21 2012///type: RNA///channel_count: 1///source_name_ch1: formalin-fixed paraffin embedded (FFPE) tissue, ovarian cancer cells///organism_ch1: Homo sapiens///characteristics_ch1: cell type: ovarian cancer cell///characteristics_ch1.1: age: 52///characteristics_ch1.2: dob: 1943-08-27///characteristics_ch1.3: race: White///characteristics_ch1.4: histo: Serous///characteristics_ch1.5: grade: Poor///characteristics_ch1.6: Stage: IIIB///characteristics_ch1.7: surgtype: Primary Surgery///characteristics_ch1.8: datedx: 1996-03-12///characteristics_ch1.9: surgdate: 1996-03-12///characteristics_ch1.10: optimal: Optimal///characteristics_ch1.11: chemtype: Adjuvant///characteristics_ch1.12: chemoresponse: CR (completely response)///characteristics_ch1.13: chemo agent: Carboplatin/Taxol///characteristics_ch1.14: date.of.relapse: 1997-09-29///characteristics_ch1.15: date.last.follow.up: 1999-01-07///characteristics_ch1.16: st.categ: 4///characteristics_ch1.17: pfi days: 566///characteristics_ch1.18: relapse(1=yes, 0=no): 1///characteristics_ch1.19: overall survival days: 1031///characteristics_ch1.20: censoring(dead=1,alive=0): 1///molecule_ch1: total RNA///extract_protocol_ch1: RNA extraction and amplification was performed with the NuGen WT-Ovation FFPE RNA Amplification kit.///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Punches of FFPE tumor tissue blocks and gene expression profiling were performed in a standard procedure by Almac Dignostics, Inc. (Durham, NC).///scan_protocol: GeneChips were scanned using the Hewlett-Packard GeneArray Scanner G2500A.///description: S0456F093.CEL///description.1: Gene expression data from stage III-IV ovarian cancer patients///data_processing: Data normalization and quality control assessment of the hybridization results were performed with the RMA Bioconductor package (http://www.bioconductor.org)///platform_id: GPL570///contact_name: Youngchul,,Kim///contact_department: Public Health Sciences///contact_institute: University of Virginia///contact_address: University street///contact_city: Charlottesville///contact_state: VA///contact_zip.postal_code: 22903///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM746nnn/GSM746913/GSM746913.CEL.gz///data_row_count: 54675
1
title: OV_FFPE_54///geo_accession: GSM746914///status: Public on Aug 21 2012///submission_date: Jun 22 2011///last_update_date: Aug 21 2012///type: RNA///channel_count: 1///source_name_ch1: formalin-fixed paraffin embedded (FFPE) tissue, ovarian cancer cells///organism_ch1: Homo sapiens///characteristics_ch1: cell type: ovarian cancer cell///characteristics_ch1.1: age: 51///characteristics_ch1.2: dob: 1952-06-04///characteristics_ch1.3: race: White///characteristics_ch1.4: histo: Serous///characteristics_ch1.5: grade: Poor///characteristics_ch1.6: Stage: IIIC///characteristics_ch1.7: surgtype: Primary Surgery///characteristics_ch1.8: datedx: 2002-07-05///characteristics_ch1.9: surgdate: 2002-07-05///characteristics_ch1.10: optimal: Optimal///characteristics_ch1.11: chemtype: Adjuvant///characteristics_ch1.12: chemoresponse: CR (completely response)///characteristics_ch1.13: chemo agent: Carboplatin/Taxol///characteristics_ch1.14: date.of.relapse: 2004-09-15///characteristics_ch1.15: date.last.follow.up: 2006-08-14///characteristics_ch1.16: st.categ: 4///characteristics_ch1.17: pfi days: 803///characteristics_ch1.18: relapse(1=yes, 0=no): 1///characteristics_ch1.19: overall survival days: 1501///characteristics_ch1.20: censoring(dead=1,alive=0): 1///molecule_ch1: total RNA///extract_protocol_ch1: RNA extraction and amplification was performed with the NuGen WT-Ovation FFPE RNA Amplification kit.///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Punches of FFPE tumor tissue blocks and gene expression profiling were performed in a standard procedure by Almac Dignostics, Inc. (Durham, NC).///scan_protocol: GeneChips were scanned using the Hewlett-Packard GeneArray Scanner G2500A.///description: S0456F095.CEL///description.1: Gene expression data from stage III-IV ovarian cancer patients///data_processing: Data normalization and quality control assessment of the hybridization results were performed with the RMA Bioconductor package (http://www.bioconductor.org)///platform_id: GPL570///contact_name: Youngchul,,Kim///contact_department: Public Health Sciences///contact_institute: University of Virginia///contact_address: University street///contact_city: Charlottesville///contact_state: VA///contact_zip.postal_code: 22903///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM746nnn/GSM746914/GSM746914.CEL.gz///data_row_count: 54675
1
title: OV_FFPE_55///geo_accession: GSM746915///status: Public on Aug 21 2012///submission_date: Jun 22 2011///last_update_date: Aug 21 2012///type: RNA///channel_count: 1///source_name_ch1: formalin-fixed paraffin embedded (FFPE) tissue, ovarian cancer cells///organism_ch1: Homo sapiens///characteristics_ch1: cell type: ovarian cancer cell///characteristics_ch1.1: age: 56///characteristics_ch1.2: dob: 1947-02-10///characteristics_ch1.3: race: White///characteristics_ch1.4: histo: Serous///characteristics_ch1.5: grade: Mod///characteristics_ch1.6: Stage: IIIC///characteristics_ch1.7: surgtype: Primary Surgery///characteristics_ch1.8: datedx: 2002-07-10///characteristics_ch1.9: surgdate: 2002-07-10///characteristics_ch1.10: optimal: Optimal///characteristics_ch1.11: chemtype: Adjuvant///characteristics_ch1.12: chemoresponse: CR (completely response)///characteristics_ch1.13: chemo agent: Carboplatin/Taxol///characteristics_ch1.14: date.of.relapse: 2003-04-01///characteristics_ch1.15: date.last.follow.up: 2007-07-30///characteristics_ch1.16: st.categ: 4///characteristics_ch1.17: pfi days: 265///characteristics_ch1.18: relapse(1=yes, 0=no): 1///characteristics_ch1.19: overall survival days: 1846///characteristics_ch1.20: censoring(dead=1,alive=0): 1///molecule_ch1: total RNA///extract_protocol_ch1: RNA extraction and amplification was performed with the NuGen WT-Ovation FFPE RNA Amplification kit.///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Punches of FFPE tumor tissue blocks and gene expression profiling were performed in a standard procedure by Almac Dignostics, Inc. (Durham, NC).///scan_protocol: GeneChips were scanned using the Hewlett-Packard GeneArray Scanner G2500A.///description: S0456F096.CEL///description.1: Gene expression data from stage III-IV ovarian cancer patients///data_processing: Data normalization and quality control assessment of the hybridization results were performed with the RMA Bioconductor package (http://www.bioconductor.org)///platform_id: GPL570///contact_name: Youngchul,,Kim///contact_department: Public Health Sciences///contact_institute: University of Virginia///contact_address: University street///contact_city: Charlottesville///contact_state: VA///contact_zip.postal_code: 22903///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM746nnn/GSM746915/GSM746915.CEL.gz///data_row_count: 54675
1
title: OV_FFPE_56///geo_accession: GSM746916///status: Public on Aug 21 2012///submission_date: Jun 22 2011///last_update_date: Aug 21 2012///type: RNA///channel_count: 1///source_name_ch1: formalin-fixed paraffin embedded (FFPE) tissue, ovarian cancer cells///organism_ch1: Homo sapiens///characteristics_ch1: cell type: ovarian cancer cell///characteristics_ch1.1: age: 44///characteristics_ch1.2: dob: 1952-02-16///characteristics_ch1.3: race: White///characteristics_ch1.4: histo: Serous///characteristics_ch1.5: grade: Poor///characteristics_ch1.6: Stage: IIIC///characteristics_ch1.7: surgtype: Primary Surgery///characteristics_ch1.8: datedx: 1997-02-11///characteristics_ch1.9: surgdate: 1997-02-11///characteristics_ch1.10: optimal: Sub-optimal///characteristics_ch1.11: chemtype: Adjuvant///characteristics_ch1.12: chemoresponse: CR (completely response)///characteristics_ch1.13: chemo agent: Carboplatin/Taxol///characteristics_ch1.14: date.of.relapse: 1998-03-25///characteristics_ch1.15: date.last.follow.up: 1998-09-16///characteristics_ch1.16: st.categ: 4///characteristics_ch1.17: pfi days: 407///characteristics_ch1.18: relapse(1=yes, 0=no): 1///characteristics_ch1.19: overall survival days: 582///characteristics_ch1.20: censoring(dead=1,alive=0): 1///molecule_ch1: total RNA///extract_protocol_ch1: RNA extraction and amplification was performed with the NuGen WT-Ovation FFPE RNA Amplification kit.///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Punches of FFPE tumor tissue blocks and gene expression profiling were performed in a standard procedure by Almac Dignostics, Inc. (Durham, NC).///scan_protocol: GeneChips were scanned using the Hewlett-Packard GeneArray Scanner G2500A.///description: S0456F098.CEL///description.1: Gene expression data from stage III-IV ovarian cancer patients///data_processing: Data normalization and quality control assessment of the hybridization results were performed with the RMA Bioconductor package (http://www.bioconductor.org)///platform_id: GPL570///contact_name: Youngchul,,Kim///contact_department: Public Health Sciences///contact_institute: University of Virginia///contact_address: University street///contact_city: Charlottesville///contact_state: VA///contact_zip.postal_code: 22903///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM746nnn/GSM746916/GSM746916.CEL.gz///data_row_count: 54675
1
title: OV_FFPE_57///geo_accession: GSM746917///status: Public on Aug 21 2012///submission_date: Jun 22 2011///last_update_date: Aug 21 2012///type: RNA///channel_count: 1///source_name_ch1: formalin-fixed paraffin embedded (FFPE) tissue, ovarian cancer cells///organism_ch1: Homo sapiens///characteristics_ch1: cell type: ovarian cancer cell///characteristics_ch1.1: age: 61///characteristics_ch1.2: dob: 1941-12-14///characteristics_ch1.3: race: White///characteristics_ch1.4: histo: Unknown///characteristics_ch1.5: grade: Poor///characteristics_ch1.6: Stage: IIIC///characteristics_ch1.7: surgtype: Primary Surgery///characteristics_ch1.8: datedx: 2002-01-31///characteristics_ch1.9: surgdate: 2002-01-31///characteristics_ch1.10: optimal: Optimal///characteristics_ch1.11: chemtype: Adjuvant///characteristics_ch1.12: chemoresponse: Unknown///characteristics_ch1.13: chemo agent: Carboplatin/Taxol///characteristics_ch1.14: date.last.follow.up: 2002-08-27///characteristics_ch1.15: st.categ: 1///characteristics_ch1.16: pfi days: 208///characteristics_ch1.17: relapse(1=yes, 0=no): UNKnown///characteristics_ch1.18: overall survival days: 208///characteristics_ch1.19: censoring(dead=1,alive=0): 0///characteristics_ch1.20: ///molecule_ch1: total RNA///extract_protocol_ch1: RNA extraction and amplification was performed with the NuGen WT-Ovation FFPE RNA Amplification kit.///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Punches of FFPE tumor tissue blocks and gene expression profiling were performed in a standard procedure by Almac Dignostics, Inc. (Durham, NC).///scan_protocol: GeneChips were scanned using the Hewlett-Packard GeneArray Scanner G2500A.///description: S0456F099.CEL///description.1: Gene expression data from stage III-IV ovarian cancer patients///data_processing: Data normalization and quality control assessment of the hybridization results were performed with the RMA Bioconductor package (http://www.bioconductor.org)///platform_id: GPL570///contact_name: Youngchul,,Kim///contact_department: Public Health Sciences///contact_institute: University of Virginia///contact_address: University street///contact_city: Charlottesville///contact_state: VA///contact_zip.postal_code: 22903///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM746nnn/GSM746917/GSM746917.CEL.gz///data_row_count: 54675
1
title: OV_FFPE_58///geo_accession: GSM746918///status: Public on Aug 21 2012///submission_date: Jun 22 2011///last_update_date: Aug 21 2012///type: RNA///channel_count: 1///source_name_ch1: formalin-fixed paraffin embedded (FFPE) tissue, ovarian cancer cells///organism_ch1: Homo sapiens///characteristics_ch1: cell type: ovarian cancer cell///characteristics_ch1.1: age: 74///characteristics_ch1.2: dob: 1920-09-07///characteristics_ch1.3: race: White///characteristics_ch1.4: histo: Serous///characteristics_ch1.5: grade: Mod///characteristics_ch1.6: Stage: IIIC///characteristics_ch1.7: surgtype: Primary Surgery///characteristics_ch1.8: datedx: 1995-08-08///characteristics_ch1.9: surgdate: 1995-08-08///characteristics_ch1.10: optimal: Sub-optimal///characteristics_ch1.11: chemtype: Adjuvant///characteristics_ch1.12: chemoresponse: PR (partial response)///characteristics_ch1.13: chemo agent: Carboplatin/Taxol///characteristics_ch1.14: date.of.relapse: 1996-06-12///characteristics_ch1.15: date.last.follow.up: 2000-02-25///characteristics_ch1.16: st.categ: 4///characteristics_ch1.17: pfi days: 309///characteristics_ch1.18: relapse(1=yes, 0=no): 1///characteristics_ch1.19: overall survival days: 1662///characteristics_ch1.20: censoring(dead=1,alive=0): 1///molecule_ch1: total RNA///extract_protocol_ch1: RNA extraction and amplification was performed with the NuGen WT-Ovation FFPE RNA Amplification kit.///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Punches of FFPE tumor tissue blocks and gene expression profiling were performed in a standard procedure by Almac Dignostics, Inc. (Durham, NC).///scan_protocol: GeneChips were scanned using the Hewlett-Packard GeneArray Scanner G2500A.///description: S0456F100.CEL///description.1: Gene expression data from stage III-IV ovarian cancer patients///data_processing: Data normalization and quality control assessment of the hybridization results were performed with the RMA Bioconductor package (http://www.bioconductor.org)///platform_id: GPL570///contact_name: Youngchul,,Kim///contact_department: Public Health Sciences///contact_institute: University of Virginia///contact_address: University street///contact_city: Charlottesville///contact_state: VA///contact_zip.postal_code: 22903///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM746nnn/GSM746918/GSM746918.CEL.gz///data_row_count: 54675
1
title: OV_FFPE_5///geo_accession: GSM746865///status: Public on Aug 21 2012///submission_date: Jun 22 2011///last_update_date: Aug 21 2012///type: RNA///channel_count: 1///source_name_ch1: formalin-fixed paraffin embedded (FFPE) tissue, ovarian cancer cells///organism_ch1: Homo sapiens///characteristics_ch1: cell type: ovarian cancer cell///characteristics_ch1.1: age: 69///characteristics_ch1.2: dob: 1934-08-29///characteristics_ch1.3: race: White///characteristics_ch1.4: histo: Clear///characteristics_ch1.5: grade: Poor///characteristics_ch1.6: Stage: IIIB///characteristics_ch1.7: surgtype: Primary Surgery///characteristics_ch1.8: datedx: 2001-12-06///characteristics_ch1.9: surgdate: 2001-12-06///characteristics_ch1.10: optimal: Optimal///characteristics_ch1.11: chemtype: Adjuvant///characteristics_ch1.12: chemoresponse: CR (completely response)///characteristics_ch1.13: chemo agent: Carboplatin/Taxol///characteristics_ch1.14: date.of.relapse: 2004-04-14///characteristics_ch1.15: date.last.follow.up: 2004-05-21///characteristics_ch1.16: st.categ: 2///characteristics_ch1.17: pfi days: 860///characteristics_ch1.18: relapse(1=yes, 0=no): 1///characteristics_ch1.19: overall survival days: 897///characteristics_ch1.20: censoring(dead=1,alive=0): 0///molecule_ch1: total RNA///extract_protocol_ch1: RNA extraction and amplification was performed with the NuGen WT-Ovation FFPE RNA Amplification kit.///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Punches of FFPE tumor tissue blocks and gene expression profiling were performed in a standard procedure by Almac Dignostics, Inc. (Durham, NC).///scan_protocol: GeneChips were scanned using the Hewlett-Packard GeneArray Scanner G2500A.///description: S0456F010.CEL///description.1: Gene expression data from stage III-IV ovarian cancer patients///data_processing: Data normalization and quality control assessment of the hybridization results were performed with the RMA Bioconductor package (http://www.bioconductor.org)///platform_id: GPL570///contact_name: Youngchul,,Kim///contact_department: Public Health Sciences///contact_institute: University of Virginia///contact_address: University street///contact_city: Charlottesville///contact_state: VA///contact_zip.postal_code: 22903///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM746nnn/GSM746865/GSM746865.CEL.gz///data_row_count: 54675
1
title: OV_FFPE_6///geo_accession: GSM746866///status: Public on Aug 21 2012///submission_date: Jun 22 2011///last_update_date: Aug 21 2012///type: RNA///channel_count: 1///source_name_ch1: formalin-fixed paraffin embedded (FFPE) tissue, ovarian cancer cells///organism_ch1: Homo sapiens///characteristics_ch1: cell type: ovarian cancer cell///characteristics_ch1.1: age: 48///characteristics_ch1.2: dob: 1950-08-03///characteristics_ch1.3: race: White///characteristics_ch1.4: histo: Serous///characteristics_ch1.5: grade: Mod///characteristics_ch1.6: Stage: IIIA///characteristics_ch1.7: surgtype: Primary Surgery///characteristics_ch1.8: datedx: 1999-04-01///characteristics_ch1.9: surgdate: 1999-04-01///characteristics_ch1.10: optimal: Optimal///characteristics_ch1.11: chemtype: Adjuvant///characteristics_ch1.12: chemoresponse: CR (completely response)///characteristics_ch1.13: chemo agent: Cisplatin/Taxol///characteristics_ch1.14: date.of.relapse: 2007-07-13///characteristics_ch1.15: date.last.follow.up: 2008-11-10///characteristics_ch1.16: st.categ: 2///characteristics_ch1.17: pfi days: 3025///characteristics_ch1.18: relapse(1=yes, 0=no): 1///characteristics_ch1.19: overall survival days: 3511///characteristics_ch1.20: censoring(dead=1,alive=0): 0///molecule_ch1: total RNA///extract_protocol_ch1: RNA extraction and amplification was performed with the NuGen WT-Ovation FFPE RNA Amplification kit.///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Punches of FFPE tumor tissue blocks and gene expression profiling were performed in a standard procedure by Almac Dignostics, Inc. (Durham, NC).///scan_protocol: GeneChips were scanned using the Hewlett-Packard GeneArray Scanner G2500A.///description: S0456F014.CEL///description.1: Gene expression data from stage III-IV ovarian cancer patients///data_processing: Data normalization and quality control assessment of the hybridization results were performed with the RMA Bioconductor package (http://www.bioconductor.org)///platform_id: GPL570///contact_name: Youngchul,,Kim///contact_department: Public Health Sciences///contact_institute: University of Virginia///contact_address: University street///contact_city: Charlottesville///contact_state: VA///contact_zip.postal_code: 22903///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM746nnn/GSM746866/GSM746866.CEL.gz///data_row_count: 54675
1
title: OV_FFPE_7///geo_accession: GSM746867///status: Public on Aug 21 2012///submission_date: Jun 22 2011///last_update_date: Aug 21 2012///type: RNA///channel_count: 1///source_name_ch1: formalin-fixed paraffin embedded (FFPE) tissue, ovarian cancer cells///organism_ch1: Homo sapiens///characteristics_ch1: cell type: ovarian cancer cell///characteristics_ch1.1: age: 52///characteristics_ch1.2: dob: 1945-11-16///characteristics_ch1.3: race: White///characteristics_ch1.4: histo: Serous///characteristics_ch1.5: grade: Poor///characteristics_ch1.6: Stage: IIIC///characteristics_ch1.7: surgtype: Primary Surgery///characteristics_ch1.8: datedx: 1998-07-28///characteristics_ch1.9: surgdate: 1998-07-28///characteristics_ch1.10: optimal: Optimal///characteristics_ch1.11: chemtype: Adjuvant///characteristics_ch1.12: chemoresponse: CR (completely response)///characteristics_ch1.13: chemo agent: Carboplatin/Taxol///characteristics_ch1.14: date.of.relapse: 1999-10-25///characteristics_ch1.15: date.last.follow.up: 2001-03-19///characteristics_ch1.16: st.categ: 4///characteristics_ch1.17: pfi days: 454///characteristics_ch1.18: relapse(1=yes, 0=no): 1///characteristics_ch1.19: overall survival days: 965///characteristics_ch1.20: censoring(dead=1,alive=0): 1///molecule_ch1: total RNA///extract_protocol_ch1: RNA extraction and amplification was performed with the NuGen WT-Ovation FFPE RNA Amplification kit.///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Punches of FFPE tumor tissue blocks and gene expression profiling were performed in a standard procedure by Almac Dignostics, Inc. (Durham, NC).///scan_protocol: GeneChips were scanned using the Hewlett-Packard GeneArray Scanner G2500A.///description: S0456F017.CEL///description.1: Gene expression data from stage III-IV ovarian cancer patients///data_processing: Data normalization and quality control assessment of the hybridization results were performed with the RMA Bioconductor package (http://www.bioconductor.org)///platform_id: GPL570///contact_name: Youngchul,,Kim///contact_department: Public Health Sciences///contact_institute: University of Virginia///contact_address: University street///contact_city: Charlottesville///contact_state: VA///contact_zip.postal_code: 22903///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM746nnn/GSM746867/GSM746867.CEL.gz///data_row_count: 54675
1
title: OV_FFPE_8///geo_accession: GSM746868///status: Public on Aug 21 2012///submission_date: Jun 22 2011///last_update_date: Aug 21 2012///type: RNA///channel_count: 1///source_name_ch1: formalin-fixed paraffin embedded (FFPE) tissue, ovarian cancer cells///organism_ch1: Homo sapiens///characteristics_ch1: cell type: ovarian cancer cell///characteristics_ch1.1: age: 55///characteristics_ch1.2: dob: 1942-12-07///characteristics_ch1.3: race: White///characteristics_ch1.4: histo: Serous///characteristics_ch1.5: grade: Poor///characteristics_ch1.6: Stage: IIIC///characteristics_ch1.7: surgtype: Primary Surgery///characteristics_ch1.8: datedx: 1998-04-23///characteristics_ch1.9: surgdate: 1998-04-23///characteristics_ch1.10: optimal: Optimal///characteristics_ch1.11: chemtype: Adjuvant///characteristics_ch1.12: chemoresponse: CR (completely response)///characteristics_ch1.13: chemo agent: Carboplatin/Taxol///characteristics_ch1.14: date.of.relapse: 1998-07-21///characteristics_ch1.15: date.last.follow.up: 2000-05-11///characteristics_ch1.16: st.categ: 4///characteristics_ch1.17: pfi days: 89///characteristics_ch1.18: relapse(1=yes, 0=no): 1///characteristics_ch1.19: overall survival days: 749///characteristics_ch1.20: censoring(dead=1,alive=0): 1///molecule_ch1: total RNA///extract_protocol_ch1: RNA extraction and amplification was performed with the NuGen WT-Ovation FFPE RNA Amplification kit.///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Punches of FFPE tumor tissue blocks and gene expression profiling were performed in a standard procedure by Almac Dignostics, Inc. (Durham, NC).///scan_protocol: GeneChips were scanned using the Hewlett-Packard GeneArray Scanner G2500A.///description: S0456F018.CEL///description.1: Gene expression data from stage III-IV ovarian cancer patients///data_processing: Data normalization and quality control assessment of the hybridization results were performed with the RMA Bioconductor package (http://www.bioconductor.org)///platform_id: GPL570///contact_name: Youngchul,,Kim///contact_department: Public Health Sciences///contact_institute: University of Virginia///contact_address: University street///contact_city: Charlottesville///contact_state: VA///contact_zip.postal_code: 22903///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM746nnn/GSM746868/GSM746868.CEL.gz///data_row_count: 54675
1
title: OV_FFPE_9///geo_accession: GSM746869///status: Public on Aug 21 2012///submission_date: Jun 22 2011///last_update_date: Aug 21 2012///type: RNA///channel_count: 1///source_name_ch1: formalin-fixed paraffin embedded (FFPE) tissue, ovarian cancer cells///organism_ch1: Homo sapiens///characteristics_ch1: cell type: ovarian cancer cell///characteristics_ch1.1: age: 48///characteristics_ch1.2: dob: 1950-02-15///characteristics_ch1.3: race: White///characteristics_ch1.4: histo: Serous///characteristics_ch1.5: grade: Poor///characteristics_ch1.6: Stage: IIIC///characteristics_ch1.7: surgtype: Primary Surgery///characteristics_ch1.8: datedx: 1998-10-20///characteristics_ch1.9: surgdate: 1998-10-29///characteristics_ch1.10: optimal: Sub-optimal///characteristics_ch1.11: chemtype: Adjuvant///characteristics_ch1.12: chemoresponse: PR (partial response)///characteristics_ch1.13: chemo agent: Carboplatin/Taxol///characteristics_ch1.14: date.of.relapse: 1999-06-29///characteristics_ch1.15: date.last.follow.up: 2000-02-08///characteristics_ch1.16: st.categ: 4///characteristics_ch1.17: pfi days: 252///characteristics_ch1.18: relapse(1=yes, 0=no): 1///characteristics_ch1.19: overall survival days: 476///characteristics_ch1.20: censoring(dead=1,alive=0): 1///molecule_ch1: total RNA///extract_protocol_ch1: RNA extraction and amplification was performed with the NuGen WT-Ovation FFPE RNA Amplification kit.///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Punches of FFPE tumor tissue blocks and gene expression profiling were performed in a standard procedure by Almac Dignostics, Inc. (Durham, NC).///scan_protocol: GeneChips were scanned using the Hewlett-Packard GeneArray Scanner G2500A.///description: S0456F019.CEL///description.1: Gene expression data from stage III-IV ovarian cancer patients///data_processing: Data normalization and quality control assessment of the hybridization results were performed with the RMA Bioconductor package (http://www.bioconductor.org)///platform_id: GPL570///contact_name: Youngchul,,Kim///contact_department: Public Health Sciences///contact_institute: University of Virginia///contact_address: University street///contact_city: Charlottesville///contact_state: VA///contact_zip.postal_code: 22903///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM746nnn/GSM746869/GSM746869.CEL.gz///data_row_count: 54675
1
An expression set
High-grade serous ovarian cancers are heterogeneous not only in terms of clinical outcome but also at the molecular level. Our aim was to establish a novel risk classification system based on a gene expression signature for predicting overall survival, leading to suggesting novel therapeutic strategies for high-risk patients.In this large-scale cross-platform study of six microarray data sets consisting of 1,054 ovarian cancer patients, we developed a gene expression signature for predicting overall survival by applying elastic net and 10-fold cross-validation to a Japanese data set A (n = 260) and evaluated the signature in five other data sets. Subsequently, we investigated differences in the biological characteristics between high- and low-risk ovarian cancer groups.An elastic net analysis identified a 126-gene expression signature for predicting overall survival in patients with ovarian cancer using the Japanese data set A (multivariate analysis, P = 4 ?? 10(-20)). We validated its predictive ability with five other data sets using multivariate analysis (Tothill's data set, P = 1 ?? 10(-5); Bonome's data set, P = 0.0033; Dressman's data set, P = 0.0016; TCGA data set, P = 0.0027; Japanese data set B, P = 0.021). Through gene ontology and pathway analyses, we identified a significant reduction in expression of immune-response-related genes, especially on the antigen presentation pathway, in high-risk ovarian cancer patients.This risk classification based on the 126-gene expression signature is an accurate predictor of clinical outcome in patients with advanced stage high-grade serous ovarian cancer and has the potential to develop new therapeutic strategies for high-grade serous ovarian cancer patients.
experimentData(eset):
Experiment data
Experimenter name: Yoshihara K, Tsunoda T, Shigemizu D, Fujiwara H et al. High-risk ovarian cancer based on 126-gene expression signature is uniquely characterized by downregulation of antigen presentation pathway. Clin Cancer Res 2012 Mar 1;18(5):1374-85.
Laboratory: Yoshihara, Tanaka 2012
Contact information:
Title: High-risk ovarian cancer based on 126-gene expression signature is uniquely characterized by downregulation of antigen presentation pathway.
URL:
PMIDs: 22241791
Abstract: A 255 word abstract is available. Use 'abstract' method.
Information is available on: preprocessing
notes:
platform_title:
Agilent-014850 Whole Human Genome Microarray 4x44K G4112F (Probe Name vers
ion)
platform_shorttitle:
Agilent G4112F
platform_summary:
hgug4112a
platform_manufacturer:
Agilent
platform_distribution:
commercial
platform_accession:
GPL6480
version:
2015-09-22 19:55:29
featureData(eset):
An object of class 'AnnotatedDataFrame'
featureNames: A_23_P100001 A_23_P100011 ... A_32_P99902 (30936 total)
varLabels: probeset gene EntrezGene.ID best_probe
varMetadata: labelDescription
assayData: 30936 features, 260 samples
Platform type:
Overall survival time-to-event summary (in years):
Call: survfit(formula = Surv(time, cens) ~ -1)
n events median 0.95LCL 0.95UCL
260.00 121.00 4.93 4.11 6.58
---------------------------
Available sample meta-data:
---------------------------
alt_sample_name:
10d 115d 116d 117d 119d 11d 120d 122d 123d 125Rd
1 1 1 1 1 1 1 1 1 1
129d 12d 130d 132d 134d 139d 140d 143d 144d 145d
1 1 1 1 1 1 1 1 1 1
146d 148d 150d 155d 156d 15d 160d 16d 171d 173d
1 1 1 1 1 1 1 1 1 1
174d 178d 17d 183d 184d 185d 186d 18d 20d 22d
1 1 1 1 1 1 1 1 1 1
23d 249d 257d 25d 260d 262d 264d 266d 267d 268d
1 1 1 1 1 1 1 1 1 1
269d 27d 299d 2d 300d 301d 302d 303d 304d 305d2
1 1 1 1 1 1 1 1 1 1
306d 307d 310d 318d 319d 320d2 323d 327d 330d 331d
1 1 1 1 1 1 1 1 1 1
333d2 335d 337d 340d 342d 346d 347d 348d2 350d 352d
1 1 1 1 1 1 1 1 1 1
353d 355d 356d 357d 358d 360d 362d 363d 365d 366d
1 1 1 1 1 1 1 1 1 1
367d 368d2 36d 38d 41d2R 42d 43d 44d 456d (Other)
1 1 1 1 1 1 1 1 1 161
sample_type:
tumor
260
histological_type:
ser
260
summarygrade:
high low
129 131
summarystage:
late
260
tumorstage:
3 4
204 56
substage:
a b c NA's
4 20 180 56
grade:
2 3
131 129
pltx:
y
260
tax:
y
260
days_to_death:
Min. 1st Qu. Median Mean 3rd Qu. Max.
30 810 1245 1344 1710 3840
vital_status:
deceased living
121 139
debulking:
optimal suboptimal
103 157
uncurated_author_metadata:
title: serous ovarian cancer 10d///geo_accession: GSM794865///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: high-grade serous ovarian cancer tumor///characteristics_ch1.1: grading: 3///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: surgery status: optimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 79///characteristics_ch1.7: rec (1): 0///characteristics_ch1.8: os (m): 79///characteristics_ch1.9: death (1): 0///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565CA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.10.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM794nnn/GSM794865/GSM794865_s10d.txt.gz///data_row_count: 41093
1
title: serous ovarian cancer 115d///geo_accession: GSM794867///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: high-grade serous ovarian cancer tumor///characteristics_ch1.1: grading: 3///characteristics_ch1.2: Stage: IIIb///characteristics_ch1.3: surgery status: suboptimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 12///characteristics_ch1.7: rec (1): 1///characteristics_ch1.8: os (m): 69///characteristics_ch1.9: death (1): 1///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565CA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.10.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM794nnn/GSM794867/GSM794867_s115d.txt.gz///data_row_count: 41093
1
title: serous ovarian cancer 116d///geo_accession: GSM794868///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: high-grade serous ovarian cancer tumor///characteristics_ch1.1: grading: 2///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: surgery status: suboptimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 14///characteristics_ch1.7: rec (1): 1///characteristics_ch1.8: os (m): 51///characteristics_ch1.9: death (1): 1///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565CA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.10.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM794nnn/GSM794868/GSM794868_s116d.txt.gz///data_row_count: 41093
1
title: serous ovarian cancer 117d///geo_accession: GSM794869///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: high-grade serous ovarian cancer tumor///characteristics_ch1.1: grading: 3///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: surgery status: optimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 18///characteristics_ch1.7: rec (1): 1///characteristics_ch1.8: os (m): 38///characteristics_ch1.9: death (1): 0///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565CA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.10.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM794nnn/GSM794869/GSM794869_s117d.txt.gz///data_row_count: 41093
1
title: serous ovarian cancer 119d///geo_accession: GSM794870///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: high-grade serous ovarian cancer tumor///characteristics_ch1.1: grading: 3///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: surgery status: optimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 40///characteristics_ch1.7: rec (1): 0///characteristics_ch1.8: os (m): 40///characteristics_ch1.9: death (1): 0///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565CA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.10.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM794nnn/GSM794870/GSM794870_s119d.txt.gz///data_row_count: 41093
1
title: serous ovarian cancer 11d///geo_accession: GSM794866///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: high-grade serous ovarian cancer tumor///characteristics_ch1.1: grading: 2///characteristics_ch1.2: Stage: IIIb///characteristics_ch1.3: surgery status: optimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 46///characteristics_ch1.7: rec (1): 1///characteristics_ch1.8: os (m): 76///characteristics_ch1.9: death (1): 0///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565CA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.10.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM794nnn/GSM794866/GSM794866_s11d.txt.gz///data_row_count: 41093
1
title: serous ovarian cancer 120d///geo_accession: GSM794872///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: high-grade serous ovarian cancer tumor///characteristics_ch1.1: grading: 2///characteristics_ch1.2: Stage: IV///characteristics_ch1.3: surgery status: suboptimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 6///characteristics_ch1.7: rec (1): 1///characteristics_ch1.8: os (m): 52///characteristics_ch1.9: death (1): 1///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565CA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.10.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM794nnn/GSM794872/GSM794872_s120d.txt.gz///data_row_count: 41093
1
title: serous ovarian cancer 122d///geo_accession: GSM794873///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: high-grade serous ovarian cancer tumor///characteristics_ch1.1: grading: 2///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: surgery status: suboptimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 8///characteristics_ch1.7: rec (1): 1///characteristics_ch1.8: os (m): 25///characteristics_ch1.9: death (1): 1///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565CA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.10.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM794nnn/GSM794873/GSM794873_s122d.txt.gz///data_row_count: 41093
1
title: serous ovarian cancer 123d///geo_accession: GSM794874///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: high-grade serous ovarian cancer tumor///characteristics_ch1.1: grading: 2///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: surgery status: suboptimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 15///characteristics_ch1.7: rec (1): 1///characteristics_ch1.8: os (m): 22///characteristics_ch1.9: death (1): 1///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565CA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.10.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM794nnn/GSM794874/GSM794874_s123d.txt.gz///data_row_count: 41093
1
title: serous ovarian cancer 125Rd///geo_accession: GSM794875///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: high-grade serous ovarian cancer tumor///characteristics_ch1.1: grading: 2///characteristics_ch1.2: Stage: IV///characteristics_ch1.3: surgery status: suboptimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 10///characteristics_ch1.7: rec (1): 1///characteristics_ch1.8: os (m): 31///characteristics_ch1.9: death (1): 1///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565CA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.10.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM794nnn/GSM794875/GSM794875_s125Rd.txt.gz///data_row_count: 41093
1
title: serous ovarian cancer 129d///geo_accession: GSM794876///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: high-grade serous ovarian cancer tumor///characteristics_ch1.1: grading: 2///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: surgery status: optimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 12///characteristics_ch1.7: rec (1): 1///characteristics_ch1.8: os (m): 13///characteristics_ch1.9: death (1): 1///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565CA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.10.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM794nnn/GSM794876/GSM794876_s129d.txt.gz///data_row_count: 41093
1
title: serous ovarian cancer 12d///geo_accession: GSM794871///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: high-grade serous ovarian cancer tumor///characteristics_ch1.1: grading: 3///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: surgery status: optimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 8///characteristics_ch1.7: rec (1): 1///characteristics_ch1.8: os (m): 24///characteristics_ch1.9: death (1): 1///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565CA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.10.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM794nnn/GSM794871/GSM794871_s12d.txt.gz///data_row_count: 41093
1
title: serous ovarian cancer 130d///geo_accession: GSM794877///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: high-grade serous ovarian cancer tumor///characteristics_ch1.1: grading: 2///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: surgery status: suboptimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 25///characteristics_ch1.7: rec (1): 1///characteristics_ch1.8: os (m): 99///characteristics_ch1.9: death (1): 0///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565CA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.10.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM794nnn/GSM794877/GSM794877_s130d.txt.gz///data_row_count: 41093
1
title: serous ovarian cancer 132d///geo_accession: GSM794878///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: high-grade serous ovarian cancer tumor///characteristics_ch1.1: grading: 3///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: surgery status: optimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 36///characteristics_ch1.7: rec (1): 1///characteristics_ch1.8: os (m): 93///characteristics_ch1.9: death (1): 0///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565CA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.10.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM794nnn/GSM794878/GSM794878_s132d.txt.gz///data_row_count: 41093
1
title: serous ovarian cancer 134d///geo_accession: GSM794879///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: high-grade serous ovarian cancer tumor///characteristics_ch1.1: grading: 2///characteristics_ch1.2: Stage: IIIa///characteristics_ch1.3: surgery status: optimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 30///characteristics_ch1.7: rec (1): 1///characteristics_ch1.8: os (m): 62///characteristics_ch1.9: death (1): 1///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565CA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.10.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM794nnn/GSM794879/GSM794879_s134d.txt.gz///data_row_count: 41093
1
title: serous ovarian cancer 139d///geo_accession: GSM794880///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: high-grade serous ovarian cancer tumor///characteristics_ch1.1: grading: 3///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: surgery status: optimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 35///characteristics_ch1.7: rec (1): 1///characteristics_ch1.8: os (m): 65///characteristics_ch1.9: death (1): 0///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565CA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.10.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM794nnn/GSM794880/GSM794880_s139d.txt.gz///data_row_count: 41093
1
title: serous ovarian cancer 140d///geo_accession: GSM794881///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: high-grade serous ovarian cancer tumor///characteristics_ch1.1: grading: 3///characteristics_ch1.2: Stage: IV///characteristics_ch1.3: surgery status: suboptimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 14///characteristics_ch1.7: rec (1): 1///characteristics_ch1.8: os (m): 28///characteristics_ch1.9: death (1): 1///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565CA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.10.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM794nnn/GSM794881/GSM794881_s140d.txt.gz///data_row_count: 41093
1
title: serous ovarian cancer 143d///geo_accession: GSM794882///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: high-grade serous ovarian cancer tumor///characteristics_ch1.1: grading: 3///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: surgery status: suboptimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 6///characteristics_ch1.7: rec (1): 1///characteristics_ch1.8: os (m): 39///characteristics_ch1.9: death (1): 0///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565CA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.10.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM794nnn/GSM794882/GSM794882_s143d.txt.gz///data_row_count: 41093
1
title: serous ovarian cancer 144d///geo_accession: GSM794883///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: high-grade serous ovarian cancer tumor///characteristics_ch1.1: grading: 2///characteristics_ch1.2: Stage: IV///characteristics_ch1.3: surgery status: suboptimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 26///characteristics_ch1.7: rec (1): 1///characteristics_ch1.8: os (m): 52///characteristics_ch1.9: death (1): 0///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565CA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.10.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM794nnn/GSM794883/GSM794883_s144d.txt.gz///data_row_count: 41093
1
title: serous ovarian cancer 145d///geo_accession: GSM794884///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: high-grade serous ovarian cancer tumor///characteristics_ch1.1: grading: 3///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: surgery status: suboptimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 24///characteristics_ch1.7: rec (1): 1///characteristics_ch1.8: os (m): 49///characteristics_ch1.9: death (1): 0///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565CA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.10.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM794nnn/GSM794884/GSM794884_s145d.txt.gz///data_row_count: 41093
1
title: serous ovarian cancer 146d///geo_accession: GSM794885///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: high-grade serous ovarian cancer tumor///characteristics_ch1.1: grading: 3///characteristics_ch1.2: Stage: IIIb///characteristics_ch1.3: surgery status: suboptimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 44///characteristics_ch1.7: rec (1): 0///characteristics_ch1.8: os (m): 44///characteristics_ch1.9: death (1): 0///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565CA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.10.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM794nnn/GSM794885/GSM794885_s146d.txt.gz///data_row_count: 41093
1
title: serous ovarian cancer 148d///geo_accession: GSM794886///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: high-grade serous ovarian cancer tumor///characteristics_ch1.1: grading: 3///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: surgery status: optimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 24///characteristics_ch1.7: rec (1): 1///characteristics_ch1.8: os (m): 35///characteristics_ch1.9: death (1): 0///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565CA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.10.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM794nnn/GSM794886/GSM794886_s148d.txt.gz///data_row_count: 41093
1
title: serous ovarian cancer 150d///geo_accession: GSM794888///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: high-grade serous ovarian cancer tumor///characteristics_ch1.1: grading: 2///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: surgery status: suboptimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 31///characteristics_ch1.7: rec (1): 1///characteristics_ch1.8: os (m): 35///characteristics_ch1.9: death (1): 0///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565CA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.10.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM794nnn/GSM794888/GSM794888_s150d.txt.gz///data_row_count: 41093
1
title: serous ovarian cancer 155d///geo_accession: GSM794889///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: high-grade serous ovarian cancer tumor///characteristics_ch1.1: grading: 3///characteristics_ch1.2: Stage: IIIb///characteristics_ch1.3: surgery status: optimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 28///characteristics_ch1.7: rec (1): 0///characteristics_ch1.8: os (m): 28///characteristics_ch1.9: death (1): 0///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565CA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.10.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM794nnn/GSM794889/GSM794889_s155d.txt.gz///data_row_count: 41093
1
title: serous ovarian cancer 156d///geo_accession: GSM794890///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: high-grade serous ovarian cancer tumor///characteristics_ch1.1: grading: 3///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: surgery status: optimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 42///characteristics_ch1.7: rec (1): 0///characteristics_ch1.8: os (m): 42///characteristics_ch1.9: death (1): 0///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565CA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.10.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM794nnn/GSM794890/GSM794890_s156d.txt.gz///data_row_count: 41093
1
title: serous ovarian cancer 15d///geo_accession: GSM794887///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: high-grade serous ovarian cancer tumor///characteristics_ch1.1: grading: 3///characteristics_ch1.2: Stage: IIIb///characteristics_ch1.3: surgery status: optimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 18///characteristics_ch1.7: rec (1): 1///characteristics_ch1.8: os (m): 71///characteristics_ch1.9: death (1): 0///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565CA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.10.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM794nnn/GSM794887/GSM794887_s15d.txt.gz///data_row_count: 41093
1
title: serous ovarian cancer 160d///geo_accession: GSM794892///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: high-grade serous ovarian cancer tumor///characteristics_ch1.1: grading: 2///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: surgery status: suboptimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 16///characteristics_ch1.7: rec (1): 1///characteristics_ch1.8: os (m): 34///characteristics_ch1.9: death (1): 0///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565CA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.10.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM794nnn/GSM794892/GSM794892_s160d.txt.gz///data_row_count: 41093
1
title: serous ovarian cancer 16d///geo_accession: GSM794891///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: high-grade serous ovarian cancer tumor///characteristics_ch1.1: grading: 2///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: surgery status: optimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 13///characteristics_ch1.7: rec (1): 1///characteristics_ch1.8: os (m): 71///characteristics_ch1.9: death (1): 0///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565CA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.10.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM794nnn/GSM794891/GSM794891_s16d.txt.gz///data_row_count: 41093
1
title: serous ovarian cancer 171d///geo_accession: GSM794894///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: high-grade serous ovarian cancer tumor///characteristics_ch1.1: grading: 3///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: surgery status: suboptimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 3///characteristics_ch1.7: rec (1): 1///characteristics_ch1.8: os (m): 15///characteristics_ch1.9: death (1): 1///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565CA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.10.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM794nnn/GSM794894/GSM794894_s171d.txt.gz///data_row_count: 41093
1
title: serous ovarian cancer 173d///geo_accession: GSM794895///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: high-grade serous ovarian cancer tumor///characteristics_ch1.1: grading: 2///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: surgery status: suboptimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 5///characteristics_ch1.7: rec (1): 1///characteristics_ch1.8: os (m): 26///characteristics_ch1.9: death (1): 1///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565CA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.10.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM794nnn/GSM794895/GSM794895_s173d.txt.gz///data_row_count: 41093
1
title: serous ovarian cancer 174d///geo_accession: GSM794896///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: high-grade serous ovarian cancer tumor///characteristics_ch1.1: grading: 3///characteristics_ch1.2: Stage: IV///characteristics_ch1.3: surgery status: optimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 23///characteristics_ch1.7: rec (1): 1///characteristics_ch1.8: os (m): 41///characteristics_ch1.9: death (1): 1///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565CA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.10.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM794nnn/GSM794896/GSM794896_s174d.txt.gz///data_row_count: 41093
1
title: serous ovarian cancer 178d///geo_accession: GSM794897///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: high-grade serous ovarian cancer tumor///characteristics_ch1.1: grading: 3///characteristics_ch1.2: Stage: IV///characteristics_ch1.3: surgery status: optimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 17///characteristics_ch1.7: rec (1): 1///characteristics_ch1.8: os (m): 47///characteristics_ch1.9: death (1): 1///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565CA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.10.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM794nnn/GSM794897/GSM794897_s178d.txt.gz///data_row_count: 41093
1
title: serous ovarian cancer 17d///geo_accession: GSM794893///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: high-grade serous ovarian cancer tumor///characteristics_ch1.1: grading: 2///characteristics_ch1.2: Stage: IIIb///characteristics_ch1.3: surgery status: optimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 70///characteristics_ch1.7: rec (1): 0///characteristics_ch1.8: os (m): 70///characteristics_ch1.9: death (1): 0///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565CA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.10.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM794nnn/GSM794893/GSM794893_s17d.txt.gz///data_row_count: 41093
1
title: serous ovarian cancer 183d///geo_accession: GSM794899///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: high-grade serous ovarian cancer tumor///characteristics_ch1.1: grading: 2///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: surgery status: suboptimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 72///characteristics_ch1.7: rec (1): 0///characteristics_ch1.8: os (m): 72///characteristics_ch1.9: death (1): 0///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565CA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.10.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM794nnn/GSM794899/GSM794899_s183d.txt.gz///data_row_count: 41093
1
title: serous ovarian cancer 184d///geo_accession: GSM794900///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: high-grade serous ovarian cancer tumor///characteristics_ch1.1: grading: 3///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: surgery status: optimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 65///characteristics_ch1.7: rec (1): 0///characteristics_ch1.8: os (m): 65///characteristics_ch1.9: death (1): 0///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565CA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.10.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM794nnn/GSM794900/GSM794900_s184d.txt.gz///data_row_count: 41093
1
title: serous ovarian cancer 185d///geo_accession: GSM794901///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: high-grade serous ovarian cancer tumor///characteristics_ch1.1: grading: 3///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: surgery status: optimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 20///characteristics_ch1.7: rec (1): 1///characteristics_ch1.8: os (m): 33///characteristics_ch1.9: death (1): 0///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565CA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.10.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM794nnn/GSM794901/GSM794901_s185d.txt.gz///data_row_count: 41093
1
title: serous ovarian cancer 186d///geo_accession: GSM794902///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: high-grade serous ovarian cancer tumor///characteristics_ch1.1: grading: 3///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: surgery status: optimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 12///characteristics_ch1.7: rec (1): 1///characteristics_ch1.8: os (m): 29///characteristics_ch1.9: death (1): 0///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565CA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.10.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM794nnn/GSM794902/GSM794902_s186d.txt.gz///data_row_count: 41093
1
title: serous ovarian cancer 18d///geo_accession: GSM794898///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: high-grade serous ovarian cancer tumor///characteristics_ch1.1: grading: 2///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: surgery status: optimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 74///characteristics_ch1.7: rec (1): 0///characteristics_ch1.8: os (m): 74///characteristics_ch1.9: death (1): 0///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565CA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.10.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM794nnn/GSM794898/GSM794898_s18d.txt.gz///data_row_count: 41093
1
title: serous ovarian cancer 20d///geo_accession: GSM794904///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: high-grade serous ovarian cancer tumor///characteristics_ch1.1: grading: 2///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: surgery status: optimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 102///characteristics_ch1.7: rec (1): 0///characteristics_ch1.8: os (m): 102///characteristics_ch1.9: death (1): 0///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565CA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.10.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM794nnn/GSM794904/GSM794904_s20d.txt.gz///data_row_count: 41093
1
title: serous ovarian cancer 22d///geo_accession: GSM794905///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: high-grade serous ovarian cancer tumor///characteristics_ch1.1: grading: 2///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: surgery status: suboptimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 15///characteristics_ch1.7: rec (1): 0///characteristics_ch1.8: os (m): 15///characteristics_ch1.9: death (1): 0///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565CA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.10.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM794nnn/GSM794905/GSM794905_s22d.txt.gz///data_row_count: 41093
1
title: serous ovarian cancer 23d///geo_accession: GSM794906///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: high-grade serous ovarian cancer tumor///characteristics_ch1.1: grading: 2///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: surgery status: suboptimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 2///characteristics_ch1.7: rec (1): 1///characteristics_ch1.8: os (m): 8///characteristics_ch1.9: death (1): 1///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565CA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.10.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM794nnn/GSM794906/GSM794906_s23d.txt.gz///data_row_count: 41093
1
title: serous ovarian cancer 249d///geo_accession: GSM794907///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: high-grade serous ovarian cancer tumor///characteristics_ch1.1: grading: 3///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: surgery status: optimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 33///characteristics_ch1.7: rec (1): 0///characteristics_ch1.8: os (m): 33///characteristics_ch1.9: death (1): 0///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565CA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.10.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM794nnn/GSM794907/GSM794907_s249d.txt.gz///data_row_count: 41093
1
title: serous ovarian cancer 257d///geo_accession: GSM794909///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: high-grade serous ovarian cancer tumor///characteristics_ch1.1: grading: 2///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: surgery status: suboptimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 36///characteristics_ch1.7: rec (1): 1///characteristics_ch1.8: os (m): 36///characteristics_ch1.9: death (1): 1///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565CA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.10.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM794nnn/GSM794909/GSM794909_s257d.txt.gz///data_row_count: 41093
1
title: serous ovarian cancer 25d///geo_accession: GSM794908///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: high-grade serous ovarian cancer tumor///characteristics_ch1.1: grading: 2///characteristics_ch1.2: Stage: IIIb///characteristics_ch1.3: surgery status: optimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 29///characteristics_ch1.7: rec (1): 1///characteristics_ch1.8: os (m): 80///characteristics_ch1.9: death (1): 1///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565CA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.10.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM794nnn/GSM794908/GSM794908_s25d.txt.gz///data_row_count: 41093
1
title: serous ovarian cancer 260d///geo_accession: GSM794910///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: high-grade serous ovarian cancer tumor///characteristics_ch1.1: grading: 2///characteristics_ch1.2: Stage: IIIb///characteristics_ch1.3: surgery status: optimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 102///characteristics_ch1.7: rec (1): 0///characteristics_ch1.8: os (m): 102///characteristics_ch1.9: death (1): 0///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565CA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.10.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM794nnn/GSM794910/GSM794910_s260d.txt.gz///data_row_count: 41093
1
title: serous ovarian cancer 262d///geo_accession: GSM794911///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: high-grade serous ovarian cancer tumor///characteristics_ch1.1: grading: 3///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: surgery status: suboptimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 12///characteristics_ch1.7: rec (1): 1///characteristics_ch1.8: os (m): 17///characteristics_ch1.9: death (1): 1///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565CA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.10.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM794nnn/GSM794911/GSM794911_s262d.txt.gz///data_row_count: 41093
1
title: serous ovarian cancer 264d///geo_accession: GSM794912///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: high-grade serous ovarian cancer tumor///characteristics_ch1.1: grading: 3///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: surgery status: suboptimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 32///characteristics_ch1.7: rec (1): 1///characteristics_ch1.8: os (m): 51///characteristics_ch1.9: death (1): 1///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565CA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.10.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM794nnn/GSM794912/GSM794912_s264d.txt.gz///data_row_count: 41093
1
title: serous ovarian cancer 266d///geo_accession: GSM794913///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: high-grade serous ovarian cancer tumor///characteristics_ch1.1: grading: 2///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: surgery status: suboptimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 25///characteristics_ch1.7: rec (1): 1///characteristics_ch1.8: os (m): 38///characteristics_ch1.9: death (1): 0///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565CA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.10.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM794nnn/GSM794913/GSM794913_s266d.txt.gz///data_row_count: 41093
1
title: serous ovarian cancer 267d///geo_accession: GSM794914///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: high-grade serous ovarian cancer tumor///characteristics_ch1.1: grading: 3///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: surgery status: optimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 34///characteristics_ch1.7: rec (1): 1///characteristics_ch1.8: os (m): 38///characteristics_ch1.9: death (1): 0///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565CA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.10.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM794nnn/GSM794914/GSM794914_s267d.txt.gz///data_row_count: 41093
1
title: serous ovarian cancer 268d///geo_accession: GSM794915///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: high-grade serous ovarian cancer tumor///characteristics_ch1.1: grading: 2///characteristics_ch1.2: Stage: IIIb///characteristics_ch1.3: surgery status: optimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 37///characteristics_ch1.7: rec (1): 0///characteristics_ch1.8: os (m): 37///characteristics_ch1.9: death (1): 0///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565CA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.10.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM794nnn/GSM794915/GSM794915_s268d.txt.gz///data_row_count: 41093
1
title: serous ovarian cancer 269d///geo_accession: GSM794916///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: high-grade serous ovarian cancer tumor///characteristics_ch1.1: grading: 2///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: surgery status: suboptimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 28///characteristics_ch1.7: rec (1): 1///characteristics_ch1.8: os (m): 37///characteristics_ch1.9: death (1): 0///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565CA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.10.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM794nnn/GSM794916/GSM794916_s269d.txt.gz///data_row_count: 41093
1
title: serous ovarian cancer 27d///geo_accession: GSM794917///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: high-grade serous ovarian cancer tumor///characteristics_ch1.1: grading: 3///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: surgery status: suboptimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 8///characteristics_ch1.7: rec (1): 1///characteristics_ch1.8: os (m): 11///characteristics_ch1.9: death (1): 1///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565CA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.10.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM794nnn/GSM794917/GSM794917_s27d.txt.gz///data_row_count: 41093
1
title: serous ovarian cancer 299d///geo_accession: GSM794918///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: high-grade serous ovarian cancer tumor///characteristics_ch1.1: grading: 2///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: surgery status: optimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 8///characteristics_ch1.7: rec (1): 1///characteristics_ch1.8: os (m): 21///characteristics_ch1.9: death (1): 1///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565CA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.10.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM794nnn/GSM794918/GSM794918_s299d.txt.gz///data_row_count: 41093
1
title: serous ovarian cancer 2d///geo_accession: GSM794903///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: high-grade serous ovarian cancer tumor///characteristics_ch1.1: grading: 2///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: surgery status: suboptimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 18///characteristics_ch1.7: rec (1): 1///characteristics_ch1.8: os (m): 49///characteristics_ch1.9: death (1): 1///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565CA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.10.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM794nnn/GSM794903/GSM794903_s2d.txt.gz///data_row_count: 41093
1
title: serous ovarian cancer 300d///geo_accession: GSM794919///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: high-grade serous ovarian cancer tumor///characteristics_ch1.1: grading: 2///characteristics_ch1.2: Stage: IV///characteristics_ch1.3: surgery status: suboptimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 12///characteristics_ch1.7: rec (1): 1///characteristics_ch1.8: os (m): 21///characteristics_ch1.9: death (1): 0///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565CA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.10.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM794nnn/GSM794919/GSM794919_s300d.txt.gz///data_row_count: 41093
1
title: serous ovarian cancer 301d///geo_accession: GSM794920///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: high-grade serous ovarian cancer tumor///characteristics_ch1.1: grading: 2///characteristics_ch1.2: Stage: IIIb///characteristics_ch1.3: surgery status: suboptimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 14///characteristics_ch1.7: rec (1): 1///characteristics_ch1.8: os (m): 21///characteristics_ch1.9: death (1): 0///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565CA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.10.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM794nnn/GSM794920/GSM794920_s301d.txt.gz///data_row_count: 41093
1
title: serous ovarian cancer 302d///geo_accession: GSM794921///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: high-grade serous ovarian cancer tumor///characteristics_ch1.1: grading: 2///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: surgery status: optimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 18///characteristics_ch1.7: rec (1): 0///characteristics_ch1.8: os (m): 18///characteristics_ch1.9: death (1): 0///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565CA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.10.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM794nnn/GSM794921/GSM794921_s302d.txt.gz///data_row_count: 41093
1
title: serous ovarian cancer 303d///geo_accession: GSM794922///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: high-grade serous ovarian cancer tumor///characteristics_ch1.1: grading: 2///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: surgery status: optimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 14///characteristics_ch1.7: rec (1): 1///characteristics_ch1.8: os (m): 14///characteristics_ch1.9: death (1): 0///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565CA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.10.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM794nnn/GSM794922/GSM794922_s303d.txt.gz///data_row_count: 41093
1
title: serous ovarian cancer 304d///geo_accession: GSM794923///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: high-grade serous ovarian cancer tumor///characteristics_ch1.1: grading: 2///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: surgery status: suboptimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 15///characteristics_ch1.7: rec (1): 0///characteristics_ch1.8: os (m): 15///characteristics_ch1.9: death (1): 0///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565CA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.10.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM794nnn/GSM794923/GSM794923_s304d.txt.gz///data_row_count: 41093
1
title: serous ovarian cancer 305d2///geo_accession: GSM794924///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: high-grade serous ovarian cancer tumor///characteristics_ch1.1: grading: 2///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: surgery status: optimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 72///characteristics_ch1.7: rec (1): 0///characteristics_ch1.8: os (m): 72///characteristics_ch1.9: death (1): 0///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565CA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.10.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM794nnn/GSM794924/GSM794924_s305d2.txt.gz///data_row_count: 41093
1
title: serous ovarian cancer 306d///geo_accession: GSM794925///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: high-grade serous ovarian cancer tumor///characteristics_ch1.1: grading: 2///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: surgery status: suboptimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 46///characteristics_ch1.7: rec (1): 0///characteristics_ch1.8: os (m): 46///characteristics_ch1.9: death (1): 0///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565CA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.10.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM794nnn/GSM794925/GSM794925_s306d.txt.gz///data_row_count: 41093
1
title: serous ovarian cancer 307d///geo_accession: GSM794926///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: high-grade serous ovarian cancer tumor///characteristics_ch1.1: grading: 3///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: surgery status: suboptimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 46///characteristics_ch1.7: rec (1): 0///characteristics_ch1.8: os (m): 46///characteristics_ch1.9: death (1): 0///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565CA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.10.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM794nnn/GSM794926/GSM794926_s307d.txt.gz///data_row_count: 41093
1
title: serous ovarian cancer 310d///geo_accession: GSM794927///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: high-grade serous ovarian cancer tumor///characteristics_ch1.1: grading: 2///characteristics_ch1.2: Stage: IIIb///characteristics_ch1.3: surgery status: optimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 6///characteristics_ch1.7: rec (1): 0///characteristics_ch1.8: os (m): 6///characteristics_ch1.9: death (1): 0///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565CA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.10.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM794nnn/GSM794927/GSM794927_s310d.txt.gz///data_row_count: 41093
1
title: serous ovarian cancer 318d///geo_accession: GSM794928///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: high-grade serous ovarian cancer tumor///characteristics_ch1.1: grading: 3///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: surgery status: suboptimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 9///characteristics_ch1.7: rec (1): 1///characteristics_ch1.8: os (m): 13///characteristics_ch1.9: death (1): 1///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565CA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.10.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM794nnn/GSM794928/GSM794928_s318d.txt.gz///data_row_count: 41093
1
title: serous ovarian cancer 319d///geo_accession: GSM794929///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: high-grade serous ovarian cancer tumor///characteristics_ch1.1: grading: 2///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: surgery status: suboptimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 12///characteristics_ch1.7: rec (1): 1///characteristics_ch1.8: os (m): 43///characteristics_ch1.9: death (1): 0///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565CA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.10.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM794nnn/GSM794929/GSM794929_s319d.txt.gz///data_row_count: 41093
1
title: serous ovarian cancer 320d2///geo_accession: GSM794930///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: high-grade serous ovarian cancer tumor///characteristics_ch1.1: grading: 2///characteristics_ch1.2: Stage: IIIb///characteristics_ch1.3: surgery status: optimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 6///characteristics_ch1.7: rec (1): 1///characteristics_ch1.8: os (m): 17///characteristics_ch1.9: death (1): 1///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565CA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.10.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM794nnn/GSM794930/GSM794930_s320d2.txt.gz///data_row_count: 41093
1
title: serous ovarian cancer 323d///geo_accession: GSM794931///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: high-grade serous ovarian cancer tumor///characteristics_ch1.1: grading: 3///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: surgery status: optimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 40///characteristics_ch1.7: rec (1): 1///characteristics_ch1.8: os (m): 57///characteristics_ch1.9: death (1): 0///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565CA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.10.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM794nnn/GSM794931/GSM794931_s323d.txt.gz///data_row_count: 41093
1
title: serous ovarian cancer 327d///geo_accession: GSM794932///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: high-grade serous ovarian cancer tumor///characteristics_ch1.1: grading: 3///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: surgery status: suboptimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 6///characteristics_ch1.7: rec (1): 1///characteristics_ch1.8: os (m): 8///characteristics_ch1.9: death (1): 1///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565CA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.10.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM794nnn/GSM794932/GSM794932_s327d.txt.gz///data_row_count: 41093
1
title: serous ovarian cancer 330d///geo_accession: GSM794933///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: high-grade serous ovarian cancer tumor///characteristics_ch1.1: grading: 3///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: surgery status: suboptimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 5///characteristics_ch1.7: rec (1): 1///characteristics_ch1.8: os (m): 9///characteristics_ch1.9: death (1): 1///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565CA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.10.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM794nnn/GSM794933/GSM794933_s330d.txt.gz///data_row_count: 41093
1
title: serous ovarian cancer 331d///geo_accession: GSM794934///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: high-grade serous ovarian cancer tumor///characteristics_ch1.1: grading: 3///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: surgery status: suboptimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 21///characteristics_ch1.7: rec (1): 1///characteristics_ch1.8: os (m): 30///characteristics_ch1.9: death (1): 0///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565CA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.10.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM794nnn/GSM794934/GSM794934_s331d.txt.gz///data_row_count: 41093
1
title: serous ovarian cancer 333d2///geo_accession: GSM794935///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: high-grade serous ovarian cancer tumor///characteristics_ch1.1: grading: 2///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: surgery status: optimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 29///characteristics_ch1.7: rec (1): 0///characteristics_ch1.8: os (m): 29///characteristics_ch1.9: death (1): 0///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565CA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.10.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM794nnn/GSM794935/GSM794935_s333d2.txt.gz///data_row_count: 41093
1
title: serous ovarian cancer 335d///geo_accession: GSM794936///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: high-grade serous ovarian cancer tumor///characteristics_ch1.1: grading: 3///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: surgery status: optimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 12///characteristics_ch1.7: rec (1): 1///characteristics_ch1.8: os (m): 16///characteristics_ch1.9: death (1): 1///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565CA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.10.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM794nnn/GSM794936/GSM794936_s335d.txt.gz///data_row_count: 41093
1
title: serous ovarian cancer 337d///geo_accession: GSM794937///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: high-grade serous ovarian cancer tumor///characteristics_ch1.1: grading: 3///characteristics_ch1.2: Stage: IV///characteristics_ch1.3: surgery status: suboptimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 13///characteristics_ch1.7: rec (1): 1///characteristics_ch1.8: os (m): 40///characteristics_ch1.9: death (1): 0///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565CA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.10.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM794nnn/GSM794937/GSM794937_s337d.txt.gz///data_row_count: 41093
1
title: serous ovarian cancer 340d///geo_accession: GSM794938///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: high-grade serous ovarian cancer tumor///characteristics_ch1.1: grading: 2///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: surgery status: suboptimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 2///characteristics_ch1.7: rec (1): 1///characteristics_ch1.8: os (m): 2///characteristics_ch1.9: death (1): 1///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565CA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.10.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM794nnn/GSM794938/GSM794938_s340d.txt.gz///data_row_count: 41093
1
title: serous ovarian cancer 342d///geo_accession: GSM794939///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: high-grade serous ovarian cancer tumor///characteristics_ch1.1: grading: 3///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: surgery status: optimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 44///characteristics_ch1.7: rec (1): 0///characteristics_ch1.8: os (m): 44///characteristics_ch1.9: death (1): 0///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565CA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.10.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM794nnn/GSM794939/GSM794939_s342d.txt.gz///data_row_count: 41093
1
title: serous ovarian cancer 346d///geo_accession: GSM794940///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: high-grade serous ovarian cancer tumor///characteristics_ch1.1: grading: 3///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: surgery status: optimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 23///characteristics_ch1.7: rec (1): 1///characteristics_ch1.8: os (m): 36///characteristics_ch1.9: death (1): 0///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565CA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.10.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM794nnn/GSM794940/GSM794940_s346d.txt.gz///data_row_count: 41093
1
title: serous ovarian cancer 347d///geo_accession: GSM794941///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: high-grade serous ovarian cancer tumor///characteristics_ch1.1: grading: 3///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: surgery status: suboptimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 18///characteristics_ch1.7: rec (1): 1///characteristics_ch1.8: os (m): 48///characteristics_ch1.9: death (1): 0///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565CA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.10.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM794nnn/GSM794941/GSM794941_s347d.txt.gz///data_row_count: 41093
1
title: serous ovarian cancer 348d2///geo_accession: GSM794942///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: high-grade serous ovarian cancer tumor///characteristics_ch1.1: grading: 3///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: surgery status: optimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 24///characteristics_ch1.7: rec (1): 1///characteristics_ch1.8: os (m): 50///characteristics_ch1.9: death (1): 0///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565CA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.10.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM794nnn/GSM794942/GSM794942_s348d2.txt.gz///data_row_count: 41093
1
title: serous ovarian cancer 350d///geo_accession: GSM794943///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: high-grade serous ovarian cancer tumor///characteristics_ch1.1: grading: 3///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: surgery status: suboptimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 2///characteristics_ch1.7: rec (1): 1///characteristics_ch1.8: os (m): 24///characteristics_ch1.9: death (1): 1///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565CA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.10.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM794nnn/GSM794943/GSM794943_s350d.txt.gz///data_row_count: 41093
1
title: serous ovarian cancer 352d///geo_accession: GSM794944///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: high-grade serous ovarian cancer tumor///characteristics_ch1.1: grading: 2///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: surgery status: suboptimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 18///characteristics_ch1.7: rec (1): 1///characteristics_ch1.8: os (m): 36///characteristics_ch1.9: death (1): 1///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565CA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.10.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM794nnn/GSM794944/GSM794944_s352d.txt.gz///data_row_count: 41093
1
title: serous ovarian cancer 353d///geo_accession: GSM794945///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: high-grade serous ovarian cancer tumor///characteristics_ch1.1: grading: 3///characteristics_ch1.2: Stage: IV///characteristics_ch1.3: surgery status: optimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 22///characteristics_ch1.7: rec (1): 1///characteristics_ch1.8: os (m): 36///characteristics_ch1.9: death (1): 1///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565CA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.10.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM794nnn/GSM794945/GSM794945_s353d.txt.gz///data_row_count: 41093
1
title: serous ovarian cancer 355d///geo_accession: GSM794946///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: high-grade serous ovarian cancer tumor///characteristics_ch1.1: grading: 2///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: surgery status: optimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 23///characteristics_ch1.7: rec (1): 1///characteristics_ch1.8: os (m): 41///characteristics_ch1.9: death (1): 1///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565CA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.10.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM794nnn/GSM794946/GSM794946_s355d.txt.gz///data_row_count: 41093
1
title: serous ovarian cancer 356d///geo_accession: GSM794947///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: high-grade serous ovarian cancer tumor///characteristics_ch1.1: grading: 2///characteristics_ch1.2: Stage: IV///characteristics_ch1.3: surgery status: optimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 58///characteristics_ch1.7: rec (1): 0///characteristics_ch1.8: os (m): 58///characteristics_ch1.9: death (1): 0///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565CA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.10.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM794nnn/GSM794947/GSM794947_s356d.txt.gz///data_row_count: 41093
1
title: serous ovarian cancer 357d///geo_accession: GSM794948///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: high-grade serous ovarian cancer tumor///characteristics_ch1.1: grading: 3///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: surgery status: suboptimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 22///characteristics_ch1.7: rec (1): 1///characteristics_ch1.8: os (m): 50///characteristics_ch1.9: death (1): 1///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565CA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.10.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM794nnn/GSM794948/GSM794948_s357d.txt.gz///data_row_count: 41093
1
title: serous ovarian cancer 358d///geo_accession: GSM794949///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: high-grade serous ovarian cancer tumor///characteristics_ch1.1: grading: 2///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: surgery status: optimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 27///characteristics_ch1.7: rec (1): 1///characteristics_ch1.8: os (m): 52///characteristics_ch1.9: death (1): 0///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565CA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.10.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM794nnn/GSM794949/GSM794949_s358d.txt.gz///data_row_count: 41093
1
title: serous ovarian cancer 360d///geo_accession: GSM794951///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: high-grade serous ovarian cancer tumor///characteristics_ch1.1: grading: 2///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: surgery status: suboptimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 32///characteristics_ch1.7: rec (1): 1///characteristics_ch1.8: os (m): 62///characteristics_ch1.9: death (1): 0///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565CA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.10.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM794nnn/GSM794951/GSM794951_s360d.txt.gz///data_row_count: 41093
1
title: serous ovarian cancer 362d///geo_accession: GSM794952///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: high-grade serous ovarian cancer tumor///characteristics_ch1.1: grading: 2///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: surgery status: suboptimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 14///characteristics_ch1.7: rec (1): 1///characteristics_ch1.8: os (m): 25///characteristics_ch1.9: death (1): 1///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565CA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.10.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM794nnn/GSM794952/GSM794952_s362d.txt.gz///data_row_count: 41093
1
title: serous ovarian cancer 363d///geo_accession: GSM794953///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: high-grade serous ovarian cancer tumor///characteristics_ch1.1: grading: 2///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: surgery status: optimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 72///characteristics_ch1.7: rec (1): 0///characteristics_ch1.8: os (m): 72///characteristics_ch1.9: death (1): 0///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565CA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.10.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM794nnn/GSM794953/GSM794953_s363d.txt.gz///data_row_count: 41093
1
title: serous ovarian cancer 365d///geo_accession: GSM794954///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: high-grade serous ovarian cancer tumor///characteristics_ch1.1: grading: 3///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: surgery status: optimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 32///characteristics_ch1.7: rec (1): 1///characteristics_ch1.8: os (m): 37///characteristics_ch1.9: death (1): 1///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565CA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.10.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM794nnn/GSM794954/GSM794954_s365d.txt.gz///data_row_count: 41093
1
title: serous ovarian cancer 366d///geo_accession: GSM794955///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: high-grade serous ovarian cancer tumor///characteristics_ch1.1: grading: 2///characteristics_ch1.2: Stage: IV///characteristics_ch1.3: surgery status: suboptimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 13///characteristics_ch1.7: rec (1): 1///characteristics_ch1.8: os (m): 18///characteristics_ch1.9: death (1): 1///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565CA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.10.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM794nnn/GSM794955/GSM794955_s366d.txt.gz///data_row_count: 41093
1
title: serous ovarian cancer 367d///geo_accession: GSM794956///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: high-grade serous ovarian cancer tumor///characteristics_ch1.1: grading: 3///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: surgery status: optimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 19///characteristics_ch1.7: rec (1): 1///characteristics_ch1.8: os (m): 49///characteristics_ch1.9: death (1): 1///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565CA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.10.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM794nnn/GSM794956/GSM794956_s367d.txt.gz///data_row_count: 41093
1
title: serous ovarian cancer 368d2///geo_accession: GSM794957///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: high-grade serous ovarian cancer tumor///characteristics_ch1.1: grading: 3///characteristics_ch1.2: Stage: IV///characteristics_ch1.3: surgery status: suboptimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 8///characteristics_ch1.7: rec (1): 1///characteristics_ch1.8: os (m): 32///characteristics_ch1.9: death (1): 1///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565CA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.10.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM794nnn/GSM794957/GSM794957_s368d2.txt.gz///data_row_count: 41093
1
title: serous ovarian cancer 36d///geo_accession: GSM794950///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: high-grade serous ovarian cancer tumor///characteristics_ch1.1: grading: 2///characteristics_ch1.2: Stage: IV///characteristics_ch1.3: surgery status: optimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 23///characteristics_ch1.7: rec (1): 1///characteristics_ch1.8: os (m): 28///characteristics_ch1.9: death (1): 1///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565CA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.10.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM794nnn/GSM794950/GSM794950_s36d.txt.gz///data_row_count: 41093
1
title: serous ovarian cancer 38d///geo_accession: GSM794958///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: high-grade serous ovarian cancer tumor///characteristics_ch1.1: grading: 2///characteristics_ch1.2: Stage: IIIb///characteristics_ch1.3: surgery status: optimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 15///characteristics_ch1.7: rec (1): 1///characteristics_ch1.8: os (m): 64///characteristics_ch1.9: death (1): 1///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565CA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.10.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM794nnn/GSM794958/GSM794958_s38d.txt.gz///data_row_count: 41093
1
title: serous ovarian cancer 41d2R///geo_accession: GSM794960///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: high-grade serous ovarian cancer tumor///characteristics_ch1.1: grading: 2///characteristics_ch1.2: Stage: IIIb///characteristics_ch1.3: surgery status: optimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 99///characteristics_ch1.7: rec (1): 1///characteristics_ch1.8: os (m): 104///characteristics_ch1.9: death (1): 0///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565CA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.10.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM794nnn/GSM794960/GSM794960_s41d2R.txt.gz///data_row_count: 41093
1
title: serous ovarian cancer 42d///geo_accession: GSM794961///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: high-grade serous ovarian cancer tumor///characteristics_ch1.1: grading: 3///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: surgery status: suboptimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 17///characteristics_ch1.7: rec (1): 1///characteristics_ch1.8: os (m): 60///characteristics_ch1.9: death (1): 1///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565CA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.10.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM794nnn/GSM794961/GSM794961_s42d.txt.gz///data_row_count: 41093
1
title: serous ovarian cancer 43d///geo_accession: GSM794962///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: high-grade serous ovarian cancer tumor///characteristics_ch1.1: grading: 3///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: surgery status: suboptimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 7///characteristics_ch1.7: rec (1): 1///characteristics_ch1.8: os (m): 34///characteristics_ch1.9: death (1): 1///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565CA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.10.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM794nnn/GSM794962/GSM794962_s43d.txt.gz///data_row_count: 41093
1
title: serous ovarian cancer 44d///geo_accession: GSM794963///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: high-grade serous ovarian cancer tumor///characteristics_ch1.1: grading: 3///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: surgery status: suboptimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 9///characteristics_ch1.7: rec (1): 1///characteristics_ch1.8: os (m): 17///characteristics_ch1.9: death (1): 1///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565CA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.10.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM794nnn/GSM794963/GSM794963_s44d.txt.gz///data_row_count: 41093
1
title: serous ovarian cancer 456d///geo_accession: GSM794965///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: high-grade serous ovarian cancer tumor///characteristics_ch1.1: grading: 2///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: surgery status: optimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 28///characteristics_ch1.7: rec (1): 0///characteristics_ch1.8: os (m): 28///characteristics_ch1.9: death (1): 0///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565CA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.10.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM794nnn/GSM794965/GSM794965_s456d.txt.gz///data_row_count: 41093
1
(Other)
161
duplicates:
GSE32062.GSE32062.GPL6480_GSM794933 GSE32062.GSE32062.GPL6480_GSM794935
1 1
NA's
258
An expression set
High-grade serous ovarian cancers are heterogeneous not only in terms of clinical outcome but also at the molecular level. Our aim was to establish a novel risk classification system based on a gene expression signature for predicting overall survival, leading to suggesting novel therapeutic strategies for high-risk patients.In this large-scale cross-platform study of six microarray data sets consisting of 1,054 ovarian cancer patients, we developed a gene expression signature for predicting overall survival by applying elastic net and 10-fold cross-validation to a Japanese data set A (n = 260) and evaluated the signature in five other data sets. Subsequently, we investigated differences in the biological characteristics between high- and low-risk ovarian cancer groups.An elastic net analysis identified a 126-gene expression signature for predicting overall survival in patients with ovarian cancer using the Japanese data set A (multivariate analysis, P = 4 ?? 10(-20)). We validated its predictive ability with five other data sets using multivariate analysis (Tothill's data set, P = 1 ?? 10(-5); Bonome's data set, P = 0.0033; Dressman's data set, P = 0.0016; TCGA data set, P = 0.0027; Japanese data set B, P = 0.021). Through gene ontology and pathway analyses, we identified a significant reduction in expression of immune-response-related genes, especially on the antigen presentation pathway, in high-risk ovarian cancer patients.This risk classification based on the 126-gene expression signature is an accurate predictor of clinical outcome in patients with advanced stage high-grade serous ovarian cancer and has the potential to develop new therapeutic strategies for high-grade serous ovarian cancer patients.
experimentData(eset):
Experiment data
Experimenter name: Yoshihara K, Tsunoda T, Shigemizu D, Fujiwara H et al. High-risk ovarian cancer based on 126-gene expression signature is uniquely characterized by downregulation of antigen presentation pathway. Clin Cancer Res 2012 Mar 1;18(5):1374-85.
Laboratory: Yoshihara, Tanaka 2012
Contact information:
Title: High-risk ovarian cancer based on 126-gene expression signature is uniquely characterized by downregulation of antigen presentation pathway.
URL:
PMIDs: 22241791
Abstract: A 255 word abstract is available. Use 'abstract' method.
Information is available on: preprocessing
notes:
platform_title:
Agilent-014850 Whole Human Genome Microarray 4x44K G4112F (Probe Name vers
ion)
platform_shorttitle:
Agilent G4112F
platform_summary:
hgug4112a
platform_manufacturer:
Agilent
platform_distribution:
commercial
platform_accession:
GPL6480
version:
2015-09-22 19:58:23
featureData(eset):
An object of class 'AnnotatedDataFrame'
featureNames: A_23_P100001 A_23_P100011 ... A_32_P99902 (30936 total)
varLabels: probeset gene EntrezGene.ID best_probe
varMetadata: labelDescription
assayData: 30936 features, 40 samples
Platform type:
Overall survival time-to-event summary (in years):
Call: survfit(formula = Surv(time, cens) ~ -1)
n events median 0.95LCL 0.95UCL
40.00 22.00 4.44 3.29 NA
---------------------------
Available sample meta-data:
---------------------------
alt_sample_name:
106 108 109R 110 111R 192 195R 196 197 198 200 203 205 206 207 213
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
222 224 226 229 230 231 274 277 278 280 281 282 283 284 285 286
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
287 288 289 291 292 294 297R 298R
1 1 1 1 1 1 1 1
sample_type:
tumor
40
histological_type:
ser
40
summarygrade:
high low
17 23
summarystage:
late
40
tumorstage:
3 4
31 9
substage:
b c NA's
3 28 9
grade:
2 3
23 17
pltx:
y
40
tax:
y
40
days_to_death:
Min. 1st Qu. Median Mean 3rd Qu. Max.
210 705 1155 1346 1792 3330
vital_status:
deceased living
22 18
debulking:
optimal suboptimal
19 21
uncurated_author_metadata:
title: serous ovarian cancer 106///geo_accession: GSM795125///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: tumor///characteristics_ch1.1: grading: 2///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: surgery status: suboptimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 15///characteristics_ch1.7: rec (1): 1///characteristics_ch1.8: os (m): 26///characteristics_ch1.9: death (1): 0///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.9.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM795nnn/GSM795125/GSM795125_s106.txt.gz///data_row_count: 41093///relation: Reanalysis of: GSM432223
1
title: serous ovarian cancer 108///geo_accession: GSM795126///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: tumor///characteristics_ch1.1: grading: 3///characteristics_ch1.2: Stage: IIIb///characteristics_ch1.3: surgery status: optimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 37///characteristics_ch1.7: rec (1): 0///characteristics_ch1.8: os (m): 37///characteristics_ch1.9: death (1): 0///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.9.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM795nnn/GSM795126/GSM795126_s108.txt.gz///data_row_count: 41093///relation: Reanalysis of: GSM432225
1
title: serous ovarian cancer 109R///geo_accession: GSM795127///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: tumor///characteristics_ch1.1: grading: 3///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: surgery status: suboptimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 7///characteristics_ch1.7: rec (1): 1///characteristics_ch1.8: os (m): 20///characteristics_ch1.9: death (1): 1///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.9.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM795nnn/GSM795127/GSM795127_s109R.txt.gz///data_row_count: 41093///relation: Reanalysis of: GSM432226
1
title: serous ovarian cancer 110///geo_accession: GSM795128///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: tumor///characteristics_ch1.1: grading: 2///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: surgery status: suboptimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 97///characteristics_ch1.7: rec (1): 0///characteristics_ch1.8: os (m): 97///characteristics_ch1.9: death (1): 0///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.9.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM795nnn/GSM795128/GSM795128_s110.txt.gz///data_row_count: 41093///relation: Reanalysis of: GSM432228
1
title: serous ovarian cancer 111R///geo_accession: GSM795129///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: tumor///characteristics_ch1.1: grading: 2///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: surgery status: suboptimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 18///characteristics_ch1.7: rec (1): 1///characteristics_ch1.8: os (m): 57///characteristics_ch1.9: death (1): 1///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.9.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM795nnn/GSM795129/GSM795129_s111R.txt.gz///data_row_count: 41093///relation: Reanalysis of: GSM432229
1
title: serous ovarian cancer 192///geo_accession: GSM795130///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: tumor///characteristics_ch1.1: grading: 2///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: surgery status: optimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 20///characteristics_ch1.7: rec (1): 1///characteristics_ch1.8: os (m): 27///characteristics_ch1.9: death (1): 1///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.9.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM795nnn/GSM795130/GSM795130_s192.txt.gz///data_row_count: 41093///relation:
1
title: serous ovarian cancer 195R///geo_accession: GSM795131///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: tumor///characteristics_ch1.1: grading: 2///characteristics_ch1.2: Stage: IV///characteristics_ch1.3: surgery status: suboptimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 6///characteristics_ch1.7: rec (1): 1///characteristics_ch1.8: os (m): 40///characteristics_ch1.9: death (1): 1///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.9.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM795nnn/GSM795131/GSM795131_s195R.txt.gz///data_row_count: 41093///relation:
1
title: serous ovarian cancer 196///geo_accession: GSM795132///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: tumor///characteristics_ch1.1: grading: 3///characteristics_ch1.2: Stage: IV///characteristics_ch1.3: surgery status: optimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 28///characteristics_ch1.7: rec (1): 1///characteristics_ch1.8: os (m): 37///characteristics_ch1.9: death (1): 0///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.9.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM795nnn/GSM795132/GSM795132_s196.txt.gz///data_row_count: 41093///relation:
1
title: serous ovarian cancer 197///geo_accession: GSM795133///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: tumor///characteristics_ch1.1: grading: 3///characteristics_ch1.2: Stage: IIIb///characteristics_ch1.3: surgery status: optimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 47///characteristics_ch1.7: rec (1): 0///characteristics_ch1.8: os (m): 47///characteristics_ch1.9: death (1): 0///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.9.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM795nnn/GSM795133/GSM795133_s197.txt.gz///data_row_count: 41093///relation:
1
title: serous ovarian cancer 198///geo_accession: GSM795134///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: tumor///characteristics_ch1.1: grading: 3///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: surgery status: suboptimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 8///characteristics_ch1.7: rec (1): 1///characteristics_ch1.8: os (m): 24///characteristics_ch1.9: death (1): 1///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.9.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM795nnn/GSM795134/GSM795134_s198.txt.gz///data_row_count: 41093///relation:
1
title: serous ovarian cancer 200///geo_accession: GSM795135///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: tumor///characteristics_ch1.1: grading: 3///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: surgery status: suboptimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 6///characteristics_ch1.7: rec (1): 1///characteristics_ch1.8: os (m): 27///characteristics_ch1.9: death (1): 1///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.9.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM795nnn/GSM795135/GSM795135_s200.txt.gz///data_row_count: 41093///relation:
1
title: serous ovarian cancer 203///geo_accession: GSM795136///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: tumor///characteristics_ch1.1: grading: 3///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: surgery status: suboptimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 26///characteristics_ch1.7: rec (1): 1///characteristics_ch1.8: os (m): 46///characteristics_ch1.9: death (1): 1///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.9.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM795nnn/GSM795136/GSM795136_s203.txt.gz///data_row_count: 41093///relation:
1
title: serous ovarian cancer 205///geo_accession: GSM795137///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: tumor///characteristics_ch1.1: grading: 2///characteristics_ch1.2: Stage: IV///characteristics_ch1.3: surgery status: suboptimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 43///characteristics_ch1.7: rec (1): 1///characteristics_ch1.8: os (m): 78///characteristics_ch1.9: death (1): 1///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.9.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM795nnn/GSM795137/GSM795137_s205.txt.gz///data_row_count: 41093///relation:
1
title: serous ovarian cancer 206///geo_accession: GSM795138///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: tumor///characteristics_ch1.1: grading: 2///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: surgery status: optimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 21///characteristics_ch1.7: rec (1): 1///characteristics_ch1.8: os (m): 87///characteristics_ch1.9: death (1): 1///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.9.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM795nnn/GSM795138/GSM795138_s206.txt.gz///data_row_count: 41093///relation:
1
title: serous ovarian cancer 207///geo_accession: GSM795139///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: tumor///characteristics_ch1.1: grading: 2///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: surgery status: suboptimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 30///characteristics_ch1.7: rec (1): 0///characteristics_ch1.8: os (m): 30///characteristics_ch1.9: death (1): 0///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.9.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM795nnn/GSM795139/GSM795139_s207.txt.gz///data_row_count: 41093///relation:
1
title: serous ovarian cancer 213///geo_accession: GSM795140///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: tumor///characteristics_ch1.1: grading: 2///characteristics_ch1.2: Stage: IV///characteristics_ch1.3: surgery status: suboptimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 15///characteristics_ch1.7: rec (1): 1///characteristics_ch1.8: os (m): 35///characteristics_ch1.9: death (1): 0///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.9.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM795nnn/GSM795140/GSM795140_s213.txt.gz///data_row_count: 41093///relation:
1
title: serous ovarian cancer 222///geo_accession: GSM795141///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: tumor///characteristics_ch1.1: grading: 2///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: surgery status: suboptimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 12///characteristics_ch1.7: rec (1): 0///characteristics_ch1.8: os (m): 12///characteristics_ch1.9: death (1): 0///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.9.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM795nnn/GSM795141/GSM795141_s222.txt.gz///data_row_count: 41093///relation:
1
title: serous ovarian cancer 224///geo_accession: GSM795142///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: tumor///characteristics_ch1.1: grading: 2///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: surgery status: suboptimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 11///characteristics_ch1.7: rec (1): 1///characteristics_ch1.8: os (m): 16///characteristics_ch1.9: death (1): 0///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.9.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM795nnn/GSM795142/GSM795142_s224.txt.gz///data_row_count: 41093///relation:
1
title: serous ovarian cancer 226///geo_accession: GSM795143///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: tumor///characteristics_ch1.1: grading: 3///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: surgery status: optimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 11///characteristics_ch1.7: rec (1): 0///characteristics_ch1.8: os (m): 11///characteristics_ch1.9: death (1): 0///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.9.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM795nnn/GSM795143/GSM795143_s226.txt.gz///data_row_count: 41093///relation:
1
title: serous ovarian cancer 229///geo_accession: GSM795144///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: tumor///characteristics_ch1.1: grading: 3///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: surgery status: optimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 9///characteristics_ch1.7: rec (1): 0///characteristics_ch1.8: os (m): 9///characteristics_ch1.9: death (1): 0///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.9.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM795nnn/GSM795144/GSM795144_s229.txt.gz///data_row_count: 41093///relation:
1
title: serous ovarian cancer 230///geo_accession: GSM795145///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: tumor///characteristics_ch1.1: grading: 2///characteristics_ch1.2: Stage: IV///characteristics_ch1.3: surgery status: optimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 8///characteristics_ch1.7: rec (1): 0///characteristics_ch1.8: os (m): 8///characteristics_ch1.9: death (1): 0///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.9.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM795nnn/GSM795145/GSM795145_s230.txt.gz///data_row_count: 41093///relation:
1
title: serous ovarian cancer 231///geo_accession: GSM795146///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: tumor///characteristics_ch1.1: grading: 2///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: surgery status: optimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 7///characteristics_ch1.7: rec (1): 0///characteristics_ch1.8: os (m): 7///characteristics_ch1.9: death (1): 0///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.9.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM795nnn/GSM795146/GSM795146_s231.txt.gz///data_row_count: 41093///relation:
1
title: serous ovarian cancer 274///geo_accession: GSM795147///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: tumor///characteristics_ch1.1: grading: 3///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: surgery status: suboptimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 35///characteristics_ch1.7: rec (1): 1///characteristics_ch1.8: os (m): 101///characteristics_ch1.9: death (1): 1///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.9.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM795nnn/GSM795147/GSM795147_s274.txt.gz///data_row_count: 41093///relation:
1
title: serous ovarian cancer 277///geo_accession: GSM795148///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: tumor///characteristics_ch1.1: grading: 2///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: surgery status: optimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 73///characteristics_ch1.7: rec (1): 1///characteristics_ch1.8: os (m): 109///characteristics_ch1.9: death (1): 1///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.9.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM795nnn/GSM795148/GSM795148_s277.txt.gz///data_row_count: 41093///relation:
1
title: serous ovarian cancer 278///geo_accession: GSM795149///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: tumor///characteristics_ch1.1: grading: 3///characteristics_ch1.2: Stage: IV///characteristics_ch1.3: surgery status: suboptimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 16///characteristics_ch1.7: rec (1): 1///characteristics_ch1.8: os (m): 21///characteristics_ch1.9: death (1): 1///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.9.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM795nnn/GSM795149/GSM795149_s278.txt.gz///data_row_count: 41093///relation:
1
title: serous ovarian cancer 280///geo_accession: GSM795150///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: tumor///characteristics_ch1.1: grading: 2///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: surgery status: optimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 68///characteristics_ch1.7: rec (1): 0///characteristics_ch1.8: os (m): 68///characteristics_ch1.9: death (1): 0///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.9.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM795nnn/GSM795150/GSM795150_s280.txt.gz///data_row_count: 41093///relation:
1
title: serous ovarian cancer 281///geo_accession: GSM795151///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: tumor///characteristics_ch1.1: grading: 2///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: surgery status: suboptimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 8///characteristics_ch1.7: rec (1): 1///characteristics_ch1.8: os (m): 15///characteristics_ch1.9: death (1): 1///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.9.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM795nnn/GSM795151/GSM795151_s281.txt.gz///data_row_count: 41093///relation:
1
title: serous ovarian cancer 282///geo_accession: GSM795152///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: tumor///characteristics_ch1.1: grading: 2///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: surgery status: optimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 82///characteristics_ch1.7: rec (1): 0///characteristics_ch1.8: os (m): 82///characteristics_ch1.9: death (1): 0///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.9.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM795nnn/GSM795152/GSM795152_s282.txt.gz///data_row_count: 41093///relation:
1
title: serous ovarian cancer 283///geo_accession: GSM795153///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: tumor///characteristics_ch1.1: grading: 3///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: surgery status: optimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 12///characteristics_ch1.7: rec (1): 1///characteristics_ch1.8: os (m): 49///characteristics_ch1.9: death (1): 1///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.9.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM795nnn/GSM795153/GSM795153_s283.txt.gz///data_row_count: 41093///relation:
1
title: serous ovarian cancer 284///geo_accession: GSM795154///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: tumor///characteristics_ch1.1: grading: 2///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: surgery status: suboptimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 111///characteristics_ch1.7: rec (1): 0///characteristics_ch1.8: os (m): 111///characteristics_ch1.9: death (1): 0///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.9.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM795nnn/GSM795154/GSM795154_s284.txt.gz///data_row_count: 41093///relation:
1
title: serous ovarian cancer 285///geo_accession: GSM795155///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: tumor///characteristics_ch1.1: grading: 3///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: surgery status: optimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 82///characteristics_ch1.7: rec (1): 0///characteristics_ch1.8: os (m): 82///characteristics_ch1.9: death (1): 0///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.9.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM795nnn/GSM795155/GSM795155_s285.txt.gz///data_row_count: 41093///relation:
1
title: serous ovarian cancer 286///geo_accession: GSM795156///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: tumor///characteristics_ch1.1: grading: 3///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: surgery status: optimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 8///characteristics_ch1.7: rec (1): 1///characteristics_ch1.8: os (m): 22///characteristics_ch1.9: death (1): 1///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.9.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM795nnn/GSM795156/GSM795156_s286.txt.gz///data_row_count: 41093///relation:
1
title: serous ovarian cancer 287///geo_accession: GSM795157///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: tumor///characteristics_ch1.1: grading: 3///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: surgery status: optimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 12///characteristics_ch1.7: rec (1): 1///characteristics_ch1.8: os (m): 40///characteristics_ch1.9: death (1): 1///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.9.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM795nnn/GSM795157/GSM795157_s287.txt.gz///data_row_count: 41093///relation:
1
title: serous ovarian cancer 288///geo_accession: GSM795158///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: tumor///characteristics_ch1.1: grading: 3///characteristics_ch1.2: Stage: IV///characteristics_ch1.3: surgery status: suboptimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 9///characteristics_ch1.7: rec (1): 1///characteristics_ch1.8: os (m): 24///characteristics_ch1.9: death (1): 1///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.9.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM795nnn/GSM795158/GSM795158_s288.txt.gz///data_row_count: 41093///relation:
1
title: serous ovarian cancer 289///geo_accession: GSM795159///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: tumor///characteristics_ch1.1: grading: 2///characteristics_ch1.2: Stage: IIIb///characteristics_ch1.3: surgery status: optimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 14///characteristics_ch1.7: rec (1): 1///characteristics_ch1.8: os (m): 40///characteristics_ch1.9: death (1): 1///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.9.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM795nnn/GSM795159/GSM795159_s289.txt.gz///data_row_count: 41093///relation:
1
title: serous ovarian cancer 291///geo_accession: GSM795160///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: tumor///characteristics_ch1.1: grading: 2///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: surgery status: suboptimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 15///characteristics_ch1.7: rec (1): 1///characteristics_ch1.8: os (m): 48///characteristics_ch1.9: death (1): 1///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.9.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM795nnn/GSM795160/GSM795160_s291.txt.gz///data_row_count: 41093///relation:
1
title: serous ovarian cancer 292///geo_accession: GSM795161///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: tumor///characteristics_ch1.1: grading: 2///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: surgery status: optimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 28///characteristics_ch1.7: rec (1): 1///characteristics_ch1.8: os (m): 54///characteristics_ch1.9: death (1): 1///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.9.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM795nnn/GSM795161/GSM795161_s292.txt.gz///data_row_count: 41093///relation:
1
title: serous ovarian cancer 294///geo_accession: GSM795162///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: tumor///characteristics_ch1.1: grading: 3///characteristics_ch1.2: Stage: IIIc///characteristics_ch1.3: surgery status: optimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 49///characteristics_ch1.7: rec (1): 1///characteristics_ch1.8: os (m): 70///characteristics_ch1.9: death (1): 0///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.9.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM795nnn/GSM795162/GSM795162_s294.txt.gz///data_row_count: 41093///relation:
1
title: serous ovarian cancer 297R///geo_accession: GSM795163///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: tumor///characteristics_ch1.1: grading: 2///characteristics_ch1.2: Stage: IV///characteristics_ch1.3: surgery status: suboptimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 2///characteristics_ch1.7: rec (1): 1///characteristics_ch1.8: os (m): 24///characteristics_ch1.9: death (1): 1///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.9.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM795nnn/GSM795163/GSM795163_s297R.txt.gz///data_row_count: 41093///relation:
1
title: serous ovarian cancer 298R///geo_accession: GSM795164///status: Public on Mar 01 2012///submission_date: Sep 12 2011///last_update_date: Mar 01 2012///type: RNA///channel_count: 1///source_name_ch1: high-grade serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tissue: tumor///characteristics_ch1.1: grading: 2///characteristics_ch1.2: Stage: IV///characteristics_ch1.3: surgery status: suboptimal///characteristics_ch1.4: taxane: 1///characteristics_ch1.5: platinum: 1///characteristics_ch1.6: pfs (m): 31///characteristics_ch1.7: rec (1): 1///characteristics_ch1.8: os (m): 57///characteristics_ch1.9: death (1): 1///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver.9.1 (Agilent Technologies) in the default settings.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: [email protected]///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM795nnn/GSM795164/GSM795164_s298R.txt.gz///data_row_count: 41093///relation:
1
An expression set
Biomarkers that predict disease progression might assist the development of better therapeutic strategies for aggressive cancers, such as ovarian cancer. Here, we investigated the role of collagen type XI alpha 1 (COL11A1) in cell invasiveness and tumor formation and the prognostic impact of COL11A1 expression in ovarian cancer. Microarray analysis suggested that COL11A1 is a disease progression-associated gene that is linked to ovarian cancer recurrence and poor survival. Small interference RNA-mediated specific reduction in COL11A1 protein levels suppressed the invasive ability and oncogenic potential of ovarian cancer cells and decreased tumor formation and lung colonization in mouse xenografts. A combination of experimental approaches, including real-time RT-PCR, casein zymography and chromatin immunoprecipitation (ChIP) assays, showed that COL11A1 knockdown attenuated MMP3 expression and suppressed binding of Ets-1 to its putative MMP3 promoter-binding site, suggesting that the Ets-1-MMP3 axis is upregulated by COL11A1. Transforming growth factor (TGF)-beta (TGF-??1) treatment triggers the activation of smad2 signaling cascades, leading to activation of COL11A1 and MMP3. Pharmacological inhibition of MMP3 abrogated the TGF-??1-triggered, COL11A1-dependent cell invasiveness. Furthermore, the NF-YA-binding site on the COL11A1 promoter was identified as the major determinant of TGF-??1-dependent COL11A1 activation. Analysis of 88 ovarian cancer patients indicated that high COL11A1 mRNA levels are associated with advanced disease stage. The 5-year recurrence-free and overall survival rates were significantly lower (P=0.006 and P=0.018, respectively) among patients with high expression levels of tissue COL11A1 mRNA compared with those with low expression. We conclude that COL11A1 may promote tumor aggressiveness via the TGF-??1-MMP3 axis and that COL11A1 expression can predict clinical outcome in ovarian cancer patients.
experimentData(eset):
Experiment data
Experimenter name: Wu Y, Chang T, Huang Y, Huang H, Chou C
Laboratory: Wu, Chou 2013
Contact information:
Title: COL11A1 promotes tumor progression and predicts poor clinical outcome in ovarian cancer.
URL:
PMIDs: 23934190
Abstract: A 260 word abstract is available. Use 'abstract' method.
Information is available on: preprocessing
notes:
platform_title:
[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array
platform_shorttitle:
Affymetrix HG-U133Plus2
platform_summary:
hgu133plus2
platform_manufacturer:
Affymetrix
platform_distribution:
commercial
platform_accession:
GPL570
platform_technology:
in situ oligonucleotide
version:
2015-09-22 20:02:05
featureData(eset):
An object of class 'AnnotatedDataFrame'
featureNames: 1007_s_at 1053_at ... AFFX-HUMISGF3A/M97935_MB_at
(42447 total)
varLabels: probeset gene EntrezGene.ID best_probe
varMetadata: labelDescription
assayData: 42447 features, 60 samples
Platform type:
---------------------------
Available sample meta-data:
---------------------------
alt_sample_name:
Tc_113 Tc_48 Tc_49 Tc_51 Tc_56 Tc_59 Tc_61 Tc_63 Tc_64 Tc_65 Tc_74
1 1 1 1 1 1 1 1 1 1 1
Tc_94 Te_69 Te_77 Te_78 Te_79 Te_84 Te_87 Te_89 Te_90 Te_91 Te_92
1 1 1 1 1 1 1 1 1 1 1
Te_93 Tm_101 Tm_102 Tm_106 Tm_107 Tm_110 Tm_95 Tm_96 Tm_97 Tm_98 Ts_11
1 1 1 1 1 1 1 1 1 1 1
Ts_14 Ts_15 Ts_17 Ts_19 Ts_2 Ts_20 Ts_21 Ts_23 Ts_24 Ts_26 Ts_28
1 1 1 1 1 1 1 1 1 1 1
Ts_3 Ts_31 Ts_32 Ts_34 Ts_35 Ts_36 Ts_37 Ts_39 Ts_4 Ts_41 Ts_43
1 1 1 1 1 1 1 1 1 1 1
Ts_45 Ts_46 Ts_47 Ts_5 Ts_8
1 1 1 1 1
sample_type:
tumor
60
histological_type:
clearcell endo mucinous ser
12 11 9 28
summarystage:
early late
25 35
tumorstage:
1 2 3 4
17 8 30 5
recurrence_status:
norecurrence recurrence
40 20
os_binary:
long short
44 16
relapse_binary:
long short
40 20
batch:
2010-09-07 2010-09-08 2010-10-14 2010-12-10 2010-12-14
20 2 18 16 4
uncurated_author_metadata:
title: Tc_113///geo_accession: GSM1078972///status: Public on Jan 01 2014///submission_date: Feb 06 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: primary surgical treatment///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian cancer cells///characteristics_ch1.1: tissue subtype: clear cell///characteristics_ch1.2: advanced disease stage: stage III///characteristics_ch1.3: recurrence status: non-recurrence///characteristics_ch1.4: survival/death: survival///treatment_protocol_ch1: Frozen rissues///growth_protocol_ch1: Frozen tissue samples were embedded, and sections were cut and mounted on slides. The slides were stained with H&E to ensure that at least 70
1
title: Tc_48///geo_accession: GSM1078973///status: Public on Jan 01 2014///submission_date: Feb 06 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: primary surgical treatment///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian cancer cells///characteristics_ch1.1: tissue subtype: clear cell///characteristics_ch1.2: advanced disease stage: stage III///characteristics_ch1.3: recurrence status: recurrence///characteristics_ch1.4: survival/death: death///treatment_protocol_ch1: Frozen rissues///growth_protocol_ch1: Frozen tissue samples were embedded, and sections were cut and mounted on slides. The slides were stained with H&E to ensure that at least 70
1
title: Tc_49///geo_accession: GSM1078974///status: Public on Jan 01 2014///submission_date: Feb 06 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: primary surgical treatment///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian cancer cells///characteristics_ch1.1: tissue subtype: clear cell///characteristics_ch1.2: advanced disease stage: stage I///characteristics_ch1.3: recurrence status: non-recurrence///characteristics_ch1.4: survival/death: survival///treatment_protocol_ch1: Frozen rissues///growth_protocol_ch1: Frozen tissue samples were embedded, and sections were cut and mounted on slides. The slides were stained with H&E to ensure that at least 70
1
title: Tc_51///geo_accession: GSM1078975///status: Public on Jan 01 2014///submission_date: Feb 06 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: primary surgical treatment///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian cancer cells///characteristics_ch1.1: tissue subtype: clear cell///characteristics_ch1.2: advanced disease stage: stage III///characteristics_ch1.3: recurrence status: non-recurrence///characteristics_ch1.4: survival/death: survival///treatment_protocol_ch1: Frozen rissues///growth_protocol_ch1: Frozen tissue samples were embedded, and sections were cut and mounted on slides. The slides were stained with H&E to ensure that at least 70
1
title: Tc_56///geo_accession: GSM1078976///status: Public on Jan 01 2014///submission_date: Feb 06 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: primary surgical treatment///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian cancer cells///characteristics_ch1.1: tissue subtype: clear cell///characteristics_ch1.2: advanced disease stage: stage I///characteristics_ch1.3: recurrence status: non-recurrence///characteristics_ch1.4: survival/death: survival///treatment_protocol_ch1: Frozen rissues///growth_protocol_ch1: Frozen tissue samples were embedded, and sections were cut and mounted on slides. The slides were stained with H&E to ensure that at least 70
1
title: Tc_59///geo_accession: GSM1078977///status: Public on Jan 01 2014///submission_date: Feb 06 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: primary surgical treatment///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian cancer cells///characteristics_ch1.1: tissue subtype: clear cell///characteristics_ch1.2: advanced disease stage: stage I///characteristics_ch1.3: recurrence status: non-recurrence///characteristics_ch1.4: survival/death: survival///treatment_protocol_ch1: Frozen rissues///growth_protocol_ch1: Frozen tissue samples were embedded, and sections were cut and mounted on slides. The slides were stained with H&E to ensure that at least 70
1
title: Tc_61///geo_accession: GSM1078978///status: Public on Jan 01 2014///submission_date: Feb 06 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: primary surgical treatment///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian cancer cells///characteristics_ch1.1: tissue subtype: clear cell///characteristics_ch1.2: advanced disease stage: stage III///characteristics_ch1.3: recurrence status: non-recurrence///characteristics_ch1.4: survival/death: survival///treatment_protocol_ch1: Frozen rissues///growth_protocol_ch1: Frozen tissue samples were embedded, and sections were cut and mounted on slides. The slides were stained with H&E to ensure that at least 70
1
title: Tc_63///geo_accession: GSM1078979///status: Public on Jan 01 2014///submission_date: Feb 06 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: primary surgical treatment///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian cancer cells///characteristics_ch1.1: tissue subtype: clear cell///characteristics_ch1.2: advanced disease stage: stage I///characteristics_ch1.3: recurrence status: non-recurrence///characteristics_ch1.4: survival/death: survival///treatment_protocol_ch1: Frozen rissues///growth_protocol_ch1: Frozen tissue samples were embedded, and sections were cut and mounted on slides. The slides were stained with H&E to ensure that at least 70
1
title: Tc_64///geo_accession: GSM1078980///status: Public on Jan 01 2014///submission_date: Feb 06 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: primary surgical treatment///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian cancer cells///characteristics_ch1.1: tissue subtype: clear cell///characteristics_ch1.2: advanced disease stage: stage I///characteristics_ch1.3: recurrence status: non-recurrence///characteristics_ch1.4: survival/death: survival///treatment_protocol_ch1: Frozen rissues///growth_protocol_ch1: Frozen tissue samples were embedded, and sections were cut and mounted on slides. The slides were stained with H&E to ensure that at least 70
1
title: Tc_65///geo_accession: GSM1078981///status: Public on Jan 01 2014///submission_date: Feb 06 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: primary surgical treatment///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian cancer cells///characteristics_ch1.1: tissue subtype: clear cell///characteristics_ch1.2: advanced disease stage: stage II///characteristics_ch1.3: recurrence status: recurrence///characteristics_ch1.4: survival/death: survival///treatment_protocol_ch1: Frozen rissues///growth_protocol_ch1: Frozen tissue samples were embedded, and sections were cut and mounted on slides. The slides were stained with H&E to ensure that at least 70
1
title: Tc_74///geo_accession: GSM1078982///status: Public on Jan 01 2014///submission_date: Feb 06 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: primary surgical treatment///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian cancer cells///characteristics_ch1.1: tissue subtype: clear cell///characteristics_ch1.2: advanced disease stage: stage IV///characteristics_ch1.3: recurrence status: recurrence///characteristics_ch1.4: survival/death: survival///treatment_protocol_ch1: Frozen rissues///growth_protocol_ch1: Frozen tissue samples were embedded, and sections were cut and mounted on slides. The slides were stained with H&E to ensure that at least 70
1
title: Tc_94///geo_accession: GSM1078983///status: Public on Jan 01 2014///submission_date: Feb 06 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: primary surgical treatment///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian cancer cells///characteristics_ch1.1: tissue subtype: clear cell///characteristics_ch1.2: advanced disease stage: stage IV///characteristics_ch1.3: recurrence status: non-recurrence///characteristics_ch1.4: survival/death: death///treatment_protocol_ch1: Frozen rissues///growth_protocol_ch1: Frozen tissue samples were embedded, and sections were cut and mounted on slides. The slides were stained with H&E to ensure that at least 70
1
title: Te_69///geo_accession: GSM1078984///status: Public on Jan 01 2014///submission_date: Feb 06 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: primary surgical treatment///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian cancer cells///characteristics_ch1.1: tissue subtype: endometrioid///characteristics_ch1.2: advanced disease stage: stage I///characteristics_ch1.3: recurrence status: non-recurrence///characteristics_ch1.4: survival/death: death///treatment_protocol_ch1: Frozen rissues///growth_protocol_ch1: Frozen tissue samples were embedded, and sections were cut and mounted on slides. The slides were stained with H&E to ensure that at least 70
1
title: Te_77///geo_accession: GSM1078985///status: Public on Jan 01 2014///submission_date: Feb 06 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: primary surgical treatment///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian cancer cells///characteristics_ch1.1: tissue subtype: endometrioid///characteristics_ch1.2: advanced disease stage: stage II///characteristics_ch1.3: recurrence status: non-recurrence///characteristics_ch1.4: survival/death: death///treatment_protocol_ch1: Frozen rissues///growth_protocol_ch1: Frozen tissue samples were embedded, and sections were cut and mounted on slides. The slides were stained with H&E to ensure that at least 70
1
title: Te_78///geo_accession: GSM1078986///status: Public on Jan 01 2014///submission_date: Feb 06 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: primary surgical treatment///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian cancer cells///characteristics_ch1.1: tissue subtype: endometrioid///characteristics_ch1.2: advanced disease stage: stage I///characteristics_ch1.3: recurrence status: non-recurrence///characteristics_ch1.4: survival/death: survival///treatment_protocol_ch1: Frozen rissues///growth_protocol_ch1: Frozen tissue samples were embedded, and sections were cut and mounted on slides. The slides were stained with H&E to ensure that at least 70
1
title: Te_79///geo_accession: GSM1078987///status: Public on Jan 01 2014///submission_date: Feb 06 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: primary surgical treatment///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian cancer cells///characteristics_ch1.1: tissue subtype: endometrioid///characteristics_ch1.2: advanced disease stage: stage I///characteristics_ch1.3: recurrence status: non-recurrence///characteristics_ch1.4: survival/death: survival///treatment_protocol_ch1: Frozen rissues///growth_protocol_ch1: Frozen tissue samples were embedded, and sections were cut and mounted on slides. The slides were stained with H&E to ensure that at least 70
1
title: Te_84///geo_accession: GSM1078988///status: Public on Jan 01 2014///submission_date: Feb 06 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: primary surgical treatment///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian cancer cells///characteristics_ch1.1: tissue subtype: endometrioid///characteristics_ch1.2: advanced disease stage: stage II///characteristics_ch1.3: recurrence status: non-recurrence///characteristics_ch1.4: survival/death: survival///treatment_protocol_ch1: Frozen rissues///growth_protocol_ch1: Frozen tissue samples were embedded, and sections were cut and mounted on slides. The slides were stained with H&E to ensure that at least 70
1
title: Te_87///geo_accession: GSM1078989///status: Public on Jan 01 2014///submission_date: Feb 06 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: primary surgical treatment///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian cancer cells///characteristics_ch1.1: tissue subtype: endometrioid///characteristics_ch1.2: advanced disease stage: stage III///characteristics_ch1.3: recurrence status: non-recurrence///characteristics_ch1.4: survival/death: survival///treatment_protocol_ch1: Frozen rissues///growth_protocol_ch1: Frozen tissue samples were embedded, and sections were cut and mounted on slides. The slides were stained with H&E to ensure that at least 70
1
title: Te_89///geo_accession: GSM1078990///status: Public on Jan 01 2014///submission_date: Feb 06 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: primary surgical treatment///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian cancer cells///characteristics_ch1.1: tissue subtype: endometrioid///characteristics_ch1.2: advanced disease stage: stage I///characteristics_ch1.3: recurrence status: non-recurrence///characteristics_ch1.4: survival/death: survival///treatment_protocol_ch1: Frozen rissues///growth_protocol_ch1: Frozen tissue samples were embedded, and sections were cut and mounted on slides. The slides were stained with H&E to ensure that at least 70
1
title: Te_90///geo_accession: GSM1078991///status: Public on Jan 01 2014///submission_date: Feb 06 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: primary surgical treatment///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian cancer cells///characteristics_ch1.1: tissue subtype: endometrioid///characteristics_ch1.2: advanced disease stage: stage IV///characteristics_ch1.3: recurrence status: non-recurrence///characteristics_ch1.4: survival/death: survival///treatment_protocol_ch1: Frozen rissues///growth_protocol_ch1: Frozen tissue samples were embedded, and sections were cut and mounted on slides. The slides were stained with H&E to ensure that at least 70
1
title: Te_91///geo_accession: GSM1078992///status: Public on Jan 01 2014///submission_date: Feb 06 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: primary surgical treatment///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian cancer cells///characteristics_ch1.1: tissue subtype: endometrioid///characteristics_ch1.2: advanced disease stage: stage III///characteristics_ch1.3: recurrence status: recurrence///characteristics_ch1.4: survival/death: death///treatment_protocol_ch1: Frozen rissues///growth_protocol_ch1: Frozen tissue samples were embedded, and sections were cut and mounted on slides. The slides were stained with H&E to ensure that at least 70
1
title: Te_92///geo_accession: GSM1078993///status: Public on Jan 01 2014///submission_date: Feb 06 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: primary surgical treatment///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian cancer cells///characteristics_ch1.1: tissue subtype: endometrioid///characteristics_ch1.2: advanced disease stage: stage I///characteristics_ch1.3: recurrence status: non-recurrence///characteristics_ch1.4: survival/death: survival///treatment_protocol_ch1: Frozen rissues///growth_protocol_ch1: Frozen tissue samples were embedded, and sections were cut and mounted on slides. The slides were stained with H&E to ensure that at least 70
1
title: Te_93///geo_accession: GSM1078994///status: Public on Jan 01 2014///submission_date: Feb 06 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: primary surgical treatment///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian cancer cells///characteristics_ch1.1: tissue subtype: endometrioid///characteristics_ch1.2: advanced disease stage: stage II///characteristics_ch1.3: recurrence status: non-recurrence///characteristics_ch1.4: survival/death: survival///treatment_protocol_ch1: Frozen rissues///growth_protocol_ch1: Frozen tissue samples were embedded, and sections were cut and mounted on slides. The slides were stained with H&E to ensure that at least 70
1
title: Tm_101///geo_accession: GSM1078995///status: Public on Jan 01 2014///submission_date: Feb 06 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: primary surgical treatment///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian cancer cells///characteristics_ch1.1: tissue subtype: mucinous///characteristics_ch1.2: advanced disease stage: stage III///characteristics_ch1.3: recurrence status: non-recurrence///characteristics_ch1.4: survival/death: death///treatment_protocol_ch1: Frozen rissues///growth_protocol_ch1: Frozen tissue samples were embedded, and sections were cut and mounted on slides. The slides were stained with H&E to ensure that at least 70
1
title: Tm_102///geo_accession: GSM1078996///status: Public on Jan 01 2014///submission_date: Feb 06 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: primary surgical treatment///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian cancer cells///characteristics_ch1.1: tissue subtype: mucinous///characteristics_ch1.2: advanced disease stage: stage I///characteristics_ch1.3: recurrence status: non-recurrence///characteristics_ch1.4: survival/death: survival///treatment_protocol_ch1: Frozen rissues///growth_protocol_ch1: Frozen tissue samples were embedded, and sections were cut and mounted on slides. The slides were stained with H&E to ensure that at least 70
1
title: Tm_106///geo_accession: GSM1078997///status: Public on Jan 01 2014///submission_date: Feb 06 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: primary surgical treatment///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian cancer cells///characteristics_ch1.1: tissue subtype: mucinous///characteristics_ch1.2: advanced disease stage: stage I///characteristics_ch1.3: recurrence status: non-recurrence///characteristics_ch1.4: survival/death: survival///treatment_protocol_ch1: Frozen rissues///growth_protocol_ch1: Frozen tissue samples were embedded, and sections were cut and mounted on slides. The slides were stained with H&E to ensure that at least 70
1
title: Tm_107///geo_accession: GSM1078998///status: Public on Jan 01 2014///submission_date: Feb 06 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: primary surgical treatment///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian cancer cells///characteristics_ch1.1: tissue subtype: mucinous///characteristics_ch1.2: advanced disease stage: stage III///characteristics_ch1.3: recurrence status: non-recurrence///characteristics_ch1.4: survival/death: survival///treatment_protocol_ch1: Frozen rissues///growth_protocol_ch1: Frozen tissue samples were embedded, and sections were cut and mounted on slides. The slides were stained with H&E to ensure that at least 70
1
title: Tm_110///geo_accession: GSM1078999///status: Public on Jan 01 2014///submission_date: Feb 06 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: primary surgical treatment///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian cancer cells///characteristics_ch1.1: tissue subtype: mucinous///characteristics_ch1.2: advanced disease stage: stage I///characteristics_ch1.3: recurrence status: non-recurrence///characteristics_ch1.4: survival/death: survival///treatment_protocol_ch1: Frozen rissues///growth_protocol_ch1: Frozen tissue samples were embedded, and sections were cut and mounted on slides. The slides were stained with H&E to ensure that at least 70
1
title: Tm_95///geo_accession: GSM1079000///status: Public on Jan 01 2014///submission_date: Feb 06 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: primary surgical treatment///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian cancer cells///characteristics_ch1.1: tissue subtype: mucinous///characteristics_ch1.2: advanced disease stage: stage I///characteristics_ch1.3: recurrence status: non-recurrence///characteristics_ch1.4: survival/death: survival///treatment_protocol_ch1: Frozen rissues///growth_protocol_ch1: Frozen tissue samples were embedded, and sections were cut and mounted on slides. The slides were stained with H&E to ensure that at least 70
1
title: Tm_96///geo_accession: GSM1079001///status: Public on Jan 01 2014///submission_date: Feb 06 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: primary surgical treatment///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian cancer cells///characteristics_ch1.1: tissue subtype: mucinous///characteristics_ch1.2: advanced disease stage: stage II///characteristics_ch1.3: recurrence status: non-recurrence///characteristics_ch1.4: survival/death: survival///treatment_protocol_ch1: Frozen rissues///growth_protocol_ch1: Frozen tissue samples were embedded, and sections were cut and mounted on slides. The slides were stained with H&E to ensure that at least 70
1
title: Tm_97///geo_accession: GSM1079002///status: Public on Jan 01 2014///submission_date: Feb 06 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: primary surgical treatment///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian cancer cells///characteristics_ch1.1: tissue subtype: mucinous///characteristics_ch1.2: advanced disease stage: stage I///characteristics_ch1.3: recurrence status: non-recurrence///characteristics_ch1.4: survival/death: survival///treatment_protocol_ch1: Frozen rissues///growth_protocol_ch1: Frozen tissue samples were embedded, and sections were cut and mounted on slides. The slides were stained with H&E to ensure that at least 70
1
title: Tm_98///geo_accession: GSM1079003///status: Public on Jan 01 2014///submission_date: Feb 06 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: primary surgical treatment///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian cancer cells///characteristics_ch1.1: tissue subtype: mucinous///characteristics_ch1.2: advanced disease stage: stage II///characteristics_ch1.3: recurrence status: recurrence///characteristics_ch1.4: survival/death: death///treatment_protocol_ch1: Frozen rissues///growth_protocol_ch1: Frozen tissue samples were embedded, and sections were cut and mounted on slides. The slides were stained with H&E to ensure that at least 70
1
title: Ts_11///geo_accession: GSM1079004///status: Public on Jan 01 2014///submission_date: Feb 06 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: primary surgical treatment///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian cancer cells///characteristics_ch1.1: tissue subtype: serous///characteristics_ch1.2: advanced disease stage: stage III///characteristics_ch1.3: recurrence status: recurrence///characteristics_ch1.4: survival/death: survival///treatment_protocol_ch1: Frozen rissues///growth_protocol_ch1: Frozen tissue samples were embedded, and sections were cut and mounted on slides. The slides were stained with H&E to ensure that at least 70
1
title: Ts_14///geo_accession: GSM1079005///status: Public on Jan 01 2014///submission_date: Feb 06 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: primary surgical treatment///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian cancer cells///characteristics_ch1.1: tissue subtype: serous///characteristics_ch1.2: advanced disease stage: stage III///characteristics_ch1.3: recurrence status: recurrence///characteristics_ch1.4: survival/death: death///treatment_protocol_ch1: Frozen rissues///growth_protocol_ch1: Frozen tissue samples were embedded, and sections were cut and mounted on slides. The slides were stained with H&E to ensure that at least 70
1
title: Ts_15///geo_accession: GSM1079006///status: Public on Jan 01 2014///submission_date: Feb 06 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: primary surgical treatment///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian cancer cells///characteristics_ch1.1: tissue subtype: serous///characteristics_ch1.2: advanced disease stage: stage I///characteristics_ch1.3: recurrence status: non-recurrence///characteristics_ch1.4: survival/death: survival///treatment_protocol_ch1: Frozen rissues///growth_protocol_ch1: Frozen tissue samples were embedded, and sections were cut and mounted on slides. The slides were stained with H&E to ensure that at least 70
1
title: Ts_17///geo_accession: GSM1079007///status: Public on Jan 01 2014///submission_date: Feb 06 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: primary surgical treatment///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian cancer cells///characteristics_ch1.1: tissue subtype: serous///characteristics_ch1.2: advanced disease stage: stage I///characteristics_ch1.3: recurrence status: recurrence///characteristics_ch1.4: survival/death: death///treatment_protocol_ch1: Frozen rissues///growth_protocol_ch1: Frozen tissue samples were embedded, and sections were cut and mounted on slides. The slides were stained with H&E to ensure that at least 70
1
title: Ts_19///geo_accession: GSM1079008///status: Public on Jan 01 2014///submission_date: Feb 06 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: primary surgical treatment///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian cancer cells///characteristics_ch1.1: tissue subtype: serous///characteristics_ch1.2: advanced disease stage: stage III///characteristics_ch1.3: recurrence status: recurrence///characteristics_ch1.4: survival/death: death///treatment_protocol_ch1: Frozen rissues///growth_protocol_ch1: Frozen tissue samples were embedded, and sections were cut and mounted on slides. The slides were stained with H&E to ensure that at least 70
1
title: Ts_20///geo_accession: GSM1079009///status: Public on Jan 01 2014///submission_date: Feb 06 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: primary surgical treatment///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian cancer cells///characteristics_ch1.1: tissue subtype: serous///characteristics_ch1.2: advanced disease stage: stage III///characteristics_ch1.3: recurrence status: non-recurrence///characteristics_ch1.4: survival/death: death///treatment_protocol_ch1: Frozen rissues///growth_protocol_ch1: Frozen tissue samples were embedded, and sections were cut and mounted on slides. The slides were stained with H&E to ensure that at least 70
1
title: Ts_21///geo_accession: GSM1079010///status: Public on Jan 01 2014///submission_date: Feb 06 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: primary surgical treatment///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian cancer cells///characteristics_ch1.1: tissue subtype: serous///characteristics_ch1.2: advanced disease stage: stage III///characteristics_ch1.3: recurrence status: recurrence///characteristics_ch1.4: survival/death: survival///treatment_protocol_ch1: Frozen rissues///growth_protocol_ch1: Frozen tissue samples were embedded, and sections were cut and mounted on slides. The slides were stained with H&E to ensure that at least 70
1
title: Ts_23///geo_accession: GSM1079011///status: Public on Jan 01 2014///submission_date: Feb 06 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: primary surgical treatment///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian cancer cells///characteristics_ch1.1: tissue subtype: serous///characteristics_ch1.2: advanced disease stage: stage III///characteristics_ch1.3: recurrence status: recurrence///characteristics_ch1.4: survival/death: death///treatment_protocol_ch1: Frozen rissues///growth_protocol_ch1: Frozen tissue samples were embedded, and sections were cut and mounted on slides. The slides were stained with H&E to ensure that at least 70
1
title: Ts_24///geo_accession: GSM1079012///status: Public on Jan 01 2014///submission_date: Feb 06 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: primary surgical treatment///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian cancer cells///characteristics_ch1.1: tissue subtype: serous///characteristics_ch1.2: advanced disease stage: stage III///characteristics_ch1.3: recurrence status: recurrence///characteristics_ch1.4: survival/death: survival///treatment_protocol_ch1: Frozen rissues///growth_protocol_ch1: Frozen tissue samples were embedded, and sections were cut and mounted on slides. The slides were stained with H&E to ensure that at least 70
1
title: Ts_26///geo_accession: GSM1079013///status: Public on Jan 01 2014///submission_date: Feb 06 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: primary surgical treatment///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian cancer cells///characteristics_ch1.1: tissue subtype: serous///characteristics_ch1.2: advanced disease stage: stage III///characteristics_ch1.3: recurrence status: recurrence///characteristics_ch1.4: survival/death: death///treatment_protocol_ch1: Frozen rissues///growth_protocol_ch1: Frozen tissue samples were embedded, and sections were cut and mounted on slides. The slides were stained with H&E to ensure that at least 70
1
title: Ts_28///geo_accession: GSM1079014///status: Public on Jan 01 2014///submission_date: Feb 06 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: primary surgical treatment///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian cancer cells///characteristics_ch1.1: tissue subtype: serous///characteristics_ch1.2: advanced disease stage: stage III///characteristics_ch1.3: recurrence status: non-recurrence///characteristics_ch1.4: survival/death: survival///treatment_protocol_ch1: Frozen rissues///growth_protocol_ch1: Frozen tissue samples were embedded, and sections were cut and mounted on slides. The slides were stained with H&E to ensure that at least 70
1
title: Ts_2///geo_accession: GSM1079015///status: Public on Jan 01 2014///submission_date: Feb 06 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: primary surgical treatment///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian cancer cells///characteristics_ch1.1: tissue subtype: serous///characteristics_ch1.2: advanced disease stage: stage III///characteristics_ch1.3: recurrence status: recurrence///characteristics_ch1.4: survival/death: death///treatment_protocol_ch1: Frozen rissues///growth_protocol_ch1: Frozen tissue samples were embedded, and sections were cut and mounted on slides. The slides were stained with H&E to ensure that at least 70
1
title: Ts_31///geo_accession: GSM1079016///status: Public on Jan 01 2014///submission_date: Feb 06 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: primary surgical treatment///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian cancer cells///characteristics_ch1.1: tissue subtype: serous///characteristics_ch1.2: advanced disease stage: stage III///characteristics_ch1.3: recurrence status: non-recurrence///characteristics_ch1.4: survival/death: survival///treatment_protocol_ch1: Frozen rissues///growth_protocol_ch1: Frozen tissue samples were embedded, and sections were cut and mounted on slides. The slides were stained with H&E to ensure that at least 70
1
title: Ts_32///geo_accession: GSM1079017///status: Public on Jan 01 2014///submission_date: Feb 06 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: primary surgical treatment///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian cancer cells///characteristics_ch1.1: tissue subtype: serous///characteristics_ch1.2: advanced disease stage: stage III///characteristics_ch1.3: recurrence status: non-recurrence///characteristics_ch1.4: survival/death: survival///treatment_protocol_ch1: Frozen rissues///growth_protocol_ch1: Frozen tissue samples were embedded, and sections were cut and mounted on slides. The slides were stained with H&E to ensure that at least 70
1
title: Ts_34///geo_accession: GSM1079018///status: Public on Jan 01 2014///submission_date: Feb 06 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: primary surgical treatment///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian cancer cells///characteristics_ch1.1: tissue subtype: serous///characteristics_ch1.2: advanced disease stage: stage III///characteristics_ch1.3: recurrence status: non-recurrence///characteristics_ch1.4: survival/death: survival///treatment_protocol_ch1: Frozen rissues///growth_protocol_ch1: Frozen tissue samples were embedded, and sections were cut and mounted on slides. The slides were stained with H&E to ensure that at least 70
1
title: Ts_35///geo_accession: GSM1079019///status: Public on Jan 01 2014///submission_date: Feb 06 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: primary surgical treatment///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian cancer cells///characteristics_ch1.1: tissue subtype: serous///characteristics_ch1.2: advanced disease stage: stage III///characteristics_ch1.3: recurrence status: non-recurrence///characteristics_ch1.4: survival/death: survival///treatment_protocol_ch1: Frozen rissues///growth_protocol_ch1: Frozen tissue samples were embedded, and sections were cut and mounted on slides. The slides were stained with H&E to ensure that at least 70
1
title: Ts_36///geo_accession: GSM1079020///status: Public on Jan 01 2014///submission_date: Feb 06 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: primary surgical treatment///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian cancer cells///characteristics_ch1.1: tissue subtype: serous///characteristics_ch1.2: advanced disease stage: stage III///characteristics_ch1.3: recurrence status: recurrence///characteristics_ch1.4: survival/death: survival///treatment_protocol_ch1: Frozen rissues///growth_protocol_ch1: Frozen tissue samples were embedded, and sections were cut and mounted on slides. The slides were stained with H&E to ensure that at least 70
1
title: Ts_37///geo_accession: GSM1079021///status: Public on Jan 01 2014///submission_date: Feb 06 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: primary surgical treatment///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian cancer cells///characteristics_ch1.1: tissue subtype: serous///characteristics_ch1.2: advanced disease stage: stage III///characteristics_ch1.3: recurrence status: non-recurrence///characteristics_ch1.4: survival/death: survival///treatment_protocol_ch1: Frozen rissues///growth_protocol_ch1: Frozen tissue samples were embedded, and sections were cut and mounted on slides. The slides were stained with H&E to ensure that at least 70
1
title: Ts_39///geo_accession: GSM1079022///status: Public on Jan 01 2014///submission_date: Feb 06 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: primary surgical treatment///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian cancer cells///characteristics_ch1.1: tissue subtype: serous///characteristics_ch1.2: advanced disease stage: stage III///characteristics_ch1.3: recurrence status: recurrence///characteristics_ch1.4: survival/death: survival///treatment_protocol_ch1: Frozen rissues///growth_protocol_ch1: Frozen tissue samples were embedded, and sections were cut and mounted on slides. The slides were stained with H&E to ensure that at least 70
1
title: Ts_3///geo_accession: GSM1079023///status: Public on Jan 01 2014///submission_date: Feb 06 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: primary surgical treatment///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian cancer cells///characteristics_ch1.1: tissue subtype: serous///characteristics_ch1.2: advanced disease stage: stage III///characteristics_ch1.3: recurrence status: recurrence///characteristics_ch1.4: survival/death: survival///treatment_protocol_ch1: Frozen rissues///growth_protocol_ch1: Frozen tissue samples were embedded, and sections were cut and mounted on slides. The slides were stained with H&E to ensure that at least 70
1
title: Ts_41///geo_accession: GSM1079024///status: Public on Jan 01 2014///submission_date: Feb 06 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: primary surgical treatment///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian cancer cells///characteristics_ch1.1: tissue subtype: serous///characteristics_ch1.2: advanced disease stage: stage III///characteristics_ch1.3: recurrence status: non-recurrence///characteristics_ch1.4: survival/death: survival///treatment_protocol_ch1: Frozen rissues///growth_protocol_ch1: Frozen tissue samples were embedded, and sections were cut and mounted on slides. The slides were stained with H&E to ensure that at least 70
1
title: Ts_43///geo_accession: GSM1079025///status: Public on Jan 01 2014///submission_date: Feb 06 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: primary surgical treatment///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian cancer cells///characteristics_ch1.1: tissue subtype: serous///characteristics_ch1.2: advanced disease stage: stage II///characteristics_ch1.3: recurrence status: non-recurrence///characteristics_ch1.4: survival/death: survival///treatment_protocol_ch1: Frozen rissues///growth_protocol_ch1: Frozen tissue samples were embedded, and sections were cut and mounted on slides. The slides were stained with H&E to ensure that at least 70
1
title: Ts_45///geo_accession: GSM1079026///status: Public on Jan 01 2014///submission_date: Feb 06 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: primary surgical treatment///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian cancer cells///characteristics_ch1.1: tissue subtype: serous///characteristics_ch1.2: advanced disease stage: stage IV///characteristics_ch1.3: recurrence status: non-recurrence///characteristics_ch1.4: survival/death: survival///treatment_protocol_ch1: Frozen rissues///growth_protocol_ch1: Frozen tissue samples were embedded, and sections were cut and mounted on slides. The slides were stained with H&E to ensure that at least 70
1
title: Ts_46///geo_accession: GSM1079027///status: Public on Jan 01 2014///submission_date: Feb 06 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: primary surgical treatment///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian cancer cells///characteristics_ch1.1: tissue subtype: serous///characteristics_ch1.2: advanced disease stage: stage II///characteristics_ch1.3: recurrence status: non-recurrence///characteristics_ch1.4: survival/death: survival///treatment_protocol_ch1: Frozen rissues///growth_protocol_ch1: Frozen tissue samples were embedded, and sections were cut and mounted on slides. The slides were stained with H&E to ensure that at least 70
1
title: Ts_47///geo_accession: GSM1079028///status: Public on Jan 01 2014///submission_date: Feb 06 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: primary surgical treatment///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian cancer cells///characteristics_ch1.1: tissue subtype: serous///characteristics_ch1.2: advanced disease stage: stage III///characteristics_ch1.3: recurrence status: non-recurrence///characteristics_ch1.4: survival/death: survival///treatment_protocol_ch1: Frozen rissues///growth_protocol_ch1: Frozen tissue samples were embedded, and sections were cut and mounted on slides. The slides were stained with H&E to ensure that at least 70
1
title: Ts_4///geo_accession: GSM1079029///status: Public on Jan 01 2014///submission_date: Feb 06 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: primary surgical treatment///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian cancer cells///characteristics_ch1.1: tissue subtype: serous///characteristics_ch1.2: advanced disease stage: stage III///characteristics_ch1.3: recurrence status: recurrence///characteristics_ch1.4: survival/death: death///treatment_protocol_ch1: Frozen rissues///growth_protocol_ch1: Frozen tissue samples were embedded, and sections were cut and mounted on slides. The slides were stained with H&E to ensure that at least 70
1
title: Ts_5///geo_accession: GSM1079030///status: Public on Jan 01 2014///submission_date: Feb 06 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: primary surgical treatment///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian cancer cells///characteristics_ch1.1: tissue subtype: serous///characteristics_ch1.2: advanced disease stage: stage IV///characteristics_ch1.3: recurrence status: recurrence///characteristics_ch1.4: survival/death: death///treatment_protocol_ch1: Frozen rissues///growth_protocol_ch1: Frozen tissue samples were embedded, and sections were cut and mounted on slides. The slides were stained with H&E to ensure that at least 70
1
title: Ts_8///geo_accession: GSM1079031///status: Public on Jan 01 2014///submission_date: Feb 06 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: primary surgical treatment///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian cancer cells///characteristics_ch1.1: tissue subtype: serous///characteristics_ch1.2: advanced disease stage: stage III///characteristics_ch1.3: recurrence status: recurrence///characteristics_ch1.4: survival/death: survival///treatment_protocol_ch1: Frozen rissues///growth_protocol_ch1: Frozen tissue samples were embedded, and sections were cut and mounted on slides. The slides were stained with H&E to ensure that at least 70
1
duplicates:
Length Class Mode
60 character character
An expression set
Most patients with epithelial ovarian cancer (EOC) are diagnosed at advanced stage and have a poor prognosis. However, a small proportion of these patients will survive, whereas others will die very quickly. Clinicopathological factors do not allow precise identification of these subgroups. Thus, we have validated a molecular subclassification as new prognostic factor in EOC. One hundred and ninety-four patients with Stage II-IV EOC were characterized by whole-genome expression profiling of tumor tissues and were classified using a published 112 gene set, derived from an International Federation of Gynecology and Obstetrics (FIGO) stage-directed supervised classification approach. The 194 tumor samples were classified into two subclasses comprising 95 (Subclass 1) and 99 (Subclass 2) tumors. All nine FIGO II tumors were grouped in Subclass 1 (P = 0.001). Subclass 2 (54% of advanced-stage tumors) was significantly correlated with peritoneal carcinomatosis and non-optimal debulking. Patients with Subclass 2 tumors had a worse overall survival for both serous and non-serous histological subtypes, as revealed by univariate analysis (hazard ratios [HR] of 3.17 and 17.11, respectively; P ??? 0.001) and in models corrected for relevant clinicopathologic parameters (HR 2.87 and 12.42, respectively; P ??? 0.023). Significance analysis of microarrays revealed 2082 genes that were differentially expressed in advanced-grade serous tumors of both subclasses and the focal adhesion pathway as the most deregulated pathway. In the present validation study, we have shown that, in advanced-stage serous ovarian cancer, two approximately equally large molecular subtypes exist, independent of classical clinocopathological parameters and presenting with highly different whole-genome expression profiles and a markedly different overall survival. Similar results were obtained in a small cohort of patients with non-serous tumors.?? 2012 Japanese Cancer Association.
experimentData(eset):
Experiment data
Experimenter name: Pils D1, Hager G, Tong D, Aust S, Heinze G, Kohl M, Schuster E, Wolf A, Sehouli J, Braicu I, Vergote I, Cadron I, Mahner S, Hofstetter G, Speiser P, Zeillinger R
Laboratory: Pils, Zeilinger 2012
Contact information:
Title: Validating the impact of a molecular subtype in ovarian cancer on outcomes: a study of the OVCAD Consortium.
URL:
PMIDs: 22497737
Abstract: A 276 word abstract is available. Use 'abstract' method.
Information is available on: preprocessing
notes:
platform_title:
ABI Human Genome Survey Microarray Version 2
platform_shorttitle:
ABI Human Genome
platform_summary:
platform_manufacturer:
Applied Biosystems
platform_distribution:
commercial
platform_accession:
GPL2986
platform_technology:
in situ oligonucleotide
version:
2015-09-22 20:04:13
featureData(eset):
An object of class 'AnnotatedDataFrame'
featureNames: 100027 100036 ... 10715781 (18439 total)
varLabels: probeset gene EntrezGene.ID best_probe
varMetadata: labelDescription
assayData: 18439 features, 204 samples
Platform type:
Overall survival time-to-event summary (in years):
Call: survfit(formula = Surv(time, cens) ~ -1)
10 observations deleted due to missingness
n events median 0.95LCL 0.95UCL
194.00 57.00 NA 3.67 NA
---------------------------
Available sample meta-data:
---------------------------
alt_sample_name:
EOC P001 EOC P002 EOC P003 EOC P004 EOC P005 EOC P006 EOC P007 EOC P008
1 1 1 1 1 1 1 1
EOC P009 EOC P010 EOC P011 EOC P012 EOC P013 EOC P014 EOC P015 EOC P016
1 1 1 1 1 1 1 1
EOC P017 EOC P018 EOC P019 EOC P020 EOC P021 EOC P022 EOC P023 EOC P024
1 1 1 1 1 1 1 1
EOC P025 EOC P026 EOC P027 EOC P028 EOC P029 EOC P030 EOC P031 EOC P032
1 1 1 1 1 1 1 1
EOC P033 EOC P034 EOC P035 EOC P036 EOC P037 EOC P038 EOC P039 EOC P040
1 1 1 1 1 1 1 1
EOC P041 EOC P042 EOC P043 EOC P044 EOC P045 EOC P046 EOC P047 EOC P048
1 1 1 1 1 1 1 1
EOC P049 EOC P050 EOC P051 EOC P052 EOC P053 EOC P054 EOC P055 EOC P056
1 1 1 1 1 1 1 1
EOC P057 EOC P058 EOC P059 EOC P060 EOC P061 EOC P062 EOC P063 EOC P064
1 1 1 1 1 1 1 1
EOC P065 EOC P066 EOC P067 EOC P068 EOC P069 EOC P070 EOC P071 EOC P072
1 1 1 1 1 1 1 1
EOC P073 EOC P074 EOC P075 EOC P076 EOC P077 EOC P078 EOC P079 EOC P080
1 1 1 1 1 1 1 1
EOC P081 EOC P082 EOC P083 EOC P084 EOC P085 EOC P086 EOC P087 EOC P088
1 1 1 1 1 1 1 1
EOC P089 EOC P090 EOC P091 EOC P092 EOC P093 EOC P094 EOC P095 EOC P096
1 1 1 1 1 1 1 1
EOC P097 EOC P098 EOC P099 (Other)
1 1 1 105
sample_type:
tumor
204
histological_type:
other ser NA's
23 171 10
summarygrade:
high low NA's
143 50 11
summarystage:
early late NA's
9 185 10
tumorstage:
2 3 4 NA's
9 154 31 10
grade:
2 3 NA's
50 143 11
age_at_initial_pathologic_diagnosis:
Min. 1st Qu. Median Mean 3rd Qu. Max. NA's
26.00 50.00 57.00 57.66 67.00 85.00 10
days_to_tumor_recurrence:
Min. 1st Qu. Median Mean 3rd Qu. Max. NA's
30.0 335.0 487.0 580.1 722.5 1461.0 10
recurrence_status:
norecurrence recurrence NA's
70 124 10
days_to_death:
Min. 1st Qu. Median Mean 3rd Qu. Max. NA's
30.0 517.0 745.5 782.9 1027.0 1491.0 10
vital_status:
deceased living NA's
57 137 10
debulking:
optimal suboptimal NA's
137 57 10
uncurated_author_metadata:
title: EOC P001///geo_accession: GSM1211536///status: Public on Jan 01 2014///submission_date: Aug 19 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor tissue///organism_ch1: Homo sapiens///characteristics_ch1: excluded: no///characteristics_ch1.1: subclass: 2///characteristics_ch1.2: age: 44///characteristics_ch1.3: histology: Serous///characteristics_ch1.4: figo grade: III///characteristics_ch1.5: grade: 3///characteristics_ch1.6: peritoneal carcinomatosis: Yes///characteristics_ch1.7: residual tumor: Yes///characteristics_ch1.8: pfs event: 1///characteristics_ch1.9: pfs month: 11///characteristics_ch1.10: os event: 0///characteristics_ch1.11: os month: 20///molecule_ch1: total RNA///extract_protocol_ch1: total RNA from epithelial ovarian cancer tissues was isolated with the ABI PRISM 6100 Nucleic Acid PrepStation (Applied Biosystems) according to the manufacturers instructions///label_ch1: DIG///label_protocol_ch1: Applied Biosystems Chemiluminescent RT Labeling Kit///taxid_ch1: 9606///hyb_protocol: Applied Biosystems Chemiluminescence Detection Kit///scan_protocol: Expression Array System Software v1.1.1///description: Human Genome Survey Microarray V2.0 (Applied Biosystems)///data_processing: R Package ABarray 1.4.2 (Filtering flags > 5000, quantile normalization, log-2 transformation), Batch correction as follows: subtraction of the batch-specific mean from each gene, and add the overall mean.///platform_id: GPL2986///contact_name: Dietmar,,Pils///contact_email: [email protected]///contact_institute: Medical University of Vienna///contact_address: Waehringer Guertel 18-20///contact_city: Vienna///contact_zip.postal_code: 1090///contact_country: Austria///supplementary_file: NONE///data_row_count: 32878
1
title: EOC P002///geo_accession: GSM1211537///status: Public on Jan 01 2014///submission_date: Aug 19 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor tissue///organism_ch1: Homo sapiens///characteristics_ch1: excluded: no///characteristics_ch1.1: subclass: 2///characteristics_ch1.2: age: 71///characteristics_ch1.3: histology: Serous///characteristics_ch1.4: figo grade: III///characteristics_ch1.5: grade: 3///characteristics_ch1.6: peritoneal carcinomatosis: Yes///characteristics_ch1.7: residual tumor: No///characteristics_ch1.8: pfs event: 1///characteristics_ch1.9: pfs month: 14///characteristics_ch1.10: os event: 1///characteristics_ch1.11: os month: 31///molecule_ch1: total RNA///extract_protocol_ch1: total RNA from epithelial ovarian cancer tissues was isolated with the ABI PRISM 6100 Nucleic Acid PrepStation (Applied Biosystems) according to the manufacturers instructions///label_ch1: DIG///label_protocol_ch1: Applied Biosystems Chemiluminescent RT Labeling Kit///taxid_ch1: 9606///hyb_protocol: Applied Biosystems Chemiluminescence Detection Kit///scan_protocol: Expression Array System Software v1.1.1///description: Human Genome Survey Microarray V2.0 (Applied Biosystems)///data_processing: R Package ABarray 1.4.2 (Filtering flags > 5000, quantile normalization, log-2 transformation), Batch correction as follows: subtraction of the batch-specific mean from each gene, and add the overall mean.///platform_id: GPL2986///contact_name: Dietmar,,Pils///contact_email: [email protected]///contact_institute: Medical University of Vienna///contact_address: Waehringer Guertel 18-20///contact_city: Vienna///contact_zip.postal_code: 1090///contact_country: Austria///supplementary_file: NONE///data_row_count: 32878
1
title: EOC P003///geo_accession: GSM1211538///status: Public on Jan 01 2014///submission_date: Aug 19 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor tissue///organism_ch1: Homo sapiens///characteristics_ch1: excluded: no///characteristics_ch1.1: subclass: 2///characteristics_ch1.2: age: 56///characteristics_ch1.3: histology: Serous///characteristics_ch1.4: figo grade: III///characteristics_ch1.5: grade: 1&2///characteristics_ch1.6: peritoneal carcinomatosis: Yes///characteristics_ch1.7: residual tumor: No///characteristics_ch1.8: pfs event: 1///characteristics_ch1.9: pfs month: 20///characteristics_ch1.10: os event: 1///characteristics_ch1.11: os month: 34///molecule_ch1: total RNA///extract_protocol_ch1: total RNA from epithelial ovarian cancer tissues was isolated with the ABI PRISM 6100 Nucleic Acid PrepStation (Applied Biosystems) according to the manufacturers instructions///label_ch1: DIG///label_protocol_ch1: Applied Biosystems Chemiluminescent RT Labeling Kit///taxid_ch1: 9606///hyb_protocol: Applied Biosystems Chemiluminescence Detection Kit///scan_protocol: Expression Array System Software v1.1.1///description: Human Genome Survey Microarray V2.0 (Applied Biosystems)///data_processing: R Package ABarray 1.4.2 (Filtering flags > 5000, quantile normalization, log-2 transformation), Batch correction as follows: subtraction of the batch-specific mean from each gene, and add the overall mean.///platform_id: GPL2986///contact_name: Dietmar,,Pils///contact_email: [email protected]///contact_institute: Medical University of Vienna///contact_address: Waehringer Guertel 18-20///contact_city: Vienna///contact_zip.postal_code: 1090///contact_country: Austria///supplementary_file: NONE///data_row_count: 32878
1
title: EOC P004///geo_accession: GSM1211539///status: Public on Jan 01 2014///submission_date: Aug 19 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor tissue///organism_ch1: Homo sapiens///characteristics_ch1: excluded: no///characteristics_ch1.1: subclass: 2///characteristics_ch1.2: age: 42///characteristics_ch1.3: histology: Serous///characteristics_ch1.4: figo grade: III///characteristics_ch1.5: grade: 1&2///characteristics_ch1.6: peritoneal carcinomatosis: No///characteristics_ch1.7: residual tumor: No///characteristics_ch1.8: pfs event: 0///characteristics_ch1.9: pfs month: 47///characteristics_ch1.10: os event: 0///characteristics_ch1.11: os month: 47///molecule_ch1: total RNA///extract_protocol_ch1: total RNA from epithelial ovarian cancer tissues was isolated with the ABI PRISM 6100 Nucleic Acid PrepStation (Applied Biosystems) according to the manufacturers instructions///label_ch1: DIG///label_protocol_ch1: Applied Biosystems Chemiluminescent RT Labeling Kit///taxid_ch1: 9606///hyb_protocol: Applied Biosystems Chemiluminescence Detection Kit///scan_protocol: Expression Array System Software v1.1.1///description: Human Genome Survey Microarray V2.0 (Applied Biosystems)///data_processing: R Package ABarray 1.4.2 (Filtering flags > 5000, quantile normalization, log-2 transformation), Batch correction as follows: subtraction of the batch-specific mean from each gene, and add the overall mean.///platform_id: GPL2986///contact_name: Dietmar,,Pils///contact_email: [email protected]///contact_institute: Medical University of Vienna///contact_address: Waehringer Guertel 18-20///contact_city: Vienna///contact_zip.postal_code: 1090///contact_country: Austria///supplementary_file: NONE///data_row_count: 32878
1
title: EOC P005///geo_accession: GSM1211540///status: Public on Jan 01 2014///submission_date: Aug 19 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor tissue///organism_ch1: Homo sapiens///characteristics_ch1: excluded: no///characteristics_ch1.1: subclass: 1///characteristics_ch1.2: age: 54///characteristics_ch1.3: histology: Serous///characteristics_ch1.4: figo grade: III///characteristics_ch1.5: grade: 3///characteristics_ch1.6: peritoneal carcinomatosis: Yes///characteristics_ch1.7: residual tumor: No///characteristics_ch1.8: pfs event: 1///characteristics_ch1.9: pfs month: 13///characteristics_ch1.10: os event: 1///characteristics_ch1.11: os month: 22///molecule_ch1: total RNA///extract_protocol_ch1: total RNA from epithelial ovarian cancer tissues was isolated with the ABI PRISM 6100 Nucleic Acid PrepStation (Applied Biosystems) according to the manufacturers instructions///label_ch1: DIG///label_protocol_ch1: Applied Biosystems Chemiluminescent RT Labeling Kit///taxid_ch1: 9606///hyb_protocol: Applied Biosystems Chemiluminescence Detection Kit///scan_protocol: Expression Array System Software v1.1.1///description: Human Genome Survey Microarray V2.0 (Applied Biosystems)///data_processing: R Package ABarray 1.4.2 (Filtering flags > 5000, quantile normalization, log-2 transformation), Batch correction as follows: subtraction of the batch-specific mean from each gene, and add the overall mean.///platform_id: GPL2986///contact_name: Dietmar,,Pils///contact_email: [email protected]///contact_institute: Medical University of Vienna///contact_address: Waehringer Guertel 18-20///contact_city: Vienna///contact_zip.postal_code: 1090///contact_country: Austria///supplementary_file: NONE///data_row_count: 32878
1
title: EOC P006///geo_accession: GSM1211541///status: Public on Jan 01 2014///submission_date: Aug 19 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor tissue///organism_ch1: Homo sapiens///characteristics_ch1: excluded: no///characteristics_ch1.1: subclass: 1///characteristics_ch1.2: age: 51///characteristics_ch1.3: histology: Serous///characteristics_ch1.4: figo grade: III///characteristics_ch1.5: grade: 1&2///characteristics_ch1.6: peritoneal carcinomatosis: Yes///characteristics_ch1.7: residual tumor: No///characteristics_ch1.8: pfs event: 1///characteristics_ch1.9: pfs month: 32///characteristics_ch1.10: os event: 0///characteristics_ch1.11: os month: 42///molecule_ch1: total RNA///extract_protocol_ch1: total RNA from epithelial ovarian cancer tissues was isolated with the ABI PRISM 6100 Nucleic Acid PrepStation (Applied Biosystems) according to the manufacturers instructions///label_ch1: DIG///label_protocol_ch1: Applied Biosystems Chemiluminescent RT Labeling Kit///taxid_ch1: 9606///hyb_protocol: Applied Biosystems Chemiluminescence Detection Kit///scan_protocol: Expression Array System Software v1.1.1///description: Human Genome Survey Microarray V2.0 (Applied Biosystems)///data_processing: R Package ABarray 1.4.2 (Filtering flags > 5000, quantile normalization, log-2 transformation), Batch correction as follows: subtraction of the batch-specific mean from each gene, and add the overall mean.///platform_id: GPL2986///contact_name: Dietmar,,Pils///contact_email: [email protected]///contact_institute: Medical University of Vienna///contact_address: Waehringer Guertel 18-20///contact_city: Vienna///contact_zip.postal_code: 1090///contact_country: Austria///supplementary_file: NONE///data_row_count: 32878
1
title: EOC P007///geo_accession: GSM1211542///status: Public on Jan 01 2014///submission_date: Aug 19 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor tissue///organism_ch1: Homo sapiens///characteristics_ch1: excluded: yes///characteristics_ch1.1: subclass: 1///characteristics_ch1.2: ///characteristics_ch1.3: ///characteristics_ch1.4: ///characteristics_ch1.5: ///characteristics_ch1.6: ///characteristics_ch1.7: ///characteristics_ch1.8: ///characteristics_ch1.9: ///characteristics_ch1.10: ///characteristics_ch1.11: ///molecule_ch1: total RNA///extract_protocol_ch1: total RNA from epithelial ovarian cancer tissues was isolated with the ABI PRISM 6100 Nucleic Acid PrepStation (Applied Biosystems) according to the manufacturers instructions///label_ch1: DIG///label_protocol_ch1: Applied Biosystems Chemiluminescent RT Labeling Kit///taxid_ch1: 9606///hyb_protocol: Applied Biosystems Chemiluminescence Detection Kit///scan_protocol: Expression Array System Software v1.1.1///description: Human Genome Survey Microarray V2.0 (Applied Biosystems)///data_processing: R Package ABarray 1.4.2 (Filtering flags > 5000, quantile normalization, log-2 transformation), Batch correction as follows: subtraction of the batch-specific mean from each gene, and add the overall mean.///platform_id: GPL2986///contact_name: Dietmar,,Pils///contact_email: [email protected]///contact_institute: Medical University of Vienna///contact_address: Waehringer Guertel 18-20///contact_city: Vienna///contact_zip.postal_code: 1090///contact_country: Austria///supplementary_file: NONE///data_row_count: 32878
1
title: EOC P008///geo_accession: GSM1211543///status: Public on Jan 01 2014///submission_date: Aug 19 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor tissue///organism_ch1: Homo sapiens///characteristics_ch1: excluded: no///characteristics_ch1.1: subclass: 2///characteristics_ch1.2: age: 43///characteristics_ch1.3: histology: Non-serous///characteristics_ch1.4: figo grade: III///characteristics_ch1.5: grade: 3///characteristics_ch1.6: peritoneal carcinomatosis: Yes///characteristics_ch1.7: residual tumor: No///characteristics_ch1.8: pfs event: 1///characteristics_ch1.9: pfs month: 9///characteristics_ch1.10: os event: 1///characteristics_ch1.11: os month: 22///molecule_ch1: total RNA///extract_protocol_ch1: total RNA from epithelial ovarian cancer tissues was isolated with the ABI PRISM 6100 Nucleic Acid PrepStation (Applied Biosystems) according to the manufacturers instructions///label_ch1: DIG///label_protocol_ch1: Applied Biosystems Chemiluminescent RT Labeling Kit///taxid_ch1: 9606///hyb_protocol: Applied Biosystems Chemiluminescence Detection Kit///scan_protocol: Expression Array System Software v1.1.1///description: Human Genome Survey Microarray V2.0 (Applied Biosystems)///data_processing: R Package ABarray 1.4.2 (Filtering flags > 5000, quantile normalization, log-2 transformation), Batch correction as follows: subtraction of the batch-specific mean from each gene, and add the overall mean.///platform_id: GPL2986///contact_name: Dietmar,,Pils///contact_email: [email protected]///contact_institute: Medical University of Vienna///contact_address: Waehringer Guertel 18-20///contact_city: Vienna///contact_zip.postal_code: 1090///contact_country: Austria///supplementary_file: NONE///data_row_count: 32878
1
title: EOC P009///geo_accession: GSM1211544///status: Public on Jan 01 2014///submission_date: Aug 19 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor tissue///organism_ch1: Homo sapiens///characteristics_ch1: excluded: no///characteristics_ch1.1: subclass: 1///characteristics_ch1.2: age: 53///characteristics_ch1.3: histology: Serous///characteristics_ch1.4: figo grade: III///characteristics_ch1.5: grade: 3///characteristics_ch1.6: peritoneal carcinomatosis: No///characteristics_ch1.7: residual tumor: No///characteristics_ch1.8: pfs event: 1///characteristics_ch1.9: pfs month: 43///characteristics_ch1.10: os event: 0///characteristics_ch1.11: os month: 44///molecule_ch1: total RNA///extract_protocol_ch1: total RNA from epithelial ovarian cancer tissues was isolated with the ABI PRISM 6100 Nucleic Acid PrepStation (Applied Biosystems) according to the manufacturers instructions///label_ch1: DIG///label_protocol_ch1: Applied Biosystems Chemiluminescent RT Labeling Kit///taxid_ch1: 9606///hyb_protocol: Applied Biosystems Chemiluminescence Detection Kit///scan_protocol: Expression Array System Software v1.1.1///description: Human Genome Survey Microarray V2.0 (Applied Biosystems)///data_processing: R Package ABarray 1.4.2 (Filtering flags > 5000, quantile normalization, log-2 transformation), Batch correction as follows: subtraction of the batch-specific mean from each gene, and add the overall mean.///platform_id: GPL2986///contact_name: Dietmar,,Pils///contact_email: [email protected]///contact_institute: Medical University of Vienna///contact_address: Waehringer Guertel 18-20///contact_city: Vienna///contact_zip.postal_code: 1090///contact_country: Austria///supplementary_file: NONE///data_row_count: 32878
1
title: EOC P010///geo_accession: GSM1211545///status: Public on Jan 01 2014///submission_date: Aug 19 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor tissue///organism_ch1: Homo sapiens///characteristics_ch1: excluded: yes///characteristics_ch1.1: subclass: 2///characteristics_ch1.2: ///characteristics_ch1.3: ///characteristics_ch1.4: ///characteristics_ch1.5: ///characteristics_ch1.6: ///characteristics_ch1.7: ///characteristics_ch1.8: ///characteristics_ch1.9: ///characteristics_ch1.10: ///characteristics_ch1.11: ///molecule_ch1: total RNA///extract_protocol_ch1: total RNA from epithelial ovarian cancer tissues was isolated with the ABI PRISM 6100 Nucleic Acid PrepStation (Applied Biosystems) according to the manufacturers instructions///label_ch1: DIG///label_protocol_ch1: Applied Biosystems Chemiluminescent RT Labeling Kit///taxid_ch1: 9606///hyb_protocol: Applied Biosystems Chemiluminescence Detection Kit///scan_protocol: Expression Array System Software v1.1.1///description: Human Genome Survey Microarray V2.0 (Applied Biosystems)///data_processing: R Package ABarray 1.4.2 (Filtering flags > 5000, quantile normalization, log-2 transformation), Batch correction as follows: subtraction of the batch-specific mean from each gene, and add the overall mean.///platform_id: GPL2986///contact_name: Dietmar,,Pils///contact_email: [email protected]///contact_institute: Medical University of Vienna///contact_address: Waehringer Guertel 18-20///contact_city: Vienna///contact_zip.postal_code: 1090///contact_country: Austria///supplementary_file: NONE///data_row_count: 32878
1
title: EOC P011///geo_accession: GSM1211546///status: Public on Jan 01 2014///submission_date: Aug 19 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor tissue///organism_ch1: Homo sapiens///characteristics_ch1: excluded: no///characteristics_ch1.1: subclass: 1///characteristics_ch1.2: age: 71///characteristics_ch1.3: histology: Serous///characteristics_ch1.4: figo grade: III///characteristics_ch1.5: grade: 3///characteristics_ch1.6: peritoneal carcinomatosis: Yes///characteristics_ch1.7: residual tumor: No///characteristics_ch1.8: pfs event: 0///characteristics_ch1.9: pfs month: 45///characteristics_ch1.10: os event: 0///characteristics_ch1.11: os month: 45///molecule_ch1: total RNA///extract_protocol_ch1: total RNA from epithelial ovarian cancer tissues was isolated with the ABI PRISM 6100 Nucleic Acid PrepStation (Applied Biosystems) according to the manufacturers instructions///label_ch1: DIG///label_protocol_ch1: Applied Biosystems Chemiluminescent RT Labeling Kit///taxid_ch1: 9606///hyb_protocol: Applied Biosystems Chemiluminescence Detection Kit///scan_protocol: Expression Array System Software v1.1.1///description: Human Genome Survey Microarray V2.0 (Applied Biosystems)///data_processing: R Package ABarray 1.4.2 (Filtering flags > 5000, quantile normalization, log-2 transformation), Batch correction as follows: subtraction of the batch-specific mean from each gene, and add the overall mean.///platform_id: GPL2986///contact_name: Dietmar,,Pils///contact_email: [email protected]///contact_institute: Medical University of Vienna///contact_address: Waehringer Guertel 18-20///contact_city: Vienna///contact_zip.postal_code: 1090///contact_country: Austria///supplementary_file: NONE///data_row_count: 32878
1
title: EOC P012///geo_accession: GSM1211547///status: Public on Jan 01 2014///submission_date: Aug 19 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor tissue///organism_ch1: Homo sapiens///characteristics_ch1: excluded: no///characteristics_ch1.1: subclass: 1///characteristics_ch1.2: age: 57///characteristics_ch1.3: histology: Serous///characteristics_ch1.4: figo grade: III///characteristics_ch1.5: grade: 3///characteristics_ch1.6: peritoneal carcinomatosis: Yes///characteristics_ch1.7: residual tumor: Yes///characteristics_ch1.8: pfs event: 1///characteristics_ch1.9: pfs month: 14///characteristics_ch1.10: os event: 0///characteristics_ch1.11: os month: 31///molecule_ch1: total RNA///extract_protocol_ch1: total RNA from epithelial ovarian cancer tissues was isolated with the ABI PRISM 6100 Nucleic Acid PrepStation (Applied Biosystems) according to the manufacturers instructions///label_ch1: DIG///label_protocol_ch1: Applied Biosystems Chemiluminescent RT Labeling Kit///taxid_ch1: 9606///hyb_protocol: Applied Biosystems Chemiluminescence Detection Kit///scan_protocol: Expression Array System Software v1.1.1///description: Human Genome Survey Microarray V2.0 (Applied Biosystems)///data_processing: R Package ABarray 1.4.2 (Filtering flags > 5000, quantile normalization, log-2 transformation), Batch correction as follows: subtraction of the batch-specific mean from each gene, and add the overall mean.///platform_id: GPL2986///contact_name: Dietmar,,Pils///contact_email: [email protected]///contact_institute: Medical University of Vienna///contact_address: Waehringer Guertel 18-20///contact_city: Vienna///contact_zip.postal_code: 1090///contact_country: Austria///supplementary_file: NONE///data_row_count: 32878
1
title: EOC P013///geo_accession: GSM1211548///status: Public on Jan 01 2014///submission_date: Aug 19 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor tissue///organism_ch1: Homo sapiens///characteristics_ch1: excluded: no///characteristics_ch1.1: subclass: 2///characteristics_ch1.2: age: 59///characteristics_ch1.3: histology: Non-serous///characteristics_ch1.4: figo grade: III///characteristics_ch1.5: grade: 1&2///characteristics_ch1.6: peritoneal carcinomatosis: Yes///characteristics_ch1.7: residual tumor: No///characteristics_ch1.8: pfs event: 1///characteristics_ch1.9: pfs month: 16///characteristics_ch1.10: os event: 1///characteristics_ch1.11: os month: 18///molecule_ch1: total RNA///extract_protocol_ch1: total RNA from epithelial ovarian cancer tissues was isolated with the ABI PRISM 6100 Nucleic Acid PrepStation (Applied Biosystems) according to the manufacturers instructions///label_ch1: DIG///label_protocol_ch1: Applied Biosystems Chemiluminescent RT Labeling Kit///taxid_ch1: 9606///hyb_protocol: Applied Biosystems Chemiluminescence Detection Kit///scan_protocol: Expression Array System Software v1.1.1///description: Human Genome Survey Microarray V2.0 (Applied Biosystems)///data_processing: R Package ABarray 1.4.2 (Filtering flags > 5000, quantile normalization, log-2 transformation), Batch correction as follows: subtraction of the batch-specific mean from each gene, and add the overall mean.///platform_id: GPL2986///contact_name: Dietmar,,Pils///contact_email: [email protected]///contact_institute: Medical University of Vienna///contact_address: Waehringer Guertel 18-20///contact_city: Vienna///contact_zip.postal_code: 1090///contact_country: Austria///supplementary_file: NONE///data_row_count: 32878
1
title: EOC P014///geo_accession: GSM1211549///status: Public on Jan 01 2014///submission_date: Aug 19 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor tissue///organism_ch1: Homo sapiens///characteristics_ch1: excluded: no///characteristics_ch1.1: subclass: 1///characteristics_ch1.2: age: 57///characteristics_ch1.3: histology: Serous///characteristics_ch1.4: figo grade: III///characteristics_ch1.5: grade: 3///characteristics_ch1.6: peritoneal carcinomatosis: No///characteristics_ch1.7: residual tumor: No///characteristics_ch1.8: pfs event: 0///characteristics_ch1.9: pfs month: 40///characteristics_ch1.10: os event: 0///characteristics_ch1.11: os month: 40///molecule_ch1: total RNA///extract_protocol_ch1: total RNA from epithelial ovarian cancer tissues was isolated with the ABI PRISM 6100 Nucleic Acid PrepStation (Applied Biosystems) according to the manufacturers instructions///label_ch1: DIG///label_protocol_ch1: Applied Biosystems Chemiluminescent RT Labeling Kit///taxid_ch1: 9606///hyb_protocol: Applied Biosystems Chemiluminescence Detection Kit///scan_protocol: Expression Array System Software v1.1.1///description: Human Genome Survey Microarray V2.0 (Applied Biosystems)///data_processing: R Package ABarray 1.4.2 (Filtering flags > 5000, quantile normalization, log-2 transformation), Batch correction as follows: subtraction of the batch-specific mean from each gene, and add the overall mean.///platform_id: GPL2986///contact_name: Dietmar,,Pils///contact_email: [email protected]///contact_institute: Medical University of Vienna///contact_address: Waehringer Guertel 18-20///contact_city: Vienna///contact_zip.postal_code: 1090///contact_country: Austria///supplementary_file: NONE///data_row_count: 32878
1
title: EOC P015///geo_accession: GSM1211550///status: Public on Jan 01 2014///submission_date: Aug 19 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor tissue///organism_ch1: Homo sapiens///characteristics_ch1: excluded: no///characteristics_ch1.1: subclass: 2///characteristics_ch1.2: age: 59///characteristics_ch1.3: histology: Serous///characteristics_ch1.4: figo grade: III///characteristics_ch1.5: grade: 3///characteristics_ch1.6: peritoneal carcinomatosis: Yes///characteristics_ch1.7: residual tumor: Yes///characteristics_ch1.8: pfs event: 1///characteristics_ch1.9: pfs month: 27///characteristics_ch1.10: os event: 0///characteristics_ch1.11: os month: 32///molecule_ch1: total RNA///extract_protocol_ch1: total RNA from epithelial ovarian cancer tissues was isolated with the ABI PRISM 6100 Nucleic Acid PrepStation (Applied Biosystems) according to the manufacturers instructions///label_ch1: DIG///label_protocol_ch1: Applied Biosystems Chemiluminescent RT Labeling Kit///taxid_ch1: 9606///hyb_protocol: Applied Biosystems Chemiluminescence Detection Kit///scan_protocol: Expression Array System Software v1.1.1///description: Human Genome Survey Microarray V2.0 (Applied Biosystems)///data_processing: R Package ABarray 1.4.2 (Filtering flags > 5000, quantile normalization, log-2 transformation), Batch correction as follows: subtraction of the batch-specific mean from each gene, and add the overall mean.///platform_id: GPL2986///contact_name: Dietmar,,Pils///contact_email: [email protected]///contact_institute: Medical University of Vienna///contact_address: Waehringer Guertel 18-20///contact_city: Vienna///contact_zip.postal_code: 1090///contact_country: Austria///supplementary_file: NONE///data_row_count: 32878
1
title: EOC P016///geo_accession: GSM1211551///status: Public on Jan 01 2014///submission_date: Aug 19 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor tissue///organism_ch1: Homo sapiens///characteristics_ch1: excluded: no///characteristics_ch1.1: subclass: 1///characteristics_ch1.2: age: 48///characteristics_ch1.3: histology: Serous///characteristics_ch1.4: figo grade: III///characteristics_ch1.5: grade: 3///characteristics_ch1.6: peritoneal carcinomatosis: Yes///characteristics_ch1.7: residual tumor: No///characteristics_ch1.8: pfs event: 1///characteristics_ch1.9: pfs month: 13///characteristics_ch1.10: os event: 0///characteristics_ch1.11: os month: 39///molecule_ch1: total RNA///extract_protocol_ch1: total RNA from epithelial ovarian cancer tissues was isolated with the ABI PRISM 6100 Nucleic Acid PrepStation (Applied Biosystems) according to the manufacturers instructions///label_ch1: DIG///label_protocol_ch1: Applied Biosystems Chemiluminescent RT Labeling Kit///taxid_ch1: 9606///hyb_protocol: Applied Biosystems Chemiluminescence Detection Kit///scan_protocol: Expression Array System Software v1.1.1///description: Human Genome Survey Microarray V2.0 (Applied Biosystems)///data_processing: R Package ABarray 1.4.2 (Filtering flags > 5000, quantile normalization, log-2 transformation), Batch correction as follows: subtraction of the batch-specific mean from each gene, and add the overall mean.///platform_id: GPL2986///contact_name: Dietmar,,Pils///contact_email: [email protected]///contact_institute: Medical University of Vienna///contact_address: Waehringer Guertel 18-20///contact_city: Vienna///contact_zip.postal_code: 1090///contact_country: Austria///supplementary_file: NONE///data_row_count: 32878
1
title: EOC P017///geo_accession: GSM1211552///status: Public on Jan 01 2014///submission_date: Aug 19 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor tissue///organism_ch1: Homo sapiens///characteristics_ch1: excluded: no///characteristics_ch1.1: subclass: 1///characteristics_ch1.2: age: 68///characteristics_ch1.3: histology: Serous///characteristics_ch1.4: figo grade: III///characteristics_ch1.5: grade: 3///characteristics_ch1.6: peritoneal carcinomatosis: Yes///characteristics_ch1.7: residual tumor: No///characteristics_ch1.8: pfs event: 1///characteristics_ch1.9: pfs month: 6///characteristics_ch1.10: os event: 1///characteristics_ch1.11: os month: 12///molecule_ch1: total RNA///extract_protocol_ch1: total RNA from epithelial ovarian cancer tissues was isolated with the ABI PRISM 6100 Nucleic Acid PrepStation (Applied Biosystems) according to the manufacturers instructions///label_ch1: DIG///label_protocol_ch1: Applied Biosystems Chemiluminescent RT Labeling Kit///taxid_ch1: 9606///hyb_protocol: Applied Biosystems Chemiluminescence Detection Kit///scan_protocol: Expression Array System Software v1.1.1///description: Human Genome Survey Microarray V2.0 (Applied Biosystems)///data_processing: R Package ABarray 1.4.2 (Filtering flags > 5000, quantile normalization, log-2 transformation), Batch correction as follows: subtraction of the batch-specific mean from each gene, and add the overall mean.///platform_id: GPL2986///contact_name: Dietmar,,Pils///contact_email: [email protected]///contact_institute: Medical University of Vienna///contact_address: Waehringer Guertel 18-20///contact_city: Vienna///contact_zip.postal_code: 1090///contact_country: Austria///supplementary_file: NONE///data_row_count: 32878
1
title: EOC P018///geo_accession: GSM1211553///status: Public on Jan 01 2014///submission_date: Aug 19 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor tissue///organism_ch1: Homo sapiens///characteristics_ch1: excluded: no///characteristics_ch1.1: subclass: 1///characteristics_ch1.2: age: 67///characteristics_ch1.3: histology: Serous///characteristics_ch1.4: figo grade: III///characteristics_ch1.5: grade: 3///characteristics_ch1.6: peritoneal carcinomatosis: Yes///characteristics_ch1.7: residual tumor: Yes///characteristics_ch1.8: pfs event: 1///characteristics_ch1.9: pfs month: 22///characteristics_ch1.10: os event: 0///characteristics_ch1.11: os month: 32///molecule_ch1: total RNA///extract_protocol_ch1: total RNA from epithelial ovarian cancer tissues was isolated with the ABI PRISM 6100 Nucleic Acid PrepStation (Applied Biosystems) according to the manufacturers instructions///label_ch1: DIG///label_protocol_ch1: Applied Biosystems Chemiluminescent RT Labeling Kit///taxid_ch1: 9606///hyb_protocol: Applied Biosystems Chemiluminescence Detection Kit///scan_protocol: Expression Array System Software v1.1.1///description: Human Genome Survey Microarray V2.0 (Applied Biosystems)///data_processing: R Package ABarray 1.4.2 (Filtering flags > 5000, quantile normalization, log-2 transformation), Batch correction as follows: subtraction of the batch-specific mean from each gene, and add the overall mean.///platform_id: GPL2986///contact_name: Dietmar,,Pils///contact_email: [email protected]///contact_institute: Medical University of Vienna///contact_address: Waehringer Guertel 18-20///contact_city: Vienna///contact_zip.postal_code: 1090///contact_country: Austria///supplementary_file: NONE///data_row_count: 32878
1
title: EOC P019///geo_accession: GSM1211554///status: Public on Jan 01 2014///submission_date: Aug 19 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor tissue///organism_ch1: Homo sapiens///characteristics_ch1: excluded: no///characteristics_ch1.1: subclass: 1///characteristics_ch1.2: age: 41///characteristics_ch1.3: histology: Non-serous///characteristics_ch1.4: figo grade: III///characteristics_ch1.5: grade: 3///characteristics_ch1.6: peritoneal carcinomatosis: Yes///characteristics_ch1.7: residual tumor: No///characteristics_ch1.8: pfs event: 1///characteristics_ch1.9: pfs month: 12///characteristics_ch1.10: os event: 0///characteristics_ch1.11: os month: 39///molecule_ch1: total RNA///extract_protocol_ch1: total RNA from epithelial ovarian cancer tissues was isolated with the ABI PRISM 6100 Nucleic Acid PrepStation (Applied Biosystems) according to the manufacturers instructions///label_ch1: DIG///label_protocol_ch1: Applied Biosystems Chemiluminescent RT Labeling Kit///taxid_ch1: 9606///hyb_protocol: Applied Biosystems Chemiluminescence Detection Kit///scan_protocol: Expression Array System Software v1.1.1///description: Human Genome Survey Microarray V2.0 (Applied Biosystems)///data_processing: R Package ABarray 1.4.2 (Filtering flags > 5000, quantile normalization, log-2 transformation), Batch correction as follows: subtraction of the batch-specific mean from each gene, and add the overall mean.///platform_id: GPL2986///contact_name: Dietmar,,Pils///contact_email: [email protected]///contact_institute: Medical University of Vienna///contact_address: Waehringer Guertel 18-20///contact_city: Vienna///contact_zip.postal_code: 1090///contact_country: Austria///supplementary_file: NONE///data_row_count: 32878
1
title: EOC P020///geo_accession: GSM1211555///status: Public on Jan 01 2014///submission_date: Aug 19 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor tissue///organism_ch1: Homo sapiens///characteristics_ch1: excluded: no///characteristics_ch1.1: subclass: 2///characteristics_ch1.2: age: 66///characteristics_ch1.3: histology: Serous///characteristics_ch1.4: figo grade: III///characteristics_ch1.5: grade: 1&2///characteristics_ch1.6: peritoneal carcinomatosis: Yes///characteristics_ch1.7: residual tumor: No///characteristics_ch1.8: pfs event: 0///characteristics_ch1.9: pfs month: 37///characteristics_ch1.10: os event: 0///characteristics_ch1.11: os month: 37///molecule_ch1: total RNA///extract_protocol_ch1: total RNA from epithelial ovarian cancer tissues was isolated with the ABI PRISM 6100 Nucleic Acid PrepStation (Applied Biosystems) according to the manufacturers instructions///label_ch1: DIG///label_protocol_ch1: Applied Biosystems Chemiluminescent RT Labeling Kit///taxid_ch1: 9606///hyb_protocol: Applied Biosystems Chemiluminescence Detection Kit///scan_protocol: Expression Array System Software v1.1.1///description: Human Genome Survey Microarray V2.0 (Applied Biosystems)///data_processing: R Package ABarray 1.4.2 (Filtering flags > 5000, quantile normalization, log-2 transformation), Batch correction as follows: subtraction of the batch-specific mean from each gene, and add the overall mean.///platform_id: GPL2986///contact_name: Dietmar,,Pils///contact_email: [email protected]///contact_institute: Medical University of Vienna///contact_address: Waehringer Guertel 18-20///contact_city: Vienna///contact_zip.postal_code: 1090///contact_country: Austria///supplementary_file: NONE///data_row_count: 32878
1
title: EOC P021///geo_accession: GSM1211556///status: Public on Jan 01 2014///submission_date: Aug 19 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor tissue///organism_ch1: Homo sapiens///characteristics_ch1: excluded: no///characteristics_ch1.1: subclass: 1///characteristics_ch1.2: age: 56///characteristics_ch1.3: histology: Serous///characteristics_ch1.4: figo grade: III///characteristics_ch1.5: grade: 1&2///characteristics_ch1.6: peritoneal carcinomatosis: Yes///characteristics_ch1.7: residual tumor: No///characteristics_ch1.8: pfs event: 1///characteristics_ch1.9: pfs month: 6///characteristics_ch1.10: os event: 0///characteristics_ch1.11: os month: 40///molecule_ch1: total RNA///extract_protocol_ch1: total RNA from epithelial ovarian cancer tissues was isolated with the ABI PRISM 6100 Nucleic Acid PrepStation (Applied Biosystems) according to the manufacturers instructions///label_ch1: DIG///label_protocol_ch1: Applied Biosystems Chemiluminescent RT Labeling Kit///taxid_ch1: 9606///hyb_protocol: Applied Biosystems Chemiluminescence Detection Kit///scan_protocol: Expression Array System Software v1.1.1///description: Human Genome Survey Microarray V2.0 (Applied Biosystems)///data_processing: R Package ABarray 1.4.2 (Filtering flags > 5000, quantile normalization, log-2 transformation), Batch correction as follows: subtraction of the batch-specific mean from each gene, and add the overall mean.///platform_id: GPL2986///contact_name: Dietmar,,Pils///contact_email: [email protected]///contact_institute: Medical University of Vienna///contact_address: Waehringer Guertel 18-20///contact_city: Vienna///contact_zip.postal_code: 1090///contact_country: Austria///supplementary_file: NONE///data_row_count: 32878
1
title: EOC P022///geo_accession: GSM1211557///status: Public on Jan 01 2014///submission_date: Aug 19 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor tissue///organism_ch1: Homo sapiens///characteristics_ch1: excluded: no///characteristics_ch1.1: subclass: 2///characteristics_ch1.2: age: 52///characteristics_ch1.3: histology: Serous///characteristics_ch1.4: figo grade: III///characteristics_ch1.5: grade: 3///characteristics_ch1.6: peritoneal carcinomatosis: Yes///characteristics_ch1.7: residual tumor: No///characteristics_ch1.8: pfs event: 1///characteristics_ch1.9: pfs month: 11///characteristics_ch1.10: os event: 0///characteristics_ch1.11: os month: 37///molecule_ch1: total RNA///extract_protocol_ch1: total RNA from epithelial ovarian cancer tissues was isolated with the ABI PRISM 6100 Nucleic Acid PrepStation (Applied Biosystems) according to the manufacturers instructions///label_ch1: DIG///label_protocol_ch1: Applied Biosystems Chemiluminescent RT Labeling Kit///taxid_ch1: 9606///hyb_protocol: Applied Biosystems Chemiluminescence Detection Kit///scan_protocol: Expression Array System Software v1.1.1///description: Human Genome Survey Microarray V2.0 (Applied Biosystems)///data_processing: R Package ABarray 1.4.2 (Filtering flags > 5000, quantile normalization, log-2 transformation), Batch correction as follows: subtraction of the batch-specific mean from each gene, and add the overall mean.///platform_id: GPL2986///contact_name: Dietmar,,Pils///contact_email: [email protected]///contact_institute: Medical University of Vienna///contact_address: Waehringer Guertel 18-20///contact_city: Vienna///contact_zip.postal_code: 1090///contact_country: Austria///supplementary_file: NONE///data_row_count: 32878
1
title: EOC P023///geo_accession: GSM1211558///status: Public on Jan 01 2014///submission_date: Aug 19 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor tissue///organism_ch1: Homo sapiens///characteristics_ch1: excluded: no///characteristics_ch1.1: subclass: 2///characteristics_ch1.2: age: 67///characteristics_ch1.3: histology: Serous///characteristics_ch1.4: figo grade: III///characteristics_ch1.5: grade: 3///characteristics_ch1.6: peritoneal carcinomatosis: Yes///characteristics_ch1.7: residual tumor: No///characteristics_ch1.8: pfs event: 1///characteristics_ch1.9: pfs month: 12///characteristics_ch1.10: os event: 1///characteristics_ch1.11: os month: 17///molecule_ch1: total RNA///extract_protocol_ch1: total RNA from epithelial ovarian cancer tissues was isolated with the ABI PRISM 6100 Nucleic Acid PrepStation (Applied Biosystems) according to the manufacturers instructions///label_ch1: DIG///label_protocol_ch1: Applied Biosystems Chemiluminescent RT Labeling Kit///taxid_ch1: 9606///hyb_protocol: Applied Biosystems Chemiluminescence Detection Kit///scan_protocol: Expression Array System Software v1.1.1///description: Human Genome Survey Microarray V2.0 (Applied Biosystems)///data_processing: R Package ABarray 1.4.2 (Filtering flags > 5000, quantile normalization, log-2 transformation), Batch correction as follows: subtraction of the batch-specific mean from each gene, and add the overall mean.///platform_id: GPL2986///contact_name: Dietmar,,Pils///contact_email: [email protected]///contact_institute: Medical University of Vienna///contact_address: Waehringer Guertel 18-20///contact_city: Vienna///contact_zip.postal_code: 1090///contact_country: Austria///supplementary_file: NONE///data_row_count: 32878
1
title: EOC P024///geo_accession: GSM1211559///status: Public on Jan 01 2014///submission_date: Aug 19 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor tissue///organism_ch1: Homo sapiens///characteristics_ch1: excluded: no///characteristics_ch1.1: subclass: 2///characteristics_ch1.2: age: 62///characteristics_ch1.3: histology: Serous///characteristics_ch1.4: figo grade: III///characteristics_ch1.5: grade: 3///characteristics_ch1.6: peritoneal carcinomatosis: Yes///characteristics_ch1.7: residual tumor: Yes///characteristics_ch1.8: pfs event: 1///characteristics_ch1.9: pfs month: 15///characteristics_ch1.10: os event: 1///characteristics_ch1.11: os month: 33///molecule_ch1: total RNA///extract_protocol_ch1: total RNA from epithelial ovarian cancer tissues was isolated with the ABI PRISM 6100 Nucleic Acid PrepStation (Applied Biosystems) according to the manufacturers instructions///label_ch1: DIG///label_protocol_ch1: Applied Biosystems Chemiluminescent RT Labeling Kit///taxid_ch1: 9606///hyb_protocol: Applied Biosystems Chemiluminescence Detection Kit///scan_protocol: Expression Array System Software v1.1.1///description: Human Genome Survey Microarray V2.0 (Applied Biosystems)///data_processing: R Package ABarray 1.4.2 (Filtering flags > 5000, quantile normalization, log-2 transformation), Batch correction as follows: subtraction of the batch-specific mean from each gene, and add the overall mean.///platform_id: GPL2986///contact_name: Dietmar,,Pils///contact_email: [email protected]///contact_institute: Medical University of Vienna///contact_address: Waehringer Guertel 18-20///contact_city: Vienna///contact_zip.postal_code: 1090///contact_country: Austria///supplementary_file: NONE///data_row_count: 32878
1
title: EOC P025///geo_accession: GSM1211560///status: Public on Jan 01 2014///submission_date: Aug 19 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor tissue///organism_ch1: Homo sapiens///characteristics_ch1: excluded: no///characteristics_ch1.1: subclass: 2///characteristics_ch1.2: age: 51///characteristics_ch1.3: histology: Non-serous///characteristics_ch1.4: figo grade: III///characteristics_ch1.5: grade: 3///characteristics_ch1.6: peritoneal carcinomatosis: Yes///characteristics_ch1.7: residual tumor: Yes///characteristics_ch1.8: pfs event: 1///characteristics_ch1.9: pfs month: 8///characteristics_ch1.10: os event: 1///characteristics_ch1.11: os month: 14///molecule_ch1: total RNA///extract_protocol_ch1: total RNA from epithelial ovarian cancer tissues was isolated with the ABI PRISM 6100 Nucleic Acid PrepStation (Applied Biosystems) according to the manufacturers instructions///label_ch1: DIG///label_protocol_ch1: Applied Biosystems Chemiluminescent RT Labeling Kit///taxid_ch1: 9606///hyb_protocol: Applied Biosystems Chemiluminescence Detection Kit///scan_protocol: Expression Array System Software v1.1.1///description: Human Genome Survey Microarray V2.0 (Applied Biosystems)///data_processing: R Package ABarray 1.4.2 (Filtering flags > 5000, quantile normalization, log-2 transformation), Batch correction as follows: subtraction of the batch-specific mean from each gene, and add the overall mean.///platform_id: GPL2986///contact_name: Dietmar,,Pils///contact_email: [email protected]///contact_institute: Medical University of Vienna///contact_address: Waehringer Guertel 18-20///contact_city: Vienna///contact_zip.postal_code: 1090///contact_country: Austria///supplementary_file: NONE///data_row_count: 32878
1
title: EOC P026///geo_accession: GSM1211561///status: Public on Jan 01 2014///submission_date: Aug 19 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor tissue///organism_ch1: Homo sapiens///characteristics_ch1: excluded: no///characteristics_ch1.1: subclass: 1///characteristics_ch1.2: age: 34///characteristics_ch1.3: histology: Serous///characteristics_ch1.4: figo grade: III///characteristics_ch1.5: grade: 1&2///characteristics_ch1.6: peritoneal carcinomatosis: Yes///characteristics_ch1.7: residual tumor: No///characteristics_ch1.8: pfs event: 0///characteristics_ch1.9: pfs month: 7///characteristics_ch1.10: os event: 0///characteristics_ch1.11: os month: 7///molecule_ch1: total RNA///extract_protocol_ch1: total RNA from epithelial ovarian cancer tissues was isolated with the ABI PRISM 6100 Nucleic Acid PrepStation (Applied Biosystems) according to the manufacturers instructions///label_ch1: DIG///label_protocol_ch1: Applied Biosystems Chemiluminescent RT Labeling Kit///taxid_ch1: 9606///hyb_protocol: Applied Biosystems Chemiluminescence Detection Kit///scan_protocol: Expression Array System Software v1.1.1///description: Human Genome Survey Microarray V2.0 (Applied Biosystems)///data_processing: R Package ABarray 1.4.2 (Filtering flags > 5000, quantile normalization, log-2 transformation), Batch correction as follows: subtraction of the batch-specific mean from each gene, and add the overall mean.///platform_id: GPL2986///contact_name: Dietmar,,Pils///contact_email: [email protected]///contact_institute: Medical University of Vienna///contact_address: Waehringer Guertel 18-20///contact_city: Vienna///contact_zip.postal_code: 1090///contact_country: Austria///supplementary_file: NONE///data_row_count: 32878
1
title: EOC P027///geo_accession: GSM1211562///status: Public on Jan 01 2014///submission_date: Aug 19 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor tissue///organism_ch1: Homo sapiens///characteristics_ch1: excluded: yes///characteristics_ch1.1: subclass: 1///characteristics_ch1.2: ///characteristics_ch1.3: ///characteristics_ch1.4: ///characteristics_ch1.5: ///characteristics_ch1.6: ///characteristics_ch1.7: ///characteristics_ch1.8: ///characteristics_ch1.9: ///characteristics_ch1.10: ///characteristics_ch1.11: ///molecule_ch1: total RNA///extract_protocol_ch1: total RNA from epithelial ovarian cancer tissues was isolated with the ABI PRISM 6100 Nucleic Acid PrepStation (Applied Biosystems) according to the manufacturers instructions///label_ch1: DIG///label_protocol_ch1: Applied Biosystems Chemiluminescent RT Labeling Kit///taxid_ch1: 9606///hyb_protocol: Applied Biosystems Chemiluminescence Detection Kit///scan_protocol: Expression Array System Software v1.1.1///description: Human Genome Survey Microarray V2.0 (Applied Biosystems)///data_processing: R Package ABarray 1.4.2 (Filtering flags > 5000, quantile normalization, log-2 transformation), Batch correction as follows: subtraction of the batch-specific mean from each gene, and add the overall mean.///platform_id: GPL2986///contact_name: Dietmar,,Pils///contact_email: [email protected]///contact_institute: Medical University of Vienna///contact_address: Waehringer Guertel 18-20///contact_city: Vienna///contact_zip.postal_code: 1090///contact_country: Austria///supplementary_file: NONE///data_row_count: 32878
1
title: EOC P028///geo_accession: GSM1211563///status: Public on Jan 01 2014///submission_date: Aug 19 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor tissue///organism_ch1: Homo sapiens///characteristics_ch1: excluded: no///characteristics_ch1.1: subclass: 2///characteristics_ch1.2: age: 79///characteristics_ch1.3: histology: Serous///characteristics_ch1.4: figo grade: III///characteristics_ch1.5: grade: 3///characteristics_ch1.6: peritoneal carcinomatosis: No///characteristics_ch1.7: residual tumor: No///characteristics_ch1.8: pfs event: 0///characteristics_ch1.9: pfs month: 31///characteristics_ch1.10: os event: 0///characteristics_ch1.11: os month: 31///molecule_ch1: total RNA///extract_protocol_ch1: total RNA from epithelial ovarian cancer tissues was isolated with the ABI PRISM 6100 Nucleic Acid PrepStation (Applied Biosystems) according to the manufacturers instructions///label_ch1: DIG///label_protocol_ch1: Applied Biosystems Chemiluminescent RT Labeling Kit///taxid_ch1: 9606///hyb_protocol: Applied Biosystems Chemiluminescence Detection Kit///scan_protocol: Expression Array System Software v1.1.1///description: Human Genome Survey Microarray V2.0 (Applied Biosystems)///data_processing: R Package ABarray 1.4.2 (Filtering flags > 5000, quantile normalization, log-2 transformation), Batch correction as follows: subtraction of the batch-specific mean from each gene, and add the overall mean.///platform_id: GPL2986///contact_name: Dietmar,,Pils///contact_email: [email protected]///contact_institute: Medical University of Vienna///contact_address: Waehringer Guertel 18-20///contact_city: Vienna///contact_zip.postal_code: 1090///contact_country: Austria///supplementary_file: NONE///data_row_count: 32878
1
title: EOC P029///geo_accession: GSM1211564///status: Public on Jan 01 2014///submission_date: Aug 19 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor tissue///organism_ch1: Homo sapiens///characteristics_ch1: excluded: no///characteristics_ch1.1: subclass: 1///characteristics_ch1.2: age: 65///characteristics_ch1.3: histology: Non-serous///characteristics_ch1.4: figo grade: II///characteristics_ch1.5: grade: 3///characteristics_ch1.6: peritoneal carcinomatosis: No///characteristics_ch1.7: residual tumor: No///characteristics_ch1.8: pfs event: 1///characteristics_ch1.9: pfs month: 33///characteristics_ch1.10: os event: 0///characteristics_ch1.11: os month: 33///molecule_ch1: total RNA///extract_protocol_ch1: total RNA from epithelial ovarian cancer tissues was isolated with the ABI PRISM 6100 Nucleic Acid PrepStation (Applied Biosystems) according to the manufacturers instructions///label_ch1: DIG///label_protocol_ch1: Applied Biosystems Chemiluminescent RT Labeling Kit///taxid_ch1: 9606///hyb_protocol: Applied Biosystems Chemiluminescence Detection Kit///scan_protocol: Expression Array System Software v1.1.1///description: Human Genome Survey Microarray V2.0 (Applied Biosystems)///data_processing: R Package ABarray 1.4.2 (Filtering flags > 5000, quantile normalization, log-2 transformation), Batch correction as follows: subtraction of the batch-specific mean from each gene, and add the overall mean.///platform_id: GPL2986///contact_name: Dietmar,,Pils///contact_email: [email protected]///contact_institute: Medical University of Vienna///contact_address: Waehringer Guertel 18-20///contact_city: Vienna///contact_zip.postal_code: 1090///contact_country: Austria///supplementary_file: NONE///data_row_count: 32878
1
title: EOC P030///geo_accession: GSM1211565///status: Public on Jan 01 2014///submission_date: Aug 19 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor tissue///organism_ch1: Homo sapiens///characteristics_ch1: excluded: no///characteristics_ch1.1: subclass: 2///characteristics_ch1.2: age: 45///characteristics_ch1.3: histology: Serous///characteristics_ch1.4: figo grade: III///characteristics_ch1.5: grade: 3///characteristics_ch1.6: peritoneal carcinomatosis: Yes///characteristics_ch1.7: residual tumor: Yes///characteristics_ch1.8: pfs event: 1///characteristics_ch1.9: pfs month: 21///characteristics_ch1.10: os event: 0///characteristics_ch1.11: os month: 35///molecule_ch1: total RNA///extract_protocol_ch1: total RNA from epithelial ovarian cancer tissues was isolated with the ABI PRISM 6100 Nucleic Acid PrepStation (Applied Biosystems) according to the manufacturers instructions///label_ch1: DIG///label_protocol_ch1: Applied Biosystems Chemiluminescent RT Labeling Kit///taxid_ch1: 9606///hyb_protocol: Applied Biosystems Chemiluminescence Detection Kit///scan_protocol: Expression Array System Software v1.1.1///description: Human Genome Survey Microarray V2.0 (Applied Biosystems)///data_processing: R Package ABarray 1.4.2 (Filtering flags > 5000, quantile normalization, log-2 transformation), Batch correction as follows: subtraction of the batch-specific mean from each gene, and add the overall mean.///platform_id: GPL2986///contact_name: Dietmar,,Pils///contact_email: [email protected]///contact_institute: Medical University of Vienna///contact_address: Waehringer Guertel 18-20///contact_city: Vienna///contact_zip.postal_code: 1090///contact_country: Austria///supplementary_file: NONE///data_row_count: 32878
1
title: EOC P031///geo_accession: GSM1211566///status: Public on Jan 01 2014///submission_date: Aug 19 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor tissue///organism_ch1: Homo sapiens///characteristics_ch1: excluded: no///characteristics_ch1.1: subclass: 1///characteristics_ch1.2: age: 43///characteristics_ch1.3: histology: Serous///characteristics_ch1.4: figo grade: III///characteristics_ch1.5: grade: 3///characteristics_ch1.6: peritoneal carcinomatosis: No///characteristics_ch1.7: residual tumor: No///characteristics_ch1.8: pfs event: 1///characteristics_ch1.9: pfs month: 17///characteristics_ch1.10: os event: 0///characteristics_ch1.11: os month: 33///molecule_ch1: total RNA///extract_protocol_ch1: total RNA from epithelial ovarian cancer tissues was isolated with the ABI PRISM 6100 Nucleic Acid PrepStation (Applied Biosystems) according to the manufacturers instructions///label_ch1: DIG///label_protocol_ch1: Applied Biosystems Chemiluminescent RT Labeling Kit///taxid_ch1: 9606///hyb_protocol: Applied Biosystems Chemiluminescence Detection Kit///scan_protocol: Expression Array System Software v1.1.1///description: Human Genome Survey Microarray V2.0 (Applied Biosystems)///data_processing: R Package ABarray 1.4.2 (Filtering flags > 5000, quantile normalization, log-2 transformation), Batch correction as follows: subtraction of the batch-specific mean from each gene, and add the overall mean.///platform_id: GPL2986///contact_name: Dietmar,,Pils///contact_email: [email protected]///contact_institute: Medical University of Vienna///contact_address: Waehringer Guertel 18-20///contact_city: Vienna///contact_zip.postal_code: 1090///contact_country: Austria///supplementary_file: NONE///data_row_count: 32878
1
title: EOC P032///geo_accession: GSM1211567///status: Public on Jan 01 2014///submission_date: Aug 19 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor tissue///organism_ch1: Homo sapiens///characteristics_ch1: excluded: no///characteristics_ch1.1: subclass: 1///characteristics_ch1.2: age: 71///characteristics_ch1.3: histology: Serous///characteristics_ch1.4: figo grade: III///characteristics_ch1.5: grade: 3///characteristics_ch1.6: peritoneal carcinomatosis: Yes///characteristics_ch1.7: residual tumor: No///characteristics_ch1.8: pfs event: 1///characteristics_ch1.9: pfs month: 20///characteristics_ch1.10: os event: 0///characteristics_ch1.11: os month: 32///molecule_ch1: total RNA///extract_protocol_ch1: total RNA from epithelial ovarian cancer tissues was isolated with the ABI PRISM 6100 Nucleic Acid PrepStation (Applied Biosystems) according to the manufacturers instructions///label_ch1: DIG///label_protocol_ch1: Applied Biosystems Chemiluminescent RT Labeling Kit///taxid_ch1: 9606///hyb_protocol: Applied Biosystems Chemiluminescence Detection Kit///scan_protocol: Expression Array System Software v1.1.1///description: Human Genome Survey Microarray V2.0 (Applied Biosystems)///data_processing: R Package ABarray 1.4.2 (Filtering flags > 5000, quantile normalization, log-2 transformation), Batch correction as follows: subtraction of the batch-specific mean from each gene, and add the overall mean.///platform_id: GPL2986///contact_name: Dietmar,,Pils///contact_email: [email protected]///contact_institute: Medical University of Vienna///contact_address: Waehringer Guertel 18-20///contact_city: Vienna///contact_zip.postal_code: 1090///contact_country: Austria///supplementary_file: NONE///data_row_count: 32878
1
title: EOC P033///geo_accession: GSM1211568///status: Public on Jan 01 2014///submission_date: Aug 19 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor tissue///organism_ch1: Homo sapiens///characteristics_ch1: excluded: yes///characteristics_ch1.1: subclass: 2///characteristics_ch1.2: ///characteristics_ch1.3: ///characteristics_ch1.4: ///characteristics_ch1.5: ///characteristics_ch1.6: ///characteristics_ch1.7: ///characteristics_ch1.8: ///characteristics_ch1.9: ///characteristics_ch1.10: ///characteristics_ch1.11: ///molecule_ch1: total RNA///extract_protocol_ch1: total RNA from epithelial ovarian cancer tissues was isolated with the ABI PRISM 6100 Nucleic Acid PrepStation (Applied Biosystems) according to the manufacturers instructions///label_ch1: DIG///label_protocol_ch1: Applied Biosystems Chemiluminescent RT Labeling Kit///taxid_ch1: 9606///hyb_protocol: Applied Biosystems Chemiluminescence Detection Kit///scan_protocol: Expression Array System Software v1.1.1///description: Human Genome Survey Microarray V2.0 (Applied Biosystems)///data_processing: R Package ABarray 1.4.2 (Filtering flags > 5000, quantile normalization, log-2 transformation), Batch correction as follows: subtraction of the batch-specific mean from each gene, and add the overall mean.///platform_id: GPL2986///contact_name: Dietmar,,Pils///contact_email: [email protected]///contact_institute: Medical University of Vienna///contact_address: Waehringer Guertel 18-20///contact_city: Vienna///contact_zip.postal_code: 1090///contact_country: Austria///supplementary_file: NONE///data_row_count: 32878
1
title: EOC P034///geo_accession: GSM1211569///status: Public on Jan 01 2014///submission_date: Aug 19 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor tissue///organism_ch1: Homo sapiens///characteristics_ch1: excluded: no///characteristics_ch1.1: subclass: 2///characteristics_ch1.2: age: 27///characteristics_ch1.3: histology: Serous///characteristics_ch1.4: figo grade: III///characteristics_ch1.5: grade: 3///characteristics_ch1.6: peritoneal carcinomatosis: Yes///characteristics_ch1.7: residual tumor: No///characteristics_ch1.8: pfs event: 1///characteristics_ch1.9: pfs month: 8///characteristics_ch1.10: os event: 1///characteristics_ch1.11: os month: 8///molecule_ch1: total RNA///extract_protocol_ch1: total RNA from epithelial ovarian cancer tissues was isolated with the ABI PRISM 6100 Nucleic Acid PrepStation (Applied Biosystems) according to the manufacturers instructions///label_ch1: DIG///label_protocol_ch1: Applied Biosystems Chemiluminescent RT Labeling Kit///taxid_ch1: 9606///hyb_protocol: Applied Biosystems Chemiluminescence Detection Kit///scan_protocol: Expression Array System Software v1.1.1///description: Human Genome Survey Microarray V2.0 (Applied Biosystems)///data_processing: R Package ABarray 1.4.2 (Filtering flags > 5000, quantile normalization, log-2 transformation), Batch correction as follows: subtraction of the batch-specific mean from each gene, and add the overall mean.///platform_id: GPL2986///contact_name: Dietmar,,Pils///contact_email: [email protected]///contact_institute: Medical University of Vienna///contact_address: Waehringer Guertel 18-20///contact_city: Vienna///contact_zip.postal_code: 1090///contact_country: Austria///supplementary_file: NONE///data_row_count: 32878
1
title: EOC P035///geo_accession: GSM1211570///status: Public on Jan 01 2014///submission_date: Aug 19 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor tissue///organism_ch1: Homo sapiens///characteristics_ch1: excluded: no///characteristics_ch1.1: subclass: 1///characteristics_ch1.2: age: 42///characteristics_ch1.3: histology: Serous///characteristics_ch1.4: figo grade: III///characteristics_ch1.5: grade: 3///characteristics_ch1.6: peritoneal carcinomatosis: No///characteristics_ch1.7: residual tumor: No///characteristics_ch1.8: pfs event: 1///characteristics_ch1.9: pfs month: 14///characteristics_ch1.10: os event: 0///characteristics_ch1.11: os month: 14///molecule_ch1: total RNA///extract_protocol_ch1: total RNA from epithelial ovarian cancer tissues was isolated with the ABI PRISM 6100 Nucleic Acid PrepStation (Applied Biosystems) according to the manufacturers instructions///label_ch1: DIG///label_protocol_ch1: Applied Biosystems Chemiluminescent RT Labeling Kit///taxid_ch1: 9606///hyb_protocol: Applied Biosystems Chemiluminescence Detection Kit///scan_protocol: Expression Array System Software v1.1.1///description: Human Genome Survey Microarray V2.0 (Applied Biosystems)///data_processing: R Package ABarray 1.4.2 (Filtering flags > 5000, quantile normalization, log-2 transformation), Batch correction as follows: subtraction of the batch-specific mean from each gene, and add the overall mean.///platform_id: GPL2986///contact_name: Dietmar,,Pils///contact_email: [email protected]///contact_institute: Medical University of Vienna///contact_address: Waehringer Guertel 18-20///contact_city: Vienna///contact_zip.postal_code: 1090///contact_country: Austria///supplementary_file: NONE///data_row_count: 32878
1
title: EOC P036///geo_accession: GSM1211571///status: Public on Jan 01 2014///submission_date: Aug 19 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor tissue///organism_ch1: Homo sapiens///characteristics_ch1: excluded: no///characteristics_ch1.1: subclass: 1///characteristics_ch1.2: age: 68///characteristics_ch1.3: histology: Serous///characteristics_ch1.4: figo grade: III///characteristics_ch1.5: grade: 3///characteristics_ch1.6: peritoneal carcinomatosis: Yes///characteristics_ch1.7: residual tumor: Yes///characteristics_ch1.8: pfs event: 0///characteristics_ch1.9: pfs month: 31///characteristics_ch1.10: os event: 0///characteristics_ch1.11: os month: 31///molecule_ch1: total RNA///extract_protocol_ch1: total RNA from epithelial ovarian cancer tissues was isolated with the ABI PRISM 6100 Nucleic Acid PrepStation (Applied Biosystems) according to the manufacturers instructions///label_ch1: DIG///label_protocol_ch1: Applied Biosystems Chemiluminescent RT Labeling Kit///taxid_ch1: 9606///hyb_protocol: Applied Biosystems Chemiluminescence Detection Kit///scan_protocol: Expression Array System Software v1.1.1///description: Human Genome Survey Microarray V2.0 (Applied Biosystems)///data_processing: R Package ABarray 1.4.2 (Filtering flags > 5000, quantile normalization, log-2 transformation), Batch correction as follows: subtraction of the batch-specific mean from each gene, and add the overall mean.///platform_id: GPL2986///contact_name: Dietmar,,Pils///contact_email: [email protected]///contact_institute: Medical University of Vienna///contact_address: Waehringer Guertel 18-20///contact_city: Vienna///contact_zip.postal_code: 1090///contact_country: Austria///supplementary_file: NONE///data_row_count: 32878
1
title: EOC P037///geo_accession: GSM1211572///status: Public on Jan 01 2014///submission_date: Aug 19 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor tissue///organism_ch1: Homo sapiens///characteristics_ch1: excluded: no///characteristics_ch1.1: subclass: 2///characteristics_ch1.2: age: 75///characteristics_ch1.3: histology: Serous///characteristics_ch1.4: figo grade: III///characteristics_ch1.5: grade: 1&2///characteristics_ch1.6: peritoneal carcinomatosis: Yes///characteristics_ch1.7: residual tumor: No///characteristics_ch1.8: pfs event: 0///characteristics_ch1.9: pfs month: 31///characteristics_ch1.10: os event: 0///characteristics_ch1.11: os month: 31///molecule_ch1: total RNA///extract_protocol_ch1: total RNA from epithelial ovarian cancer tissues was isolated with the ABI PRISM 6100 Nucleic Acid PrepStation (Applied Biosystems) according to the manufacturers instructions///label_ch1: DIG///label_protocol_ch1: Applied Biosystems Chemiluminescent RT Labeling Kit///taxid_ch1: 9606///hyb_protocol: Applied Biosystems Chemiluminescence Detection Kit///scan_protocol: Expression Array System Software v1.1.1///description: Human Genome Survey Microarray V2.0 (Applied Biosystems)///data_processing: R Package ABarray 1.4.2 (Filtering flags > 5000, quantile normalization, log-2 transformation), Batch correction as follows: subtraction of the batch-specific mean from each gene, and add the overall mean.///platform_id: GPL2986///contact_name: Dietmar,,Pils///contact_email: [email protected]///contact_institute: Medical University of Vienna///contact_address: Waehringer Guertel 18-20///contact_city: Vienna///contact_zip.postal_code: 1090///contact_country: Austria///supplementary_file: NONE///data_row_count: 32878
1
title: EOC P038///geo_accession: GSM1211573///status: Public on Jan 01 2014///submission_date: Aug 19 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor tissue///organism_ch1: Homo sapiens///characteristics_ch1: excluded: no///characteristics_ch1.1: subclass: 2///characteristics_ch1.2: age: 51///characteristics_ch1.3: histology: Serous///characteristics_ch1.4: figo grade: IV///characteristics_ch1.5: grade: 3///characteristics_ch1.6: peritoneal carcinomatosis: Yes///characteristics_ch1.7: residual tumor: Yes///characteristics_ch1.8: pfs event: 1///characteristics_ch1.9: pfs month: 6///characteristics_ch1.10: os event: 1///characteristics_ch1.11: os month: 8///molecule_ch1: total RNA///extract_protocol_ch1: total RNA from epithelial ovarian cancer tissues was isolated with the ABI PRISM 6100 Nucleic Acid PrepStation (Applied Biosystems) according to the manufacturers instructions///label_ch1: DIG///label_protocol_ch1: Applied Biosystems Chemiluminescent RT Labeling Kit///taxid_ch1: 9606///hyb_protocol: Applied Biosystems Chemiluminescence Detection Kit///scan_protocol: Expression Array System Software v1.1.1///description: Human Genome Survey Microarray V2.0 (Applied Biosystems)///data_processing: R Package ABarray 1.4.2 (Filtering flags > 5000, quantile normalization, log-2 transformation), Batch correction as follows: subtraction of the batch-specific mean from each gene, and add the overall mean.///platform_id: GPL2986///contact_name: Dietmar,,Pils///contact_email: [email protected]///contact_institute: Medical University of Vienna///contact_address: Waehringer Guertel 18-20///contact_city: Vienna///contact_zip.postal_code: 1090///contact_country: Austria///supplementary_file: NONE///data_row_count: 32878
1
title: EOC P039///geo_accession: GSM1211574///status: Public on Jan 01 2014///submission_date: Aug 19 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor tissue///organism_ch1: Homo sapiens///characteristics_ch1: excluded: no///characteristics_ch1.1: subclass: 2///characteristics_ch1.2: age: 46///characteristics_ch1.3: histology: Serous///characteristics_ch1.4: figo grade: III///characteristics_ch1.5: grade: 1&2///characteristics_ch1.6: peritoneal carcinomatosis: No///characteristics_ch1.7: residual tumor: No///characteristics_ch1.8: pfs event: 0///characteristics_ch1.9: pfs month: 30///characteristics_ch1.10: os event: 0///characteristics_ch1.11: os month: 30///molecule_ch1: total RNA///extract_protocol_ch1: total RNA from epithelial ovarian cancer tissues was isolated with the ABI PRISM 6100 Nucleic Acid PrepStation (Applied Biosystems) according to the manufacturers instructions///label_ch1: DIG///label_protocol_ch1: Applied Biosystems Chemiluminescent RT Labeling Kit///taxid_ch1: 9606///hyb_protocol: Applied Biosystems Chemiluminescence Detection Kit///scan_protocol: Expression Array System Software v1.1.1///description: Human Genome Survey Microarray V2.0 (Applied Biosystems)///data_processing: R Package ABarray 1.4.2 (Filtering flags > 5000, quantile normalization, log-2 transformation), Batch correction as follows: subtraction of the batch-specific mean from each gene, and add the overall mean.///platform_id: GPL2986///contact_name: Dietmar,,Pils///contact_email: [email protected]///contact_institute: Medical University of Vienna///contact_address: Waehringer Guertel 18-20///contact_city: Vienna///contact_zip.postal_code: 1090///contact_country: Austria///supplementary_file: NONE///data_row_count: 32878
1
title: EOC P040///geo_accession: GSM1211575///status: Public on Jan 01 2014///submission_date: Aug 19 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor tissue///organism_ch1: Homo sapiens///characteristics_ch1: excluded: no///characteristics_ch1.1: subclass: 1///characteristics_ch1.2: age: 47///characteristics_ch1.3: histology: Serous///characteristics_ch1.4: figo grade: III///characteristics_ch1.5: grade: 3///characteristics_ch1.6: peritoneal carcinomatosis: Yes///characteristics_ch1.7: residual tumor: No///characteristics_ch1.8: pfs event: 1///characteristics_ch1.9: pfs month: 19///characteristics_ch1.10: os event: 0///characteristics_ch1.11: os month: 19///molecule_ch1: total RNA///extract_protocol_ch1: total RNA from epithelial ovarian cancer tissues was isolated with the ABI PRISM 6100 Nucleic Acid PrepStation (Applied Biosystems) according to the manufacturers instructions///label_ch1: DIG///label_protocol_ch1: Applied Biosystems Chemiluminescent RT Labeling Kit///taxid_ch1: 9606///hyb_protocol: Applied Biosystems Chemiluminescence Detection Kit///scan_protocol: Expression Array System Software v1.1.1///description: Human Genome Survey Microarray V2.0 (Applied Biosystems)///data_processing: R Package ABarray 1.4.2 (Filtering flags > 5000, quantile normalization, log-2 transformation), Batch correction as follows: subtraction of the batch-specific mean from each gene, and add the overall mean.///platform_id: GPL2986///contact_name: Dietmar,,Pils///contact_email: [email protected]///contact_institute: Medical University of Vienna///contact_address: Waehringer Guertel 18-20///contact_city: Vienna///contact_zip.postal_code: 1090///contact_country: Austria///supplementary_file: NONE///data_row_count: 32878
1
title: EOC P041///geo_accession: GSM1211576///status: Public on Jan 01 2014///submission_date: Aug 19 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor tissue///organism_ch1: Homo sapiens///characteristics_ch1: excluded: no///characteristics_ch1.1: subclass: 1///characteristics_ch1.2: age: 57///characteristics_ch1.3: histology: Serous///characteristics_ch1.4: figo grade: III///characteristics_ch1.5: grade: 3///characteristics_ch1.6: peritoneal carcinomatosis: Yes///characteristics_ch1.7: residual tumor: Yes///characteristics_ch1.8: pfs event: 0///characteristics_ch1.9: pfs month: 13///characteristics_ch1.10: os event: 0///characteristics_ch1.11: os month: 13///molecule_ch1: total RNA///extract_protocol_ch1: total RNA from epithelial ovarian cancer tissues was isolated with the ABI PRISM 6100 Nucleic Acid PrepStation (Applied Biosystems) according to the manufacturers instructions///label_ch1: DIG///label_protocol_ch1: Applied Biosystems Chemiluminescent RT Labeling Kit///taxid_ch1: 9606///hyb_protocol: Applied Biosystems Chemiluminescence Detection Kit///scan_protocol: Expression Array System Software v1.1.1///description: Human Genome Survey Microarray V2.0 (Applied Biosystems)///data_processing: R Package ABarray 1.4.2 (Filtering flags > 5000, quantile normalization, log-2 transformation), Batch correction as follows: subtraction of the batch-specific mean from each gene, and add the overall mean.///platform_id: GPL2986///contact_name: Dietmar,,Pils///contact_email: [email protected]///contact_institute: Medical University of Vienna///contact_address: Waehringer Guertel 18-20///contact_city: Vienna///contact_zip.postal_code: 1090///contact_country: Austria///supplementary_file: NONE///data_row_count: 32878
1
title: EOC P042///geo_accession: GSM1211577///status: Public on Jan 01 2014///submission_date: Aug 19 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor tissue///organism_ch1: Homo sapiens///characteristics_ch1: excluded: no///characteristics_ch1.1: subclass: 2///characteristics_ch1.2: age: 48///characteristics_ch1.3: histology: Serous///characteristics_ch1.4: figo grade: III///characteristics_ch1.5: grade: 1&2///characteristics_ch1.6: peritoneal carcinomatosis: No///characteristics_ch1.7: residual tumor: No///characteristics_ch1.8: pfs event: 0///characteristics_ch1.9: pfs month: 30///characteristics_ch1.10: os event: 0///characteristics_ch1.11: os month: 30///molecule_ch1: total RNA///extract_protocol_ch1: total RNA from epithelial ovarian cancer tissues was isolated with the ABI PRISM 6100 Nucleic Acid PrepStation (Applied Biosystems) according to the manufacturers instructions///label_ch1: DIG///label_protocol_ch1: Applied Biosystems Chemiluminescent RT Labeling Kit///taxid_ch1: 9606///hyb_protocol: Applied Biosystems Chemiluminescence Detection Kit///scan_protocol: Expression Array System Software v1.1.1///description: Human Genome Survey Microarray V2.0 (Applied Biosystems)///data_processing: R Package ABarray 1.4.2 (Filtering flags > 5000, quantile normalization, log-2 transformation), Batch correction as follows: subtraction of the batch-specific mean from each gene, and add the overall mean.///platform_id: GPL2986///contact_name: Dietmar,,Pils///contact_email: [email protected]///contact_institute: Medical University of Vienna///contact_address: Waehringer Guertel 18-20///contact_city: Vienna///contact_zip.postal_code: 1090///contact_country: Austria///supplementary_file: NONE///data_row_count: 32878
1
title: EOC P043///geo_accession: GSM1211578///status: Public on Jan 01 2014///submission_date: Aug 19 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor tissue///organism_ch1: Homo sapiens///characteristics_ch1: excluded: no///characteristics_ch1.1: subclass: 2///characteristics_ch1.2: age: 53///characteristics_ch1.3: histology: Serous///characteristics_ch1.4: figo grade: III///characteristics_ch1.5: grade: 3///characteristics_ch1.6: peritoneal carcinomatosis: Yes///characteristics_ch1.7: residual tumor: No///characteristics_ch1.8: pfs event: 0///characteristics_ch1.9: pfs month: 28///characteristics_ch1.10: os event: 0///characteristics_ch1.11: os month: 28///molecule_ch1: total RNA///extract_protocol_ch1: total RNA from epithelial ovarian cancer tissues was isolated with the ABI PRISM 6100 Nucleic Acid PrepStation (Applied Biosystems) according to the manufacturers instructions///label_ch1: DIG///label_protocol_ch1: Applied Biosystems Chemiluminescent RT Labeling Kit///taxid_ch1: 9606///hyb_protocol: Applied Biosystems Chemiluminescence Detection Kit///scan_protocol: Expression Array System Software v1.1.1///description: Human Genome Survey Microarray V2.0 (Applied Biosystems)///data_processing: R Package ABarray 1.4.2 (Filtering flags > 5000, quantile normalization, log-2 transformation), Batch correction as follows: subtraction of the batch-specific mean from each gene, and add the overall mean.///platform_id: GPL2986///contact_name: Dietmar,,Pils///contact_email: [email protected]///contact_institute: Medical University of Vienna///contact_address: Waehringer Guertel 18-20///contact_city: Vienna///contact_zip.postal_code: 1090///contact_country: Austria///supplementary_file: NONE///data_row_count: 32878
1
title: EOC P044///geo_accession: GSM1211579///status: Public on Jan 01 2014///submission_date: Aug 19 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor tissue///organism_ch1: Homo sapiens///characteristics_ch1: excluded: no///characteristics_ch1.1: subclass: 2///characteristics_ch1.2: age: 46///characteristics_ch1.3: histology: Serous///characteristics_ch1.4: figo grade: III///characteristics_ch1.5: grade: 1&2///characteristics_ch1.6: peritoneal carcinomatosis: Yes///characteristics_ch1.7: residual tumor: No///characteristics_ch1.8: pfs event: 0///characteristics_ch1.9: pfs month: 27///characteristics_ch1.10: os event: 0///characteristics_ch1.11: os month: 27///molecule_ch1: total RNA///extract_protocol_ch1: total RNA from epithelial ovarian cancer tissues was isolated with the ABI PRISM 6100 Nucleic Acid PrepStation (Applied Biosystems) according to the manufacturers instructions///label_ch1: DIG///label_protocol_ch1: Applied Biosystems Chemiluminescent RT Labeling Kit///taxid_ch1: 9606///hyb_protocol: Applied Biosystems Chemiluminescence Detection Kit///scan_protocol: Expression Array System Software v1.1.1///description: Human Genome Survey Microarray V2.0 (Applied Biosystems)///data_processing: R Package ABarray 1.4.2 (Filtering flags > 5000, quantile normalization, log-2 transformation), Batch correction as follows: subtraction of the batch-specific mean from each gene, and add the overall mean.///platform_id: GPL2986///contact_name: Dietmar,,Pils///contact_email: [email protected]///contact_institute: Medical University of Vienna///contact_address: Waehringer Guertel 18-20///contact_city: Vienna///contact_zip.postal_code: 1090///contact_country: Austria///supplementary_file: NONE///data_row_count: 32878
1
title: EOC P045///geo_accession: GSM1211580///status: Public on Jan 01 2014///submission_date: Aug 19 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor tissue///organism_ch1: Homo sapiens///characteristics_ch1: excluded: no///characteristics_ch1.1: subclass: 2///characteristics_ch1.2: age: 63///characteristics_ch1.3: histology: Non-serous///characteristics_ch1.4: figo grade: III///characteristics_ch1.5: grade: 1&2///characteristics_ch1.6: peritoneal carcinomatosis: Yes///characteristics_ch1.7: residual tumor: Yes///characteristics_ch1.8: pfs event: 1///characteristics_ch1.9: pfs month: 9///characteristics_ch1.10: os event: 1///characteristics_ch1.11: os month: 21///molecule_ch1: total RNA///extract_protocol_ch1: total RNA from epithelial ovarian cancer tissues was isolated with the ABI PRISM 6100 Nucleic Acid PrepStation (Applied Biosystems) according to the manufacturers instructions///label_ch1: DIG///label_protocol_ch1: Applied Biosystems Chemiluminescent RT Labeling Kit///taxid_ch1: 9606///hyb_protocol: Applied Biosystems Chemiluminescence Detection Kit///scan_protocol: Expression Array System Software v1.1.1///description: Human Genome Survey Microarray V2.0 (Applied Biosystems)///data_processing: R Package ABarray 1.4.2 (Filtering flags > 5000, quantile normalization, log-2 transformation), Batch correction as follows: subtraction of the batch-specific mean from each gene, and add the overall mean.///platform_id: GPL2986///contact_name: Dietmar,,Pils///contact_email: [email protected]///contact_institute: Medical University of Vienna///contact_address: Waehringer Guertel 18-20///contact_city: Vienna///contact_zip.postal_code: 1090///contact_country: Austria///supplementary_file: NONE///data_row_count: 32878
1
title: EOC P046///geo_accession: GSM1211581///status: Public on Jan 01 2014///submission_date: Aug 19 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor tissue///organism_ch1: Homo sapiens///characteristics_ch1: excluded: no///characteristics_ch1.1: subclass: 1///characteristics_ch1.2: age: 51///characteristics_ch1.3: histology: Serous///characteristics_ch1.4: figo grade: III///characteristics_ch1.5: grade: 3///characteristics_ch1.6: peritoneal carcinomatosis: Yes///characteristics_ch1.7: residual tumor: No///characteristics_ch1.8: pfs event: 0///characteristics_ch1.9: pfs month: 27///characteristics_ch1.10: os event: 0///characteristics_ch1.11: os month: 27///molecule_ch1: total RNA///extract_protocol_ch1: total RNA from epithelial ovarian cancer tissues was isolated with the ABI PRISM 6100 Nucleic Acid PrepStation (Applied Biosystems) according to the manufacturers instructions///label_ch1: DIG///label_protocol_ch1: Applied Biosystems Chemiluminescent RT Labeling Kit///taxid_ch1: 9606///hyb_protocol: Applied Biosystems Chemiluminescence Detection Kit///scan_protocol: Expression Array System Software v1.1.1///description: Human Genome Survey Microarray V2.0 (Applied Biosystems)///data_processing: R Package ABarray 1.4.2 (Filtering flags > 5000, quantile normalization, log-2 transformation), Batch correction as follows: subtraction of the batch-specific mean from each gene, and add the overall mean.///platform_id: GPL2986///contact_name: Dietmar,,Pils///contact_email: [email protected]///contact_institute: Medical University of Vienna///contact_address: Waehringer Guertel 18-20///contact_city: Vienna///contact_zip.postal_code: 1090///contact_country: Austria///supplementary_file: NONE///data_row_count: 32878
1
title: EOC P047///geo_accession: GSM1211582///status: Public on Jan 01 2014///submission_date: Aug 19 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor tissue///organism_ch1: Homo sapiens///characteristics_ch1: excluded: no///characteristics_ch1.1: subclass: 2///characteristics_ch1.2: age: 56///characteristics_ch1.3: histology: Serous///characteristics_ch1.4: figo grade: III///characteristics_ch1.5: grade: 1&2///characteristics_ch1.6: peritoneal carcinomatosis: Yes///characteristics_ch1.7: residual tumor: No///characteristics_ch1.8: pfs event: 0///characteristics_ch1.9: pfs month: 17///characteristics_ch1.10: os event: 0///characteristics_ch1.11: os month: 17///molecule_ch1: total RNA///extract_protocol_ch1: total RNA from epithelial ovarian cancer tissues was isolated with the ABI PRISM 6100 Nucleic Acid PrepStation (Applied Biosystems) according to the manufacturers instructions///label_ch1: DIG///label_protocol_ch1: Applied Biosystems Chemiluminescent RT Labeling Kit///taxid_ch1: 9606///hyb_protocol: Applied Biosystems Chemiluminescence Detection Kit///scan_protocol: Expression Array System Software v1.1.1///description: Human Genome Survey Microarray V2.0 (Applied Biosystems)///data_processing: R Package ABarray 1.4.2 (Filtering flags > 5000, quantile normalization, log-2 transformation), Batch correction as follows: subtraction of the batch-specific mean from each gene, and add the overall mean.///platform_id: GPL2986///contact_name: Dietmar,,Pils///contact_email: [email protected]///contact_institute: Medical University of Vienna///contact_address: Waehringer Guertel 18-20///contact_city: Vienna///contact_zip.postal_code: 1090///contact_country: Austria///supplementary_file: NONE///data_row_count: 32878
1
title: EOC P048///geo_accession: GSM1211583///status: Public on Jan 01 2014///submission_date: Aug 19 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor tissue///organism_ch1: Homo sapiens///characteristics_ch1: excluded: no///characteristics_ch1.1: subclass: 2///characteristics_ch1.2: age: 65///characteristics_ch1.3: histology: Serous///characteristics_ch1.4: figo grade: IV///characteristics_ch1.5: grade: 3///characteristics_ch1.6: peritoneal carcinomatosis: No///characteristics_ch1.7: residual tumor: No///characteristics_ch1.8: pfs event: 1///characteristics_ch1.9: pfs month: 15///characteristics_ch1.10: os event: 1///characteristics_ch1.11: os month: 28///molecule_ch1: total RNA///extract_protocol_ch1: total RNA from epithelial ovarian cancer tissues was isolated with the ABI PRISM 6100 Nucleic Acid PrepStation (Applied Biosystems) according to the manufacturers instructions///label_ch1: DIG///label_protocol_ch1: Applied Biosystems Chemiluminescent RT Labeling Kit///taxid_ch1: 9606///hyb_protocol: Applied Biosystems Chemiluminescence Detection Kit///scan_protocol: Expression Array System Software v1.1.1///description: Human Genome Survey Microarray V2.0 (Applied Biosystems)///data_processing: R Package ABarray 1.4.2 (Filtering flags > 5000, quantile normalization, log-2 transformation), Batch correction as follows: subtraction of the batch-specific mean from each gene, and add the overall mean.///platform_id: GPL2986///contact_name: Dietmar,,Pils///contact_email: [email protected]///contact_institute: Medical University of Vienna///contact_address: Waehringer Guertel 18-20///contact_city: Vienna///contact_zip.postal_code: 1090///contact_country: Austria///supplementary_file: NONE///data_row_count: 32878
1
title: EOC P049///geo_accession: GSM1211584///status: Public on Jan 01 2014///submission_date: Aug 19 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor tissue///organism_ch1: Homo sapiens///characteristics_ch1: excluded: no///characteristics_ch1.1: subclass: 1///characteristics_ch1.2: age: 60///characteristics_ch1.3: histology: Non-serous///characteristics_ch1.4: figo grade: III///characteristics_ch1.5: grade: 3///characteristics_ch1.6: peritoneal carcinomatosis: No///characteristics_ch1.7: residual tumor: No///characteristics_ch1.8: pfs event: 1///characteristics_ch1.9: pfs month: 21///characteristics_ch1.10: os event: 0///characteristics_ch1.11: os month: 34///molecule_ch1: total RNA///extract_protocol_ch1: total RNA from epithelial ovarian cancer tissues was isolated with the ABI PRISM 6100 Nucleic Acid PrepStation (Applied Biosystems) according to the manufacturers instructions///label_ch1: DIG///label_protocol_ch1: Applied Biosystems Chemiluminescent RT Labeling Kit///taxid_ch1: 9606///hyb_protocol: Applied Biosystems Chemiluminescence Detection Kit///scan_protocol: Expression Array System Software v1.1.1///description: Human Genome Survey Microarray V2.0 (Applied Biosystems)///data_processing: R Package ABarray 1.4.2 (Filtering flags > 5000, quantile normalization, log-2 transformation), Batch correction as follows: subtraction of the batch-specific mean from each gene, and add the overall mean.///platform_id: GPL2986///contact_name: Dietmar,,Pils///contact_email: [email protected]///contact_institute: Medical University of Vienna///contact_address: Waehringer Guertel 18-20///contact_city: Vienna///contact_zip.postal_code: 1090///contact_country: Austria///supplementary_file: NONE///data_row_count: 32878
1
title: EOC P050///geo_accession: GSM1211585///status: Public on Jan 01 2014///submission_date: Aug 19 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor tissue///organism_ch1: Homo sapiens///characteristics_ch1: excluded: no///characteristics_ch1.1: subclass: 2///characteristics_ch1.2: age: 56///characteristics_ch1.3: histology: Serous///characteristics_ch1.4: figo grade: III///characteristics_ch1.5: grade: 3///characteristics_ch1.6: peritoneal carcinomatosis: Yes///characteristics_ch1.7: residual tumor: No///characteristics_ch1.8: pfs event: 1///characteristics_ch1.9: pfs month: 25///characteristics_ch1.10: os event: 0///characteristics_ch1.11: os month: 25///molecule_ch1: total RNA///extract_protocol_ch1: total RNA from epithelial ovarian cancer tissues was isolated with the ABI PRISM 6100 Nucleic Acid PrepStation (Applied Biosystems) according to the manufacturers instructions///label_ch1: DIG///label_protocol_ch1: Applied Biosystems Chemiluminescent RT Labeling Kit///taxid_ch1: 9606///hyb_protocol: Applied Biosystems Chemiluminescence Detection Kit///scan_protocol: Expression Array System Software v1.1.1///description: Human Genome Survey Microarray V2.0 (Applied Biosystems)///data_processing: R Package ABarray 1.4.2 (Filtering flags > 5000, quantile normalization, log-2 transformation), Batch correction as follows: subtraction of the batch-specific mean from each gene, and add the overall mean.///platform_id: GPL2986///contact_name: Dietmar,,Pils///contact_email: [email protected]///contact_institute: Medical University of Vienna///contact_address: Waehringer Guertel 18-20///contact_city: Vienna///contact_zip.postal_code: 1090///contact_country: Austria///supplementary_file: NONE///data_row_count: 32878
1
title: EOC P051///geo_accession: GSM1211586///status: Public on Jan 01 2014///submission_date: Aug 19 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor tissue///organism_ch1: Homo sapiens///characteristics_ch1: excluded: no///characteristics_ch1.1: subclass: 2///characteristics_ch1.2: age: 65///characteristics_ch1.3: histology: Serous///characteristics_ch1.4: figo grade: IV///characteristics_ch1.5: grade: 3///characteristics_ch1.6: peritoneal carcinomatosis: Yes///characteristics_ch1.7: residual tumor: No///characteristics_ch1.8: pfs event: 0///characteristics_ch1.9: pfs month: 26///characteristics_ch1.10: os event: 0///characteristics_ch1.11: os month: 26///molecule_ch1: total RNA///extract_protocol_ch1: total RNA from epithelial ovarian cancer tissues was isolated with the ABI PRISM 6100 Nucleic Acid PrepStation (Applied Biosystems) according to the manufacturers instructions///label_ch1: DIG///label_protocol_ch1: Applied Biosystems Chemiluminescent RT Labeling Kit///taxid_ch1: 9606///hyb_protocol: Applied Biosystems Chemiluminescence Detection Kit///scan_protocol: Expression Array System Software v1.1.1///description: Human Genome Survey Microarray V2.0 (Applied Biosystems)///data_processing: R Package ABarray 1.4.2 (Filtering flags > 5000, quantile normalization, log-2 transformation), Batch correction as follows: subtraction of the batch-specific mean from each gene, and add the overall mean.///platform_id: GPL2986///contact_name: Dietmar,,Pils///contact_email: [email protected]///contact_institute: Medical University of Vienna///contact_address: Waehringer Guertel 18-20///contact_city: Vienna///contact_zip.postal_code: 1090///contact_country: Austria///supplementary_file: NONE///data_row_count: 32878
1
title: EOC P052///geo_accession: GSM1211587///status: Public on Jan 01 2014///submission_date: Aug 19 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor tissue///organism_ch1: Homo sapiens///characteristics_ch1: excluded: no///characteristics_ch1.1: subclass: 2///characteristics_ch1.2: age: 60///characteristics_ch1.3: histology: Non-serous///characteristics_ch1.4: figo grade: III///characteristics_ch1.5: grade: 3///characteristics_ch1.6: peritoneal carcinomatosis: Yes///characteristics_ch1.7: residual tumor: No///characteristics_ch1.8: pfs event: 1///characteristics_ch1.9: pfs month: 12///characteristics_ch1.10: os event: 1///characteristics_ch1.11: os month: 20///molecule_ch1: total RNA///extract_protocol_ch1: total RNA from epithelial ovarian cancer tissues was isolated with the ABI PRISM 6100 Nucleic Acid PrepStation (Applied Biosystems) according to the manufacturers instructions///label_ch1: DIG///label_protocol_ch1: Applied Biosystems Chemiluminescent RT Labeling Kit///taxid_ch1: 9606///hyb_protocol: Applied Biosystems Chemiluminescence Detection Kit///scan_protocol: Expression Array System Software v1.1.1///description: Human Genome Survey Microarray V2.0 (Applied Biosystems)///data_processing: R Package ABarray 1.4.2 (Filtering flags > 5000, quantile normalization, log-2 transformation), Batch correction as follows: subtraction of the batch-specific mean from each gene, and add the overall mean.///platform_id: GPL2986///contact_name: Dietmar,,Pils///contact_email: [email protected]///contact_institute: Medical University of Vienna///contact_address: Waehringer Guertel 18-20///contact_city: Vienna///contact_zip.postal_code: 1090///contact_country: Austria///supplementary_file: NONE///data_row_count: 32878
1
title: EOC P053///geo_accession: GSM1211588///status: Public on Jan 01 2014///submission_date: Aug 19 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor tissue///organism_ch1: Homo sapiens///characteristics_ch1: excluded: no///characteristics_ch1.1: subclass: 2///characteristics_ch1.2: age: 58///characteristics_ch1.3: histology: Non-serous///characteristics_ch1.4: figo grade: III///characteristics_ch1.5: grade: 3///characteristics_ch1.6: peritoneal carcinomatosis: Yes///characteristics_ch1.7: residual tumor: Yes///characteristics_ch1.8: pfs event: 1///characteristics_ch1.9: pfs month: 4///characteristics_ch1.10: os event: 1///characteristics_ch1.11: os month: 4///molecule_ch1: total RNA///extract_protocol_ch1: total RNA from epithelial ovarian cancer tissues was isolated with the ABI PRISM 6100 Nucleic Acid PrepStation (Applied Biosystems) according to the manufacturers instructions///label_ch1: DIG///label_protocol_ch1: Applied Biosystems Chemiluminescent RT Labeling Kit///taxid_ch1: 9606///hyb_protocol: Applied Biosystems Chemiluminescence Detection Kit///scan_protocol: Expression Array System Software v1.1.1///description: Human Genome Survey Microarray V2.0 (Applied Biosystems)///data_processing: R Package ABarray 1.4.2 (Filtering flags > 5000, quantile normalization, log-2 transformation), Batch correction as follows: subtraction of the batch-specific mean from each gene, and add the overall mean.///platform_id: GPL2986///contact_name: Dietmar,,Pils///contact_email: [email protected]///contact_institute: Medical University of Vienna///contact_address: Waehringer Guertel 18-20///contact_city: Vienna///contact_zip.postal_code: 1090///contact_country: Austria///supplementary_file: NONE///data_row_count: 32878
1
title: EOC P054///geo_accession: GSM1211589///status: Public on Jan 01 2014///submission_date: Aug 19 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor tissue///organism_ch1: Homo sapiens///characteristics_ch1: excluded: no///characteristics_ch1.1: subclass: 1///characteristics_ch1.2: age: 49///characteristics_ch1.3: histology: Serous///characteristics_ch1.4: figo grade: IV///characteristics_ch1.5: grade: 3///characteristics_ch1.6: peritoneal carcinomatosis: No///characteristics_ch1.7: residual tumor: Yes///characteristics_ch1.8: pfs event: 0///characteristics_ch1.9: pfs month: 26///characteristics_ch1.10: os event: 0///characteristics_ch1.11: os month: 26///molecule_ch1: total RNA///extract_protocol_ch1: total RNA from epithelial ovarian cancer tissues was isolated with the ABI PRISM 6100 Nucleic Acid PrepStation (Applied Biosystems) according to the manufacturers instructions///label_ch1: DIG///label_protocol_ch1: Applied Biosystems Chemiluminescent RT Labeling Kit///taxid_ch1: 9606///hyb_protocol: Applied Biosystems Chemiluminescence Detection Kit///scan_protocol: Expression Array System Software v1.1.1///description: Human Genome Survey Microarray V2.0 (Applied Biosystems)///data_processing: R Package ABarray 1.4.2 (Filtering flags > 5000, quantile normalization, log-2 transformation), Batch correction as follows: subtraction of the batch-specific mean from each gene, and add the overall mean.///platform_id: GPL2986///contact_name: Dietmar,,Pils///contact_email: [email protected]///contact_institute: Medical University of Vienna///contact_address: Waehringer Guertel 18-20///contact_city: Vienna///contact_zip.postal_code: 1090///contact_country: Austria///supplementary_file: NONE///data_row_count: 32878
1
title: EOC P055///geo_accession: GSM1211590///status: Public on Jan 01 2014///submission_date: Aug 19 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor tissue///organism_ch1: Homo sapiens///characteristics_ch1: excluded: no///characteristics_ch1.1: subclass: 2///characteristics_ch1.2: age: 66///characteristics_ch1.3: histology: Serous///characteristics_ch1.4: figo grade: III///characteristics_ch1.5: grade: 1&2///characteristics_ch1.6: peritoneal carcinomatosis: No///characteristics_ch1.7: residual tumor: No///characteristics_ch1.8: pfs event: 0///characteristics_ch1.9: pfs month: 25///characteristics_ch1.10: os event: 0///characteristics_ch1.11: os month: 25///molecule_ch1: total RNA///extract_protocol_ch1: total RNA from epithelial ovarian cancer tissues was isolated with the ABI PRISM 6100 Nucleic Acid PrepStation (Applied Biosystems) according to the manufacturers instructions///label_ch1: DIG///label_protocol_ch1: Applied Biosystems Chemiluminescent RT Labeling Kit///taxid_ch1: 9606///hyb_protocol: Applied Biosystems Chemiluminescence Detection Kit///scan_protocol: Expression Array System Software v1.1.1///description: Human Genome Survey Microarray V2.0 (Applied Biosystems)///data_processing: R Package ABarray 1.4.2 (Filtering flags > 5000, quantile normalization, log-2 transformation), Batch correction as follows: subtraction of the batch-specific mean from each gene, and add the overall mean.///platform_id: GPL2986///contact_name: Dietmar,,Pils///contact_email: [email protected]///contact_institute: Medical University of Vienna///contact_address: Waehringer Guertel 18-20///contact_city: Vienna///contact_zip.postal_code: 1090///contact_country: Austria///supplementary_file: NONE///data_row_count: 32878
1
title: EOC P056///geo_accession: GSM1211591///status: Public on Jan 01 2014///submission_date: Aug 19 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor tissue///organism_ch1: Homo sapiens///characteristics_ch1: excluded: no///characteristics_ch1.1: subclass: 2///characteristics_ch1.2: age: 46///characteristics_ch1.3: histology: Serous///characteristics_ch1.4: figo grade: IV///characteristics_ch1.5: grade: 3///characteristics_ch1.6: peritoneal carcinomatosis: Yes///characteristics_ch1.7: residual tumor: No///characteristics_ch1.8: pfs event: 1///characteristics_ch1.9: pfs month: 17///characteristics_ch1.10: os event: 0///characteristics_ch1.11: os month: 24///molecule_ch1: total RNA///extract_protocol_ch1: total RNA from epithelial ovarian cancer tissues was isolated with the ABI PRISM 6100 Nucleic Acid PrepStation (Applied Biosystems) according to the manufacturers instructions///label_ch1: DIG///label_protocol_ch1: Applied Biosystems Chemiluminescent RT Labeling Kit///taxid_ch1: 9606///hyb_protocol: Applied Biosystems Chemiluminescence Detection Kit///scan_protocol: Expression Array System Software v1.1.1///description: Human Genome Survey Microarray V2.0 (Applied Biosystems)///data_processing: R Package ABarray 1.4.2 (Filtering flags > 5000, quantile normalization, log-2 transformation), Batch correction as follows: subtraction of the batch-specific mean from each gene, and add the overall mean.///platform_id: GPL2986///contact_name: Dietmar,,Pils///contact_email: [email protected]///contact_institute: Medical University of Vienna///contact_address: Waehringer Guertel 18-20///contact_city: Vienna///contact_zip.postal_code: 1090///contact_country: Austria///supplementary_file: NONE///data_row_count: 32878
1
title: EOC P057///geo_accession: GSM1211592///status: Public on Jan 01 2014///submission_date: Aug 19 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor tissue///organism_ch1: Homo sapiens///characteristics_ch1: excluded: no///characteristics_ch1.1: subclass: 1///characteristics_ch1.2: age: 61///characteristics_ch1.3: histology: Serous///characteristics_ch1.4: figo grade: III///characteristics_ch1.5: grade: 3///characteristics_ch1.6: peritoneal carcinomatosis: Yes///characteristics_ch1.7: residual tumor: No///characteristics_ch1.8: pfs event: 1///characteristics_ch1.9: pfs month: 21///characteristics_ch1.10: os event: 0///characteristics_ch1.11: os month: 25///molecule_ch1: total RNA///extract_protocol_ch1: total RNA from epithelial ovarian cancer tissues was isolated with the ABI PRISM 6100 Nucleic Acid PrepStation (Applied Biosystems) according to the manufacturers instructions///label_ch1: DIG///label_protocol_ch1: Applied Biosystems Chemiluminescent RT Labeling Kit///taxid_ch1: 9606///hyb_protocol: Applied Biosystems Chemiluminescence Detection Kit///scan_protocol: Expression Array System Software v1.1.1///description: Human Genome Survey Microarray V2.0 (Applied Biosystems)///data_processing: R Package ABarray 1.4.2 (Filtering flags > 5000, quantile normalization, log-2 transformation), Batch correction as follows: subtraction of the batch-specific mean from each gene, and add the overall mean.///platform_id: GPL2986///contact_name: Dietmar,,Pils///contact_email: [email protected]///contact_institute: Medical University of Vienna///contact_address: Waehringer Guertel 18-20///contact_city: Vienna///contact_zip.postal_code: 1090///contact_country: Austria///supplementary_file: NONE///data_row_count: 32878
1
title: EOC P058///geo_accession: GSM1211593///status: Public on Jan 01 2014///submission_date: Aug 19 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor tissue///organism_ch1: Homo sapiens///characteristics_ch1: excluded: no///characteristics_ch1.1: subclass: 1///characteristics_ch1.2: age: 38///characteristics_ch1.3: histology: Serous///characteristics_ch1.4: figo grade: III///characteristics_ch1.5: grade: 3///characteristics_ch1.6: peritoneal carcinomatosis: No///characteristics_ch1.7: residual tumor: No///characteristics_ch1.8: pfs event: 0///characteristics_ch1.9: pfs month: 25///characteristics_ch1.10: os event: 0///characteristics_ch1.11: os month: 25///molecule_ch1: total RNA///extract_protocol_ch1: total RNA from epithelial ovarian cancer tissues was isolated with the ABI PRISM 6100 Nucleic Acid PrepStation (Applied Biosystems) according to the manufacturers instructions///label_ch1: DIG///label_protocol_ch1: Applied Biosystems Chemiluminescent RT Labeling Kit///taxid_ch1: 9606///hyb_protocol: Applied Biosystems Chemiluminescence Detection Kit///scan_protocol: Expression Array System Software v1.1.1///description: Human Genome Survey Microarray V2.0 (Applied Biosystems)///data_processing: R Package ABarray 1.4.2 (Filtering flags > 5000, quantile normalization, log-2 transformation), Batch correction as follows: subtraction of the batch-specific mean from each gene, and add the overall mean.///platform_id: GPL2986///contact_name: Dietmar,,Pils///contact_email: [email protected]///contact_institute: Medical University of Vienna///contact_address: Waehringer Guertel 18-20///contact_city: Vienna///contact_zip.postal_code: 1090///contact_country: Austria///supplementary_file: NONE///data_row_count: 32878
1
title: EOC P059///geo_accession: GSM1211594///status: Public on Jan 01 2014///submission_date: Aug 19 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor tissue///organism_ch1: Homo sapiens///characteristics_ch1: excluded: no///characteristics_ch1.1: subclass: 2///characteristics_ch1.2: age: 56///characteristics_ch1.3: histology: Serous///characteristics_ch1.4: figo grade: III///characteristics_ch1.5: grade: 3///characteristics_ch1.6: peritoneal carcinomatosis: No///characteristics_ch1.7: residual tumor: No///characteristics_ch1.8: pfs event: 1///characteristics_ch1.9: pfs month: 19///characteristics_ch1.10: os event: 0///characteristics_ch1.11: os month: 23///molecule_ch1: total RNA///extract_protocol_ch1: total RNA from epithelial ovarian cancer tissues was isolated with the ABI PRISM 6100 Nucleic Acid PrepStation (Applied Biosystems) according to the manufacturers instructions///label_ch1: DIG///label_protocol_ch1: Applied Biosystems Chemiluminescent RT Labeling Kit///taxid_ch1: 9606///hyb_protocol: Applied Biosystems Chemiluminescence Detection Kit///scan_protocol: Expression Array System Software v1.1.1///description: Human Genome Survey Microarray V2.0 (Applied Biosystems)///data_processing: R Package ABarray 1.4.2 (Filtering flags > 5000, quantile normalization, log-2 transformation), Batch correction as follows: subtraction of the batch-specific mean from each gene, and add the overall mean.///platform_id: GPL2986///contact_name: Dietmar,,Pils///contact_email: [email protected]///contact_institute: Medical University of Vienna///contact_address: Waehringer Guertel 18-20///contact_city: Vienna///contact_zip.postal_code: 1090///contact_country: Austria///supplementary_file: NONE///data_row_count: 32878
1
title: EOC P060///geo_accession: GSM1211595///status: Public on Jan 01 2014///submission_date: Aug 19 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor tissue///organism_ch1: Homo sapiens///characteristics_ch1: excluded: no///characteristics_ch1.1: subclass: 2///characteristics_ch1.2: age: 63///characteristics_ch1.3: histology: Serous///characteristics_ch1.4: figo grade: III///characteristics_ch1.5: grade: 3///characteristics_ch1.6: peritoneal carcinomatosis: Yes///characteristics_ch1.7: residual tumor: Yes///characteristics_ch1.8: pfs event: 1///characteristics_ch1.9: pfs month: 8///characteristics_ch1.10: os event: 1///characteristics_ch1.11: os month: 8///molecule_ch1: total RNA///extract_protocol_ch1: total RNA from epithelial ovarian cancer tissues was isolated with the ABI PRISM 6100 Nucleic Acid PrepStation (Applied Biosystems) according to the manufacturers instructions///label_ch1: DIG///label_protocol_ch1: Applied Biosystems Chemiluminescent RT Labeling Kit///taxid_ch1: 9606///hyb_protocol: Applied Biosystems Chemiluminescence Detection Kit///scan_protocol: Expression Array System Software v1.1.1///description: Human Genome Survey Microarray V2.0 (Applied Biosystems)///data_processing: R Package ABarray 1.4.2 (Filtering flags > 5000, quantile normalization, log-2 transformation), Batch correction as follows: subtraction of the batch-specific mean from each gene, and add the overall mean.///platform_id: GPL2986///contact_name: Dietmar,,Pils///contact_email: [email protected]///contact_institute: Medical University of Vienna///contact_address: Waehringer Guertel 18-20///contact_city: Vienna///contact_zip.postal_code: 1090///contact_country: Austria///supplementary_file: NONE///data_row_count: 32878
1
title: EOC P061///geo_accession: GSM1211596///status: Public on Jan 01 2014///submission_date: Aug 19 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor tissue///organism_ch1: Homo sapiens///characteristics_ch1: excluded: no///characteristics_ch1.1: subclass: 2///characteristics_ch1.2: age: 66///characteristics_ch1.3: histology: Serous///characteristics_ch1.4: figo grade: III///characteristics_ch1.5: grade: 3///characteristics_ch1.6: peritoneal carcinomatosis: Yes///characteristics_ch1.7: residual tumor: No///characteristics_ch1.8: pfs event: 0///characteristics_ch1.9: pfs month: 22///characteristics_ch1.10: os event: 0///characteristics_ch1.11: os month: 22///molecule_ch1: total RNA///extract_protocol_ch1: total RNA from epithelial ovarian cancer tissues was isolated with the ABI PRISM 6100 Nucleic Acid PrepStation (Applied Biosystems) according to the manufacturers instructions///label_ch1: DIG///label_protocol_ch1: Applied Biosystems Chemiluminescent RT Labeling Kit///taxid_ch1: 9606///hyb_protocol: Applied Biosystems Chemiluminescence Detection Kit///scan_protocol: Expression Array System Software v1.1.1///description: Human Genome Survey Microarray V2.0 (Applied Biosystems)///data_processing: R Package ABarray 1.4.2 (Filtering flags > 5000, quantile normalization, log-2 transformation), Batch correction as follows: subtraction of the batch-specific mean from each gene, and add the overall mean.///platform_id: GPL2986///contact_name: Dietmar,,Pils///contact_email: [email protected]///contact_institute: Medical University of Vienna///contact_address: Waehringer Guertel 18-20///contact_city: Vienna///contact_zip.postal_code: 1090///contact_country: Austria///supplementary_file: NONE///data_row_count: 32878
1
title: EOC P062///geo_accession: GSM1211597///status: Public on Jan 01 2014///submission_date: Aug 19 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor tissue///organism_ch1: Homo sapiens///characteristics_ch1: excluded: no///characteristics_ch1.1: subclass: 1///characteristics_ch1.2: age: 51///characteristics_ch1.3: histology: Serous///characteristics_ch1.4: figo grade: III///characteristics_ch1.5: grade: 3///characteristics_ch1.6: peritoneal carcinomatosis: Yes///characteristics_ch1.7: residual tumor: No///characteristics_ch1.8: pfs event: 0///characteristics_ch1.9: pfs month: 12///characteristics_ch1.10: os event: 0///characteristics_ch1.11: os month: 12///molecule_ch1: total RNA///extract_protocol_ch1: total RNA from epithelial ovarian cancer tissues was isolated with the ABI PRISM 6100 Nucleic Acid PrepStation (Applied Biosystems) according to the manufacturers instructions///label_ch1: DIG///label_protocol_ch1: Applied Biosystems Chemiluminescent RT Labeling Kit///taxid_ch1: 9606///hyb_protocol: Applied Biosystems Chemiluminescence Detection Kit///scan_protocol: Expression Array System Software v1.1.1///description: Human Genome Survey Microarray V2.0 (Applied Biosystems)///data_processing: R Package ABarray 1.4.2 (Filtering flags > 5000, quantile normalization, log-2 transformation), Batch correction as follows: subtraction of the batch-specific mean from each gene, and add the overall mean.///platform_id: GPL2986///contact_name: Dietmar,,Pils///contact_email: [email protected]///contact_institute: Medical University of Vienna///contact_address: Waehringer Guertel 18-20///contact_city: Vienna///contact_zip.postal_code: 1090///contact_country: Austria///supplementary_file: NONE///data_row_count: 32878
1
title: EOC P063///geo_accession: GSM1211598///status: Public on Jan 01 2014///submission_date: Aug 19 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor tissue///organism_ch1: Homo sapiens///characteristics_ch1: excluded: no///characteristics_ch1.1: subclass: 1///characteristics_ch1.2: age: 36///characteristics_ch1.3: histology: Serous///characteristics_ch1.4: figo grade: III///characteristics_ch1.5: grade: 1&2///characteristics_ch1.6: peritoneal carcinomatosis: Yes///characteristics_ch1.7: residual tumor: No///characteristics_ch1.8: pfs event: 0///characteristics_ch1.9: pfs month: 26///characteristics_ch1.10: os event: 0///characteristics_ch1.11: os month: 26///molecule_ch1: total RNA///extract_protocol_ch1: total RNA from epithelial ovarian cancer tissues was isolated with the ABI PRISM 6100 Nucleic Acid PrepStation (Applied Biosystems) according to the manufacturers instructions///label_ch1: DIG///label_protocol_ch1: Applied Biosystems Chemiluminescent RT Labeling Kit///taxid_ch1: 9606///hyb_protocol: Applied Biosystems Chemiluminescence Detection Kit///scan_protocol: Expression Array System Software v1.1.1///description: Human Genome Survey Microarray V2.0 (Applied Biosystems)///data_processing: R Package ABarray 1.4.2 (Filtering flags > 5000, quantile normalization, log-2 transformation), Batch correction as follows: subtraction of the batch-specific mean from each gene, and add the overall mean.///platform_id: GPL2986///contact_name: Dietmar,,Pils///contact_email: [email protected]///contact_institute: Medical University of Vienna///contact_address: Waehringer Guertel 18-20///contact_city: Vienna///contact_zip.postal_code: 1090///contact_country: Austria///supplementary_file: NONE///data_row_count: 32878
1
title: EOC P064///geo_accession: GSM1211599///status: Public on Jan 01 2014///submission_date: Aug 19 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor tissue///organism_ch1: Homo sapiens///characteristics_ch1: excluded: no///characteristics_ch1.1: subclass: 1///characteristics_ch1.2: age: 69///characteristics_ch1.3: histology: Serous///characteristics_ch1.4: figo grade: IV///characteristics_ch1.5: grade: 3///characteristics_ch1.6: peritoneal carcinomatosis: Yes///characteristics_ch1.7: residual tumor: No///characteristics_ch1.8: pfs event: 1///characteristics_ch1.9: pfs month: 12///characteristics_ch1.10: os event: 0///characteristics_ch1.11: os month: 21///molecule_ch1: total RNA///extract_protocol_ch1: total RNA from epithelial ovarian cancer tissues was isolated with the ABI PRISM 6100 Nucleic Acid PrepStation (Applied Biosystems) according to the manufacturers instructions///label_ch1: DIG///label_protocol_ch1: Applied Biosystems Chemiluminescent RT Labeling Kit///taxid_ch1: 9606///hyb_protocol: Applied Biosystems Chemiluminescence Detection Kit///scan_protocol: Expression Array System Software v1.1.1///description: Human Genome Survey Microarray V2.0 (Applied Biosystems)///data_processing: R Package ABarray 1.4.2 (Filtering flags > 5000, quantile normalization, log-2 transformation), Batch correction as follows: subtraction of the batch-specific mean from each gene, and add the overall mean.///platform_id: GPL2986///contact_name: Dietmar,,Pils///contact_email: [email protected]///contact_institute: Medical University of Vienna///contact_address: Waehringer Guertel 18-20///contact_city: Vienna///contact_zip.postal_code: 1090///contact_country: Austria///supplementary_file: NONE///data_row_count: 32878
1
title: EOC P065///geo_accession: GSM1211600///status: Public on Jan 01 2014///submission_date: Aug 19 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor tissue///organism_ch1: Homo sapiens///characteristics_ch1: excluded: no///characteristics_ch1.1: subclass: 1///characteristics_ch1.2: age: 40///characteristics_ch1.3: histology: Non-serous///characteristics_ch1.4: figo grade: II///characteristics_ch1.5: grade: 3///characteristics_ch1.6: peritoneal carcinomatosis: No///characteristics_ch1.7: residual tumor: No///characteristics_ch1.8: pfs event: 0///characteristics_ch1.9: pfs month: 21///characteristics_ch1.10: os event: 0///characteristics_ch1.11: os month: 21///molecule_ch1: total RNA///extract_protocol_ch1: total RNA from epithelial ovarian cancer tissues was isolated with the ABI PRISM 6100 Nucleic Acid PrepStation (Applied Biosystems) according to the manufacturers instructions///label_ch1: DIG///label_protocol_ch1: Applied Biosystems Chemiluminescent RT Labeling Kit///taxid_ch1: 9606///hyb_protocol: Applied Biosystems Chemiluminescence Detection Kit///scan_protocol: Expression Array System Software v1.1.1///description: Human Genome Survey Microarray V2.0 (Applied Biosystems)///data_processing: R Package ABarray 1.4.2 (Filtering flags > 5000, quantile normalization, log-2 transformation), Batch correction as follows: subtraction of the batch-specific mean from each gene, and add the overall mean.///platform_id: GPL2986///contact_name: Dietmar,,Pils///contact_email: [email protected]///contact_institute: Medical University of Vienna///contact_address: Waehringer Guertel 18-20///contact_city: Vienna///contact_zip.postal_code: 1090///contact_country: Austria///supplementary_file: NONE///data_row_count: 32878
1
title: EOC P066///geo_accession: GSM1211601///status: Public on Jan 01 2014///submission_date: Aug 19 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor tissue///organism_ch1: Homo sapiens///characteristics_ch1: excluded: no///characteristics_ch1.1: subclass: 2///characteristics_ch1.2: age: 52///characteristics_ch1.3: histology: Serous///characteristics_ch1.4: figo grade: III///characteristics_ch1.5: grade: 3///characteristics_ch1.6: peritoneal carcinomatosis: Yes///characteristics_ch1.7: residual tumor: Yes///characteristics_ch1.8: pfs event: 1///characteristics_ch1.9: pfs month: 15///characteristics_ch1.10: os event: 0///characteristics_ch1.11: os month: 20///molecule_ch1: total RNA///extract_protocol_ch1: total RNA from epithelial ovarian cancer tissues was isolated with the ABI PRISM 6100 Nucleic Acid PrepStation (Applied Biosystems) according to the manufacturers instructions///label_ch1: DIG///label_protocol_ch1: Applied Biosystems Chemiluminescent RT Labeling Kit///taxid_ch1: 9606///hyb_protocol: Applied Biosystems Chemiluminescence Detection Kit///scan_protocol: Expression Array System Software v1.1.1///description: Human Genome Survey Microarray V2.0 (Applied Biosystems)///data_processing: R Package ABarray 1.4.2 (Filtering flags > 5000, quantile normalization, log-2 transformation), Batch correction as follows: subtraction of the batch-specific mean from each gene, and add the overall mean.///platform_id: GPL2986///contact_name: Dietmar,,Pils///contact_email: [email protected]///contact_institute: Medical University of Vienna///contact_address: Waehringer Guertel 18-20///contact_city: Vienna///contact_zip.postal_code: 1090///contact_country: Austria///supplementary_file: NONE///data_row_count: 32878
1
title: EOC P067///geo_accession: GSM1211602///status: Public on Jan 01 2014///submission_date: Aug 19 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor tissue///organism_ch1: Homo sapiens///characteristics_ch1: excluded: no///characteristics_ch1.1: subclass: 1///characteristics_ch1.2: age: 45///characteristics_ch1.3: histology: Serous///characteristics_ch1.4: figo grade: III///characteristics_ch1.5: grade: 3///characteristics_ch1.6: peritoneal carcinomatosis: Yes///characteristics_ch1.7: residual tumor: Yes///characteristics_ch1.8: pfs event: 0///characteristics_ch1.9: pfs month: 17///characteristics_ch1.10: os event: 0///characteristics_ch1.11: os month: 17///molecule_ch1: total RNA///extract_protocol_ch1: total RNA from epithelial ovarian cancer tissues was isolated with the ABI PRISM 6100 Nucleic Acid PrepStation (Applied Biosystems) according to the manufacturers instructions///label_ch1: DIG///label_protocol_ch1: Applied Biosystems Chemiluminescent RT Labeling Kit///taxid_ch1: 9606///hyb_protocol: Applied Biosystems Chemiluminescence Detection Kit///scan_protocol: Expression Array System Software v1.1.1///description: Human Genome Survey Microarray V2.0 (Applied Biosystems)///data_processing: R Package ABarray 1.4.2 (Filtering flags > 5000, quantile normalization, log-2 transformation), Batch correction as follows: subtraction of the batch-specific mean from each gene, and add the overall mean.///platform_id: GPL2986///contact_name: Dietmar,,Pils///contact_email: [email protected]///contact_institute: Medical University of Vienna///contact_address: Waehringer Guertel 18-20///contact_city: Vienna///contact_zip.postal_code: 1090///contact_country: Austria///supplementary_file: NONE///data_row_count: 32878
1
title: EOC P068///geo_accession: GSM1211603///status: Public on Jan 01 2014///submission_date: Aug 19 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor tissue///organism_ch1: Homo sapiens///characteristics_ch1: excluded: no///characteristics_ch1.1: subclass: 2///characteristics_ch1.2: age: 69///characteristics_ch1.3: histology: Serous///characteristics_ch1.4: figo grade: III///characteristics_ch1.5: grade: 3///characteristics_ch1.6: peritoneal carcinomatosis: Yes///characteristics_ch1.7: residual tumor: Yes///characteristics_ch1.8: pfs event: 1///characteristics_ch1.9: pfs month: 5///characteristics_ch1.10: os event: 1///characteristics_ch1.11: os month: 5///molecule_ch1: total RNA///extract_protocol_ch1: total RNA from epithelial ovarian cancer tissues was isolated with the ABI PRISM 6100 Nucleic Acid PrepStation (Applied Biosystems) according to the manufacturers instructions///label_ch1: DIG///label_protocol_ch1: Applied Biosystems Chemiluminescent RT Labeling Kit///taxid_ch1: 9606///hyb_protocol: Applied Biosystems Chemiluminescence Detection Kit///scan_protocol: Expression Array System Software v1.1.1///description: Human Genome Survey Microarray V2.0 (Applied Biosystems)///data_processing: R Package ABarray 1.4.2 (Filtering flags > 5000, quantile normalization, log-2 transformation), Batch correction as follows: subtraction of the batch-specific mean from each gene, and add the overall mean.///platform_id: GPL2986///contact_name: Dietmar,,Pils///contact_email: [email protected]///contact_institute: Medical University of Vienna///contact_address: Waehringer Guertel 18-20///contact_city: Vienna///contact_zip.postal_code: 1090///contact_country: Austria///supplementary_file: NONE///data_row_count: 32878
1
title: EOC P069///geo_accession: GSM1211604///status: Public on Jan 01 2014///submission_date: Aug 19 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor tissue///organism_ch1: Homo sapiens///characteristics_ch1: excluded: no///characteristics_ch1.1: subclass: 2///characteristics_ch1.2: age: 76///characteristics_ch1.3: histology: Serous///characteristics_ch1.4: figo grade: III///characteristics_ch1.5: grade: 3///characteristics_ch1.6: peritoneal carcinomatosis: Yes///characteristics_ch1.7: residual tumor: No///characteristics_ch1.8: pfs event: 0///characteristics_ch1.9: pfs month: 18///characteristics_ch1.10: os event: 0///characteristics_ch1.11: os month: 18///molecule_ch1: total RNA///extract_protocol_ch1: total RNA from epithelial ovarian cancer tissues was isolated with the ABI PRISM 6100 Nucleic Acid PrepStation (Applied Biosystems) according to the manufacturers instructions///label_ch1: DIG///label_protocol_ch1: Applied Biosystems Chemiluminescent RT Labeling Kit///taxid_ch1: 9606///hyb_protocol: Applied Biosystems Chemiluminescence Detection Kit///scan_protocol: Expression Array System Software v1.1.1///description: Human Genome Survey Microarray V2.0 (Applied Biosystems)///data_processing: R Package ABarray 1.4.2 (Filtering flags > 5000, quantile normalization, log-2 transformation), Batch correction as follows: subtraction of the batch-specific mean from each gene, and add the overall mean.///platform_id: GPL2986///contact_name: Dietmar,,Pils///contact_email: [email protected]///contact_institute: Medical University of Vienna///contact_address: Waehringer Guertel 18-20///contact_city: Vienna///contact_zip.postal_code: 1090///contact_country: Austria///supplementary_file: NONE///data_row_count: 32878
1
title: EOC P070///geo_accession: GSM1211605///status: Public on Jan 01 2014///submission_date: Aug 19 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor tissue///organism_ch1: Homo sapiens///characteristics_ch1: excluded: no///characteristics_ch1.1: subclass: 1///characteristics_ch1.2: age: 35///characteristics_ch1.3: histology: Serous///characteristics_ch1.4: figo grade: III///characteristics_ch1.5: grade: 3///characteristics_ch1.6: peritoneal carcinomatosis: No///characteristics_ch1.7: residual tumor: No///characteristics_ch1.8: pfs event: 0///characteristics_ch1.9: pfs month: 17///characteristics_ch1.10: os event: 0///characteristics_ch1.11: os month: 17///molecule_ch1: total RNA///extract_protocol_ch1: total RNA from epithelial ovarian cancer tissues was isolated with the ABI PRISM 6100 Nucleic Acid PrepStation (Applied Biosystems) according to the manufacturers instructions///label_ch1: DIG///label_protocol_ch1: Applied Biosystems Chemiluminescent RT Labeling Kit///taxid_ch1: 9606///hyb_protocol: Applied Biosystems Chemiluminescence Detection Kit///scan_protocol: Expression Array System Software v1.1.1///description: Human Genome Survey Microarray V2.0 (Applied Biosystems)///data_processing: R Package ABarray 1.4.2 (Filtering flags > 5000, quantile normalization, log-2 transformation), Batch correction as follows: subtraction of the batch-specific mean from each gene, and add the overall mean.///platform_id: GPL2986///contact_name: Dietmar,,Pils///contact_email: [email protected]///contact_institute: Medical University of Vienna///contact_address: Waehringer Guertel 18-20///contact_city: Vienna///contact_zip.postal_code: 1090///contact_country: Austria///supplementary_file: NONE///data_row_count: 32878
1
title: EOC P071///geo_accession: GSM1211606///status: Public on Jan 01 2014///submission_date: Aug 19 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor tissue///organism_ch1: Homo sapiens///characteristics_ch1: excluded: no///characteristics_ch1.1: subclass: 1///characteristics_ch1.2: age: 79///characteristics_ch1.3: histology: Serous///characteristics_ch1.4: figo grade: III///characteristics_ch1.5: grade: 1&2///characteristics_ch1.6: peritoneal carcinomatosis: Yes///characteristics_ch1.7: residual tumor: No///characteristics_ch1.8: pfs event: 0///characteristics_ch1.9: pfs month: 15///characteristics_ch1.10: os event: 0///characteristics_ch1.11: os month: 15///molecule_ch1: total RNA///extract_protocol_ch1: total RNA from epithelial ovarian cancer tissues was isolated with the ABI PRISM 6100 Nucleic Acid PrepStation (Applied Biosystems) according to the manufacturers instructions///label_ch1: DIG///label_protocol_ch1: Applied Biosystems Chemiluminescent RT Labeling Kit///taxid_ch1: 9606///hyb_protocol: Applied Biosystems Chemiluminescence Detection Kit///scan_protocol: Expression Array System Software v1.1.1///description: Human Genome Survey Microarray V2.0 (Applied Biosystems)///data_processing: R Package ABarray 1.4.2 (Filtering flags > 5000, quantile normalization, log-2 transformation), Batch correction as follows: subtraction of the batch-specific mean from each gene, and add the overall mean.///platform_id: GPL2986///contact_name: Dietmar,,Pils///contact_email: [email protected]///contact_institute: Medical University of Vienna///contact_address: Waehringer Guertel 18-20///contact_city: Vienna///contact_zip.postal_code: 1090///contact_country: Austria///supplementary_file: NONE///data_row_count: 32878
1
title: EOC P072///geo_accession: GSM1211607///status: Public on Jan 01 2014///submission_date: Aug 19 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor tissue///organism_ch1: Homo sapiens///characteristics_ch1: excluded: no///characteristics_ch1.1: subclass: 1///characteristics_ch1.2: age: 53///characteristics_ch1.3: histology: Serous///characteristics_ch1.4: figo grade: IV///characteristics_ch1.5: grade: 1&2///characteristics_ch1.6: peritoneal carcinomatosis: Yes///characteristics_ch1.7: residual tumor: Yes///characteristics_ch1.8: pfs event: 1///characteristics_ch1.9: pfs month: 8///characteristics_ch1.10: os event: 0///characteristics_ch1.11: os month: 13///molecule_ch1: total RNA///extract_protocol_ch1: total RNA from epithelial ovarian cancer tissues was isolated with the ABI PRISM 6100 Nucleic Acid PrepStation (Applied Biosystems) according to the manufacturers instructions///label_ch1: DIG///label_protocol_ch1: Applied Biosystems Chemiluminescent RT Labeling Kit///taxid_ch1: 9606///hyb_protocol: Applied Biosystems Chemiluminescence Detection Kit///scan_protocol: Expression Array System Software v1.1.1///description: Human Genome Survey Microarray V2.0 (Applied Biosystems)///data_processing: R Package ABarray 1.4.2 (Filtering flags > 5000, quantile normalization, log-2 transformation), Batch correction as follows: subtraction of the batch-specific mean from each gene, and add the overall mean.///platform_id: GPL2986///contact_name: Dietmar,,Pils///contact_email: [email protected]///contact_institute: Medical University of Vienna///contact_address: Waehringer Guertel 18-20///contact_city: Vienna///contact_zip.postal_code: 1090///contact_country: Austria///supplementary_file: NONE///data_row_count: 32878
1
title: EOC P073///geo_accession: GSM1211608///status: Public on Jan 01 2014///submission_date: Aug 19 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor tissue///organism_ch1: Homo sapiens///characteristics_ch1: excluded: no///characteristics_ch1.1: subclass: 1///characteristics_ch1.2: age: 55///characteristics_ch1.3: histology: Serous///characteristics_ch1.4: figo grade: III///characteristics_ch1.5: grade: 3///characteristics_ch1.6: peritoneal carcinomatosis: No///characteristics_ch1.7: residual tumor: No///characteristics_ch1.8: pfs event: 0///characteristics_ch1.9: pfs month: 16///characteristics_ch1.10: os event: 0///characteristics_ch1.11: os month: 16///molecule_ch1: total RNA///extract_protocol_ch1: total RNA from epithelial ovarian cancer tissues was isolated with the ABI PRISM 6100 Nucleic Acid PrepStation (Applied Biosystems) according to the manufacturers instructions///label_ch1: DIG///label_protocol_ch1: Applied Biosystems Chemiluminescent RT Labeling Kit///taxid_ch1: 9606///hyb_protocol: Applied Biosystems Chemiluminescence Detection Kit///scan_protocol: Expression Array System Software v1.1.1///description: Human Genome Survey Microarray V2.0 (Applied Biosystems)///data_processing: R Package ABarray 1.4.2 (Filtering flags > 5000, quantile normalization, log-2 transformation), Batch correction as follows: subtraction of the batch-specific mean from each gene, and add the overall mean.///platform_id: GPL2986///contact_name: Dietmar,,Pils///contact_email: [email protected]///contact_institute: Medical University of Vienna///contact_address: Waehringer Guertel 18-20///contact_city: Vienna///contact_zip.postal_code: 1090///contact_country: Austria///supplementary_file: NONE///data_row_count: 32878
1
title: EOC P074///geo_accession: GSM1211609///status: Public on Jan 01 2014///submission_date: Aug 19 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor tissue///organism_ch1: Homo sapiens///characteristics_ch1: excluded: no///characteristics_ch1.1: subclass: 2///characteristics_ch1.2: age: 62///characteristics_ch1.3: histology: Serous///characteristics_ch1.4: figo grade: IV///characteristics_ch1.5: grade: 3///characteristics_ch1.6: peritoneal carcinomatosis: Yes///characteristics_ch1.7: residual tumor: Yes///characteristics_ch1.8: pfs event: 0///characteristics_ch1.9: pfs month: 16///characteristics_ch1.10: os event: 0///characteristics_ch1.11: os month: 16///molecule_ch1: total RNA///extract_protocol_ch1: total RNA from epithelial ovarian cancer tissues was isolated with the ABI PRISM 6100 Nucleic Acid PrepStation (Applied Biosystems) according to the manufacturers instructions///label_ch1: DIG///label_protocol_ch1: Applied Biosystems Chemiluminescent RT Labeling Kit///taxid_ch1: 9606///hyb_protocol: Applied Biosystems Chemiluminescence Detection Kit///scan_protocol: Expression Array System Software v1.1.1///description: Human Genome Survey Microarray V2.0 (Applied Biosystems)///data_processing: R Package ABarray 1.4.2 (Filtering flags > 5000, quantile normalization, log-2 transformation), Batch correction as follows: subtraction of the batch-specific mean from each gene, and add the overall mean.///platform_id: GPL2986///contact_name: Dietmar,,Pils///contact_email: [email protected]///contact_institute: Medical University of Vienna///contact_address: Waehringer Guertel 18-20///contact_city: Vienna///contact_zip.postal_code: 1090///contact_country: Austria///supplementary_file: NONE///data_row_count: 32878
1
title: EOC P075///geo_accession: GSM1211610///status: Public on Jan 01 2014///submission_date: Aug 19 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor tissue///organism_ch1: Homo sapiens///characteristics_ch1: excluded: no///characteristics_ch1.1: subclass: 1///characteristics_ch1.2: age: 56///characteristics_ch1.3: histology: Serous///characteristics_ch1.4: figo grade: III///characteristics_ch1.5: grade: 3///characteristics_ch1.6: peritoneal carcinomatosis: Yes///characteristics_ch1.7: residual tumor: No///characteristics_ch1.8: pfs event: 0///characteristics_ch1.9: pfs month: 14///characteristics_ch1.10: os event: 0///characteristics_ch1.11: os month: 14///molecule_ch1: total RNA///extract_protocol_ch1: total RNA from epithelial ovarian cancer tissues was isolated with the ABI PRISM 6100 Nucleic Acid PrepStation (Applied Biosystems) according to the manufacturers instructions///label_ch1: DIG///label_protocol_ch1: Applied Biosystems Chemiluminescent RT Labeling Kit///taxid_ch1: 9606///hyb_protocol: Applied Biosystems Chemiluminescence Detection Kit///scan_protocol: Expression Array System Software v1.1.1///description: Human Genome Survey Microarray V2.0 (Applied Biosystems)///data_processing: R Package ABarray 1.4.2 (Filtering flags > 5000, quantile normalization, log-2 transformation), Batch correction as follows: subtraction of the batch-specific mean from each gene, and add the overall mean.///platform_id: GPL2986///contact_name: Dietmar,,Pils///contact_email: [email protected]///contact_institute: Medical University of Vienna///contact_address: Waehringer Guertel 18-20///contact_city: Vienna///contact_zip.postal_code: 1090///contact_country: Austria///supplementary_file: NONE///data_row_count: 32878
1
title: EOC P076///geo_accession: GSM1211611///status: Public on Jan 01 2014///submission_date: Aug 19 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor tissue///organism_ch1: Homo sapiens///characteristics_ch1: excluded: no///characteristics_ch1.1: subclass: 2///characteristics_ch1.2: age: 64///characteristics_ch1.3: histology: Serous///characteristics_ch1.4: figo grade: III///characteristics_ch1.5: grade: 3///characteristics_ch1.6: peritoneal carcinomatosis: No///characteristics_ch1.7: residual tumor: No///characteristics_ch1.8: pfs event: 0///characteristics_ch1.9: pfs month: 48///characteristics_ch1.10: os event: 0///characteristics_ch1.11: os month: 48///molecule_ch1: total RNA///extract_protocol_ch1: total RNA from epithelial ovarian cancer tissues was isolated with the ABI PRISM 6100 Nucleic Acid PrepStation (Applied Biosystems) according to the manufacturers instructions///label_ch1: DIG///label_protocol_ch1: Applied Biosystems Chemiluminescent RT Labeling Kit///taxid_ch1: 9606///hyb_protocol: Applied Biosystems Chemiluminescence Detection Kit///scan_protocol: Expression Array System Software v1.1.1///description: Human Genome Survey Microarray V2.0 (Applied Biosystems)///data_processing: R Package ABarray 1.4.2 (Filtering flags > 5000, quantile normalization, log-2 transformation), Batch correction as follows: subtraction of the batch-specific mean from each gene, and add the overall mean.///platform_id: GPL2986///contact_name: Dietmar,,Pils///contact_email: [email protected]///contact_institute: Medical University of Vienna///contact_address: Waehringer Guertel 18-20///contact_city: Vienna///contact_zip.postal_code: 1090///contact_country: Austria///supplementary_file: NONE///data_row_count: 32878
1
title: EOC P077///geo_accession: GSM1211612///status: Public on Jan 01 2014///submission_date: Aug 19 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor tissue///organism_ch1: Homo sapiens///characteristics_ch1: excluded: no///characteristics_ch1.1: subclass: 2///characteristics_ch1.2: age: 83///characteristics_ch1.3: histology: Serous///characteristics_ch1.4: figo grade: III///characteristics_ch1.5: grade: 3///characteristics_ch1.6: peritoneal carcinomatosis: Yes///characteristics_ch1.7: residual tumor: No///characteristics_ch1.8: pfs event: 1///characteristics_ch1.9: pfs month: 9///characteristics_ch1.10: os event: 1///characteristics_ch1.11: os month: 15///molecule_ch1: total RNA///extract_protocol_ch1: total RNA from epithelial ovarian cancer tissues was isolated with the ABI PRISM 6100 Nucleic Acid PrepStation (Applied Biosystems) according to the manufacturers instructions///label_ch1: DIG///label_protocol_ch1: Applied Biosystems Chemiluminescent RT Labeling Kit///taxid_ch1: 9606///hyb_protocol: Applied Biosystems Chemiluminescence Detection Kit///scan_protocol: Expression Array System Software v1.1.1///description: Human Genome Survey Microarray V2.0 (Applied Biosystems)///data_processing: R Package ABarray 1.4.2 (Filtering flags > 5000, quantile normalization, log-2 transformation), Batch correction as follows: subtraction of the batch-specific mean from each gene, and add the overall mean.///platform_id: GPL2986///contact_name: Dietmar,,Pils///contact_email: [email protected]///contact_institute: Medical University of Vienna///contact_address: Waehringer Guertel 18-20///contact_city: Vienna///contact_zip.postal_code: 1090///contact_country: Austria///supplementary_file: NONE///data_row_count: 32878
1
title: EOC P078///geo_accession: GSM1211613///status: Public on Jan 01 2014///submission_date: Aug 19 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor tissue///organism_ch1: Homo sapiens///characteristics_ch1: excluded: no///characteristics_ch1.1: subclass: 1///characteristics_ch1.2: age: 55///characteristics_ch1.3: histology: Non-serous///characteristics_ch1.4: figo grade: III///characteristics_ch1.5: grade: 3///characteristics_ch1.6: peritoneal carcinomatosis: No///characteristics_ch1.7: residual tumor: No///characteristics_ch1.8: pfs event: 0///characteristics_ch1.9: pfs month: 47///characteristics_ch1.10: os event: 0///characteristics_ch1.11: os month: 47///molecule_ch1: total RNA///extract_protocol_ch1: total RNA from epithelial ovarian cancer tissues was isolated with the ABI PRISM 6100 Nucleic Acid PrepStation (Applied Biosystems) according to the manufacturers instructions///label_ch1: DIG///label_protocol_ch1: Applied Biosystems Chemiluminescent RT Labeling Kit///taxid_ch1: 9606///hyb_protocol: Applied Biosystems Chemiluminescence Detection Kit///scan_protocol: Expression Array System Software v1.1.1///description: Human Genome Survey Microarray V2.0 (Applied Biosystems)///data_processing: R Package ABarray 1.4.2 (Filtering flags > 5000, quantile normalization, log-2 transformation), Batch correction as follows: subtraction of the batch-specific mean from each gene, and add the overall mean.///platform_id: GPL2986///contact_name: Dietmar,,Pils///contact_email: [email protected]///contact_institute: Medical University of Vienna///contact_address: Waehringer Guertel 18-20///contact_city: Vienna///contact_zip.postal_code: 1090///contact_country: Austria///supplementary_file: NONE///data_row_count: 32878
1
title: EOC P079///geo_accession: GSM1211614///status: Public on Jan 01 2014///submission_date: Aug 19 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor tissue///organism_ch1: Homo sapiens///characteristics_ch1: excluded: no///characteristics_ch1.1: subclass: 2///characteristics_ch1.2: age: 67///characteristics_ch1.3: histology: Serous///characteristics_ch1.4: figo grade: III///characteristics_ch1.5: grade: 3///characteristics_ch1.6: peritoneal carcinomatosis: Yes///characteristics_ch1.7: residual tumor: No///characteristics_ch1.8: pfs event: 0///characteristics_ch1.9: pfs month: 47///characteristics_ch1.10: os event: 0///characteristics_ch1.11: os month: 47///molecule_ch1: total RNA///extract_protocol_ch1: total RNA from epithelial ovarian cancer tissues was isolated with the ABI PRISM 6100 Nucleic Acid PrepStation (Applied Biosystems) according to the manufacturers instructions///label_ch1: DIG///label_protocol_ch1: Applied Biosystems Chemiluminescent RT Labeling Kit///taxid_ch1: 9606///hyb_protocol: Applied Biosystems Chemiluminescence Detection Kit///scan_protocol: Expression Array System Software v1.1.1///description: Human Genome Survey Microarray V2.0 (Applied Biosystems)///data_processing: R Package ABarray 1.4.2 (Filtering flags > 5000, quantile normalization, log-2 transformation), Batch correction as follows: subtraction of the batch-specific mean from each gene, and add the overall mean.///platform_id: GPL2986///contact_name: Dietmar,,Pils///contact_email: [email protected]///contact_institute: Medical University of Vienna///contact_address: Waehringer Guertel 18-20///contact_city: Vienna///contact_zip.postal_code: 1090///contact_country: Austria///supplementary_file: NONE///data_row_count: 32878
1
title: EOC P080///geo_accession: GSM1211615///status: Public on Jan 01 2014///submission_date: Aug 19 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor tissue///organism_ch1: Homo sapiens///characteristics_ch1: excluded: no///characteristics_ch1.1: subclass: 1///characteristics_ch1.2: age: 69///characteristics_ch1.3: histology: Serous///characteristics_ch1.4: figo grade: IV///characteristics_ch1.5: grade: 3///characteristics_ch1.6: peritoneal carcinomatosis: Yes///characteristics_ch1.7: residual tumor: No///characteristics_ch1.8: pfs event: 1///characteristics_ch1.9: pfs month: 15///characteristics_ch1.10: os event: 0///characteristics_ch1.11: os month: 46///molecule_ch1: total RNA///extract_protocol_ch1: total RNA from epithelial ovarian cancer tissues was isolated with the ABI PRISM 6100 Nucleic Acid PrepStation (Applied Biosystems) according to the manufacturers instructions///label_ch1: DIG///label_protocol_ch1: Applied Biosystems Chemiluminescent RT Labeling Kit///taxid_ch1: 9606///hyb_protocol: Applied Biosystems Chemiluminescence Detection Kit///scan_protocol: Expression Array System Software v1.1.1///description: Human Genome Survey Microarray V2.0 (Applied Biosystems)///data_processing: R Package ABarray 1.4.2 (Filtering flags > 5000, quantile normalization, log-2 transformation), Batch correction as follows: subtraction of the batch-specific mean from each gene, and add the overall mean.///platform_id: GPL2986///contact_name: Dietmar,,Pils///contact_email: [email protected]///contact_institute: Medical University of Vienna///contact_address: Waehringer Guertel 18-20///contact_city: Vienna///contact_zip.postal_code: 1090///contact_country: Austria///supplementary_file: NONE///data_row_count: 32878
1
title: EOC P081///geo_accession: GSM1211616///status: Public on Jan 01 2014///submission_date: Aug 19 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor tissue///organism_ch1: Homo sapiens///characteristics_ch1: excluded: no///characteristics_ch1.1: subclass: 2///characteristics_ch1.2: age: 55///characteristics_ch1.3: histology: Serous///characteristics_ch1.4: figo grade: III///characteristics_ch1.5: grade: 1&2///characteristics_ch1.6: peritoneal carcinomatosis: Yes///characteristics_ch1.7: residual tumor: No///characteristics_ch1.8: pfs event: 1///characteristics_ch1.9: pfs month: 41///characteristics_ch1.10: os event: 0///characteristics_ch1.11: os month: 45///molecule_ch1: total RNA///extract_protocol_ch1: total RNA from epithelial ovarian cancer tissues was isolated with the ABI PRISM 6100 Nucleic Acid PrepStation (Applied Biosystems) according to the manufacturers instructions///label_ch1: DIG///label_protocol_ch1: Applied Biosystems Chemiluminescent RT Labeling Kit///taxid_ch1: 9606///hyb_protocol: Applied Biosystems Chemiluminescence Detection Kit///scan_protocol: Expression Array System Software v1.1.1///description: Human Genome Survey Microarray V2.0 (Applied Biosystems)///data_processing: R Package ABarray 1.4.2 (Filtering flags > 5000, quantile normalization, log-2 transformation), Batch correction as follows: subtraction of the batch-specific mean from each gene, and add the overall mean.///platform_id: GPL2986///contact_name: Dietmar,,Pils///contact_email: [email protected]///contact_institute: Medical University of Vienna///contact_address: Waehringer Guertel 18-20///contact_city: Vienna///contact_zip.postal_code: 1090///contact_country: Austria///supplementary_file: NONE///data_row_count: 32878
1
title: EOC P082///geo_accession: GSM1211617///status: Public on Jan 01 2014///submission_date: Aug 19 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor tissue///organism_ch1: Homo sapiens///characteristics_ch1: excluded: no///characteristics_ch1.1: subclass: 2///characteristics_ch1.2: age: 64///characteristics_ch1.3: histology: Serous///characteristics_ch1.4: figo grade: III///characteristics_ch1.5: grade: 1&2///characteristics_ch1.6: peritoneal carcinomatosis: Yes///characteristics_ch1.7: residual tumor: No///characteristics_ch1.8: pfs event: 1///characteristics_ch1.9: pfs month: 12///characteristics_ch1.10: os event: 1///characteristics_ch1.11: os month: 17///molecule_ch1: total RNA///extract_protocol_ch1: total RNA from epithelial ovarian cancer tissues was isolated with the ABI PRISM 6100 Nucleic Acid PrepStation (Applied Biosystems) according to the manufacturers instructions///label_ch1: DIG///label_protocol_ch1: Applied Biosystems Chemiluminescent RT Labeling Kit///taxid_ch1: 9606///hyb_protocol: Applied Biosystems Chemiluminescence Detection Kit///scan_protocol: Expression Array System Software v1.1.1///description: Human Genome Survey Microarray V2.0 (Applied Biosystems)///data_processing: R Package ABarray 1.4.2 (Filtering flags > 5000, quantile normalization, log-2 transformation), Batch correction as follows: subtraction of the batch-specific mean from each gene, and add the overall mean.///platform_id: GPL2986///contact_name: Dietmar,,Pils///contact_email: [email protected]///contact_institute: Medical University of Vienna///contact_address: Waehringer Guertel 18-20///contact_city: Vienna///contact_zip.postal_code: 1090///contact_country: Austria///supplementary_file: NONE///data_row_count: 32878
1
title: EOC P083///geo_accession: GSM1211618///status: Public on Jan 01 2014///submission_date: Aug 19 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor tissue///organism_ch1: Homo sapiens///characteristics_ch1: excluded: no///characteristics_ch1.1: subclass: 1///characteristics_ch1.2: age: 50///characteristics_ch1.3: histology: Non-serous///characteristics_ch1.4: figo grade: III///characteristics_ch1.5: grade: 3///characteristics_ch1.6: peritoneal carcinomatosis: Yes///characteristics_ch1.7: residual tumor: No///characteristics_ch1.8: pfs event: 1///characteristics_ch1.9: pfs month: 23///characteristics_ch1.10: os event: 0///characteristics_ch1.11: os month: 40///molecule_ch1: total RNA///extract_protocol_ch1: total RNA from epithelial ovarian cancer tissues was isolated with the ABI PRISM 6100 Nucleic Acid PrepStation (Applied Biosystems) according to the manufacturers instructions///label_ch1: DIG///label_protocol_ch1: Applied Biosystems Chemiluminescent RT Labeling Kit///taxid_ch1: 9606///hyb_protocol: Applied Biosystems Chemiluminescence Detection Kit///scan_protocol: Expression Array System Software v1.1.1///description: Human Genome Survey Microarray V2.0 (Applied Biosystems)///data_processing: R Package ABarray 1.4.2 (Filtering flags > 5000, quantile normalization, log-2 transformation), Batch correction as follows: subtraction of the batch-specific mean from each gene, and add the overall mean.///platform_id: GPL2986///contact_name: Dietmar,,Pils///contact_email: [email protected]///contact_institute: Medical University of Vienna///contact_address: Waehringer Guertel 18-20///contact_city: Vienna///contact_zip.postal_code: 1090///contact_country: Austria///supplementary_file: NONE///data_row_count: 32878
1
title: EOC P084///geo_accession: GSM1211619///status: Public on Jan 01 2014///submission_date: Aug 19 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor tissue///organism_ch1: Homo sapiens///characteristics_ch1: excluded: no///characteristics_ch1.1: subclass: 2///characteristics_ch1.2: age: 46///characteristics_ch1.3: histology: Serous///characteristics_ch1.4: figo grade: IV///characteristics_ch1.5: grade: 3///characteristics_ch1.6: peritoneal carcinomatosis: Yes///characteristics_ch1.7: residual tumor: Yes///characteristics_ch1.8: pfs event: 1///characteristics_ch1.9: pfs month: 16///characteristics_ch1.10: os event: 1///characteristics_ch1.11: os month: 16///molecule_ch1: total RNA///extract_protocol_ch1: total RNA from epithelial ovarian cancer tissues was isolated with the ABI PRISM 6100 Nucleic Acid PrepStation (Applied Biosystems) according to the manufacturers instructions///label_ch1: DIG///label_protocol_ch1: Applied Biosystems Chemiluminescent RT Labeling Kit///taxid_ch1: 9606///hyb_protocol: Applied Biosystems Chemiluminescence Detection Kit///scan_protocol: Expression Array System Software v1.1.1///description: Human Genome Survey Microarray V2.0 (Applied Biosystems)///data_processing: R Package ABarray 1.4.2 (Filtering flags > 5000, quantile normalization, log-2 transformation), Batch correction as follows: subtraction of the batch-specific mean from each gene, and add the overall mean.///platform_id: GPL2986///contact_name: Dietmar,,Pils///contact_email: [email protected]///contact_institute: Medical University of Vienna///contact_address: Waehringer Guertel 18-20///contact_city: Vienna///contact_zip.postal_code: 1090///contact_country: Austria///supplementary_file: NONE///data_row_count: 32878
1
title: EOC P085///geo_accession: GSM1211620///status: Public on Jan 01 2014///submission_date: Aug 19 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor tissue///organism_ch1: Homo sapiens///characteristics_ch1: excluded: no///characteristics_ch1.1: subclass: 2///characteristics_ch1.2: age: 67///characteristics_ch1.3: histology: Serous///characteristics_ch1.4: figo grade: III///characteristics_ch1.5: grade: 3///characteristics_ch1.6: peritoneal carcinomatosis: Yes///characteristics_ch1.7: residual tumor: Yes///characteristics_ch1.8: pfs event: 1///characteristics_ch1.9: pfs month: 14///characteristics_ch1.10: os event: 1///characteristics_ch1.11: os month: 39///molecule_ch1: total RNA///extract_protocol_ch1: total RNA from epithelial ovarian cancer tissues was isolated with the ABI PRISM 6100 Nucleic Acid PrepStation (Applied Biosystems) according to the manufacturers instructions///label_ch1: DIG///label_protocol_ch1: Applied Biosystems Chemiluminescent RT Labeling Kit///taxid_ch1: 9606///hyb_protocol: Applied Biosystems Chemiluminescence Detection Kit///scan_protocol: Expression Array System Software v1.1.1///description: Human Genome Survey Microarray V2.0 (Applied Biosystems)///data_processing: R Package ABarray 1.4.2 (Filtering flags > 5000, quantile normalization, log-2 transformation), Batch correction as follows: subtraction of the batch-specific mean from each gene, and add the overall mean.///platform_id: GPL2986///contact_name: Dietmar,,Pils///contact_email: [email protected]///contact_institute: Medical University of Vienna///contact_address: Waehringer Guertel 18-20///contact_city: Vienna///contact_zip.postal_code: 1090///contact_country: Austria///supplementary_file: NONE///data_row_count: 32878
1
title: EOC P086///geo_accession: GSM1211621///status: Public on Jan 01 2014///submission_date: Aug 19 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor tissue///organism_ch1: Homo sapiens///characteristics_ch1: excluded: no///characteristics_ch1.1: subclass: 1///characteristics_ch1.2: age: 44///characteristics_ch1.3: histology: Serous///characteristics_ch1.4: figo grade: III///characteristics_ch1.5: grade: 1&2///characteristics_ch1.6: peritoneal carcinomatosis: Yes///characteristics_ch1.7: residual tumor: No///characteristics_ch1.8: pfs event: 1///characteristics_ch1.9: pfs month: 4///characteristics_ch1.10: os event: 1///characteristics_ch1.11: os month: 4///molecule_ch1: total RNA///extract_protocol_ch1: total RNA from epithelial ovarian cancer tissues was isolated with the ABI PRISM 6100 Nucleic Acid PrepStation (Applied Biosystems) according to the manufacturers instructions///label_ch1: DIG///label_protocol_ch1: Applied Biosystems Chemiluminescent RT Labeling Kit///taxid_ch1: 9606///hyb_protocol: Applied Biosystems Chemiluminescence Detection Kit///scan_protocol: Expression Array System Software v1.1.1///description: Human Genome Survey Microarray V2.0 (Applied Biosystems)///data_processing: R Package ABarray 1.4.2 (Filtering flags > 5000, quantile normalization, log-2 transformation), Batch correction as follows: subtraction of the batch-specific mean from each gene, and add the overall mean.///platform_id: GPL2986///contact_name: Dietmar,,Pils///contact_email: [email protected]///contact_institute: Medical University of Vienna///contact_address: Waehringer Guertel 18-20///contact_city: Vienna///contact_zip.postal_code: 1090///contact_country: Austria///supplementary_file: NONE///data_row_count: 32878
1
title: EOC P087///geo_accession: GSM1211622///status: Public on Jan 01 2014///submission_date: Aug 19 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor tissue///organism_ch1: Homo sapiens///characteristics_ch1: excluded: no///characteristics_ch1.1: subclass: 2///characteristics_ch1.2: age: 76///characteristics_ch1.3: histology: Serous///characteristics_ch1.4: figo grade: III///characteristics_ch1.5: grade: 1&2///characteristics_ch1.6: peritoneal carcinomatosis: Yes///characteristics_ch1.7: residual tumor: Yes///characteristics_ch1.8: pfs event: 1///characteristics_ch1.9: pfs month: 15///characteristics_ch1.10: os event: 0///characteristics_ch1.11: os month: 36///molecule_ch1: total RNA///extract_protocol_ch1: total RNA from epithelial ovarian cancer tissues was isolated with the ABI PRISM 6100 Nucleic Acid PrepStation (Applied Biosystems) according to the manufacturers instructions///label_ch1: DIG///label_protocol_ch1: Applied Biosystems Chemiluminescent RT Labeling Kit///taxid_ch1: 9606///hyb_protocol: Applied Biosystems Chemiluminescence Detection Kit///scan_protocol: Expression Array System Software v1.1.1///description: Human Genome Survey Microarray V2.0 (Applied Biosystems)///data_processing: R Package ABarray 1.4.2 (Filtering flags > 5000, quantile normalization, log-2 transformation), Batch correction as follows: subtraction of the batch-specific mean from each gene, and add the overall mean.///platform_id: GPL2986///contact_name: Dietmar,,Pils///contact_email: [email protected]///contact_institute: Medical University of Vienna///contact_address: Waehringer Guertel 18-20///contact_city: Vienna///contact_zip.postal_code: 1090///contact_country: Austria///supplementary_file: NONE///data_row_count: 32878
1
title: EOC P088///geo_accession: GSM1211623///status: Public on Jan 01 2014///submission_date: Aug 19 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor tissue///organism_ch1: Homo sapiens///characteristics_ch1: excluded: no///characteristics_ch1.1: subclass: 1///characteristics_ch1.2: age: 72///characteristics_ch1.3: histology: Serous///characteristics_ch1.4: figo grade: III///characteristics_ch1.5: grade: 3///characteristics_ch1.6: peritoneal carcinomatosis: Yes///characteristics_ch1.7: residual tumor: Yes///characteristics_ch1.8: pfs event: 1///characteristics_ch1.9: pfs month: 1///characteristics_ch1.10: os event: 1///characteristics_ch1.11: os month: 1///molecule_ch1: total RNA///extract_protocol_ch1: total RNA from epithelial ovarian cancer tissues was isolated with the ABI PRISM 6100 Nucleic Acid PrepStation (Applied Biosystems) according to the manufacturers instructions///label_ch1: DIG///label_protocol_ch1: Applied Biosystems Chemiluminescent RT Labeling Kit///taxid_ch1: 9606///hyb_protocol: Applied Biosystems Chemiluminescence Detection Kit///scan_protocol: Expression Array System Software v1.1.1///description: Human Genome Survey Microarray V2.0 (Applied Biosystems)///data_processing: R Package ABarray 1.4.2 (Filtering flags > 5000, quantile normalization, log-2 transformation), Batch correction as follows: subtraction of the batch-specific mean from each gene, and add the overall mean.///platform_id: GPL2986///contact_name: Dietmar,,Pils///contact_email: [email protected]///contact_institute: Medical University of Vienna///contact_address: Waehringer Guertel 18-20///contact_city: Vienna///contact_zip.postal_code: 1090///contact_country: Austria///supplementary_file: NONE///data_row_count: 32878
1
title: EOC P089///geo_accession: GSM1211624///status: Public on Jan 01 2014///submission_date: Aug 19 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor tissue///organism_ch1: Homo sapiens///characteristics_ch1: excluded: no///characteristics_ch1.1: subclass: 2///characteristics_ch1.2: age: 61///characteristics_ch1.3: histology: Serous///characteristics_ch1.4: figo grade: III///characteristics_ch1.5: grade: 1&2///characteristics_ch1.6: peritoneal carcinomatosis: Yes///characteristics_ch1.7: residual tumor: Yes///characteristics_ch1.8: pfs event: 0///characteristics_ch1.9: pfs month: 13///characteristics_ch1.10: os event: 0///characteristics_ch1.11: os month: 13///molecule_ch1: total RNA///extract_protocol_ch1: total RNA from epithelial ovarian cancer tissues was isolated with the ABI PRISM 6100 Nucleic Acid PrepStation (Applied Biosystems) according to the manufacturers instructions///label_ch1: DIG///label_protocol_ch1: Applied Biosystems Chemiluminescent RT Labeling Kit///taxid_ch1: 9606///hyb_protocol: Applied Biosystems Chemiluminescence Detection Kit///scan_protocol: Expression Array System Software v1.1.1///description: Human Genome Survey Microarray V2.0 (Applied Biosystems)///data_processing: R Package ABarray 1.4.2 (Filtering flags > 5000, quantile normalization, log-2 transformation), Batch correction as follows: subtraction of the batch-specific mean from each gene, and add the overall mean.///platform_id: GPL2986///contact_name: Dietmar,,Pils///contact_email: [email protected]///contact_institute: Medical University of Vienna///contact_address: Waehringer Guertel 18-20///contact_city: Vienna///contact_zip.postal_code: 1090///contact_country: Austria///supplementary_file: NONE///data_row_count: 32878
1
title: EOC P090///geo_accession: GSM1211625///status: Public on Jan 01 2014///submission_date: Aug 19 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor tissue///organism_ch1: Homo sapiens///characteristics_ch1: excluded: no///characteristics_ch1.1: subclass: 2///characteristics_ch1.2: age: 34///characteristics_ch1.3: histology: Serous///characteristics_ch1.4: figo grade: III///characteristics_ch1.5: grade: 1&2///characteristics_ch1.6: peritoneal carcinomatosis: Yes///characteristics_ch1.7: residual tumor: No///characteristics_ch1.8: pfs event: 0///characteristics_ch1.9: pfs month: 33///characteristics_ch1.10: os event: 0///characteristics_ch1.11: os month: 33///molecule_ch1: total RNA///extract_protocol_ch1: total RNA from epithelial ovarian cancer tissues was isolated with the ABI PRISM 6100 Nucleic Acid PrepStation (Applied Biosystems) according to the manufacturers instructions///label_ch1: DIG///label_protocol_ch1: Applied Biosystems Chemiluminescent RT Labeling Kit///taxid_ch1: 9606///hyb_protocol: Applied Biosystems Chemiluminescence Detection Kit///scan_protocol: Expression Array System Software v1.1.1///description: Human Genome Survey Microarray V2.0 (Applied Biosystems)///data_processing: R Package ABarray 1.4.2 (Filtering flags > 5000, quantile normalization, log-2 transformation), Batch correction as follows: subtraction of the batch-specific mean from each gene, and add the overall mean.///platform_id: GPL2986///contact_name: Dietmar,,Pils///contact_email: [email protected]///contact_institute: Medical University of Vienna///contact_address: Waehringer Guertel 18-20///contact_city: Vienna///contact_zip.postal_code: 1090///contact_country: Austria///supplementary_file: NONE///data_row_count: 32878
1
title: EOC P091///geo_accession: GSM1211626///status: Public on Jan 01 2014///submission_date: Aug 19 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor tissue///organism_ch1: Homo sapiens///characteristics_ch1: excluded: no///characteristics_ch1.1: subclass: 2///characteristics_ch1.2: age: 58///characteristics_ch1.3: histology: Serous///characteristics_ch1.4: figo grade: IV///characteristics_ch1.5: grade: #NULL!///characteristics_ch1.6: peritoneal carcinomatosis: Yes///characteristics_ch1.7: residual tumor: Yes///characteristics_ch1.8: pfs event: 1///characteristics_ch1.9: pfs month: 6///characteristics_ch1.10: os event: 1///characteristics_ch1.11: os month: 19///molecule_ch1: total RNA///extract_protocol_ch1: total RNA from epithelial ovarian cancer tissues was isolated with the ABI PRISM 6100 Nucleic Acid PrepStation (Applied Biosystems) according to the manufacturers instructions///label_ch1: DIG///label_protocol_ch1: Applied Biosystems Chemiluminescent RT Labeling Kit///taxid_ch1: 9606///hyb_protocol: Applied Biosystems Chemiluminescence Detection Kit///scan_protocol: Expression Array System Software v1.1.1///description: Human Genome Survey Microarray V2.0 (Applied Biosystems)///data_processing: R Package ABarray 1.4.2 (Filtering flags > 5000, quantile normalization, log-2 transformation), Batch correction as follows: subtraction of the batch-specific mean from each gene, and add the overall mean.///platform_id: GPL2986///contact_name: Dietmar,,Pils///contact_email: [email protected]///contact_institute: Medical University of Vienna///contact_address: Waehringer Guertel 18-20///contact_city: Vienna///contact_zip.postal_code: 1090///contact_country: Austria///supplementary_file: NONE///data_row_count: 32878
1
title: EOC P092///geo_accession: GSM1211627///status: Public on Jan 01 2014///submission_date: Aug 19 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor tissue///organism_ch1: Homo sapiens///characteristics_ch1: excluded: no///characteristics_ch1.1: subclass: 2///characteristics_ch1.2: age: 67///characteristics_ch1.3: histology: Serous///characteristics_ch1.4: figo grade: III///characteristics_ch1.5: grade: 1&2///characteristics_ch1.6: peritoneal carcinomatosis: Yes///characteristics_ch1.7: residual tumor: Yes///characteristics_ch1.8: pfs event: 1///characteristics_ch1.9: pfs month: 10///characteristics_ch1.10: os event: 0///characteristics_ch1.11: os month: 27///molecule_ch1: total RNA///extract_protocol_ch1: total RNA from epithelial ovarian cancer tissues was isolated with the ABI PRISM 6100 Nucleic Acid PrepStation (Applied Biosystems) according to the manufacturers instructions///label_ch1: DIG///label_protocol_ch1: Applied Biosystems Chemiluminescent RT Labeling Kit///taxid_ch1: 9606///hyb_protocol: Applied Biosystems Chemiluminescence Detection Kit///scan_protocol: Expression Array System Software v1.1.1///description: Human Genome Survey Microarray V2.0 (Applied Biosystems)///data_processing: R Package ABarray 1.4.2 (Filtering flags > 5000, quantile normalization, log-2 transformation), Batch correction as follows: subtraction of the batch-specific mean from each gene, and add the overall mean.///platform_id: GPL2986///contact_name: Dietmar,,Pils///contact_email: [email protected]///contact_institute: Medical University of Vienna///contact_address: Waehringer Guertel 18-20///contact_city: Vienna///contact_zip.postal_code: 1090///contact_country: Austria///supplementary_file: NONE///data_row_count: 32878
1
title: EOC P093///geo_accession: GSM1211628///status: Public on Jan 01 2014///submission_date: Aug 19 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor tissue///organism_ch1: Homo sapiens///characteristics_ch1: excluded: no///characteristics_ch1.1: subclass: 1///characteristics_ch1.2: age: 64///characteristics_ch1.3: histology: Serous///characteristics_ch1.4: figo grade: III///characteristics_ch1.5: grade: 3///characteristics_ch1.6: peritoneal carcinomatosis: Yes///characteristics_ch1.7: residual tumor: Yes///characteristics_ch1.8: pfs event: 1///characteristics_ch1.9: pfs month: 17///characteristics_ch1.10: os event: 0///characteristics_ch1.11: os month: 28///molecule_ch1: total RNA///extract_protocol_ch1: total RNA from epithelial ovarian cancer tissues was isolated with the ABI PRISM 6100 Nucleic Acid PrepStation (Applied Biosystems) according to the manufacturers instructions///label_ch1: DIG///label_protocol_ch1: Applied Biosystems Chemiluminescent RT Labeling Kit///taxid_ch1: 9606///hyb_protocol: Applied Biosystems Chemiluminescence Detection Kit///scan_protocol: Expression Array System Software v1.1.1///description: Human Genome Survey Microarray V2.0 (Applied Biosystems)///data_processing: R Package ABarray 1.4.2 (Filtering flags > 5000, quantile normalization, log-2 transformation), Batch correction as follows: subtraction of the batch-specific mean from each gene, and add the overall mean.///platform_id: GPL2986///contact_name: Dietmar,,Pils///contact_email: [email protected]///contact_institute: Medical University of Vienna///contact_address: Waehringer Guertel 18-20///contact_city: Vienna///contact_zip.postal_code: 1090///contact_country: Austria///supplementary_file: NONE///data_row_count: 32878
1
title: EOC P094///geo_accession: GSM1211629///status: Public on Jan 01 2014///submission_date: Aug 19 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor tissue///organism_ch1: Homo sapiens///characteristics_ch1: excluded: yes///characteristics_ch1.1: subclass: 2///characteristics_ch1.2: ///characteristics_ch1.3: ///characteristics_ch1.4: ///characteristics_ch1.5: ///characteristics_ch1.6: ///characteristics_ch1.7: ///characteristics_ch1.8: ///characteristics_ch1.9: ///characteristics_ch1.10: ///characteristics_ch1.11: ///molecule_ch1: total RNA///extract_protocol_ch1: total RNA from epithelial ovarian cancer tissues was isolated with the ABI PRISM 6100 Nucleic Acid PrepStation (Applied Biosystems) according to the manufacturers instructions///label_ch1: DIG///label_protocol_ch1: Applied Biosystems Chemiluminescent RT Labeling Kit///taxid_ch1: 9606///hyb_protocol: Applied Biosystems Chemiluminescence Detection Kit///scan_protocol: Expression Array System Software v1.1.1///description: Human Genome Survey Microarray V2.0 (Applied Biosystems)///data_processing: R Package ABarray 1.4.2 (Filtering flags > 5000, quantile normalization, log-2 transformation), Batch correction as follows: subtraction of the batch-specific mean from each gene, and add the overall mean.///platform_id: GPL2986///contact_name: Dietmar,,Pils///contact_email: [email protected]///contact_institute: Medical University of Vienna///contact_address: Waehringer Guertel 18-20///contact_city: Vienna///contact_zip.postal_code: 1090///contact_country: Austria///supplementary_file: NONE///data_row_count: 32878
1
title: EOC P095///geo_accession: GSM1211630///status: Public on Jan 01 2014///submission_date: Aug 19 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor tissue///organism_ch1: Homo sapiens///characteristics_ch1: excluded: no///characteristics_ch1.1: subclass: 1///characteristics_ch1.2: age: 73///characteristics_ch1.3: histology: Serous///characteristics_ch1.4: figo grade: IV///characteristics_ch1.5: grade: 1&2///characteristics_ch1.6: peritoneal carcinomatosis: No///characteristics_ch1.7: residual tumor: No///characteristics_ch1.8: pfs event: 1///characteristics_ch1.9: pfs month: 22///characteristics_ch1.10: os event: 0///characteristics_ch1.11: os month: 22///molecule_ch1: total RNA///extract_protocol_ch1: total RNA from epithelial ovarian cancer tissues was isolated with the ABI PRISM 6100 Nucleic Acid PrepStation (Applied Biosystems) according to the manufacturers instructions///label_ch1: DIG///label_protocol_ch1: Applied Biosystems Chemiluminescent RT Labeling Kit///taxid_ch1: 9606///hyb_protocol: Applied Biosystems Chemiluminescence Detection Kit///scan_protocol: Expression Array System Software v1.1.1///description: Human Genome Survey Microarray V2.0 (Applied Biosystems)///data_processing: R Package ABarray 1.4.2 (Filtering flags > 5000, quantile normalization, log-2 transformation), Batch correction as follows: subtraction of the batch-specific mean from each gene, and add the overall mean.///platform_id: GPL2986///contact_name: Dietmar,,Pils///contact_email: [email protected]///contact_institute: Medical University of Vienna///contact_address: Waehringer Guertel 18-20///contact_city: Vienna///contact_zip.postal_code: 1090///contact_country: Austria///supplementary_file: NONE///data_row_count: 32878
1
title: EOC P096///geo_accession: GSM1211631///status: Public on Jan 01 2014///submission_date: Aug 19 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor tissue///organism_ch1: Homo sapiens///characteristics_ch1: excluded: no///characteristics_ch1.1: subclass: 2///characteristics_ch1.2: age: 67///characteristics_ch1.3: histology: Serous///characteristics_ch1.4: figo grade: III///characteristics_ch1.5: grade: 1&2///characteristics_ch1.6: peritoneal carcinomatosis: No///characteristics_ch1.7: residual tumor: Yes///characteristics_ch1.8: pfs event: 0///characteristics_ch1.9: pfs month: 14///characteristics_ch1.10: os event: 0///characteristics_ch1.11: os month: 14///molecule_ch1: total RNA///extract_protocol_ch1: total RNA from epithelial ovarian cancer tissues was isolated with the ABI PRISM 6100 Nucleic Acid PrepStation (Applied Biosystems) according to the manufacturers instructions///label_ch1: DIG///label_protocol_ch1: Applied Biosystems Chemiluminescent RT Labeling Kit///taxid_ch1: 9606///hyb_protocol: Applied Biosystems Chemiluminescence Detection Kit///scan_protocol: Expression Array System Software v1.1.1///description: Human Genome Survey Microarray V2.0 (Applied Biosystems)///data_processing: R Package ABarray 1.4.2 (Filtering flags > 5000, quantile normalization, log-2 transformation), Batch correction as follows: subtraction of the batch-specific mean from each gene, and add the overall mean.///platform_id: GPL2986///contact_name: Dietmar,,Pils///contact_email: [email protected]///contact_institute: Medical University of Vienna///contact_address: Waehringer Guertel 18-20///contact_city: Vienna///contact_zip.postal_code: 1090///contact_country: Austria///supplementary_file: NONE///data_row_count: 32878
1
title: EOC P097///geo_accession: GSM1211632///status: Public on Jan 01 2014///submission_date: Aug 19 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor tissue///organism_ch1: Homo sapiens///characteristics_ch1: excluded: no///characteristics_ch1.1: subclass: 2///characteristics_ch1.2: age: 55///characteristics_ch1.3: histology: Serous///characteristics_ch1.4: figo grade: III///characteristics_ch1.5: grade: 1&2///characteristics_ch1.6: peritoneal carcinomatosis: Yes///characteristics_ch1.7: residual tumor: No///characteristics_ch1.8: pfs event: 0///characteristics_ch1.9: pfs month: 23///characteristics_ch1.10: os event: 0///characteristics_ch1.11: os month: 23///molecule_ch1: total RNA///extract_protocol_ch1: total RNA from epithelial ovarian cancer tissues was isolated with the ABI PRISM 6100 Nucleic Acid PrepStation (Applied Biosystems) according to the manufacturers instructions///label_ch1: DIG///label_protocol_ch1: Applied Biosystems Chemiluminescent RT Labeling Kit///taxid_ch1: 9606///hyb_protocol: Applied Biosystems Chemiluminescence Detection Kit///scan_protocol: Expression Array System Software v1.1.1///description: Human Genome Survey Microarray V2.0 (Applied Biosystems)///data_processing: R Package ABarray 1.4.2 (Filtering flags > 5000, quantile normalization, log-2 transformation), Batch correction as follows: subtraction of the batch-specific mean from each gene, and add the overall mean.///platform_id: GPL2986///contact_name: Dietmar,,Pils///contact_email: [email protected]///contact_institute: Medical University of Vienna///contact_address: Waehringer Guertel 18-20///contact_city: Vienna///contact_zip.postal_code: 1090///contact_country: Austria///supplementary_file: NONE///data_row_count: 32878
1
title: EOC P098///geo_accession: GSM1211633///status: Public on Jan 01 2014///submission_date: Aug 19 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor tissue///organism_ch1: Homo sapiens///characteristics_ch1: excluded: no///characteristics_ch1.1: subclass: 2///characteristics_ch1.2: age: 64///characteristics_ch1.3: histology: Serous///characteristics_ch1.4: figo grade: IV///characteristics_ch1.5: grade: 3///characteristics_ch1.6: peritoneal carcinomatosis: Yes///characteristics_ch1.7: residual tumor: Yes///characteristics_ch1.8: pfs event: 1///characteristics_ch1.9: pfs month: 19///characteristics_ch1.10: os event: 0///characteristics_ch1.11: os month: 21///molecule_ch1: total RNA///extract_protocol_ch1: total RNA from epithelial ovarian cancer tissues was isolated with the ABI PRISM 6100 Nucleic Acid PrepStation (Applied Biosystems) according to the manufacturers instructions///label_ch1: DIG///label_protocol_ch1: Applied Biosystems Chemiluminescent RT Labeling Kit///taxid_ch1: 9606///hyb_protocol: Applied Biosystems Chemiluminescence Detection Kit///scan_protocol: Expression Array System Software v1.1.1///description: Human Genome Survey Microarray V2.0 (Applied Biosystems)///data_processing: R Package ABarray 1.4.2 (Filtering flags > 5000, quantile normalization, log-2 transformation), Batch correction as follows: subtraction of the batch-specific mean from each gene, and add the overall mean.///platform_id: GPL2986///contact_name: Dietmar,,Pils///contact_email: [email protected]///contact_institute: Medical University of Vienna///contact_address: Waehringer Guertel 18-20///contact_city: Vienna///contact_zip.postal_code: 1090///contact_country: Austria///supplementary_file: NONE///data_row_count: 32878
1
title: EOC P099///geo_accession: GSM1211634///status: Public on Jan 01 2014///submission_date: Aug 19 2013///last_update_date: Jan 01 2014///type: RNA///channel_count: 1///source_name_ch1: Ovarian tumor tissue///organism_ch1: Homo sapiens///characteristics_ch1: excluded: no///characteristics_ch1.1: subclass: 2///characteristics_ch1.2: age: 65///characteristics_ch1.3: histology: Serous///characteristics_ch1.4: figo grade: III///characteristics_ch1.5: grade: 3///characteristics_ch1.6: peritoneal carcinomatosis: Yes///characteristics_ch1.7: residual tumor: No///characteristics_ch1.8: pfs event: 1///characteristics_ch1.9: pfs month: 8///characteristics_ch1.10: os event: 1///characteristics_ch1.11: os month: 12///molecule_ch1: total RNA///extract_protocol_ch1: total RNA from epithelial ovarian cancer tissues was isolated with the ABI PRISM 6100 Nucleic Acid PrepStation (Applied Biosystems) according to the manufacturers instructions///label_ch1: DIG///label_protocol_ch1: Applied Biosystems Chemiluminescent RT Labeling Kit///taxid_ch1: 9606///hyb_protocol: Applied Biosystems Chemiluminescence Detection Kit///scan_protocol: Expression Array System Software v1.1.1///description: Human Genome Survey Microarray V2.0 (Applied Biosystems)///data_processing: R Package ABarray 1.4.2 (Filtering flags > 5000, quantile normalization, log-2 transformation), Batch correction as follows: subtraction of the batch-specific mean from each gene, and add the overall mean.///platform_id: GPL2986///contact_name: Dietmar,,Pils///contact_email: [email protected]///contact_institute: Medical University of Vienna///contact_address: Waehringer Guertel 18-20///contact_city: Vienna///contact_zip.postal_code: 1090///contact_country: Austria///supplementary_file: NONE///data_row_count: 32878
1
(Other)
105
An expression set
To identify molecular prognosticators and therapeutic targets for high-grade serous epithelial ovarian cancers (EOCs) using genetic analyses driven by biologic features of EOC pathogenesis.Ovarian tissue samples (n = 172; 122 serous EOCs, 30 other EOCs, 20 normal/benign) collected prospectively from sequential patients undergoing gynecologic surgery were analyzed using RNA expression microarrays. Samples were classified based on expression of genes with potential relevance in ovarian cancer. Gene sets were defined using Rosetta Similarity Search Tool (ROAST) and analysis of variance (ANOVA). Gene copy number variations were identified by array comparative genomic hybridization.No distinct subgroups of EOC could be identified by unsupervised clustering, however, analyses based on genes correlated with periostin (POSTN) and estrogen receptor-alpha (ESR1) yielded distinct subgroups. When 95 high-grade serous EOCs were grouped by genes based on ANOVA comparing ESR1/WT1 and POSTN/TGFBI samples, overall survival (OS) was significantly shorter for 43 patients with tumors expressing genes associated with POSTN/TGFBI compared to 52 patients with tumors expressing genes associated with ESR1/WT1 (median 30 versus 49 months, respectively; P = 0.022). Several targets with therapeutic potential were identified within each subgroup. BRCA germline mutations were more frequent in the ESR1/WT1 subgroup. Proliferation-associated genes and TP53 status (mutated or wild-type) did not correlate with survival. Findings were validated using independent ovarian cancer datasets.Two distinct molecular subgroups of high-grade serous EOCs based on POSTN/TGFBI and ESR1/WT1 expressions were identified with significantly different OS. Specific differentially expressed genes between these subgroups provide potential prognostic and therapeutic targets.Copyright ?? 2013 Elsevier Inc. All rights reserved.
experimentData(eset):
Experiment data
Experimenter name: Karlan BY, Dering J, Walsh C, Orsulic S, Lester J, Anderson LA, Ginther CL, Fejzo M, Slamon D
Laboratory: Karlan, Slamon 2014
Contact information:
Title: POSTN/TGFBI-associated stromal signature predicts poor prognosis in serous epithelial ovarian cancer.
URL:
PMIDs: 24368280
Abstract: A 250 word abstract is available. Use 'abstract' method.
Information is available on: preprocessing
notes:
platform_title:
Agilent-012097 Human 1A Microarray (V2) G4110B (Probe Name version)
platform_shorttitle:
Agilent G4110B
platform_summary:
hgug4110b
platform_manufacturer:
Agilent
platform_distribution:
commercial
platform_accession:
GPL7264
platform_technology:
in situ oligonucleotide
version:
2015-09-22 20:05:48
featureData(eset):
An object of class 'AnnotatedDataFrame'
featureNames: A_23_P100001 A_23_P100011 ... A_23_P99996 (18703 total)
varLabels: probeset gene EntrezGene.ID best_probe
varMetadata: labelDescription
assayData: 18703 features, 172 samples
Platform type:
Overall survival time-to-event summary (in years):
Call: survfit(formula = Surv(time, cens) ~ -1)
20 observations deleted due to missingness
n events median 0.95LCL 0.95UCL
152.00 112.00 4.13 3.50 4.92
---------------------------
Available sample meta-data:
---------------------------
alt_sample_name:
Ov_Tumor_Ref_Mix vs. CS-OV-001 Ov_Tumor_Ref_Mix vs. CS-OV-002
1 1
Ov_Tumor_Ref_Mix vs. CS-OV-003 Ov_Tumor_Ref_Mix vs. CS-OV-004
1 1
Ov_Tumor_Ref_Mix vs. CS-OV-005 Ov_Tumor_Ref_Mix vs. CS-OV-006
1 1
Ov_Tumor_Ref_Mix vs. CS-OV-007 Ov_Tumor_Ref_Mix vs. CS-OV-008
1 1
Ov_Tumor_Ref_Mix vs. CS-OV-009 Ov_Tumor_Ref_Mix vs. CS-OV-010
1 1
Ov_Tumor_Ref_Mix vs. CS-OV-011 Ov_Tumor_Ref_Mix vs. CS-OV-012
1 1
Ov_Tumor_Ref_Mix vs. CS-OV-013 Ov_Tumor_Ref_Mix vs. CS-OV-014
1 1
Ov_Tumor_Ref_Mix vs. CS-OV-015 Ov_Tumor_Ref_Mix vs. CS-OV-016
1 1
Ov_Tumor_Ref_Mix vs. CS-OV-017 Ov_Tumor_Ref_Mix vs. CS-OV-018
1 1
Ov_Tumor_Ref_Mix vs. CS-OV-019 Ov_Tumor_Ref_Mix vs. CS-OV-020
1 1
Ov_Tumor_Ref_Mix vs. CS-OV-021 Ov_Tumor_Ref_Mix vs. CS-OV-022
1 1
Ov_Tumor_Ref_Mix vs. CS-OV-023 Ov_Tumor_Ref_Mix vs. CS-OV-024
1 1
Ov_Tumor_Ref_Mix vs. CS-OV-025 Ov_Tumor_Ref_Mix vs. CS-OV-026
1 1
Ov_Tumor_Ref_Mix vs. CS-OV-027 Ov_Tumor_Ref_Mix vs. CS-OV-028
1 1
Ov_Tumor_Ref_Mix vs. CS-OV-029 Ov_Tumor_Ref_Mix vs. CS-OV-030
1 1
Ov_Tumor_Ref_Mix vs. CS-OV-031 Ov_Tumor_Ref_Mix vs. CS-OV-032
1 1
Ov_Tumor_Ref_Mix vs. CS-OV-033 Ov_Tumor_Ref_Mix vs. CS-OV-034
1 1
Ov_Tumor_Ref_Mix vs. CS-OV-035 Ov_Tumor_Ref_Mix vs. CS-OV-036
1 1
Ov_Tumor_Ref_Mix vs. CS-OV-037 Ov_Tumor_Ref_Mix vs. CS-OV-038
1 1
Ov_Tumor_Ref_Mix vs. CS-OV-039 Ov_Tumor_Ref_Mix vs. CS-OV-040
1 1
Ov_Tumor_Ref_Mix vs. CS-OV-041 Ov_Tumor_Ref_Mix vs. CS-OV-042
1 1
Ov_Tumor_Ref_Mix vs. CS-OV-043 Ov_Tumor_Ref_Mix vs. CS-OV-044
1 1
Ov_Tumor_Ref_Mix vs. CS-OV-045 Ov_Tumor_Ref_Mix vs. CS-OV-046
1 1
Ov_Tumor_Ref_Mix vs. CS-OV-047 Ov_Tumor_Ref_Mix vs. CS-OV-048
1 1
Ov_Tumor_Ref_Mix vs. CS-OV-049 Ov_Tumor_Ref_Mix vs. CS-OV-050
1 1
Ov_Tumor_Ref_Mix vs. CS-OV-051 Ov_Tumor_Ref_Mix vs. CS-OV-052
1 1
Ov_Tumor_Ref_Mix vs. CS-OV-053 Ov_Tumor_Ref_Mix vs. CS-OV-054
1 1
Ov_Tumor_Ref_Mix vs. CS-OV-055 Ov_Tumor_Ref_Mix vs. CS-OV-056
1 1
Ov_Tumor_Ref_Mix vs. CS-OV-057 Ov_Tumor_Ref_Mix vs. CS-OV-058
1 1
Ov_Tumor_Ref_Mix vs. CS-OV-059 Ov_Tumor_Ref_Mix vs. CS-OV-060
1 1
Ov_Tumor_Ref_Mix vs. CS-OV-061 Ov_Tumor_Ref_Mix vs. CS-OV-062
1 1
Ov_Tumor_Ref_Mix vs. CS-OV-063 Ov_Tumor_Ref_Mix vs. CS-OV-064
1 1
Ov_Tumor_Ref_Mix vs. CS-OV-065 Ov_Tumor_Ref_Mix vs. CS-OV-066
1 1
Ov_Tumor_Ref_Mix vs. CS-OV-067 Ov_Tumor_Ref_Mix vs. CS-OV-068
1 1
Ov_Tumor_Ref_Mix vs. CS-OV-069 Ov_Tumor_Ref_Mix vs. CS-OV-070
1 1
Ov_Tumor_Ref_Mix vs. CS-OV-071 Ov_Tumor_Ref_Mix vs. CS-OV-072
1 1
Ov_Tumor_Ref_Mix vs. CS-OV-073 Ov_Tumor_Ref_Mix vs. CS-OV-074
1 1
Ov_Tumor_Ref_Mix vs. CS-OV-075 Ov_Tumor_Ref_Mix vs. CS-OV-076
1 1
Ov_Tumor_Ref_Mix vs. CS-OV-077 Ov_Tumor_Ref_Mix vs. CS-OV-078
1 1
Ov_Tumor_Ref_Mix vs. CS-OV-079 Ov_Tumor_Ref_Mix vs. CS-OV-080
1 1
Ov_Tumor_Ref_Mix vs. CS-OV-081 Ov_Tumor_Ref_Mix vs. CS-OV-082
1 1
Ov_Tumor_Ref_Mix vs. CS-OV-083 Ov_Tumor_Ref_Mix vs. CS-OV-084
1 1
Ov_Tumor_Ref_Mix vs. CS-OV-085 Ov_Tumor_Ref_Mix vs. CS-OV-086
1 1
Ov_Tumor_Ref_Mix vs. CS-OV-087 Ov_Tumor_Ref_Mix vs. CS-OV-088
1 1
Ov_Tumor_Ref_Mix vs. CS-OV-089 Ov_Tumor_Ref_Mix vs. CS-OV-090
1 1
Ov_Tumor_Ref_Mix vs. CS-OV-091 Ov_Tumor_Ref_Mix vs. CS-OV-092
1 1
Ov_Tumor_Ref_Mix vs. CS-OV-093 Ov_Tumor_Ref_Mix vs. CS-OV-094
1 1
Ov_Tumor_Ref_Mix vs. CS-OV-095 Ov_Tumor_Ref_Mix vs. CS-OV-096
1 1
Ov_Tumor_Ref_Mix vs. CS-OV-097 Ov_Tumor_Ref_Mix vs. CS-OV-098
1 1
Ov_Tumor_Ref_Mix vs. CS-OV-099 (Other)
1 73
sample_type:
benign borderline healthy metastatic tumor
5 12 15 17 123
histological_type:
clearcell endo mucinous other ser NA's
3 7 9 11 122 20
summarygrade:
high low NA's
119 30 23
summarystage:
early late NA's
31 120 21
tumorstage:
1 2 3 4 NA's
22 9 103 17 21
substage:
a b c NA's
17 22 94 39
grade:
0 1 2 3 NA's
8 8 14 119 23
age_at_initial_pathologic_diagnosis:
Min. 1st Qu. Median Mean 3rd Qu. Max.
26.0 49.0 57.5 58.6 68.0 91.0
neo:
n
172
recurrence_status:
norecurrence recurrence NA's
36 111 25
days_to_death:
Min. 1st Qu. Median Mean 3rd Qu. Max. NA's
30 791 1491 1835 2344 7001 20
vital_status:
deceased living NA's
112 40 20
percent_normal_cells:
30- NA's
140 32
percent_stromal_cells:
30- NA's
140 32
percent_tumor_cells:
70+ NA's
140 32
uncurated_author_metadata:
title: Ov_Tumor_Ref_Mix vs. CS-OV-001///geo_accession: GSM1238145///status: Public on Dec 26 2013///submission_date: Sep 23 2013///last_update_date: Dec 26 2013///type: RNA///channel_count: 2///source_name_ch1: 106 pooled ovarian samples///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian///characteristics_ch1.1: sample type: reference pool///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch1: Cy3///label_protocol_ch1: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch1: 9606///source_name_ch2: CS-OV-001///organism_ch2: Homo sapiens///characteristics_ch2: tissue: ovarian///characteristics_ch2.1: sample included in reference pool: YES///characteristics_ch2.2: sample rin: 9.8///characteristics_ch2.3: age at surgery: 50.45///characteristics_ch2.4: histology: MMMT///characteristics_ch2.5: Stage: IIIC///characteristics_ch2.6: grade: 3///characteristics_ch2.7: tissue status: Primary///characteristics_ch2.8: follow up months: 7///characteristics_ch2.9: disease status: Not Free///characteristics_ch2.10: patient status: Dead///characteristics_ch2.11: disease state: Malignant ovarian///characteristics_ch2.12: ///molecule_ch2: total RNA///extract_protocol_ch2: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch2: Cy5///label_protocol_ch2: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch2: 9606///hyb_protocol: Slides were incubated for 16-17 hr at 60C and washed using the SSPE method described in the Agilent 60-mer Oligo Microarray Processing Protocol, Version 2.1. Slides were treated with Agilent Stabilization and Drying Solution, a wash was used to protect the dyes from ozone degradation.///scan_protocol: Scanned on an Agilent G2565BA scanner.///description: Malignant_ovarian_sample///data_processing: Agilent Feature Extraction Software (v7.5.1) was used for local background subtraction and Linear/LOWESS normalization. RejectMethod=Interquartile Range, nonuniformity outlier flagging enabled, population outlier flag enabled, ratio error model=hybrid, dye normalization select method = Rank Consistency Filter, no spatial detrend method applied.///data_processing.1: Agilent Feature Extraced data was imported into Rosetta Resolver version 7.1.1 (Rosetta Inpharmatics LLC, Cambridge, MA). Multiple probes with the same sequence code were combined into a single value using the Rosetta Resolver error-weighted averaging method for combining repeated measures.///platform_id: GPL7264///contact_name: Judy,,Dering///contact_email: [email protected]///contact_laboratory: Translational Oncology Research///contact_department: Medicine///contact_institute: UCLA School of Medicine///contact_address: 2825 Santa Monica Blvd. Suite 200///contact_city: Santa Monica///contact_state: CA///contact_zip.postal_code: 90404///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM1238nnn/GSM1238145/GSM1238145_US22502615_251209750932_S01_A01.txt.gz///data_row_count: 20173
1
title: Ov_Tumor_Ref_Mix vs. CS-OV-002///geo_accession: GSM1238146///status: Public on Dec 26 2013///submission_date: Sep 23 2013///last_update_date: Dec 26 2013///type: RNA///channel_count: 2///source_name_ch1: 106 pooled ovarian samples///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian///characteristics_ch1.1: sample type: reference pool///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch1: Cy3///label_protocol_ch1: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch1: 9606///source_name_ch2: CS-OV-002///organism_ch2: Homo sapiens///characteristics_ch2: tissue: ovarian///characteristics_ch2.1: sample included in reference pool: NO///characteristics_ch2.2: sample rin: 8.5///characteristics_ch2.3: age at surgery: 75.69///characteristics_ch2.4: histology: Serous///characteristics_ch2.5: Stage: IIIC///characteristics_ch2.6: grade: 3///characteristics_ch2.7: tissue status: Primary///characteristics_ch2.8: follow up months: 26///characteristics_ch2.9: disease status: Not Free///characteristics_ch2.10: patient status: Dead///characteristics_ch2.11: disease state: Malignant ovarian///characteristics_ch2.12: ///molecule_ch2: total RNA///extract_protocol_ch2: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch2: Cy5///label_protocol_ch2: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch2: 9606///hyb_protocol: Slides were incubated for 16-17 hr at 60C and washed using the SSPE method described in the Agilent 60-mer Oligo Microarray Processing Protocol, Version 2.1. Slides were treated with Agilent Stabilization and Drying Solution, a wash was used to protect the dyes from ozone degradation.///scan_protocol: Scanned on an Agilent G2565BA scanner.///description: Malignant_ovarian_sample///data_processing: Agilent Feature Extraction Software (v7.5.1) was used for local background subtraction and Linear/LOWESS normalization. RejectMethod=Interquartile Range, nonuniformity outlier flagging enabled, population outlier flag enabled, ratio error model=hybrid, dye normalization select method = Rank Consistency Filter, no spatial detrend method applied.///data_processing.1: Agilent Feature Extraced data was imported into Rosetta Resolver version 7.1.1 (Rosetta Inpharmatics LLC, Cambridge, MA). Multiple probes with the same sequence code were combined into a single value using the Rosetta Resolver error-weighted averaging method for combining repeated measures.///platform_id: GPL7264///contact_name: Judy,,Dering///contact_email: [email protected]///contact_laboratory: Translational Oncology Research///contact_department: Medicine///contact_institute: UCLA School of Medicine///contact_address: 2825 Santa Monica Blvd. Suite 200///contact_city: Santa Monica///contact_state: CA///contact_zip.postal_code: 90404///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM1238nnn/GSM1238146/GSM1238146_US22502615_251209754104_S01_A01.txt.gz///data_row_count: 20173
1
title: Ov_Tumor_Ref_Mix vs. CS-OV-003///geo_accession: GSM1238147///status: Public on Dec 26 2013///submission_date: Sep 23 2013///last_update_date: Dec 26 2013///type: RNA///channel_count: 2///source_name_ch1: 106 pooled ovarian samples///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian///characteristics_ch1.1: sample type: reference pool///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch1: Cy3///label_protocol_ch1: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch1: 9606///source_name_ch2: CS-OV-003///organism_ch2: Homo sapiens///characteristics_ch2: tissue: ovarian///characteristics_ch2.1: sample included in reference pool: YES///characteristics_ch2.2: sample rin: 9.4///characteristics_ch2.3: age at surgery: 39.66///characteristics_ch2.4: histology: Serous///characteristics_ch2.5: Stage: IIIC///characteristics_ch2.6: grade: 1///characteristics_ch2.7: tissue status: Primary///characteristics_ch2.8: follow up months: 103///characteristics_ch2.9: disease status: Unknown///characteristics_ch2.10: patient status: Alive///characteristics_ch2.11: disease state: Malignant ovarian///characteristics_ch2.12: ///molecule_ch2: total RNA///extract_protocol_ch2: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch2: Cy5///label_protocol_ch2: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch2: 9606///hyb_protocol: Slides were incubated for 16-17 hr at 60C and washed using the SSPE method described in the Agilent 60-mer Oligo Microarray Processing Protocol, Version 2.1. Slides were treated with Agilent Stabilization and Drying Solution, a wash was used to protect the dyes from ozone degradation.///scan_protocol: Scanned on an Agilent G2565BA scanner.///description: Malignant_ovarian_sample///data_processing: Agilent Feature Extraction Software (v7.5.1) was used for local background subtraction and Linear/LOWESS normalization. RejectMethod=Interquartile Range, nonuniformity outlier flagging enabled, population outlier flag enabled, ratio error model=hybrid, dye normalization select method = Rank Consistency Filter, no spatial detrend method applied.///data_processing.1: Agilent Feature Extraced data was imported into Rosetta Resolver version 7.1.1 (Rosetta Inpharmatics LLC, Cambridge, MA). Multiple probes with the same sequence code were combined into a single value using the Rosetta Resolver error-weighted averaging method for combining repeated measures.///platform_id: GPL7264///contact_name: Judy,,Dering///contact_email: [email protected]///contact_laboratory: Translational Oncology Research///contact_department: Medicine///contact_institute: UCLA School of Medicine///contact_address: 2825 Santa Monica Blvd. Suite 200///contact_city: Santa Monica///contact_state: CA///contact_zip.postal_code: 90404///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM1238nnn/GSM1238147/GSM1238147_US22502615_251209750994_S01_A01.txt.gz///data_row_count: 20173
1
title: Ov_Tumor_Ref_Mix vs. CS-OV-004///geo_accession: GSM1238148///status: Public on Dec 26 2013///submission_date: Sep 23 2013///last_update_date: Dec 26 2013///type: RNA///channel_count: 2///source_name_ch1: 106 pooled ovarian samples///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian///characteristics_ch1.1: sample type: reference pool///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch1: Cy3///label_protocol_ch1: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch1: 9606///source_name_ch2: CS-OV-004///organism_ch2: Homo sapiens///characteristics_ch2: tissue: ovarian///characteristics_ch2.1: sample included in reference pool: YES///characteristics_ch2.2: sample rin: 9.2///characteristics_ch2.3: age at surgery: 69.33///characteristics_ch2.4: histology: Serous///characteristics_ch2.5: Stage: IIIC///characteristics_ch2.6: grade: 3///characteristics_ch2.7: tissue status: Primary///characteristics_ch2.8: follow up months: 33///characteristics_ch2.9: disease status: Not Free///characteristics_ch2.10: patient status: Dead///characteristics_ch2.11: disease state: Malignant ovarian///characteristics_ch2.12: ///molecule_ch2: total RNA///extract_protocol_ch2: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch2: Cy5///label_protocol_ch2: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch2: 9606///hyb_protocol: Slides were incubated for 16-17 hr at 60C and washed using the SSPE method described in the Agilent 60-mer Oligo Microarray Processing Protocol, Version 2.1. Slides were treated with Agilent Stabilization and Drying Solution, a wash was used to protect the dyes from ozone degradation.///scan_protocol: Scanned on an Agilent G2565BA scanner.///description: Malignant_ovarian_sample///data_processing: Agilent Feature Extraction Software (v7.5.1) was used for local background subtraction and Linear/LOWESS normalization. RejectMethod=Interquartile Range, nonuniformity outlier flagging enabled, population outlier flag enabled, ratio error model=hybrid, dye normalization select method = Rank Consistency Filter, no spatial detrend method applied.///data_processing.1: Agilent Feature Extraced data was imported into Rosetta Resolver version 7.1.1 (Rosetta Inpharmatics LLC, Cambridge, MA). Multiple probes with the same sequence code were combined into a single value using the Rosetta Resolver error-weighted averaging method for combining repeated measures.///platform_id: GPL7264///contact_name: Judy,,Dering///contact_email: [email protected]///contact_laboratory: Translational Oncology Research///contact_department: Medicine///contact_institute: UCLA School of Medicine///contact_address: 2825 Santa Monica Blvd. Suite 200///contact_city: Santa Monica///contact_state: CA///contact_zip.postal_code: 90404///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM1238nnn/GSM1238148/GSM1238148_US22502615_251209747186_S01_A01.txt.gz///data_row_count: 20173
1
title: Ov_Tumor_Ref_Mix vs. CS-OV-005///geo_accession: GSM1238149///status: Public on Dec 26 2013///submission_date: Sep 23 2013///last_update_date: Dec 26 2013///type: RNA///channel_count: 2///source_name_ch1: 106 pooled ovarian samples///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian///characteristics_ch1.1: sample type: reference pool///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch1: Cy3///label_protocol_ch1: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch1: 9606///source_name_ch2: CS-OV-005///organism_ch2: Homo sapiens///characteristics_ch2: tissue: ovarian///characteristics_ch2.1: sample included in reference pool: NO///characteristics_ch2.2: sample rin: 9.5///characteristics_ch2.3: age at surgery: 82.01///characteristics_ch2.4: histology: Serous///characteristics_ch2.5: Stage: IIIB///characteristics_ch2.6: grade: 3///characteristics_ch2.7: tissue status: Primary///characteristics_ch2.8: follow up months: 54///characteristics_ch2.9: disease status: Not Free///characteristics_ch2.10: patient status: Dead///characteristics_ch2.11: disease state: Malignant ovarian///characteristics_ch2.12: ///molecule_ch2: total RNA///extract_protocol_ch2: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch2: Cy5///label_protocol_ch2: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch2: 9606///hyb_protocol: Slides were incubated for 16-17 hr at 60C and washed using the SSPE method described in the Agilent 60-mer Oligo Microarray Processing Protocol, Version 2.1. Slides were treated with Agilent Stabilization and Drying Solution, a wash was used to protect the dyes from ozone degradation.///scan_protocol: Scanned on an Agilent G2565BA scanner.///description: Malignant_ovarian_sample///data_processing: Agilent Feature Extraction Software (v7.5.1) was used for local background subtraction and Linear/LOWESS normalization. RejectMethod=Interquartile Range, nonuniformity outlier flagging enabled, population outlier flag enabled, ratio error model=hybrid, dye normalization select method = Rank Consistency Filter, no spatial detrend method applied.///data_processing.1: Agilent Feature Extraced data was imported into Rosetta Resolver version 7.1.1 (Rosetta Inpharmatics LLC, Cambridge, MA). Multiple probes with the same sequence code were combined into a single value using the Rosetta Resolver error-weighted averaging method for combining repeated measures.///platform_id: GPL7264///contact_name: Judy,,Dering///contact_email: [email protected]///contact_laboratory: Translational Oncology Research///contact_department: Medicine///contact_institute: UCLA School of Medicine///contact_address: 2825 Santa Monica Blvd. Suite 200///contact_city: Santa Monica///contact_state: CA///contact_zip.postal_code: 90404///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM1238nnn/GSM1238149/GSM1238149_US22502615_251209749503_S01_A01.txt.gz///data_row_count: 20173
1
title: Ov_Tumor_Ref_Mix vs. CS-OV-006///geo_accession: GSM1238150///status: Public on Dec 26 2013///submission_date: Sep 23 2013///last_update_date: Dec 26 2013///type: RNA///channel_count: 2///source_name_ch1: 106 pooled ovarian samples///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian///characteristics_ch1.1: sample type: reference pool///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch1: Cy3///label_protocol_ch1: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch1: 9606///source_name_ch2: CS-OV-006///organism_ch2: Homo sapiens///characteristics_ch2: tissue: ovarian///characteristics_ch2.1: sample included in reference pool: NO///characteristics_ch2.2: sample rin: 7.5///characteristics_ch2.3: age at surgery: 58.56///characteristics_ch2.4: histology: Adenocarcinoma///characteristics_ch2.5: Stage: IIIC///characteristics_ch2.6: grade: 3///characteristics_ch2.7: tissue status: Primary///characteristics_ch2.8: follow up months: 41///characteristics_ch2.9: disease status: Not Free///characteristics_ch2.10: patient status: Dead///characteristics_ch2.11: disease state: Malignant ovarian///characteristics_ch2.12: ///molecule_ch2: total RNA///extract_protocol_ch2: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch2: Cy5///label_protocol_ch2: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch2: 9606///hyb_protocol: Slides were incubated for 16-17 hr at 60C and washed using the SSPE method described in the Agilent 60-mer Oligo Microarray Processing Protocol, Version 2.1. Slides were treated with Agilent Stabilization and Drying Solution, a wash was used to protect the dyes from ozone degradation.///scan_protocol: Scanned on an Agilent G2565BA scanner.///description: Malignant_ovarian_sample///data_processing: Agilent Feature Extraction Software (v7.5.1) was used for local background subtraction and Linear/LOWESS normalization. RejectMethod=Interquartile Range, nonuniformity outlier flagging enabled, population outlier flag enabled, ratio error model=hybrid, dye normalization select method = Rank Consistency Filter, no spatial detrend method applied.///data_processing.1: Agilent Feature Extraced data was imported into Rosetta Resolver version 7.1.1 (Rosetta Inpharmatics LLC, Cambridge, MA). Multiple probes with the same sequence code were combined into a single value using the Rosetta Resolver error-weighted averaging method for combining repeated measures.///platform_id: GPL7264///contact_name: Judy,,Dering///contact_email: [email protected]///contact_laboratory: Translational Oncology Research///contact_department: Medicine///contact_institute: UCLA School of Medicine///contact_address: 2825 Santa Monica Blvd. Suite 200///contact_city: Santa Monica///contact_state: CA///contact_zip.postal_code: 90404///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM1238nnn/GSM1238150/GSM1238150_US22502615_251209747514_S01_A01.txt.gz///data_row_count: 20173
1
title: Ov_Tumor_Ref_Mix vs. CS-OV-007///geo_accession: GSM1238151///status: Public on Dec 26 2013///submission_date: Sep 23 2013///last_update_date: Dec 26 2013///type: RNA///channel_count: 2///source_name_ch1: 106 pooled ovarian samples///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian///characteristics_ch1.1: sample type: reference pool///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch1: Cy3///label_protocol_ch1: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch1: 9606///source_name_ch2: CS-OV-007///organism_ch2: Homo sapiens///characteristics_ch2: tissue: ovarian///characteristics_ch2.1: sample included in reference pool: NO///characteristics_ch2.2: sample rin: 8.3///characteristics_ch2.3: age at surgery: 69.32///characteristics_ch2.4: histology: Serous///characteristics_ch2.5: Stage: IIIB///characteristics_ch2.6: grade: 3///characteristics_ch2.7: tissue status: Primary///characteristics_ch2.8: follow up months: 6///characteristics_ch2.9: disease status: Not Free///characteristics_ch2.10: patient status: Dead///characteristics_ch2.11: disease state: Malignant ovarian///characteristics_ch2.12: ///molecule_ch2: total RNA///extract_protocol_ch2: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch2: Cy5///label_protocol_ch2: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch2: 9606///hyb_protocol: Slides were incubated for 16-17 hr at 60C and washed using the SSPE method described in the Agilent 60-mer Oligo Microarray Processing Protocol, Version 2.1. Slides were treated with Agilent Stabilization and Drying Solution, a wash was used to protect the dyes from ozone degradation.///scan_protocol: Scanned on an Agilent G2565BA scanner.///description: Malignant_ovarian_sample///data_processing: Agilent Feature Extraction Software (v7.5.1) was used for local background subtraction and Linear/LOWESS normalization. RejectMethod=Interquartile Range, nonuniformity outlier flagging enabled, population outlier flag enabled, ratio error model=hybrid, dye normalization select method = Rank Consistency Filter, no spatial detrend method applied.///data_processing.1: Agilent Feature Extraced data was imported into Rosetta Resolver version 7.1.1 (Rosetta Inpharmatics LLC, Cambridge, MA). Multiple probes with the same sequence code were combined into a single value using the Rosetta Resolver error-weighted averaging method for combining repeated measures.///platform_id: GPL7264///contact_name: Judy,,Dering///contact_email: [email protected]///contact_laboratory: Translational Oncology Research///contact_department: Medicine///contact_institute: UCLA School of Medicine///contact_address: 2825 Santa Monica Blvd. Suite 200///contact_city: Santa Monica///contact_state: CA///contact_zip.postal_code: 90404///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM1238nnn/GSM1238151/GSM1238151_US22502615_251209754110_S01_A01.txt.gz///data_row_count: 20173
1
title: Ov_Tumor_Ref_Mix vs. CS-OV-008///geo_accession: GSM1238152///status: Public on Dec 26 2013///submission_date: Sep 23 2013///last_update_date: Dec 26 2013///type: RNA///channel_count: 2///source_name_ch1: 106 pooled ovarian samples///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian///characteristics_ch1.1: sample type: reference pool///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch1: Cy3///label_protocol_ch1: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch1: 9606///source_name_ch2: CS-OV-008///organism_ch2: Homo sapiens///characteristics_ch2: tissue: ovarian///characteristics_ch2.1: sample included in reference pool: YES///characteristics_ch2.2: sample rin: 9.4///characteristics_ch2.3: age at surgery: 63.54///characteristics_ch2.4: histology: MMMT///characteristics_ch2.5: Stage: IIB///characteristics_ch2.6: grade: 3///characteristics_ch2.7: tissue status: Primary///characteristics_ch2.8: follow up months: 9///characteristics_ch2.9: disease status: Not Free///characteristics_ch2.10: patient status: Dead///characteristics_ch2.11: disease state: Malignant ovarian///characteristics_ch2.12: ///molecule_ch2: total RNA///extract_protocol_ch2: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch2: Cy5///label_protocol_ch2: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch2: 9606///hyb_protocol: Slides were incubated for 16-17 hr at 60C and washed using the SSPE method described in the Agilent 60-mer Oligo Microarray Processing Protocol, Version 2.1. Slides were treated with Agilent Stabilization and Drying Solution, a wash was used to protect the dyes from ozone degradation.///scan_protocol: Scanned on an Agilent G2565BA scanner.///description: Malignant_ovarian_sample///data_processing: Agilent Feature Extraction Software (v7.5.1) was used for local background subtraction and Linear/LOWESS normalization. RejectMethod=Interquartile Range, nonuniformity outlier flagging enabled, population outlier flag enabled, ratio error model=hybrid, dye normalization select method = Rank Consistency Filter, no spatial detrend method applied.///data_processing.1: Agilent Feature Extraced data was imported into Rosetta Resolver version 7.1.1 (Rosetta Inpharmatics LLC, Cambridge, MA). Multiple probes with the same sequence code were combined into a single value using the Rosetta Resolver error-weighted averaging method for combining repeated measures.///platform_id: GPL7264///contact_name: Judy,,Dering///contact_email: [email protected]///contact_laboratory: Translational Oncology Research///contact_department: Medicine///contact_institute: UCLA School of Medicine///contact_address: 2825 Santa Monica Blvd. Suite 200///contact_city: Santa Monica///contact_state: CA///contact_zip.postal_code: 90404///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM1238nnn/GSM1238152/GSM1238152_US22502615_251209750954_S01_A01.txt.gz///data_row_count: 20173
1
title: Ov_Tumor_Ref_Mix vs. CS-OV-009///geo_accession: GSM1238153///status: Public on Dec 26 2013///submission_date: Sep 23 2013///last_update_date: Dec 26 2013///type: RNA///channel_count: 2///source_name_ch1: 106 pooled ovarian samples///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian///characteristics_ch1.1: sample type: reference pool///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch1: Cy3///label_protocol_ch1: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch1: 9606///source_name_ch2: CS-OV-009///organism_ch2: Homo sapiens///characteristics_ch2: tissue: ovarian///characteristics_ch2.1: sample included in reference pool: NO///characteristics_ch2.2: sample rin: 9.2///characteristics_ch2.3: age at surgery: 67.91///characteristics_ch2.4: histology: Serous///characteristics_ch2.5: Stage: IIIC///characteristics_ch2.6: grade: 3///characteristics_ch2.7: tissue status: Primary///characteristics_ch2.8: follow up months: 22///characteristics_ch2.9: disease status: Not Free///characteristics_ch2.10: patient status: Dead///characteristics_ch2.11: disease state: Malignant ovarian///characteristics_ch2.12: ///molecule_ch2: total RNA///extract_protocol_ch2: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch2: Cy5///label_protocol_ch2: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch2: 9606///hyb_protocol: Slides were incubated for 16-17 hr at 60C and washed using the SSPE method described in the Agilent 60-mer Oligo Microarray Processing Protocol, Version 2.1. Slides were treated with Agilent Stabilization and Drying Solution, a wash was used to protect the dyes from ozone degradation.///scan_protocol: Scanned on an Agilent G2565BA scanner.///description: Malignant_ovarian_sample///data_processing: Agilent Feature Extraction Software (v7.5.1) was used for local background subtraction and Linear/LOWESS normalization. RejectMethod=Interquartile Range, nonuniformity outlier flagging enabled, population outlier flag enabled, ratio error model=hybrid, dye normalization select method = Rank Consistency Filter, no spatial detrend method applied.///data_processing.1: Agilent Feature Extraced data was imported into Rosetta Resolver version 7.1.1 (Rosetta Inpharmatics LLC, Cambridge, MA). Multiple probes with the same sequence code were combined into a single value using the Rosetta Resolver error-weighted averaging method for combining repeated measures.///platform_id: GPL7264///contact_name: Judy,,Dering///contact_email: [email protected]///contact_laboratory: Translational Oncology Research///contact_department: Medicine///contact_institute: UCLA School of Medicine///contact_address: 2825 Santa Monica Blvd. Suite 200///contact_city: Santa Monica///contact_state: CA///contact_zip.postal_code: 90404///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM1238nnn/GSM1238153/GSM1238153_US22502615_251209754145_S01_A01.txt.gz///data_row_count: 20173
1
title: Ov_Tumor_Ref_Mix vs. CS-OV-010///geo_accession: GSM1238154///status: Public on Dec 26 2013///submission_date: Sep 23 2013///last_update_date: Dec 26 2013///type: RNA///channel_count: 2///source_name_ch1: 106 pooled ovarian samples///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian///characteristics_ch1.1: sample type: reference pool///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch1: Cy3///label_protocol_ch1: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch1: 9606///source_name_ch2: CS-OV-010///organism_ch2: Homo sapiens///characteristics_ch2: tissue: ovarian///characteristics_ch2.1: sample included in reference pool: NO///characteristics_ch2.2: sample rin: 9.3///characteristics_ch2.3: age at surgery: 85.58///characteristics_ch2.4: histology: Serous///characteristics_ch2.5: Stage: IV///characteristics_ch2.6: grade: 3///characteristics_ch2.7: tissue status: Primary///characteristics_ch2.8: follow up months: 9///characteristics_ch2.9: disease status: Not Free///characteristics_ch2.10: patient status: Dead///characteristics_ch2.11: disease state: Malignant ovarian///characteristics_ch2.12: ///molecule_ch2: total RNA///extract_protocol_ch2: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch2: Cy5///label_protocol_ch2: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch2: 9606///hyb_protocol: Slides were incubated for 16-17 hr at 60C and washed using the SSPE method described in the Agilent 60-mer Oligo Microarray Processing Protocol, Version 2.1. Slides were treated with Agilent Stabilization and Drying Solution, a wash was used to protect the dyes from ozone degradation.///scan_protocol: Scanned on an Agilent G2565BA scanner.///description: Malignant_ovarian_sample///data_processing: Agilent Feature Extraction Software (v7.5.1) was used for local background subtraction and Linear/LOWESS normalization. RejectMethod=Interquartile Range, nonuniformity outlier flagging enabled, population outlier flag enabled, ratio error model=hybrid, dye normalization select method = Rank Consistency Filter, no spatial detrend method applied.///data_processing.1: Agilent Feature Extraced data was imported into Rosetta Resolver version 7.1.1 (Rosetta Inpharmatics LLC, Cambridge, MA). Multiple probes with the same sequence code were combined into a single value using the Rosetta Resolver error-weighted averaging method for combining repeated measures.///platform_id: GPL7264///contact_name: Judy,,Dering///contact_email: [email protected]///contact_laboratory: Translational Oncology Research///contact_department: Medicine///contact_institute: UCLA School of Medicine///contact_address: 2825 Santa Monica Blvd. Suite 200///contact_city: Santa Monica///contact_state: CA///contact_zip.postal_code: 90404///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM1238nnn/GSM1238154/GSM1238154_US22502615_251209749837_S01_A01.txt.gz///data_row_count: 20173
1
title: Ov_Tumor_Ref_Mix vs. CS-OV-011///geo_accession: GSM1238155///status: Public on Dec 26 2013///submission_date: Sep 23 2013///last_update_date: Dec 26 2013///type: RNA///channel_count: 2///source_name_ch1: 106 pooled ovarian samples///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian///characteristics_ch1.1: sample type: reference pool///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch1: Cy3///label_protocol_ch1: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch1: 9606///source_name_ch2: CS-OV-011///organism_ch2: Homo sapiens///characteristics_ch2: tissue: ovarian///characteristics_ch2.1: sample included in reference pool: NO///characteristics_ch2.2: sample rin: 8.9///characteristics_ch2.3: age at surgery: 39.50///characteristics_ch2.4: histology: Mucinous///characteristics_ch2.5: Stage: IA///characteristics_ch2.6: grade: 0///characteristics_ch2.7: tissue status: Primary///characteristics_ch2.8: follow up months: 67///characteristics_ch2.9: disease status: Free///characteristics_ch2.10: patient status: Alive///characteristics_ch2.11: disease state: Borderline ovarian///characteristics_ch2.12: ///molecule_ch2: total RNA///extract_protocol_ch2: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch2: Cy5///label_protocol_ch2: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch2: 9606///hyb_protocol: Slides were incubated for 16-17 hr at 60C and washed using the SSPE method described in the Agilent 60-mer Oligo Microarray Processing Protocol, Version 2.1. Slides were treated with Agilent Stabilization and Drying Solution, a wash was used to protect the dyes from ozone degradation.///scan_protocol: Scanned on an Agilent G2565BA scanner.///description: Borderline_ovarian_sample///data_processing: Agilent Feature Extraction Software (v7.5.1) was used for local background subtraction and Linear/LOWESS normalization. RejectMethod=Interquartile Range, nonuniformity outlier flagging enabled, population outlier flag enabled, ratio error model=hybrid, dye normalization select method = Rank Consistency Filter, no spatial detrend method applied.///data_processing.1: Agilent Feature Extraced data was imported into Rosetta Resolver version 7.1.1 (Rosetta Inpharmatics LLC, Cambridge, MA). Multiple probes with the same sequence code were combined into a single value using the Rosetta Resolver error-weighted averaging method for combining repeated measures.///platform_id: GPL7264///contact_name: Judy,,Dering///contact_email: [email protected]///contact_laboratory: Translational Oncology Research///contact_department: Medicine///contact_institute: UCLA School of Medicine///contact_address: 2825 Santa Monica Blvd. Suite 200///contact_city: Santa Monica///contact_state: CA///contact_zip.postal_code: 90404///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM1238nnn/GSM1238155/GSM1238155_US22502615_251209754811_S01_A01.txt.gz///data_row_count: 20173
1
title: Ov_Tumor_Ref_Mix vs. CS-OV-012///geo_accession: GSM1238156///status: Public on Dec 26 2013///submission_date: Sep 23 2013///last_update_date: Dec 26 2013///type: RNA///channel_count: 2///source_name_ch1: 106 pooled ovarian samples///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian///characteristics_ch1.1: sample type: reference pool///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch1: Cy3///label_protocol_ch1: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch1: 9606///source_name_ch2: CS-OV-012///organism_ch2: Homo sapiens///characteristics_ch2: tissue: ovarian///characteristics_ch2.1: sample included in reference pool: NO///characteristics_ch2.2: sample rin: 7.9///characteristics_ch2.3: age at surgery: 68.16///characteristics_ch2.4: histology: Serous///characteristics_ch2.5: Stage: IIIC///characteristics_ch2.6: grade: 3///characteristics_ch2.7: tissue status: Primary///characteristics_ch2.8: follow up months: 42///characteristics_ch2.9: disease status: Unknown///characteristics_ch2.10: patient status: Dead///characteristics_ch2.11: disease state: Malignant ovarian///characteristics_ch2.12: ///molecule_ch2: total RNA///extract_protocol_ch2: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch2: Cy5///label_protocol_ch2: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch2: 9606///hyb_protocol: Slides were incubated for 16-17 hr at 60C and washed using the SSPE method described in the Agilent 60-mer Oligo Microarray Processing Protocol, Version 2.1. Slides were treated with Agilent Stabilization and Drying Solution, a wash was used to protect the dyes from ozone degradation.///scan_protocol: Scanned on an Agilent G2565BA scanner.///description: Malignant_ovarian_sample///data_processing: Agilent Feature Extraction Software (v7.5.1) was used for local background subtraction and Linear/LOWESS normalization. RejectMethod=Interquartile Range, nonuniformity outlier flagging enabled, population outlier flag enabled, ratio error model=hybrid, dye normalization select method = Rank Consistency Filter, no spatial detrend method applied.///data_processing.1: Agilent Feature Extraced data was imported into Rosetta Resolver version 7.1.1 (Rosetta Inpharmatics LLC, Cambridge, MA). Multiple probes with the same sequence code were combined into a single value using the Rosetta Resolver error-weighted averaging method for combining repeated measures.///platform_id: GPL7264///contact_name: Judy,,Dering///contact_email: [email protected]///contact_laboratory: Translational Oncology Research///contact_department: Medicine///contact_institute: UCLA School of Medicine///contact_address: 2825 Santa Monica Blvd. Suite 200///contact_city: Santa Monica///contact_state: CA///contact_zip.postal_code: 90404///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM1238nnn/GSM1238156/GSM1238156_US22502615_251209754098_S01_A01.txt.gz///data_row_count: 20173
1
title: Ov_Tumor_Ref_Mix vs. CS-OV-013///geo_accession: GSM1238157///status: Public on Dec 26 2013///submission_date: Sep 23 2013///last_update_date: Dec 26 2013///type: RNA///channel_count: 2///source_name_ch1: 106 pooled ovarian samples///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian///characteristics_ch1.1: sample type: reference pool///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch1: Cy3///label_protocol_ch1: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch1: 9606///source_name_ch2: CS-OV-013///organism_ch2: Homo sapiens///characteristics_ch2: tissue: ovarian///characteristics_ch2.1: sample included in reference pool: YES///characteristics_ch2.2: sample rin: 9.9///characteristics_ch2.3: age at surgery: 44.95///characteristics_ch2.4: histology: Normal///characteristics_ch2.5: tissue status: Benign///characteristics_ch2.6: disease status: Benign///characteristics_ch2.7: patient status: Benign///characteristics_ch2.8: disease state: Normal ovarian///characteristics_ch2.9: ///characteristics_ch2.10: ///characteristics_ch2.11: ///characteristics_ch2.12: ///molecule_ch2: total RNA///extract_protocol_ch2: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch2: Cy5///label_protocol_ch2: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch2: 9606///hyb_protocol: Slides were incubated for 16-17 hr at 60C and washed using the SSPE method described in the Agilent 60-mer Oligo Microarray Processing Protocol, Version 2.1. Slides were treated with Agilent Stabilization and Drying Solution, a wash was used to protect the dyes from ozone degradation.///scan_protocol: Scanned on an Agilent G2565BA scanner.///description: Normal_ovarian_sample///data_processing: Agilent Feature Extraction Software (v7.5.1) was used for local background subtraction and Linear/LOWESS normalization. RejectMethod=Interquartile Range, nonuniformity outlier flagging enabled, population outlier flag enabled, ratio error model=hybrid, dye normalization select method = Rank Consistency Filter, no spatial detrend method applied.///data_processing.1: Agilent Feature Extraced data was imported into Rosetta Resolver version 7.1.1 (Rosetta Inpharmatics LLC, Cambridge, MA). Multiple probes with the same sequence code were combined into a single value using the Rosetta Resolver error-weighted averaging method for combining repeated measures.///platform_id: GPL7264///contact_name: Judy,,Dering///contact_email: [email protected]///contact_laboratory: Translational Oncology Research///contact_department: Medicine///contact_institute: UCLA School of Medicine///contact_address: 2825 Santa Monica Blvd. Suite 200///contact_city: Santa Monica///contact_state: CA///contact_zip.postal_code: 90404///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM1238nnn/GSM1238157/GSM1238157_US22502615_251209747185_S01_A01.txt.gz///data_row_count: 20173
1
title: Ov_Tumor_Ref_Mix vs. CS-OV-014///geo_accession: GSM1238158///status: Public on Dec 26 2013///submission_date: Sep 23 2013///last_update_date: Dec 26 2013///type: RNA///channel_count: 2///source_name_ch1: 106 pooled ovarian samples///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian///characteristics_ch1.1: sample type: reference pool///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch1: Cy3///label_protocol_ch1: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch1: 9606///source_name_ch2: CS-OV-014///organism_ch2: Homo sapiens///characteristics_ch2: tissue: ovarian///characteristics_ch2.1: sample included in reference pool: YES///characteristics_ch2.2: sample rin: 9///characteristics_ch2.3: age at surgery: 59.66///characteristics_ch2.4: histology: Serous///characteristics_ch2.5: Stage: IIIC///characteristics_ch2.6: grade: 3///characteristics_ch2.7: tissue status: Primary///characteristics_ch2.8: follow up months: 66///characteristics_ch2.9: disease status: Not Free///characteristics_ch2.10: patient status: Dead///characteristics_ch2.11: disease state: Malignant ovarian///characteristics_ch2.12: ///molecule_ch2: total RNA///extract_protocol_ch2: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch2: Cy5///label_protocol_ch2: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch2: 9606///hyb_protocol: Slides were incubated for 16-17 hr at 60C and washed using the SSPE method described in the Agilent 60-mer Oligo Microarray Processing Protocol, Version 2.1. Slides were treated with Agilent Stabilization and Drying Solution, a wash was used to protect the dyes from ozone degradation.///scan_protocol: Scanned on an Agilent G2565BA scanner.///description: Malignant_ovarian_sample///data_processing: Agilent Feature Extraction Software (v7.5.1) was used for local background subtraction and Linear/LOWESS normalization. RejectMethod=Interquartile Range, nonuniformity outlier flagging enabled, population outlier flag enabled, ratio error model=hybrid, dye normalization select method = Rank Consistency Filter, no spatial detrend method applied.///data_processing.1: Agilent Feature Extraced data was imported into Rosetta Resolver version 7.1.1 (Rosetta Inpharmatics LLC, Cambridge, MA). Multiple probes with the same sequence code were combined into a single value using the Rosetta Resolver error-weighted averaging method for combining repeated measures.///platform_id: GPL7264///contact_name: Judy,,Dering///contact_email: [email protected]///contact_laboratory: Translational Oncology Research///contact_department: Medicine///contact_institute: UCLA School of Medicine///contact_address: 2825 Santa Monica Blvd. Suite 200///contact_city: Santa Monica///contact_state: CA///contact_zip.postal_code: 90404///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM1238nnn/GSM1238158/GSM1238158_US22502615_251209751008_S01_A01.txt.gz///data_row_count: 20173
1
title: Ov_Tumor_Ref_Mix vs. CS-OV-015///geo_accession: GSM1238159///status: Public on Dec 26 2013///submission_date: Sep 23 2013///last_update_date: Dec 26 2013///type: RNA///channel_count: 2///source_name_ch1: 106 pooled ovarian samples///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian///characteristics_ch1.1: sample type: reference pool///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch1: Cy3///label_protocol_ch1: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch1: 9606///source_name_ch2: CS-OV-015///organism_ch2: Homo sapiens///characteristics_ch2: tissue: ovarian///characteristics_ch2.1: sample included in reference pool: NO///characteristics_ch2.2: sample rin: 8.2///characteristics_ch2.3: age at surgery: 62.28///characteristics_ch2.4: histology: Serous///characteristics_ch2.5: Stage: IIIC///characteristics_ch2.6: grade: 3///characteristics_ch2.7: tissue status: Primary///characteristics_ch2.8: follow up months: 73///characteristics_ch2.9: disease status: Not Free///characteristics_ch2.10: patient status: Dead///characteristics_ch2.11: disease state: Malignant ovarian///characteristics_ch2.12: ///molecule_ch2: total RNA///extract_protocol_ch2: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch2: Cy5///label_protocol_ch2: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch2: 9606///hyb_protocol: Slides were incubated for 16-17 hr at 60C and washed using the SSPE method described in the Agilent 60-mer Oligo Microarray Processing Protocol, Version 2.1. Slides were treated with Agilent Stabilization and Drying Solution, a wash was used to protect the dyes from ozone degradation.///scan_protocol: Scanned on an Agilent G2565BA scanner.///description: Malignant_ovarian_sample///data_processing: Agilent Feature Extraction Software (v7.5.1) was used for local background subtraction and Linear/LOWESS normalization. RejectMethod=Interquartile Range, nonuniformity outlier flagging enabled, population outlier flag enabled, ratio error model=hybrid, dye normalization select method = Rank Consistency Filter, no spatial detrend method applied.///data_processing.1: Agilent Feature Extraced data was imported into Rosetta Resolver version 7.1.1 (Rosetta Inpharmatics LLC, Cambridge, MA). Multiple probes with the same sequence code were combined into a single value using the Rosetta Resolver error-weighted averaging method for combining repeated measures.///platform_id: GPL7264///contact_name: Judy,,Dering///contact_email: [email protected]///contact_laboratory: Translational Oncology Research///contact_department: Medicine///contact_institute: UCLA School of Medicine///contact_address: 2825 Santa Monica Blvd. Suite 200///contact_city: Santa Monica///contact_state: CA///contact_zip.postal_code: 90404///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM1238nnn/GSM1238159/GSM1238159_US22502615_251209754814_S01_A01.txt.gz///data_row_count: 20173
1
title: Ov_Tumor_Ref_Mix vs. CS-OV-016///geo_accession: GSM1238160///status: Public on Dec 26 2013///submission_date: Sep 23 2013///last_update_date: Dec 26 2013///type: RNA///channel_count: 2///source_name_ch1: 106 pooled ovarian samples///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian///characteristics_ch1.1: sample type: reference pool///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch1: Cy3///label_protocol_ch1: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch1: 9606///source_name_ch2: CS-OV-016///organism_ch2: Homo sapiens///characteristics_ch2: tissue: ovarian///characteristics_ch2.1: sample included in reference pool: YES///characteristics_ch2.2: sample rin: 9.2///characteristics_ch2.3: age at surgery: 90.78///characteristics_ch2.4: histology: Serous///characteristics_ch2.5: grade: unknown///characteristics_ch2.6: tissue status: Primary///characteristics_ch2.7: follow up months: Unknown///characteristics_ch2.8: disease status: Unknown///characteristics_ch2.9: patient status: Unknown///characteristics_ch2.10: disease state: Malignant ovarian///characteristics_ch2.11: ///characteristics_ch2.12: ///molecule_ch2: total RNA///extract_protocol_ch2: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch2: Cy5///label_protocol_ch2: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch2: 9606///hyb_protocol: Slides were incubated for 16-17 hr at 60C and washed using the SSPE method described in the Agilent 60-mer Oligo Microarray Processing Protocol, Version 2.1. Slides were treated with Agilent Stabilization and Drying Solution, a wash was used to protect the dyes from ozone degradation.///scan_protocol: Scanned on an Agilent G2565BA scanner.///description: Malignant_ovarian_sample///data_processing: Agilent Feature Extraction Software (v7.5.1) was used for local background subtraction and Linear/LOWESS normalization. RejectMethod=Interquartile Range, nonuniformity outlier flagging enabled, population outlier flag enabled, ratio error model=hybrid, dye normalization select method = Rank Consistency Filter, no spatial detrend method applied.///data_processing.1: Agilent Feature Extraced data was imported into Rosetta Resolver version 7.1.1 (Rosetta Inpharmatics LLC, Cambridge, MA). Multiple probes with the same sequence code were combined into a single value using the Rosetta Resolver error-weighted averaging method for combining repeated measures.///platform_id: GPL7264///contact_name: Judy,,Dering///contact_email: [email protected]///contact_laboratory: Translational Oncology Research///contact_department: Medicine///contact_institute: UCLA School of Medicine///contact_address: 2825 Santa Monica Blvd. Suite 200///contact_city: Santa Monica///contact_state: CA///contact_zip.postal_code: 90404///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM1238nnn/GSM1238160/GSM1238160_US22502615_251209747447_S01_A01.txt.gz///data_row_count: 20173
1
title: Ov_Tumor_Ref_Mix vs. CS-OV-017///geo_accession: GSM1238161///status: Public on Dec 26 2013///submission_date: Sep 23 2013///last_update_date: Dec 26 2013///type: RNA///channel_count: 2///source_name_ch1: 106 pooled ovarian samples///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian///characteristics_ch1.1: sample type: reference pool///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch1: Cy3///label_protocol_ch1: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch1: 9606///source_name_ch2: CS-OV-017///organism_ch2: Homo sapiens///characteristics_ch2: tissue: ovarian///characteristics_ch2.1: sample included in reference pool: YES///characteristics_ch2.2: sample rin: 10///characteristics_ch2.3: age at surgery: 60.85///characteristics_ch2.4: histology: Serous///characteristics_ch2.5: Stage: IV///characteristics_ch2.6: grade: 3///characteristics_ch2.7: tissue status: Primary///characteristics_ch2.8: tcga id: TCGA-23-1031///characteristics_ch2.9: follow up months: 19///characteristics_ch2.10: disease status: Not Free///characteristics_ch2.11: patient status: Dead///characteristics_ch2.12: disease state: Malignant ovarian///molecule_ch2: total RNA///extract_protocol_ch2: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch2: Cy5///label_protocol_ch2: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch2: 9606///hyb_protocol: Slides were incubated for 16-17 hr at 60C and washed using the SSPE method described in the Agilent 60-mer Oligo Microarray Processing Protocol, Version 2.1. Slides were treated with Agilent Stabilization and Drying Solution, a wash was used to protect the dyes from ozone degradation.///scan_protocol: Scanned on an Agilent G2565BA scanner.///description: Malignant_ovarian_sample///data_processing: Agilent Feature Extraction Software (v7.5.1) was used for local background subtraction and Linear/LOWESS normalization. RejectMethod=Interquartile Range, nonuniformity outlier flagging enabled, population outlier flag enabled, ratio error model=hybrid, dye normalization select method = Rank Consistency Filter, no spatial detrend method applied.///data_processing.1: Agilent Feature Extraced data was imported into Rosetta Resolver version 7.1.1 (Rosetta Inpharmatics LLC, Cambridge, MA). Multiple probes with the same sequence code were combined into a single value using the Rosetta Resolver error-weighted averaging method for combining repeated measures.///platform_id: GPL7264///contact_name: Judy,,Dering///contact_email: [email protected]///contact_laboratory: Translational Oncology Research///contact_department: Medicine///contact_institute: UCLA School of Medicine///contact_address: 2825 Santa Monica Blvd. Suite 200///contact_city: Santa Monica///contact_state: CA///contact_zip.postal_code: 90404///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM1238nnn/GSM1238161/GSM1238161_US22502615_251209750982_S02_A01.txt.gz///data_row_count: 20173
1
title: Ov_Tumor_Ref_Mix vs. CS-OV-018///geo_accession: GSM1238162///status: Public on Dec 26 2013///submission_date: Sep 23 2013///last_update_date: Dec 26 2013///type: RNA///channel_count: 2///source_name_ch1: 106 pooled ovarian samples///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian///characteristics_ch1.1: sample type: reference pool///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch1: Cy3///label_protocol_ch1: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch1: 9606///source_name_ch2: CS-OV-018///organism_ch2: Homo sapiens///characteristics_ch2: tissue: ovarian///characteristics_ch2.1: sample included in reference pool: YES///characteristics_ch2.2: sample rin: 9.8///characteristics_ch2.3: age at surgery: 43.81///characteristics_ch2.4: histology: Serous///characteristics_ch2.5: Stage: IIIC///characteristics_ch2.6: grade: 3///characteristics_ch2.7: tissue status: Primary///characteristics_ch2.8: tcga id: TCGA-23-1028///characteristics_ch2.9: follow up months: 55///characteristics_ch2.10: disease status: Not Free///characteristics_ch2.11: patient status: Dead///characteristics_ch2.12: disease state: Malignant ovarian///molecule_ch2: total RNA///extract_protocol_ch2: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch2: Cy5///label_protocol_ch2: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch2: 9606///hyb_protocol: Slides were incubated for 16-17 hr at 60C and washed using the SSPE method described in the Agilent 60-mer Oligo Microarray Processing Protocol, Version 2.1. Slides were treated with Agilent Stabilization and Drying Solution, a wash was used to protect the dyes from ozone degradation.///scan_protocol: Scanned on an Agilent G2565BA scanner.///description: Malignant_ovarian_sample///data_processing: Agilent Feature Extraction Software (v7.5.1) was used for local background subtraction and Linear/LOWESS normalization. RejectMethod=Interquartile Range, nonuniformity outlier flagging enabled, population outlier flag enabled, ratio error model=hybrid, dye normalization select method = Rank Consistency Filter, no spatial detrend method applied.///data_processing.1: Agilent Feature Extraced data was imported into Rosetta Resolver version 7.1.1 (Rosetta Inpharmatics LLC, Cambridge, MA). Multiple probes with the same sequence code were combined into a single value using the Rosetta Resolver error-weighted averaging method for combining repeated measures.///platform_id: GPL7264///contact_name: Judy,,Dering///contact_email: [email protected]///contact_laboratory: Translational Oncology Research///contact_department: Medicine///contact_institute: UCLA School of Medicine///contact_address: 2825 Santa Monica Blvd. Suite 200///contact_city: Santa Monica///contact_state: CA///contact_zip.postal_code: 90404///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM1238nnn/GSM1238162/GSM1238162_US22502615_251209747422_S01_A01.txt.gz///data_row_count: 20173
1
title: Ov_Tumor_Ref_Mix vs. CS-OV-019///geo_accession: GSM1238163///status: Public on Dec 26 2013///submission_date: Sep 23 2013///last_update_date: Dec 26 2013///type: RNA///channel_count: 2///source_name_ch1: 106 pooled ovarian samples///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian///characteristics_ch1.1: sample type: reference pool///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch1: Cy3///label_protocol_ch1: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch1: 9606///source_name_ch2: CS-OV-019///organism_ch2: Homo sapiens///characteristics_ch2: tissue: ovarian///characteristics_ch2.1: sample included in reference pool: YES///characteristics_ch2.2: sample rin: 9.1///characteristics_ch2.3: age at surgery: 45.53///characteristics_ch2.4: histology: Serous///characteristics_ch2.5: Stage: IIC///characteristics_ch2.6: grade: 3///characteristics_ch2.7: tissue status: Primary///characteristics_ch2.8: follow up months: 26///characteristics_ch2.9: disease status: Not Free///characteristics_ch2.10: patient status: Dead///characteristics_ch2.11: disease state: Malignant ovarian///characteristics_ch2.12: ///molecule_ch2: total RNA///extract_protocol_ch2: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch2: Cy5///label_protocol_ch2: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch2: 9606///hyb_protocol: Slides were incubated for 16-17 hr at 60C and washed using the SSPE method described in the Agilent 60-mer Oligo Microarray Processing Protocol, Version 2.1. Slides were treated with Agilent Stabilization and Drying Solution, a wash was used to protect the dyes from ozone degradation.///scan_protocol: Scanned on an Agilent G2565BA scanner.///description: Malignant_ovarian_sample///data_processing: Agilent Feature Extraction Software (v7.5.1) was used for local background subtraction and Linear/LOWESS normalization. RejectMethod=Interquartile Range, nonuniformity outlier flagging enabled, population outlier flag enabled, ratio error model=hybrid, dye normalization select method = Rank Consistency Filter, no spatial detrend method applied.///data_processing.1: Agilent Feature Extraced data was imported into Rosetta Resolver version 7.1.1 (Rosetta Inpharmatics LLC, Cambridge, MA). Multiple probes with the same sequence code were combined into a single value using the Rosetta Resolver error-weighted averaging method for combining repeated measures.///platform_id: GPL7264///contact_name: Judy,,Dering///contact_email: [email protected]///contact_laboratory: Translational Oncology Research///contact_department: Medicine///contact_institute: UCLA School of Medicine///contact_address: 2825 Santa Monica Blvd. Suite 200///contact_city: Santa Monica///contact_state: CA///contact_zip.postal_code: 90404///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM1238nnn/GSM1238163/GSM1238163_US22502615_251209747425_S01_A01.txt.gz///data_row_count: 20173
1
title: Ov_Tumor_Ref_Mix vs. CS-OV-020///geo_accession: GSM1238164///status: Public on Dec 26 2013///submission_date: Sep 23 2013///last_update_date: Dec 26 2013///type: RNA///channel_count: 2///source_name_ch1: 106 pooled ovarian samples///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian///characteristics_ch1.1: sample type: reference pool///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch1: Cy3///label_protocol_ch1: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch1: 9606///source_name_ch2: CS-OV-020///organism_ch2: Homo sapiens///characteristics_ch2: tissue: ovarian///characteristics_ch2.1: sample included in reference pool: YES///characteristics_ch2.2: sample rin: 9.6///characteristics_ch2.3: age at surgery: 37.07///characteristics_ch2.4: histology: Serous///characteristics_ch2.5: Stage: IC///characteristics_ch2.6: grade: unknown///characteristics_ch2.7: tissue status: Primary///characteristics_ch2.8: follow up months: 68///characteristics_ch2.9: disease status: Free///characteristics_ch2.10: patient status: Alive///characteristics_ch2.11: disease state: Borderline ovarian///characteristics_ch2.12: ///molecule_ch2: total RNA///extract_protocol_ch2: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch2: Cy5///label_protocol_ch2: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch2: 9606///hyb_protocol: Slides were incubated for 16-17 hr at 60C and washed using the SSPE method described in the Agilent 60-mer Oligo Microarray Processing Protocol, Version 2.1. Slides were treated with Agilent Stabilization and Drying Solution, a wash was used to protect the dyes from ozone degradation.///scan_protocol: Scanned on an Agilent G2565BA scanner.///description: Borderline_ovarian_sample///data_processing: Agilent Feature Extraction Software (v7.5.1) was used for local background subtraction and Linear/LOWESS normalization. RejectMethod=Interquartile Range, nonuniformity outlier flagging enabled, population outlier flag enabled, ratio error model=hybrid, dye normalization select method = Rank Consistency Filter, no spatial detrend method applied.///data_processing.1: Agilent Feature Extraced data was imported into Rosetta Resolver version 7.1.1 (Rosetta Inpharmatics LLC, Cambridge, MA). Multiple probes with the same sequence code were combined into a single value using the Rosetta Resolver error-weighted averaging method for combining repeated measures.///platform_id: GPL7264///contact_name: Judy,,Dering///contact_email: [email protected]///contact_laboratory: Translational Oncology Research///contact_department: Medicine///contact_institute: UCLA School of Medicine///contact_address: 2825 Santa Monica Blvd. Suite 200///contact_city: Santa Monica///contact_state: CA///contact_zip.postal_code: 90404///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM1238nnn/GSM1238164/GSM1238164_US22502615_251209749022_S01_A01.txt.gz///data_row_count: 20173
1
title: Ov_Tumor_Ref_Mix vs. CS-OV-021///geo_accession: GSM1238165///status: Public on Dec 26 2013///submission_date: Sep 23 2013///last_update_date: Dec 26 2013///type: RNA///channel_count: 2///source_name_ch1: 106 pooled ovarian samples///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian///characteristics_ch1.1: sample type: reference pool///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch1: Cy3///label_protocol_ch1: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch1: 9606///source_name_ch2: CS-OV-021///organism_ch2: Homo sapiens///characteristics_ch2: tissue: ovarian///characteristics_ch2.1: sample included in reference pool: NO///characteristics_ch2.2: sample rin: 7.8///characteristics_ch2.3: age at surgery: 80.24///characteristics_ch2.4: histology: Serous///characteristics_ch2.5: Stage: IIIB///characteristics_ch2.6: grade: 3///characteristics_ch2.7: tissue status: Primary///characteristics_ch2.8: follow up months: 73///characteristics_ch2.9: disease status: Not Free///characteristics_ch2.10: patient status: Dead///characteristics_ch2.11: disease state: Malignant ovarian///characteristics_ch2.12: ///molecule_ch2: total RNA///extract_protocol_ch2: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch2: Cy5///label_protocol_ch2: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch2: 9606///hyb_protocol: Slides were incubated for 16-17 hr at 60C and washed using the SSPE method described in the Agilent 60-mer Oligo Microarray Processing Protocol, Version 2.1. Slides were treated with Agilent Stabilization and Drying Solution, a wash was used to protect the dyes from ozone degradation.///scan_protocol: Scanned on an Agilent G2565BA scanner.///description: Malignant_ovarian_sample///data_processing: Agilent Feature Extraction Software (v7.5.1) was used for local background subtraction and Linear/LOWESS normalization. RejectMethod=Interquartile Range, nonuniformity outlier flagging enabled, population outlier flag enabled, ratio error model=hybrid, dye normalization select method = Rank Consistency Filter, no spatial detrend method applied.///data_processing.1: Agilent Feature Extraced data was imported into Rosetta Resolver version 7.1.1 (Rosetta Inpharmatics LLC, Cambridge, MA). Multiple probes with the same sequence code were combined into a single value using the Rosetta Resolver error-weighted averaging method for combining repeated measures.///platform_id: GPL7264///contact_name: Judy,,Dering///contact_email: [email protected]///contact_laboratory: Translational Oncology Research///contact_department: Medicine///contact_institute: UCLA School of Medicine///contact_address: 2825 Santa Monica Blvd. Suite 200///contact_city: Santa Monica///contact_state: CA///contact_zip.postal_code: 90404///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM1238nnn/GSM1238165/GSM1238165_US22502615_251209749840_S01_A01.txt.gz///data_row_count: 20173
1
title: Ov_Tumor_Ref_Mix vs. CS-OV-022///geo_accession: GSM1238166///status: Public on Dec 26 2013///submission_date: Sep 23 2013///last_update_date: Dec 26 2013///type: RNA///channel_count: 2///source_name_ch1: 106 pooled ovarian samples///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian///characteristics_ch1.1: sample type: reference pool///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch1: Cy3///label_protocol_ch1: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch1: 9606///source_name_ch2: CS-OV-022///organism_ch2: Homo sapiens///characteristics_ch2: tissue: ovarian///characteristics_ch2.1: sample included in reference pool: YES///characteristics_ch2.2: sample rin: 9.1///characteristics_ch2.3: age at surgery: 65.60///characteristics_ch2.4: histology: Serous///characteristics_ch2.5: Stage: IIIC///characteristics_ch2.6: grade: 3///characteristics_ch2.7: tissue status: Recurrence///characteristics_ch2.8: follow up months: 76///characteristics_ch2.9: disease status: Not Free///characteristics_ch2.10: patient status: Dead///characteristics_ch2.11: disease state: Malignant ovarian///characteristics_ch2.12: ///molecule_ch2: total RNA///extract_protocol_ch2: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch2: Cy5///label_protocol_ch2: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch2: 9606///hyb_protocol: Slides were incubated for 16-17 hr at 60C and washed using the SSPE method described in the Agilent 60-mer Oligo Microarray Processing Protocol, Version 2.1. Slides were treated with Agilent Stabilization and Drying Solution, a wash was used to protect the dyes from ozone degradation.///scan_protocol: Scanned on an Agilent G2565BA scanner.///description: Malignant_ovarian_sample///data_processing: Agilent Feature Extraction Software (v7.5.1) was used for local background subtraction and Linear/LOWESS normalization. RejectMethod=Interquartile Range, nonuniformity outlier flagging enabled, population outlier flag enabled, ratio error model=hybrid, dye normalization select method = Rank Consistency Filter, no spatial detrend method applied.///data_processing.1: Agilent Feature Extraced data was imported into Rosetta Resolver version 7.1.1 (Rosetta Inpharmatics LLC, Cambridge, MA). Multiple probes with the same sequence code were combined into a single value using the Rosetta Resolver error-weighted averaging method for combining repeated measures.///platform_id: GPL7264///contact_name: Judy,,Dering///contact_email: [email protected]///contact_laboratory: Translational Oncology Research///contact_department: Medicine///contact_institute: UCLA School of Medicine///contact_address: 2825 Santa Monica Blvd. Suite 200///contact_city: Santa Monica///contact_state: CA///contact_zip.postal_code: 90404///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM1238nnn/GSM1238166/GSM1238166_US22502615_251209749644_S01_A01.txt.gz///data_row_count: 20173
1
title: Ov_Tumor_Ref_Mix vs. CS-OV-023///geo_accession: GSM1238167///status: Public on Dec 26 2013///submission_date: Sep 23 2013///last_update_date: Dec 26 2013///type: RNA///channel_count: 2///source_name_ch1: 106 pooled ovarian samples///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian///characteristics_ch1.1: sample type: reference pool///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch1: Cy3///label_protocol_ch1: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch1: 9606///source_name_ch2: CS-OV-023///organism_ch2: Homo sapiens///characteristics_ch2: tissue: ovarian///characteristics_ch2.1: sample included in reference pool: YES///characteristics_ch2.2: sample rin: 9.7///characteristics_ch2.3: age at surgery: 45.98///characteristics_ch2.4: histology: Serous///characteristics_ch2.5: Stage: IIIC///characteristics_ch2.6: grade: 3///characteristics_ch2.7: tissue status: Primary///characteristics_ch2.8: follow up months: 57///characteristics_ch2.9: disease status: Not Free///characteristics_ch2.10: patient status: Dead///characteristics_ch2.11: disease state: Malignant ovarian///characteristics_ch2.12: ///molecule_ch2: total RNA///extract_protocol_ch2: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch2: Cy5///label_protocol_ch2: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch2: 9606///hyb_protocol: Slides were incubated for 16-17 hr at 60C and washed using the SSPE method described in the Agilent 60-mer Oligo Microarray Processing Protocol, Version 2.1. Slides were treated with Agilent Stabilization and Drying Solution, a wash was used to protect the dyes from ozone degradation.///scan_protocol: Scanned on an Agilent G2565BA scanner.///description: Malignant_ovarian_sample///data_processing: Agilent Feature Extraction Software (v7.5.1) was used for local background subtraction and Linear/LOWESS normalization. RejectMethod=Interquartile Range, nonuniformity outlier flagging enabled, population outlier flag enabled, ratio error model=hybrid, dye normalization select method = Rank Consistency Filter, no spatial detrend method applied.///data_processing.1: Agilent Feature Extraced data was imported into Rosetta Resolver version 7.1.1 (Rosetta Inpharmatics LLC, Cambridge, MA). Multiple probes with the same sequence code were combined into a single value using the Rosetta Resolver error-weighted averaging method for combining repeated measures.///platform_id: GPL7264///contact_name: Judy,,Dering///contact_email: [email protected]///contact_laboratory: Translational Oncology Research///contact_department: Medicine///contact_institute: UCLA School of Medicine///contact_address: 2825 Santa Monica Blvd. Suite 200///contact_city: Santa Monica///contact_state: CA///contact_zip.postal_code: 90404///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM1238nnn/GSM1238167/GSM1238167_US22502615_251209750936_S02_A01.txt.gz///data_row_count: 20173
1
title: Ov_Tumor_Ref_Mix vs. CS-OV-024///geo_accession: GSM1238168///status: Public on Dec 26 2013///submission_date: Sep 23 2013///last_update_date: Dec 26 2013///type: RNA///channel_count: 2///source_name_ch1: 106 pooled ovarian samples///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian///characteristics_ch1.1: sample type: reference pool///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch1: Cy3///label_protocol_ch1: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch1: 9606///source_name_ch2: CS-OV-024///organism_ch2: Homo sapiens///characteristics_ch2: tissue: ovarian///characteristics_ch2.1: sample included in reference pool: NO///characteristics_ch2.2: sample rin: 8.9///characteristics_ch2.3: age at surgery: 62.98///characteristics_ch2.4: histology: Serous///characteristics_ch2.5: Stage: IIIC///characteristics_ch2.6: grade: 3///characteristics_ch2.7: tissue status: Primary///characteristics_ch2.8: tcga id: TCGA-23-1109///characteristics_ch2.9: follow up months: 51///characteristics_ch2.10: disease status: Not Free///characteristics_ch2.11: patient status: Dead///characteristics_ch2.12: disease state: Malignant ovarian///molecule_ch2: total RNA///extract_protocol_ch2: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch2: Cy5///label_protocol_ch2: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch2: 9606///hyb_protocol: Slides were incubated for 16-17 hr at 60C and washed using the SSPE method described in the Agilent 60-mer Oligo Microarray Processing Protocol, Version 2.1. Slides were treated with Agilent Stabilization and Drying Solution, a wash was used to protect the dyes from ozone degradation.///scan_protocol: Scanned on an Agilent G2565BA scanner.///description: Malignant_ovarian_sample///data_processing: Agilent Feature Extraction Software (v7.5.1) was used for local background subtraction and Linear/LOWESS normalization. RejectMethod=Interquartile Range, nonuniformity outlier flagging enabled, population outlier flag enabled, ratio error model=hybrid, dye normalization select method = Rank Consistency Filter, no spatial detrend method applied.///data_processing.1: Agilent Feature Extraced data was imported into Rosetta Resolver version 7.1.1 (Rosetta Inpharmatics LLC, Cambridge, MA). Multiple probes with the same sequence code were combined into a single value using the Rosetta Resolver error-weighted averaging method for combining repeated measures.///platform_id: GPL7264///contact_name: Judy,,Dering///contact_email: [email protected]///contact_laboratory: Translational Oncology Research///contact_department: Medicine///contact_institute: UCLA School of Medicine///contact_address: 2825 Santa Monica Blvd. Suite 200///contact_city: Santa Monica///contact_state: CA///contact_zip.postal_code: 90404///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM1238nnn/GSM1238168/GSM1238168_US22502615_251209754217_S01_A01.txt.gz///data_row_count: 20173
1
title: Ov_Tumor_Ref_Mix vs. CS-OV-025///geo_accession: GSM1238169///status: Public on Dec 26 2013///submission_date: Sep 23 2013///last_update_date: Dec 26 2013///type: RNA///channel_count: 2///source_name_ch1: 106 pooled ovarian samples///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian///characteristics_ch1.1: sample type: reference pool///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch1: Cy3///label_protocol_ch1: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch1: 9606///source_name_ch2: CS-OV-025///organism_ch2: Homo sapiens///characteristics_ch2: tissue: ovarian///characteristics_ch2.1: sample included in reference pool: YES///characteristics_ch2.2: sample rin: 9.9///characteristics_ch2.3: age at surgery: 52.79///characteristics_ch2.4: histology: Serous///characteristics_ch2.5: Stage: IV///characteristics_ch2.6: grade: 3///characteristics_ch2.7: tissue status: Primary///characteristics_ch2.8: follow up months: 11///characteristics_ch2.9: disease status: Not Free///characteristics_ch2.10: patient status: Dead///characteristics_ch2.11: disease state: Malignant ovarian///characteristics_ch2.12: ///molecule_ch2: total RNA///extract_protocol_ch2: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch2: Cy5///label_protocol_ch2: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch2: 9606///hyb_protocol: Slides were incubated for 16-17 hr at 60C and washed using the SSPE method described in the Agilent 60-mer Oligo Microarray Processing Protocol, Version 2.1. Slides were treated with Agilent Stabilization and Drying Solution, a wash was used to protect the dyes from ozone degradation.///scan_protocol: Scanned on an Agilent G2565BA scanner.///description: Malignant_ovarian_sample///data_processing: Agilent Feature Extraction Software (v7.5.1) was used for local background subtraction and Linear/LOWESS normalization. RejectMethod=Interquartile Range, nonuniformity outlier flagging enabled, population outlier flag enabled, ratio error model=hybrid, dye normalization select method = Rank Consistency Filter, no spatial detrend method applied.///data_processing.1: Agilent Feature Extraced data was imported into Rosetta Resolver version 7.1.1 (Rosetta Inpharmatics LLC, Cambridge, MA). Multiple probes with the same sequence code were combined into a single value using the Rosetta Resolver error-weighted averaging method for combining repeated measures.///platform_id: GPL7264///contact_name: Judy,,Dering///contact_email: [email protected]///contact_laboratory: Translational Oncology Research///contact_department: Medicine///contact_institute: UCLA School of Medicine///contact_address: 2825 Santa Monica Blvd. Suite 200///contact_city: Santa Monica///contact_state: CA///contact_zip.postal_code: 90404///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM1238nnn/GSM1238169/GSM1238169_US22502615_251209750984_S01_A01.txt.gz///data_row_count: 20173
1
title: Ov_Tumor_Ref_Mix vs. CS-OV-026///geo_accession: GSM1238170///status: Public on Dec 26 2013///submission_date: Sep 23 2013///last_update_date: Dec 26 2013///type: RNA///channel_count: 2///source_name_ch1: 106 pooled ovarian samples///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian///characteristics_ch1.1: sample type: reference pool///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch1: Cy3///label_protocol_ch1: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch1: 9606///source_name_ch2: CS-OV-026///organism_ch2: Homo sapiens///characteristics_ch2: tissue: ovarian///characteristics_ch2.1: sample included in reference pool: YES///characteristics_ch2.2: sample rin: 9.5///characteristics_ch2.3: age at surgery: 52.25///characteristics_ch2.4: histology: Normal///characteristics_ch2.5: tissue status: Benign///characteristics_ch2.6: disease status: Benign///characteristics_ch2.7: patient status: Benign///characteristics_ch2.8: disease state: Normal ovarian///characteristics_ch2.9: ///characteristics_ch2.10: ///characteristics_ch2.11: ///characteristics_ch2.12: ///molecule_ch2: total RNA///extract_protocol_ch2: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch2: Cy5///label_protocol_ch2: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch2: 9606///hyb_protocol: Slides were incubated for 16-17 hr at 60C and washed using the SSPE method described in the Agilent 60-mer Oligo Microarray Processing Protocol, Version 2.1. Slides were treated with Agilent Stabilization and Drying Solution, a wash was used to protect the dyes from ozone degradation.///scan_protocol: Scanned on an Agilent G2565BA scanner.///description: Normal_ovarian_sample///data_processing: Agilent Feature Extraction Software (v7.5.1) was used for local background subtraction and Linear/LOWESS normalization. RejectMethod=Interquartile Range, nonuniformity outlier flagging enabled, population outlier flag enabled, ratio error model=hybrid, dye normalization select method = Rank Consistency Filter, no spatial detrend method applied.///data_processing.1: Agilent Feature Extraced data was imported into Rosetta Resolver version 7.1.1 (Rosetta Inpharmatics LLC, Cambridge, MA). Multiple probes with the same sequence code were combined into a single value using the Rosetta Resolver error-weighted averaging method for combining repeated measures.///platform_id: GPL7264///contact_name: Judy,,Dering///contact_email: [email protected]///contact_laboratory: Translational Oncology Research///contact_department: Medicine///contact_institute: UCLA School of Medicine///contact_address: 2825 Santa Monica Blvd. Suite 200///contact_city: Santa Monica///contact_state: CA///contact_zip.postal_code: 90404///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM1238nnn/GSM1238170/GSM1238170_US22502615_251209747043_S01_A01.txt.gz///data_row_count: 20173
1
title: Ov_Tumor_Ref_Mix vs. CS-OV-027///geo_accession: GSM1238171///status: Public on Dec 26 2013///submission_date: Sep 23 2013///last_update_date: Dec 26 2013///type: RNA///channel_count: 2///source_name_ch1: 106 pooled ovarian samples///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian///characteristics_ch1.1: sample type: reference pool///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch1: Cy3///label_protocol_ch1: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch1: 9606///source_name_ch2: CS-OV-027///organism_ch2: Homo sapiens///characteristics_ch2: tissue: ovarian///characteristics_ch2.1: sample included in reference pool: YES///characteristics_ch2.2: sample rin: 9.1///characteristics_ch2.3: age at surgery: 56.86///characteristics_ch2.4: histology: Serous///characteristics_ch2.5: Stage: IV///characteristics_ch2.6: grade: 3///characteristics_ch2.7: tissue status: Primary///characteristics_ch2.8: follow up months: 49///characteristics_ch2.9: disease status: Free///characteristics_ch2.10: patient status: Dead///characteristics_ch2.11: disease state: Malignant ovarian///characteristics_ch2.12: ///molecule_ch2: total RNA///extract_protocol_ch2: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch2: Cy5///label_protocol_ch2: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch2: 9606///hyb_protocol: Slides were incubated for 16-17 hr at 60C and washed using the SSPE method described in the Agilent 60-mer Oligo Microarray Processing Protocol, Version 2.1. Slides were treated with Agilent Stabilization and Drying Solution, a wash was used to protect the dyes from ozone degradation.///scan_protocol: Scanned on an Agilent G2565BA scanner.///description: Malignant_ovarian_sample///data_processing: Agilent Feature Extraction Software (v7.5.1) was used for local background subtraction and Linear/LOWESS normalization. RejectMethod=Interquartile Range, nonuniformity outlier flagging enabled, population outlier flag enabled, ratio error model=hybrid, dye normalization select method = Rank Consistency Filter, no spatial detrend method applied.///data_processing.1: Agilent Feature Extraced data was imported into Rosetta Resolver version 7.1.1 (Rosetta Inpharmatics LLC, Cambridge, MA). Multiple probes with the same sequence code were combined into a single value using the Rosetta Resolver error-weighted averaging method for combining repeated measures.///platform_id: GPL7264///contact_name: Judy,,Dering///contact_email: [email protected]///contact_laboratory: Translational Oncology Research///contact_department: Medicine///contact_institute: UCLA School of Medicine///contact_address: 2825 Santa Monica Blvd. Suite 200///contact_city: Santa Monica///contact_state: CA///contact_zip.postal_code: 90404///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM1238nnn/GSM1238171/GSM1238171_US22502615_251209749047_S01_A01.txt.gz///data_row_count: 20173
1
title: Ov_Tumor_Ref_Mix vs. CS-OV-028///geo_accession: GSM1238172///status: Public on Dec 26 2013///submission_date: Sep 23 2013///last_update_date: Dec 26 2013///type: RNA///channel_count: 2///source_name_ch1: 106 pooled ovarian samples///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian///characteristics_ch1.1: sample type: reference pool///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch1: Cy3///label_protocol_ch1: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch1: 9606///source_name_ch2: CS-OV-028///organism_ch2: Homo sapiens///characteristics_ch2: tissue: ovarian///characteristics_ch2.1: sample included in reference pool: NO///characteristics_ch2.2: sample rin: 8.9///characteristics_ch2.3: age at surgery: 26.44///characteristics_ch2.4: histology: Serous///characteristics_ch2.5: Stage: IIIC///characteristics_ch2.6: grade: 0///characteristics_ch2.7: tissue status: Primary///characteristics_ch2.8: follow up months: 59///characteristics_ch2.9: disease status: Not Free///characteristics_ch2.10: patient status: Dead///characteristics_ch2.11: disease state: Borderline ovarian///characteristics_ch2.12: ///molecule_ch2: total RNA///extract_protocol_ch2: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch2: Cy5///label_protocol_ch2: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch2: 9606///hyb_protocol: Slides were incubated for 16-17 hr at 60C and washed using the SSPE method described in the Agilent 60-mer Oligo Microarray Processing Protocol, Version 2.1. Slides were treated with Agilent Stabilization and Drying Solution, a wash was used to protect the dyes from ozone degradation.///scan_protocol: Scanned on an Agilent G2565BA scanner.///description: Borderline_ovarian_sample///data_processing: Agilent Feature Extraction Software (v7.5.1) was used for local background subtraction and Linear/LOWESS normalization. RejectMethod=Interquartile Range, nonuniformity outlier flagging enabled, population outlier flag enabled, ratio error model=hybrid, dye normalization select method = Rank Consistency Filter, no spatial detrend method applied.///data_processing.1: Agilent Feature Extraced data was imported into Rosetta Resolver version 7.1.1 (Rosetta Inpharmatics LLC, Cambridge, MA). Multiple probes with the same sequence code were combined into a single value using the Rosetta Resolver error-weighted averaging method for combining repeated measures.///platform_id: GPL7264///contact_name: Judy,,Dering///contact_email: [email protected]///contact_laboratory: Translational Oncology Research///contact_department: Medicine///contact_institute: UCLA School of Medicine///contact_address: 2825 Santa Monica Blvd. Suite 200///contact_city: Santa Monica///contact_state: CA///contact_zip.postal_code: 90404///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM1238nnn/GSM1238172/GSM1238172_US22502615_251209749774_S01_A01.txt.gz///data_row_count: 20173
1
title: Ov_Tumor_Ref_Mix vs. CS-OV-029///geo_accession: GSM1238173///status: Public on Dec 26 2013///submission_date: Sep 23 2013///last_update_date: Dec 26 2013///type: RNA///channel_count: 2///source_name_ch1: 106 pooled ovarian samples///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian///characteristics_ch1.1: sample type: reference pool///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch1: Cy3///label_protocol_ch1: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch1: 9606///source_name_ch2: CS-OV-029///organism_ch2: Homo sapiens///characteristics_ch2: tissue: ovarian///characteristics_ch2.1: sample included in reference pool: YES///characteristics_ch2.2: sample rin: 9.3///characteristics_ch2.3: age at surgery: 55.66///characteristics_ch2.4: histology: Serous///characteristics_ch2.5: Stage: IIIC///characteristics_ch2.6: grade: 3///characteristics_ch2.7: tissue status: Primary///characteristics_ch2.8: follow up months: 18///characteristics_ch2.9: disease status: Not Free///characteristics_ch2.10: patient status: Dead///characteristics_ch2.11: disease state: Malignant ovarian///characteristics_ch2.12: ///molecule_ch2: total RNA///extract_protocol_ch2: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch2: Cy5///label_protocol_ch2: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch2: 9606///hyb_protocol: Slides were incubated for 16-17 hr at 60C and washed using the SSPE method described in the Agilent 60-mer Oligo Microarray Processing Protocol, Version 2.1. Slides were treated with Agilent Stabilization and Drying Solution, a wash was used to protect the dyes from ozone degradation.///scan_protocol: Scanned on an Agilent G2565BA scanner.///description: Malignant_ovarian_sample///data_processing: Agilent Feature Extraction Software (v7.5.1) was used for local background subtraction and Linear/LOWESS normalization. RejectMethod=Interquartile Range, nonuniformity outlier flagging enabled, population outlier flag enabled, ratio error model=hybrid, dye normalization select method = Rank Consistency Filter, no spatial detrend method applied.///data_processing.1: Agilent Feature Extraced data was imported into Rosetta Resolver version 7.1.1 (Rosetta Inpharmatics LLC, Cambridge, MA). Multiple probes with the same sequence code were combined into a single value using the Rosetta Resolver error-weighted averaging method for combining repeated measures.///platform_id: GPL7264///contact_name: Judy,,Dering///contact_email: [email protected]///contact_laboratory: Translational Oncology Research///contact_department: Medicine///contact_institute: UCLA School of Medicine///contact_address: 2825 Santa Monica Blvd. Suite 200///contact_city: Santa Monica///contact_state: CA///contact_zip.postal_code: 90404///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM1238nnn/GSM1238173/GSM1238173_US22502615_251209750969_S01_A01.txt.gz///data_row_count: 20173
1
title: Ov_Tumor_Ref_Mix vs. CS-OV-030///geo_accession: GSM1238174///status: Public on Dec 26 2013///submission_date: Sep 23 2013///last_update_date: Dec 26 2013///type: RNA///channel_count: 2///source_name_ch1: 106 pooled ovarian samples///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian///characteristics_ch1.1: sample type: reference pool///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch1: Cy3///label_protocol_ch1: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch1: 9606///source_name_ch2: CS-OV-030///organism_ch2: Homo sapiens///characteristics_ch2: tissue: ovarian///characteristics_ch2.1: sample included in reference pool: NO///characteristics_ch2.2: sample rin: 9.7///characteristics_ch2.3: age at surgery: 60.03///characteristics_ch2.4: histology: Serous///characteristics_ch2.5: Stage: IIIC///characteristics_ch2.6: grade: 2///characteristics_ch2.7: tissue status: Primary///characteristics_ch2.8: follow up months: 11///characteristics_ch2.9: disease status: Not Free///characteristics_ch2.10: patient status: Dead///characteristics_ch2.11: disease state: Malignant ovarian///characteristics_ch2.12: ///molecule_ch2: total RNA///extract_protocol_ch2: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch2: Cy5///label_protocol_ch2: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch2: 9606///hyb_protocol: Slides were incubated for 16-17 hr at 60C and washed using the SSPE method described in the Agilent 60-mer Oligo Microarray Processing Protocol, Version 2.1. Slides were treated with Agilent Stabilization and Drying Solution, a wash was used to protect the dyes from ozone degradation.///scan_protocol: Scanned on an Agilent G2565BA scanner.///description: Malignant_ovarian_sample///data_processing: Agilent Feature Extraction Software (v7.5.1) was used for local background subtraction and Linear/LOWESS normalization. RejectMethod=Interquartile Range, nonuniformity outlier flagging enabled, population outlier flag enabled, ratio error model=hybrid, dye normalization select method = Rank Consistency Filter, no spatial detrend method applied.///data_processing.1: Agilent Feature Extraced data was imported into Rosetta Resolver version 7.1.1 (Rosetta Inpharmatics LLC, Cambridge, MA). Multiple probes with the same sequence code were combined into a single value using the Rosetta Resolver error-weighted averaging method for combining repeated measures.///platform_id: GPL7264///contact_name: Judy,,Dering///contact_email: [email protected]///contact_laboratory: Translational Oncology Research///contact_department: Medicine///contact_institute: UCLA School of Medicine///contact_address: 2825 Santa Monica Blvd. Suite 200///contact_city: Santa Monica///contact_state: CA///contact_zip.postal_code: 90404///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM1238nnn/GSM1238174/GSM1238174_US22502615_251209754146_S01_A01.txt.gz///data_row_count: 20173
1
title: Ov_Tumor_Ref_Mix vs. CS-OV-031///geo_accession: GSM1238175///status: Public on Dec 26 2013///submission_date: Sep 23 2013///last_update_date: Dec 26 2013///type: RNA///channel_count: 2///source_name_ch1: 106 pooled ovarian samples///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian///characteristics_ch1.1: sample type: reference pool///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch1: Cy3///label_protocol_ch1: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch1: 9606///source_name_ch2: CS-OV-031///organism_ch2: Homo sapiens///characteristics_ch2: tissue: ovarian///characteristics_ch2.1: sample included in reference pool: YES///characteristics_ch2.2: age at surgery: 45.32///characteristics_ch2.3: histology: Serous///characteristics_ch2.4: Stage: IV///characteristics_ch2.5: grade: 3///characteristics_ch2.6: tissue status: Primary///characteristics_ch2.7: tcga id: TCGA-23-2077///characteristics_ch2.8: follow up months: 120///characteristics_ch2.9: disease status: Free///characteristics_ch2.10: patient status: Alive///characteristics_ch2.11: disease state: Malignant ovarian///characteristics_ch2.12: ///molecule_ch2: total RNA///extract_protocol_ch2: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch2: Cy5///label_protocol_ch2: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch2: 9606///hyb_protocol: Slides were incubated for 16-17 hr at 60C and washed using the SSPE method described in the Agilent 60-mer Oligo Microarray Processing Protocol, Version 2.1. Slides were treated with Agilent Stabilization and Drying Solution, a wash was used to protect the dyes from ozone degradation.///scan_protocol: Scanned on an Agilent G2565BA scanner.///description: Malignant_ovarian_sample///data_processing: Agilent Feature Extraction Software (v7.5.1) was used for local background subtraction and Linear/LOWESS normalization. RejectMethod=Interquartile Range, nonuniformity outlier flagging enabled, population outlier flag enabled, ratio error model=hybrid, dye normalization select method = Rank Consistency Filter, no spatial detrend method applied.///data_processing.1: Agilent Feature Extraced data was imported into Rosetta Resolver version 7.1.1 (Rosetta Inpharmatics LLC, Cambridge, MA). Multiple probes with the same sequence code were combined into a single value using the Rosetta Resolver error-weighted averaging method for combining repeated measures.///platform_id: GPL7264///contact_name: Judy,,Dering///contact_email: [email protected]///contact_laboratory: Translational Oncology Research///contact_department: Medicine///contact_institute: UCLA School of Medicine///contact_address: 2825 Santa Monica Blvd. Suite 200///contact_city: Santa Monica///contact_state: CA///contact_zip.postal_code: 90404///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM1238nnn/GSM1238175/GSM1238175_US22502615_251209750933_S01_A01.txt.gz///data_row_count: 20173
1
title: Ov_Tumor_Ref_Mix vs. CS-OV-032///geo_accession: GSM1238176///status: Public on Dec 26 2013///submission_date: Sep 23 2013///last_update_date: Dec 26 2013///type: RNA///channel_count: 2///source_name_ch1: 106 pooled ovarian samples///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian///characteristics_ch1.1: sample type: reference pool///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch1: Cy3///label_protocol_ch1: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch1: 9606///source_name_ch2: CS-OV-032///organism_ch2: Homo sapiens///characteristics_ch2: tissue: ovarian///characteristics_ch2.1: sample included in reference pool: NO///characteristics_ch2.2: sample rin: 9.4///characteristics_ch2.3: age at surgery: 60.71///characteristics_ch2.4: histology: Serous///characteristics_ch2.5: Stage: IIIC///characteristics_ch2.6: grade: 3///characteristics_ch2.7: tissue status: Primary///characteristics_ch2.8: follow up months: 49///characteristics_ch2.9: disease status: Free///characteristics_ch2.10: patient status: Alive///characteristics_ch2.11: disease state: Malignant ovarian///characteristics_ch2.12: ///molecule_ch2: total RNA///extract_protocol_ch2: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch2: Cy5///label_protocol_ch2: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch2: 9606///hyb_protocol: Slides were incubated for 16-17 hr at 60C and washed using the SSPE method described in the Agilent 60-mer Oligo Microarray Processing Protocol, Version 2.1. Slides were treated with Agilent Stabilization and Drying Solution, a wash was used to protect the dyes from ozone degradation.///scan_protocol: Scanned on an Agilent G2565BA scanner.///description: Malignant_ovarian_sample///data_processing: Agilent Feature Extraction Software (v7.5.1) was used for local background subtraction and Linear/LOWESS normalization. RejectMethod=Interquartile Range, nonuniformity outlier flagging enabled, population outlier flag enabled, ratio error model=hybrid, dye normalization select method = Rank Consistency Filter, no spatial detrend method applied.///data_processing.1: Agilent Feature Extraced data was imported into Rosetta Resolver version 7.1.1 (Rosetta Inpharmatics LLC, Cambridge, MA). Multiple probes with the same sequence code were combined into a single value using the Rosetta Resolver error-weighted averaging method for combining repeated measures.///platform_id: GPL7264///contact_name: Judy,,Dering///contact_email: [email protected]///contact_laboratory: Translational Oncology Research///contact_department: Medicine///contact_institute: UCLA School of Medicine///contact_address: 2825 Santa Monica Blvd. Suite 200///contact_city: Santa Monica///contact_state: CA///contact_zip.postal_code: 90404///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM1238nnn/GSM1238176/GSM1238176_US22502615_251209754797_S01_A01.txt.gz///data_row_count: 20173
1
title: Ov_Tumor_Ref_Mix vs. CS-OV-033///geo_accession: GSM1238177///status: Public on Dec 26 2013///submission_date: Sep 23 2013///last_update_date: Dec 26 2013///type: RNA///channel_count: 2///source_name_ch1: 106 pooled ovarian samples///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian///characteristics_ch1.1: sample type: reference pool///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch1: Cy3///label_protocol_ch1: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch1: 9606///source_name_ch2: CS-OV-033///organism_ch2: Homo sapiens///characteristics_ch2: tissue: ovarian///characteristics_ch2.1: sample included in reference pool: NO///characteristics_ch2.2: sample rin: 9.2///characteristics_ch2.3: age at surgery: 55.26///characteristics_ch2.4: histology: Normal///characteristics_ch2.5: tissue status: Benign///characteristics_ch2.6: disease status: Benign///characteristics_ch2.7: patient status: Benign///characteristics_ch2.8: disease state: Normal ovarian///characteristics_ch2.9: ///characteristics_ch2.10: ///characteristics_ch2.11: ///characteristics_ch2.12: ///molecule_ch2: total RNA///extract_protocol_ch2: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch2: Cy5///label_protocol_ch2: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch2: 9606///hyb_protocol: Slides were incubated for 16-17 hr at 60C and washed using the SSPE method described in the Agilent 60-mer Oligo Microarray Processing Protocol, Version 2.1. Slides were treated with Agilent Stabilization and Drying Solution, a wash was used to protect the dyes from ozone degradation.///scan_protocol: Scanned on an Agilent G2565BA scanner.///description: Normal_ovarian_sample///data_processing: Agilent Feature Extraction Software (v7.5.1) was used for local background subtraction and Linear/LOWESS normalization. RejectMethod=Interquartile Range, nonuniformity outlier flagging enabled, population outlier flag enabled, ratio error model=hybrid, dye normalization select method = Rank Consistency Filter, no spatial detrend method applied.///data_processing.1: Agilent Feature Extraced data was imported into Rosetta Resolver version 7.1.1 (Rosetta Inpharmatics LLC, Cambridge, MA). Multiple probes with the same sequence code were combined into a single value using the Rosetta Resolver error-weighted averaging method for combining repeated measures.///platform_id: GPL7264///contact_name: Judy,,Dering///contact_email: [email protected]///contact_laboratory: Translational Oncology Research///contact_department: Medicine///contact_institute: UCLA School of Medicine///contact_address: 2825 Santa Monica Blvd. Suite 200///contact_city: Santa Monica///contact_state: CA///contact_zip.postal_code: 90404///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM1238nnn/GSM1238177/GSM1238177_US22502615_251209749469_S01_A01.txt.gz///data_row_count: 20173
1
title: Ov_Tumor_Ref_Mix vs. CS-OV-034///geo_accession: GSM1238178///status: Public on Dec 26 2013///submission_date: Sep 23 2013///last_update_date: Dec 26 2013///type: RNA///channel_count: 2///source_name_ch1: 106 pooled ovarian samples///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian///characteristics_ch1.1: sample type: reference pool///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch1: Cy3///label_protocol_ch1: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch1: 9606///source_name_ch2: CS-OV-034///organism_ch2: Homo sapiens///characteristics_ch2: tissue: ovarian///characteristics_ch2.1: sample included in reference pool: NO///characteristics_ch2.2: sample rin: 9.6///characteristics_ch2.3: age at surgery: 34.28///characteristics_ch2.4: histology: Mucinous///characteristics_ch2.5: Stage: IA///characteristics_ch2.6: grade: 2///characteristics_ch2.7: tissue status: Primary///characteristics_ch2.8: follow up months: 210///characteristics_ch2.9: disease status: Free///characteristics_ch2.10: patient status: Alive///characteristics_ch2.11: disease state: Malignant ovarian///characteristics_ch2.12: ///molecule_ch2: total RNA///extract_protocol_ch2: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch2: Cy5///label_protocol_ch2: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch2: 9606///hyb_protocol: Slides were incubated for 16-17 hr at 60C and washed using the SSPE method described in the Agilent 60-mer Oligo Microarray Processing Protocol, Version 2.1. Slides were treated with Agilent Stabilization and Drying Solution, a wash was used to protect the dyes from ozone degradation.///scan_protocol: Scanned on an Agilent G2565BA scanner.///description: Malignant_ovarian_sample///data_processing: Agilent Feature Extraction Software (v7.5.1) was used for local background subtraction and Linear/LOWESS normalization. RejectMethod=Interquartile Range, nonuniformity outlier flagging enabled, population outlier flag enabled, ratio error model=hybrid, dye normalization select method = Rank Consistency Filter, no spatial detrend method applied.///data_processing.1: Agilent Feature Extraced data was imported into Rosetta Resolver version 7.1.1 (Rosetta Inpharmatics LLC, Cambridge, MA). Multiple probes with the same sequence code were combined into a single value using the Rosetta Resolver error-weighted averaging method for combining repeated measures.///platform_id: GPL7264///contact_name: Judy,,Dering///contact_email: [email protected]///contact_laboratory: Translational Oncology Research///contact_department: Medicine///contact_institute: UCLA School of Medicine///contact_address: 2825 Santa Monica Blvd. Suite 200///contact_city: Santa Monica///contact_state: CA///contact_zip.postal_code: 90404///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM1238nnn/GSM1238178/GSM1238178_US22502615_251209754210_S01_A01.txt.gz///data_row_count: 20173
1
title: Ov_Tumor_Ref_Mix vs. CS-OV-035///geo_accession: GSM1238179///status: Public on Dec 26 2013///submission_date: Sep 23 2013///last_update_date: Dec 26 2013///type: RNA///channel_count: 2///source_name_ch1: 106 pooled ovarian samples///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian///characteristics_ch1.1: sample type: reference pool///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch1: Cy3///label_protocol_ch1: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch1: 9606///source_name_ch2: CS-OV-035///organism_ch2: Homo sapiens///characteristics_ch2: tissue: ovarian///characteristics_ch2.1: sample included in reference pool: YES///characteristics_ch2.2: sample rin: 9.3///characteristics_ch2.3: age at surgery: 74.26///characteristics_ch2.4: histology: Serous///characteristics_ch2.5: Stage: IIIA///characteristics_ch2.6: grade: 3///characteristics_ch2.7: tissue status: Primary///characteristics_ch2.8: follow up months: 37///characteristics_ch2.9: disease status: Not Free///characteristics_ch2.10: patient status: Dead///characteristics_ch2.11: disease state: Malignant ovarian///characteristics_ch2.12: ///molecule_ch2: total RNA///extract_protocol_ch2: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch2: Cy5///label_protocol_ch2: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch2: 9606///hyb_protocol: Slides were incubated for 16-17 hr at 60C and washed using the SSPE method described in the Agilent 60-mer Oligo Microarray Processing Protocol, Version 2.1. Slides were treated with Agilent Stabilization and Drying Solution, a wash was used to protect the dyes from ozone degradation.///scan_protocol: Scanned on an Agilent G2565BA scanner.///description: Malignant_ovarian_sample///data_processing: Agilent Feature Extraction Software (v7.5.1) was used for local background subtraction and Linear/LOWESS normalization. RejectMethod=Interquartile Range, nonuniformity outlier flagging enabled, population outlier flag enabled, ratio error model=hybrid, dye normalization select method = Rank Consistency Filter, no spatial detrend method applied.///data_processing.1: Agilent Feature Extraced data was imported into Rosetta Resolver version 7.1.1 (Rosetta Inpharmatics LLC, Cambridge, MA). Multiple probes with the same sequence code were combined into a single value using the Rosetta Resolver error-weighted averaging method for combining repeated measures.///platform_id: GPL7264///contact_name: Judy,,Dering///contact_email: [email protected]///contact_laboratory: Translational Oncology Research///contact_department: Medicine///contact_institute: UCLA School of Medicine///contact_address: 2825 Santa Monica Blvd. Suite 200///contact_city: Santa Monica///contact_state: CA///contact_zip.postal_code: 90404///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM1238nnn/GSM1238179/GSM1238179_US22502615_251209747091_S01_A01.txt.gz///data_row_count: 20173
1
title: Ov_Tumor_Ref_Mix vs. CS-OV-036///geo_accession: GSM1238180///status: Public on Dec 26 2013///submission_date: Sep 23 2013///last_update_date: Dec 26 2013///type: RNA///channel_count: 2///source_name_ch1: 106 pooled ovarian samples///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian///characteristics_ch1.1: sample type: reference pool///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch1: Cy3///label_protocol_ch1: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch1: 9606///source_name_ch2: CS-OV-036///organism_ch2: Homo sapiens///characteristics_ch2: tissue: ovarian///characteristics_ch2.1: sample included in reference pool: YES///characteristics_ch2.2: sample rin: 9.3///characteristics_ch2.3: age at surgery: 47.47///characteristics_ch2.4: histology: Mucinous///characteristics_ch2.5: Stage: IC///characteristics_ch2.6: grade: 3///characteristics_ch2.7: tissue status: Primary///characteristics_ch2.8: follow up months: 176///characteristics_ch2.9: disease status: Free///characteristics_ch2.10: patient status: Alive///characteristics_ch2.11: disease state: Malignant ovarian///characteristics_ch2.12: ///molecule_ch2: total RNA///extract_protocol_ch2: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch2: Cy5///label_protocol_ch2: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch2: 9606///hyb_protocol: Slides were incubated for 16-17 hr at 60C and washed using the SSPE method described in the Agilent 60-mer Oligo Microarray Processing Protocol, Version 2.1. Slides were treated with Agilent Stabilization and Drying Solution, a wash was used to protect the dyes from ozone degradation.///scan_protocol: Scanned on an Agilent G2565BA scanner.///description: Malignant_ovarian_sample///data_processing: Agilent Feature Extraction Software (v7.5.1) was used for local background subtraction and Linear/LOWESS normalization. RejectMethod=Interquartile Range, nonuniformity outlier flagging enabled, population outlier flag enabled, ratio error model=hybrid, dye normalization select method = Rank Consistency Filter, no spatial detrend method applied.///data_processing.1: Agilent Feature Extraced data was imported into Rosetta Resolver version 7.1.1 (Rosetta Inpharmatics LLC, Cambridge, MA). Multiple probes with the same sequence code were combined into a single value using the Rosetta Resolver error-weighted averaging method for combining repeated measures.///platform_id: GPL7264///contact_name: Judy,,Dering///contact_email: [email protected]///contact_laboratory: Translational Oncology Research///contact_department: Medicine///contact_institute: UCLA School of Medicine///contact_address: 2825 Santa Monica Blvd. Suite 200///contact_city: Santa Monica///contact_state: CA///contact_zip.postal_code: 90404///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM1238nnn/GSM1238180/GSM1238180_US22502615_251209749642_S01_A01.txt.gz///data_row_count: 20173
1
title: Ov_Tumor_Ref_Mix vs. CS-OV-037///geo_accession: GSM1238181///status: Public on Dec 26 2013///submission_date: Sep 23 2013///last_update_date: Dec 26 2013///type: RNA///channel_count: 2///source_name_ch1: 106 pooled ovarian samples///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian///characteristics_ch1.1: sample type: reference pool///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch1: Cy3///label_protocol_ch1: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch1: 9606///source_name_ch2: CS-OV-037///organism_ch2: Homo sapiens///characteristics_ch2: tissue: ovarian///characteristics_ch2.1: sample included in reference pool: NO///characteristics_ch2.2: sample rin: 8.6///characteristics_ch2.3: age at surgery: 78.02///characteristics_ch2.4: histology: Serous///characteristics_ch2.5: Stage: IIIC///characteristics_ch2.6: grade: 3///characteristics_ch2.7: tissue status: Recurrence///characteristics_ch2.8: follow up months: 39///characteristics_ch2.9: disease status: Not Free///characteristics_ch2.10: patient status: Dead///characteristics_ch2.11: disease state: Malignant ovarian///characteristics_ch2.12: ///molecule_ch2: total RNA///extract_protocol_ch2: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch2: Cy5///label_protocol_ch2: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch2: 9606///hyb_protocol: Slides were incubated for 16-17 hr at 60C and washed using the SSPE method described in the Agilent 60-mer Oligo Microarray Processing Protocol, Version 2.1. Slides were treated with Agilent Stabilization and Drying Solution, a wash was used to protect the dyes from ozone degradation.///scan_protocol: Scanned on an Agilent G2565BA scanner.///description: Malignant_ovarian_sample///data_processing: Agilent Feature Extraction Software (v7.5.1) was used for local background subtraction and Linear/LOWESS normalization. RejectMethod=Interquartile Range, nonuniformity outlier flagging enabled, population outlier flag enabled, ratio error model=hybrid, dye normalization select method = Rank Consistency Filter, no spatial detrend method applied.///data_processing.1: Agilent Feature Extraced data was imported into Rosetta Resolver version 7.1.1 (Rosetta Inpharmatics LLC, Cambridge, MA). Multiple probes with the same sequence code were combined into a single value using the Rosetta Resolver error-weighted averaging method for combining repeated measures.///platform_id: GPL7264///contact_name: Judy,,Dering///contact_email: [email protected]///contact_laboratory: Translational Oncology Research///contact_department: Medicine///contact_institute: UCLA School of Medicine///contact_address: 2825 Santa Monica Blvd. Suite 200///contact_city: Santa Monica///contact_state: CA///contact_zip.postal_code: 90404///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM1238nnn/GSM1238181/GSM1238181_US22502615_251209754165_S01_A01.txt.gz///data_row_count: 20173
1
title: Ov_Tumor_Ref_Mix vs. CS-OV-038///geo_accession: GSM1238182///status: Public on Dec 26 2013///submission_date: Sep 23 2013///last_update_date: Dec 26 2013///type: RNA///channel_count: 2///source_name_ch1: 106 pooled ovarian samples///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian///characteristics_ch1.1: sample type: reference pool///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch1: Cy3///label_protocol_ch1: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch1: 9606///source_name_ch2: CS-OV-038///organism_ch2: Homo sapiens///characteristics_ch2: tissue: ovarian///characteristics_ch2.1: sample included in reference pool: NO///characteristics_ch2.2: sample rin: 8.9///characteristics_ch2.3: age at surgery: 80.72///characteristics_ch2.4: histology: Serous///characteristics_ch2.5: Stage: IIIC///characteristics_ch2.6: grade: 3///characteristics_ch2.7: tissue status: Primary///characteristics_ch2.8: follow up months: 17///characteristics_ch2.9: disease status: Not Free///characteristics_ch2.10: patient status: Dead///characteristics_ch2.11: disease state: Malignant ovarian///characteristics_ch2.12: ///molecule_ch2: total RNA///extract_protocol_ch2: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch2: Cy5///label_protocol_ch2: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch2: 9606///hyb_protocol: Slides were incubated for 16-17 hr at 60C and washed using the SSPE method described in the Agilent 60-mer Oligo Microarray Processing Protocol, Version 2.1. Slides were treated with Agilent Stabilization and Drying Solution, a wash was used to protect the dyes from ozone degradation.///scan_protocol: Scanned on an Agilent G2565BA scanner.///description: Malignant_ovarian_sample///data_processing: Agilent Feature Extraction Software (v7.5.1) was used for local background subtraction and Linear/LOWESS normalization. RejectMethod=Interquartile Range, nonuniformity outlier flagging enabled, population outlier flag enabled, ratio error model=hybrid, dye normalization select method = Rank Consistency Filter, no spatial detrend method applied.///data_processing.1: Agilent Feature Extraced data was imported into Rosetta Resolver version 7.1.1 (Rosetta Inpharmatics LLC, Cambridge, MA). Multiple probes with the same sequence code were combined into a single value using the Rosetta Resolver error-weighted averaging method for combining repeated measures.///platform_id: GPL7264///contact_name: Judy,,Dering///contact_email: [email protected]///contact_laboratory: Translational Oncology Research///contact_department: Medicine///contact_institute: UCLA School of Medicine///contact_address: 2825 Santa Monica Blvd. Suite 200///contact_city: Santa Monica///contact_state: CA///contact_zip.postal_code: 90404///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM1238nnn/GSM1238182/GSM1238182_US22502615_251209754214_S01_A01.txt.gz///data_row_count: 20173
1
title: Ov_Tumor_Ref_Mix vs. CS-OV-039///geo_accession: GSM1238183///status: Public on Dec 26 2013///submission_date: Sep 23 2013///last_update_date: Dec 26 2013///type: RNA///channel_count: 2///source_name_ch1: 106 pooled ovarian samples///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian///characteristics_ch1.1: sample type: reference pool///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch1: Cy3///label_protocol_ch1: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch1: 9606///source_name_ch2: CS-OV-039///organism_ch2: Homo sapiens///characteristics_ch2: tissue: ovarian///characteristics_ch2.1: sample included in reference pool: NO///characteristics_ch2.2: sample rin: 8///characteristics_ch2.3: age at surgery: 52.40///characteristics_ch2.4: histology: Endometrioid///characteristics_ch2.5: Stage: IC///characteristics_ch2.6: grade: 2///characteristics_ch2.7: tissue status: Primary///characteristics_ch2.8: follow up months: 209///characteristics_ch2.9: disease status: Free///characteristics_ch2.10: patient status: Alive///characteristics_ch2.11: disease state: Malignant ovarian///characteristics_ch2.12: ///molecule_ch2: total RNA///extract_protocol_ch2: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch2: Cy5///label_protocol_ch2: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch2: 9606///hyb_protocol: Slides were incubated for 16-17 hr at 60C and washed using the SSPE method described in the Agilent 60-mer Oligo Microarray Processing Protocol, Version 2.1. Slides were treated with Agilent Stabilization and Drying Solution, a wash was used to protect the dyes from ozone degradation.///scan_protocol: Scanned on an Agilent G2565BA scanner.///description: Malignant_ovarian_sample///data_processing: Agilent Feature Extraction Software (v7.5.1) was used for local background subtraction and Linear/LOWESS normalization. RejectMethod=Interquartile Range, nonuniformity outlier flagging enabled, population outlier flag enabled, ratio error model=hybrid, dye normalization select method = Rank Consistency Filter, no spatial detrend method applied.///data_processing.1: Agilent Feature Extraced data was imported into Rosetta Resolver version 7.1.1 (Rosetta Inpharmatics LLC, Cambridge, MA). Multiple probes with the same sequence code were combined into a single value using the Rosetta Resolver error-weighted averaging method for combining repeated measures.///platform_id: GPL7264///contact_name: Judy,,Dering///contact_email: [email protected]///contact_laboratory: Translational Oncology Research///contact_department: Medicine///contact_institute: UCLA School of Medicine///contact_address: 2825 Santa Monica Blvd. Suite 200///contact_city: Santa Monica///contact_state: CA///contact_zip.postal_code: 90404///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM1238nnn/GSM1238183/GSM1238183_US22502615_251209754164_S01_A01.txt.gz///data_row_count: 20173
1
title: Ov_Tumor_Ref_Mix vs. CS-OV-040///geo_accession: GSM1238184///status: Public on Dec 26 2013///submission_date: Sep 23 2013///last_update_date: Dec 26 2013///type: RNA///channel_count: 2///source_name_ch1: 106 pooled ovarian samples///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian///characteristics_ch1.1: sample type: reference pool///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch1: Cy3///label_protocol_ch1: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch1: 9606///source_name_ch2: CS-OV-040///organism_ch2: Homo sapiens///characteristics_ch2: tissue: ovarian///characteristics_ch2.1: sample included in reference pool: YES///characteristics_ch2.2: sample rin: 9.5///characteristics_ch2.3: age at surgery: 61.69///characteristics_ch2.4: histology: Serous///characteristics_ch2.5: Stage: IIIB///characteristics_ch2.6: grade: 3///characteristics_ch2.7: tissue status: Primary///characteristics_ch2.8: follow up months: 31///characteristics_ch2.9: disease status: Not Free///characteristics_ch2.10: patient status: Dead///characteristics_ch2.11: disease state: Malignant ovarian///characteristics_ch2.12: ///molecule_ch2: total RNA///extract_protocol_ch2: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch2: Cy5///label_protocol_ch2: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch2: 9606///hyb_protocol: Slides were incubated for 16-17 hr at 60C and washed using the SSPE method described in the Agilent 60-mer Oligo Microarray Processing Protocol, Version 2.1. Slides were treated with Agilent Stabilization and Drying Solution, a wash was used to protect the dyes from ozone degradation.///scan_protocol: Scanned on an Agilent G2565BA scanner.///description: Malignant_ovarian_sample///data_processing: Agilent Feature Extraction Software (v7.5.1) was used for local background subtraction and Linear/LOWESS normalization. RejectMethod=Interquartile Range, nonuniformity outlier flagging enabled, population outlier flag enabled, ratio error model=hybrid, dye normalization select method = Rank Consistency Filter, no spatial detrend method applied.///data_processing.1: Agilent Feature Extraced data was imported into Rosetta Resolver version 7.1.1 (Rosetta Inpharmatics LLC, Cambridge, MA). Multiple probes with the same sequence code were combined into a single value using the Rosetta Resolver error-weighted averaging method for combining repeated measures.///platform_id: GPL7264///contact_name: Judy,,Dering///contact_email: [email protected]///contact_laboratory: Translational Oncology Research///contact_department: Medicine///contact_institute: UCLA School of Medicine///contact_address: 2825 Santa Monica Blvd. Suite 200///contact_city: Santa Monica///contact_state: CA///contact_zip.postal_code: 90404///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM1238nnn/GSM1238184/GSM1238184_US22502615_251209750938_S02_A01.txt.gz///data_row_count: 20173
1
title: Ov_Tumor_Ref_Mix vs. CS-OV-041///geo_accession: GSM1238185///status: Public on Dec 26 2013///submission_date: Sep 23 2013///last_update_date: Dec 26 2013///type: RNA///channel_count: 2///source_name_ch1: 106 pooled ovarian samples///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian///characteristics_ch1.1: sample type: reference pool///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch1: Cy3///label_protocol_ch1: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch1: 9606///source_name_ch2: CS-OV-041///organism_ch2: Homo sapiens///characteristics_ch2: tissue: ovarian///characteristics_ch2.1: sample included in reference pool: NO///characteristics_ch2.2: sample rin: 8.3///characteristics_ch2.3: age at surgery: 73.50///characteristics_ch2.4: histology: Normal///characteristics_ch2.5: tissue status: Benign///characteristics_ch2.6: disease status: Benign///characteristics_ch2.7: patient status: Benign///characteristics_ch2.8: disease state: Normal ovarian///characteristics_ch2.9: ///characteristics_ch2.10: ///characteristics_ch2.11: ///characteristics_ch2.12: ///molecule_ch2: total RNA///extract_protocol_ch2: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch2: Cy5///label_protocol_ch2: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch2: 9606///hyb_protocol: Slides were incubated for 16-17 hr at 60C and washed using the SSPE method described in the Agilent 60-mer Oligo Microarray Processing Protocol, Version 2.1. Slides were treated with Agilent Stabilization and Drying Solution, a wash was used to protect the dyes from ozone degradation.///scan_protocol: Scanned on an Agilent G2565BA scanner.///description: Normal_ovarian_sample///data_processing: Agilent Feature Extraction Software (v7.5.1) was used for local background subtraction and Linear/LOWESS normalization. RejectMethod=Interquartile Range, nonuniformity outlier flagging enabled, population outlier flag enabled, ratio error model=hybrid, dye normalization select method = Rank Consistency Filter, no spatial detrend method applied.///data_processing.1: Agilent Feature Extraced data was imported into Rosetta Resolver version 7.1.1 (Rosetta Inpharmatics LLC, Cambridge, MA). Multiple probes with the same sequence code were combined into a single value using the Rosetta Resolver error-weighted averaging method for combining repeated measures.///platform_id: GPL7264///contact_name: Judy,,Dering///contact_email: [email protected]///contact_laboratory: Translational Oncology Research///contact_department: Medicine///contact_institute: UCLA School of Medicine///contact_address: 2825 Santa Monica Blvd. Suite 200///contact_city: Santa Monica///contact_state: CA///contact_zip.postal_code: 90404///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM1238nnn/GSM1238185/GSM1238185_US22502615_251209747511_S01_A01.txt.gz///data_row_count: 20173
1
title: Ov_Tumor_Ref_Mix vs. CS-OV-042///geo_accession: GSM1238186///status: Public on Dec 26 2013///submission_date: Sep 23 2013///last_update_date: Dec 26 2013///type: RNA///channel_count: 2///source_name_ch1: 106 pooled ovarian samples///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian///characteristics_ch1.1: sample type: reference pool///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch1: Cy3///label_protocol_ch1: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch1: 9606///source_name_ch2: CS-OV-042///organism_ch2: Homo sapiens///characteristics_ch2: tissue: ovarian///characteristics_ch2.1: sample included in reference pool: YES///characteristics_ch2.2: sample rin: 9.1///characteristics_ch2.3: age at surgery: 45.10///characteristics_ch2.4: histology: Serous///characteristics_ch2.5: Stage: IIIC///characteristics_ch2.6: grade: 3///characteristics_ch2.7: tissue status: Primary///characteristics_ch2.8: tcga id: TCGA-23-1118///characteristics_ch2.9: follow up months: 113///characteristics_ch2.10: disease status: Free///characteristics_ch2.11: patient status: Alive///characteristics_ch2.12: disease state: Malignant ovarian///molecule_ch2: total RNA///extract_protocol_ch2: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch2: Cy5///label_protocol_ch2: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch2: 9606///hyb_protocol: Slides were incubated for 16-17 hr at 60C and washed using the SSPE method described in the Agilent 60-mer Oligo Microarray Processing Protocol, Version 2.1. Slides were treated with Agilent Stabilization and Drying Solution, a wash was used to protect the dyes from ozone degradation.///scan_protocol: Scanned on an Agilent G2565BA scanner.///description: Malignant_ovarian_sample///data_processing: Agilent Feature Extraction Software (v7.5.1) was used for local background subtraction and Linear/LOWESS normalization. RejectMethod=Interquartile Range, nonuniformity outlier flagging enabled, population outlier flag enabled, ratio error model=hybrid, dye normalization select method = Rank Consistency Filter, no spatial detrend method applied.///data_processing.1: Agilent Feature Extraced data was imported into Rosetta Resolver version 7.1.1 (Rosetta Inpharmatics LLC, Cambridge, MA). Multiple probes with the same sequence code were combined into a single value using the Rosetta Resolver error-weighted averaging method for combining repeated measures.///platform_id: GPL7264///contact_name: Judy,,Dering///contact_email: [email protected]///contact_laboratory: Translational Oncology Research///contact_department: Medicine///contact_institute: UCLA School of Medicine///contact_address: 2825 Santa Monica Blvd. Suite 200///contact_city: Santa Monica///contact_state: CA///contact_zip.postal_code: 90404///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM1238nnn/GSM1238186/GSM1238186_US22502615_251209747044_S01_A01.txt.gz///data_row_count: 20173
1
title: Ov_Tumor_Ref_Mix vs. CS-OV-043///geo_accession: GSM1238187///status: Public on Dec 26 2013///submission_date: Sep 23 2013///last_update_date: Dec 26 2013///type: RNA///channel_count: 2///source_name_ch1: 106 pooled ovarian samples///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian///characteristics_ch1.1: sample type: reference pool///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch1: Cy3///label_protocol_ch1: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch1: 9606///source_name_ch2: CS-OV-043///organism_ch2: Homo sapiens///characteristics_ch2: tissue: ovarian///characteristics_ch2.1: sample included in reference pool: YES///characteristics_ch2.2: sample rin: 9.8///characteristics_ch2.3: age at surgery: 55.27///characteristics_ch2.4: histology: Normal///characteristics_ch2.5: tissue status: Benign///characteristics_ch2.6: disease status: Benign///characteristics_ch2.7: patient status: Benign///characteristics_ch2.8: disease state: Normal ovarian///characteristics_ch2.9: ///characteristics_ch2.10: ///characteristics_ch2.11: ///characteristics_ch2.12: ///molecule_ch2: total RNA///extract_protocol_ch2: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch2: Cy5///label_protocol_ch2: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch2: 9606///hyb_protocol: Slides were incubated for 16-17 hr at 60C and washed using the SSPE method described in the Agilent 60-mer Oligo Microarray Processing Protocol, Version 2.1. Slides were treated with Agilent Stabilization and Drying Solution, a wash was used to protect the dyes from ozone degradation.///scan_protocol: Scanned on an Agilent G2565BA scanner.///description: Normal_ovarian_sample///data_processing: Agilent Feature Extraction Software (v7.5.1) was used for local background subtraction and Linear/LOWESS normalization. RejectMethod=Interquartile Range, nonuniformity outlier flagging enabled, population outlier flag enabled, ratio error model=hybrid, dye normalization select method = Rank Consistency Filter, no spatial detrend method applied.///data_processing.1: Agilent Feature Extraced data was imported into Rosetta Resolver version 7.1.1 (Rosetta Inpharmatics LLC, Cambridge, MA). Multiple probes with the same sequence code were combined into a single value using the Rosetta Resolver error-weighted averaging method for combining repeated measures.///platform_id: GPL7264///contact_name: Judy,,Dering///contact_email: [email protected]///contact_laboratory: Translational Oncology Research///contact_department: Medicine///contact_institute: UCLA School of Medicine///contact_address: 2825 Santa Monica Blvd. Suite 200///contact_city: Santa Monica///contact_state: CA///contact_zip.postal_code: 90404///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM1238nnn/GSM1238187/GSM1238187_US22502615_251209750940_S02_A01.txt.gz///data_row_count: 20173
1
title: Ov_Tumor_Ref_Mix vs. CS-OV-044///geo_accession: GSM1238188///status: Public on Dec 26 2013///submission_date: Sep 23 2013///last_update_date: Dec 26 2013///type: RNA///channel_count: 2///source_name_ch1: 106 pooled ovarian samples///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian///characteristics_ch1.1: sample type: reference pool///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch1: Cy3///label_protocol_ch1: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch1: 9606///source_name_ch2: CS-OV-044///organism_ch2: Homo sapiens///characteristics_ch2: tissue: ovarian///characteristics_ch2.1: sample included in reference pool: NO///characteristics_ch2.2: sample rin: 8.5///characteristics_ch2.3: age at surgery: 43.37///characteristics_ch2.4: histology: Serous///characteristics_ch2.5: Stage: IIIC///characteristics_ch2.6: grade: 3///characteristics_ch2.7: tissue status: Primary///characteristics_ch2.8: follow up months: 26///characteristics_ch2.9: disease status: Not Free///characteristics_ch2.10: patient status: Dead///characteristics_ch2.11: disease state: Malignant ovarian///characteristics_ch2.12: ///molecule_ch2: total RNA///extract_protocol_ch2: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch2: Cy5///label_protocol_ch2: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch2: 9606///hyb_protocol: Slides were incubated for 16-17 hr at 60C and washed using the SSPE method described in the Agilent 60-mer Oligo Microarray Processing Protocol, Version 2.1. Slides were treated with Agilent Stabilization and Drying Solution, a wash was used to protect the dyes from ozone degradation.///scan_protocol: Scanned on an Agilent G2565BA scanner.///description: Malignant_ovarian_sample///data_processing: Agilent Feature Extraction Software (v7.5.1) was used for local background subtraction and Linear/LOWESS normalization. RejectMethod=Interquartile Range, nonuniformity outlier flagging enabled, population outlier flag enabled, ratio error model=hybrid, dye normalization select method = Rank Consistency Filter, no spatial detrend method applied.///data_processing.1: Agilent Feature Extraced data was imported into Rosetta Resolver version 7.1.1 (Rosetta Inpharmatics LLC, Cambridge, MA). Multiple probes with the same sequence code were combined into a single value using the Rosetta Resolver error-weighted averaging method for combining repeated measures.///platform_id: GPL7264///contact_name: Judy,,Dering///contact_email: [email protected]///contact_laboratory: Translational Oncology Research///contact_department: Medicine///contact_institute: UCLA School of Medicine///contact_address: 2825 Santa Monica Blvd. Suite 200///contact_city: Santa Monica///contact_state: CA///contact_zip.postal_code: 90404///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM1238nnn/GSM1238188/GSM1238188_US22502615_251209754234_S01_A01.txt.gz///data_row_count: 20173
1
title: Ov_Tumor_Ref_Mix vs. CS-OV-045///geo_accession: GSM1238189///status: Public on Dec 26 2013///submission_date: Sep 23 2013///last_update_date: Dec 26 2013///type: RNA///channel_count: 2///source_name_ch1: 106 pooled ovarian samples///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian///characteristics_ch1.1: sample type: reference pool///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch1: Cy3///label_protocol_ch1: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch1: 9606///source_name_ch2: CS-OV-045///organism_ch2: Homo sapiens///characteristics_ch2: tissue: ovarian///characteristics_ch2.1: sample included in reference pool: NO///characteristics_ch2.2: sample rin: 8.6///characteristics_ch2.3: age at surgery: 72.37///characteristics_ch2.4: histology: Serous///characteristics_ch2.5: Stage: IIIC///characteristics_ch2.6: grade: 3///characteristics_ch2.7: tissue status: Primary///characteristics_ch2.8: follow up months: 14///characteristics_ch2.9: disease status: Not Free///characteristics_ch2.10: patient status: Dead///characteristics_ch2.11: disease state: Malignant ovarian///characteristics_ch2.12: ///molecule_ch2: total RNA///extract_protocol_ch2: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch2: Cy5///label_protocol_ch2: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch2: 9606///hyb_protocol: Slides were incubated for 16-17 hr at 60C and washed using the SSPE method described in the Agilent 60-mer Oligo Microarray Processing Protocol, Version 2.1. Slides were treated with Agilent Stabilization and Drying Solution, a wash was used to protect the dyes from ozone degradation.///scan_protocol: Scanned on an Agilent G2565BA scanner.///description: Malignant_ovarian_sample///data_processing: Agilent Feature Extraction Software (v7.5.1) was used for local background subtraction and Linear/LOWESS normalization. RejectMethod=Interquartile Range, nonuniformity outlier flagging enabled, population outlier flag enabled, ratio error model=hybrid, dye normalization select method = Rank Consistency Filter, no spatial detrend method applied.///data_processing.1: Agilent Feature Extraced data was imported into Rosetta Resolver version 7.1.1 (Rosetta Inpharmatics LLC, Cambridge, MA). Multiple probes with the same sequence code were combined into a single value using the Rosetta Resolver error-weighted averaging method for combining repeated measures.///platform_id: GPL7264///contact_name: Judy,,Dering///contact_email: [email protected]///contact_laboratory: Translational Oncology Research///contact_department: Medicine///contact_institute: UCLA School of Medicine///contact_address: 2825 Santa Monica Blvd. Suite 200///contact_city: Santa Monica///contact_state: CA///contact_zip.postal_code: 90404///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM1238nnn/GSM1238189/GSM1238189_US22502615_251209749468_S01_A01.txt.gz///data_row_count: 20173
1
title: Ov_Tumor_Ref_Mix vs. CS-OV-046///geo_accession: GSM1238190///status: Public on Dec 26 2013///submission_date: Sep 23 2013///last_update_date: Dec 26 2013///type: RNA///channel_count: 2///source_name_ch1: 106 pooled ovarian samples///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian///characteristics_ch1.1: sample type: reference pool///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch1: Cy3///label_protocol_ch1: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch1: 9606///source_name_ch2: CS-OV-046///organism_ch2: Homo sapiens///characteristics_ch2: tissue: ovarian///characteristics_ch2.1: sample included in reference pool: NO///characteristics_ch2.2: sample rin: 9.4///characteristics_ch2.3: age at surgery: 67.44///characteristics_ch2.4: histology: Serous///characteristics_ch2.5: Stage: IIIC///characteristics_ch2.6: grade: 3///characteristics_ch2.7: tissue status: Primary///characteristics_ch2.8: follow up months: 2///characteristics_ch2.9: disease status: Not Free///characteristics_ch2.10: patient status: Dead///characteristics_ch2.11: disease state: Malignant ovarian///characteristics_ch2.12: ///molecule_ch2: total RNA///extract_protocol_ch2: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch2: Cy5///label_protocol_ch2: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch2: 9606///hyb_protocol: Slides were incubated for 16-17 hr at 60C and washed using the SSPE method described in the Agilent 60-mer Oligo Microarray Processing Protocol, Version 2.1. Slides were treated with Agilent Stabilization and Drying Solution, a wash was used to protect the dyes from ozone degradation.///scan_protocol: Scanned on an Agilent G2565BA scanner.///description: Malignant_ovarian_sample///data_processing: Agilent Feature Extraction Software (v7.5.1) was used for local background subtraction and Linear/LOWESS normalization. RejectMethod=Interquartile Range, nonuniformity outlier flagging enabled, population outlier flag enabled, ratio error model=hybrid, dye normalization select method = Rank Consistency Filter, no spatial detrend method applied.///data_processing.1: Agilent Feature Extraced data was imported into Rosetta Resolver version 7.1.1 (Rosetta Inpharmatics LLC, Cambridge, MA). Multiple probes with the same sequence code were combined into a single value using the Rosetta Resolver error-weighted averaging method for combining repeated measures.///platform_id: GPL7264///contact_name: Judy,,Dering///contact_email: [email protected]///contact_laboratory: Translational Oncology Research///contact_department: Medicine///contact_institute: UCLA School of Medicine///contact_address: 2825 Santa Monica Blvd. Suite 200///contact_city: Santa Monica///contact_state: CA///contact_zip.postal_code: 90404///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM1238nnn/GSM1238190/GSM1238190_US22502615_251209749773_S01_A01.txt.gz///data_row_count: 20173
1
title: Ov_Tumor_Ref_Mix vs. CS-OV-047///geo_accession: GSM1238191///status: Public on Dec 26 2013///submission_date: Sep 23 2013///last_update_date: Dec 26 2013///type: RNA///channel_count: 2///source_name_ch1: 106 pooled ovarian samples///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian///characteristics_ch1.1: sample type: reference pool///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch1: Cy3///label_protocol_ch1: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch1: 9606///source_name_ch2: CS-OV-047///organism_ch2: Homo sapiens///characteristics_ch2: tissue: ovarian///characteristics_ch2.1: sample included in reference pool: YES///characteristics_ch2.2: sample rin: 9.6///characteristics_ch2.3: age at surgery: 54.39///characteristics_ch2.4: histology: Serous///characteristics_ch2.5: Stage: IA///characteristics_ch2.6: grade: 0///characteristics_ch2.7: tissue status: Primary///characteristics_ch2.8: follow up months: 80///characteristics_ch2.9: disease status: Free///characteristics_ch2.10: patient status: Alive///characteristics_ch2.11: disease state: Borderline ovarian///characteristics_ch2.12: ///molecule_ch2: total RNA///extract_protocol_ch2: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch2: Cy5///label_protocol_ch2: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch2: 9606///hyb_protocol: Slides were incubated for 16-17 hr at 60C and washed using the SSPE method described in the Agilent 60-mer Oligo Microarray Processing Protocol, Version 2.1. Slides were treated with Agilent Stabilization and Drying Solution, a wash was used to protect the dyes from ozone degradation.///scan_protocol: Scanned on an Agilent G2565BA scanner.///description: Borderline_ovarian_sample///data_processing: Agilent Feature Extraction Software (v7.5.1) was used for local background subtraction and Linear/LOWESS normalization. RejectMethod=Interquartile Range, nonuniformity outlier flagging enabled, population outlier flag enabled, ratio error model=hybrid, dye normalization select method = Rank Consistency Filter, no spatial detrend method applied.///data_processing.1: Agilent Feature Extraced data was imported into Rosetta Resolver version 7.1.1 (Rosetta Inpharmatics LLC, Cambridge, MA). Multiple probes with the same sequence code were combined into a single value using the Rosetta Resolver error-weighted averaging method for combining repeated measures.///platform_id: GPL7264///contact_name: Judy,,Dering///contact_email: [email protected]///contact_laboratory: Translational Oncology Research///contact_department: Medicine///contact_institute: UCLA School of Medicine///contact_address: 2825 Santa Monica Blvd. Suite 200///contact_city: Santa Monica///contact_state: CA///contact_zip.postal_code: 90404///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM1238nnn/GSM1238191/GSM1238191_US22502615_251209749048_S01_A01.txt.gz///data_row_count: 20173
1
title: Ov_Tumor_Ref_Mix vs. CS-OV-048///geo_accession: GSM1238192///status: Public on Dec 26 2013///submission_date: Sep 23 2013///last_update_date: Dec 26 2013///type: RNA///channel_count: 2///source_name_ch1: 106 pooled ovarian samples///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian///characteristics_ch1.1: sample type: reference pool///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch1: Cy3///label_protocol_ch1: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch1: 9606///source_name_ch2: CS-OV-048///organism_ch2: Homo sapiens///characteristics_ch2: tissue: ovarian///characteristics_ch2.1: sample included in reference pool: NO///characteristics_ch2.2: sample rin: 10///characteristics_ch2.3: age at surgery: 39.97///characteristics_ch2.4: histology: Serous///characteristics_ch2.5: Stage: IIIC///characteristics_ch2.6: grade: 3///characteristics_ch2.7: tissue status: Primary///characteristics_ch2.8: follow up months: 90///characteristics_ch2.9: disease status: Not Free///characteristics_ch2.10: patient status: Dead///characteristics_ch2.11: disease state: Malignant ovarian///characteristics_ch2.12: ///molecule_ch2: total RNA///extract_protocol_ch2: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch2: Cy5///label_protocol_ch2: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch2: 9606///hyb_protocol: Slides were incubated for 16-17 hr at 60C and washed using the SSPE method described in the Agilent 60-mer Oligo Microarray Processing Protocol, Version 2.1. Slides were treated with Agilent Stabilization and Drying Solution, a wash was used to protect the dyes from ozone degradation.///scan_protocol: Scanned on an Agilent G2565BA scanner.///description: Malignant_ovarian_sample///data_processing: Agilent Feature Extraction Software (v7.5.1) was used for local background subtraction and Linear/LOWESS normalization. RejectMethod=Interquartile Range, nonuniformity outlier flagging enabled, population outlier flag enabled, ratio error model=hybrid, dye normalization select method = Rank Consistency Filter, no spatial detrend method applied.///data_processing.1: Agilent Feature Extraced data was imported into Rosetta Resolver version 7.1.1 (Rosetta Inpharmatics LLC, Cambridge, MA). Multiple probes with the same sequence code were combined into a single value using the Rosetta Resolver error-weighted averaging method for combining repeated measures.///platform_id: GPL7264///contact_name: Judy,,Dering///contact_email: [email protected]///contact_laboratory: Translational Oncology Research///contact_department: Medicine///contact_institute: UCLA School of Medicine///contact_address: 2825 Santa Monica Blvd. Suite 200///contact_city: Santa Monica///contact_state: CA///contact_zip.postal_code: 90404///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM1238nnn/GSM1238192/GSM1238192_US22502615_251209754157_S01_A01.txt.gz///data_row_count: 20173
1
title: Ov_Tumor_Ref_Mix vs. CS-OV-049///geo_accession: GSM1238193///status: Public on Dec 26 2013///submission_date: Sep 23 2013///last_update_date: Dec 26 2013///type: RNA///channel_count: 2///source_name_ch1: 106 pooled ovarian samples///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian///characteristics_ch1.1: sample type: reference pool///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch1: Cy3///label_protocol_ch1: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch1: 9606///source_name_ch2: CS-OV-049///organism_ch2: Homo sapiens///characteristics_ch2: tissue: ovarian///characteristics_ch2.1: sample included in reference pool: YES///characteristics_ch2.2: sample rin: 9.5///characteristics_ch2.3: age at surgery: 80.67///characteristics_ch2.4: histology: Serous///characteristics_ch2.5: Stage: IIIC///characteristics_ch2.6: grade: 3///characteristics_ch2.7: tissue status: Primary///characteristics_ch2.8: follow up months: 18///characteristics_ch2.9: disease status: Not Free///characteristics_ch2.10: patient status: Dead///characteristics_ch2.11: disease state: Malignant ovarian///characteristics_ch2.12: ///molecule_ch2: total RNA///extract_protocol_ch2: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch2: Cy5///label_protocol_ch2: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch2: 9606///hyb_protocol: Slides were incubated for 16-17 hr at 60C and washed using the SSPE method described in the Agilent 60-mer Oligo Microarray Processing Protocol, Version 2.1. Slides were treated with Agilent Stabilization and Drying Solution, a wash was used to protect the dyes from ozone degradation.///scan_protocol: Scanned on an Agilent G2565BA scanner.///description: Malignant_ovarian_sample///data_processing: Agilent Feature Extraction Software (v7.5.1) was used for local background subtraction and Linear/LOWESS normalization. RejectMethod=Interquartile Range, nonuniformity outlier flagging enabled, population outlier flag enabled, ratio error model=hybrid, dye normalization select method = Rank Consistency Filter, no spatial detrend method applied.///data_processing.1: Agilent Feature Extraced data was imported into Rosetta Resolver version 7.1.1 (Rosetta Inpharmatics LLC, Cambridge, MA). Multiple probes with the same sequence code were combined into a single value using the Rosetta Resolver error-weighted averaging method for combining repeated measures.///platform_id: GPL7264///contact_name: Judy,,Dering///contact_email: [email protected]///contact_laboratory: Translational Oncology Research///contact_department: Medicine///contact_institute: UCLA School of Medicine///contact_address: 2825 Santa Monica Blvd. Suite 200///contact_city: Santa Monica///contact_state: CA///contact_zip.postal_code: 90404///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM1238nnn/GSM1238193/GSM1238193_US22502615_251209747538_S01_A01.txt.gz///data_row_count: 20173
1
title: Ov_Tumor_Ref_Mix vs. CS-OV-050///geo_accession: GSM1238194///status: Public on Dec 26 2013///submission_date: Sep 23 2013///last_update_date: Dec 26 2013///type: RNA///channel_count: 2///source_name_ch1: 106 pooled ovarian samples///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian///characteristics_ch1.1: sample type: reference pool///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch1: Cy3///label_protocol_ch1: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch1: 9606///source_name_ch2: CS-OV-050///organism_ch2: Homo sapiens///characteristics_ch2: tissue: ovarian///characteristics_ch2.1: sample included in reference pool: NO///characteristics_ch2.2: sample rin: 9///characteristics_ch2.3: age at surgery: 75.58///characteristics_ch2.4: histology: Endometrioid///characteristics_ch2.5: Stage: IIIC///characteristics_ch2.6: grade: 3///characteristics_ch2.7: tissue status: Primary///characteristics_ch2.8: follow up months: 58///characteristics_ch2.9: disease status: Not Free///characteristics_ch2.10: patient status: Dead///characteristics_ch2.11: disease state: Malignant ovarian///characteristics_ch2.12: ///molecule_ch2: total RNA///extract_protocol_ch2: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch2: Cy5///label_protocol_ch2: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch2: 9606///hyb_protocol: Slides were incubated for 16-17 hr at 60C and washed using the SSPE method described in the Agilent 60-mer Oligo Microarray Processing Protocol, Version 2.1. Slides were treated with Agilent Stabilization and Drying Solution, a wash was used to protect the dyes from ozone degradation.///scan_protocol: Scanned on an Agilent G2565BA scanner.///description: Malignant_ovarian_sample///data_processing: Agilent Feature Extraction Software (v7.5.1) was used for local background subtraction and Linear/LOWESS normalization. RejectMethod=Interquartile Range, nonuniformity outlier flagging enabled, population outlier flag enabled, ratio error model=hybrid, dye normalization select method = Rank Consistency Filter, no spatial detrend method applied.///data_processing.1: Agilent Feature Extraced data was imported into Rosetta Resolver version 7.1.1 (Rosetta Inpharmatics LLC, Cambridge, MA). Multiple probes with the same sequence code were combined into a single value using the Rosetta Resolver error-weighted averaging method for combining repeated measures.///platform_id: GPL7264///contact_name: Judy,,Dering///contact_email: [email protected]///contact_laboratory: Translational Oncology Research///contact_department: Medicine///contact_institute: UCLA School of Medicine///contact_address: 2825 Santa Monica Blvd. Suite 200///contact_city: Santa Monica///contact_state: CA///contact_zip.postal_code: 90404///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM1238nnn/GSM1238194/GSM1238194_US22502615_251209754775_S01_A01.txt.gz///data_row_count: 20173
1
title: Ov_Tumor_Ref_Mix vs. CS-OV-051///geo_accession: GSM1238195///status: Public on Dec 26 2013///submission_date: Sep 23 2013///last_update_date: Dec 26 2013///type: RNA///channel_count: 2///source_name_ch1: 106 pooled ovarian samples///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian///characteristics_ch1.1: sample type: reference pool///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch1: Cy3///label_protocol_ch1: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch1: 9606///source_name_ch2: CS-OV-051///organism_ch2: Homo sapiens///characteristics_ch2: tissue: ovarian///characteristics_ch2.1: sample included in reference pool: YES///characteristics_ch2.2: sample rin: 9.7///characteristics_ch2.3: age at surgery: 57.98///characteristics_ch2.4: histology: Serous///characteristics_ch2.5: Stage: IIIC///characteristics_ch2.6: grade: 3///characteristics_ch2.7: tissue status: Primary///characteristics_ch2.8: follow up months: 29///characteristics_ch2.9: disease status: Not Free///characteristics_ch2.10: patient status: Dead///characteristics_ch2.11: disease state: Malignant ovarian///characteristics_ch2.12: ///molecule_ch2: total RNA///extract_protocol_ch2: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch2: Cy5///label_protocol_ch2: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch2: 9606///hyb_protocol: Slides were incubated for 16-17 hr at 60C and washed using the SSPE method described in the Agilent 60-mer Oligo Microarray Processing Protocol, Version 2.1. Slides were treated with Agilent Stabilization and Drying Solution, a wash was used to protect the dyes from ozone degradation.///scan_protocol: Scanned on an Agilent G2565BA scanner.///description: Malignant_ovarian_sample///data_processing: Agilent Feature Extraction Software (v7.5.1) was used for local background subtraction and Linear/LOWESS normalization. RejectMethod=Interquartile Range, nonuniformity outlier flagging enabled, population outlier flag enabled, ratio error model=hybrid, dye normalization select method = Rank Consistency Filter, no spatial detrend method applied.///data_processing.1: Agilent Feature Extraced data was imported into Rosetta Resolver version 7.1.1 (Rosetta Inpharmatics LLC, Cambridge, MA). Multiple probes with the same sequence code were combined into a single value using the Rosetta Resolver error-weighted averaging method for combining repeated measures.///platform_id: GPL7264///contact_name: Judy,,Dering///contact_email: [email protected]///contact_laboratory: Translational Oncology Research///contact_department: Medicine///contact_institute: UCLA School of Medicine///contact_address: 2825 Santa Monica Blvd. Suite 200///contact_city: Santa Monica///contact_state: CA///contact_zip.postal_code: 90404///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM1238nnn/GSM1238195/GSM1238195_US22502615_251209747187_S01_A01.txt.gz///data_row_count: 20173
1
title: Ov_Tumor_Ref_Mix vs. CS-OV-052///geo_accession: GSM1238196///status: Public on Dec 26 2013///submission_date: Sep 23 2013///last_update_date: Dec 26 2013///type: RNA///channel_count: 2///source_name_ch1: 106 pooled ovarian samples///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian///characteristics_ch1.1: sample type: reference pool///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch1: Cy3///label_protocol_ch1: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch1: 9606///source_name_ch2: CS-OV-052///organism_ch2: Homo sapiens///characteristics_ch2: tissue: ovarian///characteristics_ch2.1: sample included in reference pool: YES///characteristics_ch2.2: sample rin: 9.2///characteristics_ch2.3: age at surgery: 41.63///characteristics_ch2.4: histology: Serous///characteristics_ch2.5: Stage: IV///characteristics_ch2.6: grade: 3///characteristics_ch2.7: tissue status: Primary///characteristics_ch2.8: follow up months: 8///characteristics_ch2.9: disease status: Not Free///characteristics_ch2.10: patient status: Dead///characteristics_ch2.11: disease state: Malignant ovarian///characteristics_ch2.12: ///molecule_ch2: total RNA///extract_protocol_ch2: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch2: Cy5///label_protocol_ch2: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch2: 9606///hyb_protocol: Slides were incubated for 16-17 hr at 60C and washed using the SSPE method described in the Agilent 60-mer Oligo Microarray Processing Protocol, Version 2.1. Slides were treated with Agilent Stabilization and Drying Solution, a wash was used to protect the dyes from ozone degradation.///scan_protocol: Scanned on an Agilent G2565BA scanner.///description: Malignant_ovarian_sample///data_processing: Agilent Feature Extraction Software (v7.5.1) was used for local background subtraction and Linear/LOWESS normalization. RejectMethod=Interquartile Range, nonuniformity outlier flagging enabled, population outlier flag enabled, ratio error model=hybrid, dye normalization select method = Rank Consistency Filter, no spatial detrend method applied.///data_processing.1: Agilent Feature Extraced data was imported into Rosetta Resolver version 7.1.1 (Rosetta Inpharmatics LLC, Cambridge, MA). Multiple probes with the same sequence code were combined into a single value using the Rosetta Resolver error-weighted averaging method for combining repeated measures.///platform_id: GPL7264///contact_name: Judy,,Dering///contact_email: [email protected]///contact_laboratory: Translational Oncology Research///contact_department: Medicine///contact_institute: UCLA School of Medicine///contact_address: 2825 Santa Monica Blvd. Suite 200///contact_city: Santa Monica///contact_state: CA///contact_zip.postal_code: 90404///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM1238nnn/GSM1238196/GSM1238196_US22502615_251209750951_S01_A01.txt.gz///data_row_count: 20173
1
title: Ov_Tumor_Ref_Mix vs. CS-OV-053///geo_accession: GSM1238197///status: Public on Dec 26 2013///submission_date: Sep 23 2013///last_update_date: Dec 26 2013///type: RNA///channel_count: 2///source_name_ch1: 106 pooled ovarian samples///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian///characteristics_ch1.1: sample type: reference pool///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch1: Cy3///label_protocol_ch1: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch1: 9606///source_name_ch2: CS-OV-053///organism_ch2: Homo sapiens///characteristics_ch2: tissue: ovarian///characteristics_ch2.1: sample included in reference pool: NO///characteristics_ch2.2: sample rin: 10///characteristics_ch2.3: age at surgery: 63.56///characteristics_ch2.4: histology: Serous///characteristics_ch2.5: Stage: IIIC///characteristics_ch2.6: grade: 3///characteristics_ch2.7: tissue status: Primary///characteristics_ch2.8: follow up months: 11///characteristics_ch2.9: disease status: Not Free///characteristics_ch2.10: patient status: Dead///characteristics_ch2.11: disease state: Malignant ovarian///characteristics_ch2.12: ///molecule_ch2: total RNA///extract_protocol_ch2: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch2: Cy5///label_protocol_ch2: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch2: 9606///hyb_protocol: Slides were incubated for 16-17 hr at 60C and washed using the SSPE method described in the Agilent 60-mer Oligo Microarray Processing Protocol, Version 2.1. Slides were treated with Agilent Stabilization and Drying Solution, a wash was used to protect the dyes from ozone degradation.///scan_protocol: Scanned on an Agilent G2565BA scanner.///description: Malignant_ovarian_sample///data_processing: Agilent Feature Extraction Software (v7.5.1) was used for local background subtraction and Linear/LOWESS normalization. RejectMethod=Interquartile Range, nonuniformity outlier flagging enabled, population outlier flag enabled, ratio error model=hybrid, dye normalization select method = Rank Consistency Filter, no spatial detrend method applied.///data_processing.1: Agilent Feature Extraced data was imported into Rosetta Resolver version 7.1.1 (Rosetta Inpharmatics LLC, Cambridge, MA). Multiple probes with the same sequence code were combined into a single value using the Rosetta Resolver error-weighted averaging method for combining repeated measures.///platform_id: GPL7264///contact_name: Judy,,Dering///contact_email: [email protected]///contact_laboratory: Translational Oncology Research///contact_department: Medicine///contact_institute: UCLA School of Medicine///contact_address: 2825 Santa Monica Blvd. Suite 200///contact_city: Santa Monica///contact_state: CA///contact_zip.postal_code: 90404///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM1238nnn/GSM1238197/GSM1238197_US22502615_251209754150_S01_A01.txt.gz///data_row_count: 20173
1
title: Ov_Tumor_Ref_Mix vs. CS-OV-054///geo_accession: GSM1238198///status: Public on Dec 26 2013///submission_date: Sep 23 2013///last_update_date: Dec 26 2013///type: RNA///channel_count: 2///source_name_ch1: 106 pooled ovarian samples///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian///characteristics_ch1.1: sample type: reference pool///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch1: Cy3///label_protocol_ch1: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch1: 9606///source_name_ch2: CS-OV-054///organism_ch2: Homo sapiens///characteristics_ch2: tissue: ovarian///characteristics_ch2.1: sample included in reference pool: NO///characteristics_ch2.2: sample rin: 7.4///characteristics_ch2.3: age at surgery: 54.26///characteristics_ch2.4: histology: Mucinous///characteristics_ch2.5: Stage: IA///characteristics_ch2.6: grade: 0///characteristics_ch2.7: tissue status: Primary///characteristics_ch2.8: follow up months: 72///characteristics_ch2.9: disease status: Free///characteristics_ch2.10: patient status: Alive///characteristics_ch2.11: disease state: Borderline ovarian///characteristics_ch2.12: ///molecule_ch2: total RNA///extract_protocol_ch2: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch2: Cy5///label_protocol_ch2: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch2: 9606///hyb_protocol: Slides were incubated for 16-17 hr at 60C and washed using the SSPE method described in the Agilent 60-mer Oligo Microarray Processing Protocol, Version 2.1. Slides were treated with Agilent Stabilization and Drying Solution, a wash was used to protect the dyes from ozone degradation.///scan_protocol: Scanned on an Agilent G2565BA scanner.///description: Borderline_ovarian_sample///data_processing: Agilent Feature Extraction Software (v7.5.1) was used for local background subtraction and Linear/LOWESS normalization. RejectMethod=Interquartile Range, nonuniformity outlier flagging enabled, population outlier flag enabled, ratio error model=hybrid, dye normalization select method = Rank Consistency Filter, no spatial detrend method applied.///data_processing.1: Agilent Feature Extraced data was imported into Rosetta Resolver version 7.1.1 (Rosetta Inpharmatics LLC, Cambridge, MA). Multiple probes with the same sequence code were combined into a single value using the Rosetta Resolver error-weighted averaging method for combining repeated measures.///platform_id: GPL7264///contact_name: Judy,,Dering///contact_email: [email protected]///contact_laboratory: Translational Oncology Research///contact_department: Medicine///contact_institute: UCLA School of Medicine///contact_address: 2825 Santa Monica Blvd. Suite 200///contact_city: Santa Monica///contact_state: CA///contact_zip.postal_code: 90404///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM1238nnn/GSM1238198/GSM1238198_US22502615_251209747550_S01_A01.txt.gz///data_row_count: 20173
1
title: Ov_Tumor_Ref_Mix vs. CS-OV-055///geo_accession: GSM1238199///status: Public on Dec 26 2013///submission_date: Sep 23 2013///last_update_date: Dec 26 2013///type: RNA///channel_count: 2///source_name_ch1: 106 pooled ovarian samples///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian///characteristics_ch1.1: sample type: reference pool///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch1: Cy3///label_protocol_ch1: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch1: 9606///source_name_ch2: CS-OV-055///organism_ch2: Homo sapiens///characteristics_ch2: tissue: ovarian///characteristics_ch2.1: sample included in reference pool: NO///characteristics_ch2.2: sample rin: 8.8///characteristics_ch2.3: age at surgery: 66.46///characteristics_ch2.4: histology: Serous///characteristics_ch2.5: Stage: IV///characteristics_ch2.6: grade: 3///characteristics_ch2.7: tissue status: Recurrence///characteristics_ch2.8: follow up months: 152///characteristics_ch2.9: disease status: Not Free///characteristics_ch2.10: patient status: Dead///characteristics_ch2.11: disease state: Malignant ovarian///characteristics_ch2.12: ///molecule_ch2: total RNA///extract_protocol_ch2: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch2: Cy5///label_protocol_ch2: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch2: 9606///hyb_protocol: Slides were incubated for 16-17 hr at 60C and washed using the SSPE method described in the Agilent 60-mer Oligo Microarray Processing Protocol, Version 2.1. Slides were treated with Agilent Stabilization and Drying Solution, a wash was used to protect the dyes from ozone degradation.///scan_protocol: Scanned on an Agilent G2565BA scanner.///description: Malignant_ovarian_sample///data_processing: Agilent Feature Extraction Software (v7.5.1) was used for local background subtraction and Linear/LOWESS normalization. RejectMethod=Interquartile Range, nonuniformity outlier flagging enabled, population outlier flag enabled, ratio error model=hybrid, dye normalization select method = Rank Consistency Filter, no spatial detrend method applied.///data_processing.1: Agilent Feature Extraced data was imported into Rosetta Resolver version 7.1.1 (Rosetta Inpharmatics LLC, Cambridge, MA). Multiple probes with the same sequence code were combined into a single value using the Rosetta Resolver error-weighted averaging method for combining repeated measures.///platform_id: GPL7264///contact_name: Judy,,Dering///contact_email: [email protected]///contact_laboratory: Translational Oncology Research///contact_department: Medicine///contact_institute: UCLA School of Medicine///contact_address: 2825 Santa Monica Blvd. Suite 200///contact_city: Santa Monica///contact_state: CA///contact_zip.postal_code: 90404///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM1238nnn/GSM1238199/GSM1238199_US22502615_251209754168_S01_A01.txt.gz///data_row_count: 20173
1
title: Ov_Tumor_Ref_Mix vs. CS-OV-056///geo_accession: GSM1238200///status: Public on Dec 26 2013///submission_date: Sep 23 2013///last_update_date: Dec 26 2013///type: RNA///channel_count: 2///source_name_ch1: 106 pooled ovarian samples///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian///characteristics_ch1.1: sample type: reference pool///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch1: Cy3///label_protocol_ch1: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch1: 9606///source_name_ch2: CS-OV-056///organism_ch2: Homo sapiens///characteristics_ch2: tissue: ovarian///characteristics_ch2.1: sample included in reference pool: YES///characteristics_ch2.2: sample rin: 9.8///characteristics_ch2.3: age at surgery: 57.97///characteristics_ch2.4: histology: Serous///characteristics_ch2.5: Stage: IIIC///characteristics_ch2.6: grade: 3///characteristics_ch2.7: tissue status: Primary///characteristics_ch2.8: follow up months: 15///characteristics_ch2.9: disease status: Not Free///characteristics_ch2.10: patient status: Dead///characteristics_ch2.11: disease state: Malignant ovarian///characteristics_ch2.12: ///molecule_ch2: total RNA///extract_protocol_ch2: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch2: Cy5///label_protocol_ch2: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch2: 9606///hyb_protocol: Slides were incubated for 16-17 hr at 60C and washed using the SSPE method described in the Agilent 60-mer Oligo Microarray Processing Protocol, Version 2.1. Slides were treated with Agilent Stabilization and Drying Solution, a wash was used to protect the dyes from ozone degradation.///scan_protocol: Scanned on an Agilent G2565BA scanner.///description: Malignant_ovarian_sample///data_processing: Agilent Feature Extraction Software (v7.5.1) was used for local background subtraction and Linear/LOWESS normalization. RejectMethod=Interquartile Range, nonuniformity outlier flagging enabled, population outlier flag enabled, ratio error model=hybrid, dye normalization select method = Rank Consistency Filter, no spatial detrend method applied.///data_processing.1: Agilent Feature Extraced data was imported into Rosetta Resolver version 7.1.1 (Rosetta Inpharmatics LLC, Cambridge, MA). Multiple probes with the same sequence code were combined into a single value using the Rosetta Resolver error-weighted averaging method for combining repeated measures.///platform_id: GPL7264///contact_name: Judy,,Dering///contact_email: [email protected]///contact_laboratory: Translational Oncology Research///contact_department: Medicine///contact_institute: UCLA School of Medicine///contact_address: 2825 Santa Monica Blvd. Suite 200///contact_city: Santa Monica///contact_state: CA///contact_zip.postal_code: 90404///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM1238nnn/GSM1238200/GSM1238200_US22502615_251209748613_S01_A01.txt.gz///data_row_count: 20173
1
title: Ov_Tumor_Ref_Mix vs. CS-OV-057///geo_accession: GSM1238201///status: Public on Dec 26 2013///submission_date: Sep 23 2013///last_update_date: Dec 26 2013///type: RNA///channel_count: 2///source_name_ch1: 106 pooled ovarian samples///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian///characteristics_ch1.1: sample type: reference pool///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch1: Cy3///label_protocol_ch1: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch1: 9606///source_name_ch2: CS-OV-057///organism_ch2: Homo sapiens///characteristics_ch2: tissue: ovarian///characteristics_ch2.1: sample included in reference pool: YES///characteristics_ch2.2: sample rin: 9.4///characteristics_ch2.3: age at surgery: 53.07///characteristics_ch2.4: histology: Serous///characteristics_ch2.5: Stage: IIIA///characteristics_ch2.6: grade: 2///characteristics_ch2.7: tissue status: Primary///characteristics_ch2.8: follow up months: 205///characteristics_ch2.9: disease status: Unknown///characteristics_ch2.10: patient status: Alive///characteristics_ch2.11: disease state: Malignant ovarian///characteristics_ch2.12: ///molecule_ch2: total RNA///extract_protocol_ch2: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch2: Cy5///label_protocol_ch2: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch2: 9606///hyb_protocol: Slides were incubated for 16-17 hr at 60C and washed using the SSPE method described in the Agilent 60-mer Oligo Microarray Processing Protocol, Version 2.1. Slides were treated with Agilent Stabilization and Drying Solution, a wash was used to protect the dyes from ozone degradation.///scan_protocol: Scanned on an Agilent G2565BA scanner.///description: Malignant_ovarian_sample///data_processing: Agilent Feature Extraction Software (v7.5.1) was used for local background subtraction and Linear/LOWESS normalization. RejectMethod=Interquartile Range, nonuniformity outlier flagging enabled, population outlier flag enabled, ratio error model=hybrid, dye normalization select method = Rank Consistency Filter, no spatial detrend method applied.///data_processing.1: Agilent Feature Extraced data was imported into Rosetta Resolver version 7.1.1 (Rosetta Inpharmatics LLC, Cambridge, MA). Multiple probes with the same sequence code were combined into a single value using the Rosetta Resolver error-weighted averaging method for combining repeated measures.///platform_id: GPL7264///contact_name: Judy,,Dering///contact_email: [email protected]///contact_laboratory: Translational Oncology Research///contact_department: Medicine///contact_institute: UCLA School of Medicine///contact_address: 2825 Santa Monica Blvd. Suite 200///contact_city: Santa Monica///contact_state: CA///contact_zip.postal_code: 90404///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM1238nnn/GSM1238201/GSM1238201_US22502615_251209750953_S01_A01.txt.gz///data_row_count: 20173
1
title: Ov_Tumor_Ref_Mix vs. CS-OV-058///geo_accession: GSM1238202///status: Public on Dec 26 2013///submission_date: Sep 23 2013///last_update_date: Dec 26 2013///type: RNA///channel_count: 2///source_name_ch1: 106 pooled ovarian samples///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian///characteristics_ch1.1: sample type: reference pool///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch1: Cy3///label_protocol_ch1: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch1: 9606///source_name_ch2: CS-OV-058///organism_ch2: Homo sapiens///characteristics_ch2: tissue: ovarian///characteristics_ch2.1: sample included in reference pool: YES///characteristics_ch2.2: sample rin: 9.4///characteristics_ch2.3: age at surgery: 83.07///characteristics_ch2.4: histology: MMMT///characteristics_ch2.5: Stage: IC///characteristics_ch2.6: grade: 3///characteristics_ch2.7: tissue status: Primary///characteristics_ch2.8: follow up months: 1///characteristics_ch2.9: disease status: Not Free///characteristics_ch2.10: patient status: Dead///characteristics_ch2.11: disease state: Malignant ovarian///characteristics_ch2.12: ///molecule_ch2: total RNA///extract_protocol_ch2: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch2: Cy5///label_protocol_ch2: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch2: 9606///hyb_protocol: Slides were incubated for 16-17 hr at 60C and washed using the SSPE method described in the Agilent 60-mer Oligo Microarray Processing Protocol, Version 2.1. Slides were treated with Agilent Stabilization and Drying Solution, a wash was used to protect the dyes from ozone degradation.///scan_protocol: Scanned on an Agilent G2565BA scanner.///description: Malignant_ovarian_sample///data_processing: Agilent Feature Extraction Software (v7.5.1) was used for local background subtraction and Linear/LOWESS normalization. RejectMethod=Interquartile Range, nonuniformity outlier flagging enabled, population outlier flag enabled, ratio error model=hybrid, dye normalization select method = Rank Consistency Filter, no spatial detrend method applied.///data_processing.1: Agilent Feature Extraced data was imported into Rosetta Resolver version 7.1.1 (Rosetta Inpharmatics LLC, Cambridge, MA). Multiple probes with the same sequence code were combined into a single value using the Rosetta Resolver error-weighted averaging method for combining repeated measures.///platform_id: GPL7264///contact_name: Judy,,Dering///contact_email: [email protected]///contact_laboratory: Translational Oncology Research///contact_department: Medicine///contact_institute: UCLA School of Medicine///contact_address: 2825 Santa Monica Blvd. Suite 200///contact_city: Santa Monica///contact_state: CA///contact_zip.postal_code: 90404///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM1238nnn/GSM1238202/GSM1238202_US22502615_251209751001_S01_A01.txt.gz///data_row_count: 20173
1
title: Ov_Tumor_Ref_Mix vs. CS-OV-059///geo_accession: GSM1238203///status: Public on Dec 26 2013///submission_date: Sep 23 2013///last_update_date: Dec 26 2013///type: RNA///channel_count: 2///source_name_ch1: 106 pooled ovarian samples///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian///characteristics_ch1.1: sample type: reference pool///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch1: Cy3///label_protocol_ch1: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch1: 9606///source_name_ch2: CS-OV-059///organism_ch2: Homo sapiens///characteristics_ch2: tissue: ovarian///characteristics_ch2.1: sample included in reference pool: YES///characteristics_ch2.2: sample rin: 9.3///characteristics_ch2.3: age at surgery: 42.17///characteristics_ch2.4: histology: Serous///characteristics_ch2.5: Stage: IA///characteristics_ch2.6: grade: 3///characteristics_ch2.7: tissue status: Recurrence///characteristics_ch2.8: follow up months: 16///characteristics_ch2.9: disease status: Not Free///characteristics_ch2.10: patient status: Dead///characteristics_ch2.11: disease state: Malignant ovarian///characteristics_ch2.12: ///molecule_ch2: total RNA///extract_protocol_ch2: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch2: Cy5///label_protocol_ch2: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch2: 9606///hyb_protocol: Slides were incubated for 16-17 hr at 60C and washed using the SSPE method described in the Agilent 60-mer Oligo Microarray Processing Protocol, Version 2.1. Slides were treated with Agilent Stabilization and Drying Solution, a wash was used to protect the dyes from ozone degradation.///scan_protocol: Scanned on an Agilent G2565BA scanner.///description: Malignant_ovarian_sample///data_processing: Agilent Feature Extraction Software (v7.5.1) was used for local background subtraction and Linear/LOWESS normalization. RejectMethod=Interquartile Range, nonuniformity outlier flagging enabled, population outlier flag enabled, ratio error model=hybrid, dye normalization select method = Rank Consistency Filter, no spatial detrend method applied.///data_processing.1: Agilent Feature Extraced data was imported into Rosetta Resolver version 7.1.1 (Rosetta Inpharmatics LLC, Cambridge, MA). Multiple probes with the same sequence code were combined into a single value using the Rosetta Resolver error-weighted averaging method for combining repeated measures.///platform_id: GPL7264///contact_name: Judy,,Dering///contact_email: [email protected]///contact_laboratory: Translational Oncology Research///contact_department: Medicine///contact_institute: UCLA School of Medicine///contact_address: 2825 Santa Monica Blvd. Suite 200///contact_city: Santa Monica///contact_state: CA///contact_zip.postal_code: 90404///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM1238nnn/GSM1238203/GSM1238203_US22502615_251209751002_S01_A01.txt.gz///data_row_count: 20173
1
title: Ov_Tumor_Ref_Mix vs. CS-OV-060///geo_accession: GSM1238204///status: Public on Dec 26 2013///submission_date: Sep 23 2013///last_update_date: Dec 26 2013///type: RNA///channel_count: 2///source_name_ch1: 106 pooled ovarian samples///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian///characteristics_ch1.1: sample type: reference pool///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch1: Cy3///label_protocol_ch1: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch1: 9606///source_name_ch2: CS-OV-060///organism_ch2: Homo sapiens///characteristics_ch2: tissue: ovarian///characteristics_ch2.1: sample included in reference pool: NO///characteristics_ch2.2: sample rin: 9.6///characteristics_ch2.3: age at surgery: 51.58///characteristics_ch2.4: histology: Endometrioid///characteristics_ch2.5: Stage: IIIB///characteristics_ch2.6: grade: 2///characteristics_ch2.7: tissue status: Recurrence///characteristics_ch2.8: follow up months: 56///characteristics_ch2.9: disease status: Not Free///characteristics_ch2.10: patient status: Dead///characteristics_ch2.11: disease state: Malignant ovarian///characteristics_ch2.12: ///molecule_ch2: total RNA///extract_protocol_ch2: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch2: Cy5///label_protocol_ch2: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch2: 9606///hyb_protocol: Slides were incubated for 16-17 hr at 60C and washed using the SSPE method described in the Agilent 60-mer Oligo Microarray Processing Protocol, Version 2.1. Slides were treated with Agilent Stabilization and Drying Solution, a wash was used to protect the dyes from ozone degradation.///scan_protocol: Scanned on an Agilent G2565BA scanner.///description: Malignant_ovarian_sample///data_processing: Agilent Feature Extraction Software (v7.5.1) was used for local background subtraction and Linear/LOWESS normalization. RejectMethod=Interquartile Range, nonuniformity outlier flagging enabled, population outlier flag enabled, ratio error model=hybrid, dye normalization select method = Rank Consistency Filter, no spatial detrend method applied.///data_processing.1: Agilent Feature Extraced data was imported into Rosetta Resolver version 7.1.1 (Rosetta Inpharmatics LLC, Cambridge, MA). Multiple probes with the same sequence code were combined into a single value using the Rosetta Resolver error-weighted averaging method for combining repeated measures.///platform_id: GPL7264///contact_name: Judy,,Dering///contact_email: [email protected]///contact_laboratory: Translational Oncology Research///contact_department: Medicine///contact_institute: UCLA School of Medicine///contact_address: 2825 Santa Monica Blvd. Suite 200///contact_city: Santa Monica///contact_state: CA///contact_zip.postal_code: 90404///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM1238nnn/GSM1238204/GSM1238204_US22502615_251209754144_S01_A01.txt.gz///data_row_count: 20173
1
title: Ov_Tumor_Ref_Mix vs. CS-OV-061///geo_accession: GSM1238205///status: Public on Dec 26 2013///submission_date: Sep 23 2013///last_update_date: Dec 26 2013///type: RNA///channel_count: 2///source_name_ch1: 106 pooled ovarian samples///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian///characteristics_ch1.1: sample type: reference pool///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch1: Cy3///label_protocol_ch1: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch1: 9606///source_name_ch2: CS-OV-061///organism_ch2: Homo sapiens///characteristics_ch2: tissue: ovarian///characteristics_ch2.1: sample included in reference pool: YES///characteristics_ch2.2: sample rin: 10///characteristics_ch2.3: age at surgery: 30.32///characteristics_ch2.4: histology: Serous///characteristics_ch2.5: Stage: IIIC///characteristics_ch2.6: grade: 1///characteristics_ch2.7: tissue status: Primary///characteristics_ch2.8: follow up months: 90///characteristics_ch2.9: disease status: Free///characteristics_ch2.10: patient status: Alive///characteristics_ch2.11: disease state: Borderline ovarian///characteristics_ch2.12: ///molecule_ch2: total RNA///extract_protocol_ch2: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch2: Cy5///label_protocol_ch2: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch2: 9606///hyb_protocol: Slides were incubated for 16-17 hr at 60C and washed using the SSPE method described in the Agilent 60-mer Oligo Microarray Processing Protocol, Version 2.1. Slides were treated with Agilent Stabilization and Drying Solution, a wash was used to protect the dyes from ozone degradation.///scan_protocol: Scanned on an Agilent G2565BA scanner.///description: Borderline_ovarian_sample///data_processing: Agilent Feature Extraction Software (v7.5.1) was used for local background subtraction and Linear/LOWESS normalization. RejectMethod=Interquartile Range, nonuniformity outlier flagging enabled, population outlier flag enabled, ratio error model=hybrid, dye normalization select method = Rank Consistency Filter, no spatial detrend method applied.///data_processing.1: Agilent Feature Extraced data was imported into Rosetta Resolver version 7.1.1 (Rosetta Inpharmatics LLC, Cambridge, MA). Multiple probes with the same sequence code were combined into a single value using the Rosetta Resolver error-weighted averaging method for combining repeated measures.///platform_id: GPL7264///contact_name: Judy,,Dering///contact_email: [email protected]///contact_laboratory: Translational Oncology Research///contact_department: Medicine///contact_institute: UCLA School of Medicine///contact_address: 2825 Santa Monica Blvd. Suite 200///contact_city: Santa Monica///contact_state: CA///contact_zip.postal_code: 90404///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM1238nnn/GSM1238205/GSM1238205_US22502615_251209750996_S01_A01.txt.gz///data_row_count: 20173
1
title: Ov_Tumor_Ref_Mix vs. CS-OV-062///geo_accession: GSM1238206///status: Public on Dec 26 2013///submission_date: Sep 23 2013///last_update_date: Dec 26 2013///type: RNA///channel_count: 2///source_name_ch1: 106 pooled ovarian samples///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian///characteristics_ch1.1: sample type: reference pool///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch1: Cy3///label_protocol_ch1: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch1: 9606///source_name_ch2: CS-OV-062///organism_ch2: Homo sapiens///characteristics_ch2: tissue: ovarian///characteristics_ch2.1: sample included in reference pool: YES///characteristics_ch2.2: sample rin: 9.9///characteristics_ch2.3: age at surgery: 48.71///characteristics_ch2.4: histology: Serous///characteristics_ch2.5: Stage: IV///characteristics_ch2.6: grade: 3///characteristics_ch2.7: tissue status: Primary///characteristics_ch2.8: tcga id: TCGA-23-1113///characteristics_ch2.9: follow up months: 31///characteristics_ch2.10: disease status: Not Free///characteristics_ch2.11: patient status: Dead///characteristics_ch2.12: disease state: Malignant ovarian///molecule_ch2: total RNA///extract_protocol_ch2: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch2: Cy5///label_protocol_ch2: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch2: 9606///hyb_protocol: Slides were incubated for 16-17 hr at 60C and washed using the SSPE method described in the Agilent 60-mer Oligo Microarray Processing Protocol, Version 2.1. Slides were treated with Agilent Stabilization and Drying Solution, a wash was used to protect the dyes from ozone degradation.///scan_protocol: Scanned on an Agilent G2565BA scanner.///description: Malignant_ovarian_sample///data_processing: Agilent Feature Extraction Software (v7.5.1) was used for local background subtraction and Linear/LOWESS normalization. RejectMethod=Interquartile Range, nonuniformity outlier flagging enabled, population outlier flag enabled, ratio error model=hybrid, dye normalization select method = Rank Consistency Filter, no spatial detrend method applied.///data_processing.1: Agilent Feature Extraced data was imported into Rosetta Resolver version 7.1.1 (Rosetta Inpharmatics LLC, Cambridge, MA). Multiple probes with the same sequence code were combined into a single value using the Rosetta Resolver error-weighted averaging method for combining repeated measures.///platform_id: GPL7264///contact_name: Judy,,Dering///contact_email: [email protected]///contact_laboratory: Translational Oncology Research///contact_department: Medicine///contact_institute: UCLA School of Medicine///contact_address: 2825 Santa Monica Blvd. Suite 200///contact_city: Santa Monica///contact_state: CA///contact_zip.postal_code: 90404///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM1238nnn/GSM1238206/GSM1238206_US22502615_251209750995_S01_A01.txt.gz///data_row_count: 20173
1
title: Ov_Tumor_Ref_Mix vs. CS-OV-063///geo_accession: GSM1238207///status: Public on Dec 26 2013///submission_date: Sep 23 2013///last_update_date: Dec 26 2013///type: RNA///channel_count: 2///source_name_ch1: 106 pooled ovarian samples///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian///characteristics_ch1.1: sample type: reference pool///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch1: Cy3///label_protocol_ch1: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch1: 9606///source_name_ch2: CS-OV-063///organism_ch2: Homo sapiens///characteristics_ch2: tissue: ovarian///characteristics_ch2.1: sample included in reference pool: NO///characteristics_ch2.2: sample rin: 8.6///characteristics_ch2.3: age at surgery: 59.96///characteristics_ch2.4: histology: Serous///characteristics_ch2.5: Stage: IIIC///characteristics_ch2.6: grade: 3///characteristics_ch2.7: tissue status: Recurrence///characteristics_ch2.8: follow up months: 47///characteristics_ch2.9: disease status: Not Free///characteristics_ch2.10: patient status: Dead///characteristics_ch2.11: disease state: Malignant ovarian///characteristics_ch2.12: ///molecule_ch2: total RNA///extract_protocol_ch2: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch2: Cy5///label_protocol_ch2: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch2: 9606///hyb_protocol: Slides were incubated for 16-17 hr at 60C and washed using the SSPE method described in the Agilent 60-mer Oligo Microarray Processing Protocol, Version 2.1. Slides were treated with Agilent Stabilization and Drying Solution, a wash was used to protect the dyes from ozone degradation.///scan_protocol: Scanned on an Agilent G2565BA scanner.///description: Malignant_ovarian_sample///data_processing: Agilent Feature Extraction Software (v7.5.1) was used for local background subtraction and Linear/LOWESS normalization. RejectMethod=Interquartile Range, nonuniformity outlier flagging enabled, population outlier flag enabled, ratio error model=hybrid, dye normalization select method = Rank Consistency Filter, no spatial detrend method applied.///data_processing.1: Agilent Feature Extraced data was imported into Rosetta Resolver version 7.1.1 (Rosetta Inpharmatics LLC, Cambridge, MA). Multiple probes with the same sequence code were combined into a single value using the Rosetta Resolver error-weighted averaging method for combining repeated measures.///platform_id: GPL7264///contact_name: Judy,,Dering///contact_email: [email protected]///contact_laboratory: Translational Oncology Research///contact_department: Medicine///contact_institute: UCLA School of Medicine///contact_address: 2825 Santa Monica Blvd. Suite 200///contact_city: Santa Monica///contact_state: CA///contact_zip.postal_code: 90404///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM1238nnn/GSM1238207/GSM1238207_US22502615_251209749839_S01_A01.txt.gz///data_row_count: 20173
1
title: Ov_Tumor_Ref_Mix vs. CS-OV-064///geo_accession: GSM1238208///status: Public on Dec 26 2013///submission_date: Sep 23 2013///last_update_date: Dec 26 2013///type: RNA///channel_count: 2///source_name_ch1: 106 pooled ovarian samples///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian///characteristics_ch1.1: sample type: reference pool///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch1: Cy3///label_protocol_ch1: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch1: 9606///source_name_ch2: CS-OV-064///organism_ch2: Homo sapiens///characteristics_ch2: tissue: ovarian///characteristics_ch2.1: sample included in reference pool: NO///characteristics_ch2.2: sample rin: 9.1///characteristics_ch2.3: age at surgery: 54.02///characteristics_ch2.4: histology: Serous///characteristics_ch2.5: Stage: IIIC/IA///characteristics_ch2.6: grade: 3///characteristics_ch2.7: tissue status: Primary///characteristics_ch2.8: follow up months: 64///characteristics_ch2.9: disease status: Free///characteristics_ch2.10: patient status: Alive///characteristics_ch2.11: disease state: Malignant ovarian///characteristics_ch2.12: ///molecule_ch2: total RNA///extract_protocol_ch2: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch2: Cy5///label_protocol_ch2: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch2: 9606///hyb_protocol: Slides were incubated for 16-17 hr at 60C and washed using the SSPE method described in the Agilent 60-mer Oligo Microarray Processing Protocol, Version 2.1. Slides were treated with Agilent Stabilization and Drying Solution, a wash was used to protect the dyes from ozone degradation.///scan_protocol: Scanned on an Agilent G2565BA scanner.///description: Malignant_ovarian_sample///data_processing: Agilent Feature Extraction Software (v7.5.1) was used for local background subtraction and Linear/LOWESS normalization. RejectMethod=Interquartile Range, nonuniformity outlier flagging enabled, population outlier flag enabled, ratio error model=hybrid, dye normalization select method = Rank Consistency Filter, no spatial detrend method applied.///data_processing.1: Agilent Feature Extraced data was imported into Rosetta Resolver version 7.1.1 (Rosetta Inpharmatics LLC, Cambridge, MA). Multiple probes with the same sequence code were combined into a single value using the Rosetta Resolver error-weighted averaging method for combining repeated measures.///platform_id: GPL7264///contact_name: Judy,,Dering///contact_email: [email protected]///contact_laboratory: Translational Oncology Research///contact_department: Medicine///contact_institute: UCLA School of Medicine///contact_address: 2825 Santa Monica Blvd. Suite 200///contact_city: Santa Monica///contact_state: CA///contact_zip.postal_code: 90404///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM1238nnn/GSM1238208/GSM1238208_US22502615_251209754725_S01_A01.txt.gz///data_row_count: 20173
1
title: Ov_Tumor_Ref_Mix vs. CS-OV-065///geo_accession: GSM1238209///status: Public on Dec 26 2013///submission_date: Sep 23 2013///last_update_date: Dec 26 2013///type: RNA///channel_count: 2///source_name_ch1: 106 pooled ovarian samples///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian///characteristics_ch1.1: sample type: reference pool///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch1: Cy3///label_protocol_ch1: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch1: 9606///source_name_ch2: CS-OV-065///organism_ch2: Homo sapiens///characteristics_ch2: tissue: ovarian///characteristics_ch2.1: sample included in reference pool: NO///characteristics_ch2.2: sample rin: 9.9///characteristics_ch2.3: age at surgery: 45.16///characteristics_ch2.4: histology: Serous///characteristics_ch2.5: Stage: IV///characteristics_ch2.6: grade: 3///characteristics_ch2.7: tissue status: Primary///characteristics_ch2.8: tcga id: TCGA-23-2084///characteristics_ch2.9: follow up months: 50///characteristics_ch2.10: disease status: Not Free///characteristics_ch2.11: patient status: Dead///characteristics_ch2.12: disease state: Malignant ovarian///molecule_ch2: total RNA///extract_protocol_ch2: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch2: Cy5///label_protocol_ch2: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch2: 9606///hyb_protocol: Slides were incubated for 16-17 hr at 60C and washed using the SSPE method described in the Agilent 60-mer Oligo Microarray Processing Protocol, Version 2.1. Slides were treated with Agilent Stabilization and Drying Solution, a wash was used to protect the dyes from ozone degradation.///scan_protocol: Scanned on an Agilent G2565BA scanner.///description: Malignant_ovarian_sample///data_processing: Agilent Feature Extraction Software (v7.5.1) was used for local background subtraction and Linear/LOWESS normalization. RejectMethod=Interquartile Range, nonuniformity outlier flagging enabled, population outlier flag enabled, ratio error model=hybrid, dye normalization select method = Rank Consistency Filter, no spatial detrend method applied.///data_processing.1: Agilent Feature Extraced data was imported into Rosetta Resolver version 7.1.1 (Rosetta Inpharmatics LLC, Cambridge, MA). Multiple probes with the same sequence code were combined into a single value using the Rosetta Resolver error-weighted averaging method for combining repeated measures.///platform_id: GPL7264///contact_name: Judy,,Dering///contact_email: [email protected]///contact_laboratory: Translational Oncology Research///contact_department: Medicine///contact_institute: UCLA School of Medicine///contact_address: 2825 Santa Monica Blvd. Suite 200///contact_city: Santa Monica///contact_state: CA///contact_zip.postal_code: 90404///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM1238nnn/GSM1238209/GSM1238209_US22502615_251209754133_S01_A01.txt.gz///data_row_count: 20173
1
title: Ov_Tumor_Ref_Mix vs. CS-OV-066///geo_accession: GSM1238210///status: Public on Dec 26 2013///submission_date: Sep 23 2013///last_update_date: Dec 26 2013///type: RNA///channel_count: 2///source_name_ch1: 106 pooled ovarian samples///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian///characteristics_ch1.1: sample type: reference pool///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch1: Cy3///label_protocol_ch1: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch1: 9606///source_name_ch2: CS-OV-066///organism_ch2: Homo sapiens///characteristics_ch2: tissue: ovarian///characteristics_ch2.1: sample included in reference pool: YES///characteristics_ch2.2: sample rin: 9.2///characteristics_ch2.3: age at surgery: 83.94///characteristics_ch2.4: histology: Serous///characteristics_ch2.5: Stage: IB///characteristics_ch2.6: grade: unknown///characteristics_ch2.7: tissue status: Primary///characteristics_ch2.8: follow up months: 159///characteristics_ch2.9: disease status: Free///characteristics_ch2.10: patient status: Dead///characteristics_ch2.11: disease state: Borderline ovarian///characteristics_ch2.12: ///molecule_ch2: total RNA///extract_protocol_ch2: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch2: Cy5///label_protocol_ch2: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch2: 9606///hyb_protocol: Slides were incubated for 16-17 hr at 60C and washed using the SSPE method described in the Agilent 60-mer Oligo Microarray Processing Protocol, Version 2.1. Slides were treated with Agilent Stabilization and Drying Solution, a wash was used to protect the dyes from ozone degradation.///scan_protocol: Scanned on an Agilent G2565BA scanner.///description: Borderline_ovarian_sample///data_processing: Agilent Feature Extraction Software (v7.5.1) was used for local background subtraction and Linear/LOWESS normalization. RejectMethod=Interquartile Range, nonuniformity outlier flagging enabled, population outlier flag enabled, ratio error model=hybrid, dye normalization select method = Rank Consistency Filter, no spatial detrend method applied.///data_processing.1: Agilent Feature Extraced data was imported into Rosetta Resolver version 7.1.1 (Rosetta Inpharmatics LLC, Cambridge, MA). Multiple probes with the same sequence code were combined into a single value using the Rosetta Resolver error-weighted averaging method for combining repeated measures.///platform_id: GPL7264///contact_name: Judy,,Dering///contact_email: [email protected]///contact_laboratory: Translational Oncology Research///contact_department: Medicine///contact_institute: UCLA School of Medicine///contact_address: 2825 Santa Monica Blvd. Suite 200///contact_city: Santa Monica///contact_state: CA///contact_zip.postal_code: 90404///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM1238nnn/GSM1238210/GSM1238210_US22502615_251209749643_S01_A01.txt.gz///data_row_count: 20173
1
title: Ov_Tumor_Ref_Mix vs. CS-OV-067///geo_accession: GSM1238211///status: Public on Dec 26 2013///submission_date: Sep 23 2013///last_update_date: Dec 26 2013///type: RNA///channel_count: 2///source_name_ch1: 106 pooled ovarian samples///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian///characteristics_ch1.1: sample type: reference pool///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch1: Cy3///label_protocol_ch1: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch1: 9606///source_name_ch2: CS-OV-067///organism_ch2: Homo sapiens///characteristics_ch2: tissue: ovarian///characteristics_ch2.1: sample included in reference pool: NO///characteristics_ch2.2: sample rin: 7.2///characteristics_ch2.3: age at surgery: 67.48///characteristics_ch2.4: histology: Serous///characteristics_ch2.5: Stage: IB///characteristics_ch2.6: grade: 1///characteristics_ch2.7: tissue status: Primary///characteristics_ch2.8: follow up months: 74///characteristics_ch2.9: disease status: Free///characteristics_ch2.10: patient status: Alive///characteristics_ch2.11: disease state: Borderline ovarian///characteristics_ch2.12: ///molecule_ch2: total RNA///extract_protocol_ch2: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch2: Cy5///label_protocol_ch2: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch2: 9606///hyb_protocol: Slides were incubated for 16-17 hr at 60C and washed using the SSPE method described in the Agilent 60-mer Oligo Microarray Processing Protocol, Version 2.1. Slides were treated with Agilent Stabilization and Drying Solution, a wash was used to protect the dyes from ozone degradation.///scan_protocol: Scanned on an Agilent G2565BA scanner.///description: Borderline_ovarian_sample///data_processing: Agilent Feature Extraction Software (v7.5.1) was used for local background subtraction and Linear/LOWESS normalization. RejectMethod=Interquartile Range, nonuniformity outlier flagging enabled, population outlier flag enabled, ratio error model=hybrid, dye normalization select method = Rank Consistency Filter, no spatial detrend method applied.///data_processing.1: Agilent Feature Extraced data was imported into Rosetta Resolver version 7.1.1 (Rosetta Inpharmatics LLC, Cambridge, MA). Multiple probes with the same sequence code were combined into a single value using the Rosetta Resolver error-weighted averaging method for combining repeated measures.///platform_id: GPL7264///contact_name: Judy,,Dering///contact_email: [email protected]///contact_laboratory: Translational Oncology Research///contact_department: Medicine///contact_institute: UCLA School of Medicine///contact_address: 2825 Santa Monica Blvd. Suite 200///contact_city: Santa Monica///contact_state: CA///contact_zip.postal_code: 90404///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM1238nnn/GSM1238211/GSM1238211_US22502615_251209754132_S01_A01.txt.gz///data_row_count: 20173
1
title: Ov_Tumor_Ref_Mix vs. CS-OV-068///geo_accession: GSM1238212///status: Public on Dec 26 2013///submission_date: Sep 23 2013///last_update_date: Dec 26 2013///type: RNA///channel_count: 2///source_name_ch1: 106 pooled ovarian samples///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian///characteristics_ch1.1: sample type: reference pool///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch1: Cy3///label_protocol_ch1: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch1: 9606///source_name_ch2: CS-OV-068///organism_ch2: Homo sapiens///characteristics_ch2: tissue: ovarian///characteristics_ch2.1: sample included in reference pool: NO///characteristics_ch2.2: sample rin: 8.9///characteristics_ch2.3: age at surgery: 63.58///characteristics_ch2.4: histology: Benign///characteristics_ch2.5: tissue status: Benign///characteristics_ch2.6: follow up months: 87///characteristics_ch2.7: disease status: Free///characteristics_ch2.8: patient status: Alive///characteristics_ch2.9: disease state: Benign ovarian///characteristics_ch2.10: ///characteristics_ch2.11: ///characteristics_ch2.12: ///molecule_ch2: total RNA///extract_protocol_ch2: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch2: Cy5///label_protocol_ch2: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch2: 9606///hyb_protocol: Slides were incubated for 16-17 hr at 60C and washed using the SSPE method described in the Agilent 60-mer Oligo Microarray Processing Protocol, Version 2.1. Slides were treated with Agilent Stabilization and Drying Solution, a wash was used to protect the dyes from ozone degradation.///scan_protocol: Scanned on an Agilent G2565BA scanner.///description: Benign_ovarian_sample///data_processing: Agilent Feature Extraction Software (v7.5.1) was used for local background subtraction and Linear/LOWESS normalization. RejectMethod=Interquartile Range, nonuniformity outlier flagging enabled, population outlier flag enabled, ratio error model=hybrid, dye normalization select method = Rank Consistency Filter, no spatial detrend method applied.///data_processing.1: Agilent Feature Extraced data was imported into Rosetta Resolver version 7.1.1 (Rosetta Inpharmatics LLC, Cambridge, MA). Multiple probes with the same sequence code were combined into a single value using the Rosetta Resolver error-weighted averaging method for combining repeated measures.///platform_id: GPL7264///contact_name: Judy,,Dering///contact_email: [email protected]///contact_laboratory: Translational Oncology Research///contact_department: Medicine///contact_institute: UCLA School of Medicine///contact_address: 2825 Santa Monica Blvd. Suite 200///contact_city: Santa Monica///contact_state: CA///contact_zip.postal_code: 90404///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM1238nnn/GSM1238212/GSM1238212_US22502615_251209754111_S01_A01.txt.gz///data_row_count: 20173
1
title: Ov_Tumor_Ref_Mix vs. CS-OV-069///geo_accession: GSM1238213///status: Public on Dec 26 2013///submission_date: Sep 23 2013///last_update_date: Dec 26 2013///type: RNA///channel_count: 2///source_name_ch1: 106 pooled ovarian samples///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian///characteristics_ch1.1: sample type: reference pool///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch1: Cy3///label_protocol_ch1: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch1: 9606///source_name_ch2: CS-OV-069///organism_ch2: Homo sapiens///characteristics_ch2: tissue: ovarian///characteristics_ch2.1: sample included in reference pool: NO///characteristics_ch2.2: sample rin: 9.1///characteristics_ch2.3: age at surgery: 57.43///characteristics_ch2.4: histology: Serous///characteristics_ch2.5: Stage: IIIC///characteristics_ch2.6: grade: 3///characteristics_ch2.7: tissue status: Primary///characteristics_ch2.8: follow up months: 101///characteristics_ch2.9: disease status: Free///characteristics_ch2.10: patient status: Alive///characteristics_ch2.11: disease state: Malignant ovarian///characteristics_ch2.12: ///molecule_ch2: total RNA///extract_protocol_ch2: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch2: Cy5///label_protocol_ch2: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch2: 9606///hyb_protocol: Slides were incubated for 16-17 hr at 60C and washed using the SSPE method described in the Agilent 60-mer Oligo Microarray Processing Protocol, Version 2.1. Slides were treated with Agilent Stabilization and Drying Solution, a wash was used to protect the dyes from ozone degradation.///scan_protocol: Scanned on an Agilent G2565BA scanner.///description: Malignant_ovarian_sample///data_processing: Agilent Feature Extraction Software (v7.5.1) was used for local background subtraction and Linear/LOWESS normalization. RejectMethod=Interquartile Range, nonuniformity outlier flagging enabled, population outlier flag enabled, ratio error model=hybrid, dye normalization select method = Rank Consistency Filter, no spatial detrend method applied.///data_processing.1: Agilent Feature Extraced data was imported into Rosetta Resolver version 7.1.1 (Rosetta Inpharmatics LLC, Cambridge, MA). Multiple probes with the same sequence code were combined into a single value using the Rosetta Resolver error-weighted averaging method for combining repeated measures.///platform_id: GPL7264///contact_name: Judy,,Dering///contact_email: [email protected]///contact_laboratory: Translational Oncology Research///contact_department: Medicine///contact_institute: UCLA School of Medicine///contact_address: 2825 Santa Monica Blvd. Suite 200///contact_city: Santa Monica///contact_state: CA///contact_zip.postal_code: 90404///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM1238nnn/GSM1238213/GSM1238213_US22502615_251209749502_S01_A01.txt.gz///data_row_count: 20173
1
title: Ov_Tumor_Ref_Mix vs. CS-OV-070///geo_accession: GSM1238214///status: Public on Dec 26 2013///submission_date: Sep 23 2013///last_update_date: Dec 26 2013///type: RNA///channel_count: 2///source_name_ch1: 106 pooled ovarian samples///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian///characteristics_ch1.1: sample type: reference pool///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch1: Cy3///label_protocol_ch1: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch1: 9606///source_name_ch2: CS-OV-070///organism_ch2: Homo sapiens///characteristics_ch2: tissue: ovarian///characteristics_ch2.1: sample included in reference pool: YES///characteristics_ch2.2: sample rin: 9.9///characteristics_ch2.3: age at surgery: 80.93///characteristics_ch2.4: histology: Clear Cell///characteristics_ch2.5: Stage: IA///characteristics_ch2.6: grade: 3///characteristics_ch2.7: tissue status: Primary///characteristics_ch2.8: follow up months: 96///characteristics_ch2.9: disease status: Not Free///characteristics_ch2.10: patient status: Dead///characteristics_ch2.11: disease state: Malignant ovarian///characteristics_ch2.12: ///molecule_ch2: total RNA///extract_protocol_ch2: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch2: Cy5///label_protocol_ch2: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch2: 9606///hyb_protocol: Slides were incubated for 16-17 hr at 60C and washed using the SSPE method described in the Agilent 60-mer Oligo Microarray Processing Protocol, Version 2.1. Slides were treated with Agilent Stabilization and Drying Solution, a wash was used to protect the dyes from ozone degradation.///scan_protocol: Scanned on an Agilent G2565BA scanner.///description: Malignant_ovarian_sample///data_processing: Agilent Feature Extraction Software (v7.5.1) was used for local background subtraction and Linear/LOWESS normalization. RejectMethod=Interquartile Range, nonuniformity outlier flagging enabled, population outlier flag enabled, ratio error model=hybrid, dye normalization select method = Rank Consistency Filter, no spatial detrend method applied.///data_processing.1: Agilent Feature Extraced data was imported into Rosetta Resolver version 7.1.1 (Rosetta Inpharmatics LLC, Cambridge, MA). Multiple probes with the same sequence code were combined into a single value using the Rosetta Resolver error-weighted averaging method for combining repeated measures.///platform_id: GPL7264///contact_name: Judy,,Dering///contact_email: [email protected]///contact_laboratory: Translational Oncology Research///contact_department: Medicine///contact_institute: UCLA School of Medicine///contact_address: 2825 Santa Monica Blvd. Suite 200///contact_city: Santa Monica///contact_state: CA///contact_zip.postal_code: 90404///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM1238nnn/GSM1238214/GSM1238214_US22502615_251209751009_S01_A01.txt.gz///data_row_count: 20173
1
title: Ov_Tumor_Ref_Mix vs. CS-OV-071///geo_accession: GSM1238215///status: Public on Dec 26 2013///submission_date: Sep 23 2013///last_update_date: Dec 26 2013///type: RNA///channel_count: 2///source_name_ch1: 106 pooled ovarian samples///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian///characteristics_ch1.1: sample type: reference pool///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch1: Cy3///label_protocol_ch1: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch1: 9606///source_name_ch2: CS-OV-071///organism_ch2: Homo sapiens///characteristics_ch2: tissue: ovarian///characteristics_ch2.1: sample included in reference pool: YES///characteristics_ch2.2: sample rin: 9.4///characteristics_ch2.3: age at surgery: 28.39///characteristics_ch2.4: histology: Serous///characteristics_ch2.5: Stage: IIIC///characteristics_ch2.6: grade: 3///characteristics_ch2.7: tissue status: Recurrence///characteristics_ch2.8: follow up months: 43///characteristics_ch2.9: disease status: Not Free///characteristics_ch2.10: patient status: Dead///characteristics_ch2.11: disease state: Malignant ovarian///characteristics_ch2.12: ///molecule_ch2: total RNA///extract_protocol_ch2: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch2: Cy5///label_protocol_ch2: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch2: 9606///hyb_protocol: Slides were incubated for 16-17 hr at 60C and washed using the SSPE method described in the Agilent 60-mer Oligo Microarray Processing Protocol, Version 2.1. Slides were treated with Agilent Stabilization and Drying Solution, a wash was used to protect the dyes from ozone degradation.///scan_protocol: Scanned on an Agilent G2565BA scanner.///description: Malignant_ovarian_sample///data_processing: Agilent Feature Extraction Software (v7.5.1) was used for local background subtraction and Linear/LOWESS normalization. RejectMethod=Interquartile Range, nonuniformity outlier flagging enabled, population outlier flag enabled, ratio error model=hybrid, dye normalization select method = Rank Consistency Filter, no spatial detrend method applied.///data_processing.1: Agilent Feature Extraced data was imported into Rosetta Resolver version 7.1.1 (Rosetta Inpharmatics LLC, Cambridge, MA). Multiple probes with the same sequence code were combined into a single value using the Rosetta Resolver error-weighted averaging method for combining repeated measures.///platform_id: GPL7264///contact_name: Judy,,Dering///contact_email: [email protected]///contact_laboratory: Translational Oncology Research///contact_department: Medicine///contact_institute: UCLA School of Medicine///contact_address: 2825 Santa Monica Blvd. Suite 200///contact_city: Santa Monica///contact_state: CA///contact_zip.postal_code: 90404///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM1238nnn/GSM1238215/GSM1238215_US22502615_251209747450_S01_A01.txt.gz///data_row_count: 20173
1
title: Ov_Tumor_Ref_Mix vs. CS-OV-072///geo_accession: GSM1238216///status: Public on Dec 26 2013///submission_date: Sep 23 2013///last_update_date: Dec 26 2013///type: RNA///channel_count: 2///source_name_ch1: 106 pooled ovarian samples///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian///characteristics_ch1.1: sample type: reference pool///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch1: Cy3///label_protocol_ch1: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch1: 9606///source_name_ch2: CS-OV-072///organism_ch2: Homo sapiens///characteristics_ch2: tissue: ovarian///characteristics_ch2.1: sample included in reference pool: NO///characteristics_ch2.2: sample rin: 9.7///characteristics_ch2.3: age at surgery: 73.52///characteristics_ch2.4: histology: Serous///characteristics_ch2.5: Stage: IIIB///characteristics_ch2.6: grade: 1///characteristics_ch2.7: tissue status: Primary///characteristics_ch2.8: follow up months: 36///characteristics_ch2.9: disease status: Not Free///characteristics_ch2.10: patient status: Dead///characteristics_ch2.11: disease state: Malignant ovarian///characteristics_ch2.12: ///molecule_ch2: total RNA///extract_protocol_ch2: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch2: Cy5///label_protocol_ch2: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch2: 9606///hyb_protocol: Slides were incubated for 16-17 hr at 60C and washed using the SSPE method described in the Agilent 60-mer Oligo Microarray Processing Protocol, Version 2.1. Slides were treated with Agilent Stabilization and Drying Solution, a wash was used to protect the dyes from ozone degradation.///scan_protocol: Scanned on an Agilent G2565BA scanner.///description: Malignant_ovarian_sample///data_processing: Agilent Feature Extraction Software (v7.5.1) was used for local background subtraction and Linear/LOWESS normalization. RejectMethod=Interquartile Range, nonuniformity outlier flagging enabled, population outlier flag enabled, ratio error model=hybrid, dye normalization select method = Rank Consistency Filter, no spatial detrend method applied.///data_processing.1: Agilent Feature Extraced data was imported into Rosetta Resolver version 7.1.1 (Rosetta Inpharmatics LLC, Cambridge, MA). Multiple probes with the same sequence code were combined into a single value using the Rosetta Resolver error-weighted averaging method for combining repeated measures.///platform_id: GPL7264///contact_name: Judy,,Dering///contact_email: [email protected]///contact_laboratory: Translational Oncology Research///contact_department: Medicine///contact_institute: UCLA School of Medicine///contact_address: 2825 Santa Monica Blvd. Suite 200///contact_city: Santa Monica///contact_state: CA///contact_zip.postal_code: 90404///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM1238nnn/GSM1238216/GSM1238216_US22502615_251209754724_S01_A01.txt.gz///data_row_count: 20173
1
title: Ov_Tumor_Ref_Mix vs. CS-OV-073///geo_accession: GSM1238217///status: Public on Dec 26 2013///submission_date: Sep 23 2013///last_update_date: Dec 26 2013///type: RNA///channel_count: 2///source_name_ch1: 106 pooled ovarian samples///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian///characteristics_ch1.1: sample type: reference pool///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch1: Cy3///label_protocol_ch1: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch1: 9606///source_name_ch2: CS-OV-073///organism_ch2: Homo sapiens///characteristics_ch2: tissue: ovarian///characteristics_ch2.1: sample included in reference pool: NO///characteristics_ch2.2: sample rin: 9.3///characteristics_ch2.3: age at surgery: 65.23///characteristics_ch2.4: histology: Serous///characteristics_ch2.5: Stage: IIIC///characteristics_ch2.6: grade: 3///characteristics_ch2.7: tissue status: Primary///characteristics_ch2.8: tcga id: TCGA-23-1023///characteristics_ch2.9: follow up months: 67///characteristics_ch2.10: disease status: Not Free///characteristics_ch2.11: patient status: Alive///characteristics_ch2.12: disease state: Malignant ovarian///molecule_ch2: total RNA///extract_protocol_ch2: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch2: Cy5///label_protocol_ch2: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch2: 9606///hyb_protocol: Slides were incubated for 16-17 hr at 60C and washed using the SSPE method described in the Agilent 60-mer Oligo Microarray Processing Protocol, Version 2.1. Slides were treated with Agilent Stabilization and Drying Solution, a wash was used to protect the dyes from ozone degradation.///scan_protocol: Scanned on an Agilent G2565BA scanner.///description: Malignant_ovarian_sample///data_processing: Agilent Feature Extraction Software (v7.5.1) was used for local background subtraction and Linear/LOWESS normalization. RejectMethod=Interquartile Range, nonuniformity outlier flagging enabled, population outlier flag enabled, ratio error model=hybrid, dye normalization select method = Rank Consistency Filter, no spatial detrend method applied.///data_processing.1: Agilent Feature Extraced data was imported into Rosetta Resolver version 7.1.1 (Rosetta Inpharmatics LLC, Cambridge, MA). Multiple probes with the same sequence code were combined into a single value using the Rosetta Resolver error-weighted averaging method for combining repeated measures.///platform_id: GPL7264///contact_name: Judy,,Dering///contact_email: [email protected]///contact_laboratory: Translational Oncology Research///contact_department: Medicine///contact_institute: UCLA School of Medicine///contact_address: 2825 Santa Monica Blvd. Suite 200///contact_city: Santa Monica///contact_state: CA///contact_zip.postal_code: 90404///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM1238nnn/GSM1238217/GSM1238217_US22502615_251209754782_S01_A01.txt.gz///data_row_count: 20173
1
title: Ov_Tumor_Ref_Mix vs. CS-OV-074///geo_accession: GSM1238218///status: Public on Dec 26 2013///submission_date: Sep 23 2013///last_update_date: Dec 26 2013///type: RNA///channel_count: 2///source_name_ch1: 106 pooled ovarian samples///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian///characteristics_ch1.1: sample type: reference pool///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch1: Cy3///label_protocol_ch1: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch1: 9606///source_name_ch2: CS-OV-074///organism_ch2: Homo sapiens///characteristics_ch2: tissue: ovarian///characteristics_ch2.1: sample included in reference pool: YES///characteristics_ch2.2: sample rin: 9///characteristics_ch2.3: age at surgery: 45.61///characteristics_ch2.4: histology: Benign///characteristics_ch2.5: tissue status: Benign///characteristics_ch2.6: disease status: Benign///characteristics_ch2.7: patient status: Benign///characteristics_ch2.8: disease state: Benign ovarian///characteristics_ch2.9: ///characteristics_ch2.10: ///characteristics_ch2.11: ///characteristics_ch2.12: ///molecule_ch2: total RNA///extract_protocol_ch2: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch2: Cy5///label_protocol_ch2: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch2: 9606///hyb_protocol: Slides were incubated for 16-17 hr at 60C and washed using the SSPE method described in the Agilent 60-mer Oligo Microarray Processing Protocol, Version 2.1. Slides were treated with Agilent Stabilization and Drying Solution, a wash was used to protect the dyes from ozone degradation.///scan_protocol: Scanned on an Agilent G2565BA scanner.///description: Benign_ovarian_sample///data_processing: Agilent Feature Extraction Software (v7.5.1) was used for local background subtraction and Linear/LOWESS normalization. RejectMethod=Interquartile Range, nonuniformity outlier flagging enabled, population outlier flag enabled, ratio error model=hybrid, dye normalization select method = Rank Consistency Filter, no spatial detrend method applied.///data_processing.1: Agilent Feature Extraced data was imported into Rosetta Resolver version 7.1.1 (Rosetta Inpharmatics LLC, Cambridge, MA). Multiple probes with the same sequence code were combined into a single value using the Rosetta Resolver error-weighted averaging method for combining repeated measures.///platform_id: GPL7264///contact_name: Judy,,Dering///contact_email: [email protected]///contact_laboratory: Translational Oncology Research///contact_department: Medicine///contact_institute: UCLA School of Medicine///contact_address: 2825 Santa Monica Blvd. Suite 200///contact_city: Santa Monica///contact_state: CA///contact_zip.postal_code: 90404///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM1238nnn/GSM1238218/GSM1238218_US22502615_251209747078_S01_A01.txt.gz///data_row_count: 20173
1
title: Ov_Tumor_Ref_Mix vs. CS-OV-075///geo_accession: GSM1238219///status: Public on Dec 26 2013///submission_date: Sep 23 2013///last_update_date: Dec 26 2013///type: RNA///channel_count: 2///source_name_ch1: 106 pooled ovarian samples///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian///characteristics_ch1.1: sample type: reference pool///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch1: Cy3///label_protocol_ch1: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch1: 9606///source_name_ch2: CS-OV-075///organism_ch2: Homo sapiens///characteristics_ch2: tissue: ovarian///characteristics_ch2.1: sample included in reference pool: NO///characteristics_ch2.2: sample rin: 8.9///characteristics_ch2.3: age at surgery: 72.21///characteristics_ch2.4: histology: Serous///characteristics_ch2.5: Stage: IC///characteristics_ch2.6: grade: 0///characteristics_ch2.7: tissue status: Primary///characteristics_ch2.8: follow up months: 98///characteristics_ch2.9: disease status: Unknown///characteristics_ch2.10: patient status: Dead///characteristics_ch2.11: disease state: Borderline ovarian///characteristics_ch2.12: ///molecule_ch2: total RNA///extract_protocol_ch2: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch2: Cy5///label_protocol_ch2: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch2: 9606///hyb_protocol: Slides were incubated for 16-17 hr at 60C and washed using the SSPE method described in the Agilent 60-mer Oligo Microarray Processing Protocol, Version 2.1. Slides were treated with Agilent Stabilization and Drying Solution, a wash was used to protect the dyes from ozone degradation.///scan_protocol: Scanned on an Agilent G2565BA scanner.///description: Borderline_ovarian_sample///data_processing: Agilent Feature Extraction Software (v7.5.1) was used for local background subtraction and Linear/LOWESS normalization. RejectMethod=Interquartile Range, nonuniformity outlier flagging enabled, population outlier flag enabled, ratio error model=hybrid, dye normalization select method = Rank Consistency Filter, no spatial detrend method applied.///data_processing.1: Agilent Feature Extraced data was imported into Rosetta Resolver version 7.1.1 (Rosetta Inpharmatics LLC, Cambridge, MA). Multiple probes with the same sequence code were combined into a single value using the Rosetta Resolver error-weighted averaging method for combining repeated measures.///platform_id: GPL7264///contact_name: Judy,,Dering///contact_email: [email protected]///contact_laboratory: Translational Oncology Research///contact_department: Medicine///contact_institute: UCLA School of Medicine///contact_address: 2825 Santa Monica Blvd. Suite 200///contact_city: Santa Monica///contact_state: CA///contact_zip.postal_code: 90404///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM1238nnn/GSM1238219/GSM1238219_US22502615_251209754148_S01_A01.txt.gz///data_row_count: 20173
1
title: Ov_Tumor_Ref_Mix vs. CS-OV-076///geo_accession: GSM1238220///status: Public on Dec 26 2013///submission_date: Sep 23 2013///last_update_date: Dec 26 2013///type: RNA///channel_count: 2///source_name_ch1: 106 pooled ovarian samples///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian///characteristics_ch1.1: sample type: reference pool///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch1: Cy3///label_protocol_ch1: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch1: 9606///source_name_ch2: CS-OV-076///organism_ch2: Homo sapiens///characteristics_ch2: tissue: ovarian///characteristics_ch2.1: sample included in reference pool: NO///characteristics_ch2.2: sample rin: 8///characteristics_ch2.3: age at surgery: 67.35///characteristics_ch2.4: histology: Serous///characteristics_ch2.5: Stage: IIIC///characteristics_ch2.6: grade: 2///characteristics_ch2.7: tissue status: Primary///characteristics_ch2.8: follow up months: 37///characteristics_ch2.9: disease status: Not Free///characteristics_ch2.10: patient status: Dead///characteristics_ch2.11: disease state: Malignant ovarian///characteristics_ch2.12: ///molecule_ch2: total RNA///extract_protocol_ch2: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch2: Cy5///label_protocol_ch2: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch2: 9606///hyb_protocol: Slides were incubated for 16-17 hr at 60C and washed using the SSPE method described in the Agilent 60-mer Oligo Microarray Processing Protocol, Version 2.1. Slides were treated with Agilent Stabilization and Drying Solution, a wash was used to protect the dyes from ozone degradation.///scan_protocol: Scanned on an Agilent G2565BA scanner.///description: Malignant_ovarian_sample///data_processing: Agilent Feature Extraction Software (v7.5.1) was used for local background subtraction and Linear/LOWESS normalization. RejectMethod=Interquartile Range, nonuniformity outlier flagging enabled, population outlier flag enabled, ratio error model=hybrid, dye normalization select method = Rank Consistency Filter, no spatial detrend method applied.///data_processing.1: Agilent Feature Extraced data was imported into Rosetta Resolver version 7.1.1 (Rosetta Inpharmatics LLC, Cambridge, MA). Multiple probes with the same sequence code were combined into a single value using the Rosetta Resolver error-weighted averaging method for combining repeated measures.///platform_id: GPL7264///contact_name: Judy,,Dering///contact_email: [email protected]///contact_laboratory: Translational Oncology Research///contact_department: Medicine///contact_institute: UCLA School of Medicine///contact_address: 2825 Santa Monica Blvd. Suite 200///contact_city: Santa Monica///contact_state: CA///contact_zip.postal_code: 90404///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM1238nnn/GSM1238220/GSM1238220_US22502615_251209754237_S01_A01.txt.gz///data_row_count: 20173
1
title: Ov_Tumor_Ref_Mix vs. CS-OV-077///geo_accession: GSM1238221///status: Public on Dec 26 2013///submission_date: Sep 23 2013///last_update_date: Dec 26 2013///type: RNA///channel_count: 2///source_name_ch1: 106 pooled ovarian samples///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian///characteristics_ch1.1: sample type: reference pool///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch1: Cy3///label_protocol_ch1: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch1: 9606///source_name_ch2: CS-OV-077///organism_ch2: Homo sapiens///characteristics_ch2: tissue: ovarian///characteristics_ch2.1: sample included in reference pool: NO///characteristics_ch2.2: sample rin: 9.4///characteristics_ch2.3: age at surgery: 48.15///characteristics_ch2.4: histology: Serous///characteristics_ch2.5: Stage: IIIC///characteristics_ch2.6: grade: 3///characteristics_ch2.7: tissue status: Primary///characteristics_ch2.8: tcga id: TCGA-23-1027///characteristics_ch2.9: follow up months: 32///characteristics_ch2.10: disease status: Not Free///characteristics_ch2.11: patient status: Dead///characteristics_ch2.12: disease state: Malignant ovarian///molecule_ch2: total RNA///extract_protocol_ch2: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch2: Cy5///label_protocol_ch2: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch2: 9606///hyb_protocol: Slides were incubated for 16-17 hr at 60C and washed using the SSPE method described in the Agilent 60-mer Oligo Microarray Processing Protocol, Version 2.1. Slides were treated with Agilent Stabilization and Drying Solution, a wash was used to protect the dyes from ozone degradation.///scan_protocol: Scanned on an Agilent G2565BA scanner.///description: Malignant_ovarian_sample///data_processing: Agilent Feature Extraction Software (v7.5.1) was used for local background subtraction and Linear/LOWESS normalization. RejectMethod=Interquartile Range, nonuniformity outlier flagging enabled, population outlier flag enabled, ratio error model=hybrid, dye normalization select method = Rank Consistency Filter, no spatial detrend method applied.///data_processing.1: Agilent Feature Extraced data was imported into Rosetta Resolver version 7.1.1 (Rosetta Inpharmatics LLC, Cambridge, MA). Multiple probes with the same sequence code were combined into a single value using the Rosetta Resolver error-weighted averaging method for combining repeated measures.///platform_id: GPL7264///contact_name: Judy,,Dering///contact_email: [email protected]///contact_laboratory: Translational Oncology Research///contact_department: Medicine///contact_institute: UCLA School of Medicine///contact_address: 2825 Santa Monica Blvd. Suite 200///contact_city: Santa Monica///contact_state: CA///contact_zip.postal_code: 90404///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM1238nnn/GSM1238221/GSM1238221_US22502615_251209754776_S01_A01.txt.gz///data_row_count: 20173
1
title: Ov_Tumor_Ref_Mix vs. CS-OV-078///geo_accession: GSM1238222///status: Public on Dec 26 2013///submission_date: Sep 23 2013///last_update_date: Dec 26 2013///type: RNA///channel_count: 2///source_name_ch1: 106 pooled ovarian samples///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian///characteristics_ch1.1: sample type: reference pool///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch1: Cy3///label_protocol_ch1: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch1: 9606///source_name_ch2: CS-OV-078///organism_ch2: Homo sapiens///characteristics_ch2: tissue: ovarian///characteristics_ch2.1: sample included in reference pool: YES///characteristics_ch2.2: sample rin: 9///characteristics_ch2.3: age at surgery: 68.88///characteristics_ch2.4: histology: Serous///characteristics_ch2.5: Stage: IV///characteristics_ch2.6: grade: 3///characteristics_ch2.7: tissue status: Primary///characteristics_ch2.8: follow up months: 12///characteristics_ch2.9: disease status: Not Free///characteristics_ch2.10: patient status: Dead///characteristics_ch2.11: disease state: Malignant ovarian///characteristics_ch2.12: ///molecule_ch2: total RNA///extract_protocol_ch2: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch2: Cy5///label_protocol_ch2: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch2: 9606///hyb_protocol: Slides were incubated for 16-17 hr at 60C and washed using the SSPE method described in the Agilent 60-mer Oligo Microarray Processing Protocol, Version 2.1. Slides were treated with Agilent Stabilization and Drying Solution, a wash was used to protect the dyes from ozone degradation.///scan_protocol: Scanned on an Agilent G2565BA scanner.///description: Malignant_ovarian_sample///data_processing: Agilent Feature Extraction Software (v7.5.1) was used for local background subtraction and Linear/LOWESS normalization. RejectMethod=Interquartile Range, nonuniformity outlier flagging enabled, population outlier flag enabled, ratio error model=hybrid, dye normalization select method = Rank Consistency Filter, no spatial detrend method applied.///data_processing.1: Agilent Feature Extraced data was imported into Rosetta Resolver version 7.1.1 (Rosetta Inpharmatics LLC, Cambridge, MA). Multiple probes with the same sequence code were combined into a single value using the Rosetta Resolver error-weighted averaging method for combining repeated measures.///platform_id: GPL7264///contact_name: Judy,,Dering///contact_email: [email protected]///contact_laboratory: Translational Oncology Research///contact_department: Medicine///contact_institute: UCLA School of Medicine///contact_address: 2825 Santa Monica Blvd. Suite 200///contact_city: Santa Monica///contact_state: CA///contact_zip.postal_code: 90404///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM1238nnn/GSM1238222/GSM1238222_US22502615_251209747449_S01_A01.txt.gz///data_row_count: 20173
1
title: Ov_Tumor_Ref_Mix vs. CS-OV-079///geo_accession: GSM1238223///status: Public on Dec 26 2013///submission_date: Sep 23 2013///last_update_date: Dec 26 2013///type: RNA///channel_count: 2///source_name_ch1: 106 pooled ovarian samples///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian///characteristics_ch1.1: sample type: reference pool///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch1: Cy3///label_protocol_ch1: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch1: 9606///source_name_ch2: CS-OV-079///organism_ch2: Homo sapiens///characteristics_ch2: tissue: ovarian///characteristics_ch2.1: sample included in reference pool: NO///characteristics_ch2.2: sample rin: 9.2///characteristics_ch2.3: age at surgery: 63.50///characteristics_ch2.4: histology: Serous///characteristics_ch2.5: Stage: IIIC///characteristics_ch2.6: grade: 2///characteristics_ch2.7: tissue status: Primary///characteristics_ch2.8: follow up months: 27///characteristics_ch2.9: disease status: Not Free///characteristics_ch2.10: patient status: Dead///characteristics_ch2.11: disease state: Malignant ovarian///characteristics_ch2.12: ///molecule_ch2: total RNA///extract_protocol_ch2: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch2: Cy5///label_protocol_ch2: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch2: 9606///hyb_protocol: Slides were incubated for 16-17 hr at 60C and washed using the SSPE method described in the Agilent 60-mer Oligo Microarray Processing Protocol, Version 2.1. Slides were treated with Agilent Stabilization and Drying Solution, a wash was used to protect the dyes from ozone degradation.///scan_protocol: Scanned on an Agilent G2565BA scanner.///description: Malignant_ovarian_sample///data_processing: Agilent Feature Extraction Software (v7.5.1) was used for local background subtraction and Linear/LOWESS normalization. RejectMethod=Interquartile Range, nonuniformity outlier flagging enabled, population outlier flag enabled, ratio error model=hybrid, dye normalization select method = Rank Consistency Filter, no spatial detrend method applied.///data_processing.1: Agilent Feature Extraced data was imported into Rosetta Resolver version 7.1.1 (Rosetta Inpharmatics LLC, Cambridge, MA). Multiple probes with the same sequence code were combined into a single value using the Rosetta Resolver error-weighted averaging method for combining repeated measures.///platform_id: GPL7264///contact_name: Judy,,Dering///contact_email: [email protected]///contact_laboratory: Translational Oncology Research///contact_department: Medicine///contact_institute: UCLA School of Medicine///contact_address: 2825 Santa Monica Blvd. Suite 200///contact_city: Santa Monica///contact_state: CA///contact_zip.postal_code: 90404///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM1238nnn/GSM1238223/GSM1238223_US22502615_251209754155_S01_A01.txt.gz///data_row_count: 20173
1
title: Ov_Tumor_Ref_Mix vs. CS-OV-080///geo_accession: GSM1238224///status: Public on Dec 26 2013///submission_date: Sep 23 2013///last_update_date: Dec 26 2013///type: RNA///channel_count: 2///source_name_ch1: 106 pooled ovarian samples///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian///characteristics_ch1.1: sample type: reference pool///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch1: Cy3///label_protocol_ch1: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch1: 9606///source_name_ch2: CS-OV-080///organism_ch2: Homo sapiens///characteristics_ch2: tissue: ovarian///characteristics_ch2.1: sample included in reference pool: YES///characteristics_ch2.2: sample rin: 8.3///characteristics_ch2.3: age at surgery: 67.53///characteristics_ch2.4: histology: Serous///characteristics_ch2.5: Stage: IIIC///characteristics_ch2.6: grade: 3///characteristics_ch2.7: tissue status: Primary///characteristics_ch2.8: follow up months: 25///characteristics_ch2.9: disease status: Not Free///characteristics_ch2.10: patient status: Dead///characteristics_ch2.11: disease state: Malignant ovarian///characteristics_ch2.12: ///molecule_ch2: total RNA///extract_protocol_ch2: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch2: Cy5///label_protocol_ch2: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch2: 9606///hyb_protocol: Slides were incubated for 16-17 hr at 60C and washed using the SSPE method described in the Agilent 60-mer Oligo Microarray Processing Protocol, Version 2.1. Slides were treated with Agilent Stabilization and Drying Solution, a wash was used to protect the dyes from ozone degradation.///scan_protocol: Scanned on an Agilent G2565BA scanner.///description: Malignant_ovarian_sample///data_processing: Agilent Feature Extraction Software (v7.5.1) was used for local background subtraction and Linear/LOWESS normalization. RejectMethod=Interquartile Range, nonuniformity outlier flagging enabled, population outlier flag enabled, ratio error model=hybrid, dye normalization select method = Rank Consistency Filter, no spatial detrend method applied.///data_processing.1: Agilent Feature Extraced data was imported into Rosetta Resolver version 7.1.1 (Rosetta Inpharmatics LLC, Cambridge, MA). Multiple probes with the same sequence code were combined into a single value using the Rosetta Resolver error-weighted averaging method for combining repeated measures.///platform_id: GPL7264///contact_name: Judy,,Dering///contact_email: [email protected]///contact_laboratory: Translational Oncology Research///contact_department: Medicine///contact_institute: UCLA School of Medicine///contact_address: 2825 Santa Monica Blvd. Suite 200///contact_city: Santa Monica///contact_state: CA///contact_zip.postal_code: 90404///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM1238nnn/GSM1238224/GSM1238224_US22502615_251209747092_S01_A01.txt.gz///data_row_count: 20173
1
title: Ov_Tumor_Ref_Mix vs. CS-OV-081///geo_accession: GSM1238225///status: Public on Dec 26 2013///submission_date: Sep 23 2013///last_update_date: Dec 26 2013///type: RNA///channel_count: 2///source_name_ch1: 106 pooled ovarian samples///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian///characteristics_ch1.1: sample type: reference pool///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch1: Cy3///label_protocol_ch1: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch1: 9606///source_name_ch2: CS-OV-081///organism_ch2: Homo sapiens///characteristics_ch2: tissue: ovarian///characteristics_ch2.1: sample included in reference pool: NO///characteristics_ch2.2: sample rin: 9.8///characteristics_ch2.3: age at surgery: 55.90///characteristics_ch2.4: histology: Serous///characteristics_ch2.5: Stage: IIIC///characteristics_ch2.6: grade: 3///characteristics_ch2.7: tissue status: Primary///characteristics_ch2.8: follow up months: 32///characteristics_ch2.9: disease status: Not Free///characteristics_ch2.10: patient status: Dead///characteristics_ch2.11: disease state: Malignant ovarian///characteristics_ch2.12: ///molecule_ch2: total RNA///extract_protocol_ch2: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch2: Cy5///label_protocol_ch2: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch2: 9606///hyb_protocol: Slides were incubated for 16-17 hr at 60C and washed using the SSPE method described in the Agilent 60-mer Oligo Microarray Processing Protocol, Version 2.1. Slides were treated with Agilent Stabilization and Drying Solution, a wash was used to protect the dyes from ozone degradation.///scan_protocol: Scanned on an Agilent G2565BA scanner.///description: Malignant_ovarian_sample///data_processing: Agilent Feature Extraction Software (v7.5.1) was used for local background subtraction and Linear/LOWESS normalization. RejectMethod=Interquartile Range, nonuniformity outlier flagging enabled, population outlier flag enabled, ratio error model=hybrid, dye normalization select method = Rank Consistency Filter, no spatial detrend method applied.///data_processing.1: Agilent Feature Extraced data was imported into Rosetta Resolver version 7.1.1 (Rosetta Inpharmatics LLC, Cambridge, MA). Multiple probes with the same sequence code were combined into a single value using the Rosetta Resolver error-weighted averaging method for combining repeated measures.///platform_id: GPL7264///contact_name: Judy,,Dering///contact_email: [email protected]///contact_laboratory: Translational Oncology Research///contact_department: Medicine///contact_institute: UCLA School of Medicine///contact_address: 2825 Santa Monica Blvd. Suite 200///contact_city: Santa Monica///contact_state: CA///contact_zip.postal_code: 90404///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM1238nnn/GSM1238225/GSM1238225_US22502615_251209749836_S01_A01.txt.gz///data_row_count: 20173
1
title: Ov_Tumor_Ref_Mix vs. CS-OV-082///geo_accession: GSM1238226///status: Public on Dec 26 2013///submission_date: Sep 23 2013///last_update_date: Dec 26 2013///type: RNA///channel_count: 2///source_name_ch1: 106 pooled ovarian samples///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian///characteristics_ch1.1: sample type: reference pool///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch1: Cy3///label_protocol_ch1: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch1: 9606///source_name_ch2: CS-OV-082///organism_ch2: Homo sapiens///characteristics_ch2: tissue: ovarian///characteristics_ch2.1: sample included in reference pool: YES///characteristics_ch2.2: sample rin: 9.4///characteristics_ch2.3: age at surgery: 52.05///characteristics_ch2.4: histology: Serous///characteristics_ch2.5: Stage: IIIC///characteristics_ch2.6: grade: 3///characteristics_ch2.7: tissue status: Recurrence///characteristics_ch2.8: follow up months: 36///characteristics_ch2.9: disease status: Not Free///characteristics_ch2.10: patient status: Dead///characteristics_ch2.11: disease state: Malignant ovarian///characteristics_ch2.12: ///molecule_ch2: total RNA///extract_protocol_ch2: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch2: Cy5///label_protocol_ch2: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch2: 9606///hyb_protocol: Slides were incubated for 16-17 hr at 60C and washed using the SSPE method described in the Agilent 60-mer Oligo Microarray Processing Protocol, Version 2.1. Slides were treated with Agilent Stabilization and Drying Solution, a wash was used to protect the dyes from ozone degradation.///scan_protocol: Scanned on an Agilent G2565BA scanner.///description: Malignant_ovarian_sample///data_processing: Agilent Feature Extraction Software (v7.5.1) was used for local background subtraction and Linear/LOWESS normalization. RejectMethod=Interquartile Range, nonuniformity outlier flagging enabled, population outlier flag enabled, ratio error model=hybrid, dye normalization select method = Rank Consistency Filter, no spatial detrend method applied.///data_processing.1: Agilent Feature Extraced data was imported into Rosetta Resolver version 7.1.1 (Rosetta Inpharmatics LLC, Cambridge, MA). Multiple probes with the same sequence code were combined into a single value using the Rosetta Resolver error-weighted averaging method for combining repeated measures.///platform_id: GPL7264///contact_name: Judy,,Dering///contact_email: [email protected]///contact_laboratory: Translational Oncology Research///contact_department: Medicine///contact_institute: UCLA School of Medicine///contact_address: 2825 Santa Monica Blvd. Suite 200///contact_city: Santa Monica///contact_state: CA///contact_zip.postal_code: 90404///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM1238nnn/GSM1238226/GSM1238226_US22502615_251209750955_S01_A01.txt.gz///data_row_count: 20173
1
title: Ov_Tumor_Ref_Mix vs. CS-OV-083///geo_accession: GSM1238227///status: Public on Dec 26 2013///submission_date: Sep 23 2013///last_update_date: Dec 26 2013///type: RNA///channel_count: 2///source_name_ch1: 106 pooled ovarian samples///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian///characteristics_ch1.1: sample type: reference pool///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch1: Cy3///label_protocol_ch1: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch1: 9606///source_name_ch2: CS-OV-083///organism_ch2: Homo sapiens///characteristics_ch2: tissue: ovarian///characteristics_ch2.1: sample included in reference pool: NO///characteristics_ch2.2: sample rin: 8.5///characteristics_ch2.3: age at surgery: 85.52///characteristics_ch2.4: histology: Serous///characteristics_ch2.5: Stage: IV///characteristics_ch2.6: grade: 3///characteristics_ch2.7: tissue status: Primary///characteristics_ch2.8: follow up months: 14///characteristics_ch2.9: disease status: Not Free///characteristics_ch2.10: patient status: Dead///characteristics_ch2.11: disease state: Malignant ovarian///characteristics_ch2.12: ///molecule_ch2: total RNA///extract_protocol_ch2: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch2: Cy5///label_protocol_ch2: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch2: 9606///hyb_protocol: Slides were incubated for 16-17 hr at 60C and washed using the SSPE method described in the Agilent 60-mer Oligo Microarray Processing Protocol, Version 2.1. Slides were treated with Agilent Stabilization and Drying Solution, a wash was used to protect the dyes from ozone degradation.///scan_protocol: Scanned on an Agilent G2565BA scanner.///description: Malignant_ovarian_sample///data_processing: Agilent Feature Extraction Software (v7.5.1) was used for local background subtraction and Linear/LOWESS normalization. RejectMethod=Interquartile Range, nonuniformity outlier flagging enabled, population outlier flag enabled, ratio error model=hybrid, dye normalization select method = Rank Consistency Filter, no spatial detrend method applied.///data_processing.1: Agilent Feature Extraced data was imported into Rosetta Resolver version 7.1.1 (Rosetta Inpharmatics LLC, Cambridge, MA). Multiple probes with the same sequence code were combined into a single value using the Rosetta Resolver error-weighted averaging method for combining repeated measures.///platform_id: GPL7264///contact_name: Judy,,Dering///contact_email: [email protected]///contact_laboratory: Translational Oncology Research///contact_department: Medicine///contact_institute: UCLA School of Medicine///contact_address: 2825 Santa Monica Blvd. Suite 200///contact_city: Santa Monica///contact_state: CA///contact_zip.postal_code: 90404///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM1238nnn/GSM1238227/GSM1238227_US22502615_251209754808_S01_A01.txt.gz///data_row_count: 20173
1
title: Ov_Tumor_Ref_Mix vs. CS-OV-084///geo_accession: GSM1238228///status: Public on Dec 26 2013///submission_date: Sep 23 2013///last_update_date: Dec 26 2013///type: RNA///channel_count: 2///source_name_ch1: 106 pooled ovarian samples///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian///characteristics_ch1.1: sample type: reference pool///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch1: Cy3///label_protocol_ch1: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch1: 9606///source_name_ch2: CS-OV-084///organism_ch2: Homo sapiens///characteristics_ch2: tissue: ovarian///characteristics_ch2.1: sample included in reference pool: YES///characteristics_ch2.2: sample rin: 9.3///characteristics_ch2.3: age at surgery: 51.36///characteristics_ch2.4: histology: Serous///characteristics_ch2.5: Stage: IIIC///characteristics_ch2.6: grade: 3///characteristics_ch2.7: tissue status: Primary///characteristics_ch2.8: follow up months: 210///characteristics_ch2.9: disease status: Free///characteristics_ch2.10: patient status: Alive///characteristics_ch2.11: disease state: Malignant ovarian///characteristics_ch2.12: ///molecule_ch2: total RNA///extract_protocol_ch2: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch2: Cy5///label_protocol_ch2: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch2: 9606///hyb_protocol: Slides were incubated for 16-17 hr at 60C and washed using the SSPE method described in the Agilent 60-mer Oligo Microarray Processing Protocol, Version 2.1. Slides were treated with Agilent Stabilization and Drying Solution, a wash was used to protect the dyes from ozone degradation.///scan_protocol: Scanned on an Agilent G2565BA scanner.///description: Malignant_ovarian_sample///data_processing: Agilent Feature Extraction Software (v7.5.1) was used for local background subtraction and Linear/LOWESS normalization. RejectMethod=Interquartile Range, nonuniformity outlier flagging enabled, population outlier flag enabled, ratio error model=hybrid, dye normalization select method = Rank Consistency Filter, no spatial detrend method applied.///data_processing.1: Agilent Feature Extraced data was imported into Rosetta Resolver version 7.1.1 (Rosetta Inpharmatics LLC, Cambridge, MA). Multiple probes with the same sequence code were combined into a single value using the Rosetta Resolver error-weighted averaging method for combining repeated measures.///platform_id: GPL7264///contact_name: Judy,,Dering///contact_email: [email protected]///contact_laboratory: Translational Oncology Research///contact_department: Medicine///contact_institute: UCLA School of Medicine///contact_address: 2825 Santa Monica Blvd. Suite 200///contact_city: Santa Monica///contact_state: CA///contact_zip.postal_code: 90404///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM1238nnn/GSM1238228/GSM1238228_US22502615_251209749355_S01_A01.txt.gz///data_row_count: 20173
1
title: Ov_Tumor_Ref_Mix vs. CS-OV-085///geo_accession: GSM1238229///status: Public on Dec 26 2013///submission_date: Sep 23 2013///last_update_date: Dec 26 2013///type: RNA///channel_count: 2///source_name_ch1: 106 pooled ovarian samples///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian///characteristics_ch1.1: sample type: reference pool///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch1: Cy3///label_protocol_ch1: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch1: 9606///source_name_ch2: CS-OV-085///organism_ch2: Homo sapiens///characteristics_ch2: tissue: ovarian///characteristics_ch2.1: sample included in reference pool: NO///characteristics_ch2.2: sample rin: 8.9///characteristics_ch2.3: age at surgery: 56.74///characteristics_ch2.4: histology: Serous///characteristics_ch2.5: Stage: IIIC///characteristics_ch2.6: grade: 3///characteristics_ch2.7: tissue status: Primary///characteristics_ch2.8: follow up months: 50///characteristics_ch2.9: disease status: Not Free///characteristics_ch2.10: patient status: Dead///characteristics_ch2.11: disease state: Malignant ovarian///characteristics_ch2.12: ///molecule_ch2: total RNA///extract_protocol_ch2: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch2: Cy5///label_protocol_ch2: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch2: 9606///hyb_protocol: Slides were incubated for 16-17 hr at 60C and washed using the SSPE method described in the Agilent 60-mer Oligo Microarray Processing Protocol, Version 2.1. Slides were treated with Agilent Stabilization and Drying Solution, a wash was used to protect the dyes from ozone degradation.///scan_protocol: Scanned on an Agilent G2565BA scanner.///description: Malignant_ovarian_sample///data_processing: Agilent Feature Extraction Software (v7.5.1) was used for local background subtraction and Linear/LOWESS normalization. RejectMethod=Interquartile Range, nonuniformity outlier flagging enabled, population outlier flag enabled, ratio error model=hybrid, dye normalization select method = Rank Consistency Filter, no spatial detrend method applied.///data_processing.1: Agilent Feature Extraced data was imported into Rosetta Resolver version 7.1.1 (Rosetta Inpharmatics LLC, Cambridge, MA). Multiple probes with the same sequence code were combined into a single value using the Rosetta Resolver error-weighted averaging method for combining repeated measures.///platform_id: GPL7264///contact_name: Judy,,Dering///contact_email: [email protected]///contact_laboratory: Translational Oncology Research///contact_department: Medicine///contact_institute: UCLA School of Medicine///contact_address: 2825 Santa Monica Blvd. Suite 200///contact_city: Santa Monica///contact_state: CA///contact_zip.postal_code: 90404///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM1238nnn/GSM1238229/GSM1238229_US22502615_251209754088_S01_A01.txt.gz///data_row_count: 20173
1
title: Ov_Tumor_Ref_Mix vs. CS-OV-086///geo_accession: GSM1238230///status: Public on Dec 26 2013///submission_date: Sep 23 2013///last_update_date: Dec 26 2013///type: RNA///channel_count: 2///source_name_ch1: 106 pooled ovarian samples///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian///characteristics_ch1.1: sample type: reference pool///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch1: Cy3///label_protocol_ch1: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch1: 9606///source_name_ch2: CS-OV-086///organism_ch2: Homo sapiens///characteristics_ch2: tissue: ovarian///characteristics_ch2.1: sample included in reference pool: NO///characteristics_ch2.2: sample rin: 9.6///characteristics_ch2.3: age at surgery: 75.01///characteristics_ch2.4: histology: Endometrioid///characteristics_ch2.5: Stage: IIC///characteristics_ch2.6: grade: 2///characteristics_ch2.7: tissue status: Primary///characteristics_ch2.8: follow up months: 67///characteristics_ch2.9: disease status: Free///characteristics_ch2.10: patient status: Dead///characteristics_ch2.11: disease state: Malignant ovarian///characteristics_ch2.12: ///molecule_ch2: total RNA///extract_protocol_ch2: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch2: Cy5///label_protocol_ch2: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch2: 9606///hyb_protocol: Slides were incubated for 16-17 hr at 60C and washed using the SSPE method described in the Agilent 60-mer Oligo Microarray Processing Protocol, Version 2.1. Slides were treated with Agilent Stabilization and Drying Solution, a wash was used to protect the dyes from ozone degradation.///scan_protocol: Scanned on an Agilent G2565BA scanner.///description: Malignant_ovarian_sample///data_processing: Agilent Feature Extraction Software (v7.5.1) was used for local background subtraction and Linear/LOWESS normalization. RejectMethod=Interquartile Range, nonuniformity outlier flagging enabled, population outlier flag enabled, ratio error model=hybrid, dye normalization select method = Rank Consistency Filter, no spatial detrend method applied.///data_processing.1: Agilent Feature Extraced data was imported into Rosetta Resolver version 7.1.1 (Rosetta Inpharmatics LLC, Cambridge, MA). Multiple probes with the same sequence code were combined into a single value using the Rosetta Resolver error-weighted averaging method for combining repeated measures.///platform_id: GPL7264///contact_name: Judy,,Dering///contact_email: [email protected]///contact_laboratory: Translational Oncology Research///contact_department: Medicine///contact_institute: UCLA School of Medicine///contact_address: 2825 Santa Monica Blvd. Suite 200///contact_city: Santa Monica///contact_state: CA///contact_zip.postal_code: 90404///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM1238nnn/GSM1238230/GSM1238230_US22502615_251209754135_S01_A01.txt.gz///data_row_count: 20173
1
title: Ov_Tumor_Ref_Mix vs. CS-OV-087///geo_accession: GSM1238231///status: Public on Dec 26 2013///submission_date: Sep 23 2013///last_update_date: Dec 26 2013///type: RNA///channel_count: 2///source_name_ch1: 106 pooled ovarian samples///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian///characteristics_ch1.1: sample type: reference pool///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch1: Cy3///label_protocol_ch1: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch1: 9606///source_name_ch2: CS-OV-087///organism_ch2: Homo sapiens///characteristics_ch2: tissue: ovarian///characteristics_ch2.1: sample included in reference pool: NO///characteristics_ch2.2: sample rin: 8.3///characteristics_ch2.3: age at surgery: 62.84///characteristics_ch2.4: histology: Serous///characteristics_ch2.5: Stage: IIIC/IB///characteristics_ch2.6: grade: 3///characteristics_ch2.7: tissue status: Primary///characteristics_ch2.8: follow up months: 51///characteristics_ch2.9: disease status: Not Free///characteristics_ch2.10: patient status: Dead///characteristics_ch2.11: disease state: Malignant ovarian///characteristics_ch2.12: ///molecule_ch2: total RNA///extract_protocol_ch2: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch2: Cy5///label_protocol_ch2: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch2: 9606///hyb_protocol: Slides were incubated for 16-17 hr at 60C and washed using the SSPE method described in the Agilent 60-mer Oligo Microarray Processing Protocol, Version 2.1. Slides were treated with Agilent Stabilization and Drying Solution, a wash was used to protect the dyes from ozone degradation.///scan_protocol: Scanned on an Agilent G2565BA scanner.///description: Malignant_ovarian_sample///data_processing: Agilent Feature Extraction Software (v7.5.1) was used for local background subtraction and Linear/LOWESS normalization. RejectMethod=Interquartile Range, nonuniformity outlier flagging enabled, population outlier flag enabled, ratio error model=hybrid, dye normalization select method = Rank Consistency Filter, no spatial detrend method applied.///data_processing.1: Agilent Feature Extraced data was imported into Rosetta Resolver version 7.1.1 (Rosetta Inpharmatics LLC, Cambridge, MA). Multiple probes with the same sequence code were combined into a single value using the Rosetta Resolver error-weighted averaging method for combining repeated measures.///platform_id: GPL7264///contact_name: Judy,,Dering///contact_email: [email protected]///contact_laboratory: Translational Oncology Research///contact_department: Medicine///contact_institute: UCLA School of Medicine///contact_address: 2825 Santa Monica Blvd. Suite 200///contact_city: Santa Monica///contact_state: CA///contact_zip.postal_code: 90404///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM1238nnn/GSM1238231/GSM1238231_US22502615_251209754787_S01_A01.txt.gz///data_row_count: 20173
1
title: Ov_Tumor_Ref_Mix vs. CS-OV-088///geo_accession: GSM1238232///status: Public on Dec 26 2013///submission_date: Sep 23 2013///last_update_date: Dec 26 2013///type: RNA///channel_count: 2///source_name_ch1: 106 pooled ovarian samples///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian///characteristics_ch1.1: sample type: reference pool///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch1: Cy3///label_protocol_ch1: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch1: 9606///source_name_ch2: CS-OV-088///organism_ch2: Homo sapiens///characteristics_ch2: tissue: ovarian///characteristics_ch2.1: sample included in reference pool: NO///characteristics_ch2.2: sample rin: 8.9///characteristics_ch2.3: age at surgery: 45.02///characteristics_ch2.4: histology: Serous///characteristics_ch2.5: Stage: IIIB///characteristics_ch2.6: grade: 3///characteristics_ch2.7: tissue status: Primary///characteristics_ch2.8: tcga id: TCGA-23-1026///characteristics_ch2.9: follow up months: 50///characteristics_ch2.10: disease status: Not Free///characteristics_ch2.11: patient status: Alive///characteristics_ch2.12: disease state: Malignant ovarian///molecule_ch2: total RNA///extract_protocol_ch2: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch2: Cy5///label_protocol_ch2: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch2: 9606///hyb_protocol: Slides were incubated for 16-17 hr at 60C and washed using the SSPE method described in the Agilent 60-mer Oligo Microarray Processing Protocol, Version 2.1. Slides were treated with Agilent Stabilization and Drying Solution, a wash was used to protect the dyes from ozone degradation.///scan_protocol: Scanned on an Agilent G2565BA scanner.///description: Malignant_ovarian_sample///data_processing: Agilent Feature Extraction Software (v7.5.1) was used for local background subtraction and Linear/LOWESS normalization. RejectMethod=Interquartile Range, nonuniformity outlier flagging enabled, population outlier flag enabled, ratio error model=hybrid, dye normalization select method = Rank Consistency Filter, no spatial detrend method applied.///data_processing.1: Agilent Feature Extraced data was imported into Rosetta Resolver version 7.1.1 (Rosetta Inpharmatics LLC, Cambridge, MA). Multiple probes with the same sequence code were combined into a single value using the Rosetta Resolver error-weighted averaging method for combining repeated measures.///platform_id: GPL7264///contact_name: Judy,,Dering///contact_email: [email protected]///contact_laboratory: Translational Oncology Research///contact_department: Medicine///contact_institute: UCLA School of Medicine///contact_address: 2825 Santa Monica Blvd. Suite 200///contact_city: Santa Monica///contact_state: CA///contact_zip.postal_code: 90404///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM1238nnn/GSM1238232/GSM1238232_US22502615_251209754151_S01_A01.txt.gz///data_row_count: 20173
1
title: Ov_Tumor_Ref_Mix vs. CS-OV-089///geo_accession: GSM1238233///status: Public on Dec 26 2013///submission_date: Sep 23 2013///last_update_date: Dec 26 2013///type: RNA///channel_count: 2///source_name_ch1: 106 pooled ovarian samples///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian///characteristics_ch1.1: sample type: reference pool///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch1: Cy3///label_protocol_ch1: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch1: 9606///source_name_ch2: CS-OV-089///organism_ch2: Homo sapiens///characteristics_ch2: tissue: ovarian///characteristics_ch2.1: sample included in reference pool: YES///characteristics_ch2.2: sample rin: 9.9///characteristics_ch2.3: age at surgery: 42.79///characteristics_ch2.4: histology: Mucinous///characteristics_ch2.5: Stage: IA///characteristics_ch2.6: grade: 0///characteristics_ch2.7: tissue status: Primary///characteristics_ch2.8: follow up months: 79///characteristics_ch2.9: disease status: Free///characteristics_ch2.10: patient status: Alive///characteristics_ch2.11: disease state: Borderline ovarian///characteristics_ch2.12: ///molecule_ch2: total RNA///extract_protocol_ch2: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch2: Cy5///label_protocol_ch2: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch2: 9606///hyb_protocol: Slides were incubated for 16-17 hr at 60C and washed using the SSPE method described in the Agilent 60-mer Oligo Microarray Processing Protocol, Version 2.1. Slides were treated with Agilent Stabilization and Drying Solution, a wash was used to protect the dyes from ozone degradation.///scan_protocol: Scanned on an Agilent G2565BA scanner.///description: Borderline_ovarian_sample///data_processing: Agilent Feature Extraction Software (v7.5.1) was used for local background subtraction and Linear/LOWESS normalization. RejectMethod=Interquartile Range, nonuniformity outlier flagging enabled, population outlier flag enabled, ratio error model=hybrid, dye normalization select method = Rank Consistency Filter, no spatial detrend method applied.///data_processing.1: Agilent Feature Extraced data was imported into Rosetta Resolver version 7.1.1 (Rosetta Inpharmatics LLC, Cambridge, MA). Multiple probes with the same sequence code were combined into a single value using the Rosetta Resolver error-weighted averaging method for combining repeated measures.///platform_id: GPL7264///contact_name: Judy,,Dering///contact_email: [email protected]///contact_laboratory: Translational Oncology Research///contact_department: Medicine///contact_institute: UCLA School of Medicine///contact_address: 2825 Santa Monica Blvd. Suite 200///contact_city: Santa Monica///contact_state: CA///contact_zip.postal_code: 90404///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM1238nnn/GSM1238233/GSM1238233_US22502615_251209749024_S01_A01.txt.gz///data_row_count: 20173
1
title: Ov_Tumor_Ref_Mix vs. CS-OV-090///geo_accession: GSM1238234///status: Public on Dec 26 2013///submission_date: Sep 23 2013///last_update_date: Dec 26 2013///type: RNA///channel_count: 2///source_name_ch1: 106 pooled ovarian samples///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian///characteristics_ch1.1: sample type: reference pool///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch1: Cy3///label_protocol_ch1: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch1: 9606///source_name_ch2: CS-OV-090///organism_ch2: Homo sapiens///characteristics_ch2: tissue: ovarian///characteristics_ch2.1: sample included in reference pool: NO///characteristics_ch2.2: sample rin: 8.9///characteristics_ch2.3: age at surgery: 64.32///characteristics_ch2.4: histology: Endometrioid///characteristics_ch2.5: Stage: IA///characteristics_ch2.6: grade: 3///characteristics_ch2.7: tissue status: Primary///characteristics_ch2.8: follow up months: 211///characteristics_ch2.9: disease status: Free///characteristics_ch2.10: patient status: Alive///characteristics_ch2.11: disease state: Malignant ovarian///characteristics_ch2.12: ///molecule_ch2: total RNA///extract_protocol_ch2: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch2: Cy5///label_protocol_ch2: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch2: 9606///hyb_protocol: Slides were incubated for 16-17 hr at 60C and washed using the SSPE method described in the Agilent 60-mer Oligo Microarray Processing Protocol, Version 2.1. Slides were treated with Agilent Stabilization and Drying Solution, a wash was used to protect the dyes from ozone degradation.///scan_protocol: Scanned on an Agilent G2565BA scanner.///description: Malignant_ovarian_sample///data_processing: Agilent Feature Extraction Software (v7.5.1) was used for local background subtraction and Linear/LOWESS normalization. RejectMethod=Interquartile Range, nonuniformity outlier flagging enabled, population outlier flag enabled, ratio error model=hybrid, dye normalization select method = Rank Consistency Filter, no spatial detrend method applied.///data_processing.1: Agilent Feature Extraced data was imported into Rosetta Resolver version 7.1.1 (Rosetta Inpharmatics LLC, Cambridge, MA). Multiple probes with the same sequence code were combined into a single value using the Rosetta Resolver error-weighted averaging method for combining repeated measures.///platform_id: GPL7264///contact_name: Judy,,Dering///contact_email: [email protected]///contact_laboratory: Translational Oncology Research///contact_department: Medicine///contact_institute: UCLA School of Medicine///contact_address: 2825 Santa Monica Blvd. Suite 200///contact_city: Santa Monica///contact_state: CA///contact_zip.postal_code: 90404///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM1238nnn/GSM1238234/GSM1238234_US22502615_251209754235_S01_A01.txt.gz///data_row_count: 20173
1
title: Ov_Tumor_Ref_Mix vs. CS-OV-091///geo_accession: GSM1238235///status: Public on Dec 26 2013///submission_date: Sep 23 2013///last_update_date: Dec 26 2013///type: RNA///channel_count: 2///source_name_ch1: 106 pooled ovarian samples///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian///characteristics_ch1.1: sample type: reference pool///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch1: Cy3///label_protocol_ch1: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch1: 9606///source_name_ch2: CS-OV-091///organism_ch2: Homo sapiens///characteristics_ch2: tissue: ovarian///characteristics_ch2.1: sample included in reference pool: YES///characteristics_ch2.2: sample rin: 10///characteristics_ch2.3: age at surgery: 64.85///characteristics_ch2.4: histology: Serous///characteristics_ch2.5: Stage: IIIC///characteristics_ch2.6: grade: 3///characteristics_ch2.7: tissue status: Primary///characteristics_ch2.8: tcga id: TCGA-23-1119///characteristics_ch2.9: follow up months: 140///characteristics_ch2.10: disease status: Free///characteristics_ch2.11: patient status: Alive///characteristics_ch2.12: disease state: Malignant ovarian///molecule_ch2: total RNA///extract_protocol_ch2: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch2: Cy5///label_protocol_ch2: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch2: 9606///hyb_protocol: Slides were incubated for 16-17 hr at 60C and washed using the SSPE method described in the Agilent 60-mer Oligo Microarray Processing Protocol, Version 2.1. Slides were treated with Agilent Stabilization and Drying Solution, a wash was used to protect the dyes from ozone degradation.///scan_protocol: Scanned on an Agilent G2565BA scanner.///description: Malignant_ovarian_sample///data_processing: Agilent Feature Extraction Software (v7.5.1) was used for local background subtraction and Linear/LOWESS normalization. RejectMethod=Interquartile Range, nonuniformity outlier flagging enabled, population outlier flag enabled, ratio error model=hybrid, dye normalization select method = Rank Consistency Filter, no spatial detrend method applied.///data_processing.1: Agilent Feature Extraced data was imported into Rosetta Resolver version 7.1.1 (Rosetta Inpharmatics LLC, Cambridge, MA). Multiple probes with the same sequence code were combined into a single value using the Rosetta Resolver error-weighted averaging method for combining repeated measures.///platform_id: GPL7264///contact_name: Judy,,Dering///contact_email: [email protected]///contact_laboratory: Translational Oncology Research///contact_department: Medicine///contact_institute: UCLA School of Medicine///contact_address: 2825 Santa Monica Blvd. Suite 200///contact_city: Santa Monica///contact_state: CA///contact_zip.postal_code: 90404///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM1238nnn/GSM1238235/GSM1238235_US22502615_251209750935_S01_A01.txt.gz///data_row_count: 20173
1
title: Ov_Tumor_Ref_Mix vs. CS-OV-092///geo_accession: GSM1238236///status: Public on Dec 26 2013///submission_date: Sep 23 2013///last_update_date: Dec 26 2013///type: RNA///channel_count: 2///source_name_ch1: 106 pooled ovarian samples///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian///characteristics_ch1.1: sample type: reference pool///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch1: Cy3///label_protocol_ch1: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch1: 9606///source_name_ch2: CS-OV-092///organism_ch2: Homo sapiens///characteristics_ch2: tissue: ovarian///characteristics_ch2.1: sample included in reference pool: NO///characteristics_ch2.2: sample rin: 9.6///characteristics_ch2.3: age at surgery: 44.53///characteristics_ch2.4: histology: Serous///characteristics_ch2.5: Stage: IIIA///characteristics_ch2.6: grade: 1///characteristics_ch2.7: tissue status: Primary///characteristics_ch2.8: follow up months: 34///characteristics_ch2.9: disease status: Not Free///characteristics_ch2.10: patient status: Dead///characteristics_ch2.11: disease state: Malignant ovarian///characteristics_ch2.12: ///molecule_ch2: total RNA///extract_protocol_ch2: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch2: Cy5///label_protocol_ch2: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch2: 9606///hyb_protocol: Slides were incubated for 16-17 hr at 60C and washed using the SSPE method described in the Agilent 60-mer Oligo Microarray Processing Protocol, Version 2.1. Slides were treated with Agilent Stabilization and Drying Solution, a wash was used to protect the dyes from ozone degradation.///scan_protocol: Scanned on an Agilent G2565BA scanner.///description: Malignant_ovarian_sample///data_processing: Agilent Feature Extraction Software (v7.5.1) was used for local background subtraction and Linear/LOWESS normalization. RejectMethod=Interquartile Range, nonuniformity outlier flagging enabled, population outlier flag enabled, ratio error model=hybrid, dye normalization select method = Rank Consistency Filter, no spatial detrend method applied.///data_processing.1: Agilent Feature Extraced data was imported into Rosetta Resolver version 7.1.1 (Rosetta Inpharmatics LLC, Cambridge, MA). Multiple probes with the same sequence code were combined into a single value using the Rosetta Resolver error-weighted averaging method for combining repeated measures.///platform_id: GPL7264///contact_name: Judy,,Dering///contact_email: [email protected]///contact_laboratory: Translational Oncology Research///contact_department: Medicine///contact_institute: UCLA School of Medicine///contact_address: 2825 Santa Monica Blvd. Suite 200///contact_city: Santa Monica///contact_state: CA///contact_zip.postal_code: 90404///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM1238nnn/GSM1238236/GSM1238236_US22502615_251209754798_S01_A01.txt.gz///data_row_count: 20173
1
title: Ov_Tumor_Ref_Mix vs. CS-OV-093///geo_accession: GSM1238237///status: Public on Dec 26 2013///submission_date: Sep 23 2013///last_update_date: Dec 26 2013///type: RNA///channel_count: 2///source_name_ch1: 106 pooled ovarian samples///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian///characteristics_ch1.1: sample type: reference pool///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch1: Cy3///label_protocol_ch1: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch1: 9606///source_name_ch2: CS-OV-093///organism_ch2: Homo sapiens///characteristics_ch2: tissue: ovarian///characteristics_ch2.1: sample included in reference pool: YES///characteristics_ch2.2: sample rin: 9.3///characteristics_ch2.3: age at surgery: 53.49///characteristics_ch2.4: histology: Serous///characteristics_ch2.5: Stage: IIIC///characteristics_ch2.6: grade: 3///characteristics_ch2.7: tissue status: Primary///characteristics_ch2.8: tcga id: TCGA-23-1102///characteristics_ch2.9: follow up months: 39///characteristics_ch2.10: disease status: Not Free///characteristics_ch2.11: patient status: Dead///characteristics_ch2.12: disease state: Malignant ovarian///molecule_ch2: total RNA///extract_protocol_ch2: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch2: Cy5///label_protocol_ch2: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch2: 9606///hyb_protocol: Slides were incubated for 16-17 hr at 60C and washed using the SSPE method described in the Agilent 60-mer Oligo Microarray Processing Protocol, Version 2.1. Slides were treated with Agilent Stabilization and Drying Solution, a wash was used to protect the dyes from ozone degradation.///scan_protocol: Scanned on an Agilent G2565BA scanner.///description: Malignant_ovarian_sample///data_processing: Agilent Feature Extraction Software (v7.5.1) was used for local background subtraction and Linear/LOWESS normalization. RejectMethod=Interquartile Range, nonuniformity outlier flagging enabled, population outlier flag enabled, ratio error model=hybrid, dye normalization select method = Rank Consistency Filter, no spatial detrend method applied.///data_processing.1: Agilent Feature Extraced data was imported into Rosetta Resolver version 7.1.1 (Rosetta Inpharmatics LLC, Cambridge, MA). Multiple probes with the same sequence code were combined into a single value using the Rosetta Resolver error-weighted averaging method for combining repeated measures.///platform_id: GPL7264///contact_name: Judy,,Dering///contact_email: [email protected]///contact_laboratory: Translational Oncology Research///contact_department: Medicine///contact_institute: UCLA School of Medicine///contact_address: 2825 Santa Monica Blvd. Suite 200///contact_city: Santa Monica///contact_state: CA///contact_zip.postal_code: 90404///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM1238nnn/GSM1238237/GSM1238237_US22502615_251209747093_S01_A01.txt.gz///data_row_count: 20173
1
title: Ov_Tumor_Ref_Mix vs. CS-OV-094///geo_accession: GSM1238238///status: Public on Dec 26 2013///submission_date: Sep 23 2013///last_update_date: Dec 26 2013///type: RNA///channel_count: 2///source_name_ch1: 106 pooled ovarian samples///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian///characteristics_ch1.1: sample type: reference pool///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch1: Cy3///label_protocol_ch1: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch1: 9606///source_name_ch2: CS-OV-094///organism_ch2: Homo sapiens///characteristics_ch2: tissue: ovarian///characteristics_ch2.1: sample included in reference pool: NO///characteristics_ch2.2: sample rin: 8.4///characteristics_ch2.3: age at surgery: 63.21///characteristics_ch2.4: histology: Transitional Cell///characteristics_ch2.5: Stage: IIA///characteristics_ch2.6: grade: 3///characteristics_ch2.7: tissue status: Primary///characteristics_ch2.8: follow up months: 77///characteristics_ch2.9: disease status: Free///characteristics_ch2.10: patient status: Alive///characteristics_ch2.11: disease state: Malignant ovarian///characteristics_ch2.12: ///molecule_ch2: total RNA///extract_protocol_ch2: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch2: Cy5///label_protocol_ch2: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch2: 9606///hyb_protocol: Slides were incubated for 16-17 hr at 60C and washed using the SSPE method described in the Agilent 60-mer Oligo Microarray Processing Protocol, Version 2.1. Slides were treated with Agilent Stabilization and Drying Solution, a wash was used to protect the dyes from ozone degradation.///scan_protocol: Scanned on an Agilent G2565BA scanner.///description: Malignant_ovarian_sample///data_processing: Agilent Feature Extraction Software (v7.5.1) was used for local background subtraction and Linear/LOWESS normalization. RejectMethod=Interquartile Range, nonuniformity outlier flagging enabled, population outlier flag enabled, ratio error model=hybrid, dye normalization select method = Rank Consistency Filter, no spatial detrend method applied.///data_processing.1: Agilent Feature Extraced data was imported into Rosetta Resolver version 7.1.1 (Rosetta Inpharmatics LLC, Cambridge, MA). Multiple probes with the same sequence code were combined into a single value using the Rosetta Resolver error-weighted averaging method for combining repeated measures.///platform_id: GPL7264///contact_name: Judy,,Dering///contact_email: [email protected]///contact_laboratory: Translational Oncology Research///contact_department: Medicine///contact_institute: UCLA School of Medicine///contact_address: 2825 Santa Monica Blvd. Suite 200///contact_city: Santa Monica///contact_state: CA///contact_zip.postal_code: 90404///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM1238nnn/GSM1238238/GSM1238238_US22502615_251209754213_S01_A01.txt.gz///data_row_count: 20173
1
title: Ov_Tumor_Ref_Mix vs. CS-OV-095///geo_accession: GSM1238239///status: Public on Dec 26 2013///submission_date: Sep 23 2013///last_update_date: Dec 26 2013///type: RNA///channel_count: 2///source_name_ch1: 106 pooled ovarian samples///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian///characteristics_ch1.1: sample type: reference pool///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch1: Cy3///label_protocol_ch1: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch1: 9606///source_name_ch2: CS-OV-095///organism_ch2: Homo sapiens///characteristics_ch2: tissue: ovarian///characteristics_ch2.1: sample included in reference pool: NO///characteristics_ch2.2: sample rin: 8.9///characteristics_ch2.3: age at surgery: 68.12///characteristics_ch2.4: histology: Mucinous///characteristics_ch2.5: Stage: IIIC///characteristics_ch2.6: grade: 3///characteristics_ch2.7: tissue status: Primary///characteristics_ch2.8: follow up months: 24///characteristics_ch2.9: disease status: Not Free///characteristics_ch2.10: patient status: Dead///characteristics_ch2.11: disease state: Malignant ovarian///characteristics_ch2.12: ///molecule_ch2: total RNA///extract_protocol_ch2: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch2: Cy5///label_protocol_ch2: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch2: 9606///hyb_protocol: Slides were incubated for 16-17 hr at 60C and washed using the SSPE method described in the Agilent 60-mer Oligo Microarray Processing Protocol, Version 2.1. Slides were treated with Agilent Stabilization and Drying Solution, a wash was used to protect the dyes from ozone degradation.///scan_protocol: Scanned on an Agilent G2565BA scanner.///description: Malignant_ovarian_sample///data_processing: Agilent Feature Extraction Software (v7.5.1) was used for local background subtraction and Linear/LOWESS normalization. RejectMethod=Interquartile Range, nonuniformity outlier flagging enabled, population outlier flag enabled, ratio error model=hybrid, dye normalization select method = Rank Consistency Filter, no spatial detrend method applied.///data_processing.1: Agilent Feature Extraced data was imported into Rosetta Resolver version 7.1.1 (Rosetta Inpharmatics LLC, Cambridge, MA). Multiple probes with the same sequence code were combined into a single value using the Rosetta Resolver error-weighted averaging method for combining repeated measures.///platform_id: GPL7264///contact_name: Judy,,Dering///contact_email: [email protected]///contact_laboratory: Translational Oncology Research///contact_department: Medicine///contact_institute: UCLA School of Medicine///contact_address: 2825 Santa Monica Blvd. Suite 200///contact_city: Santa Monica///contact_state: CA///contact_zip.postal_code: 90404///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM1238nnn/GSM1238239/GSM1238239_US22502615_251209754154_S01_A01.txt.gz///data_row_count: 20173
1
title: Ov_Tumor_Ref_Mix vs. CS-OV-096///geo_accession: GSM1238240///status: Public on Dec 26 2013///submission_date: Sep 23 2013///last_update_date: Dec 26 2013///type: RNA///channel_count: 2///source_name_ch1: 106 pooled ovarian samples///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian///characteristics_ch1.1: sample type: reference pool///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch1: Cy3///label_protocol_ch1: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch1: 9606///source_name_ch2: CS-OV-096///organism_ch2: Homo sapiens///characteristics_ch2: tissue: ovarian///characteristics_ch2.1: sample included in reference pool: YES///characteristics_ch2.2: sample rin: 10///characteristics_ch2.3: age at surgery: 66.32///characteristics_ch2.4: histology: Endometrioid///characteristics_ch2.5: Stage: IA///characteristics_ch2.6: grade: 1///characteristics_ch2.7: tissue status: Primary///characteristics_ch2.8: follow up months: 57///characteristics_ch2.9: disease status: Not Free///characteristics_ch2.10: patient status: Dead///characteristics_ch2.11: disease state: Malignant ovarian///characteristics_ch2.12: ///molecule_ch2: total RNA///extract_protocol_ch2: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch2: Cy5///label_protocol_ch2: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch2: 9606///hyb_protocol: Slides were incubated for 16-17 hr at 60C and washed using the SSPE method described in the Agilent 60-mer Oligo Microarray Processing Protocol, Version 2.1. Slides were treated with Agilent Stabilization and Drying Solution, a wash was used to protect the dyes from ozone degradation.///scan_protocol: Scanned on an Agilent G2565BA scanner.///description: Malignant_ovarian_sample///data_processing: Agilent Feature Extraction Software (v7.5.1) was used for local background subtraction and Linear/LOWESS normalization. RejectMethod=Interquartile Range, nonuniformity outlier flagging enabled, population outlier flag enabled, ratio error model=hybrid, dye normalization select method = Rank Consistency Filter, no spatial detrend method applied.///data_processing.1: Agilent Feature Extraced data was imported into Rosetta Resolver version 7.1.1 (Rosetta Inpharmatics LLC, Cambridge, MA). Multiple probes with the same sequence code were combined into a single value using the Rosetta Resolver error-weighted averaging method for combining repeated measures.///platform_id: GPL7264///contact_name: Judy,,Dering///contact_email: [email protected]///contact_laboratory: Translational Oncology Research///contact_department: Medicine///contact_institute: UCLA School of Medicine///contact_address: 2825 Santa Monica Blvd. Suite 200///contact_city: Santa Monica///contact_state: CA///contact_zip.postal_code: 90404///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM1238nnn/GSM1238240/GSM1238240_US22502615_251209747077_S01_A01.txt.gz///data_row_count: 20173
1
title: Ov_Tumor_Ref_Mix vs. CS-OV-097///geo_accession: GSM1238241///status: Public on Dec 26 2013///submission_date: Sep 23 2013///last_update_date: Dec 26 2013///type: RNA///channel_count: 2///source_name_ch1: 106 pooled ovarian samples///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian///characteristics_ch1.1: sample type: reference pool///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch1: Cy3///label_protocol_ch1: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch1: 9606///source_name_ch2: CS-OV-097///organism_ch2: Homo sapiens///characteristics_ch2: tissue: ovarian///characteristics_ch2.1: sample included in reference pool: NO///characteristics_ch2.2: sample rin: 9.4///characteristics_ch2.3: age at surgery: 64.44///characteristics_ch2.4: histology: Serous///characteristics_ch2.5: Stage: IIIC///characteristics_ch2.6: grade: 3///characteristics_ch2.7: tissue status: Primary///characteristics_ch2.8: follow up months: 19///characteristics_ch2.9: disease status: Not Free///characteristics_ch2.10: patient status: Dead///characteristics_ch2.11: disease state: Malignant ovarian///characteristics_ch2.12: ///molecule_ch2: total RNA///extract_protocol_ch2: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch2: Cy5///label_protocol_ch2: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch2: 9606///hyb_protocol: Slides were incubated for 16-17 hr at 60C and washed using the SSPE method described in the Agilent 60-mer Oligo Microarray Processing Protocol, Version 2.1. Slides were treated with Agilent Stabilization and Drying Solution, a wash was used to protect the dyes from ozone degradation.///scan_protocol: Scanned on an Agilent G2565BA scanner.///description: Malignant_ovarian_sample///data_processing: Agilent Feature Extraction Software (v7.5.1) was used for local background subtraction and Linear/LOWESS normalization. RejectMethod=Interquartile Range, nonuniformity outlier flagging enabled, population outlier flag enabled, ratio error model=hybrid, dye normalization select method = Rank Consistency Filter, no spatial detrend method applied.///data_processing.1: Agilent Feature Extraced data was imported into Rosetta Resolver version 7.1.1 (Rosetta Inpharmatics LLC, Cambridge, MA). Multiple probes with the same sequence code were combined into a single value using the Rosetta Resolver error-weighted averaging method for combining repeated measures.///platform_id: GPL7264///contact_name: Judy,,Dering///contact_email: [email protected]///contact_laboratory: Translational Oncology Research///contact_department: Medicine///contact_institute: UCLA School of Medicine///contact_address: 2825 Santa Monica Blvd. Suite 200///contact_city: Santa Monica///contact_state: CA///contact_zip.postal_code: 90404///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM1238nnn/GSM1238241/GSM1238241_US22502615_251209754166_S01_A01.txt.gz///data_row_count: 20173
1
title: Ov_Tumor_Ref_Mix vs. CS-OV-098///geo_accession: GSM1238242///status: Public on Dec 26 2013///submission_date: Sep 23 2013///last_update_date: Dec 26 2013///type: RNA///channel_count: 2///source_name_ch1: 106 pooled ovarian samples///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian///characteristics_ch1.1: sample type: reference pool///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch1: Cy3///label_protocol_ch1: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch1: 9606///source_name_ch2: CS-OV-098///organism_ch2: Homo sapiens///characteristics_ch2: tissue: ovarian///characteristics_ch2.1: sample included in reference pool: NO///characteristics_ch2.2: sample rin: 8.1///characteristics_ch2.3: age at surgery: 73.61///characteristics_ch2.4: histology: MMMT///characteristics_ch2.5: Stage: IIIC///characteristics_ch2.6: grade: 3///characteristics_ch2.7: tissue status: Primary///characteristics_ch2.8: follow up months: 17///characteristics_ch2.9: disease status: Not Free///characteristics_ch2.10: patient status: Dead///characteristics_ch2.11: disease state: Malignant ovarian///characteristics_ch2.12: ///molecule_ch2: total RNA///extract_protocol_ch2: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch2: Cy5///label_protocol_ch2: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch2: 9606///hyb_protocol: Slides were incubated for 16-17 hr at 60C and washed using the SSPE method described in the Agilent 60-mer Oligo Microarray Processing Protocol, Version 2.1. Slides were treated with Agilent Stabilization and Drying Solution, a wash was used to protect the dyes from ozone degradation.///scan_protocol: Scanned on an Agilent G2565BA scanner.///description: Malignant_ovarian_sample///data_processing: Agilent Feature Extraction Software (v7.5.1) was used for local background subtraction and Linear/LOWESS normalization. RejectMethod=Interquartile Range, nonuniformity outlier flagging enabled, population outlier flag enabled, ratio error model=hybrid, dye normalization select method = Rank Consistency Filter, no spatial detrend method applied.///data_processing.1: Agilent Feature Extraced data was imported into Rosetta Resolver version 7.1.1 (Rosetta Inpharmatics LLC, Cambridge, MA). Multiple probes with the same sequence code were combined into a single value using the Rosetta Resolver error-weighted averaging method for combining repeated measures.///platform_id: GPL7264///contact_name: Judy,,Dering///contact_email: [email protected]///contact_laboratory: Translational Oncology Research///contact_department: Medicine///contact_institute: UCLA School of Medicine///contact_address: 2825 Santa Monica Blvd. Suite 200///contact_city: Santa Monica///contact_state: CA///contact_zip.postal_code: 90404///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM1238nnn/GSM1238242/GSM1238242_US22502615_251209754147_S01_A01.txt.gz///data_row_count: 20173
1
title: Ov_Tumor_Ref_Mix vs. CS-OV-099///geo_accession: GSM1238243///status: Public on Dec 26 2013///submission_date: Sep 23 2013///last_update_date: Dec 26 2013///type: RNA///channel_count: 2///source_name_ch1: 106 pooled ovarian samples///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian///characteristics_ch1.1: sample type: reference pool///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch1: Cy3///label_protocol_ch1: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch1: 9606///source_name_ch2: CS-OV-099///organism_ch2: Homo sapiens///characteristics_ch2: tissue: ovarian///characteristics_ch2.1: sample included in reference pool: NO///characteristics_ch2.2: sample rin: 8.7///characteristics_ch2.3: age at surgery: 68.22///characteristics_ch2.4: histology: Serous///characteristics_ch2.5: Stage: IIIC///characteristics_ch2.6: grade: 2///characteristics_ch2.7: tissue status: Primary///characteristics_ch2.8: follow up months: 14///characteristics_ch2.9: disease status: Not Free///characteristics_ch2.10: patient status: Dead///characteristics_ch2.11: disease state: Malignant ovarian///characteristics_ch2.12: ///molecule_ch2: total RNA///extract_protocol_ch2: Total RNA was isolated using RNeasy (Qiagen Inc., Valencia, CA),quantitated using a Nanodrop Spectrophotometer (Agilent Technolies, Canta Clara, CA), and purified on RNeasy Mini columns (Qiagen Inc.)///label_ch2: Cy5///label_protocol_ch2: Total RNA (750ng) was labeled with cyanine 5-CTP or cyanine 3-CTP using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies)///taxid_ch2: 9606///hyb_protocol: Slides were incubated for 16-17 hr at 60C and washed using the SSPE method described in the Agilent 60-mer Oligo Microarray Processing Protocol, Version 2.1. Slides were treated with Agilent Stabilization and Drying Solution, a wash was used to protect the dyes from ozone degradation.///scan_protocol: Scanned on an Agilent G2565BA scanner.///description: Malignant_ovarian_sample///data_processing: Agilent Feature Extraction Software (v7.5.1) was used for local background subtraction and Linear/LOWESS normalization. RejectMethod=Interquartile Range, nonuniformity outlier flagging enabled, population outlier flag enabled, ratio error model=hybrid, dye normalization select method = Rank Consistency Filter, no spatial detrend method applied.///data_processing.1: Agilent Feature Extraced data was imported into Rosetta Resolver version 7.1.1 (Rosetta Inpharmatics LLC, Cambridge, MA). Multiple probes with the same sequence code were combined into a single value using the Rosetta Resolver error-weighted averaging method for combining repeated measures.///platform_id: GPL7264///contact_name: Judy,,Dering///contact_email: [email protected]///contact_laboratory: Translational Oncology Research///contact_department: Medicine///contact_institute: UCLA School of Medicine///contact_address: 2825 Santa Monica Blvd. Suite 200///contact_city: Santa Monica///contact_state: CA///contact_zip.postal_code: 90404///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM1238nnn/GSM1238243/GSM1238243_US22502615_251209749771_S01_A01.txt.gz///data_row_count: 20173
1
(Other)
73
An expression set
Lysophosphatidic acid (LPA) governs a number of physiologic and pathophysiological processes. Malignant ascites fluid is rich in LPA, and LPA receptors are aberrantly expressed by ovarian cancer cells, implicating LPA in the initiation and progression of ovarian cancer. However, there is an absence of systematic data critically analyzing the transcriptional changes induced by LPA in ovarian cancer.In this study, gene expression profiling was used to examine LPA-mediated transcription by exogenously adding LPA to human epithelial ovarian cancer cells for 24 h to mimic long-term stimulation in the tumor microenvironment. The resultant transcriptional profile comprised a 39-gene signature that closely correlated to serous epithelial ovarian carcinoma. Hierarchical clustering of ovarian cancer patient specimens demonstrated that the signature is associated with worsened prognosis. Patients with LPA-signature-positive ovarian tumors have reduced disease-specific and progression-free survival times. They have a higher frequency of stage IIIc serous carcinoma and a greater proportion is deceased. Among the 39-gene signature, a group of seven genes associated with cell adhesion recapitulated the results. Out of those seven, claudin-1, an adhesion molecule and phenotypic epithelial marker, is the only independent biomarker of serous epithelial ovarian carcinoma. Knockdown of claudin-1 expression in ovarian cancer cells reduces LPA-mediated cellular adhesion, enhances suspended cells and reduces LPA-mediated migration.The data suggest that transcriptional events mediated by LPA in the tumor microenvironment influence tumor progression through modulation of cell adhesion molecules like claudin-1 and, for the first time, report an LPA-mediated expression signature in ovarian cancer that predicts a worse prognosis.
experimentData(eset):
Experiment data
Experimenter name: Murph MM, Liu W, Yu S, Lu Y, Hall H, Hennessy BT, Lahad J, Schaner M, Helland A, Kristensen G, Brresen-Dale AL, Mills GB. Lysophosphatidic acid-induced transcriptional profile represents serous epithelial ovarian carcinoma and worsened prognosis. PLoS One. 2009; 4(5):e5583.
Laboratory: Murph, Mills 2009
Contact information:
Title: Lysophosphatidic acid-induced transcriptional profile represents serous epithelial ovarian carcinoma and worsened prognosis.
URL:
PMIDs: 19440550
Abstract: A 247 word abstract is available. Use 'abstract' method.
Information is available on: preprocessing
notes:
platform_title:
[HG-U133A] Affymetrix Human Genome U133A Array
platform_shorttitle:
Affymetrix HG-U133A
platform_summary:
hgu133a
platform_manufacturer:
Affymetrix
platform_distribution:
commercial
platform_accession:
GPL96
version:
2015-09-22 20:07:11
featureData(eset):
An object of class 'AnnotatedDataFrame'
featureNames: 1007_s_at 1053_at ... AFFX-HUMISGF3A/M97935_MB_at
(20967 total)
varLabels: probeset gene EntrezGene.ID best_probe
varMetadata: labelDescription
assayData: 20967 features, 103 samples
Platform type:
---------------------------
Available sample meta-data:
---------------------------
alt_sample_name:
Ovarian_Tumor_ClearCell_CHTN-OC-004 Ovarian_Tumor_ClearCell_CHTN-OC-012
1 1
Ovarian_Tumor_ClearCell_CHTN-OC-028 Ovarian_Tumor_ClearCell_KU-OC-003
1 1
Ovarian_Tumor_ClearCell_KU-OC-004 Ovarian_Tumor_ClearCell_KU-OC-005
1 1
Ovarian_Tumor_ClearCell_KU-OC-006 Ovarian_Tumor_ClearCell_KU-OC-007
1 1
Ovarian_Tumor_Endometrioid_CHTN-OE-005 Ovarian_Tumor_Endometrioid_CHTN-OE-011
1 1
Ovarian_Tumor_Endometrioid_CHTN-OE-014 Ovarian_Tumor_Endometrioid_CHTN-OE-017
1 1
Ovarian_Tumor_Endometrioid_CHTN-OE-018 Ovarian_Tumor_Endometrioid_CHTN-OE-019
1 1
Ovarian_Tumor_Endometrioid_CHTN-OE-023 Ovarian_Tumor_Endometrioid_CHTN-OE-029
1 1
Ovarian_Tumor_Endometrioid_CHTN-OE-033 Ovarian_Tumor_Endometrioid_CHTN-OE-035
1 1
Ovarian_Tumor_Endometrioid_CHTN-OE-036 Ovarian_Tumor_Endometrioid_CHTN-OE-038
1 1
Ovarian_Tumor_Endometrioid_CHTN-OE-039 Ovarian_Tumor_Endometrioid_CHTN-OE-040
1 1
Ovarian_Tumor_Endometrioid_CHTN-OE-042 Ovarian_Tumor_Endometrioid_CHTN-OE-046
1 1
Ovarian_Tumor_Endometrioid_CHTN-OE-047 Ovarian_Tumor_Endometrioid_CHTN-OE-048
1 1
Ovarian_Tumor_Endometrioid_CHTN-OE-053 Ovarian_Tumor_Endometrioid_CHTN-OE-054
1 1
Ovarian_Tumor_Endometrioid_CHTN-OE-056 Ovarian_Tumor_Endometrioid_CHTN-OE-059
1 1
Ovarian_Tumor_Endometrioid_CHTN-OE-060 Ovarian_Tumor_Endometrioid_CHTN-OE-061
1 1
Ovarian_Tumor_Endometrioid_CHTN-OE-065 Ovarian_Tumor_Endometrioid_CHTN-OE-069
1 1
Ovarian_Tumor_Endometrioid_CHTN-OE-076 Ovarian_Tumor_Endometrioid_CHTN-OE-077
1 1
Ovarian_Tumor_Endometrioid_CHTN-OE-080 Ovarian_Tumor_Endometrioid_CHTN-OE-082
1 1
Ovarian_Tumor_Endometrioid_CHTN-OE-087 Ovarian_Tumor_Endometrioid_CHTN-OE-092
1 1
Ovarian_Tumor_Endometrioid_JH-OE-2T Ovarian_Tumor_Endometrioid_KU-OE-003
1 1
Ovarian_Tumor_Endometrioid_KU-OE-004 Ovarian_Tumor_Endometrioid_KU-OE-007
1 1
Ovarian_Tumor_Endometrioid_UM-OE-1T Ovarian_Tumor_Mucinous_CHTN-OM-007
1 1
Ovarian_Tumor_Mucinous_CHTN-OM-017 Ovarian_Tumor_Mucinous_CHTN-OM-023
1 1
Ovarian_Tumor_Mucinous_CHTN-OM-029 Ovarian_Tumor_Mucinous_CHTN-OM-032
1 1
Ovarian_Tumor_Mucinous_CHTN-OM-035 Ovarian_Tumor_Mucinous_CHTN-OM-036
1 1
Ovarian_Tumor_Mucinous_KU-OM-003 Ovarian_Tumor_Mucinous_KU-OM-004
1 1
Ovarian_Tumor_Mucinous_KU-OM-006 Ovarian_Tumor_Mucinous_KU-OM-007
1 1
Ovarian_Tumor_Mucinous_UM-OM-01 Ovarian_Tumor_Mucinous_UM-OM-03
1 1
Ovarian_Tumor_Serous_CHTN-OS-002 Ovarian_Tumor_Serous_CHTN-OS-003
1 1
Ovarian_Tumor_Serous_CHTN-OS-009 Ovarian_Tumor_Serous_CHTN-OS-010
1 1
Ovarian_Tumor_Serous_CHTN-OS-011 Ovarian_Tumor_Serous_CHTN-OS-018
1 1
Ovarian_Tumor_Serous_CHTN-OS-020 Ovarian_Tumor_Serous_CHTN-OS-029
1 1
Ovarian_Tumor_Serous_CHTN-OS-038 Ovarian_Tumor_Serous_CHTN-OS-041
1 1
Ovarian_Tumor_Serous_CHTN-OS-044 Ovarian_Tumor_Serous_CHTN-OS-046
1 1
Ovarian_Tumor_Serous_CHTN-OS-048 Ovarian_Tumor_Serous_CHTN-OS-053
1 1
Ovarian_Tumor_Serous_CHTN-OS-055 Ovarian_Tumor_Serous_CHTN-OS-068
1 1
Ovarian_Tumor_Serous_CHTN-OS-072 Ovarian_Tumor_Serous_CHTN-OS-081
1 1
Ovarian_Tumor_Serous_CHTN-OS-089 Ovarian_Tumor_Serous_CHTN-OS-093
1 1
Ovarian_Tumor_Serous_CHTN-OS-098 Ovarian_Tumor_Serous_CU-OS-04
1 1
Ovarian_Tumor_Serous_CU-OS-05 Ovarian_Tumor_Serous_KU-OS-001
1 1
Ovarian_Tumor_Serous_KU-OS-002 Ovarian_Tumor_Serous_KU-OS-003
1 1
Ovarian_Tumor_Serous_KU-OS-005 Ovarian_Tumor_Serous_KU-OS-007
1 1
Ovarian_Tumor_Serous_KU-OS-009 Ovarian_Tumor_Serous_KU-OS-011
1 1
Ovarian_Tumor_Serous_KU-OS-012 Ovarian_Tumor_Serous_KU-OS-013
1 1
Ovarian_Tumor_Serous_KU-OS-015 Ovarian_Tumor_Serous_KU-OS-018
1 1
Ovarian_Tumor_Serous_KU-OS-021 Ovarian_Tumor_Serous_KU-OS-022
1 1
Ovarian_Tumor_Serous_UM-OS-02 Ovarian_Tumor_Serous_UM-OS-07
1 1
Ovarian_Tumor_Serous_UM-OS-09 Ovarian_Tumor_Serous_UM-OS-10
1 1
Ovarian_Tumor_Serous_UM-OS-11 (Other)
1 4
sample_type:
healthy tumor
4 99
histological_type:
clearcell endo mucinous ser NA's
8 37 13 41 4
primarysite:
ov
103
summarygrade:
high low NA's
38 36 29
summarystage:
early late NA's
42 53 8
tumorstage:
1 2 3 4 NA's
35 11 44 9 4
substage:
a b c d NA's
19 2 54 1 27
grade:
1 2 3 NA's
19 17 38 29
batch:
2002-04-03 2002-04-04 2002-04-09 2002-04-10 2002-04-12 2002-08-13 2002-08-15
3 8 9 2 3 4 4
2002-08-22 2002-08-23 2002-08-27 2002-08-28 2002-08-29 2002-08-30 2002-09-11
8 8 5 6 16 14 9
2006-01-27
4
uncurated_author_metadata:
title: Ovarian_Tumor_ClearCell_CHTN-OC-004///geo_accession: GSM139377///status: Public on Apr 09 2007///submission_date: Oct 10 2006///last_update_date: Apr 09 2007///type: RNA///channel_count: 1///source_name_ch1: Ovarian_Tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tumor_Type: Clear_Cell///characteristics_ch1.1: stage: 3C///characteristics_ch1.2: grade: 3///characteristics_ch1.3: B-canenin_nuclear_accumulation: N/A///characteristics_ch1.4: CTNNB1_mutation: N/A///characteristics_ch1.5: APC_mutation: N/A///characteristics_ch1.6: PTEN_mutation: N/A///characteristics_ch1.7: PTEN_immunohistochemistry: N/A///characteristics_ch1.8: KRAS_mutation: N/A///characteristics_ch1.9: PIK3CA_mutation: N/A///characteristics_ch1.10: TP53_mutation: N/A///characteristics_ch1.11: P53_immunohistochemistry: N/A///characteristics_ch1.12: CEL_file_name: CHTN-OC-004.CEL///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from the tissue lysate using an RNeasy kit (Qiagen).///label_ch1: biotin///label_protocol_ch1: 3-5 g of total RNA was processed to produce biotinylated cRNA targets.///taxid_ch1: 9606///hyb_protocol: standard Affymetrix procedures///scan_protocol: standard Affymetrix procedures///description: ovarian tumor: clear cell///data_processing: Ann Arbor quantile-normalized trimmed-mean method///platform_id: GPL96///contact_name: Rork,,Kuick///contact_email: [email protected]///contact_phone: 734-936-9241///contact_institute: University of Michigan///contact_address: NI8D17, 300 North Ingals Building, U. of Michigan///contact_city: Ann Arbor///contact_state: MI///contact_zip.postal_code: 48109-5473///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM139nnn/GSM139377/GSM139377.CEL.gz///data_row_count: 22283
1
title: Ovarian_Tumor_ClearCell_CHTN-OC-012///geo_accession: GSM139378///status: Public on Apr 09 2007///submission_date: Oct 10 2006///last_update_date: Apr 09 2007///type: RNA///channel_count: 1///source_name_ch1: Ovarian_Tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tumor_Type: Clear_Cell///characteristics_ch1.1: stage: 4///characteristics_ch1.2: grade: 3///characteristics_ch1.3: B-canenin_nuclear_accumulation: N/A///characteristics_ch1.4: CTNNB1_mutation: N/A///characteristics_ch1.5: APC_mutation: N/A///characteristics_ch1.6: PTEN_mutation: N/A///characteristics_ch1.7: PTEN_immunohistochemistry: N/A///characteristics_ch1.8: KRAS_mutation: N/A///characteristics_ch1.9: PIK3CA_mutation: N/A///characteristics_ch1.10: TP53_mutation: N/A///characteristics_ch1.11: P53_immunohistochemistry: N/A///characteristics_ch1.12: CEL_file_name: CHTN-OC-012.CEL///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from the tissue lysate using an RNeasy kit (Qiagen).///label_ch1: biotin///label_protocol_ch1: 3-5 g of total RNA was processed to produce biotinylated cRNA targets.///taxid_ch1: 9606///hyb_protocol: standard Affymetrix procedures///scan_protocol: standard Affymetrix procedures///description: ovarian tumor: clear cell///data_processing: Ann Arbor quantile-normalized trimmed-mean method///platform_id: GPL96///contact_name: Rork,,Kuick///contact_email: [email protected]///contact_phone: 734-936-9241///contact_institute: University of Michigan///contact_address: NI8D17, 300 North Ingals Building, U. of Michigan///contact_city: Ann Arbor///contact_state: MI///contact_zip.postal_code: 48109-5473///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM139nnn/GSM139378/GSM139378.CEL.gz///data_row_count: 22283
1
title: Ovarian_Tumor_ClearCell_CHTN-OC-028///geo_accession: GSM139379///status: Public on Apr 09 2007///submission_date: Oct 10 2006///last_update_date: Apr 09 2007///type: RNA///channel_count: 1///source_name_ch1: Ovarian_Tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tumor_Type: Clear_Cell///characteristics_ch1.1: stage: 1///characteristics_ch1.2: grade: 3///characteristics_ch1.3: B-canenin_nuclear_accumulation: N/A///characteristics_ch1.4: CTNNB1_mutation: N/A///characteristics_ch1.5: APC_mutation: N/A///characteristics_ch1.6: PTEN_mutation: N/A///characteristics_ch1.7: PTEN_immunohistochemistry: N/A///characteristics_ch1.8: KRAS_mutation: N/A///characteristics_ch1.9: PIK3CA_mutation: N/A///characteristics_ch1.10: TP53_mutation: N/A///characteristics_ch1.11: P53_immunohistochemistry: N/A///characteristics_ch1.12: CEL_file_name: CHTN-OC-028.CEL///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from the tissue lysate using an RNeasy kit (Qiagen).///label_ch1: biotin///label_protocol_ch1: 3-5 g of total RNA was processed to produce biotinylated cRNA targets.///taxid_ch1: 9606///hyb_protocol: standard Affymetrix procedures///scan_protocol: standard Affymetrix procedures///description: ovarian tumor: clear cell///data_processing: Ann Arbor quantile-normalized trimmed-mean method///platform_id: GPL96///contact_name: Rork,,Kuick///contact_email: [email protected]///contact_phone: 734-936-9241///contact_institute: University of Michigan///contact_address: NI8D17, 300 North Ingals Building, U. of Michigan///contact_city: Ann Arbor///contact_state: MI///contact_zip.postal_code: 48109-5473///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM139nnn/GSM139379/GSM139379.CEL.gz///data_row_count: 22283
1
title: Ovarian_Tumor_ClearCell_KU-OC-003///geo_accession: GSM139380///status: Public on Apr 09 2007///submission_date: Oct 10 2006///last_update_date: Apr 09 2007///type: RNA///channel_count: 1///source_name_ch1: Ovarian_Tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tumor_Type: Clear_Cell///characteristics_ch1.1: stage: 1a///characteristics_ch1.2: grade: N/A///characteristics_ch1.3: B-canenin_nuclear_accumulation: N/A///characteristics_ch1.4: CTNNB1_mutation: N/A///characteristics_ch1.5: APC_mutation: N/A///characteristics_ch1.6: PTEN_mutation: N/A///characteristics_ch1.7: PTEN_immunohistochemistry: N/A///characteristics_ch1.8: KRAS_mutation: N/A///characteristics_ch1.9: PIK3CA_mutation: N/A///characteristics_ch1.10: TP53_mutation: N/A///characteristics_ch1.11: P53_immunohistochemistry: N/A///characteristics_ch1.12: CEL_file_name: KU-OC-003.CEL///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from the tissue lysate using an RNeasy kit (Qiagen).///label_ch1: biotin///label_protocol_ch1: 3-5 g of total RNA was processed to produce biotinylated cRNA targets.///taxid_ch1: 9606///hyb_protocol: standard Affymetrix procedures///scan_protocol: standard Affymetrix procedures///description: ovarian tumor: clear cell///data_processing: Ann Arbor quantile-normalized trimmed-mean method///platform_id: GPL96///contact_name: Rork,,Kuick///contact_email: [email protected]///contact_phone: 734-936-9241///contact_institute: University of Michigan///contact_address: NI8D17, 300 North Ingals Building, U. of Michigan///contact_city: Ann Arbor///contact_state: MI///contact_zip.postal_code: 48109-5473///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM139nnn/GSM139380/GSM139380.CEL.gz///data_row_count: 22283
1
title: Ovarian_Tumor_ClearCell_KU-OC-004///geo_accession: GSM139381///status: Public on Apr 09 2007///submission_date: Oct 10 2006///last_update_date: Apr 09 2007///type: RNA///channel_count: 1///source_name_ch1: Ovarian_Tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tumor_Type: Clear_Cell///characteristics_ch1.1: stage: 2c///characteristics_ch1.2: grade: N/A///characteristics_ch1.3: B-canenin_nuclear_accumulation: N/A///characteristics_ch1.4: CTNNB1_mutation: N/A///characteristics_ch1.5: APC_mutation: N/A///characteristics_ch1.6: PTEN_mutation: N/A///characteristics_ch1.7: PTEN_immunohistochemistry: N/A///characteristics_ch1.8: KRAS_mutation: N/A///characteristics_ch1.9: PIK3CA_mutation: N/A///characteristics_ch1.10: TP53_mutation: N/A///characteristics_ch1.11: P53_immunohistochemistry: N/A///characteristics_ch1.12: CEL_file_name: KU-OC-004.CEL///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from the tissue lysate using an RNeasy kit (Qiagen).///label_ch1: biotin///label_protocol_ch1: 3-5 g of total RNA was processed to produce biotinylated cRNA targets.///taxid_ch1: 9606///hyb_protocol: standard Affymetrix procedures///scan_protocol: standard Affymetrix procedures///description: ovarian tumor: clear cell///data_processing: Ann Arbor quantile-normalized trimmed-mean method///platform_id: GPL96///contact_name: Rork,,Kuick///contact_email: [email protected]///contact_phone: 734-936-9241///contact_institute: University of Michigan///contact_address: NI8D17, 300 North Ingals Building, U. of Michigan///contact_city: Ann Arbor///contact_state: MI///contact_zip.postal_code: 48109-5473///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM139nnn/GSM139381/GSM139381.CEL.gz///data_row_count: 22283
1
title: Ovarian_Tumor_ClearCell_KU-OC-005///geo_accession: GSM139382///status: Public on Apr 09 2007///submission_date: Oct 10 2006///last_update_date: Apr 09 2007///type: RNA///channel_count: 1///source_name_ch1: Ovarian_Tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tumor_Type: Clear_Cell///characteristics_ch1.1: stage: 1a///characteristics_ch1.2: grade: N/A///characteristics_ch1.3: B-canenin_nuclear_accumulation: N/A///characteristics_ch1.4: CTNNB1_mutation: N/A///characteristics_ch1.5: APC_mutation: N/A///characteristics_ch1.6: PTEN_mutation: N/A///characteristics_ch1.7: PTEN_immunohistochemistry: N/A///characteristics_ch1.8: KRAS_mutation: N/A///characteristics_ch1.9: PIK3CA_mutation: N/A///characteristics_ch1.10: TP53_mutation: N/A///characteristics_ch1.11: P53_immunohistochemistry: N/A///characteristics_ch1.12: CEL_file_name: KU-OC-005.CEL///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from the tissue lysate using an RNeasy kit (Qiagen).///label_ch1: biotin///label_protocol_ch1: 3-5 g of total RNA was processed to produce biotinylated cRNA targets.///taxid_ch1: 9606///hyb_protocol: standard Affymetrix procedures///scan_protocol: standard Affymetrix procedures///description: ovarian tumor: clear cell///data_processing: Ann Arbor quantile-normalized trimmed-mean method///platform_id: GPL96///contact_name: Rork,,Kuick///contact_email: [email protected]///contact_phone: 734-936-9241///contact_institute: University of Michigan///contact_address: NI8D17, 300 North Ingals Building, U. of Michigan///contact_city: Ann Arbor///contact_state: MI///contact_zip.postal_code: 48109-5473///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM139nnn/GSM139382/GSM139382.CEL.gz///data_row_count: 22283
1
title: Ovarian_Tumor_ClearCell_KU-OC-006///geo_accession: GSM139383///status: Public on Apr 09 2007///submission_date: Oct 10 2006///last_update_date: Apr 09 2007///type: RNA///channel_count: 1///source_name_ch1: Ovarian_Tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tumor_Type: Clear_Cell///characteristics_ch1.1: stage: 1a///characteristics_ch1.2: grade: N/A///characteristics_ch1.3: B-canenin_nuclear_accumulation: N/A///characteristics_ch1.4: CTNNB1_mutation: N/A///characteristics_ch1.5: APC_mutation: N/A///characteristics_ch1.6: PTEN_mutation: N/A///characteristics_ch1.7: PTEN_immunohistochemistry: N/A///characteristics_ch1.8: KRAS_mutation: N/A///characteristics_ch1.9: PIK3CA_mutation: N/A///characteristics_ch1.10: TP53_mutation: N/A///characteristics_ch1.11: P53_immunohistochemistry: N/A///characteristics_ch1.12: CEL_file_name: KU-OC-006.CEL///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from the tissue lysate using an RNeasy kit (Qiagen).///label_ch1: biotin///label_protocol_ch1: 3-5 g of total RNA was processed to produce biotinylated cRNA targets.///taxid_ch1: 9606///hyb_protocol: standard Affymetrix procedures///scan_protocol: standard Affymetrix procedures///description: ovarian tumor: clear cell///data_processing: Ann Arbor quantile-normalized trimmed-mean method///platform_id: GPL96///contact_name: Rork,,Kuick///contact_email: [email protected]///contact_phone: 734-936-9241///contact_institute: University of Michigan///contact_address: NI8D17, 300 North Ingals Building, U. of Michigan///contact_city: Ann Arbor///contact_state: MI///contact_zip.postal_code: 48109-5473///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM139nnn/GSM139383/GSM139383.CEL.gz///data_row_count: 22283
1
title: Ovarian_Tumor_ClearCell_KU-OC-007///geo_accession: GSM139384///status: Public on Apr 09 2007///submission_date: Oct 10 2006///last_update_date: Apr 09 2007///type: RNA///channel_count: 1///source_name_ch1: Ovarian_Tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tumor_Type: Clear_Cell///characteristics_ch1.1: stage: 1c///characteristics_ch1.2: grade: N/A///characteristics_ch1.3: B-canenin_nuclear_accumulation: N/A///characteristics_ch1.4: CTNNB1_mutation: N/A///characteristics_ch1.5: APC_mutation: N/A///characteristics_ch1.6: PTEN_mutation: N/A///characteristics_ch1.7: PTEN_immunohistochemistry: N/A///characteristics_ch1.8: KRAS_mutation: N/A///characteristics_ch1.9: PIK3CA_mutation: N/A///characteristics_ch1.10: TP53_mutation: N/A///characteristics_ch1.11: P53_immunohistochemistry: N/A///characteristics_ch1.12: CEL_file_name: KU-OC-007.CEL///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from the tissue lysate using an RNeasy kit (Qiagen).///label_ch1: biotin///label_protocol_ch1: 3-5 g of total RNA was processed to produce biotinylated cRNA targets.///taxid_ch1: 9606///hyb_protocol: standard Affymetrix procedures///scan_protocol: standard Affymetrix procedures///description: ovarian tumor: clear cell///data_processing: Ann Arbor quantile-normalized trimmed-mean method///platform_id: GPL96///contact_name: Rork,,Kuick///contact_email: [email protected]///contact_phone: 734-936-9241///contact_institute: University of Michigan///contact_address: NI8D17, 300 North Ingals Building, U. of Michigan///contact_city: Ann Arbor///contact_state: MI///contact_zip.postal_code: 48109-5473///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM139nnn/GSM139384/GSM139384.CEL.gz///data_row_count: 22283
1
title: Ovarian_Tumor_Endometrioid_CHTN-OE-005///geo_accession: GSM139385///status: Public on Apr 09 2007///submission_date: Oct 10 2006///last_update_date: Apr 09 2007///type: RNA///channel_count: 1///source_name_ch1: Ovarian_Tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tumor_Type: Endometrioid///characteristics_ch1.1: stage: 4///characteristics_ch1.2: grade: 3///characteristics_ch1.3: B-canenin_nuclear_accumulation: N///characteristics_ch1.4: CTNNB1_mutation: N///characteristics_ch1.5: APC_mutation: N/A///characteristics_ch1.6: PTEN_mutation: N///characteristics_ch1.7: PTEN_immunohistochemistry: present///characteristics_ch1.8: KRAS_mutation: N///characteristics_ch1.9: PIK3CA_mutation: N///characteristics_ch1.10: TP53_mutation: N///characteristics_ch1.11: P53_immunohistochemistry: present///characteristics_ch1.12: CEL_file_name: CHTN-OE-005.CEL///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from the tissue lysate using an RNeasy kit (Qiagen).///label_ch1: biotin///label_protocol_ch1: 3-5 g of total RNA was processed to produce biotinylated cRNA targets.///taxid_ch1: 9606///hyb_protocol: standard Affymetrix procedures///scan_protocol: standard Affymetrix procedures///description: ovarian tumor: endometrioid///data_processing: Ann Arbor quantile-normalized trimmed-mean method///platform_id: GPL96///contact_name: Rork,,Kuick///contact_email: [email protected]///contact_phone: 734-936-9241///contact_institute: University of Michigan///contact_address: NI8D17, 300 North Ingals Building, U. of Michigan///contact_city: Ann Arbor///contact_state: MI///contact_zip.postal_code: 48109-5473///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM139nnn/GSM139385/GSM139385.CEL.gz///data_row_count: 22283
1
title: Ovarian_Tumor_Endometrioid_CHTN-OE-011///geo_accession: GSM139386///status: Public on Apr 09 2007///submission_date: Oct 10 2006///last_update_date: Apr 09 2007///type: RNA///channel_count: 1///source_name_ch1: Ovarian_Tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tumor_Type: Endometrioid///characteristics_ch1.1: stage: 1A///characteristics_ch1.2: grade: 1///characteristics_ch1.3: B-canenin_nuclear_accumulation: N///characteristics_ch1.4: CTNNB1_mutation: Y///characteristics_ch1.5: APC_mutation: N/A///characteristics_ch1.6: PTEN_mutation: Y///characteristics_ch1.7: PTEN_immunohistochemistry: absent///characteristics_ch1.8: KRAS_mutation: N///characteristics_ch1.9: PIK3CA_mutation: N///characteristics_ch1.10: TP53_mutation: Y///characteristics_ch1.11: P53_immunohistochemistry: absent///characteristics_ch1.12: CEL_file_name: CHTN-OE-011.CEL///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from the tissue lysate using an RNeasy kit (Qiagen).///label_ch1: biotin///label_protocol_ch1: 3-5 g of total RNA was processed to produce biotinylated cRNA targets.///taxid_ch1: 9606///hyb_protocol: standard Affymetrix procedures///scan_protocol: standard Affymetrix procedures///description: ovarian tumor: endometrioid///data_processing: Ann Arbor quantile-normalized trimmed-mean method///platform_id: GPL96///contact_name: Rork,,Kuick///contact_email: [email protected]///contact_phone: 734-936-9241///contact_institute: University of Michigan///contact_address: NI8D17, 300 North Ingals Building, U. of Michigan///contact_city: Ann Arbor///contact_state: MI///contact_zip.postal_code: 48109-5473///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM139nnn/GSM139386/GSM139386.CEL.gz///data_row_count: 22283
1
title: Ovarian_Tumor_Endometrioid_CHTN-OE-014///geo_accession: GSM139387///status: Public on Apr 09 2007///submission_date: Oct 10 2006///last_update_date: Apr 09 2007///type: RNA///channel_count: 1///source_name_ch1: Ovarian_Tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tumor_Type: Endometrioid///characteristics_ch1.1: stage: 4///characteristics_ch1.2: grade: 2///characteristics_ch1.3: B-canenin_nuclear_accumulation: N///characteristics_ch1.4: CTNNB1_mutation: N///characteristics_ch1.5: APC_mutation: N/A///characteristics_ch1.6: PTEN_mutation: N///characteristics_ch1.7: PTEN_immunohistochemistry: present///characteristics_ch1.8: KRAS_mutation: N///characteristics_ch1.9: PIK3CA_mutation: N///characteristics_ch1.10: TP53_mutation: N///characteristics_ch1.11: P53_immunohistochemistry: present///characteristics_ch1.12: CEL_file_name: CHTN-OE-014.CEL///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from the tissue lysate using an RNeasy kit (Qiagen).///label_ch1: biotin///label_protocol_ch1: 3-5 g of total RNA was processed to produce biotinylated cRNA targets.///taxid_ch1: 9606///hyb_protocol: standard Affymetrix procedures///scan_protocol: standard Affymetrix procedures///description: ovarian tumor: endometrioid///data_processing: Ann Arbor quantile-normalized trimmed-mean method///platform_id: GPL96///contact_name: Rork,,Kuick///contact_email: [email protected]///contact_phone: 734-936-9241///contact_institute: University of Michigan///contact_address: NI8D17, 300 North Ingals Building, U. of Michigan///contact_city: Ann Arbor///contact_state: MI///contact_zip.postal_code: 48109-5473///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM139nnn/GSM139387/GSM139387.CEL.gz///data_row_count: 22283
1
title: Ovarian_Tumor_Endometrioid_CHTN-OE-017///geo_accession: GSM139388///status: Public on Apr 09 2007///submission_date: Oct 10 2006///last_update_date: Apr 09 2007///type: RNA///channel_count: 1///source_name_ch1: Ovarian_Tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tumor_Type: Endometrioid///characteristics_ch1.1: stage: 2A///characteristics_ch1.2: grade: 2///characteristics_ch1.3: B-canenin_nuclear_accumulation: Y///characteristics_ch1.4: CTNNB1_mutation: Y///characteristics_ch1.5: APC_mutation: N/A///characteristics_ch1.6: PTEN_mutation: N///characteristics_ch1.7: PTEN_immunohistochemistry: absent///characteristics_ch1.8: KRAS_mutation: N///characteristics_ch1.9: PIK3CA_mutation: N///characteristics_ch1.10: TP53_mutation: N///characteristics_ch1.11: P53_immunohistochemistry: absent///characteristics_ch1.12: CEL_file_name: CHTN-OE-017.CEL///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from the tissue lysate using an RNeasy kit (Qiagen).///label_ch1: biotin///label_protocol_ch1: 3-5 g of total RNA was processed to produce biotinylated cRNA targets.///taxid_ch1: 9606///hyb_protocol: standard Affymetrix procedures///scan_protocol: standard Affymetrix procedures///description: ovarian tumor: endometrioid///data_processing: Ann Arbor quantile-normalized trimmed-mean method///platform_id: GPL96///contact_name: Rork,,Kuick///contact_email: [email protected]///contact_phone: 734-936-9241///contact_institute: University of Michigan///contact_address: NI8D17, 300 North Ingals Building, U. of Michigan///contact_city: Ann Arbor///contact_state: MI///contact_zip.postal_code: 48109-5473///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM139nnn/GSM139388/GSM139388.CEL.gz///data_row_count: 22283
1
title: Ovarian_Tumor_Endometrioid_CHTN-OE-018///geo_accession: GSM139389///status: Public on Apr 09 2007///submission_date: Oct 10 2006///last_update_date: Apr 09 2007///type: RNA///channel_count: 1///source_name_ch1: Ovarian_Tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tumor_Type: Endometrioid///characteristics_ch1.1: stage: 3C///characteristics_ch1.2: grade: 2-3///characteristics_ch1.3: B-canenin_nuclear_accumulation: N///characteristics_ch1.4: CTNNB1_mutation: N///characteristics_ch1.5: APC_mutation: N/A///characteristics_ch1.6: PTEN_mutation: Y///characteristics_ch1.7: PTEN_immunohistochemistry: absent///characteristics_ch1.8: KRAS_mutation: N///characteristics_ch1.9: PIK3CA_mutation: Y///characteristics_ch1.10: TP53_mutation: N///characteristics_ch1.11: P53_immunohistochemistry: absent///characteristics_ch1.12: CEL_file_name: CHTN-OE-018.CEL///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from the tissue lysate using an RNeasy kit (Qiagen).///label_ch1: biotin///label_protocol_ch1: 3-5 g of total RNA was processed to produce biotinylated cRNA targets.///taxid_ch1: 9606///hyb_protocol: standard Affymetrix procedures///scan_protocol: standard Affymetrix procedures///description: ovarian tumor: endometrioid///data_processing: Ann Arbor quantile-normalized trimmed-mean method///platform_id: GPL96///contact_name: Rork,,Kuick///contact_email: [email protected]///contact_phone: 734-936-9241///contact_institute: University of Michigan///contact_address: NI8D17, 300 North Ingals Building, U. of Michigan///contact_city: Ann Arbor///contact_state: MI///contact_zip.postal_code: 48109-5473///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM139nnn/GSM139389/GSM139389.CEL.gz///data_row_count: 22283
1
title: Ovarian_Tumor_Endometrioid_CHTN-OE-019///geo_accession: GSM139390///status: Public on Apr 09 2007///submission_date: Oct 10 2006///last_update_date: Apr 09 2007///type: RNA///channel_count: 1///source_name_ch1: Ovarian_Tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tumor_Type: Endometrioid///characteristics_ch1.1: stage: 1A///characteristics_ch1.2: grade: 1///characteristics_ch1.3: B-canenin_nuclear_accumulation: Y///characteristics_ch1.4: CTNNB1_mutation: Y///characteristics_ch1.5: APC_mutation: N/A///characteristics_ch1.6: PTEN_mutation: N///characteristics_ch1.7: PTEN_immunohistochemistry: absent///characteristics_ch1.8: KRAS_mutation: N///characteristics_ch1.9: PIK3CA_mutation: N///characteristics_ch1.10: TP53_mutation: N///characteristics_ch1.11: P53_immunohistochemistry: absent///characteristics_ch1.12: CEL_file_name: CHTN-OE-019.CEL///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from the tissue lysate using an RNeasy kit (Qiagen).///label_ch1: biotin///label_protocol_ch1: 3-5 g of total RNA was processed to produce biotinylated cRNA targets.///taxid_ch1: 9606///hyb_protocol: standard Affymetrix procedures///scan_protocol: standard Affymetrix procedures///description: ovarian tumor: endometrioid///data_processing: Ann Arbor quantile-normalized trimmed-mean method///platform_id: GPL96///contact_name: Rork,,Kuick///contact_email: [email protected]///contact_phone: 734-936-9241///contact_institute: University of Michigan///contact_address: NI8D17, 300 North Ingals Building, U. of Michigan///contact_city: Ann Arbor///contact_state: MI///contact_zip.postal_code: 48109-5473///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM139nnn/GSM139390/GSM139390.CEL.gz///data_row_count: 22283
1
title: Ovarian_Tumor_Endometrioid_CHTN-OE-023///geo_accession: GSM139391///status: Public on Apr 09 2007///submission_date: Oct 10 2006///last_update_date: Apr 09 2007///type: RNA///channel_count: 1///source_name_ch1: Ovarian_Tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tumor_Type: Endometrioid///characteristics_ch1.1: stage: 1C///characteristics_ch1.2: grade: 1///characteristics_ch1.3: B-canenin_nuclear_accumulation: Y///characteristics_ch1.4: CTNNB1_mutation: N///characteristics_ch1.5: APC_mutation: Y///characteristics_ch1.6: PTEN_mutation: N///characteristics_ch1.7: PTEN_immunohistochemistry: absent///characteristics_ch1.8: KRAS_mutation: N///characteristics_ch1.9: PIK3CA_mutation: N/A///characteristics_ch1.10: TP53_mutation: N///characteristics_ch1.11: P53_immunohistochemistry: absent///characteristics_ch1.12: CEL_file_name: CHTN-OE-023.CEL///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from the tissue lysate using an RNeasy kit (Qiagen).///label_ch1: biotin///label_protocol_ch1: 3-5 g of total RNA was processed to produce biotinylated cRNA targets.///taxid_ch1: 9606///hyb_protocol: standard Affymetrix procedures///scan_protocol: standard Affymetrix procedures///description: ovarian tumor: endometrioid///data_processing: Ann Arbor quantile-normalized trimmed-mean method///platform_id: GPL96///contact_name: Rork,,Kuick///contact_email: [email protected]///contact_phone: 734-936-9241///contact_institute: University of Michigan///contact_address: NI8D17, 300 North Ingals Building, U. of Michigan///contact_city: Ann Arbor///contact_state: MI///contact_zip.postal_code: 48109-5473///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM139nnn/GSM139391/GSM139391.CEL.gz///data_row_count: 22283
1
title: Ovarian_Tumor_Endometrioid_CHTN-OE-029///geo_accession: GSM139392///status: Public on Apr 09 2007///submission_date: Oct 10 2006///last_update_date: Apr 09 2007///type: RNA///channel_count: 1///source_name_ch1: Ovarian_Tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tumor_Type: Endometrioid///characteristics_ch1.1: stage: 1c///characteristics_ch1.2: grade: 1///characteristics_ch1.3: B-canenin_nuclear_accumulation: Y///characteristics_ch1.4: CTNNB1_mutation: Y///characteristics_ch1.5: APC_mutation: N/A///characteristics_ch1.6: PTEN_mutation: Y///characteristics_ch1.7: PTEN_immunohistochemistry: absent///characteristics_ch1.8: KRAS_mutation: N///characteristics_ch1.9: PIK3CA_mutation: N///characteristics_ch1.10: TP53_mutation: N///characteristics_ch1.11: P53_immunohistochemistry: absent///characteristics_ch1.12: CEL_file_name: CHTN-OE-029.CEL///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from the tissue lysate using an RNeasy kit (Qiagen).///label_ch1: biotin///label_protocol_ch1: 3-5 g of total RNA was processed to produce biotinylated cRNA targets.///taxid_ch1: 9606///hyb_protocol: standard Affymetrix procedures///scan_protocol: standard Affymetrix procedures///description: ovarian tumor: endometrioid///data_processing: Ann Arbor quantile-normalized trimmed-mean method///platform_id: GPL96///contact_name: Rork,,Kuick///contact_email: [email protected]///contact_phone: 734-936-9241///contact_institute: University of Michigan///contact_address: NI8D17, 300 North Ingals Building, U. of Michigan///contact_city: Ann Arbor///contact_state: MI///contact_zip.postal_code: 48109-5473///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM139nnn/GSM139392/GSM139392.CEL.gz///data_row_count: 22283
1
title: Ovarian_Tumor_Endometrioid_CHTN-OE-033///geo_accession: GSM139393///status: Public on Apr 09 2007///submission_date: Oct 10 2006///last_update_date: Apr 09 2007///type: RNA///channel_count: 1///source_name_ch1: Ovarian_Tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tumor_Type: Endometrioid///characteristics_ch1.1: stage: 3C///characteristics_ch1.2: grade: 1///characteristics_ch1.3: B-canenin_nuclear_accumulation: N///characteristics_ch1.4: CTNNB1_mutation: N///characteristics_ch1.5: APC_mutation: N/A///characteristics_ch1.6: PTEN_mutation: N///characteristics_ch1.7: PTEN_immunohistochemistry: present///characteristics_ch1.8: KRAS_mutation: N///characteristics_ch1.9: PIK3CA_mutation: N///characteristics_ch1.10: TP53_mutation: Y///characteristics_ch1.11: P53_immunohistochemistry: present///characteristics_ch1.12: CEL_file_name: CHTN-OE-033.CEL///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from the tissue lysate using an RNeasy kit (Qiagen).///label_ch1: biotin///label_protocol_ch1: 3-5 g of total RNA was processed to produce biotinylated cRNA targets.///taxid_ch1: 9606///hyb_protocol: standard Affymetrix procedures///scan_protocol: standard Affymetrix procedures///description: ovarian tumor: endometrioid///data_processing: Ann Arbor quantile-normalized trimmed-mean method///platform_id: GPL96///contact_name: Rork,,Kuick///contact_email: [email protected]///contact_phone: 734-936-9241///contact_institute: University of Michigan///contact_address: NI8D17, 300 North Ingals Building, U. of Michigan///contact_city: Ann Arbor///contact_state: MI///contact_zip.postal_code: 48109-5473///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM139nnn/GSM139393/GSM139393.CEL.gz///data_row_count: 22283
1
title: Ovarian_Tumor_Endometrioid_CHTN-OE-035///geo_accession: GSM139394///status: Public on Apr 09 2007///submission_date: Oct 10 2006///last_update_date: Apr 09 2007///type: RNA///channel_count: 1///source_name_ch1: Ovarian_Tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tumor_Type: Endometrioid///characteristics_ch1.1: stage: 1///characteristics_ch1.2: grade: 2///characteristics_ch1.3: B-canenin_nuclear_accumulation: N///characteristics_ch1.4: CTNNB1_mutation: N///characteristics_ch1.5: APC_mutation: N/A///characteristics_ch1.6: PTEN_mutation: N///characteristics_ch1.7: PTEN_immunohistochemistry: present///characteristics_ch1.8: KRAS_mutation: N///characteristics_ch1.9: PIK3CA_mutation: N///characteristics_ch1.10: TP53_mutation: N///characteristics_ch1.11: P53_immunohistochemistry: absent///characteristics_ch1.12: CEL_file_name: CHTN-OE-035.CEL///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from the tissue lysate using an RNeasy kit (Qiagen).///label_ch1: biotin///label_protocol_ch1: 3-5 g of total RNA was processed to produce biotinylated cRNA targets.///taxid_ch1: 9606///hyb_protocol: standard Affymetrix procedures///scan_protocol: standard Affymetrix procedures///description: ovarian tumor: endometrioid///data_processing: Ann Arbor quantile-normalized trimmed-mean method///platform_id: GPL96///contact_name: Rork,,Kuick///contact_email: [email protected]///contact_phone: 734-936-9241///contact_institute: University of Michigan///contact_address: NI8D17, 300 North Ingals Building, U. of Michigan///contact_city: Ann Arbor///contact_state: MI///contact_zip.postal_code: 48109-5473///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM139nnn/GSM139394/GSM139394.CEL.gz///data_row_count: 22283
1
title: Ovarian_Tumor_Endometrioid_CHTN-OE-036///geo_accession: GSM139395///status: Public on Apr 09 2007///submission_date: Oct 10 2006///last_update_date: Apr 09 2007///type: RNA///channel_count: 1///source_name_ch1: Ovarian_Tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tumor_Type: Endometrioid///characteristics_ch1.1: stage: 3///characteristics_ch1.2: grade: 3///characteristics_ch1.3: B-canenin_nuclear_accumulation: N///characteristics_ch1.4: CTNNB1_mutation: N///characteristics_ch1.5: APC_mutation: N/A///characteristics_ch1.6: PTEN_mutation: N///characteristics_ch1.7: PTEN_immunohistochemistry: absent///characteristics_ch1.8: KRAS_mutation: N///characteristics_ch1.9: PIK3CA_mutation: N///characteristics_ch1.10: TP53_mutation: Y///characteristics_ch1.11: P53_immunohistochemistry: present///characteristics_ch1.12: CEL_file_name: CHTN-OE-036.CEL///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from the tissue lysate using an RNeasy kit (Qiagen).///label_ch1: biotin///label_protocol_ch1: 3-5 g of total RNA was processed to produce biotinylated cRNA targets.///taxid_ch1: 9606///hyb_protocol: standard Affymetrix procedures///scan_protocol: standard Affymetrix procedures///description: ovarian tumor: endometrioid///data_processing: Ann Arbor quantile-normalized trimmed-mean method///platform_id: GPL96///contact_name: Rork,,Kuick///contact_email: [email protected]///contact_phone: 734-936-9241///contact_institute: University of Michigan///contact_address: NI8D17, 300 North Ingals Building, U. of Michigan///contact_city: Ann Arbor///contact_state: MI///contact_zip.postal_code: 48109-5473///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM139nnn/GSM139395/GSM139395.CEL.gz///data_row_count: 22283
1
title: Ovarian_Tumor_Endometrioid_CHTN-OE-038///geo_accession: GSM139396///status: Public on Apr 09 2007///submission_date: Oct 10 2006///last_update_date: Apr 09 2007///type: RNA///channel_count: 1///source_name_ch1: Ovarian_Tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tumor_Type: Endometrioid///characteristics_ch1.1: stage: 1C///characteristics_ch1.2: grade: 2///characteristics_ch1.3: B-canenin_nuclear_accumulation: N///characteristics_ch1.4: CTNNB1_mutation: N///characteristics_ch1.5: APC_mutation: N/A///characteristics_ch1.6: PTEN_mutation: N///characteristics_ch1.7: PTEN_immunohistochemistry: present///characteristics_ch1.8: KRAS_mutation: N///characteristics_ch1.9: PIK3CA_mutation: N///characteristics_ch1.10: TP53_mutation: Y///characteristics_ch1.11: P53_immunohistochemistry: present///characteristics_ch1.12: CEL_file_name: CHTN-OE-038.CEL///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from the tissue lysate using an RNeasy kit (Qiagen).///label_ch1: biotin///label_protocol_ch1: 3-5 g of total RNA was processed to produce biotinylated cRNA targets.///taxid_ch1: 9606///hyb_protocol: standard Affymetrix procedures///scan_protocol: standard Affymetrix procedures///description: ovarian tumor: endometrioid///data_processing: Ann Arbor quantile-normalized trimmed-mean method///platform_id: GPL96///contact_name: Rork,,Kuick///contact_email: [email protected]///contact_phone: 734-936-9241///contact_institute: University of Michigan///contact_address: NI8D17, 300 North Ingals Building, U. of Michigan///contact_city: Ann Arbor///contact_state: MI///contact_zip.postal_code: 48109-5473///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM139nnn/GSM139396/GSM139396.CEL.gz///data_row_count: 22283
1
title: Ovarian_Tumor_Endometrioid_CHTN-OE-039///geo_accession: GSM139397///status: Public on Apr 09 2007///submission_date: Oct 10 2006///last_update_date: Apr 09 2007///type: RNA///channel_count: 1///source_name_ch1: Ovarian_Tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tumor_Type: Endometrioid///characteristics_ch1.1: stage: 1A///characteristics_ch1.2: grade: 2///characteristics_ch1.3: B-canenin_nuclear_accumulation: Y///characteristics_ch1.4: CTNNB1_mutation: Y///characteristics_ch1.5: APC_mutation: N///characteristics_ch1.6: PTEN_mutation: Y///characteristics_ch1.7: PTEN_immunohistochemistry: absent///characteristics_ch1.8: KRAS_mutation: N///characteristics_ch1.9: PIK3CA_mutation: N///characteristics_ch1.10: TP53_mutation: N///characteristics_ch1.11: P53_immunohistochemistry: absent///characteristics_ch1.12: CEL_file_name: CHTN-OE-039.CEL///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from the tissue lysate using an RNeasy kit (Qiagen).///label_ch1: biotin///label_protocol_ch1: 3-5 g of total RNA was processed to produce biotinylated cRNA targets.///taxid_ch1: 9606///hyb_protocol: standard Affymetrix procedures///scan_protocol: standard Affymetrix procedures///description: ovarian tumor: endometrioid///data_processing: Ann Arbor quantile-normalized trimmed-mean method///platform_id: GPL96///contact_name: Rork,,Kuick///contact_email: [email protected]///contact_phone: 734-936-9241///contact_institute: University of Michigan///contact_address: NI8D17, 300 North Ingals Building, U. of Michigan///contact_city: Ann Arbor///contact_state: MI///contact_zip.postal_code: 48109-5473///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM139nnn/GSM139397/GSM139397.CEL.gz///data_row_count: 22283
1
title: Ovarian_Tumor_Endometrioid_CHTN-OE-040///geo_accession: GSM139398///status: Public on Apr 09 2007///submission_date: Oct 10 2006///last_update_date: Apr 09 2007///type: RNA///channel_count: 1///source_name_ch1: Ovarian_Tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tumor_Type: Endometrioid///characteristics_ch1.1: stage: 4///characteristics_ch1.2: grade: 3///characteristics_ch1.3: B-canenin_nuclear_accumulation: N///characteristics_ch1.4: CTNNB1_mutation: N///characteristics_ch1.5: APC_mutation: N/A///characteristics_ch1.6: PTEN_mutation: N///characteristics_ch1.7: PTEN_immunohistochemistry: present///characteristics_ch1.8: KRAS_mutation: N///characteristics_ch1.9: PIK3CA_mutation: N///characteristics_ch1.10: TP53_mutation: Y///characteristics_ch1.11: P53_immunohistochemistry: present///characteristics_ch1.12: CEL_file_name: CHTN-OE-040.CEL///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from the tissue lysate using an RNeasy kit (Qiagen).///label_ch1: biotin///label_protocol_ch1: 3-5 g of total RNA was processed to produce biotinylated cRNA targets.///taxid_ch1: 9606///hyb_protocol: standard Affymetrix procedures///scan_protocol: standard Affymetrix procedures///description: ovarian tumor: endometrioid///data_processing: Ann Arbor quantile-normalized trimmed-mean method///platform_id: GPL96///contact_name: Rork,,Kuick///contact_email: [email protected]///contact_phone: 734-936-9241///contact_institute: University of Michigan///contact_address: NI8D17, 300 North Ingals Building, U. of Michigan///contact_city: Ann Arbor///contact_state: MI///contact_zip.postal_code: 48109-5473///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM139nnn/GSM139398/GSM139398.CEL.gz///data_row_count: 22283
1
title: Ovarian_Tumor_Endometrioid_CHTN-OE-042///geo_accession: GSM139399///status: Public on Apr 09 2007///submission_date: Oct 10 2006///last_update_date: Apr 09 2007///type: RNA///channel_count: 1///source_name_ch1: Ovarian_Tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tumor_Type: Endometrioid///characteristics_ch1.1: stage: 1C///characteristics_ch1.2: grade: 3///characteristics_ch1.3: B-canenin_nuclear_accumulation: N///characteristics_ch1.4: CTNNB1_mutation: N///characteristics_ch1.5: APC_mutation: N///characteristics_ch1.6: PTEN_mutation: N///characteristics_ch1.7: PTEN_immunohistochemistry: present///characteristics_ch1.8: KRAS_mutation: N///characteristics_ch1.9: PIK3CA_mutation: N///characteristics_ch1.10: TP53_mutation: N///characteristics_ch1.11: P53_immunohistochemistry: absent///characteristics_ch1.12: CEL_file_name: CHTN-OE-042.CEL///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from the tissue lysate using an RNeasy kit (Qiagen).///label_ch1: biotin///label_protocol_ch1: 3-5 g of total RNA was processed to produce biotinylated cRNA targets.///taxid_ch1: 9606///hyb_protocol: standard Affymetrix procedures///scan_protocol: standard Affymetrix procedures///description: ovarian tumor: endometrioid///data_processing: Ann Arbor quantile-normalized trimmed-mean method///platform_id: GPL96///contact_name: Rork,,Kuick///contact_email: [email protected]///contact_phone: 734-936-9241///contact_institute: University of Michigan///contact_address: NI8D17, 300 North Ingals Building, U. of Michigan///contact_city: Ann Arbor///contact_state: MI///contact_zip.postal_code: 48109-5473///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM139nnn/GSM139399/GSM139399.CEL.gz///data_row_count: 22283
1
title: Ovarian_Tumor_Endometrioid_CHTN-OE-046///geo_accession: GSM139400///status: Public on Apr 09 2007///submission_date: Oct 10 2006///last_update_date: Apr 09 2007///type: RNA///channel_count: 1///source_name_ch1: Ovarian_Tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tumor_Type: Endometrioid///characteristics_ch1.1: stage: 1C///characteristics_ch1.2: grade: 2///characteristics_ch1.3: B-canenin_nuclear_accumulation: Y///characteristics_ch1.4: CTNNB1_mutation: Y///characteristics_ch1.5: APC_mutation: N/A///characteristics_ch1.6: PTEN_mutation: N///characteristics_ch1.7: PTEN_immunohistochemistry: present///characteristics_ch1.8: KRAS_mutation: N///characteristics_ch1.9: PIK3CA_mutation: N///characteristics_ch1.10: TP53_mutation: N///characteristics_ch1.11: P53_immunohistochemistry: absent///characteristics_ch1.12: CEL_file_name: CHTN-OE-046.CEL///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from the tissue lysate using an RNeasy kit (Qiagen).///label_ch1: biotin///label_protocol_ch1: 3-5 g of total RNA was processed to produce biotinylated cRNA targets.///taxid_ch1: 9606///hyb_protocol: standard Affymetrix procedures///scan_protocol: standard Affymetrix procedures///description: ovarian tumor: endometrioid///data_processing: Ann Arbor quantile-normalized trimmed-mean method///platform_id: GPL96///contact_name: Rork,,Kuick///contact_email: [email protected]///contact_phone: 734-936-9241///contact_institute: University of Michigan///contact_address: NI8D17, 300 North Ingals Building, U. of Michigan///contact_city: Ann Arbor///contact_state: MI///contact_zip.postal_code: 48109-5473///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM139nnn/GSM139400/GSM139400.CEL.gz///data_row_count: 22283
1
title: Ovarian_Tumor_Endometrioid_CHTN-OE-047///geo_accession: GSM139401///status: Public on Apr 09 2007///submission_date: Oct 10 2006///last_update_date: Apr 09 2007///type: RNA///channel_count: 1///source_name_ch1: Ovarian_Tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tumor_Type: Endometrioid///characteristics_ch1.1: stage: 2B///characteristics_ch1.2: grade: 3///characteristics_ch1.3: B-canenin_nuclear_accumulation: N///characteristics_ch1.4: CTNNB1_mutation: N///characteristics_ch1.5: APC_mutation: N/A///characteristics_ch1.6: PTEN_mutation: N///characteristics_ch1.7: PTEN_immunohistochemistry: present///characteristics_ch1.8: KRAS_mutation: N///characteristics_ch1.9: PIK3CA_mutation: N///characteristics_ch1.10: TP53_mutation: N///characteristics_ch1.11: P53_immunohistochemistry: absent///characteristics_ch1.12: CEL_file_name: CHTN-OE-047.CEL///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from the tissue lysate using an RNeasy kit (Qiagen).///label_ch1: biotin///label_protocol_ch1: 3-5 g of total RNA was processed to produce biotinylated cRNA targets.///taxid_ch1: 9606///hyb_protocol: standard Affymetrix procedures///scan_protocol: standard Affymetrix procedures///description: ovarian tumor: endometrioid///data_processing: Ann Arbor quantile-normalized trimmed-mean method///platform_id: GPL96///contact_name: Rork,,Kuick///contact_email: [email protected]///contact_phone: 734-936-9241///contact_institute: University of Michigan///contact_address: NI8D17, 300 North Ingals Building, U. of Michigan///contact_city: Ann Arbor///contact_state: MI///contact_zip.postal_code: 48109-5473///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM139nnn/GSM139401/GSM139401.CEL.gz///data_row_count: 22283
1
title: Ovarian_Tumor_Endometrioid_CHTN-OE-048///geo_accession: GSM139402///status: Public on Apr 09 2007///submission_date: Oct 10 2006///last_update_date: Apr 09 2007///type: RNA///channel_count: 1///source_name_ch1: Ovarian_Tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tumor_Type: Endometrioid///characteristics_ch1.1: stage: 1A///characteristics_ch1.2: grade: 1///characteristics_ch1.3: B-canenin_nuclear_accumulation: Y///characteristics_ch1.4: CTNNB1_mutation: Y///characteristics_ch1.5: APC_mutation: N/A///characteristics_ch1.6: PTEN_mutation: N///characteristics_ch1.7: PTEN_immunohistochemistry: present///characteristics_ch1.8: KRAS_mutation: N///characteristics_ch1.9: PIK3CA_mutation: N///characteristics_ch1.10: TP53_mutation: N///characteristics_ch1.11: P53_immunohistochemistry: absent///characteristics_ch1.12: CEL_file_name: CHTN-OE-048.CEL///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from the tissue lysate using an RNeasy kit (Qiagen).///label_ch1: biotin///label_protocol_ch1: 3-5 g of total RNA was processed to produce biotinylated cRNA targets.///taxid_ch1: 9606///hyb_protocol: standard Affymetrix procedures///scan_protocol: standard Affymetrix procedures///description: ovarian tumor: endometrioid///data_processing: Ann Arbor quantile-normalized trimmed-mean method///platform_id: GPL96///contact_name: Rork,,Kuick///contact_email: [email protected]///contact_phone: 734-936-9241///contact_institute: University of Michigan///contact_address: NI8D17, 300 North Ingals Building, U. of Michigan///contact_city: Ann Arbor///contact_state: MI///contact_zip.postal_code: 48109-5473///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM139nnn/GSM139402/GSM139402.CEL.gz///data_row_count: 22283
1
title: Ovarian_Tumor_Endometrioid_CHTN-OE-053///geo_accession: GSM139403///status: Public on Apr 09 2007///submission_date: Oct 10 2006///last_update_date: Apr 09 2007///type: RNA///channel_count: 1///source_name_ch1: Ovarian_Tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tumor_Type: Endometrioid///characteristics_ch1.1: stage: 1///characteristics_ch1.2: grade: 1///characteristics_ch1.3: B-canenin_nuclear_accumulation: Y///characteristics_ch1.4: CTNNB1_mutation: Y///characteristics_ch1.5: APC_mutation: N/A///characteristics_ch1.6: PTEN_mutation: N///characteristics_ch1.7: PTEN_immunohistochemistry: present///characteristics_ch1.8: KRAS_mutation: N///characteristics_ch1.9: PIK3CA_mutation: N///characteristics_ch1.10: TP53_mutation: N///characteristics_ch1.11: P53_immunohistochemistry: absent///characteristics_ch1.12: CEL_file_name: CHTN-OE-053.CEL///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from the tissue lysate using an RNeasy kit (Qiagen).///label_ch1: biotin///label_protocol_ch1: 3-5 g of total RNA was processed to produce biotinylated cRNA targets.///taxid_ch1: 9606///hyb_protocol: standard Affymetrix procedures///scan_protocol: standard Affymetrix procedures///description: ovarian tumor: endometrioid///data_processing: Ann Arbor quantile-normalized trimmed-mean method///platform_id: GPL96///contact_name: Rork,,Kuick///contact_email: [email protected]///contact_phone: 734-936-9241///contact_institute: University of Michigan///contact_address: NI8D17, 300 North Ingals Building, U. of Michigan///contact_city: Ann Arbor///contact_state: MI///contact_zip.postal_code: 48109-5473///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM139nnn/GSM139403/GSM139403.CEL.gz///data_row_count: 22283
1
title: Ovarian_Tumor_Endometrioid_CHTN-OE-054///geo_accession: GSM139404///status: Public on Apr 09 2007///submission_date: Oct 10 2006///last_update_date: Apr 09 2007///type: RNA///channel_count: 1///source_name_ch1: Ovarian_Tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tumor_Type: Endometrioid///characteristics_ch1.1: stage: 3///characteristics_ch1.2: grade: 3///characteristics_ch1.3: B-canenin_nuclear_accumulation: N///characteristics_ch1.4: CTNNB1_mutation: N///characteristics_ch1.5: APC_mutation: N/A///characteristics_ch1.6: PTEN_mutation: N///characteristics_ch1.7: PTEN_immunohistochemistry: present///characteristics_ch1.8: KRAS_mutation: N///characteristics_ch1.9: PIK3CA_mutation: N///characteristics_ch1.10: TP53_mutation: Y///characteristics_ch1.11: P53_immunohistochemistry: absent///characteristics_ch1.12: CEL_file_name: CHTN-OE-054.CEL///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from the tissue lysate using an RNeasy kit (Qiagen).///label_ch1: biotin///label_protocol_ch1: 3-5 g of total RNA was processed to produce biotinylated cRNA targets.///taxid_ch1: 9606///hyb_protocol: standard Affymetrix procedures///scan_protocol: standard Affymetrix procedures///description: ovarian tumor: endometrioid///data_processing: Ann Arbor quantile-normalized trimmed-mean method///platform_id: GPL96///contact_name: Rork,,Kuick///contact_email: [email protected]///contact_phone: 734-936-9241///contact_institute: University of Michigan///contact_address: NI8D17, 300 North Ingals Building, U. of Michigan///contact_city: Ann Arbor///contact_state: MI///contact_zip.postal_code: 48109-5473///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM139nnn/GSM139404/GSM139404.CEL.gz///data_row_count: 22283
1
title: Ovarian_Tumor_Endometrioid_CHTN-OE-056///geo_accession: GSM139405///status: Public on Apr 09 2007///submission_date: Oct 10 2006///last_update_date: Apr 09 2007///type: RNA///channel_count: 1///source_name_ch1: Ovarian_Tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tumor_Type: Endometrioid///characteristics_ch1.1: stage: 2A///characteristics_ch1.2: grade: 2///characteristics_ch1.3: B-canenin_nuclear_accumulation: N///characteristics_ch1.4: CTNNB1_mutation: N///characteristics_ch1.5: APC_mutation: N/A///characteristics_ch1.6: PTEN_mutation: N///characteristics_ch1.7: PTEN_immunohistochemistry: present///characteristics_ch1.8: KRAS_mutation: N///characteristics_ch1.9: PIK3CA_mutation: N///characteristics_ch1.10: TP53_mutation: Y///characteristics_ch1.11: P53_immunohistochemistry: present///characteristics_ch1.12: CEL_file_name: CHTN-OE-056.CEL///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from the tissue lysate using an RNeasy kit (Qiagen).///label_ch1: biotin///label_protocol_ch1: 3-5 g of total RNA was processed to produce biotinylated cRNA targets.///taxid_ch1: 9606///hyb_protocol: standard Affymetrix procedures///scan_protocol: standard Affymetrix procedures///description: ovarian tumor: endometrioid///data_processing: Ann Arbor quantile-normalized trimmed-mean method///platform_id: GPL96///contact_name: Rork,,Kuick///contact_email: [email protected]///contact_phone: 734-936-9241///contact_institute: University of Michigan///contact_address: NI8D17, 300 North Ingals Building, U. of Michigan///contact_city: Ann Arbor///contact_state: MI///contact_zip.postal_code: 48109-5473///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM139nnn/GSM139405/GSM139405.CEL.gz///data_row_count: 22283
1
title: Ovarian_Tumor_Endometrioid_CHTN-OE-059///geo_accession: GSM139406///status: Public on Apr 09 2007///submission_date: Oct 10 2006///last_update_date: Apr 09 2007///type: RNA///channel_count: 1///source_name_ch1: Ovarian_Tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tumor_Type: Endometrioid///characteristics_ch1.1: stage: 1A///characteristics_ch1.2: grade: 2-3///characteristics_ch1.3: B-canenin_nuclear_accumulation: N///characteristics_ch1.4: CTNNB1_mutation: N///characteristics_ch1.5: APC_mutation: N/A///characteristics_ch1.6: PTEN_mutation: N///characteristics_ch1.7: PTEN_immunohistochemistry: present///characteristics_ch1.8: KRAS_mutation: N///characteristics_ch1.9: PIK3CA_mutation: N///characteristics_ch1.10: TP53_mutation: Y///characteristics_ch1.11: P53_immunohistochemistry: present///characteristics_ch1.12: CEL_file_name: CHTN-OE-059.CEL///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from the tissue lysate using an RNeasy kit (Qiagen).///label_ch1: biotin///label_protocol_ch1: 3-5 g of total RNA was processed to produce biotinylated cRNA targets.///taxid_ch1: 9606///hyb_protocol: standard Affymetrix procedures///scan_protocol: standard Affymetrix procedures///description: ovarian tumor: endometrioid///data_processing: Ann Arbor quantile-normalized trimmed-mean method///platform_id: GPL96///contact_name: Rork,,Kuick///contact_email: [email protected]///contact_phone: 734-936-9241///contact_institute: University of Michigan///contact_address: NI8D17, 300 North Ingals Building, U. of Michigan///contact_city: Ann Arbor///contact_state: MI///contact_zip.postal_code: 48109-5473///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM139nnn/GSM139406/GSM139406.CEL.gz///data_row_count: 22283
1
title: Ovarian_Tumor_Endometrioid_CHTN-OE-060///geo_accession: GSM139407///status: Public on Apr 09 2007///submission_date: Oct 10 2006///last_update_date: Apr 09 2007///type: RNA///channel_count: 1///source_name_ch1: Ovarian_Tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tumor_Type: Endometrioid///characteristics_ch1.1: stage: 3C///characteristics_ch1.2: grade: 3///characteristics_ch1.3: B-canenin_nuclear_accumulation: N///characteristics_ch1.4: CTNNB1_mutation: N///characteristics_ch1.5: APC_mutation: N/A///characteristics_ch1.6: PTEN_mutation: N///characteristics_ch1.7: PTEN_immunohistochemistry: present///characteristics_ch1.8: KRAS_mutation: N///characteristics_ch1.9: PIK3CA_mutation: N///characteristics_ch1.10: TP53_mutation: Y///characteristics_ch1.11: P53_immunohistochemistry: present///characteristics_ch1.12: CEL_file_name: CHTN-OE-060.CEL///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from the tissue lysate using an RNeasy kit (Qiagen).///label_ch1: biotin///label_protocol_ch1: 3-5 g of total RNA was processed to produce biotinylated cRNA targets.///taxid_ch1: 9606///hyb_protocol: standard Affymetrix procedures///scan_protocol: standard Affymetrix procedures///description: ovarian tumor: endometrioid///data_processing: Ann Arbor quantile-normalized trimmed-mean method///platform_id: GPL96///contact_name: Rork,,Kuick///contact_email: [email protected]///contact_phone: 734-936-9241///contact_institute: University of Michigan///contact_address: NI8D17, 300 North Ingals Building, U. of Michigan///contact_city: Ann Arbor///contact_state: MI///contact_zip.postal_code: 48109-5473///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM139nnn/GSM139407/GSM139407.CEL.gz///data_row_count: 22283
1
title: Ovarian_Tumor_Endometrioid_CHTN-OE-061///geo_accession: GSM139408///status: Public on Apr 09 2007///submission_date: Oct 10 2006///last_update_date: Apr 09 2007///type: RNA///channel_count: 1///source_name_ch1: Ovarian_Tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tumor_Type: Endometrioid///characteristics_ch1.1: stage: 2C///characteristics_ch1.2: grade: 3///characteristics_ch1.3: B-canenin_nuclear_accumulation: N///characteristics_ch1.4: CTNNB1_mutation: N///characteristics_ch1.5: APC_mutation: N/A///characteristics_ch1.6: PTEN_mutation: N///characteristics_ch1.7: PTEN_immunohistochemistry: present///characteristics_ch1.8: KRAS_mutation: N///characteristics_ch1.9: PIK3CA_mutation: N///characteristics_ch1.10: TP53_mutation: Y///characteristics_ch1.11: P53_immunohistochemistry: present///characteristics_ch1.12: CEL_file_name: CHTN-OE-061.CEL///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from the tissue lysate using an RNeasy kit (Qiagen).///label_ch1: biotin///label_protocol_ch1: 3-5 g of total RNA was processed to produce biotinylated cRNA targets.///taxid_ch1: 9606///hyb_protocol: standard Affymetrix procedures///scan_protocol: standard Affymetrix procedures///description: ovarian tumor: endometrioid///data_processing: Ann Arbor quantile-normalized trimmed-mean method///platform_id: GPL96///contact_name: Rork,,Kuick///contact_email: [email protected]///contact_phone: 734-936-9241///contact_institute: University of Michigan///contact_address: NI8D17, 300 North Ingals Building, U. of Michigan///contact_city: Ann Arbor///contact_state: MI///contact_zip.postal_code: 48109-5473///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM139nnn/GSM139408/GSM139408.CEL.gz///data_row_count: 22283
1
title: Ovarian_Tumor_Endometrioid_CHTN-OE-065///geo_accession: GSM139409///status: Public on Apr 09 2007///submission_date: Oct 10 2006///last_update_date: Apr 09 2007///type: RNA///channel_count: 1///source_name_ch1: Ovarian_Tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tumor_Type: Endometrioid///characteristics_ch1.1: stage: 2A///characteristics_ch1.2: grade: 2///characteristics_ch1.3: B-canenin_nuclear_accumulation: N///characteristics_ch1.4: CTNNB1_mutation: N///characteristics_ch1.5: APC_mutation: N/A///characteristics_ch1.6: PTEN_mutation: Y///characteristics_ch1.7: PTEN_immunohistochemistry: absent///characteristics_ch1.8: KRAS_mutation: N///characteristics_ch1.9: PIK3CA_mutation: N///characteristics_ch1.10: TP53_mutation: N///characteristics_ch1.11: P53_immunohistochemistry: absent///characteristics_ch1.12: CEL_file_name: CHTN-OE-065.CEL///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from the tissue lysate using an RNeasy kit (Qiagen).///label_ch1: biotin///label_protocol_ch1: 3-5 g of total RNA was processed to produce biotinylated cRNA targets.///taxid_ch1: 9606///hyb_protocol: standard Affymetrix procedures///scan_protocol: standard Affymetrix procedures///description: ovarian tumor: endometrioid///data_processing: Ann Arbor quantile-normalized trimmed-mean method///platform_id: GPL96///contact_name: Rork,,Kuick///contact_email: [email protected]///contact_phone: 734-936-9241///contact_institute: University of Michigan///contact_address: NI8D17, 300 North Ingals Building, U. of Michigan///contact_city: Ann Arbor///contact_state: MI///contact_zip.postal_code: 48109-5473///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM139nnn/GSM139409/GSM139409.CEL.gz///data_row_count: 22283
1
title: Ovarian_Tumor_Endometrioid_CHTN-OE-069///geo_accession: GSM139410///status: Public on Apr 09 2007///submission_date: Oct 10 2006///last_update_date: Apr 09 2007///type: RNA///channel_count: 1///source_name_ch1: Ovarian_Tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tumor_Type: Endometrioid///characteristics_ch1.1: stage: 3C///characteristics_ch1.2: grade: 3///characteristics_ch1.3: B-canenin_nuclear_accumulation: N///characteristics_ch1.4: CTNNB1_mutation: N///characteristics_ch1.5: APC_mutation: N/A///characteristics_ch1.6: PTEN_mutation: N///characteristics_ch1.7: PTEN_immunohistochemistry: present///characteristics_ch1.8: KRAS_mutation: N///characteristics_ch1.9: PIK3CA_mutation: N///characteristics_ch1.10: TP53_mutation: N///characteristics_ch1.11: P53_immunohistochemistry: absent///characteristics_ch1.12: CEL_file_name: CHTN-OE-069.CEL///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from the tissue lysate using an RNeasy kit (Qiagen).///label_ch1: biotin///label_protocol_ch1: 3-5 g of total RNA was processed to produce biotinylated cRNA targets.///taxid_ch1: 9606///hyb_protocol: standard Affymetrix procedures///scan_protocol: standard Affymetrix procedures///description: ovarian tumor: endometrioid///data_processing: Ann Arbor quantile-normalized trimmed-mean method///platform_id: GPL96///contact_name: Rork,,Kuick///contact_email: [email protected]///contact_phone: 734-936-9241///contact_institute: University of Michigan///contact_address: NI8D17, 300 North Ingals Building, U. of Michigan///contact_city: Ann Arbor///contact_state: MI///contact_zip.postal_code: 48109-5473///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM139nnn/GSM139410/GSM139410.CEL.gz///data_row_count: 22283
1
title: Ovarian_Tumor_Endometrioid_CHTN-OE-076///geo_accession: GSM139411///status: Public on Apr 09 2007///submission_date: Oct 10 2006///last_update_date: Apr 09 2007///type: RNA///channel_count: 1///source_name_ch1: Ovarian_Tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tumor_Type: Endometrioid///characteristics_ch1.1: stage: 1///characteristics_ch1.2: grade: 1///characteristics_ch1.3: B-canenin_nuclear_accumulation: N///characteristics_ch1.4: CTNNB1_mutation: N///characteristics_ch1.5: APC_mutation: N/A///characteristics_ch1.6: PTEN_mutation: N///characteristics_ch1.7: PTEN_immunohistochemistry: present///characteristics_ch1.8: KRAS_mutation: N///characteristics_ch1.9: PIK3CA_mutation: N///characteristics_ch1.10: TP53_mutation: N///characteristics_ch1.11: P53_immunohistochemistry: absent///characteristics_ch1.12: CEL_file_name: CHTN-OE-076.CEL///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from the tissue lysate using an RNeasy kit (Qiagen).///label_ch1: biotin///label_protocol_ch1: 3-5 g of total RNA was processed to produce biotinylated cRNA targets.///taxid_ch1: 9606///hyb_protocol: standard Affymetrix procedures///scan_protocol: standard Affymetrix procedures///description: ovarian tumor: endometrioid///data_processing: Ann Arbor quantile-normalized trimmed-mean method///platform_id: GPL96///contact_name: Rork,,Kuick///contact_email: [email protected]///contact_phone: 734-936-9241///contact_institute: University of Michigan///contact_address: NI8D17, 300 North Ingals Building, U. of Michigan///contact_city: Ann Arbor///contact_state: MI///contact_zip.postal_code: 48109-5473///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM139nnn/GSM139411/GSM139411.CEL.gz///data_row_count: 22283
1
title: Ovarian_Tumor_Endometrioid_CHTN-OE-077///geo_accession: GSM139412///status: Public on Apr 09 2007///submission_date: Oct 10 2006///last_update_date: Apr 09 2007///type: RNA///channel_count: 1///source_name_ch1: Ovarian_Tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tumor_Type: Endometrioid///characteristics_ch1.1: stage: 3C///characteristics_ch1.2: grade: 3///characteristics_ch1.3: B-canenin_nuclear_accumulation: N///characteristics_ch1.4: CTNNB1_mutation: N///characteristics_ch1.5: APC_mutation: N/A///characteristics_ch1.6: PTEN_mutation: N///characteristics_ch1.7: PTEN_immunohistochemistry: present///characteristics_ch1.8: KRAS_mutation: N///characteristics_ch1.9: PIK3CA_mutation: N///characteristics_ch1.10: TP53_mutation: Y///characteristics_ch1.11: P53_immunohistochemistry: absent///characteristics_ch1.12: CEL_file_name: CHTN-OE-077.CEL///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from the tissue lysate using an RNeasy kit (Qiagen).///label_ch1: biotin///label_protocol_ch1: 3-5 g of total RNA was processed to produce biotinylated cRNA targets.///taxid_ch1: 9606///hyb_protocol: standard Affymetrix procedures///scan_protocol: standard Affymetrix procedures///description: ovarian tumor: endometrioid///data_processing: Ann Arbor quantile-normalized trimmed-mean method///platform_id: GPL96///contact_name: Rork,,Kuick///contact_email: [email protected]///contact_phone: 734-936-9241///contact_institute: University of Michigan///contact_address: NI8D17, 300 North Ingals Building, U. of Michigan///contact_city: Ann Arbor///contact_state: MI///contact_zip.postal_code: 48109-5473///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM139nnn/GSM139412/GSM139412.CEL.gz///data_row_count: 22283
1
title: Ovarian_Tumor_Endometrioid_CHTN-OE-080///geo_accession: GSM139413///status: Public on Apr 09 2007///submission_date: Oct 10 2006///last_update_date: Apr 09 2007///type: RNA///channel_count: 1///source_name_ch1: Ovarian_Tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tumor_Type: Endometrioid///characteristics_ch1.1: stage: 3///characteristics_ch1.2: grade: 2///characteristics_ch1.3: B-canenin_nuclear_accumulation: N///characteristics_ch1.4: CTNNB1_mutation: N///characteristics_ch1.5: APC_mutation: N/A///characteristics_ch1.6: PTEN_mutation: N///characteristics_ch1.7: PTEN_immunohistochemistry: present///characteristics_ch1.8: KRAS_mutation: N///characteristics_ch1.9: PIK3CA_mutation: N///characteristics_ch1.10: TP53_mutation: N///characteristics_ch1.11: P53_immunohistochemistry: absent///characteristics_ch1.12: CEL_file_name: CHTN-OE-080.CEL///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from the tissue lysate using an RNeasy kit (Qiagen).///label_ch1: biotin///label_protocol_ch1: 3-5 g of total RNA was processed to produce biotinylated cRNA targets.///taxid_ch1: 9606///hyb_protocol: standard Affymetrix procedures///scan_protocol: standard Affymetrix procedures///description: ovarian tumor: endometrioid///data_processing: Ann Arbor quantile-normalized trimmed-mean method///platform_id: GPL96///contact_name: Rork,,Kuick///contact_email: [email protected]///contact_phone: 734-936-9241///contact_institute: University of Michigan///contact_address: NI8D17, 300 North Ingals Building, U. of Michigan///contact_city: Ann Arbor///contact_state: MI///contact_zip.postal_code: 48109-5473///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM139nnn/GSM139413/GSM139413.CEL.gz///data_row_count: 22283
1
title: Ovarian_Tumor_Endometrioid_CHTN-OE-082///geo_accession: GSM139414///status: Public on Apr 09 2007///submission_date: Oct 10 2006///last_update_date: Apr 09 2007///type: RNA///channel_count: 1///source_name_ch1: Ovarian_Tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tumor_Type: Endometrioid///characteristics_ch1.1: stage: 3///characteristics_ch1.2: grade: 3///characteristics_ch1.3: B-canenin_nuclear_accumulation: N///characteristics_ch1.4: CTNNB1_mutation: N///characteristics_ch1.5: APC_mutation: N/A///characteristics_ch1.6: PTEN_mutation: N///characteristics_ch1.7: PTEN_immunohistochemistry: present///characteristics_ch1.8: KRAS_mutation: N///characteristics_ch1.9: PIK3CA_mutation: N///characteristics_ch1.10: TP53_mutation: N///characteristics_ch1.11: P53_immunohistochemistry: absent///characteristics_ch1.12: CEL_file_name: CHTN-OE-082.CEL///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from the tissue lysate using an RNeasy kit (Qiagen).///label_ch1: biotin///label_protocol_ch1: 3-5 g of total RNA was processed to produce biotinylated cRNA targets.///taxid_ch1: 9606///hyb_protocol: standard Affymetrix procedures///scan_protocol: standard Affymetrix procedures///description: ovarian tumor: endometrioid///data_processing: Ann Arbor quantile-normalized trimmed-mean method///platform_id: GPL96///contact_name: Rork,,Kuick///contact_email: [email protected]///contact_phone: 734-936-9241///contact_institute: University of Michigan///contact_address: NI8D17, 300 North Ingals Building, U. of Michigan///contact_city: Ann Arbor///contact_state: MI///contact_zip.postal_code: 48109-5473///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM139nnn/GSM139414/GSM139414.CEL.gz///data_row_count: 22283
1
title: Ovarian_Tumor_Endometrioid_CHTN-OE-087///geo_accession: GSM139415///status: Public on Apr 09 2007///submission_date: Oct 10 2006///last_update_date: Apr 09 2007///type: RNA///channel_count: 1///source_name_ch1: Ovarian_Tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tumor_Type: Endometrioid///characteristics_ch1.1: stage: 1A///characteristics_ch1.2: grade: 1///characteristics_ch1.3: B-canenin_nuclear_accumulation: Y///characteristics_ch1.4: CTNNB1_mutation: Y///characteristics_ch1.5: APC_mutation: N/A///characteristics_ch1.6: PTEN_mutation: Y///characteristics_ch1.7: PTEN_immunohistochemistry: absent///characteristics_ch1.8: KRAS_mutation: N///characteristics_ch1.9: PIK3CA_mutation: Y///characteristics_ch1.10: TP53_mutation: N///characteristics_ch1.11: P53_immunohistochemistry: absent///characteristics_ch1.12: CEL_file_name: CHTN-OE-087.CEL///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from the tissue lysate using an RNeasy kit (Qiagen).///label_ch1: biotin///label_protocol_ch1: 3-5 g of total RNA was processed to produce biotinylated cRNA targets.///taxid_ch1: 9606///hyb_protocol: standard Affymetrix procedures///scan_protocol: standard Affymetrix procedures///description: ovarian tumor: endometrioid///data_processing: Ann Arbor quantile-normalized trimmed-mean method///platform_id: GPL96///contact_name: Rork,,Kuick///contact_email: [email protected]///contact_phone: 734-936-9241///contact_institute: University of Michigan///contact_address: NI8D17, 300 North Ingals Building, U. of Michigan///contact_city: Ann Arbor///contact_state: MI///contact_zip.postal_code: 48109-5473///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM139nnn/GSM139415/GSM139415.CEL.gz///data_row_count: 22283
1
title: Ovarian_Tumor_Endometrioid_CHTN-OE-092///geo_accession: GSM139416///status: Public on Apr 09 2007///submission_date: Oct 10 2006///last_update_date: Apr 09 2007///type: RNA///channel_count: 1///source_name_ch1: Ovarian_Tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tumor_Type: Endometrioid///characteristics_ch1.1: stage: 3///characteristics_ch1.2: grade: 3///characteristics_ch1.3: B-canenin_nuclear_accumulation: N///characteristics_ch1.4: CTNNB1_mutation: N///characteristics_ch1.5: APC_mutation: N/A///characteristics_ch1.6: PTEN_mutation: N///characteristics_ch1.7: PTEN_immunohistochemistry: present///characteristics_ch1.8: KRAS_mutation: N///characteristics_ch1.9: PIK3CA_mutation: N///characteristics_ch1.10: TP53_mutation: Y///characteristics_ch1.11: P53_immunohistochemistry: present///characteristics_ch1.12: CEL_file_name: CHTN-OE-092.CEL///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from the tissue lysate using an RNeasy kit (Qiagen).///label_ch1: biotin///label_protocol_ch1: 3-5 g of total RNA was processed to produce biotinylated cRNA targets.///taxid_ch1: 9606///hyb_protocol: standard Affymetrix procedures///scan_protocol: standard Affymetrix procedures///description: ovarian tumor: endometrioid///data_processing: Ann Arbor quantile-normalized trimmed-mean method///platform_id: GPL96///contact_name: Rork,,Kuick///contact_email: [email protected]///contact_phone: 734-936-9241///contact_institute: University of Michigan///contact_address: NI8D17, 300 North Ingals Building, U. of Michigan///contact_city: Ann Arbor///contact_state: MI///contact_zip.postal_code: 48109-5473///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM139nnn/GSM139416/GSM139416.CEL.gz///data_row_count: 22283
1
title: Ovarian_Tumor_Endometrioid_JH-OE-2T///geo_accession: GSM139417///status: Public on Apr 09 2007///submission_date: Oct 10 2006///last_update_date: Apr 09 2007///type: RNA///channel_count: 1///source_name_ch1: Ovarian_Tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tumor_Type: Endometrioid///characteristics_ch1.1: stage: 1///characteristics_ch1.2: grade: 1///characteristics_ch1.3: B-canenin_nuclear_accumulation: Y///characteristics_ch1.4: CTNNB1_mutation: Y///characteristics_ch1.5: APC_mutation: N/A///characteristics_ch1.6: PTEN_mutation: N///characteristics_ch1.7: PTEN_immunohistochemistry: absent///characteristics_ch1.8: KRAS_mutation: N///characteristics_ch1.9: PIK3CA_mutation: N///characteristics_ch1.10: TP53_mutation: N///characteristics_ch1.11: P53_immunohistochemistry: absent///characteristics_ch1.12: CEL_file_name: JH-OE-2T.CEL///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from the tissue lysate using an RNeasy kit (Qiagen).///label_ch1: biotin///label_protocol_ch1: 3-5 g of total RNA was processed to produce biotinylated cRNA targets.///taxid_ch1: 9606///hyb_protocol: standard Affymetrix procedures///scan_protocol: standard Affymetrix procedures///description: ovarian tumor: endometrioid///data_processing: Ann Arbor quantile-normalized trimmed-mean method///platform_id: GPL96///contact_name: Rork,,Kuick///contact_email: [email protected]///contact_phone: 734-936-9241///contact_institute: University of Michigan///contact_address: NI8D17, 300 North Ingals Building, U. of Michigan///contact_city: Ann Arbor///contact_state: MI///contact_zip.postal_code: 48109-5473///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM139nnn/GSM139417/GSM139417.CEL.gz///data_row_count: 22283
1
title: Ovarian_Tumor_Endometrioid_KU-OE-003///geo_accession: GSM139418///status: Public on Apr 09 2007///submission_date: Oct 10 2006///last_update_date: Apr 09 2007///type: RNA///channel_count: 1///source_name_ch1: Ovarian_Tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tumor_Type: Endometrioid///characteristics_ch1.1: stage: 1C///characteristics_ch1.2: grade: 2///characteristics_ch1.3: B-canenin_nuclear_accumulation: Y///characteristics_ch1.4: CTNNB1_mutation: N///characteristics_ch1.5: APC_mutation: N/A///characteristics_ch1.6: PTEN_mutation: N///characteristics_ch1.7: PTEN_immunohistochemistry: absent///characteristics_ch1.8: KRAS_mutation: N///characteristics_ch1.9: PIK3CA_mutation: N///characteristics_ch1.10: TP53_mutation: Y///characteristics_ch1.11: P53_immunohistochemistry: present///characteristics_ch1.12: CEL_file_name: KU-OE-003.CEL///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from the tissue lysate using an RNeasy kit (Qiagen).///label_ch1: biotin///label_protocol_ch1: 3-5 g of total RNA was processed to produce biotinylated cRNA targets.///taxid_ch1: 9606///hyb_protocol: standard Affymetrix procedures///scan_protocol: standard Affymetrix procedures///description: ovarian tumor: endometrioid///data_processing: Ann Arbor quantile-normalized trimmed-mean method///platform_id: GPL96///contact_name: Rork,,Kuick///contact_email: [email protected]///contact_phone: 734-936-9241///contact_institute: University of Michigan///contact_address: NI8D17, 300 North Ingals Building, U. of Michigan///contact_city: Ann Arbor///contact_state: MI///contact_zip.postal_code: 48109-5473///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM139nnn/GSM139418/GSM139418.CEL.gz///data_row_count: 22283
1
title: Ovarian_Tumor_Endometrioid_KU-OE-004///geo_accession: GSM139419///status: Public on Apr 09 2007///submission_date: Oct 10 2006///last_update_date: Apr 09 2007///type: RNA///channel_count: 1///source_name_ch1: Ovarian_Tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tumor_Type: Endometrioid///characteristics_ch1.1: stage: 3C///characteristics_ch1.2: grade: 3///characteristics_ch1.3: B-canenin_nuclear_accumulation: N///characteristics_ch1.4: CTNNB1_mutation: N///characteristics_ch1.5: APC_mutation: N/A///characteristics_ch1.6: PTEN_mutation: N///characteristics_ch1.7: PTEN_immunohistochemistry: present///characteristics_ch1.8: KRAS_mutation: N///characteristics_ch1.9: PIK3CA_mutation: N///characteristics_ch1.10: TP53_mutation: Y///characteristics_ch1.11: P53_immunohistochemistry: present///characteristics_ch1.12: CEL_file_name: KU-OE-004.CEL///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from the tissue lysate using an RNeasy kit (Qiagen).///label_ch1: biotin///label_protocol_ch1: 3-5 g of total RNA was processed to produce biotinylated cRNA targets.///taxid_ch1: 9606///hyb_protocol: standard Affymetrix procedures///scan_protocol: standard Affymetrix procedures///description: ovarian tumor: endometrioid///data_processing: Ann Arbor quantile-normalized trimmed-mean method///platform_id: GPL96///contact_name: Rork,,Kuick///contact_email: [email protected]///contact_phone: 734-936-9241///contact_institute: University of Michigan///contact_address: NI8D17, 300 North Ingals Building, U. of Michigan///contact_city: Ann Arbor///contact_state: MI///contact_zip.postal_code: 48109-5473///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM139nnn/GSM139419/GSM139419.CEL.gz///data_row_count: 22283
1
title: Ovarian_Tumor_Endometrioid_KU-OE-007///geo_accession: GSM139420///status: Public on Apr 09 2007///submission_date: Oct 10 2006///last_update_date: Apr 09 2007///type: RNA///channel_count: 1///source_name_ch1: Ovarian_Tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tumor_Type: Endometrioid///characteristics_ch1.1: stage: 1C///characteristics_ch1.2: grade: 1///characteristics_ch1.3: B-canenin_nuclear_accumulation: Y///characteristics_ch1.4: CTNNB1_mutation: Y///characteristics_ch1.5: APC_mutation: N/A///characteristics_ch1.6: PTEN_mutation: N///characteristics_ch1.7: PTEN_immunohistochemistry: present///characteristics_ch1.8: KRAS_mutation: N///characteristics_ch1.9: PIK3CA_mutation: N///characteristics_ch1.10: TP53_mutation: Y///characteristics_ch1.11: P53_immunohistochemistry: present///characteristics_ch1.12: CEL_file_name: KU-OE-007.CEL///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from the tissue lysate using an RNeasy kit (Qiagen).///label_ch1: biotin///label_protocol_ch1: 3-5 g of total RNA was processed to produce biotinylated cRNA targets.///taxid_ch1: 9606///hyb_protocol: standard Affymetrix procedures///scan_protocol: standard Affymetrix procedures///description: ovarian tumor: endometrioid///data_processing: Ann Arbor quantile-normalized trimmed-mean method///platform_id: GPL96///contact_name: Rork,,Kuick///contact_email: [email protected]///contact_phone: 734-936-9241///contact_institute: University of Michigan///contact_address: NI8D17, 300 North Ingals Building, U. of Michigan///contact_city: Ann Arbor///contact_state: MI///contact_zip.postal_code: 48109-5473///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM139nnn/GSM139420/GSM139420.CEL.gz///data_row_count: 22283
1
title: Ovarian_Tumor_Endometrioid_UM-OE-1T///geo_accession: GSM139421///status: Public on Apr 09 2007///submission_date: Oct 10 2006///last_update_date: Apr 09 2007///type: RNA///channel_count: 1///source_name_ch1: Ovarian_Tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tumor_Type: Endometrioid///characteristics_ch1.1: stage: 1C///characteristics_ch1.2: grade: 2///characteristics_ch1.3: B-canenin_nuclear_accumulation: Y///characteristics_ch1.4: CTNNB1_mutation: Y///characteristics_ch1.5: APC_mutation: N/A///characteristics_ch1.6: PTEN_mutation: N///characteristics_ch1.7: PTEN_immunohistochemistry: present///characteristics_ch1.8: KRAS_mutation: N///characteristics_ch1.9: PIK3CA_mutation: Y///characteristics_ch1.10: TP53_mutation: N///characteristics_ch1.11: P53_immunohistochemistry: absent///characteristics_ch1.12: CEL_file_name: UM-OE-1T.CEL///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from the tissue lysate using an RNeasy kit (Qiagen).///label_ch1: biotin///label_protocol_ch1: 3-5 g of total RNA was processed to produce biotinylated cRNA targets.///taxid_ch1: 9606///hyb_protocol: standard Affymetrix procedures///scan_protocol: standard Affymetrix procedures///description: ovarian tumor: endometrioid///data_processing: Ann Arbor quantile-normalized trimmed-mean method///platform_id: GPL96///contact_name: Rork,,Kuick///contact_email: [email protected]///contact_phone: 734-936-9241///contact_institute: University of Michigan///contact_address: NI8D17, 300 North Ingals Building, U. of Michigan///contact_city: Ann Arbor///contact_state: MI///contact_zip.postal_code: 48109-5473///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM139nnn/GSM139421/GSM139421.CEL.gz///data_row_count: 22283
1
title: Ovarian_Tumor_Mucinous_CHTN-OM-007///geo_accession: GSM139422///status: Public on Apr 09 2007///submission_date: Oct 10 2006///last_update_date: Apr 09 2007///type: RNA///channel_count: 1///source_name_ch1: Ovarian_Tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tumor_Type: Mucinous///characteristics_ch1.1: stage: 2C///characteristics_ch1.2: grade: 2-3///characteristics_ch1.3: B-canenin_nuclear_accumulation: N/A///characteristics_ch1.4: CTNNB1_mutation: N/A///characteristics_ch1.5: APC_mutation: N/A///characteristics_ch1.6: PTEN_mutation: N/A///characteristics_ch1.7: PTEN_immunohistochemistry: N/A///characteristics_ch1.8: KRAS_mutation: N/A///characteristics_ch1.9: PIK3CA_mutation: N/A///characteristics_ch1.10: TP53_mutation: N/A///characteristics_ch1.11: P53_immunohistochemistry: N/A///characteristics_ch1.12: CEL_file_name: CHTN-OM-007.CEL///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from the tissue lysate using an RNeasy kit (Qiagen).///label_ch1: biotin///label_protocol_ch1: 3-5 g of total RNA was processed to produce biotinylated cRNA targets.///taxid_ch1: 9606///hyb_protocol: standard Affymetrix procedures///scan_protocol: standard Affymetrix procedures///description: ovarian tumor: mucinous///data_processing: Ann Arbor quantile-normalized trimmed-mean method///platform_id: GPL96///contact_name: Rork,,Kuick///contact_email: [email protected]///contact_phone: 734-936-9241///contact_institute: University of Michigan///contact_address: NI8D17, 300 North Ingals Building, U. of Michigan///contact_city: Ann Arbor///contact_state: MI///contact_zip.postal_code: 48109-5473///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM139nnn/GSM139422/GSM139422.CEL.gz///data_row_count: 22283
1
title: Ovarian_Tumor_Mucinous_CHTN-OM-017///geo_accession: GSM139423///status: Public on Apr 09 2007///submission_date: Oct 10 2006///last_update_date: Apr 09 2007///type: RNA///channel_count: 1///source_name_ch1: Ovarian_Tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tumor_Type: Mucinous///characteristics_ch1.1: stage: 1A///characteristics_ch1.2: grade: 1///characteristics_ch1.3: B-canenin_nuclear_accumulation: N/A///characteristics_ch1.4: CTNNB1_mutation: N/A///characteristics_ch1.5: APC_mutation: N/A///characteristics_ch1.6: PTEN_mutation: N/A///characteristics_ch1.7: PTEN_immunohistochemistry: N/A///characteristics_ch1.8: KRAS_mutation: N/A///characteristics_ch1.9: PIK3CA_mutation: N/A///characteristics_ch1.10: TP53_mutation: N/A///characteristics_ch1.11: P53_immunohistochemistry: N/A///characteristics_ch1.12: CEL_file_name: CHTN-OM-017.CEL///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from the tissue lysate using an RNeasy kit (Qiagen).///label_ch1: biotin///label_protocol_ch1: 3-5 g of total RNA was processed to produce biotinylated cRNA targets.///taxid_ch1: 9606///hyb_protocol: standard Affymetrix procedures///scan_protocol: standard Affymetrix procedures///description: ovarian tumor: mucinous///data_processing: Ann Arbor quantile-normalized trimmed-mean method///platform_id: GPL96///contact_name: Rork,,Kuick///contact_email: [email protected]///contact_phone: 734-936-9241///contact_institute: University of Michigan///contact_address: NI8D17, 300 North Ingals Building, U. of Michigan///contact_city: Ann Arbor///contact_state: MI///contact_zip.postal_code: 48109-5473///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM139nnn/GSM139423/GSM139423.CEL.gz///data_row_count: 22283
1
title: Ovarian_Tumor_Mucinous_CHTN-OM-023///geo_accession: GSM139424///status: Public on Apr 09 2007///submission_date: Oct 10 2006///last_update_date: Apr 09 2007///type: RNA///channel_count: 1///source_name_ch1: Ovarian_Tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tumor_Type: Mucinous///characteristics_ch1.1: stage: 3///characteristics_ch1.2: grade: 2-3///characteristics_ch1.3: B-canenin_nuclear_accumulation: N/A///characteristics_ch1.4: CTNNB1_mutation: N/A///characteristics_ch1.5: APC_mutation: N/A///characteristics_ch1.6: PTEN_mutation: N/A///characteristics_ch1.7: PTEN_immunohistochemistry: N/A///characteristics_ch1.8: KRAS_mutation: N/A///characteristics_ch1.9: PIK3CA_mutation: N/A///characteristics_ch1.10: TP53_mutation: N/A///characteristics_ch1.11: P53_immunohistochemistry: N/A///characteristics_ch1.12: CEL_file_name: CHTN-OM-023.CEL///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from the tissue lysate using an RNeasy kit (Qiagen).///label_ch1: biotin///label_protocol_ch1: 3-5 g of total RNA was processed to produce biotinylated cRNA targets.///taxid_ch1: 9606///hyb_protocol: standard Affymetrix procedures///scan_protocol: standard Affymetrix procedures///description: ovarian tumor: mucinous///data_processing: Ann Arbor quantile-normalized trimmed-mean method///platform_id: GPL96///contact_name: Rork,,Kuick///contact_email: [email protected]///contact_phone: 734-936-9241///contact_institute: University of Michigan///contact_address: NI8D17, 300 North Ingals Building, U. of Michigan///contact_city: Ann Arbor///contact_state: MI///contact_zip.postal_code: 48109-5473///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM139nnn/GSM139424/GSM139424.CEL.gz///data_row_count: 22283
1
title: Ovarian_Tumor_Mucinous_CHTN-OM-029///geo_accession: GSM139425///status: Public on Apr 09 2007///submission_date: Oct 10 2006///last_update_date: Apr 09 2007///type: RNA///channel_count: 1///source_name_ch1: Ovarian_Tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tumor_Type: Mucinous///characteristics_ch1.1: stage: 1A///characteristics_ch1.2: grade: 1///characteristics_ch1.3: B-canenin_nuclear_accumulation: N/A///characteristics_ch1.4: CTNNB1_mutation: N/A///characteristics_ch1.5: APC_mutation: N/A///characteristics_ch1.6: PTEN_mutation: N/A///characteristics_ch1.7: PTEN_immunohistochemistry: N/A///characteristics_ch1.8: KRAS_mutation: N/A///characteristics_ch1.9: PIK3CA_mutation: N/A///characteristics_ch1.10: TP53_mutation: N/A///characteristics_ch1.11: P53_immunohistochemistry: N/A///characteristics_ch1.12: CEL_file_name: CHTN-OM-029.CEL///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from the tissue lysate using an RNeasy kit (Qiagen).///label_ch1: biotin///label_protocol_ch1: 3-5 g of total RNA was processed to produce biotinylated cRNA targets.///taxid_ch1: 9606///hyb_protocol: standard Affymetrix procedures///scan_protocol: standard Affymetrix procedures///description: ovarian tumor: mucinous///data_processing: Ann Arbor quantile-normalized trimmed-mean method///platform_id: GPL96///contact_name: Rork,,Kuick///contact_email: [email protected]///contact_phone: 734-936-9241///contact_institute: University of Michigan///contact_address: NI8D17, 300 North Ingals Building, U. of Michigan///contact_city: Ann Arbor///contact_state: MI///contact_zip.postal_code: 48109-5473///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM139nnn/GSM139425/GSM139425.CEL.gz///data_row_count: 22283
1
title: Ovarian_Tumor_Mucinous_CHTN-OM-032///geo_accession: GSM139426///status: Public on Apr 09 2007///submission_date: Oct 10 2006///last_update_date: Apr 09 2007///type: RNA///channel_count: 1///source_name_ch1: Ovarian_Tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tumor_Type: Mucinous///characteristics_ch1.1: stage: 1A///characteristics_ch1.2: grade: 1///characteristics_ch1.3: B-canenin_nuclear_accumulation: N/A///characteristics_ch1.4: CTNNB1_mutation: N/A///characteristics_ch1.5: APC_mutation: N/A///characteristics_ch1.6: PTEN_mutation: N/A///characteristics_ch1.7: PTEN_immunohistochemistry: N/A///characteristics_ch1.8: KRAS_mutation: N/A///characteristics_ch1.9: PIK3CA_mutation: N/A///characteristics_ch1.10: TP53_mutation: N/A///characteristics_ch1.11: P53_immunohistochemistry: N/A///characteristics_ch1.12: CEL_file_name: CHTN-OM-032.CEL///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from the tissue lysate using an RNeasy kit (Qiagen).///label_ch1: biotin///label_protocol_ch1: 3-5 g of total RNA was processed to produce biotinylated cRNA targets.///taxid_ch1: 9606///hyb_protocol: standard Affymetrix procedures///scan_protocol: standard Affymetrix procedures///description: ovarian tumor: mucinous///data_processing: Ann Arbor quantile-normalized trimmed-mean method///platform_id: GPL96///contact_name: Rork,,Kuick///contact_email: [email protected]///contact_phone: 734-936-9241///contact_institute: University of Michigan///contact_address: NI8D17, 300 North Ingals Building, U. of Michigan///contact_city: Ann Arbor///contact_state: MI///contact_zip.postal_code: 48109-5473///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM139nnn/GSM139426/GSM139426.CEL.gz///data_row_count: 22283
1
title: Ovarian_Tumor_Mucinous_CHTN-OM-035///geo_accession: GSM139427///status: Public on Apr 09 2007///submission_date: Oct 10 2006///last_update_date: Apr 09 2007///type: RNA///channel_count: 1///source_name_ch1: Ovarian_Tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tumor_Type: Mucinous///characteristics_ch1.1: stage: 1A///characteristics_ch1.2: grade: 1///characteristics_ch1.3: B-canenin_nuclear_accumulation: N/A///characteristics_ch1.4: CTNNB1_mutation: N/A///characteristics_ch1.5: APC_mutation: N/A///characteristics_ch1.6: PTEN_mutation: N/A///characteristics_ch1.7: PTEN_immunohistochemistry: N/A///characteristics_ch1.8: KRAS_mutation: N/A///characteristics_ch1.9: PIK3CA_mutation: N/A///characteristics_ch1.10: TP53_mutation: N/A///characteristics_ch1.11: P53_immunohistochemistry: N/A///characteristics_ch1.12: CEL_file_name: CHTN-OM-035.CEL///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from the tissue lysate using an RNeasy kit (Qiagen).///label_ch1: biotin///label_protocol_ch1: 3-5 g of total RNA was processed to produce biotinylated cRNA targets.///taxid_ch1: 9606///hyb_protocol: standard Affymetrix procedures///scan_protocol: standard Affymetrix procedures///description: ovarian tumor: mucinous///data_processing: Ann Arbor quantile-normalized trimmed-mean method///platform_id: GPL96///contact_name: Rork,,Kuick///contact_email: [email protected]///contact_phone: 734-936-9241///contact_institute: University of Michigan///contact_address: NI8D17, 300 North Ingals Building, U. of Michigan///contact_city: Ann Arbor///contact_state: MI///contact_zip.postal_code: 48109-5473///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM139nnn/GSM139427/GSM139427.CEL.gz///data_row_count: 22283
1
title: Ovarian_Tumor_Mucinous_CHTN-OM-036///geo_accession: GSM139428///status: Public on Apr 09 2007///submission_date: Oct 10 2006///last_update_date: Apr 09 2007///type: RNA///channel_count: 1///source_name_ch1: Ovarian_Tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tumor_Type: Mucinous///characteristics_ch1.1: stage: 3C///characteristics_ch1.2: grade: 1///characteristics_ch1.3: B-canenin_nuclear_accumulation: N/A///characteristics_ch1.4: CTNNB1_mutation: N/A///characteristics_ch1.5: APC_mutation: N/A///characteristics_ch1.6: PTEN_mutation: N/A///characteristics_ch1.7: PTEN_immunohistochemistry: N/A///characteristics_ch1.8: KRAS_mutation: N/A///characteristics_ch1.9: PIK3CA_mutation: N/A///characteristics_ch1.10: TP53_mutation: N/A///characteristics_ch1.11: P53_immunohistochemistry: N/A///characteristics_ch1.12: CEL_file_name: CHTN-OM-036.CEL///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from the tissue lysate using an RNeasy kit (Qiagen).///label_ch1: biotin///label_protocol_ch1: 3-5 g of total RNA was processed to produce biotinylated cRNA targets.///taxid_ch1: 9606///hyb_protocol: standard Affymetrix procedures///scan_protocol: standard Affymetrix procedures///description: ovarian tumor: mucinous///data_processing: Ann Arbor quantile-normalized trimmed-mean method///platform_id: GPL96///contact_name: Rork,,Kuick///contact_email: [email protected]///contact_phone: 734-936-9241///contact_institute: University of Michigan///contact_address: NI8D17, 300 North Ingals Building, U. of Michigan///contact_city: Ann Arbor///contact_state: MI///contact_zip.postal_code: 48109-5473///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM139nnn/GSM139428/GSM139428.CEL.gz///data_row_count: 22283
1
title: Ovarian_Tumor_Mucinous_KU-OM-003///geo_accession: GSM139429///status: Public on Apr 09 2007///submission_date: Oct 10 2006///last_update_date: Apr 09 2007///type: RNA///channel_count: 1///source_name_ch1: Ovarian_Tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tumor_Type: Mucinous///characteristics_ch1.1: stage: I c///characteristics_ch1.2: grade: N/A///characteristics_ch1.3: B-canenin_nuclear_accumulation: N/A///characteristics_ch1.4: CTNNB1_mutation: N/A///characteristics_ch1.5: APC_mutation: N/A///characteristics_ch1.6: PTEN_mutation: N/A///characteristics_ch1.7: PTEN_immunohistochemistry: N/A///characteristics_ch1.8: KRAS_mutation: N/A///characteristics_ch1.9: PIK3CA_mutation: N/A///characteristics_ch1.10: TP53_mutation: N/A///characteristics_ch1.11: P53_immunohistochemistry: N/A///characteristics_ch1.12: CEL_file_name: KU-OM-003.CEL///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from the tissue lysate using an RNeasy kit (Qiagen).///label_ch1: biotin///label_protocol_ch1: 3-5 g of total RNA was processed to produce biotinylated cRNA targets.///taxid_ch1: 9606///hyb_protocol: standard Affymetrix procedures///scan_protocol: standard Affymetrix procedures///description: ovarian tumor: mucinous///data_processing: Ann Arbor quantile-normalized trimmed-mean method///platform_id: GPL96///contact_name: Rork,,Kuick///contact_email: [email protected]///contact_phone: 734-936-9241///contact_institute: University of Michigan///contact_address: NI8D17, 300 North Ingals Building, U. of Michigan///contact_city: Ann Arbor///contact_state: MI///contact_zip.postal_code: 48109-5473///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM139nnn/GSM139429/GSM139429.CEL.gz///data_row_count: 22283
1
title: Ovarian_Tumor_Mucinous_KU-OM-004///geo_accession: GSM139430///status: Public on Apr 09 2007///submission_date: Oct 10 2006///last_update_date: Apr 09 2007///type: RNA///channel_count: 1///source_name_ch1: Ovarian_Tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tumor_Type: Mucinous///characteristics_ch1.1: stage: I c///characteristics_ch1.2: grade: N/A///characteristics_ch1.3: B-canenin_nuclear_accumulation: N/A///characteristics_ch1.4: CTNNB1_mutation: N/A///characteristics_ch1.5: APC_mutation: N/A///characteristics_ch1.6: PTEN_mutation: N/A///characteristics_ch1.7: PTEN_immunohistochemistry: N/A///characteristics_ch1.8: KRAS_mutation: N/A///characteristics_ch1.9: PIK3CA_mutation: N/A///characteristics_ch1.10: TP53_mutation: N/A///characteristics_ch1.11: P53_immunohistochemistry: N/A///characteristics_ch1.12: CEL_file_name: KU-OM-004.CEL///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from the tissue lysate using an RNeasy kit (Qiagen).///label_ch1: biotin///label_protocol_ch1: 3-5 g of total RNA was processed to produce biotinylated cRNA targets.///taxid_ch1: 9606///hyb_protocol: standard Affymetrix procedures///scan_protocol: standard Affymetrix procedures///description: ovarian tumor: mucinous///data_processing: Ann Arbor quantile-normalized trimmed-mean method///platform_id: GPL96///contact_name: Rork,,Kuick///contact_email: [email protected]///contact_phone: 734-936-9241///contact_institute: University of Michigan///contact_address: NI8D17, 300 North Ingals Building, U. of Michigan///contact_city: Ann Arbor///contact_state: MI///contact_zip.postal_code: 48109-5473///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM139nnn/GSM139430/GSM139430.CEL.gz///data_row_count: 22283
1
title: Ovarian_Tumor_Mucinous_KU-OM-006///geo_accession: GSM139431///status: Public on Apr 09 2007///submission_date: Oct 10 2006///last_update_date: Apr 09 2007///type: RNA///channel_count: 1///source_name_ch1: Ovarian_Tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tumor_Type: Mucinous///characteristics_ch1.1: stage: I a///characteristics_ch1.2: grade: N/A///characteristics_ch1.3: B-canenin_nuclear_accumulation: N/A///characteristics_ch1.4: CTNNB1_mutation: N/A///characteristics_ch1.5: APC_mutation: N/A///characteristics_ch1.6: PTEN_mutation: N/A///characteristics_ch1.7: PTEN_immunohistochemistry: N/A///characteristics_ch1.8: KRAS_mutation: N/A///characteristics_ch1.9: PIK3CA_mutation: N/A///characteristics_ch1.10: TP53_mutation: N/A///characteristics_ch1.11: P53_immunohistochemistry: N/A///characteristics_ch1.12: CEL_file_name: KU-OM-006.CEL///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from the tissue lysate using an RNeasy kit (Qiagen).///label_ch1: biotin///label_protocol_ch1: 3-5 g of total RNA was processed to produce biotinylated cRNA targets.///taxid_ch1: 9606///hyb_protocol: standard Affymetrix procedures///scan_protocol: standard Affymetrix procedures///description: ovarian tumor: mucinous///data_processing: Ann Arbor quantile-normalized trimmed-mean method///platform_id: GPL96///contact_name: Rork,,Kuick///contact_email: [email protected]///contact_phone: 734-936-9241///contact_institute: University of Michigan///contact_address: NI8D17, 300 North Ingals Building, U. of Michigan///contact_city: Ann Arbor///contact_state: MI///contact_zip.postal_code: 48109-5473///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM139nnn/GSM139431/GSM139431.CEL.gz///data_row_count: 22283
1
title: Ovarian_Tumor_Mucinous_KU-OM-007///geo_accession: GSM139432///status: Public on Apr 09 2007///submission_date: Oct 10 2006///last_update_date: Apr 09 2007///type: RNA///channel_count: 1///source_name_ch1: Ovarian_Tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tumor_Type: Mucinous///characteristics_ch1.1: stage: I c///characteristics_ch1.2: grade: N/A///characteristics_ch1.3: B-canenin_nuclear_accumulation: N/A///characteristics_ch1.4: CTNNB1_mutation: N/A///characteristics_ch1.5: APC_mutation: N/A///characteristics_ch1.6: PTEN_mutation: N/A///characteristics_ch1.7: PTEN_immunohistochemistry: N/A///characteristics_ch1.8: KRAS_mutation: N/A///characteristics_ch1.9: PIK3CA_mutation: N/A///characteristics_ch1.10: TP53_mutation: N/A///characteristics_ch1.11: P53_immunohistochemistry: N/A///characteristics_ch1.12: CEL_file_name: KU-OM-007.CEL///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from the tissue lysate using an RNeasy kit (Qiagen).///label_ch1: biotin///label_protocol_ch1: 3-5 g of total RNA was processed to produce biotinylated cRNA targets.///taxid_ch1: 9606///hyb_protocol: standard Affymetrix procedures///scan_protocol: standard Affymetrix procedures///description: ovarian tumor: mucinous///data_processing: Ann Arbor quantile-normalized trimmed-mean method///platform_id: GPL96///contact_name: Rork,,Kuick///contact_email: [email protected]///contact_phone: 734-936-9241///contact_institute: University of Michigan///contact_address: NI8D17, 300 North Ingals Building, U. of Michigan///contact_city: Ann Arbor///contact_state: MI///contact_zip.postal_code: 48109-5473///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM139nnn/GSM139432/GSM139432.CEL.gz///data_row_count: 22283
1
title: Ovarian_Tumor_Mucinous_UM-OM-01///geo_accession: GSM139433///status: Public on Apr 09 2007///submission_date: Oct 10 2006///last_update_date: Apr 09 2007///type: RNA///channel_count: 1///source_name_ch1: Ovarian_Tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tumor_Type: Mucinous///characteristics_ch1.1: stage: 3c///characteristics_ch1.2: grade: 2///characteristics_ch1.3: B-canenin_nuclear_accumulation: N/A///characteristics_ch1.4: CTNNB1_mutation: N/A///characteristics_ch1.5: APC_mutation: N/A///characteristics_ch1.6: PTEN_mutation: N/A///characteristics_ch1.7: PTEN_immunohistochemistry: N/A///characteristics_ch1.8: KRAS_mutation: N/A///characteristics_ch1.9: PIK3CA_mutation: N/A///characteristics_ch1.10: TP53_mutation: N/A///characteristics_ch1.11: P53_immunohistochemistry: N/A///characteristics_ch1.12: CEL_file_name: UM-OM-01.CEL///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from the tissue lysate using an RNeasy kit (Qiagen).///label_ch1: biotin///label_protocol_ch1: 3-5 g of total RNA was processed to produce biotinylated cRNA targets.///taxid_ch1: 9606///hyb_protocol: standard Affymetrix procedures///scan_protocol: standard Affymetrix procedures///description: ovarian tumor: mucinous///data_processing: Ann Arbor quantile-normalized trimmed-mean method///platform_id: GPL96///contact_name: Rork,,Kuick///contact_email: [email protected]///contact_phone: 734-936-9241///contact_institute: University of Michigan///contact_address: NI8D17, 300 North Ingals Building, U. of Michigan///contact_city: Ann Arbor///contact_state: MI///contact_zip.postal_code: 48109-5473///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM139nnn/GSM139433/GSM139433.CEL.gz///data_row_count: 22283
1
title: Ovarian_Tumor_Mucinous_UM-OM-03///geo_accession: GSM139434///status: Public on Apr 09 2007///submission_date: Oct 10 2006///last_update_date: Apr 09 2007///type: RNA///channel_count: 1///source_name_ch1: Ovarian_Tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tumor_Type: Mucinous///characteristics_ch1.1: stage: 2a///characteristics_ch1.2: grade: 1///characteristics_ch1.3: B-canenin_nuclear_accumulation: N/A///characteristics_ch1.4: CTNNB1_mutation: N/A///characteristics_ch1.5: APC_mutation: N/A///characteristics_ch1.6: PTEN_mutation: N/A///characteristics_ch1.7: PTEN_immunohistochemistry: N/A///characteristics_ch1.8: KRAS_mutation: N/A///characteristics_ch1.9: PIK3CA_mutation: N/A///characteristics_ch1.10: TP53_mutation: N/A///characteristics_ch1.11: P53_immunohistochemistry: N/A///characteristics_ch1.12: CEL_file_name: UM-OM-03.CEL///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from the tissue lysate using an RNeasy kit (Qiagen).///label_ch1: biotin///label_protocol_ch1: 3-5 g of total RNA was processed to produce biotinylated cRNA targets.///taxid_ch1: 9606///hyb_protocol: standard Affymetrix procedures///scan_protocol: standard Affymetrix procedures///description: ovarian tumor: mucinous///data_processing: Ann Arbor quantile-normalized trimmed-mean method///platform_id: GPL96///contact_name: Rork,,Kuick///contact_email: [email protected]///contact_phone: 734-936-9241///contact_institute: University of Michigan///contact_address: NI8D17, 300 North Ingals Building, U. of Michigan///contact_city: Ann Arbor///contact_state: MI///contact_zip.postal_code: 48109-5473///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM139nnn/GSM139434/GSM139434.CEL.gz///data_row_count: 22283
1
title: Ovarian_Tumor_Serous_CHTN-OS-002///geo_accession: GSM139435///status: Public on Apr 09 2007///submission_date: Oct 10 2006///last_update_date: Apr 09 2007///type: RNA///channel_count: 1///source_name_ch1: Ovarian_Tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tumor_Type: Serous///characteristics_ch1.1: stage: 3C///characteristics_ch1.2: grade: 3///characteristics_ch1.3: B-canenin_nuclear_accumulation: N/A///characteristics_ch1.4: CTNNB1_mutation: N/A///characteristics_ch1.5: APC_mutation: N/A///characteristics_ch1.6: PTEN_mutation: N/A///characteristics_ch1.7: PTEN_immunohistochemistry: N/A///characteristics_ch1.8: KRAS_mutation: N/A///characteristics_ch1.9: PIK3CA_mutation: N/A///characteristics_ch1.10: TP53_mutation: N/A///characteristics_ch1.11: P53_immunohistochemistry: N/A///characteristics_ch1.12: CEL_file_name: CHTN-OS-002.CEL///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from the tissue lysate using an RNeasy kit (Qiagen).///label_ch1: biotin///label_protocol_ch1: 3-5 g of total RNA was processed to produce biotinylated cRNA targets.///taxid_ch1: 9606///hyb_protocol: standard Affymetrix procedures///scan_protocol: standard Affymetrix procedures///description: ovarian tumor: serous///data_processing: Ann Arbor quantile-normalized trimmed-mean method///platform_id: GPL96///contact_name: Rork,,Kuick///contact_email: [email protected]///contact_phone: 734-936-9241///contact_institute: University of Michigan///contact_address: NI8D17, 300 North Ingals Building, U. of Michigan///contact_city: Ann Arbor///contact_state: MI///contact_zip.postal_code: 48109-5473///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM139nnn/GSM139435/GSM139435.CEL.gz///data_row_count: 22283
1
title: Ovarian_Tumor_Serous_CHTN-OS-003///geo_accession: GSM139436///status: Public on Apr 09 2007///submission_date: Oct 10 2006///last_update_date: Apr 09 2007///type: RNA///channel_count: 1///source_name_ch1: Ovarian_Tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tumor_Type: Serous///characteristics_ch1.1: stage: 4///characteristics_ch1.2: grade: 3///characteristics_ch1.3: B-canenin_nuclear_accumulation: N/A///characteristics_ch1.4: CTNNB1_mutation: N/A///characteristics_ch1.5: APC_mutation: N/A///characteristics_ch1.6: PTEN_mutation: N/A///characteristics_ch1.7: PTEN_immunohistochemistry: N/A///characteristics_ch1.8: KRAS_mutation: N/A///characteristics_ch1.9: PIK3CA_mutation: N/A///characteristics_ch1.10: TP53_mutation: N/A///characteristics_ch1.11: P53_immunohistochemistry: N/A///characteristics_ch1.12: CEL_file_name: CHTN-OS-003.CEL///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from the tissue lysate using an RNeasy kit (Qiagen).///label_ch1: biotin///label_protocol_ch1: 3-5 g of total RNA was processed to produce biotinylated cRNA targets.///taxid_ch1: 9606///hyb_protocol: standard Affymetrix procedures///scan_protocol: standard Affymetrix procedures///description: ovarian tumor: serous///data_processing: Ann Arbor quantile-normalized trimmed-mean method///platform_id: GPL96///contact_name: Rork,,Kuick///contact_email: [email protected]///contact_phone: 734-936-9241///contact_institute: University of Michigan///contact_address: NI8D17, 300 North Ingals Building, U. of Michigan///contact_city: Ann Arbor///contact_state: MI///contact_zip.postal_code: 48109-5473///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM139nnn/GSM139436/GSM139436.CEL.gz///data_row_count: 22283
1
title: Ovarian_Tumor_Serous_CHTN-OS-009///geo_accession: GSM139437///status: Public on Apr 09 2007///submission_date: Oct 10 2006///last_update_date: Apr 09 2007///type: RNA///channel_count: 1///source_name_ch1: Ovarian_Tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tumor_Type: Serous///characteristics_ch1.1: stage: 3C///characteristics_ch1.2: grade: 3///characteristics_ch1.3: B-canenin_nuclear_accumulation: N/A///characteristics_ch1.4: CTNNB1_mutation: N/A///characteristics_ch1.5: APC_mutation: N/A///characteristics_ch1.6: PTEN_mutation: N/A///characteristics_ch1.7: PTEN_immunohistochemistry: N/A///characteristics_ch1.8: KRAS_mutation: N/A///characteristics_ch1.9: PIK3CA_mutation: N/A///characteristics_ch1.10: TP53_mutation: N/A///characteristics_ch1.11: P53_immunohistochemistry: N/A///characteristics_ch1.12: CEL_file_name: CHTN-OS-009.CEL///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from the tissue lysate using an RNeasy kit (Qiagen).///label_ch1: biotin///label_protocol_ch1: 3-5 g of total RNA was processed to produce biotinylated cRNA targets.///taxid_ch1: 9606///hyb_protocol: standard Affymetrix procedures///scan_protocol: standard Affymetrix procedures///description: ovarian tumor: serous///data_processing: Ann Arbor quantile-normalized trimmed-mean method///platform_id: GPL96///contact_name: Rork,,Kuick///contact_email: [email protected]///contact_phone: 734-936-9241///contact_institute: University of Michigan///contact_address: NI8D17, 300 North Ingals Building, U. of Michigan///contact_city: Ann Arbor///contact_state: MI///contact_zip.postal_code: 48109-5473///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM139nnn/GSM139437/GSM139437.CEL.gz///data_row_count: 22283
1
title: Ovarian_Tumor_Serous_CHTN-OS-010///geo_accession: GSM139438///status: Public on Apr 09 2007///submission_date: Oct 10 2006///last_update_date: Apr 09 2007///type: RNA///channel_count: 1///source_name_ch1: Ovarian_Tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tumor_Type: Serous///characteristics_ch1.1: stage: 3C///characteristics_ch1.2: grade: 3///characteristics_ch1.3: B-canenin_nuclear_accumulation: N/A///characteristics_ch1.4: CTNNB1_mutation: N/A///characteristics_ch1.5: APC_mutation: N/A///characteristics_ch1.6: PTEN_mutation: N/A///characteristics_ch1.7: PTEN_immunohistochemistry: N/A///characteristics_ch1.8: KRAS_mutation: N/A///characteristics_ch1.9: PIK3CA_mutation: N/A///characteristics_ch1.10: TP53_mutation: N/A///characteristics_ch1.11: P53_immunohistochemistry: N/A///characteristics_ch1.12: CEL_file_name: CHTN-OS-010.CEL///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from the tissue lysate using an RNeasy kit (Qiagen).///label_ch1: biotin///label_protocol_ch1: 3-5 g of total RNA was processed to produce biotinylated cRNA targets.///taxid_ch1: 9606///hyb_protocol: standard Affymetrix procedures///scan_protocol: standard Affymetrix procedures///description: ovarian tumor: serous///data_processing: Ann Arbor quantile-normalized trimmed-mean method///platform_id: GPL96///contact_name: Rork,,Kuick///contact_email: [email protected]///contact_phone: 734-936-9241///contact_institute: University of Michigan///contact_address: NI8D17, 300 North Ingals Building, U. of Michigan///contact_city: Ann Arbor///contact_state: MI///contact_zip.postal_code: 48109-5473///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM139nnn/GSM139438/GSM139438.CEL.gz///data_row_count: 22283
1
title: Ovarian_Tumor_Serous_CHTN-OS-011///geo_accession: GSM139439///status: Public on Apr 09 2007///submission_date: Oct 10 2006///last_update_date: Apr 09 2007///type: RNA///channel_count: 1///source_name_ch1: Ovarian_Tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tumor_Type: Serous///characteristics_ch1.1: stage: 3B///characteristics_ch1.2: grade: 2///characteristics_ch1.3: B-canenin_nuclear_accumulation: N/A///characteristics_ch1.4: CTNNB1_mutation: N/A///characteristics_ch1.5: APC_mutation: N/A///characteristics_ch1.6: PTEN_mutation: N/A///characteristics_ch1.7: PTEN_immunohistochemistry: N/A///characteristics_ch1.8: KRAS_mutation: N/A///characteristics_ch1.9: PIK3CA_mutation: N/A///characteristics_ch1.10: TP53_mutation: N/A///characteristics_ch1.11: P53_immunohistochemistry: N/A///characteristics_ch1.12: CEL_file_name: CHTN-OS-011.CEL///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from the tissue lysate using an RNeasy kit (Qiagen).///label_ch1: biotin///label_protocol_ch1: 3-5 g of total RNA was processed to produce biotinylated cRNA targets.///taxid_ch1: 9606///hyb_protocol: standard Affymetrix procedures///scan_protocol: standard Affymetrix procedures///description: ovarian tumor: serous///data_processing: Ann Arbor quantile-normalized trimmed-mean method///platform_id: GPL96///contact_name: Rork,,Kuick///contact_email: [email protected]///contact_phone: 734-936-9241///contact_institute: University of Michigan///contact_address: NI8D17, 300 North Ingals Building, U. of Michigan///contact_city: Ann Arbor///contact_state: MI///contact_zip.postal_code: 48109-5473///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM139nnn/GSM139439/GSM139439.CEL.gz///data_row_count: 22283
1
title: Ovarian_Tumor_Serous_CHTN-OS-018///geo_accession: GSM139440///status: Public on Apr 09 2007///submission_date: Oct 10 2006///last_update_date: Apr 09 2007///type: RNA///channel_count: 1///source_name_ch1: Ovarian_Tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tumor_Type: Serous///characteristics_ch1.1: stage: 3C///characteristics_ch1.2: grade: 2///characteristics_ch1.3: B-canenin_nuclear_accumulation: N/A///characteristics_ch1.4: CTNNB1_mutation: N/A///characteristics_ch1.5: APC_mutation: N/A///characteristics_ch1.6: PTEN_mutation: N/A///characteristics_ch1.7: PTEN_immunohistochemistry: N/A///characteristics_ch1.8: KRAS_mutation: N/A///characteristics_ch1.9: PIK3CA_mutation: N/A///characteristics_ch1.10: TP53_mutation: N/A///characteristics_ch1.11: P53_immunohistochemistry: N/A///characteristics_ch1.12: CEL_file_name: CHTN-OS-018.CEL///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from the tissue lysate using an RNeasy kit (Qiagen).///label_ch1: biotin///label_protocol_ch1: 3-5 g of total RNA was processed to produce biotinylated cRNA targets.///taxid_ch1: 9606///hyb_protocol: standard Affymetrix procedures///scan_protocol: standard Affymetrix procedures///description: ovarian tumor: serous///data_processing: Ann Arbor quantile-normalized trimmed-mean method///platform_id: GPL96///contact_name: Rork,,Kuick///contact_email: [email protected]///contact_phone: 734-936-9241///contact_institute: University of Michigan///contact_address: NI8D17, 300 North Ingals Building, U. of Michigan///contact_city: Ann Arbor///contact_state: MI///contact_zip.postal_code: 48109-5473///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM139nnn/GSM139440/GSM139440.CEL.gz///data_row_count: 22283
1
title: Ovarian_Tumor_Serous_CHTN-OS-020///geo_accession: GSM139441///status: Public on Apr 09 2007///submission_date: Oct 10 2006///last_update_date: Apr 09 2007///type: RNA///channel_count: 1///source_name_ch1: Ovarian_Tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tumor_Type: Serous///characteristics_ch1.1: stage: 3C///characteristics_ch1.2: grade: 3///characteristics_ch1.3: B-canenin_nuclear_accumulation: N/A///characteristics_ch1.4: CTNNB1_mutation: N/A///characteristics_ch1.5: APC_mutation: N/A///characteristics_ch1.6: PTEN_mutation: N/A///characteristics_ch1.7: PTEN_immunohistochemistry: N/A///characteristics_ch1.8: KRAS_mutation: N/A///characteristics_ch1.9: PIK3CA_mutation: N/A///characteristics_ch1.10: TP53_mutation: N/A///characteristics_ch1.11: P53_immunohistochemistry: N/A///characteristics_ch1.12: CEL_file_name: CHTN-OS-020.CEL///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from the tissue lysate using an RNeasy kit (Qiagen).///label_ch1: biotin///label_protocol_ch1: 3-5 g of total RNA was processed to produce biotinylated cRNA targets.///taxid_ch1: 9606///hyb_protocol: standard Affymetrix procedures///scan_protocol: standard Affymetrix procedures///description: ovarian tumor: serous///data_processing: Ann Arbor quantile-normalized trimmed-mean method///platform_id: GPL96///contact_name: Rork,,Kuick///contact_email: [email protected]///contact_phone: 734-936-9241///contact_institute: University of Michigan///contact_address: NI8D17, 300 North Ingals Building, U. of Michigan///contact_city: Ann Arbor///contact_state: MI///contact_zip.postal_code: 48109-5473///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM139nnn/GSM139441/GSM139441.CEL.gz///data_row_count: 22283
1
title: Ovarian_Tumor_Serous_CHTN-OS-029///geo_accession: GSM139442///status: Public on Apr 09 2007///submission_date: Oct 10 2006///last_update_date: Apr 09 2007///type: RNA///channel_count: 1///source_name_ch1: Ovarian_Tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tumor_Type: Serous///characteristics_ch1.1: stage: 3C///characteristics_ch1.2: grade: N/A///characteristics_ch1.3: B-canenin_nuclear_accumulation: N/A///characteristics_ch1.4: CTNNB1_mutation: N/A///characteristics_ch1.5: APC_mutation: N/A///characteristics_ch1.6: PTEN_mutation: N/A///characteristics_ch1.7: PTEN_immunohistochemistry: N/A///characteristics_ch1.8: KRAS_mutation: N/A///characteristics_ch1.9: PIK3CA_mutation: N/A///characteristics_ch1.10: TP53_mutation: N/A///characteristics_ch1.11: P53_immunohistochemistry: N/A///characteristics_ch1.12: CEL_file_name: CHTN-OS-029.CEL///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from the tissue lysate using an RNeasy kit (Qiagen).///label_ch1: biotin///label_protocol_ch1: 3-5 g of total RNA was processed to produce biotinylated cRNA targets.///taxid_ch1: 9606///hyb_protocol: standard Affymetrix procedures///scan_protocol: standard Affymetrix procedures///description: ovarian tumor: serous///data_processing: Ann Arbor quantile-normalized trimmed-mean method///platform_id: GPL96///contact_name: Rork,,Kuick///contact_email: [email protected]///contact_phone: 734-936-9241///contact_institute: University of Michigan///contact_address: NI8D17, 300 North Ingals Building, U. of Michigan///contact_city: Ann Arbor///contact_state: MI///contact_zip.postal_code: 48109-5473///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM139nnn/GSM139442/GSM139442.CEL.gz///data_row_count: 22283
1
title: Ovarian_Tumor_Serous_CHTN-OS-038///geo_accession: GSM139443///status: Public on Apr 09 2007///submission_date: Oct 10 2006///last_update_date: Apr 09 2007///type: RNA///channel_count: 1///source_name_ch1: Ovarian_Tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tumor_Type: Serous///characteristics_ch1.1: stage: 3C///characteristics_ch1.2: grade: N/A///characteristics_ch1.3: B-canenin_nuclear_accumulation: N/A///characteristics_ch1.4: CTNNB1_mutation: N/A///characteristics_ch1.5: APC_mutation: N/A///characteristics_ch1.6: PTEN_mutation: N/A///characteristics_ch1.7: PTEN_immunohistochemistry: N/A///characteristics_ch1.8: KRAS_mutation: N/A///characteristics_ch1.9: PIK3CA_mutation: N/A///characteristics_ch1.10: TP53_mutation: N/A///characteristics_ch1.11: P53_immunohistochemistry: N/A///characteristics_ch1.12: CEL_file_name: CHTN-OS-038.CEL///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from the tissue lysate using an RNeasy kit (Qiagen).///label_ch1: biotin///label_protocol_ch1: 3-5 g of total RNA was processed to produce biotinylated cRNA targets.///taxid_ch1: 9606///hyb_protocol: standard Affymetrix procedures///scan_protocol: standard Affymetrix procedures///description: ovarian tumor: serous///data_processing: Ann Arbor quantile-normalized trimmed-mean method///platform_id: GPL96///contact_name: Rork,,Kuick///contact_email: [email protected]///contact_phone: 734-936-9241///contact_institute: University of Michigan///contact_address: NI8D17, 300 North Ingals Building, U. of Michigan///contact_city: Ann Arbor///contact_state: MI///contact_zip.postal_code: 48109-5473///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM139nnn/GSM139443/GSM139443.CEL.gz///data_row_count: 22283
1
title: Ovarian_Tumor_Serous_CHTN-OS-041///geo_accession: GSM139444///status: Public on Apr 09 2007///submission_date: Oct 10 2006///last_update_date: Apr 09 2007///type: RNA///channel_count: 1///source_name_ch1: Ovarian_Tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tumor_Type: Serous///characteristics_ch1.1: stage: 1C///characteristics_ch1.2: grade: 3///characteristics_ch1.3: B-canenin_nuclear_accumulation: N/A///characteristics_ch1.4: CTNNB1_mutation: N/A///characteristics_ch1.5: APC_mutation: N/A///characteristics_ch1.6: PTEN_mutation: N/A///characteristics_ch1.7: PTEN_immunohistochemistry: N/A///characteristics_ch1.8: KRAS_mutation: N/A///characteristics_ch1.9: PIK3CA_mutation: N/A///characteristics_ch1.10: TP53_mutation: N/A///characteristics_ch1.11: P53_immunohistochemistry: N/A///characteristics_ch1.12: CEL_file_name: CHTN-OS-041.CEL///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from the tissue lysate using an RNeasy kit (Qiagen).///label_ch1: biotin///label_protocol_ch1: 3-5 g of total RNA was processed to produce biotinylated cRNA targets.///taxid_ch1: 9606///hyb_protocol: standard Affymetrix procedures///scan_protocol: standard Affymetrix procedures///description: ovarian tumor: serous///data_processing: Ann Arbor quantile-normalized trimmed-mean method///platform_id: GPL96///contact_name: Rork,,Kuick///contact_email: [email protected]///contact_phone: 734-936-9241///contact_institute: University of Michigan///contact_address: NI8D17, 300 North Ingals Building, U. of Michigan///contact_city: Ann Arbor///contact_state: MI///contact_zip.postal_code: 48109-5473///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM139nnn/GSM139444/GSM139444.CEL.gz///data_row_count: 22283
1
title: Ovarian_Tumor_Serous_CHTN-OS-044///geo_accession: GSM139445///status: Public on Apr 09 2007///submission_date: Oct 10 2006///last_update_date: Apr 09 2007///type: RNA///channel_count: 1///source_name_ch1: Ovarian_Tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tumor_Type: Serous///characteristics_ch1.1: stage: 4///characteristics_ch1.2: grade: 3///characteristics_ch1.3: B-canenin_nuclear_accumulation: N/A///characteristics_ch1.4: CTNNB1_mutation: N/A///characteristics_ch1.5: APC_mutation: N/A///characteristics_ch1.6: PTEN_mutation: N/A///characteristics_ch1.7: PTEN_immunohistochemistry: N/A///characteristics_ch1.8: KRAS_mutation: N/A///characteristics_ch1.9: PIK3CA_mutation: N/A///characteristics_ch1.10: TP53_mutation: N/A///characteristics_ch1.11: P53_immunohistochemistry: N/A///characteristics_ch1.12: CEL_file_name: CHTN-OS-044.CEL///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from the tissue lysate using an RNeasy kit (Qiagen).///label_ch1: biotin///label_protocol_ch1: 3-5 g of total RNA was processed to produce biotinylated cRNA targets.///taxid_ch1: 9606///hyb_protocol: standard Affymetrix procedures///scan_protocol: standard Affymetrix procedures///description: ovarian tumor: serous///data_processing: Ann Arbor quantile-normalized trimmed-mean method///platform_id: GPL96///contact_name: Rork,,Kuick///contact_email: [email protected]///contact_phone: 734-936-9241///contact_institute: University of Michigan///contact_address: NI8D17, 300 North Ingals Building, U. of Michigan///contact_city: Ann Arbor///contact_state: MI///contact_zip.postal_code: 48109-5473///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM139nnn/GSM139445/GSM139445.CEL.gz///data_row_count: 22283
1
title: Ovarian_Tumor_Serous_CHTN-OS-046///geo_accession: GSM139446///status: Public on Apr 09 2007///submission_date: Oct 10 2006///last_update_date: Apr 09 2007///type: RNA///channel_count: 1///source_name_ch1: Ovarian_Tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tumor_Type: Serous///characteristics_ch1.1: stage: 2C///characteristics_ch1.2: grade: 2///characteristics_ch1.3: B-canenin_nuclear_accumulation: N/A///characteristics_ch1.4: CTNNB1_mutation: N/A///characteristics_ch1.5: APC_mutation: N/A///characteristics_ch1.6: PTEN_mutation: N/A///characteristics_ch1.7: PTEN_immunohistochemistry: N/A///characteristics_ch1.8: KRAS_mutation: N/A///characteristics_ch1.9: PIK3CA_mutation: N/A///characteristics_ch1.10: TP53_mutation: N/A///characteristics_ch1.11: P53_immunohistochemistry: N/A///characteristics_ch1.12: CEL_file_name: CHTN-OS-046.CEL///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from the tissue lysate using an RNeasy kit (Qiagen).///label_ch1: biotin///label_protocol_ch1: 3-5 g of total RNA was processed to produce biotinylated cRNA targets.///taxid_ch1: 9606///hyb_protocol: standard Affymetrix procedures///scan_protocol: standard Affymetrix procedures///description: ovarian tumor: serous///data_processing: Ann Arbor quantile-normalized trimmed-mean method///platform_id: GPL96///contact_name: Rork,,Kuick///contact_email: [email protected]///contact_phone: 734-936-9241///contact_institute: University of Michigan///contact_address: NI8D17, 300 North Ingals Building, U. of Michigan///contact_city: Ann Arbor///contact_state: MI///contact_zip.postal_code: 48109-5473///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM139nnn/GSM139446/GSM139446.CEL.gz///data_row_count: 22283
1
title: Ovarian_Tumor_Serous_CHTN-OS-048///geo_accession: GSM139447///status: Public on Apr 09 2007///submission_date: Oct 10 2006///last_update_date: Apr 09 2007///type: RNA///channel_count: 1///source_name_ch1: Ovarian_Tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tumor_Type: Serous///characteristics_ch1.1: stage: 4///characteristics_ch1.2: grade: 2///characteristics_ch1.3: B-canenin_nuclear_accumulation: N/A///characteristics_ch1.4: CTNNB1_mutation: N/A///characteristics_ch1.5: APC_mutation: N/A///characteristics_ch1.6: PTEN_mutation: N/A///characteristics_ch1.7: PTEN_immunohistochemistry: N/A///characteristics_ch1.8: KRAS_mutation: N/A///characteristics_ch1.9: PIK3CA_mutation: N/A///characteristics_ch1.10: TP53_mutation: N/A///characteristics_ch1.11: P53_immunohistochemistry: N/A///characteristics_ch1.12: CEL_file_name: CHTN-OS-048.CEL///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from the tissue lysate using an RNeasy kit (Qiagen).///label_ch1: biotin///label_protocol_ch1: 3-5 g of total RNA was processed to produce biotinylated cRNA targets.///taxid_ch1: 9606///hyb_protocol: standard Affymetrix procedures///scan_protocol: standard Affymetrix procedures///description: ovarian tumor: serous///data_processing: Ann Arbor quantile-normalized trimmed-mean method///platform_id: GPL96///contact_name: Rork,,Kuick///contact_email: [email protected]///contact_phone: 734-936-9241///contact_institute: University of Michigan///contact_address: NI8D17, 300 North Ingals Building, U. of Michigan///contact_city: Ann Arbor///contact_state: MI///contact_zip.postal_code: 48109-5473///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM139nnn/GSM139447/GSM139447.CEL.gz///data_row_count: 22283
1
title: Ovarian_Tumor_Serous_CHTN-OS-053///geo_accession: GSM139448///status: Public on Apr 09 2007///submission_date: Oct 10 2006///last_update_date: Apr 09 2007///type: RNA///channel_count: 1///source_name_ch1: Ovarian_Tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tumor_Type: Serous///characteristics_ch1.1: stage: 3D///characteristics_ch1.2: grade: 3///characteristics_ch1.3: B-canenin_nuclear_accumulation: N/A///characteristics_ch1.4: CTNNB1_mutation: N/A///characteristics_ch1.5: APC_mutation: N/A///characteristics_ch1.6: PTEN_mutation: N/A///characteristics_ch1.7: PTEN_immunohistochemistry: N/A///characteristics_ch1.8: KRAS_mutation: N/A///characteristics_ch1.9: PIK3CA_mutation: N/A///characteristics_ch1.10: TP53_mutation: N/A///characteristics_ch1.11: P53_immunohistochemistry: N/A///characteristics_ch1.12: CEL_file_name: CHTN-OS-053.CEL///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from the tissue lysate using an RNeasy kit (Qiagen).///label_ch1: biotin///label_protocol_ch1: 3-5 g of total RNA was processed to produce biotinylated cRNA targets.///taxid_ch1: 9606///hyb_protocol: standard Affymetrix procedures///scan_protocol: standard Affymetrix procedures///description: ovarian tumor: serous///data_processing: Ann Arbor quantile-normalized trimmed-mean method///platform_id: GPL96///contact_name: Rork,,Kuick///contact_email: [email protected]///contact_phone: 734-936-9241///contact_institute: University of Michigan///contact_address: NI8D17, 300 North Ingals Building, U. of Michigan///contact_city: Ann Arbor///contact_state: MI///contact_zip.postal_code: 48109-5473///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM139nnn/GSM139448/GSM139448.CEL.gz///data_row_count: 22283
1
title: Ovarian_Tumor_Serous_CHTN-OS-055///geo_accession: GSM139449///status: Public on Apr 09 2007///submission_date: Oct 10 2006///last_update_date: Apr 09 2007///type: RNA///channel_count: 1///source_name_ch1: Ovarian_Tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tumor_Type: Serous///characteristics_ch1.1: stage: 3C///characteristics_ch1.2: grade: 1///characteristics_ch1.3: B-canenin_nuclear_accumulation: N/A///characteristics_ch1.4: CTNNB1_mutation: N/A///characteristics_ch1.5: APC_mutation: N/A///characteristics_ch1.6: PTEN_mutation: N/A///characteristics_ch1.7: PTEN_immunohistochemistry: N/A///characteristics_ch1.8: KRAS_mutation: N/A///characteristics_ch1.9: PIK3CA_mutation: N/A///characteristics_ch1.10: TP53_mutation: N/A///characteristics_ch1.11: P53_immunohistochemistry: N/A///characteristics_ch1.12: CEL_file_name: CHTN-OS-055.CEL///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from the tissue lysate using an RNeasy kit (Qiagen).///label_ch1: biotin///label_protocol_ch1: 3-5 g of total RNA was processed to produce biotinylated cRNA targets.///taxid_ch1: 9606///hyb_protocol: standard Affymetrix procedures///scan_protocol: standard Affymetrix procedures///description: ovarian tumor: serous///data_processing: Ann Arbor quantile-normalized trimmed-mean method///platform_id: GPL96///contact_name: Rork,,Kuick///contact_email: [email protected]///contact_phone: 734-936-9241///contact_institute: University of Michigan///contact_address: NI8D17, 300 North Ingals Building, U. of Michigan///contact_city: Ann Arbor///contact_state: MI///contact_zip.postal_code: 48109-5473///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM139nnn/GSM139449/GSM139449.CEL.gz///data_row_count: 22283
1
title: Ovarian_Tumor_Serous_CHTN-OS-068///geo_accession: GSM139450///status: Public on Apr 09 2007///submission_date: Oct 10 2006///last_update_date: Apr 09 2007///type: RNA///channel_count: 1///source_name_ch1: Ovarian_Tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tumor_Type: Serous///characteristics_ch1.1: stage: 3C///characteristics_ch1.2: grade: N/A///characteristics_ch1.3: B-canenin_nuclear_accumulation: N/A///characteristics_ch1.4: CTNNB1_mutation: N/A///characteristics_ch1.5: APC_mutation: N/A///characteristics_ch1.6: PTEN_mutation: N/A///characteristics_ch1.7: PTEN_immunohistochemistry: N/A///characteristics_ch1.8: KRAS_mutation: N/A///characteristics_ch1.9: PIK3CA_mutation: N/A///characteristics_ch1.10: TP53_mutation: N/A///characteristics_ch1.11: P53_immunohistochemistry: N/A///characteristics_ch1.12: CEL_file_name: CHTN-OS-068.CEL///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from the tissue lysate using an RNeasy kit (Qiagen).///label_ch1: biotin///label_protocol_ch1: 3-5 g of total RNA was processed to produce biotinylated cRNA targets.///taxid_ch1: 9606///hyb_protocol: standard Affymetrix procedures///scan_protocol: standard Affymetrix procedures///description: ovarian tumor: serous///data_processing: Ann Arbor quantile-normalized trimmed-mean method///platform_id: GPL96///contact_name: Rork,,Kuick///contact_email: [email protected]///contact_phone: 734-936-9241///contact_institute: University of Michigan///contact_address: NI8D17, 300 North Ingals Building, U. of Michigan///contact_city: Ann Arbor///contact_state: MI///contact_zip.postal_code: 48109-5473///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM139nnn/GSM139450/GSM139450.CEL.gz///data_row_count: 22283
1
title: Ovarian_Tumor_Serous_CHTN-OS-072///geo_accession: GSM139451///status: Public on Apr 09 2007///submission_date: Oct 10 2006///last_update_date: Apr 09 2007///type: RNA///channel_count: 1///source_name_ch1: Ovarian_Tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tumor_Type: Serous///characteristics_ch1.1: stage: 3C///characteristics_ch1.2: grade: 3///characteristics_ch1.3: B-canenin_nuclear_accumulation: N/A///characteristics_ch1.4: CTNNB1_mutation: N/A///characteristics_ch1.5: APC_mutation: N/A///characteristics_ch1.6: PTEN_mutation: N/A///characteristics_ch1.7: PTEN_immunohistochemistry: N/A///characteristics_ch1.8: KRAS_mutation: N/A///characteristics_ch1.9: PIK3CA_mutation: N/A///characteristics_ch1.10: TP53_mutation: N/A///characteristics_ch1.11: P53_immunohistochemistry: N/A///characteristics_ch1.12: CEL_file_name: CHTN-OS-072.CEL///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from the tissue lysate using an RNeasy kit (Qiagen).///label_ch1: biotin///label_protocol_ch1: 3-5 g of total RNA was processed to produce biotinylated cRNA targets.///taxid_ch1: 9606///hyb_protocol: standard Affymetrix procedures///scan_protocol: standard Affymetrix procedures///description: ovarian tumor: serous///data_processing: Ann Arbor quantile-normalized trimmed-mean method///platform_id: GPL96///contact_name: Rork,,Kuick///contact_email: [email protected]///contact_phone: 734-936-9241///contact_institute: University of Michigan///contact_address: NI8D17, 300 North Ingals Building, U. of Michigan///contact_city: Ann Arbor///contact_state: MI///contact_zip.postal_code: 48109-5473///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM139nnn/GSM139451/GSM139451.CEL.gz///data_row_count: 22283
1
title: Ovarian_Tumor_Serous_CHTN-OS-081///geo_accession: GSM139452///status: Public on Apr 09 2007///submission_date: Oct 10 2006///last_update_date: Apr 09 2007///type: RNA///channel_count: 1///source_name_ch1: Ovarian_Tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tumor_Type: Serous///characteristics_ch1.1: stage: 3C///characteristics_ch1.2: grade: 3///characteristics_ch1.3: B-canenin_nuclear_accumulation: N/A///characteristics_ch1.4: CTNNB1_mutation: N/A///characteristics_ch1.5: APC_mutation: N/A///characteristics_ch1.6: PTEN_mutation: N/A///characteristics_ch1.7: PTEN_immunohistochemistry: N/A///characteristics_ch1.8: KRAS_mutation: N/A///characteristics_ch1.9: PIK3CA_mutation: N/A///characteristics_ch1.10: TP53_mutation: N/A///characteristics_ch1.11: P53_immunohistochemistry: N/A///characteristics_ch1.12: CEL_file_name: CHTN-OS-081.CEL///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from the tissue lysate using an RNeasy kit (Qiagen).///label_ch1: biotin///label_protocol_ch1: 3-5 g of total RNA was processed to produce biotinylated cRNA targets.///taxid_ch1: 9606///hyb_protocol: standard Affymetrix procedures///scan_protocol: standard Affymetrix procedures///description: ovarian tumor: serous///data_processing: Ann Arbor quantile-normalized trimmed-mean method///platform_id: GPL96///contact_name: Rork,,Kuick///contact_email: [email protected]///contact_phone: 734-936-9241///contact_institute: University of Michigan///contact_address: NI8D17, 300 North Ingals Building, U. of Michigan///contact_city: Ann Arbor///contact_state: MI///contact_zip.postal_code: 48109-5473///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM139nnn/GSM139452/GSM139452.CEL.gz///data_row_count: 22283
1
title: Ovarian_Tumor_Serous_CHTN-OS-089///geo_accession: GSM139453///status: Public on Apr 09 2007///submission_date: Oct 10 2006///last_update_date: Apr 09 2007///type: RNA///channel_count: 1///source_name_ch1: Ovarian_Tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tumor_Type: Serous///characteristics_ch1.1: stage: 3C///characteristics_ch1.2: grade: 3///characteristics_ch1.3: B-canenin_nuclear_accumulation: N/A///characteristics_ch1.4: CTNNB1_mutation: N/A///characteristics_ch1.5: APC_mutation: N/A///characteristics_ch1.6: PTEN_mutation: N/A///characteristics_ch1.7: PTEN_immunohistochemistry: N/A///characteristics_ch1.8: KRAS_mutation: N/A///characteristics_ch1.9: PIK3CA_mutation: N/A///characteristics_ch1.10: TP53_mutation: N/A///characteristics_ch1.11: P53_immunohistochemistry: N/A///characteristics_ch1.12: CEL_file_name: CHTN-OS-089.CEL///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from the tissue lysate using an RNeasy kit (Qiagen).///label_ch1: biotin///label_protocol_ch1: 3-5 g of total RNA was processed to produce biotinylated cRNA targets.///taxid_ch1: 9606///hyb_protocol: standard Affymetrix procedures///scan_protocol: standard Affymetrix procedures///description: ovarian tumor: serous///data_processing: Ann Arbor quantile-normalized trimmed-mean method///platform_id: GPL96///contact_name: Rork,,Kuick///contact_email: [email protected]///contact_phone: 734-936-9241///contact_institute: University of Michigan///contact_address: NI8D17, 300 North Ingals Building, U. of Michigan///contact_city: Ann Arbor///contact_state: MI///contact_zip.postal_code: 48109-5473///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM139nnn/GSM139453/GSM139453.CEL.gz///data_row_count: 22283
1
title: Ovarian_Tumor_Serous_CHTN-OS-093///geo_accession: GSM139454///status: Public on Apr 09 2007///submission_date: Oct 10 2006///last_update_date: Apr 09 2007///type: RNA///channel_count: 1///source_name_ch1: Ovarian_Tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tumor_Type: Serous///characteristics_ch1.1: stage: 3C///characteristics_ch1.2: grade: 3///characteristics_ch1.3: B-canenin_nuclear_accumulation: N/A///characteristics_ch1.4: CTNNB1_mutation: N/A///characteristics_ch1.5: APC_mutation: N/A///characteristics_ch1.6: PTEN_mutation: N/A///characteristics_ch1.7: PTEN_immunohistochemistry: N/A///characteristics_ch1.8: KRAS_mutation: N/A///characteristics_ch1.9: PIK3CA_mutation: N/A///characteristics_ch1.10: TP53_mutation: N/A///characteristics_ch1.11: P53_immunohistochemistry: N/A///characteristics_ch1.12: CEL_file_name: CHTN-OS-093.CEL///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from the tissue lysate using an RNeasy kit (Qiagen).///label_ch1: biotin///label_protocol_ch1: 3-5 g of total RNA was processed to produce biotinylated cRNA targets.///taxid_ch1: 9606///hyb_protocol: standard Affymetrix procedures///scan_protocol: standard Affymetrix procedures///description: ovarian tumor: serous///data_processing: Ann Arbor quantile-normalized trimmed-mean method///platform_id: GPL96///contact_name: Rork,,Kuick///contact_email: [email protected]///contact_phone: 734-936-9241///contact_institute: University of Michigan///contact_address: NI8D17, 300 North Ingals Building, U. of Michigan///contact_city: Ann Arbor///contact_state: MI///contact_zip.postal_code: 48109-5473///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM139nnn/GSM139454/GSM139454.CEL.gz///data_row_count: 22283
1
title: Ovarian_Tumor_Serous_CHTN-OS-098///geo_accession: GSM139455///status: Public on Apr 09 2007///submission_date: Oct 10 2006///last_update_date: Apr 09 2007///type: RNA///channel_count: 1///source_name_ch1: Ovarian_Tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tumor_Type: Serous///characteristics_ch1.1: stage: 1A///characteristics_ch1.2: grade: 2///characteristics_ch1.3: B-canenin_nuclear_accumulation: N/A///characteristics_ch1.4: CTNNB1_mutation: N/A///characteristics_ch1.5: APC_mutation: N/A///characteristics_ch1.6: PTEN_mutation: N/A///characteristics_ch1.7: PTEN_immunohistochemistry: N/A///characteristics_ch1.8: KRAS_mutation: N/A///characteristics_ch1.9: PIK3CA_mutation: N/A///characteristics_ch1.10: TP53_mutation: N/A///characteristics_ch1.11: P53_immunohistochemistry: N/A///characteristics_ch1.12: CEL_file_name: CHTN-OS-098.CEL///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from the tissue lysate using an RNeasy kit (Qiagen).///label_ch1: biotin///label_protocol_ch1: 3-5 g of total RNA was processed to produce biotinylated cRNA targets.///taxid_ch1: 9606///hyb_protocol: standard Affymetrix procedures///scan_protocol: standard Affymetrix procedures///description: ovarian tumor: serous///data_processing: Ann Arbor quantile-normalized trimmed-mean method///platform_id: GPL96///contact_name: Rork,,Kuick///contact_email: [email protected]///contact_phone: 734-936-9241///contact_institute: University of Michigan///contact_address: NI8D17, 300 North Ingals Building, U. of Michigan///contact_city: Ann Arbor///contact_state: MI///contact_zip.postal_code: 48109-5473///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM139nnn/GSM139455/GSM139455.CEL.gz///data_row_count: 22283
1
title: Ovarian_Tumor_Serous_CU-OS-04///geo_accession: GSM139456///status: Public on Apr 09 2007///submission_date: Oct 10 2006///last_update_date: Apr 09 2007///type: RNA///channel_count: 1///source_name_ch1: Ovarian_Tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tumor_Type: Serous///characteristics_ch1.1: stage: 3///characteristics_ch1.2: grade: 3///characteristics_ch1.3: B-canenin_nuclear_accumulation: N/A///characteristics_ch1.4: CTNNB1_mutation: N/A///characteristics_ch1.5: APC_mutation: N/A///characteristics_ch1.6: PTEN_mutation: N/A///characteristics_ch1.7: PTEN_immunohistochemistry: N/A///characteristics_ch1.8: KRAS_mutation: N/A///characteristics_ch1.9: PIK3CA_mutation: N/A///characteristics_ch1.10: TP53_mutation: N/A///characteristics_ch1.11: P53_immunohistochemistry: N/A///characteristics_ch1.12: CEL_file_name: CU-OS-04.CEL///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from the tissue lysate using an RNeasy kit (Qiagen).///label_ch1: biotin///label_protocol_ch1: 3-5 g of total RNA was processed to produce biotinylated cRNA targets.///taxid_ch1: 9606///hyb_protocol: standard Affymetrix procedures///scan_protocol: standard Affymetrix procedures///description: ovarian tumor: serous///data_processing: Ann Arbor quantile-normalized trimmed-mean method///platform_id: GPL96///contact_name: Rork,,Kuick///contact_email: [email protected]///contact_phone: 734-936-9241///contact_institute: University of Michigan///contact_address: NI8D17, 300 North Ingals Building, U. of Michigan///contact_city: Ann Arbor///contact_state: MI///contact_zip.postal_code: 48109-5473///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM139nnn/GSM139456/GSM139456.CEL.gz///data_row_count: 22283
1
title: Ovarian_Tumor_Serous_CU-OS-05///geo_accession: GSM139457///status: Public on Apr 09 2007///submission_date: Oct 10 2006///last_update_date: Apr 09 2007///type: RNA///channel_count: 1///source_name_ch1: Ovarian_Tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tumor_Type: Serous///characteristics_ch1.1: stage: 2///characteristics_ch1.2: grade: 3///characteristics_ch1.3: B-canenin_nuclear_accumulation: N/A///characteristics_ch1.4: CTNNB1_mutation: N/A///characteristics_ch1.5: APC_mutation: N/A///characteristics_ch1.6: PTEN_mutation: N/A///characteristics_ch1.7: PTEN_immunohistochemistry: N/A///characteristics_ch1.8: KRAS_mutation: N/A///characteristics_ch1.9: PIK3CA_mutation: N/A///characteristics_ch1.10: TP53_mutation: N/A///characteristics_ch1.11: P53_immunohistochemistry: N/A///characteristics_ch1.12: CEL_file_name: CU-OS-05.CEL///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from the tissue lysate using an RNeasy kit (Qiagen).///label_ch1: biotin///label_protocol_ch1: 3-5 g of total RNA was processed to produce biotinylated cRNA targets.///taxid_ch1: 9606///hyb_protocol: standard Affymetrix procedures///scan_protocol: standard Affymetrix procedures///description: ovarian tumor: serous///data_processing: Ann Arbor quantile-normalized trimmed-mean method///platform_id: GPL96///contact_name: Rork,,Kuick///contact_email: [email protected]///contact_phone: 734-936-9241///contact_institute: University of Michigan///contact_address: NI8D17, 300 North Ingals Building, U. of Michigan///contact_city: Ann Arbor///contact_state: MI///contact_zip.postal_code: 48109-5473///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM139nnn/GSM139457/GSM139457.CEL.gz///data_row_count: 22283
1
title: Ovarian_Tumor_Serous_KU-OS-001///geo_accession: GSM139458///status: Public on Apr 09 2007///submission_date: Oct 10 2006///last_update_date: Apr 09 2007///type: RNA///channel_count: 1///source_name_ch1: Ovarian_Tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tumor_Type: Serous///characteristics_ch1.1: stage: 4///characteristics_ch1.2: grade: N/A///characteristics_ch1.3: B-canenin_nuclear_accumulation: N/A///characteristics_ch1.4: CTNNB1_mutation: N/A///characteristics_ch1.5: APC_mutation: N/A///characteristics_ch1.6: PTEN_mutation: N/A///characteristics_ch1.7: PTEN_immunohistochemistry: N/A///characteristics_ch1.8: KRAS_mutation: N/A///characteristics_ch1.9: PIK3CA_mutation: N/A///characteristics_ch1.10: TP53_mutation: N/A///characteristics_ch1.11: P53_immunohistochemistry: N/A///characteristics_ch1.12: CEL_file_name: KU-OS-001.CEL///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from the tissue lysate using an RNeasy kit (Qiagen).///label_ch1: biotin///label_protocol_ch1: 3-5 g of total RNA was processed to produce biotinylated cRNA targets.///taxid_ch1: 9606///hyb_protocol: standard Affymetrix procedures///scan_protocol: standard Affymetrix procedures///description: ovarian tumor: serous///data_processing: Ann Arbor quantile-normalized trimmed-mean method///platform_id: GPL96///contact_name: Rork,,Kuick///contact_email: [email protected]///contact_phone: 734-936-9241///contact_institute: University of Michigan///contact_address: NI8D17, 300 North Ingals Building, U. of Michigan///contact_city: Ann Arbor///contact_state: MI///contact_zip.postal_code: 48109-5473///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM139nnn/GSM139458/GSM139458.CEL.gz///data_row_count: 22283
1
title: Ovarian_Tumor_Serous_KU-OS-002///geo_accession: GSM139459///status: Public on Apr 09 2007///submission_date: Oct 10 2006///last_update_date: Apr 09 2007///type: RNA///channel_count: 1///source_name_ch1: Ovarian_Tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tumor_Type: Serous///characteristics_ch1.1: stage: 4///characteristics_ch1.2: grade: N/A///characteristics_ch1.3: B-canenin_nuclear_accumulation: N/A///characteristics_ch1.4: CTNNB1_mutation: N/A///characteristics_ch1.5: APC_mutation: N/A///characteristics_ch1.6: PTEN_mutation: N/A///characteristics_ch1.7: PTEN_immunohistochemistry: N/A///characteristics_ch1.8: KRAS_mutation: N/A///characteristics_ch1.9: PIK3CA_mutation: N/A///characteristics_ch1.10: TP53_mutation: N/A///characteristics_ch1.11: P53_immunohistochemistry: N/A///characteristics_ch1.12: CEL_file_name: KU-OS-002.CEL///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from the tissue lysate using an RNeasy kit (Qiagen).///label_ch1: biotin///label_protocol_ch1: 3-5 g of total RNA was processed to produce biotinylated cRNA targets.///taxid_ch1: 9606///hyb_protocol: standard Affymetrix procedures///scan_protocol: standard Affymetrix procedures///description: ovarian tumor: serous///data_processing: Ann Arbor quantile-normalized trimmed-mean method///platform_id: GPL96///contact_name: Rork,,Kuick///contact_email: [email protected]///contact_phone: 734-936-9241///contact_institute: University of Michigan///contact_address: NI8D17, 300 North Ingals Building, U. of Michigan///contact_city: Ann Arbor///contact_state: MI///contact_zip.postal_code: 48109-5473///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM139nnn/GSM139459/GSM139459.CEL.gz///data_row_count: 22283
1
title: Ovarian_Tumor_Serous_KU-OS-003///geo_accession: GSM139460///status: Public on Apr 09 2007///submission_date: Oct 10 2006///last_update_date: Apr 09 2007///type: RNA///channel_count: 1///source_name_ch1: Ovarian_Tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tumor_Type: Serous///characteristics_ch1.1: stage: 3c///characteristics_ch1.2: grade: N/A///characteristics_ch1.3: B-canenin_nuclear_accumulation: N/A///characteristics_ch1.4: CTNNB1_mutation: N/A///characteristics_ch1.5: APC_mutation: N/A///characteristics_ch1.6: PTEN_mutation: N/A///characteristics_ch1.7: PTEN_immunohistochemistry: N/A///characteristics_ch1.8: KRAS_mutation: N/A///characteristics_ch1.9: PIK3CA_mutation: N/A///characteristics_ch1.10: TP53_mutation: N/A///characteristics_ch1.11: P53_immunohistochemistry: N/A///characteristics_ch1.12: CEL_file_name: KU-OS-003.CEL///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from the tissue lysate using an RNeasy kit (Qiagen).///label_ch1: biotin///label_protocol_ch1: 3-5 g of total RNA was processed to produce biotinylated cRNA targets.///taxid_ch1: 9606///hyb_protocol: standard Affymetrix procedures///scan_protocol: standard Affymetrix procedures///description: ovarian tumor: serous///data_processing: Ann Arbor quantile-normalized trimmed-mean method///platform_id: GPL96///contact_name: Rork,,Kuick///contact_email: [email protected]///contact_phone: 734-936-9241///contact_institute: University of Michigan///contact_address: NI8D17, 300 North Ingals Building, U. of Michigan///contact_city: Ann Arbor///contact_state: MI///contact_zip.postal_code: 48109-5473///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM139nnn/GSM139460/GSM139460.CEL.gz///data_row_count: 22283
1
title: Ovarian_Tumor_Serous_KU-OS-005///geo_accession: GSM139461///status: Public on Apr 09 2007///submission_date: Oct 10 2006///last_update_date: Apr 09 2007///type: RNA///channel_count: 1///source_name_ch1: Ovarian_Tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tumor_Type: Serous///characteristics_ch1.1: stage: 3c///characteristics_ch1.2: grade: N/A///characteristics_ch1.3: B-canenin_nuclear_accumulation: N/A///characteristics_ch1.4: CTNNB1_mutation: N/A///characteristics_ch1.5: APC_mutation: N/A///characteristics_ch1.6: PTEN_mutation: N/A///characteristics_ch1.7: PTEN_immunohistochemistry: N/A///characteristics_ch1.8: KRAS_mutation: N/A///characteristics_ch1.9: PIK3CA_mutation: N/A///characteristics_ch1.10: TP53_mutation: N/A///characteristics_ch1.11: P53_immunohistochemistry: N/A///characteristics_ch1.12: CEL_file_name: KU-OS-005.CEL///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from the tissue lysate using an RNeasy kit (Qiagen).///label_ch1: biotin///label_protocol_ch1: 3-5 g of total RNA was processed to produce biotinylated cRNA targets.///taxid_ch1: 9606///hyb_protocol: standard Affymetrix procedures///scan_protocol: standard Affymetrix procedures///description: ovarian tumor: serous///data_processing: Ann Arbor quantile-normalized trimmed-mean method///platform_id: GPL96///contact_name: Rork,,Kuick///contact_email: [email protected]///contact_phone: 734-936-9241///contact_institute: University of Michigan///contact_address: NI8D17, 300 North Ingals Building, U. of Michigan///contact_city: Ann Arbor///contact_state: MI///contact_zip.postal_code: 48109-5473///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM139nnn/GSM139461/GSM139461.CEL.gz///data_row_count: 22283
1
title: Ovarian_Tumor_Serous_KU-OS-007///geo_accession: GSM139462///status: Public on Apr 09 2007///submission_date: Oct 10 2006///last_update_date: Apr 09 2007///type: RNA///channel_count: 1///source_name_ch1: Ovarian_Tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tumor_Type: Serous///characteristics_ch1.1: stage: 3c///characteristics_ch1.2: grade: N/A///characteristics_ch1.3: B-canenin_nuclear_accumulation: N/A///characteristics_ch1.4: CTNNB1_mutation: N/A///characteristics_ch1.5: APC_mutation: N/A///characteristics_ch1.6: PTEN_mutation: N/A///characteristics_ch1.7: PTEN_immunohistochemistry: N/A///characteristics_ch1.8: KRAS_mutation: N/A///characteristics_ch1.9: PIK3CA_mutation: N/A///characteristics_ch1.10: TP53_mutation: N/A///characteristics_ch1.11: P53_immunohistochemistry: N/A///characteristics_ch1.12: CEL_file_name: KU-OS-007.CEL///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from the tissue lysate using an RNeasy kit (Qiagen).///label_ch1: biotin///label_protocol_ch1: 3-5 g of total RNA was processed to produce biotinylated cRNA targets.///taxid_ch1: 9606///hyb_protocol: standard Affymetrix procedures///scan_protocol: standard Affymetrix procedures///description: ovarian tumor: serous///data_processing: Ann Arbor quantile-normalized trimmed-mean method///platform_id: GPL96///contact_name: Rork,,Kuick///contact_email: [email protected]///contact_phone: 734-936-9241///contact_institute: University of Michigan///contact_address: NI8D17, 300 North Ingals Building, U. of Michigan///contact_city: Ann Arbor///contact_state: MI///contact_zip.postal_code: 48109-5473///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM139nnn/GSM139462/GSM139462.CEL.gz///data_row_count: 22283
1
title: Ovarian_Tumor_Serous_KU-OS-009///geo_accession: GSM139463///status: Public on Apr 09 2007///submission_date: Oct 10 2006///last_update_date: Apr 09 2007///type: RNA///channel_count: 1///source_name_ch1: Ovarian_Tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tumor_Type: Serous///characteristics_ch1.1: stage: 3c///characteristics_ch1.2: grade: N/A///characteristics_ch1.3: B-canenin_nuclear_accumulation: N/A///characteristics_ch1.4: CTNNB1_mutation: N/A///characteristics_ch1.5: APC_mutation: N/A///characteristics_ch1.6: PTEN_mutation: N/A///characteristics_ch1.7: PTEN_immunohistochemistry: N/A///characteristics_ch1.8: KRAS_mutation: N/A///characteristics_ch1.9: PIK3CA_mutation: N/A///characteristics_ch1.10: TP53_mutation: N/A///characteristics_ch1.11: P53_immunohistochemistry: N/A///characteristics_ch1.12: CEL_file_name: KU-OS-009.CEL///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from the tissue lysate using an RNeasy kit (Qiagen).///label_ch1: biotin///label_protocol_ch1: 3-5 g of total RNA was processed to produce biotinylated cRNA targets.///taxid_ch1: 9606///hyb_protocol: standard Affymetrix procedures///scan_protocol: standard Affymetrix procedures///description: ovarian tumor: serous///data_processing: Ann Arbor quantile-normalized trimmed-mean method///platform_id: GPL96///contact_name: Rork,,Kuick///contact_email: [email protected]///contact_phone: 734-936-9241///contact_institute: University of Michigan///contact_address: NI8D17, 300 North Ingals Building, U. of Michigan///contact_city: Ann Arbor///contact_state: MI///contact_zip.postal_code: 48109-5473///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM139nnn/GSM139463/GSM139463.CEL.gz///data_row_count: 22283
1
title: Ovarian_Tumor_Serous_KU-OS-011///geo_accession: GSM139464///status: Public on Apr 09 2007///submission_date: Oct 10 2006///last_update_date: Apr 09 2007///type: RNA///channel_count: 1///source_name_ch1: Ovarian_Tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tumor_Type: Serous///characteristics_ch1.1: stage: 1c///characteristics_ch1.2: grade: N/A///characteristics_ch1.3: B-canenin_nuclear_accumulation: N/A///characteristics_ch1.4: CTNNB1_mutation: N/A///characteristics_ch1.5: APC_mutation: N/A///characteristics_ch1.6: PTEN_mutation: N/A///characteristics_ch1.7: PTEN_immunohistochemistry: N/A///characteristics_ch1.8: KRAS_mutation: N/A///characteristics_ch1.9: PIK3CA_mutation: N/A///characteristics_ch1.10: TP53_mutation: N/A///characteristics_ch1.11: P53_immunohistochemistry: N/A///characteristics_ch1.12: CEL_file_name: KU-OS-011.CEL///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from the tissue lysate using an RNeasy kit (Qiagen).///label_ch1: biotin///label_protocol_ch1: 3-5 g of total RNA was processed to produce biotinylated cRNA targets.///taxid_ch1: 9606///hyb_protocol: standard Affymetrix procedures///scan_protocol: standard Affymetrix procedures///description: ovarian tumor: serous///data_processing: Ann Arbor quantile-normalized trimmed-mean method///platform_id: GPL96///contact_name: Rork,,Kuick///contact_email: [email protected]///contact_phone: 734-936-9241///contact_institute: University of Michigan///contact_address: NI8D17, 300 North Ingals Building, U. of Michigan///contact_city: Ann Arbor///contact_state: MI///contact_zip.postal_code: 48109-5473///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM139nnn/GSM139464/GSM139464.CEL.gz///data_row_count: 22283
1
title: Ovarian_Tumor_Serous_KU-OS-012///geo_accession: GSM139465///status: Public on Apr 09 2007///submission_date: Oct 10 2006///last_update_date: Apr 09 2007///type: RNA///channel_count: 1///source_name_ch1: Ovarian_Tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tumor_Type: Serous///characteristics_ch1.1: stage: 2c///characteristics_ch1.2: grade: N/A///characteristics_ch1.3: B-canenin_nuclear_accumulation: N/A///characteristics_ch1.4: CTNNB1_mutation: N/A///characteristics_ch1.5: APC_mutation: N/A///characteristics_ch1.6: PTEN_mutation: N/A///characteristics_ch1.7: PTEN_immunohistochemistry: N/A///characteristics_ch1.8: KRAS_mutation: N/A///characteristics_ch1.9: PIK3CA_mutation: N/A///characteristics_ch1.10: TP53_mutation: N/A///characteristics_ch1.11: P53_immunohistochemistry: N/A///characteristics_ch1.12: CEL_file_name: KU-OS-012.CEL///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from the tissue lysate using an RNeasy kit (Qiagen).///label_ch1: biotin///label_protocol_ch1: 3-5 g of total RNA was processed to produce biotinylated cRNA targets.///taxid_ch1: 9606///hyb_protocol: standard Affymetrix procedures///scan_protocol: standard Affymetrix procedures///description: ovarian tumor: serous///data_processing: Ann Arbor quantile-normalized trimmed-mean method///platform_id: GPL96///contact_name: Rork,,Kuick///contact_email: [email protected]///contact_phone: 734-936-9241///contact_institute: University of Michigan///contact_address: NI8D17, 300 North Ingals Building, U. of Michigan///contact_city: Ann Arbor///contact_state: MI///contact_zip.postal_code: 48109-5473///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM139nnn/GSM139465/GSM139465.CEL.gz///data_row_count: 22283
1
title: Ovarian_Tumor_Serous_KU-OS-013///geo_accession: GSM139466///status: Public on Apr 09 2007///submission_date: Oct 10 2006///last_update_date: Apr 09 2007///type: RNA///channel_count: 1///source_name_ch1: Ovarian_Tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tumor_Type: Serous///characteristics_ch1.1: stage: 3c///characteristics_ch1.2: grade: N/A///characteristics_ch1.3: B-canenin_nuclear_accumulation: N/A///characteristics_ch1.4: CTNNB1_mutation: N/A///characteristics_ch1.5: APC_mutation: N/A///characteristics_ch1.6: PTEN_mutation: N/A///characteristics_ch1.7: PTEN_immunohistochemistry: N/A///characteristics_ch1.8: KRAS_mutation: N/A///characteristics_ch1.9: PIK3CA_mutation: N/A///characteristics_ch1.10: TP53_mutation: N/A///characteristics_ch1.11: P53_immunohistochemistry: N/A///characteristics_ch1.12: CEL_file_name: KU-OS-013.CEL///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from the tissue lysate using an RNeasy kit (Qiagen).///label_ch1: biotin///label_protocol_ch1: 3-5 g of total RNA was processed to produce biotinylated cRNA targets.///taxid_ch1: 9606///hyb_protocol: standard Affymetrix procedures///scan_protocol: standard Affymetrix procedures///description: ovarian tumor: serous///data_processing: Ann Arbor quantile-normalized trimmed-mean method///platform_id: GPL96///contact_name: Rork,,Kuick///contact_email: [email protected]///contact_phone: 734-936-9241///contact_institute: University of Michigan///contact_address: NI8D17, 300 North Ingals Building, U. of Michigan///contact_city: Ann Arbor///contact_state: MI///contact_zip.postal_code: 48109-5473///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM139nnn/GSM139466/GSM139466.CEL.gz///data_row_count: 22283
1
title: Ovarian_Tumor_Serous_KU-OS-015///geo_accession: GSM139467///status: Public on Apr 09 2007///submission_date: Oct 10 2006///last_update_date: Apr 09 2007///type: RNA///channel_count: 1///source_name_ch1: Ovarian_Tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tumor_Type: Serous///characteristics_ch1.1: stage: 3c///characteristics_ch1.2: grade: N/A///characteristics_ch1.3: B-canenin_nuclear_accumulation: N/A///characteristics_ch1.4: CTNNB1_mutation: N/A///characteristics_ch1.5: APC_mutation: N/A///characteristics_ch1.6: PTEN_mutation: N/A///characteristics_ch1.7: PTEN_immunohistochemistry: N/A///characteristics_ch1.8: KRAS_mutation: N/A///characteristics_ch1.9: PIK3CA_mutation: N/A///characteristics_ch1.10: TP53_mutation: N/A///characteristics_ch1.11: P53_immunohistochemistry: N/A///characteristics_ch1.12: CEL_file_name: KU-OS-015.CEL///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from the tissue lysate using an RNeasy kit (Qiagen).///label_ch1: biotin///label_protocol_ch1: 3-5 g of total RNA was processed to produce biotinylated cRNA targets.///taxid_ch1: 9606///hyb_protocol: standard Affymetrix procedures///scan_protocol: standard Affymetrix procedures///description: ovarian tumor: serous///data_processing: Ann Arbor quantile-normalized trimmed-mean method///platform_id: GPL96///contact_name: Rork,,Kuick///contact_email: [email protected]///contact_phone: 734-936-9241///contact_institute: University of Michigan///contact_address: NI8D17, 300 North Ingals Building, U. of Michigan///contact_city: Ann Arbor///contact_state: MI///contact_zip.postal_code: 48109-5473///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM139nnn/GSM139467/GSM139467.CEL.gz///data_row_count: 22283
1
title: Ovarian_Tumor_Serous_KU-OS-018///geo_accession: GSM139468///status: Public on Apr 09 2007///submission_date: Oct 10 2006///last_update_date: Apr 09 2007///type: RNA///channel_count: 1///source_name_ch1: Ovarian_Tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tumor_Type: Serous///characteristics_ch1.1: stage: 1c///characteristics_ch1.2: grade: N/A///characteristics_ch1.3: B-canenin_nuclear_accumulation: N/A///characteristics_ch1.4: CTNNB1_mutation: N/A///characteristics_ch1.5: APC_mutation: N/A///characteristics_ch1.6: PTEN_mutation: N/A///characteristics_ch1.7: PTEN_immunohistochemistry: N/A///characteristics_ch1.8: KRAS_mutation: N/A///characteristics_ch1.9: PIK3CA_mutation: N/A///characteristics_ch1.10: TP53_mutation: N/A///characteristics_ch1.11: P53_immunohistochemistry: N/A///characteristics_ch1.12: CEL_file_name: KU-OS-018.CEL///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from the tissue lysate using an RNeasy kit (Qiagen).///label_ch1: biotin///label_protocol_ch1: 3-5 g of total RNA was processed to produce biotinylated cRNA targets.///taxid_ch1: 9606///hyb_protocol: standard Affymetrix procedures///scan_protocol: standard Affymetrix procedures///description: ovarian tumor: serous///data_processing: Ann Arbor quantile-normalized trimmed-mean method///platform_id: GPL96///contact_name: Rork,,Kuick///contact_email: [email protected]///contact_phone: 734-936-9241///contact_institute: University of Michigan///contact_address: NI8D17, 300 North Ingals Building, U. of Michigan///contact_city: Ann Arbor///contact_state: MI///contact_zip.postal_code: 48109-5473///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM139nnn/GSM139468/GSM139468.CEL.gz///data_row_count: 22283
1
title: Ovarian_Tumor_Serous_KU-OS-021///geo_accession: GSM139469///status: Public on Apr 09 2007///submission_date: Oct 10 2006///last_update_date: Apr 09 2007///type: RNA///channel_count: 1///source_name_ch1: Ovarian_Tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tumor_Type: Serous///characteristics_ch1.1: stage: 3c///characteristics_ch1.2: grade: N/A///characteristics_ch1.3: B-canenin_nuclear_accumulation: N/A///characteristics_ch1.4: CTNNB1_mutation: N/A///characteristics_ch1.5: APC_mutation: N/A///characteristics_ch1.6: PTEN_mutation: N/A///characteristics_ch1.7: PTEN_immunohistochemistry: N/A///characteristics_ch1.8: KRAS_mutation: N/A///characteristics_ch1.9: PIK3CA_mutation: N/A///characteristics_ch1.10: TP53_mutation: N/A///characteristics_ch1.11: P53_immunohistochemistry: N/A///characteristics_ch1.12: CEL_file_name: KU-OS-021.CEL///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from the tissue lysate using an RNeasy kit (Qiagen).///label_ch1: biotin///label_protocol_ch1: 3-5 g of total RNA was processed to produce biotinylated cRNA targets.///taxid_ch1: 9606///hyb_protocol: standard Affymetrix procedures///scan_protocol: standard Affymetrix procedures///description: ovarian tumor: serous///data_processing: Ann Arbor quantile-normalized trimmed-mean method///platform_id: GPL96///contact_name: Rork,,Kuick///contact_email: [email protected]///contact_phone: 734-936-9241///contact_institute: University of Michigan///contact_address: NI8D17, 300 North Ingals Building, U. of Michigan///contact_city: Ann Arbor///contact_state: MI///contact_zip.postal_code: 48109-5473///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM139nnn/GSM139469/GSM139469.CEL.gz///data_row_count: 22283
1
title: Ovarian_Tumor_Serous_KU-OS-022///geo_accession: GSM139470///status: Public on Apr 09 2007///submission_date: Oct 10 2006///last_update_date: Apr 09 2007///type: RNA///channel_count: 1///source_name_ch1: Ovarian_Tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tumor_Type: Serous///characteristics_ch1.1: stage: 3c///characteristics_ch1.2: grade: N/A///characteristics_ch1.3: B-canenin_nuclear_accumulation: N/A///characteristics_ch1.4: CTNNB1_mutation: N/A///characteristics_ch1.5: APC_mutation: N/A///characteristics_ch1.6: PTEN_mutation: N/A///characteristics_ch1.7: PTEN_immunohistochemistry: N/A///characteristics_ch1.8: KRAS_mutation: N/A///characteristics_ch1.9: PIK3CA_mutation: N/A///characteristics_ch1.10: TP53_mutation: N/A///characteristics_ch1.11: P53_immunohistochemistry: N/A///characteristics_ch1.12: CEL_file_name: KU-OS-022.CEL///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from the tissue lysate using an RNeasy kit (Qiagen).///label_ch1: biotin///label_protocol_ch1: 3-5 g of total RNA was processed to produce biotinylated cRNA targets.///taxid_ch1: 9606///hyb_protocol: standard Affymetrix procedures///scan_protocol: standard Affymetrix procedures///description: ovarian tumor: serous///data_processing: Ann Arbor quantile-normalized trimmed-mean method///platform_id: GPL96///contact_name: Rork,,Kuick///contact_email: [email protected]///contact_phone: 734-936-9241///contact_institute: University of Michigan///contact_address: NI8D17, 300 North Ingals Building, U. of Michigan///contact_city: Ann Arbor///contact_state: MI///contact_zip.postal_code: 48109-5473///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM139nnn/GSM139470/GSM139470.CEL.gz///data_row_count: 22283
1
title: Ovarian_Tumor_Serous_UM-OS-02///geo_accession: GSM139471///status: Public on Apr 09 2007///submission_date: Oct 10 2006///last_update_date: Apr 09 2007///type: RNA///channel_count: 1///source_name_ch1: Ovarian_Tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tumor_Type: Serous///characteristics_ch1.1: stage: 3c///characteristics_ch1.2: grade: 2-3///characteristics_ch1.3: B-canenin_nuclear_accumulation: N/A///characteristics_ch1.4: CTNNB1_mutation: N/A///characteristics_ch1.5: APC_mutation: N/A///characteristics_ch1.6: PTEN_mutation: N/A///characteristics_ch1.7: PTEN_immunohistochemistry: N/A///characteristics_ch1.8: KRAS_mutation: N/A///characteristics_ch1.9: PIK3CA_mutation: N/A///characteristics_ch1.10: TP53_mutation: N/A///characteristics_ch1.11: P53_immunohistochemistry: N/A///characteristics_ch1.12: CEL_file_name: UM-OS-02.CEL///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from the tissue lysate using an RNeasy kit (Qiagen).///label_ch1: biotin///label_protocol_ch1: 3-5 g of total RNA was processed to produce biotinylated cRNA targets.///taxid_ch1: 9606///hyb_protocol: standard Affymetrix procedures///scan_protocol: standard Affymetrix procedures///description: ovarian tumor: serous///data_processing: Ann Arbor quantile-normalized trimmed-mean method///platform_id: GPL96///contact_name: Rork,,Kuick///contact_email: [email protected]///contact_phone: 734-936-9241///contact_institute: University of Michigan///contact_address: NI8D17, 300 North Ingals Building, U. of Michigan///contact_city: Ann Arbor///contact_state: MI///contact_zip.postal_code: 48109-5473///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM139nnn/GSM139471/GSM139471.CEL.gz///data_row_count: 22283
1
title: Ovarian_Tumor_Serous_UM-OS-07///geo_accession: GSM139472///status: Public on Apr 09 2007///submission_date: Oct 10 2006///last_update_date: Apr 09 2007///type: RNA///channel_count: 1///source_name_ch1: Ovarian_Tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tumor_Type: Serous///characteristics_ch1.1: stage: 3c///characteristics_ch1.2: grade: 3///characteristics_ch1.3: B-canenin_nuclear_accumulation: N/A///characteristics_ch1.4: CTNNB1_mutation: N/A///characteristics_ch1.5: APC_mutation: N/A///characteristics_ch1.6: PTEN_mutation: N/A///characteristics_ch1.7: PTEN_immunohistochemistry: N/A///characteristics_ch1.8: KRAS_mutation: N/A///characteristics_ch1.9: PIK3CA_mutation: N/A///characteristics_ch1.10: TP53_mutation: N/A///characteristics_ch1.11: P53_immunohistochemistry: N/A///characteristics_ch1.12: CEL_file_name: UM-OS-07.CEL///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from the tissue lysate using an RNeasy kit (Qiagen).///label_ch1: biotin///label_protocol_ch1: 3-5 g of total RNA was processed to produce biotinylated cRNA targets.///taxid_ch1: 9606///hyb_protocol: standard Affymetrix procedures///scan_protocol: standard Affymetrix procedures///description: ovarian tumor: serous///data_processing: Ann Arbor quantile-normalized trimmed-mean method///platform_id: GPL96///contact_name: Rork,,Kuick///contact_email: [email protected]///contact_phone: 734-936-9241///contact_institute: University of Michigan///contact_address: NI8D17, 300 North Ingals Building, U. of Michigan///contact_city: Ann Arbor///contact_state: MI///contact_zip.postal_code: 48109-5473///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM139nnn/GSM139472/GSM139472.CEL.gz///data_row_count: 22283
1
title: Ovarian_Tumor_Serous_UM-OS-09///geo_accession: GSM139473///status: Public on Apr 09 2007///submission_date: Oct 10 2006///last_update_date: Apr 09 2007///type: RNA///channel_count: 1///source_name_ch1: Ovarian_Tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tumor_Type: Serous///characteristics_ch1.1: stage: 3c///characteristics_ch1.2: grade: 3///characteristics_ch1.3: B-canenin_nuclear_accumulation: N/A///characteristics_ch1.4: CTNNB1_mutation: N/A///characteristics_ch1.5: APC_mutation: N/A///characteristics_ch1.6: PTEN_mutation: N/A///characteristics_ch1.7: PTEN_immunohistochemistry: N/A///characteristics_ch1.8: KRAS_mutation: N/A///characteristics_ch1.9: PIK3CA_mutation: N/A///characteristics_ch1.10: TP53_mutation: N/A///characteristics_ch1.11: P53_immunohistochemistry: N/A///characteristics_ch1.12: CEL_file_name: UM-OS-09.CEL///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from the tissue lysate using an RNeasy kit (Qiagen).///label_ch1: biotin///label_protocol_ch1: 3-5 g of total RNA was processed to produce biotinylated cRNA targets.///taxid_ch1: 9606///hyb_protocol: standard Affymetrix procedures///scan_protocol: standard Affymetrix procedures///description: ovarian tumor: serous///data_processing: Ann Arbor quantile-normalized trimmed-mean method///platform_id: GPL96///contact_name: Rork,,Kuick///contact_email: [email protected]///contact_phone: 734-936-9241///contact_institute: University of Michigan///contact_address: NI8D17, 300 North Ingals Building, U. of Michigan///contact_city: Ann Arbor///contact_state: MI///contact_zip.postal_code: 48109-5473///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM139nnn/GSM139473/GSM139473.CEL.gz///data_row_count: 22283
1
title: Ovarian_Tumor_Serous_UM-OS-10///geo_accession: GSM139474///status: Public on Apr 09 2007///submission_date: Oct 10 2006///last_update_date: Apr 09 2007///type: RNA///channel_count: 1///source_name_ch1: Ovarian_Tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tumor_Type: Serous///characteristics_ch1.1: stage: 3///characteristics_ch1.2: grade: 1///characteristics_ch1.3: B-canenin_nuclear_accumulation: N/A///characteristics_ch1.4: CTNNB1_mutation: N/A///characteristics_ch1.5: APC_mutation: N/A///characteristics_ch1.6: PTEN_mutation: N/A///characteristics_ch1.7: PTEN_immunohistochemistry: N/A///characteristics_ch1.8: KRAS_mutation: N/A///characteristics_ch1.9: PIK3CA_mutation: N/A///characteristics_ch1.10: TP53_mutation: N/A///characteristics_ch1.11: P53_immunohistochemistry: N/A///characteristics_ch1.12: CEL_file_name: UM-OS-10.CEL///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from the tissue lysate using an RNeasy kit (Qiagen).///label_ch1: biotin///label_protocol_ch1: 3-5 g of total RNA was processed to produce biotinylated cRNA targets.///taxid_ch1: 9606///hyb_protocol: standard Affymetrix procedures///scan_protocol: standard Affymetrix procedures///description: ovarian tumor: serous///data_processing: Ann Arbor quantile-normalized trimmed-mean method///platform_id: GPL96///contact_name: Rork,,Kuick///contact_email: [email protected]///contact_phone: 734-936-9241///contact_institute: University of Michigan///contact_address: NI8D17, 300 North Ingals Building, U. of Michigan///contact_city: Ann Arbor///contact_state: MI///contact_zip.postal_code: 48109-5473///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM139nnn/GSM139474/GSM139474.CEL.gz///data_row_count: 22283
1
title: Ovarian_Tumor_Serous_UM-OS-11///geo_accession: GSM139475///status: Public on Apr 09 2007///submission_date: Oct 10 2006///last_update_date: Apr 09 2007///type: RNA///channel_count: 1///source_name_ch1: Ovarian_Tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tumor_Type: Serous///characteristics_ch1.1: stage: 3c///characteristics_ch1.2: grade: 3///characteristics_ch1.3: B-canenin_nuclear_accumulation: N/A///characteristics_ch1.4: CTNNB1_mutation: N/A///characteristics_ch1.5: APC_mutation: N/A///characteristics_ch1.6: PTEN_mutation: N/A///characteristics_ch1.7: PTEN_immunohistochemistry: N/A///characteristics_ch1.8: KRAS_mutation: N/A///characteristics_ch1.9: PIK3CA_mutation: N/A///characteristics_ch1.10: TP53_mutation: N/A///characteristics_ch1.11: P53_immunohistochemistry: N/A///characteristics_ch1.12: CEL_file_name: UM-OS-11.CEL///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from the tissue lysate using an RNeasy kit (Qiagen).///label_ch1: biotin///label_protocol_ch1: 3-5 g of total RNA was processed to produce biotinylated cRNA targets.///taxid_ch1: 9606///hyb_protocol: standard Affymetrix procedures///scan_protocol: standard Affymetrix procedures///description: ovarian tumor: serous///data_processing: Ann Arbor quantile-normalized trimmed-mean method///platform_id: GPL96///contact_name: Rork,,Kuick///contact_email: [email protected]///contact_phone: 734-936-9241///contact_institute: University of Michigan///contact_address: NI8D17, 300 North Ingals Building, U. of Michigan///contact_city: Ann Arbor///contact_state: MI///contact_zip.postal_code: 48109-5473///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM139nnn/GSM139475/GSM139475.CEL.gz///data_row_count: 22283
1
(Other)
4
duplicates:
GSE6008.GSE6008_GSM139476///GSE6008.GSE6008_GSM139477
1
GSE6008.GSE6008_GSM139476///GSE6008.GSE6008_GSM139478
1
GSE6008.GSE6008_GSM139477///GSE6008.GSE6008_GSM139478
1
NA's
100
An expression set
Ouellet V, Provencher DM, Maugard CM, Le Page C, Ren F, Lussier C, Novak J, Ge B, Hudson TJ, Tonin PN, Mes-Masson A-M: Discrimination between serous low malignant potential and invasive epithelial ovarian tumors using molecular profiling. Oncogene 2005, 24:4672-4687.
experimentData(eset):
Experiment data
Experimenter name: Ouellet V, Provencher DM, Maugard CM, Le Page C, Ren F, Lussier C, Novak J, Ge B, Hudson TJ, Tonin PN, Mes-Masson A-M: Discrimination between serous low malignant potential and invasive epithelial ovarian tumors using molecular profiling. Oncogene 2005, 24:4672-4687.
Laboratory: Ouellet, Mes-Masson 2005
Contact information:
Title: Classification of ovarian tumor samples
URL:
PMIDs: PMID unknown
Abstract: A 40 word abstract is available. Use 'abstract' method.
Information is available on: preprocessing
notes:
platform_title:
[Hu6800] Affymetrix Human Full Length HuGeneFL Array
platform_shorttitle:
Affymetrix Hu6800
platform_summary:
hu6800
platform_manufacturer:
Affymetrix
platform_distribution:
commercial
platform_accession:
GPL80
version:
2015-09-22 20:07:22
featureData(eset):
An object of class 'AnnotatedDataFrame'
featureNames: A28102_at AB000114_at ... Z97074_at (6407 total)
varLabels: probeset gene EntrezGene.ID best_probe
varMetadata: labelDescription
assayData: 6407 features, 66 samples
Platform type:
---------------------------
Available sample meta-data:
---------------------------
alt_sample_name:
Ovarian tumor AM053 Ovarian tumor AM122 Ovarian tumor AM124 Ovarian tumor AM125
1 1 1 1
Ovarian tumor AM127 Ovarian tumor AM137 Ovarian tumor AM138 Ovarian tumor AM144
1 1 1 1
Ovarian tumor AM178 Ovarian tumor AM179 Ovarian tumor AM182 Ovarian tumor AM195
1 1 1 1
Ovarian tumor AM196 Ovarian tumor AM198 Ovarian tumor AM200 Ovarian tumor AM201
1 1 1 1
Ovarian tumor AM202 Ovarian tumor AM203 Ovarian tumor AM204 Ovarian tumor AM207
1 1 1 1
Ovarian tumor AM208 Ovarian tumor AM209 Ovarian tumor AM225 Ovarian tumor AM226
1 1 1 1
Ovarian tumor AM228 Ovarian tumor AM233 Ovarian tumor AM250 Ovarian tumor AM252
1 1 1 1
Ovarian tumor AM253 Ovarian tumor AM255 Ovarian tumor AM256 Ovarian tumor AM259
1 1 1 1
Ovarian tumor AM261 Ovarian tumor AM263 Ovarian tumor AM268 Ovarian tumor AM269
1 1 1 1
Ovarian tumor AM287 Ovarian tumor AM288 Ovarian tumor AM289 Ovarian tumor AM290
1 1 1 1
Ovarian tumor AM292 Ovarian tumor AM293 Ovarian tumor AM294 Ovarian tumor AM311
1 1 1 1
Ovarian tumor AM313 Ovarian tumor AM315 Ovarian tumor AM317 Ovarian tumor AM333
1 1 1 1
Ovarian tumor AM335 Ovarian tumor AM339 Ovarian tumor AM341 Ovarian tumor AM344
1 1 1 1
Ovarian tumor AM345 Ovarian tumor AM347 Ovarian tumor AM348 Ovarian tumor AM349
1 1 1 1
Ovarian tumor AM354 Ovarian tumor AM364 Ovarian tumor AM367 Ovarian tumor AM368
1 1 1 1
Ovarian tumor AM381 Ovarian tumor AM382 Ovarian tumor AM398 Ovarian tumor AM429
1 1 1 1
Ovarian tumor AM431 Ovarian tumor AM438
1 1
sample_type:
tumor
66
histological_type:
clearcell endo mix mucinous
11 7 3 1
ser undifferentiated
41 3
primarysite:
ov
66
summarygrade:
high low NA's
40 15 11
grade:
1 2 3 NA's
1 14 40 11
batch:
2000-12-21 2001-05-03 2001-05-29 2001-06-12 2001-09-25 2001-09-26 2001-09-27
1 1 3 3 1 5 8
2002-02-14 2002-04-17 2002-04-18 2002-07-18 2002-07-24 2002-10-20 2002-10-30
4 1 9 7 4 10 5
2002-11-01 2002-11-13
2 2
uncurated_author_metadata:
title: Ovarian tumor AM053///geo_accession: GSM157229///status: Public on Dec 31 2007///submission_date: Jan 22 2007///last_update_date: Feb 25 2008///type: RNA///channel_count: 1///source_name_ch1: epithelian ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tissue: epithelial ovarian tumor, Tumor type: serous, Tumor stage: invasive grade 3///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction of total RNA was performed according to the manufacturer's instructions.///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 15 microg total RNA.///taxid_ch1: 9606///hyb_protocol: 15ug of total RNA was reverse-transcribed with oligo-dT primer containing a T7 RNA polymerase-binding site. An in vitro transcription was performed on this cDNA. DNA from the samples was fragmented in 40 mM Tris acetate, 100 mM potassium acetate, and 30 mM MgCl2 (pH 8.1) at 95C to reduce secondary structures. 15 ug of cRNA were hybridized to an Affymetrix HuGeneFL microarray, washed and stained.///scan_protocol: Scanned with a Hewlett Packard Gene Array Scanner///description: invasive///data_processing: Raw values assigned by MAS 4///platform_id: GPL80///contact_name: Jaroslav,Petr,Novak///contact_email: [email protected], [email protected]///contact_phone: 450-465-1383///contact_fax: 450-465-3033///contact_department: Microarray Platform///contact_institute: McGill University and Genome Quebec Innovation Centre///contact_address: 740, Dr Penfield Avenue///contact_city: Montreal///contact_state: Quebec///contact_zip.postal_code: H3A 1A4///contact_country: Canada///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM157nnn/GSM157229/GSM157229.CEL.gz///data_row_count: 7129
1
title: Ovarian tumor AM122///geo_accession: GSM157231///status: Public on Dec 31 2007///submission_date: Jan 22 2007///last_update_date: Feb 25 2008///type: RNA///channel_count: 1///source_name_ch1: epithelian ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tissue: epithelial ovarian tumor, Tumor type: serous, Tumor stage: invasive grade 3, potentially from extra-ovarian origin///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction of total RNA was performed according to the manufacturer's instructions.///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 15 microg total RNA.///taxid_ch1: 9606///hyb_protocol: 15ug of total RNA was reverse-transcribed with oligo-dT primer containing a T7 RNA polymerase-binding site. An in vitro transcription was performed on this cDNA. DNA from the samples was fragmented in 40 mM Tris acetate, 100 mM potassium acetate, and 30 mM MgCl2 (pH 8.1) at 95C to reduce secondary structures. 15 ug of cRNA were hybridized to an Affymetrix HuGeneFL microarray, washed and stained.///scan_protocol: Scanned with a Hewlett Packard Gene Array Scanner///description: invasive///data_processing: Raw values assigned by MAS 4///platform_id: GPL80///contact_name: Jaroslav,Petr,Novak///contact_email: [email protected], [email protected]///contact_phone: 450-465-1383///contact_fax: 450-465-3033///contact_department: Microarray Platform///contact_institute: McGill University and Genome Quebec Innovation Centre///contact_address: 740, Dr Penfield Avenue///contact_city: Montreal///contact_state: Quebec///contact_zip.postal_code: H3A 1A4///contact_country: Canada///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM157nnn/GSM157231/GSM157231.CEL.gz///data_row_count: 7129
1
title: Ovarian tumor AM124///geo_accession: GSM157232///status: Public on Dec 31 2007///submission_date: Jan 22 2007///last_update_date: Feb 25 2008///type: RNA///channel_count: 1///source_name_ch1: epithelian ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tissue: epithelial ovarian tumor, Tumor type: serous, Tumor stage: invasive grade 3///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction of total RNA was performed according to the manufacturer's instructions.///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 15 microg total RNA.///taxid_ch1: 9606///hyb_protocol: 15ug of total RNA was reverse-transcribed with oligo-dT primer containing a T7 RNA polymerase-binding site. An in vitro transcription was performed on this cDNA. DNA from the samples was fragmented in 40 mM Tris acetate, 100 mM potassium acetate, and 30 mM MgCl2 (pH 8.1) at 95C to reduce secondary structures. 15 ug of cRNA were hybridized to an Affymetrix HuGeneFL microarray, washed and stained.///scan_protocol: Scanned with a Hewlett Packard Gene Array Scanner///description: invasive///data_processing: Raw values assigned by MAS 4///platform_id: GPL80///contact_name: Jaroslav,Petr,Novak///contact_email: [email protected], [email protected]///contact_phone: 450-465-1383///contact_fax: 450-465-3033///contact_department: Microarray Platform///contact_institute: McGill University and Genome Quebec Innovation Centre///contact_address: 740, Dr Penfield Avenue///contact_city: Montreal///contact_state: Quebec///contact_zip.postal_code: H3A 1A4///contact_country: Canada///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM157nnn/GSM157232/GSM157232.CEL.gz///data_row_count: 7129
1
title: Ovarian tumor AM125///geo_accession: GSM157233///status: Public on Dec 31 2007///submission_date: Jan 22 2007///last_update_date: Feb 25 2008///type: RNA///channel_count: 1///source_name_ch1: epithelian ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tissue: epithelial ovarian tumor, Tumor type: serous, Tumor stage: invasive grade 2///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction of total RNA was performed according to the manufacturer's instructions.///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 15 microg total RNA.///taxid_ch1: 9606///hyb_protocol: 15ug of total RNA was reverse-transcribed with oligo-dT primer containing a T7 RNA polymerase-binding site. An in vitro transcription was performed on this cDNA. DNA from the samples was fragmented in 40 mM Tris acetate, 100 mM potassium acetate, and 30 mM MgCl2 (pH 8.1) at 95C to reduce secondary structures. 15 ug of cRNA were hybridized to an Affymetrix HuGeneFL microarray, washed and stained.///scan_protocol: Scanned with a Hewlett Packard Gene Array Scanner///description: invasive///data_processing: Raw values assigned by MAS 4///platform_id: GPL80///contact_name: Jaroslav,Petr,Novak///contact_email: [email protected], [email protected]///contact_phone: 450-465-1383///contact_fax: 450-465-3033///contact_department: Microarray Platform///contact_institute: McGill University and Genome Quebec Innovation Centre///contact_address: 740, Dr Penfield Avenue///contact_city: Montreal///contact_state: Quebec///contact_zip.postal_code: H3A 1A4///contact_country: Canada///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM157nnn/GSM157233/GSM157233.CEL.gz///data_row_count: 7129
1
title: Ovarian tumor AM127///geo_accession: GSM157234///status: Public on Dec 31 2007///submission_date: Jan 22 2007///last_update_date: Feb 25 2008///type: RNA///channel_count: 1///source_name_ch1: epithelian ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tissue: epithelial ovarian tumor, Tumor type: serous, Tumor stage: invasive grade 3, post-chemotherapy sample///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction of total RNA was performed according to the manufacturer's instructions.///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 15 microg total RNA.///taxid_ch1: 9606///hyb_protocol: 15ug of total RNA was reverse-transcribed with oligo-dT primer containing a T7 RNA polymerase-binding site. An in vitro transcription was performed on this cDNA. DNA from the samples was fragmented in 40 mM Tris acetate, 100 mM potassium acetate, and 30 mM MgCl2 (pH 8.1) at 95C to reduce secondary structures. 15 ug of cRNA were hybridized to an Affymetrix HuGeneFL microarray, washed and stained.///scan_protocol: Scanned with a Hewlett Packard Gene Array Scanner///description: invasive///data_processing: Raw values assigned by MAS 4///platform_id: GPL80///contact_name: Jaroslav,Petr,Novak///contact_email: [email protected], [email protected]///contact_phone: 450-465-1383///contact_fax: 450-465-3033///contact_department: Microarray Platform///contact_institute: McGill University and Genome Quebec Innovation Centre///contact_address: 740, Dr Penfield Avenue///contact_city: Montreal///contact_state: Quebec///contact_zip.postal_code: H3A 1A4///contact_country: Canada///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM157nnn/GSM157234/GSM157234.CEL.gz///data_row_count: 7129
1
title: Ovarian tumor AM137///geo_accession: GSM157238///status: Public on Dec 31 2007///submission_date: Jan 22 2007///last_update_date: Feb 25 2008///type: RNA///channel_count: 1///source_name_ch1: epithelian ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tissue: epithelial ovarian tumor, Tumor type: serous, Tumor stage: borderline///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction of total RNA was performed according to the manufacturer's instructions.///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 15 microg total RNA.///taxid_ch1: 9606///hyb_protocol: 15ug of total RNA was reverse-transcribed with oligo-dT primer containing a T7 RNA polymerase-binding site. An in vitro transcription was performed on this cDNA. DNA from the samples was fragmented in 40 mM Tris acetate, 100 mM potassium acetate, and 30 mM MgCl2 (pH 8.1) at 95C to reduce secondary structures. 15 ug of cRNA were hybridized to an Affymetrix HuGeneFL microarray, washed and stained.///scan_protocol: Scanned with a Hewlett Packard Gene Array Scanner///description: low malignant potential///data_processing: Raw values assigned by MAS 4///platform_id: GPL80///contact_name: Jaroslav,Petr,Novak///contact_email: [email protected], [email protected]///contact_phone: 450-465-1383///contact_fax: 450-465-3033///contact_department: Microarray Platform///contact_institute: McGill University and Genome Quebec Innovation Centre///contact_address: 740, Dr Penfield Avenue///contact_city: Montreal///contact_state: Quebec///contact_zip.postal_code: H3A 1A4///contact_country: Canada///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM157nnn/GSM157238/GSM157238.CEL.gz///data_row_count: 7129
1
title: Ovarian tumor AM138///geo_accession: GSM157239///status: Public on Dec 31 2007///submission_date: Jan 22 2007///last_update_date: Feb 25 2008///type: RNA///channel_count: 1///source_name_ch1: epithelian ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tissue: epithelial ovarian tumor, Tumor type: serous, Tumor stage: borderline///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction of total RNA was performed according to the manufacturer's instructions.///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 15 microg total RNA.///taxid_ch1: 9606///hyb_protocol: 15ug of total RNA was reverse-transcribed with oligo-dT primer containing a T7 RNA polymerase-binding site. An in vitro transcription was performed on this cDNA. DNA from the samples was fragmented in 40 mM Tris acetate, 100 mM potassium acetate, and 30 mM MgCl2 (pH 8.1) at 95C to reduce secondary structures. 15 ug of cRNA were hybridized to an Affymetrix HuGeneFL microarray, washed and stained.///scan_protocol: Scanned with a Hewlett Packard Gene Array Scanner///description: low malignant potential///data_processing: Raw values assigned by MAS 4///platform_id: GPL80///contact_name: Jaroslav,Petr,Novak///contact_email: [email protected], [email protected]///contact_phone: 450-465-1383///contact_fax: 450-465-3033///contact_department: Microarray Platform///contact_institute: McGill University and Genome Quebec Innovation Centre///contact_address: 740, Dr Penfield Avenue///contact_city: Montreal///contact_state: Quebec///contact_zip.postal_code: H3A 1A4///contact_country: Canada///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM157nnn/GSM157239/GSM157239.CEL.gz///data_row_count: 7129
1
title: Ovarian tumor AM144///geo_accession: GSM157240///status: Public on Dec 31 2007///submission_date: Jan 22 2007///last_update_date: Feb 25 2008///type: RNA///channel_count: 1///source_name_ch1: epithelian ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tissue: epithelial ovarian tumor, Tumor type: endometrioid, Tumor stage: invasive grade 3///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction of total RNA was performed according to the manufacturer's instructions.///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 15 microg total RNA.///taxid_ch1: 9606///hyb_protocol: 15ug of total RNA was reverse-transcribed with oligo-dT primer containing a T7 RNA polymerase-binding site. An in vitro transcription was performed on this cDNA. DNA from the samples was fragmented in 40 mM Tris acetate, 100 mM potassium acetate, and 30 mM MgCl2 (pH 8.1) at 95C to reduce secondary structures. 15 ug of cRNA were hybridized to an Affymetrix HuGeneFL microarray, washed and stained.///scan_protocol: Scanned with a Hewlett Packard Gene Array Scanner///description: invasive///data_processing: Raw values assigned by MAS 4///platform_id: GPL80///contact_name: Jaroslav,Petr,Novak///contact_email: [email protected], [email protected]///contact_phone: 450-465-1383///contact_fax: 450-465-3033///contact_department: Microarray Platform///contact_institute: McGill University and Genome Quebec Innovation Centre///contact_address: 740, Dr Penfield Avenue///contact_city: Montreal///contact_state: Quebec///contact_zip.postal_code: H3A 1A4///contact_country: Canada///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM157nnn/GSM157240/GSM157240.CEL.gz///data_row_count: 7129
1
title: Ovarian tumor AM178///geo_accession: GSM157241///status: Public on Dec 31 2007///submission_date: Jan 22 2007///last_update_date: Feb 25 2008///type: RNA///channel_count: 1///source_name_ch1: epithelian ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tissue: epithelial ovarian tumor, Tumor type: serous, Tumor stage: invasive grade 3///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction of total RNA was performed according to the manufacturer's instructions.///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 15 microg total RNA.///taxid_ch1: 9606///hyb_protocol: 15ug of total RNA was reverse-transcribed with oligo-dT primer containing a T7 RNA polymerase-binding site. An in vitro transcription was performed on this cDNA. DNA from the samples was fragmented in 40 mM Tris acetate, 100 mM potassium acetate, and 30 mM MgCl2 (pH 8.1) at 95C to reduce secondary structures. 15 ug of cRNA were hybridized to an Affymetrix HuGeneFL microarray, washed and stained.///scan_protocol: Scanned with a Hewlett Packard Gene Array Scanner///description: invasive///data_processing: Raw values assigned by MAS 4///platform_id: GPL80///contact_name: Jaroslav,Petr,Novak///contact_email: [email protected], [email protected]///contact_phone: 450-465-1383///contact_fax: 450-465-3033///contact_department: Microarray Platform///contact_institute: McGill University and Genome Quebec Innovation Centre///contact_address: 740, Dr Penfield Avenue///contact_city: Montreal///contact_state: Quebec///contact_zip.postal_code: H3A 1A4///contact_country: Canada///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM157nnn/GSM157241/GSM157241.CEL.gz///data_row_count: 7129
1
title: Ovarian tumor AM179///geo_accession: GSM157242///status: Public on Dec 31 2007///submission_date: Jan 22 2007///last_update_date: Feb 25 2008///type: RNA///channel_count: 1///source_name_ch1: epithelian ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tissue: epithelial ovarian tumor, Tumor type: serous, Tumor stage: borderline///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction of total RNA was performed according to the manufacturer's instructions.///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 15 microg total RNA.///taxid_ch1: 9606///hyb_protocol: 15ug of total RNA was reverse-transcribed with oligo-dT primer containing a T7 RNA polymerase-binding site. An in vitro transcription was performed on this cDNA. DNA from the samples was fragmented in 40 mM Tris acetate, 100 mM potassium acetate, and 30 mM MgCl2 (pH 8.1) at 95C to reduce secondary structures. 15 ug of cRNA were hybridized to an Affymetrix HuGeneFL microarray, washed and stained.///scan_protocol: Scanned with a Hewlett Packard Gene Array Scanner///description: low malignant potential///data_processing: Raw values assigned by MAS 4///platform_id: GPL80///contact_name: Jaroslav,Petr,Novak///contact_email: [email protected], [email protected]///contact_phone: 450-465-1383///contact_fax: 450-465-3033///contact_department: Microarray Platform///contact_institute: McGill University and Genome Quebec Innovation Centre///contact_address: 740, Dr Penfield Avenue///contact_city: Montreal///contact_state: Quebec///contact_zip.postal_code: H3A 1A4///contact_country: Canada///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM157nnn/GSM157242/GSM157242.CEL.gz///data_row_count: 7129
1
title: Ovarian tumor AM182///geo_accession: GSM157243///status: Public on Dec 31 2007///submission_date: Jan 22 2007///last_update_date: Feb 25 2008///type: RNA///channel_count: 1///source_name_ch1: epithelian ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tissue: epithelial ovarian tumor, Tumor type: endometrioid, Tumor stage: invasive grade 3///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction of total RNA was performed according to the manufacturer's instructions.///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 15 microg total RNA.///taxid_ch1: 9606///hyb_protocol: 15ug of total RNA was reverse-transcribed with oligo-dT primer containing a T7 RNA polymerase-binding site. An in vitro transcription was performed on this cDNA. DNA from the samples was fragmented in 40 mM Tris acetate, 100 mM potassium acetate, and 30 mM MgCl2 (pH 8.1) at 95C to reduce secondary structures. 15 ug of cRNA were hybridized to an Affymetrix HuGeneFL microarray, washed and stained.///scan_protocol: Scanned with a Hewlett Packard Gene Array Scanner///description: invasive///data_processing: Raw values assigned by MAS 4///platform_id: GPL80///contact_name: Jaroslav,Petr,Novak///contact_email: [email protected], [email protected]///contact_phone: 450-465-1383///contact_fax: 450-465-3033///contact_department: Microarray Platform///contact_institute: McGill University and Genome Quebec Innovation Centre///contact_address: 740, Dr Penfield Avenue///contact_city: Montreal///contact_state: Quebec///contact_zip.postal_code: H3A 1A4///contact_country: Canada///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM157nnn/GSM157243/GSM157243.CEL.gz///data_row_count: 7129
1
title: Ovarian tumor AM195///geo_accession: GSM157244///status: Public on Dec 31 2007///submission_date: Jan 22 2007///last_update_date: Feb 25 2008///type: RNA///channel_count: 1///source_name_ch1: epithelian ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tissue: epithelial ovarian tumor, Tumor type: serous, Tumor stage: invasive grade 2///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction of total RNA was performed according to the manufacturer's instructions.///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 15 microg total RNA.///taxid_ch1: 9606///hyb_protocol: 15ug of total RNA was reverse-transcribed with oligo-dT primer containing a T7 RNA polymerase-binding site. An in vitro transcription was performed on this cDNA. DNA from the samples was fragmented in 40 mM Tris acetate, 100 mM potassium acetate, and 30 mM MgCl2 (pH 8.1) at 95C to reduce secondary structures. 15 ug of cRNA were hybridized to an Affymetrix HuGeneFL microarray, washed and stained.///scan_protocol: Scanned with a Hewlett Packard Gene Array Scanner///description: invasive///data_processing: Raw values assigned by MAS 4///platform_id: GPL80///contact_name: Jaroslav,Petr,Novak///contact_email: [email protected], [email protected]///contact_phone: 450-465-1383///contact_fax: 450-465-3033///contact_department: Microarray Platform///contact_institute: McGill University and Genome Quebec Innovation Centre///contact_address: 740, Dr Penfield Avenue///contact_city: Montreal///contact_state: Quebec///contact_zip.postal_code: H3A 1A4///contact_country: Canada///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM157nnn/GSM157244/GSM157244.CEL.gz///data_row_count: 7129
1
title: Ovarian tumor AM196///geo_accession: GSM157245///status: Public on Dec 31 2007///submission_date: Jan 22 2007///last_update_date: Feb 25 2008///type: RNA///channel_count: 1///source_name_ch1: epithelian ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tissue: epithelial ovarian tumor, Tumor type: serous, Tumor stage: borderline///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction of total RNA was performed according to the manufacturer's instructions.///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 15 microg total RNA.///taxid_ch1: 9606///hyb_protocol: 15ug of total RNA was reverse-transcribed with oligo-dT primer containing a T7 RNA polymerase-binding site. An in vitro transcription was performed on this cDNA. DNA from the samples was fragmented in 40 mM Tris acetate, 100 mM potassium acetate, and 30 mM MgCl2 (pH 8.1) at 95C to reduce secondary structures. 15 ug of cRNA were hybridized to an Affymetrix HuGeneFL microarray, washed and stained.///scan_protocol: Scanned with a Hewlett Packard Gene Array Scanner///description: low malignant potential///data_processing: Raw values assigned by MAS 4///platform_id: GPL80///contact_name: Jaroslav,Petr,Novak///contact_email: [email protected], [email protected]///contact_phone: 450-465-1383///contact_fax: 450-465-3033///contact_department: Microarray Platform///contact_institute: McGill University and Genome Quebec Innovation Centre///contact_address: 740, Dr Penfield Avenue///contact_city: Montreal///contact_state: Quebec///contact_zip.postal_code: H3A 1A4///contact_country: Canada///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM157nnn/GSM157245/GSM157245.CEL.gz///data_row_count: 7129
1
title: Ovarian tumor AM198///geo_accession: GSM157246///status: Public on Dec 31 2007///submission_date: Jan 22 2007///last_update_date: Feb 25 2008///type: RNA///channel_count: 1///source_name_ch1: epithelian ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tissue: epithelial ovarian tumor, Tumor type: clear cell, Tumor stage: invasive grade 2///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction of total RNA was performed according to the manufacturer's instructions.///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 15 microg total RNA.///taxid_ch1: 9606///hyb_protocol: 15ug of total RNA was reverse-transcribed with oligo-dT primer containing a T7 RNA polymerase-binding site. An in vitro transcription was performed on this cDNA. DNA from the samples was fragmented in 40 mM Tris acetate, 100 mM potassium acetate, and 30 mM MgCl2 (pH 8.1) at 95C to reduce secondary structures. 15 ug of cRNA were hybridized to an Affymetrix HuGeneFL microarray, washed and stained.///scan_protocol: Scanned with a Hewlett Packard Gene Array Scanner///description: invasive///data_processing: Raw values assigned by MAS 4///platform_id: GPL80///contact_name: Jaroslav,Petr,Novak///contact_email: [email protected], [email protected]///contact_phone: 450-465-1383///contact_fax: 450-465-3033///contact_department: Microarray Platform///contact_institute: McGill University and Genome Quebec Innovation Centre///contact_address: 740, Dr Penfield Avenue///contact_city: Montreal///contact_state: Quebec///contact_zip.postal_code: H3A 1A4///contact_country: Canada///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM157nnn/GSM157246/GSM157246.CEL.gz///data_row_count: 7129
1
title: Ovarian tumor AM200///geo_accession: GSM157247///status: Public on Dec 31 2007///submission_date: Jan 22 2007///last_update_date: Feb 25 2008///type: RNA///channel_count: 1///source_name_ch1: epithelian ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tissue: epithelial ovarian tumor, Tumor type: endometrioid, Tumor stage: invasive grade 3///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction of total RNA was performed according to the manufacturer's instructions.///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 15 microg total RNA.///taxid_ch1: 9606///hyb_protocol: 15ug of total RNA was reverse-transcribed with oligo-dT primer containing a T7 RNA polymerase-binding site. An in vitro transcription was performed on this cDNA. DNA from the samples was fragmented in 40 mM Tris acetate, 100 mM potassium acetate, and 30 mM MgCl2 (pH 8.1) at 95C to reduce secondary structures. 15 ug of cRNA were hybridized to an Affymetrix HuGeneFL microarray, washed and stained.///scan_protocol: Scanned with a Hewlett Packard Gene Array Scanner///description: invasive///data_processing: Raw values assigned by MAS 4///platform_id: GPL80///contact_name: Jaroslav,Petr,Novak///contact_email: [email protected], [email protected]///contact_phone: 450-465-1383///contact_fax: 450-465-3033///contact_department: Microarray Platform///contact_institute: McGill University and Genome Quebec Innovation Centre///contact_address: 740, Dr Penfield Avenue///contact_city: Montreal///contact_state: Quebec///contact_zip.postal_code: H3A 1A4///contact_country: Canada///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM157nnn/GSM157247/GSM157247.CEL.gz///data_row_count: 7129
1
title: Ovarian tumor AM201///geo_accession: GSM157248///status: Public on Dec 31 2007///submission_date: Jan 22 2007///last_update_date: Feb 25 2008///type: RNA///channel_count: 1///source_name_ch1: epithelian ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tissue: epithelial ovarian tumor, Tumor type: clear cell, Tumor stage: invasive grade 3///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction of total RNA was performed according to the manufacturer's instructions.///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 15 microg total RNA.///taxid_ch1: 9606///hyb_protocol: 15ug of total RNA was reverse-transcribed with oligo-dT primer containing a T7 RNA polymerase-binding site. An in vitro transcription was performed on this cDNA. DNA from the samples was fragmented in 40 mM Tris acetate, 100 mM potassium acetate, and 30 mM MgCl2 (pH 8.1) at 95C to reduce secondary structures. 15 ug of cRNA were hybridized to an Affymetrix HuGeneFL microarray, washed and stained.///scan_protocol: Scanned with a Hewlett Packard Gene Array Scanner///description: invasive///data_processing: Raw values assigned by MAS 4///platform_id: GPL80///contact_name: Jaroslav,Petr,Novak///contact_email: [email protected], [email protected]///contact_phone: 450-465-1383///contact_fax: 450-465-3033///contact_department: Microarray Platform///contact_institute: McGill University and Genome Quebec Innovation Centre///contact_address: 740, Dr Penfield Avenue///contact_city: Montreal///contact_state: Quebec///contact_zip.postal_code: H3A 1A4///contact_country: Canada///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM157nnn/GSM157248/GSM157248.CEL.gz///data_row_count: 7129
1
title: Ovarian tumor AM202///geo_accession: GSM157249///status: Public on Dec 31 2007///submission_date: Jan 22 2007///last_update_date: Feb 25 2008///type: RNA///channel_count: 1///source_name_ch1: epithelian ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tissue: epithelial ovarian tumor, Tumor type: clear cell, Tumor stage: invasive grade 3///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction of total RNA was performed according to the manufacturer's instructions.///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 15 microg total RNA.///taxid_ch1: 9606///hyb_protocol: 15ug of total RNA was reverse-transcribed with oligo-dT primer containing a T7 RNA polymerase-binding site. An in vitro transcription was performed on this cDNA. DNA from the samples was fragmented in 40 mM Tris acetate, 100 mM potassium acetate, and 30 mM MgCl2 (pH 8.1) at 95C to reduce secondary structures. 15 ug of cRNA were hybridized to an Affymetrix HuGeneFL microarray, washed and stained.///scan_protocol: Scanned with a Hewlett Packard Gene Array Scanner///description: invasive///data_processing: Raw values assigned by MAS 4///platform_id: GPL80///contact_name: Jaroslav,Petr,Novak///contact_email: [email protected], [email protected]///contact_phone: 450-465-1383///contact_fax: 450-465-3033///contact_department: Microarray Platform///contact_institute: McGill University and Genome Quebec Innovation Centre///contact_address: 740, Dr Penfield Avenue///contact_city: Montreal///contact_state: Quebec///contact_zip.postal_code: H3A 1A4///contact_country: Canada///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM157nnn/GSM157249/GSM157249.CEL.gz///data_row_count: 7129
1
title: Ovarian tumor AM203///geo_accession: GSM157250///status: Public on Dec 31 2007///submission_date: Jan 22 2007///last_update_date: Feb 25 2008///type: RNA///channel_count: 1///source_name_ch1: epithelian ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tissue: epithelial ovarian tumor, Tumor type: endometrioid, Tumor stage: invasive grade 3///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction of total RNA was performed according to the manufacturer's instructions.///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 15 microg total RNA.///taxid_ch1: 9606///hyb_protocol: 15ug of total RNA was reverse-transcribed with oligo-dT primer containing a T7 RNA polymerase-binding site. An in vitro transcription was performed on this cDNA. DNA from the samples was fragmented in 40 mM Tris acetate, 100 mM potassium acetate, and 30 mM MgCl2 (pH 8.1) at 95C to reduce secondary structures. 15 ug of cRNA were hybridized to an Affymetrix HuGeneFL microarray, washed and stained.///scan_protocol: Scanned with a Hewlett Packard Gene Array Scanner///description: invasive///data_processing: Raw values assigned by MAS 4///platform_id: GPL80///contact_name: Jaroslav,Petr,Novak///contact_email: [email protected], [email protected]///contact_phone: 450-465-1383///contact_fax: 450-465-3033///contact_department: Microarray Platform///contact_institute: McGill University and Genome Quebec Innovation Centre///contact_address: 740, Dr Penfield Avenue///contact_city: Montreal///contact_state: Quebec///contact_zip.postal_code: H3A 1A4///contact_country: Canada///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM157nnn/GSM157250/GSM157250.CEL.gz///data_row_count: 7129
1
title: Ovarian tumor AM204///geo_accession: GSM157251///status: Public on Dec 31 2007///submission_date: Jan 22 2007///last_update_date: Feb 25 2008///type: RNA///channel_count: 1///source_name_ch1: epithelian ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tissue: epithelial ovarian tumor, Tumor type: clear cell, Tumor stage: invasive grade 2///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction of total RNA was performed according to the manufacturer's instructions.///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 15 microg total RNA.///taxid_ch1: 9606///hyb_protocol: 15ug of total RNA was reverse-transcribed with oligo-dT primer containing a T7 RNA polymerase-binding site. An in vitro transcription was performed on this cDNA. DNA from the samples was fragmented in 40 mM Tris acetate, 100 mM potassium acetate, and 30 mM MgCl2 (pH 8.1) at 95C to reduce secondary structures. 15 ug of cRNA were hybridized to an Affymetrix HuGeneFL microarray, washed and stained.///scan_protocol: Scanned with a Hewlett Packard Gene Array Scanner///description: invasive///data_processing: Raw values assigned by MAS 4///platform_id: GPL80///contact_name: Jaroslav,Petr,Novak///contact_email: [email protected], [email protected]///contact_phone: 450-465-1383///contact_fax: 450-465-3033///contact_department: Microarray Platform///contact_institute: McGill University and Genome Quebec Innovation Centre///contact_address: 740, Dr Penfield Avenue///contact_city: Montreal///contact_state: Quebec///contact_zip.postal_code: H3A 1A4///contact_country: Canada///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM157nnn/GSM157251/GSM157251.CEL.gz///data_row_count: 7129
1
title: Ovarian tumor AM207///geo_accession: GSM157252///status: Public on Dec 31 2007///submission_date: Jan 22 2007///last_update_date: Feb 25 2008///type: RNA///channel_count: 1///source_name_ch1: epithelian ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tissue: epithelial ovarian tumor, Tumor type: clear cell, Tumor stage: invasive grade 3///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction of total RNA was performed according to the manufacturer's instructions.///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 15 microg total RNA.///taxid_ch1: 9606///hyb_protocol: 15ug of total RNA was reverse-transcribed with oligo-dT primer containing a T7 RNA polymerase-binding site. An in vitro transcription was performed on this cDNA. DNA from the samples was fragmented in 40 mM Tris acetate, 100 mM potassium acetate, and 30 mM MgCl2 (pH 8.1) at 95C to reduce secondary structures. 15 ug of cRNA were hybridized to an Affymetrix HuGeneFL microarray, washed and stained.///scan_protocol: Scanned with a Hewlett Packard Gene Array Scanner///description: invasive///data_processing: Raw values assigned by MAS 4///platform_id: GPL80///contact_name: Jaroslav,Petr,Novak///contact_email: [email protected], [email protected]///contact_phone: 450-465-1383///contact_fax: 450-465-3033///contact_department: Microarray Platform///contact_institute: McGill University and Genome Quebec Innovation Centre///contact_address: 740, Dr Penfield Avenue///contact_city: Montreal///contact_state: Quebec///contact_zip.postal_code: H3A 1A4///contact_country: Canada///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM157nnn/GSM157252/GSM157252.CEL.gz///data_row_count: 7129
1
title: Ovarian tumor AM208///geo_accession: GSM157253///status: Public on Dec 31 2007///submission_date: Jan 22 2007///last_update_date: Feb 25 2008///type: RNA///channel_count: 1///source_name_ch1: epithelian ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tissue: epithelial ovarian tumor, Tumor type: clear cell, Tumor stage: invasive grade 2///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction of total RNA was performed according to the manufacturer's instructions.///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 15 microg total RNA.///taxid_ch1: 9606///hyb_protocol: 15ug of total RNA was reverse-transcribed with oligo-dT primer containing a T7 RNA polymerase-binding site. An in vitro transcription was performed on this cDNA. DNA from the samples was fragmented in 40 mM Tris acetate, 100 mM potassium acetate, and 30 mM MgCl2 (pH 8.1) at 95C to reduce secondary structures. 15 ug of cRNA were hybridized to an Affymetrix HuGeneFL microarray, washed and stained.///scan_protocol: Scanned with a Hewlett Packard Gene Array Scanner///description: invasive///data_processing: Raw values assigned by MAS 4///platform_id: GPL80///contact_name: Jaroslav,Petr,Novak///contact_email: [email protected], [email protected]///contact_phone: 450-465-1383///contact_fax: 450-465-3033///contact_department: Microarray Platform///contact_institute: McGill University and Genome Quebec Innovation Centre///contact_address: 740, Dr Penfield Avenue///contact_city: Montreal///contact_state: Quebec///contact_zip.postal_code: H3A 1A4///contact_country: Canada///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM157nnn/GSM157253/GSM157253.CEL.gz///data_row_count: 7129
1
title: Ovarian tumor AM209///geo_accession: GSM157254///status: Public on Dec 31 2007///submission_date: Jan 22 2007///last_update_date: Feb 25 2008///type: RNA///channel_count: 1///source_name_ch1: epithelian ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tissue: epithelial ovarian tumor, Tumor type: clear cell, Tumor stage: invasive grade 3///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction of total RNA was performed according to the manufacturer's instructions.///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 15 microg total RNA.///taxid_ch1: 9606///hyb_protocol: 15ug of total RNA was reverse-transcribed with oligo-dT primer containing a T7 RNA polymerase-binding site. An in vitro transcription was performed on this cDNA. DNA from the samples was fragmented in 40 mM Tris acetate, 100 mM potassium acetate, and 30 mM MgCl2 (pH 8.1) at 95C to reduce secondary structures. 15 ug of cRNA were hybridized to an Affymetrix HuGeneFL microarray, washed and stained.///scan_protocol: Scanned with a Hewlett Packard Gene Array Scanner///description: invasive///data_processing: Raw values assigned by MAS 4///platform_id: GPL80///contact_name: Jaroslav,Petr,Novak///contact_email: [email protected], [email protected]///contact_phone: 450-465-1383///contact_fax: 450-465-3033///contact_department: Microarray Platform///contact_institute: McGill University and Genome Quebec Innovation Centre///contact_address: 740, Dr Penfield Avenue///contact_city: Montreal///contact_state: Quebec///contact_zip.postal_code: H3A 1A4///contact_country: Canada///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM157nnn/GSM157254/GSM157254.CEL.gz///data_row_count: 7129
1
title: Ovarian tumor AM225///geo_accession: GSM157255///status: Public on Dec 31 2007///submission_date: Jan 22 2007///last_update_date: Feb 25 2008///type: RNA///channel_count: 1///source_name_ch1: epithelian ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tissue: epithelial ovarian tumor, Tumor type: serous, Tumor stage: benign///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction of total RNA was performed according to the manufacturer's instructions.///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 15 microg total RNA.///taxid_ch1: 9606///hyb_protocol: 15ug of total RNA was reverse-transcribed with oligo-dT primer containing a T7 RNA polymerase-binding site. An in vitro transcription was performed on this cDNA. DNA from the samples was fragmented in 40 mM Tris acetate, 100 mM potassium acetate, and 30 mM MgCl2 (pH 8.1) at 95C to reduce secondary structures. 15 ug of cRNA were hybridized to an Affymetrix HuGeneFL microarray, washed and stained.///scan_protocol: Scanned with a Hewlett Packard Gene Array Scanner///description: low malignant potential///data_processing: Raw values assigned by MAS 4///platform_id: GPL80///contact_name: Jaroslav,Petr,Novak///contact_email: [email protected], [email protected]///contact_phone: 450-465-1383///contact_fax: 450-465-3033///contact_department: Microarray Platform///contact_institute: McGill University and Genome Quebec Innovation Centre///contact_address: 740, Dr Penfield Avenue///contact_city: Montreal///contact_state: Quebec///contact_zip.postal_code: H3A 1A4///contact_country: Canada///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM157nnn/GSM157255/GSM157255.CEL.gz///data_row_count: 7129
1
title: Ovarian tumor AM226///geo_accession: GSM157256///status: Public on Dec 31 2007///submission_date: Jan 22 2007///last_update_date: Feb 25 2008///type: RNA///channel_count: 1///source_name_ch1: epithelian ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tissue: epithelial ovarian tumor, Tumor type: serous, Tumor stage: benign///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction of total RNA was performed according to the manufacturer's instructions.///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 15 microg total RNA.///taxid_ch1: 9606///hyb_protocol: 15ug of total RNA was reverse-transcribed with oligo-dT primer containing a T7 RNA polymerase-binding site. An in vitro transcription was performed on this cDNA. DNA from the samples was fragmented in 40 mM Tris acetate, 100 mM potassium acetate, and 30 mM MgCl2 (pH 8.1) at 95C to reduce secondary structures. 15 ug of cRNA were hybridized to an Affymetrix HuGeneFL microarray, washed and stained.///scan_protocol: Scanned with a Hewlett Packard Gene Array Scanner///description: low malignant potential///data_processing: Raw values assigned by MAS 4///platform_id: GPL80///contact_name: Jaroslav,Petr,Novak///contact_email: [email protected], [email protected]///contact_phone: 450-465-1383///contact_fax: 450-465-3033///contact_department: Microarray Platform///contact_institute: McGill University and Genome Quebec Innovation Centre///contact_address: 740, Dr Penfield Avenue///contact_city: Montreal///contact_state: Quebec///contact_zip.postal_code: H3A 1A4///contact_country: Canada///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM157nnn/GSM157256/GSM157256.CEL.gz///data_row_count: 7129
1
title: Ovarian tumor AM228///geo_accession: GSM157257///status: Public on Dec 31 2007///submission_date: Jan 22 2007///last_update_date: Feb 25 2008///type: RNA///channel_count: 1///source_name_ch1: epithelian ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tissue: epithelial ovarian tumor, Tumor type: serous, Tumor stage: benign///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction of total RNA was performed according to the manufacturer's instructions.///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 15 microg total RNA.///taxid_ch1: 9606///hyb_protocol: 15ug of total RNA was reverse-transcribed with oligo-dT primer containing a T7 RNA polymerase-binding site. An in vitro transcription was performed on this cDNA. DNA from the samples was fragmented in 40 mM Tris acetate, 100 mM potassium acetate, and 30 mM MgCl2 (pH 8.1) at 95C to reduce secondary structures. 15 ug of cRNA were hybridized to an Affymetrix HuGeneFL microarray, washed and stained.///scan_protocol: Scanned with a Hewlett Packard Gene Array Scanner///description: low malignant potential///data_processing: Raw values assigned by MAS 4///platform_id: GPL80///contact_name: Jaroslav,Petr,Novak///contact_email: [email protected], [email protected]///contact_phone: 450-465-1383///contact_fax: 450-465-3033///contact_department: Microarray Platform///contact_institute: McGill University and Genome Quebec Innovation Centre///contact_address: 740, Dr Penfield Avenue///contact_city: Montreal///contact_state: Quebec///contact_zip.postal_code: H3A 1A4///contact_country: Canada///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM157nnn/GSM157257/GSM157257.CEL.gz///data_row_count: 7129
1
title: Ovarian tumor AM233///geo_accession: GSM157258///status: Public on Dec 31 2007///submission_date: Jan 22 2007///last_update_date: Feb 25 2008///type: RNA///channel_count: 1///source_name_ch1: epithelian ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tissue: epithelial ovarian tumor, Tumor type: serous, Tumor stage: benign///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction of total RNA was performed according to the manufacturer's instructions.///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 15 microg total RNA.///taxid_ch1: 9606///hyb_protocol: 15ug of total RNA was reverse-transcribed with oligo-dT primer containing a T7 RNA polymerase-binding site. An in vitro transcription was performed on this cDNA. DNA from the samples was fragmented in 40 mM Tris acetate, 100 mM potassium acetate, and 30 mM MgCl2 (pH 8.1) at 95C to reduce secondary structures. 15 ug of cRNA were hybridized to an Affymetrix HuGeneFL microarray, washed and stained.///scan_protocol: Scanned with a Hewlett Packard Gene Array Scanner///description: low malignant potential///data_processing: Raw values assigned by MAS 4///platform_id: GPL80///contact_name: Jaroslav,Petr,Novak///contact_email: [email protected], [email protected]///contact_phone: 450-465-1383///contact_fax: 450-465-3033///contact_department: Microarray Platform///contact_institute: McGill University and Genome Quebec Innovation Centre///contact_address: 740, Dr Penfield Avenue///contact_city: Montreal///contact_state: Quebec///contact_zip.postal_code: H3A 1A4///contact_country: Canada///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM157nnn/GSM157258/GSM157258.CEL.gz///data_row_count: 7129
1
title: Ovarian tumor AM250///geo_accession: GSM157259///status: Public on Dec 31 2007///submission_date: Jan 22 2007///last_update_date: Feb 25 2008///type: RNA///channel_count: 1///source_name_ch1: epithelian ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tissue: epithelial ovarian tumor, Tumor type: mixed, Tumor stage: invasive grade 3///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction of total RNA was performed according to the manufacturer's instructions.///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 15 microg total RNA.///taxid_ch1: 9606///hyb_protocol: 15ug of total RNA was reverse-transcribed with oligo-dT primer containing a T7 RNA polymerase-binding site. An in vitro transcription was performed on this cDNA. DNA from the samples was fragmented in 40 mM Tris acetate, 100 mM potassium acetate, and 30 mM MgCl2 (pH 8.1) at 95C to reduce secondary structures. 15 ug of cRNA were hybridized to an Affymetrix HuGeneFL microarray, washed and stained.///scan_protocol: Scanned with a Hewlett Packard Gene Array Scanner///description: invasive///data_processing: Raw values assigned by MAS 4///platform_id: GPL80///contact_name: Jaroslav,Petr,Novak///contact_email: [email protected], [email protected]///contact_phone: 450-465-1383///contact_fax: 450-465-3033///contact_department: Microarray Platform///contact_institute: McGill University and Genome Quebec Innovation Centre///contact_address: 740, Dr Penfield Avenue///contact_city: Montreal///contact_state: Quebec///contact_zip.postal_code: H3A 1A4///contact_country: Canada///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM157nnn/GSM157259/GSM157259.CEL.gz///data_row_count: 7129
1
title: Ovarian tumor AM252///geo_accession: GSM157260///status: Public on Dec 31 2007///submission_date: Jan 22 2007///last_update_date: Feb 25 2008///type: RNA///channel_count: 1///source_name_ch1: epithelian ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tissue: epithelial ovarian tumor, Tumor type: endometrioid, Tumor stage: invasive grade 2///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction of total RNA was performed according to the manufacturer's instructions.///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 15 microg total RNA.///taxid_ch1: 9606///hyb_protocol: 15ug of total RNA was reverse-transcribed with oligo-dT primer containing a T7 RNA polymerase-binding site. An in vitro transcription was performed on this cDNA. DNA from the samples was fragmented in 40 mM Tris acetate, 100 mM potassium acetate, and 30 mM MgCl2 (pH 8.1) at 95C to reduce secondary structures. 15 ug of cRNA were hybridized to an Affymetrix HuGeneFL microarray, washed and stained.///scan_protocol: Scanned with a Hewlett Packard Gene Array Scanner///description: invasive///data_processing: Raw values assigned by MAS 4///platform_id: GPL80///contact_name: Jaroslav,Petr,Novak///contact_email: [email protected], [email protected]///contact_phone: 450-465-1383///contact_fax: 450-465-3033///contact_department: Microarray Platform///contact_institute: McGill University and Genome Quebec Innovation Centre///contact_address: 740, Dr Penfield Avenue///contact_city: Montreal///contact_state: Quebec///contact_zip.postal_code: H3A 1A4///contact_country: Canada///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM157nnn/GSM157260/GSM157260.CEL.gz///data_row_count: 7129
1
title: Ovarian tumor AM253///geo_accession: GSM157261///status: Public on Dec 31 2007///submission_date: Jan 22 2007///last_update_date: Feb 25 2008///type: RNA///channel_count: 1///source_name_ch1: epithelian ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tissue: epithelial ovarian tumor, Tumor type: serous, Tumor stage: borderline///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction of total RNA was performed according to the manufacturer's instructions.///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 15 microg total RNA.///taxid_ch1: 9606///hyb_protocol: 15ug of total RNA was reverse-transcribed with oligo-dT primer containing a T7 RNA polymerase-binding site. An in vitro transcription was performed on this cDNA. DNA from the samples was fragmented in 40 mM Tris acetate, 100 mM potassium acetate, and 30 mM MgCl2 (pH 8.1) at 95C to reduce secondary structures. 15 ug of cRNA were hybridized to an Affymetrix HuGeneFL microarray, washed and stained.///scan_protocol: Scanned with a Hewlett Packard Gene Array Scanner///description: low malignant potential///data_processing: Raw values assigned by MAS 4///platform_id: GPL80///contact_name: Jaroslav,Petr,Novak///contact_email: [email protected], [email protected]///contact_phone: 450-465-1383///contact_fax: 450-465-3033///contact_department: Microarray Platform///contact_institute: McGill University and Genome Quebec Innovation Centre///contact_address: 740, Dr Penfield Avenue///contact_city: Montreal///contact_state: Quebec///contact_zip.postal_code: H3A 1A4///contact_country: Canada///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM157nnn/GSM157261/GSM157261.CEL.gz///data_row_count: 7129
1
title: Ovarian tumor AM255///geo_accession: GSM157262///status: Public on Dec 31 2007///submission_date: Jan 22 2007///last_update_date: Feb 25 2008///type: RNA///channel_count: 1///source_name_ch1: epithelian ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tissue: epithelial ovarian tumor, Tumor type: serous, Tumor stage: invasive grade 3///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction of total RNA was performed according to the manufacturer's instructions.///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 15 microg total RNA.///taxid_ch1: 9606///hyb_protocol: 15ug of total RNA was reverse-transcribed with oligo-dT primer containing a T7 RNA polymerase-binding site. An in vitro transcription was performed on this cDNA. DNA from the samples was fragmented in 40 mM Tris acetate, 100 mM potassium acetate, and 30 mM MgCl2 (pH 8.1) at 95C to reduce secondary structures. 15 ug of cRNA were hybridized to an Affymetrix HuGeneFL microarray, washed and stained.///scan_protocol: Scanned with a Hewlett Packard Gene Array Scanner///description: invasive///data_processing: Raw values assigned by MAS 4///platform_id: GPL80///contact_name: Jaroslav,Petr,Novak///contact_email: [email protected], [email protected]///contact_phone: 450-465-1383///contact_fax: 450-465-3033///contact_department: Microarray Platform///contact_institute: McGill University and Genome Quebec Innovation Centre///contact_address: 740, Dr Penfield Avenue///contact_city: Montreal///contact_state: Quebec///contact_zip.postal_code: H3A 1A4///contact_country: Canada///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM157nnn/GSM157262/GSM157262.CEL.gz///data_row_count: 7129
1
title: Ovarian tumor AM256///geo_accession: GSM157263///status: Public on Dec 31 2007///submission_date: Jan 22 2007///last_update_date: Feb 25 2008///type: RNA///channel_count: 1///source_name_ch1: epithelian ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tissue: epithelial ovarian tumor, Tumor type: serous, Tumor stage: invasive grade 3///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction of total RNA was performed according to the manufacturer's instructions.///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 15 microg total RNA.///taxid_ch1: 9606///hyb_protocol: 15ug of total RNA was reverse-transcribed with oligo-dT primer containing a T7 RNA polymerase-binding site. An in vitro transcription was performed on this cDNA. DNA from the samples was fragmented in 40 mM Tris acetate, 100 mM potassium acetate, and 30 mM MgCl2 (pH 8.1) at 95C to reduce secondary structures. 15 ug of cRNA were hybridized to an Affymetrix HuGeneFL microarray, washed and stained.///scan_protocol: Scanned with a Hewlett Packard Gene Array Scanner///description: invasive///data_processing: Raw values assigned by MAS 4///platform_id: GPL80///contact_name: Jaroslav,Petr,Novak///contact_email: [email protected], [email protected]///contact_phone: 450-465-1383///contact_fax: 450-465-3033///contact_department: Microarray Platform///contact_institute: McGill University and Genome Quebec Innovation Centre///contact_address: 740, Dr Penfield Avenue///contact_city: Montreal///contact_state: Quebec///contact_zip.postal_code: H3A 1A4///contact_country: Canada///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM157nnn/GSM157263/GSM157263.CEL.gz///data_row_count: 7129
1
title: Ovarian tumor AM259///geo_accession: GSM157264///status: Public on Dec 31 2007///submission_date: Jan 22 2007///last_update_date: Feb 25 2008///type: RNA///channel_count: 1///source_name_ch1: epithelian ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tissue: epithelial ovarian tumor, Tumor type: serous, Tumor stage: microinvasion of grade 3///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction of total RNA was performed according to the manufacturer's instructions.///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 15 microg total RNA.///taxid_ch1: 9606///hyb_protocol: 15ug of total RNA was reverse-transcribed with oligo-dT primer containing a T7 RNA polymerase-binding site. An in vitro transcription was performed on this cDNA. DNA from the samples was fragmented in 40 mM Tris acetate, 100 mM potassium acetate, and 30 mM MgCl2 (pH 8.1) at 95C to reduce secondary structures. 15 ug of cRNA were hybridized to an Affymetrix HuGeneFL microarray, washed and stained.///scan_protocol: Scanned with a Hewlett Packard Gene Array Scanner///description: invasive///data_processing: Raw values assigned by MAS 4///platform_id: GPL80///contact_name: Jaroslav,Petr,Novak///contact_email: [email protected], [email protected]///contact_phone: 450-465-1383///contact_fax: 450-465-3033///contact_department: Microarray Platform///contact_institute: McGill University and Genome Quebec Innovation Centre///contact_address: 740, Dr Penfield Avenue///contact_city: Montreal///contact_state: Quebec///contact_zip.postal_code: H3A 1A4///contact_country: Canada///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM157nnn/GSM157264/GSM157264.CEL.gz///data_row_count: 7129
1
title: Ovarian tumor AM261///geo_accession: GSM157265///status: Public on Dec 31 2007///submission_date: Jan 22 2007///last_update_date: Feb 25 2008///type: RNA///channel_count: 1///source_name_ch1: epithelian ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tissue: epithelial ovarian tumor, Tumor type: serous, Tumor stage: invasive grade 3///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction of total RNA was performed according to the manufacturer's instructions.///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 15 microg total RNA.///taxid_ch1: 9606///hyb_protocol: 15ug of total RNA was reverse-transcribed with oligo-dT primer containing a T7 RNA polymerase-binding site. An in vitro transcription was performed on this cDNA. DNA from the samples was fragmented in 40 mM Tris acetate, 100 mM potassium acetate, and 30 mM MgCl2 (pH 8.1) at 95C to reduce secondary structures. 15 ug of cRNA were hybridized to an Affymetrix HuGeneFL microarray, washed and stained.///scan_protocol: Scanned with a Hewlett Packard Gene Array Scanner///description: invasive///data_processing: Raw values assigned by MAS 4///platform_id: GPL80///contact_name: Jaroslav,Petr,Novak///contact_email: [email protected], [email protected]///contact_phone: 450-465-1383///contact_fax: 450-465-3033///contact_department: Microarray Platform///contact_institute: McGill University and Genome Quebec Innovation Centre///contact_address: 740, Dr Penfield Avenue///contact_city: Montreal///contact_state: Quebec///contact_zip.postal_code: H3A 1A4///contact_country: Canada///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM157nnn/GSM157265/GSM157265.CEL.gz///data_row_count: 7129
1
title: Ovarian tumor AM263///geo_accession: GSM157266///status: Public on Dec 31 2007///submission_date: Jan 22 2007///last_update_date: Feb 25 2008///type: RNA///channel_count: 1///source_name_ch1: epithelian ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tissue: epithelial ovarian tumor, Tumor type: serous, Tumor stage: invasive grade 3///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction of total RNA was performed according to the manufacturer's instructions.///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 15 microg total RNA.///taxid_ch1: 9606///hyb_protocol: 15ug of total RNA was reverse-transcribed with oligo-dT primer containing a T7 RNA polymerase-binding site. An in vitro transcription was performed on this cDNA. DNA from the samples was fragmented in 40 mM Tris acetate, 100 mM potassium acetate, and 30 mM MgCl2 (pH 8.1) at 95C to reduce secondary structures. 15 ug of cRNA were hybridized to an Affymetrix HuGeneFL microarray, washed and stained.///scan_protocol: Scanned with a Hewlett Packard Gene Array Scanner///description: invasive///data_processing: Raw values assigned by MAS 4///platform_id: GPL80///contact_name: Jaroslav,Petr,Novak///contact_email: [email protected], [email protected]///contact_phone: 450-465-1383///contact_fax: 450-465-3033///contact_department: Microarray Platform///contact_institute: McGill University and Genome Quebec Innovation Centre///contact_address: 740, Dr Penfield Avenue///contact_city: Montreal///contact_state: Quebec///contact_zip.postal_code: H3A 1A4///contact_country: Canada///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM157nnn/GSM157266/GSM157266.CEL.gz///data_row_count: 7129
1
title: Ovarian tumor AM268///geo_accession: GSM157267///status: Public on Dec 31 2007///submission_date: Jan 22 2007///last_update_date: Feb 25 2008///type: RNA///channel_count: 1///source_name_ch1: epithelian ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tissue: epithelial ovarian tumor, Tumor type: serous, Tumor stage: invasive grade 2///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction of total RNA was performed according to the manufacturer's instructions.///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 15 microg total RNA.///taxid_ch1: 9606///hyb_protocol: 15ug of total RNA was reverse-transcribed with oligo-dT primer containing a T7 RNA polymerase-binding site. An in vitro transcription was performed on this cDNA. DNA from the samples was fragmented in 40 mM Tris acetate, 100 mM potassium acetate, and 30 mM MgCl2 (pH 8.1) at 95C to reduce secondary structures. 15 ug of cRNA were hybridized to an Affymetrix HuGeneFL microarray, washed and stained.///scan_protocol: Scanned with a Hewlett Packard Gene Array Scanner///description: invasive///data_processing: Raw values assigned by MAS 4///platform_id: GPL80///contact_name: Jaroslav,Petr,Novak///contact_email: [email protected], [email protected]///contact_phone: 450-465-1383///contact_fax: 450-465-3033///contact_department: Microarray Platform///contact_institute: McGill University and Genome Quebec Innovation Centre///contact_address: 740, Dr Penfield Avenue///contact_city: Montreal///contact_state: Quebec///contact_zip.postal_code: H3A 1A4///contact_country: Canada///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM157nnn/GSM157267/GSM157267.CEL.gz///data_row_count: 7129
1
title: Ovarian tumor AM269///geo_accession: GSM157268///status: Public on Dec 31 2007///submission_date: Jan 22 2007///last_update_date: Feb 25 2008///type: RNA///channel_count: 1///source_name_ch1: epithelian ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tissue: epithelial ovarian tumor, Tumor type: serous, Tumor stage: invasive grade 2///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction of total RNA was performed according to the manufacturer's instructions.///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 15 microg total RNA.///taxid_ch1: 9606///hyb_protocol: 15ug of total RNA was reverse-transcribed with oligo-dT primer containing a T7 RNA polymerase-binding site. An in vitro transcription was performed on this cDNA. DNA from the samples was fragmented in 40 mM Tris acetate, 100 mM potassium acetate, and 30 mM MgCl2 (pH 8.1) at 95C to reduce secondary structures. 15 ug of cRNA were hybridized to an Affymetrix HuGeneFL microarray, washed and stained.///scan_protocol: Scanned with a Hewlett Packard Gene Array Scanner///description: invasive///data_processing: Raw values assigned by MAS 4///platform_id: GPL80///contact_name: Jaroslav,Petr,Novak///contact_email: [email protected], [email protected]///contact_phone: 450-465-1383///contact_fax: 450-465-3033///contact_department: Microarray Platform///contact_institute: McGill University and Genome Quebec Innovation Centre///contact_address: 740, Dr Penfield Avenue///contact_city: Montreal///contact_state: Quebec///contact_zip.postal_code: H3A 1A4///contact_country: Canada///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM157nnn/GSM157268/GSM157268.CEL.gz///data_row_count: 7129
1
title: Ovarian tumor AM287///geo_accession: GSM157269///status: Public on Dec 31 2007///submission_date: Jan 22 2007///last_update_date: Feb 25 2008///type: RNA///channel_count: 1///source_name_ch1: epithelian ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tissue: epithelial ovarian tumor, Tumor type: undetermined, Tumor stage: invasive, small foci of grade 3 tumor///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction of total RNA was performed according to the manufacturer's instructions.///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 15 microg total RNA.///taxid_ch1: 9606///hyb_protocol: 15ug of total RNA was reverse-transcribed with oligo-dT primer containing a T7 RNA polymerase-binding site. An in vitro transcription was performed on this cDNA. DNA from the samples was fragmented in 40 mM Tris acetate, 100 mM potassium acetate, and 30 mM MgCl2 (pH 8.1) at 95C to reduce secondary structures. 15 ug of cRNA were hybridized to an Affymetrix HuGeneFL microarray, washed and stained.///scan_protocol: Scanned with a Hewlett Packard Gene Array Scanner///description: invasive///data_processing: Raw values assigned by MAS 4///platform_id: GPL80///contact_name: Jaroslav,Petr,Novak///contact_email: [email protected], [email protected]///contact_phone: 450-465-1383///contact_fax: 450-465-3033///contact_department: Microarray Platform///contact_institute: McGill University and Genome Quebec Innovation Centre///contact_address: 740, Dr Penfield Avenue///contact_city: Montreal///contact_state: Quebec///contact_zip.postal_code: H3A 1A4///contact_country: Canada///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM157nnn/GSM157269/GSM157269.CEL.gz///data_row_count: 7129
1
title: Ovarian tumor AM288///geo_accession: GSM157270///status: Public on Dec 31 2007///submission_date: Jan 22 2007///last_update_date: Feb 25 2008///type: RNA///channel_count: 1///source_name_ch1: epithelian ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tissue: epithelial ovarian tumor, Tumor type: undetermined, Tumor stage: invasive, small foci of grade 3 tumor///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction of total RNA was performed according to the manufacturer's instructions.///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 15 microg total RNA.///taxid_ch1: 9606///hyb_protocol: 15ug of total RNA was reverse-transcribed with oligo-dT primer containing a T7 RNA polymerase-binding site. An in vitro transcription was performed on this cDNA. DNA from the samples was fragmented in 40 mM Tris acetate, 100 mM potassium acetate, and 30 mM MgCl2 (pH 8.1) at 95C to reduce secondary structures. 15 ug of cRNA were hybridized to an Affymetrix HuGeneFL microarray, washed and stained.///scan_protocol: Scanned with a Hewlett Packard Gene Array Scanner///description: invasive///data_processing: Raw values assigned by MAS 4///platform_id: GPL80///contact_name: Jaroslav,Petr,Novak///contact_email: [email protected], [email protected]///contact_phone: 450-465-1383///contact_fax: 450-465-3033///contact_department: Microarray Platform///contact_institute: McGill University and Genome Quebec Innovation Centre///contact_address: 740, Dr Penfield Avenue///contact_city: Montreal///contact_state: Quebec///contact_zip.postal_code: H3A 1A4///contact_country: Canada///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM157nnn/GSM157270/GSM157270.CEL.gz///data_row_count: 7129
1
title: Ovarian tumor AM289///geo_accession: GSM157271///status: Public on Dec 31 2007///submission_date: Jan 22 2007///last_update_date: Feb 25 2008///type: RNA///channel_count: 1///source_name_ch1: epithelian ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tissue: epithelial ovarian tumor, Tumor type: serous, Tumor stage: invasive grade 3///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction of total RNA was performed according to the manufacturer's instructions.///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 15 microg total RNA.///taxid_ch1: 9606///hyb_protocol: 15ug of total RNA was reverse-transcribed with oligo-dT primer containing a T7 RNA polymerase-binding site. An in vitro transcription was performed on this cDNA. DNA from the samples was fragmented in 40 mM Tris acetate, 100 mM potassium acetate, and 30 mM MgCl2 (pH 8.1) at 95C to reduce secondary structures. 15 ug of cRNA were hybridized to an Affymetrix HuGeneFL microarray, washed and stained.///scan_protocol: Scanned with a Hewlett Packard Gene Array Scanner///description: invasive///data_processing: Raw values assigned by MAS 4///platform_id: GPL80///contact_name: Jaroslav,Petr,Novak///contact_email: [email protected], [email protected]///contact_phone: 450-465-1383///contact_fax: 450-465-3033///contact_department: Microarray Platform///contact_institute: McGill University and Genome Quebec Innovation Centre///contact_address: 740, Dr Penfield Avenue///contact_city: Montreal///contact_state: Quebec///contact_zip.postal_code: H3A 1A4///contact_country: Canada///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM157nnn/GSM157271/GSM157271.CEL.gz///data_row_count: 7129
1
title: Ovarian tumor AM290///geo_accession: GSM157272///status: Public on Dec 31 2007///submission_date: Jan 22 2007///last_update_date: Feb 25 2008///type: RNA///channel_count: 1///source_name_ch1: epithelian ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tissue: epithelial ovarian tumor, Tumor type: serous, Tumor stage: invasive grade 3///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction of total RNA was performed according to the manufacturer's instructions.///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 15 microg total RNA.///taxid_ch1: 9606///hyb_protocol: 15ug of total RNA was reverse-transcribed with oligo-dT primer containing a T7 RNA polymerase-binding site. An in vitro transcription was performed on this cDNA. DNA from the samples was fragmented in 40 mM Tris acetate, 100 mM potassium acetate, and 30 mM MgCl2 (pH 8.1) at 95C to reduce secondary structures. 15 ug of cRNA were hybridized to an Affymetrix HuGeneFL microarray, washed and stained.///scan_protocol: Scanned with a Hewlett Packard Gene Array Scanner///description: invasive///data_processing: Raw values assigned by MAS 4///platform_id: GPL80///contact_name: Jaroslav,Petr,Novak///contact_email: [email protected], [email protected]///contact_phone: 450-465-1383///contact_fax: 450-465-3033///contact_department: Microarray Platform///contact_institute: McGill University and Genome Quebec Innovation Centre///contact_address: 740, Dr Penfield Avenue///contact_city: Montreal///contact_state: Quebec///contact_zip.postal_code: H3A 1A4///contact_country: Canada///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM157nnn/GSM157272/GSM157272.CEL.gz///data_row_count: 7129
1
title: Ovarian tumor AM292///geo_accession: GSM157273///status: Public on Dec 31 2007///submission_date: Jan 22 2007///last_update_date: Feb 25 2008///type: RNA///channel_count: 1///source_name_ch1: epithelian ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tissue: epithelial ovarian tumor, Tumor type: undetermined, Tumor stage: invasive, small foci of grade 3 tumor///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction of total RNA was performed according to the manufacturer's instructions.///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 15 microg total RNA.///taxid_ch1: 9606///hyb_protocol: 15ug of total RNA was reverse-transcribed with oligo-dT primer containing a T7 RNA polymerase-binding site. An in vitro transcription was performed on this cDNA. DNA from the samples was fragmented in 40 mM Tris acetate, 100 mM potassium acetate, and 30 mM MgCl2 (pH 8.1) at 95C to reduce secondary structures. 15 ug of cRNA were hybridized to an Affymetrix HuGeneFL microarray, washed and stained.///scan_protocol: Scanned with a Hewlett Packard Gene Array Scanner///description: invasive///data_processing: Raw values assigned by MAS 4///platform_id: GPL80///contact_name: Jaroslav,Petr,Novak///contact_email: [email protected], [email protected]///contact_phone: 450-465-1383///contact_fax: 450-465-3033///contact_department: Microarray Platform///contact_institute: McGill University and Genome Quebec Innovation Centre///contact_address: 740, Dr Penfield Avenue///contact_city: Montreal///contact_state: Quebec///contact_zip.postal_code: H3A 1A4///contact_country: Canada///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM157nnn/GSM157273/GSM157273.CEL.gz///data_row_count: 7129
1
title: Ovarian tumor AM293///geo_accession: GSM157274///status: Public on Dec 31 2007///submission_date: Jan 22 2007///last_update_date: Feb 25 2008///type: RNA///channel_count: 1///source_name_ch1: epithelian ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tissue: epithelial ovarian tumor, Tumor type: serous, Tumor stage: invasive grade 3///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction of total RNA was performed according to the manufacturer's instructions.///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 15 microg total RNA.///taxid_ch1: 9606///hyb_protocol: 15ug of total RNA was reverse-transcribed with oligo-dT primer containing a T7 RNA polymerase-binding site. An in vitro transcription was performed on this cDNA. DNA from the samples was fragmented in 40 mM Tris acetate, 100 mM potassium acetate, and 30 mM MgCl2 (pH 8.1) at 95C to reduce secondary structures. 15 ug of cRNA were hybridized to an Affymetrix HuGeneFL microarray, washed and stained.///scan_protocol: Scanned with a Hewlett Packard Gene Array Scanner///description: invasive///data_processing: Raw values assigned by MAS 4///platform_id: GPL80///contact_name: Jaroslav,Petr,Novak///contact_email: [email protected], [email protected]///contact_phone: 450-465-1383///contact_fax: 450-465-3033///contact_department: Microarray Platform///contact_institute: McGill University and Genome Quebec Innovation Centre///contact_address: 740, Dr Penfield Avenue///contact_city: Montreal///contact_state: Quebec///contact_zip.postal_code: H3A 1A4///contact_country: Canada///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM157nnn/GSM157274/GSM157274.CEL.gz///data_row_count: 7129
1
title: Ovarian tumor AM294///geo_accession: GSM157275///status: Public on Dec 31 2007///submission_date: Jan 22 2007///last_update_date: Feb 25 2008///type: RNA///channel_count: 1///source_name_ch1: epithelian ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tissue: epithelial ovarian tumor, Tumor type: serous, Tumor stage: invasive grade 3///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction of total RNA was performed according to the manufacturer's instructions.///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 15 microg total RNA.///taxid_ch1: 9606///hyb_protocol: 15ug of total RNA was reverse-transcribed with oligo-dT primer containing a T7 RNA polymerase-binding site. An in vitro transcription was performed on this cDNA. DNA from the samples was fragmented in 40 mM Tris acetate, 100 mM potassium acetate, and 30 mM MgCl2 (pH 8.1) at 95C to reduce secondary structures. 15 ug of cRNA were hybridized to an Affymetrix HuGeneFL microarray, washed and stained.///scan_protocol: Scanned with a Hewlett Packard Gene Array Scanner///description: invasive///data_processing: Raw values assigned by MAS 4///platform_id: GPL80///contact_name: Jaroslav,Petr,Novak///contact_email: [email protected], [email protected]///contact_phone: 450-465-1383///contact_fax: 450-465-3033///contact_department: Microarray Platform///contact_institute: McGill University and Genome Quebec Innovation Centre///contact_address: 740, Dr Penfield Avenue///contact_city: Montreal///contact_state: Quebec///contact_zip.postal_code: H3A 1A4///contact_country: Canada///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM157nnn/GSM157275/GSM157275.CEL.gz///data_row_count: 7129
1
title: Ovarian tumor AM311///geo_accession: GSM157276///status: Public on Dec 31 2007///submission_date: Jan 22 2007///last_update_date: Feb 25 2008///type: RNA///channel_count: 1///source_name_ch1: epithelian ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tissue: epithelial ovarian tumor, Tumor type: endometrioid, Tumor stage: invasive grade 1///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction of total RNA was performed according to the manufacturer's instructions.///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 15 microg total RNA.///taxid_ch1: 9606///hyb_protocol: 15ug of total RNA was reverse-transcribed with oligo-dT primer containing a T7 RNA polymerase-binding site. An in vitro transcription was performed on this cDNA. DNA from the samples was fragmented in 40 mM Tris acetate, 100 mM potassium acetate, and 30 mM MgCl2 (pH 8.1) at 95C to reduce secondary structures. 15 ug of cRNA were hybridized to an Affymetrix HuGeneFL microarray, washed and stained.///scan_protocol: Scanned with a Hewlett Packard Gene Array Scanner///description: invasive///data_processing: Raw values assigned by MAS 4///platform_id: GPL80///contact_name: Jaroslav,Petr,Novak///contact_email: [email protected], [email protected]///contact_phone: 450-465-1383///contact_fax: 450-465-3033///contact_department: Microarray Platform///contact_institute: McGill University and Genome Quebec Innovation Centre///contact_address: 740, Dr Penfield Avenue///contact_city: Montreal///contact_state: Quebec///contact_zip.postal_code: H3A 1A4///contact_country: Canada///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM157nnn/GSM157276/GSM157276.CEL.gz///data_row_count: 7129
1
title: Ovarian tumor AM313///geo_accession: GSM157277///status: Public on Dec 31 2007///submission_date: Jan 22 2007///last_update_date: Feb 25 2008///type: RNA///channel_count: 1///source_name_ch1: epithelian ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tissue: epithelial ovarian tumor, Tumor type: serous, Tumor stage: invasive grade 2/3///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction of total RNA was performed according to the manufacturer's instructions.///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 15 microg total RNA.///taxid_ch1: 9606///hyb_protocol: 15ug of total RNA was reverse-transcribed with oligo-dT primer containing a T7 RNA polymerase-binding site. An in vitro transcription was performed on this cDNA. DNA from the samples was fragmented in 40 mM Tris acetate, 100 mM potassium acetate, and 30 mM MgCl2 (pH 8.1) at 95C to reduce secondary structures. 15 ug of cRNA were hybridized to an Affymetrix HuGeneFL microarray, washed and stained.///scan_protocol: Scanned with a Hewlett Packard Gene Array Scanner///description: invasive///data_processing: Raw values assigned by MAS 4///platform_id: GPL80///contact_name: Jaroslav,Petr,Novak///contact_email: [email protected], [email protected]///contact_phone: 450-465-1383///contact_fax: 450-465-3033///contact_department: Microarray Platform///contact_institute: McGill University and Genome Quebec Innovation Centre///contact_address: 740, Dr Penfield Avenue///contact_city: Montreal///contact_state: Quebec///contact_zip.postal_code: H3A 1A4///contact_country: Canada///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM157nnn/GSM157277/GSM157277.CEL.gz///data_row_count: 7129
1
title: Ovarian tumor AM315///geo_accession: GSM157278///status: Public on Dec 31 2007///submission_date: Jan 22 2007///last_update_date: Feb 25 2008///type: RNA///channel_count: 1///source_name_ch1: epithelian ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tissue: epithelial ovarian tumor, Tumor type: serous, Tumor stage: invasive grade 2/3///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction of total RNA was performed according to the manufacturer's instructions.///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 15 microg total RNA.///taxid_ch1: 9606///hyb_protocol: 15ug of total RNA was reverse-transcribed with oligo-dT primer containing a T7 RNA polymerase-binding site. An in vitro transcription was performed on this cDNA. DNA from the samples was fragmented in 40 mM Tris acetate, 100 mM potassium acetate, and 30 mM MgCl2 (pH 8.1) at 95C to reduce secondary structures. 15 ug of cRNA were hybridized to an Affymetrix HuGeneFL microarray, washed and stained.///scan_protocol: Scanned with a Hewlett Packard Gene Array Scanner///description: invasive///data_processing: Raw values assigned by MAS 4///platform_id: GPL80///contact_name: Jaroslav,Petr,Novak///contact_email: [email protected], [email protected]///contact_phone: 450-465-1383///contact_fax: 450-465-3033///contact_department: Microarray Platform///contact_institute: McGill University and Genome Quebec Innovation Centre///contact_address: 740, Dr Penfield Avenue///contact_city: Montreal///contact_state: Quebec///contact_zip.postal_code: H3A 1A4///contact_country: Canada///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM157nnn/GSM157278/GSM157278.CEL.gz///data_row_count: 7129
1
title: Ovarian tumor AM317///geo_accession: GSM157279///status: Public on Dec 31 2007///submission_date: Jan 22 2007///last_update_date: Feb 25 2008///type: RNA///channel_count: 1///source_name_ch1: epithelian ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tissue: epithelial ovarian tumor, Tumor type: clear cell, Tumor stage: invasive grade 2///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction of total RNA was performed according to the manufacturer's instructions.///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 15 microg total RNA.///taxid_ch1: 9606///hyb_protocol: 15ug of total RNA was reverse-transcribed with oligo-dT primer containing a T7 RNA polymerase-binding site. An in vitro transcription was performed on this cDNA. DNA from the samples was fragmented in 40 mM Tris acetate, 100 mM potassium acetate, and 30 mM MgCl2 (pH 8.1) at 95C to reduce secondary structures. 15 ug of cRNA were hybridized to an Affymetrix HuGeneFL microarray, washed and stained.///scan_protocol: Scanned with a Hewlett Packard Gene Array Scanner///description: invasive///data_processing: Raw values assigned by MAS 4///platform_id: GPL80///contact_name: Jaroslav,Petr,Novak///contact_email: [email protected], [email protected]///contact_phone: 450-465-1383///contact_fax: 450-465-3033///contact_department: Microarray Platform///contact_institute: McGill University and Genome Quebec Innovation Centre///contact_address: 740, Dr Penfield Avenue///contact_city: Montreal///contact_state: Quebec///contact_zip.postal_code: H3A 1A4///contact_country: Canada///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM157nnn/GSM157279/GSM157279.CEL.gz///data_row_count: 7129
1
title: Ovarian tumor AM333///geo_accession: GSM157280///status: Public on Dec 31 2007///submission_date: Jan 22 2007///last_update_date: Feb 25 2008///type: RNA///channel_count: 1///source_name_ch1: epithelian ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tissue: epithelial ovarian tumor, Tumor type: clear cell, Tumor stage: invasive grade 2///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction of total RNA was performed according to the manufacturer's instructions.///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 15 microg total RNA.///taxid_ch1: 9606///hyb_protocol: 15ug of total RNA was reverse-transcribed with oligo-dT primer containing a T7 RNA polymerase-binding site. An in vitro transcription was performed on this cDNA. DNA from the samples was fragmented in 40 mM Tris acetate, 100 mM potassium acetate, and 30 mM MgCl2 (pH 8.1) at 95C to reduce secondary structures. 15 ug of cRNA were hybridized to an Affymetrix HuGeneFL microarray, washed and stained.///scan_protocol: Scanned with a Hewlett Packard Gene Array Scanner///description: invasive///data_processing: Raw values assigned by MAS 4///platform_id: GPL80///contact_name: Jaroslav,Petr,Novak///contact_email: [email protected], [email protected]///contact_phone: 450-465-1383///contact_fax: 450-465-3033///contact_department: Microarray Platform///contact_institute: McGill University and Genome Quebec Innovation Centre///contact_address: 740, Dr Penfield Avenue///contact_city: Montreal///contact_state: Quebec///contact_zip.postal_code: H3A 1A4///contact_country: Canada///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM157nnn/GSM157280/GSM157280.CEL.gz///data_row_count: 7129
1
title: Ovarian tumor AM335///geo_accession: GSM157281///status: Public on Dec 31 2007///submission_date: Jan 22 2007///last_update_date: Feb 25 2008///type: RNA///channel_count: 1///source_name_ch1: epithelian ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tissue: epithelial ovarian tumor, Tumor type: serous, Tumor stage: invasive grade 3///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction of total RNA was performed according to the manufacturer's instructions.///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 15 microg total RNA.///taxid_ch1: 9606///hyb_protocol: 15ug of total RNA was reverse-transcribed with oligo-dT primer containing a T7 RNA polymerase-binding site. An in vitro transcription was performed on this cDNA. DNA from the samples was fragmented in 40 mM Tris acetate, 100 mM potassium acetate, and 30 mM MgCl2 (pH 8.1) at 95C to reduce secondary structures. 15 ug of cRNA were hybridized to an Affymetrix HuGeneFL microarray, washed and stained.///scan_protocol: Scanned with a Hewlett Packard Gene Array Scanner///description: invasive///data_processing: Raw values assigned by MAS 4///platform_id: GPL80///contact_name: Jaroslav,Petr,Novak///contact_email: [email protected], [email protected]///contact_phone: 450-465-1383///contact_fax: 450-465-3033///contact_department: Microarray Platform///contact_institute: McGill University and Genome Quebec Innovation Centre///contact_address: 740, Dr Penfield Avenue///contact_city: Montreal///contact_state: Quebec///contact_zip.postal_code: H3A 1A4///contact_country: Canada///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM157nnn/GSM157281/GSM157281.CEL.gz///data_row_count: 7129
1
title: Ovarian tumor AM339///geo_accession: GSM157282///status: Public on Dec 31 2007///submission_date: Jan 22 2007///last_update_date: Feb 25 2008///type: RNA///channel_count: 1///source_name_ch1: epithelian ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tissue: epithelial ovarian tumor, Tumor type: serous, Tumor stage: invasive grade 3///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction of total RNA was performed according to the manufacturer's instructions.///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 15 microg total RNA.///taxid_ch1: 9606///hyb_protocol: 15ug of total RNA was reverse-transcribed with oligo-dT primer containing a T7 RNA polymerase-binding site. An in vitro transcription was performed on this cDNA. DNA from the samples was fragmented in 40 mM Tris acetate, 100 mM potassium acetate, and 30 mM MgCl2 (pH 8.1) at 95C to reduce secondary structures. 15 ug of cRNA were hybridized to an Affymetrix HuGeneFL microarray, washed and stained.///scan_protocol: Scanned with a Hewlett Packard Gene Array Scanner///description: invasive///data_processing: Raw values assigned by MAS 4///platform_id: GPL80///contact_name: Jaroslav,Petr,Novak///contact_email: [email protected], [email protected]///contact_phone: 450-465-1383///contact_fax: 450-465-3033///contact_department: Microarray Platform///contact_institute: McGill University and Genome Quebec Innovation Centre///contact_address: 740, Dr Penfield Avenue///contact_city: Montreal///contact_state: Quebec///contact_zip.postal_code: H3A 1A4///contact_country: Canada///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM157nnn/GSM157282/GSM157282.CEL.gz///data_row_count: 7129
1
title: Ovarian tumor AM341///geo_accession: GSM157283///status: Public on Dec 31 2007///submission_date: Jan 22 2007///last_update_date: Feb 25 2008///type: RNA///channel_count: 1///source_name_ch1: epithelian ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tissue: epithelial ovarian tumor, Tumor type: mixed, Tumor stage: invasive grade 2/3///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction of total RNA was performed according to the manufacturer's instructions.///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 15 microg total RNA.///taxid_ch1: 9606///hyb_protocol: 15ug of total RNA was reverse-transcribed with oligo-dT primer containing a T7 RNA polymerase-binding site. An in vitro transcription was performed on this cDNA. DNA from the samples was fragmented in 40 mM Tris acetate, 100 mM potassium acetate, and 30 mM MgCl2 (pH 8.1) at 95C to reduce secondary structures. 15 ug of cRNA were hybridized to an Affymetrix HuGeneFL microarray, washed and stained.///scan_protocol: Scanned with a Hewlett Packard Gene Array Scanner///description: invasive///data_processing: Raw values assigned by MAS 4///platform_id: GPL80///contact_name: Jaroslav,Petr,Novak///contact_email: [email protected], [email protected]///contact_phone: 450-465-1383///contact_fax: 450-465-3033///contact_department: Microarray Platform///contact_institute: McGill University and Genome Quebec Innovation Centre///contact_address: 740, Dr Penfield Avenue///contact_city: Montreal///contact_state: Quebec///contact_zip.postal_code: H3A 1A4///contact_country: Canada///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM157nnn/GSM157283/GSM157283.CEL.gz///data_row_count: 7129
1
title: Ovarian tumor AM344///geo_accession: GSM157284///status: Public on Dec 31 2007///submission_date: Jan 22 2007///last_update_date: Feb 25 2008///type: RNA///channel_count: 1///source_name_ch1: epithelian ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tissue: epithelial ovarian tumor, Tumor type: serous, Tumor stage: benign///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction of total RNA was performed according to the manufacturer's instructions.///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 15 microg total RNA.///taxid_ch1: 9606///hyb_protocol: 15ug of total RNA was reverse-transcribed with oligo-dT primer containing a T7 RNA polymerase-binding site. An in vitro transcription was performed on this cDNA. DNA from the samples was fragmented in 40 mM Tris acetate, 100 mM potassium acetate, and 30 mM MgCl2 (pH 8.1) at 95C to reduce secondary structures. 15 ug of cRNA were hybridized to an Affymetrix HuGeneFL microarray, washed and stained.///scan_protocol: Scanned with a Hewlett Packard Gene Array Scanner///description: low malignant potential///data_processing: Raw values assigned by MAS 4///platform_id: GPL80///contact_name: Jaroslav,Petr,Novak///contact_email: [email protected], [email protected]///contact_phone: 450-465-1383///contact_fax: 450-465-3033///contact_department: Microarray Platform///contact_institute: McGill University and Genome Quebec Innovation Centre///contact_address: 740, Dr Penfield Avenue///contact_city: Montreal///contact_state: Quebec///contact_zip.postal_code: H3A 1A4///contact_country: Canada///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM157nnn/GSM157284/GSM157284.CEL.gz///data_row_count: 7129
1
title: Ovarian tumor AM345///geo_accession: GSM157285///status: Public on Dec 31 2007///submission_date: Jan 22 2007///last_update_date: Feb 25 2008///type: RNA///channel_count: 1///source_name_ch1: epithelian ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tissue: epithelial ovarian tumor, Tumor type: serous, Tumor stage: invasive grade 3///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction of total RNA was performed according to the manufacturer's instructions.///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 15 microg total RNA.///taxid_ch1: 9606///hyb_protocol: 15ug of total RNA was reverse-transcribed with oligo-dT primer containing a T7 RNA polymerase-binding site. An in vitro transcription was performed on this cDNA. DNA from the samples was fragmented in 40 mM Tris acetate, 100 mM potassium acetate, and 30 mM MgCl2 (pH 8.1) at 95C to reduce secondary structures. 15 ug of cRNA were hybridized to an Affymetrix HuGeneFL microarray, washed and stained.///scan_protocol: Scanned with a Hewlett Packard Gene Array Scanner///description: invasive///data_processing: Raw values assigned by MAS 4///platform_id: GPL80///contact_name: Jaroslav,Petr,Novak///contact_email: [email protected], [email protected]///contact_phone: 450-465-1383///contact_fax: 450-465-3033///contact_department: Microarray Platform///contact_institute: McGill University and Genome Quebec Innovation Centre///contact_address: 740, Dr Penfield Avenue///contact_city: Montreal///contact_state: Quebec///contact_zip.postal_code: H3A 1A4///contact_country: Canada///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM157nnn/GSM157285/GSM157285.CEL.gz///data_row_count: 7129
1
title: Ovarian tumor AM347///geo_accession: GSM157286///status: Public on Dec 31 2007///submission_date: Jan 22 2007///last_update_date: Feb 25 2008///type: RNA///channel_count: 1///source_name_ch1: epithelian ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tissue: epithelial ovarian tumor, Tumor type: serous, Tumor stage: invasive grade 2, post-chemotherapy sample///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction of total RNA was performed according to the manufacturer's instructions.///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 15 microg total RNA.///taxid_ch1: 9606///hyb_protocol: 15ug of total RNA was reverse-transcribed with oligo-dT primer containing a T7 RNA polymerase-binding site. An in vitro transcription was performed on this cDNA. DNA from the samples was fragmented in 40 mM Tris acetate, 100 mM potassium acetate, and 30 mM MgCl2 (pH 8.1) at 95C to reduce secondary structures. 15 ug of cRNA were hybridized to an Affymetrix HuGeneFL microarray, washed and stained.///scan_protocol: Scanned with a Hewlett Packard Gene Array Scanner///description: invasive///data_processing: Raw values assigned by MAS 4///platform_id: GPL80///contact_name: Jaroslav,Petr,Novak///contact_email: [email protected], [email protected]///contact_phone: 450-465-1383///contact_fax: 450-465-3033///contact_department: Microarray Platform///contact_institute: McGill University and Genome Quebec Innovation Centre///contact_address: 740, Dr Penfield Avenue///contact_city: Montreal///contact_state: Quebec///contact_zip.postal_code: H3A 1A4///contact_country: Canada///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM157nnn/GSM157286/GSM157286.CEL.gz///data_row_count: 7129
1
title: Ovarian tumor AM348///geo_accession: GSM157287///status: Public on Dec 31 2007///submission_date: Jan 22 2007///last_update_date: Feb 25 2008///type: RNA///channel_count: 1///source_name_ch1: epithelian ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tissue: epithelial ovarian tumor, Tumor type: serous, Tumor stage: invasive grade 3///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction of total RNA was performed according to the manufacturer's instructions.///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 15 microg total RNA.///taxid_ch1: 9606///hyb_protocol: 15ug of total RNA was reverse-transcribed with oligo-dT primer containing a T7 RNA polymerase-binding site. An in vitro transcription was performed on this cDNA. DNA from the samples was fragmented in 40 mM Tris acetate, 100 mM potassium acetate, and 30 mM MgCl2 (pH 8.1) at 95C to reduce secondary structures. 15 ug of cRNA were hybridized to an Affymetrix HuGeneFL microarray, washed and stained.///scan_protocol: Scanned with a Hewlett Packard Gene Array Scanner///description: invasive///data_processing: Raw values assigned by MAS 4///platform_id: GPL80///contact_name: Jaroslav,Petr,Novak///contact_email: [email protected], [email protected]///contact_phone: 450-465-1383///contact_fax: 450-465-3033///contact_department: Microarray Platform///contact_institute: McGill University and Genome Quebec Innovation Centre///contact_address: 740, Dr Penfield Avenue///contact_city: Montreal///contact_state: Quebec///contact_zip.postal_code: H3A 1A4///contact_country: Canada///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM157nnn/GSM157287/GSM157287.CEL.gz///data_row_count: 7129
1
title: Ovarian tumor AM349///geo_accession: GSM157288///status: Public on Dec 31 2007///submission_date: Jan 22 2007///last_update_date: Feb 25 2008///type: RNA///channel_count: 1///source_name_ch1: epithelian ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tissue: epithelial ovarian tumor, Tumor type: serous, Tumor stage: invasive grade 3///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction of total RNA was performed according to the manufacturer's instructions.///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 15 microg total RNA.///taxid_ch1: 9606///hyb_protocol: 15ug of total RNA was reverse-transcribed with oligo-dT primer containing a T7 RNA polymerase-binding site. An in vitro transcription was performed on this cDNA. DNA from the samples was fragmented in 40 mM Tris acetate, 100 mM potassium acetate, and 30 mM MgCl2 (pH 8.1) at 95C to reduce secondary structures. 15 ug of cRNA were hybridized to an Affymetrix HuGeneFL microarray, washed and stained.///scan_protocol: Scanned with a Hewlett Packard Gene Array Scanner///description: invasive///data_processing: Raw values assigned by MAS 4///platform_id: GPL80///contact_name: Jaroslav,Petr,Novak///contact_email: [email protected], [email protected]///contact_phone: 450-465-1383///contact_fax: 450-465-3033///contact_department: Microarray Platform///contact_institute: McGill University and Genome Quebec Innovation Centre///contact_address: 740, Dr Penfield Avenue///contact_city: Montreal///contact_state: Quebec///contact_zip.postal_code: H3A 1A4///contact_country: Canada///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM157nnn/GSM157288/GSM157288.CEL.gz///data_row_count: 7129
1
title: Ovarian tumor AM354///geo_accession: GSM157289///status: Public on Dec 31 2007///submission_date: Jan 22 2007///last_update_date: Feb 25 2008///type: RNA///channel_count: 1///source_name_ch1: epithelian ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tissue: epithelial ovarian tumor, Tumor type: clear cell, Tumor stage: invasive grade 2///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction of total RNA was performed according to the manufacturer's instructions.///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 15 microg total RNA.///taxid_ch1: 9606///hyb_protocol: 15ug of total RNA was reverse-transcribed with oligo-dT primer containing a T7 RNA polymerase-binding site. An in vitro transcription was performed on this cDNA. DNA from the samples was fragmented in 40 mM Tris acetate, 100 mM potassium acetate, and 30 mM MgCl2 (pH 8.1) at 95C to reduce secondary structures. 15 ug of cRNA were hybridized to an Affymetrix HuGeneFL microarray, washed and stained.///scan_protocol: Scanned with a Hewlett Packard Gene Array Scanner///description: invasive///data_processing: Raw values assigned by MAS 4///platform_id: GPL80///contact_name: Jaroslav,Petr,Novak///contact_email: [email protected], [email protected]///contact_phone: 450-465-1383///contact_fax: 450-465-3033///contact_department: Microarray Platform///contact_institute: McGill University and Genome Quebec Innovation Centre///contact_address: 740, Dr Penfield Avenue///contact_city: Montreal///contact_state: Quebec///contact_zip.postal_code: H3A 1A4///contact_country: Canada///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM157nnn/GSM157289/GSM157289.CEL.gz///data_row_count: 7129
1
title: Ovarian tumor AM364///geo_accession: GSM157290///status: Public on Dec 31 2007///submission_date: Jan 22 2007///last_update_date: Feb 25 2008///type: RNA///channel_count: 1///source_name_ch1: epithelian ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tissue: epithelial ovarian tumor, Tumor type: mucinous, Tumor stage: borderline///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction of total RNA was performed according to the manufacturer's instructions.///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 15 microg total RNA.///taxid_ch1: 9606///hyb_protocol: 15ug of total RNA was reverse-transcribed with oligo-dT primer containing a T7 RNA polymerase-binding site. An in vitro transcription was performed on this cDNA. DNA from the samples was fragmented in 40 mM Tris acetate, 100 mM potassium acetate, and 30 mM MgCl2 (pH 8.1) at 95C to reduce secondary structures. 15 ug of cRNA were hybridized to an Affymetrix HuGeneFL microarray, washed and stained.///scan_protocol: Scanned with a Hewlett Packard Gene Array Scanner///description: low malignant potential///data_processing: Raw values assigned by MAS 4///platform_id: GPL80///contact_name: Jaroslav,Petr,Novak///contact_email: [email protected], [email protected]///contact_phone: 450-465-1383///contact_fax: 450-465-3033///contact_department: Microarray Platform///contact_institute: McGill University and Genome Quebec Innovation Centre///contact_address: 740, Dr Penfield Avenue///contact_city: Montreal///contact_state: Quebec///contact_zip.postal_code: H3A 1A4///contact_country: Canada///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM157nnn/GSM157290/GSM157290.CEL.gz///data_row_count: 7129
1
title: Ovarian tumor AM367///geo_accession: GSM157291///status: Public on Dec 31 2007///submission_date: Jan 22 2007///last_update_date: Feb 25 2008///type: RNA///channel_count: 1///source_name_ch1: epithelian ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tissue: epithelial ovarian tumor, Tumor type: serous, Tumor stage: invasive grade 3///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction of total RNA was performed according to the manufacturer's instructions.///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 15 microg total RNA.///taxid_ch1: 9606///hyb_protocol: 15ug of total RNA was reverse-transcribed with oligo-dT primer containing a T7 RNA polymerase-binding site. An in vitro transcription was performed on this cDNA. DNA from the samples was fragmented in 40 mM Tris acetate, 100 mM potassium acetate, and 30 mM MgCl2 (pH 8.1) at 95C to reduce secondary structures. 15 ug of cRNA were hybridized to an Affymetrix HuGeneFL microarray, washed and stained.///scan_protocol: Scanned with a Hewlett Packard Gene Array Scanner///description: invasive///data_processing: Raw values assigned by MAS 4///platform_id: GPL80///contact_name: Jaroslav,Petr,Novak///contact_email: [email protected], [email protected]///contact_phone: 450-465-1383///contact_fax: 450-465-3033///contact_department: Microarray Platform///contact_institute: McGill University and Genome Quebec Innovation Centre///contact_address: 740, Dr Penfield Avenue///contact_city: Montreal///contact_state: Quebec///contact_zip.postal_code: H3A 1A4///contact_country: Canada///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM157nnn/GSM157291/GSM157291.CEL.gz///data_row_count: 7129
1
title: Ovarian tumor AM368///geo_accession: GSM157292///status: Public on Dec 31 2007///submission_date: Jan 22 2007///last_update_date: Feb 25 2008///type: RNA///channel_count: 1///source_name_ch1: epithelian ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tissue: epithelial ovarian tumor, Tumor type: serous, Tumor stage: invasive grade 2///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction of total RNA was performed according to the manufacturer's instructions.///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 15 microg total RNA.///taxid_ch1: 9606///hyb_protocol: 15ug of total RNA was reverse-transcribed with oligo-dT primer containing a T7 RNA polymerase-binding site. An in vitro transcription was performed on this cDNA. DNA from the samples was fragmented in 40 mM Tris acetate, 100 mM potassium acetate, and 30 mM MgCl2 (pH 8.1) at 95C to reduce secondary structures. 15 ug of cRNA were hybridized to an Affymetrix HuGeneFL microarray, washed and stained.///scan_protocol: Scanned with a Hewlett Packard Gene Array Scanner///description: invasive///data_processing: Raw values assigned by MAS 4///platform_id: GPL80///contact_name: Jaroslav,Petr,Novak///contact_email: [email protected], [email protected]///contact_phone: 450-465-1383///contact_fax: 450-465-3033///contact_department: Microarray Platform///contact_institute: McGill University and Genome Quebec Innovation Centre///contact_address: 740, Dr Penfield Avenue///contact_city: Montreal///contact_state: Quebec///contact_zip.postal_code: H3A 1A4///contact_country: Canada///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM157nnn/GSM157292/GSM157292.CEL.gz///data_row_count: 7129
1
title: Ovarian tumor AM381///geo_accession: GSM157293///status: Public on Dec 31 2007///submission_date: Jan 22 2007///last_update_date: Feb 25 2008///type: RNA///channel_count: 1///source_name_ch1: epithelian ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tissue: epithelial ovarian tumor, Tumor type: serous, Tumor stage: invasive grade 3///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction of total RNA was performed according to the manufacturer's instructions.///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 15 microg total RNA.///taxid_ch1: 9606///hyb_protocol: 15ug of total RNA was reverse-transcribed with oligo-dT primer containing a T7 RNA polymerase-binding site. An in vitro transcription was performed on this cDNA. DNA from the samples was fragmented in 40 mM Tris acetate, 100 mM potassium acetate, and 30 mM MgCl2 (pH 8.1) at 95C to reduce secondary structures. 15 ug of cRNA were hybridized to an Affymetrix HuGeneFL microarray, washed and stained.///scan_protocol: Scanned with a Hewlett Packard Gene Array Scanner///description: invasive///data_processing: Raw values assigned by MAS 4///platform_id: GPL80///contact_name: Jaroslav,Petr,Novak///contact_email: [email protected], [email protected]///contact_phone: 450-465-1383///contact_fax: 450-465-3033///contact_department: Microarray Platform///contact_institute: McGill University and Genome Quebec Innovation Centre///contact_address: 740, Dr Penfield Avenue///contact_city: Montreal///contact_state: Quebec///contact_zip.postal_code: H3A 1A4///contact_country: Canada///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM157nnn/GSM157293/GSM157293.CEL.gz///data_row_count: 7129
1
title: Ovarian tumor AM382///geo_accession: GSM157294///status: Public on Dec 31 2007///submission_date: Jan 22 2007///last_update_date: Feb 25 2008///type: RNA///channel_count: 1///source_name_ch1: epithelian ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tissue: epithelial ovarian tumor, Tumor type: serous, Tumor stage: invasive grade 3///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction of total RNA was performed according to the manufacturer's instructions.///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 15 microg total RNA.///taxid_ch1: 9606///hyb_protocol: 15ug of total RNA was reverse-transcribed with oligo-dT primer containing a T7 RNA polymerase-binding site. An in vitro transcription was performed on this cDNA. DNA from the samples was fragmented in 40 mM Tris acetate, 100 mM potassium acetate, and 30 mM MgCl2 (pH 8.1) at 95C to reduce secondary structures. 15 ug of cRNA were hybridized to an Affymetrix HuGeneFL microarray, washed and stained.///scan_protocol: Scanned with a Hewlett Packard Gene Array Scanner///description: invasive///data_processing: Raw values assigned by MAS 4///platform_id: GPL80///contact_name: Jaroslav,Petr,Novak///contact_email: [email protected], [email protected]///contact_phone: 450-465-1383///contact_fax: 450-465-3033///contact_department: Microarray Platform///contact_institute: McGill University and Genome Quebec Innovation Centre///contact_address: 740, Dr Penfield Avenue///contact_city: Montreal///contact_state: Quebec///contact_zip.postal_code: H3A 1A4///contact_country: Canada///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM157nnn/GSM157294/GSM157294.CEL.gz///data_row_count: 7129
1
title: Ovarian tumor AM398///geo_accession: GSM157295///status: Public on Dec 31 2007///submission_date: Jan 22 2007///last_update_date: Feb 25 2008///type: RNA///channel_count: 1///source_name_ch1: epithelian ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tissue: epithelial ovarian tumor, Tumor type: endometrioid, Tumor stage: invasive grade 3, xenograft of an EOC cell line///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction of total RNA was performed according to the manufacturer's instructions.///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 15 microg total RNA.///taxid_ch1: 9606///hyb_protocol: 15ug of total RNA was reverse-transcribed with oligo-dT primer containing a T7 RNA polymerase-binding site. An in vitro transcription was performed on this cDNA. DNA from the samples was fragmented in 40 mM Tris acetate, 100 mM potassium acetate, and 30 mM MgCl2 (pH 8.1) at 95C to reduce secondary structures. 15 ug of cRNA were hybridized to an Affymetrix HuGeneFL microarray, washed and stained.///scan_protocol: Scanned with a Hewlett Packard Gene Array Scanner///description: invasive///data_processing: Raw values assigned by MAS 4///platform_id: GPL80///contact_name: Jaroslav,Petr,Novak///contact_email: [email protected], [email protected]///contact_phone: 450-465-1383///contact_fax: 450-465-3033///contact_department: Microarray Platform///contact_institute: McGill University and Genome Quebec Innovation Centre///contact_address: 740, Dr Penfield Avenue///contact_city: Montreal///contact_state: Quebec///contact_zip.postal_code: H3A 1A4///contact_country: Canada///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM157nnn/GSM157295/GSM157295.CEL.gz///data_row_count: 7129
1
title: Ovarian tumor AM429///geo_accession: GSM157296///status: Public on Dec 31 2007///submission_date: Jan 22 2007///last_update_date: Feb 25 2008///type: RNA///channel_count: 1///source_name_ch1: epithelian ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tissue: epithelial ovarian tumor, Tumor type: clear cell, Tumor stage: invasive grade 3, xenograft of an EOC cell line///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction of total RNA was performed according to the manufacturer's instructions.///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 15 microg total RNA.///taxid_ch1: 9606///hyb_protocol: 15ug of total RNA was reverse-transcribed with oligo-dT primer containing a T7 RNA polymerase-binding site. An in vitro transcription was performed on this cDNA. DNA from the samples was fragmented in 40 mM Tris acetate, 100 mM potassium acetate, and 30 mM MgCl2 (pH 8.1) at 95C to reduce secondary structures. 15 ug of cRNA were hybridized to an Affymetrix HuGeneFL microarray, washed and stained.///scan_protocol: Scanned with a Hewlett Packard Gene Array Scanner///description: invasive///data_processing: Raw values assigned by MAS 4///platform_id: GPL80///contact_name: Jaroslav,Petr,Novak///contact_email: [email protected], [email protected]///contact_phone: 450-465-1383///contact_fax: 450-465-3033///contact_department: Microarray Platform///contact_institute: McGill University and Genome Quebec Innovation Centre///contact_address: 740, Dr Penfield Avenue///contact_city: Montreal///contact_state: Quebec///contact_zip.postal_code: H3A 1A4///contact_country: Canada///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM157nnn/GSM157296/GSM157296.CEL.gz///data_row_count: 7129
1
title: Ovarian tumor AM431///geo_accession: GSM157297///status: Public on Dec 31 2007///submission_date: Jan 22 2007///last_update_date: Feb 25 2008///type: RNA///channel_count: 1///source_name_ch1: epithelian ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tissue: epithelial ovarian tumor, Tumor type: serous, Tumor stage: invasive grade 2///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction of total RNA was performed according to the manufacturer's instructions.///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 15 microg total RNA.///taxid_ch1: 9606///hyb_protocol: 15ug of total RNA was reverse-transcribed with oligo-dT primer containing a T7 RNA polymerase-binding site. An in vitro transcription was performed on this cDNA. DNA from the samples was fragmented in 40 mM Tris acetate, 100 mM potassium acetate, and 30 mM MgCl2 (pH 8.1) at 95C to reduce secondary structures. 15 ug of cRNA were hybridized to an Affymetrix HuGeneFL microarray, washed and stained.///scan_protocol: Scanned with a Hewlett Packard Gene Array Scanner///description: invasive///data_processing: Raw values assigned by MAS 4///platform_id: GPL80///contact_name: Jaroslav,Petr,Novak///contact_email: [email protected], [email protected]///contact_phone: 450-465-1383///contact_fax: 450-465-3033///contact_department: Microarray Platform///contact_institute: McGill University and Genome Quebec Innovation Centre///contact_address: 740, Dr Penfield Avenue///contact_city: Montreal///contact_state: Quebec///contact_zip.postal_code: H3A 1A4///contact_country: Canada///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM157nnn/GSM157297/GSM157297.CEL.gz///data_row_count: 7129
1
title: Ovarian tumor AM438///geo_accession: GSM157298///status: Public on Dec 31 2007///submission_date: Jan 22 2007///last_update_date: Feb 25 2008///type: RNA///channel_count: 1///source_name_ch1: epithelian ovarian tumor///organism_ch1: Homo sapiens///characteristics_ch1: Tissue: epithelial ovarian tumor, Tumor type: mixed, Tumor stage: invasive grade 3///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction of total RNA was performed according to the manufacturer's instructions.///label_ch1: Biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 15 microg total RNA.///taxid_ch1: 9606///hyb_protocol: 15ug of total RNA was reverse-transcribed with oligo-dT primer containing a T7 RNA polymerase-binding site. An in vitro transcription was performed on this cDNA. DNA from the samples was fragmented in 40 mM Tris acetate, 100 mM potassium acetate, and 30 mM MgCl2 (pH 8.1) at 95C to reduce secondary structures. 15 ug of cRNA were hybridized to an Affymetrix HuGeneFL microarray, washed and stained.///scan_protocol: Scanned with a Hewlett Packard Gene Array Scanner///description: invasive///data_processing: Raw values assigned by MAS 4///platform_id: GPL80///contact_name: Jaroslav,Petr,Novak///contact_email: [email protected], [email protected]///contact_phone: 450-465-1383///contact_fax: 450-465-3033///contact_department: Microarray Platform///contact_institute: McGill University and Genome Quebec Innovation Centre///contact_address: 740, Dr Penfield Avenue///contact_city: Montreal///contact_state: Quebec///contact_zip.postal_code: H3A 1A4///contact_country: Canada///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM157nnn/GSM157298/GSM157298.CEL.gz///data_row_count: 7129
1
duplicates:
Length Class Mode
66 character character
An expression set
Gene expression profile was analyzed in 68 stage I and 15 borderline ovarian cancers to determine if different clinical features of stage I ovarian cancer such as histotype, grade, and survival are related to differential gene expression.Tumors were obtained directly at surgery and immediately frozen in liquid nitrogen until analysis. Glass arrays containing 16,000 genes were used in a dual-color assay labeling protocol.Unsupervised analysis identified eight major patient partitions, one of which was statistically associated to overall survival, grading, and histotype and another with grading and histotype. Supervised analysis allowed detection of gene profiles clearly associated to histotype or to degree of differentiation. No difference was found between borderline and grade 1 tumors. As to recurrence, a subset of genes able to differentiate relapsers from nonrelapsers was identified. Among these, cyclin E and minichromosome maintenance protein 5 were found particularly relevant, as their expression was inversely correlated to progression-free survival (P = 0.00033 and 0.017, respectively).Specific molecular signatures define different histotypes and prognosis of stage I ovarian cancer. Mucinous and clear cells histotypes can be distinguished from the others regardless of tumor grade. Cyclin E and minichromosome maintenance protein 5, whose expression was found previously to be related to a bad prognosis of advanced ovarian cancer, appear to be potential prognostic markers in stage I ovarian cancer too, independent of other pathologic and clinical variables.
experimentData(eset):
Experiment data
Experimenter name: Marchini S, Mariani P, Chiorino G, Marrazzo E, Bonomi R, Fruscio R, Clivio L, Garbi A, Torri V, Cinquini M, Dell'Anna T, Apolone G, Broggini M, D'Incalci M.Analysis of gene expression in early-stage ovarian cancer. Clin Cancer Res. 2008 Dec 1; 14(23):7850-60.
Laboratory: Marchini, D'Incalci 2008
Contact information:
Title: Analysis of gene expression in early-stage ovarian cancer.
URL:
PMIDs: 19047114
Abstract: A 225 word abstract is available. Use 'abstract' method.
Information is available on: preprocessing
notes:
platform_title:
Agilent Human 1 cDNA Microarray (G4100A)
platform_shorttitle:
Agilent G4100A cDNA
platform_summary:
hgug4100a
platform_manufacturer:
Agilent
platform_distribution:
custom-commerical
platform_accession:
GPL5689
platform_technology:
spotted DNA/cDNA
version:
2015-09-22 20:07:40
featureData(eset):
An object of class 'AnnotatedDataFrame'
featureNames: 1 2 ... 8864 (7809 total)
varLabels: probeset gene EntrezGene.ID best_probe
varMetadata: labelDescription
assayData: 7809 features, 83 samples
Platform type:
Overall survival time-to-event summary (in years):
Call: survfit(formula = Surv(time, cens) ~ -1)
n events median 0.95LCL 0.95UCL
83 15 NA 12 NA
---------------------------
Available sample meta-data:
---------------------------
alt_sample_name:
p0102bis sample_Ovarian tumor p0103bis sample_Ovarian tumor
1 1
p0112bis sample_Ovarian tumor p0114bis sample_Ovarian tumor
1 1
p0125bis sample_Ovarian tumor p0128bis sample_Ovarian tumor
1 1
p0143bis sample_Ovarian tumor p0146bis sample_Ovarian tumor
1 1
p0188bis sample_Ovarian tumor p0208bis sample_Ovarian tumor
1 1
p0210bis sample_Ovarian tumor p0217bis sample_Ovarian tumor
1 1
p057bis sample_Ovarian tumor p070bis sample_Ovarian tumor
1 1
p080bis sample_Ovarian tumor p091bis sample_Ovarian tumor
1 1
p139bis sample_Ovarian tumor p13bis sample_Ovarian tumor
1 1
p141bis sample_Ovarian tumor p166bis sample_Ovarian tumor
1 1
p171bis sample_Ovarian tumor p17bis sample_Ovarian tumor
1 1
p183bis sample_Ovarian tumor p209bis sample_Ovarian tumor
1 1
p212bis sample_Ovarian tumor p213bis sample_Ovarian tumor
1 1
p243bis sample_Ovarian tumor p246bis sample_Ovarian tumor
1 1
p261bis sample_Ovarian tumor p284bis sample_Ovarian tumor
1 1
p293bis sample_Ovarian tumor p310bis sample_Ovarian tumor
1 1
p31bis sample_Ovarian tumor p320bis sample_Ovarian tumor
1 1
p331bis sample_Ovarian tumor p336bis sample_Ovarian tumor
1 1
p350bis sample_Ovarian tumor p375bis sample_Ovarian tumor
1 1
p382bis sample_Ovarian tumor p383bis sample_Ovarian tumor
1 1
p386bis sample_Ovarian tumor p388bis sample_Ovarian tumor
1 1
p398bis sample_Ovarian tumor p39bis sample_Ovarian tumor
1 1
p401bis sample_Ovarian tumor p414bis sample_Ovarian tumor
1 1
p421bis sample_Ovarian tumor p429bis sample_Ovarian tumor
1 1
p433bis sample_Ovarian tumor p448bis sample_Ovarian tumor
1 1
p455bis sample_Ovarian tumor p459bis sample_Ovarian tumor
1 1
p462bis sample_Ovarian tumor p482bis sample_Ovarian tumor
1 1
p487bis sample_Ovarian tumor p497bis sample_Ovarian tumor
1 1
p502bis sample_Ovarian tumor p540bis sample_Ovarian tumor
1 1
p541bis sample_Ovarian tumor p549bis sample_Ovarian tumor
1 1
p550bis sample_Ovarian tumor p567bis sample_Ovarian tumor
1 1
p56bis sample_Ovarian tumor p573bis sample_Ovarian tumor
1 1
p586bis sample_Ovarian tumor p597bis sample_Ovarian tumor
1 1
p616bis sample_Ovarian tumor p63bis sample_Ovarian tumor
1 1
p646bis sample_Ovarian tumor p66bis sample_Ovarian tumor
1 1
p68bis sample_Ovarian tumor p690bis sample_Ovarian tumor
1 1
p692bis sample_Ovarian tumor p725bis sample_Ovarian tumor
1 1
p73bis sample_Ovarian tumor p760bis sample_Ovarian tumor
1 1
p770bis sample_Ovarian tumor p772bis sample_Ovarian tumor
1 1
p775bis sample_Ovarian tumor p793bis sample_Ovarian tumor
1 1
p79bis sample_Ovarian tumor p84bis sample_Ovarian tumor
1 1
p90bis sample_Ovarian tumor
1
sample_type:
borderline tumor
15 68
histological_type:
clearcell endo mucinous other
16 17 17 1
ser undifferentiated
31 1
primarysite:
ov
83
summarygrade:
high low NA's
35 33 15
summarystage:
early
83
tumorstage:
1
83
substage:
a b c
25 5 53
grade:
1 2 3 NA's
13 20 35 15
age_at_initial_pathologic_diagnosis:
Min. 1st Qu. Median Mean 3rd Qu. Max.
21.00 43.00 50.00 51.25 61.00 87.00
recurrence_status:
norecurrence recurrence
62 21
days_to_death:
Min. 1st Qu. Median Mean 3rd Qu. Max.
0 1192 2248 2273 3048 5824
vital_status:
deceased living
15 68
uncurated_author_metadata:
title: p0102bis sample_Ovarian tumor///geo_accession: GSM214010///status: Public on Aug 25 2007///submission_date: Jul 31 2007///last_update_date: Aug 24 2007///type: RNA///channel_count: 2///source_name_ch1: Total RNA extracted from frozen biopsies of ovarian tumors///organism_ch1: Homo sapiens///characteristics_ch1: Gender: Female///characteristics_ch1.1: Status:alive no evidence of disease///characteristics_ch1.2: FIGO Stage:1///characteristics_ch1.3: FIGO Substage:c///characteristics_ch1.4: Histotype:serous///characteristics_ch1.5: Grade:3///characteristics_ch1.6: Relapsed:yes///characteristics_ch1.7: Age(years):45.6///characteristics_ch1.8: Overall Survival(days):3903///characteristics_ch1.9: Progression Free Survival(days):3903///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification from human biopsies were performed using the SV Total RNA Isolation System -cat:#z3100 from Promega.///label_ch1: Cy5///label_protocol_ch1: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch1: 9606///source_name_ch2: Clontech Universal Reference///organism_ch2: Homo sapiens///characteristics_ch2: Human Atlas high pure control total RNA extracted from a pool of 60 human cell lines (BD Biosciences)///molecule_ch2: total RNA///extract_protocol_ch2: see the producer web site: http//clontech.com/products/detail.asp?tabno=2&catalog_id=636538&page=all&faq_id=153665///label_ch2: Cy3///label_protocol_ch2: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch2: 9606///hyb_protocol: Microarray hybridization: Add to each Sample 2.5 ul Cot-1 DNA and 12.50 ul 2X Hybridization Buffer. Heat samples for 2 min at 65 C. Centrifuge. Pipet the cDNA array and 22 ul of sample. Incubate for 16 hr at 65 C. Used Atlas Glass Microarray User Manual PT3453-1 instructions for post-hybridization wash.///scan_protocol: Arrays were scanned using a laser-scanner Axon 4000-B, (Axon Instruments, Union City, CA), using 5-micron resolution. Within the GenePix program were chosen photo-multiplier parameters that defined the quanta intensity density distribution of the array to give a Cy3/Cy5 ratio close to 1.0 and produced not too much saturated signals for each array. Separate 16-bit images were acquired for Cy3 and Cy5.///description: none///data_processing: Images were analysed using the GenePix Pro software (Axon Instruments) version 3.0. GenePix Result files (GPR) and the related scan images, together with the Agilent cDNA pattern file and information on the hybridised samples and labelling signs (positive for normal labelling and negative for dye-swap labelling), were then loaded into the Rosetta Resolver SE software. The Axon GenePix error model was applied to transform data and then duplicate ratio profiles were combined to obtain one ratio experiment for each patient. Log ratios, log ratio errors and p-values were thus available for the non flagged sequences of each ratio experiment.///platform_id: GPL5689///contact_name: Pietro,,Mariani///contact_institute: Mario Negri Institute///contact_address: Via La Masa 19///contact_city: Milan///contact_zip.postal_code: 20156///contact_country: Italy///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM214nnn/GSM214010/GSM214010_raw.txt.gz///data_row_count: 16281
1
title: p0103bis sample_Ovarian tumor///geo_accession: GSM214078///status: Public on Aug 25 2007///submission_date: Jul 31 2007///last_update_date: Aug 24 2007///type: RNA///channel_count: 2///source_name_ch1: Total RNA extracted from frozen biopsies of ovarian tumors///organism_ch1: Homo sapiens///characteristics_ch1: Gender: Female///characteristics_ch1.1: Status:alive no evidence of disease///characteristics_ch1.2: FIGO Stage:1///characteristics_ch1.3: FIGO Substage:a///characteristics_ch1.4: Histotype:serous///characteristics_ch1.5: Grade:Borderline///characteristics_ch1.6: Relapsed:no///characteristics_ch1.7: Age(years):25.6///characteristics_ch1.8: Overall Survival(days):5824///characteristics_ch1.9: Progression Free Survival(days):5824///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification from human biopsies were performed using the SV Total RNA Isolation System -cat:#z3100 from Promega.///label_ch1: Cy5///label_protocol_ch1: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch1: 9606///source_name_ch2: Clontech Universal Reference///organism_ch2: Homo sapiens///characteristics_ch2: Human Atlas high pure control total RNA extracted from a pool of 60 human cell lines (BD Biosciences)///molecule_ch2: total RNA///extract_protocol_ch2: see the producer web site: http//clontech.com/products/detail.asp?tabno=2&catalog_id=636538&page=all&faq_id=153665///label_ch2: Cy3///label_protocol_ch2: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch2: 9606///hyb_protocol: Microarray hybridization: Add to each Sample 2.5 ul Cot-1 DNA and 12.50 ul 2X Hybridization Buffer. Heat samples for 2 min at 65 C. Centrifuge. Pipet the cDNA array and 22 ul of sample. Incubate for 16 hr at 65 C. Used Atlas Glass Microarray User Manual PT3453-1 instructions for post-hybridization wash.///scan_protocol: Arrays were scanned using a laser-scanner Axon 4000-B, (Axon Instruments, Union City, CA), using 5-micron resolution. Within the GenePix program were chosen photo-multiplier parameters that defined the quanta intensity density distribution of the array to give a Cy3/Cy5 ratio close to 1.0 and produced not too much saturated signals for each array. Separate 16-bit images were acquired for Cy3 and Cy5.///description: none///data_processing: Images were analysed using the GenePix Pro software (Axon Instruments) version 3.0. GenePix Result files (GPR) and the related scan images, together with the Agilent cDNA pattern file and information on the hybridised samples and labelling signs (positive for normal labelling and negative for dye-swap labelling), were then loaded into the Rosetta Resolver SE software. The Axon GenePix error model was applied to transform data and then duplicate ratio profiles were combined to obtain one ratio experiment for each patient. Log ratios, log ratio errors and p-values were thus available for the non flagged sequences of each ratio experiment.///platform_id: GPL5689///contact_name: Pietro,,Mariani///contact_institute: Mario Negri Institute///contact_address: Via La Masa 19///contact_city: Milan///contact_zip.postal_code: 20156///contact_country: Italy///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM214nnn/GSM214078/GSM214078_raw.txt.gz///data_row_count: 16281
1
title: p0112bis sample_Ovarian tumor///geo_accession: GSM214040///status: Public on Aug 25 2007///submission_date: Jul 31 2007///last_update_date: Aug 24 2007///type: RNA///channel_count: 2///source_name_ch1: Total RNA extracted from frozen biopsies of ovarian tumors///organism_ch1: Homo sapiens///characteristics_ch1: Gender: Female///characteristics_ch1.1: Status:death related to cancer///characteristics_ch1.2: FIGO Stage:1///characteristics_ch1.3: FIGO Substage:c///characteristics_ch1.4: Histotype:serous///characteristics_ch1.5: Grade:1///characteristics_ch1.6: Relapsed:yes///characteristics_ch1.7: Age(years):52.07///characteristics_ch1.8: Overall Survival(days):4366///characteristics_ch1.9: Progression Free Survival(days):4366///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification from human biopsies were performed using the SV Total RNA Isolation System -cat:#z3100 from Promega.///label_ch1: Cy5///label_protocol_ch1: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch1: 9606///source_name_ch2: Clontech Universal Reference///organism_ch2: Homo sapiens///characteristics_ch2: Human Atlas high pure control total RNA extracted from a pool of 60 human cell lines (BD Biosciences)///molecule_ch2: total RNA///extract_protocol_ch2: see the producer web site: http//clontech.com/products/detail.asp?tabno=2&catalog_id=636538&page=all&faq_id=153665///label_ch2: Cy3///label_protocol_ch2: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch2: 9606///hyb_protocol: Microarray hybridization: Add to each Sample 2.5 ul Cot-1 DNA and 12.50 ul 2X Hybridization Buffer. Heat samples for 2 min at 65 C. Centrifuge. Pipet the cDNA array and 22 ul of sample. Incubate for 16 hr at 65 C. Used Atlas Glass Microarray User Manual PT3453-1 instructions for post-hybridization wash.///scan_protocol: Arrays were scanned using a laser-scanner Axon 4000-B, (Axon Instruments, Union City, CA), using 5-micron resolution. Within the GenePix program were chosen photo-multiplier parameters that defined the quanta intensity density distribution of the array to give a Cy3/Cy5 ratio close to 1.0 and produced not too much saturated signals for each array. Separate 16-bit images were acquired for Cy3 and Cy5.///description: none///data_processing: Images were analysed using the GenePix Pro software (Axon Instruments) version 3.0. GenePix Result files (GPR) and the related scan images, together with the Agilent cDNA pattern file and information on the hybridised samples and labelling signs (positive for normal labelling and negative for dye-swap labelling), were then loaded into the Rosetta Resolver SE software. The Axon GenePix error model was applied to transform data and then duplicate ratio profiles were combined to obtain one ratio experiment for each patient. Log ratios, log ratio errors and p-values were thus available for the non flagged sequences of each ratio experiment.///platform_id: GPL5689///contact_name: Pietro,,Mariani///contact_institute: Mario Negri Institute///contact_address: Via La Masa 19///contact_city: Milan///contact_zip.postal_code: 20156///contact_country: Italy///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM214nnn/GSM214040/GSM214040_raw.txt.gz///data_row_count: 16281
1
title: p0114bis sample_Ovarian tumor///geo_accession: GSM214016///status: Public on Aug 25 2007///submission_date: Jul 31 2007///last_update_date: Aug 24 2007///type: RNA///channel_count: 2///source_name_ch1: Total RNA extracted from frozen biopsies of ovarian tumors///organism_ch1: Homo sapiens///characteristics_ch1: Gender: Female///characteristics_ch1.1: Status:in progression///characteristics_ch1.2: FIGO Stage:1///characteristics_ch1.3: FIGO Substage:c///characteristics_ch1.4: Histotype:serous///characteristics_ch1.5: Grade:3///characteristics_ch1.6: Relapsed:yes///characteristics_ch1.7: Age(years):45.28///characteristics_ch1.8: Overall Survival(days):3592///characteristics_ch1.9: Progression Free Survival(days):3592///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification from human biopsies were performed using the SV Total RNA Isolation System -cat:#z3100 from Promega.///label_ch1: Cy5///label_protocol_ch1: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch1: 9606///source_name_ch2: Clontech Universal Reference///organism_ch2: Homo sapiens///characteristics_ch2: Human Atlas high pure control total RNA extracted from a pool of 60 human cell lines (BD Biosciences)///molecule_ch2: total RNA///extract_protocol_ch2: see the producer web site: http//clontech.com/products/detail.asp?tabno=2&catalog_id=636538&page=all&faq_id=153665///label_ch2: Cy3///label_protocol_ch2: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch2: 9606///hyb_protocol: Microarray hybridization: Add to each Sample 2.5 ul Cot-1 DNA and 12.50 ul 2X Hybridization Buffer. Heat samples for 2 min at 65 C. Centrifuge. Pipet the cDNA array and 22 ul of sample. Incubate for 16 hr at 65 C. Used Atlas Glass Microarray User Manual PT3453-1 instructions for post-hybridization wash.///scan_protocol: Arrays were scanned using a laser-scanner Axon 4000-B, (Axon Instruments, Union City, CA), using 5-micron resolution. Within the GenePix program were chosen photo-multiplier parameters that defined the quanta intensity density distribution of the array to give a Cy3/Cy5 ratio close to 1.0 and produced not too much saturated signals for each array. Separate 16-bit images were acquired for Cy3 and Cy5.///description: none///data_processing: Images were analysed using the GenePix Pro software (Axon Instruments) version 3.0. GenePix Result files (GPR) and the related scan images, together with the Agilent cDNA pattern file and information on the hybridised samples and labelling signs (positive for normal labelling and negative for dye-swap labelling), were then loaded into the Rosetta Resolver SE software. The Axon GenePix error model was applied to transform data and then duplicate ratio profiles were combined to obtain one ratio experiment for each patient. Log ratios, log ratio errors and p-values were thus available for the non flagged sequences of each ratio experiment.///platform_id: GPL5689///contact_name: Pietro,,Mariani///contact_institute: Mario Negri Institute///contact_address: Via La Masa 19///contact_city: Milan///contact_zip.postal_code: 20156///contact_country: Italy///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM214nnn/GSM214016/GSM214016_raw.txt.gz///data_row_count: 16281
1
title: p0125bis sample_Ovarian tumor///geo_accession: GSM214009///status: Public on Aug 25 2007///submission_date: Jul 31 2007///last_update_date: Aug 24 2007///type: RNA///channel_count: 2///source_name_ch1: Total RNA extracted from frozen biopsies of ovarian tumors///organism_ch1: Homo sapiens///characteristics_ch1: Gender: Female///characteristics_ch1.1: Status:alive no evidence of disease///characteristics_ch1.2: FIGO Stage:1///characteristics_ch1.3: FIGO Substage:a///characteristics_ch1.4: Histotype:serous///characteristics_ch1.5: Grade:1///characteristics_ch1.6: Relapsed:no///characteristics_ch1.7: Age(years):64.22///characteristics_ch1.8: Overall Survival(days):4176///characteristics_ch1.9: Progression Free Survival(days):4176///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification from human biopsies were performed using the SV Total RNA Isolation System -cat:#z3100 from Promega.///label_ch1: Cy5///label_protocol_ch1: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch1: 9606///source_name_ch2: Clontech Universal Reference///organism_ch2: Homo sapiens///characteristics_ch2: Human Atlas high pure control total RNA extracted from a pool of 60 human cell lines (BD Biosciences)///molecule_ch2: total RNA///extract_protocol_ch2: see the producer web site: http//clontech.com/products/detail.asp?tabno=2&catalog_id=636538&page=all&faq_id=153665///label_ch2: Cy3///label_protocol_ch2: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch2: 9606///hyb_protocol: Microarray hybridization: Add to each Sample 2.5 ul Cot-1 DNA and 12.50 ul 2X Hybridization Buffer. Heat samples for 2 min at 65 C. Centrifuge. Pipet the cDNA array and 22 ul of sample. Incubate for 16 hr at 65 C. Used Atlas Glass Microarray User Manual PT3453-1 instructions for post-hybridization wash.///scan_protocol: Arrays were scanned using a laser-scanner Axon 4000-B, (Axon Instruments, Union City, CA), using 5-micron resolution. Within the GenePix program were chosen photo-multiplier parameters that defined the quanta intensity density distribution of the array to give a Cy3/Cy5 ratio close to 1.0 and produced not too much saturated signals for each array. Separate 16-bit images were acquired for Cy3 and Cy5.///description: none///data_processing: Images were analysed using the GenePix Pro software (Axon Instruments) version 3.0. GenePix Result files (GPR) and the related scan images, together with the Agilent cDNA pattern file and information on the hybridised samples and labelling signs (positive for normal labelling and negative for dye-swap labelling), were then loaded into the Rosetta Resolver SE software. The Axon GenePix error model was applied to transform data and then duplicate ratio profiles were combined to obtain one ratio experiment for each patient. Log ratios, log ratio errors and p-values were thus available for the non flagged sequences of each ratio experiment.///platform_id: GPL5689///contact_name: Pietro,,Mariani///contact_institute: Mario Negri Institute///contact_address: Via La Masa 19///contact_city: Milan///contact_zip.postal_code: 20156///contact_country: Italy///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM214nnn/GSM214009/GSM214009_raw.txt.gz///data_row_count: 16281
1
title: p0128bis sample_Ovarian tumor///geo_accession: GSM214030///status: Public on Aug 25 2007///submission_date: Jul 31 2007///last_update_date: Aug 24 2007///type: RNA///channel_count: 2///source_name_ch1: Total RNA extracted from frozen biopsies of ovarian tumors///organism_ch1: Homo sapiens///characteristics_ch1: Gender: Female///characteristics_ch1.1: Status:death related to cancer///characteristics_ch1.2: FIGO Stage:1///characteristics_ch1.3: FIGO Substage:c///characteristics_ch1.4: Histotype:serous///characteristics_ch1.5: Grade:2///characteristics_ch1.6: Relapsed:yes///characteristics_ch1.7: Age(years):31.85///characteristics_ch1.8: Overall Survival(days):689///characteristics_ch1.9: Progression Free Survival(days):689///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification from human biopsies were performed using the SV Total RNA Isolation System -cat:#z3100 from Promega.///label_ch1: Cy5///label_protocol_ch1: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch1: 9606///source_name_ch2: Clontech Universal Reference///organism_ch2: Homo sapiens///characteristics_ch2: Human Atlas high pure control total RNA extracted from a pool of 60 human cell lines (BD Biosciences)///molecule_ch2: total RNA///extract_protocol_ch2: see the producer web site: http//clontech.com/products/detail.asp?tabno=2&catalog_id=636538&page=all&faq_id=153665///label_ch2: Cy3///label_protocol_ch2: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch2: 9606///hyb_protocol: Microarray hybridization: Add to each Sample 2.5 ul Cot-1 DNA and 12.50 ul 2X Hybridization Buffer. Heat samples for 2 min at 65 C. Centrifuge. Pipet the cDNA array and 22 ul of sample. Incubate for 16 hr at 65 C. Used Atlas Glass Microarray User Manual PT3453-1 instructions for post-hybridization wash.///scan_protocol: Arrays were scanned using a laser-scanner Axon 4000-B, (Axon Instruments, Union City, CA), using 5-micron resolution. Within the GenePix program were chosen photo-multiplier parameters that defined the quanta intensity density distribution of the array to give a Cy3/Cy5 ratio close to 1.0 and produced not too much saturated signals for each array. Separate 16-bit images were acquired for Cy3 and Cy5.///description: none///data_processing: Images were analysed using the GenePix Pro software (Axon Instruments) version 3.0. GenePix Result files (GPR) and the related scan images, together with the Agilent cDNA pattern file and information on the hybridised samples and labelling signs (positive for normal labelling and negative for dye-swap labelling), were then loaded into the Rosetta Resolver SE software. The Axon GenePix error model was applied to transform data and then duplicate ratio profiles were combined to obtain one ratio experiment for each patient. Log ratios, log ratio errors and p-values were thus available for the non flagged sequences of each ratio experiment.///platform_id: GPL5689///contact_name: Pietro,,Mariani///contact_institute: Mario Negri Institute///contact_address: Via La Masa 19///contact_city: Milan///contact_zip.postal_code: 20156///contact_country: Italy///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM214nnn/GSM214030/GSM214030_raw.txt.gz///data_row_count: 16281
1
title: p0143bis sample_Ovarian tumor///geo_accession: GSM214012///status: Public on Aug 25 2007///submission_date: Jul 31 2007///last_update_date: Aug 24 2007///type: RNA///channel_count: 2///source_name_ch1: Total RNA extracted from frozen biopsies of ovarian tumors///organism_ch1: Homo sapiens///characteristics_ch1: Gender: Female///characteristics_ch1.1: Status:alive no evidence of disease///characteristics_ch1.2: FIGO Stage:1///characteristics_ch1.3: FIGO Substage:b///characteristics_ch1.4: Histotype:serous///characteristics_ch1.5: Grade:3///characteristics_ch1.6: Relapsed:no///characteristics_ch1.7: Age(years):55.16///characteristics_ch1.8: Overall Survival(days):4478///characteristics_ch1.9: Progression Free Survival(days):4478///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification from human biopsies were performed using the SV Total RNA Isolation System -cat:#z3100 from Promega.///label_ch1: Cy5///label_protocol_ch1: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch1: 9606///source_name_ch2: Clontech Universal Reference///organism_ch2: Homo sapiens///characteristics_ch2: Human Atlas high pure control total RNA extracted from a pool of 60 human cell lines (BD Biosciences)///molecule_ch2: total RNA///extract_protocol_ch2: see the producer web site: http//clontech.com/products/detail.asp?tabno=2&catalog_id=636538&page=all&faq_id=153665///label_ch2: Cy3///label_protocol_ch2: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch2: 9606///hyb_protocol: Microarray hybridization: Add to each Sample 2.5 ul Cot-1 DNA and 12.50 ul 2X Hybridization Buffer. Heat samples for 2 min at 65 C. Centrifuge. Pipet the cDNA array and 22 ul of sample. Incubate for 16 hr at 65 C. Used Atlas Glass Microarray User Manual PT3453-1 instructions for post-hybridization wash.///scan_protocol: Arrays were scanned using a laser-scanner Axon 4000-B, (Axon Instruments, Union City, CA), using 5-micron resolution. Within the GenePix program were chosen photo-multiplier parameters that defined the quanta intensity density distribution of the array to give a Cy3/Cy5 ratio close to 1.0 and produced not too much saturated signals for each array. Separate 16-bit images were acquired for Cy3 and Cy5.///description: none///data_processing: Images were analysed using the GenePix Pro software (Axon Instruments) version 3.0. GenePix Result files (GPR) and the related scan images, together with the Agilent cDNA pattern file and information on the hybridised samples and labelling signs (positive for normal labelling and negative for dye-swap labelling), were then loaded into the Rosetta Resolver SE software. The Axon GenePix error model was applied to transform data and then duplicate ratio profiles were combined to obtain one ratio experiment for each patient. Log ratios, log ratio errors and p-values were thus available for the non flagged sequences of each ratio experiment.///platform_id: GPL5689///contact_name: Pietro,,Mariani///contact_institute: Mario Negri Institute///contact_address: Via La Masa 19///contact_city: Milan///contact_zip.postal_code: 20156///contact_country: Italy///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM214nnn/GSM214012/GSM214012_raw.txt.gz///data_row_count: 16281
1
title: p0146bis sample_Ovarian tumor///geo_accession: GSM214033///status: Public on Aug 25 2007///submission_date: Jul 31 2007///last_update_date: Aug 24 2007///type: RNA///channel_count: 2///source_name_ch1: Total RNA extracted from frozen biopsies of ovarian tumors///organism_ch1: Homo sapiens///characteristics_ch1: Gender: Female///characteristics_ch1.1: Status:alive no evidence of disease///characteristics_ch1.2: FIGO Stage:1///characteristics_ch1.3: FIGO Substage:a///characteristics_ch1.4: Histotype:serous///characteristics_ch1.5: Grade:1///characteristics_ch1.6: Relapsed:no///characteristics_ch1.7: Age(years):45.83///characteristics_ch1.8: Overall Survival(days):3561///characteristics_ch1.9: Progression Free Survival(days):3561///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification from human biopsies were performed using the SV Total RNA Isolation System -cat:#z3100 from Promega.///label_ch1: Cy5///label_protocol_ch1: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch1: 9606///source_name_ch2: Clontech Universal Reference///organism_ch2: Homo sapiens///characteristics_ch2: Human Atlas high pure control total RNA extracted from a pool of 60 human cell lines (BD Biosciences)///molecule_ch2: total RNA///extract_protocol_ch2: see the producer web site: http//clontech.com/products/detail.asp?tabno=2&catalog_id=636538&page=all&faq_id=153665///label_ch2: Cy3///label_protocol_ch2: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch2: 9606///hyb_protocol: Microarray hybridization: Add to each Sample 2.5 ul Cot-1 DNA and 12.50 ul 2X Hybridization Buffer. Heat samples for 2 min at 65 C. Centrifuge. Pipet the cDNA array and 22 ul of sample. Incubate for 16 hr at 65 C. Used Atlas Glass Microarray User Manual PT3453-1 instructions for post-hybridization wash.///scan_protocol: Arrays were scanned using a laser-scanner Axon 4000-B, (Axon Instruments, Union City, CA), using 5-micron resolution. Within the GenePix program were chosen photo-multiplier parameters that defined the quanta intensity density distribution of the array to give a Cy3/Cy5 ratio close to 1.0 and produced not too much saturated signals for each array. Separate 16-bit images were acquired for Cy3 and Cy5.///description: none///data_processing: Images were analysed using the GenePix Pro software (Axon Instruments) version 3.0. GenePix Result files (GPR) and the related scan images, together with the Agilent cDNA pattern file and information on the hybridised samples and labelling signs (positive for normal labelling and negative for dye-swap labelling), were then loaded into the Rosetta Resolver SE software. The Axon GenePix error model was applied to transform data and then duplicate ratio profiles were combined to obtain one ratio experiment for each patient. Log ratios, log ratio errors and p-values were thus available for the non flagged sequences of each ratio experiment.///platform_id: GPL5689///contact_name: Pietro,,Mariani///contact_institute: Mario Negri Institute///contact_address: Via La Masa 19///contact_city: Milan///contact_zip.postal_code: 20156///contact_country: Italy///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM214nnn/GSM214033/GSM214033_raw.txt.gz///data_row_count: 16281
1
title: p0188bis sample_Ovarian tumor///geo_accession: GSM214041///status: Public on Aug 25 2007///submission_date: Jul 31 2007///last_update_date: Aug 24 2007///type: RNA///channel_count: 2///source_name_ch1: Total RNA extracted from frozen biopsies of ovarian tumors///organism_ch1: Homo sapiens///characteristics_ch1: Gender: Female///characteristics_ch1.1: Status:death related to cancer///characteristics_ch1.2: FIGO Stage:1///characteristics_ch1.3: FIGO Substage:a///characteristics_ch1.4: Histotype:serous///characteristics_ch1.5: Grade:3///characteristics_ch1.6: Relapsed:yes///characteristics_ch1.7: Age(years):52.3///characteristics_ch1.8: Overall Survival(days):716///characteristics_ch1.9: Progression Free Survival(days):716///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification from human biopsies were performed using the SV Total RNA Isolation System -cat:#z3100 from Promega.///label_ch1: Cy5///label_protocol_ch1: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch1: 9606///source_name_ch2: Clontech Universal Reference///organism_ch2: Homo sapiens///characteristics_ch2: Human Atlas high pure control total RNA extracted from a pool of 60 human cell lines (BD Biosciences)///molecule_ch2: total RNA///extract_protocol_ch2: see the producer web site: http//clontech.com/products/detail.asp?tabno=2&catalog_id=636538&page=all&faq_id=153665///label_ch2: Cy3///label_protocol_ch2: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch2: 9606///hyb_protocol: Microarray hybridization: Add to each Sample 2.5 ul Cot-1 DNA and 12.50 ul 2X Hybridization Buffer. Heat samples for 2 min at 65 C. Centrifuge. Pipet the cDNA array and 22 ul of sample. Incubate for 16 hr at 65 C. Used Atlas Glass Microarray User Manual PT3453-1 instructions for post-hybridization wash.///scan_protocol: Arrays were scanned using a laser-scanner Axon 4000-B, (Axon Instruments, Union City, CA), using 5-micron resolution. Within the GenePix program were chosen photo-multiplier parameters that defined the quanta intensity density distribution of the array to give a Cy3/Cy5 ratio close to 1.0 and produced not too much saturated signals for each array. Separate 16-bit images were acquired for Cy3 and Cy5.///description: none///data_processing: Images were analysed using the GenePix Pro software (Axon Instruments) version 3.0. GenePix Result files (GPR) and the related scan images, together with the Agilent cDNA pattern file and information on the hybridised samples and labelling signs (positive for normal labelling and negative for dye-swap labelling), were then loaded into the Rosetta Resolver SE software. The Axon GenePix error model was applied to transform data and then duplicate ratio profiles were combined to obtain one ratio experiment for each patient. Log ratios, log ratio errors and p-values were thus available for the non flagged sequences of each ratio experiment.///platform_id: GPL5689///contact_name: Pietro,,Mariani///contact_institute: Mario Negri Institute///contact_address: Via La Masa 19///contact_city: Milan///contact_zip.postal_code: 20156///contact_country: Italy///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM214nnn/GSM214041/GSM214041_raw.txt.gz///data_row_count: 16281
1
title: p0208bis sample_Ovarian tumor///geo_accession: GSM214011///status: Public on Aug 25 2007///submission_date: Jul 31 2007///last_update_date: Aug 24 2007///type: RNA///channel_count: 2///source_name_ch1: Total RNA extracted from frozen biopsies of ovarian tumors///organism_ch1: Homo sapiens///characteristics_ch1: Gender: Female///characteristics_ch1.1: Status:death unrelated to cancer///characteristics_ch1.2: FIGO Stage:1///characteristics_ch1.3: FIGO Substage:c///characteristics_ch1.4: Histotype:mucinous///characteristics_ch1.5: Grade:2///characteristics_ch1.6: Relapsed:no///characteristics_ch1.7: Age(years):64.04///characteristics_ch1.8: Overall Survival(days):2788///characteristics_ch1.9: Progression Free Survival(days):2788///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification from human biopsies were performed using the SV Total RNA Isolation System -cat:#z3100 from Promega.///label_ch1: Cy5///label_protocol_ch1: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch1: 9606///source_name_ch2: Clontech Universal Reference///organism_ch2: Homo sapiens///characteristics_ch2: Human Atlas high pure control total RNA extracted from a pool of 60 human cell lines (BD Biosciences)///molecule_ch2: total RNA///extract_protocol_ch2: see the producer web site: http//clontech.com/products/detail.asp?tabno=2&catalog_id=636538&page=all&faq_id=153665///label_ch2: Cy3///label_protocol_ch2: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch2: 9606///hyb_protocol: Microarray hybridization: Add to each Sample 2.5 ul Cot-1 DNA and 12.50 ul 2X Hybridization Buffer. Heat samples for 2 min at 65 C. Centrifuge. Pipet the cDNA array and 22 ul of sample. Incubate for 16 hr at 65 C. Used Atlas Glass Microarray User Manual PT3453-1 instructions for post-hybridization wash.///scan_protocol: Arrays were scanned using a laser-scanner Axon 4000-B, (Axon Instruments, Union City, CA), using 5-micron resolution. Within the GenePix program were chosen photo-multiplier parameters that defined the quanta intensity density distribution of the array to give a Cy3/Cy5 ratio close to 1.0 and produced not too much saturated signals for each array. Separate 16-bit images were acquired for Cy3 and Cy5.///description: none///data_processing: Images were analysed using the GenePix Pro software (Axon Instruments) version 3.0. GenePix Result files (GPR) and the related scan images, together with the Agilent cDNA pattern file and information on the hybridised samples and labelling signs (positive for normal labelling and negative for dye-swap labelling), were then loaded into the Rosetta Resolver SE software. The Axon GenePix error model was applied to transform data and then duplicate ratio profiles were combined to obtain one ratio experiment for each patient. Log ratios, log ratio errors and p-values were thus available for the non flagged sequences of each ratio experiment.///platform_id: GPL5689///contact_name: Pietro,,Mariani///contact_institute: Mario Negri Institute///contact_address: Via La Masa 19///contact_city: Milan///contact_zip.postal_code: 20156///contact_country: Italy///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM214nnn/GSM214011/GSM214011_raw.txt.gz///data_row_count: 16281
1
title: p0210bis sample_Ovarian tumor///geo_accession: GSM214031///status: Public on Aug 25 2007///submission_date: Jul 31 2007///last_update_date: Aug 24 2007///type: RNA///channel_count: 2///source_name_ch1: Total RNA extracted from frozen biopsies of ovarian tumors///organism_ch1: Homo sapiens///characteristics_ch1: Gender: Female///characteristics_ch1.1: Status:alive no evidence of disease///characteristics_ch1.2: FIGO Stage:1///characteristics_ch1.3: FIGO Substage:c///characteristics_ch1.4: Histotype:serous///characteristics_ch1.5: Grade:2///characteristics_ch1.6: Relapsed:yes///characteristics_ch1.7: Age(years):60.38///characteristics_ch1.8: Overall Survival(days):4615///characteristics_ch1.9: Progression Free Survival(days):4615///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification from human biopsies were performed using the SV Total RNA Isolation System -cat:#z3100 from Promega.///label_ch1: Cy5///label_protocol_ch1: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch1: 9606///source_name_ch2: Clontech Universal Reference///organism_ch2: Homo sapiens///characteristics_ch2: Human Atlas high pure control total RNA extracted from a pool of 60 human cell lines (BD Biosciences)///molecule_ch2: total RNA///extract_protocol_ch2: see the producer web site: http//clontech.com/products/detail.asp?tabno=2&catalog_id=636538&page=all&faq_id=153665///label_ch2: Cy3///label_protocol_ch2: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch2: 9606///hyb_protocol: Microarray hybridization: Add to each Sample 2.5 ul Cot-1 DNA and 12.50 ul 2X Hybridization Buffer. Heat samples for 2 min at 65 C. Centrifuge. Pipet the cDNA array and 22 ul of sample. Incubate for 16 hr at 65 C. Used Atlas Glass Microarray User Manual PT3453-1 instructions for post-hybridization wash.///scan_protocol: Arrays were scanned using a laser-scanner Axon 4000-B, (Axon Instruments, Union City, CA), using 5-micron resolution. Within the GenePix program were chosen photo-multiplier parameters that defined the quanta intensity density distribution of the array to give a Cy3/Cy5 ratio close to 1.0 and produced not too much saturated signals for each array. Separate 16-bit images were acquired for Cy3 and Cy5.///description: none///data_processing: Images were analysed using the GenePix Pro software (Axon Instruments) version 3.0. GenePix Result files (GPR) and the related scan images, together with the Agilent cDNA pattern file and information on the hybridised samples and labelling signs (positive for normal labelling and negative for dye-swap labelling), were then loaded into the Rosetta Resolver SE software. The Axon GenePix error model was applied to transform data and then duplicate ratio profiles were combined to obtain one ratio experiment for each patient. Log ratios, log ratio errors and p-values were thus available for the non flagged sequences of each ratio experiment.///platform_id: GPL5689///contact_name: Pietro,,Mariani///contact_institute: Mario Negri Institute///contact_address: Via La Masa 19///contact_city: Milan///contact_zip.postal_code: 20156///contact_country: Italy///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM214nnn/GSM214031/GSM214031_raw.txt.gz///data_row_count: 16281
1
title: p0217bis sample_Ovarian tumor///geo_accession: GSM214008///status: Public on Aug 25 2007///submission_date: Jul 31 2007///last_update_date: Aug 24 2007///type: RNA///channel_count: 2///source_name_ch1: Total RNA extracted from frozen biopsies of ovarian tumors///organism_ch1: Homo sapiens///characteristics_ch1: Gender: Female///characteristics_ch1.1: Status:death related to cancer///characteristics_ch1.2: FIGO Stage:1///characteristics_ch1.3: FIGO Substage:b///characteristics_ch1.4: Histotype:serous///characteristics_ch1.5: Grade:3///characteristics_ch1.6: Relapsed:yes///characteristics_ch1.7: Age(years):58.71///characteristics_ch1.8: Overall Survival(days):2248///characteristics_ch1.9: Progression Free Survival(days):2248///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification from human biopsies were performed using the SV Total RNA Isolation System -cat:#z3100 from Promega.///label_ch1: Cy5///label_protocol_ch1: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch1: 9606///source_name_ch2: Clontech Universal Reference///organism_ch2: Homo sapiens///characteristics_ch2: Human Atlas high pure control total RNA extracted from a pool of 60 human cell lines (BD Biosciences)///molecule_ch2: total RNA///extract_protocol_ch2: see the producer web site: http//clontech.com/products/detail.asp?tabno=2&catalog_id=636538&page=all&faq_id=153665///label_ch2: Cy3///label_protocol_ch2: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch2: 9606///hyb_protocol: Microarray hybridization: Add to each Sample 2.5 ul Cot-1 DNA and 12.50 ul 2X Hybridization Buffer. Heat samples for 2 min at 65 C. Centrifuge. Pipet the cDNA array and 22 ul of sample. Incubate for 16 hr at 65 C. Used Atlas Glass Microarray User Manual PT3453-1 instructions for post-hybridization wash.///scan_protocol: Arrays were scanned using a laser-scanner Axon 4000-B, (Axon Instruments, Union City, CA), using 5-micron resolution. Within the GenePix program were chosen photo-multiplier parameters that defined the quanta intensity density distribution of the array to give a Cy3/Cy5 ratio close to 1.0 and produced not too much saturated signals for each array. Separate 16-bit images were acquired for Cy3 and Cy5.///description: none///data_processing: Images were analysed using the GenePix Pro software (Axon Instruments) version 3.0. GenePix Result files (GPR) and the related scan images, together with the Agilent cDNA pattern file and information on the hybridised samples and labelling signs (positive for normal labelling and negative for dye-swap labelling), were then loaded into the Rosetta Resolver SE software. The Axon GenePix error model was applied to transform data and then duplicate ratio profiles were combined to obtain one ratio experiment for each patient. Log ratios, log ratio errors and p-values were thus available for the non flagged sequences of each ratio experiment.///platform_id: GPL5689///contact_name: Pietro,,Mariani///contact_institute: Mario Negri Institute///contact_address: Via La Masa 19///contact_city: Milan///contact_zip.postal_code: 20156///contact_country: Italy///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM214nnn/GSM214008/GSM214008_raw.txt.gz///data_row_count: 16281
1
title: p057bis sample_Ovarian tumor///geo_accession: GSM214064///status: Public on Aug 25 2007///submission_date: Jul 31 2007///last_update_date: Aug 24 2007///type: RNA///channel_count: 2///source_name_ch1: Total RNA extracted from frozen biopsies of ovarian tumors///organism_ch1: Homo sapiens///characteristics_ch1: Gender: Female///characteristics_ch1.1: Status:alive no evidence of disease///characteristics_ch1.2: FIGO Stage:1///characteristics_ch1.3: FIGO Substage:a///characteristics_ch1.4: Histotype:clear cells///characteristics_ch1.5: Grade:3///characteristics_ch1.6: Relapsed:no///characteristics_ch1.7: Age(years):61.31///characteristics_ch1.8: Overall Survival(days):4324///characteristics_ch1.9: Progression Free Survival(days):4324///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification from human biopsies were performed using the SV Total RNA Isolation System -cat:#z3100 from Promega.///label_ch1: Cy5///label_protocol_ch1: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch1: 9606///source_name_ch2: Clontech Universal Reference///organism_ch2: Homo sapiens///characteristics_ch2: Human Atlas high pure control total RNA extracted from a pool of 60 human cell lines (BD Biosciences)///molecule_ch2: total RNA///extract_protocol_ch2: see the producer web site: http//clontech.com/products/detail.asp?tabno=2&catalog_id=636538&page=all&faq_id=153665///label_ch2: Cy3///label_protocol_ch2: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch2: 9606///hyb_protocol: Microarray hybridization: Add to each Sample 2.5 ul Cot-1 DNA and 12.50 ul 2X Hybridization Buffer. Heat samples for 2 min at 65 C. Centrifuge. Pipet the cDNA array and 22 ul of sample. Incubate for 16 hr at 65 C. Used Atlas Glass Microarray User Manual PT3453-1 instructions for post-hybridization wash.///scan_protocol: Arrays were scanned using a laser-scanner Axon 4000-B, (Axon Instruments, Union City, CA), using 5-micron resolution. Within the GenePix program were chosen photo-multiplier parameters that defined the quanta intensity density distribution of the array to give a Cy3/Cy5 ratio close to 1.0 and produced not too much saturated signals for each array. Separate 16-bit images were acquired for Cy3 and Cy5.///description: none///data_processing: Images were analysed using the GenePix Pro software (Axon Instruments) version 3.0. GenePix Result files (GPR) and the related scan images, together with the Agilent cDNA pattern file and information on the hybridised samples and labelling signs (positive for normal labelling and negative for dye-swap labelling), were then loaded into the Rosetta Resolver SE software. The Axon GenePix error model was applied to transform data and then duplicate ratio profiles were combined to obtain one ratio experiment for each patient. Log ratios, log ratio errors and p-values were thus available for the non flagged sequences of each ratio experiment.///platform_id: GPL5689///contact_name: Pietro,,Mariani///contact_institute: Mario Negri Institute///contact_address: Via La Masa 19///contact_city: Milan///contact_zip.postal_code: 20156///contact_country: Italy///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM214nnn/GSM214064/GSM214064_raw.txt.gz///data_row_count: 16281
1
title: p070bis sample_Ovarian tumor///geo_accession: GSM214032///status: Public on Aug 25 2007///submission_date: Jul 31 2007///last_update_date: Aug 24 2007///type: RNA///channel_count: 2///source_name_ch1: Total RNA extracted from frozen biopsies of ovarian tumors///organism_ch1: Homo sapiens///characteristics_ch1: Gender: Female///characteristics_ch1.1: Status:death related to cancer///characteristics_ch1.2: FIGO Stage:1///characteristics_ch1.3: FIGO Substage:c///characteristics_ch1.4: Histotype:clear cells///characteristics_ch1.5: Grade:3///characteristics_ch1.6: Relapsed:yes///characteristics_ch1.7: Age(years):51.56///characteristics_ch1.8: Overall Survival(days):609///characteristics_ch1.9: Progression Free Survival(days):609///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification from human biopsies were performed using the SV Total RNA Isolation System -cat:#z3100 from Promega.///label_ch1: Cy5///label_protocol_ch1: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch1: 9606///source_name_ch2: Clontech Universal Reference///organism_ch2: Homo sapiens///characteristics_ch2: Human Atlas high pure control total RNA extracted from a pool of 60 human cell lines (BD Biosciences)///molecule_ch2: total RNA///extract_protocol_ch2: see the producer web site: http//clontech.com/products/detail.asp?tabno=2&catalog_id=636538&page=all&faq_id=153665///label_ch2: Cy3///label_protocol_ch2: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch2: 9606///hyb_protocol: Microarray hybridization: Add to each Sample 2.5 ul Cot-1 DNA and 12.50 ul 2X Hybridization Buffer. Heat samples for 2 min at 65 C. Centrifuge. Pipet the cDNA array and 22 ul of sample. Incubate for 16 hr at 65 C. Used Atlas Glass Microarray User Manual PT3453-1 instructions for post-hybridization wash.///scan_protocol: Arrays were scanned using a laser-scanner Axon 4000-B, (Axon Instruments, Union City, CA), using 5-micron resolution. Within the GenePix program were chosen photo-multiplier parameters that defined the quanta intensity density distribution of the array to give a Cy3/Cy5 ratio close to 1.0 and produced not too much saturated signals for each array. Separate 16-bit images were acquired for Cy3 and Cy5.///description: none///data_processing: Images were analysed using the GenePix Pro software (Axon Instruments) version 3.0. GenePix Result files (GPR) and the related scan images, together with the Agilent cDNA pattern file and information on the hybridised samples and labelling signs (positive for normal labelling and negative for dye-swap labelling), were then loaded into the Rosetta Resolver SE software. The Axon GenePix error model was applied to transform data and then duplicate ratio profiles were combined to obtain one ratio experiment for each patient. Log ratios, log ratio errors and p-values were thus available for the non flagged sequences of each ratio experiment.///platform_id: GPL5689///contact_name: Pietro,,Mariani///contact_institute: Mario Negri Institute///contact_address: Via La Masa 19///contact_city: Milan///contact_zip.postal_code: 20156///contact_country: Italy///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM214nnn/GSM214032/GSM214032_raw.txt.gz///data_row_count: 16281
1
title: p080bis sample_Ovarian tumor///geo_accession: GSM214017///status: Public on Aug 25 2007///submission_date: Jul 31 2007///last_update_date: Aug 24 2007///type: RNA///channel_count: 2///source_name_ch1: Total RNA extracted from frozen biopsies of ovarian tumors///organism_ch1: Homo sapiens///characteristics_ch1: Gender: Female///characteristics_ch1.1: Status:death related to cancer///characteristics_ch1.2: FIGO Stage:1///characteristics_ch1.3: FIGO Substage:c///characteristics_ch1.4: Histotype:endometrioid///characteristics_ch1.5: Grade:2///characteristics_ch1.6: Relapsed:yes///characteristics_ch1.7: Age(years):55.16///characteristics_ch1.8: Overall Survival(days):2810///characteristics_ch1.9: Progression Free Survival(days):2810///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification from human biopsies were performed using the SV Total RNA Isolation System -cat:#z3100 from Promega.///label_ch1: Cy5///label_protocol_ch1: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch1: 9606///source_name_ch2: Clontech Universal Reference///organism_ch2: Homo sapiens///characteristics_ch2: Human Atlas high pure control total RNA extracted from a pool of 60 human cell lines (BD Biosciences)///molecule_ch2: total RNA///extract_protocol_ch2: see the producer web site: http//clontech.com/products/detail.asp?tabno=2&catalog_id=636538&page=all&faq_id=153665///label_ch2: Cy3///label_protocol_ch2: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch2: 9606///hyb_protocol: Microarray hybridization: Add to each Sample 2.5 ul Cot-1 DNA and 12.50 ul 2X Hybridization Buffer. Heat samples for 2 min at 65 C. Centrifuge. Pipet the cDNA array and 22 ul of sample. Incubate for 16 hr at 65 C. Used Atlas Glass Microarray User Manual PT3453-1 instructions for post-hybridization wash.///scan_protocol: Arrays were scanned using a laser-scanner Axon 4000-B, (Axon Instruments, Union City, CA), using 5-micron resolution. Within the GenePix program were chosen photo-multiplier parameters that defined the quanta intensity density distribution of the array to give a Cy3/Cy5 ratio close to 1.0 and produced not too much saturated signals for each array. Separate 16-bit images were acquired for Cy3 and Cy5.///description: none///data_processing: Images were analysed using the GenePix Pro software (Axon Instruments) version 3.0. GenePix Result files (GPR) and the related scan images, together with the Agilent cDNA pattern file and information on the hybridised samples and labelling signs (positive for normal labelling and negative for dye-swap labelling), were then loaded into the Rosetta Resolver SE software. The Axon GenePix error model was applied to transform data and then duplicate ratio profiles were combined to obtain one ratio experiment for each patient. Log ratios, log ratio errors and p-values were thus available for the non flagged sequences of each ratio experiment.///platform_id: GPL5689///contact_name: Pietro,,Mariani///contact_institute: Mario Negri Institute///contact_address: Via La Masa 19///contact_city: Milan///contact_zip.postal_code: 20156///contact_country: Italy///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM214nnn/GSM214017/GSM214017_raw.txt.gz///data_row_count: 16281
1
title: p091bis sample_Ovarian tumor///geo_accession: GSM214024///status: Public on Aug 25 2007///submission_date: Jul 31 2007///last_update_date: Aug 24 2007///type: RNA///channel_count: 2///source_name_ch1: Total RNA extracted from frozen biopsies of ovarian tumors///organism_ch1: Homo sapiens///characteristics_ch1: Gender: Female///characteristics_ch1.1: Status:alive no evidence of disease///characteristics_ch1.2: FIGO Stage:1///characteristics_ch1.3: FIGO Substage:c///characteristics_ch1.4: Histotype:serous///characteristics_ch1.5: Grade:3///characteristics_ch1.6: Relapsed:yes///characteristics_ch1.7: Age(years):62.15///characteristics_ch1.8: Overall Survival(days):4673///characteristics_ch1.9: Progression Free Survival(days):4673///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification from human biopsies were performed using the SV Total RNA Isolation System -cat:#z3100 from Promega.///label_ch1: Cy5///label_protocol_ch1: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch1: 9606///source_name_ch2: Clontech Universal Reference///organism_ch2: Homo sapiens///characteristics_ch2: Human Atlas high pure control total RNA extracted from a pool of 60 human cell lines (BD Biosciences)///molecule_ch2: total RNA///extract_protocol_ch2: see the producer web site: http//clontech.com/products/detail.asp?tabno=2&catalog_id=636538&page=all&faq_id=153665///label_ch2: Cy3///label_protocol_ch2: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch2: 9606///hyb_protocol: Microarray hybridization: Add to each Sample 2.5 ul Cot-1 DNA and 12.50 ul 2X Hybridization Buffer. Heat samples for 2 min at 65 C. Centrifuge. Pipet the cDNA array and 22 ul of sample. Incubate for 16 hr at 65 C. Used Atlas Glass Microarray User Manual PT3453-1 instructions for post-hybridization wash.///scan_protocol: Arrays were scanned using a laser-scanner Axon 4000-B, (Axon Instruments, Union City, CA), using 5-micron resolution. Within the GenePix program were chosen photo-multiplier parameters that defined the quanta intensity density distribution of the array to give a Cy3/Cy5 ratio close to 1.0 and produced not too much saturated signals for each array. Separate 16-bit images were acquired for Cy3 and Cy5.///description: none///data_processing: Images were analysed using the GenePix Pro software (Axon Instruments) version 3.0. GenePix Result files (GPR) and the related scan images, together with the Agilent cDNA pattern file and information on the hybridised samples and labelling signs (positive for normal labelling and negative for dye-swap labelling), were then loaded into the Rosetta Resolver SE software. The Axon GenePix error model was applied to transform data and then duplicate ratio profiles were combined to obtain one ratio experiment for each patient. Log ratios, log ratio errors and p-values were thus available for the non flagged sequences of each ratio experiment.///platform_id: GPL5689///contact_name: Pietro,,Mariani///contact_institute: Mario Negri Institute///contact_address: Via La Masa 19///contact_city: Milan///contact_zip.postal_code: 20156///contact_country: Italy///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM214nnn/GSM214024/GSM214024_raw.txt.gz///data_row_count: 16281
1
title: p139bis sample_Ovarian tumor///geo_accession: GSM214047///status: Public on Aug 25 2007///submission_date: Jul 31 2007///last_update_date: Aug 24 2007///type: RNA///channel_count: 2///source_name_ch1: Total RNA extracted from frozen biopsies of ovarian tumors///organism_ch1: Homo sapiens///characteristics_ch1: Gender: Female///characteristics_ch1.1: Status:alive no evidence of disease///characteristics_ch1.2: FIGO Stage:1///characteristics_ch1.3: FIGO Substage:a///characteristics_ch1.4: Histotype:serous///characteristics_ch1.5: Grade:1///characteristics_ch1.6: Relapsed:no///characteristics_ch1.7: Age(years):49.4///characteristics_ch1.8: Overall Survival(days):3050///characteristics_ch1.9: Progression Free Survival(days):3050///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification from human biopsies were performed using the SV Total RNA Isolation System -cat:#z3100 from Promega.///label_ch1: Cy5///label_protocol_ch1: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch1: 9606///source_name_ch2: Clontech Universal Reference///organism_ch2: Homo sapiens///characteristics_ch2: Human Atlas high pure control total RNA extracted from a pool of 60 human cell lines (BD Biosciences)///molecule_ch2: total RNA///extract_protocol_ch2: see the producer web site: http//clontech.com/products/detail.asp?tabno=2&catalog_id=636538&page=all&faq_id=153665///label_ch2: Cy3///label_protocol_ch2: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch2: 9606///hyb_protocol: Microarray hybridization: Add to each Sample 2.5 ul Cot-1 DNA and 12.50 ul 2X Hybridization Buffer. Heat samples for 2 min at 65 C. Centrifuge. Pipet the cDNA array and 22 ul of sample. Incubate for 16 hr at 65 C. Used Atlas Glass Microarray User Manual PT3453-1 instructions for post-hybridization wash.///scan_protocol: Arrays were scanned using a laser-scanner Axon 4000-B, (Axon Instruments, Union City, CA), using 5-micron resolution. Within the GenePix program were chosen photo-multiplier parameters that defined the quanta intensity density distribution of the array to give a Cy3/Cy5 ratio close to 1.0 and produced not too much saturated signals for each array. Separate 16-bit images were acquired for Cy3 and Cy5.///description: none///data_processing: Images were analysed using the GenePix Pro software (Axon Instruments) version 3.0. GenePix Result files (GPR) and the related scan images, together with the Agilent cDNA pattern file and information on the hybridised samples and labelling signs (positive for normal labelling and negative for dye-swap labelling), were then loaded into the Rosetta Resolver SE software. The Axon GenePix error model was applied to transform data and then duplicate ratio profiles were combined to obtain one ratio experiment for each patient. Log ratios, log ratio errors and p-values were thus available for the non flagged sequences of each ratio experiment.///platform_id: GPL5689///contact_name: Pietro,,Mariani///contact_institute: Mario Negri Institute///contact_address: Via La Masa 19///contact_city: Milan///contact_zip.postal_code: 20156///contact_country: Italy///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM214nnn/GSM214047/GSM214047_raw.txt.gz///data_row_count: 16281
1
title: p13bis sample_Ovarian tumor///geo_accession: GSM214043///status: Public on Aug 25 2007///submission_date: Jul 31 2007///last_update_date: Aug 24 2007///type: RNA///channel_count: 2///source_name_ch1: Total RNA extracted from frozen biopsies of ovarian tumors///organism_ch1: Homo sapiens///characteristics_ch1: Gender: Female///characteristics_ch1.1: Status:alive no evidence of disease///characteristics_ch1.2: FIGO Stage:1///characteristics_ch1.3: FIGO Substage:a///characteristics_ch1.4: Histotype:serous///characteristics_ch1.5: Grade:2///characteristics_ch1.6: Relapsed:no///characteristics_ch1.7: Age(years):47.24///characteristics_ch1.8: Overall Survival(days):3766///characteristics_ch1.9: Progression Free Survival(days):3766///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification from human biopsies were performed using the SV Total RNA Isolation System -cat:#z3100 from Promega.///label_ch1: Cy5///label_protocol_ch1: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch1: 9606///source_name_ch2: Clontech Universal Reference///organism_ch2: Homo sapiens///characteristics_ch2: Human Atlas high pure control total RNA extracted from a pool of 60 human cell lines (BD Biosciences)///molecule_ch2: total RNA///extract_protocol_ch2: see the producer web site: http//clontech.com/products/detail.asp?tabno=2&catalog_id=636538&page=all&faq_id=153665///label_ch2: Cy3///label_protocol_ch2: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch2: 9606///hyb_protocol: Microarray hybridization: Add to each Sample 2.5 ul Cot-1 DNA and 12.50 ul 2X Hybridization Buffer. Heat samples for 2 min at 65 C. Centrifuge. Pipet the cDNA array and 22 ul of sample. Incubate for 16 hr at 65 C. Used Atlas Glass Microarray User Manual PT3453-1 instructions for post-hybridization wash.///scan_protocol: Arrays were scanned using a laser-scanner Axon 4000-B, (Axon Instruments, Union City, CA), using 5-micron resolution. Within the GenePix program were chosen photo-multiplier parameters that defined the quanta intensity density distribution of the array to give a Cy3/Cy5 ratio close to 1.0 and produced not too much saturated signals for each array. Separate 16-bit images were acquired for Cy3 and Cy5.///description: none///data_processing: Images were analysed using the GenePix Pro software (Axon Instruments) version 3.0. GenePix Result files (GPR) and the related scan images, together with the Agilent cDNA pattern file and information on the hybridised samples and labelling signs (positive for normal labelling and negative for dye-swap labelling), were then loaded into the Rosetta Resolver SE software. The Axon GenePix error model was applied to transform data and then duplicate ratio profiles were combined to obtain one ratio experiment for each patient. Log ratios, log ratio errors and p-values were thus available for the non flagged sequences of each ratio experiment.///platform_id: GPL5689///contact_name: Pietro,,Mariani///contact_institute: Mario Negri Institute///contact_address: Via La Masa 19///contact_city: Milan///contact_zip.postal_code: 20156///contact_country: Italy///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM214nnn/GSM214043/GSM214043_raw.txt.gz///data_row_count: 16281
1
title: p141bis sample_Ovarian tumor///geo_accession: GSM214081///status: Public on Aug 25 2007///submission_date: Jul 31 2007///last_update_date: Aug 24 2007///type: RNA///channel_count: 2///source_name_ch1: Total RNA extracted from frozen biopsies of ovarian tumors///organism_ch1: Homo sapiens///characteristics_ch1: Gender: Female///characteristics_ch1.1: Status:death unrelated to cancer///characteristics_ch1.2: FIGO Stage:1///characteristics_ch1.3: FIGO Substage:c///characteristics_ch1.4: Histotype:mucinous///characteristics_ch1.5: Grade:Borderline///characteristics_ch1.6: Relapsed:no///characteristics_ch1.7: Age(years):87.13///characteristics_ch1.8: Overall Survival(days):2861///characteristics_ch1.9: Progression Free Survival(days):2861///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification from human biopsies were performed using the SV Total RNA Isolation System -cat:#z3100 from Promega.///label_ch1: Cy5///label_protocol_ch1: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch1: 9606///source_name_ch2: Clontech Universal Reference///organism_ch2: Homo sapiens///characteristics_ch2: Human Atlas high pure control total RNA extracted from a pool of 60 human cell lines (BD Biosciences)///molecule_ch2: total RNA///extract_protocol_ch2: see the producer web site: http//clontech.com/products/detail.asp?tabno=2&catalog_id=636538&page=all&faq_id=153665///label_ch2: Cy3///label_protocol_ch2: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch2: 9606///hyb_protocol: Microarray hybridization: Add to each Sample 2.5 ul Cot-1 DNA and 12.50 ul 2X Hybridization Buffer. Heat samples for 2 min at 65 C. Centrifuge. Pipet the cDNA array and 22 ul of sample. Incubate for 16 hr at 65 C. Used Atlas Glass Microarray User Manual PT3453-1 instructions for post-hybridization wash.///scan_protocol: Arrays were scanned using a laser-scanner Axon 4000-B, (Axon Instruments, Union City, CA), using 5-micron resolution. Within the GenePix program were chosen photo-multiplier parameters that defined the quanta intensity density distribution of the array to give a Cy3/Cy5 ratio close to 1.0 and produced not too much saturated signals for each array. Separate 16-bit images were acquired for Cy3 and Cy5.///description: none///data_processing: Images were analysed using the GenePix Pro software (Axon Instruments) version 3.0. GenePix Result files (GPR) and the related scan images, together with the Agilent cDNA pattern file and information on the hybridised samples and labelling signs (positive for normal labelling and negative for dye-swap labelling), were then loaded into the Rosetta Resolver SE software. The Axon GenePix error model was applied to transform data and then duplicate ratio profiles were combined to obtain one ratio experiment for each patient. Log ratios, log ratio errors and p-values were thus available for the non flagged sequences of each ratio experiment.///platform_id: GPL5689///contact_name: Pietro,,Mariani///contact_institute: Mario Negri Institute///contact_address: Via La Masa 19///contact_city: Milan///contact_zip.postal_code: 20156///contact_country: Italy///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM214nnn/GSM214081/GSM214081_raw.txt.gz///data_row_count: 16281
1
title: p166bis sample_Ovarian tumor///geo_accession: GSM214013///status: Public on Aug 25 2007///submission_date: Jul 31 2007///last_update_date: Aug 24 2007///type: RNA///channel_count: 2///source_name_ch1: Total RNA extracted from frozen biopsies of ovarian tumors///organism_ch1: Homo sapiens///characteristics_ch1: Gender: Female///characteristics_ch1.1: Status:alive no evidence of disease///characteristics_ch1.2: FIGO Stage:1///characteristics_ch1.3: FIGO Substage:c///characteristics_ch1.4: Histotype:endometrioid///characteristics_ch1.5: Grade:2///characteristics_ch1.6: Relapsed:no///characteristics_ch1.7: Age(years):49.38///characteristics_ch1.8: Overall Survival(days):3006///characteristics_ch1.9: Progression Free Survival(days):3006///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification from human biopsies were performed using the SV Total RNA Isolation System -cat:#z3100 from Promega.///label_ch1: Cy5///label_protocol_ch1: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch1: 9606///source_name_ch2: Clontech Universal Reference///organism_ch2: Homo sapiens///characteristics_ch2: Human Atlas high pure control total RNA extracted from a pool of 60 human cell lines (BD Biosciences)///molecule_ch2: total RNA///extract_protocol_ch2: see the producer web site: http//clontech.com/products/detail.asp?tabno=2&catalog_id=636538&page=all&faq_id=153665///label_ch2: Cy3///label_protocol_ch2: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch2: 9606///hyb_protocol: Microarray hybridization: Add to each Sample 2.5 ul Cot-1 DNA and 12.50 ul 2X Hybridization Buffer. Heat samples for 2 min at 65 C. Centrifuge. Pipet the cDNA array and 22 ul of sample. Incubate for 16 hr at 65 C. Used Atlas Glass Microarray User Manual PT3453-1 instructions for post-hybridization wash.///scan_protocol: Arrays were scanned using a laser-scanner Axon 4000-B, (Axon Instruments, Union City, CA), using 5-micron resolution. Within the GenePix program were chosen photo-multiplier parameters that defined the quanta intensity density distribution of the array to give a Cy3/Cy5 ratio close to 1.0 and produced not too much saturated signals for each array. Separate 16-bit images were acquired for Cy3 and Cy5.///description: none///data_processing: Images were analysed using the GenePix Pro software (Axon Instruments) version 3.0. GenePix Result files (GPR) and the related scan images, together with the Agilent cDNA pattern file and information on the hybridised samples and labelling signs (positive for normal labelling and negative for dye-swap labelling), were then loaded into the Rosetta Resolver SE software. The Axon GenePix error model was applied to transform data and then duplicate ratio profiles were combined to obtain one ratio experiment for each patient. Log ratios, log ratio errors and p-values were thus available for the non flagged sequences of each ratio experiment.///platform_id: GPL5689///contact_name: Pietro,,Mariani///contact_institute: Mario Negri Institute///contact_address: Via La Masa 19///contact_city: Milan///contact_zip.postal_code: 20156///contact_country: Italy///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM214nnn/GSM214013/GSM214013_raw.txt.gz///data_row_count: 16281
1
title: p171bis sample_Ovarian tumor///geo_accession: GSM214014///status: Public on Aug 25 2007///submission_date: Jul 31 2007///last_update_date: Aug 24 2007///type: RNA///channel_count: 2///source_name_ch1: Total RNA extracted from frozen biopsies of ovarian tumors///organism_ch1: Homo sapiens///characteristics_ch1: Gender: Female///characteristics_ch1.1: Status:death related to cancer///characteristics_ch1.2: FIGO Stage:1///characteristics_ch1.3: FIGO Substage:c///characteristics_ch1.4: Histotype:clear cells///characteristics_ch1.5: Grade:3///characteristics_ch1.6: Relapsed:yes///characteristics_ch1.7: Age(years):51.79///characteristics_ch1.8: Overall Survival(days):743///characteristics_ch1.9: Progression Free Survival(days):743///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification from human biopsies were performed using the SV Total RNA Isolation System -cat:#z3100 from Promega.///label_ch1: Cy5///label_protocol_ch1: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch1: 9606///source_name_ch2: Clontech Universal Reference///organism_ch2: Homo sapiens///characteristics_ch2: Human Atlas high pure control total RNA extracted from a pool of 60 human cell lines (BD Biosciences)///molecule_ch2: total RNA///extract_protocol_ch2: see the producer web site: http//clontech.com/products/detail.asp?tabno=2&catalog_id=636538&page=all&faq_id=153665///label_ch2: Cy3///label_protocol_ch2: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch2: 9606///hyb_protocol: Microarray hybridization: Add to each Sample 2.5 ul Cot-1 DNA and 12.50 ul 2X Hybridization Buffer. Heat samples for 2 min at 65 C. Centrifuge. Pipet the cDNA array and 22 ul of sample. Incubate for 16 hr at 65 C. Used Atlas Glass Microarray User Manual PT3453-1 instructions for post-hybridization wash.///scan_protocol: Arrays were scanned using a laser-scanner Axon 4000-B, (Axon Instruments, Union City, CA), using 5-micron resolution. Within the GenePix program were chosen photo-multiplier parameters that defined the quanta intensity density distribution of the array to give a Cy3/Cy5 ratio close to 1.0 and produced not too much saturated signals for each array. Separate 16-bit images were acquired for Cy3 and Cy5.///description: none///data_processing: Images were analysed using the GenePix Pro software (Axon Instruments) version 3.0. GenePix Result files (GPR) and the related scan images, together with the Agilent cDNA pattern file and information on the hybridised samples and labelling signs (positive for normal labelling and negative for dye-swap labelling), were then loaded into the Rosetta Resolver SE software. The Axon GenePix error model was applied to transform data and then duplicate ratio profiles were combined to obtain one ratio experiment for each patient. Log ratios, log ratio errors and p-values were thus available for the non flagged sequences of each ratio experiment.///platform_id: GPL5689///contact_name: Pietro,,Mariani///contact_institute: Mario Negri Institute///contact_address: Via La Masa 19///contact_city: Milan///contact_zip.postal_code: 20156///contact_country: Italy///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM214nnn/GSM214014/GSM214014_raw.txt.gz///data_row_count: 16281
1
title: p17bis sample_Ovarian tumor///geo_accession: GSM214080///status: Public on Aug 25 2007///submission_date: Jul 31 2007///last_update_date: Aug 24 2007///type: RNA///channel_count: 2///source_name_ch1: Total RNA extracted from frozen biopsies of ovarian tumors///organism_ch1: Homo sapiens///characteristics_ch1: Gender: Female///characteristics_ch1.1: Status:alive no evidence of disease///characteristics_ch1.2: FIGO Stage:1///characteristics_ch1.3: FIGO Substage:c///characteristics_ch1.4: Histotype:serous///characteristics_ch1.5: Grade:Borderline///characteristics_ch1.6: Relapsed:yes///characteristics_ch1.7: Age(years):23.61///characteristics_ch1.8: Overall Survival(days):4404///characteristics_ch1.9: Progression Free Survival(days):4404///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification from human biopsies were performed using the SV Total RNA Isolation System -cat:#z3100 from Promega.///label_ch1: Cy5///label_protocol_ch1: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch1: 9606///source_name_ch2: Clontech Universal Reference///organism_ch2: Homo sapiens///characteristics_ch2: Human Atlas high pure control total RNA extracted from a pool of 60 human cell lines (BD Biosciences)///molecule_ch2: total RNA///extract_protocol_ch2: see the producer web site: http//clontech.com/products/detail.asp?tabno=2&catalog_id=636538&page=all&faq_id=153665///label_ch2: Cy3///label_protocol_ch2: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch2: 9606///hyb_protocol: Microarray hybridization: Add to each Sample 2.5 ul Cot-1 DNA and 12.50 ul 2X Hybridization Buffer. Heat samples for 2 min at 65 C. Centrifuge. Pipet the cDNA array and 22 ul of sample. Incubate for 16 hr at 65 C. Used Atlas Glass Microarray User Manual PT3453-1 instructions for post-hybridization wash.///scan_protocol: Arrays were scanned using a laser-scanner Axon 4000-B, (Axon Instruments, Union City, CA), using 5-micron resolution. Within the GenePix program were chosen photo-multiplier parameters that defined the quanta intensity density distribution of the array to give a Cy3/Cy5 ratio close to 1.0 and produced not too much saturated signals for each array. Separate 16-bit images were acquired for Cy3 and Cy5.///description: none///data_processing: Images were analysed using the GenePix Pro software (Axon Instruments) version 3.0. GenePix Result files (GPR) and the related scan images, together with the Agilent cDNA pattern file and information on the hybridised samples and labelling signs (positive for normal labelling and negative for dye-swap labelling), were then loaded into the Rosetta Resolver SE software. The Axon GenePix error model was applied to transform data and then duplicate ratio profiles were combined to obtain one ratio experiment for each patient. Log ratios, log ratio errors and p-values were thus available for the non flagged sequences of each ratio experiment.///platform_id: GPL5689///contact_name: Pietro,,Mariani///contact_institute: Mario Negri Institute///contact_address: Via La Masa 19///contact_city: Milan///contact_zip.postal_code: 20156///contact_country: Italy///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM214nnn/GSM214080/GSM214080_raw.txt.gz///data_row_count: 16281
1
title: p183bis sample_Ovarian tumor///geo_accession: GSM214015///status: Public on Aug 25 2007///submission_date: Jul 31 2007///last_update_date: Aug 24 2007///type: RNA///channel_count: 2///source_name_ch1: Total RNA extracted from frozen biopsies of ovarian tumors///organism_ch1: Homo sapiens///characteristics_ch1: Gender: Female///characteristics_ch1.1: Status:alive no evidence of disease///characteristics_ch1.2: FIGO Stage:1///characteristics_ch1.3: FIGO Substage:c///characteristics_ch1.4: Histotype:serous///characteristics_ch1.5: Grade:3///characteristics_ch1.6: Relapsed:no///characteristics_ch1.7: Age(years):55.93///characteristics_ch1.8: Overall Survival(days):3045///characteristics_ch1.9: Progression Free Survival(days):3045///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification from human biopsies were performed using the SV Total RNA Isolation System -cat:#z3100 from Promega.///label_ch1: Cy5///label_protocol_ch1: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch1: 9606///source_name_ch2: Clontech Universal Reference///organism_ch2: Homo sapiens///characteristics_ch2: Human Atlas high pure control total RNA extracted from a pool of 60 human cell lines (BD Biosciences)///molecule_ch2: total RNA///extract_protocol_ch2: see the producer web site: http//clontech.com/products/detail.asp?tabno=2&catalog_id=636538&page=all&faq_id=153665///label_ch2: Cy3///label_protocol_ch2: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch2: 9606///hyb_protocol: Microarray hybridization: Add to each Sample 2.5 ul Cot-1 DNA and 12.50 ul 2X Hybridization Buffer. Heat samples for 2 min at 65 C. Centrifuge. Pipet the cDNA array and 22 ul of sample. Incubate for 16 hr at 65 C. Used Atlas Glass Microarray User Manual PT3453-1 instructions for post-hybridization wash.///scan_protocol: Arrays were scanned using a laser-scanner Axon 4000-B, (Axon Instruments, Union City, CA), using 5-micron resolution. Within the GenePix program were chosen photo-multiplier parameters that defined the quanta intensity density distribution of the array to give a Cy3/Cy5 ratio close to 1.0 and produced not too much saturated signals for each array. Separate 16-bit images were acquired for Cy3 and Cy5.///description: none///data_processing: Images were analysed using the GenePix Pro software (Axon Instruments) version 3.0. GenePix Result files (GPR) and the related scan images, together with the Agilent cDNA pattern file and information on the hybridised samples and labelling signs (positive for normal labelling and negative for dye-swap labelling), were then loaded into the Rosetta Resolver SE software. The Axon GenePix error model was applied to transform data and then duplicate ratio profiles were combined to obtain one ratio experiment for each patient. Log ratios, log ratio errors and p-values were thus available for the non flagged sequences of each ratio experiment.///platform_id: GPL5689///contact_name: Pietro,,Mariani///contact_institute: Mario Negri Institute///contact_address: Via La Masa 19///contact_city: Milan///contact_zip.postal_code: 20156///contact_country: Italy///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM214nnn/GSM214015/GSM214015_raw.txt.gz///data_row_count: 16281
1
title: p209bis sample_Ovarian tumor///geo_accession: GSM214090///status: Public on Aug 25 2007///submission_date: Jul 31 2007///last_update_date: Aug 24 2007///type: RNA///channel_count: 2///source_name_ch1: Total RNA extracted from frozen biopsies of ovarian tumors///organism_ch1: Homo sapiens///characteristics_ch1: Gender: Female///characteristics_ch1.1: Status:alive no evidence of disease///characteristics_ch1.2: FIGO Stage:1///characteristics_ch1.3: FIGO Substage:c///characteristics_ch1.4: Histotype:serous///characteristics_ch1.5: Grade:Borderline///characteristics_ch1.6: Relapsed:yes///characteristics_ch1.7: Age(years):53.75///characteristics_ch1.8: Overall Survival(days):2669///characteristics_ch1.9: Progression Free Survival(days):2669///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification from human biopsies were performed using the SV Total RNA Isolation System -cat:#z3100 from Promega.///label_ch1: Cy5///label_protocol_ch1: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch1: 9606///source_name_ch2: Clontech Universal Reference///organism_ch2: Homo sapiens///characteristics_ch2: Human Atlas high pure control total RNA extracted from a pool of 60 human cell lines (BD Biosciences)///molecule_ch2: total RNA///extract_protocol_ch2: see the producer web site: http//clontech.com/products/detail.asp?tabno=2&catalog_id=636538&page=all&faq_id=153665///label_ch2: Cy3///label_protocol_ch2: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch2: 9606///hyb_protocol: Microarray hybridization: Add to each Sample 2.5 ul Cot-1 DNA and 12.50 ul 2X Hybridization Buffer. Heat samples for 2 min at 65 C. Centrifuge. Pipet the cDNA array and 22 ul of sample. Incubate for 16 hr at 65 C. Used Atlas Glass Microarray User Manual PT3453-1 instructions for post-hybridization wash.///scan_protocol: Arrays were scanned using a laser-scanner Axon 4000-B, (Axon Instruments, Union City, CA), using 5-micron resolution. Within the GenePix program were chosen photo-multiplier parameters that defined the quanta intensity density distribution of the array to give a Cy3/Cy5 ratio close to 1.0 and produced not too much saturated signals for each array. Separate 16-bit images were acquired for Cy3 and Cy5.///description: none///data_processing: Images were analysed using the GenePix Pro software (Axon Instruments) version 3.0. GenePix Result files (GPR) and the related scan images, together with the Agilent cDNA pattern file and information on the hybridised samples and labelling signs (positive for normal labelling and negative for dye-swap labelling), were then loaded into the Rosetta Resolver SE software. The Axon GenePix error model was applied to transform data and then duplicate ratio profiles were combined to obtain one ratio experiment for each patient. Log ratios, log ratio errors and p-values were thus available for the non flagged sequences of each ratio experiment.///platform_id: GPL5689///contact_name: Pietro,,Mariani///contact_institute: Mario Negri Institute///contact_address: Via La Masa 19///contact_city: Milan///contact_zip.postal_code: 20156///contact_country: Italy///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM214nnn/GSM214090/GSM214090_raw.txt.gz///data_row_count: 16281
1
title: p212bis sample_Ovarian tumor///geo_accession: GSM214065///status: Public on Aug 25 2007///submission_date: Jul 31 2007///last_update_date: Aug 24 2007///type: RNA///channel_count: 2///source_name_ch1: Total RNA extracted from frozen biopsies of ovarian tumors///organism_ch1: Homo sapiens///characteristics_ch1: Gender: Female///characteristics_ch1.1: Status:alive no evidence of disease///characteristics_ch1.2: FIGO Stage:1///characteristics_ch1.3: FIGO Substage:c///characteristics_ch1.4: Histotype:clear cells///characteristics_ch1.5: Grade:3///characteristics_ch1.6: Relapsed:no///characteristics_ch1.7: Age(years):49.36///characteristics_ch1.8: Overall Survival(days):2926///characteristics_ch1.9: Progression Free Survival(days):2926///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification from human biopsies were performed using the SV Total RNA Isolation System -cat:#z3100 from Promega.///label_ch1: Cy5///label_protocol_ch1: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch1: 9606///source_name_ch2: Clontech Universal Reference///organism_ch2: Homo sapiens///characteristics_ch2: Human Atlas high pure control total RNA extracted from a pool of 60 human cell lines (BD Biosciences)///molecule_ch2: total RNA///extract_protocol_ch2: see the producer web site: http//clontech.com/products/detail.asp?tabno=2&catalog_id=636538&page=all&faq_id=153665///label_ch2: Cy3///label_protocol_ch2: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch2: 9606///hyb_protocol: Microarray hybridization: Add to each Sample 2.5 ul Cot-1 DNA and 12.50 ul 2X Hybridization Buffer. Heat samples for 2 min at 65 C. Centrifuge. Pipet the cDNA array and 22 ul of sample. Incubate for 16 hr at 65 C. Used Atlas Glass Microarray User Manual PT3453-1 instructions for post-hybridization wash.///scan_protocol: Arrays were scanned using a laser-scanner Axon 4000-B, (Axon Instruments, Union City, CA), using 5-micron resolution. Within the GenePix program were chosen photo-multiplier parameters that defined the quanta intensity density distribution of the array to give a Cy3/Cy5 ratio close to 1.0 and produced not too much saturated signals for each array. Separate 16-bit images were acquired for Cy3 and Cy5.///description: none///data_processing: Images were analysed using the GenePix Pro software (Axon Instruments) version 3.0. GenePix Result files (GPR) and the related scan images, together with the Agilent cDNA pattern file and information on the hybridised samples and labelling signs (positive for normal labelling and negative for dye-swap labelling), were then loaded into the Rosetta Resolver SE software. The Axon GenePix error model was applied to transform data and then duplicate ratio profiles were combined to obtain one ratio experiment for each patient. Log ratios, log ratio errors and p-values were thus available for the non flagged sequences of each ratio experiment.///platform_id: GPL5689///contact_name: Pietro,,Mariani///contact_institute: Mario Negri Institute///contact_address: Via La Masa 19///contact_city: Milan///contact_zip.postal_code: 20156///contact_country: Italy///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM214nnn/GSM214065/GSM214065_raw.txt.gz///data_row_count: 16281
1
title: p213bis sample_Ovarian tumor///geo_accession: GSM214018///status: Public on Aug 25 2007///submission_date: Jul 31 2007///last_update_date: Aug 24 2007///type: RNA///channel_count: 2///source_name_ch1: Total RNA extracted from frozen biopsies of ovarian tumors///organism_ch1: Homo sapiens///characteristics_ch1: Gender: Female///characteristics_ch1.1: Status:alive no evidence of disease///characteristics_ch1.2: FIGO Stage:1///characteristics_ch1.3: FIGO Substage:c///characteristics_ch1.4: Histotype:mucinous///characteristics_ch1.5: Grade:1///characteristics_ch1.6: Relapsed:no///characteristics_ch1.7: Age(years):33.81///characteristics_ch1.8: Overall Survival(days):2910///characteristics_ch1.9: Progression Free Survival(days):2910///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification from human biopsies were performed using the SV Total RNA Isolation System -cat:#z3100 from Promega.///label_ch1: Cy5///label_protocol_ch1: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch1: 9606///source_name_ch2: Clontech Universal Reference///organism_ch2: Homo sapiens///characteristics_ch2: Human Atlas high pure control total RNA extracted from a pool of 60 human cell lines (BD Biosciences)///molecule_ch2: total RNA///extract_protocol_ch2: see the producer web site: http//clontech.com/products/detail.asp?tabno=2&catalog_id=636538&page=all&faq_id=153665///label_ch2: Cy3///label_protocol_ch2: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch2: 9606///hyb_protocol: Microarray hybridization: Add to each Sample 2.5 ul Cot-1 DNA and 12.50 ul 2X Hybridization Buffer. Heat samples for 2 min at 65 C. Centrifuge. Pipet the cDNA array and 22 ul of sample. Incubate for 16 hr at 65 C. Used Atlas Glass Microarray User Manual PT3453-1 instructions for post-hybridization wash.///scan_protocol: Arrays were scanned using a laser-scanner Axon 4000-B, (Axon Instruments, Union City, CA), using 5-micron resolution. Within the GenePix program were chosen photo-multiplier parameters that defined the quanta intensity density distribution of the array to give a Cy3/Cy5 ratio close to 1.0 and produced not too much saturated signals for each array. Separate 16-bit images were acquired for Cy3 and Cy5.///description: none///data_processing: Images were analysed using the GenePix Pro software (Axon Instruments) version 3.0. GenePix Result files (GPR) and the related scan images, together with the Agilent cDNA pattern file and information on the hybridised samples and labelling signs (positive for normal labelling and negative for dye-swap labelling), were then loaded into the Rosetta Resolver SE software. The Axon GenePix error model was applied to transform data and then duplicate ratio profiles were combined to obtain one ratio experiment for each patient. Log ratios, log ratio errors and p-values were thus available for the non flagged sequences of each ratio experiment.///platform_id: GPL5689///contact_name: Pietro,,Mariani///contact_institute: Mario Negri Institute///contact_address: Via La Masa 19///contact_city: Milan///contact_zip.postal_code: 20156///contact_country: Italy///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM214nnn/GSM214018/GSM214018_raw.txt.gz///data_row_count: 16281
1
title: p243bis sample_Ovarian tumor///geo_accession: GSM214042///status: Public on Aug 25 2007///submission_date: Jul 31 2007///last_update_date: Aug 24 2007///type: RNA///channel_count: 2///source_name_ch1: Total RNA extracted from frozen biopsies of ovarian tumors///organism_ch1: Homo sapiens///characteristics_ch1: Gender: Female///characteristics_ch1.1: Status:alive no evidence of disease///characteristics_ch1.2: FIGO Stage:1///characteristics_ch1.3: FIGO Substage:a///characteristics_ch1.4: Histotype:mucinous///characteristics_ch1.5: Grade:2///characteristics_ch1.6: Relapsed:no///characteristics_ch1.7: Age(years):56.65///characteristics_ch1.8: Overall Survival(days):2702///characteristics_ch1.9: Progression Free Survival(days):2702///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification from human biopsies were performed using the SV Total RNA Isolation System -cat:#z3100 from Promega.///label_ch1: Cy5///label_protocol_ch1: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch1: 9606///source_name_ch2: Clontech Universal Reference///organism_ch2: Homo sapiens///characteristics_ch2: Human Atlas high pure control total RNA extracted from a pool of 60 human cell lines (BD Biosciences)///molecule_ch2: total RNA///extract_protocol_ch2: see the producer web site: http//clontech.com/products/detail.asp?tabno=2&catalog_id=636538&page=all&faq_id=153665///label_ch2: Cy3///label_protocol_ch2: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch2: 9606///hyb_protocol: Microarray hybridization: Add to each Sample 2.5 ul Cot-1 DNA and 12.50 ul 2X Hybridization Buffer. Heat samples for 2 min at 65 C. Centrifuge. Pipet the cDNA array and 22 ul of sample. Incubate for 16 hr at 65 C. Used Atlas Glass Microarray User Manual PT3453-1 instructions for post-hybridization wash.///scan_protocol: Arrays were scanned using a laser-scanner Axon 4000-B, (Axon Instruments, Union City, CA), using 5-micron resolution. Within the GenePix program were chosen photo-multiplier parameters that defined the quanta intensity density distribution of the array to give a Cy3/Cy5 ratio close to 1.0 and produced not too much saturated signals for each array. Separate 16-bit images were acquired for Cy3 and Cy5.///description: none///data_processing: Images were analysed using the GenePix Pro software (Axon Instruments) version 3.0. GenePix Result files (GPR) and the related scan images, together with the Agilent cDNA pattern file and information on the hybridised samples and labelling signs (positive for normal labelling and negative for dye-swap labelling), were then loaded into the Rosetta Resolver SE software. The Axon GenePix error model was applied to transform data and then duplicate ratio profiles were combined to obtain one ratio experiment for each patient. Log ratios, log ratio errors and p-values were thus available for the non flagged sequences of each ratio experiment.///platform_id: GPL5689///contact_name: Pietro,,Mariani///contact_institute: Mario Negri Institute///contact_address: Via La Masa 19///contact_city: Milan///contact_zip.postal_code: 20156///contact_country: Italy///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM214nnn/GSM214042/GSM214042_raw.txt.gz///data_row_count: 16281
1
title: p246bis sample_Ovarian tumor///geo_accession: GSM214055///status: Public on Aug 25 2007///submission_date: Jul 31 2007///last_update_date: Aug 24 2007///type: RNA///channel_count: 2///source_name_ch1: Total RNA extracted from frozen biopsies of ovarian tumors///organism_ch1: Homo sapiens///characteristics_ch1: Gender: Female///characteristics_ch1.1: Status:alive no evidence of disease///characteristics_ch1.2: FIGO Stage:1///characteristics_ch1.3: FIGO Substage:c///characteristics_ch1.4: Histotype:endometrioid///characteristics_ch1.5: Grade:1///characteristics_ch1.6: Relapsed:no///characteristics_ch1.7: Age(years):44.32///characteristics_ch1.8: Overall Survival(days):2814///characteristics_ch1.9: Progression Free Survival(days):2814///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification from human biopsies were performed using the SV Total RNA Isolation System -cat:#z3100 from Promega.///label_ch1: Cy5///label_protocol_ch1: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch1: 9606///source_name_ch2: Clontech Universal Reference///organism_ch2: Homo sapiens///characteristics_ch2: Human Atlas high pure control total RNA extracted from a pool of 60 human cell lines (BD Biosciences)///molecule_ch2: total RNA///extract_protocol_ch2: see the producer web site: http//clontech.com/products/detail.asp?tabno=2&catalog_id=636538&page=all&faq_id=153665///label_ch2: Cy3///label_protocol_ch2: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch2: 9606///hyb_protocol: Microarray hybridization: Add to each Sample 2.5 ul Cot-1 DNA and 12.50 ul 2X Hybridization Buffer. Heat samples for 2 min at 65 C. Centrifuge. Pipet the cDNA array and 22 ul of sample. Incubate for 16 hr at 65 C. Used Atlas Glass Microarray User Manual PT3453-1 instructions for post-hybridization wash.///scan_protocol: Arrays were scanned using a laser-scanner Axon 4000-B, (Axon Instruments, Union City, CA), using 5-micron resolution. Within the GenePix program were chosen photo-multiplier parameters that defined the quanta intensity density distribution of the array to give a Cy3/Cy5 ratio close to 1.0 and produced not too much saturated signals for each array. Separate 16-bit images were acquired for Cy3 and Cy5.///description: none///data_processing: Images were analysed using the GenePix Pro software (Axon Instruments) version 3.0. GenePix Result files (GPR) and the related scan images, together with the Agilent cDNA pattern file and information on the hybridised samples and labelling signs (positive for normal labelling and negative for dye-swap labelling), were then loaded into the Rosetta Resolver SE software. The Axon GenePix error model was applied to transform data and then duplicate ratio profiles were combined to obtain one ratio experiment for each patient. Log ratios, log ratio errors and p-values were thus available for the non flagged sequences of each ratio experiment.///platform_id: GPL5689///contact_name: Pietro,,Mariani///contact_institute: Mario Negri Institute///contact_address: Via La Masa 19///contact_city: Milan///contact_zip.postal_code: 20156///contact_country: Italy///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM214nnn/GSM214055/GSM214055_raw.txt.gz///data_row_count: 16281
1
title: p261bis sample_Ovarian tumor///geo_accession: GSM214034///status: Public on Aug 25 2007///submission_date: Jul 31 2007///last_update_date: Aug 24 2007///type: RNA///channel_count: 2///source_name_ch1: Total RNA extracted from frozen biopsies of ovarian tumors///organism_ch1: Homo sapiens///characteristics_ch1: Gender: Female///characteristics_ch1.1: Status:alive no evidence of disease///characteristics_ch1.2: FIGO Stage:1///characteristics_ch1.3: FIGO Substage:b///characteristics_ch1.4: Histotype:serous///characteristics_ch1.5: Grade:2///characteristics_ch1.6: Relapsed:no///characteristics_ch1.7: Age(years):48.88///characteristics_ch1.8: Overall Survival(days):2281///characteristics_ch1.9: Progression Free Survival(days):2281///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification from human biopsies were performed using the SV Total RNA Isolation System -cat:#z3100 from Promega.///label_ch1: Cy5///label_protocol_ch1: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch1: 9606///source_name_ch2: Clontech Universal Reference///organism_ch2: Homo sapiens///characteristics_ch2: Human Atlas high pure control total RNA extracted from a pool of 60 human cell lines (BD Biosciences)///molecule_ch2: total RNA///extract_protocol_ch2: see the producer web site: http//clontech.com/products/detail.asp?tabno=2&catalog_id=636538&page=all&faq_id=153665///label_ch2: Cy3///label_protocol_ch2: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch2: 9606///hyb_protocol: Microarray hybridization: Add to each Sample 2.5 ul Cot-1 DNA and 12.50 ul 2X Hybridization Buffer. Heat samples for 2 min at 65 C. Centrifuge. Pipet the cDNA array and 22 ul of sample. Incubate for 16 hr at 65 C. Used Atlas Glass Microarray User Manual PT3453-1 instructions for post-hybridization wash.///scan_protocol: Arrays were scanned using a laser-scanner Axon 4000-B, (Axon Instruments, Union City, CA), using 5-micron resolution. Within the GenePix program were chosen photo-multiplier parameters that defined the quanta intensity density distribution of the array to give a Cy3/Cy5 ratio close to 1.0 and produced not too much saturated signals for each array. Separate 16-bit images were acquired for Cy3 and Cy5.///description: none///data_processing: Images were analysed using the GenePix Pro software (Axon Instruments) version 3.0. GenePix Result files (GPR) and the related scan images, together with the Agilent cDNA pattern file and information on the hybridised samples and labelling signs (positive for normal labelling and negative for dye-swap labelling), were then loaded into the Rosetta Resolver SE software. The Axon GenePix error model was applied to transform data and then duplicate ratio profiles were combined to obtain one ratio experiment for each patient. Log ratios, log ratio errors and p-values were thus available for the non flagged sequences of each ratio experiment.///platform_id: GPL5689///contact_name: Pietro,,Mariani///contact_institute: Mario Negri Institute///contact_address: Via La Masa 19///contact_city: Milan///contact_zip.postal_code: 20156///contact_country: Italy///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM214nnn/GSM214034/GSM214034_raw.txt.gz///data_row_count: 16281
1
title: p284bis sample_Ovarian tumor///geo_accession: GSM214049///status: Public on Aug 25 2007///submission_date: Jul 31 2007///last_update_date: Aug 24 2007///type: RNA///channel_count: 2///source_name_ch1: Total RNA extracted from frozen biopsies of ovarian tumors///organism_ch1: Homo sapiens///characteristics_ch1: Gender: Female///characteristics_ch1.1: Status:in progression///characteristics_ch1.2: FIGO Stage:1///characteristics_ch1.3: FIGO Substage:c///characteristics_ch1.4: Histotype:serous///characteristics_ch1.5: Grade:3///characteristics_ch1.6: Relapsed:yes///characteristics_ch1.7: Age(years):54.1///characteristics_ch1.8: Overall Survival(days):1053///characteristics_ch1.9: Progression Free Survival(days):1053///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification from human biopsies were performed using the SV Total RNA Isolation System -cat:#z3100 from Promega.///label_ch1: Cy5///label_protocol_ch1: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch1: 9606///source_name_ch2: Clontech Universal Reference///organism_ch2: Homo sapiens///characteristics_ch2: Human Atlas high pure control total RNA extracted from a pool of 60 human cell lines (BD Biosciences)///molecule_ch2: total RNA///extract_protocol_ch2: see the producer web site: http//clontech.com/products/detail.asp?tabno=2&catalog_id=636538&page=all&faq_id=153665///label_ch2: Cy3///label_protocol_ch2: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch2: 9606///hyb_protocol: Microarray hybridization: Add to each Sample 2.5 ul Cot-1 DNA and 12.50 ul 2X Hybridization Buffer. Heat samples for 2 min at 65 C. Centrifuge. Pipet the cDNA array and 22 ul of sample. Incubate for 16 hr at 65 C. Used Atlas Glass Microarray User Manual PT3453-1 instructions for post-hybridization wash.///scan_protocol: Arrays were scanned using a laser-scanner Axon 4000-B, (Axon Instruments, Union City, CA), using 5-micron resolution. Within the GenePix program were chosen photo-multiplier parameters that defined the quanta intensity density distribution of the array to give a Cy3/Cy5 ratio close to 1.0 and produced not too much saturated signals for each array. Separate 16-bit images were acquired for Cy3 and Cy5.///description: none///data_processing: Images were analysed using the GenePix Pro software (Axon Instruments) version 3.0. GenePix Result files (GPR) and the related scan images, together with the Agilent cDNA pattern file and information on the hybridised samples and labelling signs (positive for normal labelling and negative for dye-swap labelling), were then loaded into the Rosetta Resolver SE software. The Axon GenePix error model was applied to transform data and then duplicate ratio profiles were combined to obtain one ratio experiment for each patient. Log ratios, log ratio errors and p-values were thus available for the non flagged sequences of each ratio experiment.///platform_id: GPL5689///contact_name: Pietro,,Mariani///contact_institute: Mario Negri Institute///contact_address: Via La Masa 19///contact_city: Milan///contact_zip.postal_code: 20156///contact_country: Italy///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM214nnn/GSM214049/GSM214049_raw.txt.gz///data_row_count: 16281
1
title: p293bis sample_Ovarian tumor///geo_accession: GSM214035///status: Public on Aug 25 2007///submission_date: Jul 31 2007///last_update_date: Aug 24 2007///type: RNA///channel_count: 2///source_name_ch1: Total RNA extracted from frozen biopsies of ovarian tumors///organism_ch1: Homo sapiens///characteristics_ch1: Gender: Female///characteristics_ch1.1: Status:alive no evidence of disease///characteristics_ch1.2: FIGO Stage:1///characteristics_ch1.3: FIGO Substage:c///characteristics_ch1.4: Histotype:endometrioid///characteristics_ch1.5: Grade:2///characteristics_ch1.6: Relapsed:no///characteristics_ch1.7: Age(years):49.86///characteristics_ch1.8: Overall Survival(days):2199///characteristics_ch1.9: Progression Free Survival(days):2199///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification from human biopsies were performed using the SV Total RNA Isolation System -cat:#z3100 from Promega.///label_ch1: Cy5///label_protocol_ch1: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch1: 9606///source_name_ch2: Clontech Universal Reference///organism_ch2: Homo sapiens///characteristics_ch2: Human Atlas high pure control total RNA extracted from a pool of 60 human cell lines (BD Biosciences)///molecule_ch2: total RNA///extract_protocol_ch2: see the producer web site: http//clontech.com/products/detail.asp?tabno=2&catalog_id=636538&page=all&faq_id=153665///label_ch2: Cy3///label_protocol_ch2: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch2: 9606///hyb_protocol: Microarray hybridization: Add to each Sample 2.5 ul Cot-1 DNA and 12.50 ul 2X Hybridization Buffer. Heat samples for 2 min at 65 C. Centrifuge. Pipet the cDNA array and 22 ul of sample. Incubate for 16 hr at 65 C. Used Atlas Glass Microarray User Manual PT3453-1 instructions for post-hybridization wash.///scan_protocol: Arrays were scanned using a laser-scanner Axon 4000-B, (Axon Instruments, Union City, CA), using 5-micron resolution. Within the GenePix program were chosen photo-multiplier parameters that defined the quanta intensity density distribution of the array to give a Cy3/Cy5 ratio close to 1.0 and produced not too much saturated signals for each array. Separate 16-bit images were acquired for Cy3 and Cy5.///description: none///data_processing: Images were analysed using the GenePix Pro software (Axon Instruments) version 3.0. GenePix Result files (GPR) and the related scan images, together with the Agilent cDNA pattern file and information on the hybridised samples and labelling signs (positive for normal labelling and negative for dye-swap labelling), were then loaded into the Rosetta Resolver SE software. The Axon GenePix error model was applied to transform data and then duplicate ratio profiles were combined to obtain one ratio experiment for each patient. Log ratios, log ratio errors and p-values were thus available for the non flagged sequences of each ratio experiment.///platform_id: GPL5689///contact_name: Pietro,,Mariani///contact_institute: Mario Negri Institute///contact_address: Via La Masa 19///contact_city: Milan///contact_zip.postal_code: 20156///contact_country: Italy///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM214nnn/GSM214035/GSM214035_raw.txt.gz///data_row_count: 16281
1
title: p310bis sample_Ovarian tumor///geo_accession: GSM214083///status: Public on Aug 25 2007///submission_date: Jul 31 2007///last_update_date: Aug 24 2007///type: RNA///channel_count: 2///source_name_ch1: Total RNA extracted from frozen biopsies of ovarian tumors///organism_ch1: Homo sapiens///characteristics_ch1: Gender: Female///characteristics_ch1.1: Status:alive no evidence of disease///characteristics_ch1.2: FIGO Stage:1///characteristics_ch1.3: FIGO Substage:c///characteristics_ch1.4: Histotype:mucinous///characteristics_ch1.5: Grade:Borderline///characteristics_ch1.6: Relapsed:no///characteristics_ch1.7: Age(years):41.49///characteristics_ch1.8: Overall Survival(days):2451///characteristics_ch1.9: Progression Free Survival(days):2451///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification from human biopsies were performed using the SV Total RNA Isolation System -cat:#z3100 from Promega.///label_ch1: Cy5///label_protocol_ch1: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch1: 9606///source_name_ch2: Clontech Universal Reference///organism_ch2: Homo sapiens///characteristics_ch2: Human Atlas high pure control total RNA extracted from a pool of 60 human cell lines (BD Biosciences)///molecule_ch2: total RNA///extract_protocol_ch2: see the producer web site: http//clontech.com/products/detail.asp?tabno=2&catalog_id=636538&page=all&faq_id=153665///label_ch2: Cy3///label_protocol_ch2: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch2: 9606///hyb_protocol: Microarray hybridization: Add to each Sample 2.5 ul Cot-1 DNA and 12.50 ul 2X Hybridization Buffer. Heat samples for 2 min at 65 C. Centrifuge. Pipet the cDNA array and 22 ul of sample. Incubate for 16 hr at 65 C. Used Atlas Glass Microarray User Manual PT3453-1 instructions for post-hybridization wash.///scan_protocol: Arrays were scanned using a laser-scanner Axon 4000-B, (Axon Instruments, Union City, CA), using 5-micron resolution. Within the GenePix program were chosen photo-multiplier parameters that defined the quanta intensity density distribution of the array to give a Cy3/Cy5 ratio close to 1.0 and produced not too much saturated signals for each array. Separate 16-bit images were acquired for Cy3 and Cy5.///description: none///data_processing: Images were analysed using the GenePix Pro software (Axon Instruments) version 3.0. GenePix Result files (GPR) and the related scan images, together with the Agilent cDNA pattern file and information on the hybridised samples and labelling signs (positive for normal labelling and negative for dye-swap labelling), were then loaded into the Rosetta Resolver SE software. The Axon GenePix error model was applied to transform data and then duplicate ratio profiles were combined to obtain one ratio experiment for each patient. Log ratios, log ratio errors and p-values were thus available for the non flagged sequences of each ratio experiment.///platform_id: GPL5689///contact_name: Pietro,,Mariani///contact_institute: Mario Negri Institute///contact_address: Via La Masa 19///contact_city: Milan///contact_zip.postal_code: 20156///contact_country: Italy///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM214nnn/GSM214083/GSM214083_raw.txt.gz///data_row_count: 16281
1
title: p31bis sample_Ovarian tumor///geo_accession: GSM214019///status: Public on Aug 25 2007///submission_date: Jul 31 2007///last_update_date: Aug 24 2007///type: RNA///channel_count: 2///source_name_ch1: Total RNA extracted from frozen biopsies of ovarian tumors///organism_ch1: Homo sapiens///characteristics_ch1: Gender: Female///characteristics_ch1.1: Status:alive no evidence of disease///characteristics_ch1.2: FIGO Stage:1///characteristics_ch1.3: FIGO Substage:a///characteristics_ch1.4: Histotype:mucinous///characteristics_ch1.5: Grade:1///characteristics_ch1.6: Relapsed:no///characteristics_ch1.7: Age(years):40.25///characteristics_ch1.8: Overall Survival(days):3656///characteristics_ch1.9: Progression Free Survival(days):3656///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification from human biopsies were performed using the SV Total RNA Isolation System -cat:#z3100 from Promega.///label_ch1: Cy5///label_protocol_ch1: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch1: 9606///source_name_ch2: Clontech Universal Reference///organism_ch2: Homo sapiens///characteristics_ch2: Human Atlas high pure control total RNA extracted from a pool of 60 human cell lines (BD Biosciences)///molecule_ch2: total RNA///extract_protocol_ch2: see the producer web site: http//clontech.com/products/detail.asp?tabno=2&catalog_id=636538&page=all&faq_id=153665///label_ch2: Cy3///label_protocol_ch2: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch2: 9606///hyb_protocol: Microarray hybridization: Add to each Sample 2.5 ul Cot-1 DNA and 12.50 ul 2X Hybridization Buffer. Heat samples for 2 min at 65 C. Centrifuge. Pipet the cDNA array and 22 ul of sample. Incubate for 16 hr at 65 C. Used Atlas Glass Microarray User Manual PT3453-1 instructions for post-hybridization wash.///scan_protocol: Arrays were scanned using a laser-scanner Axon 4000-B, (Axon Instruments, Union City, CA), using 5-micron resolution. Within the GenePix program were chosen photo-multiplier parameters that defined the quanta intensity density distribution of the array to give a Cy3/Cy5 ratio close to 1.0 and produced not too much saturated signals for each array. Separate 16-bit images were acquired for Cy3 and Cy5.///description: none///data_processing: Images were analysed using the GenePix Pro software (Axon Instruments) version 3.0. GenePix Result files (GPR) and the related scan images, together with the Agilent cDNA pattern file and information on the hybridised samples and labelling signs (positive for normal labelling and negative for dye-swap labelling), were then loaded into the Rosetta Resolver SE software. The Axon GenePix error model was applied to transform data and then duplicate ratio profiles were combined to obtain one ratio experiment for each patient. Log ratios, log ratio errors and p-values were thus available for the non flagged sequences of each ratio experiment.///platform_id: GPL5689///contact_name: Pietro,,Mariani///contact_institute: Mario Negri Institute///contact_address: Via La Masa 19///contact_city: Milan///contact_zip.postal_code: 20156///contact_country: Italy///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM214nnn/GSM214019/GSM214019_raw.txt.gz///data_row_count: 16281
1
title: p320bis sample_Ovarian tumor///geo_accession: GSM214020///status: Public on Aug 25 2007///submission_date: Jul 31 2007///last_update_date: Aug 24 2007///type: RNA///channel_count: 2///source_name_ch1: Total RNA extracted from frozen biopsies of ovarian tumors///organism_ch1: Homo sapiens///characteristics_ch1: Gender: Female///characteristics_ch1.1: Status:alive no evidence of disease///characteristics_ch1.2: FIGO Stage:1///characteristics_ch1.3: FIGO Substage:c///characteristics_ch1.4: Histotype:mucinous///characteristics_ch1.5: Grade:1///characteristics_ch1.6: Relapsed:no///characteristics_ch1.7: Age(years):38.5///characteristics_ch1.8: Overall Survival(days):2541///characteristics_ch1.9: Progression Free Survival(days):2541///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification from human biopsies were performed using the SV Total RNA Isolation System -cat:#z3100 from Promega.///label_ch1: Cy5///label_protocol_ch1: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch1: 9606///source_name_ch2: Clontech Universal Reference///organism_ch2: Homo sapiens///characteristics_ch2: Human Atlas high pure control total RNA extracted from a pool of 60 human cell lines (BD Biosciences)///molecule_ch2: total RNA///extract_protocol_ch2: see the producer web site: http//clontech.com/products/detail.asp?tabno=2&catalog_id=636538&page=all&faq_id=153665///label_ch2: Cy3///label_protocol_ch2: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch2: 9606///hyb_protocol: Microarray hybridization: Add to each Sample 2.5 ul Cot-1 DNA and 12.50 ul 2X Hybridization Buffer. Heat samples for 2 min at 65 C. Centrifuge. Pipet the cDNA array and 22 ul of sample. Incubate for 16 hr at 65 C. Used Atlas Glass Microarray User Manual PT3453-1 instructions for post-hybridization wash.///scan_protocol: Arrays were scanned using a laser-scanner Axon 4000-B, (Axon Instruments, Union City, CA), using 5-micron resolution. Within the GenePix program were chosen photo-multiplier parameters that defined the quanta intensity density distribution of the array to give a Cy3/Cy5 ratio close to 1.0 and produced not too much saturated signals for each array. Separate 16-bit images were acquired for Cy3 and Cy5.///description: none///data_processing: Images were analysed using the GenePix Pro software (Axon Instruments) version 3.0. GenePix Result files (GPR) and the related scan images, together with the Agilent cDNA pattern file and information on the hybridised samples and labelling signs (positive for normal labelling and negative for dye-swap labelling), were then loaded into the Rosetta Resolver SE software. The Axon GenePix error model was applied to transform data and then duplicate ratio profiles were combined to obtain one ratio experiment for each patient. Log ratios, log ratio errors and p-values were thus available for the non flagged sequences of each ratio experiment.///platform_id: GPL5689///contact_name: Pietro,,Mariani///contact_institute: Mario Negri Institute///contact_address: Via La Masa 19///contact_city: Milan///contact_zip.postal_code: 20156///contact_country: Italy///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM214nnn/GSM214020/GSM214020_raw.txt.gz///data_row_count: 16281
1
title: p331bis sample_Ovarian tumor///geo_accession: GSM214021///status: Public on Aug 25 2007///submission_date: Jul 31 2007///last_update_date: Aug 24 2007///type: RNA///channel_count: 2///source_name_ch1: Total RNA extracted from frozen biopsies of ovarian tumors///organism_ch1: Homo sapiens///characteristics_ch1: Gender: Female///characteristics_ch1.1: Status:alive no evidence of disease///characteristics_ch1.2: FIGO Stage:1///characteristics_ch1.3: FIGO Substage:c///characteristics_ch1.4: Histotype:clear cells///characteristics_ch1.5: Grade:3///characteristics_ch1.6: Relapsed:no///characteristics_ch1.7: Age(years):67.04///characteristics_ch1.8: Overall Survival(days):2682///characteristics_ch1.9: Progression Free Survival(days):2682///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification from human biopsies were performed using the SV Total RNA Isolation System -cat:#z3100 from Promega.///label_ch1: Cy5///label_protocol_ch1: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch1: 9606///source_name_ch2: Clontech Universal Reference///organism_ch2: Homo sapiens///characteristics_ch2: Human Atlas high pure control total RNA extracted from a pool of 60 human cell lines (BD Biosciences)///molecule_ch2: total RNA///extract_protocol_ch2: see the producer web site: http//clontech.com/products/detail.asp?tabno=2&catalog_id=636538&page=all&faq_id=153665///label_ch2: Cy3///label_protocol_ch2: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch2: 9606///hyb_protocol: Microarray hybridization: Add to each Sample 2.5 ul Cot-1 DNA and 12.50 ul 2X Hybridization Buffer. Heat samples for 2 min at 65 C. Centrifuge. Pipet the cDNA array and 22 ul of sample. Incubate for 16 hr at 65 C. Used Atlas Glass Microarray User Manual PT3453-1 instructions for post-hybridization wash.///scan_protocol: Arrays were scanned using a laser-scanner Axon 4000-B, (Axon Instruments, Union City, CA), using 5-micron resolution. Within the GenePix program were chosen photo-multiplier parameters that defined the quanta intensity density distribution of the array to give a Cy3/Cy5 ratio close to 1.0 and produced not too much saturated signals for each array. Separate 16-bit images were acquired for Cy3 and Cy5.///description: none///data_processing: Images were analysed using the GenePix Pro software (Axon Instruments) version 3.0. GenePix Result files (GPR) and the related scan images, together with the Agilent cDNA pattern file and information on the hybridised samples and labelling signs (positive for normal labelling and negative for dye-swap labelling), were then loaded into the Rosetta Resolver SE software. The Axon GenePix error model was applied to transform data and then duplicate ratio profiles were combined to obtain one ratio experiment for each patient. Log ratios, log ratio errors and p-values were thus available for the non flagged sequences of each ratio experiment.///platform_id: GPL5689///contact_name: Pietro,,Mariani///contact_institute: Mario Negri Institute///contact_address: Via La Masa 19///contact_city: Milan///contact_zip.postal_code: 20156///contact_country: Italy///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM214nnn/GSM214021/GSM214021_raw.txt.gz///data_row_count: 16281
1
title: p336bis sample_Ovarian tumor///geo_accession: GSM214056///status: Public on Aug 25 2007///submission_date: Jul 31 2007///last_update_date: Aug 24 2007///type: RNA///channel_count: 2///source_name_ch1: Total RNA extracted from frozen biopsies of ovarian tumors///organism_ch1: Homo sapiens///characteristics_ch1: Gender: Female///characteristics_ch1.1: Status:alive no evidence of disease///characteristics_ch1.2: FIGO Stage:1///characteristics_ch1.3: FIGO Substage:c///characteristics_ch1.4: Histotype:serous///characteristics_ch1.5: Grade:2///characteristics_ch1.6: Relapsed:no///characteristics_ch1.7: Age(years):40.55///characteristics_ch1.8: Overall Survival(days):2497///characteristics_ch1.9: Progression Free Survival(days):2497///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification from human biopsies were performed using the SV Total RNA Isolation System -cat:#z3100 from Promega.///label_ch1: Cy5///label_protocol_ch1: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch1: 9606///source_name_ch2: Clontech Universal Reference///organism_ch2: Homo sapiens///characteristics_ch2: Human Atlas high pure control total RNA extracted from a pool of 60 human cell lines (BD Biosciences)///molecule_ch2: total RNA///extract_protocol_ch2: see the producer web site: http//clontech.com/products/detail.asp?tabno=2&catalog_id=636538&page=all&faq_id=153665///label_ch2: Cy3///label_protocol_ch2: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch2: 9606///hyb_protocol: Microarray hybridization: Add to each Sample 2.5 ul Cot-1 DNA and 12.50 ul 2X Hybridization Buffer. Heat samples for 2 min at 65 C. Centrifuge. Pipet the cDNA array and 22 ul of sample. Incubate for 16 hr at 65 C. Used Atlas Glass Microarray User Manual PT3453-1 instructions for post-hybridization wash.///scan_protocol: Arrays were scanned using a laser-scanner Axon 4000-B, (Axon Instruments, Union City, CA), using 5-micron resolution. Within the GenePix program were chosen photo-multiplier parameters that defined the quanta intensity density distribution of the array to give a Cy3/Cy5 ratio close to 1.0 and produced not too much saturated signals for each array. Separate 16-bit images were acquired for Cy3 and Cy5.///description: none///data_processing: Images were analysed using the GenePix Pro software (Axon Instruments) version 3.0. GenePix Result files (GPR) and the related scan images, together with the Agilent cDNA pattern file and information on the hybridised samples and labelling signs (positive for normal labelling and negative for dye-swap labelling), were then loaded into the Rosetta Resolver SE software. The Axon GenePix error model was applied to transform data and then duplicate ratio profiles were combined to obtain one ratio experiment for each patient. Log ratios, log ratio errors and p-values were thus available for the non flagged sequences of each ratio experiment.///platform_id: GPL5689///contact_name: Pietro,,Mariani///contact_institute: Mario Negri Institute///contact_address: Via La Masa 19///contact_city: Milan///contact_zip.postal_code: 20156///contact_country: Italy///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM214nnn/GSM214056/GSM214056_raw.txt.gz///data_row_count: 16281
1
title: p350bis sample_Ovarian tumor///geo_accession: GSM214036///status: Public on Aug 25 2007///submission_date: Jul 31 2007///last_update_date: Aug 24 2007///type: RNA///channel_count: 2///source_name_ch1: Total RNA extracted from frozen biopsies of ovarian tumors///organism_ch1: Homo sapiens///characteristics_ch1: Gender: Female///characteristics_ch1.1: Status:alive no evidence of disease///characteristics_ch1.2: FIGO Stage:1///characteristics_ch1.3: FIGO Substage:a///characteristics_ch1.4: Histotype:endometrioid///characteristics_ch1.5: Grade:2///characteristics_ch1.6: Relapsed:no///characteristics_ch1.7: Age(years):49.42///characteristics_ch1.8: Overall Survival(days):2528///characteristics_ch1.9: Progression Free Survival(days):2528///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification from human biopsies were performed using the SV Total RNA Isolation System -cat:#z3100 from Promega.///label_ch1: Cy5///label_protocol_ch1: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch1: 9606///source_name_ch2: Clontech Universal Reference///organism_ch2: Homo sapiens///characteristics_ch2: Human Atlas high pure control total RNA extracted from a pool of 60 human cell lines (BD Biosciences)///molecule_ch2: total RNA///extract_protocol_ch2: see the producer web site: http//clontech.com/products/detail.asp?tabno=2&catalog_id=636538&page=all&faq_id=153665///label_ch2: Cy3///label_protocol_ch2: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch2: 9606///hyb_protocol: Microarray hybridization: Add to each Sample 2.5 ul Cot-1 DNA and 12.50 ul 2X Hybridization Buffer. Heat samples for 2 min at 65 C. Centrifuge. Pipet the cDNA array and 22 ul of sample. Incubate for 16 hr at 65 C. Used Atlas Glass Microarray User Manual PT3453-1 instructions for post-hybridization wash.///scan_protocol: Arrays were scanned using a laser-scanner Axon 4000-B, (Axon Instruments, Union City, CA), using 5-micron resolution. Within the GenePix program were chosen photo-multiplier parameters that defined the quanta intensity density distribution of the array to give a Cy3/Cy5 ratio close to 1.0 and produced not too much saturated signals for each array. Separate 16-bit images were acquired for Cy3 and Cy5.///description: none///data_processing: Images were analysed using the GenePix Pro software (Axon Instruments) version 3.0. GenePix Result files (GPR) and the related scan images, together with the Agilent cDNA pattern file and information on the hybridised samples and labelling signs (positive for normal labelling and negative for dye-swap labelling), were then loaded into the Rosetta Resolver SE software. The Axon GenePix error model was applied to transform data and then duplicate ratio profiles were combined to obtain one ratio experiment for each patient. Log ratios, log ratio errors and p-values were thus available for the non flagged sequences of each ratio experiment.///platform_id: GPL5689///contact_name: Pietro,,Mariani///contact_institute: Mario Negri Institute///contact_address: Via La Masa 19///contact_city: Milan///contact_zip.postal_code: 20156///contact_country: Italy///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM214nnn/GSM214036/GSM214036_raw.txt.gz///data_row_count: 16281
1
title: p375bis sample_Ovarian tumor///geo_accession: GSM214048///status: Public on Aug 25 2007///submission_date: Jul 31 2007///last_update_date: Aug 24 2007///type: RNA///channel_count: 2///source_name_ch1: Total RNA extracted from frozen biopsies of ovarian tumors///organism_ch1: Homo sapiens///characteristics_ch1: Gender: Female///characteristics_ch1.1: Status:alive no evidence of disease///characteristics_ch1.2: FIGO Stage:1///characteristics_ch1.3: FIGO Substage:a///characteristics_ch1.4: Histotype:endometrioid///characteristics_ch1.5: Grade:1///characteristics_ch1.6: Relapsed:no///characteristics_ch1.7: Age(years):43.94///characteristics_ch1.8: Overall Survival(days):2287///characteristics_ch1.9: Progression Free Survival(days):2287///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification from human biopsies were performed using the SV Total RNA Isolation System -cat:#z3100 from Promega.///label_ch1: Cy5///label_protocol_ch1: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch1: 9606///source_name_ch2: Clontech Universal Reference///organism_ch2: Homo sapiens///characteristics_ch2: Human Atlas high pure control total RNA extracted from a pool of 60 human cell lines (BD Biosciences)///molecule_ch2: total RNA///extract_protocol_ch2: see the producer web site: http//clontech.com/products/detail.asp?tabno=2&catalog_id=636538&page=all&faq_id=153665///label_ch2: Cy3///label_protocol_ch2: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch2: 9606///hyb_protocol: Microarray hybridization: Add to each Sample 2.5 ul Cot-1 DNA and 12.50 ul 2X Hybridization Buffer. Heat samples for 2 min at 65 C. Centrifuge. Pipet the cDNA array and 22 ul of sample. Incubate for 16 hr at 65 C. Used Atlas Glass Microarray User Manual PT3453-1 instructions for post-hybridization wash.///scan_protocol: Arrays were scanned using a laser-scanner Axon 4000-B, (Axon Instruments, Union City, CA), using 5-micron resolution. Within the GenePix program were chosen photo-multiplier parameters that defined the quanta intensity density distribution of the array to give a Cy3/Cy5 ratio close to 1.0 and produced not too much saturated signals for each array. Separate 16-bit images were acquired for Cy3 and Cy5.///description: none///data_processing: Images were analysed using the GenePix Pro software (Axon Instruments) version 3.0. GenePix Result files (GPR) and the related scan images, together with the Agilent cDNA pattern file and information on the hybridised samples and labelling signs (positive for normal labelling and negative for dye-swap labelling), were then loaded into the Rosetta Resolver SE software. The Axon GenePix error model was applied to transform data and then duplicate ratio profiles were combined to obtain one ratio experiment for each patient. Log ratios, log ratio errors and p-values were thus available for the non flagged sequences of each ratio experiment.///platform_id: GPL5689///contact_name: Pietro,,Mariani///contact_institute: Mario Negri Institute///contact_address: Via La Masa 19///contact_city: Milan///contact_zip.postal_code: 20156///contact_country: Italy///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM214nnn/GSM214048/GSM214048_raw.txt.gz///data_row_count: 16281
1
title: p382bis sample_Ovarian tumor///geo_accession: GSM214037///status: Public on Aug 25 2007///submission_date: Jul 31 2007///last_update_date: Aug 24 2007///type: RNA///channel_count: 2///source_name_ch1: Total RNA extracted from frozen biopsies of ovarian tumors///organism_ch1: Homo sapiens///characteristics_ch1: Gender: Female///characteristics_ch1.1: Status:alive no evidence of disease///characteristics_ch1.2: FIGO Stage:1///characteristics_ch1.3: FIGO Substage:c///characteristics_ch1.4: Histotype:serous///characteristics_ch1.5: Grade:3///characteristics_ch1.6: Relapsed:no///characteristics_ch1.7: Age(years):67.83///characteristics_ch1.8: Overall Survival(days):1864///characteristics_ch1.9: Progression Free Survival(days):1864///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification from human biopsies were performed using the SV Total RNA Isolation System -cat:#z3100 from Promega.///label_ch1: Cy5///label_protocol_ch1: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch1: 9606///source_name_ch2: Clontech Universal Reference///organism_ch2: Homo sapiens///characteristics_ch2: Human Atlas high pure control total RNA extracted from a pool of 60 human cell lines (BD Biosciences)///molecule_ch2: total RNA///extract_protocol_ch2: see the producer web site: http//clontech.com/products/detail.asp?tabno=2&catalog_id=636538&page=all&faq_id=153665///label_ch2: Cy3///label_protocol_ch2: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch2: 9606///hyb_protocol: Microarray hybridization: Add to each Sample 2.5 ul Cot-1 DNA and 12.50 ul 2X Hybridization Buffer. Heat samples for 2 min at 65 C. Centrifuge. Pipet the cDNA array and 22 ul of sample. Incubate for 16 hr at 65 C. Used Atlas Glass Microarray User Manual PT3453-1 instructions for post-hybridization wash.///scan_protocol: Arrays were scanned using a laser-scanner Axon 4000-B, (Axon Instruments, Union City, CA), using 5-micron resolution. Within the GenePix program were chosen photo-multiplier parameters that defined the quanta intensity density distribution of the array to give a Cy3/Cy5 ratio close to 1.0 and produced not too much saturated signals for each array. Separate 16-bit images were acquired for Cy3 and Cy5.///description: none///data_processing: Images were analysed using the GenePix Pro software (Axon Instruments) version 3.0. GenePix Result files (GPR) and the related scan images, together with the Agilent cDNA pattern file and information on the hybridised samples and labelling signs (positive for normal labelling and negative for dye-swap labelling), were then loaded into the Rosetta Resolver SE software. The Axon GenePix error model was applied to transform data and then duplicate ratio profiles were combined to obtain one ratio experiment for each patient. Log ratios, log ratio errors and p-values were thus available for the non flagged sequences of each ratio experiment.///platform_id: GPL5689///contact_name: Pietro,,Mariani///contact_institute: Mario Negri Institute///contact_address: Via La Masa 19///contact_city: Milan///contact_zip.postal_code: 20156///contact_country: Italy///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM214nnn/GSM214037/GSM214037_raw.txt.gz///data_row_count: 16281
1
title: p383bis sample_Ovarian tumor///geo_accession: GSM214029///status: Public on Aug 25 2007///submission_date: Jul 31 2007///last_update_date: Aug 24 2007///type: RNA///channel_count: 2///source_name_ch1: Total RNA extracted from frozen biopsies of ovarian tumors///organism_ch1: Homo sapiens///characteristics_ch1: Gender: Female///characteristics_ch1.1: Status:alive no evidence of disease///characteristics_ch1.2: FIGO Stage:1///characteristics_ch1.3: FIGO Substage:a///characteristics_ch1.4: Histotype:serous///characteristics_ch1.5: Grade:3///characteristics_ch1.6: Relapsed:no///characteristics_ch1.7: Age(years):55.75///characteristics_ch1.8: Overall Survival(days):2093///characteristics_ch1.9: Progression Free Survival(days):2093///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification from human biopsies were performed using the SV Total RNA Isolation System -cat:#z3100 from Promega.///label_ch1: Cy5///label_protocol_ch1: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch1: 9606///source_name_ch2: Clontech Universal Reference///organism_ch2: Homo sapiens///characteristics_ch2: Human Atlas high pure control total RNA extracted from a pool of 60 human cell lines (BD Biosciences)///molecule_ch2: total RNA///extract_protocol_ch2: see the producer web site: http//clontech.com/products/detail.asp?tabno=2&catalog_id=636538&page=all&faq_id=153665///label_ch2: Cy3///label_protocol_ch2: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch2: 9606///hyb_protocol: Microarray hybridization: Add to each Sample 2.5 ul Cot-1 DNA and 12.50 ul 2X Hybridization Buffer. Heat samples for 2 min at 65 C. Centrifuge. Pipet the cDNA array and 22 ul of sample. Incubate for 16 hr at 65 C. Used Atlas Glass Microarray User Manual PT3453-1 instructions for post-hybridization wash.///scan_protocol: Arrays were scanned using a laser-scanner Axon 4000-B, (Axon Instruments, Union City, CA), using 5-micron resolution. Within the GenePix program were chosen photo-multiplier parameters that defined the quanta intensity density distribution of the array to give a Cy3/Cy5 ratio close to 1.0 and produced not too much saturated signals for each array. Separate 16-bit images were acquired for Cy3 and Cy5.///description: none///data_processing: Images were analysed using the GenePix Pro software (Axon Instruments) version 3.0. GenePix Result files (GPR) and the related scan images, together with the Agilent cDNA pattern file and information on the hybridised samples and labelling signs (positive for normal labelling and negative for dye-swap labelling), were then loaded into the Rosetta Resolver SE software. The Axon GenePix error model was applied to transform data and then duplicate ratio profiles were combined to obtain one ratio experiment for each patient. Log ratios, log ratio errors and p-values were thus available for the non flagged sequences of each ratio experiment.///platform_id: GPL5689///contact_name: Pietro,,Mariani///contact_institute: Mario Negri Institute///contact_address: Via La Masa 19///contact_city: Milan///contact_zip.postal_code: 20156///contact_country: Italy///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM214nnn/GSM214029/GSM214029_raw.txt.gz///data_row_count: 16281
1
title: p386bis sample_Ovarian tumor///geo_accession: GSM214038///status: Public on Aug 25 2007///submission_date: Jul 31 2007///last_update_date: Aug 24 2007///type: RNA///channel_count: 2///source_name_ch1: Total RNA extracted from frozen biopsies of ovarian tumors///organism_ch1: Homo sapiens///characteristics_ch1: Gender: Female///characteristics_ch1.1: Status:alive no evidence of disease///characteristics_ch1.2: FIGO Stage:1///characteristics_ch1.3: FIGO Substage:a///characteristics_ch1.4: Histotype:serous///characteristics_ch1.5: Grade:1///characteristics_ch1.6: Relapsed:no///characteristics_ch1.7: Age(years):56.04///characteristics_ch1.8: Overall Survival(days):2032///characteristics_ch1.9: Progression Free Survival(days):2032///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification from human biopsies were performed using the SV Total RNA Isolation System -cat:#z3100 from Promega.///label_ch1: Cy5///label_protocol_ch1: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch1: 9606///source_name_ch2: Clontech Universal Reference///organism_ch2: Homo sapiens///characteristics_ch2: Human Atlas high pure control total RNA extracted from a pool of 60 human cell lines (BD Biosciences)///molecule_ch2: total RNA///extract_protocol_ch2: see the producer web site: http//clontech.com/products/detail.asp?tabno=2&catalog_id=636538&page=all&faq_id=153665///label_ch2: Cy3///label_protocol_ch2: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch2: 9606///hyb_protocol: Microarray hybridization: Add to each Sample 2.5 ul Cot-1 DNA and 12.50 ul 2X Hybridization Buffer. Heat samples for 2 min at 65 C. Centrifuge. Pipet the cDNA array and 22 ul of sample. Incubate for 16 hr at 65 C. Used Atlas Glass Microarray User Manual PT3453-1 instructions for post-hybridization wash.///scan_protocol: Arrays were scanned using a laser-scanner Axon 4000-B, (Axon Instruments, Union City, CA), using 5-micron resolution. Within the GenePix program were chosen photo-multiplier parameters that defined the quanta intensity density distribution of the array to give a Cy3/Cy5 ratio close to 1.0 and produced not too much saturated signals for each array. Separate 16-bit images were acquired for Cy3 and Cy5.///description: none///data_processing: Images were analysed using the GenePix Pro software (Axon Instruments) version 3.0. GenePix Result files (GPR) and the related scan images, together with the Agilent cDNA pattern file and information on the hybridised samples and labelling signs (positive for normal labelling and negative for dye-swap labelling), were then loaded into the Rosetta Resolver SE software. The Axon GenePix error model was applied to transform data and then duplicate ratio profiles were combined to obtain one ratio experiment for each patient. Log ratios, log ratio errors and p-values were thus available for the non flagged sequences of each ratio experiment.///platform_id: GPL5689///contact_name: Pietro,,Mariani///contact_institute: Mario Negri Institute///contact_address: Via La Masa 19///contact_city: Milan///contact_zip.postal_code: 20156///contact_country: Italy///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM214nnn/GSM214038/GSM214038_raw.txt.gz///data_row_count: 16281
1
title: p388bis sample_Ovarian tumor///geo_accession: GSM214059///status: Public on Aug 25 2007///submission_date: Jul 31 2007///last_update_date: Aug 24 2007///type: RNA///channel_count: 2///source_name_ch1: Total RNA extracted from frozen biopsies of ovarian tumors///organism_ch1: Homo sapiens///characteristics_ch1: Gender: Female///characteristics_ch1.1: Status:alive no evidence of disease///characteristics_ch1.2: FIGO Stage:1///characteristics_ch1.3: FIGO Substage:b///characteristics_ch1.4: Histotype:serous///characteristics_ch1.5: Grade:3///characteristics_ch1.6: Relapsed:no///characteristics_ch1.7: Age(years):55.12///characteristics_ch1.8: Overall Survival(days):2234///characteristics_ch1.9: Progression Free Survival(days):2234///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification from human biopsies were performed using the SV Total RNA Isolation System -cat:#z3100 from Promega.///label_ch1: Cy5///label_protocol_ch1: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch1: 9606///source_name_ch2: Clontech Universal Reference///organism_ch2: Homo sapiens///characteristics_ch2: Human Atlas high pure control total RNA extracted from a pool of 60 human cell lines (BD Biosciences)///molecule_ch2: total RNA///extract_protocol_ch2: see the producer web site: http//clontech.com/products/detail.asp?tabno=2&catalog_id=636538&page=all&faq_id=153665///label_ch2: Cy3///label_protocol_ch2: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch2: 9606///hyb_protocol: Microarray hybridization: Add to each Sample 2.5 ul Cot-1 DNA and 12.50 ul 2X Hybridization Buffer. Heat samples for 2 min at 65 C. Centrifuge. Pipet the cDNA array and 22 ul of sample. Incubate for 16 hr at 65 C. Used Atlas Glass Microarray User Manual PT3453-1 instructions for post-hybridization wash.///scan_protocol: Arrays were scanned using a laser-scanner Axon 4000-B, (Axon Instruments, Union City, CA), using 5-micron resolution. Within the GenePix program were chosen photo-multiplier parameters that defined the quanta intensity density distribution of the array to give a Cy3/Cy5 ratio close to 1.0 and produced not too much saturated signals for each array. Separate 16-bit images were acquired for Cy3 and Cy5.///description: none///data_processing: Images were analysed using the GenePix Pro software (Axon Instruments) version 3.0. GenePix Result files (GPR) and the related scan images, together with the Agilent cDNA pattern file and information on the hybridised samples and labelling signs (positive for normal labelling and negative for dye-swap labelling), were then loaded into the Rosetta Resolver SE software. The Axon GenePix error model was applied to transform data and then duplicate ratio profiles were combined to obtain one ratio experiment for each patient. Log ratios, log ratio errors and p-values were thus available for the non flagged sequences of each ratio experiment.///platform_id: GPL5689///contact_name: Pietro,,Mariani///contact_institute: Mario Negri Institute///contact_address: Via La Masa 19///contact_city: Milan///contact_zip.postal_code: 20156///contact_country: Italy///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM214nnn/GSM214059/GSM214059_raw.txt.gz///data_row_count: 16281
1
title: p398bis sample_Ovarian tumor///geo_accession: GSM214066///status: Public on Aug 25 2007///submission_date: Jul 31 2007///last_update_date: Aug 24 2007///type: RNA///channel_count: 2///source_name_ch1: Total RNA extracted from frozen biopsies of ovarian tumors///organism_ch1: Homo sapiens///characteristics_ch1: Gender: Female///characteristics_ch1.1: Status:death related to cancer///characteristics_ch1.2: FIGO Stage:1///characteristics_ch1.3: FIGO Substage:c///characteristics_ch1.4: Histotype:clear cells///characteristics_ch1.5: Grade:3///characteristics_ch1.6: Relapsed:yes///characteristics_ch1.7: Age(years):51.53///characteristics_ch1.8: Overall Survival(days):1076///characteristics_ch1.9: Progression Free Survival(days):1076///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification from human biopsies were performed using the SV Total RNA Isolation System -cat:#z3100 from Promega.///label_ch1: Cy5///label_protocol_ch1: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch1: 9606///source_name_ch2: Clontech Universal Reference///organism_ch2: Homo sapiens///characteristics_ch2: Human Atlas high pure control total RNA extracted from a pool of 60 human cell lines (BD Biosciences)///molecule_ch2: total RNA///extract_protocol_ch2: see the producer web site: http//clontech.com/products/detail.asp?tabno=2&catalog_id=636538&page=all&faq_id=153665///label_ch2: Cy3///label_protocol_ch2: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch2: 9606///hyb_protocol: Microarray hybridization: Add to each Sample 2.5 ul Cot-1 DNA and 12.50 ul 2X Hybridization Buffer. Heat samples for 2 min at 65 C. Centrifuge. Pipet the cDNA array and 22 ul of sample. Incubate for 16 hr at 65 C. Used Atlas Glass Microarray User Manual PT3453-1 instructions for post-hybridization wash.///scan_protocol: Arrays were scanned using a laser-scanner Axon 4000-B, (Axon Instruments, Union City, CA), using 5-micron resolution. Within the GenePix program were chosen photo-multiplier parameters that defined the quanta intensity density distribution of the array to give a Cy3/Cy5 ratio close to 1.0 and produced not too much saturated signals for each array. Separate 16-bit images were acquired for Cy3 and Cy5.///description: none///data_processing: Images were analysed using the GenePix Pro software (Axon Instruments) version 3.0. GenePix Result files (GPR) and the related scan images, together with the Agilent cDNA pattern file and information on the hybridised samples and labelling signs (positive for normal labelling and negative for dye-swap labelling), were then loaded into the Rosetta Resolver SE software. The Axon GenePix error model was applied to transform data and then duplicate ratio profiles were combined to obtain one ratio experiment for each patient. Log ratios, log ratio errors and p-values were thus available for the non flagged sequences of each ratio experiment.///platform_id: GPL5689///contact_name: Pietro,,Mariani///contact_institute: Mario Negri Institute///contact_address: Via La Masa 19///contact_city: Milan///contact_zip.postal_code: 20156///contact_country: Italy///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM214nnn/GSM214066/GSM214066_raw.txt.gz///data_row_count: 16281
1
title: p39bis sample_Ovarian tumor///geo_accession: GSM214076///status: Public on Aug 25 2007///submission_date: Jul 31 2007///last_update_date: Aug 24 2007///type: RNA///channel_count: 2///source_name_ch1: Total RNA extracted from frozen biopsies of ovarian tumors///organism_ch1: Homo sapiens///characteristics_ch1: Gender: Female///characteristics_ch1.1: Status:alive no evidence of disease///characteristics_ch1.2: FIGO Stage:1///characteristics_ch1.3: FIGO Substage:a///characteristics_ch1.4: Histotype:mucinous///characteristics_ch1.5: Grade:Borderline///characteristics_ch1.6: Relapsed:no///characteristics_ch1.7: Age(years):38.02///characteristics_ch1.8: Overall Survival(days):3452///characteristics_ch1.9: Progression Free Survival(days):3452///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification from human biopsies were performed using the SV Total RNA Isolation System -cat:#z3100 from Promega.///label_ch1: Cy5///label_protocol_ch1: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch1: 9606///source_name_ch2: Clontech Universal Reference///organism_ch2: Homo sapiens///characteristics_ch2: Human Atlas high pure control total RNA extracted from a pool of 60 human cell lines (BD Biosciences)///molecule_ch2: total RNA///extract_protocol_ch2: see the producer web site: http//clontech.com/products/detail.asp?tabno=2&catalog_id=636538&page=all&faq_id=153665///label_ch2: Cy3///label_protocol_ch2: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch2: 9606///hyb_protocol: Microarray hybridization: Add to each Sample 2.5 ul Cot-1 DNA and 12.50 ul 2X Hybridization Buffer. Heat samples for 2 min at 65 C. Centrifuge. Pipet the cDNA array and 22 ul of sample. Incubate for 16 hr at 65 C. Used Atlas Glass Microarray User Manual PT3453-1 instructions for post-hybridization wash.///scan_protocol: Arrays were scanned using a laser-scanner Axon 4000-B, (Axon Instruments, Union City, CA), using 5-micron resolution. Within the GenePix program were chosen photo-multiplier parameters that defined the quanta intensity density distribution of the array to give a Cy3/Cy5 ratio close to 1.0 and produced not too much saturated signals for each array. Separate 16-bit images were acquired for Cy3 and Cy5.///description: none///data_processing: Images were analysed using the GenePix Pro software (Axon Instruments) version 3.0. GenePix Result files (GPR) and the related scan images, together with the Agilent cDNA pattern file and information on the hybridised samples and labelling signs (positive for normal labelling and negative for dye-swap labelling), were then loaded into the Rosetta Resolver SE software. The Axon GenePix error model was applied to transform data and then duplicate ratio profiles were combined to obtain one ratio experiment for each patient. Log ratios, log ratio errors and p-values were thus available for the non flagged sequences of each ratio experiment.///platform_id: GPL5689///contact_name: Pietro,,Mariani///contact_institute: Mario Negri Institute///contact_address: Via La Masa 19///contact_city: Milan///contact_zip.postal_code: 20156///contact_country: Italy///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM214nnn/GSM214076/GSM214076_raw.txt.gz///data_row_count: 16281
1
title: p401bis sample_Ovarian tumor///geo_accession: GSM214022///status: Public on Aug 25 2007///submission_date: Jul 31 2007///last_update_date: Aug 24 2007///type: RNA///channel_count: 2///source_name_ch1: Total RNA extracted from frozen biopsies of ovarian tumors///organism_ch1: Homo sapiens///characteristics_ch1: Gender: Female///characteristics_ch1.1: Status:alive no evidence of disease///characteristics_ch1.2: FIGO Stage:1///characteristics_ch1.3: FIGO Substage:c///characteristics_ch1.4: Histotype:mucinous///characteristics_ch1.5: Grade:1///characteristics_ch1.6: Relapsed:no///characteristics_ch1.7: Age(years):49.36///characteristics_ch1.8: Overall Survival(days):2178///characteristics_ch1.9: Progression Free Survival(days):2178///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification from human biopsies were performed using the SV Total RNA Isolation System -cat:#z3100 from Promega.///label_ch1: Cy5///label_protocol_ch1: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch1: 9606///source_name_ch2: Clontech Universal Reference///organism_ch2: Homo sapiens///characteristics_ch2: Human Atlas high pure control total RNA extracted from a pool of 60 human cell lines (BD Biosciences)///molecule_ch2: total RNA///extract_protocol_ch2: see the producer web site: http//clontech.com/products/detail.asp?tabno=2&catalog_id=636538&page=all&faq_id=153665///label_ch2: Cy3///label_protocol_ch2: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch2: 9606///hyb_protocol: Microarray hybridization: Add to each Sample 2.5 ul Cot-1 DNA and 12.50 ul 2X Hybridization Buffer. Heat samples for 2 min at 65 C. Centrifuge. Pipet the cDNA array and 22 ul of sample. Incubate for 16 hr at 65 C. Used Atlas Glass Microarray User Manual PT3453-1 instructions for post-hybridization wash.///scan_protocol: Arrays were scanned using a laser-scanner Axon 4000-B, (Axon Instruments, Union City, CA), using 5-micron resolution. Within the GenePix program were chosen photo-multiplier parameters that defined the quanta intensity density distribution of the array to give a Cy3/Cy5 ratio close to 1.0 and produced not too much saturated signals for each array. Separate 16-bit images were acquired for Cy3 and Cy5.///description: none///data_processing: Images were analysed using the GenePix Pro software (Axon Instruments) version 3.0. GenePix Result files (GPR) and the related scan images, together with the Agilent cDNA pattern file and information on the hybridised samples and labelling signs (positive for normal labelling and negative for dye-swap labelling), were then loaded into the Rosetta Resolver SE software. The Axon GenePix error model was applied to transform data and then duplicate ratio profiles were combined to obtain one ratio experiment for each patient. Log ratios, log ratio errors and p-values were thus available for the non flagged sequences of each ratio experiment.///platform_id: GPL5689///contact_name: Pietro,,Mariani///contact_institute: Mario Negri Institute///contact_address: Via La Masa 19///contact_city: Milan///contact_zip.postal_code: 20156///contact_country: Italy///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM214nnn/GSM214022/GSM214022_raw.txt.gz///data_row_count: 16281
1
title: p414bis sample_Ovarian tumor///geo_accession: GSM214051///status: Public on Aug 25 2007///submission_date: Jul 31 2007///last_update_date: Aug 24 2007///type: RNA///channel_count: 2///source_name_ch1: Total RNA extracted from frozen biopsies of ovarian tumors///organism_ch1: Homo sapiens///characteristics_ch1: Gender: Female///characteristics_ch1.1: Status:alive no evidence of disease///characteristics_ch1.2: FIGO Stage:1///characteristics_ch1.3: FIGO Substage:c///characteristics_ch1.4: Histotype:endometrioid///characteristics_ch1.5: Grade:2///characteristics_ch1.6: Relapsed:no///characteristics_ch1.7: Age(years):49.19///characteristics_ch1.8: Overall Survival(days):1800///characteristics_ch1.9: Progression Free Survival(days):1800///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification from human biopsies were performed using the SV Total RNA Isolation System -cat:#z3100 from Promega.///label_ch1: Cy5///label_protocol_ch1: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch1: 9606///source_name_ch2: Clontech Universal Reference///organism_ch2: Homo sapiens///characteristics_ch2: Human Atlas high pure control total RNA extracted from a pool of 60 human cell lines (BD Biosciences)///molecule_ch2: total RNA///extract_protocol_ch2: see the producer web site: http//clontech.com/products/detail.asp?tabno=2&catalog_id=636538&page=all&faq_id=153665///label_ch2: Cy3///label_protocol_ch2: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch2: 9606///hyb_protocol: Microarray hybridization: Add to each Sample 2.5 ul Cot-1 DNA and 12.50 ul 2X Hybridization Buffer. Heat samples for 2 min at 65 C. Centrifuge. Pipet the cDNA array and 22 ul of sample. Incubate for 16 hr at 65 C. Used Atlas Glass Microarray User Manual PT3453-1 instructions for post-hybridization wash.///scan_protocol: Arrays were scanned using a laser-scanner Axon 4000-B, (Axon Instruments, Union City, CA), using 5-micron resolution. Within the GenePix program were chosen photo-multiplier parameters that defined the quanta intensity density distribution of the array to give a Cy3/Cy5 ratio close to 1.0 and produced not too much saturated signals for each array. Separate 16-bit images were acquired for Cy3 and Cy5.///description: none///data_processing: Images were analysed using the GenePix Pro software (Axon Instruments) version 3.0. GenePix Result files (GPR) and the related scan images, together with the Agilent cDNA pattern file and information on the hybridised samples and labelling signs (positive for normal labelling and negative for dye-swap labelling), were then loaded into the Rosetta Resolver SE software. The Axon GenePix error model was applied to transform data and then duplicate ratio profiles were combined to obtain one ratio experiment for each patient. Log ratios, log ratio errors and p-values were thus available for the non flagged sequences of each ratio experiment.///platform_id: GPL5689///contact_name: Pietro,,Mariani///contact_institute: Mario Negri Institute///contact_address: Via La Masa 19///contact_city: Milan///contact_zip.postal_code: 20156///contact_country: Italy///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM214nnn/GSM214051/GSM214051_raw.txt.gz///data_row_count: 16281
1
title: p421bis sample_Ovarian tumor///geo_accession: GSM214023///status: Public on Aug 25 2007///submission_date: Jul 31 2007///last_update_date: Aug 24 2007///type: RNA///channel_count: 2///source_name_ch1: Total RNA extracted from frozen biopsies of ovarian tumors///organism_ch1: Homo sapiens///characteristics_ch1: Gender: Female///characteristics_ch1.1: Status:death related to cancer///characteristics_ch1.2: FIGO Stage:1///characteristics_ch1.3: FIGO Substage:c///characteristics_ch1.4: Histotype:clear cells///characteristics_ch1.5: Grade:3///characteristics_ch1.6: Relapsed:yes///characteristics_ch1.7: Age(years):70.78///characteristics_ch1.8: Overall Survival(days):787///characteristics_ch1.9: Progression Free Survival(days):787///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification from human biopsies were performed using the SV Total RNA Isolation System -cat:#z3100 from Promega.///label_ch1: Cy5///label_protocol_ch1: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch1: 9606///source_name_ch2: Clontech Universal Reference///organism_ch2: Homo sapiens///characteristics_ch2: Human Atlas high pure control total RNA extracted from a pool of 60 human cell lines (BD Biosciences)///molecule_ch2: total RNA///extract_protocol_ch2: see the producer web site: http//clontech.com/products/detail.asp?tabno=2&catalog_id=636538&page=all&faq_id=153665///label_ch2: Cy3///label_protocol_ch2: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch2: 9606///hyb_protocol: Microarray hybridization: Add to each Sample 2.5 ul Cot-1 DNA and 12.50 ul 2X Hybridization Buffer. Heat samples for 2 min at 65 C. Centrifuge. Pipet the cDNA array and 22 ul of sample. Incubate for 16 hr at 65 C. Used Atlas Glass Microarray User Manual PT3453-1 instructions for post-hybridization wash.///scan_protocol: Arrays were scanned using a laser-scanner Axon 4000-B, (Axon Instruments, Union City, CA), using 5-micron resolution. Within the GenePix program were chosen photo-multiplier parameters that defined the quanta intensity density distribution of the array to give a Cy3/Cy5 ratio close to 1.0 and produced not too much saturated signals for each array. Separate 16-bit images were acquired for Cy3 and Cy5.///description: none///data_processing: Images were analysed using the GenePix Pro software (Axon Instruments) version 3.0. GenePix Result files (GPR) and the related scan images, together with the Agilent cDNA pattern file and information on the hybridised samples and labelling signs (positive for normal labelling and negative for dye-swap labelling), were then loaded into the Rosetta Resolver SE software. The Axon GenePix error model was applied to transform data and then duplicate ratio profiles were combined to obtain one ratio experiment for each patient. Log ratios, log ratio errors and p-values were thus available for the non flagged sequences of each ratio experiment.///platform_id: GPL5689///contact_name: Pietro,,Mariani///contact_institute: Mario Negri Institute///contact_address: Via La Masa 19///contact_city: Milan///contact_zip.postal_code: 20156///contact_country: Italy///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM214nnn/GSM214023/GSM214023_raw.txt.gz///data_row_count: 16281
1
title: p429bis sample_Ovarian tumor///geo_accession: GSM214067///status: Public on Aug 25 2007///submission_date: Jul 31 2007///last_update_date: Aug 24 2007///type: RNA///channel_count: 2///source_name_ch1: Total RNA extracted from frozen biopsies of ovarian tumors///organism_ch1: Homo sapiens///characteristics_ch1: Gender: Female///characteristics_ch1.1: Status:death related to cancer///characteristics_ch1.2: FIGO Stage:1///characteristics_ch1.3: FIGO Substage:c///characteristics_ch1.4: Histotype:mucinous///characteristics_ch1.5: Grade:3///characteristics_ch1.6: Relapsed:yes///characteristics_ch1.7: Age(years):64.71///characteristics_ch1.8: Overall Survival(days):429///characteristics_ch1.9: Progression Free Survival(days):429///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification from human biopsies were performed using the SV Total RNA Isolation System -cat:#z3100 from Promega.///label_ch1: Cy5///label_protocol_ch1: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch1: 9606///source_name_ch2: Clontech Universal Reference///organism_ch2: Homo sapiens///characteristics_ch2: Human Atlas high pure control total RNA extracted from a pool of 60 human cell lines (BD Biosciences)///molecule_ch2: total RNA///extract_protocol_ch2: see the producer web site: http//clontech.com/products/detail.asp?tabno=2&catalog_id=636538&page=all&faq_id=153665///label_ch2: Cy3///label_protocol_ch2: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch2: 9606///hyb_protocol: Microarray hybridization: Add to each Sample 2.5 ul Cot-1 DNA and 12.50 ul 2X Hybridization Buffer. Heat samples for 2 min at 65 C. Centrifuge. Pipet the cDNA array and 22 ul of sample. Incubate for 16 hr at 65 C. Used Atlas Glass Microarray User Manual PT3453-1 instructions for post-hybridization wash.///scan_protocol: Arrays were scanned using a laser-scanner Axon 4000-B, (Axon Instruments, Union City, CA), using 5-micron resolution. Within the GenePix program were chosen photo-multiplier parameters that defined the quanta intensity density distribution of the array to give a Cy3/Cy5 ratio close to 1.0 and produced not too much saturated signals for each array. Separate 16-bit images were acquired for Cy3 and Cy5.///description: none///data_processing: Images were analysed using the GenePix Pro software (Axon Instruments) version 3.0. GenePix Result files (GPR) and the related scan images, together with the Agilent cDNA pattern file and information on the hybridised samples and labelling signs (positive for normal labelling and negative for dye-swap labelling), were then loaded into the Rosetta Resolver SE software. The Axon GenePix error model was applied to transform data and then duplicate ratio profiles were combined to obtain one ratio experiment for each patient. Log ratios, log ratio errors and p-values were thus available for the non flagged sequences of each ratio experiment.///platform_id: GPL5689///contact_name: Pietro,,Mariani///contact_institute: Mario Negri Institute///contact_address: Via La Masa 19///contact_city: Milan///contact_zip.postal_code: 20156///contact_country: Italy///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM214nnn/GSM214067/GSM214067_raw.txt.gz///data_row_count: 16281
1
title: p433bis sample_Ovarian tumor///geo_accession: GSM214079///status: Public on Aug 25 2007///submission_date: Jul 31 2007///last_update_date: Aug 24 2007///type: RNA///channel_count: 2///source_name_ch1: Total RNA extracted from frozen biopsies of ovarian tumors///organism_ch1: Homo sapiens///characteristics_ch1: Gender: Female///characteristics_ch1.1: Status:alive no evidence of disease///characteristics_ch1.2: FIGO Stage:1///characteristics_ch1.3: FIGO Substage:a///characteristics_ch1.4: Histotype:mucinous///characteristics_ch1.5: Grade:Borderline///characteristics_ch1.6: Relapsed:no///characteristics_ch1.7: Age(years):70.94///characteristics_ch1.8: Overall Survival(days):1839///characteristics_ch1.9: Progression Free Survival(days):1839///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification from human biopsies were performed using the SV Total RNA Isolation System -cat:#z3100 from Promega.///label_ch1: Cy5///label_protocol_ch1: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch1: 9606///source_name_ch2: Clontech Universal Reference///organism_ch2: Homo sapiens///characteristics_ch2: Human Atlas high pure control total RNA extracted from a pool of 60 human cell lines (BD Biosciences)///molecule_ch2: total RNA///extract_protocol_ch2: see the producer web site: http//clontech.com/products/detail.asp?tabno=2&catalog_id=636538&page=all&faq_id=153665///label_ch2: Cy3///label_protocol_ch2: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch2: 9606///hyb_protocol: Microarray hybridization: Add to each Sample 2.5 ul Cot-1 DNA and 12.50 ul 2X Hybridization Buffer. Heat samples for 2 min at 65 C. Centrifuge. Pipet the cDNA array and 22 ul of sample. Incubate for 16 hr at 65 C. Used Atlas Glass Microarray User Manual PT3453-1 instructions for post-hybridization wash.///scan_protocol: Arrays were scanned using a laser-scanner Axon 4000-B, (Axon Instruments, Union City, CA), using 5-micron resolution. Within the GenePix program were chosen photo-multiplier parameters that defined the quanta intensity density distribution of the array to give a Cy3/Cy5 ratio close to 1.0 and produced not too much saturated signals for each array. Separate 16-bit images were acquired for Cy3 and Cy5.///description: none///data_processing: Images were analysed using the GenePix Pro software (Axon Instruments) version 3.0. GenePix Result files (GPR) and the related scan images, together with the Agilent cDNA pattern file and information on the hybridised samples and labelling signs (positive for normal labelling and negative for dye-swap labelling), were then loaded into the Rosetta Resolver SE software. The Axon GenePix error model was applied to transform data and then duplicate ratio profiles were combined to obtain one ratio experiment for each patient. Log ratios, log ratio errors and p-values were thus available for the non flagged sequences of each ratio experiment.///platform_id: GPL5689///contact_name: Pietro,,Mariani///contact_institute: Mario Negri Institute///contact_address: Via La Masa 19///contact_city: Milan///contact_zip.postal_code: 20156///contact_country: Italy///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM214nnn/GSM214079/GSM214079_raw.txt.gz///data_row_count: 16281
1
title: p448bis sample_Ovarian tumor///geo_accession: GSM214068///status: Public on Aug 25 2007///submission_date: Jul 31 2007///last_update_date: Aug 24 2007///type: RNA///channel_count: 2///source_name_ch1: Total RNA extracted from frozen biopsies of ovarian tumors///organism_ch1: Homo sapiens///characteristics_ch1: Gender: Female///characteristics_ch1.1: Status:alive no evidence of disease///characteristics_ch1.2: FIGO Stage:1///characteristics_ch1.3: FIGO Substage:a///characteristics_ch1.4: Histotype:mucinous///characteristics_ch1.5: Grade:3///characteristics_ch1.6: Relapsed:no///characteristics_ch1.7: Age(years):45.23///characteristics_ch1.8: Overall Survival(days):2095///characteristics_ch1.9: Progression Free Survival(days):2095///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification from human biopsies were performed using the SV Total RNA Isolation System -cat:#z3100 from Promega.///label_ch1: Cy5///label_protocol_ch1: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch1: 9606///source_name_ch2: Clontech Universal Reference///organism_ch2: Homo sapiens///characteristics_ch2: Human Atlas high pure control total RNA extracted from a pool of 60 human cell lines (BD Biosciences)///molecule_ch2: total RNA///extract_protocol_ch2: see the producer web site: http//clontech.com/products/detail.asp?tabno=2&catalog_id=636538&page=all&faq_id=153665///label_ch2: Cy3///label_protocol_ch2: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch2: 9606///hyb_protocol: Microarray hybridization: Add to each Sample 2.5 ul Cot-1 DNA and 12.50 ul 2X Hybridization Buffer. Heat samples for 2 min at 65 C. Centrifuge. Pipet the cDNA array and 22 ul of sample. Incubate for 16 hr at 65 C. Used Atlas Glass Microarray User Manual PT3453-1 instructions for post-hybridization wash.///scan_protocol: Arrays were scanned using a laser-scanner Axon 4000-B, (Axon Instruments, Union City, CA), using 5-micron resolution. Within the GenePix program were chosen photo-multiplier parameters that defined the quanta intensity density distribution of the array to give a Cy3/Cy5 ratio close to 1.0 and produced not too much saturated signals for each array. Separate 16-bit images were acquired for Cy3 and Cy5.///description: none///data_processing: Images were analysed using the GenePix Pro software (Axon Instruments) version 3.0. GenePix Result files (GPR) and the related scan images, together with the Agilent cDNA pattern file and information on the hybridised samples and labelling signs (positive for normal labelling and negative for dye-swap labelling), were then loaded into the Rosetta Resolver SE software. The Axon GenePix error model was applied to transform data and then duplicate ratio profiles were combined to obtain one ratio experiment for each patient. Log ratios, log ratio errors and p-values were thus available for the non flagged sequences of each ratio experiment.///platform_id: GPL5689///contact_name: Pietro,,Mariani///contact_institute: Mario Negri Institute///contact_address: Via La Masa 19///contact_city: Milan///contact_zip.postal_code: 20156///contact_country: Italy///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM214nnn/GSM214068/GSM214068_raw.txt.gz///data_row_count: 16281
1
title: p455bis sample_Ovarian tumor///geo_accession: GSM214069///status: Public on Aug 25 2007///submission_date: Jul 31 2007///last_update_date: Aug 24 2007///type: RNA///channel_count: 2///source_name_ch1: Total RNA extracted from frozen biopsies of ovarian tumors///organism_ch1: Homo sapiens///characteristics_ch1: Gender: Female///characteristics_ch1.1: Status:alive no evidence of disease///characteristics_ch1.2: FIGO Stage:1///characteristics_ch1.3: FIGO Substage:c///characteristics_ch1.4: Histotype:mucinous///characteristics_ch1.5: Grade:1///characteristics_ch1.6: Relapsed:no///characteristics_ch1.7: Age(years):58///characteristics_ch1.8: Overall Survival(days):1974///characteristics_ch1.9: Progression Free Survival(days):1974///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification from human biopsies were performed using the SV Total RNA Isolation System -cat:#z3100 from Promega.///label_ch1: Cy5///label_protocol_ch1: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch1: 9606///source_name_ch2: Clontech Universal Reference///organism_ch2: Homo sapiens///characteristics_ch2: Human Atlas high pure control total RNA extracted from a pool of 60 human cell lines (BD Biosciences)///molecule_ch2: total RNA///extract_protocol_ch2: see the producer web site: http//clontech.com/products/detail.asp?tabno=2&catalog_id=636538&page=all&faq_id=153665///label_ch2: Cy3///label_protocol_ch2: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch2: 9606///hyb_protocol: Microarray hybridization: Add to each Sample 2.5 ul Cot-1 DNA and 12.50 ul 2X Hybridization Buffer. Heat samples for 2 min at 65 C. Centrifuge. Pipet the cDNA array and 22 ul of sample. Incubate for 16 hr at 65 C. Used Atlas Glass Microarray User Manual PT3453-1 instructions for post-hybridization wash.///scan_protocol: Arrays were scanned using a laser-scanner Axon 4000-B, (Axon Instruments, Union City, CA), using 5-micron resolution. Within the GenePix program were chosen photo-multiplier parameters that defined the quanta intensity density distribution of the array to give a Cy3/Cy5 ratio close to 1.0 and produced not too much saturated signals for each array. Separate 16-bit images were acquired for Cy3 and Cy5.///description: none///data_processing: Images were analysed using the GenePix Pro software (Axon Instruments) version 3.0. GenePix Result files (GPR) and the related scan images, together with the Agilent cDNA pattern file and information on the hybridised samples and labelling signs (positive for normal labelling and negative for dye-swap labelling), were then loaded into the Rosetta Resolver SE software. The Axon GenePix error model was applied to transform data and then duplicate ratio profiles were combined to obtain one ratio experiment for each patient. Log ratios, log ratio errors and p-values were thus available for the non flagged sequences of each ratio experiment.///platform_id: GPL5689///contact_name: Pietro,,Mariani///contact_institute: Mario Negri Institute///contact_address: Via La Masa 19///contact_city: Milan///contact_zip.postal_code: 20156///contact_country: Italy///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM214nnn/GSM214069/GSM214069_raw.txt.gz///data_row_count: 16281
1
title: p459bis sample_Ovarian tumor///geo_accession: GSM214025///status: Public on Aug 25 2007///submission_date: Jul 31 2007///last_update_date: Aug 24 2007///type: RNA///channel_count: 2///source_name_ch1: Total RNA extracted from frozen biopsies of ovarian tumors///organism_ch1: Homo sapiens///characteristics_ch1: Gender: Female///characteristics_ch1.1: Status:alive no evidence of disease///characteristics_ch1.2: FIGO Stage:1///characteristics_ch1.3: FIGO Substage:a///characteristics_ch1.4: Histotype:endometrioid///characteristics_ch1.5: Grade:3///characteristics_ch1.6: Relapsed:no///characteristics_ch1.7: Age(years):61.16///characteristics_ch1.8: Overall Survival(days):1891///characteristics_ch1.9: Progression Free Survival(days):1891///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification from human biopsies were performed using the SV Total RNA Isolation System -cat:#z3100 from Promega.///label_ch1: Cy5///label_protocol_ch1: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch1: 9606///source_name_ch2: Clontech Universal Reference///organism_ch2: Homo sapiens///characteristics_ch2: Human Atlas high pure control total RNA extracted from a pool of 60 human cell lines (BD Biosciences)///molecule_ch2: total RNA///extract_protocol_ch2: see the producer web site: http//clontech.com/products/detail.asp?tabno=2&catalog_id=636538&page=all&faq_id=153665///label_ch2: Cy3///label_protocol_ch2: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch2: 9606///hyb_protocol: Microarray hybridization: Add to each Sample 2.5 ul Cot-1 DNA and 12.50 ul 2X Hybridization Buffer. Heat samples for 2 min at 65 C. Centrifuge. Pipet the cDNA array and 22 ul of sample. Incubate for 16 hr at 65 C. Used Atlas Glass Microarray User Manual PT3453-1 instructions for post-hybridization wash.///scan_protocol: Arrays were scanned using a laser-scanner Axon 4000-B, (Axon Instruments, Union City, CA), using 5-micron resolution. Within the GenePix program were chosen photo-multiplier parameters that defined the quanta intensity density distribution of the array to give a Cy3/Cy5 ratio close to 1.0 and produced not too much saturated signals for each array. Separate 16-bit images were acquired for Cy3 and Cy5.///description: none///data_processing: Images were analysed using the GenePix Pro software (Axon Instruments) version 3.0. GenePix Result files (GPR) and the related scan images, together with the Agilent cDNA pattern file and information on the hybridised samples and labelling signs (positive for normal labelling and negative for dye-swap labelling), were then loaded into the Rosetta Resolver SE software. The Axon GenePix error model was applied to transform data and then duplicate ratio profiles were combined to obtain one ratio experiment for each patient. Log ratios, log ratio errors and p-values were thus available for the non flagged sequences of each ratio experiment.///platform_id: GPL5689///contact_name: Pietro,,Mariani///contact_institute: Mario Negri Institute///contact_address: Via La Masa 19///contact_city: Milan///contact_zip.postal_code: 20156///contact_country: Italy///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM214nnn/GSM214025/GSM214025_raw.txt.gz///data_row_count: 16281
1
title: p462bis sample_Ovarian tumor///geo_accession: GSM214084///status: Public on Aug 25 2007///submission_date: Jul 31 2007///last_update_date: Aug 24 2007///type: RNA///channel_count: 2///source_name_ch1: Total RNA extracted from frozen biopsies of ovarian tumors///organism_ch1: Homo sapiens///characteristics_ch1: Gender: Female///characteristics_ch1.1: Status:alive no evidence of disease///characteristics_ch1.2: FIGO Stage:1///characteristics_ch1.3: FIGO Substage:a///characteristics_ch1.4: Histotype:mucinous///characteristics_ch1.5: Grade:Borderline///characteristics_ch1.6: Relapsed:no///characteristics_ch1.7: Age(years):38.12///characteristics_ch1.8: Overall Survival(days):1745///characteristics_ch1.9: Progression Free Survival(days):1745///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification from human biopsies were performed using the SV Total RNA Isolation System -cat:#z3100 from Promega.///label_ch1: Cy5///label_protocol_ch1: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch1: 9606///source_name_ch2: Clontech Universal Reference///organism_ch2: Homo sapiens///characteristics_ch2: Human Atlas high pure control total RNA extracted from a pool of 60 human cell lines (BD Biosciences)///molecule_ch2: total RNA///extract_protocol_ch2: see the producer web site: http//clontech.com/products/detail.asp?tabno=2&catalog_id=636538&page=all&faq_id=153665///label_ch2: Cy3///label_protocol_ch2: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch2: 9606///hyb_protocol: Microarray hybridization: Add to each Sample 2.5 ul Cot-1 DNA and 12.50 ul 2X Hybridization Buffer. Heat samples for 2 min at 65 C. Centrifuge. Pipet the cDNA array and 22 ul of sample. Incubate for 16 hr at 65 C. Used Atlas Glass Microarray User Manual PT3453-1 instructions for post-hybridization wash.///scan_protocol: Arrays were scanned using a laser-scanner Axon 4000-B, (Axon Instruments, Union City, CA), using 5-micron resolution. Within the GenePix program were chosen photo-multiplier parameters that defined the quanta intensity density distribution of the array to give a Cy3/Cy5 ratio close to 1.0 and produced not too much saturated signals for each array. Separate 16-bit images were acquired for Cy3 and Cy5.///description: none///data_processing: Images were analysed using the GenePix Pro software (Axon Instruments) version 3.0. GenePix Result files (GPR) and the related scan images, together with the Agilent cDNA pattern file and information on the hybridised samples and labelling signs (positive for normal labelling and negative for dye-swap labelling), were then loaded into the Rosetta Resolver SE software. The Axon GenePix error model was applied to transform data and then duplicate ratio profiles were combined to obtain one ratio experiment for each patient. Log ratios, log ratio errors and p-values were thus available for the non flagged sequences of each ratio experiment.///platform_id: GPL5689///contact_name: Pietro,,Mariani///contact_institute: Mario Negri Institute///contact_address: Via La Masa 19///contact_city: Milan///contact_zip.postal_code: 20156///contact_country: Italy///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM214nnn/GSM214084/GSM214084_raw.txt.gz///data_row_count: 16281
1
title: p482bis sample_Ovarian tumor///geo_accession: GSM214050///status: Public on Aug 25 2007///submission_date: Jul 31 2007///last_update_date: Aug 24 2007///type: RNA///channel_count: 2///source_name_ch1: Total RNA extracted from frozen biopsies of ovarian tumors///organism_ch1: Homo sapiens///characteristics_ch1: Gender: Female///characteristics_ch1.1: Status:alive no evidence of disease///characteristics_ch1.2: FIGO Stage:1///characteristics_ch1.3: FIGO Substage:a///characteristics_ch1.4: Histotype:mucinous///characteristics_ch1.5: Grade:2///characteristics_ch1.6: Relapsed:no///characteristics_ch1.7: Age(years):32.75///characteristics_ch1.8: Overall Survival(days):1742///characteristics_ch1.9: Progression Free Survival(days):1742///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification from human biopsies were performed using the SV Total RNA Isolation System -cat:#z3100 from Promega.///label_ch1: Cy5///label_protocol_ch1: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch1: 9606///source_name_ch2: Clontech Universal Reference///organism_ch2: Homo sapiens///characteristics_ch2: Human Atlas high pure control total RNA extracted from a pool of 60 human cell lines (BD Biosciences)///molecule_ch2: total RNA///extract_protocol_ch2: see the producer web site: http//clontech.com/products/detail.asp?tabno=2&catalog_id=636538&page=all&faq_id=153665///label_ch2: Cy3///label_protocol_ch2: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch2: 9606///hyb_protocol: Microarray hybridization: Add to each Sample 2.5 ul Cot-1 DNA and 12.50 ul 2X Hybridization Buffer. Heat samples for 2 min at 65 C. Centrifuge. Pipet the cDNA array and 22 ul of sample. Incubate for 16 hr at 65 C. Used Atlas Glass Microarray User Manual PT3453-1 instructions for post-hybridization wash.///scan_protocol: Arrays were scanned using a laser-scanner Axon 4000-B, (Axon Instruments, Union City, CA), using 5-micron resolution. Within the GenePix program were chosen photo-multiplier parameters that defined the quanta intensity density distribution of the array to give a Cy3/Cy5 ratio close to 1.0 and produced not too much saturated signals for each array. Separate 16-bit images were acquired for Cy3 and Cy5.///description: none///data_processing: Images were analysed using the GenePix Pro software (Axon Instruments) version 3.0. GenePix Result files (GPR) and the related scan images, together with the Agilent cDNA pattern file and information on the hybridised samples and labelling signs (positive for normal labelling and negative for dye-swap labelling), were then loaded into the Rosetta Resolver SE software. The Axon GenePix error model was applied to transform data and then duplicate ratio profiles were combined to obtain one ratio experiment for each patient. Log ratios, log ratio errors and p-values were thus available for the non flagged sequences of each ratio experiment.///platform_id: GPL5689///contact_name: Pietro,,Mariani///contact_institute: Mario Negri Institute///contact_address: Via La Masa 19///contact_city: Milan///contact_zip.postal_code: 20156///contact_country: Italy///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM214nnn/GSM214050/GSM214050_raw.txt.gz///data_row_count: 16281
1
title: p487bis sample_Ovarian tumor///geo_accession: GSM214026///status: Public on Aug 25 2007///submission_date: Jul 31 2007///last_update_date: Aug 24 2007///type: RNA///channel_count: 2///source_name_ch1: Total RNA extracted from frozen biopsies of ovarian tumors///organism_ch1: Homo sapiens///characteristics_ch1: Gender: Female///characteristics_ch1.1: Status:alive no evidence of disease///characteristics_ch1.2: FIGO Stage:1///characteristics_ch1.3: FIGO Substage:c///characteristics_ch1.4: Histotype:clear cells///characteristics_ch1.5: Grade:3///characteristics_ch1.6: Relapsed:no///characteristics_ch1.7: Age(years):49.66///characteristics_ch1.8: Overall Survival(days):1794///characteristics_ch1.9: Progression Free Survival(days):1794///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification from human biopsies were performed using the SV Total RNA Isolation System -cat:#z3100 from Promega.///label_ch1: Cy5///label_protocol_ch1: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch1: 9606///source_name_ch2: Clontech Universal Reference///organism_ch2: Homo sapiens///characteristics_ch2: Human Atlas high pure control total RNA extracted from a pool of 60 human cell lines (BD Biosciences)///molecule_ch2: total RNA///extract_protocol_ch2: see the producer web site: http//clontech.com/products/detail.asp?tabno=2&catalog_id=636538&page=all&faq_id=153665///label_ch2: Cy3///label_protocol_ch2: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch2: 9606///hyb_protocol: Microarray hybridization: Add to each Sample 2.5 ul Cot-1 DNA and 12.50 ul 2X Hybridization Buffer. Heat samples for 2 min at 65 C. Centrifuge. Pipet the cDNA array and 22 ul of sample. Incubate for 16 hr at 65 C. Used Atlas Glass Microarray User Manual PT3453-1 instructions for post-hybridization wash.///scan_protocol: Arrays were scanned using a laser-scanner Axon 4000-B, (Axon Instruments, Union City, CA), using 5-micron resolution. Within the GenePix program were chosen photo-multiplier parameters that defined the quanta intensity density distribution of the array to give a Cy3/Cy5 ratio close to 1.0 and produced not too much saturated signals for each array. Separate 16-bit images were acquired for Cy3 and Cy5.///description: none///data_processing: Images were analysed using the GenePix Pro software (Axon Instruments) version 3.0. GenePix Result files (GPR) and the related scan images, together with the Agilent cDNA pattern file and information on the hybridised samples and labelling signs (positive for normal labelling and negative for dye-swap labelling), were then loaded into the Rosetta Resolver SE software. The Axon GenePix error model was applied to transform data and then duplicate ratio profiles were combined to obtain one ratio experiment for each patient. Log ratios, log ratio errors and p-values were thus available for the non flagged sequences of each ratio experiment.///platform_id: GPL5689///contact_name: Pietro,,Mariani///contact_institute: Mario Negri Institute///contact_address: Via La Masa 19///contact_city: Milan///contact_zip.postal_code: 20156///contact_country: Italy///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM214nnn/GSM214026/GSM214026_raw.txt.gz///data_row_count: 16281
1
title: p497bis sample_Ovarian tumor///geo_accession: GSM214052///status: Public on Aug 25 2007///submission_date: Jul 31 2007///last_update_date: Aug 24 2007///type: RNA///channel_count: 2///source_name_ch1: Total RNA extracted from frozen biopsies of ovarian tumors///organism_ch1: Homo sapiens///characteristics_ch1: Gender: Female///characteristics_ch1.1: Status:death related to cancer///characteristics_ch1.2: FIGO Stage:1///characteristics_ch1.3: FIGO Substage:c///characteristics_ch1.4: Histotype:clear cells///characteristics_ch1.5: Grade:3///characteristics_ch1.6: Relapsed:yes///characteristics_ch1.7: Age(years):64.5///characteristics_ch1.8: Overall Survival(days):695///characteristics_ch1.9: Progression Free Survival(days):695///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification from human biopsies were performed using the SV Total RNA Isolation System -cat:#z3100 from Promega.///label_ch1: Cy5///label_protocol_ch1: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch1: 9606///source_name_ch2: Clontech Universal Reference///organism_ch2: Homo sapiens///characteristics_ch2: Human Atlas high pure control total RNA extracted from a pool of 60 human cell lines (BD Biosciences)///molecule_ch2: total RNA///extract_protocol_ch2: see the producer web site: http//clontech.com/products/detail.asp?tabno=2&catalog_id=636538&page=all&faq_id=153665///label_ch2: Cy3///label_protocol_ch2: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch2: 9606///hyb_protocol: Microarray hybridization: Add to each Sample 2.5 ul Cot-1 DNA and 12.50 ul 2X Hybridization Buffer. Heat samples for 2 min at 65 C. Centrifuge. Pipet the cDNA array and 22 ul of sample. Incubate for 16 hr at 65 C. Used Atlas Glass Microarray User Manual PT3453-1 instructions for post-hybridization wash.///scan_protocol: Arrays were scanned using a laser-scanner Axon 4000-B, (Axon Instruments, Union City, CA), using 5-micron resolution. Within the GenePix program were chosen photo-multiplier parameters that defined the quanta intensity density distribution of the array to give a Cy3/Cy5 ratio close to 1.0 and produced not too much saturated signals for each array. Separate 16-bit images were acquired for Cy3 and Cy5.///description: none///data_processing: Images were analysed using the GenePix Pro software (Axon Instruments) version 3.0. GenePix Result files (GPR) and the related scan images, together with the Agilent cDNA pattern file and information on the hybridised samples and labelling signs (positive for normal labelling and negative for dye-swap labelling), were then loaded into the Rosetta Resolver SE software. The Axon GenePix error model was applied to transform data and then duplicate ratio profiles were combined to obtain one ratio experiment for each patient. Log ratios, log ratio errors and p-values were thus available for the non flagged sequences of each ratio experiment.///platform_id: GPL5689///contact_name: Pietro,,Mariani///contact_institute: Mario Negri Institute///contact_address: Via La Masa 19///contact_city: Milan///contact_zip.postal_code: 20156///contact_country: Italy///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM214nnn/GSM214052/GSM214052_raw.txt.gz///data_row_count: 16281
1
title: p502bis sample_Ovarian tumor///geo_accession: GSM214070///status: Public on Aug 25 2007///submission_date: Jul 31 2007///last_update_date: Aug 24 2007///type: RNA///channel_count: 2///source_name_ch1: Total RNA extracted from frozen biopsies of ovarian tumors///organism_ch1: Homo sapiens///characteristics_ch1: Gender: Female///characteristics_ch1.1: Status:alive no evidence of disease///characteristics_ch1.2: FIGO Stage:1///characteristics_ch1.3: FIGO Substage:c///characteristics_ch1.4: Histotype:endometrioid///characteristics_ch1.5: Grade:3///characteristics_ch1.6: Relapsed:no///characteristics_ch1.7: Age(years):47.78///characteristics_ch1.8: Overall Survival(days):178///characteristics_ch1.9: Progression Free Survival(days):178///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification from human biopsies were performed using the SV Total RNA Isolation System -cat:#z3100 from Promega.///label_ch1: Cy5///label_protocol_ch1: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch1: 9606///source_name_ch2: Clontech Universal Reference///organism_ch2: Homo sapiens///characteristics_ch2: Human Atlas high pure control total RNA extracted from a pool of 60 human cell lines (BD Biosciences)///molecule_ch2: total RNA///extract_protocol_ch2: see the producer web site: http//clontech.com/products/detail.asp?tabno=2&catalog_id=636538&page=all&faq_id=153665///label_ch2: Cy3///label_protocol_ch2: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch2: 9606///hyb_protocol: Microarray hybridization: Add to each Sample 2.5 ul Cot-1 DNA and 12.50 ul 2X Hybridization Buffer. Heat samples for 2 min at 65 C. Centrifuge. Pipet the cDNA array and 22 ul of sample. Incubate for 16 hr at 65 C. Used Atlas Glass Microarray User Manual PT3453-1 instructions for post-hybridization wash.///scan_protocol: Arrays were scanned using a laser-scanner Axon 4000-B, (Axon Instruments, Union City, CA), using 5-micron resolution. Within the GenePix program were chosen photo-multiplier parameters that defined the quanta intensity density distribution of the array to give a Cy3/Cy5 ratio close to 1.0 and produced not too much saturated signals for each array. Separate 16-bit images were acquired for Cy3 and Cy5.///description: none///data_processing: Images were analysed using the GenePix Pro software (Axon Instruments) version 3.0. GenePix Result files (GPR) and the related scan images, together with the Agilent cDNA pattern file and information on the hybridised samples and labelling signs (positive for normal labelling and negative for dye-swap labelling), were then loaded into the Rosetta Resolver SE software. The Axon GenePix error model was applied to transform data and then duplicate ratio profiles were combined to obtain one ratio experiment for each patient. Log ratios, log ratio errors and p-values were thus available for the non flagged sequences of each ratio experiment.///platform_id: GPL5689///contact_name: Pietro,,Mariani///contact_institute: Mario Negri Institute///contact_address: Via La Masa 19///contact_city: Milan///contact_zip.postal_code: 20156///contact_country: Italy///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM214nnn/GSM214070/GSM214070_raw.txt.gz///data_row_count: 16281
1
title: p540bis sample_Ovarian tumor///geo_accession: GSM214085///status: Public on Aug 25 2007///submission_date: Jul 31 2007///last_update_date: Aug 24 2007///type: RNA///channel_count: 2///source_name_ch1: Total RNA extracted from frozen biopsies of ovarian tumors///organism_ch1: Homo sapiens///characteristics_ch1: Gender: Female///characteristics_ch1.1: Status:alive no evidence of disease///characteristics_ch1.2: FIGO Stage:1///characteristics_ch1.3: FIGO Substage:c///characteristics_ch1.4: Histotype:serous///characteristics_ch1.5: Grade:Borderline///characteristics_ch1.6: Relapsed:no///characteristics_ch1.7: Age(years):68.4///characteristics_ch1.8: Overall Survival(days):1507///characteristics_ch1.9: Progression Free Survival(days):1507///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification from human biopsies were performed using the SV Total RNA Isolation System -cat:#z3100 from Promega.///label_ch1: Cy5///label_protocol_ch1: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch1: 9606///source_name_ch2: Clontech Universal Reference///organism_ch2: Homo sapiens///characteristics_ch2: Human Atlas high pure control total RNA extracted from a pool of 60 human cell lines (BD Biosciences)///molecule_ch2: total RNA///extract_protocol_ch2: see the producer web site: http//clontech.com/products/detail.asp?tabno=2&catalog_id=636538&page=all&faq_id=153665///label_ch2: Cy3///label_protocol_ch2: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch2: 9606///hyb_protocol: Microarray hybridization: Add to each Sample 2.5 ul Cot-1 DNA and 12.50 ul 2X Hybridization Buffer. Heat samples for 2 min at 65 C. Centrifuge. Pipet the cDNA array and 22 ul of sample. Incubate for 16 hr at 65 C. Used Atlas Glass Microarray User Manual PT3453-1 instructions for post-hybridization wash.///scan_protocol: Arrays were scanned using a laser-scanner Axon 4000-B, (Axon Instruments, Union City, CA), using 5-micron resolution. Within the GenePix program were chosen photo-multiplier parameters that defined the quanta intensity density distribution of the array to give a Cy3/Cy5 ratio close to 1.0 and produced not too much saturated signals for each array. Separate 16-bit images were acquired for Cy3 and Cy5.///description: none///data_processing: Images were analysed using the GenePix Pro software (Axon Instruments) version 3.0. GenePix Result files (GPR) and the related scan images, together with the Agilent cDNA pattern file and information on the hybridised samples and labelling signs (positive for normal labelling and negative for dye-swap labelling), were then loaded into the Rosetta Resolver SE software. The Axon GenePix error model was applied to transform data and then duplicate ratio profiles were combined to obtain one ratio experiment for each patient. Log ratios, log ratio errors and p-values were thus available for the non flagged sequences of each ratio experiment.///platform_id: GPL5689///contact_name: Pietro,,Mariani///contact_institute: Mario Negri Institute///contact_address: Via La Masa 19///contact_city: Milan///contact_zip.postal_code: 20156///contact_country: Italy///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM214nnn/GSM214085/GSM214085_raw.txt.gz///data_row_count: 16281
1
title: p541bis sample_Ovarian tumor///geo_accession: GSM214082///status: Public on Aug 25 2007///submission_date: Jul 31 2007///last_update_date: Aug 24 2007///type: RNA///channel_count: 2///source_name_ch1: Total RNA extracted from frozen biopsies of ovarian tumors///organism_ch1: Homo sapiens///characteristics_ch1: Gender: Female///characteristics_ch1.1: Status:alive no evidence of disease///characteristics_ch1.2: FIGO Stage:1///characteristics_ch1.3: FIGO Substage:a///characteristics_ch1.4: Histotype:serous///characteristics_ch1.5: Grade:Borderline///characteristics_ch1.6: Relapsed:yes///characteristics_ch1.7: Age(years):27.25///characteristics_ch1.8: Overall Survival(days):2705///characteristics_ch1.9: Progression Free Survival(days):2705///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification from human biopsies were performed using the SV Total RNA Isolation System -cat:#z3100 from Promega.///label_ch1: Cy5///label_protocol_ch1: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch1: 9606///source_name_ch2: Clontech Universal Reference///organism_ch2: Homo sapiens///characteristics_ch2: Human Atlas high pure control total RNA extracted from a pool of 60 human cell lines (BD Biosciences)///molecule_ch2: total RNA///extract_protocol_ch2: see the producer web site: http//clontech.com/products/detail.asp?tabno=2&catalog_id=636538&page=all&faq_id=153665///label_ch2: Cy3///label_protocol_ch2: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch2: 9606///hyb_protocol: Microarray hybridization: Add to each Sample 2.5 ul Cot-1 DNA and 12.50 ul 2X Hybridization Buffer. Heat samples for 2 min at 65 C. Centrifuge. Pipet the cDNA array and 22 ul of sample. Incubate for 16 hr at 65 C. Used Atlas Glass Microarray User Manual PT3453-1 instructions for post-hybridization wash.///scan_protocol: Arrays were scanned using a laser-scanner Axon 4000-B, (Axon Instruments, Union City, CA), using 5-micron resolution. Within the GenePix program were chosen photo-multiplier parameters that defined the quanta intensity density distribution of the array to give a Cy3/Cy5 ratio close to 1.0 and produced not too much saturated signals for each array. Separate 16-bit images were acquired for Cy3 and Cy5.///description: none///data_processing: Images were analysed using the GenePix Pro software (Axon Instruments) version 3.0. GenePix Result files (GPR) and the related scan images, together with the Agilent cDNA pattern file and information on the hybridised samples and labelling signs (positive for normal labelling and negative for dye-swap labelling), were then loaded into the Rosetta Resolver SE software. The Axon GenePix error model was applied to transform data and then duplicate ratio profiles were combined to obtain one ratio experiment for each patient. Log ratios, log ratio errors and p-values were thus available for the non flagged sequences of each ratio experiment.///platform_id: GPL5689///contact_name: Pietro,,Mariani///contact_institute: Mario Negri Institute///contact_address: Via La Masa 19///contact_city: Milan///contact_zip.postal_code: 20156///contact_country: Italy///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM214nnn/GSM214082/GSM214082_raw.txt.gz///data_row_count: 16281
1
title: p549bis sample_Ovarian tumor///geo_accession: GSM214086///status: Public on Aug 25 2007///submission_date: Jul 31 2007///last_update_date: Aug 24 2007///type: RNA///channel_count: 2///source_name_ch1: Total RNA extracted from frozen biopsies of ovarian tumors///organism_ch1: Homo sapiens///characteristics_ch1: Gender: Female///characteristics_ch1.1: Status:alive no evidence of disease///characteristics_ch1.2: FIGO Stage:1///characteristics_ch1.3: FIGO Substage:a///characteristics_ch1.4: Histotype:mucinous///characteristics_ch1.5: Grade:Borderline///characteristics_ch1.6: Relapsed:no///characteristics_ch1.7: Age(years):35.32///characteristics_ch1.8: Overall Survival(days):1189///characteristics_ch1.9: Progression Free Survival(days):1189///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification from human biopsies were performed using the SV Total RNA Isolation System -cat:#z3100 from Promega.///label_ch1: Cy5///label_protocol_ch1: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch1: 9606///source_name_ch2: Clontech Universal Reference///organism_ch2: Homo sapiens///characteristics_ch2: Human Atlas high pure control total RNA extracted from a pool of 60 human cell lines (BD Biosciences)///molecule_ch2: total RNA///extract_protocol_ch2: see the producer web site: http//clontech.com/products/detail.asp?tabno=2&catalog_id=636538&page=all&faq_id=153665///label_ch2: Cy3///label_protocol_ch2: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch2: 9606///hyb_protocol: Microarray hybridization: Add to each Sample 2.5 ul Cot-1 DNA and 12.50 ul 2X Hybridization Buffer. Heat samples for 2 min at 65 C. Centrifuge. Pipet the cDNA array and 22 ul of sample. Incubate for 16 hr at 65 C. Used Atlas Glass Microarray User Manual PT3453-1 instructions for post-hybridization wash.///scan_protocol: Arrays were scanned using a laser-scanner Axon 4000-B, (Axon Instruments, Union City, CA), using 5-micron resolution. Within the GenePix program were chosen photo-multiplier parameters that defined the quanta intensity density distribution of the array to give a Cy3/Cy5 ratio close to 1.0 and produced not too much saturated signals for each array. Separate 16-bit images were acquired for Cy3 and Cy5.///description: none///data_processing: Images were analysed using the GenePix Pro software (Axon Instruments) version 3.0. GenePix Result files (GPR) and the related scan images, together with the Agilent cDNA pattern file and information on the hybridised samples and labelling signs (positive for normal labelling and negative for dye-swap labelling), were then loaded into the Rosetta Resolver SE software. The Axon GenePix error model was applied to transform data and then duplicate ratio profiles were combined to obtain one ratio experiment for each patient. Log ratios, log ratio errors and p-values were thus available for the non flagged sequences of each ratio experiment.///platform_id: GPL5689///contact_name: Pietro,,Mariani///contact_institute: Mario Negri Institute///contact_address: Via La Masa 19///contact_city: Milan///contact_zip.postal_code: 20156///contact_country: Italy///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM214nnn/GSM214086/GSM214086_raw.txt.gz///data_row_count: 16281
1
title: p550bis sample_Ovarian tumor///geo_accession: GSM214053///status: Public on Aug 25 2007///submission_date: Jul 31 2007///last_update_date: Aug 24 2007///type: RNA///channel_count: 2///source_name_ch1: Total RNA extracted from frozen biopsies of ovarian tumors///organism_ch1: Homo sapiens///characteristics_ch1: Gender: Female///characteristics_ch1.1: Status:death related to cancer///characteristics_ch1.2: FIGO Stage:1///characteristics_ch1.3: FIGO Substage:c///characteristics_ch1.4: Histotype:clear cells///characteristics_ch1.5: Grade:3///characteristics_ch1.6: Relapsed:yes///characteristics_ch1.7: Age(years):65.96///characteristics_ch1.8: Overall Survival(days):1369///characteristics_ch1.9: Progression Free Survival(days):1369///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification from human biopsies were performed using the SV Total RNA Isolation System -cat:#z3100 from Promega.///label_ch1: Cy5///label_protocol_ch1: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch1: 9606///source_name_ch2: Clontech Universal Reference///organism_ch2: Homo sapiens///characteristics_ch2: Human Atlas high pure control total RNA extracted from a pool of 60 human cell lines (BD Biosciences)///molecule_ch2: total RNA///extract_protocol_ch2: see the producer web site: http//clontech.com/products/detail.asp?tabno=2&catalog_id=636538&page=all&faq_id=153665///label_ch2: Cy3///label_protocol_ch2: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch2: 9606///hyb_protocol: Microarray hybridization: Add to each Sample 2.5 ul Cot-1 DNA and 12.50 ul 2X Hybridization Buffer. Heat samples for 2 min at 65 C. Centrifuge. Pipet the cDNA array and 22 ul of sample. Incubate for 16 hr at 65 C. Used Atlas Glass Microarray User Manual PT3453-1 instructions for post-hybridization wash.///scan_protocol: Arrays were scanned using a laser-scanner Axon 4000-B, (Axon Instruments, Union City, CA), using 5-micron resolution. Within the GenePix program were chosen photo-multiplier parameters that defined the quanta intensity density distribution of the array to give a Cy3/Cy5 ratio close to 1.0 and produced not too much saturated signals for each array. Separate 16-bit images were acquired for Cy3 and Cy5.///description: none///data_processing: Images were analysed using the GenePix Pro software (Axon Instruments) version 3.0. GenePix Result files (GPR) and the related scan images, together with the Agilent cDNA pattern file and information on the hybridised samples and labelling signs (positive for normal labelling and negative for dye-swap labelling), were then loaded into the Rosetta Resolver SE software. The Axon GenePix error model was applied to transform data and then duplicate ratio profiles were combined to obtain one ratio experiment for each patient. Log ratios, log ratio errors and p-values were thus available for the non flagged sequences of each ratio experiment.///platform_id: GPL5689///contact_name: Pietro,,Mariani///contact_institute: Mario Negri Institute///contact_address: Via La Masa 19///contact_city: Milan///contact_zip.postal_code: 20156///contact_country: Italy///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM214nnn/GSM214053/GSM214053_raw.txt.gz///data_row_count: 16281
1
title: p567bis sample_Ovarian tumor///geo_accession: GSM214054///status: Public on Aug 25 2007///submission_date: Jul 31 2007///last_update_date: Aug 24 2007///type: RNA///channel_count: 2///source_name_ch1: Total RNA extracted from frozen biopsies of ovarian tumors///organism_ch1: Homo sapiens///characteristics_ch1: Gender: Female///characteristics_ch1.1: Status:alive no evidence of disease///characteristics_ch1.2: FIGO Stage:1///characteristics_ch1.3: FIGO Substage:c///characteristics_ch1.4: Histotype:endometrioid///characteristics_ch1.5: Grade:2///characteristics_ch1.6: Relapsed:no///characteristics_ch1.7: Age(years):21.06///characteristics_ch1.8: Overall Survival(days):1266///characteristics_ch1.9: Progression Free Survival(days):1266///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification from human biopsies were performed using the SV Total RNA Isolation System -cat:#z3100 from Promega.///label_ch1: Cy5///label_protocol_ch1: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch1: 9606///source_name_ch2: Clontech Universal Reference///organism_ch2: Homo sapiens///characteristics_ch2: Human Atlas high pure control total RNA extracted from a pool of 60 human cell lines (BD Biosciences)///molecule_ch2: total RNA///extract_protocol_ch2: see the producer web site: http//clontech.com/products/detail.asp?tabno=2&catalog_id=636538&page=all&faq_id=153665///label_ch2: Cy3///label_protocol_ch2: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch2: 9606///hyb_protocol: Microarray hybridization: Add to each Sample 2.5 ul Cot-1 DNA and 12.50 ul 2X Hybridization Buffer. Heat samples for 2 min at 65 C. Centrifuge. Pipet the cDNA array and 22 ul of sample. Incubate for 16 hr at 65 C. Used Atlas Glass Microarray User Manual PT3453-1 instructions for post-hybridization wash.///scan_protocol: Arrays were scanned using a laser-scanner Axon 4000-B, (Axon Instruments, Union City, CA), using 5-micron resolution. Within the GenePix program were chosen photo-multiplier parameters that defined the quanta intensity density distribution of the array to give a Cy3/Cy5 ratio close to 1.0 and produced not too much saturated signals for each array. Separate 16-bit images were acquired for Cy3 and Cy5.///description: none///data_processing: Images were analysed using the GenePix Pro software (Axon Instruments) version 3.0. GenePix Result files (GPR) and the related scan images, together with the Agilent cDNA pattern file and information on the hybridised samples and labelling signs (positive for normal labelling and negative for dye-swap labelling), were then loaded into the Rosetta Resolver SE software. The Axon GenePix error model was applied to transform data and then duplicate ratio profiles were combined to obtain one ratio experiment for each patient. Log ratios, log ratio errors and p-values were thus available for the non flagged sequences of each ratio experiment.///platform_id: GPL5689///contact_name: Pietro,,Mariani///contact_institute: Mario Negri Institute///contact_address: Via La Masa 19///contact_city: Milan///contact_zip.postal_code: 20156///contact_country: Italy///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM214nnn/GSM214054/GSM214054_raw.txt.gz///data_row_count: 16281
1
title: p56bis sample_Ovarian tumor///geo_accession: GSM214044///status: Public on Aug 25 2007///submission_date: Jul 31 2007///last_update_date: Aug 24 2007///type: RNA///channel_count: 2///source_name_ch1: Total RNA extracted from frozen biopsies of ovarian tumors///organism_ch1: Homo sapiens///characteristics_ch1: Gender: Female///characteristics_ch1.1: Status:alive no evidence of disease///characteristics_ch1.2: FIGO Stage:1///characteristics_ch1.3: FIGO Substage:c///characteristics_ch1.4: Histotype:serous///characteristics_ch1.5: Grade:3///characteristics_ch1.6: Relapsed:no///characteristics_ch1.7: Age(years):59.04///characteristics_ch1.8: Overall Survival(days):3516///characteristics_ch1.9: Progression Free Survival(days):3516///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification from human biopsies were performed using the SV Total RNA Isolation System -cat:#z3100 from Promega.///label_ch1: Cy5///label_protocol_ch1: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch1: 9606///source_name_ch2: Clontech Universal Reference///organism_ch2: Homo sapiens///characteristics_ch2: Human Atlas high pure control total RNA extracted from a pool of 60 human cell lines (BD Biosciences)///molecule_ch2: total RNA///extract_protocol_ch2: see the producer web site: http//clontech.com/products/detail.asp?tabno=2&catalog_id=636538&page=all&faq_id=153665///label_ch2: Cy3///label_protocol_ch2: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch2: 9606///hyb_protocol: Microarray hybridization: Add to each Sample 2.5 ul Cot-1 DNA and 12.50 ul 2X Hybridization Buffer. Heat samples for 2 min at 65 C. Centrifuge. Pipet the cDNA array and 22 ul of sample. Incubate for 16 hr at 65 C. Used Atlas Glass Microarray User Manual PT3453-1 instructions for post-hybridization wash.///scan_protocol: Arrays were scanned using a laser-scanner Axon 4000-B, (Axon Instruments, Union City, CA), using 5-micron resolution. Within the GenePix program were chosen photo-multiplier parameters that defined the quanta intensity density distribution of the array to give a Cy3/Cy5 ratio close to 1.0 and produced not too much saturated signals for each array. Separate 16-bit images were acquired for Cy3 and Cy5.///description: none///data_processing: Images were analysed using the GenePix Pro software (Axon Instruments) version 3.0. GenePix Result files (GPR) and the related scan images, together with the Agilent cDNA pattern file and information on the hybridised samples and labelling signs (positive for normal labelling and negative for dye-swap labelling), were then loaded into the Rosetta Resolver SE software. The Axon GenePix error model was applied to transform data and then duplicate ratio profiles were combined to obtain one ratio experiment for each patient. Log ratios, log ratio errors and p-values were thus available for the non flagged sequences of each ratio experiment.///platform_id: GPL5689///contact_name: Pietro,,Mariani///contact_institute: Mario Negri Institute///contact_address: Via La Masa 19///contact_city: Milan///contact_zip.postal_code: 20156///contact_country: Italy///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM214nnn/GSM214044/GSM214044_raw.txt.gz///data_row_count: 16281
1
title: p573bis sample_Ovarian tumor///geo_accession: GSM214060///status: Public on Aug 25 2007///submission_date: Jul 31 2007///last_update_date: Aug 24 2007///type: RNA///channel_count: 2///source_name_ch1: Total RNA extracted from frozen biopsies of ovarian tumors///organism_ch1: Homo sapiens///characteristics_ch1: Gender: Female///characteristics_ch1.1: Status:alive no evidence of disease///characteristics_ch1.2: FIGO Stage:1///characteristics_ch1.3: FIGO Substage:c///characteristics_ch1.4: Histotype:clear cells///characteristics_ch1.5: Grade:3///characteristics_ch1.6: Relapsed:no///characteristics_ch1.7: Age(years):71.29///characteristics_ch1.8: Overall Survival(days):1393///characteristics_ch1.9: Progression Free Survival(days):1393///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification from human biopsies were performed using the SV Total RNA Isolation System -cat:#z3100 from Promega.///label_ch1: Cy5///label_protocol_ch1: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch1: 9606///source_name_ch2: Clontech Universal Reference///organism_ch2: Homo sapiens///characteristics_ch2: Human Atlas high pure control total RNA extracted from a pool of 60 human cell lines (BD Biosciences)///molecule_ch2: total RNA///extract_protocol_ch2: see the producer web site: http//clontech.com/products/detail.asp?tabno=2&catalog_id=636538&page=all&faq_id=153665///label_ch2: Cy3///label_protocol_ch2: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch2: 9606///hyb_protocol: Microarray hybridization: Add to each Sample 2.5 ul Cot-1 DNA and 12.50 ul 2X Hybridization Buffer. Heat samples for 2 min at 65 C. Centrifuge. Pipet the cDNA array and 22 ul of sample. Incubate for 16 hr at 65 C. Used Atlas Glass Microarray User Manual PT3453-1 instructions for post-hybridization wash.///scan_protocol: Arrays were scanned using a laser-scanner Axon 4000-B, (Axon Instruments, Union City, CA), using 5-micron resolution. Within the GenePix program were chosen photo-multiplier parameters that defined the quanta intensity density distribution of the array to give a Cy3/Cy5 ratio close to 1.0 and produced not too much saturated signals for each array. Separate 16-bit images were acquired for Cy3 and Cy5.///description: none///data_processing: Images were analysed using the GenePix Pro software (Axon Instruments) version 3.0. GenePix Result files (GPR) and the related scan images, together with the Agilent cDNA pattern file and information on the hybridised samples and labelling signs (positive for normal labelling and negative for dye-swap labelling), were then loaded into the Rosetta Resolver SE software. The Axon GenePix error model was applied to transform data and then duplicate ratio profiles were combined to obtain one ratio experiment for each patient. Log ratios, log ratio errors and p-values were thus available for the non flagged sequences of each ratio experiment.///platform_id: GPL5689///contact_name: Pietro,,Mariani///contact_institute: Mario Negri Institute///contact_address: Via La Masa 19///contact_city: Milan///contact_zip.postal_code: 20156///contact_country: Italy///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM214nnn/GSM214060/GSM214060_raw.txt.gz///data_row_count: 16281
1
title: p586bis sample_Ovarian tumor///geo_accession: GSM214061///status: Public on Aug 25 2007///submission_date: Jul 31 2007///last_update_date: Aug 24 2007///type: RNA///channel_count: 2///source_name_ch1: Total RNA extracted from frozen biopsies of ovarian tumors///organism_ch1: Homo sapiens///characteristics_ch1: Gender: Female///characteristics_ch1.1: Status:alive no evidence of disease///characteristics_ch1.2: FIGO Stage:1///characteristics_ch1.3: FIGO Substage:c///characteristics_ch1.4: Histotype:endometrioid///characteristics_ch1.5: Grade:2///characteristics_ch1.6: Relapsed:no///characteristics_ch1.7: Age(years):42.6///characteristics_ch1.8: Overall Survival(days):1111///characteristics_ch1.9: Progression Free Survival(days):1111///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification from human biopsies were performed using the SV Total RNA Isolation System -cat:#z3100 from Promega.///label_ch1: Cy5///label_protocol_ch1: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch1: 9606///source_name_ch2: Clontech Universal Reference///organism_ch2: Homo sapiens///characteristics_ch2: Human Atlas high pure control total RNA extracted from a pool of 60 human cell lines (BD Biosciences)///molecule_ch2: total RNA///extract_protocol_ch2: see the producer web site: http//clontech.com/products/detail.asp?tabno=2&catalog_id=636538&page=all&faq_id=153665///label_ch2: Cy3///label_protocol_ch2: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch2: 9606///hyb_protocol: Microarray hybridization: Add to each Sample 2.5 ul Cot-1 DNA and 12.50 ul 2X Hybridization Buffer. Heat samples for 2 min at 65 C. Centrifuge. Pipet the cDNA array and 22 ul of sample. Incubate for 16 hr at 65 C. Used Atlas Glass Microarray User Manual PT3453-1 instructions for post-hybridization wash.///scan_protocol: Arrays were scanned using a laser-scanner Axon 4000-B, (Axon Instruments, Union City, CA), using 5-micron resolution. Within the GenePix program were chosen photo-multiplier parameters that defined the quanta intensity density distribution of the array to give a Cy3/Cy5 ratio close to 1.0 and produced not too much saturated signals for each array. Separate 16-bit images were acquired for Cy3 and Cy5.///description: none///data_processing: Images were analysed using the GenePix Pro software (Axon Instruments) version 3.0. GenePix Result files (GPR) and the related scan images, together with the Agilent cDNA pattern file and information on the hybridised samples and labelling signs (positive for normal labelling and negative for dye-swap labelling), were then loaded into the Rosetta Resolver SE software. The Axon GenePix error model was applied to transform data and then duplicate ratio profiles were combined to obtain one ratio experiment for each patient. Log ratios, log ratio errors and p-values were thus available for the non flagged sequences of each ratio experiment.///platform_id: GPL5689///contact_name: Pietro,,Mariani///contact_institute: Mario Negri Institute///contact_address: Via La Masa 19///contact_city: Milan///contact_zip.postal_code: 20156///contact_country: Italy///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM214nnn/GSM214061/GSM214061_raw.txt.gz///data_row_count: 16281
1
title: p597bis sample_Ovarian tumor///geo_accession: GSM214088///status: Public on Aug 25 2007///submission_date: Jul 31 2007///last_update_date: Aug 24 2007///type: RNA///channel_count: 2///source_name_ch1: Total RNA extracted from frozen biopsies of ovarian tumors///organism_ch1: Homo sapiens///characteristics_ch1: Gender: Female///characteristics_ch1.1: Status:alive no evidence of disease///characteristics_ch1.2: FIGO Stage:1///characteristics_ch1.3: FIGO Substage:a///characteristics_ch1.4: Histotype:other///characteristics_ch1.5: Grade:Borderline///characteristics_ch1.6: Relapsed:no///characteristics_ch1.7: Age(years):34.67///characteristics_ch1.8: Overall Survival(days):1136///characteristics_ch1.9: Progression Free Survival(days):1136///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification from human biopsies were performed using the SV Total RNA Isolation System -cat:#z3100 from Promega.///label_ch1: Cy5///label_protocol_ch1: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch1: 9606///source_name_ch2: Clontech Universal Reference///organism_ch2: Homo sapiens///characteristics_ch2: Human Atlas high pure control total RNA extracted from a pool of 60 human cell lines (BD Biosciences)///molecule_ch2: total RNA///extract_protocol_ch2: see the producer web site: http//clontech.com/products/detail.asp?tabno=2&catalog_id=636538&page=all&faq_id=153665///label_ch2: Cy3///label_protocol_ch2: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch2: 9606///hyb_protocol: Microarray hybridization: Add to each Sample 2.5 ul Cot-1 DNA and 12.50 ul 2X Hybridization Buffer. Heat samples for 2 min at 65 C. Centrifuge. Pipet the cDNA array and 22 ul of sample. Incubate for 16 hr at 65 C. Used Atlas Glass Microarray User Manual PT3453-1 instructions for post-hybridization wash.///scan_protocol: Arrays were scanned using a laser-scanner Axon 4000-B, (Axon Instruments, Union City, CA), using 5-micron resolution. Within the GenePix program were chosen photo-multiplier parameters that defined the quanta intensity density distribution of the array to give a Cy3/Cy5 ratio close to 1.0 and produced not too much saturated signals for each array. Separate 16-bit images were acquired for Cy3 and Cy5.///description: none///data_processing: Images were analysed using the GenePix Pro software (Axon Instruments) version 3.0. GenePix Result files (GPR) and the related scan images, together with the Agilent cDNA pattern file and information on the hybridised samples and labelling signs (positive for normal labelling and negative for dye-swap labelling), were then loaded into the Rosetta Resolver SE software. The Axon GenePix error model was applied to transform data and then duplicate ratio profiles were combined to obtain one ratio experiment for each patient. Log ratios, log ratio errors and p-values were thus available for the non flagged sequences of each ratio experiment.///platform_id: GPL5689///contact_name: Pietro,,Mariani///contact_institute: Mario Negri Institute///contact_address: Via La Masa 19///contact_city: Milan///contact_zip.postal_code: 20156///contact_country: Italy///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM214nnn/GSM214088/GSM214088_raw.txt.gz///data_row_count: 16281
1
title: p616bis sample_Ovarian tumor///geo_accession: GSM214071///status: Public on Aug 25 2007///submission_date: Jul 31 2007///last_update_date: Aug 24 2007///type: RNA///channel_count: 2///source_name_ch1: Total RNA extracted from frozen biopsies of ovarian tumors///organism_ch1: Homo sapiens///characteristics_ch1: Gender: Female///characteristics_ch1.1: Status:alive no evidence of disease///characteristics_ch1.2: FIGO Stage:1///characteristics_ch1.3: FIGO Substage:c///characteristics_ch1.4: Histotype:clear cells///characteristics_ch1.5: Grade:3///characteristics_ch1.6: Relapsed:no///characteristics_ch1.7: Age(years):43.99///characteristics_ch1.8: Overall Survival(days):1220///characteristics_ch1.9: Progression Free Survival(days):1220///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification from human biopsies were performed using the SV Total RNA Isolation System -cat:#z3100 from Promega.///label_ch1: Cy5///label_protocol_ch1: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch1: 9606///source_name_ch2: Clontech Universal Reference///organism_ch2: Homo sapiens///characteristics_ch2: Human Atlas high pure control total RNA extracted from a pool of 60 human cell lines (BD Biosciences)///molecule_ch2: total RNA///extract_protocol_ch2: see the producer web site: http//clontech.com/products/detail.asp?tabno=2&catalog_id=636538&page=all&faq_id=153665///label_ch2: Cy3///label_protocol_ch2: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch2: 9606///hyb_protocol: Microarray hybridization: Add to each Sample 2.5 ul Cot-1 DNA and 12.50 ul 2X Hybridization Buffer. Heat samples for 2 min at 65 C. Centrifuge. Pipet the cDNA array and 22 ul of sample. Incubate for 16 hr at 65 C. Used Atlas Glass Microarray User Manual PT3453-1 instructions for post-hybridization wash.///scan_protocol: Arrays were scanned using a laser-scanner Axon 4000-B, (Axon Instruments, Union City, CA), using 5-micron resolution. Within the GenePix program were chosen photo-multiplier parameters that defined the quanta intensity density distribution of the array to give a Cy3/Cy5 ratio close to 1.0 and produced not too much saturated signals for each array. Separate 16-bit images were acquired for Cy3 and Cy5.///description: none///data_processing: Images were analysed using the GenePix Pro software (Axon Instruments) version 3.0. GenePix Result files (GPR) and the related scan images, together with the Agilent cDNA pattern file and information on the hybridised samples and labelling signs (positive for normal labelling and negative for dye-swap labelling), were then loaded into the Rosetta Resolver SE software. The Axon GenePix error model was applied to transform data and then duplicate ratio profiles were combined to obtain one ratio experiment for each patient. Log ratios, log ratio errors and p-values were thus available for the non flagged sequences of each ratio experiment.///platform_id: GPL5689///contact_name: Pietro,,Mariani///contact_institute: Mario Negri Institute///contact_address: Via La Masa 19///contact_city: Milan///contact_zip.postal_code: 20156///contact_country: Italy///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM214nnn/GSM214071/GSM214071_raw.txt.gz///data_row_count: 16281
1
title: p63bis sample_Ovarian tumor///geo_accession: GSM214027///status: Public on Aug 25 2007///submission_date: Jul 31 2007///last_update_date: Aug 24 2007///type: RNA///channel_count: 2///source_name_ch1: Total RNA extracted from frozen biopsies of ovarian tumors///organism_ch1: Homo sapiens///characteristics_ch1: Gender: Female///characteristics_ch1.1: Status:alive no evidence of disease///characteristics_ch1.2: FIGO Stage:1///characteristics_ch1.3: FIGO Substage:c///characteristics_ch1.4: Histotype:endometrioid///characteristics_ch1.5: Grade:2///characteristics_ch1.6: Relapsed:no///characteristics_ch1.7: Age(years):65.94///characteristics_ch1.8: Overall Survival(days):3359///characteristics_ch1.9: Progression Free Survival(days):3359///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification from human biopsies were performed using the SV Total RNA Isolation System -cat:#z3100 from Promega.///label_ch1: Cy5///label_protocol_ch1: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch1: 9606///source_name_ch2: Clontech Universal Reference///organism_ch2: Homo sapiens///characteristics_ch2: Human Atlas high pure control total RNA extracted from a pool of 60 human cell lines (BD Biosciences)///molecule_ch2: total RNA///extract_protocol_ch2: see the producer web site: http//clontech.com/products/detail.asp?tabno=2&catalog_id=636538&page=all&faq_id=153665///label_ch2: Cy3///label_protocol_ch2: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch2: 9606///hyb_protocol: Microarray hybridization: Add to each Sample 2.5 ul Cot-1 DNA and 12.50 ul 2X Hybridization Buffer. Heat samples for 2 min at 65 C. Centrifuge. Pipet the cDNA array and 22 ul of sample. Incubate for 16 hr at 65 C. Used Atlas Glass Microarray User Manual PT3453-1 instructions for post-hybridization wash.///scan_protocol: Arrays were scanned using a laser-scanner Axon 4000-B, (Axon Instruments, Union City, CA), using 5-micron resolution. Within the GenePix program were chosen photo-multiplier parameters that defined the quanta intensity density distribution of the array to give a Cy3/Cy5 ratio close to 1.0 and produced not too much saturated signals for each array. Separate 16-bit images were acquired for Cy3 and Cy5.///description: none///data_processing: Images were analysed using the GenePix Pro software (Axon Instruments) version 3.0. GenePix Result files (GPR) and the related scan images, together with the Agilent cDNA pattern file and information on the hybridised samples and labelling signs (positive for normal labelling and negative for dye-swap labelling), were then loaded into the Rosetta Resolver SE software. The Axon GenePix error model was applied to transform data and then duplicate ratio profiles were combined to obtain one ratio experiment for each patient. Log ratios, log ratio errors and p-values were thus available for the non flagged sequences of each ratio experiment.///platform_id: GPL5689///contact_name: Pietro,,Mariani///contact_institute: Mario Negri Institute///contact_address: Via La Masa 19///contact_city: Milan///contact_zip.postal_code: 20156///contact_country: Italy///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM214nnn/GSM214027/GSM214027_raw.txt.gz///data_row_count: 16281
1
title: p646bis sample_Ovarian tumor///geo_accession: GSM214087///status: Public on Aug 25 2007///submission_date: Jul 31 2007///last_update_date: Aug 24 2007///type: RNA///channel_count: 2///source_name_ch1: Total RNA extracted from frozen biopsies of ovarian tumors///organism_ch1: Homo sapiens///characteristics_ch1: Gender: Female///characteristics_ch1.1: Status:alive no evidence of disease///characteristics_ch1.2: FIGO Stage:1///characteristics_ch1.3: FIGO Substage:c///characteristics_ch1.4: Histotype:serous///characteristics_ch1.5: Grade:Borderline///characteristics_ch1.6: Relapsed:no///characteristics_ch1.7: Age(years):41.49///characteristics_ch1.8: Overall Survival(days):1196///characteristics_ch1.9: Progression Free Survival(days):1196///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification from human biopsies were performed using the SV Total RNA Isolation System -cat:#z3100 from Promega.///label_ch1: Cy5///label_protocol_ch1: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch1: 9606///source_name_ch2: Clontech Universal Reference///organism_ch2: Homo sapiens///characteristics_ch2: Human Atlas high pure control total RNA extracted from a pool of 60 human cell lines (BD Biosciences)///molecule_ch2: total RNA///extract_protocol_ch2: see the producer web site: http//clontech.com/products/detail.asp?tabno=2&catalog_id=636538&page=all&faq_id=153665///label_ch2: Cy3///label_protocol_ch2: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch2: 9606///hyb_protocol: Microarray hybridization: Add to each Sample 2.5 ul Cot-1 DNA and 12.50 ul 2X Hybridization Buffer. Heat samples for 2 min at 65 C. Centrifuge. Pipet the cDNA array and 22 ul of sample. Incubate for 16 hr at 65 C. Used Atlas Glass Microarray User Manual PT3453-1 instructions for post-hybridization wash.///scan_protocol: Arrays were scanned using a laser-scanner Axon 4000-B, (Axon Instruments, Union City, CA), using 5-micron resolution. Within the GenePix program were chosen photo-multiplier parameters that defined the quanta intensity density distribution of the array to give a Cy3/Cy5 ratio close to 1.0 and produced not too much saturated signals for each array. Separate 16-bit images were acquired for Cy3 and Cy5.///description: none///data_processing: Images were analysed using the GenePix Pro software (Axon Instruments) version 3.0. GenePix Result files (GPR) and the related scan images, together with the Agilent cDNA pattern file and information on the hybridised samples and labelling signs (positive for normal labelling and negative for dye-swap labelling), were then loaded into the Rosetta Resolver SE software. The Axon GenePix error model was applied to transform data and then duplicate ratio profiles were combined to obtain one ratio experiment for each patient. Log ratios, log ratio errors and p-values were thus available for the non flagged sequences of each ratio experiment.///platform_id: GPL5689///contact_name: Pietro,,Mariani///contact_institute: Mario Negri Institute///contact_address: Via La Masa 19///contact_city: Milan///contact_zip.postal_code: 20156///contact_country: Italy///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM214nnn/GSM214087/GSM214087_raw.txt.gz///data_row_count: 16281
1
title: p66bis sample_Ovarian tumor///geo_accession: GSM214045///status: Public on Aug 25 2007///submission_date: Jul 31 2007///last_update_date: Aug 24 2007///type: RNA///channel_count: 2///source_name_ch1: Total RNA extracted from frozen biopsies of ovarian tumors///organism_ch1: Homo sapiens///characteristics_ch1: Gender: Female///characteristics_ch1.1: Status:alive no evidence of disease///characteristics_ch1.2: FIGO Stage:1///characteristics_ch1.3: FIGO Substage:c///characteristics_ch1.4: Histotype:endometrioid///characteristics_ch1.5: Grade:2///characteristics_ch1.6: Relapsed:no///characteristics_ch1.7: Age(years):38.18///characteristics_ch1.8: Overall Survival(days):3459///characteristics_ch1.9: Progression Free Survival(days):3459///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification from human biopsies were performed using the SV Total RNA Isolation System -cat:#z3100 from Promega.///label_ch1: Cy5///label_protocol_ch1: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch1: 9606///source_name_ch2: Clontech Universal Reference///organism_ch2: Homo sapiens///characteristics_ch2: Human Atlas high pure control total RNA extracted from a pool of 60 human cell lines (BD Biosciences)///molecule_ch2: total RNA///extract_protocol_ch2: see the producer web site: http//clontech.com/products/detail.asp?tabno=2&catalog_id=636538&page=all&faq_id=153665///label_ch2: Cy3///label_protocol_ch2: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch2: 9606///hyb_protocol: Microarray hybridization: Add to each Sample 2.5 ul Cot-1 DNA and 12.50 ul 2X Hybridization Buffer. Heat samples for 2 min at 65 C. Centrifuge. Pipet the cDNA array and 22 ul of sample. Incubate for 16 hr at 65 C. Used Atlas Glass Microarray User Manual PT3453-1 instructions for post-hybridization wash.///scan_protocol: Arrays were scanned using a laser-scanner Axon 4000-B, (Axon Instruments, Union City, CA), using 5-micron resolution. Within the GenePix program were chosen photo-multiplier parameters that defined the quanta intensity density distribution of the array to give a Cy3/Cy5 ratio close to 1.0 and produced not too much saturated signals for each array. Separate 16-bit images were acquired for Cy3 and Cy5.///description: none///data_processing: Images were analysed using the GenePix Pro software (Axon Instruments) version 3.0. GenePix Result files (GPR) and the related scan images, together with the Agilent cDNA pattern file and information on the hybridised samples and labelling signs (positive for normal labelling and negative for dye-swap labelling), were then loaded into the Rosetta Resolver SE software. The Axon GenePix error model was applied to transform data and then duplicate ratio profiles were combined to obtain one ratio experiment for each patient. Log ratios, log ratio errors and p-values were thus available for the non flagged sequences of each ratio experiment.///platform_id: GPL5689///contact_name: Pietro,,Mariani///contact_institute: Mario Negri Institute///contact_address: Via La Masa 19///contact_city: Milan///contact_zip.postal_code: 20156///contact_country: Italy///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM214nnn/GSM214045/GSM214045_raw.txt.gz///data_row_count: 16281
1
title: p68bis sample_Ovarian tumor///geo_accession: GSM214046///status: Public on Aug 25 2007///submission_date: Jul 31 2007///last_update_date: Aug 24 2007///type: RNA///channel_count: 2///source_name_ch1: Total RNA extracted from frozen biopsies of ovarian tumors///organism_ch1: Homo sapiens///characteristics_ch1: Gender: Female///characteristics_ch1.1: Status:alive no evidence of disease///characteristics_ch1.2: FIGO Stage:1///characteristics_ch1.3: FIGO Substage:c///characteristics_ch1.4: Histotype:clear cells///characteristics_ch1.5: Grade:2///characteristics_ch1.6: Relapsed:no///characteristics_ch1.7: Age(years):42.65///characteristics_ch1.8: Overall Survival(days):3473///characteristics_ch1.9: Progression Free Survival(days):3473///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification from human biopsies were performed using the SV Total RNA Isolation System -cat:#z3100 from Promega.///label_ch1: Cy5///label_protocol_ch1: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch1: 9606///source_name_ch2: Clontech Universal Reference///organism_ch2: Homo sapiens///characteristics_ch2: Human Atlas high pure control total RNA extracted from a pool of 60 human cell lines (BD Biosciences)///molecule_ch2: total RNA///extract_protocol_ch2: see the producer web site: http//clontech.com/products/detail.asp?tabno=2&catalog_id=636538&page=all&faq_id=153665///label_ch2: Cy3///label_protocol_ch2: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch2: 9606///hyb_protocol: Microarray hybridization: Add to each Sample 2.5 ul Cot-1 DNA and 12.50 ul 2X Hybridization Buffer. Heat samples for 2 min at 65 C. Centrifuge. Pipet the cDNA array and 22 ul of sample. Incubate for 16 hr at 65 C. Used Atlas Glass Microarray User Manual PT3453-1 instructions for post-hybridization wash.///scan_protocol: Arrays were scanned using a laser-scanner Axon 4000-B, (Axon Instruments, Union City, CA), using 5-micron resolution. Within the GenePix program were chosen photo-multiplier parameters that defined the quanta intensity density distribution of the array to give a Cy3/Cy5 ratio close to 1.0 and produced not too much saturated signals for each array. Separate 16-bit images were acquired for Cy3 and Cy5.///description: none///data_processing: Images were analysed using the GenePix Pro software (Axon Instruments) version 3.0. GenePix Result files (GPR) and the related scan images, together with the Agilent cDNA pattern file and information on the hybridised samples and labelling signs (positive for normal labelling and negative for dye-swap labelling), were then loaded into the Rosetta Resolver SE software. The Axon GenePix error model was applied to transform data and then duplicate ratio profiles were combined to obtain one ratio experiment for each patient. Log ratios, log ratio errors and p-values were thus available for the non flagged sequences of each ratio experiment.///platform_id: GPL5689///contact_name: Pietro,,Mariani///contact_institute: Mario Negri Institute///contact_address: Via La Masa 19///contact_city: Milan///contact_zip.postal_code: 20156///contact_country: Italy///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM214nnn/GSM214046/GSM214046_raw.txt.gz///data_row_count: 16281
1
title: p690bis sample_Ovarian tumor///geo_accession: GSM214072///status: Public on Aug 25 2007///submission_date: Jul 31 2007///last_update_date: Aug 24 2007///type: RNA///channel_count: 2///source_name_ch1: Total RNA extracted from frozen biopsies of ovarian tumors///organism_ch1: Homo sapiens///characteristics_ch1: Gender: Female///characteristics_ch1.1: Status:alive no evidence of disease///characteristics_ch1.2: FIGO Stage:1///characteristics_ch1.3: FIGO Substage:c///characteristics_ch1.4: Histotype:serous///characteristics_ch1.5: Grade:3///characteristics_ch1.6: Relapsed:no///characteristics_ch1.7: Age(years):49.17///characteristics_ch1.8: Overall Survival(days):1084///characteristics_ch1.9: Progression Free Survival(days):1084///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification from human biopsies were performed using the SV Total RNA Isolation System -cat:#z3100 from Promega.///label_ch1: Cy5///label_protocol_ch1: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch1: 9606///source_name_ch2: Clontech Universal Reference///organism_ch2: Homo sapiens///characteristics_ch2: Human Atlas high pure control total RNA extracted from a pool of 60 human cell lines (BD Biosciences)///molecule_ch2: total RNA///extract_protocol_ch2: see the producer web site: http//clontech.com/products/detail.asp?tabno=2&catalog_id=636538&page=all&faq_id=153665///label_ch2: Cy3///label_protocol_ch2: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch2: 9606///hyb_protocol: Microarray hybridization: Add to each Sample 2.5 ul Cot-1 DNA and 12.50 ul 2X Hybridization Buffer. Heat samples for 2 min at 65 C. Centrifuge. Pipet the cDNA array and 22 ul of sample. Incubate for 16 hr at 65 C. Used Atlas Glass Microarray User Manual PT3453-1 instructions for post-hybridization wash.///scan_protocol: Arrays were scanned using a laser-scanner Axon 4000-B, (Axon Instruments, Union City, CA), using 5-micron resolution. Within the GenePix program were chosen photo-multiplier parameters that defined the quanta intensity density distribution of the array to give a Cy3/Cy5 ratio close to 1.0 and produced not too much saturated signals for each array. Separate 16-bit images were acquired for Cy3 and Cy5.///description: none///data_processing: Images were analysed using the GenePix Pro software (Axon Instruments) version 3.0. GenePix Result files (GPR) and the related scan images, together with the Agilent cDNA pattern file and information on the hybridised samples and labelling signs (positive for normal labelling and negative for dye-swap labelling), were then loaded into the Rosetta Resolver SE software. The Axon GenePix error model was applied to transform data and then duplicate ratio profiles were combined to obtain one ratio experiment for each patient. Log ratios, log ratio errors and p-values were thus available for the non flagged sequences of each ratio experiment.///platform_id: GPL5689///contact_name: Pietro,,Mariani///contact_institute: Mario Negri Institute///contact_address: Via La Masa 19///contact_city: Milan///contact_zip.postal_code: 20156///contact_country: Italy///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM214nnn/GSM214072/GSM214072_raw.txt.gz///data_row_count: 16281
1
title: p692bis sample_Ovarian tumor///geo_accession: GSM214073///status: Public on Aug 25 2007///submission_date: Jul 31 2007///last_update_date: Aug 24 2007///type: RNA///channel_count: 2///source_name_ch1: Total RNA extracted from frozen biopsies of ovarian tumors///organism_ch1: Homo sapiens///characteristics_ch1: Gender: Female///characteristics_ch1.1: Status:alive no evidence of disease///characteristics_ch1.2: FIGO Stage:1///characteristics_ch1.3: FIGO Substage:c///characteristics_ch1.4: Histotype:endometrioid///characteristics_ch1.5: Grade:3///characteristics_ch1.6: Relapsed:no///characteristics_ch1.7: Age(years):42.71///characteristics_ch1.8: Overall Survival(days):887///characteristics_ch1.9: Progression Free Survival(days):887///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification from human biopsies were performed using the SV Total RNA Isolation System -cat:#z3100 from Promega.///label_ch1: Cy5///label_protocol_ch1: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch1: 9606///source_name_ch2: Clontech Universal Reference///organism_ch2: Homo sapiens///characteristics_ch2: Human Atlas high pure control total RNA extracted from a pool of 60 human cell lines (BD Biosciences)///molecule_ch2: total RNA///extract_protocol_ch2: see the producer web site: http//clontech.com/products/detail.asp?tabno=2&catalog_id=636538&page=all&faq_id=153665///label_ch2: Cy3///label_protocol_ch2: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch2: 9606///hyb_protocol: Microarray hybridization: Add to each Sample 2.5 ul Cot-1 DNA and 12.50 ul 2X Hybridization Buffer. Heat samples for 2 min at 65 C. Centrifuge. Pipet the cDNA array and 22 ul of sample. Incubate for 16 hr at 65 C. Used Atlas Glass Microarray User Manual PT3453-1 instructions for post-hybridization wash.///scan_protocol: Arrays were scanned using a laser-scanner Axon 4000-B, (Axon Instruments, Union City, CA), using 5-micron resolution. Within the GenePix program were chosen photo-multiplier parameters that defined the quanta intensity density distribution of the array to give a Cy3/Cy5 ratio close to 1.0 and produced not too much saturated signals for each array. Separate 16-bit images were acquired for Cy3 and Cy5.///description: none///data_processing: Images were analysed using the GenePix Pro software (Axon Instruments) version 3.0. GenePix Result files (GPR) and the related scan images, together with the Agilent cDNA pattern file and information on the hybridised samples and labelling signs (positive for normal labelling and negative for dye-swap labelling), were then loaded into the Rosetta Resolver SE software. The Axon GenePix error model was applied to transform data and then duplicate ratio profiles were combined to obtain one ratio experiment for each patient. Log ratios, log ratio errors and p-values were thus available for the non flagged sequences of each ratio experiment.///platform_id: GPL5689///contact_name: Pietro,,Mariani///contact_institute: Mario Negri Institute///contact_address: Via La Masa 19///contact_city: Milan///contact_zip.postal_code: 20156///contact_country: Italy///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM214nnn/GSM214073/GSM214073_raw.txt.gz///data_row_count: 16281
1
title: p725bis sample_Ovarian tumor///geo_accession: GSM214057///status: Public on Aug 25 2007///submission_date: Jul 31 2007///last_update_date: Aug 24 2007///type: RNA///channel_count: 2///source_name_ch1: Total RNA extracted from frozen biopsies of ovarian tumors///organism_ch1: Homo sapiens///characteristics_ch1: Gender: Female///characteristics_ch1.1: Status:alive no evidence of disease///characteristics_ch1.2: FIGO Stage:1///characteristics_ch1.3: FIGO Substage:c///characteristics_ch1.4: Histotype:endometrioid///characteristics_ch1.5: Grade:2///characteristics_ch1.6: Relapsed:no///characteristics_ch1.7: Age(years):81.77///characteristics_ch1.8: Overall Survival(days):531///characteristics_ch1.9: Progression Free Survival(days):531///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification from human biopsies were performed using the SV Total RNA Isolation System -cat:#z3100 from Promega.///label_ch1: Cy5///label_protocol_ch1: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch1: 9606///source_name_ch2: Clontech Universal Reference///organism_ch2: Homo sapiens///characteristics_ch2: Human Atlas high pure control total RNA extracted from a pool of 60 human cell lines (BD Biosciences)///molecule_ch2: total RNA///extract_protocol_ch2: see the producer web site: http//clontech.com/products/detail.asp?tabno=2&catalog_id=636538&page=all&faq_id=153665///label_ch2: Cy3///label_protocol_ch2: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch2: 9606///hyb_protocol: Microarray hybridization: Add to each Sample 2.5 ul Cot-1 DNA and 12.50 ul 2X Hybridization Buffer. Heat samples for 2 min at 65 C. Centrifuge. Pipet the cDNA array and 22 ul of sample. Incubate for 16 hr at 65 C. Used Atlas Glass Microarray User Manual PT3453-1 instructions for post-hybridization wash.///scan_protocol: Arrays were scanned using a laser-scanner Axon 4000-B, (Axon Instruments, Union City, CA), using 5-micron resolution. Within the GenePix program were chosen photo-multiplier parameters that defined the quanta intensity density distribution of the array to give a Cy3/Cy5 ratio close to 1.0 and produced not too much saturated signals for each array. Separate 16-bit images were acquired for Cy3 and Cy5.///description: none///data_processing: Images were analysed using the GenePix Pro software (Axon Instruments) version 3.0. GenePix Result files (GPR) and the related scan images, together with the Agilent cDNA pattern file and information on the hybridised samples and labelling signs (positive for normal labelling and negative for dye-swap labelling), were then loaded into the Rosetta Resolver SE software. The Axon GenePix error model was applied to transform data and then duplicate ratio profiles were combined to obtain one ratio experiment for each patient. Log ratios, log ratio errors and p-values were thus available for the non flagged sequences of each ratio experiment.///platform_id: GPL5689///contact_name: Pietro,,Mariani///contact_institute: Mario Negri Institute///contact_address: Via La Masa 19///contact_city: Milan///contact_zip.postal_code: 20156///contact_country: Italy///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM214nnn/GSM214057/GSM214057_raw.txt.gz///data_row_count: 16281
1
title: p73bis sample_Ovarian tumor///geo_accession: GSM214028///status: Public on Aug 25 2007///submission_date: Jul 31 2007///last_update_date: Aug 24 2007///type: RNA///channel_count: 2///source_name_ch1: Total RNA extracted from frozen biopsies of ovarian tumors///organism_ch1: Homo sapiens///characteristics_ch1: Gender: Female///characteristics_ch1.1: Status:alive no evidence of disease///characteristics_ch1.2: FIGO Stage:1///characteristics_ch1.3: FIGO Substage:a///characteristics_ch1.4: Histotype:endometrioid///characteristics_ch1.5: Grade:2///characteristics_ch1.6: Relapsed:no///characteristics_ch1.7: Age(years):64.09///characteristics_ch1.8: Overall Survival(days):2997///characteristics_ch1.9: Progression Free Survival(days):2997///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification from human biopsies were performed using the SV Total RNA Isolation System -cat:#z3100 from Promega.///label_ch1: Cy5///label_protocol_ch1: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch1: 9606///source_name_ch2: Clontech Universal Reference///organism_ch2: Homo sapiens///characteristics_ch2: Human Atlas high pure control total RNA extracted from a pool of 60 human cell lines (BD Biosciences)///molecule_ch2: total RNA///extract_protocol_ch2: see the producer web site: http//clontech.com/products/detail.asp?tabno=2&catalog_id=636538&page=all&faq_id=153665///label_ch2: Cy3///label_protocol_ch2: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch2: 9606///hyb_protocol: Microarray hybridization: Add to each Sample 2.5 ul Cot-1 DNA and 12.50 ul 2X Hybridization Buffer. Heat samples for 2 min at 65 C. Centrifuge. Pipet the cDNA array and 22 ul of sample. Incubate for 16 hr at 65 C. Used Atlas Glass Microarray User Manual PT3453-1 instructions for post-hybridization wash.///scan_protocol: Arrays were scanned using a laser-scanner Axon 4000-B, (Axon Instruments, Union City, CA), using 5-micron resolution. Within the GenePix program were chosen photo-multiplier parameters that defined the quanta intensity density distribution of the array to give a Cy3/Cy5 ratio close to 1.0 and produced not too much saturated signals for each array. Separate 16-bit images were acquired for Cy3 and Cy5.///description: none///data_processing: Images were analysed using the GenePix Pro software (Axon Instruments) version 3.0. GenePix Result files (GPR) and the related scan images, together with the Agilent cDNA pattern file and information on the hybridised samples and labelling signs (positive for normal labelling and negative for dye-swap labelling), were then loaded into the Rosetta Resolver SE software. The Axon GenePix error model was applied to transform data and then duplicate ratio profiles were combined to obtain one ratio experiment for each patient. Log ratios, log ratio errors and p-values were thus available for the non flagged sequences of each ratio experiment.///platform_id: GPL5689///contact_name: Pietro,,Mariani///contact_institute: Mario Negri Institute///contact_address: Via La Masa 19///contact_city: Milan///contact_zip.postal_code: 20156///contact_country: Italy///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM214nnn/GSM214028/GSM214028_raw.txt.gz///data_row_count: 16281
1
title: p760bis sample_Ovarian tumor///geo_accession: GSM214062///status: Public on Aug 25 2007///submission_date: Jul 31 2007///last_update_date: Aug 24 2007///type: RNA///channel_count: 2///source_name_ch1: Total RNA extracted from frozen biopsies of ovarian tumors///organism_ch1: Homo sapiens///characteristics_ch1: Gender: Female///characteristics_ch1.1: Status:alive no evidence of disease///characteristics_ch1.2: FIGO Stage:1///characteristics_ch1.3: FIGO Substage:c///characteristics_ch1.4: Histotype:serous///characteristics_ch1.5: Grade:1///characteristics_ch1.6: Relapsed:no///characteristics_ch1.7: Age(years):23.48///characteristics_ch1.8: Overall Survival(days):381///characteristics_ch1.9: Progression Free Survival(days):381///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification from human biopsies were performed using the SV Total RNA Isolation System -cat:#z3100 from Promega.///label_ch1: Cy5///label_protocol_ch1: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch1: 9606///source_name_ch2: Clontech Universal Reference///organism_ch2: Homo sapiens///characteristics_ch2: Human Atlas high pure control total RNA extracted from a pool of 60 human cell lines (BD Biosciences)///molecule_ch2: total RNA///extract_protocol_ch2: see the producer web site: http//clontech.com/products/detail.asp?tabno=2&catalog_id=636538&page=all&faq_id=153665///label_ch2: Cy3///label_protocol_ch2: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch2: 9606///hyb_protocol: Microarray hybridization: Add to each Sample 2.5 ul Cot-1 DNA and 12.50 ul 2X Hybridization Buffer. Heat samples for 2 min at 65 C. Centrifuge. Pipet the cDNA array and 22 ul of sample. Incubate for 16 hr at 65 C. Used Atlas Glass Microarray User Manual PT3453-1 instructions for post-hybridization wash.///scan_protocol: Arrays were scanned using a laser-scanner Axon 4000-B, (Axon Instruments, Union City, CA), using 5-micron resolution. Within the GenePix program were chosen photo-multiplier parameters that defined the quanta intensity density distribution of the array to give a Cy3/Cy5 ratio close to 1.0 and produced not too much saturated signals for each array. Separate 16-bit images were acquired for Cy3 and Cy5.///description: none///data_processing: Images were analysed using the GenePix Pro software (Axon Instruments) version 3.0. GenePix Result files (GPR) and the related scan images, together with the Agilent cDNA pattern file and information on the hybridised samples and labelling signs (positive for normal labelling and negative for dye-swap labelling), were then loaded into the Rosetta Resolver SE software. The Axon GenePix error model was applied to transform data and then duplicate ratio profiles were combined to obtain one ratio experiment for each patient. Log ratios, log ratio errors and p-values were thus available for the non flagged sequences of each ratio experiment.///platform_id: GPL5689///contact_name: Pietro,,Mariani///contact_institute: Mario Negri Institute///contact_address: Via La Masa 19///contact_city: Milan///contact_zip.postal_code: 20156///contact_country: Italy///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM214nnn/GSM214062/GSM214062_raw.txt.gz///data_row_count: 16281
1
title: p770bis sample_Ovarian tumor///geo_accession: GSM214089///status: Public on Aug 25 2007///submission_date: Jul 31 2007///last_update_date: Aug 24 2007///type: RNA///channel_count: 2///source_name_ch1: Total RNA extracted from frozen biopsies of ovarian tumors///organism_ch1: Homo sapiens///characteristics_ch1: Gender: Female///characteristics_ch1.1: Status:alive no evidence of disease///characteristics_ch1.2: FIGO Stage:1///characteristics_ch1.3: FIGO Substage:b///characteristics_ch1.4: Histotype:serous///characteristics_ch1.5: Grade:Borderline///characteristics_ch1.6: Relapsed:no///characteristics_ch1.7: Age(years):72.7///characteristics_ch1.8: Overall Survival(days):0///characteristics_ch1.9: Progression Free Survival(days):0///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification from human biopsies were performed using the SV Total RNA Isolation System -cat:#z3100 from Promega.///label_ch1: Cy5///label_protocol_ch1: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch1: 9606///source_name_ch2: Clontech Universal Reference///organism_ch2: Homo sapiens///characteristics_ch2: Human Atlas high pure control total RNA extracted from a pool of 60 human cell lines (BD Biosciences)///molecule_ch2: total RNA///extract_protocol_ch2: see the producer web site: http//clontech.com/products/detail.asp?tabno=2&catalog_id=636538&page=all&faq_id=153665///label_ch2: Cy3///label_protocol_ch2: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch2: 9606///hyb_protocol: Microarray hybridization: Add to each Sample 2.5 ul Cot-1 DNA and 12.50 ul 2X Hybridization Buffer. Heat samples for 2 min at 65 C. Centrifuge. Pipet the cDNA array and 22 ul of sample. Incubate for 16 hr at 65 C. Used Atlas Glass Microarray User Manual PT3453-1 instructions for post-hybridization wash.///scan_protocol: Arrays were scanned using a laser-scanner Axon 4000-B, (Axon Instruments, Union City, CA), using 5-micron resolution. Within the GenePix program were chosen photo-multiplier parameters that defined the quanta intensity density distribution of the array to give a Cy3/Cy5 ratio close to 1.0 and produced not too much saturated signals for each array. Separate 16-bit images were acquired for Cy3 and Cy5.///description: none///data_processing: Images were analysed using the GenePix Pro software (Axon Instruments) version 3.0. GenePix Result files (GPR) and the related scan images, together with the Agilent cDNA pattern file and information on the hybridised samples and labelling signs (positive for normal labelling and negative for dye-swap labelling), were then loaded into the Rosetta Resolver SE software. The Axon GenePix error model was applied to transform data and then duplicate ratio profiles were combined to obtain one ratio experiment for each patient. Log ratios, log ratio errors and p-values were thus available for the non flagged sequences of each ratio experiment.///platform_id: GPL5689///contact_name: Pietro,,Mariani///contact_institute: Mario Negri Institute///contact_address: Via La Masa 19///contact_city: Milan///contact_zip.postal_code: 20156///contact_country: Italy///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM214nnn/GSM214089/GSM214089_raw.txt.gz///data_row_count: 16281
1
title: p772bis sample_Ovarian tumor///geo_accession: GSM214058///status: Public on Aug 25 2007///submission_date: Jul 31 2007///last_update_date: Aug 24 2007///type: RNA///channel_count: 2///source_name_ch1: Total RNA extracted from frozen biopsies of ovarian tumors///organism_ch1: Homo sapiens///characteristics_ch1: Gender: Female///characteristics_ch1.1: Status:alive no evidence of disease///characteristics_ch1.2: FIGO Stage:1///characteristics_ch1.3: FIGO Substage:c///characteristics_ch1.4: Histotype:clear cells///characteristics_ch1.5: Grade:3///characteristics_ch1.6: Relapsed:no///characteristics_ch1.7: Age(years):64.22///characteristics_ch1.8: Overall Survival(days):482///characteristics_ch1.9: Progression Free Survival(days):482///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification from human biopsies were performed using the SV Total RNA Isolation System -cat:#z3100 from Promega.///label_ch1: Cy5///label_protocol_ch1: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch1: 9606///source_name_ch2: Clontech Universal Reference///organism_ch2: Homo sapiens///characteristics_ch2: Human Atlas high pure control total RNA extracted from a pool of 60 human cell lines (BD Biosciences)///molecule_ch2: total RNA///extract_protocol_ch2: see the producer web site: http//clontech.com/products/detail.asp?tabno=2&catalog_id=636538&page=all&faq_id=153665///label_ch2: Cy3///label_protocol_ch2: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch2: 9606///hyb_protocol: Microarray hybridization: Add to each Sample 2.5 ul Cot-1 DNA and 12.50 ul 2X Hybridization Buffer. Heat samples for 2 min at 65 C. Centrifuge. Pipet the cDNA array and 22 ul of sample. Incubate for 16 hr at 65 C. Used Atlas Glass Microarray User Manual PT3453-1 instructions for post-hybridization wash.///scan_protocol: Arrays were scanned using a laser-scanner Axon 4000-B, (Axon Instruments, Union City, CA), using 5-micron resolution. Within the GenePix program were chosen photo-multiplier parameters that defined the quanta intensity density distribution of the array to give a Cy3/Cy5 ratio close to 1.0 and produced not too much saturated signals for each array. Separate 16-bit images were acquired for Cy3 and Cy5.///description: none///data_processing: Images were analysed using the GenePix Pro software (Axon Instruments) version 3.0. GenePix Result files (GPR) and the related scan images, together with the Agilent cDNA pattern file and information on the hybridised samples and labelling signs (positive for normal labelling and negative for dye-swap labelling), were then loaded into the Rosetta Resolver SE software. The Axon GenePix error model was applied to transform data and then duplicate ratio profiles were combined to obtain one ratio experiment for each patient. Log ratios, log ratio errors and p-values were thus available for the non flagged sequences of each ratio experiment.///platform_id: GPL5689///contact_name: Pietro,,Mariani///contact_institute: Mario Negri Institute///contact_address: Via La Masa 19///contact_city: Milan///contact_zip.postal_code: 20156///contact_country: Italy///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM214nnn/GSM214058/GSM214058_raw.txt.gz///data_row_count: 16281
1
title: p775bis sample_Ovarian tumor///geo_accession: GSM214074///status: Public on Aug 25 2007///submission_date: Jul 31 2007///last_update_date: Aug 24 2007///type: RNA///channel_count: 2///source_name_ch1: Total RNA extracted from frozen biopsies of ovarian tumors///organism_ch1: Homo sapiens///characteristics_ch1: Gender: Female///characteristics_ch1.1: Status:alive no evidence of disease///characteristics_ch1.2: FIGO Stage:1///characteristics_ch1.3: FIGO Substage:c///characteristics_ch1.4: Histotype:endometrioid///characteristics_ch1.5: Grade:3///characteristics_ch1.6: Relapsed:no///characteristics_ch1.7: Age(years):45.17///characteristics_ch1.8: Overall Survival(days):490///characteristics_ch1.9: Progression Free Survival(days):490///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification from human biopsies were performed using the SV Total RNA Isolation System -cat:#z3100 from Promega.///label_ch1: Cy5///label_protocol_ch1: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch1: 9606///source_name_ch2: Clontech Universal Reference///organism_ch2: Homo sapiens///characteristics_ch2: Human Atlas high pure control total RNA extracted from a pool of 60 human cell lines (BD Biosciences)///molecule_ch2: total RNA///extract_protocol_ch2: see the producer web site: http//clontech.com/products/detail.asp?tabno=2&catalog_id=636538&page=all&faq_id=153665///label_ch2: Cy3///label_protocol_ch2: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch2: 9606///hyb_protocol: Microarray hybridization: Add to each Sample 2.5 ul Cot-1 DNA and 12.50 ul 2X Hybridization Buffer. Heat samples for 2 min at 65 C. Centrifuge. Pipet the cDNA array and 22 ul of sample. Incubate for 16 hr at 65 C. Used Atlas Glass Microarray User Manual PT3453-1 instructions for post-hybridization wash.///scan_protocol: Arrays were scanned using a laser-scanner Axon 4000-B, (Axon Instruments, Union City, CA), using 5-micron resolution. Within the GenePix program were chosen photo-multiplier parameters that defined the quanta intensity density distribution of the array to give a Cy3/Cy5 ratio close to 1.0 and produced not too much saturated signals for each array. Separate 16-bit images were acquired for Cy3 and Cy5.///description: none///data_processing: Images were analysed using the GenePix Pro software (Axon Instruments) version 3.0. GenePix Result files (GPR) and the related scan images, together with the Agilent cDNA pattern file and information on the hybridised samples and labelling signs (positive for normal labelling and negative for dye-swap labelling), were then loaded into the Rosetta Resolver SE software. The Axon GenePix error model was applied to transform data and then duplicate ratio profiles were combined to obtain one ratio experiment for each patient. Log ratios, log ratio errors and p-values were thus available for the non flagged sequences of each ratio experiment.///platform_id: GPL5689///contact_name: Pietro,,Mariani///contact_institute: Mario Negri Institute///contact_address: Via La Masa 19///contact_city: Milan///contact_zip.postal_code: 20156///contact_country: Italy///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM214nnn/GSM214074/GSM214074_raw.txt.gz///data_row_count: 16281
1
title: p793bis sample_Ovarian tumor///geo_accession: GSM214075///status: Public on Aug 25 2007///submission_date: Jul 31 2007///last_update_date: Aug 24 2007///type: RNA///channel_count: 2///source_name_ch1: Total RNA extracted from frozen biopsies of ovarian tumors///organism_ch1: Homo sapiens///characteristics_ch1: Gender: Female///characteristics_ch1.1: Status:alive no evidence of disease///characteristics_ch1.2: FIGO Stage:1///characteristics_ch1.3: FIGO Substage:a///characteristics_ch1.4: Histotype:clear cells///characteristics_ch1.5: Grade:3///characteristics_ch1.6: Relapsed:no///characteristics_ch1.7: Age(years):68.41///characteristics_ch1.8: Overall Survival(days):427///characteristics_ch1.9: Progression Free Survival(days):427///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification from human biopsies were performed using the SV Total RNA Isolation System -cat:#z3100 from Promega.///label_ch1: Cy5///label_protocol_ch1: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch1: 9606///source_name_ch2: Clontech Universal Reference///organism_ch2: Homo sapiens///characteristics_ch2: Human Atlas high pure control total RNA extracted from a pool of 60 human cell lines (BD Biosciences)///molecule_ch2: total RNA///extract_protocol_ch2: see the producer web site: http//clontech.com/products/detail.asp?tabno=2&catalog_id=636538&page=all&faq_id=153665///label_ch2: Cy3///label_protocol_ch2: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch2: 9606///hyb_protocol: Microarray hybridization: Add to each Sample 2.5 ul Cot-1 DNA and 12.50 ul 2X Hybridization Buffer. Heat samples for 2 min at 65 C. Centrifuge. Pipet the cDNA array and 22 ul of sample. Incubate for 16 hr at 65 C. Used Atlas Glass Microarray User Manual PT3453-1 instructions for post-hybridization wash.///scan_protocol: Arrays were scanned using a laser-scanner Axon 4000-B, (Axon Instruments, Union City, CA), using 5-micron resolution. Within the GenePix program were chosen photo-multiplier parameters that defined the quanta intensity density distribution of the array to give a Cy3/Cy5 ratio close to 1.0 and produced not too much saturated signals for each array. Separate 16-bit images were acquired for Cy3 and Cy5.///description: none///data_processing: Images were analysed using the GenePix Pro software (Axon Instruments) version 3.0. GenePix Result files (GPR) and the related scan images, together with the Agilent cDNA pattern file and information on the hybridised samples and labelling signs (positive for normal labelling and negative for dye-swap labelling), were then loaded into the Rosetta Resolver SE software. The Axon GenePix error model was applied to transform data and then duplicate ratio profiles were combined to obtain one ratio experiment for each patient. Log ratios, log ratio errors and p-values were thus available for the non flagged sequences of each ratio experiment.///platform_id: GPL5689///contact_name: Pietro,,Mariani///contact_institute: Mario Negri Institute///contact_address: Via La Masa 19///contact_city: Milan///contact_zip.postal_code: 20156///contact_country: Italy///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM214nnn/GSM214075/GSM214075_raw.txt.gz///data_row_count: 16281
1
title: p79bis sample_Ovarian tumor///geo_accession: GSM214063///status: Public on Aug 25 2007///submission_date: Jul 31 2007///last_update_date: Aug 24 2007///type: RNA///channel_count: 2///source_name_ch1: Total RNA extracted from frozen biopsies of ovarian tumors///organism_ch1: Homo sapiens///characteristics_ch1: Gender: Female///characteristics_ch1.1: Status:death related to cancer///characteristics_ch1.2: FIGO Stage:1///characteristics_ch1.3: FIGO Substage:c///characteristics_ch1.4: Histotype:undifferentiated///characteristics_ch1.5: Grade:3///characteristics_ch1.6: Relapsed:yes///characteristics_ch1.7: Age(years):65.67///characteristics_ch1.8: Overall Survival(days):2267///characteristics_ch1.9: Progression Free Survival(days):2267///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification from human biopsies were performed using the SV Total RNA Isolation System -cat:#z3100 from Promega.///label_ch1: Cy5///label_protocol_ch1: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch1: 9606///source_name_ch2: Clontech Universal Reference///organism_ch2: Homo sapiens///characteristics_ch2: Human Atlas high pure control total RNA extracted from a pool of 60 human cell lines (BD Biosciences)///molecule_ch2: total RNA///extract_protocol_ch2: see the producer web site: http//clontech.com/products/detail.asp?tabno=2&catalog_id=636538&page=all&faq_id=153665///label_ch2: Cy3///label_protocol_ch2: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch2: 9606///hyb_protocol: Microarray hybridization: Add to each Sample 2.5 ul Cot-1 DNA and 12.50 ul 2X Hybridization Buffer. Heat samples for 2 min at 65 C. Centrifuge. Pipet the cDNA array and 22 ul of sample. Incubate for 16 hr at 65 C. Used Atlas Glass Microarray User Manual PT3453-1 instructions for post-hybridization wash.///scan_protocol: Arrays were scanned using a laser-scanner Axon 4000-B, (Axon Instruments, Union City, CA), using 5-micron resolution. Within the GenePix program were chosen photo-multiplier parameters that defined the quanta intensity density distribution of the array to give a Cy3/Cy5 ratio close to 1.0 and produced not too much saturated signals for each array. Separate 16-bit images were acquired for Cy3 and Cy5.///description: none///data_processing: Images were analysed using the GenePix Pro software (Axon Instruments) version 3.0. GenePix Result files (GPR) and the related scan images, together with the Agilent cDNA pattern file and information on the hybridised samples and labelling signs (positive for normal labelling and negative for dye-swap labelling), were then loaded into the Rosetta Resolver SE software. The Axon GenePix error model was applied to transform data and then duplicate ratio profiles were combined to obtain one ratio experiment for each patient. Log ratios, log ratio errors and p-values were thus available for the non flagged sequences of each ratio experiment.///platform_id: GPL5689///contact_name: Pietro,,Mariani///contact_institute: Mario Negri Institute///contact_address: Via La Masa 19///contact_city: Milan///contact_zip.postal_code: 20156///contact_country: Italy///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM214nnn/GSM214063/GSM214063_raw.txt.gz///data_row_count: 16281
1
title: p84bis sample_Ovarian tumor///geo_accession: GSM214039///status: Public on Aug 25 2007///submission_date: Jul 31 2007///last_update_date: Aug 24 2007///type: RNA///channel_count: 2///source_name_ch1: Total RNA extracted from frozen biopsies of ovarian tumors///organism_ch1: Homo sapiens///characteristics_ch1: Gender: Female///characteristics_ch1.1: Status:alive no evidence of disease///characteristics_ch1.2: FIGO Stage:1///characteristics_ch1.3: FIGO Substage:c///characteristics_ch1.4: Histotype:clear cells///characteristics_ch1.5: Grade:3///characteristics_ch1.6: Relapsed:no///characteristics_ch1.7: Age(years):53.37///characteristics_ch1.8: Overall Survival(days):3500///characteristics_ch1.9: Progression Free Survival(days):3500///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification from human biopsies were performed using the SV Total RNA Isolation System -cat:#z3100 from Promega.///label_ch1: Cy5///label_protocol_ch1: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch1: 9606///source_name_ch2: Clontech Universal Reference///organism_ch2: Homo sapiens///characteristics_ch2: Human Atlas high pure control total RNA extracted from a pool of 60 human cell lines (BD Biosciences)///molecule_ch2: total RNA///extract_protocol_ch2: see the producer web site: http//clontech.com/products/detail.asp?tabno=2&catalog_id=636538&page=all&faq_id=153665///label_ch2: Cy3///label_protocol_ch2: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch2: 9606///hyb_protocol: Microarray hybridization: Add to each Sample 2.5 ul Cot-1 DNA and 12.50 ul 2X Hybridization Buffer. Heat samples for 2 min at 65 C. Centrifuge. Pipet the cDNA array and 22 ul of sample. Incubate for 16 hr at 65 C. Used Atlas Glass Microarray User Manual PT3453-1 instructions for post-hybridization wash.///scan_protocol: Arrays were scanned using a laser-scanner Axon 4000-B, (Axon Instruments, Union City, CA), using 5-micron resolution. Within the GenePix program were chosen photo-multiplier parameters that defined the quanta intensity density distribution of the array to give a Cy3/Cy5 ratio close to 1.0 and produced not too much saturated signals for each array. Separate 16-bit images were acquired for Cy3 and Cy5.///description: none///data_processing: Images were analysed using the GenePix Pro software (Axon Instruments) version 3.0. GenePix Result files (GPR) and the related scan images, together with the Agilent cDNA pattern file and information on the hybridised samples and labelling signs (positive for normal labelling and negative for dye-swap labelling), were then loaded into the Rosetta Resolver SE software. The Axon GenePix error model was applied to transform data and then duplicate ratio profiles were combined to obtain one ratio experiment for each patient. Log ratios, log ratio errors and p-values were thus available for the non flagged sequences of each ratio experiment.///platform_id: GPL5689///contact_name: Pietro,,Mariani///contact_institute: Mario Negri Institute///contact_address: Via La Masa 19///contact_city: Milan///contact_zip.postal_code: 20156///contact_country: Italy///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM214nnn/GSM214039/GSM214039_raw.txt.gz///data_row_count: 16281
1
title: p90bis sample_Ovarian tumor///geo_accession: GSM214077///status: Public on Aug 25 2007///submission_date: Jul 31 2007///last_update_date: Aug 24 2007///type: RNA///channel_count: 2///source_name_ch1: Total RNA extracted from frozen biopsies of ovarian tumors///organism_ch1: Homo sapiens///characteristics_ch1: Gender: Female///characteristics_ch1.1: Status:alive no evidence of disease///characteristics_ch1.2: FIGO Stage:1///characteristics_ch1.3: FIGO Substage:a///characteristics_ch1.4: Histotype:mucinous///characteristics_ch1.5: Grade:Borderline///characteristics_ch1.6: Relapsed:no///characteristics_ch1.7: Age(years):33.73///characteristics_ch1.8: Overall Survival(days):3395///characteristics_ch1.9: Progression Free Survival(days):3395///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA purification from human biopsies were performed using the SV Total RNA Isolation System -cat:#z3100 from Promega.///label_ch1: Cy5///label_protocol_ch1: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch1: 9606///source_name_ch2: Clontech Universal Reference///organism_ch2: Homo sapiens///characteristics_ch2: Human Atlas high pure control total RNA extracted from a pool of 60 human cell lines (BD Biosciences)///molecule_ch2: total RNA///extract_protocol_ch2: see the producer web site: http//clontech.com/products/detail.asp?tabno=2&catalog_id=636538&page=all&faq_id=153665///label_ch2: Cy3///label_protocol_ch2: RNA amplification for array analysis was performed using Ambion MessageAmp aRNA Kit, cat 1750. cDNA labeling was performed using Amino Allyl cDNA Labeling Kit - cat 1705 by Ambion.///taxid_ch2: 9606///hyb_protocol: Microarray hybridization: Add to each Sample 2.5 ul Cot-1 DNA and 12.50 ul 2X Hybridization Buffer. Heat samples for 2 min at 65 C. Centrifuge. Pipet the cDNA array and 22 ul of sample. Incubate for 16 hr at 65 C. Used Atlas Glass Microarray User Manual PT3453-1 instructions for post-hybridization wash.///scan_protocol: Arrays were scanned using a laser-scanner Axon 4000-B, (Axon Instruments, Union City, CA), using 5-micron resolution. Within the GenePix program were chosen photo-multiplier parameters that defined the quanta intensity density distribution of the array to give a Cy3/Cy5 ratio close to 1.0 and produced not too much saturated signals for each array. Separate 16-bit images were acquired for Cy3 and Cy5.///description: none///data_processing: Images were analysed using the GenePix Pro software (Axon Instruments) version 3.0. GenePix Result files (GPR) and the related scan images, together with the Agilent cDNA pattern file and information on the hybridised samples and labelling signs (positive for normal labelling and negative for dye-swap labelling), were then loaded into the Rosetta Resolver SE software. The Axon GenePix error model was applied to transform data and then duplicate ratio profiles were combined to obtain one ratio experiment for each patient. Log ratios, log ratio errors and p-values were thus available for the non flagged sequences of each ratio experiment.///platform_id: GPL5689///contact_name: Pietro,,Mariani///contact_institute: Mario Negri Institute///contact_address: Via La Masa 19///contact_city: Milan///contact_zip.postal_code: 20156///contact_country: Italy///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM214nnn/GSM214077/GSM214077_raw.txt.gz///data_row_count: 16281
1
An expression set
The study aim to identify novel molecular subtypes of ovarian cancer by gene expression profiling with linkage to clinical and pathologic features.Microarray gene expression profiling was done on 285 serous and endometrioid tumors of the ovary, peritoneum, and fallopian tube. K-means clustering was applied to identify robust molecular subtypes. Statistical analysis identified differentially expressed genes, pathways, and gene ontologies. Laser capture microdissection, pathology review, and immunohistochemistry validated the array-based findings. Patient survival within k-means groups was evaluated using Cox proportional hazards models. Class prediction validated k-means groups in an independent dataset. A semisupervised survival analysis of the array data was used to compare against unsupervised clustering results.Optimal clustering of array data identified six molecular subtypes. Two subtypes represented predominantly serous low malignant potential and low-grade endometrioid subtypes, respectively. The remaining four subtypes represented higher grade and advanced stage cancers of serous and endometrioid morphology. A novel subtype of high-grade serous cancers reflected a mesenchymal cell type, characterized by overexpression of N-cadherin and P-cadherin and low expression of differentiation markers, including CA125 and MUC1. A poor prognosis subtype was defined by a reactive stroma gene expression signature, correlating with extensive desmoplasia in such samples. A similar poor prognosis signature could be found using a semisupervised analysis. Each subtype displayed distinct levels and patterns of immune cell infiltration. Class prediction identified similar subtypes in an independent ovarian dataset with similar prognostic trends.Gene expression profiling identified molecular subtypes of ovarian cancer of biological and clinical importance.
experimentData(eset):
Experiment data
Experimenter name: Tothill RW, Tinker AV, George J, Brown R, Fox SB, Lade S, Johnson DS, Trivett MK, Etemadmoghadam D, Locandro B, Traficante N, Fereday S, Hung JA, Chiew YE, Haviv I, Gertig D, DeFazio A, Bowtell DD.Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res. 2008 Aug 15; 14(16):5198-208.
Laboratory: Tothill, Bowtell 2008
Contact information:
Title: Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome.
URL:
PMIDs: 18698038
Abstract: A 243 word abstract is available. Use 'abstract' method.
Information is available on: preprocessing
notes:
platform_title:
[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array
platform_shorttitle:
Affymetrix HG-U133Plus2
platform_summary:
hgu133plus2
platform_manufacturer:
Affymetrix
platform_distribution:
commercial
platform_accession:
GPL570
version:
2015-09-22 20:16:32
featureData(eset):
An object of class 'AnnotatedDataFrame'
featureNames: 1007_s_at 1053_at ... AFFX-HUMISGF3A/M97935_MB_at
(42447 total)
varLabels: probeset gene EntrezGene.ID best_probe
varMetadata: labelDescription
assayData: 42447 features, 285 samples
Platform type:
Overall survival time-to-event summary (in years):
Call: survfit(formula = Surv(time, cens) ~ -1)
7 observations deleted due to missingness
n events median 0.95LCL 0.95UCL
278.00 113.00 3.95 3.53 5.01
---------------------------
Available sample meta-data:
---------------------------
alt_sample_name:
X129 X146 X152 X20019 X20025 X20027 X20031 X20032 X20041 X20046
1 1 1 1 1 1 1 1 1 1
X20074 X22002 X22012 X22013 X22020 X22023 X22027 X22029 X22031 X22037
1 1 1 1 1 1 1 1 1 1
X22046 X22047 X22048 X22057 X22058 X2219 X2227 X23026 X23030 X23036
1 1 1 1 1 1 1 1 1 1
X23043 X23052 X23053 X23055 X23066 X23070 X23074 X23077 X23084 X23098
1 1 1 1 1 1 1 1 1 1
X23102 X23106 X23116 X23128 X23139 X23143 X23162 X23165 X23167 X23170
1 1 1 1 1 1 1 1 1 1
X23172 X23177 X23178 X23182 X23187 X23197 X23202 X23204 X23210 X23212
1 1 1 1 1 1 1 1 1 1
X23213 X23221 X26047 X261 X27006 X27098 X32013 X32022 X32032 X32034
1 1 1 1 1 1 1 1 1 1
X32048 X32049 X32054 X32055 X32089 X32098 X32103 X32117 X34019 X34049
1 1 1 1 1 1 1 1 1 1
X34066 X34078 X34080 X34085 X34086 X34090 X34102 X34103 X34111 X34113
1 1 1 1 1 1 1 1 1 1
X34117 X34125 X34165 X34168 X34172 X34186 X34202 X34207 X34801 (Other)
1 1 1 1 1 1 1 1 1 186
sample_type:
tumor
285
histological_type:
endo other ser
20 1 264
primarysite:
ft other ov
8 34 243
arrayedsite:
ft other ov
2 83 200
summarygrade:
high low NA's
163 116 6
summarystage:
early late NA's
42 240 3
tumorstage:
1 2 3 4 NA's
24 18 218 22 3
substage:
a b c NA's
26 19 212 28
grade:
1 2 3 NA's
19 97 163 6
age_at_initial_pathologic_diagnosis:
Min. 1st Qu. Median Mean 3rd Qu. Max. NA's
22.00 53.00 59.00 59.62 68.00 80.00 3
pltx:
n y NA's
39 243 3
tax:
n y NA's
87 195 3
neo:
n y NA's
264 18 3
days_to_tumor_recurrence:
Min. 1st Qu. Median Mean 3rd Qu. Max. NA's
0.0 300.0 450.0 618.9 810.0 4980.0 10
recurrence_status:
norecurrence recurrence NA's
94 188 3
days_to_death:
Min. 1st Qu. Median Mean 3rd Qu. Max. NA's
0.0 547.5 855.0 955.1 1252.0 6420.0 7
vital_status:
deceased living NA's
113 169 3
debulking:
optimal suboptimal NA's
160 88 37
batch:
2004-12-03 2004-12-23 2005-01-12 2005-01-17 2005-01-24 2005-01-31 2005-02-21
3 4 7 7 8 10 10
2005-03-17 2005-05-05 2005-05-09 2005-05-25 2005-05-27 2005-05-30 2005-06-02
2 1 1 2 3 3 6
2005-06-06 2005-06-08 2005-06-16 2005-06-17 2005-06-24 2005-07-06 2005-07-15
4 5 3 5 6 2 9
2005-07-20 2005-07-29 2005-08-03 2005-08-05 2005-08-18 2005-08-24 2005-08-26
7 5 6 3 4 8 4
2005-09-09 2005-09-14 2005-09-16 2005-09-21 2005-10-05 2005-10-26 2005-10-28
4 6 6 4 5 2 4
2005-11-04 2005-11-09 2005-11-11 2005-11-23 2005-12-15 2005-12-21 2006-01-20
6 3 7 4 7 8 3
2006-01-31 2006-02-08 2006-02-28 2006-04-05 2006-04-06 2006-04-12 2006-04-13
7 3 3 7 3 7 4
2006-04-28 2006-05-03 2006-06-06 2006-06-07 2006-06-22 2006-07-07 2006-07-19
6 9 6 3 9 4 7
uncurated_author_metadata:
title: X129///geo_accession: GSM250001///status: Public on Mar 01 2008///submission_date: Dec 14 2007///last_update_date: Dec 19 2007///type: RNA///channel_count: 1///source_name_ch1: Carcinoma of ovary, fallopian tube or peritonem///organism_ch1: Homo sapiens///characteristics_ch1: Primary.Site : Ovary///characteristics_ch1.1: Type : Malignant///characteristics_ch1.2: Subtype : Ser/PapSer///characteristics_ch1.3: StageCode : IIIC///characteristics_ch1.4: Consolidated.Grade : 3///treatment_protocol_ch1: Frozen tissue stored at -80oC taken after surgery///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction and column chromotogrpahy///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip Drosophila Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.///scan_protocol: GeneChips were scanned using Affymetrix GS300-7G scanner///description: Gene expression data from human ovarian carcinoma///data_processing: The data were analyzed with Gene Chip Operating Software Version 1.4 using Affymetrix default analysis settings. The CEL files generated was later normalized using the RMA method///platform_id: GPL570///contact_name: Prof David,,Bowtell PhD.///contact_email: [email protected]///contact_phone: +613 96561287///contact_fax: +613 96561414///contact_department: Research Division///contact_institute: PeterMacCallum Cancer Centre///contact_address: Locked Bag 1 A' Beckett St///contact_city: Melbourne///contact_state: VIC///contact_zip.postal_code: 8006///contact_country: Australia///contact_web_link: http://www.petermac-research.org.au///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM250nnn/GSM250001/GSM250001.CEL.gz///data_row_count: 54621///ID: X129///k.meansGroup: 1///Type: MAL///HistologicalSubtype: Ser///PrimarySite: OV///FIGOStage: III///Grade: 3///PatientAge.Years.: 65///PatientStatus: D///Pltx: Y///Tax: N///Neo: N///TimeToRelapseorLastFollow.Up.Months.: 7///TimeToDeathorLastFollow.Up.Months.: 15///ResidualDisease: >1///ArrayedSite: PE
1
title: X146///geo_accession: GSM250000///status: Public on Mar 01 2008///submission_date: Dec 14 2007///last_update_date: Dec 19 2007///type: RNA///channel_count: 1///source_name_ch1: Carcinoma of ovary, fallopian tube or peritonem///organism_ch1: Homo sapiens///characteristics_ch1: Primary.Site : Ovary///characteristics_ch1.1: Type : Malignant///characteristics_ch1.2: Subtype : Ser/PapSer///characteristics_ch1.3: StageCode : III///characteristics_ch1.4: Consolidated.Grade : 3///treatment_protocol_ch1: Frozen tissue stored at -80oC taken after surgery///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction and column chromotogrpahy///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip Drosophila Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.///scan_protocol: GeneChips were scanned using Affymetrix GS300-7G scanner///description: Gene expression data from human ovarian carcinoma///data_processing: The data were analyzed with Gene Chip Operating Software Version 1.4 using Affymetrix default analysis settings. The CEL files generated was later normalized using the RMA method///platform_id: GPL570///contact_name: Prof David,,Bowtell PhD.///contact_email: [email protected]///contact_phone: +613 96561287///contact_fax: +613 96561414///contact_department: Research Division///contact_institute: PeterMacCallum Cancer Centre///contact_address: Locked Bag 1 A' Beckett St///contact_city: Melbourne///contact_state: VIC///contact_zip.postal_code: 8006///contact_country: Australia///contact_web_link: http://www.petermac-research.org.au///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM250nnn/GSM250000/GSM250000.CEL.gz///data_row_count: 54621///ID: X146///k.meansGroup: NC///Type: MAL///HistologicalSubtype: Ser///PrimarySite: OV///FIGOStage: III///Grade: 3///PatientAge.Years.: 56///PatientStatus: PF///Pltx: Y///Tax: N///Neo: N///TimeToRelapseorLastFollow.Up.Months.: 166///TimeToDeathorLastFollow.Up.Months.: 166///ResidualDisease: >1///ArrayedSite: OV
1
title: X152///geo_accession: GSM249999///status: Public on Mar 01 2008///submission_date: Dec 14 2007///last_update_date: Dec 19 2007///type: RNA///channel_count: 1///source_name_ch1: Carcinoma of ovary, fallopian tube or peritonem///organism_ch1: Homo sapiens///characteristics_ch1: Primary.Site : Ovary///characteristics_ch1.1: Type : Malignant///characteristics_ch1.2: Subtype : Ser/PapSer///characteristics_ch1.3: StageCode : IIIC///characteristics_ch1.4: Consolidated.Grade : 2///treatment_protocol_ch1: Frozen tissue stored at -80oC taken after surgery///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction and column chromotogrpahy///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip Drosophila Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.///scan_protocol: GeneChips were scanned using Affymetrix GS300-7G scanner///description: Gene expression data from human ovarian carcinoma///data_processing: The data were analyzed with Gene Chip Operating Software Version 1.4 using Affymetrix default analysis settings. The CEL files generated was later normalized using the RMA method///platform_id: GPL570///contact_name: Prof David,,Bowtell PhD.///contact_email: [email protected]///contact_phone: +613 96561287///contact_fax: +613 96561414///contact_department: Research Division///contact_institute: PeterMacCallum Cancer Centre///contact_address: Locked Bag 1 A' Beckett St///contact_city: Melbourne///contact_state: VIC///contact_zip.postal_code: 8006///contact_country: Australia///contact_web_link: http://www.petermac-research.org.au///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM249nnn/GSM249999/GSM249999.CEL.gz///data_row_count: 54621///ID: X152///k.meansGroup: 5///Type: MAL///HistologicalSubtype: Ser///PrimarySite: OV///FIGOStage: III///Grade: 2///PatientAge.Years.: 49///PatientStatus: D///Pltx: Y///Tax: N///Neo: N///TimeToRelapseorLastFollow.Up.Months.: 18///TimeToDeathorLastFollow.Up.Months.: 81///ResidualDisease: macrosizeNK///ArrayedSite: OV
1
title: X20019///geo_accession: GSM249998///status: Public on Mar 01 2008///submission_date: Dec 14 2007///last_update_date: Dec 19 2007///type: RNA///channel_count: 1///source_name_ch1: Carcinoma of ovary, fallopian tube or peritonem///organism_ch1: Homo sapiens///characteristics_ch1: Primary.Site : Ovary///characteristics_ch1.1: Type : Malignant///characteristics_ch1.2: Subtype : Ser/PapSer///characteristics_ch1.3: StageCode : IIC///characteristics_ch1.4: Consolidated.Grade : 3///treatment_protocol_ch1: Frozen tissue stored at -80oC taken after surgery///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction and column chromotogrpahy///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip Drosophila Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.///scan_protocol: GeneChips were scanned using Affymetrix GS300-7G scanner///description: Gene expression data from human ovarian carcinoma///data_processing: The data were analyzed with Gene Chip Operating Software Version 1.4 using Affymetrix default analysis settings. The CEL files generated was later normalized using the RMA method///platform_id: GPL570///contact_name: Prof David,,Bowtell PhD.///contact_email: [email protected]///contact_phone: +613 96561287///contact_fax: +613 96561414///contact_department: Research Division///contact_institute: PeterMacCallum Cancer Centre///contact_address: Locked Bag 1 A' Beckett St///contact_city: Melbourne///contact_state: VIC///contact_zip.postal_code: 8006///contact_country: Australia///contact_web_link: http://www.petermac-research.org.au///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM249nnn/GSM249998/GSM249998.CEL.gz///data_row_count: 54621///ID: X20019///k.meansGroup: 4///Type: MAL///HistologicalSubtype: Ser///PrimarySite: OV///FIGOStage: II///Grade: 3///PatientAge.Years.: 58///PatientStatus: PF///Pltx: N///Tax: N///Neo: N///TimeToRelapseorLastFollow.Up.Months.: NA///TimeToDeathorLastFollow.Up.Months.: NA///ResidualDisease: >1///ArrayedSite: OV
1
title: X20025///geo_accession: GSM249997///status: Public on Mar 01 2008///submission_date: Dec 14 2007///last_update_date: Dec 19 2007///type: RNA///channel_count: 1///source_name_ch1: Carcinoma of ovary, fallopian tube or peritonem///organism_ch1: Homo sapiens///characteristics_ch1: Primary.Site : Peritoneum///characteristics_ch1.1: Type : Malignant///characteristics_ch1.2: Subtype : Ser/PapSer///characteristics_ch1.3: StageCode : IIIC///characteristics_ch1.4: Consolidated.Grade : 3///treatment_protocol_ch1: Frozen tissue stored at -80oC taken after surgery///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction and column chromotogrpahy///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip Drosophila Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.///scan_protocol: GeneChips were scanned using Affymetrix GS300-7G scanner///description: Gene expression data from human ovarian carcinoma///data_processing: The data were analyzed with Gene Chip Operating Software Version 1.4 using Affymetrix default analysis settings. The CEL files generated was later normalized using the RMA method///platform_id: GPL570///contact_name: Prof David,,Bowtell PhD.///contact_email: [email protected]///contact_phone: +613 96561287///contact_fax: +613 96561414///contact_department: Research Division///contact_institute: PeterMacCallum Cancer Centre///contact_address: Locked Bag 1 A' Beckett St///contact_city: Melbourne///contact_state: VIC///contact_zip.postal_code: 8006///contact_country: Australia///contact_web_link: http://www.petermac-research.org.au///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM249nnn/GSM249997/GSM249997.CEL.gz///data_row_count: 54621///ID: X20025///k.meansGroup: 1///Type: MAL///HistologicalSubtype: Ser///PrimarySite: PE///FIGOStage: III///Grade: 3///PatientAge.Years.: 80///PatientStatus: D///Pltx: Y///Tax: N///Neo: N///TimeToRelapseorLastFollow.Up.Months.: 12///TimeToDeathorLastFollow.Up.Months.: 43///ResidualDisease: nil///ArrayedSite: PE
1
title: X20027///geo_accession: GSM249996///status: Public on Mar 01 2008///submission_date: Dec 14 2007///last_update_date: Dec 19 2007///type: RNA///channel_count: 1///source_name_ch1: Carcinoma of ovary, fallopian tube or peritonem///organism_ch1: Homo sapiens///characteristics_ch1: Primary.Site : Ovary///characteristics_ch1.1: Type : Malignant///characteristics_ch1.2: Subtype : Ser/PapSer///characteristics_ch1.3: StageCode : IIIC///characteristics_ch1.4: Consolidated.Grade : 3///treatment_protocol_ch1: Frozen tissue stored at -80oC taken after surgery///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction and column chromotogrpahy///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip Drosophila Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.///scan_protocol: GeneChips were scanned using Affymetrix GS300-7G scanner///description: Gene expression data from human ovarian carcinoma///data_processing: The data were analyzed with Gene Chip Operating Software Version 1.4 using Affymetrix default analysis settings. The CEL files generated was later normalized using the RMA method///platform_id: GPL570///contact_name: Prof David,,Bowtell PhD.///contact_email: [email protected]///contact_phone: +613 96561287///contact_fax: +613 96561414///contact_department: Research Division///contact_institute: PeterMacCallum Cancer Centre///contact_address: Locked Bag 1 A' Beckett St///contact_city: Melbourne///contact_state: VIC///contact_zip.postal_code: 8006///contact_country: Australia///contact_web_link: http://www.petermac-research.org.au///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM249nnn/GSM249996/GSM249996.CEL.gz///data_row_count: 54621///ID: X20027///k.meansGroup: 4///Type: MAL///HistologicalSubtype: Ser///PrimarySite: OV///FIGOStage: III///Grade: 3///PatientAge.Years.: 71///PatientStatus: D*///Pltx: N///Tax: N///Neo: N///TimeToRelapseorLastFollow.Up.Months.: 1///TimeToDeathorLastFollow.Up.Months.: 1///ResidualDisease: <1///ArrayedSite: OV
1
title: X20031///geo_accession: GSM249995///status: Public on Mar 01 2008///submission_date: Dec 14 2007///last_update_date: Dec 19 2007///type: RNA///channel_count: 1///source_name_ch1: Carcinoma of ovary, fallopian tube or peritonem///organism_ch1: Homo sapiens///characteristics_ch1: Primary.Site : Ovary///characteristics_ch1.1: Type : Malignant///characteristics_ch1.2: Subtype : Endo///characteristics_ch1.3: StageCode : IIC///characteristics_ch1.4: Consolidated.Grade : 2///treatment_protocol_ch1: Frozen tissue stored at -80oC taken after surgery///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction and column chromotogrpahy///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip Drosophila Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.///scan_protocol: GeneChips were scanned using Affymetrix GS300-7G scanner///description: Gene expression data from human ovarian carcinoma///data_processing: The data were analyzed with Gene Chip Operating Software Version 1.4 using Affymetrix default analysis settings. The CEL files generated was later normalized using the RMA method///platform_id: GPL570///contact_name: Prof David,,Bowtell PhD.///contact_email: [email protected]///contact_phone: +613 96561287///contact_fax: +613 96561414///contact_department: Research Division///contact_institute: PeterMacCallum Cancer Centre///contact_address: Locked Bag 1 A' Beckett St///contact_city: Melbourne///contact_state: VIC///contact_zip.postal_code: 8006///contact_country: Australia///contact_web_link: http://www.petermac-research.org.au///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM249nnn/GSM249995/GSM249995.CEL.gz///data_row_count: 54621///ID: X20031///k.meansGroup: 5///Type: MAL///HistologicalSubtype: Endo///PrimarySite: OV///FIGOStage: II///Grade: 2///PatientAge.Years.: 56///PatientStatus: R///Pltx: Y///Tax: Y///Neo: N///TimeToRelapseorLastFollow.Up.Months.: 30///TimeToDeathorLastFollow.Up.Months.: 43///ResidualDisease: nil///ArrayedSite: OV
1
title: X20032///geo_accession: GSM249994///status: Public on Mar 01 2008///submission_date: Dec 14 2007///last_update_date: Dec 19 2007///type: RNA///channel_count: 1///source_name_ch1: Carcinoma of ovary, fallopian tube or peritonem///organism_ch1: Homo sapiens///characteristics_ch1: Primary.Site : Ovary///characteristics_ch1.1: Type : Malignant///characteristics_ch1.2: Subtype : Ser/PapSer///characteristics_ch1.3: StageCode : IV///characteristics_ch1.4: Consolidated.Grade : 2///treatment_protocol_ch1: Frozen tissue stored at -80oC taken after surgery///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction and column chromotogrpahy///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip Drosophila Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.///scan_protocol: GeneChips were scanned using Affymetrix GS300-7G scanner///description: Gene expression data from human ovarian carcinoma///data_processing: The data were analyzed with Gene Chip Operating Software Version 1.4 using Affymetrix default analysis settings. The CEL files generated was later normalized using the RMA method///platform_id: GPL570///contact_name: Prof David,,Bowtell PhD.///contact_email: [email protected]///contact_phone: +613 96561287///contact_fax: +613 96561414///contact_department: Research Division///contact_institute: PeterMacCallum Cancer Centre///contact_address: Locked Bag 1 A' Beckett St///contact_city: Melbourne///contact_state: VIC///contact_zip.postal_code: 8006///contact_country: Australia///contact_web_link: http://www.petermac-research.org.au///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM249nnn/GSM249994/GSM249994.CEL.gz///data_row_count: 54621///ID: X20032///k.meansGroup: 2///Type: MAL///HistologicalSubtype: Ser///PrimarySite: OV///FIGOStage: IV///Grade: 2///PatientAge.Years.: 63///PatientStatus: D///Pltx: Y///Tax: Y///Neo: Y///TimeToRelapseorLastFollow.Up.Months.: 11///TimeToDeathorLastFollow.Up.Months.: 15///ResidualDisease: <1///ArrayedSite: OV
1
title: X20041///geo_accession: GSM249993///status: Public on Mar 01 2008///submission_date: Dec 14 2007///last_update_date: Dec 19 2007///type: RNA///channel_count: 1///source_name_ch1: Carcinoma of ovary, fallopian tube or peritonem///organism_ch1: Homo sapiens///characteristics_ch1: Primary.Site : Ovary///characteristics_ch1.1: Type : Malignant///characteristics_ch1.2: Subtype : Ser/PapSer///characteristics_ch1.3: StageCode : IIC///characteristics_ch1.4: Consolidated.Grade : 3///treatment_protocol_ch1: Frozen tissue stored at -80oC taken after surgery///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction and column chromotogrpahy///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip Drosophila Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.///scan_protocol: GeneChips were scanned using Affymetrix GS300-7G scanner///description: Gene expression data from human ovarian carcinoma///data_processing: The data were analyzed with Gene Chip Operating Software Version 1.4 using Affymetrix default analysis settings. The CEL files generated was later normalized using the RMA method///platform_id: GPL570///contact_name: Prof David,,Bowtell PhD.///contact_email: [email protected]///contact_phone: +613 96561287///contact_fax: +613 96561414///contact_department: Research Division///contact_institute: PeterMacCallum Cancer Centre///contact_address: Locked Bag 1 A' Beckett St///contact_city: Melbourne///contact_state: VIC///contact_zip.postal_code: 8006///contact_country: Australia///contact_web_link: http://www.petermac-research.org.au///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM249nnn/GSM249993/GSM249993.CEL.gz///data_row_count: 54621///ID: X20041///k.meansGroup: 2///Type: MAL///HistologicalSubtype: Ser///PrimarySite: OV///FIGOStage: II///Grade: 3///PatientAge.Years.: 43///PatientStatus: R///Pltx: Y///Tax: Y///Neo: N///TimeToRelapseorLastFollow.Up.Months.: 37///TimeToDeathorLastFollow.Up.Months.: 37///ResidualDisease: nil///ArrayedSite: OV
1
title: X20046///geo_accession: GSM249992///status: Public on Mar 01 2008///submission_date: Dec 14 2007///last_update_date: Dec 19 2007///type: RNA///channel_count: 1///source_name_ch1: Carcinoma of ovary, fallopian tube or peritonem///organism_ch1: Homo sapiens///characteristics_ch1: Primary.Site : Ovary///characteristics_ch1.1: Type : Malignant///characteristics_ch1.2: Subtype : Ser/PapSer///characteristics_ch1.3: StageCode : IIIA///characteristics_ch1.4: Consolidated.Grade : 2///treatment_protocol_ch1: Frozen tissue stored at -80oC taken after surgery///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction and column chromotogrpahy///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip Drosophila Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.///scan_protocol: GeneChips were scanned using Affymetrix GS300-7G scanner///description: Gene expression data from human ovarian carcinoma///data_processing: The data were analyzed with Gene Chip Operating Software Version 1.4 using Affymetrix default analysis settings. The CEL files generated was later normalized using the RMA method///platform_id: GPL570///contact_name: Prof David,,Bowtell PhD.///contact_email: [email protected]///contact_phone: +613 96561287///contact_fax: +613 96561414///contact_department: Research Division///contact_institute: PeterMacCallum Cancer Centre///contact_address: Locked Bag 1 A' Beckett St///contact_city: Melbourne///contact_state: VIC///contact_zip.postal_code: 8006///contact_country: Australia///contact_web_link: http://www.petermac-research.org.au///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM249nnn/GSM249992/GSM249992.CEL.gz///data_row_count: 54621///ID: X20046///k.meansGroup: 1///Type: MAL///HistologicalSubtype: Ser///PrimarySite: OV///FIGOStage: III///Grade: 2///PatientAge.Years.: 65///PatientStatus: PF///Pltx: Y///Tax: Y///Neo: N///TimeToRelapseorLastFollow.Up.Months.: 33///TimeToDeathorLastFollow.Up.Months.: 33///ResidualDisease: nil///ArrayedSite: OV
1
title: X20074///geo_accession: GSM249991///status: Public on Mar 01 2008///submission_date: Dec 14 2007///last_update_date: Dec 19 2007///type: RNA///channel_count: 1///source_name_ch1: Carcinoma of ovary, fallopian tube or peritonem///organism_ch1: Homo sapiens///characteristics_ch1: Primary.Site : Fallopian///characteristics_ch1.1: Type : Malignant///characteristics_ch1.2: Subtype : Ser/PapSer///characteristics_ch1.3: StageCode : IIIB///characteristics_ch1.4: Consolidated.Grade : 3///treatment_protocol_ch1: Frozen tissue stored at -80oC taken after surgery///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction and column chromotogrpahy///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip Drosophila Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.///scan_protocol: GeneChips were scanned using Affymetrix GS300-7G scanner///description: Gene expression data from human ovarian carcinoma///data_processing: The data were analyzed with Gene Chip Operating Software Version 1.4 using Affymetrix default analysis settings. The CEL files generated was later normalized using the RMA method///platform_id: GPL570///contact_name: Prof David,,Bowtell PhD.///contact_email: [email protected]///contact_phone: +613 96561287///contact_fax: +613 96561414///contact_department: Research Division///contact_institute: PeterMacCallum Cancer Centre///contact_address: Locked Bag 1 A' Beckett St///contact_city: Melbourne///contact_state: VIC///contact_zip.postal_code: 8006///contact_country: Australia///contact_web_link: http://www.petermac-research.org.au///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM249nnn/GSM249991/GSM249991.CEL.gz///data_row_count: 54621///ID: X20074///k.meansGroup: 5///Type: MAL///HistologicalSubtype: Ser///PrimarySite: FT///FIGOStage: III///Grade: 3///PatientAge.Years.: 58///PatientStatus: R///Pltx: Y///Tax: Y///Neo: N///TimeToRelapseorLastFollow.Up.Months.: 27///TimeToDeathorLastFollow.Up.Months.: 31///ResidualDisease: nil///ArrayedSite: CO
1
title: X22002///geo_accession: GSM249728///status: Public on Mar 01 2008///submission_date: Dec 14 2007///last_update_date: Dec 19 2007///type: RNA///channel_count: 1///source_name_ch1: Carcinoma of ovary, fallopian tube or peritonem///organism_ch1: Homo sapiens///characteristics_ch1: Primary.Site : Ovary///characteristics_ch1.1: Type : LMP///characteristics_ch1.2: Subtype : Ser/PapSer///characteristics_ch1.3: StageCode : IIIB///characteristics_ch1.4: Consolidated.Grade : 3///treatment_protocol_ch1: Frozen tissue stored at -80oC taken after surgery///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction and column chromotogrpahy///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip Drosophila Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.///scan_protocol: GeneChips were scanned using Affymetrix GS300-7G scanner///description: Gene expression data from human ovarian carcinoma///data_processing: The data were analyzed with Gene Chip Operating Software Version 1.4 using Affymetrix default analysis settings. The CEL files generated was later normalized using the RMA method///platform_id: GPL570///contact_name: Prof David,,Bowtell PhD.///contact_email: [email protected]///contact_phone: +613 96561287///contact_fax: +613 96561414///contact_department: Research Division///contact_institute: PeterMacCallum Cancer Centre///contact_address: Locked Bag 1 A' Beckett St///contact_city: Melbourne///contact_state: VIC///contact_zip.postal_code: 8006///contact_country: Australia///contact_web_link: http://www.petermac-research.org.au///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM249nnn/GSM249728/GSM249728.CEL.gz///data_row_count: 54621///ID: X22002///k.meansGroup: 3///Type: LMP///HistologicalSubtype: Ser///PrimarySite: OV///FIGOStage: III///Grade: 3///PatientAge.Years.: 72///PatientStatus: PF///Pltx: N///Tax: N///Neo: N///TimeToRelapseorLastFollow.Up.Months.: 36///TimeToDeathorLastFollow.Up.Months.: 36///ResidualDisease: nil///ArrayedSite: OV
1
title: X22012///geo_accession: GSM249990///status: Public on Mar 01 2008///submission_date: Dec 14 2007///last_update_date: Dec 19 2007///type: RNA///channel_count: 1///source_name_ch1: Carcinoma of ovary, fallopian tube or peritonem///organism_ch1: Homo sapiens///characteristics_ch1: Primary.Site : Ovary///characteristics_ch1.1: Type : Malignant///characteristics_ch1.2: Subtype : Ser/PapSer///characteristics_ch1.3: StageCode : IIIC///characteristics_ch1.4: Consolidated.Grade : 3///treatment_protocol_ch1: Frozen tissue stored at -80oC taken after surgery///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction and column chromotogrpahy///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip Drosophila Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.///scan_protocol: GeneChips were scanned using Affymetrix GS300-7G scanner///description: Gene expression data from human ovarian carcinoma///data_processing: The data were analyzed with Gene Chip Operating Software Version 1.4 using Affymetrix default analysis settings. The CEL files generated was later normalized using the RMA method///platform_id: GPL570///contact_name: Prof David,,Bowtell PhD.///contact_email: [email protected]///contact_phone: +613 96561287///contact_fax: +613 96561414///contact_department: Research Division///contact_institute: PeterMacCallum Cancer Centre///contact_address: Locked Bag 1 A' Beckett St///contact_city: Melbourne///contact_state: VIC///contact_zip.postal_code: 8006///contact_country: Australia///contact_web_link: http://www.petermac-research.org.au///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM249nnn/GSM249990/GSM249990.CEL.gz///data_row_count: 54621///ID: X22012///k.meansGroup: 1///Type: MAL///HistologicalSubtype: Ser///PrimarySite: OV///FIGOStage: III///Grade: 3///PatientAge.Years.: 50///PatientStatus: R///Pltx: Y///Tax: Y///Neo: N///TimeToRelapseorLastFollow.Up.Months.: 27///TimeToDeathorLastFollow.Up.Months.: 43///ResidualDisease: >1///ArrayedSite: OV
1
title: X22013///geo_accession: GSM249989///status: Public on Mar 01 2008///submission_date: Dec 14 2007///last_update_date: Dec 19 2007///type: RNA///channel_count: 1///source_name_ch1: Carcinoma of ovary, fallopian tube or peritonem///organism_ch1: Homo sapiens///characteristics_ch1: Primary.Site : Peritoneum///characteristics_ch1.1: Type : Malignant///characteristics_ch1.2: Subtype : Ser/PapSer///characteristics_ch1.3: StageCode : IIIA///characteristics_ch1.4: Consolidated.Grade : 2///treatment_protocol_ch1: Frozen tissue stored at -80oC taken after surgery///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction and column chromotogrpahy///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip Drosophila Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.///scan_protocol: GeneChips were scanned using Affymetrix GS300-7G scanner///description: Gene expression data from human ovarian carcinoma///data_processing: The data were analyzed with Gene Chip Operating Software Version 1.4 using Affymetrix default analysis settings. The CEL files generated was later normalized using the RMA method///platform_id: GPL570///contact_name: Prof David,,Bowtell PhD.///contact_email: [email protected]///contact_phone: +613 96561287///contact_fax: +613 96561414///contact_department: Research Division///contact_institute: PeterMacCallum Cancer Centre///contact_address: Locked Bag 1 A' Beckett St///contact_city: Melbourne///contact_state: VIC///contact_zip.postal_code: 8006///contact_country: Australia///contact_web_link: http://www.petermac-research.org.au///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM249nnn/GSM249989/GSM249989.CEL.gz///data_row_count: 54621///ID: X22013///k.meansGroup: 1///Type: MAL///HistologicalSubtype: Ser///PrimarySite: PE///FIGOStage: III///Grade: 2///PatientAge.Years.: 55///PatientStatus: PF///Pltx: Y///Tax: Y///Neo: N///TimeToRelapseorLastFollow.Up.Months.: 47///TimeToDeathorLastFollow.Up.Months.: 47///ResidualDisease: <1///ArrayedSite: CO
1
title: X22020///geo_accession: GSM249988///status: Public on Mar 01 2008///submission_date: Dec 14 2007///last_update_date: Dec 19 2007///type: RNA///channel_count: 1///source_name_ch1: Carcinoma of ovary, fallopian tube or peritonem///organism_ch1: Homo sapiens///characteristics_ch1: Primary.Site : Ovary///characteristics_ch1.1: Type : Malignant///characteristics_ch1.2: Subtype : Ser/PapSer///characteristics_ch1.3: StageCode : IIIC///characteristics_ch1.4: Consolidated.Grade : 3///treatment_protocol_ch1: Frozen tissue stored at -80oC taken after surgery///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction and column chromotogrpahy///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip Drosophila Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.///scan_protocol: GeneChips were scanned using Affymetrix GS300-7G scanner///description: Gene expression data from human ovarian carcinoma///data_processing: The data were analyzed with Gene Chip Operating Software Version 1.4 using Affymetrix default analysis settings. The CEL files generated was later normalized using the RMA method///platform_id: GPL570///contact_name: Prof David,,Bowtell PhD.///contact_email: [email protected]///contact_phone: +613 96561287///contact_fax: +613 96561414///contact_department: Research Division///contact_institute: PeterMacCallum Cancer Centre///contact_address: Locked Bag 1 A' Beckett St///contact_city: Melbourne///contact_state: VIC///contact_zip.postal_code: 8006///contact_country: Australia///contact_web_link: http://www.petermac-research.org.au///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM249nnn/GSM249988/GSM249988.CEL.gz///data_row_count: 54621///ID: X22020///k.meansGroup: 1///Type: MAL///HistologicalSubtype: Ser///PrimarySite: OV///FIGOStage: III///Grade: 3///PatientAge.Years.: 41///PatientStatus: R///Pltx: Y///Tax: Y///Neo: N///TimeToRelapseorLastFollow.Up.Months.: 9///TimeToDeathorLastFollow.Up.Months.: 12///ResidualDisease: >1///ArrayedSite: OV
1
title: X22023///geo_accession: GSM249987///status: Public on Mar 01 2008///submission_date: Dec 14 2007///last_update_date: Dec 19 2007///type: RNA///channel_count: 1///source_name_ch1: Carcinoma of ovary, fallopian tube or peritonem///organism_ch1: Homo sapiens///characteristics_ch1: Primary.Site : Ovary///characteristics_ch1.1: Type : Malignant///characteristics_ch1.2: Subtype : Ser/PapSer///characteristics_ch1.3: StageCode : IIIC///characteristics_ch1.4: Consolidated.Grade : 2///treatment_protocol_ch1: Frozen tissue stored at -80oC taken after surgery///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction and column chromotogrpahy///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip Drosophila Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.///scan_protocol: GeneChips were scanned using Affymetrix GS300-7G scanner///description: Gene expression data from human ovarian carcinoma///data_processing: The data were analyzed with Gene Chip Operating Software Version 1.4 using Affymetrix default analysis settings. The CEL files generated was later normalized using the RMA method///platform_id: GPL570///contact_name: Prof David,,Bowtell PhD.///contact_email: [email protected]///contact_phone: +613 96561287///contact_fax: +613 96561414///contact_department: Research Division///contact_institute: PeterMacCallum Cancer Centre///contact_address: Locked Bag 1 A' Beckett St///contact_city: Melbourne///contact_state: VIC///contact_zip.postal_code: 8006///contact_country: Australia///contact_web_link: http://www.petermac-research.org.au///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM249nnn/GSM249987/GSM249987.CEL.gz///data_row_count: 54621///ID: X22023///k.meansGroup: 4///Type: MAL///HistologicalSubtype: Ser///PrimarySite: OV///FIGOStage: III///Grade: 2///PatientAge.Years.: 46///PatientStatus: PF///Pltx: Y///Tax: Y///Neo: N///TimeToRelapseorLastFollow.Up.Months.: 41///TimeToDeathorLastFollow.Up.Months.: 41///ResidualDisease: >1///ArrayedSite: OV
1
title: X22027///geo_accession: GSM249725///status: Public on Mar 01 2008///submission_date: Dec 14 2007///last_update_date: Dec 19 2007///type: RNA///channel_count: 1///source_name_ch1: Carcinoma of ovary, fallopian tube or peritonem///organism_ch1: Homo sapiens///characteristics_ch1: Primary.Site : Ovary///characteristics_ch1.1: Type : LMP///characteristics_ch1.2: Subtype : Ser/PapSer///characteristics_ch1.3: StageCode : IIA///characteristics_ch1.4: Consolidated.Grade : 1///treatment_protocol_ch1: Frozen tissue stored at -80oC taken after surgery///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction and column chromotogrpahy///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip Drosophila Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.///scan_protocol: GeneChips were scanned using Affymetrix GS300-7G scanner///description: Gene expression data from human ovarian carcinoma///data_processing: The data were analyzed with Gene Chip Operating Software Version 1.4 using Affymetrix default analysis settings. The CEL files generated was later normalized using the RMA method///platform_id: GPL570///contact_name: Prof David,,Bowtell PhD.///contact_email: [email protected]///contact_phone: +613 96561287///contact_fax: +613 96561414///contact_department: Research Division///contact_institute: PeterMacCallum Cancer Centre///contact_address: Locked Bag 1 A' Beckett St///contact_city: Melbourne///contact_state: VIC///contact_zip.postal_code: 8006///contact_country: Australia///contact_web_link: http://www.petermac-research.org.au///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM249nnn/GSM249725/GSM249725.CEL.gz///data_row_count: 54621///ID: X22027///k.meansGroup: 3///Type: LMP///HistologicalSubtype: Ser///PrimarySite: OV///FIGOStage: II///Grade: 1///PatientAge.Years.: 47///PatientStatus: PF///Pltx: N///Tax: N///Neo: N///TimeToRelapseorLastFollow.Up.Months.: 44///TimeToDeathorLastFollow.Up.Months.: 44///ResidualDisease: nil///ArrayedSite: OV
1
title: X22029///geo_accession: GSM249986///status: Public on Mar 01 2008///submission_date: Dec 14 2007///last_update_date: Dec 19 2007///type: RNA///channel_count: 1///source_name_ch1: Carcinoma of ovary, fallopian tube or peritonem///organism_ch1: Homo sapiens///characteristics_ch1: Primary.Site : Ovary///characteristics_ch1.1: Type : Malignant///characteristics_ch1.2: Subtype : Ser/PapSer///characteristics_ch1.3: StageCode : IV///characteristics_ch1.4: Consolidated.Grade : 3///treatment_protocol_ch1: Frozen tissue stored at -80oC taken after surgery///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction and column chromotogrpahy///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip Drosophila Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.///scan_protocol: GeneChips were scanned using Affymetrix GS300-7G scanner///description: Gene expression data from human ovarian carcinoma///data_processing: The data were analyzed with Gene Chip Operating Software Version 1.4 using Affymetrix default analysis settings. The CEL files generated was later normalized using the RMA method///platform_id: GPL570///contact_name: Prof David,,Bowtell PhD.///contact_email: [email protected]///contact_phone: +613 96561287///contact_fax: +613 96561414///contact_department: Research Division///contact_institute: PeterMacCallum Cancer Centre///contact_address: Locked Bag 1 A' Beckett St///contact_city: Melbourne///contact_state: VIC///contact_zip.postal_code: 8006///contact_country: Australia///contact_web_link: http://www.petermac-research.org.au///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM249nnn/GSM249986/GSM249986.CEL.gz///data_row_count: 54621///ID: X22029///k.meansGroup: NC///Type: MAL///HistologicalSubtype: Ser///PrimarySite: OV///FIGOStage: IV///Grade: 3///PatientAge.Years.: 58///PatientStatus: D///Pltx: Y///Tax: Y///Neo: N///TimeToRelapseorLastFollow.Up.Months.: 18///TimeToDeathorLastFollow.Up.Months.: 19///ResidualDisease: >1///ArrayedSite: OV
1
title: X22031///geo_accession: GSM249985///status: Public on Mar 01 2008///submission_date: Dec 14 2007///last_update_date: Dec 19 2007///type: RNA///channel_count: 1///source_name_ch1: Carcinoma of ovary, fallopian tube or peritonem///organism_ch1: Homo sapiens///characteristics_ch1: Primary.Site : Ovary///characteristics_ch1.1: Type : Malignant///characteristics_ch1.2: Subtype : Endo///characteristics_ch1.3: StageCode : IIIC///characteristics_ch1.4: Consolidated.Grade : 2///treatment_protocol_ch1: Frozen tissue stored at -80oC taken after surgery///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction and column chromotogrpahy///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip Drosophila Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.///scan_protocol: GeneChips were scanned using Affymetrix GS300-7G scanner///description: Gene expression data from human ovarian carcinoma///data_processing: The data were analyzed with Gene Chip Operating Software Version 1.4 using Affymetrix default analysis settings. The CEL files generated was later normalized using the RMA method///platform_id: GPL570///contact_name: Prof David,,Bowtell PhD.///contact_email: [email protected]///contact_phone: +613 96561287///contact_fax: +613 96561414///contact_department: Research Division///contact_institute: PeterMacCallum Cancer Centre///contact_address: Locked Bag 1 A' Beckett St///contact_city: Melbourne///contact_state: VIC///contact_zip.postal_code: 8006///contact_country: Australia///contact_web_link: http://www.petermac-research.org.au///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM249nnn/GSM249985/GSM249985.CEL.gz///data_row_count: 54621///ID: X22031///k.meansGroup: 4///Type: MAL///HistologicalSubtype: Endo///PrimarySite: OV///FIGOStage: III///Grade: 2///PatientAge.Years.: 58///PatientStatus: PF///Pltx: Y///Tax: Y///Neo: N///TimeToRelapseorLastFollow.Up.Months.: 42///TimeToDeathorLastFollow.Up.Months.: 42///ResidualDisease: <1///ArrayedSite: OV
1
title: X22037///geo_accession: GSM249984///status: Public on Mar 01 2008///submission_date: Dec 14 2007///last_update_date: Dec 19 2007///type: RNA///channel_count: 1///source_name_ch1: Carcinoma of ovary, fallopian tube or peritonem///organism_ch1: Homo sapiens///characteristics_ch1: Primary.Site : Ovary///characteristics_ch1.1: Type : Malignant///characteristics_ch1.2: Subtype : Ser/PapSer///characteristics_ch1.3: StageCode : IIIC///characteristics_ch1.4: Consolidated.Grade : 2///treatment_protocol_ch1: Frozen tissue stored at -80oC taken after surgery///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction and column chromotogrpahy///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip Drosophila Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.///scan_protocol: GeneChips were scanned using Affymetrix GS300-7G scanner///description: Gene expression data from human ovarian carcinoma///data_processing: The data were analyzed with Gene Chip Operating Software Version 1.4 using Affymetrix default analysis settings. The CEL files generated was later normalized using the RMA method///platform_id: GPL570///contact_name: Prof David,,Bowtell PhD.///contact_email: [email protected]///contact_phone: +613 96561287///contact_fax: +613 96561414///contact_department: Research Division///contact_institute: PeterMacCallum Cancer Centre///contact_address: Locked Bag 1 A' Beckett St///contact_city: Melbourne///contact_state: VIC///contact_zip.postal_code: 8006///contact_country: Australia///contact_web_link: http://www.petermac-research.org.au///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM249nnn/GSM249984/GSM249984.CEL.gz///data_row_count: 54621///ID: X22037///k.meansGroup: NC///Type: MAL///HistologicalSubtype: Ser///PrimarySite: OV///FIGOStage: III///Grade: 2///PatientAge.Years.: 78///PatientStatus: D///Pltx: Y///Tax: N///Neo: N///TimeToRelapseorLastFollow.Up.Months.: 8///TimeToDeathorLastFollow.Up.Months.: 17///ResidualDisease: >1///ArrayedSite: PE
1
title: X22046///geo_accession: GSM249983///status: Public on Mar 01 2008///submission_date: Dec 14 2007///last_update_date: Dec 19 2007///type: RNA///channel_count: 1///source_name_ch1: Carcinoma of ovary, fallopian tube or peritonem///organism_ch1: Homo sapiens///characteristics_ch1: Primary.Site : Ovary///characteristics_ch1.1: Type : Malignant///characteristics_ch1.2: Subtype : Ser/PapSer///characteristics_ch1.3: StageCode : IIIC///characteristics_ch1.4: Consolidated.Grade : 3///treatment_protocol_ch1: Frozen tissue stored at -80oC taken after surgery///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction and column chromotogrpahy///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip Drosophila Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.///scan_protocol: GeneChips were scanned using Affymetrix GS300-7G scanner///description: Gene expression data from human ovarian carcinoma///data_processing: The data were analyzed with Gene Chip Operating Software Version 1.4 using Affymetrix default analysis settings. The CEL files generated was later normalized using the RMA method///platform_id: GPL570///contact_name: Prof David,,Bowtell PhD.///contact_email: [email protected]///contact_phone: +613 96561287///contact_fax: +613 96561414///contact_department: Research Division///contact_institute: PeterMacCallum Cancer Centre///contact_address: Locked Bag 1 A' Beckett St///contact_city: Melbourne///contact_state: VIC///contact_zip.postal_code: 8006///contact_country: Australia///contact_web_link: http://www.petermac-research.org.au///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM249nnn/GSM249983/GSM249983.CEL.gz///data_row_count: 54621///ID: X22046///k.meansGroup: 4///Type: MAL///HistologicalSubtype: Ser///PrimarySite: OV///FIGOStage: III///Grade: 3///PatientAge.Years.: 71///PatientStatus: D///Pltx: Y///Tax: Y///Neo: N///TimeToRelapseorLastFollow.Up.Months.: 10///TimeToDeathorLastFollow.Up.Months.: 14///ResidualDisease: >1///ArrayedSite: OV
1
title: X22047///geo_accession: GSM249982///status: Public on Mar 01 2008///submission_date: Dec 14 2007///last_update_date: Dec 19 2007///type: RNA///channel_count: 1///source_name_ch1: Carcinoma of ovary, fallopian tube or peritonem///organism_ch1: Homo sapiens///characteristics_ch1: Primary.Site : Peritoneum///characteristics_ch1.1: Type : Malignant///characteristics_ch1.2: Subtype : Ser/PapSer///characteristics_ch1.3: StageCode : IIIC///characteristics_ch1.4: Consolidated.Grade : 3///treatment_protocol_ch1: Frozen tissue stored at -80oC taken after surgery///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction and column chromotogrpahy///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip Drosophila Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.///scan_protocol: GeneChips were scanned using Affymetrix GS300-7G scanner///description: Gene expression data from human ovarian carcinoma///data_processing: The data were analyzed with Gene Chip Operating Software Version 1.4 using Affymetrix default analysis settings. The CEL files generated was later normalized using the RMA method///platform_id: GPL570///contact_name: Prof David,,Bowtell PhD.///contact_email: [email protected]///contact_phone: +613 96561287///contact_fax: +613 96561414///contact_department: Research Division///contact_institute: PeterMacCallum Cancer Centre///contact_address: Locked Bag 1 A' Beckett St///contact_city: Melbourne///contact_state: VIC///contact_zip.postal_code: 8006///contact_country: Australia///contact_web_link: http://www.petermac-research.org.au///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM249nnn/GSM249982/GSM249982.CEL.gz///data_row_count: 54621///ID: X22047///k.meansGroup: 1///Type: MAL///HistologicalSubtype: Ser///PrimarySite: PE///FIGOStage: III///Grade: 3///PatientAge.Years.: 45///PatientStatus: D///Pltx: Y///Tax: Y///Neo: N///TimeToRelapseorLastFollow.Up.Months.: 9///TimeToDeathorLastFollow.Up.Months.: 22///ResidualDisease: >1///ArrayedSite: OV
1
title: X22048///geo_accession: GSM249981///status: Public on Mar 01 2008///submission_date: Dec 14 2007///last_update_date: Dec 19 2007///type: RNA///channel_count: 1///source_name_ch1: Carcinoma of ovary, fallopian tube or peritonem///organism_ch1: Homo sapiens///characteristics_ch1: Primary.Site : Ovary///characteristics_ch1.1: Type : Malignant///characteristics_ch1.2: Subtype : Ser/PapSer///characteristics_ch1.3: StageCode : IIC///characteristics_ch1.4: Consolidated.Grade : 2///treatment_protocol_ch1: Frozen tissue stored at -80oC taken after surgery///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction and column chromotogrpahy///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip Drosophila Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.///scan_protocol: GeneChips were scanned using Affymetrix GS300-7G scanner///description: Gene expression data from human ovarian carcinoma///data_processing: The data were analyzed with Gene Chip Operating Software Version 1.4 using Affymetrix default analysis settings. The CEL files generated was later normalized using the RMA method///platform_id: GPL570///contact_name: Prof David,,Bowtell PhD.///contact_email: [email protected]///contact_phone: +613 96561287///contact_fax: +613 96561414///contact_department: Research Division///contact_institute: PeterMacCallum Cancer Centre///contact_address: Locked Bag 1 A' Beckett St///contact_city: Melbourne///contact_state: VIC///contact_zip.postal_code: 8006///contact_country: Australia///contact_web_link: http://www.petermac-research.org.au///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM249nnn/GSM249981/GSM249981.CEL.gz///data_row_count: 54621///ID: X22048///k.meansGroup: 4///Type: MAL///HistologicalSubtype: Ser///PrimarySite: OV///FIGOStage: II///Grade: 2///PatientAge.Years.: 70///PatientStatus: PF///Pltx: Y///Tax: Y///Neo: N///TimeToRelapseorLastFollow.Up.Months.: 35///TimeToDeathorLastFollow.Up.Months.: 35///ResidualDisease: nil///ArrayedSite: OV
1
title: X22057///geo_accession: GSM249980///status: Public on Mar 01 2008///submission_date: Dec 14 2007///last_update_date: Dec 19 2007///type: RNA///channel_count: 1///source_name_ch1: Carcinoma of ovary, fallopian tube or peritonem///organism_ch1: Homo sapiens///characteristics_ch1: Primary.Site : Ovary///characteristics_ch1.1: Type : Malignant///characteristics_ch1.2: Subtype : Ser/PapSer///characteristics_ch1.3: StageCode : IIIC///characteristics_ch1.4: Consolidated.Grade : 2///treatment_protocol_ch1: Frozen tissue stored at -80oC taken after surgery///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction and column chromotogrpahy///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip Drosophila Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.///scan_protocol: GeneChips were scanned using Affymetrix GS300-7G scanner///description: Gene expression data from human ovarian carcinoma///data_processing: The data were analyzed with Gene Chip Operating Software Version 1.4 using Affymetrix default analysis settings. The CEL files generated was later normalized using the RMA method///platform_id: GPL570///contact_name: Prof David,,Bowtell PhD.///contact_email: [email protected]///contact_phone: +613 96561287///contact_fax: +613 96561414///contact_department: Research Division///contact_institute: PeterMacCallum Cancer Centre///contact_address: Locked Bag 1 A' Beckett St///contact_city: Melbourne///contact_state: VIC///contact_zip.postal_code: 8006///contact_country: Australia///contact_web_link: http://www.petermac-research.org.au///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM249nnn/GSM249980/GSM249980.CEL.gz///data_row_count: 54621///ID: X22057///k.meansGroup: 5///Type: MAL///HistologicalSubtype: Ser///PrimarySite: OV///FIGOStage: III///Grade: 2///PatientAge.Years.: 60///PatientStatus: PF///Pltx: Y///Tax: Y///Neo: N///TimeToRelapseorLastFollow.Up.Months.: 23///TimeToDeathorLastFollow.Up.Months.: 23///ResidualDisease: nil///ArrayedSite: PE
1
title: X22058///geo_accession: GSM249979///status: Public on Mar 01 2008///submission_date: Dec 14 2007///last_update_date: Dec 19 2007///type: RNA///channel_count: 1///source_name_ch1: Carcinoma of ovary, fallopian tube or peritonem///organism_ch1: Homo sapiens///characteristics_ch1: Primary.Site : Peritoneum///characteristics_ch1.1: Type : Malignant///characteristics_ch1.2: Subtype : Ser/PapSer///characteristics_ch1.3: StageCode : IV///characteristics_ch1.4: Consolidated.Grade : 3///treatment_protocol_ch1: Frozen tissue stored at -80oC taken after surgery///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction and column chromotogrpahy///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip Drosophila Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.///scan_protocol: GeneChips were scanned using Affymetrix GS300-7G scanner///description: Gene expression data from human ovarian carcinoma///data_processing: The data were analyzed with Gene Chip Operating Software Version 1.4 using Affymetrix default analysis settings. The CEL files generated was later normalized using the RMA method///platform_id: GPL570///contact_name: Prof David,,Bowtell PhD.///contact_email: [email protected]///contact_phone: +613 96561287///contact_fax: +613 96561414///contact_department: Research Division///contact_institute: PeterMacCallum Cancer Centre///contact_address: Locked Bag 1 A' Beckett St///contact_city: Melbourne///contact_state: VIC///contact_zip.postal_code: 8006///contact_country: Australia///contact_web_link: http://www.petermac-research.org.au///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM249nnn/GSM249979/GSM249979.CEL.gz///data_row_count: 54621///ID: X22058///k.meansGroup: 1///Type: MAL///HistologicalSubtype: Ser///PrimarySite: PE///FIGOStage: IV///Grade: 3///PatientAge.Years.: 45///PatientStatus: D///Pltx: Y///Tax: Y///Neo: N///TimeToRelapseorLastFollow.Up.Months.: 7///TimeToDeathorLastFollow.Up.Months.: 9///ResidualDisease: <1///ArrayedSite: PE
1
title: X2219///geo_accession: GSM249978///status: Public on Mar 01 2008///submission_date: Dec 14 2007///last_update_date: Dec 19 2007///type: RNA///channel_count: 1///source_name_ch1: Carcinoma of ovary, fallopian tube or peritonem///organism_ch1: Homo sapiens///characteristics_ch1: Primary.Site : Ovary///characteristics_ch1.1: Type : Malignant///characteristics_ch1.2: Subtype : Ser/PapSer///characteristics_ch1.3: StageCode : NA///characteristics_ch1.4: Consolidated.Grade : 3///treatment_protocol_ch1: Frozen tissue stored at -80oC taken after surgery///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction and column chromotogrpahy///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip Drosophila Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.///scan_protocol: GeneChips were scanned using Affymetrix GS300-7G scanner///description: Gene expression data from human ovarian carcinoma///data_processing: The data were analyzed with Gene Chip Operating Software Version 1.4 using Affymetrix default analysis settings. The CEL files generated was later normalized using the RMA method///platform_id: GPL570///contact_name: Prof David,,Bowtell PhD.///contact_email: [email protected]///contact_phone: +613 96561287///contact_fax: +613 96561414///contact_department: Research Division///contact_institute: PeterMacCallum Cancer Centre///contact_address: Locked Bag 1 A' Beckett St///contact_city: Melbourne///contact_state: VIC///contact_zip.postal_code: 8006///contact_country: Australia///contact_web_link: http://www.petermac-research.org.au///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM249nnn/GSM249978/GSM249978.CEL.gz///data_row_count: 54621///ID: X2219///k.meansGroup: 1///Type: MAL///HistologicalSubtype: Ser///PrimarySite: OV///FIGOStage: 3///Grade: NA///PatientAge.Years.: NA///PatientStatus: ///Pltx: ///Tax: ///Neo: ///TimeToRelapseorLastFollow.Up.Months.: NA///TimeToDeathorLastFollow.Up.Months.: NA///ResidualDisease: NK///ArrayedSite: Other
1
title: X2227///geo_accession: GSM249977///status: Public on Mar 01 2008///submission_date: Dec 14 2007///last_update_date: Dec 19 2007///type: RNA///channel_count: 1///source_name_ch1: Carcinoma of ovary, fallopian tube or peritonem///organism_ch1: Homo sapiens///characteristics_ch1: Primary.Site : Ovary///characteristics_ch1.1: Type : Malignant///characteristics_ch1.2: Subtype : Endo///characteristics_ch1.3: StageCode : NA///characteristics_ch1.4: Consolidated.Grade : NA///treatment_protocol_ch1: Frozen tissue stored at -80oC taken after surgery///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction and column chromotogrpahy///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip Drosophila Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.///scan_protocol: GeneChips were scanned using Affymetrix GS300-7G scanner///description: Gene expression data from human ovarian carcinoma///data_processing: The data were analyzed with Gene Chip Operating Software Version 1.4 using Affymetrix default analysis settings. The CEL files generated was later normalized using the RMA method///platform_id: GPL570///contact_name: Prof David,,Bowtell PhD.///contact_email: [email protected]///contact_phone: +613 96561287///contact_fax: +613 96561414///contact_department: Research Division///contact_institute: PeterMacCallum Cancer Centre///contact_address: Locked Bag 1 A' Beckett St///contact_city: Melbourne///contact_state: VIC///contact_zip.postal_code: 8006///contact_country: Australia///contact_web_link: http://www.petermac-research.org.au///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM249nnn/GSM249977/GSM249977.CEL.gz///data_row_count: 54621///ID: X2227///k.meansGroup: 2///Type: MAL///HistologicalSubtype: Endo///PrimarySite: OV///FIGOStage: ///Grade: NA///PatientAge.Years.: NA///PatientStatus: ///Pltx: ///Tax: ///Neo: ///TimeToRelapseorLastFollow.Up.Months.: NA///TimeToDeathorLastFollow.Up.Months.: NA///ResidualDisease: NK///ArrayedSite: Other
1
title: X23026///geo_accession: GSM249976///status: Public on Mar 01 2008///submission_date: Dec 14 2007///last_update_date: Dec 19 2007///type: RNA///channel_count: 1///source_name_ch1: Carcinoma of ovary, fallopian tube or peritonem///organism_ch1: Homo sapiens///characteristics_ch1: Primary.Site : Ovary///characteristics_ch1.1: Type : Malignant///characteristics_ch1.2: Subtype : Ser/PapSer///characteristics_ch1.3: StageCode : IIIC///characteristics_ch1.4: Consolidated.Grade : 3///treatment_protocol_ch1: Frozen tissue stored at -80oC taken after surgery///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction and column chromotogrpahy///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip Drosophila Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.///scan_protocol: GeneChips were scanned using Affymetrix GS300-7G scanner///description: Gene expression data from human ovarian carcinoma///data_processing: The data were analyzed with Gene Chip Operating Software Version 1.4 using Affymetrix default analysis settings. The CEL files generated was later normalized using the RMA method///platform_id: GPL570///contact_name: Prof David,,Bowtell PhD.///contact_email: [email protected]///contact_phone: +613 96561287///contact_fax: +613 96561414///contact_department: Research Division///contact_institute: PeterMacCallum Cancer Centre///contact_address: Locked Bag 1 A' Beckett St///contact_city: Melbourne///contact_state: VIC///contact_zip.postal_code: 8006///contact_country: Australia///contact_web_link: http://www.petermac-research.org.au///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM249nnn/GSM249976/GSM249976.CEL.gz///data_row_count: 54621///ID: X23026///k.meansGroup: 4///Type: MAL///HistologicalSubtype: Ser///PrimarySite: OV///FIGOStage: III///Grade: 3///PatientAge.Years.: 57///PatientStatus: R///Pltx: Y///Tax: Y///Neo: N///TimeToRelapseorLastFollow.Up.Months.: 13///TimeToDeathorLastFollow.Up.Months.: 36///ResidualDisease: NK///ArrayedSite: OV
1
title: X23030///geo_accession: GSM249975///status: Public on Mar 01 2008///submission_date: Dec 14 2007///last_update_date: Dec 19 2007///type: RNA///channel_count: 1///source_name_ch1: Carcinoma of ovary, fallopian tube or peritonem///organism_ch1: Homo sapiens///characteristics_ch1: Primary.Site : Ovary///characteristics_ch1.1: Type : Malignant///characteristics_ch1.2: Subtype : Ser/PapSer///characteristics_ch1.3: StageCode : IIIC///characteristics_ch1.4: Consolidated.Grade : 3///treatment_protocol_ch1: Frozen tissue stored at -80oC taken after surgery///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction and column chromotogrpahy///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip Drosophila Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.///scan_protocol: GeneChips were scanned using Affymetrix GS300-7G scanner///description: Gene expression data from human ovarian carcinoma///data_processing: The data were analyzed with Gene Chip Operating Software Version 1.4 using Affymetrix default analysis settings. The CEL files generated was later normalized using the RMA method///platform_id: GPL570///contact_name: Prof David,,Bowtell PhD.///contact_email: [email protected]///contact_phone: +613 96561287///contact_fax: +613 96561414///contact_department: Research Division///contact_institute: PeterMacCallum Cancer Centre///contact_address: Locked Bag 1 A' Beckett St///contact_city: Melbourne///contact_state: VIC///contact_zip.postal_code: 8006///contact_country: Australia///contact_web_link: http://www.petermac-research.org.au///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM249nnn/GSM249975/GSM249975.CEL.gz///data_row_count: 54621///ID: X23030///k.meansGroup: NC///Type: MAL///HistologicalSubtype: Ser///PrimarySite: OV///FIGOStage: III///Grade: 3///PatientAge.Years.: 67///PatientStatus: R///Pltx: Y///Tax: Y///Neo: N///TimeToRelapseorLastFollow.Up.Months.: 19///TimeToDeathorLastFollow.Up.Months.: 44///ResidualDisease: <1///ArrayedSite: OV
1
title: X23036///geo_accession: GSM249727///status: Public on Mar 01 2008///submission_date: Dec 14 2007///last_update_date: Dec 19 2007///type: RNA///channel_count: 1///source_name_ch1: Carcinoma of ovary, fallopian tube or peritonem///organism_ch1: Homo sapiens///characteristics_ch1: Primary.Site : Ovary///characteristics_ch1.1: Type : LMP///characteristics_ch1.2: Subtype : Ser/PapSer///characteristics_ch1.3: StageCode : IIIC///characteristics_ch1.4: Consolidated.Grade : 2///treatment_protocol_ch1: Frozen tissue stored at -80oC taken after surgery///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction and column chromotogrpahy///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip Drosophila Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.///scan_protocol: GeneChips were scanned using Affymetrix GS300-7G scanner///description: Gene expression data from human ovarian carcinoma///data_processing: The data were analyzed with Gene Chip Operating Software Version 1.4 using Affymetrix default analysis settings. The CEL files generated was later normalized using the RMA method///platform_id: GPL570///contact_name: Prof David,,Bowtell PhD.///contact_email: [email protected]///contact_phone: +613 96561287///contact_fax: +613 96561414///contact_department: Research Division///contact_institute: PeterMacCallum Cancer Centre///contact_address: Locked Bag 1 A' Beckett St///contact_city: Melbourne///contact_state: VIC///contact_zip.postal_code: 8006///contact_country: Australia///contact_web_link: http://www.petermac-research.org.au///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM249nnn/GSM249727/GSM249727.CEL.gz///data_row_count: 54621///ID: X23036///k.meansGroup: 3///Type: LMP///HistologicalSubtype: Ser///PrimarySite: OV///FIGOStage: III///Grade: 3///PatientAge.Years.: 40///PatientStatus: PF///Pltx: N///Tax: N///Neo: N///TimeToRelapseorLastFollow.Up.Months.: 39///TimeToDeathorLastFollow.Up.Months.: 39///ResidualDisease: nil///ArrayedSite: OV
1
title: X23043///geo_accession: GSM249974///status: Public on Mar 01 2008///submission_date: Dec 14 2007///last_update_date: Dec 19 2007///type: RNA///channel_count: 1///source_name_ch1: Carcinoma of ovary, fallopian tube or peritonem///organism_ch1: Homo sapiens///characteristics_ch1: Primary.Site : Ovary///characteristics_ch1.1: Type : Malignant///characteristics_ch1.2: Subtype : Endo///characteristics_ch1.3: StageCode : IIC///characteristics_ch1.4: Consolidated.Grade : 2///treatment_protocol_ch1: Frozen tissue stored at -80oC taken after surgery///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction and column chromotogrpahy///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip Drosophila Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.///scan_protocol: GeneChips were scanned using Affymetrix GS300-7G scanner///description: Gene expression data from human ovarian carcinoma///data_processing: The data were analyzed with Gene Chip Operating Software Version 1.4 using Affymetrix default analysis settings. The CEL files generated was later normalized using the RMA method///platform_id: GPL570///contact_name: Prof David,,Bowtell PhD.///contact_email: [email protected]///contact_phone: +613 96561287///contact_fax: +613 96561414///contact_department: Research Division///contact_institute: PeterMacCallum Cancer Centre///contact_address: Locked Bag 1 A' Beckett St///contact_city: Melbourne///contact_state: VIC///contact_zip.postal_code: 8006///contact_country: Australia///contact_web_link: http://www.petermac-research.org.au///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM249nnn/GSM249974/GSM249974.CEL.gz///data_row_count: 54621///ID: X23043///k.meansGroup: 6///Type: MAL///HistologicalSubtype: Endo///PrimarySite: OV///FIGOStage: II///Grade: 2///PatientAge.Years.: 43///PatientStatus: PF///Pltx: N///Tax: N///Neo: N///TimeToRelapseorLastFollow.Up.Months.: 43///TimeToDeathorLastFollow.Up.Months.: 43///ResidualDisease: nil///ArrayedSite: OV
1
title: X23052///geo_accession: GSM249721///status: Public on Mar 01 2008///submission_date: Dec 14 2007///last_update_date: Dec 19 2007///type: RNA///channel_count: 1///source_name_ch1: Carcinoma of ovary, fallopian tube or peritonem///organism_ch1: Homo sapiens///characteristics_ch1: Primary.Site : Ovary///characteristics_ch1.1: Type : LMP///characteristics_ch1.2: Subtype : Ser/PapSer///characteristics_ch1.3: StageCode : IA///characteristics_ch1.4: Consolidated.Grade : 3///treatment_protocol_ch1: Frozen tissue stored at -80oC taken after surgery///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction and column chromotogrpahy///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip Drosophila Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.///scan_protocol: GeneChips were scanned using Affymetrix GS300-7G scanner///description: Gene expression data from human ovarian carcinoma///data_processing: The data were analyzed with Gene Chip Operating Software Version 1.4 using Affymetrix default analysis settings. The CEL files generated was later normalized using the RMA method///platform_id: GPL570///contact_name: Prof David,,Bowtell PhD.///contact_email: [email protected]///contact_phone: +613 96561287///contact_fax: +613 96561414///contact_department: Research Division///contact_institute: PeterMacCallum Cancer Centre///contact_address: Locked Bag 1 A' Beckett St///contact_city: Melbourne///contact_state: VIC///contact_zip.postal_code: 8006///contact_country: Australia///contact_web_link: http://www.petermac-research.org.au///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM249nnn/GSM249721/GSM249721.CEL.gz///data_row_count: 54621///ID: X23052///k.meansGroup: 3///Type: LMP///HistologicalSubtype: Ser///PrimarySite: OV///FIGOStage: I///Grade: 3///PatientAge.Years.: 46///PatientStatus: PF///Pltx: N///Tax: N///Neo: N///TimeToRelapseorLastFollow.Up.Months.: 22///TimeToDeathorLastFollow.Up.Months.: 22///ResidualDisease: nil///ArrayedSite: OV
1
title: X23053///geo_accession: GSM249973///status: Public on Mar 01 2008///submission_date: Dec 14 2007///last_update_date: Dec 19 2007///type: RNA///channel_count: 1///source_name_ch1: Carcinoma of ovary, fallopian tube or peritonem///organism_ch1: Homo sapiens///characteristics_ch1: Primary.Site : Ovary///characteristics_ch1.1: Type : Malignant///characteristics_ch1.2: Subtype : Ser/PapSer///characteristics_ch1.3: StageCode : IIIC///characteristics_ch1.4: Consolidated.Grade : 3///treatment_protocol_ch1: Frozen tissue stored at -80oC taken after surgery///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction and column chromotogrpahy///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip Drosophila Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.///scan_protocol: GeneChips were scanned using Affymetrix GS300-7G scanner///description: Gene expression data from human ovarian carcinoma///data_processing: The data were analyzed with Gene Chip Operating Software Version 1.4 using Affymetrix default analysis settings. The CEL files generated was later normalized using the RMA method///platform_id: GPL570///contact_name: Prof David,,Bowtell PhD.///contact_email: [email protected]///contact_phone: +613 96561287///contact_fax: +613 96561414///contact_department: Research Division///contact_institute: PeterMacCallum Cancer Centre///contact_address: Locked Bag 1 A' Beckett St///contact_city: Melbourne///contact_state: VIC///contact_zip.postal_code: 8006///contact_country: Australia///contact_web_link: http://www.petermac-research.org.au///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM249nnn/GSM249973/GSM249973.CEL.gz///data_row_count: 54621///ID: X23053///k.meansGroup: 4///Type: MAL///HistologicalSubtype: Ser///PrimarySite: OV///FIGOStage: III///Grade: 3///PatientAge.Years.: 73///PatientStatus: R///Pltx: Y///Tax: Y///Neo: N///TimeToRelapseorLastFollow.Up.Months.: 21///TimeToDeathorLastFollow.Up.Months.: 41///ResidualDisease: >1///ArrayedSite: OV
1
title: X23055///geo_accession: GSM249972///status: Public on Mar 01 2008///submission_date: Dec 14 2007///last_update_date: Dec 19 2007///type: RNA///channel_count: 1///source_name_ch1: Carcinoma of ovary, fallopian tube or peritonem///organism_ch1: Homo sapiens///characteristics_ch1: Primary.Site : Ovary///characteristics_ch1.1: Type : Malignant///characteristics_ch1.2: Subtype : Ser/PapSer///characteristics_ch1.3: StageCode : IIIC///characteristics_ch1.4: Consolidated.Grade : 3///treatment_protocol_ch1: Frozen tissue stored at -80oC taken after surgery///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction and column chromotogrpahy///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip Drosophila Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.///scan_protocol: GeneChips were scanned using Affymetrix GS300-7G scanner///description: Gene expression data from human ovarian carcinoma///data_processing: The data were analyzed with Gene Chip Operating Software Version 1.4 using Affymetrix default analysis settings. The CEL files generated was later normalized using the RMA method///platform_id: GPL570///contact_name: Prof David,,Bowtell PhD.///contact_email: [email protected]///contact_phone: +613 96561287///contact_fax: +613 96561414///contact_department: Research Division///contact_institute: PeterMacCallum Cancer Centre///contact_address: Locked Bag 1 A' Beckett St///contact_city: Melbourne///contact_state: VIC///contact_zip.postal_code: 8006///contact_country: Australia///contact_web_link: http://www.petermac-research.org.au///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM249nnn/GSM249972/GSM249972.CEL.gz///data_row_count: 54621///ID: X23055///k.meansGroup: NC///Type: MAL///HistologicalSubtype: Ser///PrimarySite: OV///FIGOStage: III///Grade: 3///PatientAge.Years.: 57///PatientStatus: R///Pltx: Y///Tax: Y///Neo: N///TimeToRelapseorLastFollow.Up.Months.: 15///TimeToDeathorLastFollow.Up.Months.: 31///ResidualDisease: <1///ArrayedSite: OV
1
title: X23066///geo_accession: GSM249716///status: Public on Mar 01 2008///submission_date: Dec 14 2007///last_update_date: Dec 19 2007///type: RNA///channel_count: 1///source_name_ch1: Carcinoma of ovary, fallopian tube or peritonem///organism_ch1: Homo sapiens///characteristics_ch1: Primary.Site : Ovary///characteristics_ch1.1: Type : LMP///characteristics_ch1.2: Subtype : Ser/PapSer///characteristics_ch1.3: StageCode : IIIA///characteristics_ch1.4: Consolidated.Grade : 1///treatment_protocol_ch1: Frozen tissue stored at -80oC taken after surgery///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction and column chromotogrpahy///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip Drosophila Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.///scan_protocol: GeneChips were scanned using Affymetrix GS300-7G scanner///description: Gene expression data from human ovarian carcinoma///data_processing: The data were analyzed with Gene Chip Operating Software Version 1.4 using Affymetrix default analysis settings. The CEL files generated was later normalized using the RMA method///platform_id: GPL570///contact_name: Prof David,,Bowtell PhD.///contact_email: [email protected]///contact_phone: +613 96561287///contact_fax: +613 96561414///contact_department: Research Division///contact_institute: PeterMacCallum Cancer Centre///contact_address: Locked Bag 1 A' Beckett St///contact_city: Melbourne///contact_state: VIC///contact_zip.postal_code: 8006///contact_country: Australia///contact_web_link: http://www.petermac-research.org.au///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM249nnn/GSM249716/GSM249716.CEL.gz///data_row_count: 54621///ID: X23066///k.meansGroup: 3///Type: LMP///HistologicalSubtype: Ser///PrimarySite: OV///FIGOStage: III///Grade: 1///PatientAge.Years.: 64///PatientStatus: PF///Pltx: N///Tax: N///Neo: N///TimeToRelapseorLastFollow.Up.Months.: 18///TimeToDeathorLastFollow.Up.Months.: 18///ResidualDisease: nil///ArrayedSite: OV
1
title: X23070///geo_accession: GSM249971///status: Public on Mar 01 2008///submission_date: Dec 14 2007///last_update_date: Dec 19 2007///type: RNA///channel_count: 1///source_name_ch1: Carcinoma of ovary, fallopian tube or peritonem///organism_ch1: Homo sapiens///characteristics_ch1: Primary.Site : Ovary///characteristics_ch1.1: Type : Malignant///characteristics_ch1.2: Subtype : Ser/PapSer///characteristics_ch1.3: StageCode : IV///characteristics_ch1.4: Consolidated.Grade : 2///treatment_protocol_ch1: Frozen tissue stored at -80oC taken after surgery///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction and column chromotogrpahy///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip Drosophila Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.///scan_protocol: GeneChips were scanned using Affymetrix GS300-7G scanner///description: Gene expression data from human ovarian carcinoma///data_processing: The data were analyzed with Gene Chip Operating Software Version 1.4 using Affymetrix default analysis settings. The CEL files generated was later normalized using the RMA method///platform_id: GPL570///contact_name: Prof David,,Bowtell PhD.///contact_email: [email protected]///contact_phone: +613 96561287///contact_fax: +613 96561414///contact_department: Research Division///contact_institute: PeterMacCallum Cancer Centre///contact_address: Locked Bag 1 A' Beckett St///contact_city: Melbourne///contact_state: VIC///contact_zip.postal_code: 8006///contact_country: Australia///contact_web_link: http://www.petermac-research.org.au///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM249nnn/GSM249971/GSM249971.CEL.gz///data_row_count: 54621///ID: X23070///k.meansGroup: NC///Type: MAL///HistologicalSubtype: Ser///PrimarySite: OV///FIGOStage: IV///Grade: 2///PatientAge.Years.: 48///PatientStatus: D///Pltx: Y///Tax: Y///Neo: Y///TimeToRelapseorLastFollow.Up.Months.: 10///TimeToDeathorLastFollow.Up.Months.: 24///ResidualDisease: <1///ArrayedSite: OV
1
title: X23074///geo_accession: GSM249970///status: Public on Mar 01 2008///submission_date: Dec 14 2007///last_update_date: Dec 19 2007///type: RNA///channel_count: 1///source_name_ch1: Carcinoma of ovary, fallopian tube or peritonem///organism_ch1: Homo sapiens///characteristics_ch1: Primary.Site : Fallopian///characteristics_ch1.1: Type : Malignant///characteristics_ch1.2: Subtype : Ser/PapSer///characteristics_ch1.3: StageCode : IC///characteristics_ch1.4: Consolidated.Grade : 3///treatment_protocol_ch1: Frozen tissue stored at -80oC taken after surgery///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction and column chromotogrpahy///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip Drosophila Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.///scan_protocol: GeneChips were scanned using Affymetrix GS300-7G scanner///description: Gene expression data from human ovarian carcinoma///data_processing: The data were analyzed with Gene Chip Operating Software Version 1.4 using Affymetrix default analysis settings. The CEL files generated was later normalized using the RMA method///platform_id: GPL570///contact_name: Prof David,,Bowtell PhD.///contact_email: [email protected]///contact_phone: +613 96561287///contact_fax: +613 96561414///contact_department: Research Division///contact_institute: PeterMacCallum Cancer Centre///contact_address: Locked Bag 1 A' Beckett St///contact_city: Melbourne///contact_state: VIC///contact_zip.postal_code: 8006///contact_country: Australia///contact_web_link: http://www.petermac-research.org.au///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM249nnn/GSM249970/GSM249970.CEL.gz///data_row_count: 54621///ID: X23074///k.meansGroup: 1///Type: MAL///HistologicalSubtype: Ser///PrimarySite: FT///FIGOStage: I///Grade: 3///PatientAge.Years.: 77///PatientStatus: D///Pltx: Y///Tax: N///Neo: N///TimeToRelapseorLastFollow.Up.Months.: 20///TimeToDeathorLastFollow.Up.Months.: 20///ResidualDisease: nil///ArrayedSite: FT
1
title: X23077///geo_accession: GSM249969///status: Public on Mar 01 2008///submission_date: Dec 14 2007///last_update_date: Dec 19 2007///type: RNA///channel_count: 1///source_name_ch1: Carcinoma of ovary, fallopian tube or peritonem///organism_ch1: Homo sapiens///characteristics_ch1: Primary.Site : Ovary///characteristics_ch1.1: Type : Malignant///characteristics_ch1.2: Subtype : Ser/PapSer///characteristics_ch1.3: StageCode : IIIC///characteristics_ch1.4: Consolidated.Grade : 3///treatment_protocol_ch1: Frozen tissue stored at -80oC taken after surgery///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction and column chromotogrpahy///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip Drosophila Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.///scan_protocol: GeneChips were scanned using Affymetrix GS300-7G scanner///description: Gene expression data from human ovarian carcinoma///data_processing: The data were analyzed with Gene Chip Operating Software Version 1.4 using Affymetrix default analysis settings. The CEL files generated was later normalized using the RMA method///platform_id: GPL570///contact_name: Prof David,,Bowtell PhD.///contact_email: [email protected]///contact_phone: +613 96561287///contact_fax: +613 96561414///contact_department: Research Division///contact_institute: PeterMacCallum Cancer Centre///contact_address: Locked Bag 1 A' Beckett St///contact_city: Melbourne///contact_state: VIC///contact_zip.postal_code: 8006///contact_country: Australia///contact_web_link: http://www.petermac-research.org.au///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM249nnn/GSM249969/GSM249969.CEL.gz///data_row_count: 54621///ID: X23077///k.meansGroup: NC///Type: MAL///HistologicalSubtype: Ser///PrimarySite: OV///FIGOStage: III///Grade: 3///PatientAge.Years.: 58///PatientStatus: D///Pltx: Y///Tax: Y///Neo: N///TimeToRelapseorLastFollow.Up.Months.: 7///TimeToDeathorLastFollow.Up.Months.: 35///ResidualDisease: >1///ArrayedSite: OV
1
title: X23084///geo_accession: GSM249968///status: Public on Mar 01 2008///submission_date: Dec 14 2007///last_update_date: Dec 19 2007///type: RNA///channel_count: 1///source_name_ch1: Carcinoma of ovary, fallopian tube or peritonem///organism_ch1: Homo sapiens///characteristics_ch1: Primary.Site : Ovary///characteristics_ch1.1: Type : Malignant///characteristics_ch1.2: Subtype : Ser/PapSer///characteristics_ch1.3: StageCode : IIIB///characteristics_ch1.4: Consolidated.Grade : 3///treatment_protocol_ch1: Frozen tissue stored at -80oC taken after surgery///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction and column chromotogrpahy///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip Drosophila Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.///scan_protocol: GeneChips were scanned using Affymetrix GS300-7G scanner///description: Gene expression data from human ovarian carcinoma///data_processing: The data were analyzed with Gene Chip Operating Software Version 1.4 using Affymetrix default analysis settings. The CEL files generated was later normalized using the RMA method///platform_id: GPL570///contact_name: Prof David,,Bowtell PhD.///contact_email: [email protected]///contact_phone: +613 96561287///contact_fax: +613 96561414///contact_department: Research Division///contact_institute: PeterMacCallum Cancer Centre///contact_address: Locked Bag 1 A' Beckett St///contact_city: Melbourne///contact_state: VIC///contact_zip.postal_code: 8006///contact_country: Australia///contact_web_link: http://www.petermac-research.org.au///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM249nnn/GSM249968/GSM249968.CEL.gz///data_row_count: 54621///ID: X23084///k.meansGroup: 4///Type: MAL///HistologicalSubtype: Ser///PrimarySite: OV///FIGOStage: III///Grade: 3///PatientAge.Years.: 59///PatientStatus: R///Pltx: Y///Tax: Y///Neo: N///TimeToRelapseorLastFollow.Up.Months.: 22///TimeToDeathorLastFollow.Up.Months.: 28///ResidualDisease: <1///ArrayedSite: OV
1
title: X23098///geo_accession: GSM249967///status: Public on Mar 01 2008///submission_date: Dec 14 2007///last_update_date: Dec 19 2007///type: RNA///channel_count: 1///source_name_ch1: Carcinoma of ovary, fallopian tube or peritonem///organism_ch1: Homo sapiens///characteristics_ch1: Primary.Site : Ovary///characteristics_ch1.1: Type : Malignant///characteristics_ch1.2: Subtype : Ser/PapSer///characteristics_ch1.3: StageCode : IIC///characteristics_ch1.4: Consolidated.Grade : 2///treatment_protocol_ch1: Frozen tissue stored at -80oC taken after surgery///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction and column chromotogrpahy///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip Drosophila Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.///scan_protocol: GeneChips were scanned using Affymetrix GS300-7G scanner///description: Gene expression data from human ovarian carcinoma///data_processing: The data were analyzed with Gene Chip Operating Software Version 1.4 using Affymetrix default analysis settings. The CEL files generated was later normalized using the RMA method///platform_id: GPL570///contact_name: Prof David,,Bowtell PhD.///contact_email: [email protected]///contact_phone: +613 96561287///contact_fax: +613 96561414///contact_department: Research Division///contact_institute: PeterMacCallum Cancer Centre///contact_address: Locked Bag 1 A' Beckett St///contact_city: Melbourne///contact_state: VIC///contact_zip.postal_code: 8006///contact_country: Australia///contact_web_link: http://www.petermac-research.org.au///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM249nnn/GSM249967/GSM249967.CEL.gz///data_row_count: 54621///ID: X23098///k.meansGroup: NC///Type: MAL///HistologicalSubtype: Ser///PrimarySite: OV///FIGOStage: II///Grade: 2///PatientAge.Years.: 77///PatientStatus: PF///Pltx: Y///Tax: N///Neo: N///TimeToRelapseorLastFollow.Up.Months.: 34///TimeToDeathorLastFollow.Up.Months.: 34///ResidualDisease: nil///ArrayedSite: OV
1
title: X23102///geo_accession: GSM249966///status: Public on Mar 01 2008///submission_date: Dec 14 2007///last_update_date: Dec 19 2007///type: RNA///channel_count: 1///source_name_ch1: Carcinoma of ovary, fallopian tube or peritonem///organism_ch1: Homo sapiens///characteristics_ch1: Primary.Site : Ovary///characteristics_ch1.1: Type : Malignant///characteristics_ch1.2: Subtype : Endo///characteristics_ch1.3: StageCode : IIIB///characteristics_ch1.4: Consolidated.Grade : 2///treatment_protocol_ch1: Frozen tissue stored at -80oC taken after surgery///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction and column chromotogrpahy///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip Drosophila Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.///scan_protocol: GeneChips were scanned using Affymetrix GS300-7G scanner///description: Gene expression data from human ovarian carcinoma///data_processing: The data were analyzed with Gene Chip Operating Software Version 1.4 using Affymetrix default analysis settings. The CEL files generated was later normalized using the RMA method///platform_id: GPL570///contact_name: Prof David,,Bowtell PhD.///contact_email: [email protected]///contact_phone: +613 96561287///contact_fax: +613 96561414///contact_department: Research Division///contact_institute: PeterMacCallum Cancer Centre///contact_address: Locked Bag 1 A' Beckett St///contact_city: Melbourne///contact_state: VIC///contact_zip.postal_code: 8006///contact_country: Australia///contact_web_link: http://www.petermac-research.org.au///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM249nnn/GSM249966/GSM249966.CEL.gz///data_row_count: 54621///ID: X23102///k.meansGroup: 4///Type: MAL///HistologicalSubtype: Endo///PrimarySite: OV///FIGOStage: III///Grade: 2///PatientAge.Years.: 49///PatientStatus: R///Pltx: Y///Tax: Y///Neo: N///TimeToRelapseorLastFollow.Up.Months.: 33///TimeToDeathorLastFollow.Up.Months.: 33///ResidualDisease: nil///ArrayedSite: OV
1
title: X23106///geo_accession: GSM249965///status: Public on Mar 01 2008///submission_date: Dec 14 2007///last_update_date: Dec 19 2007///type: RNA///channel_count: 1///source_name_ch1: Carcinoma of ovary, fallopian tube or peritonem///organism_ch1: Homo sapiens///characteristics_ch1: Primary.Site : Ovary///characteristics_ch1.1: Type : Malignant///characteristics_ch1.2: Subtype : Ser/PapSer///characteristics_ch1.3: StageCode : IIIC///characteristics_ch1.4: Consolidated.Grade : 3///treatment_protocol_ch1: Frozen tissue stored at -80oC taken after surgery///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction and column chromotogrpahy///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip Drosophila Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.///scan_protocol: GeneChips were scanned using Affymetrix GS300-7G scanner///description: Gene expression data from human ovarian carcinoma///data_processing: The data were analyzed with Gene Chip Operating Software Version 1.4 using Affymetrix default analysis settings. The CEL files generated was later normalized using the RMA method///platform_id: GPL570///contact_name: Prof David,,Bowtell PhD.///contact_email: [email protected]///contact_phone: +613 96561287///contact_fax: +613 96561414///contact_department: Research Division///contact_institute: PeterMacCallum Cancer Centre///contact_address: Locked Bag 1 A' Beckett St///contact_city: Melbourne///contact_state: VIC///contact_zip.postal_code: 8006///contact_country: Australia///contact_web_link: http://www.petermac-research.org.au///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM249nnn/GSM249965/GSM249965.CEL.gz///data_row_count: 54621///ID: X23106///k.meansGroup: 2///Type: MAL///HistologicalSubtype: Ser///PrimarySite: OV///FIGOStage: III///Grade: 3///PatientAge.Years.: 78///PatientStatus: PF///Pltx: Y///Tax: Y///Neo: N///TimeToRelapseorLastFollow.Up.Months.: 11///TimeToDeathorLastFollow.Up.Months.: 11///ResidualDisease: macrosizeNK///ArrayedSite: OV
1
title: X23116///geo_accession: GSM249964///status: Public on Mar 01 2008///submission_date: Dec 14 2007///last_update_date: Dec 19 2007///type: RNA///channel_count: 1///source_name_ch1: Carcinoma of ovary, fallopian tube or peritonem///organism_ch1: Homo sapiens///characteristics_ch1: Primary.Site : Peritoneum///characteristics_ch1.1: Type : Malignant///characteristics_ch1.2: Subtype : Ser/PapSer///characteristics_ch1.3: StageCode : IIIC///characteristics_ch1.4: Consolidated.Grade : 3///treatment_protocol_ch1: Frozen tissue stored at -80oC taken after surgery///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction and column chromotogrpahy///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip Drosophila Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.///scan_protocol: GeneChips were scanned using Affymetrix GS300-7G scanner///description: Gene expression data from human ovarian carcinoma///data_processing: The data were analyzed with Gene Chip Operating Software Version 1.4 using Affymetrix default analysis settings. The CEL files generated was later normalized using the RMA method///platform_id: GPL570///contact_name: Prof David,,Bowtell PhD.///contact_email: [email protected]///contact_phone: +613 96561287///contact_fax: +613 96561414///contact_department: Research Division///contact_institute: PeterMacCallum Cancer Centre///contact_address: Locked Bag 1 A' Beckett St///contact_city: Melbourne///contact_state: VIC///contact_zip.postal_code: 8006///contact_country: Australia///contact_web_link: http://www.petermac-research.org.au///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM249nnn/GSM249964/GSM249964.CEL.gz///data_row_count: 54621///ID: X23116///k.meansGroup: NC///Type: MAL///HistologicalSubtype: Ser///PrimarySite: PE///FIGOStage: III///Grade: 3///PatientAge.Years.: 68///PatientStatus: D///Pltx: N///Tax: N///Neo: Y///TimeToRelapseorLastFollow.Up.Months.: 4///TimeToDeathorLastFollow.Up.Months.: 8///ResidualDisease: NK///ArrayedSite: PE
1
title: X23128///geo_accession: GSM249963///status: Public on Mar 01 2008///submission_date: Dec 14 2007///last_update_date: Dec 19 2007///type: RNA///channel_count: 1///source_name_ch1: Carcinoma of ovary, fallopian tube or peritonem///organism_ch1: Homo sapiens///characteristics_ch1: Primary.Site : Ovary///characteristics_ch1.1: Type : Malignant///characteristics_ch1.2: Subtype : Ser/PapSer///characteristics_ch1.3: StageCode : IIIC///characteristics_ch1.4: Consolidated.Grade : 3///treatment_protocol_ch1: Frozen tissue stored at -80oC taken after surgery///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction and column chromotogrpahy///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip Drosophila Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.///scan_protocol: GeneChips were scanned using Affymetrix GS300-7G scanner///description: Gene expression data from human ovarian carcinoma///data_processing: The data were analyzed with Gene Chip Operating Software Version 1.4 using Affymetrix default analysis settings. The CEL files generated was later normalized using the RMA method///platform_id: GPL570///contact_name: Prof David,,Bowtell PhD.///contact_email: [email protected]///contact_phone: +613 96561287///contact_fax: +613 96561414///contact_department: Research Division///contact_institute: PeterMacCallum Cancer Centre///contact_address: Locked Bag 1 A' Beckett St///contact_city: Melbourne///contact_state: VIC///contact_zip.postal_code: 8006///contact_country: Australia///contact_web_link: http://www.petermac-research.org.au///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM249nnn/GSM249963/GSM249963.CEL.gz///data_row_count: 54621///ID: X23128///k.meansGroup: 2///Type: MAL///HistologicalSubtype: Ser///PrimarySite: OV///FIGOStage: III///Grade: 3///PatientAge.Years.: 65///PatientStatus: R///Pltx: Y///Tax: Y///Neo: N///TimeToRelapseorLastFollow.Up.Months.: 13///TimeToDeathorLastFollow.Up.Months.: 34///ResidualDisease: <1///ArrayedSite: PE
1
title: X23139///geo_accession: GSM249962///status: Public on Mar 01 2008///submission_date: Dec 14 2007///last_update_date: Dec 19 2007///type: RNA///channel_count: 1///source_name_ch1: Carcinoma of ovary, fallopian tube or peritonem///organism_ch1: Homo sapiens///characteristics_ch1: Primary.Site : Ovary///characteristics_ch1.1: Type : Malignant///characteristics_ch1.2: Subtype : Ser/PapSer///characteristics_ch1.3: StageCode : IIIC///characteristics_ch1.4: Consolidated.Grade : 2///treatment_protocol_ch1: Frozen tissue stored at -80oC taken after surgery///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction and column chromotogrpahy///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip Drosophila Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.///scan_protocol: GeneChips were scanned using Affymetrix GS300-7G scanner///description: Gene expression data from human ovarian carcinoma///data_processing: The data were analyzed with Gene Chip Operating Software Version 1.4 using Affymetrix default analysis settings. The CEL files generated was later normalized using the RMA method///platform_id: GPL570///contact_name: Prof David,,Bowtell PhD.///contact_email: [email protected]///contact_phone: +613 96561287///contact_fax: +613 96561414///contact_department: Research Division///contact_institute: PeterMacCallum Cancer Centre///contact_address: Locked Bag 1 A' Beckett St///contact_city: Melbourne///contact_state: VIC///contact_zip.postal_code: 8006///contact_country: Australia///contact_web_link: http://www.petermac-research.org.au///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM249nnn/GSM249962/GSM249962.CEL.gz///data_row_count: 54621///ID: X23139///k.meansGroup: 2///Type: MAL///HistologicalSubtype: Ser///PrimarySite: OV///FIGOStage: III///Grade: 2///PatientAge.Years.: 62///PatientStatus: R///Pltx: Y///Tax: Y///Neo: Y///TimeToRelapseorLastFollow.Up.Months.: 9///TimeToDeathorLastFollow.Up.Months.: 31///ResidualDisease: nil///ArrayedSite: OV
1
title: X23143///geo_accession: GSM249961///status: Public on Mar 01 2008///submission_date: Dec 14 2007///last_update_date: Dec 19 2007///type: RNA///channel_count: 1///source_name_ch1: Carcinoma of ovary, fallopian tube or peritonem///organism_ch1: Homo sapiens///characteristics_ch1: Primary.Site : Ovary///characteristics_ch1.1: Type : Malignant///characteristics_ch1.2: Subtype : Ser/PapSer///characteristics_ch1.3: StageCode : IIIB///characteristics_ch1.4: Consolidated.Grade : 2///treatment_protocol_ch1: Frozen tissue stored at -80oC taken after surgery///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction and column chromotogrpahy///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip Drosophila Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.///scan_protocol: GeneChips were scanned using Affymetrix GS300-7G scanner///description: Gene expression data from human ovarian carcinoma///data_processing: The data were analyzed with Gene Chip Operating Software Version 1.4 using Affymetrix default analysis settings. The CEL files generated was later normalized using the RMA method///platform_id: GPL570///contact_name: Prof David,,Bowtell PhD.///contact_email: [email protected]///contact_phone: +613 96561287///contact_fax: +613 96561414///contact_department: Research Division///contact_institute: PeterMacCallum Cancer Centre///contact_address: Locked Bag 1 A' Beckett St///contact_city: Melbourne///contact_state: VIC///contact_zip.postal_code: 8006///contact_country: Australia///contact_web_link: http://www.petermac-research.org.au///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM249nnn/GSM249961/GSM249961.CEL.gz///data_row_count: 54621///ID: X23143///k.meansGroup: 4///Type: MAL///HistologicalSubtype: Ser///PrimarySite: OV///FIGOStage: III///Grade: 2///PatientAge.Years.: 57///PatientStatus: R///Pltx: Y///Tax: Y///Neo: N///TimeToRelapseorLastFollow.Up.Months.: 24///TimeToDeathorLastFollow.Up.Months.: 29///ResidualDisease: <1///ArrayedSite: OV
1
title: X23162///geo_accession: GSM249960///status: Public on Mar 01 2008///submission_date: Dec 14 2007///last_update_date: Dec 19 2007///type: RNA///channel_count: 1///source_name_ch1: Carcinoma of ovary, fallopian tube or peritonem///organism_ch1: Homo sapiens///characteristics_ch1: Primary.Site : Ovary///characteristics_ch1.1: Type : Malignant///characteristics_ch1.2: Subtype : Ser/PapSer///characteristics_ch1.3: StageCode : IIIC///characteristics_ch1.4: Consolidated.Grade : 3///treatment_protocol_ch1: Frozen tissue stored at -80oC taken after surgery///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction and column chromotogrpahy///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip Drosophila Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.///scan_protocol: GeneChips were scanned using Affymetrix GS300-7G scanner///description: Gene expression data from human ovarian carcinoma///data_processing: The data were analyzed with Gene Chip Operating Software Version 1.4 using Affymetrix default analysis settings. The CEL files generated was later normalized using the RMA method///platform_id: GPL570///contact_name: Prof David,,Bowtell PhD.///contact_email: [email protected]///contact_phone: +613 96561287///contact_fax: +613 96561414///contact_department: Research Division///contact_institute: PeterMacCallum Cancer Centre///contact_address: Locked Bag 1 A' Beckett St///contact_city: Melbourne///contact_state: VIC///contact_zip.postal_code: 8006///contact_country: Australia///contact_web_link: http://www.petermac-research.org.au///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM249nnn/GSM249960/GSM249960.CEL.gz///data_row_count: 54621///ID: X23162///k.meansGroup: 2///Type: MAL///HistologicalSubtype: Ser///PrimarySite: OV///FIGOStage: III///Grade: 3///PatientAge.Years.: 46///PatientStatus: PF///Pltx: Y///Tax: Y///Neo: N///TimeToRelapseorLastFollow.Up.Months.: 24///TimeToDeathorLastFollow.Up.Months.: 24///ResidualDisease: nil///ArrayedSite: OV
1
title: X23165///geo_accession: GSM249959///status: Public on Mar 01 2008///submission_date: Dec 14 2007///last_update_date: Dec 19 2007///type: RNA///channel_count: 1///source_name_ch1: Carcinoma of ovary, fallopian tube or peritonem///organism_ch1: Homo sapiens///characteristics_ch1: Primary.Site : Ovary///characteristics_ch1.1: Type : Malignant///characteristics_ch1.2: Subtype : Ser/PapSer///characteristics_ch1.3: StageCode : IIIC///characteristics_ch1.4: Consolidated.Grade : 2///treatment_protocol_ch1: Frozen tissue stored at -80oC taken after surgery///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction and column chromotogrpahy///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip Drosophila Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.///scan_protocol: GeneChips were scanned using Affymetrix GS300-7G scanner///description: Gene expression data from human ovarian carcinoma///data_processing: The data were analyzed with Gene Chip Operating Software Version 1.4 using Affymetrix default analysis settings. The CEL files generated was later normalized using the RMA method///platform_id: GPL570///contact_name: Prof David,,Bowtell PhD.///contact_email: [email protected]///contact_phone: +613 96561287///contact_fax: +613 96561414///contact_department: Research Division///contact_institute: PeterMacCallum Cancer Centre///contact_address: Locked Bag 1 A' Beckett St///contact_city: Melbourne///contact_state: VIC///contact_zip.postal_code: 8006///contact_country: Australia///contact_web_link: http://www.petermac-research.org.au///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM249nnn/GSM249959/GSM249959.CEL.gz///data_row_count: 54621///ID: X23165///k.meansGroup: 4///Type: MAL///HistologicalSubtype: Ser///PrimarySite: OV///FIGOStage: III///Grade: 2///PatientAge.Years.: 62///PatientStatus: R///Pltx: Y///Tax: Y///Neo: N///TimeToRelapseorLastFollow.Up.Months.: 17///TimeToDeathorLastFollow.Up.Months.: 24///ResidualDisease: <1///ArrayedSite: OV
1
title: X23167///geo_accession: GSM249958///status: Public on Mar 01 2008///submission_date: Dec 14 2007///last_update_date: Dec 19 2007///type: RNA///channel_count: 1///source_name_ch1: Carcinoma of ovary, fallopian tube or peritonem///organism_ch1: Homo sapiens///characteristics_ch1: Primary.Site : Ovary///characteristics_ch1.1: Type : Malignant///characteristics_ch1.2: Subtype : Ser/PapSer///characteristics_ch1.3: StageCode : IIIC///characteristics_ch1.4: Consolidated.Grade : 3///treatment_protocol_ch1: Frozen tissue stored at -80oC taken after surgery///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction and column chromotogrpahy///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip Drosophila Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.///scan_protocol: GeneChips were scanned using Affymetrix GS300-7G scanner///description: Gene expression data from human ovarian carcinoma///data_processing: The data were analyzed with Gene Chip Operating Software Version 1.4 using Affymetrix default analysis settings. The CEL files generated was later normalized using the RMA method///platform_id: GPL570///contact_name: Prof David,,Bowtell PhD.///contact_email: [email protected]///contact_phone: +613 96561287///contact_fax: +613 96561414///contact_department: Research Division///contact_institute: PeterMacCallum Cancer Centre///contact_address: Locked Bag 1 A' Beckett St///contact_city: Melbourne///contact_state: VIC///contact_zip.postal_code: 8006///contact_country: Australia///contact_web_link: http://www.petermac-research.org.au///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM249nnn/GSM249958/GSM249958.CEL.gz///data_row_count: 54621///ID: X23167///k.meansGroup: NC///Type: MAL///HistologicalSubtype: Ser///PrimarySite: OV///FIGOStage: III///Grade: 3///PatientAge.Years.: 59///PatientStatus: R///Pltx: Y///Tax: Y///Neo: N///TimeToRelapseorLastFollow.Up.Months.: 12///TimeToDeathorLastFollow.Up.Months.: 21///ResidualDisease: <1///ArrayedSite: OV
1
title: X23170///geo_accession: GSM249957///status: Public on Mar 01 2008///submission_date: Dec 14 2007///last_update_date: Dec 19 2007///type: RNA///channel_count: 1///source_name_ch1: Carcinoma of ovary, fallopian tube or peritonem///organism_ch1: Homo sapiens///characteristics_ch1: Primary.Site : Ovary///characteristics_ch1.1: Type : Malignant///characteristics_ch1.2: Subtype : Ser/PapSer///characteristics_ch1.3: StageCode : IIIC///characteristics_ch1.4: Consolidated.Grade : 3///treatment_protocol_ch1: Frozen tissue stored at -80oC taken after surgery///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction and column chromotogrpahy///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip Drosophila Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.///scan_protocol: GeneChips were scanned using Affymetrix GS300-7G scanner///description: Gene expression data from human ovarian carcinoma///data_processing: The data were analyzed with Gene Chip Operating Software Version 1.4 using Affymetrix default analysis settings. The CEL files generated was later normalized using the RMA method///platform_id: GPL570///contact_name: Prof David,,Bowtell PhD.///contact_email: [email protected]///contact_phone: +613 96561287///contact_fax: +613 96561414///contact_department: Research Division///contact_institute: PeterMacCallum Cancer Centre///contact_address: Locked Bag 1 A' Beckett St///contact_city: Melbourne///contact_state: VIC///contact_zip.postal_code: 8006///contact_country: Australia///contact_web_link: http://www.petermac-research.org.au///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM249nnn/GSM249957/GSM249957.CEL.gz///data_row_count: 54621///ID: X23170///k.meansGroup: 1///Type: MAL///HistologicalSubtype: Ser///PrimarySite: OV///FIGOStage: III///Grade: 3///PatientAge.Years.: 49///PatientStatus: PF///Pltx: Y///Tax: Y///Neo: N///TimeToRelapseorLastFollow.Up.Months.: 12///TimeToDeathorLastFollow.Up.Months.: 12///ResidualDisease: <1///ArrayedSite: OV
1
title: X23172///geo_accession: GSM249956///status: Public on Mar 01 2008///submission_date: Dec 14 2007///last_update_date: Dec 19 2007///type: RNA///channel_count: 1///source_name_ch1: Carcinoma of ovary, fallopian tube or peritonem///organism_ch1: Homo sapiens///characteristics_ch1: Primary.Site : Ovary///characteristics_ch1.1: Type : Malignant///characteristics_ch1.2: Subtype : Ser/PapSer///characteristics_ch1.3: StageCode : IIIC///characteristics_ch1.4: Consolidated.Grade : 3///treatment_protocol_ch1: Frozen tissue stored at -80oC taken after surgery///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction and column chromotogrpahy///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip Drosophila Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.///scan_protocol: GeneChips were scanned using Affymetrix GS300-7G scanner///description: Gene expression data from human ovarian carcinoma///data_processing: The data were analyzed with Gene Chip Operating Software Version 1.4 using Affymetrix default analysis settings. The CEL files generated was later normalized using the RMA method///platform_id: GPL570///contact_name: Prof David,,Bowtell PhD.///contact_email: [email protected]///contact_phone: +613 96561287///contact_fax: +613 96561414///contact_department: Research Division///contact_institute: PeterMacCallum Cancer Centre///contact_address: Locked Bag 1 A' Beckett St///contact_city: Melbourne///contact_state: VIC///contact_zip.postal_code: 8006///contact_country: Australia///contact_web_link: http://www.petermac-research.org.au///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM249nnn/GSM249956/GSM249956.CEL.gz///data_row_count: 54621///ID: X23172///k.meansGroup: 1///Type: MAL///HistologicalSubtype: Ser///PrimarySite: OV///FIGOStage: III///Grade: 3///PatientAge.Years.: 59///PatientStatus: D///Pltx: Y///Tax: Y///Neo: N///TimeToRelapseorLastFollow.Up.Months.: 8///TimeToDeathorLastFollow.Up.Months.: 16///ResidualDisease: >1///ArrayedSite: OV
1
title: X23177///geo_accession: GSM249720///status: Public on Mar 01 2008///submission_date: Dec 14 2007///last_update_date: Dec 19 2007///type: RNA///channel_count: 1///source_name_ch1: Carcinoma of ovary, fallopian tube or peritonem///organism_ch1: Homo sapiens///characteristics_ch1: Primary.Site : Ovary///characteristics_ch1.1: Type : LMP///characteristics_ch1.2: Subtype : Ser/PapSer///characteristics_ch1.3: StageCode : IC///characteristics_ch1.4: Consolidated.Grade : 2///treatment_protocol_ch1: Frozen tissue stored at -80oC taken after surgery///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction and column chromotogrpahy///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip Drosophila Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.///scan_protocol: GeneChips were scanned using Affymetrix GS300-7G scanner///description: Gene expression data from human ovarian carcinoma///data_processing: The data were analyzed with Gene Chip Operating Software Version 1.4 using Affymetrix default analysis settings. The CEL files generated was later normalized using the RMA method///platform_id: GPL570///contact_name: Prof David,,Bowtell PhD.///contact_email: [email protected]///contact_phone: +613 96561287///contact_fax: +613 96561414///contact_department: Research Division///contact_institute: PeterMacCallum Cancer Centre///contact_address: Locked Bag 1 A' Beckett St///contact_city: Melbourne///contact_state: VIC///contact_zip.postal_code: 8006///contact_country: Australia///contact_web_link: http://www.petermac-research.org.au///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM249nnn/GSM249720/GSM249720.CEL.gz///data_row_count: 54621///ID: X23177///k.meansGroup: 3///Type: LMP///HistologicalSubtype: Ser///PrimarySite: OV///FIGOStage: I///Grade: 3///PatientAge.Years.: 52///PatientStatus: PF///Pltx: N///Tax: N///Neo: N///TimeToRelapseorLastFollow.Up.Months.: 23///TimeToDeathorLastFollow.Up.Months.: 23///ResidualDisease: nil///ArrayedSite: OV
1
title: X23178///geo_accession: GSM249955///status: Public on Mar 01 2008///submission_date: Dec 14 2007///last_update_date: Dec 19 2007///type: RNA///channel_count: 1///source_name_ch1: Carcinoma of ovary, fallopian tube or peritonem///organism_ch1: Homo sapiens///characteristics_ch1: Primary.Site : Ovary///characteristics_ch1.1: Type : Malignant///characteristics_ch1.2: Subtype : Endo///characteristics_ch1.3: StageCode : IIIC///characteristics_ch1.4: Consolidated.Grade : 3///treatment_protocol_ch1: Frozen tissue stored at -80oC taken after surgery///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction and column chromotogrpahy///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip Drosophila Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.///scan_protocol: GeneChips were scanned using Affymetrix GS300-7G scanner///description: Gene expression data from human ovarian carcinoma///data_processing: The data were analyzed with Gene Chip Operating Software Version 1.4 using Affymetrix default analysis settings. The CEL files generated was later normalized using the RMA method///platform_id: GPL570///contact_name: Prof David,,Bowtell PhD.///contact_email: [email protected]///contact_phone: +613 96561287///contact_fax: +613 96561414///contact_department: Research Division///contact_institute: PeterMacCallum Cancer Centre///contact_address: Locked Bag 1 A' Beckett St///contact_city: Melbourne///contact_state: VIC///contact_zip.postal_code: 8006///contact_country: Australia///contact_web_link: http://www.petermac-research.org.au///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM249nnn/GSM249955/GSM249955.CEL.gz///data_row_count: 54621///ID: X23178///k.meansGroup: NC///Type: MAL///HistologicalSubtype: Endo///PrimarySite: OV///FIGOStage: III///Grade: 3///PatientAge.Years.: 49///PatientStatus: R///Pltx: Y///Tax: Y///Neo: N///TimeToRelapseorLastFollow.Up.Months.: 13///TimeToDeathorLastFollow.Up.Months.: 24///ResidualDisease: <1///ArrayedSite: OV
1
title: X23182///geo_accession: GSM249954///status: Public on Mar 01 2008///submission_date: Dec 14 2007///last_update_date: Dec 19 2007///type: RNA///channel_count: 1///source_name_ch1: Carcinoma of ovary, fallopian tube or peritonem///organism_ch1: Homo sapiens///characteristics_ch1: Primary.Site : Ovary///characteristics_ch1.1: Type : Malignant///characteristics_ch1.2: Subtype : Ser/PapSer///characteristics_ch1.3: StageCode : IIC///characteristics_ch1.4: Consolidated.Grade : 2///treatment_protocol_ch1: Frozen tissue stored at -80oC taken after surgery///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction and column chromotogrpahy///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip Drosophila Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.///scan_protocol: GeneChips were scanned using Affymetrix GS300-7G scanner///description: Gene expression data from human ovarian carcinoma///data_processing: The data were analyzed with Gene Chip Operating Software Version 1.4 using Affymetrix default analysis settings. The CEL files generated was later normalized using the RMA method///platform_id: GPL570///contact_name: Prof David,,Bowtell PhD.///contact_email: [email protected]///contact_phone: +613 96561287///contact_fax: +613 96561414///contact_department: Research Division///contact_institute: PeterMacCallum Cancer Centre///contact_address: Locked Bag 1 A' Beckett St///contact_city: Melbourne///contact_state: VIC///contact_zip.postal_code: 8006///contact_country: Australia///contact_web_link: http://www.petermac-research.org.au///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM249nnn/GSM249954/GSM249954.CEL.gz///data_row_count: 54621///ID: X23182///k.meansGroup: 4///Type: MAL///HistologicalSubtype: Ser///PrimarySite: OV///FIGOStage: II///Grade: 2///PatientAge.Years.: 73///PatientStatus: PF///Pltx: Y///Tax: N///Neo: N///TimeToRelapseorLastFollow.Up.Months.: 18///TimeToDeathorLastFollow.Up.Months.: 18///ResidualDisease: nil///ArrayedSite: OV
1
title: X23187///geo_accession: GSM249953///status: Public on Mar 01 2008///submission_date: Dec 14 2007///last_update_date: Dec 19 2007///type: RNA///channel_count: 1///source_name_ch1: Carcinoma of ovary, fallopian tube or peritonem///organism_ch1: Homo sapiens///characteristics_ch1: Primary.Site : Ovary///characteristics_ch1.1: Type : Malignant///characteristics_ch1.2: Subtype : Ser/PapSer///characteristics_ch1.3: StageCode : IIIC///characteristics_ch1.4: Consolidated.Grade : 3///treatment_protocol_ch1: Frozen tissue stored at -80oC taken after surgery///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction and column chromotogrpahy///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip Drosophila Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.///scan_protocol: GeneChips were scanned using Affymetrix GS300-7G scanner///description: Gene expression data from human ovarian carcinoma///data_processing: The data were analyzed with Gene Chip Operating Software Version 1.4 using Affymetrix default analysis settings. The CEL files generated was later normalized using the RMA method///platform_id: GPL570///contact_name: Prof David,,Bowtell PhD.///contact_email: [email protected]///contact_phone: +613 96561287///contact_fax: +613 96561414///contact_department: Research Division///contact_institute: PeterMacCallum Cancer Centre///contact_address: Locked Bag 1 A' Beckett St///contact_city: Melbourne///contact_state: VIC///contact_zip.postal_code: 8006///contact_country: Australia///contact_web_link: http://www.petermac-research.org.au///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM249nnn/GSM249953/GSM249953.CEL.gz///data_row_count: 54621///ID: X23187///k.meansGroup: 5///Type: MAL///HistologicalSubtype: Ser///PrimarySite: OV///FIGOStage: III///Grade: 3///PatientAge.Years.: 76///PatientStatus: PF///Pltx: Y///Tax: Y///Neo: N///TimeToRelapseorLastFollow.Up.Months.: 23///TimeToDeathorLastFollow.Up.Months.: 23///ResidualDisease: <1///ArrayedSite: OV
1
title: X23197///geo_accession: GSM249951///status: Public on Mar 01 2008///submission_date: Dec 14 2007///last_update_date: Dec 19 2007///type: RNA///channel_count: 1///source_name_ch1: Carcinoma of ovary, fallopian tube or peritonem///organism_ch1: Homo sapiens///characteristics_ch1: Primary.Site : Ovary///characteristics_ch1.1: Type : Malignant///characteristics_ch1.2: Subtype : Ser/PapSer///characteristics_ch1.3: StageCode : IIIC///characteristics_ch1.4: Consolidated.Grade : 2///treatment_protocol_ch1: Frozen tissue stored at -80oC taken after surgery///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction and column chromotogrpahy///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip Drosophila Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.///scan_protocol: GeneChips were scanned using Affymetrix GS300-7G scanner///description: Gene expression data from human ovarian carcinoma///data_processing: The data were analyzed with Gene Chip Operating Software Version 1.4 using Affymetrix default analysis settings. The CEL files generated was later normalized using the RMA method///platform_id: GPL570///contact_name: Prof David,,Bowtell PhD.///contact_email: [email protected]///contact_phone: +613 96561287///contact_fax: +613 96561414///contact_department: Research Division///contact_institute: PeterMacCallum Cancer Centre///contact_address: Locked Bag 1 A' Beckett St///contact_city: Melbourne///contact_state: VIC///contact_zip.postal_code: 8006///contact_country: Australia///contact_web_link: http://www.petermac-research.org.au///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM249nnn/GSM249951/GSM249951.CEL.gz///data_row_count: 54621///ID: X23197///k.meansGroup: 1///Type: MAL///HistologicalSubtype: Ser///PrimarySite: OV///FIGOStage: III///Grade: 2///PatientAge.Years.: 66///PatientStatus: PF///Pltx: Y///Tax: Y///Neo: Y///TimeToRelapseorLastFollow.Up.Months.: 8///TimeToDeathorLastFollow.Up.Months.: 8///ResidualDisease: >1///ArrayedSite: OV
1
title: X23202///geo_accession: GSM249950///status: Public on Mar 01 2008///submission_date: Dec 14 2007///last_update_date: Dec 19 2007///type: RNA///channel_count: 1///source_name_ch1: Carcinoma of ovary, fallopian tube or peritonem///organism_ch1: Homo sapiens///characteristics_ch1: Primary.Site : Ovary///characteristics_ch1.1: Type : Malignant///characteristics_ch1.2: Subtype : Ser/PapSer///characteristics_ch1.3: StageCode : IIIC///characteristics_ch1.4: Consolidated.Grade : 3///treatment_protocol_ch1: Frozen tissue stored at -80oC taken after surgery///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction and column chromotogrpahy///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip Drosophila Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.///scan_protocol: GeneChips were scanned using Affymetrix GS300-7G scanner///description: Gene expression data from human ovarian carcinoma///data_processing: The data were analyzed with Gene Chip Operating Software Version 1.4 using Affymetrix default analysis settings. The CEL files generated was later normalized using the RMA method///platform_id: GPL570///contact_name: Prof David,,Bowtell PhD.///contact_email: [email protected]///contact_phone: +613 96561287///contact_fax: +613 96561414///contact_department: Research Division///contact_institute: PeterMacCallum Cancer Centre///contact_address: Locked Bag 1 A' Beckett St///contact_city: Melbourne///contact_state: VIC///contact_zip.postal_code: 8006///contact_country: Australia///contact_web_link: http://www.petermac-research.org.au///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM249nnn/GSM249950/GSM249950.CEL.gz///data_row_count: 54621///ID: X23202///k.meansGroup: NC///Type: MAL///HistologicalSubtype: Ser///PrimarySite: OV///FIGOStage: III///Grade: 3///PatientAge.Years.: 58///PatientStatus: PF///Pltx: N///Tax: N///Neo: N///TimeToRelapseorLastFollow.Up.Months.: 19///TimeToDeathorLastFollow.Up.Months.: 19///ResidualDisease: <1///ArrayedSite: OV
1
title: X23204///geo_accession: GSM249949///status: Public on Mar 01 2008///submission_date: Dec 14 2007///last_update_date: Dec 19 2007///type: RNA///channel_count: 1///source_name_ch1: Carcinoma of ovary, fallopian tube or peritonem///organism_ch1: Homo sapiens///characteristics_ch1: Primary.Site : Fallopian///characteristics_ch1.1: Type : Malignant///characteristics_ch1.2: Subtype : Ser/PapSer///characteristics_ch1.3: StageCode : IA///characteristics_ch1.4: Consolidated.Grade : 3///treatment_protocol_ch1: Frozen tissue stored at -80oC taken after surgery///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction and column chromotogrpahy///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip Drosophila Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.///scan_protocol: GeneChips were scanned using Affymetrix GS300-7G scanner///description: Gene expression data from human ovarian carcinoma///data_processing: The data were analyzed with Gene Chip Operating Software Version 1.4 using Affymetrix default analysis settings. The CEL files generated was later normalized using the RMA method///platform_id: GPL570///contact_name: Prof David,,Bowtell PhD.///contact_email: [email protected]///contact_phone: +613 96561287///contact_fax: +613 96561414///contact_department: Research Division///contact_institute: PeterMacCallum Cancer Centre///contact_address: Locked Bag 1 A' Beckett St///contact_city: Melbourne///contact_state: VIC///contact_zip.postal_code: 8006///contact_country: Australia///contact_web_link: http://www.petermac-research.org.au///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM249nnn/GSM249949/GSM249949.CEL.gz///data_row_count: 54621///ID: X23204///k.meansGroup: 2///Type: MAL///HistologicalSubtype: Ser///PrimarySite: FT///FIGOStage: I///Grade: 3///PatientAge.Years.: 67///PatientStatus: PF///Pltx: Y///Tax: Y///Neo: N///TimeToRelapseorLastFollow.Up.Months.: 10///TimeToDeathorLastFollow.Up.Months.: 10///ResidualDisease: nil///ArrayedSite: OV
1
title: X23210///geo_accession: GSM249948///status: Public on Mar 01 2008///submission_date: Dec 14 2007///last_update_date: Dec 19 2007///type: RNA///channel_count: 1///source_name_ch1: Carcinoma of ovary, fallopian tube or peritonem///organism_ch1: Homo sapiens///characteristics_ch1: Primary.Site : Ovary///characteristics_ch1.1: Type : Malignant///characteristics_ch1.2: Subtype : Adeno///characteristics_ch1.3: StageCode : IIIC///characteristics_ch1.4: Consolidated.Grade : 3///treatment_protocol_ch1: Frozen tissue stored at -80oC taken after surgery///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction and column chromotogrpahy///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip Drosophila Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.///scan_protocol: GeneChips were scanned using Affymetrix GS300-7G scanner///description: Gene expression data from human ovarian carcinoma///data_processing: The data were analyzed with Gene Chip Operating Software Version 1.4 using Affymetrix default analysis settings. The CEL files generated was later normalized using the RMA method///platform_id: GPL570///contact_name: Prof David,,Bowtell PhD.///contact_email: [email protected]///contact_phone: +613 96561287///contact_fax: +613 96561414///contact_department: Research Division///contact_institute: PeterMacCallum Cancer Centre///contact_address: Locked Bag 1 A' Beckett St///contact_city: Melbourne///contact_state: VIC///contact_zip.postal_code: 8006///contact_country: Australia///contact_web_link: http://www.petermac-research.org.au///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM249nnn/GSM249948/GSM249948.CEL.gz///data_row_count: 54621///ID: X23210///k.meansGroup: 2///Type: MAL///HistologicalSubtype: Adeno///PrimarySite: OV///FIGOStage: III///Grade: 3///PatientAge.Years.: 62///PatientStatus: R///Pltx: Y///Tax: Y///Neo: N///TimeToRelapseorLastFollow.Up.Months.: 18///TimeToDeathorLastFollow.Up.Months.: 20///ResidualDisease: <1///ArrayedSite: OV
1
title: X23212///geo_accession: GSM249947///status: Public on Mar 01 2008///submission_date: Dec 14 2007///last_update_date: Dec 19 2007///type: RNA///channel_count: 1///source_name_ch1: Carcinoma of ovary, fallopian tube or peritonem///organism_ch1: Homo sapiens///characteristics_ch1: Primary.Site : Peritoneum///characteristics_ch1.1: Type : Malignant///characteristics_ch1.2: Subtype : Ser/PapSer///characteristics_ch1.3: StageCode : IIIC///characteristics_ch1.4: Consolidated.Grade : 2///treatment_protocol_ch1: Frozen tissue stored at -80oC taken after surgery///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction and column chromotogrpahy///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip Drosophila Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.///scan_protocol: GeneChips were scanned using Affymetrix GS300-7G scanner///description: Gene expression data from human ovarian carcinoma///data_processing: The data were analyzed with Gene Chip Operating Software Version 1.4 using Affymetrix default analysis settings. The CEL files generated was later normalized using the RMA method///platform_id: GPL570///contact_name: Prof David,,Bowtell PhD.///contact_email: [email protected]///contact_phone: +613 96561287///contact_fax: +613 96561414///contact_department: Research Division///contact_institute: PeterMacCallum Cancer Centre///contact_address: Locked Bag 1 A' Beckett St///contact_city: Melbourne///contact_state: VIC///contact_zip.postal_code: 8006///contact_country: Australia///contact_web_link: http://www.petermac-research.org.au///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM249nnn/GSM249947/GSM249947.CEL.gz///data_row_count: 54621///ID: X23212///k.meansGroup: 1///Type: MAL///HistologicalSubtype: Ser///PrimarySite: PE///FIGOStage: III///Grade: 2///PatientAge.Years.: 75///PatientStatus: PF///Pltx: N///Tax: N///Neo: N///TimeToRelapseorLastFollow.Up.Months.: 3///TimeToDeathorLastFollow.Up.Months.: 3///ResidualDisease: <1///ArrayedSite: PE
1
title: X23213///geo_accession: GSM249946///status: Public on Mar 01 2008///submission_date: Dec 14 2007///last_update_date: Dec 19 2007///type: RNA///channel_count: 1///source_name_ch1: Carcinoma of ovary, fallopian tube or peritonem///organism_ch1: Homo sapiens///characteristics_ch1: Primary.Site : Ovary///characteristics_ch1.1: Type : Malignant///characteristics_ch1.2: Subtype : Ser/PapSer///characteristics_ch1.3: StageCode : IIIC///characteristics_ch1.4: Consolidated.Grade : 1///treatment_protocol_ch1: Frozen tissue stored at -80oC taken after surgery///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction and column chromotogrpahy///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip Drosophila Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.///scan_protocol: GeneChips were scanned using Affymetrix GS300-7G scanner///description: Gene expression data from human ovarian carcinoma///data_processing: The data were analyzed with Gene Chip Operating Software Version 1.4 using Affymetrix default analysis settings. The CEL files generated was later normalized using the RMA method///platform_id: GPL570///contact_name: Prof David,,Bowtell PhD.///contact_email: [email protected]///contact_phone: +613 96561287///contact_fax: +613 96561414///contact_department: Research Division///contact_institute: PeterMacCallum Cancer Centre///contact_address: Locked Bag 1 A' Beckett St///contact_city: Melbourne///contact_state: VIC///contact_zip.postal_code: 8006///contact_country: Australia///contact_web_link: http://www.petermac-research.org.au///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM249nnn/GSM249946/GSM249946.CEL.gz///data_row_count: 54621///ID: X23213///k.meansGroup: 1///Type: MAL///HistologicalSubtype: Ser///PrimarySite: OV///FIGOStage: III///Grade: 1///PatientAge.Years.: 58///PatientStatus: D///Pltx: Y///Tax: Y///Neo: Y///TimeToRelapseorLastFollow.Up.Months.: 2///TimeToDeathorLastFollow.Up.Months.: 11///ResidualDisease: >1///ArrayedSite: PE
1
title: X23221///geo_accession: GSM249945///status: Public on Mar 01 2008///submission_date: Dec 14 2007///last_update_date: Dec 19 2007///type: RNA///channel_count: 1///source_name_ch1: Carcinoma of ovary, fallopian tube or peritonem///organism_ch1: Homo sapiens///characteristics_ch1: Primary.Site : Peritoneum///characteristics_ch1.1: Type : Malignant///characteristics_ch1.2: Subtype : Ser/PapSer///characteristics_ch1.3: StageCode : IIIC///characteristics_ch1.4: Consolidated.Grade : 3///treatment_protocol_ch1: Frozen tissue stored at -80oC taken after surgery///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction and column chromotogrpahy///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip Drosophila Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.///scan_protocol: GeneChips were scanned using Affymetrix GS300-7G scanner///description: Gene expression data from human ovarian carcinoma///data_processing: The data were analyzed with Gene Chip Operating Software Version 1.4 using Affymetrix default analysis settings. The CEL files generated was later normalized using the RMA method///platform_id: GPL570///contact_name: Prof David,,Bowtell PhD.///contact_email: [email protected]///contact_phone: +613 96561287///contact_fax: +613 96561414///contact_department: Research Division///contact_institute: PeterMacCallum Cancer Centre///contact_address: Locked Bag 1 A' Beckett St///contact_city: Melbourne///contact_state: VIC///contact_zip.postal_code: 8006///contact_country: Australia///contact_web_link: http://www.petermac-research.org.au///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM249nnn/GSM249945/GSM249945.CEL.gz///data_row_count: 54621///ID: X23221///k.meansGroup: 1///Type: MAL///HistologicalSubtype: Ser///PrimarySite: PE///FIGOStage: III///Grade: 3///PatientAge.Years.: 67///PatientStatus: R///Pltx: Y///Tax: Y///Neo: Y///TimeToRelapseorLastFollow.Up.Months.: 4///TimeToDeathorLastFollow.Up.Months.: 18///ResidualDisease: <1///ArrayedSite: PE
1
title: X26047///geo_accession: GSM249944///status: Public on Mar 01 2008///submission_date: Dec 14 2007///last_update_date: Dec 19 2007///type: RNA///channel_count: 1///source_name_ch1: Carcinoma of ovary, fallopian tube or peritonem///organism_ch1: Homo sapiens///characteristics_ch1: Primary.Site : Peritoneum///characteristics_ch1.1: Type : Malignant///characteristics_ch1.2: Subtype : Ser/PapSer///characteristics_ch1.3: StageCode : IIIC///characteristics_ch1.4: Consolidated.Grade : 2///treatment_protocol_ch1: Frozen tissue stored at -80oC taken after surgery///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction and column chromotogrpahy///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip Drosophila Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.///scan_protocol: GeneChips were scanned using Affymetrix GS300-7G scanner///description: Gene expression data from human ovarian carcinoma///data_processing: The data were analyzed with Gene Chip Operating Software Version 1.4 using Affymetrix default analysis settings. The CEL files generated was later normalized using the RMA method///platform_id: GPL570///contact_name: Prof David,,Bowtell PhD.///contact_email: [email protected]///contact_phone: +613 96561287///contact_fax: +613 96561414///contact_department: Research Division///contact_institute: PeterMacCallum Cancer Centre///contact_address: Locked Bag 1 A' Beckett St///contact_city: Melbourne///contact_state: VIC///contact_zip.postal_code: 8006///contact_country: Australia///contact_web_link: http://www.petermac-research.org.au///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM249nnn/GSM249944/GSM249944.CEL.gz///data_row_count: 54621///ID: X26047///k.meansGroup: NC///Type: MAL///HistologicalSubtype: Ser///PrimarySite: PE///FIGOStage: III///Grade: 2///PatientAge.Years.: 72///PatientStatus: R///Pltx: N///Tax: Y///Neo: Y///TimeToRelapseorLastFollow.Up.Months.: 6///TimeToDeathorLastFollow.Up.Months.: 31///ResidualDisease: >1///ArrayedSite: PE
1
title: X261///geo_accession: GSM249943///status: Public on Mar 01 2008///submission_date: Dec 14 2007///last_update_date: Dec 19 2007///type: RNA///channel_count: 1///source_name_ch1: Carcinoma of ovary, fallopian tube or peritonem///organism_ch1: Homo sapiens///characteristics_ch1: Primary.Site : Ovary///characteristics_ch1.1: Type : Malignant///characteristics_ch1.2: Subtype : Ser/PapSer///characteristics_ch1.3: StageCode : IV///characteristics_ch1.4: Consolidated.Grade : 2///treatment_protocol_ch1: Frozen tissue stored at -80oC taken after surgery///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction and column chromotogrpahy///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip Drosophila Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.///scan_protocol: GeneChips were scanned using Affymetrix GS300-7G scanner///description: Gene expression data from human ovarian carcinoma///data_processing: The data were analyzed with Gene Chip Operating Software Version 1.4 using Affymetrix default analysis settings. The CEL files generated was later normalized using the RMA method///platform_id: GPL570///contact_name: Prof David,,Bowtell PhD.///contact_email: [email protected]///contact_phone: +613 96561287///contact_fax: +613 96561414///contact_department: Research Division///contact_institute: PeterMacCallum Cancer Centre///contact_address: Locked Bag 1 A' Beckett St///contact_city: Melbourne///contact_state: VIC///contact_zip.postal_code: 8006///contact_country: Australia///contact_web_link: http://www.petermac-research.org.au///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM249nnn/GSM249943/GSM249943.CEL.gz///data_row_count: 54621///ID: X261///k.meansGroup: NC///Type: MAL///HistologicalSubtype: Ser///PrimarySite: OV///FIGOStage: IV///Grade: 2///PatientAge.Years.: 55///PatientStatus: D///Pltx: Y///Tax: N///Neo: N///TimeToRelapseorLastFollow.Up.Months.: 6///TimeToDeathorLastFollow.Up.Months.: 13///ResidualDisease: >1///ArrayedSite: OV
1
title: X27006///geo_accession: GSM249942///status: Public on Mar 01 2008///submission_date: Dec 14 2007///last_update_date: Dec 19 2007///type: RNA///channel_count: 1///source_name_ch1: Carcinoma of ovary, fallopian tube or peritonem///organism_ch1: Homo sapiens///characteristics_ch1: Primary.Site : Ovary///characteristics_ch1.1: Type : Malignant///characteristics_ch1.2: Subtype : Ser/PapSer///characteristics_ch1.3: StageCode : IIIC///characteristics_ch1.4: Consolidated.Grade : 2///treatment_protocol_ch1: Frozen tissue stored at -80oC taken after surgery///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction and column chromotogrpahy///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip Drosophila Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.///scan_protocol: GeneChips were scanned using Affymetrix GS300-7G scanner///description: Gene expression data from human ovarian carcinoma///data_processing: The data were analyzed with Gene Chip Operating Software Version 1.4 using Affymetrix default analysis settings. The CEL files generated was later normalized using the RMA method///platform_id: GPL570///contact_name: Prof David,,Bowtell PhD.///contact_email: [email protected]///contact_phone: +613 96561287///contact_fax: +613 96561414///contact_department: Research Division///contact_institute: PeterMacCallum Cancer Centre///contact_address: Locked Bag 1 A' Beckett St///contact_city: Melbourne///contact_state: VIC///contact_zip.postal_code: 8006///contact_country: Australia///contact_web_link: http://www.petermac-research.org.au///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM249nnn/GSM249942/GSM249942.CEL.gz///data_row_count: 54621///ID: X27006///k.meansGroup: 5///Type: MAL///HistologicalSubtype: Ser///PrimarySite: OV///FIGOStage: III///Grade: 2///PatientAge.Years.: 73///PatientStatus: D///Pltx: Y///Tax: Y///Neo: N///TimeToRelapseorLastFollow.Up.Months.: 11///TimeToDeathorLastFollow.Up.Months.: 23///ResidualDisease: <1///ArrayedSite: OV
1
title: X27098///geo_accession: GSM249941///status: Public on Mar 01 2008///submission_date: Dec 14 2007///last_update_date: Dec 19 2007///type: RNA///channel_count: 1///source_name_ch1: Carcinoma of ovary, fallopian tube or peritonem///organism_ch1: Homo sapiens///characteristics_ch1: Primary.Site : Ovary///characteristics_ch1.1: Type : Malignant///characteristics_ch1.2: Subtype : Ser/PapSer///characteristics_ch1.3: StageCode : IIIC///characteristics_ch1.4: Consolidated.Grade : 2///treatment_protocol_ch1: Frozen tissue stored at -80oC taken after surgery///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction and column chromotogrpahy///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip Drosophila Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.///scan_protocol: GeneChips were scanned using Affymetrix GS300-7G scanner///description: Gene expression data from human ovarian carcinoma///data_processing: The data were analyzed with Gene Chip Operating Software Version 1.4 using Affymetrix default analysis settings. The CEL files generated was later normalized using the RMA method///platform_id: GPL570///contact_name: Prof David,,Bowtell PhD.///contact_email: [email protected]///contact_phone: +613 96561287///contact_fax: +613 96561414///contact_department: Research Division///contact_institute: PeterMacCallum Cancer Centre///contact_address: Locked Bag 1 A' Beckett St///contact_city: Melbourne///contact_state: VIC///contact_zip.postal_code: 8006///contact_country: Australia///contact_web_link: http://www.petermac-research.org.au///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM249nnn/GSM249941/GSM249941.CEL.gz///data_row_count: 54621///ID: X27098///k.meansGroup: 5///Type: MAL///HistologicalSubtype: Ser///PrimarySite: OV///FIGOStage: III///Grade: 2///PatientAge.Years.: 61///PatientStatus: R///Pltx: N///Tax: N///Neo: N///TimeToRelapseorLastFollow.Up.Months.: 23///TimeToDeathorLastFollow.Up.Months.: 23///ResidualDisease: nil///ArrayedSite: OV
1
title: X32013///geo_accession: GSM249940///status: Public on Mar 01 2008///submission_date: Dec 14 2007///last_update_date: Dec 19 2007///type: RNA///channel_count: 1///source_name_ch1: Carcinoma of ovary, fallopian tube or peritonem///organism_ch1: Homo sapiens///characteristics_ch1: Primary.Site : Ovary///characteristics_ch1.1: Type : Malignant///characteristics_ch1.2: Subtype : Ser/PapSer///characteristics_ch1.3: StageCode : IIIC///characteristics_ch1.4: Consolidated.Grade : 2///treatment_protocol_ch1: Frozen tissue stored at -80oC taken after surgery///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction and column chromotogrpahy///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip Drosophila Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.///scan_protocol: GeneChips were scanned using Affymetrix GS300-7G scanner///description: Gene expression data from human ovarian carcinoma///data_processing: The data were analyzed with Gene Chip Operating Software Version 1.4 using Affymetrix default analysis settings. The CEL files generated was later normalized using the RMA method///platform_id: GPL570///contact_name: Prof David,,Bowtell PhD.///contact_email: [email protected]///contact_phone: +613 96561287///contact_fax: +613 96561414///contact_department: Research Division///contact_institute: PeterMacCallum Cancer Centre///contact_address: Locked Bag 1 A' Beckett St///contact_city: Melbourne///contact_state: VIC///contact_zip.postal_code: 8006///contact_country: Australia///contact_web_link: http://www.petermac-research.org.au///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM249nnn/GSM249940/GSM249940.CEL.gz///data_row_count: 54621///ID: X32013///k.meansGroup: 5///Type: MAL///HistologicalSubtype: Ser///PrimarySite: OV///FIGOStage: III///Grade: 2///PatientAge.Years.: 68///PatientStatus: D///Pltx: Y///Tax: N///Neo: N///TimeToRelapseorLastFollow.Up.Months.: 2///TimeToDeathorLastFollow.Up.Months.: 2///ResidualDisease: NK///ArrayedSite: OV
1
title: X32022///geo_accession: GSM249939///status: Public on Mar 01 2008///submission_date: Dec 14 2007///last_update_date: Dec 19 2007///type: RNA///channel_count: 1///source_name_ch1: Carcinoma of ovary, fallopian tube or peritonem///organism_ch1: Homo sapiens///characteristics_ch1: Primary.Site : Ovary///characteristics_ch1.1: Type : Malignant///characteristics_ch1.2: Subtype : Ser/PapSer///characteristics_ch1.3: StageCode : IIIC///characteristics_ch1.4: Consolidated.Grade : 3///treatment_protocol_ch1: Frozen tissue stored at -80oC taken after surgery///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction and column chromotogrpahy///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip Drosophila Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.///scan_protocol: GeneChips were scanned using Affymetrix GS300-7G scanner///description: Gene expression data from human ovarian carcinoma///data_processing: The data were analyzed with Gene Chip Operating Software Version 1.4 using Affymetrix default analysis settings. The CEL files generated was later normalized using the RMA method///platform_id: GPL570///contact_name: Prof David,,Bowtell PhD.///contact_email: [email protected]///contact_phone: +613 96561287///contact_fax: +613 96561414///contact_department: Research Division///contact_institute: PeterMacCallum Cancer Centre///contact_address: Locked Bag 1 A' Beckett St///contact_city: Melbourne///contact_state: VIC///contact_zip.postal_code: 8006///contact_country: Australia///contact_web_link: http://www.petermac-research.org.au///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM249nnn/GSM249939/GSM249939.CEL.gz///data_row_count: 54621///ID: X32022///k.meansGroup: 4///Type: MAL///HistologicalSubtype: Ser///PrimarySite: OV///FIGOStage: III///Grade: 3///PatientAge.Years.: 68///PatientStatus: R///Pltx: Y///Tax: Y///Neo: N///TimeToRelapseorLastFollow.Up.Months.: 32///TimeToDeathorLastFollow.Up.Months.: 37///ResidualDisease: >1///ArrayedSite: OV
1
title: X32032///geo_accession: GSM249938///status: Public on Mar 01 2008///submission_date: Dec 14 2007///last_update_date: Dec 19 2007///type: RNA///channel_count: 1///source_name_ch1: Carcinoma of ovary, fallopian tube or peritonem///organism_ch1: Homo sapiens///characteristics_ch1: Primary.Site : Fallopian///characteristics_ch1.1: Type : Malignant///characteristics_ch1.2: Subtype : Ser/PapSer///characteristics_ch1.3: StageCode : IIC///characteristics_ch1.4: Consolidated.Grade : 3///treatment_protocol_ch1: Frozen tissue stored at -80oC taken after surgery///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction and column chromotogrpahy///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip Drosophila Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.///scan_protocol: GeneChips were scanned using Affymetrix GS300-7G scanner///description: Gene expression data from human ovarian carcinoma///data_processing: The data were analyzed with Gene Chip Operating Software Version 1.4 using Affymetrix default analysis settings. The CEL files generated was later normalized using the RMA method///platform_id: GPL570///contact_name: Prof David,,Bowtell PhD.///contact_email: [email protected]///contact_phone: +613 96561287///contact_fax: +613 96561414///contact_department: Research Division///contact_institute: PeterMacCallum Cancer Centre///contact_address: Locked Bag 1 A' Beckett St///contact_city: Melbourne///contact_state: VIC///contact_zip.postal_code: 8006///contact_country: Australia///contact_web_link: http://www.petermac-research.org.au///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM249nnn/GSM249938/GSM249938.CEL.gz///data_row_count: 54621///ID: X32032///k.meansGroup: 2///Type: MAL///HistologicalSubtype: Ser///PrimarySite: FT///FIGOStage: II///Grade: 3///PatientAge.Years.: 60///PatientStatus: PF///Pltx: Y///Tax: Y///Neo: N///TimeToRelapseorLastFollow.Up.Months.: 35///TimeToDeathorLastFollow.Up.Months.: 35///ResidualDisease: nil///ArrayedSite: FT
1
title: X32034///geo_accession: GSM249937///status: Public on Mar 01 2008///submission_date: Dec 14 2007///last_update_date: Dec 19 2007///type: RNA///channel_count: 1///source_name_ch1: Carcinoma of ovary, fallopian tube or peritonem///organism_ch1: Homo sapiens///characteristics_ch1: Primary.Site : Peritoneum///characteristics_ch1.1: Type : Malignant///characteristics_ch1.2: Subtype : Ser/PapSer///characteristics_ch1.3: StageCode : IIIC///characteristics_ch1.4: Consolidated.Grade : 3///treatment_protocol_ch1: Frozen tissue stored at -80oC taken after surgery///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction and column chromotogrpahy///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip Drosophila Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.///scan_protocol: GeneChips were scanned using Affymetrix GS300-7G scanner///description: Gene expression data from human ovarian carcinoma///data_processing: The data were analyzed with Gene Chip Operating Software Version 1.4 using Affymetrix default analysis settings. The CEL files generated was later normalized using the RMA method///platform_id: GPL570///contact_name: Prof David,,Bowtell PhD.///contact_email: [email protected]///contact_phone: +613 96561287///contact_fax: +613 96561414///contact_department: Research Division///contact_institute: PeterMacCallum Cancer Centre///contact_address: Locked Bag 1 A' Beckett St///contact_city: Melbourne///contact_state: VIC///contact_zip.postal_code: 8006///contact_country: Australia///contact_web_link: http://www.petermac-research.org.au///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM249nnn/GSM249937/GSM249937.CEL.gz///data_row_count: 54621///ID: X32034///k.meansGroup: 5///Type: MAL///HistologicalSubtype: Ser///PrimarySite: PE///FIGOStage: III///Grade: 3///PatientAge.Years.: 58///PatientStatus: PF///Pltx: Y///Tax: Y///Neo: N///TimeToRelapseorLastFollow.Up.Months.: 11///TimeToDeathorLastFollow.Up.Months.: 11///ResidualDisease: >1///ArrayedSite: OV
1
title: X32048///geo_accession: GSM249936///status: Public on Mar 01 2008///submission_date: Dec 14 2007///last_update_date: Dec 19 2007///type: RNA///channel_count: 1///source_name_ch1: Carcinoma of ovary, fallopian tube or peritonem///organism_ch1: Homo sapiens///characteristics_ch1: Primary.Site : Ovary///characteristics_ch1.1: Type : Malignant///characteristics_ch1.2: Subtype : Ser/PapSer///characteristics_ch1.3: StageCode : IIIA///characteristics_ch1.4: Consolidated.Grade : 3///treatment_protocol_ch1: Frozen tissue stored at -80oC taken after surgery///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction and column chromotogrpahy///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip Drosophila Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.///scan_protocol: GeneChips were scanned using Affymetrix GS300-7G scanner///description: Gene expression data from human ovarian carcinoma///data_processing: The data were analyzed with Gene Chip Operating Software Version 1.4 using Affymetrix default analysis settings. The CEL files generated was later normalized using the RMA method///platform_id: GPL570///contact_name: Prof David,,Bowtell PhD.///contact_email: [email protected]///contact_phone: +613 96561287///contact_fax: +613 96561414///contact_department: Research Division///contact_institute: PeterMacCallum Cancer Centre///contact_address: Locked Bag 1 A' Beckett St///contact_city: Melbourne///contact_state: VIC///contact_zip.postal_code: 8006///contact_country: Australia///contact_web_link: http://www.petermac-research.org.au///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM249nnn/GSM249936/GSM249936.CEL.gz///data_row_count: 54621///ID: X32048///k.meansGroup: 4///Type: MAL///HistologicalSubtype: Ser///PrimarySite: OV///FIGOStage: III///Grade: 3///PatientAge.Years.: 69///PatientStatus: PF///Pltx: Y///Tax: Y///Neo: N///TimeToRelapseorLastFollow.Up.Months.: 41///TimeToDeathorLastFollow.Up.Months.: 41///ResidualDisease: nil///ArrayedSite: OV
1
title: X32049///geo_accession: GSM249935///status: Public on Mar 01 2008///submission_date: Dec 14 2007///last_update_date: Dec 19 2007///type: RNA///channel_count: 1///source_name_ch1: Carcinoma of ovary, fallopian tube or peritonem///organism_ch1: Homo sapiens///characteristics_ch1: Primary.Site : Fallopian///characteristics_ch1.1: Type : Malignant///characteristics_ch1.2: Subtype : Ser/PapSer///characteristics_ch1.3: StageCode : IIIC///characteristics_ch1.4: Consolidated.Grade : 3///treatment_protocol_ch1: Frozen tissue stored at -80oC taken after surgery///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction and column chromotogrpahy///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip Drosophila Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.///scan_protocol: GeneChips were scanned using Affymetrix GS300-7G scanner///description: Gene expression data from human ovarian carcinoma///data_processing: The data were analyzed with Gene Chip Operating Software Version 1.4 using Affymetrix default analysis settings. The CEL files generated was later normalized using the RMA method///platform_id: GPL570///contact_name: Prof David,,Bowtell PhD.///contact_email: [email protected]///contact_phone: +613 96561287///contact_fax: +613 96561414///contact_department: Research Division///contact_institute: PeterMacCallum Cancer Centre///contact_address: Locked Bag 1 A' Beckett St///contact_city: Melbourne///contact_state: VIC///contact_zip.postal_code: 8006///contact_country: Australia///contact_web_link: http://www.petermac-research.org.au///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM249nnn/GSM249935/GSM249935.CEL.gz///data_row_count: 54621///ID: X32049///k.meansGroup: 1///Type: MAL///HistologicalSubtype: Ser///PrimarySite: FT///FIGOStage: III///Grade: 3///PatientAge.Years.: 57///PatientStatus: R///Pltx: Y///Tax: N///Neo: N///TimeToRelapseorLastFollow.Up.Months.: 11///TimeToDeathorLastFollow.Up.Months.: 29///ResidualDisease: >1///ArrayedSite: PE
1
title: X32054///geo_accession: GSM249934///status: Public on Mar 01 2008///submission_date: Dec 14 2007///last_update_date: Dec 19 2007///type: RNA///channel_count: 1///source_name_ch1: Carcinoma of ovary, fallopian tube or peritonem///organism_ch1: Homo sapiens///characteristics_ch1: Primary.Site : Ovary///characteristics_ch1.1: Type : Malignant///characteristics_ch1.2: Subtype : Ser/PapSer///characteristics_ch1.3: StageCode : IIIC///characteristics_ch1.4: Consolidated.Grade : 2///treatment_protocol_ch1: Frozen tissue stored at -80oC taken after surgery///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction and column chromotogrpahy///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip Drosophila Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.///scan_protocol: GeneChips were scanned using Affymetrix GS300-7G scanner///description: Gene expression data from human ovarian carcinoma///data_processing: The data were analyzed with Gene Chip Operating Software Version 1.4 using Affymetrix default analysis settings. The CEL files generated was later normalized using the RMA method///platform_id: GPL570///contact_name: Prof David,,Bowtell PhD.///contact_email: [email protected]///contact_phone: +613 96561287///contact_fax: +613 96561414///contact_department: Research Division///contact_institute: PeterMacCallum Cancer Centre///contact_address: Locked Bag 1 A' Beckett St///contact_city: Melbourne///contact_state: VIC///contact_zip.postal_code: 8006///contact_country: Australia///contact_web_link: http://www.petermac-research.org.au///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM249nnn/GSM249934/GSM249934.CEL.gz///data_row_count: 54621///ID: X32054///k.meansGroup: 3///Type: MAL///HistologicalSubtype: Ser///PrimarySite: OV///FIGOStage: III///Grade: 2///PatientAge.Years.: 45///PatientStatus: R///Pltx: Y///Tax: Y///Neo: N///TimeToRelapseorLastFollow.Up.Months.: 11///TimeToDeathorLastFollow.Up.Months.: 36///ResidualDisease: >1///ArrayedSite: OV
1
title: X32055///geo_accession: GSM249933///status: Public on Mar 01 2008///submission_date: Dec 14 2007///last_update_date: Dec 19 2007///type: RNA///channel_count: 1///source_name_ch1: Carcinoma of ovary, fallopian tube or peritonem///organism_ch1: Homo sapiens///characteristics_ch1: Primary.Site : Ovary///characteristics_ch1.1: Type : Malignant///characteristics_ch1.2: Subtype : Ser/PapSer///characteristics_ch1.3: StageCode : IV///characteristics_ch1.4: Consolidated.Grade : 2///treatment_protocol_ch1: Frozen tissue stored at -80oC taken after surgery///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction and column chromotogrpahy///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip Drosophila Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.///scan_protocol: GeneChips were scanned using Affymetrix GS300-7G scanner///description: Gene expression data from human ovarian carcinoma///data_processing: The data were analyzed with Gene Chip Operating Software Version 1.4 using Affymetrix default analysis settings. The CEL files generated was later normalized using the RMA method///platform_id: GPL570///contact_name: Prof David,,Bowtell PhD.///contact_email: [email protected]///contact_phone: +613 96561287///contact_fax: +613 96561414///contact_department: Research Division///contact_institute: PeterMacCallum Cancer Centre///contact_address: Locked Bag 1 A' Beckett St///contact_city: Melbourne///contact_state: VIC///contact_zip.postal_code: 8006///contact_country: Australia///contact_web_link: http://www.petermac-research.org.au///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM249nnn/GSM249933/GSM249933.CEL.gz///data_row_count: 54621///ID: X32055///k.meansGroup: 2///Type: MAL///HistologicalSubtype: Ser///PrimarySite: OV///FIGOStage: IV///Grade: 2///PatientAge.Years.: 59///PatientStatus: D///Pltx: Y///Tax: Y///Neo: Y///TimeToRelapseorLastFollow.Up.Months.: 8///TimeToDeathorLastFollow.Up.Months.: 16///ResidualDisease: NK///ArrayedSite: OV
1
title: X32089///geo_accession: GSM249932///status: Public on Mar 01 2008///submission_date: Dec 14 2007///last_update_date: Dec 19 2007///type: RNA///channel_count: 1///source_name_ch1: Carcinoma of ovary, fallopian tube or peritonem///organism_ch1: Homo sapiens///characteristics_ch1: Primary.Site : Ovary///characteristics_ch1.1: Type : Malignant///characteristics_ch1.2: Subtype : Ser/PapSer///characteristics_ch1.3: StageCode : IIIC///characteristics_ch1.4: Consolidated.Grade : 3///treatment_protocol_ch1: Frozen tissue stored at -80oC taken after surgery///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction and column chromotogrpahy///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip Drosophila Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.///scan_protocol: GeneChips were scanned using Affymetrix GS300-7G scanner///description: Gene expression data from human ovarian carcinoma///data_processing: The data were analyzed with Gene Chip Operating Software Version 1.4 using Affymetrix default analysis settings. The CEL files generated was later normalized using the RMA method///platform_id: GPL570///contact_name: Prof David,,Bowtell PhD.///contact_email: [email protected]///contact_phone: +613 96561287///contact_fax: +613 96561414///contact_department: Research Division///contact_institute: PeterMacCallum Cancer Centre///contact_address: Locked Bag 1 A' Beckett St///contact_city: Melbourne///contact_state: VIC///contact_zip.postal_code: 8006///contact_country: Australia///contact_web_link: http://www.petermac-research.org.au///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM249nnn/GSM249932/GSM249932.CEL.gz///data_row_count: 54621///ID: X32089///k.meansGroup: 3///Type: MAL///HistologicalSubtype: Ser///PrimarySite: OV///FIGOStage: III///Grade: 3///PatientAge.Years.: 49///PatientStatus: R///Pltx: N///Tax: N///Neo: N///TimeToRelapseorLastFollow.Up.Months.: 21///TimeToDeathorLastFollow.Up.Months.: 22///ResidualDisease: macrosizeNK///ArrayedSite: OV
1
title: X32098///geo_accession: GSM249931///status: Public on Mar 01 2008///submission_date: Dec 14 2007///last_update_date: Dec 19 2007///type: RNA///channel_count: 1///source_name_ch1: Carcinoma of ovary, fallopian tube or peritonem///organism_ch1: Homo sapiens///characteristics_ch1: Primary.Site : Peritoneum///characteristics_ch1.1: Type : Malignant///characteristics_ch1.2: Subtype : Ser/PapSer///characteristics_ch1.3: StageCode : IIIC///characteristics_ch1.4: Consolidated.Grade : 2///treatment_protocol_ch1: Frozen tissue stored at -80oC taken after surgery///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction and column chromotogrpahy///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip Drosophila Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.///scan_protocol: GeneChips were scanned using Affymetrix GS300-7G scanner///description: Gene expression data from human ovarian carcinoma///data_processing: The data were analyzed with Gene Chip Operating Software Version 1.4 using Affymetrix default analysis settings. The CEL files generated was later normalized using the RMA method///platform_id: GPL570///contact_name: Prof David,,Bowtell PhD.///contact_email: [email protected]///contact_phone: +613 96561287///contact_fax: +613 96561414///contact_department: Research Division///contact_institute: PeterMacCallum Cancer Centre///contact_address: Locked Bag 1 A' Beckett St///contact_city: Melbourne///contact_state: VIC///contact_zip.postal_code: 8006///contact_country: Australia///contact_web_link: http://www.petermac-research.org.au///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM249nnn/GSM249931/GSM249931.CEL.gz///data_row_count: 54621///ID: X32098///k.meansGroup: 1///Type: MAL///HistologicalSubtype: Ser///PrimarySite: PE///FIGOStage: III///Grade: 2///PatientAge.Years.: 77///PatientStatus: D///Pltx: N///Tax: N///Neo: N///TimeToRelapseorLastFollow.Up.Months.: 1///TimeToDeathorLastFollow.Up.Months.: 1///ResidualDisease: >1///ArrayedSite: PE
1
title: X32103///geo_accession: GSM249930///status: Public on Mar 01 2008///submission_date: Dec 14 2007///last_update_date: Dec 19 2007///type: RNA///channel_count: 1///source_name_ch1: Carcinoma of ovary, fallopian tube or peritonem///organism_ch1: Homo sapiens///characteristics_ch1: Primary.Site : Ovary///characteristics_ch1.1: Type : Malignant///characteristics_ch1.2: Subtype : Ser/PapSer///characteristics_ch1.3: StageCode : IIIA///characteristics_ch1.4: Consolidated.Grade : 3///treatment_protocol_ch1: Frozen tissue stored at -80oC taken after surgery///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction and column chromotogrpahy///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip Drosophila Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.///scan_protocol: GeneChips were scanned using Affymetrix GS300-7G scanner///description: Gene expression data from human ovarian carcinoma///data_processing: The data were analyzed with Gene Chip Operating Software Version 1.4 using Affymetrix default analysis settings. The CEL files generated was later normalized using the RMA method///platform_id: GPL570///contact_name: Prof David,,Bowtell PhD.///contact_email: [email protected]///contact_phone: +613 96561287///contact_fax: +613 96561414///contact_department: Research Division///contact_institute: PeterMacCallum Cancer Centre///contact_address: Locked Bag 1 A' Beckett St///contact_city: Melbourne///contact_state: VIC///contact_zip.postal_code: 8006///contact_country: Australia///contact_web_link: http://www.petermac-research.org.au///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM249nnn/GSM249930/GSM249930.CEL.gz///data_row_count: 54621///ID: X32103///k.meansGroup: 4///Type: MAL///HistologicalSubtype: Ser///PrimarySite: OV///FIGOStage: III///Grade: 3///PatientAge.Years.: 75///PatientStatus: R///Pltx: Y///Tax: Y///Neo: N///TimeToRelapseorLastFollow.Up.Months.: 19///TimeToDeathorLastFollow.Up.Months.: 24///ResidualDisease: nil///ArrayedSite: OV
1
title: X32117///geo_accession: GSM249715///status: Public on Mar 01 2008///submission_date: Dec 14 2007///last_update_date: Dec 19 2007///type: RNA///channel_count: 1///source_name_ch1: Carcinoma of ovary, fallopian tube or peritonem///organism_ch1: Homo sapiens///characteristics_ch1: Primary.Site : Ovary///characteristics_ch1.1: Type : LMP///characteristics_ch1.2: Subtype : Ser/PapSer///characteristics_ch1.3: StageCode : IIA///characteristics_ch1.4: Consolidated.Grade : 1///treatment_protocol_ch1: Frozen tissue stored at -80oC taken after surgery///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction and column chromotogrpahy///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip Drosophila Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.///scan_protocol: GeneChips were scanned using Affymetrix GS300-7G scanner///description: Gene expression data from human ovarian carcinoma///data_processing: The data were analyzed with Gene Chip Operating Software Version 1.4 using Affymetrix default analysis settings. The CEL files generated was later normalized using the RMA method///platform_id: GPL570///contact_name: Prof David,,Bowtell PhD.///contact_email: [email protected]///contact_phone: +613 96561287///contact_fax: +613 96561414///contact_department: Research Division///contact_institute: PeterMacCallum Cancer Centre///contact_address: Locked Bag 1 A' Beckett St///contact_city: Melbourne///contact_state: VIC///contact_zip.postal_code: 8006///contact_country: Australia///contact_web_link: http://www.petermac-research.org.au///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM249nnn/GSM249715/GSM249715.CEL.gz///data_row_count: 54621///ID: X32117///k.meansGroup: 3///Type: LMP///HistologicalSubtype: Ser///PrimarySite: OV///FIGOStage: II///Grade: 1///PatientAge.Years.: 26///PatientStatus: PF///Pltx: N///Tax: N///Neo: N///TimeToRelapseorLastFollow.Up.Months.: 8///TimeToDeathorLastFollow.Up.Months.: 8///ResidualDisease: nil///ArrayedSite: OV
1
title: X34019///geo_accession: GSM249929///status: Public on Mar 01 2008///submission_date: Dec 14 2007///last_update_date: Dec 19 2007///type: RNA///channel_count: 1///source_name_ch1: Carcinoma of ovary, fallopian tube or peritonem///organism_ch1: Homo sapiens///characteristics_ch1: Primary.Site : Ovary///characteristics_ch1.1: Type : Malignant///characteristics_ch1.2: Subtype : Ser/PapSer///characteristics_ch1.3: StageCode : IIIC///characteristics_ch1.4: Consolidated.Grade : 3///treatment_protocol_ch1: Frozen tissue stored at -80oC taken after surgery///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction and column chromotogrpahy///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip Drosophila Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.///scan_protocol: GeneChips were scanned using Affymetrix GS300-7G scanner///description: Gene expression data from human ovarian carcinoma///data_processing: The data were analyzed with Gene Chip Operating Software Version 1.4 using Affymetrix default analysis settings. The CEL files generated was later normalized using the RMA method///platform_id: GPL570///contact_name: Prof David,,Bowtell PhD.///contact_email: [email protected]///contact_phone: +613 96561287///contact_fax: +613 96561414///contact_department: Research Division///contact_institute: PeterMacCallum Cancer Centre///contact_address: Locked Bag 1 A' Beckett St///contact_city: Melbourne///contact_state: VIC///contact_zip.postal_code: 8006///contact_country: Australia///contact_web_link: http://www.petermac-research.org.au///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM249nnn/GSM249929/GSM249929.CEL.gz///data_row_count: 54621///ID: X34019///k.meansGroup: 4///Type: MAL///HistologicalSubtype: Ser///PrimarySite: OV///FIGOStage: III///Grade: 3///PatientAge.Years.: 57///PatientStatus: D///Pltx: Y///Tax: Y///Neo: N///TimeToRelapseorLastFollow.Up.Months.: 11///TimeToDeathorLastFollow.Up.Months.: 22///ResidualDisease: <1///ArrayedSite: OV
1
title: X34049///geo_accession: GSM249928///status: Public on Mar 01 2008///submission_date: Dec 14 2007///last_update_date: Dec 19 2007///type: RNA///channel_count: 1///source_name_ch1: Carcinoma of ovary, fallopian tube or peritonem///organism_ch1: Homo sapiens///characteristics_ch1: Primary.Site : Ovary///characteristics_ch1.1: Type : Malignant///characteristics_ch1.2: Subtype : Ser/PapSer///characteristics_ch1.3: StageCode : IA///characteristics_ch1.4: Consolidated.Grade : 3///treatment_protocol_ch1: Frozen tissue stored at -80oC taken after surgery///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction and column chromotogrpahy///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip Drosophila Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.///scan_protocol: GeneChips were scanned using Affymetrix GS300-7G scanner///description: Gene expression data from human ovarian carcinoma///data_processing: The data were analyzed with Gene Chip Operating Software Version 1.4 using Affymetrix default analysis settings. The CEL files generated was later normalized using the RMA method///platform_id: GPL570///contact_name: Prof David,,Bowtell PhD.///contact_email: [email protected]///contact_phone: +613 96561287///contact_fax: +613 96561414///contact_department: Research Division///contact_institute: PeterMacCallum Cancer Centre///contact_address: Locked Bag 1 A' Beckett St///contact_city: Melbourne///contact_state: VIC///contact_zip.postal_code: 8006///contact_country: Australia///contact_web_link: http://www.petermac-research.org.au///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM249nnn/GSM249928/GSM249928.CEL.gz///data_row_count: 54621///ID: X34049///k.meansGroup: 5///Type: MAL///HistologicalSubtype: Ser///PrimarySite: OV///FIGOStage: I///Grade: 3///PatientAge.Years.: 56///PatientStatus: PF///Pltx: Y///Tax: Y///Neo: N///TimeToRelapseorLastFollow.Up.Months.: 40///TimeToDeathorLastFollow.Up.Months.: 40///ResidualDisease: nil///ArrayedSite: OV
1
title: X34066///geo_accession: GSM249927///status: Public on Mar 01 2008///submission_date: Dec 14 2007///last_update_date: Dec 19 2007///type: RNA///channel_count: 1///source_name_ch1: Carcinoma of ovary, fallopian tube or peritonem///organism_ch1: Homo sapiens///characteristics_ch1: Primary.Site : Ovary///characteristics_ch1.1: Type : Malignant///characteristics_ch1.2: Subtype : Ser/PapSer///characteristics_ch1.3: StageCode : IIIC///characteristics_ch1.4: Consolidated.Grade : 2///treatment_protocol_ch1: Frozen tissue stored at -80oC taken after surgery///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction and column chromotogrpahy///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip Drosophila Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.///scan_protocol: GeneChips were scanned using Affymetrix GS300-7G scanner///description: Gene expression data from human ovarian carcinoma///data_processing: The data were analyzed with Gene Chip Operating Software Version 1.4 using Affymetrix default analysis settings. The CEL files generated was later normalized using the RMA method///platform_id: GPL570///contact_name: Prof David,,Bowtell PhD.///contact_email: [email protected]///contact_phone: +613 96561287///contact_fax: +613 96561414///contact_department: Research Division///contact_institute: PeterMacCallum Cancer Centre///contact_address: Locked Bag 1 A' Beckett St///contact_city: Melbourne///contact_state: VIC///contact_zip.postal_code: 8006///contact_country: Australia///contact_web_link: http://www.petermac-research.org.au///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM249nnn/GSM249927/GSM249927.CEL.gz///data_row_count: 54621///ID: X34066///k.meansGroup: 1///Type: MAL///HistologicalSubtype: Ser///PrimarySite: OV///FIGOStage: III///Grade: 2///PatientAge.Years.: 47///PatientStatus: D///Pltx: Y///Tax: Y///Neo: N///TimeToRelapseorLastFollow.Up.Months.: 14///TimeToDeathorLastFollow.Up.Months.: 26///ResidualDisease: nil///ArrayedSite: OV
1
title: X34078///geo_accession: GSM249926///status: Public on Mar 01 2008///submission_date: Dec 14 2007///last_update_date: Dec 19 2007///type: RNA///channel_count: 1///source_name_ch1: Carcinoma of ovary, fallopian tube or peritonem///organism_ch1: Homo sapiens///characteristics_ch1: Primary.Site : Ovary///characteristics_ch1.1: Type : Malignant///characteristics_ch1.2: Subtype : Ser/PapSer///characteristics_ch1.3: StageCode : IIIC///characteristics_ch1.4: Consolidated.Grade : 3///treatment_protocol_ch1: Frozen tissue stored at -80oC taken after surgery///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction and column chromotogrpahy///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip Drosophila Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.///scan_protocol: GeneChips were scanned using Affymetrix GS300-7G scanner///description: Gene expression data from human ovarian carcinoma///data_processing: The data were analyzed with Gene Chip Operating Software Version 1.4 using Affymetrix default analysis settings. The CEL files generated was later normalized using the RMA method///platform_id: GPL570///contact_name: Prof David,,Bowtell PhD.///contact_email: [email protected]///contact_phone: +613 96561287///contact_fax: +613 96561414///contact_department: Research Division///contact_institute: PeterMacCallum Cancer Centre///contact_address: Locked Bag 1 A' Beckett St///contact_city: Melbourne///contact_state: VIC///contact_zip.postal_code: 8006///contact_country: Australia///contact_web_link: http://www.petermac-research.org.au///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM249nnn/GSM249926/GSM249926.CEL.gz///data_row_count: 54621///ID: X34078///k.meansGroup: 2///Type: MAL///HistologicalSubtype: Ser///PrimarySite: OV///FIGOStage: III///Grade: 3///PatientAge.Years.: 53///PatientStatus: PF///Pltx: Y///Tax: Y///Neo: Y///TimeToRelapseorLastFollow.Up.Months.: 32///TimeToDeathorLastFollow.Up.Months.: 32///ResidualDisease: <1///ArrayedSite: OV
1
title: X34080///geo_accession: GSM249925///status: Public on Mar 01 2008///submission_date: Dec 14 2007///last_update_date: Dec 19 2007///type: RNA///channel_count: 1///source_name_ch1: Carcinoma of ovary, fallopian tube or peritonem///organism_ch1: Homo sapiens///characteristics_ch1: Primary.Site : Ovary///characteristics_ch1.1: Type : Malignant///characteristics_ch1.2: Subtype : Ser/PapSer///characteristics_ch1.3: StageCode : IIIC///characteristics_ch1.4: Consolidated.Grade : 3///treatment_protocol_ch1: Frozen tissue stored at -80oC taken after surgery///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction and column chromotogrpahy///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip Drosophila Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.///scan_protocol: GeneChips were scanned using Affymetrix GS300-7G scanner///description: Gene expression data from human ovarian carcinoma///data_processing: The data were analyzed with Gene Chip Operating Software Version 1.4 using Affymetrix default analysis settings. The CEL files generated was later normalized using the RMA method///platform_id: GPL570///contact_name: Prof David,,Bowtell PhD.///contact_email: [email protected]///contact_phone: +613 96561287///contact_fax: +613 96561414///contact_department: Research Division///contact_institute: PeterMacCallum Cancer Centre///contact_address: Locked Bag 1 A' Beckett St///contact_city: Melbourne///contact_state: VIC///contact_zip.postal_code: 8006///contact_country: Australia///contact_web_link: http://www.petermac-research.org.au///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM249nnn/GSM249925/GSM249925.CEL.gz///data_row_count: 54621///ID: X34080///k.meansGroup: 1///Type: MAL///HistologicalSubtype: Ser///PrimarySite: OV///FIGOStage: III///Grade: 3///PatientAge.Years.: 60///PatientStatus: D///Pltx: Y///Tax: Y///Neo: N///TimeToRelapseorLastFollow.Up.Months.: 10///TimeToDeathorLastFollow.Up.Months.: 14///ResidualDisease: <1///ArrayedSite: PE
1
title: X34085///geo_accession: GSM249924///status: Public on Mar 01 2008///submission_date: Dec 14 2007///last_update_date: Dec 19 2007///type: RNA///channel_count: 1///source_name_ch1: Carcinoma of ovary, fallopian tube or peritonem///organism_ch1: Homo sapiens///characteristics_ch1: Primary.Site : Ovary///characteristics_ch1.1: Type : Malignant///characteristics_ch1.2: Subtype : Ser/PapSer///characteristics_ch1.3: StageCode : IIIC///characteristics_ch1.4: Consolidated.Grade : 2///treatment_protocol_ch1: Frozen tissue stored at -80oC taken after surgery///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction and column chromotogrpahy///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip Drosophila Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.///scan_protocol: GeneChips were scanned using Affymetrix GS300-7G scanner///description: Gene expression data from human ovarian carcinoma///data_processing: The data were analyzed with Gene Chip Operating Software Version 1.4 using Affymetrix default analysis settings. The CEL files generated was later normalized using the RMA method///platform_id: GPL570///contact_name: Prof David,,Bowtell PhD.///contact_email: [email protected]///contact_phone: +613 96561287///contact_fax: +613 96561414///contact_department: Research Division///contact_institute: PeterMacCallum Cancer Centre///contact_address: Locked Bag 1 A' Beckett St///contact_city: Melbourne///contact_state: VIC///contact_zip.postal_code: 8006///contact_country: Australia///contact_web_link: http://www.petermac-research.org.au///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM249nnn/GSM249924/GSM249924.CEL.gz///data_row_count: 54621///ID: X34085///k.meansGroup: NC///Type: MAL///HistologicalSubtype: Ser///PrimarySite: OV///FIGOStage: III///Grade: 2///PatientAge.Years.: 74///PatientStatus: PF///Pltx: N///Tax: N///Neo: N///TimeToRelapseorLastFollow.Up.Months.: NA///TimeToDeathorLastFollow.Up.Months.: NA///ResidualDisease: >1///ArrayedSite: PE
1
title: X34086///geo_accession: GSM249923///status: Public on Mar 01 2008///submission_date: Dec 14 2007///last_update_date: Dec 19 2007///type: RNA///channel_count: 1///source_name_ch1: Carcinoma of ovary, fallopian tube or peritonem///organism_ch1: Homo sapiens///characteristics_ch1: Primary.Site : Ovary///characteristics_ch1.1: Type : Malignant///characteristics_ch1.2: Subtype : Ser/PapSer///characteristics_ch1.3: StageCode : IIIC///characteristics_ch1.4: Consolidated.Grade : 3///treatment_protocol_ch1: Frozen tissue stored at -80oC taken after surgery///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction and column chromotogrpahy///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip Drosophila Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.///scan_protocol: GeneChips were scanned using Affymetrix GS300-7G scanner///description: Gene expression data from human ovarian carcinoma///data_processing: The data were analyzed with Gene Chip Operating Software Version 1.4 using Affymetrix default analysis settings. The CEL files generated was later normalized using the RMA method///platform_id: GPL570///contact_name: Prof David,,Bowtell PhD.///contact_email: [email protected]///contact_phone: +613 96561287///contact_fax: +613 96561414///contact_department: Research Division///contact_institute: PeterMacCallum Cancer Centre///contact_address: Locked Bag 1 A' Beckett St///contact_city: Melbourne///contact_state: VIC///contact_zip.postal_code: 8006///contact_country: Australia///contact_web_link: http://www.petermac-research.org.au///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM249nnn/GSM249923/GSM249923.CEL.gz///data_row_count: 54621///ID: X34086///k.meansGroup: 1///Type: MAL///HistologicalSubtype: Ser///PrimarySite: OV///FIGOStage: III///Grade: 3///PatientAge.Years.: 74///PatientStatus: PF///Pltx: N///Tax: N///Neo: N///TimeToRelapseorLastFollow.Up.Months.: 3///TimeToDeathorLastFollow.Up.Months.: 3///ResidualDisease: >1///ArrayedSite: PE
1
title: X34090///geo_accession: GSM249922///status: Public on Mar 01 2008///submission_date: Dec 14 2007///last_update_date: Dec 19 2007///type: RNA///channel_count: 1///source_name_ch1: Carcinoma of ovary, fallopian tube or peritonem///organism_ch1: Homo sapiens///characteristics_ch1: Primary.Site : Ovary///characteristics_ch1.1: Type : Malignant///characteristics_ch1.2: Subtype : Endo///characteristics_ch1.3: StageCode : IB///characteristics_ch1.4: Consolidated.Grade : 3///treatment_protocol_ch1: Frozen tissue stored at -80oC taken after surgery///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction and column chromotogrpahy///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip Drosophila Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.///scan_protocol: GeneChips were scanned using Affymetrix GS300-7G scanner///description: Gene expression data from human ovarian carcinoma///data_processing: The data were analyzed with Gene Chip Operating Software Version 1.4 using Affymetrix default analysis settings. The CEL files generated was later normalized using the RMA method///platform_id: GPL570///contact_name: Prof David,,Bowtell PhD.///contact_email: [email protected]///contact_phone: +613 96561287///contact_fax: +613 96561414///contact_department: Research Division///contact_institute: PeterMacCallum Cancer Centre///contact_address: Locked Bag 1 A' Beckett St///contact_city: Melbourne///contact_state: VIC///contact_zip.postal_code: 8006///contact_country: Australia///contact_web_link: http://www.petermac-research.org.au///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM249nnn/GSM249922/GSM249922.CEL.gz///data_row_count: 54621///ID: X34090///k.meansGroup: 6///Type: MAL///HistologicalSubtype: Endo///PrimarySite: OV///FIGOStage: I///Grade: 3///PatientAge.Years.: 57///PatientStatus: PF///Pltx: Y///Tax: Y///Neo: N///TimeToRelapseorLastFollow.Up.Months.: 32///TimeToDeathorLastFollow.Up.Months.: 32///ResidualDisease: nil///ArrayedSite: OV
1
title: X34102///geo_accession: GSM249921///status: Public on Mar 01 2008///submission_date: Dec 14 2007///last_update_date: Dec 19 2007///type: RNA///channel_count: 1///source_name_ch1: Carcinoma of ovary, fallopian tube or peritonem///organism_ch1: Homo sapiens///characteristics_ch1: Primary.Site : Peritoneum///characteristics_ch1.1: Type : Malignant///characteristics_ch1.2: Subtype : Ser/PapSer///characteristics_ch1.3: StageCode : IIIC///characteristics_ch1.4: Consolidated.Grade : 3///treatment_protocol_ch1: Frozen tissue stored at -80oC taken after surgery///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction and column chromotogrpahy///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip Drosophila Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.///scan_protocol: GeneChips were scanned using Affymetrix GS300-7G scanner///description: Gene expression data from human ovarian carcinoma///data_processing: The data were analyzed with Gene Chip Operating Software Version 1.4 using Affymetrix default analysis settings. The CEL files generated was later normalized using the RMA method///platform_id: GPL570///contact_name: Prof David,,Bowtell PhD.///contact_email: [email protected]///contact_phone: +613 96561287///contact_fax: +613 96561414///contact_department: Research Division///contact_institute: PeterMacCallum Cancer Centre///contact_address: Locked Bag 1 A' Beckett St///contact_city: Melbourne///contact_state: VIC///contact_zip.postal_code: 8006///contact_country: Australia///contact_web_link: http://www.petermac-research.org.au///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM249nnn/GSM249921/GSM249921.CEL.gz///data_row_count: 54621///ID: X34102///k.meansGroup: 4///Type: MAL///HistologicalSubtype: Ser///PrimarySite: PE///FIGOStage: III///Grade: 3///PatientAge.Years.: 70///PatientStatus: D///Pltx: Y///Tax: Y///Neo: N///TimeToRelapseorLastFollow.Up.Months.: 10///TimeToDeathorLastFollow.Up.Months.: 24///ResidualDisease: >1///ArrayedSite: PE
1
title: X34103///geo_accession: GSM249920///status: Public on Mar 01 2008///submission_date: Dec 14 2007///last_update_date: Dec 19 2007///type: RNA///channel_count: 1///source_name_ch1: Carcinoma of ovary, fallopian tube or peritonem///organism_ch1: Homo sapiens///characteristics_ch1: Primary.Site : Ovary///characteristics_ch1.1: Type : Malignant///characteristics_ch1.2: Subtype : Ser/PapSer///characteristics_ch1.3: StageCode : IIIC///characteristics_ch1.4: Consolidated.Grade : 3///treatment_protocol_ch1: Frozen tissue stored at -80oC taken after surgery///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction and column chromotogrpahy///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip Drosophila Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.///scan_protocol: GeneChips were scanned using Affymetrix GS300-7G scanner///description: Gene expression data from human ovarian carcinoma///data_processing: The data were analyzed with Gene Chip Operating Software Version 1.4 using Affymetrix default analysis settings. The CEL files generated was later normalized using the RMA method///platform_id: GPL570///contact_name: Prof David,,Bowtell PhD.///contact_email: [email protected]///contact_phone: +613 96561287///contact_fax: +613 96561414///contact_department: Research Division///contact_institute: PeterMacCallum Cancer Centre///contact_address: Locked Bag 1 A' Beckett St///contact_city: Melbourne///contact_state: VIC///contact_zip.postal_code: 8006///contact_country: Australia///contact_web_link: http://www.petermac-research.org.au///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM249nnn/GSM249920/GSM249920.CEL.gz///data_row_count: 54621///ID: X34103///k.meansGroup: 5///Type: MAL///HistologicalSubtype: Ser///PrimarySite: OV///FIGOStage: III///Grade: 3///PatientAge.Years.: 33///PatientStatus: D///Pltx: Y///Tax: Y///Neo: N///TimeToRelapseorLastFollow.Up.Months.: 15///TimeToDeathorLastFollow.Up.Months.: 37///ResidualDisease: >1///ArrayedSite: OV
1
title: X34111///geo_accession: GSM249919///status: Public on Mar 01 2008///submission_date: Dec 14 2007///last_update_date: Dec 19 2007///type: RNA///channel_count: 1///source_name_ch1: Carcinoma of ovary, fallopian tube or peritonem///organism_ch1: Homo sapiens///characteristics_ch1: Primary.Site : Ovary///characteristics_ch1.1: Type : Malignant///characteristics_ch1.2: Subtype : Ser/PapSer///characteristics_ch1.3: StageCode : IIIC///characteristics_ch1.4: Consolidated.Grade : 3///treatment_protocol_ch1: Frozen tissue stored at -80oC taken after surgery///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction and column chromotogrpahy///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip Drosophila Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.///scan_protocol: GeneChips were scanned using Affymetrix GS300-7G scanner///description: Gene expression data from human ovarian carcinoma///data_processing: The data were analyzed with Gene Chip Operating Software Version 1.4 using Affymetrix default analysis settings. The CEL files generated was later normalized using the RMA method///platform_id: GPL570///contact_name: Prof David,,Bowtell PhD.///contact_email: [email protected]///contact_phone: +613 96561287///contact_fax: +613 96561414///contact_department: Research Division///contact_institute: PeterMacCallum Cancer Centre///contact_address: Locked Bag 1 A' Beckett St///contact_city: Melbourne///contact_state: VIC///contact_zip.postal_code: 8006///contact_country: Australia///contact_web_link: http://www.petermac-research.org.au///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM249nnn/GSM249919/GSM249919.CEL.gz///data_row_count: 54621///ID: X34111///k.meansGroup: NC///Type: MAL///HistologicalSubtype: Ser///PrimarySite: OV///FIGOStage: III///Grade: 3///PatientAge.Years.: 60///PatientStatus: D///Pltx: Y///Tax: Y///Neo: N///TimeToRelapseorLastFollow.Up.Months.: 10///TimeToDeathorLastFollow.Up.Months.: 22///ResidualDisease: <1///ArrayedSite: OV
1
title: X34113///geo_accession: GSM249918///status: Public on Mar 01 2008///submission_date: Dec 14 2007///last_update_date: Dec 19 2007///type: RNA///channel_count: 1///source_name_ch1: Carcinoma of ovary, fallopian tube or peritonem///organism_ch1: Homo sapiens///characteristics_ch1: Primary.Site : Ovary///characteristics_ch1.1: Type : Malignant///characteristics_ch1.2: Subtype : Ser/PapSer///characteristics_ch1.3: StageCode : IIIC///characteristics_ch1.4: Consolidated.Grade : 2///treatment_protocol_ch1: Frozen tissue stored at -80oC taken after surgery///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction and column chromotogrpahy///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip Drosophila Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.///scan_protocol: GeneChips were scanned using Affymetrix GS300-7G scanner///description: Gene expression data from human ovarian carcinoma///data_processing: The data were analyzed with Gene Chip Operating Software Version 1.4 using Affymetrix default analysis settings. The CEL files generated was later normalized using the RMA method///platform_id: GPL570///contact_name: Prof David,,Bowtell PhD.///contact_email: [email protected]///contact_phone: +613 96561287///contact_fax: +613 96561414///contact_department: Research Division///contact_institute: PeterMacCallum Cancer Centre///contact_address: Locked Bag 1 A' Beckett St///contact_city: Melbourne///contact_state: VIC///contact_zip.postal_code: 8006///contact_country: Australia///contact_web_link: http://www.petermac-research.org.au///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM249nnn/GSM249918/GSM249918.CEL.gz///data_row_count: 54621///ID: X34113///k.meansGroup: 6///Type: MAL///HistologicalSubtype: Ser///PrimarySite: OV///FIGOStage: III///Grade: 2///PatientAge.Years.: 54///PatientStatus: PF///Pltx: Y///Tax: Y///Neo: N///TimeToRelapseorLastFollow.Up.Months.: 30///TimeToDeathorLastFollow.Up.Months.: 30///ResidualDisease: nil///ArrayedSite: OV
1
title: X34117///geo_accession: GSM249917///status: Public on Mar 01 2008///submission_date: Dec 14 2007///last_update_date: Dec 19 2007///type: RNA///channel_count: 1///source_name_ch1: Carcinoma of ovary, fallopian tube or peritonem///organism_ch1: Homo sapiens///characteristics_ch1: Primary.Site : Ovary///characteristics_ch1.1: Type : Malignant///characteristics_ch1.2: Subtype : Ser/PapSer///characteristics_ch1.3: StageCode : IIIC///characteristics_ch1.4: Consolidated.Grade : 3///treatment_protocol_ch1: Frozen tissue stored at -80oC taken after surgery///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction and column chromotogrpahy///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip Drosophila Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.///scan_protocol: GeneChips were scanned using Affymetrix GS300-7G scanner///description: Gene expression data from human ovarian carcinoma///data_processing: The data were analyzed with Gene Chip Operating Software Version 1.4 using Affymetrix default analysis settings. The CEL files generated was later normalized using the RMA method///platform_id: GPL570///contact_name: Prof David,,Bowtell PhD.///contact_email: [email protected]///contact_phone: +613 96561287///contact_fax: +613 96561414///contact_department: Research Division///contact_institute: PeterMacCallum Cancer Centre///contact_address: Locked Bag 1 A' Beckett St///contact_city: Melbourne///contact_state: VIC///contact_zip.postal_code: 8006///contact_country: Australia///contact_web_link: http://www.petermac-research.org.au///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM249nnn/GSM249917/GSM249917.CEL.gz///data_row_count: 54621///ID: X34117///k.meansGroup: 1///Type: MAL///HistologicalSubtype: Ser///PrimarySite: OV///FIGOStage: III///Grade: 3///PatientAge.Years.: 60///PatientStatus: R///Pltx: Y///Tax: Y///Neo: N///TimeToRelapseorLastFollow.Up.Months.: 12///TimeToDeathorLastFollow.Up.Months.: 36///ResidualDisease: NK///ArrayedSite: PE
1
title: X34125///geo_accession: GSM249916///status: Public on Mar 01 2008///submission_date: Dec 14 2007///last_update_date: Dec 19 2007///type: RNA///channel_count: 1///source_name_ch1: Carcinoma of ovary, fallopian tube or peritonem///organism_ch1: Homo sapiens///characteristics_ch1: Primary.Site : Ovary///characteristics_ch1.1: Type : Malignant///characteristics_ch1.2: Subtype : Ser/PapSer///characteristics_ch1.3: StageCode : IIIC///characteristics_ch1.4: Consolidated.Grade : 3///treatment_protocol_ch1: Frozen tissue stored at -80oC taken after surgery///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction and column chromotogrpahy///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip Drosophila Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.///scan_protocol: GeneChips were scanned using Affymetrix GS300-7G scanner///description: Gene expression data from human ovarian carcinoma///data_processing: The data were analyzed with Gene Chip Operating Software Version 1.4 using Affymetrix default analysis settings. The CEL files generated was later normalized using the RMA method///platform_id: GPL570///contact_name: Prof David,,Bowtell PhD.///contact_email: [email protected]///contact_phone: +613 96561287///contact_fax: +613 96561414///contact_department: Research Division///contact_institute: PeterMacCallum Cancer Centre///contact_address: Locked Bag 1 A' Beckett St///contact_city: Melbourne///contact_state: VIC///contact_zip.postal_code: 8006///contact_country: Australia///contact_web_link: http://www.petermac-research.org.au///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM249nnn/GSM249916/GSM249916.CEL.gz///data_row_count: 54621///ID: X34125///k.meansGroup: 5///Type: MAL///HistologicalSubtype: Ser///PrimarySite: OV///FIGOStage: III///Grade: 3///PatientAge.Years.: 44///PatientStatus: PF///Pltx: Y///Tax: Y///Neo: N///TimeToRelapseorLastFollow.Up.Months.: 30///TimeToDeathorLastFollow.Up.Months.: 30///ResidualDisease: <1///ArrayedSite: OV
1
title: X34165///geo_accession: GSM249915///status: Public on Mar 01 2008///submission_date: Dec 14 2007///last_update_date: Dec 19 2007///type: RNA///channel_count: 1///source_name_ch1: Carcinoma of ovary, fallopian tube or peritonem///organism_ch1: Homo sapiens///characteristics_ch1: Primary.Site : Ovary///characteristics_ch1.1: Type : Malignant///characteristics_ch1.2: Subtype : Ser/PapSer///characteristics_ch1.3: StageCode : IIIC///characteristics_ch1.4: Consolidated.Grade : 2///treatment_protocol_ch1: Frozen tissue stored at -80oC taken after surgery///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction and column chromotogrpahy///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip Drosophila Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.///scan_protocol: GeneChips were scanned using Affymetrix GS300-7G scanner///description: Gene expression data from human ovarian carcinoma///data_processing: The data were analyzed with Gene Chip Operating Software Version 1.4 using Affymetrix default analysis settings. The CEL files generated was later normalized using the RMA method///platform_id: GPL570///contact_name: Prof David,,Bowtell PhD.///contact_email: [email protected]///contact_phone: +613 96561287///contact_fax: +613 96561414///contact_department: Research Division///contact_institute: PeterMacCallum Cancer Centre///contact_address: Locked Bag 1 A' Beckett St///contact_city: Melbourne///contact_state: VIC///contact_zip.postal_code: 8006///contact_country: Australia///contact_web_link: http://www.petermac-research.org.au///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM249nnn/GSM249915/GSM249915.CEL.gz///data_row_count: 54621///ID: X34165///k.meansGroup: 1///Type: MAL///HistologicalSubtype: Ser///PrimarySite: OV///FIGOStage: III///Grade: 2///PatientAge.Years.: 43///PatientStatus: R///Pltx: Y///Tax: Y///Neo: N///TimeToRelapseorLastFollow.Up.Months.: 13///TimeToDeathorLastFollow.Up.Months.: 30///ResidualDisease: <1///ArrayedSite: PE
1
title: X34168///geo_accession: GSM249914///status: Public on Mar 01 2008///submission_date: Dec 14 2007///last_update_date: Dec 19 2007///type: RNA///channel_count: 1///source_name_ch1: Carcinoma of ovary, fallopian tube or peritonem///organism_ch1: Homo sapiens///characteristics_ch1: Primary.Site : Peritoneum///characteristics_ch1.1: Type : Malignant///characteristics_ch1.2: Subtype : Ser/PapSer///characteristics_ch1.3: StageCode : IIIC///characteristics_ch1.4: Consolidated.Grade : 3///treatment_protocol_ch1: Frozen tissue stored at -80oC taken after surgery///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction and column chromotogrpahy///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip Drosophila Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.///scan_protocol: GeneChips were scanned using Affymetrix GS300-7G scanner///description: Gene expression data from human ovarian carcinoma///data_processing: The data were analyzed with Gene Chip Operating Software Version 1.4 using Affymetrix default analysis settings. The CEL files generated was later normalized using the RMA method///platform_id: GPL570///contact_name: Prof David,,Bowtell PhD.///contact_email: [email protected]///contact_phone: +613 96561287///contact_fax: +613 96561414///contact_department: Research Division///contact_institute: PeterMacCallum Cancer Centre///contact_address: Locked Bag 1 A' Beckett St///contact_city: Melbourne///contact_state: VIC///contact_zip.postal_code: 8006///contact_country: Australia///contact_web_link: http://www.petermac-research.org.au///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM249nnn/GSM249914/GSM249914.CEL.gz///data_row_count: 54621///ID: X34168///k.meansGroup: 1///Type: MAL///HistologicalSubtype: Ser///PrimarySite: PE///FIGOStage: III///Grade: 3///PatientAge.Years.: 63///PatientStatus: D///Pltx: Y///Tax: Y///Neo: N///TimeToRelapseorLastFollow.Up.Months.: 5///TimeToDeathorLastFollow.Up.Months.: 13///ResidualDisease: >1///ArrayedSite: PE
1
title: X34172///geo_accession: GSM249913///status: Public on Mar 01 2008///submission_date: Dec 14 2007///last_update_date: Dec 19 2007///type: RNA///channel_count: 1///source_name_ch1: Carcinoma of ovary, fallopian tube or peritonem///organism_ch1: Homo sapiens///characteristics_ch1: Primary.Site : Ovary///characteristics_ch1.1: Type : Malignant///characteristics_ch1.2: Subtype : Ser/PapSer///characteristics_ch1.3: StageCode : IIIC///characteristics_ch1.4: Consolidated.Grade : 3///treatment_protocol_ch1: Frozen tissue stored at -80oC taken after surgery///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction and column chromotogrpahy///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip Drosophila Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.///scan_protocol: GeneChips were scanned using Affymetrix GS300-7G scanner///description: Gene expression data from human ovarian carcinoma///data_processing: The data were analyzed with Gene Chip Operating Software Version 1.4 using Affymetrix default analysis settings. The CEL files generated was later normalized using the RMA method///platform_id: GPL570///contact_name: Prof David,,Bowtell PhD.///contact_email: [email protected]///contact_phone: +613 96561287///contact_fax: +613 96561414///contact_department: Research Division///contact_institute: PeterMacCallum Cancer Centre///contact_address: Locked Bag 1 A' Beckett St///contact_city: Melbourne///contact_state: VIC///contact_zip.postal_code: 8006///contact_country: Australia///contact_web_link: http://www.petermac-research.org.au///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM249nnn/GSM249913/GSM249913.CEL.gz///data_row_count: 54621///ID: X34172///k.meansGroup: 5///Type: MAL///HistologicalSubtype: Ser///PrimarySite: OV///FIGOStage: III///Grade: 3///PatientAge.Years.: 71///PatientStatus: R///Pltx: Y///Tax: Y///Neo: N///TimeToRelapseorLastFollow.Up.Months.: 14///TimeToDeathorLastFollow.Up.Months.: 24///ResidualDisease: >1///ArrayedSite: OV
1
title: X34186///geo_accession: GSM249912///status: Public on Mar 01 2008///submission_date: Dec 14 2007///last_update_date: Dec 19 2007///type: RNA///channel_count: 1///source_name_ch1: Carcinoma of ovary, fallopian tube or peritonem///organism_ch1: Homo sapiens///characteristics_ch1: Primary.Site : Ovary///characteristics_ch1.1: Type : Malignant///characteristics_ch1.2: Subtype : Ser/PapSer///characteristics_ch1.3: StageCode : IIIC///characteristics_ch1.4: Consolidated.Grade : 2///treatment_protocol_ch1: Frozen tissue stored at -80oC taken after surgery///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction and column chromotogrpahy///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip Drosophila Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.///scan_protocol: GeneChips were scanned using Affymetrix GS300-7G scanner///description: Gene expression data from human ovarian carcinoma///data_processing: The data were analyzed with Gene Chip Operating Software Version 1.4 using Affymetrix default analysis settings. The CEL files generated was later normalized using the RMA method///platform_id: GPL570///contact_name: Prof David,,Bowtell PhD.///contact_email: [email protected]///contact_phone: +613 96561287///contact_fax: +613 96561414///contact_department: Research Division///contact_institute: PeterMacCallum Cancer Centre///contact_address: Locked Bag 1 A' Beckett St///contact_city: Melbourne///contact_state: VIC///contact_zip.postal_code: 8006///contact_country: Australia///contact_web_link: http://www.petermac-research.org.au///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM249nnn/GSM249912/GSM249912.CEL.gz///data_row_count: 54621///ID: X34186///k.meansGroup: 4///Type: MAL///HistologicalSubtype: Ser///PrimarySite: OV///FIGOStage: III///Grade: 2///PatientAge.Years.: 55///PatientStatus: PF///Pltx: Y///Tax: Y///Neo: N///TimeToRelapseorLastFollow.Up.Months.: 21///TimeToDeathorLastFollow.Up.Months.: 21///ResidualDisease: <1///ArrayedSite: PE
1
title: X34202///geo_accession: GSM249911///status: Public on Mar 01 2008///submission_date: Dec 14 2007///last_update_date: Dec 19 2007///type: RNA///channel_count: 1///source_name_ch1: Carcinoma of ovary, fallopian tube or peritonem///organism_ch1: Homo sapiens///characteristics_ch1: Primary.Site : Peritoneum///characteristics_ch1.1: Type : Malignant///characteristics_ch1.2: Subtype : Ser/PapSer///characteristics_ch1.3: StageCode : IIIC///characteristics_ch1.4: Consolidated.Grade : 3///treatment_protocol_ch1: Frozen tissue stored at -80oC taken after surgery///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction and column chromotogrpahy///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip Drosophila Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.///scan_protocol: GeneChips were scanned using Affymetrix GS300-7G scanner///description: Gene expression data from human ovarian carcinoma///data_processing: The data were analyzed with Gene Chip Operating Software Version 1.4 using Affymetrix default analysis settings. The CEL files generated was later normalized using the RMA method///platform_id: GPL570///contact_name: Prof David,,Bowtell PhD.///contact_email: [email protected]///contact_phone: +613 96561287///contact_fax: +613 96561414///contact_department: Research Division///contact_institute: PeterMacCallum Cancer Centre///contact_address: Locked Bag 1 A' Beckett St///contact_city: Melbourne///contact_state: VIC///contact_zip.postal_code: 8006///contact_country: Australia///contact_web_link: http://www.petermac-research.org.au///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM249nnn/GSM249911/GSM249911.CEL.gz///data_row_count: 54621///ID: X34202///k.meansGroup: 1///Type: MAL///HistologicalSubtype: Ser///PrimarySite: PE///FIGOStage: III///Grade: 3///PatientAge.Years.: 62///PatientStatus: D///Pltx: Y///Tax: Y///Neo: N///TimeToRelapseorLastFollow.Up.Months.: 11///TimeToDeathorLastFollow.Up.Months.: 20///ResidualDisease: <1///ArrayedSite: OV
1
title: X34207///geo_accession: GSM249910///status: Public on Mar 01 2008///submission_date: Dec 14 2007///last_update_date: Dec 19 2007///type: RNA///channel_count: 1///source_name_ch1: Carcinoma of ovary, fallopian tube or peritonem///organism_ch1: Homo sapiens///characteristics_ch1: Primary.Site : Ovary///characteristics_ch1.1: Type : Malignant///characteristics_ch1.2: Subtype : Ser/PapSer///characteristics_ch1.3: StageCode : IIIC///characteristics_ch1.4: Consolidated.Grade : 1///treatment_protocol_ch1: Frozen tissue stored at -80oC taken after surgery///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction and column chromotogrpahy///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip Drosophila Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.///scan_protocol: GeneChips were scanned using Affymetrix GS300-7G scanner///description: Gene expression data from human ovarian carcinoma///data_processing: The data were analyzed with Gene Chip Operating Software Version 1.4 using Affymetrix default analysis settings. The CEL files generated was later normalized using the RMA method///platform_id: GPL570///contact_name: Prof David,,Bowtell PhD.///contact_email: [email protected]///contact_phone: +613 96561287///contact_fax: +613 96561414///contact_department: Research Division///contact_institute: PeterMacCallum Cancer Centre///contact_address: Locked Bag 1 A' Beckett St///contact_city: Melbourne///contact_state: VIC///contact_zip.postal_code: 8006///contact_country: Australia///contact_web_link: http://www.petermac-research.org.au///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM249nnn/GSM249910/GSM249910.CEL.gz///data_row_count: 54621///ID: X34207///k.meansGroup: 3///Type: MAL///HistologicalSubtype: Ser///PrimarySite: OV///FIGOStage: III///Grade: 1///PatientAge.Years.: 52///PatientStatus: PF///Pltx: N///Tax: N///Neo: N///TimeToRelapseorLastFollow.Up.Months.: 23///TimeToDeathorLastFollow.Up.Months.: 23///ResidualDisease: nil///ArrayedSite: OV
1
title: X34801///geo_accession: GSM249909///status: Public on Mar 01 2008///submission_date: Dec 14 2007///last_update_date: Dec 19 2007///type: RNA///channel_count: 1///source_name_ch1: Carcinoma of ovary, fallopian tube or peritonem///organism_ch1: Homo sapiens///characteristics_ch1: Primary.Site : Ovary///characteristics_ch1.1: Type : Malignant///characteristics_ch1.2: Subtype : Ser/PapSer///characteristics_ch1.3: StageCode : IIIC///characteristics_ch1.4: Consolidated.Grade : 3///treatment_protocol_ch1: Frozen tissue stored at -80oC taken after surgery///molecule_ch1: total RNA///extract_protocol_ch1: Trizol extraction and column chromotogrpahy///label_ch1: biotin///label_protocol_ch1: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).///taxid_ch1: 9606///hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip Drosophila Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.///scan_protocol: GeneChips were scanned using Affymetrix GS300-7G scanner///description: Gene expression data from human ovarian carcinoma///data_processing: The data were analyzed with Gene Chip Operating Software Version 1.4 using Affymetrix default analysis settings. The CEL files generated was later normalized using the RMA method///platform_id: GPL570///contact_name: Prof David,,Bowtell PhD.///contact_email: [email protected]///contact_phone: +613 96561287///contact_fax: +613 96561414///contact_department: Research Division///contact_institute: PeterMacCallum Cancer Centre///contact_address: Locked Bag 1 A' Beckett St///contact_city: Melbourne///contact_state: VIC///contact_zip.postal_code: 8006///contact_country: Australia///contact_web_link: http://www.petermac-research.org.au///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM249nnn/GSM249909/GSM249909.CEL.gz///data_row_count: 54621///ID: X34801///k.meansGroup: 1///Type: MAL///HistologicalSubtype: Ser///PrimarySite: OV///FIGOStage: III///Grade: 3///PatientAge.Years.: 60///PatientStatus: PF///Pltx: N///Tax: N///Neo: N///TimeToRelapseorLastFollow.Up.Months.: NA///TimeToDeathorLastFollow.Up.Months.: NA///ResidualDisease: >1///ArrayedSite: PE
1
(Other)
186
An expression set
A better understanding of the underlying biology of invasive serous ovarian cancer is critical for the development of early detection strategies and new therapeutics. The objective of this study was to define gene expression patterns associated with favorable survival.RNA from 65 serous ovarian cancers was analyzed using Affymetrix U133A microarrays. This included 54 stage III/IV cases (30 short-term survivors who lived <3 years and 24 long-term survivors who lived >7 years) and 11 stage I/II cases. Genes were screened on the basis of their level of and variability in expression, leaving 7,821 for use in developing a predictive model for survival. A composite predictive model was developed that combines Bayesian classification tree and multivariate discriminant models. Leave-one-out cross-validation was used to select and evaluate models.Patterns of genes were identified that distinguish short-term and long-term ovarian cancer survivors. The expression model developed for advanced stage disease classified all 11 early-stage ovarian cancers as long-term survivors. The MAL gene, which has been shown to confer resistance to cancer therapy, was most highly overexpressed in short-term survivors (3-fold compared with long-term survivors, and 29-fold compared with early-stage cases). These results suggest that gene expression patterns underlie differences in outcome, and an examination of the genes that provide this discrimination reveals that many are implicated in processes that define the malignant phenotype.Differences in survival of advanced ovarian cancers are reflected by distinct patterns of gene expression. This biological distinction is further emphasized by the finding that early-stage cancers share expression patterns with the advanced stage long-term survivors, suggesting a shared favorable biology.
experimentData(eset):
Experiment data
Experimenter name: Berchuck A, Iversen ES, Lancaster JM, Pittman J, Luo J, Lee P, Murphy S, Dressman HK, Febbo PG, West M, Nevins JR, Marks JR.Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers. Clin Cancer Res. 2005 May 15; 11(10):3686-96.
Laboratory: Berchuck, Marks 2005
Contact information:
Title: Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers.
URL:
PMIDs: 15897565
Abstract: A 258 word abstract is available. Use 'abstract' method.
Information is available on: preprocessing
notes:
platform_title:
[HG-U133A] Affymetrix Human Genome U133A Array
platform_shorttitle:
Affymetrix HG-U133A
platform_summary:
hgu133a
platform_manufacturer:
Affymetrix
platform_distribution:
commercial
platform_accession:
GPL96
warnings:
These samples are a subset of PMID17290060.
version:
2015-09-22 20:17:53
featureData(eset):
An object of class 'AnnotatedDataFrame'
featureNames: 1007_s_at 1053_at ... AFFX-HUMISGF3A/M97935_MB_at
(20967 total)
varLabels: probeset gene EntrezGene.ID best_probe
varMetadata: labelDescription
assayData: 20967 features, 63 samples
Platform type:
---------------------------
Available sample meta-data:
---------------------------
alt_sample_name:
Min. 1st Qu. Median Mean 3rd Qu. Max.
1761 1828 1907 2001 2032 2536
sample_type:
tumor
63
histological_type:
ser
63
primarysite:
ov
63
summarygrade:
high low NA's
25 37 1
summarystage:
early late
11 52
tumorstage:
1 2 3 4
7 4 48 4
grade:
1 2 3 4 NA's
2 35 24 1 1
age_at_initial_pathologic_diagnosis:
Min. 1st Qu. Median Mean 3rd Qu. Max.
33.00 52.50 59.00 59.21 67.00 79.00
os_binary:
long short NA's
24 28 11
debulking:
optimal suboptimal NA's
24 28 11
batch:
2002-09-20 2002-10-23 2002-11-12 2002-12-16 2002-12-21 2003-01-03 2003-05-30
15 9 10 1 3 11 13
2003-07-02
1
uncurated_author_metadata:
Genome.ID..File.name....0074_GenomeID_h133a_2802.cel: 1761///Cancer.Type: Early stage///AgeDx: 72///STAGE: IC///GRADE: 2///Debulking: ///X: NA
1
Genome.ID..File.name....0074_GenomeID_h133a_2802.cel: 1762///Cancer.Type: Early stage///AgeDx: 52///STAGE: IA///GRADE: 3///Debulking: ///X: NA
1
Genome.ID..File.name....0074_GenomeID_h133a_2802.cel: 1763///Cancer.Type: Early stage///AgeDx: 58///STAGE: IIC///GRADE: 2///Debulking: ///X: NA
1
Genome.ID..File.name....0074_GenomeID_h133a_2802.cel: 1764///Cancer.Type: Early stage///AgeDx: 48///STAGE: IC///GRADE: 3///Debulking: ///X: NA
1
Genome.ID..File.name....0074_GenomeID_h133a_2802.cel: 1765///Cancer.Type: Early stage///AgeDx: 45///STAGE: IA///GRADE: 2///Debulking: ///X: NA
1
Genome.ID..File.name....0074_GenomeID_h133a_2802.cel: 1772///Cancer.Type: Long///AgeDx: 33///STAGE: IIIC///GRADE: 3///Debulking: S///X: NA
1
Genome.ID..File.name....0074_GenomeID_h133a_2802.cel: 1773///Cancer.Type: Long///AgeDx: 68///STAGE: IIIC///GRADE: 2///Debulking: S///X: NA
1
Genome.ID..File.name....0074_GenomeID_h133a_2802.cel: 1774///Cancer.Type: Long///AgeDx: 56///STAGE: IIIC///GRADE: 3///Debulking: S///X: NA
1
Genome.ID..File.name....0074_GenomeID_h133a_2802.cel: 1775///Cancer.Type: Long///AgeDx: 60///STAGE: IIIC///GRADE: 2///Debulking: O///X: NA
1
Genome.ID..File.name....0074_GenomeID_h133a_2802.cel: 1776///Cancer.Type: Long///AgeDx: 40///STAGE: IIIC///GRADE: 2///Debulking: S///X: NA
1
Genome.ID..File.name....0074_GenomeID_h133a_2802.cel: 1777///Cancer.Type: Long///AgeDx: 78///STAGE: IIIB///GRADE: 3///Debulking: O///X: NA
1
Genome.ID..File.name....0074_GenomeID_h133a_2802.cel: 1778///Cancer.Type: Long///AgeDx: 66///STAGE: IIIB///GRADE: 2///Debulking: O///X: NA
1
Genome.ID..File.name....0074_GenomeID_h133a_2802.cel: 1779///Cancer.Type: Long///AgeDx: 53///STAGE: IIIC///GRADE: 3///Debulking: O///X: NA
1
Genome.ID..File.name....0074_GenomeID_h133a_2802.cel: 1780///Cancer.Type: Long///AgeDx: 63///STAGE: IIIC///GRADE: 2///Debulking: O///X: NA
1
Genome.ID..File.name....0074_GenomeID_h133a_2802.cel: 1781///Cancer.Type: Long///AgeDx: 73///STAGE: IIIC///GRADE: 3///Debulking: O///X: NA
1
Genome.ID..File.name....0074_GenomeID_h133a_2802.cel: 1828///Cancer.Type: Short///AgeDx: 59///STAGE: IV///GRADE: 3///Debulking: O///X: NA
1
Genome.ID..File.name....0074_GenomeID_h133a_2802.cel: 1829///Cancer.Type: Short///AgeDx: 65///STAGE: IIIC///GRADE: 3///Debulking: S///X: NA
1
Genome.ID..File.name....0074_GenomeID_h133a_2802.cel: 1830///Cancer.Type: Short///AgeDx: 79///STAGE: IIIC///GRADE: 2///Debulking: S///X: NA
1
Genome.ID..File.name....0074_GenomeID_h133a_2802.cel: 1831///Cancer.Type: Short///AgeDx: 70///STAGE: IIIC///GRADE: 2///Debulking: S///X: NA
1
Genome.ID..File.name....0074_GenomeID_h133a_2802.cel: 1832///Cancer.Type: Short///AgeDx: 59///STAGE: IIIC///GRADE: 2///Debulking: S///X: NA
1
Genome.ID..File.name....0074_GenomeID_h133a_2802.cel: 1833///Cancer.Type: Short///AgeDx: 55///STAGE: IIIC///GRADE: 3///Debulking: S///X: NA
1
Genome.ID..File.name....0074_GenomeID_h133a_2802.cel: 1834///Cancer.Type: Short///AgeDx: 48///STAGE: IIIC///GRADE: 2///Debulking: S///X: NA
1
Genome.ID..File.name....0074_GenomeID_h133a_2802.cel: 1835///Cancer.Type: Short///AgeDx: 54///STAGE: IIIC///GRADE: 2///Debulking: S///X: NA
1
Genome.ID..File.name....0074_GenomeID_h133a_2802.cel: 1836///Cancer.Type: Short///AgeDx: 57///STAGE: IIIC///GRADE: 3///Debulking: S///X: NA
1
Genome.ID..File.name....0074_GenomeID_h133a_2802.cel: 1900///Cancer.Type: Long///AgeDx: 62///STAGE: IIIA///GRADE: 3///Debulking: O///X: NA
1
Genome.ID..File.name....0074_GenomeID_h133a_2802.cel: 1901///Cancer.Type: Long///AgeDx: 50///STAGE: IIIC///GRADE: 2///Debulking: O///X: NA
1
Genome.ID..File.name....0074_GenomeID_h133a_2802.cel: 1902///Cancer.Type: Long///AgeDx: 67///STAGE: IIIC///GRADE: 1///Debulking: O///X: NA
1
Genome.ID..File.name....0074_GenomeID_h133a_2802.cel: 1903///Cancer.Type: Early stage///AgeDx: 73///STAGE: IIC///GRADE: 3///Debulking: ///X: NA
1
Genome.ID..File.name....0074_GenomeID_h133a_2802.cel: 1904///Cancer.Type: Long///AgeDx: 70///STAGE: IIIC///GRADE: 3///Debulking: O///X: NA
1
Genome.ID..File.name....0074_GenomeID_h133a_2802.cel: 1905///Cancer.Type: Short///AgeDx: 70///STAGE: IIIC///GRADE: 2///Debulking: O///X: NA
1
Genome.ID..File.name....0074_GenomeID_h133a_2802.cel: 1906///Cancer.Type: Short///AgeDx: 75///STAGE: IIIB///GRADE: 2///Debulking: O///X: NA
1
Genome.ID..File.name....0074_GenomeID_h133a_2802.cel: 1907///Cancer.Type: Long///AgeDx: 73///STAGE: IIIC///GRADE: 4///Debulking: S///X: NA
1
Genome.ID..File.name....0074_GenomeID_h133a_2802.cel: 1908///Cancer.Type: Short///AgeDx: 59///STAGE: IIIC///GRADE: 3///Debulking: O///X: NA
1
Genome.ID..File.name....0074_GenomeID_h133a_2802.cel: 1909///Cancer.Type: Short///AgeDx: 65///STAGE: IIIC///GRADE: 3///Debulking: S///X: NA
1
Genome.ID..File.name....0074_GenomeID_h133a_2802.cel: 1989///Cancer.Type: Long///AgeDx: 67///STAGE: IIIC///GRADE: 2///Debulking: S///X: NA
1
Genome.ID..File.name....0074_GenomeID_h133a_2802.cel: 2003///Cancer.Type: Short///AgeDx: 49///STAGE: IIIC///GRADE: 3///Debulking: S///X: NA
1
Genome.ID..File.name....0074_GenomeID_h133a_2802.cel: 2004///Cancer.Type: Short///AgeDx: 55///STAGE: IIIC///GRADE: 2///Debulking: S///X: NA
1
Genome.ID..File.name....0074_GenomeID_h133a_2802.cel: 2005///Cancer.Type: Short///AgeDx: 47///STAGE: IIIC///GRADE: ?///Debulking: S///X: NA
1
Genome.ID..File.name....0074_GenomeID_h133a_2802.cel: 2019///Cancer.Type: Long///AgeDx: 48///STAGE: IIIC///GRADE: 2///Debulking: O///X: NA
1
Genome.ID..File.name....0074_GenomeID_h133a_2802.cel: 2020///Cancer.Type: Long///AgeDx: 58///STAGE: IIIC///GRADE: 2///Debulking: O///X: NA
1
Genome.ID..File.name....0074_GenomeID_h133a_2802.cel: 2021///Cancer.Type: Long///AgeDx: 62///STAGE: IIIC///GRADE: 2///Debulking: S///X: NA
1
Genome.ID..File.name....0074_GenomeID_h133a_2802.cel: 2026///Cancer.Type: Short///AgeDx: 46///STAGE: IIIC///GRADE: 3///Debulking: S///X: NA
1
Genome.ID..File.name....0074_GenomeID_h133a_2802.cel: 2027///Cancer.Type: Short///AgeDx: 65///STAGE: IIIC///GRADE: 2///Debulking: O///X: NA
1
Genome.ID..File.name....0074_GenomeID_h133a_2802.cel: 2028///Cancer.Type: Short///AgeDx: 71///STAGE: IIIC///GRADE: 3///Debulking: S///X: NA
1
Genome.ID..File.name....0074_GenomeID_h133a_2802.cel: 2029///Cancer.Type: Short///AgeDx: 68///STAGE: IIIC///GRADE: 3///Debulking: S///X: NA
1
Genome.ID..File.name....0074_GenomeID_h133a_2802.cel: 2030///Cancer.Type: Short///AgeDx: 54///STAGE: IV///GRADE: 3///Debulking: S///X: NA
1
Genome.ID..File.name....0074_GenomeID_h133a_2802.cel: 2031///Cancer.Type: Long///AgeDx: 63///STAGE: IIIC///GRADE: 2///Debulking: O///X: NA
1
Genome.ID..File.name....0074_GenomeID_h133a_2802.cel: 2032///Cancer.Type: Long///AgeDx: 58///STAGE: IIIC///GRADE: 2///Debulking: S///X: NA
1
Genome.ID..File.name....0074_GenomeID_h133a_2802.cel: 2033///Cancer.Type: Long///AgeDx: 57///STAGE: IIIC///GRADE: 2///Debulking: S///X: NA
1
Genome.ID..File.name....0074_GenomeID_h133a_2802.cel: 2390///Cancer.Type: Early stage///AgeDx: 66///STAGE: IA///GRADE: 2///Debulking: ///X: NA
1
Genome.ID..File.name....0074_GenomeID_h133a_2802.cel: 2391///Cancer.Type: Early stage///AgeDx: 77///STAGE: IA///GRADE: 3///Debulking: ///X: NA
1
Genome.ID..File.name....0074_GenomeID_h133a_2802.cel: 2392///Cancer.Type: Early stage///AgeDx: 46///STAGE: IIC///GRADE: 3///Debulking: ///X: NA
1
Genome.ID..File.name....0074_GenomeID_h133a_2802.cel: 2393///Cancer.Type: Early stage///AgeDx: 49///STAGE: IIC///GRADE: 2///Debulking: ///X: NA
1
Genome.ID..File.name....0074_GenomeID_h133a_2802.cel: 2394///Cancer.Type: Long///AgeDx: 62///STAGE: IIIC///GRADE: 2///Debulking: O///X: NA
1
Genome.ID..File.name....0074_GenomeID_h133a_2802.cel: 2395///Cancer.Type: Long///AgeDx: 40///STAGE: IIIC///GRADE: 2///Debulking: S///X: NA
1
Genome.ID..File.name....0074_GenomeID_h133a_2802.cel: 2396///Cancer.Type: Short///AgeDx: 73///STAGE: IIIC///GRADE: 2///Debulking: O///X: NA
1
Genome.ID..File.name....0074_GenomeID_h133a_2802.cel: 2397///Cancer.Type: Short///AgeDx: 57///STAGE: IIIC///GRADE: 2///Debulking: S///X: NA
1
Genome.ID..File.name....0074_GenomeID_h133a_2802.cel: 2398///Cancer.Type: Short///AgeDx: 37///STAGE: IV///GRADE: 2///Debulking: O///X: NA
1
Genome.ID..File.name....0074_GenomeID_h133a_2802.cel: 2399///Cancer.Type: Short///AgeDx: 62///STAGE: IIIC///GRADE: 2///Debulking: S///X: NA
1
Genome.ID..File.name....0074_GenomeID_h133a_2802.cel: 2400///Cancer.Type: Short///AgeDx: 62///STAGE: IIIC///GRADE: 3///Debulking: O///X: NA
1
Genome.ID..File.name....0074_GenomeID_h133a_2802.cel: 2401///Cancer.Type: Short///AgeDx: 57///STAGE: IIIC///GRADE: 2///Debulking: O///X: NA
1
Genome.ID..File.name....0074_GenomeID_h133a_2802.cel: 2402///Cancer.Type: Short///AgeDx: 57///STAGE: IV///GRADE: 2///Debulking: O///X: NA
1
Genome.ID..File.name....0074_GenomeID_h133a_2802.cel: 2536///Cancer.Type: Early stage///AgeDx: 42///STAGE: IA///GRADE: 1///Debulking: ///X: NA
1
An expression set
The purpose of this study was to develop an integrated genomic-based approach to personalized treatment of patients with advanced-stage ovarian cancer. We have used gene expression profiles to identify patients likely to be resistant to primary platinum-based chemotherapy and also to identify alternate targeted therapeutic options for patients with de novo platinum-resistant disease.A gene expression model that predicts response to platinum-based therapy was developed using a training set of 83 advanced-stage serous ovarian cancers and tested on a 36-sample external validation set. In parallel, expression signatures that define the status of oncogenic signaling pathways were evaluated in 119 primary ovarian cancers and 12 ovarian cancer cell lines. In an effort to increase chemotherapy sensitivity, pathways shown to be activated in platinum-resistant cancers were subject to targeted therapy in ovarian cancer cell lines.Gene expression profiles identified patients with ovarian cancer likely to be resistant to primary platinum-based chemotherapy with greater than 80% accuracy. In patients with platinum-resistant disease, we identified expression signatures consistent with activation of Src and Rb/E2F pathways, components of which were successfully targeted to increase response in ovarian cancer cell lines.We have defined a strategy for treatment of patients with advanced-stage ovarian cancer that uses therapeutic stratification based on predictions of response to chemotherapy, coupled with prediction of oncogenic pathway deregulation, as a method to direct the use of targeted agents.
experimentData(eset):
Experiment data
Experimenter name: Dressman HK, Berchuck A, Chan G, Zhai J, Bild A, Sayer R, Cragun J, Clarke J, Whitaker RS, Li L, Gray J, Marks J, Ginsburg GS, Potti A, West M, Nevins JR, Lancaster JM.An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. J Clin Oncol. 2007 Feb 10; 25(5):517-25.
Laboratory: Dressman, Lancaster 2007
Contact information:
Title: An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer.
URL:
PMIDs: 17290060
Abstract: A 223 word abstract is available. Use 'abstract' method.
Information is available on: preprocessing
notes:
platform_title:
[HG-U133A] Affymetrix Human Genome U133A Array
platform_shorttitle:
Affymetrix HG-U133A
platform_summary:
hgu133a
platform_manufacturer:
Affymetrix
platform_distribution:
commercial
platform_accession:
GPL96
warnings:
This paper has been retracted.
version:
2015-09-22 20:19:16
featureData(eset):
An object of class 'AnnotatedDataFrame'
featureNames: 1007_s_at 1053_at ... AFFX-HUMISGF3A/M97935_MB_at
(20967 total)
varLabels: probeset gene EntrezGene.ID best_probe
varMetadata: labelDescription
assayData: 20967 features, 117 samples
Platform type:
Overall survival time-to-event summary (in years):
Call: survfit(formula = Surv(time, cens) ~ -1)
n events median 0.95LCL 0.95UCL
117.00 67.00 5.26 2.79 7.48
---------------------------
Available sample meta-data:
---------------------------
alt_sample_name:
1024 1447 1451 1504 1526 1552 1578 1590 1615 1623
1 1 1 1 1 1 1 1 1 1
1665 1674 1675 1774 1784 1834 1846 1877 1913 1929
1 1 1 1 1 1 1 1 1 1
2046 2063 2064 2075 2198 2204 2324 2419 2422 2424
1 1 1 1 1 1 1 1 1 1
2465 2476 2479 2505 2542 2573 2673 2739 2802 2849
1 1 1 1 1 1 1 1 1 1
2895 2967 2981 2999 3018 3090 3102 3107 3142 860
1 1 1 1 1 1 1 1 1 1
872 922 D1805 D1837 D1859 D2098 D2208 D2332 D2342 D2358
1 1 1 1 1 1 1 1 1 1
D2421 D2432 D2433 D2480 D2557 D2559 D2560 D2572 D2575 D2576
1 1 1 1 1 1 1 1 1 1
D2581 D2603 D2611 D2629 D2640 D2648 D2668 D2689 D2691 D2700
1 1 1 1 1 1 1 1 1 1
D2726 D2727 D2733 D2738 D2749 D2776 D2792 M1054 M1055 M120
1 1 1 1 1 1 1 1 1 1
M1241 M1390 M1503 M1572 M17 M1891 M2070 M2097 M2184 (Other)
1 1 1 1 1 1 1 1 1 18
sample_type:
tumor
117
histological_type:
ser
117
primarysite:
ov
117
summarygrade:
high low NA's
57 57 3
summarystage:
early late NA's
1 115 1
tumorstage:
2 3 4 NA's
1 98 17 1
grade:
1 2 3 4 NA's
4 53 56 1 3
days_to_death:
Min. 1st Qu. Median Mean 3rd Qu. Max.
30 510 1020 1496 2220 5550
vital_status:
deceased living
67 50
primary_therapy_outcome_success:
completeresponse progressivedisease
85 32
debulking:
optimal suboptimal
63 54
batch:
2002-09-20 2002-10-23 2002-11-12 2002-12-16 2002-12-21 2003-01-03 2003-05-30
10 8 9 1 3 11 10
2004-03-09 2004-03-16 2004-04-20 2004-05-18 2004-05-21 2004-05-27 2004-06-22
16 6 5 15 7 7 1
2004-06-23
8
uncurated_author_metadata:
OVC.TumorID: 1024///Survival: 13///X0...alive...1...dead: 1///Assigned.Stage: 4///GRADE: 3///Debulk: S///CA125.POST: 12///response.0.NR..1.CR.: 1///X: NA///X.1: NA///X.2: NA
1
OVC.TumorID: 1447///Survival: 75///X0...alive...1...dead: 1///Assigned.Stage: 3///GRADE: 2///Debulk: S///CA125.POST: 8.6///response.0.NR..1.CR.: 1///X: NA///X.1: NA///X.2: NA
1
OVC.TumorID: 1451///Survival: 132///X0...alive...1...dead: 1///Assigned.Stage: 3///GRADE: 3///Debulk: S///CA125.POST: 16///response.0.NR..1.CR.: 1///X: NA///X.1: NA///X.2: NA
1
OVC.TumorID: 1504///Survival: 108///X0...alive...1...dead: 1///Assigned.Stage: 3///GRADE: 3///Debulk: O///CA125.POST: 4///response.0.NR..1.CR.: 1///X: NA///X.1: NA///X.2: NA
1
OVC.TumorID: 1526///Survival: 74///X0...alive...1...dead: 1///Assigned.Stage: 3///GRADE: 2///Debulk: O///CA125.POST: 5.1///response.0.NR..1.CR.: 1///X: NA///X.1: NA///X.2: NA
1
OVC.TumorID: 1552///Survival: 33///X0...alive...1...dead: 1///Assigned.Stage: 3///GRADE: 2///Debulk: S///CA125.POST: 9.9///response.0.NR..1.CR.: 1///X: NA///X.1: NA///X.2: NA
1
OVC.TumorID: 1578///Survival: 33///X0...alive...1...dead: 1///Assigned.Stage: 4///GRADE: 2///Debulk: O///CA125.POST: 8.7///response.0.NR..1.CR.: 1///X: NA///X.1: NA///X.2: NA
1
OVC.TumorID: 1590///Survival: 148///X0...alive...1...dead: 0///Assigned.Stage: 3///GRADE: 2///Debulk: O///CA125.POST: 7///response.0.NR..1.CR.: 1///X: NA///X.1: NA///X.2: NA
1
OVC.TumorID: 1615///Survival: 13///X0...alive...1...dead: 1///Assigned.Stage: 3///GRADE: 3///Debulk: S///CA125.POST: 875///response.0.NR..1.CR.: 0///X: NA///X.1: NA///X.2: NA
1
OVC.TumorID: 1623///Survival: 147///X0...alive...1...dead: 0///Assigned.Stage: 3///GRADE: 1///Debulk: O///CA125.POST: 4///response.0.NR..1.CR.: 1///X: NA///X.1: NA///X.2: NA
1
OVC.TumorID: 1665///Survival: 15///X0...alive...1...dead: 1///Assigned.Stage: 3///GRADE: 2///Debulk: S///CA125.POST: 500///response.0.NR..1.CR.: 0///X: NA///X.1: NA///X.2: NA
1
OVC.TumorID: 1674///Survival: 18///X0...alive...1...dead: 1///Assigned.Stage: 3///GRADE: 2///Debulk: O///CA125.POST: 15///response.0.NR..1.CR.: 1///X: NA///X.1: NA///X.2: NA
1
OVC.TumorID: 1675///Survival: 34///X0...alive...1...dead: 1///Assigned.Stage: 3///GRADE: 2///Debulk: S///CA125.POST: 14.4///response.0.NR..1.CR.: 1///X: NA///X.1: NA///X.2: NA
1
OVC.TumorID: 1774///Survival: 22///X0...alive...1...dead: 1///Assigned.Stage: 3///GRADE: 2///Debulk: O///CA125.POST: 33.3///response.0.NR..1.CR.: 1///X: NA///X.1: NA///X.2: NA
1
OVC.TumorID: 1784///Survival: 78///X0...alive...1...dead: 1///Assigned.Stage: 3///GRADE: 2///Debulk: S///CA125.POST: 32///response.0.NR..1.CR.: 1///X: NA///X.1: NA///X.2: NA
1
OVC.TumorID: 1834///Survival: 118///X0...alive...1...dead: 1///Assigned.Stage: 3///GRADE: 3///Debulk: O///CA125.POST: 17///response.0.NR..1.CR.: 1///X: NA///X.1: NA///X.2: NA
1
OVC.TumorID: 1846///Survival: 142///X0...alive...1...dead: 0///Assigned.Stage: 3///GRADE: 2///Debulk: O///CA125.POST: 9///response.0.NR..1.CR.: 1///X: NA///X.1: NA///X.2: NA
1
OVC.TumorID: 1877///Survival: 119///X0...alive...1...dead: 1///Assigned.Stage: 3///GRADE: 2///Debulk: O///CA125.POST: 7///response.0.NR..1.CR.: 1///X: NA///X.1: NA///X.2: NA
1
OVC.TumorID: 1913///Survival: 32///X0...alive...1...dead: 1///Assigned.Stage: 3///GRADE: 2///Debulk: O///CA125.POST: <20///response.0.NR..1.CR.: 1///X: NA///X.1: NA///X.2: NA
1
OVC.TumorID: 1929///Survival: 134///X0...alive...1...dead: 0///Assigned.Stage: 3///GRADE: 4///Debulk: S///CA125.POST: 7///response.0.NR..1.CR.: 1///X: NA///X.1: NA///X.2: NA
1
OVC.TumorID: 2046///Survival: 127///X0...alive...1...dead: 0///Assigned.Stage: 3///GRADE: 2///Debulk: O///CA125.POST: 6///response.0.NR..1.CR.: 1///X: NA///X.1: NA///X.2: NA
1
OVC.TumorID: 2063///Survival: 16///X0...alive...1...dead: 1///Assigned.Stage: 3///GRADE: 3///Debulk: S///CA125.POST: 26.8///response.0.NR..1.CR.: 1///X: NA///X.1: NA///X.2: NA
1
OVC.TumorID: 2064///Survival: 27///X0...alive...1...dead: 1///Assigned.Stage: 3///GRADE: 3///Debulk: O///CA125.POST: ELEVATED///response.0.NR..1.CR.: 0///X: NA///X.1: NA///X.2: NA
1
OVC.TumorID: 2075///Survival: 87///X0...alive...1...dead: 1///Assigned.Stage: 3///GRADE: 3///Debulk: O///CA125.POST: 8///response.0.NR..1.CR.: 1///X: NA///X.1: NA///X.2: NA
1
OVC.TumorID: 2198///Survival: 91///X0...alive...1...dead: 1///Assigned.Stage: 3///GRADE: 2///Debulk: S///CA125.POST: 7///response.0.NR..1.CR.: 1///X: NA///X.1: NA///X.2: NA
1
OVC.TumorID: 2204///Survival: 118///X0...alive...1...dead: 0///Assigned.Stage: 3///GRADE: 2///Debulk: O///CA125.POST: 7///response.0.NR..1.CR.: 1///X: NA///X.1: NA///X.2: NA
1
OVC.TumorID: 2324///Survival: 98///X0...alive...1...dead: 1///Assigned.Stage: 3///GRADE: 3///Debulk: O///CA125.POST: 7///response.0.NR..1.CR.: 1///X: NA///X.1: NA///X.2: NA
1
OVC.TumorID: 2419///Survival: 107///X0...alive...1...dead: 0///Assigned.Stage: 3///GRADE: 3///Debulk: O///CA125.POST: 10///response.0.NR..1.CR.: 1///X: NA///X.1: NA///X.2: NA
1
OVC.TumorID: 2422///Survival: 20///X0...alive...1...dead: 1///Assigned.Stage: 3///GRADE: 3///Debulk: S///CA125.POST: 8///response.0.NR..1.CR.: 1///X: NA///X.1: NA///X.2: NA
1
OVC.TumorID: 2424///Survival: 16///X0...alive...1...dead: 1///Assigned.Stage: 3///GRADE: 3///Debulk: S///CA125.POST: 1117///response.0.NR..1.CR.: 0///X: NA///X.1: NA///X.2: NA
1
OVC.TumorID: 2465///Survival: 17///X0...alive...1...dead: 1///Assigned.Stage: 3///GRADE: 2///Debulk: S///CA125.POST: 4928///response.0.NR..1.CR.: 0///X: NA///X.1: NA///X.2: NA
1
OVC.TumorID: 2476///Survival: 86///X0...alive...1...dead: 1///Assigned.Stage: 3///GRADE: 2///Debulk: O///CA125.POST: 56.1///response.0.NR..1.CR.: 0///X: NA///X.1: NA///X.2: NA
1
OVC.TumorID: 2479///Survival: 95///X0...alive...1...dead: 0///Assigned.Stage: 3///GRADE: 2///Debulk: S///CA125.POST: 16.5///response.0.NR..1.CR.: 1///X: NA///X.1: NA///X.2: NA
1
OVC.TumorID: 2505///Survival: 95///X0...alive...1...dead: 0///Assigned.Stage: 3///GRADE: 2///Debulk: S///CA125.POST: 12///response.0.NR..1.CR.: 1///X: NA///X.1: NA///X.2: NA
1
OVC.TumorID: 2542///Survival: 36///X0...alive...1...dead: 1///Assigned.Stage: 3///GRADE: 2///Debulk: O///CA125.POST: 8///response.0.NR..1.CR.: 1///X: NA///X.1: NA///X.2: NA
1
OVC.TumorID: 2573///Survival: 7///X0...alive...1...dead: 1///Assigned.Stage: 3///GRADE: 3///Debulk: S///CA125.POST: 641.3///response.0.NR..1.CR.: 0///X: NA///X.1: NA///X.2: NA
1
OVC.TumorID: 2673///Survival: 74///X0...alive...1...dead: 0///Assigned.Stage: 3///GRADE: 2///Debulk: S///CA125.POST: 11.5///response.0.NR..1.CR.: 1///X: NA///X.1: NA///X.2: NA
1
OVC.TumorID: 2739///Survival: 67///X0...alive...1...dead: 0///Assigned.Stage: 3///GRADE: 2///Debulk: O///CA125.POST: 10///response.0.NR..1.CR.: 1///X: NA///X.1: NA///X.2: NA
1
OVC.TumorID: 2802///Survival: 24///X0...alive...1...dead: 1///Assigned.Stage: 3///GRADE: 3///Debulk: S///CA125.POST: 402///response.0.NR..1.CR.: 0///X: NA///X.1: NA///X.2: NA
1
OVC.TumorID: 2849///Survival: 23///X0...alive...1...dead: 1///Assigned.Stage: 3///GRADE: 2///Debulk: S///CA125.POST: 37.6///response.0.NR..1.CR.: 0///X: NA///X.1: NA///X.2: NA
1
OVC.TumorID: 2895///Survival: 9///X0...alive...1...dead: 1///Assigned.Stage: 3///GRADE: 3///Debulk: O///CA125.POST: 41.6///response.0.NR..1.CR.: 0///X: NA///X.1: NA///X.2: NA
1
OVC.TumorID: 2967///Survival: 22///X0...alive...1...dead: 1///Assigned.Stage: 3///GRADE: 3///Debulk: S///CA125.POST: 26///response.0.NR..1.CR.: 1///X: NA///X.1: NA///X.2: NA
1
OVC.TumorID: 2981///Survival: 6///X0...alive...1...dead: 1///Assigned.Stage: 3///GRADE: 2///Debulk: S///CA125.POST: 30.6///response.0.NR..1.CR.: 1///X: NA///X.1: NA///X.2: NA
1
OVC.TumorID: 2999///Survival: 16///X0...alive...1...dead: 1///Assigned.Stage: 3///GRADE: 2///Debulk: S///CA125.POST: 2291///response.0.NR..1.CR.: 0///X: NA///X.1: NA///X.2: NA
1
OVC.TumorID: 3018///Survival: 16///X0...alive...1...dead: 1///Assigned.Stage: 3///GRADE: 2///Debulk: O///CA125.POST: 6.2///response.0.NR..1.CR.: 1///X: NA///X.1: NA///X.2: NA
1
OVC.TumorID: 3090///Survival: 16///X0...alive...1...dead: 1///Assigned.Stage: 4///GRADE: 2///Debulk: O///CA125.POST: 10.8///response.0.NR..1.CR.: 1///X: NA///X.1: NA///X.2: NA
1
OVC.TumorID: 3102///Survival: 10///X0...alive...1...dead: 1///Assigned.Stage: 3///GRADE: ?///Debulk: S///CA125.POST: 127.3///response.0.NR..1.CR.: 0///X: NA///X.1: NA///X.2: NA
1
OVC.TumorID: 3107///Survival: 31///X0...alive...1...dead: 1///Assigned.Stage: 3///GRADE: 2///Debulk: S///CA125.POST: 11.2///response.0.NR..1.CR.: 1///X: NA///X.1: NA///X.2: NA
1
OVC.TumorID: 3142///Survival: 18///X0...alive...1...dead: 1///Assigned.Stage: 3///GRADE: 3///Debulk: S///CA125.POST: 52///response.0.NR..1.CR.: 0///X: NA///X.1: NA///X.2: NA
1
OVC.TumorID: 860///Survival: 17///X0...alive...1...dead: 1///Assigned.Stage: 4///GRADE: 3///Debulk: O///CA125.POST: 133///response.0.NR..1.CR.: 0///X: NA///X.1: NA///X.2: NA
1
OVC.TumorID: 872///Survival: 185///X0...alive...1...dead: 0///Assigned.Stage: 3///GRADE: 3///Debulk: S///CA125.POST: 3.1///response.0.NR..1.CR.: 1///X: NA///X.1: NA///X.2: NA
1
OVC.TumorID: 922///Survival: 183///X0...alive...1...dead: 0///Assigned.Stage: 3///GRADE: 2///Debulk: S///CA125.POST: 9///response.0.NR..1.CR.: 1///X: NA///X.1: NA///X.2: NA
1
OVC.TumorID: D1805///Survival: 9///X0...alive...1...dead: 1///Assigned.Stage: 4///GRADE: 2///Debulk: S///CA125.POST: 331///response.0.NR..1.CR.: 0///X: NA///X.1: NA///X.2: NA
1
OVC.TumorID: D1837///Survival: 83///X0...alive...1...dead: 0///Assigned.Stage: 3///GRADE: 3///Debulk: O///CA125.POST: 11.3///response.0.NR..1.CR.: 1///X: NA///X.1: NA///X.2: NA
1
OVC.TumorID: D1859///Survival: 110///X0...alive...1...dead: 1///Assigned.Stage: 3///GRADE: 3///Debulk: O///CA125.POST: 15///response.0.NR..1.CR.: 1///X: NA///X.1: NA///X.2: NA
1
OVC.TumorID: D2098///Survival: 42///X0...alive...1...dead: 1///Assigned.Stage: 3///GRADE: 3///Debulk: S///CA125.POST: NA///response.0.NR..1.CR.: 0///X: NA///X.1: NA///X.2: NA
1
OVC.TumorID: D2208///Survival: 2///X0...alive...1...dead: 0///Assigned.Stage: 4///GRADE: 3///Debulk: S///CA125.POST: 808.6///response.0.NR..1.CR.: 0///X: NA///X.1: NA///X.2: NA
1
OVC.TumorID: D2332///Survival: 27///X0...alive...1...dead: 1///Assigned.Stage: 3///GRADE: 2///Debulk: S///CA125.POST: 11///response.0.NR..1.CR.: 1///X: NA///X.1: NA///X.2: NA
1
OVC.TumorID: D2342///Survival: 20///X0...alive...1...dead: 1///Assigned.Stage: 3///GRADE: 3///Debulk: S///CA125.POST: 473///response.0.NR..1.CR.: 0///X: NA///X.1: NA///X.2: NA
1
OVC.TumorID: D2358///Survival: 9///X0...alive...1...dead: 1///Assigned.Stage: 4///GRADE: 2///Debulk: O///CA125.POST: 29///response.0.NR..1.CR.: 1///X: NA///X.1: NA///X.2: NA
1
OVC.TumorID: D2421///Survival: 12///X0...alive...1...dead: 1///Assigned.Stage: 3///GRADE: 2///Debulk: O///CA125.POST: 35///response.0.NR..1.CR.: 1///X: NA///X.1: NA///X.2: NA
1
OVC.TumorID: D2432///Survival: 34///X0...alive...1...dead: 1///Assigned.Stage: 3///GRADE: 2///Debulk: S///CA125.POST: 9///response.0.NR..1.CR.: 1///X: NA///X.1: NA///X.2: NA
1
OVC.TumorID: D2433///Survival: 49///X0...alive...1...dead: 0///Assigned.Stage: 3///GRADE: 2///Debulk: O///CA125.POST: 12.7///response.0.NR..1.CR.: 1///X: NA///X.1: NA///X.2: NA
1
OVC.TumorID: D2480///Survival: 34///X0...alive...1...dead: 1///Assigned.Stage: 3///GRADE: 3///Debulk: O///CA125.POST: 29.6///response.0.NR..1.CR.: 1///X: NA///X.1: NA///X.2: NA
1
OVC.TumorID: D2557///Survival: 62///X0...alive...1...dead: 0///Assigned.Stage: 3///GRADE: 2///Debulk: O///CA125.POST: 1920///response.0.NR..1.CR.: 0///X: NA///X.1: NA///X.2: NA
1
OVC.TumorID: D2559///Survival: 5///X0...alive...1...dead: 1///Assigned.Stage: 4///GRADE: 3///Debulk: O///CA125.POST: 9.6///response.0.NR..1.CR.: 1///X: NA///X.1: NA///X.2: NA
1
OVC.TumorID: D2560///Survival: 91///X0...alive...1...dead: 0///Assigned.Stage: 3///GRADE: 2///Debulk: S///CA125.POST: 10.5///response.0.NR..1.CR.: 1///X: NA///X.1: NA///X.2: NA
1
OVC.TumorID: D2572///Survival: 37///X0...alive...1...dead: 0///Assigned.Stage: 3///GRADE: 2///Debulk: S///CA125.POST: 24///response.0.NR..1.CR.: 1///X: NA///X.1: NA///X.2: NA
1
OVC.TumorID: D2575///Survival: 33///X0...alive...1...dead: 1///Assigned.Stage: 4///GRADE: 2///Debulk: O///CA125.POST: 13.7///response.0.NR..1.CR.: 1///X: NA///X.1: NA///X.2: NA
1
OVC.TumorID: D2576///Survival: 17///X0...alive...1...dead: 1///Assigned.Stage: 3///GRADE: 3///Debulk: S///CA125.POST: 43.1///response.0.NR..1.CR.: 0///X: NA///X.1: NA///X.2: NA
1
OVC.TumorID: D2581///Survival: 63///X0...alive...1...dead: 0///Assigned.Stage: 3///GRADE: 1///Debulk: O///CA125.POST: 48///response.0.NR..1.CR.: 0///X: NA///X.1: NA///X.2: NA
1
OVC.TumorID: D2603///Survival: 42///X0...alive...1...dead: 0///Assigned.Stage: 3///GRADE: 3///Debulk: O///CA125.POST: 15.2///response.0.NR..1.CR.: 1///X: NA///X.1: NA///X.2: NA
1
OVC.TumorID: D2611///Survival: 2///X0...alive...1...dead: 1///Assigned.Stage: 3///GRADE: 2///Debulk: O///CA125.POST: 134///response.0.NR..1.CR.: 0///X: NA///X.1: NA///X.2: NA
1
OVC.TumorID: D2629///Survival: 36///X0...alive...1...dead: 0///Assigned.Stage: 4///GRADE: 2///Debulk: S///CA125.POST: 56///response.0.NR..1.CR.: 0///X: NA///X.1: NA///X.2: NA
1
OVC.TumorID: D2640///Survival: 1///X0...alive...1...dead: 1///Assigned.Stage: 3///GRADE: 2///Debulk: S///CA125.POST: 158.3///response.0.NR..1.CR.: 0///X: NA///X.1: NA///X.2: NA
1
OVC.TumorID: D2648///Survival: 35///X0...alive...1...dead: 1///Assigned.Stage: 3///GRADE: 2///Debulk: S///CA125.POST: 58.7///response.0.NR..1.CR.: 0///X: NA///X.1: NA///X.2: NA
1
OVC.TumorID: D2668///Survival: 40///X0...alive...1...dead: 1///Assigned.Stage: 3///GRADE: ///Debulk: S///CA125.POST: ///response.0.NR..1.CR.: 1///X: NA///X.1: NA///X.2: NA
1
OVC.TumorID: D2689///Survival: 45///X0...alive...1...dead: 0///Assigned.Stage: 3///GRADE: 2///Debulk: S///CA125.POST: 13.5///response.0.NR..1.CR.: 1///X: NA///X.1: NA///X.2: NA
1
OVC.TumorID: D2691///Survival: 63///X0...alive...1...dead: 0///Assigned.Stage: 3///GRADE: 2///Debulk: O///CA125.POST: 16.5///response.0.NR..1.CR.: 1///X: NA///X.1: NA///X.2: NA
1
OVC.TumorID: D2700///Survival: 74///X0...alive...1...dead: 0///Assigned.Stage: 3///GRADE: 2///Debulk: S///CA125.POST: 13.9///response.0.NR..1.CR.: 1///X: NA///X.1: NA///X.2: NA
1
OVC.TumorID: D2726///Survival: 71///X0...alive...1...dead: 0///Assigned.Stage: 3///GRADE: 2///Debulk: S///CA125.POST: 6.6///response.0.NR..1.CR.: 1///X: NA///X.1: NA///X.2: NA
1
OVC.TumorID: D2727///Survival: 53///X0...alive...1...dead: 0///Assigned.Stage: 3///GRADE: 3///Debulk: S///CA125.POST: 44///response.0.NR..1.CR.: 0///X: NA///X.1: NA///X.2: NA
1
OVC.TumorID: D2733///Survival: 55///X0...alive...1...dead: 0///Assigned.Stage: 3///GRADE: 3///Debulk: S///CA125.POST: 12.1///response.0.NR..1.CR.: 1///X: NA///X.1: NA///X.2: NA
1
OVC.TumorID: D2738///Survival: 68///X0...alive...1...dead: 0///Assigned.Stage: 3///GRADE: 2///Debulk: O///CA125.POST: 37.9///response.0.NR..1.CR.: 0///X: NA///X.1: NA///X.2: NA
1
OVC.TumorID: D2749///Survival: 24///X0...alive...1...dead: 1///Assigned.Stage: 3///GRADE: 2///Debulk: O///CA125.POST: 16.3///response.0.NR..1.CR.: 1///X: NA///X.1: NA///X.2: NA
1
OVC.TumorID: D2776///Survival: 10///X0...alive...1...dead: 1///Assigned.Stage: 3///GRADE: 3///Debulk: S///CA125.POST: 41.2///response.0.NR..1.CR.: 0///X: NA///X.1: NA///X.2: NA
1
OVC.TumorID: D2792///Survival: 16///X0...alive...1...dead: 1///Assigned.Stage: 3///GRADE: 3///Debulk: S///CA125.POST: 32.6///response.0.NR..1.CR.: 1///X: NA///X.1: NA///X.2: NA
1
OVC.TumorID: M1054///Survival: 101///X0...alive...1...dead: 0///Assigned.Stage: 3///GRADE: UNK///Debulk: Optimal///CA125.POST: 46///response.0.NR..1.CR.: 0///X: NA///X.1: NA///X.2: NA
1
OVC.TumorID: M1055///Survival: 13///X0...alive...1...dead: 0///Assigned.Stage: 3///GRADE: 3 ///Debulk: Optimal///CA125.POST: UNK///response.0.NR..1.CR.: 1///X: NA///X.1: NA///X.2: NA
1
OVC.TumorID: M120///Survival: 35///X0...alive...1...dead: 1///Assigned.Stage: 3///GRADE: 3 ///Debulk: Optimal///CA125.POST: 2///response.0.NR..1.CR.: 1///X: NA///X.1: NA///X.2: NA
1
OVC.TumorID: M1241///Survival: 95///X0...alive...1...dead: 0///Assigned.Stage: 4///GRADE: 3 ///Debulk: Suboptimal///CA125.POST: 10///response.0.NR..1.CR.: 1///X: NA///X.1: NA///X.2: NA
1
OVC.TumorID: M1390///Survival: 46///X0...alive...1...dead: 0///Assigned.Stage: 4///GRADE: 3///Debulk: O///CA125.POST: UNK///response.0.NR..1.CR.: 1///X: NA///X.1: NA///X.2: NA
1
OVC.TumorID: M1503///Survival: 53///X0...alive...1...dead: 1///Assigned.Stage: 3///GRADE: 2/3///Debulk: Optimal///CA125.POST: 19///response.0.NR..1.CR.: 1///X: NA///X.1: NA///X.2: NA
1
OVC.TumorID: M1572///Survival: 22///X0...alive...1...dead: 1///Assigned.Stage: 3///GRADE: 3 ///Debulk: Optimal///CA125.POST: 49///response.0.NR..1.CR.: 0///X: NA///X.1: NA///X.2: NA
1
OVC.TumorID: M17///Survival: 17///X0...alive...1...dead: 0///Assigned.Stage: 4///GRADE: 2 ///Debulk: Suboptimal///CA125.POST: 4700///response.0.NR..1.CR.: 0///X: NA///X.1: NA///X.2: NA
1
OVC.TumorID: M1891///Survival: 12///X0...alive...1...dead: 0///Assigned.Stage: 4///GRADE: 1 ///Debulk: Suboptimal (10/3/97)///CA125.POST: 17///response.0.NR..1.CR.: 1///X: NA///X.1: NA///X.2: NA
1
OVC.TumorID: M2070///Survival: 65///X0...alive...1...dead: 0///Assigned.Stage: 3///GRADE: 3 ///Debulk: Suboptimal///CA125.POST: 22///response.0.NR..1.CR.: 1///X: NA///X.1: NA///X.2: NA
1
OVC.TumorID: M2097///Survival: 58///X0...alive...1...dead: 0///Assigned.Stage: 2///GRADE: 2/3///Debulk: Optimal///CA125.POST: ///response.0.NR..1.CR.: 1///X: NA///X.1: NA///X.2: NA
1
OVC.TumorID: M2184///Survival: 34///X0...alive...1...dead: 0///Assigned.Stage: 3///GRADE: 3 ///Debulk: Optimal///CA125.POST: 10///response.0.NR..1.CR.: 1///X: NA///X.1: NA///X.2: NA
1
(Other)
18
An expression set
Although few women with advanced serous ovarian cancer are cured, detection of the disease at an early stage is associated with a much higher likelihood of survival. We previously used gene expression array analysis to distinguish subsets of advanced cancers based on disease outcome. In the present study, we report on gene expression of early-stage cancers and validate our prognostic model for advanced-stage cancers.Frozen specimens from 39 stage I/II, 42 stage III/IV, and 20 low malignant potential cancers were obtained from four different sites. A linear discriminant model was used to predict survival based upon array data.We validated the late-stage survival model and show that three of the most differentially expressed genes continue to be predictive of outcome. Most early-stage cancers (38 of 39 invasive, 15 of 20 low malignant potential) were classified as long-term survivors (median probabilities 0.97 and 0.86). MAL, the most differentially expressed gene, was further validated at the protein level and found to be an independent predictor of poor survival in an unselected group of advanced serous cancers (P = 0.0004).These data suggest that serous ovarian cancers detected at an early stage generally have a favorable underlying biology similar to advanced-stage cases that are long-term survivors. Conversely, most late-stage ovarian cancers seem to have a more virulent biology. This insight suggests that if screening approaches are to succeed it will be necessary to develop approaches that are able to detect these virulent cancers at an early stage.
experimentData(eset):
Experiment data
Experimenter name: Berchuck A, Iversen ES, Luo J, Clarke JP, Horne H, Levine DA, Boyd J, Alonso MA, Secord AA, Bernardini MQ, Barnett JC, Boren T, Murphy SK, Dressman HK, Marks JR, Lancaster JM.Microarray analysis of early stage serous ovarian cancers shows profiles predictive of favorable outcome. Clin Cancer Res. 2009 Apr 1; 15(7):2448-55.
Laboratory: Berchuck, Lancaster 2009
Contact information:
Title: Microarray analysis of early stage serous ovarian cancers shows profiles predictive of favorable outcome.
URL:
PMIDs: 19318476
Abstract: A 241 word abstract is available. Use 'abstract' method.
Information is available on: preprocessing
notes:
platform_title:
[HG-U133A] Affymetrix Human Genome U133A Array
platform_shorttitle:
Affymetrix HG-U133A
platform_summary:
hgu133a
platform_manufacturer:
Affymetrix
platform_distribution:
commercial
platform_accession:
GPL96
warnings:
These samples are a subset of PMID17290060.
version:
2015-09-22 20:20:30
featureData(eset):
An object of class 'AnnotatedDataFrame'
featureNames: 1007_s_at 1053_at ... AFFX-HUMISGF3A/M97935_MB_at
(20967 total)
varLabels: probeset gene EntrezGene.ID best_probe
varMetadata: labelDescription
assayData: 20967 features, 42 samples
Platform type:
Overall survival time-to-event summary (in years):
Call: survfit(formula = Surv(time, cens) ~ -1)
n events median 0.95LCL 0.95UCL
42.00 22.00 2.79 2.30 NA
---------------------------
Available sample meta-data:
---------------------------
alt_sample_name:
D1462 D1805 D2171 D2208 D2247 D2332 D2432 D2480 D2559 D2560 D2575 D2576 D2611
1 1 1 1 1 1 1 1 1 1 1 1 1
D2629 D2640 D2648 D2736 D2749 D2776 D2792 M1025 M1054 M1055 M120 M1241 M1572
1 1 1 1 1 1 1 1 1 1 1 1 1
M17 M1777 M1891 M2184 M2515 M2807 M3035 M337 M3484 M359 M4161 M444 M503
1 1 1 1 1 1 1 1 1 1 1 1 1
M5668 M5775 M806
1 1 1
sample_type:
tumor
42
histological_type:
ser
42
summarygrade:
high low NA's
24 17 1
summarystage:
early late NA's
2 39 1
tumorstage:
1 2 3 4 NA's
1 1 29 10 1
substage:
a b c NA's
1 1 29 11
grade:
1 2 3 NA's
2 15 24 1
age_at_initial_pathologic_diagnosis:
Min. 1st Qu. Median Mean 3rd Qu. Max. NA's
33.00 55.00 62.00 61.46 70.00 81.00 1
recurrence_status:
norecurrence recurrence
6 36
days_to_death:
Min. 1st Qu. Median Mean 3rd Qu. Max.
30.0 367.5 825.0 1105.0 1050.0 3420.0
vital_status:
deceased living
22 20
debulking:
optimal suboptimal NA's
20 21 1
batch:
2004-03-09 2004-03-16 2004-04-20 2004-05-18 2004-05-21 2004-05-27 2004-06-22
14 3 4 8 6 5 1
2004-06-23
1
uncurated_author_metadata:
Tumor: D1462///NEW.Response: ///SHORT.LONG: NA///AgeDx: 52///DateDx: 11/29/1990///Status: 10/8/91, DOD///Survival..months.: 11///X: 1///STAGE: IIIC///GRADE: 3///Race: b///Debulk: S
1
Tumor: D1805///NEW.Response: NR///SHORT.LONG: NA///AgeDx: 62///DateDx: 3/25/1992///Status: 11/21/92, DOD///Survival..months.: 9///X: 1///STAGE: IV///GRADE: 2///Race: I///Debulk: S
1
Tumor: D2171///NEW.Response: ///SHORT.LONG: NA///AgeDx: 66///DateDx: 10/19/1993///Status: 4/25/03, NED///Survival..months.: 114///X: 0///STAGE: IIIA///GRADE: 3///Race: B///Debulk: O
1
Tumor: D2208///NEW.Response: NR///SHORT.LONG: NA///AgeDx: 62///DateDx: 1/18/1994///Status: 3/22/94, AWD - lost to follow-up///Survival..months.: 2///X: 0///STAGE: IV///GRADE: 3///Race: W///Debulk: S
1
Tumor: D2247///NEW.Response: ///SHORT.LONG: NA///AgeDx: 41///DateDx: 4/21/1994///Status: DOD///Survival..months.: 112///X: 1///STAGE: IIIC///GRADE: 2///Race: B///Debulk: S
1
Tumor: D2332///NEW.Response: CR///SHORT.LONG: NA///AgeDx: 53///DateDx: 12/20/1994///Status: DOD///Survival..months.: 27///X: 1///STAGE: IIIC///GRADE: 2///Race: W///Debulk: S
1
Tumor: D2432///NEW.Response: CR///SHORT.LONG: NA///AgeDx: 61///DateDx: 8/24/1995///Status: DOD///Survival..months.: 35///X: 1///STAGE: IIIC///GRADE: 2///Race: b///Debulk: S
1
Tumor: D2480///NEW.Response: CR///SHORT.LONG: NA///AgeDx: 79///DateDx: 11/15/1995///Status: DOD///Survival..months.: 34///X: 1///STAGE: IIIC///GRADE: 3///Race: W///Debulk: O
1
Tumor: D2559///NEW.Response: CR///SHORT.LONG: NA///AgeDx: 46///DateDx: 10/11/1994///Status: DOD///Survival..months.: 5///X: 1///STAGE: IV///GRADE: 3///Race: W///Debulk: O
1
Tumor: D2560///NEW.Response: CR///SHORT.LONG: NA///AgeDx: 60///DateDx: 5/14/1996///Status: 12/9/03, AWD - despite an elevated CA-125 of 6000, patient is asymptomatic and CT scan shows no definitive measurable disease///Survival..months.: 91///X: 0///STAGE: IIIC///GRADE: 2///Race: W///Debulk: S
1
Tumor: D2575///NEW.Response: CR///SHORT.LONG: NA///AgeDx: 71///DateDx: 07/31/96///Status: DOD///Survival..months.: 33///X: 1///STAGE: IV///GRADE: 2///Race: W///Debulk: O
1
Tumor: D2576///NEW.Response: NR///SHORT.LONG: NA///AgeDx: 71///DateDx: 8/13/1996///Status: DOD///Survival..months.: 17///X: 1///STAGE: IIIC///GRADE: 3///Race: W///Debulk: S
1
Tumor: D2611///NEW.Response: NR///SHORT.LONG: NA///AgeDx: 56///DateDx: 1/22/1997///Status: DOD///Survival..months.: 2///X: 1///STAGE: IIIC///GRADE: 2///Race: W///Debulk: O
1
Tumor: D2629///NEW.Response: NR///SHORT.LONG: NA///AgeDx: 55///DateDx: 2/18/1997///Status: 2/9/00, AWD - on 2/4/00, CA-125 was 6721///Survival..months.: 36///X: 0///STAGE: IV///GRADE: 2///Race: B///Debulk: S
1
Tumor: D2640///NEW.Response: NR///SHORT.LONG: NA///AgeDx: 64///DateDx: 5/27/1997///Status: DOD///Survival..months.: 1///X: 1///STAGE: IIIC///GRADE: 2///Race: W///Debulk: S
1
Tumor: D2648///NEW.Response: NR///SHORT.LONG: NA///AgeDx: 70///DateDx: 6/2/1997///Status: DOD///Survival..months.: 35///X: 1///STAGE: IIIC///GRADE: 2///Race: W///Debulk: S
1
Tumor: D2736///NEW.Response: ///SHORT.LONG: NA///AgeDx: 55///DateDx: 3/10/1998///Status: DOD///Survival..months.: 31///X: 1///STAGE: IIIC///GRADE: 3///Race: b///Debulk: S
1
Tumor: D2749///NEW.Response: CR///SHORT.LONG: NA///AgeDx: 69///DateDx: 4/9/1998///Status: 4/13/00, DOD///Survival..months.: 24///X: 1///STAGE: IIIC///GRADE: 2///Race: w///Debulk: O
1
Tumor: D2776///NEW.Response: NR///SHORT.LONG: NA///AgeDx: 81///DateDx: 5/15/1998///Status: 3/21/99, DOD///Survival..months.: 10///X: 1///STAGE: IIIC///GRADE: 3///Race: w///Debulk: S
1
Tumor: D2792///NEW.Response: CR///SHORT.LONG: NA///AgeDx: 62///DateDx: 7/29/1998///Status: DOD///Survival..months.: 16///X: 1///STAGE: IIIC///GRADE: 3///Race: U///Debulk: S
1
Tumor: M1025///NEW.Response: ///SHORT.LONG: NA///AgeDx: 64///DateDx: 3/21/1996///Status: 9/18/2003, NED///Survival..months.: 90///X: 0///STAGE: IIC///GRADE: 3///Race: W///Debulk: O
1
Tumor: M1054///NEW.Response: NR///SHORT.LONG: NA///AgeDx: NA///DateDx: 4/9/1996///Status: 9/15/2004, AWD///Survival..months.: 101///X: 0///STAGE: ///GRADE: NA///Race: ///Debulk:
1
Tumor: M1055///NEW.Response: CR///SHORT.LONG: NA///AgeDx: 67///DateDx: 3/28/1996///Status: 4/8/1997, AWD///Survival..months.: 13///X: 0///STAGE: IIIC///GRADE: 3///Race: Hisp///Debulk: O
1
Tumor: M120///NEW.Response: CR///SHORT.LONG: NA///AgeDx: 51///DateDx: 5/18/1993///Status: 4/10/1996, DOD///Survival..months.: 35///X: 1///STAGE: IIIC///GRADE: 3///Race: W///Debulk: O
1
Tumor: M1241///NEW.Response: CR///SHORT.LONG: NA///AgeDx: 60///DateDx: 8/15/1996///Status: 7/2/2004, AWD///Survival..months.: 95///X: 0///STAGE: IV///GRADE: 3///Race: W///Debulk: S
1
Tumor: M1572///NEW.Response: NR///SHORT.LONG: NA///AgeDx: 61///DateDx: 4/15/1997///Status: 2/24/1999, DOD///Survival..months.: 22///X: 1///STAGE: IIIC///GRADE: 3///Race: W///Debulk: O
1
Tumor: M1777///NEW.Response: ///SHORT.LONG: NA///AgeDx: 72///DateDx: 7/31/1997///Status: 7/23/2004, AWD///Survival..months.: 84///X: 0///STAGE: IIIC///GRADE: 3///Race: W///Debulk: S
1
Tumor: M17///NEW.Response: NR///SHORT.LONG: NA///AgeDx: 76///DateDx: 5/29/1992///Status: 10/26/1993, AWD///Survival..months.: 17///X: 0///STAGE: IV///GRADE: 2///Race: W///Debulk: S
1
Tumor: M1891///NEW.Response: CR///SHORT.LONG: NA///AgeDx: 40///DateDx: 9/19/1997///Status: 9/30/1998, AWD///Survival..months.: 12///X: 0///STAGE: IV///GRADE: 1///Race: W///Debulk: S
1
Tumor: M2184///NEW.Response: CR///SHORT.LONG: NA///AgeDx: 57///DateDx: 3/31/1998///Status: 2/7/2001, AWD///Survival..months.: 34///X: 0///STAGE: IIIC///GRADE: 3///Race: W///Debulk: O
1
Tumor: M2515///NEW.Response: CR///SHORT.LONG: NA///AgeDx: 73///DateDx: 9/10/1998///Status: 7/7/2001, Dead unknown cause///Survival..months.: 34///X: 1///STAGE: IIIC///GRADE: 3///Race: W///Debulk: S
1
Tumor: M2807///NEW.Response: CR///SHORT.LONG: NA///AgeDx: 54///DateDx: 1/25/1999///Status: 5/17/1999, NED///Survival..months.: 4///X: 0///STAGE: IIIC///GRADE: 3///Race: W///Debulk: S
1
Tumor: M3035///NEW.Response: CR///SHORT.LONG: NA///AgeDx: 63///DateDx: 4/22/1999///Status: 8/25/2001, DOD///Survival..months.: 28///X: 1///STAGE: IV///GRADE: 2///Race: W///Debulk: S
1
Tumor: M337///NEW.Response: CR///SHORT.LONG: NA///AgeDx: 69///DateDx: 7/26/1994///Status: 3/5/2003, NED///Survival..months.: 103///X: 0///STAGE: IIIC///GRADE: 3///Race: W///Debulk: O
1
Tumor: M3484///NEW.Response: CR///SHORT.LONG: NA///AgeDx: 60///DateDx: 1/20/2000///Status: 1/22/2001, AWD///Survival..months.: 12///X: 0///STAGE: IIIB///GRADE: 3///Race: W///Debulk: O
1
Tumor: M359///NEW.Response: NR///SHORT.LONG: NA///AgeDx: 71///DateDx: 8/16/1994///Status: 6/02/1997, AWD///Survival..months.: 34///X: 0///STAGE: IIIC///GRADE: 2///Race: W///Debulk: O
1
Tumor: M4161///NEW.Response: CR///SHORT.LONG: NA///AgeDx: 60///DateDx: 11/8/2000///Status: 3/26/2003, AWD///Survival..months.: 29///X: 0///STAGE: IIIC///GRADE: 3///Race: W///Debulk: O
1
Tumor: M444///NEW.Response: CR///SHORT.LONG: NA///AgeDx: 33///DateDx: 12/20/1994///Status: 13/3/1995, DOD///Survival..months.: 11///X: 1///STAGE: IIIC///GRADE: 3///Race: W///Debulk: O
1
Tumor: M503///NEW.Response: CR///SHORT.LONG: NA///AgeDx: 74///DateDx: 1/27/1995///Status: 6/18/1996, AWD///Survival..months.: 17///X: 0///STAGE: IIIC///GRADE: 1///Race: W///Debulk: O
1
Tumor: M5668///NEW.Response: CR///SHORT.LONG: NA///AgeDx: 73///DateDx: 2/13/2003///Status: 6/20/2004, DOD///Survival..months.: 16///X: 1///STAGE: IV///GRADE: 3///Race: W///Debulk: O
1
Tumor: M5775///NEW.Response: CR///SHORT.LONG: NA///AgeDx: 52///DateDx: 3/21/2003///Status: 7/20/2004, AWD///Survival..months.: 16///X: 0///STAGE: IIIC///GRADE: 3///Race: W///Debulk: O
1
Tumor: M806///NEW.Response: ///SHORT.LONG: NA///AgeDx: 54///DateDx: 10/1/1995///Status: 9/9/2003, NED///Survival..months.: 95///X: 0///STAGE: IC///GRADE: 2///Race: W///Debulk: O
1
An expression set
A catalogue of molecular aberrations that cause ovarian cancer is critical for developing and deploying therapies that will improve patients' lives. The Cancer Genome Atlas project has analysed messenger RNA expression, microRNA expression, promoter methylation and DNA copy number in 489 high-grade serous ovarian adenocarcinomas and the DNA sequences of exons from coding genes in 316 of these tumours. Here we report that high-grade serous ovarian cancer is characterized by TP53 mutations in almost all tumours (96%); low prevalence but statistically recurrent somatic mutations in nine further genes including NF1, BRCA1, BRCA2, RB1 and CDK12; 113 significant focal DNA copy number aberrations; and promoter methylation events involving 168 genes. Analyses delineated four ovarian cancer transcriptional subtypes, three microRNA subtypes, four promoter methylation subtypes and a transcriptional signature associated with survival duration, and shed new light on the impact that tumours with BRCA1/2 (BRCA1 or BRCA2) and CCNE1 aberrations have on survival. Pathway analyses suggested that homologous recombination is defective in about half of the tumours analysed, and that NOTCH and FOXM1 signalling are involved in serous ovarian cancer pathophysiology.
experimentData(eset):
Experiment data
Experimenter name: Integrated genomic analyses of ovarian carcinoma. Nature 2011, 474:609-615.
Laboratory: Cancer Genome Atlas Research Network 2011
Contact information:
Title: Integrated genomic analyses of ovarian carcinoma.
URL:
PMIDs: 21720365
Abstract: A 179 word abstract is available. Use 'abstract' method.
Information is available on: preprocessing
notes:
platform_title:
[RNASeqV2] Illumina HiSeq RNA sequencing
platform_shorttitle:
Illumina HiSeq RNA sequencing
platform_summary:
NA
platform_manufacturer:
Illumina
platform_distribution:
sequencing
platform_accession:
NA
platform_technology:
RNA sequencing
version:
2015-09-22 20:27:26
featureData(eset):
An object of class 'AnnotatedDataFrame'
featureNames: ?|100133144 ?|100134869 ... ZZZ3|26009 (20471 total)
varLabels: probeset gene EntrezGene.ID best_probe
varMetadata: labelDescription
assayData: 20471 features, 261 samples
Platform type:
Overall survival time-to-event summary (in years):
Call: survfit(formula = Surv(time, cens) ~ -1)
5 observations deleted due to missingness
n events median 0.95LCL 0.95UCL
256.00 143.00 3.62 3.19 4.03
---------------------------
Available sample meta-data:
---------------------------
alt_sample_name:
TCGA-04-1348-01A-01R-1565-13 TCGA-04-1357-01A-01R-1565-13
1 1
TCGA-04-1362-01A-01R-1565-13 TCGA-04-1364-01A-01R-1565-13
1 1
TCGA-04-1365-01A-01R-1565-13 TCGA-04-1514-01A-01R-1566-13
1 1
TCGA-04-1519-01A-01R-1565-13 TCGA-09-0364-01A-02R-1564-13
1 1
TCGA-09-0366-01A-01R-1564-13 TCGA-09-0367-01A-01R-1564-13
1 1
TCGA-09-0369-01A-01R-1564-13 TCGA-09-1662-01A-01R-1566-13
1 1
TCGA-09-1666-01A-01R-1566-13 TCGA-09-1667-01C-01R-1566-13
1 1
TCGA-09-1668-01B-01R-1566-13 TCGA-09-1669-01A-01R-1566-13
1 1
TCGA-09-1670-01A-01R-1566-13 TCGA-09-1673-01A-01R-1566-13
1 1
TCGA-09-1674-01A-01R-1566-13 TCGA-09-2044-01B-01R-1568-13
1 1
TCGA-09-2045-01A-01R-1568-13 TCGA-09-2048-01A-01R-1568-13
1 1
TCGA-09-2051-01A-01R-1568-13 TCGA-09-2054-01A-01R-1568-13
1 1
TCGA-09-2056-01B-01R-1568-13 TCGA-10-0928-01A-02R-1564-13
1 1
TCGA-10-0936-01A-01R-1564-13 TCGA-13-0730-01A-01R-1564-13
1 1
TCGA-13-0799-01A-01R-1564-13 TCGA-13-0800-01A-01R-1564-13
1 1
TCGA-13-0801-01A-01R-1564-13 TCGA-13-0890-01A-01R-1564-13
1 1
TCGA-13-0893-01B-01R-1565-13 TCGA-13-0897-01A-01R-1564-13
1 1
TCGA-13-0899-01A-01R-1564-13 TCGA-13-0913-01A-01R-1564-13
1 1
TCGA-13-0916-01A-01R-1564-13 TCGA-13-0920-01A-01R-1564-13
1 1
TCGA-13-0924-01A-01R-1564-13 TCGA-13-1403-01A-01R-1565-13
1 1
TCGA-13-1405-01A-01R-1565-13 TCGA-13-1410-01A-01R-1565-13
1 1
TCGA-13-1481-01A-01R-1565-13 TCGA-13-1497-01A-01R-1565-13
1 1
TCGA-13-1498-01A-01R-1565-13 TCGA-13-1505-01A-01R-1565-13
1 1
TCGA-13-1506-01A-01R-1565-13 TCGA-13-1507-01A-01R-1565-13
1 1
TCGA-13-1511-01A-01R-1565-13 TCGA-13-1512-01A-01R-1565-13
1 1
TCGA-13-2060-01A-01R-1568-13 TCGA-20-1682-01A-01R-1564-13
1 1
TCGA-20-1683-01A-01R-1566-13 TCGA-20-1684-01A-01R-1566-13
1 1
TCGA-20-1685-01A-01R-1566-13 TCGA-20-1687-01A-01R-1566-13
1 1
TCGA-23-1023-01A-02R-1564-13 TCGA-23-1026-01B-01R-1569-13
1 1
TCGA-23-1027-01A-02R-1564-13 TCGA-23-1029-01B-01R-1567-13
1 1
TCGA-23-1109-01A-01R-1564-13 TCGA-23-1111-01A-01R-1567-13
1 1
TCGA-23-1114-01B-01R-1566-13 TCGA-23-1120-01A-02R-1565-13
1 1
TCGA-23-1122-01A-01R-1565-13 TCGA-23-1123-01A-01R-1565-13
1 1
TCGA-23-1809-01A-01R-1566-13 TCGA-23-2077-01A-01R-1568-13
1 1
TCGA-23-2081-01A-01R-1568-13 TCGA-23-2084-01A-02R-1568-13
1 1
TCGA-24-0975-01A-02R-1565-13 TCGA-24-1103-01A-01R-1565-13
1 1
TCGA-24-1413-01A-01R-1565-13 TCGA-24-1416-01A-01R-1565-13
1 1
TCGA-24-1417-01A-01R-1565-13 TCGA-24-1418-01A-01R-1565-13
1 1
TCGA-24-1419-01A-01R-1565-13 TCGA-24-1423-01A-01R-1565-13
1 1
TCGA-24-1424-01A-01R-1565-13 TCGA-24-1427-01A-01R-1565-13
1 1
TCGA-24-1428-01A-01R-1564-13 TCGA-24-1430-01A-01R-1566-13
1 1
TCGA-24-1436-01A-01R-1566-13 TCGA-24-1467-01A-01R-1566-13
1 1
TCGA-24-1469-01A-01R-1566-13 TCGA-24-1474-01A-01R-1566-13
1 1
TCGA-24-1544-01A-01R-1566-13 TCGA-24-1548-01A-01R-1566-13
1 1
TCGA-24-1549-01A-01R-1566-13 TCGA-24-1550-01A-01R-1566-13
1 1
TCGA-24-1551-01A-01R-1566-13 TCGA-24-1552-01A-01R-1566-13
1 1
TCGA-24-1553-01A-01R-1566-13 TCGA-24-1555-01A-01R-1566-13
1 1
TCGA-24-1556-01A-01R-1566-13 TCGA-24-1557-01A-01R-1566-13
1 1
TCGA-24-1558-01A-01R-1566-13 TCGA-24-1560-01A-01R-1566-13
1 1
TCGA-24-1562-01A-01R-1566-13 (Other)
1 162
unique_patient_ID:
TCGA-04-1348 TCGA-04-1357 TCGA-04-1362 TCGA-04-1364 TCGA-04-1365 TCGA-04-1514
1 1 1 1 1 1
TCGA-04-1519 TCGA-09-0364 TCGA-09-0366 TCGA-09-0367 TCGA-09-0369 TCGA-09-1662
1 1 1 1 1 1
TCGA-09-1666 TCGA-09-1667 TCGA-09-1668 TCGA-09-1669 TCGA-09-1670 TCGA-09-1673
1 1 1 1 1 1
TCGA-09-1674 TCGA-09-2044 TCGA-09-2045 TCGA-09-2048 TCGA-09-2051 TCGA-09-2054
1 1 1 1 1 1
TCGA-09-2056 TCGA-10-0928 TCGA-10-0936 TCGA-13-0730 TCGA-13-0799 TCGA-13-0800
1 1 1 1 1 1
TCGA-13-0801 TCGA-13-0890 TCGA-13-0893 TCGA-13-0897 TCGA-13-0899 TCGA-13-0913
1 1 1 1 1 1
TCGA-13-0916 TCGA-13-0920 TCGA-13-0924 TCGA-13-1403 TCGA-13-1405 TCGA-13-1410
1 1 1 1 1 1
TCGA-13-1481 TCGA-13-1497 TCGA-13-1498 TCGA-13-1505 TCGA-13-1506 TCGA-13-1507
1 1 1 1 1 1
TCGA-13-1511 TCGA-13-1512 TCGA-13-2060 TCGA-20-1682 TCGA-20-1683 TCGA-20-1684
1 1 1 1 1 1
TCGA-20-1685 TCGA-20-1687 TCGA-23-1023 TCGA-23-1026 TCGA-23-1027 TCGA-23-1029
1 1 1 1 1 1
TCGA-23-1109 TCGA-23-1111 TCGA-23-1114 TCGA-23-1120 TCGA-23-1122 TCGA-23-1123
1 1 1 1 1 1
TCGA-23-1809 TCGA-23-2077 TCGA-23-2081 TCGA-23-2084 TCGA-24-0975 TCGA-24-1103
1 1 1 1 1 1
TCGA-24-1413 TCGA-24-1416 TCGA-24-1417 TCGA-24-1418 TCGA-24-1419 TCGA-24-1423
1 1 1 1 1 1
TCGA-24-1424 TCGA-24-1427 TCGA-24-1428 TCGA-24-1430 TCGA-24-1436 TCGA-24-1467
1 1 1 1 1 1
TCGA-24-1469 TCGA-24-1474 TCGA-24-1544 TCGA-24-1548 TCGA-24-1549 TCGA-24-1550
1 1 1 1 1 1
TCGA-24-1551 TCGA-24-1552 TCGA-24-1553 TCGA-24-1555 TCGA-24-1556 TCGA-24-1557
1 1 1 1 1 1
TCGA-24-1558 TCGA-24-1560 TCGA-24-1562 (Other)
1 1 1 162
sample_type:
tumor
261
histological_type:
ser
261
primarysite:
other ov
1 260
summarygrade:
high low NA's
226 29 6
summarystage:
early late NA's
18 242 1
tumorstage:
2 3 4 NA's
18 209 33 1
substage:
b c NA's
16 211 34
grade:
1 2 3 4 NA's
1 28 225 1 6
age_at_initial_pathologic_diagnosis:
Min. 1st Qu. Median Mean 3rd Qu. Max.
34.00 51.00 58.00 58.84 66.00 87.00
pltx:
n y NA's
17 215 29
tax:
n y NA's
17 215 29
neo:
n NA's
232 29
days_to_tumor_recurrence:
Min. 1st Qu. Median Mean 3rd Qu. Max. NA's
9.0 225.0 426.5 585.3 755.0 5480.0 19
recurrence_status:
norecurrence recurrence
123 138
days_to_death:
Min. 1st Qu. Median Mean 3rd Qu. Max. NA's
9.0 341.8 878.0 1018.0 1446.0 5480.0 5
vital_status:
deceased living NA's
143 114 4
site_of_tumor_first_recurrence:
locoregional metastasis NA's
82 56 123
primary_therapy_outcome_success:
completeresponse partialresponse progressivedisease stabledisease
147 30 15 15
NA's
54
debulking:
optimal suboptimal NA's
171 60 30
percent_normal_cells:
Min. 1st Qu. Median Mean 3rd Qu. Max. NA's
0.000 0.000 0.000 2.066 0.000 55.000 5
percent_stromal_cells:
Min. 1st Qu. Median Mean 3rd Qu. Max. NA's
0.00 5.00 10.00 11.43 15.00 70.00 4
percent_tumor_cells:
Min. 1st Qu. Median Mean 3rd Qu. Max. NA's
0.00 77.00 85.00 82.07 90.00 100.00 4
uncurated_author_metadata:
age_at_initial_pathologic_diagnosis: 34///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: f9793a4b-c0e7-4475-bf80-69543b7ee2f6///days_to_birth: -12772///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1416///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 24///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IV///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2008///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: cf7ad1d4-c805-41b7-8c74-2e09210bfd7e///chemo_therapy: YES///day_of_form_completion: 1///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 194///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 4///performance_status_scale_timing: NA///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-24-1416-01A-01R-1565-13///unique_patient_id: TCGA-24-1416
1
age_at_initial_pathologic_diagnosis: 38///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 1c0318d9-0472-4840-add4-46bb9f914a30///days_to_birth: -13894///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Excisional Biopsy///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G1///patient_id: 1721///pretreatment_history: YES///race: WHITE///residual_tumor: NA///tissue_source_site: 61///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: NA///tumor_stage: IV///tumor_tissue_site: OVARY///venous_invasion: YES///year_of_initial_pathologic_diagnosis: 2008///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 902be45d-0481-4e42-8dc7-10a185ca8ade///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 338///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-61-1721-01A-01R-1569-13///unique_patient_id: TCGA-61-1721
1
age_at_initial_pathologic_diagnosis: 38///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 22178c3c-6b04-46d8-8041-dc83fa195029///days_to_birth: -14184///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 2404///pretreatment_history: NO///race: AMERICAN INDIAN OR ALASKA NATIVE///residual_tumor: NA///tissue_source_site: 25///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2005///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NO///bcr_followup_uuid: 8b0b1002-3ed9-4317-ba15-982dc5522748///chemo_therapy: YES///day_of_form_completion: 5///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 882///days_to_last_followup: 882///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 425///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 1///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT and Molecular Marker - CA125///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2010///Extract.Name: TCGA-25-2404-01A-01R-1569-13///unique_patient_id: TCGA-25-2404
1
age_at_initial_pathologic_diagnosis: 38///anatomic_organ_subdivision: NA///bcr_patient_uuid: 79fd602b-3e8e-4353-aa78-4f5f170b607d///days_to_birth: -13910///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: NA///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1328///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 25///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2001///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: YES///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 9b2cf6b3-c423-4721-90b4-ae9c1fb5c92f///chemo_therapy: YES///day_of_form_completion: 27///days_to_additional_surgery_locoregional_procedure: 244///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 2009///days_to_last_followup: 1979///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 244///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 3///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Partial Response///progression_determined_by: First Seen At Further Surgery///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-25-1328-01A-01R-1565-13///unique_patient_id: TCGA-25-1328
1
age_at_initial_pathologic_diagnosis: 39///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 05019013-7ea5-4905-ac79-901146ba2ee2///days_to_birth: -14574///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G2///patient_id: 1688///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 29///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: NA///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: YES///year_of_initial_pathologic_diagnosis: 1992///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: YES///additional_surgery_locoregional_procedure: YES///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: eb9c7a54-595c-42ce-bf50-83f92050181d///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: 183///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 2399///days_to_last_followup: 2399///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 183///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Stable Disease///progression_determined_by: First Seen At Further Surgery///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-29-1688-01A-01R-1566-13///unique_patient_id: TCGA-29-1688
1
age_at_initial_pathologic_diagnosis: 40///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 3ac45a71-c463-4f0f-b030-58c475a34418///days_to_birth: -14791///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G2///patient_id: 2008///pretreatment_history: NO///race: ASIAN///residual_tumor: NA///tissue_source_site: 61///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IIC///tumor_tissue_site: OVARY///venous_invasion: YES///year_of_initial_pathologic_diagnosis: 2007///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: YES///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: f45f3fe2-1f97-4e6f-afc7-d3abf0f3311a///chemo_therapy: YES///day_of_form_completion: 8///days_to_additional_surgery_locoregional_procedure: 827///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 931///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 817///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 12///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-61-2008-01A-02R-1568-13///unique_patient_id: TCGA-61-2008
1
age_at_initial_pathologic_diagnosis: 40///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: a6eb0cd0-fe57-41b0-8593-776208684293///days_to_birth: -14782///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 1725///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 61///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 11-20 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: YES///year_of_initial_pathologic_diagnosis: 2007///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 4795b469-2ea1-4e65-bb8f-5b401b6632d5///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 955///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 843///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Stable Disease///progression_determined_by: Imaging Study///progression_determined_by_notes: CT Scan; Molecular marker-CA125///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-61-1725-01A-01R-1567-13///unique_patient_id: TCGA-61-1725
1
age_at_initial_pathologic_diagnosis: 40///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: dc5a6ce7-01e5-408d-812e-e3e0ddc1cde5///days_to_birth: -14899///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Cytology (e.g. Peritoneal or pleural fluid)///jewish_origin: NA///lymphatic_invasion: NO///neoplasm_histologic_grade: G3///patient_id: 2109///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 61///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: >20 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NO///year_of_initial_pathologic_diagnosis: 1999///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 716014bf-2f9f-4dc8-81fe-c2baa9c4303c///chemo_therapy: YES///day_of_form_completion: 7///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 629///days_to_last_followup: 629///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 465///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 12///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: NA///progression_determined_by: Molecular Marker(S)///progression_determined_by_notes: CA125///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-61-2109-01A-01R-1568-13///unique_patient_id: TCGA-61-2109
1
age_at_initial_pathologic_diagnosis: 40///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: f4d95c8e-fb84-46ca-acc0-827015cc9d0a///days_to_birth: [Completed]///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NO///neoplasm_histologic_grade: G3///patient_id: 2363///pretreatment_history: NO///race: ASIAN///residual_tumor: R0///tissue_source_site: 59///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IIIA///tumor_tissue_site: OVARY///venous_invasion: NO///year_of_initial_pathologic_diagnosis: 2007///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: b9fa6c71-a686-47cc-8b85-ba5cca27a399///chemo_therapy: YES///day_of_form_completion: 12///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 164///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 2///performance_status_scale_timing: NA///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2010///Extract.Name: TCGA-59-2363-01A-01R-1569-13///unique_patient_id: TCGA-59-2363
1
age_at_initial_pathologic_diagnosis: 42///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 02594e5e-8751-47c1-9245-90c66984b665///days_to_birth: -15650///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: ASHKENAZI///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 2051///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 9///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: YES///year_of_initial_pathologic_diagnosis: 2004///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: YES///bcr_followup_uuid: 94294882-49ef-4a27-9a2a-03646c87209d///chemo_therapy: YES///day_of_form_completion: 3///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: 875///days_to_death: NA///days_to_last_followup: 1919///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 583///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 11///performance_status_scale_timing: NA///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT; Other method Ca 125 rising///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-09-2051-01A-01R-1568-13///unique_patient_id: TCGA-09-2051
1
age_at_initial_pathologic_diagnosis: 42///anatomic_organ_subdivision: NA///bcr_patient_uuid: 0b2ea4b7-98bb-4190-b682-2c75b447c90a///days_to_birth: -15462///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: NA///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1314///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 25///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IV///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2000///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: YES///additional_surgery_metastatic_procedure: NO///bcr_followup_uuid: fe94fad3-1f4c-4204-ad9b-d8a1ab9b75cc///chemo_therapy: YES///day_of_form_completion: 27///days_to_additional_surgery_locoregional_procedure: 273///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1003///days_to_last_followup: 973///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: 273///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 3///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Partial Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-25-1314-01A-01R-1565-13///unique_patient_id: TCGA-25-1314
1
age_at_initial_pathologic_diagnosis: 43///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 242da7d0-8c6a-4395-9a0d-aa36e7c25ce6///days_to_birth: -16021///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G2///patient_id: 1763///pretreatment_history: NO///race: BLACK OR AFRICAN AMERICAN///residual_tumor: NA///tissue_source_site: 29///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2004///additional_chemo_therapy: YES///additional_drug_therapy: YES///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: YES///additional_surgery_locoregional_procedure: YES///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 5ab2d1a0-ed91-44b1-97ec-51a9f633cbea///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: 1868///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 2031///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 428///eastern_cancer_oncology_group: 0///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: Other///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Other Method: Specify In Notes///progression_determined_by_notes: Biopsy///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: YES///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-29-1763-01A-02R-1567-13///unique_patient_id: TCGA-29-1763
1
age_at_initial_pathologic_diagnosis: 43///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 931738a7-4b5b-46dc-b69f-72600862d8af///days_to_birth: -16016///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 1995///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 61///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: YES///year_of_initial_pathologic_diagnosis: 2009///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 23cec1cb-18f5-4261-bb98-4a4260f7306c///chemo_therapy: YES///day_of_form_completion: 8///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 60///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 12///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Stable Disease///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-61-1995-01A-01R-1568-13///unique_patient_id: TCGA-61-1995
1
age_at_initial_pathologic_diagnosis: 43///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: e294b940-2828-499c-be24-47ef6c2e9035///days_to_birth: -15803///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Cytology (e.g. Peritoneal or pleural fluid)///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G2///patient_id: 1577///pretreatment_history: NO///race: ASIAN///residual_tumor: NA///tissue_source_site: 36///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2007///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 210fbda1-7211-4d2b-9eea-f48f0d3f8567///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 783///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: YES///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-36-1577-01A-01R-1566-13///unique_patient_id: TCGA-36-1577
1
age_at_initial_pathologic_diagnosis: 43///anatomic_organ_subdivision: Right///bcr_patient_uuid: 8a98a6e6-b763-4824-858b-fd2738e6c9a3///days_to_birth: -15818///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NO///neoplasm_histologic_grade: G2///patient_id: 1696///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 29///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2003///additional_chemo_therapy: YES///additional_drug_therapy: YES///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: YES///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 82bd749e-d9aa-4da7-bd7d-57255e9c7e2e///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: 454///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1032///days_to_last_followup: 1025///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 342///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Partial Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-29-1696-01A-01R-1567-13///unique_patient_id: TCGA-29-1696
1
age_at_initial_pathologic_diagnosis: 44///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: ad2939e6-b8b8-475a-90e2-6a369c3d3167///days_to_birth: -16400///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NO///neoplasm_histologic_grade: G3///patient_id: 1718///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 30///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NO///year_of_initial_pathologic_diagnosis: 2002///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 634effee-a1bd-4dd7-a813-4f04f2c4a872///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1579///days_to_last_followup: 1579///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 896///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: YES///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: NA///progression_determined_by: Imaging Study///progression_determined_by_notes: DECT; Other CA 125///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-30-1718-01A-01R-1567-13///unique_patient_id: TCGA-30-1718
1
age_at_initial_pathologic_diagnosis: 44///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: b9418c6d-94f7-4db4-a1e4-f384b09d54cb///days_to_birth: -16170///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 799///pretreatment_history: NO///race: ASIAN///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2008///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 20105ff9-cc71-41ab-942d-44454c233406///chemo_therapy: YES///day_of_form_completion: 25///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 237///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: 80///month_of_form_completion: 2///performance_status_scale_timing: Pre-Adjuvant Therapy///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-13-0799-01A-01R-1564-13///unique_patient_id: TCGA-13-0799
1
age_at_initial_pathologic_diagnosis: 44///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: e978a457-92ff-4eab-b759-ec6e74d973e8///days_to_birth: [Completed]///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 2350///pretreatment_history: NO///race: NA///residual_tumor: NA///tissue_source_site: 59///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IV///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 1995///additional_chemo_therapy: NA///additional_drug_therapy: NA///additional_immuno_therapy: NA///additional_pharmaceutical_therapy: NA///additional_radiation_therapy: NA///additional_surgery_locoregional_procedure: YES///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 3623594b-c07c-40e0-9eba-0a95a662d146///chemo_therapy: NA///day_of_form_completion: 29///days_to_additional_surgery_locoregional_procedure: 211///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 679///days_to_last_followup: 679///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: 211///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NA///immuno_therapy: NA///karnofsky_performance_score: NA///month_of_form_completion: 1///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Partial Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NA///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NA///vital_status: DECEASED///year_of_form_completion: 2010///Extract.Name: TCGA-59-2350-01A-01R-1569-13///unique_patient_id: TCGA-59-2350
1
age_at_initial_pathologic_diagnosis: 44///anatomic_organ_subdivision: NA///bcr_patient_uuid: f7752d6e-f9cd-4dc9-ab01-3ab87acb21e4///days_to_birth: -16236///days_to_initial_pathologic_diagnosis: 0///ethnicity: HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: NA///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 1348///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 4///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIB///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2004///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: YES///bcr_followup_uuid: 4bd91396-4007-4ff3-9673-58e37b089fe6///chemo_therapy: YES///day_of_form_completion: 26///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1483///days_to_last_followup: 1483///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 574///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 3///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Molecular Marker(S)///progression_determined_by_notes: CA125///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-04-1348-01A-01R-1565-13///unique_patient_id: TCGA-04-1348
1
age_at_initial_pathologic_diagnosis: 45///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 0a2d29de-869a-4dc8-ad11-6ee0d0a3a895///days_to_birth: -16612///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Excisional Biopsy///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 1736///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 61///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: NA///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: YES///year_of_initial_pathologic_diagnosis: 2005///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: YES///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: dbee91e2-9410-4570-9c69-8e43beb8887d///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: 812///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1484///days_to_last_followup: 1484///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 764///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT Scan///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-61-1736-01B-01R-1568-13///unique_patient_id: TCGA-61-1736
1
age_at_initial_pathologic_diagnosis: 45///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 1cc02c64-a34e-46ae-9bc7-5d50f2fefb31///days_to_birth: -16733///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1506///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: NA///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2008///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: c38894f1-b486-48fd-acc2-f53027cb3ffa///chemo_therapy: YES///day_of_form_completion: 31///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 134///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: 80///month_of_form_completion: 3///performance_status_scale_timing: Pre-Adjuvant Therapy///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-13-1506-01A-01R-1565-13///unique_patient_id: TCGA-13-1506
1
age_at_initial_pathologic_diagnosis: 45///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 1db60f09-7f5a-4f21-8003-06a6abc781db///days_to_birth: -16522///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: GX///patient_id: 1694///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 29///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 11-20 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2002///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: YES///additional_radiation_therapy: YES///additional_surgery_locoregional_procedure: YES///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: a17e36f4-a75c-4d56-a8a4-f79d48e9513b///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: 206///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1187///days_to_last_followup: 1172///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: 1///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: Other///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Stable Disease///progression_determined_by: First Seen At Further Surgery///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-29-1694-01A-01R-1567-13///unique_patient_id: TCGA-29-1694
1
age_at_initial_pathologic_diagnosis: 45///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 21966708-4e66-4211-add0-f1515b09e362///days_to_birth: -16529///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Excisional Biopsy///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 1847///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 24///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IV///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2009///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: a302ccb0-5b86-4a6a-8121-fdf54689c24c///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 343///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-24-1847-01A-01R-1566-13///unique_patient_id: TCGA-24-1847
1
age_at_initial_pathologic_diagnosis: 45///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 3491d67a-4f83-4f67-8085-bbb9fe942be5///days_to_birth: -16689///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1918///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 61///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IV///tumor_tissue_site: OVARY///venous_invasion: YES///year_of_initial_pathologic_diagnosis: 2002///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: f5f189d5-ceda-430f-996d-dbd6cdbb24a2///chemo_therapy: YES///day_of_form_completion: 30///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 479///days_to_last_followup: 479///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 413///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 11///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT scan and CA 125 elevation///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-61-1918-01A-01R-1568-13///unique_patient_id: TCGA-61-1918
1
age_at_initial_pathologic_diagnosis: 45///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 67f526f1-def5-43b4-bc89-154baae190fc///days_to_birth: -16533///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 1846///pretreatment_history: NO///race: NA///residual_tumor: NA///tissue_source_site: 24///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2009///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: e73b1ede-abff-4032-af69-0c538317414f///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 133///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: 1///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: Other///person_neoplasm_cancer_status: NA///primary_therapy_outcome_success: NA///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-24-1846-01A-01R-1567-13///unique_patient_id: TCGA-24-1846
1
age_at_initial_pathologic_diagnosis: 45///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: cbc5b936-ead5-4858-ab90-e639402789b0///days_to_birth: -16745///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NO///neoplasm_histologic_grade: G3///patient_id: 1685///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 20///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NO///year_of_initial_pathologic_diagnosis: 2008///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NO///bcr_followup_uuid: f74f942b-3336-4eab-b6f5-96ea2715a52e///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 507///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: 0///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: Post-Adjuvant Therapy///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-20-1685-01A-01R-1566-13///unique_patient_id: TCGA-20-1685
1
age_at_initial_pathologic_diagnosis: 45///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: e9483296-cb91-497a-b955-39a3c3289dac///days_to_birth: -16724///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NO///neoplasm_histologic_grade: G2///patient_id: 1514///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 4///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IIIA///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2004///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: YES///bcr_followup_uuid: 5d6ed657-10c2-447e-bd5e-9a72631507ab///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: 1284///days_to_death: 1720///days_to_last_followup: 1720///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 1221///eastern_cancer_oncology_group: 1///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: Pre-Operative///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT Scan///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-04-1514-01A-01R-1566-13///unique_patient_id: TCGA-04-1514
1
age_at_initial_pathologic_diagnosis: 45///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: f58e49fc-9641-4b46-be4c-766445ec70a3///days_to_birth: -16485///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G2///patient_id: 1711///pretreatment_history: NO///race: BLACK OR AFRICAN AMERICAN///residual_tumor: NA///tissue_source_site: 29///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2006///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 764f8125-40f5-4183-8365-5d97c30cbdf0///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 1053///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: 0///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: Post-Adjuvant Therapy///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: YES///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-29-1711-01A-01R-1567-13///unique_patient_id: TCGA-29-1711
1
age_at_initial_pathologic_diagnosis: 45///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: fbb45305-de8d-4baf-8bd0-047b29c2e9d9///days_to_birth: -16670///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Cytology (e.g. Peritoneal or pleural fluid)///jewish_origin: ASHKENAZI///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 924///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IV///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2008///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: fae23792-aeda-4037-82cf-b8d048036938///chemo_therapy: YES///day_of_form_completion: 25///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 185///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 2///performance_status_scale_timing: NA///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: YES///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-13-0924-01A-01R-1564-13///unique_patient_id: TCGA-13-0924
1
age_at_initial_pathologic_diagnosis: 45///anatomic_organ_subdivision: Left///bcr_patient_uuid: ef57bc45-858f-4d4e-8407-b7eadfa43be5///days_to_birth: -16551///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NO///neoplasm_histologic_grade: G3///patient_id: 2077///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 23///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: YES///year_of_initial_pathologic_diagnosis: 1999///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: YES///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: f560f5c0-882a-44ba-b631-892ccda55b7e///chemo_therapy: YES///day_of_form_completion: 20///days_to_additional_surgery_locoregional_procedure: 1345///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 3525///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 1232///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 11///performance_status_scale_timing: NA///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT Scan///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-23-2077-01A-01R-1568-13///unique_patient_id: TCGA-23-2077
1
age_at_initial_pathologic_diagnosis: 45///anatomic_organ_subdivision: NA///bcr_patient_uuid: c6ede8ae-881c-47a0-a0ef-745ed4b7764a///days_to_birth: -16442///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: NA///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1026///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 23///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2004///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: YES///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: adc0c0f8-0f93-40af-862a-f2efc4dd6cf1///chemo_therapy: YES///day_of_form_completion: 23///days_to_additional_surgery_locoregional_procedure: 816///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 816///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 797///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 2///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-23-1026-01B-01R-1569-13///unique_patient_id: TCGA-23-1026
1
age_at_initial_pathologic_diagnosis: 45///anatomic_organ_subdivision: Right///bcr_patient_uuid: 2cb82948-7cbe-4b6c-8414-c02f662de2d0///days_to_birth: -16493///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: ASHKENAZI///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 2084///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 23///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IV///tumor_tissue_site: OVARY///venous_invasion: YES///year_of_initial_pathologic_diagnosis: 2000///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: YES///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 64e0a5f8-5338-401d-9c5b-85d0b1c484d4///chemo_therapy: YES///day_of_form_completion: 18///days_to_additional_surgery_locoregional_procedure: 627///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1516///days_to_last_followup: 1516///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 619///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 11///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT Scan; Molecular marker- Ca 125///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-23-2084-01A-02R-1568-13///unique_patient_id: TCGA-23-2084
1
age_at_initial_pathologic_diagnosis: 46///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 9bf16a89-2fc7-4c08-93bc-3105eec5c3cc///days_to_birth: -16960///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Cytology (e.g. Peritoneal or pleural fluid)///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 1687///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 20///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IV///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2008///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: f16936bd-4107-4e50-bcd0-da8f76ba03eb///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 81///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-20-1687-01A-01R-1566-13///unique_patient_id: TCGA-20-1687
1
age_at_initial_pathologic_diagnosis: 46///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: b8c3d99c-429b-42a3-b486-6fbcb90cc2e0///days_to_birth: -16811///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Cytology (e.g. Peritoneal or pleural fluid)///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 801///pretreatment_history: NO///race: BLACK OR AFRICAN AMERICAN///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2008///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NO///bcr_followup_uuid: 7198f423-8333-4349-8ee6-65e5a4322771///chemo_therapy: YES///day_of_form_completion: 25///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 252///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: 80///month_of_form_completion: 2///performance_status_scale_timing: Pre-Adjuvant Therapy///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-13-0801-01A-01R-1564-13///unique_patient_id: TCGA-13-0801
1
age_at_initial_pathologic_diagnosis: 46///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: bbad2efe-e9c7-4f8f-924b-ebbbe4c181d4///days_to_birth: -17009///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 2019///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 24///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2009///additional_chemo_therapy: NA///additional_drug_therapy: NA///additional_immuno_therapy: NA///additional_pharmaceutical_therapy: NA///additional_radiation_therapy: NA///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 478f18ec-c7d2-485e-b83d-1b416c86ac20///chemo_therapy: YES///day_of_form_completion: 16///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 148///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: 1///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 3///performance_status_scale_timing: Other///person_neoplasm_cancer_status: NA///primary_therapy_outcome_success: NA///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2010///Extract.Name: TCGA-24-2019-01A-02R-1568-13///unique_patient_id: TCGA-24-2019
1
age_at_initial_pathologic_diagnosis: 46///anatomic_organ_subdivision: Right///bcr_patient_uuid: 4d71dd15-cd01-4dae-ad70-6dc325140207///days_to_birth: -16889///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1029///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 23///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2007///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NO///bcr_followup_uuid: b21097d0-d714-4e0c-a8b9-fecac7ce4111///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 268///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-23-1029-01B-01R-1567-13///unique_patient_id: TCGA-23-1029
1
age_at_initial_pathologic_diagnosis: 47///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 2ae65a06-df0f-4de1-a536-537cae0cc260///days_to_birth: -17168///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 1724///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 61///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: YES///year_of_initial_pathologic_diagnosis: 2007///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: YES///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 81734ce6-1983-4b83-a2ac-394d263fefb0///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: 186///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 637///days_to_last_followup: 637///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Progressive Disease///progression_determined_by: Imaging Study///progression_determined_by_notes: CT Abd///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-61-1724-01A-01R-1568-13///unique_patient_id: TCGA-61-1724
1
age_at_initial_pathologic_diagnosis: 47///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 6fee41dc-b8a9-4347-8085-b7e05f813ad0///days_to_birth: -17207///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 1944///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 31///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: YES///year_of_initial_pathologic_diagnosis: 2005///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: YES///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: YES///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: d1397f20-f35b-48a1-8d55-fdf484d16766///chemo_therapy: YES///day_of_form_completion: 19///days_to_additional_surgery_locoregional_procedure: 701///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 1386///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 678///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 10///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-31-1944-01A-01R-1568-13///unique_patient_id: TCGA-31-1944
1
age_at_initial_pathologic_diagnosis: 47///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: ed21615c-0de3-421c-9e8d-8996026c4431///days_to_birth: -17257///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 1584///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 57///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: YES///year_of_initial_pathologic_diagnosis: 2007///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: YES///bcr_followup_uuid: aca7dfdd-2755-43e1-a775-1687dee80c72///chemo_therapy: NO///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: 532///days_to_death: NA///days_to_last_followup: 643///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 530///eastern_cancer_oncology_group: 0///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: Pre-Adjuvant Therapy///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: NA///progression_determined_by: Imaging Study///progression_determined_by_notes: CT of abdomen and pelvis with contrast///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-57-1584-01A-01R-1566-13///unique_patient_id: TCGA-57-1584
1
age_at_initial_pathologic_diagnosis: 47///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: f9c835db-2ab6-4bf5-826f-48723493c0ec///days_to_birth: -17530///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G2///patient_id: 1705///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 29///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: >20 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2005///additional_chemo_therapy: YES///additional_drug_therapy: YES///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: YES///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 1fe3bcd4-e15d-4d28-a88d-81ce50f34996///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: 434///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 555///days_to_last_followup: 555///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 283///eastern_cancer_oncology_group: 0///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: Post-Adjuvant Therapy///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-29-1705-01A-01R-1567-13///unique_patient_id: TCGA-29-1705
1
age_at_initial_pathologic_diagnosis: 47///anatomic_organ_subdivision: NA///bcr_patient_uuid: bc4bc342-20bf-40c3-af26-2c6f942da93d///days_to_birth: -17528///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Cytology (e.g. Peritoneal or pleural fluid)///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1497///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: NA///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2004///additional_chemo_therapy: YES///additional_drug_therapy: YES///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: YES///bcr_followup_uuid: d8a1710d-bba3-4b22-9c76-124568b7b543///chemo_therapy: YES///day_of_form_completion: 31///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: 861///days_to_death: NA///days_to_last_followup: 1652///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 813///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: 80///month_of_form_completion: 3///performance_status_scale_timing: Pre-Adjuvant Therapy///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT scan///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: YES///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-13-1497-01A-01R-1565-13///unique_patient_id: TCGA-13-1497
1
age_at_initial_pathologic_diagnosis: 48///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 565d06a1-3640-4274-8fb3-8cad7e578876///days_to_birth: -17855///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 1998///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 61///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: YES///year_of_initial_pathologic_diagnosis: 2009///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 0d0da8b8-e9f8-4dbb-9a7f-ff76d2dc734f///chemo_therapy: YES///day_of_form_completion: 8///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 168///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 12///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: NA///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-61-1998-01A-01R-1568-13///unique_patient_id: TCGA-61-1998
1
age_at_initial_pathologic_diagnosis: 48///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: eeb9d147-608d-4692-8adf-2f601d23a8ff///days_to_birth: -17847///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1574///pretreatment_history: NO///race: ASIAN///residual_tumor: NA///tissue_source_site: 36///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: >20 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2007///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: a362d009-06b1-4ec1-a13b-762036f060a8///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 686///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 648///eastern_cancer_oncology_group: 0///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: Pre-Operative///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-36-1574-01A-01R-1566-13///unique_patient_id: TCGA-36-1574
1
age_at_initial_pathologic_diagnosis: 48///anatomic_organ_subdivision: NA///bcr_patient_uuid: 0d5e232d-5aa2-4f6f-be58-ffd5f15ee0b8///days_to_birth: -17697///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: NA///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1403///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: NA///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2008///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 1b8ebf1f-79f6-4198-ad79-00cec38ef301///chemo_therapy: YES///day_of_form_completion: 20///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 331///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 3///performance_status_scale_timing: NA///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-13-1403-01A-01R-1565-13///unique_patient_id: TCGA-13-1403
1
age_at_initial_pathologic_diagnosis: 48///anatomic_organ_subdivision: NA///bcr_patient_uuid: 15170c7f-5880-4fb6-82ce-68d3df0dfb68///days_to_birth: -17573///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: NA///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 893///pretreatment_history: NO///race: BLACK OR AFRICAN AMERICAN///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 11-20 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2003///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 2e198688-0234-4ff0-bae5-0472ce5af182///chemo_therapy: YES///day_of_form_completion: 20///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1319///days_to_last_followup: 1319///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 461///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: YES///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 3///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Partial Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT scan; Molecular marker CA 125///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-13-0893-01B-01R-1565-13///unique_patient_id: TCGA-13-0893
1
age_at_initial_pathologic_diagnosis: 48///anatomic_organ_subdivision: NA///bcr_patient_uuid: c9e58844-9d61-44a2-aee6-1760bc19711b///days_to_birth: -17588///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: NA///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 1027///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 23///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: YES///year_of_initial_pathologic_diagnosis: 2005///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NO///bcr_followup_uuid: 517a109a-a6a8-4855-837c-b8d6a48412d3///chemo_therapy: YES///day_of_form_completion: 24///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 975///days_to_last_followup: 965///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 114///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 2///performance_status_scale_timing: NA///person_neoplasm_cancer_status: NA///primary_therapy_outcome_success: Progressive Disease///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: YES///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-23-1027-01A-02R-1564-13///unique_patient_id: TCGA-23-1027
1
age_at_initial_pathologic_diagnosis: 48///anatomic_organ_subdivision: NA///bcr_patient_uuid: e9b5336e-d724-4e7d-8c81-1147abd0a80d///days_to_birth: -17670///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: NA///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1519///pretreatment_history: NO///race: NA///residual_tumor: NA///tissue_source_site: 4///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: NA///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2007///additional_chemo_therapy: NA///additional_drug_therapy: NA///additional_immuno_therapy: NA///additional_pharmaceutical_therapy: NA///additional_radiation_therapy: NA///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: NA///chemo_therapy: NA///day_of_form_completion: NA///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: NA///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NA///immuno_therapy: NA///karnofsky_performance_score: NA///month_of_form_completion: NA///performance_status_scale_timing: NA///person_neoplasm_cancer_status: NA///primary_therapy_outcome_success: NA///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NA///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NA///vital_status: NA///year_of_form_completion: NA///Extract.Name: TCGA-04-1519-01A-01R-1565-13///unique_patient_id: TCGA-04-1519
1
age_at_initial_pathologic_diagnosis: 49///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 09c77947-a333-4392-b18d-a6c1f08764a1///days_to_birth: -18227///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 1842///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 24///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2009///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: ea813aa8-df86-407b-aea1-092fb2c8608e///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 253///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: 0///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: Other///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: YES///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-24-1842-01A-01R-1567-13///unique_patient_id: TCGA-24-1842
1
age_at_initial_pathologic_diagnosis: 49///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 0f530b3e-5b6d-4892-9ebd-9138d76fdca7///days_to_birth: -17955///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 1570///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 36///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: >20 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: YES///year_of_initial_pathologic_diagnosis: 2007///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 15fa99c0-2fe6-4a73-9c6b-612cf8d56d53///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 655///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 375///eastern_cancer_oncology_group: 0///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: Pre-Operative///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Partial Response///progression_determined_by: Physical Examination///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-36-1570-01A-01R-1566-13///unique_patient_id: TCGA-36-1570
1
age_at_initial_pathologic_diagnosis: 49///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 41178cbc-db73-4007-b5d8-febebf7f578d///days_to_birth: -18161///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: ASHKENAZI///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 2081///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 23///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IV///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2000///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: YES///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 3bed5a01-64cb-41cf-9ed8-4d91eecc4adf///chemo_therapy: YES///day_of_form_completion: 20///days_to_additional_surgery_locoregional_procedure: 250///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 2342///days_to_last_followup: 2342///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 11///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Progressive Disease///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-23-2081-01A-01R-1568-13///unique_patient_id: TCGA-23-2081
1
age_at_initial_pathologic_diagnosis: 49///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 5f60bc2d-738f-43fc-a3fb-61ec6e80e3d4///days_to_birth: -18189///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 916///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2006///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: e104764b-efb0-4872-8f3f-d164a3d89d09///chemo_therapy: YES///day_of_form_completion: 25///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 643///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 2///performance_status_scale_timing: NA///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: YES///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-13-0916-01A-01R-1564-13///unique_patient_id: TCGA-13-0916
1
age_at_initial_pathologic_diagnosis: 49///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 7dcc809b-e33a-4453-b92a-c00786f48cb0///days_to_birth: -17943///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1557///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 24///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: >20 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2000///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: YES///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 300786cc-f4e9-45c3-8987-c78cb62f21ea///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1213///days_to_last_followup: 1213///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: 447///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Partial Response///progression_determined_by: Imaging Study///progression_determined_by_notes: Abdomin MIR;Molecular marker CA 125///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-24-1557-01A-01R-1566-13///unique_patient_id: TCGA-24-1557
1
age_at_initial_pathologic_diagnosis: 49///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 82093ed9-a3c8-4e34-931f-4ec7ae745711///days_to_birth: -18134///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Fine needle aspiration biopsy///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1512///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2008///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 440d2b6f-c84d-4658-b921-7d114ea5c138///chemo_therapy: YES///day_of_form_completion: 31///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 94///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: 60///month_of_form_completion: 3///performance_status_scale_timing: Pre-Adjuvant Therapy///person_neoplasm_cancer_status: NA///primary_therapy_outcome_success: NA///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-13-1512-01A-01R-1565-13///unique_patient_id: TCGA-13-1512
1
age_at_initial_pathologic_diagnosis: 49///anatomic_organ_subdivision: Left///bcr_patient_uuid: 1858b58f-fdf4-413c-9c29-96ae85b88a74///days_to_birth: -18048///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1550///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 24///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 1997///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: YES///additional_surgery_metastatic_procedure: NO///bcr_followup_uuid: 5bda2645-5465-4ed5-a000-c378ffe3ba62///chemo_therapy: YES///day_of_form_completion: 13///days_to_additional_surgery_locoregional_procedure: 1121///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1249///days_to_last_followup: 1249///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 892///eastern_cancer_oncology_group: 1///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 5///performance_status_scale_timing: Post-Adjuvant Therapy///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: Abdomen CT Scan; Molucular marker CA125///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-24-1550-01A-01R-1566-13///unique_patient_id: TCGA-24-1550
1
age_at_initial_pathologic_diagnosis: 49///anatomic_organ_subdivision: NA///bcr_patient_uuid: 29dccd25-4c4a-463b-a353-38a193337f38///days_to_birth: -18218///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: NA///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1405///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IV///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2008///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 94feaf68-9597-4648-bc84-fe7e67afc7c7///chemo_therapy: YES///day_of_form_completion: 20///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 224///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: 80///month_of_form_completion: 3///performance_status_scale_timing: Pre-Adjuvant Therapy///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-13-1405-01A-01R-1565-13///unique_patient_id: TCGA-13-1405
1
age_at_initial_pathologic_diagnosis: 50///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 3768d34f-1527-40db-b116-cd80cee5ec3a///days_to_birth: -18285///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G2///patient_id: 2045///pretreatment_history: NO///race: ASIAN///residual_tumor: NA///tissue_source_site: 9///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IV///tumor_tissue_site: OVARY///venous_invasion: YES///year_of_initial_pathologic_diagnosis: 1996///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 0174cdfc-8808-4567-97bc-03c86ce40b50///chemo_therapy: YES///day_of_form_completion: 3///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1069///days_to_last_followup: 1069///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 631///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 11///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Stable Disease///progression_determined_by: Physical Examination///progression_determined_by_notes: Image study and Other method was CA125///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-09-2045-01A-01R-1568-13///unique_patient_id: TCGA-09-2045
1
age_at_initial_pathologic_diagnosis: 50///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 4e6f88de-7624-4719-8234-4c9e5b2e2988///days_to_birth: -18599///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 1673///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 9///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: >20 mm///tumor_stage: IV///tumor_tissue_site: OVARY///venous_invasion: YES///year_of_initial_pathologic_diagnosis: 2008///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 7596faa8-43be-4930-a899-cefee1f4f8c7///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 92///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: NA///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-09-1673-01A-01R-1566-13///unique_patient_id: TCGA-09-1673
1
age_at_initial_pathologic_diagnosis: 50///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 5d36676e-4140-44b5-aa0e-b2af092b7dc0///days_to_birth: -18403///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1555///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 24///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: NA///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 1997///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NO///bcr_followup_uuid: 5867b96d-991e-437a-9e0c-b4c7846721ad///chemo_therapy: YES///day_of_form_completion: 13///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 2692///days_to_last_followup: 2692///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 1577///eastern_cancer_oncology_group: 0///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 5///performance_status_scale_timing: Other///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: Abdomen CT scan; Moleular marker CA125///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-24-1555-01A-01R-1566-13///unique_patient_id: TCGA-24-1555
1
age_at_initial_pathologic_diagnosis: 50///anatomic_organ_subdivision: Left///bcr_patient_uuid: 4ea50685-3b63-440a-b037-597ef2529e7d///days_to_birth: [Completed]///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 1582///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 57///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: YES///year_of_initial_pathologic_diagnosis: 2006///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: d6ebac21-c97c-456d-b42e-726017a129d6///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 731///days_to_last_followup: 731///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Progressive Disease///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-57-1582-01A-01R-1566-13///unique_patient_id: TCGA-57-1582
1
age_at_initial_pathologic_diagnosis: 50///anatomic_organ_subdivision: Left///bcr_patient_uuid: 7592a659-7175-486f-a16e-24a4b4365a36///days_to_birth: -18516///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1556///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 24///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIB///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2000///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: YES///additional_surgery_locoregional_procedure: YES///additional_surgery_metastatic_procedure: NO///bcr_followup_uuid: ae13e174-65c7-41d1-a531-10166f114bfe///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: 762///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 2148///days_to_last_followup: 2148///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 549///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: Abdomin MIR; Molecular CA 125///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-24-1556-01A-01R-1566-13///unique_patient_id: TCGA-24-1556
1
age_at_initial_pathologic_diagnosis: 50///anatomic_organ_subdivision: Left///bcr_patient_uuid: 9c744ff8-1cde-4176-b6d7-0ab62bf42620///days_to_birth: -18306///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1428///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 24///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2008///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 51f0a185-1a9f-486d-ae86-8816f919f682///chemo_therapy: YES///day_of_form_completion: 16///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 528///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 448///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 4///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: Per CRF Notes: No Recurrence; 06/11/10 Image study-pevlic and abdomen CT; Molecular marker-CA125///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-24-1428-01A-01R-1564-13///unique_patient_id: TCGA-24-1428
1
age_at_initial_pathologic_diagnosis: 50///anatomic_organ_subdivision: NA///bcr_patient_uuid: 635f5335-b008-428e-b005-615776a6643f///days_to_birth: -18263///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: NA///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1315///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 25///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2000///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: YES///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 5f76897a-afa8-4e00-a593-08ad2e7a93d7///chemo_therapy: YES///day_of_form_completion: 27///days_to_additional_surgery_locoregional_procedure: 153///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1583///days_to_last_followup: 1553///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: 153///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 3///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Partial Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-25-1315-01A-01R-1565-13///unique_patient_id: TCGA-25-1315
1
age_at_initial_pathologic_diagnosis: 50///anatomic_organ_subdivision: NA///bcr_patient_uuid: c9226204-cb61-40b8-8a94-a7e71c14ea3a///days_to_birth: -18582///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 2036///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 24///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIA///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 1996///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: YES///additional_radiation_therapy: YES///additional_surgery_locoregional_procedure: YES///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 18df747d-b014-45a6-a225-5400d8ac2b53///chemo_therapy: YES///day_of_form_completion: 19///days_to_additional_surgery_locoregional_procedure: 579///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1947///days_to_last_followup: 1947///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 914///eastern_cancer_oncology_group: 0///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 2///performance_status_scale_timing: Other///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Physical Examination///progression_determined_by_notes: Image Study- Abdominal; Molecular marker-CA125///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2010///Extract.Name: TCGA-24-2036-01A-01R-1568-13///unique_patient_id: TCGA-24-2036
1
age_at_initial_pathologic_diagnosis: 50///anatomic_organ_subdivision: NA///bcr_patient_uuid: f34aa3b6-e966-49c6-bc55-130545772c53///days_to_birth: -18583///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: NA///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1103///pretreatment_history: NO///race: BLACK OR AFRICAN AMERICAN///residual_tumor: NA///tissue_source_site: 24///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2001///additional_chemo_therapy: YES///additional_drug_therapy: NA///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 37eac75a-a99b-46ea-ab5f-172ea3b9cbb4///chemo_therapy: YES///day_of_form_completion: 9///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1645///days_to_last_followup: 1645///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 677///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 3///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: Abdominal CR;Mollecular-CA125///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-24-1103-01A-01R-1565-13///unique_patient_id: TCGA-24-1103
1
age_at_initial_pathologic_diagnosis: 51///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 16829472-5666-4fba-9bf9-360ec1689aa0///days_to_birth: [Completed]///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 2351///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 59///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 1999///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: YES///additional_surgery_metastatic_procedure: YES///bcr_followup_uuid: 714f1bfd-54f3-4a05-bbc7-3bc9bc5ace8e///chemo_therapy: NA///day_of_form_completion: 29///days_to_additional_surgery_locoregional_procedure: 2154///days_to_additional_surgery_metastatic_procedure: 2154///days_to_death: NA///days_to_last_followup: 3532///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: 2139///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NA///immuno_therapy: NA///karnofsky_performance_score: NA///month_of_form_completion: 1///performance_status_scale_timing: NA///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT Scan; site of tumor first recurrence is also Metastasis///radiation_therapy: NA///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NA///vital_status: LIVING///year_of_form_completion: 2010///Extract.Name: TCGA-59-2351-01A-01R-1569-13///unique_patient_id: TCGA-59-2351
1
age_at_initial_pathologic_diagnosis: 51///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 196f4600-b6c9-4652-9f77-65c92883f8c1///days_to_birth: -18635///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Cytology (e.g. Peritoneal or pleural fluid)///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 2060///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IV///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2009///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 970fa6e8-453c-4cff-b1e0-f5cadfc60973///chemo_therapy: YES///day_of_form_completion: 16///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 261///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: 80///month_of_form_completion: 12///performance_status_scale_timing: Pre-Adjuvant Therapy///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-13-2060-01A-01R-1568-13///unique_patient_id: TCGA-13-2060
1
age_at_initial_pathologic_diagnosis: 51///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 219f54ef-4235-482d-b799-f2fa9930105c///days_to_birth: -18835///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 2027///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 24///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: >20 mm///tumor_stage: IV///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 1995///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 734e79c4-b7b3-4238-aa0b-d3f1fe501a3b///chemo_therapy: YES///day_of_form_completion: 15///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 3336///days_to_last_followup: 3336///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 617///eastern_cancer_oncology_group: 0///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 3///performance_status_scale_timing: Other///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: Abdominal CT; Molecular marker- CA125///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2010///Extract.Name: TCGA-24-2027-01A-01R-1567-13///unique_patient_id: TCGA-24-2027
1
age_at_initial_pathologic_diagnosis: 51///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 242943fe-1fa0-4a12-8f7e-9c6c4af1194d///days_to_birth: -18769///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NO///neoplasm_histologic_grade: G3///patient_id: 2088///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 61///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NO///year_of_initial_pathologic_diagnosis: 2009///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 90f9f7a2-99d8-496e-9276-a94390ef4587///chemo_therapy: YES///day_of_form_completion: 7///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 145///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 12///performance_status_scale_timing: NA///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: NA///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-61-2088-01A-01R-1568-13///unique_patient_id: TCGA-61-2088
1
age_at_initial_pathologic_diagnosis: 51///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 512de609-757b-42be-8b30-c414f71af422///days_to_birth: -18788///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 2016///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 61///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: YES///year_of_initial_pathologic_diagnosis: 2006///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 991e4692-11e2-4ff7-9ca7-f07af311826f///chemo_therapy: YES///day_of_form_completion: 8///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 36///days_to_last_followup: 36///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 12///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Progressive Disease///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-61-2016-01A-01R-1568-13///unique_patient_id: TCGA-61-2016
1
age_at_initial_pathologic_diagnosis: 51///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 94030805-8beb-441a-af73-11a80768edb5///days_to_birth: -18755///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NO///neoplasm_histologic_grade: G3///patient_id: 1684///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 20///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NO///year_of_initial_pathologic_diagnosis: 2007///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NO///bcr_followup_uuid: c1f2eb5c-51d5-469f-9319-30cfcaec69e4///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 580///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: 0///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: Post-Adjuvant Therapy///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-20-1684-01A-01R-1566-13///unique_patient_id: TCGA-20-1684
1
age_at_initial_pathologic_diagnosis: 51///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: b4225c44-b9b6-46c5-aabf-7b0d9a9fe20b///days_to_birth: -18664///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G2///patient_id: 1691///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 29///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 1995///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: YES///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: YES///bcr_followup_uuid: cd9c0017-f19f-4f93-983c-3b4f58156aed///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: 624///days_to_death: 1470///days_to_last_followup: 1435///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 613///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-29-1691-01A-01R-1566-13///unique_patient_id: TCGA-29-1691
1
age_at_initial_pathologic_diagnosis: 51///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: ef653772-e5d2-46ec-8610-f81d75d7353c///days_to_birth: -18963///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Cytology (e.g. Peritoneal or pleural fluid)///jewish_origin: NA///lymphatic_invasion: NO///neoplasm_histologic_grade: G3///patient_id: 1900///pretreatment_history: NO///race: BLACK OR AFRICAN AMERICAN///residual_tumor: NA///tissue_source_site: 61///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IIIB///tumor_tissue_site: OVARY///venous_invasion: NO///year_of_initial_pathologic_diagnosis: 2008///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 8b7bebba-673b-4d44-b33d-6a5d7409982f///chemo_therapy: YES///day_of_form_completion: 1///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 176///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 10///performance_status_scale_timing: NA///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Stable Disease///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-61-1900-01A-01R-1567-13///unique_patient_id: TCGA-61-1900
1
age_at_initial_pathologic_diagnosis: 51///anatomic_organ_subdivision: Left///bcr_patient_uuid: afd92922-b8dc-48bd-a9c0-bc8d95855eb7///days_to_birth: -18670///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G4///patient_id: 1560///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 24///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 1999///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NO///bcr_followup_uuid: f5657f7d-8bbe-49b7-875c-32d3c45a6b02///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1341///days_to_last_followup: 1341///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 143///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: Abdominal MIR; Moleuclar marker CA 125///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-24-1560-01A-01R-1566-13///unique_patient_id: TCGA-24-1560
1
age_at_initial_pathologic_diagnosis: 51///anatomic_organ_subdivision: NA///bcr_patient_uuid: 3fc8f799-5bd3-4f48-baf0-c458ce86ab7e///days_to_birth: -18845///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: NA///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 1413///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 24///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2008///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 00e61bdc-fccd-47a7-bd23-8ce0506d6b7b///chemo_therapy: YES///day_of_form_completion: 9///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 192///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 3///performance_status_scale_timing: NA///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-24-1413-01A-01R-1565-13///unique_patient_id: TCGA-24-1413
1
age_at_initial_pathologic_diagnosis: 51///anatomic_organ_subdivision: Right///bcr_patient_uuid: 34f545ab-d420-4dd2-8db4-3159896efd23///days_to_birth: -18652///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 1467///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 24///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 1998///additional_chemo_therapy: YES///additional_drug_therapy: YES///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: YES///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: YES///bcr_followup_uuid: 0b7db63c-a9e8-47c4-8459-b34e4260d092///chemo_therapy: YES///day_of_form_completion: 16///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: 1252///days_to_death: 3224///days_to_last_followup: 3224///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 1252///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 4///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Molecular Marker(S)///progression_determined_by_notes: CT Scan, CA125///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-24-1467-01A-01R-1566-13///unique_patient_id: TCGA-24-1467
1
age_at_initial_pathologic_diagnosis: 52///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 390eed6b-50af-48a9-9fd6-3a68a2bbb7f9///days_to_birth: -19086///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 800///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2008///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NO///bcr_followup_uuid: 217432e2-4489-425f-a6e6-79c90c55f1f9///chemo_therapy: YES///day_of_form_completion: 25///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 247///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 2///performance_status_scale_timing: NA///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-13-0800-01A-01R-1564-13///unique_patient_id: TCGA-13-0800
1
age_at_initial_pathologic_diagnosis: 52///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 61feee94-3ac9-42fe-aaa3-dc6a3efe563c///days_to_birth: -19063///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NO///neoplasm_histologic_grade: G3///patient_id: 1953///pretreatment_history: NO///race: ASIAN///residual_tumor: NA///tissue_source_site: 31///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: NA///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NO///year_of_initial_pathologic_diagnosis: 2008///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 0b48f22b-fc99-4647-bd44-0e2a250c6d91///chemo_therapy: YES///day_of_form_completion: 20///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 204///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 70///eastern_cancer_oncology_group: 1///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 10///performance_status_scale_timing: Pre-Adjuvant Therapy///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Progressive Disease///progression_determined_by: Imaging Study///progression_determined_by_notes: CT///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-31-1953-01A-01R-1568-13///unique_patient_id: TCGA-31-1953
1
age_at_initial_pathologic_diagnosis: 52///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 756f6768-e69a-4fe9-aa41-7c58aabe4577///days_to_birth: -19258///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Cytology (e.g. Peritoneal or pleural fluid)///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1511///pretreatment_history: NO///race: ASIAN///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: >20 mm///tumor_stage: IV///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2008///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 4b9ab047-2f5e-4454-8f69-f40a45d563cf///chemo_therapy: YES///day_of_form_completion: 31///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 118///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: 60///month_of_form_completion: 3///performance_status_scale_timing: Pre-Adjuvant Therapy///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Partial Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-13-1511-01A-01R-1565-13///unique_patient_id: TCGA-13-1511
1
age_at_initial_pathologic_diagnosis: 52///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: de548bdd-14ca-486b-bd16-a6fbdd5b50d2///days_to_birth: -19311///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NO///neoplasm_histologic_grade: G3///patient_id: 1568///pretreatment_history: NO///race: NA///residual_tumor: NA///tissue_source_site: 36///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: NA///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2007///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 8050daa1-0821-4b10-9f7e-13838a72c862///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 874///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 547///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NA///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Partial Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT abd/pelvis///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NA///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-36-1568-01A-01R-1566-13///unique_patient_id: TCGA-36-1568
1
age_at_initial_pathologic_diagnosis: 52///anatomic_organ_subdivision: NA///bcr_patient_uuid: feda41d8-ca56-425d-b149-4d5485328107///days_to_birth: -18998///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: NA///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1357///pretreatment_history: NO///race: NA///residual_tumor: NA///tissue_source_site: 4///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: NA///tumor_stage: IIIB///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2005///additional_chemo_therapy: NA///additional_drug_therapy: NA///additional_immuno_therapy: NA///additional_pharmaceutical_therapy: NA///additional_radiation_therapy: NA///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 111f374e-4892-4400-8dd3-60c2e3d4f213///chemo_therapy: YES///day_of_form_completion: 26///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: NA///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 3///performance_status_scale_timing: NA///person_neoplasm_cancer_status: NA///primary_therapy_outcome_success: NA///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-04-1357-01A-01R-1565-13///unique_patient_id: TCGA-04-1357
1
age_at_initial_pathologic_diagnosis: 53///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 05263959-c4f5-4540-b6d2-d8c8a128861f///days_to_birth: -19432///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G2///patient_id: 2104///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 61///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IIC///tumor_tissue_site: OVARY///venous_invasion: NO///year_of_initial_pathologic_diagnosis: 2003///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: YES///bcr_followup_uuid: 02ac5e72-78e8-458e-9966-f78a3fb86f69///chemo_therapy: YES///day_of_form_completion: 7///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: 1680///days_to_death: NA///days_to_last_followup: 2337///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 1680///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 12///performance_status_scale_timing: NA///person_neoplasm_cancer_status: NA///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: PET Scan///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-61-2104-01A-01R-1568-13///unique_patient_id: TCGA-61-2104
1
age_at_initial_pathologic_diagnosis: 53///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 08c64000-d320-4e4d-974b-da503d48890c///days_to_birth: -19393///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1553///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 24///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIB///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 1997///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: YES///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 7622d214-fe68-459f-80a3-c4740b69af22///chemo_therapy: YES///day_of_form_completion: 13///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1767///days_to_last_followup: 1767///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 553///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 5///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: Abdomen CT scan; Molecular marker CA125///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-24-1553-01A-01R-1566-13///unique_patient_id: TCGA-24-1553
1
age_at_initial_pathologic_diagnosis: 53///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 12581634-eebb-4841-8498-71dc9d78c546///days_to_birth: -19608///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NO///neoplasm_histologic_grade: G3///patient_id: 1571///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 36///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IIIB///tumor_tissue_site: OVARY///venous_invasion: NO///year_of_initial_pathologic_diagnosis: 2007///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 00574d51-b04f-42c8-ba1a-f4d8af2e4ebd///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 695///days_to_last_followup: 695///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 374///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT abd/pelvis///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-36-1571-01A-01R-1566-13///unique_patient_id: TCGA-36-1571
1
age_at_initial_pathologic_diagnosis: 53///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 19427350-619b-4b9c-a3ba-37f667bb2843///days_to_birth: -19681///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1603///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 24///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: NA///tumor_stage: IIIB///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 1996///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NO///bcr_followup_uuid: 7aa0d9f9-ecbe-4159-89a9-08c599697834///chemo_therapy: YES///day_of_form_completion: 13///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 2742///days_to_last_followup: 2742///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 992///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 5///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: Abdomen CT scan; Molecular markers CA125///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-24-1603-01A-01R-1566-13///unique_patient_id: TCGA-24-1603
1
age_at_initial_pathologic_diagnosis: 53///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 3e8a51bf-7e1f-4eab-af83-3c60d04db1bf///days_to_birth: -19572///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 913///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2006///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: YES///bcr_followup_uuid: 2196fa5e-c624-4376-a480-5aacc1c81f86///chemo_therapy: YES///day_of_form_completion: 25///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: 912///days_to_death: NA///days_to_last_followup: 912///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 871///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: 80///month_of_form_completion: 2///performance_status_scale_timing: Pre-Adjuvant Therapy///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: Molecular marker(s)///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-13-0913-01A-01R-1564-13///unique_patient_id: TCGA-13-0913
1
age_at_initial_pathologic_diagnosis: 53///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 499a9b57-ee1a-4012-bbab-c6ad955b5e0a///days_to_birth: -19661///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1551///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 24///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 1997///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NO///bcr_followup_uuid: bbe90a89-5f83-4b5d-9ef9-9a9e8a5159fd///chemo_therapy: YES///day_of_form_completion: 13///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1579///days_to_last_followup: 1579///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 764///eastern_cancer_oncology_group: 1///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 5///performance_status_scale_timing: Other///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: Abdomen C scan; molecular markers CA125///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-24-1551-01A-01R-1566-13///unique_patient_id: TCGA-24-1551
1
age_at_initial_pathologic_diagnosis: 53///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 62efb5ae-43dc-4a4c-a898-6cd9c6dba027///days_to_birth: -19387///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1930///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 24///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 1998///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: YES///additional_surgery_locoregional_procedure: YES///additional_surgery_metastatic_procedure: YES///bcr_followup_uuid: 4e109663-798b-40df-a011-0527bb6151ff///chemo_therapy: YES///day_of_form_completion: 5///days_to_additional_surgery_locoregional_procedure: 1922///days_to_additional_surgery_metastatic_procedure: 670///days_to_death: 2467///days_to_last_followup: 2467///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 543///eastern_cancer_oncology_group: 0///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: 100///month_of_form_completion: 4///performance_status_scale_timing: Post-Adjuvant Therapy///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: Brain MRI; Molecular marker-CA125///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2010///Extract.Name: TCGA-24-1930-01A-01R-1567-13///unique_patient_id: TCGA-24-1930
1
age_at_initial_pathologic_diagnosis: 53///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: a3e26259-732b-49fb-bc95-2f0ec7a0494e///days_to_birth: -19365///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G2///patient_id: 1743///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 61///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2004///additional_chemo_therapy: NA///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: YES///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: b213f402-12f7-443a-bce1-f344086505fb///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: 829///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1329///days_to_last_followup: 1329///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 809///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-61-1743-01A-01R-1568-13///unique_patient_id: TCGA-61-1743
1
age_at_initial_pathologic_diagnosis: 53///anatomic_organ_subdivision: NA///bcr_patient_uuid: d2c0d320-d1c5-4eed-af4f-15540e60db0b///days_to_birth: -19537///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: NA///jewish_origin: NA///lymphatic_invasion: NO///neoplasm_histologic_grade: G3///patient_id: 1122///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 23///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 1998///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: YES///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: YES///bcr_followup_uuid: 835873b9-9590-4af3-b5ac-33688f902940///chemo_therapy: YES///day_of_form_completion: 19///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1189///days_to_last_followup: 1189///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 447///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 2///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT and MRI///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-23-1122-01A-01R-1565-13///unique_patient_id: TCGA-23-1122
1
age_at_initial_pathologic_diagnosis: 53///anatomic_organ_subdivision: Right///bcr_patient_uuid: 71faa2c1-0d5b-4dcc-bdf9-f2405f29907c///days_to_birth: -19722///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 2113///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 61///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: NA///tumor_stage: IIC///tumor_tissue_site: OVARY///venous_invasion: YES///year_of_initial_pathologic_diagnosis: 1999///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 58e8e9bc-2bf0-47e6-a806-3a51341022fb///chemo_therapy: YES///day_of_form_completion: 7///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 676///days_to_last_followup: 676///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 291///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 12///performance_status_scale_timing: NA///person_neoplasm_cancer_status: NA///primary_therapy_outcome_success: NA///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-61-2113-01A-01R-1568-13///unique_patient_id: TCGA-61-2113
1
age_at_initial_pathologic_diagnosis: 54///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 2cb50c2d-e749-4172-b101-d975507435c5///days_to_birth: -19843///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1567///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 24///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIB///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 1999///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 282f1e10-3acf-4ade-bf0f-83cf6b487059///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 524///days_to_last_followup: 524///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 335///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: NA///progression_determined_by: Molecular Marker(S)///progression_determined_by_notes: CA125///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-24-1567-01A-01R-1566-13///unique_patient_id: TCGA-24-1567
1
age_at_initial_pathologic_diagnosis: 54///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 4261267c-7042-4c6e-83ed-12fb401003fc///days_to_birth: -19968///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G2///patient_id: 1710///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 29///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2006///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: YES///bcr_followup_uuid: 6a1d6bdf-cecf-4c60-a745-f3cf0ebcb1bb///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: 878///days_to_death: 951///days_to_last_followup: 889///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 315///eastern_cancer_oncology_group: 0///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: Post-Adjuvant Therapy///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Partial Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT (fist seen on CT, confirmed with FNA; Other method- FNA///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: YES///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-29-1710-01A-02R-1567-13///unique_patient_id: TCGA-29-1710
1
age_at_initial_pathologic_diagnosis: 54///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 5201ee13-2aed-4641-9169-4d5ee07a23da///days_to_birth: -19900///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 2023///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 24///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIA///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 1994///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 478e3654-2c9e-4ee7-b80d-d63e0a5c5ebe///chemo_therapy: YES///day_of_form_completion: 16///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1364///days_to_last_followup: 1364///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 1069///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 3///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Molecular Marker(S)///progression_determined_by_notes: CA125///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2010///Extract.Name: TCGA-24-2023-01A-01R-1567-13///unique_patient_id: TCGA-24-2023
1
age_at_initial_pathologic_diagnosis: 54///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 5abb6d80-fc39-49a4-8db5-3db24543feb6///days_to_birth: -20014///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G2///patient_id: 1770///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 29///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2007///additional_chemo_therapy: YES///additional_drug_therapy: YES///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: YES///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: d7a26e91-ab1f-4ada-b736-84f1de3922b1///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: 432///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 741///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 377///eastern_cancer_oncology_group: 0///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: Post-Adjuvant Therapy///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-29-1770-01A-01R-1567-13///unique_patient_id: TCGA-29-1770
1
age_at_initial_pathologic_diagnosis: 54///anatomic_organ_subdivision: Left///bcr_patient_uuid: 48f831b0-5d91-44ae-bc4e-db57ca84fe46///days_to_birth: -19775///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1417///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 24///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IV///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2008///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 6f2f5940-f189-4422-93fc-7571c6f994ba///chemo_therapy: YES///day_of_form_completion: 1///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 238///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 4///performance_status_scale_timing: NA///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-24-1417-01A-01R-1565-13///unique_patient_id: TCGA-24-1417
1
age_at_initial_pathologic_diagnosis: 54///anatomic_organ_subdivision: NA///bcr_patient_uuid: 13319c20-02f6-4b5f-b24f-3d8f4084094c///days_to_birth: -19755///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: NA///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1318///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 25///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2000///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: YES///bcr_followup_uuid: f632b553-5ecb-48ef-84bc-d5372657f82a///chemo_therapy: YES///day_of_form_completion: 27///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1064///days_to_last_followup: 1064///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 185///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 3///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Partial Response///progression_determined_by: First Seen At Further Surgery///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-25-1318-01A-01R-1565-13///unique_patient_id: TCGA-25-1318
1
age_at_initial_pathologic_diagnosis: 54///anatomic_organ_subdivision: Right///bcr_patient_uuid: 79e6e31c-22a1-481c-903b-ab5499cbd450///days_to_birth: -19894///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Cytology (e.g. Peritoneal or pleural fluid)///jewish_origin: ASHKENAZI///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 897///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2004///additional_chemo_therapy: YES///additional_drug_therapy: YES///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: YES///additional_surgery_metastatic_procedure: NO///bcr_followup_uuid: 575c5f5c-ba76-49e9-8a0b-fe1f1223bd4d///chemo_therapy: YES///day_of_form_completion: 25///days_to_additional_surgery_locoregional_procedure: 567///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 1748///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 553///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: 80///month_of_form_completion: 2///performance_status_scale_timing: Pre-Adjuvant Therapy///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: YES///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-13-0897-01A-01R-1564-13///unique_patient_id: TCGA-13-0897
1
age_at_initial_pathologic_diagnosis: 54///anatomic_organ_subdivision: Right///bcr_patient_uuid: b1c90c69-6149-4105-8182-ab9212f196be///days_to_birth: -20052///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NO///neoplasm_histologic_grade: G3///patient_id: 1669///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 9///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IIIA///tumor_tissue_site: OVARY///venous_invasion: NO///year_of_initial_pathologic_diagnosis: 2004///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: be4d9604-3e6b-4bf2-bd2a-0be49751832a///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 927///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///Extract.Name: TCGA-09-1669-01A-01R-1566-13///unique_patient_id: TCGA-09-1669
1
age_at_initial_pathologic_diagnosis: 55///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 23771dab-2aab-4d2b-95e2-9af7092cee6b///days_to_birth: -20440///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NO///neoplasm_histologic_grade: G3///patient_id: 366///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 9///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NO///year_of_initial_pathologic_diagnosis: 1999///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: YES///additional_surgery_metastatic_procedure: NO///bcr_followup_uuid: 06ba5b59-0675-4fde-a4aa-237171de4442///chemo_therapy: YES///day_of_form_completion: 4///days_to_additional_surgery_locoregional_procedure: 189///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1756///days_to_last_followup: 1756///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 189///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 3///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Stable Disease///progression_determined_by: Imaging Study///progression_determined_by_notes: CT & CA125///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///Extract.Name: TCGA-09-0366-01A-01R-1564-13///unique_patient_id: TCGA-09-0366
1
(Other)
162
An expression set
A catalogue of molecular aberrations that cause ovarian cancer is critical for developing and deploying therapies that will improve patients' lives. The Cancer Genome Atlas project has analysed messenger RNA expression, microRNA expression, promoter methylation and DNA copy number in 489 high-grade serous ovarian adenocarcinomas and the DNA sequences of exons from coding genes in 316 of these tumours. Here we report that high-grade serous ovarian cancer is characterized by TP53 mutations in almost all tumours (96%); low prevalence but statistically recurrent somatic mutations in nine further genes including NF1, BRCA1, BRCA2, RB1 and CDK12; 113 significant focal DNA copy number aberrations; and promoter methylation events involving 168 genes. Analyses delineated four ovarian cancer transcriptional subtypes, three microRNA subtypes, four promoter methylation subtypes and a transcriptional signature associated with survival duration, and shed new light on the impact that tumours with BRCA1/2 (BRCA1 or BRCA2) and CCNE1 aberrations have on survival. Pathway analyses suggested that homologous recombination is defective in about half of the tumours analysed, and that NOTCH and FOXM1 signalling are involved in serous ovarian cancer pathophysiology.
experimentData(eset):
Experiment data
Experimenter name: Integrated genomic analyses of ovarian carcinoma. Nature 2011, 474:609-615.
Laboratory: Cancer Genome Atlas Research Network 2011
Contact information:
Title: Integrated genomic analyses of ovarian carcinoma.
URL:
PMIDs: 21720365
Abstract: A 179 word abstract is available. Use 'abstract' method.
Information is available on: preprocessing
notes:
platform_title:
[HT_HG-U133A] Affymetrix HT Human Genome U133A Array
platform_shorttitle:
Affymetrix HT_HG-U133A
platform_summary:
hthgu133a
platform_manufacturer:
Affymetrix
platform_distribution:
commercial
platform_accession:
GPL3921
warnings:
The following samples are likely from specimens also used in GSE26712: TCG
A.13.0725, TCGA.13.0885, TCGA.13.0887, TCGA.13.0890, TCGA.13.0886, TCGA.13
.0714, TCGA.13.0727, TCGA.13.1817, TCGA.13.1499, TCGA.13.0883
version:
2015-09-22 20:25:15
featureData(eset):
An object of class 'AnnotatedDataFrame'
featureNames: 1007_s_at 1053_at ... AFFX-M27830_M_at (21260 total)
varLabels: probeset gene EntrezGene.ID best_probe
varMetadata: labelDescription
assayData: 21260 features, 578 samples
Platform type:
Overall survival time-to-event summary (in years):
Call: survfit(formula = Surv(time, cens) ~ -1)
21 observations deleted due to missingness
n events median 0.95LCL 0.95UCL
557.00 290.00 3.73 3.45 4.06
---------------------------
Available sample meta-data:
---------------------------
alt_sample_name:
TCGA-01-0628-11A-01R-0362-01 TCGA-01-0630-11A-01R-0362-01
1 1
TCGA-01-0631-11A-01R-0362-01 TCGA-01-0633-11A-01R-0362-01
1 1
TCGA-01-0636-11A-01R-0362-01 TCGA-01-0637-11A-01R-0362-01
1 1
TCGA-01-0639-11A-01R-0362-01 TCGA-01-0642-11A-02R-0362-01
1 1
TCGA-04-1331-01A-01R-0434-01 TCGA-04-1332-01A-01R-0434-01
1 1
TCGA-04-1335-01A-01R-0434-01 TCGA-04-1336-01A-01R-0434-01
1 1
TCGA-04-1337-01A-01R-0434-01 TCGA-04-1338-01A-01R-0434-01
1 1
TCGA-04-1341-01A-01R-0434-01 TCGA-04-1342-01A-01R-0434-01
1 1
TCGA-04-1343-01A-01R-0434-01 TCGA-04-1346-01A-01R-0434-01
1 1
TCGA-04-1347-01A-01R-0434-01 TCGA-04-1348-01A-01R-0453-01
1 1
TCGA-04-1349-01A-01R-0453-01 TCGA-04-1350-01A-01R-0453-01
1 1
TCGA-04-1351-01A-01R-0453-01 TCGA-04-1353-01A-01R-1048-01
1 1
TCGA-04-1356-01A-01R-0453-01 TCGA-04-1357-01A-01R-0453-01
1 1
TCGA-04-1360-01A-01R-0453-01 TCGA-04-1361-01A-01R-0453-01
1 1
TCGA-04-1362-01A-01R-0453-01 TCGA-04-1364-01A-01R-0453-01
1 1
TCGA-04-1365-01A-01R-0453-01 TCGA-04-1367-01A-01R-0453-01
1 1
TCGA-04-1369-01A-02R-1048-01 TCGA-04-1371-01A-01R-0453-01
1 1
TCGA-04-1514-01A-01R-0502-01 TCGA-04-1516-01A-01R-1048-01
1 1
TCGA-04-1517-01A-01R-0538-01 TCGA-04-1519-01A-01R-0538-01
1 1
TCGA-04-1525-01A-01R-0538-01 TCGA-04-1530-01A-02R-0502-01
1 1
TCGA-04-1536-01A-01R-0538-01 TCGA-04-1542-01A-01R-0502-01
1 1
TCGA-04-1638-01A-01R-0582-01 TCGA-04-1644-01B-01R-1048-01
1 1
TCGA-04-1646-01A-01R-0582-01 TCGA-04-1648-01A-01R-0582-01
1 1
TCGA-04-1649-01A-01R-0582-01 TCGA-04-1651-01A-01R-0582-01
1 1
TCGA-04-1652-01A-01R-0582-01 TCGA-04-1654-01A-02R-0653-01
1 1
TCGA-04-1655-01A-01R-0564-01 TCGA-09-0364-01A-02R-0362-01
1 1
TCGA-09-0365-01A-02R-0362-01 TCGA-09-0366-01A-01R-0362-01
1 1
TCGA-09-0367-01A-01R-0362-01 TCGA-09-0369-01A-01R-0362-01
1 1
TCGA-09-1659-01B-01R-0538-01 TCGA-09-1661-01B-01R-0538-01
1 1
TCGA-09-1662-01A-01R-0538-01 TCGA-09-1664-01A-01R-0582-01
1 1
TCGA-09-1665-01B-01R-0538-01 TCGA-09-1666-01A-01R-0538-01
1 1
TCGA-09-1667-01C-01R-0538-01 TCGA-09-1668-01B-01R-0538-01
1 1
TCGA-09-1669-01A-01R-0538-01 TCGA-09-1670-01A-01R-0564-01
1 1
TCGA-09-1672-01A-01R-0564-01 TCGA-09-1673-01A-01R-0564-01
1 1
TCGA-09-1674-01A-01R-0564-01 TCGA-09-1675-01B-01R-0564-01
1 1
TCGA-09-2043-01A-01R-0709-01 TCGA-09-2044-01B-01R-0709-01
1 1
TCGA-09-2045-01A-01R-0709-01 TCGA-09-2048-01A-01R-0709-01
1 1
TCGA-09-2049-01D-01R-0709-01 TCGA-09-2050-01A-01R-0709-01
1 1
TCGA-09-2051-01A-01R-0709-01 TCGA-09-2053-01C-01R-0668-01
1 1
TCGA-09-2054-01A-01R-0668-01 TCGA-09-2055-01B-01R-0709-01
1 1
TCGA-09-2056-01B-01R-0668-01 TCGA-10-0925-01B-01R-0653-01
1 1
TCGA-10-0926-01A-01R-0404-01 TCGA-10-0927-01A-02R-0404-01
1 1
TCGA-10-0928-01A-02R-0404-01 TCGA-10-0930-01A-02R-0404-01
1 1
TCGA-10-0931-01A-01R-0404-01 TCGA-10-0933-01A-01R-0404-01
1 1
TCGA-10-0934-01A-02R-0404-01 TCGA-10-0935-01A-02R-0404-01
1 1
TCGA-10-0936-01A-01R-0404-01 TCGA-10-0937-01A-02R-0404-01
1 1
TCGA-10-0938-01A-02R-0404-01 TCGA-13-0714-01A-01R-0362-01
1 1
TCGA-13-0717-01A-01R-0362-01 TCGA-13-0720-01A-01R-0362-01
1 1
TCGA-13-0723-01A-02R-0362-01 TCGA-13-0724-01A-01R-0362-01
1 1
(Other) NA's
479 1
unique_patient_ID:
TCGA-01-0628 TCGA-01-0630 TCGA-01-0631 TCGA-01-0633 TCGA-01-0636 TCGA-01-0637
1 1 1 1 1 1
TCGA-01-0639 TCGA-01-0642 TCGA-04-1331 TCGA-04-1332 TCGA-04-1335 TCGA-04-1336
1 1 1 1 1 1
TCGA-04-1337 TCGA-04-1338 TCGA-04-1341 TCGA-04-1342 TCGA-04-1343 TCGA-04-1346
1 1 1 1 1 1
TCGA-04-1347 TCGA-04-1348 TCGA-04-1349 TCGA-04-1350 TCGA-04-1351 TCGA-04-1353
1 1 1 1 1 1
TCGA-04-1356 TCGA-04-1357 TCGA-04-1360 TCGA-04-1361 TCGA-04-1362 TCGA-04-1364
1 1 1 1 1 1
TCGA-04-1365 TCGA-04-1367 TCGA-04-1369 TCGA-04-1371 TCGA-04-1514 TCGA-04-1516
1 1 1 1 1 1
TCGA-04-1517 TCGA-04-1519 TCGA-04-1525 TCGA-04-1530 TCGA-04-1536 TCGA-04-1542
1 1 1 1 1 1
TCGA-04-1638 TCGA-04-1644 TCGA-04-1646 TCGA-04-1648 TCGA-04-1649 TCGA-04-1651
1 1 1 1 1 1
TCGA-04-1652 TCGA-04-1654 TCGA-04-1655 TCGA-09-0364 TCGA-09-0365 TCGA-09-0366
1 1 1 1 1 1
TCGA-09-0367 TCGA-09-0369 TCGA-09-1659 TCGA-09-1661 TCGA-09-1662 TCGA-09-1664
1 1 1 1 1 1
TCGA-09-1665 TCGA-09-1666 TCGA-09-1667 TCGA-09-1668 TCGA-09-1669 TCGA-09-1670
1 1 1 1 1 1
TCGA-09-1672 TCGA-09-1673 TCGA-09-1674 TCGA-09-1675 TCGA-09-2043 TCGA-09-2044
1 1 1 1 1 1
TCGA-09-2045 TCGA-09-2048 TCGA-09-2049 TCGA-09-2050 TCGA-09-2051 TCGA-09-2053
1 1 1 1 1 1
TCGA-09-2054 TCGA-09-2055 TCGA-09-2056 TCGA-10-0925 TCGA-10-0926 TCGA-10-0927
1 1 1 1 1 1
TCGA-10-0928 TCGA-10-0930 TCGA-10-0931 TCGA-10-0933 TCGA-10-0934 TCGA-10-0935
1 1 1 1 1 1
TCGA-10-0936 TCGA-10-0937 TCGA-10-0938 TCGA-13-0714 TCGA-13-0717 TCGA-13-0720
1 1 1 1 1 1
TCGA-13-0723 TCGA-13-0724 TCGA-13-0725 (Other)
1 1 1 479
sample_type:
adjacentnormal tumor
8 570
histological_type:
ser NA's
568 10
primarysite:
other ov NA's
4 564 10
summarygrade:
high low NA's
480 75 23
summarystage:
early late NA's
43 520 15
tumorstage:
1 2 3 4 NA's
16 27 436 84 15
substage:
b c NA's
31 448 99
grade:
1 2 3 4 NA's
6 69 479 1 23
age_at_initial_pathologic_diagnosis:
Min. 1st Qu. Median Mean 3rd Qu. Max. NA's
26.00 51.00 59.00 59.70 68.25 89.00 10
pltx:
n y NA's
19 492 67
tax:
n y NA's
43 468 67
neo:
n NA's
511 67
days_to_tumor_recurrence:
Min. 1st Qu. Median Mean 3rd Qu. Max. NA's
8.0 238.2 443.5 623.7 812.0 5480.0 56
recurrence_status:
norecurrence recurrence
279 299
days_to_death:
Min. 1st Qu. Median Mean 3rd Qu. Max. NA's
8 349 881 1010 1446 5480 21
vital_status:
deceased living NA's
290 270 18
site_of_tumor_first_recurrence:
locoregional locoregional_plus_metastatic
153 3
metastasis NA's
143 279
primary_therapy_outcome_success:
completeresponse partialresponse progressivedisease stabledisease
318 65 41 30
NA's
124
debulking:
optimal suboptimal NA's
367 140 71
percent_normal_cells:
Min. 1st Qu. Median Mean 3rd Qu. Max. NA's
0.000 0.000 0.000 2.385 0.000 55.000 19
percent_stromal_cells:
Min. 1st Qu. Median Mean 3rd Qu. Max. NA's
0.00 5.00 10.00 12.85 20.00 70.00 25
percent_tumor_cells:
Min. 1st Qu. Median Mean 3rd Qu. Max. NA's
0.00 75.00 85.00 80.64 90.00 100.00 22
batch:
Min. 1st Qu. Median Mean 3rd Qu. Max. NA's
9.00 13.00 17.00 18.55 22.00 40.00 1
uncurated_author_metadata:
age_at_initial_pathologic_diagnosis: 26///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 30c7efdd-5a86-4418-a33c-a5d27fe56e42///days_to_birth: -9760///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G1///patient_id: 2540///pretreatment_history: NO///race: WHITE///residual_tumor: R1///tissue_source_site: 36///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: >20 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: YES///year_of_initial_pathologic_diagnosis: 2008///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: e4383d0b-9cc4-4fb5-a4a1-312928dd2e34///chemo_therapy: YES///day_of_form_completion: 18///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 724///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 665///eastern_cancer_oncology_group: 0///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 8///performance_status_scale_timing: Pre-Operative///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT///radiation_therapy: NO///site_of_tumor_first_recurrence: Locoregional and Metastasis///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2010///unique_patient_ID: TCGA-36-2540///batch: 40///Extract.Name: TCGA-36-2540-01A-01R-1048-01
1
age_at_initial_pathologic_diagnosis: 30///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: da274941-3edd-420b-9262-bbd959923c67///days_to_birth: -11145///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NO///neoplasm_histologic_grade: G3///patient_id: 1946///pretreatment_history: NO///race: NA///residual_tumor: NA///tissue_source_site: 31///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: YES///year_of_initial_pathologic_diagnosis: 2006///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 5a829c07-1749-4281-9d01-caab3b1caf7c///chemo_therapy: YES///day_of_form_completion: 20///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 918///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 664///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 10///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: NA///progression_determined_by: Physical Examination///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///unique_patient_ID: TCGA-31-1946///batch: 21///Extract.Name: TCGA-31-1946-01A-01R-0653-01
1
age_at_initial_pathologic_diagnosis: 34///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: f9793a4b-c0e7-4475-bf80-69543b7ee2f6///days_to_birth: -12772///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1416///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 24///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IV///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2008///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: cf7ad1d4-c805-41b7-8c74-2e09210bfd7e///chemo_therapy: YES///day_of_form_completion: 1///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 194///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 4///performance_status_scale_timing: NA///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///unique_patient_ID: TCGA-24-1416///batch: 14///Extract.Name: TCGA-24-1416-01A-01R-0477-01
1
age_at_initial_pathologic_diagnosis: 36///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 295231ab-477b-4077-a368-db34f867102c///days_to_birth: -13345///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G2///patient_id: 2436///pretreatment_history: NO///race: WHITE///residual_tumor: R0///tissue_source_site: 29///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: YES///year_of_initial_pathologic_diagnosis: 2009///additional_chemo_therapy: NA///additional_drug_therapy: NA///additional_immuno_therapy: NA///additional_pharmaceutical_therapy: NA///additional_radiation_therapy: NA///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 1d73fbe8-7e0f-4030-a6ac-73851d305020///chemo_therapy: YES///day_of_form_completion: 7///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 297///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2010///unique_patient_ID: TCGA-29-2436///batch: 40///Extract.Name: TCGA-29-2436-01A-01R-1048-01
1
age_at_initial_pathologic_diagnosis: 36///anatomic_organ_subdivision: NA///bcr_patient_uuid: 7e01f23a-0b0e-46a2-9f30-c3a9d2c779d2///days_to_birth: -13187///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: NA///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1105///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 24///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2001///additional_chemo_therapy: YES///additional_drug_therapy: YES///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: YES///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: da2b0e1e-ff62-4999-aa12-32768135104d///chemo_therapy: YES///day_of_form_completion: 9///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1442///days_to_last_followup: 1442///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 470///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 3///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: Abdominal CT; Molecular CA125///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///unique_patient_ID: TCGA-24-1105///batch: 12///Extract.Name: TCGA-24-1105-01A-01R-0434-01
1
age_at_initial_pathologic_diagnosis: 37///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 3438c018-9856-4628-ae59-7d365713647f///days_to_birth: -13739///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NO///neoplasm_histologic_grade: G1///patient_id: 1664///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 9///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NO///year_of_initial_pathologic_diagnosis: 2002///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: c96ac4bb-27ed-4e18-8939-9b1cfc8ead4d///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 2278///days_to_last_followup: 2278///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: NA///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///unique_patient_ID: TCGA-09-1664///batch: 19///Extract.Name: TCGA-09-1664-01A-01R-0582-01
1
age_at_initial_pathologic_diagnosis: 37///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: fdd4adb8-9295-480a-9352-305b5eb51187///days_to_birth: -13606///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G2///patient_id: 2408///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 25///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IV///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2005///additional_chemo_therapy: NA///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: YES///bcr_followup_uuid: f82208f0-6255-4dd7-8523-c0c9da6e0800///chemo_therapy: YES///day_of_form_completion: 5///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: 333///days_to_death: 942///days_to_last_followup: 942///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 333///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 1///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Partial Response///progression_determined_by: First Seen At Further Surgery///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2010///unique_patient_ID: TCGA-25-2408///batch: 24///Extract.Name: TCGA-25-2408-01A-01R-0709-01
1
age_at_initial_pathologic_diagnosis: 37///anatomic_organ_subdivision: Right///bcr_patient_uuid: 3ea880f4-7a78-4cb7-bfe4-54b3c30a812e///days_to_birth: -13681///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Cytology (e.g. Peritoneal or pleural fluid)///jewish_origin: NA///lymphatic_invasion: NO///neoplasm_histologic_grade: G3///patient_id: 2538///pretreatment_history: NO///race: NA///residual_tumor: R1///tissue_source_site: 36///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 11-20 mm///tumor_stage: IIIB///tumor_tissue_site: OVARY///venous_invasion: NO///year_of_initial_pathologic_diagnosis: 2008///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NO///bcr_followup_uuid: 89084cd7-3421-4d79-be7e-f24a2bdf54c6///chemo_therapy: YES///day_of_form_completion: 18///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 763///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 523///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 8///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT Abdomen/Pelvis///radiation_therapy: NO///site_of_tumor_first_recurrence: Locoregional and Metastasis///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2010///unique_patient_ID: TCGA-36-2538///batch: 40///Extract.Name: TCGA-36-2538-01A-01R-1048-01
1
age_at_initial_pathologic_diagnosis: 38///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 1c0318d9-0472-4840-add4-46bb9f914a30///days_to_birth: -13894///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Excisional Biopsy///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G1///patient_id: 1721///pretreatment_history: YES///race: WHITE///residual_tumor: NA///tissue_source_site: 61///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: NA///tumor_stage: IV///tumor_tissue_site: OVARY///venous_invasion: YES///year_of_initial_pathologic_diagnosis: 2008///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 902be45d-0481-4e42-8dc7-10a185ca8ade///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 338///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///unique_patient_ID: TCGA-61-1721///batch: 21///Extract.Name: TCGA-61-1721-01A-01R-0653-01
1
age_at_initial_pathologic_diagnosis: 38///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 22178c3c-6b04-46d8-8041-dc83fa195029///days_to_birth: -14184///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 2404///pretreatment_history: NO///race: AMERICAN INDIAN OR ALASKA NATIVE///residual_tumor: NA///tissue_source_site: 25///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2005///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NO///bcr_followup_uuid: 8b0b1002-3ed9-4317-ba15-982dc5522748///chemo_therapy: YES///day_of_form_completion: 5///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 882///days_to_last_followup: 882///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 425///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 1///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT and Molecular Marker - CA125///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2010///unique_patient_ID: TCGA-25-2404///batch: 24///Extract.Name: TCGA-25-2404-01A-01R-0709-01
1
age_at_initial_pathologic_diagnosis: 38///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 92a1a8f3-54f2-4983-bb14-dcb73658d897///days_to_birth: -13885///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Cytology (e.g. Peritoneal or pleural fluid)///jewish_origin: NA///lymphatic_invasion: NO///neoplasm_histologic_grade: G3///patient_id: 2530///pretreatment_history: NO///race: ASIAN///residual_tumor: R1///tissue_source_site: 36///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 11-20 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2007///additional_chemo_therapy: YES///additional_drug_therapy: YES///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NO///bcr_followup_uuid: eb2af194-4072-4aae-8504-3c74a9900431///chemo_therapy: YES///day_of_form_completion: 17///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 1004///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 630///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 8///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT abdomen/pelvis///radiation_therapy: NO///site_of_tumor_first_recurrence: Locoregional and Metastasis///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2010///unique_patient_ID: TCGA-36-2530///batch: 40///Extract.Name: TCGA-36-2530-01A-01R-1048-01
1
age_at_initial_pathologic_diagnosis: 38///anatomic_organ_subdivision: NA///bcr_patient_uuid: 79fd602b-3e8e-4353-aa78-4f5f170b607d///days_to_birth: -13910///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: NA///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1328///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 25///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2001///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: YES///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 9b2cf6b3-c423-4721-90b4-ae9c1fb5c92f///chemo_therapy: YES///day_of_form_completion: 27///days_to_additional_surgery_locoregional_procedure: 244///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 2009///days_to_last_followup: 1979///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 244///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 3///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Partial Response///progression_determined_by: First Seen At Further Surgery///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///unique_patient_ID: TCGA-25-1328///batch: 13///Extract.Name: TCGA-25-1328-01A-01R-0453-01
1
age_at_initial_pathologic_diagnosis: 39///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 05019013-7ea5-4905-ac79-901146ba2ee2///days_to_birth: -14574///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G2///patient_id: 1688///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 29///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: NA///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: YES///year_of_initial_pathologic_diagnosis: 1992///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: YES///additional_surgery_locoregional_procedure: YES///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: eb9c7a54-595c-42ce-bf50-83f92050181d///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: 183///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 2399///days_to_last_followup: 2399///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 183///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Stable Disease///progression_determined_by: First Seen At Further Surgery///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///unique_patient_ID: TCGA-29-1688///batch: 18///Extract.Name: TCGA-29-1688-01A-01R-0564-01
1
age_at_initial_pathologic_diagnosis: 39///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 5075cdc1-1b7c-4e25-98ea-fb568bd35f2d///days_to_birth: -14594///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Cytology (e.g. Peritoneal or pleural fluid)///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 2537///pretreatment_history: NO///race: NA///residual_tumor: R1///tissue_source_site: 36///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: >20 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2008///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 16ec4be7-a32c-4b9e-bae5-30c468066390///chemo_therapy: YES///day_of_form_completion: 18///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 788///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: 431///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: 2///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 8///performance_status_scale_timing: Pre-Adjuvant Therapy///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Partial Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT Abdomen/pelvis///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2010///unique_patient_ID: TCGA-36-2537///batch: 40///Extract.Name: TCGA-36-2537-01A-01R-1048-01
1
age_at_initial_pathologic_diagnosis: 39///anatomic_organ_subdivision: NA///bcr_patient_uuid: 63a75e0b-9241-4f0e-9236-01a2e2c05b7e///days_to_birth: -14538///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: NA///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 884///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 1999///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: YES///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: e819d979-7efe-4737-b8b4-0a64e5588d4b///chemo_therapy: YES///day_of_form_completion: 20///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 3260///days_to_last_followup: 3260///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 1251///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 3///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT Scan; Molecular marker CA 125///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///unique_patient_ID: TCGA-13-0884///batch: 13///Extract.Name: TCGA-13-0884-01B-01R-0453-01
1
age_at_initial_pathologic_diagnosis: 40///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 3ac45a71-c463-4f0f-b030-58c475a34418///days_to_birth: -14791///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G2///patient_id: 2008///pretreatment_history: NO///race: ASIAN///residual_tumor: NA///tissue_source_site: 61///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IIC///tumor_tissue_site: OVARY///venous_invasion: YES///year_of_initial_pathologic_diagnosis: 2007///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: YES///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: f45f3fe2-1f97-4e6f-afc7-d3abf0f3311a///chemo_therapy: YES///day_of_form_completion: 8///days_to_additional_surgery_locoregional_procedure: 827///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 931///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 817///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 12///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///unique_patient_ID: TCGA-61-2008///batch: 22///Extract.Name: TCGA-61-2008-01A-02R-0668-01
1
age_at_initial_pathologic_diagnosis: 40///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 94769f2c-b6fd-48ec-af34-b41165340b7c///days_to_birth: -14753///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NO///neoplasm_histologic_grade: G3///patient_id: 1769///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 29///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2007///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: b97223f7-bb76-4b6f-a938-a615aa68414a///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 699///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: 0///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: YES///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: Post-Adjuvant Therapy///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///unique_patient_ID: TCGA-29-1769///batch: 19///Extract.Name: TCGA-29-1769-01A-01R-0582-01
1
age_at_initial_pathologic_diagnosis: 40///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: a6eb0cd0-fe57-41b0-8593-776208684293///days_to_birth: -14782///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 1725///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 61///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 11-20 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: YES///year_of_initial_pathologic_diagnosis: 2007///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 4795b469-2ea1-4e65-bb8f-5b401b6632d5///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 955///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 843///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Stable Disease///progression_determined_by: Imaging Study///progression_determined_by_notes: CT Scan; Molecular marker-CA125///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///unique_patient_ID: TCGA-61-1725///batch: 19///Extract.Name: TCGA-61-1725-01A-01R-0582-01
1
age_at_initial_pathologic_diagnosis: 40///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: c11cae7e-91cd-4470-a9d8-188a4f6b8fa1///days_to_birth: -14729///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 792///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2005///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 1b6ba623-902c-40fa-bd13-a9e55cf9d4b0///chemo_therapy: YES///day_of_form_completion: 24///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 1117///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 816///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: 80///month_of_form_completion: 2///performance_status_scale_timing: Pre-Adjuvant Therapy///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: Molecular marker(s)///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///unique_patient_ID: TCGA-13-0792///batch: 9///Extract.Name: TCGA-13-0792-01A-01R-0362-01
1
age_at_initial_pathologic_diagnosis: 40///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: dc5a6ce7-01e5-408d-812e-e3e0ddc1cde5///days_to_birth: -14899///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Cytology (e.g. Peritoneal or pleural fluid)///jewish_origin: NA///lymphatic_invasion: NO///neoplasm_histologic_grade: G3///patient_id: 2109///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 61///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: >20 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NO///year_of_initial_pathologic_diagnosis: 1999///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 716014bf-2f9f-4dc8-81fe-c2baa9c4303c///chemo_therapy: YES///day_of_form_completion: 7///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 629///days_to_last_followup: 629///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 465///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 12///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: NA///progression_determined_by: Molecular Marker(S)///progression_determined_by_notes: CA125///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///unique_patient_ID: TCGA-61-2109///batch: 22///Extract.Name: TCGA-61-2109-01A-01R-0668-01
1
age_at_initial_pathologic_diagnosis: 40///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: f4d95c8e-fb84-46ca-acc0-827015cc9d0a///days_to_birth: [Completed]///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NO///neoplasm_histologic_grade: G3///patient_id: 2363///pretreatment_history: NO///race: ASIAN///residual_tumor: R0///tissue_source_site: 59///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IIIA///tumor_tissue_site: OVARY///venous_invasion: NO///year_of_initial_pathologic_diagnosis: 2007///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: b9fa6c71-a686-47cc-8b85-ba5cca27a399///chemo_therapy: YES///day_of_form_completion: 12///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 164///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 2///performance_status_scale_timing: NA///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2010///unique_patient_ID: TCGA-59-2363///batch: 24///Extract.Name: TCGA-59-2363-01A-01R-0709-01
1
age_at_initial_pathologic_diagnosis: 40///anatomic_organ_subdivision: Left///bcr_patient_uuid: 5e90e1ed-cbfd-44ba-a6ff-63ff576b3c73///days_to_birth: -14707///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 793///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IV///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2006///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NO///bcr_followup_uuid: a19d6f1b-9782-4721-89d1-65d0aaf06ea7///chemo_therapy: YES///day_of_form_completion: 24///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 873///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 351///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: YES///karnofsky_performance_score: 80///month_of_form_completion: 2///performance_status_scale_timing: Pre-Adjuvant Therapy///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///unique_patient_ID: TCGA-13-0793///batch: 9///Extract.Name: TCGA-13-0793-01A-01R-0362-01
1
age_at_initial_pathologic_diagnosis: 41///anatomic_organ_subdivision: Left///bcr_patient_uuid: 7fd6ab8a-201e-431d-a886-6ab553b6ca36///days_to_birth: -15017///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NO///neoplasm_histologic_grade: G3///patient_id: 1707///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 29///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2006///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: YES///bcr_followup_uuid: eefdc8c2-4c4c-4b1d-94b8-2e7210df54c3///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: 1247///days_to_death: NA///days_to_last_followup: 1276///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 1200///eastern_cancer_oncology_group: 0///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: Post-Adjuvant Therapy///person_neoplasm_cancer_status: NA///primary_therapy_outcome_success: Complete Response///progression_determined_by: Other Method: Specify In Notes///progression_determined_by_notes: CT///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///unique_patient_ID: TCGA-29-1707///batch: 18///Extract.Name: TCGA-29-1707-01A-01R-0564-01
1
age_at_initial_pathologic_diagnosis: 41///anatomic_organ_subdivision: NA///bcr_patient_uuid: 27920e1e-b9ab-4587-970a-0cba7025becb///days_to_birth: -15333///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: NA///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 901///pretreatment_history: NO///race: ASIAN///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: >20 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2004///additional_chemo_therapy: YES///additional_drug_therapy: YES///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 98ec4905-62a5-4fb5-9da0-a73e7e2b4368///chemo_therapy: YES///day_of_form_completion: 20///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 589///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 390///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: 80///month_of_form_completion: 3///performance_status_scale_timing: Pre-Adjuvant Therapy///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT Scan; Molecular marker CA-125///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: YES///vital_status: LIVING///year_of_form_completion: 2009///unique_patient_ID: TCGA-13-0901///batch: 13///Extract.Name: TCGA-13-0901-01B-01R-0453-01
1
age_at_initial_pathologic_diagnosis: 41///anatomic_organ_subdivision: NA///bcr_patient_uuid: 44493c23-82e9-4d9f-8e3c-7b3f9ae44970///days_to_birth: -15119///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: NA///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1412///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IV///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2008///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: a831a5dd-ab90-4720-9a9d-91228986100a///chemo_therapy: YES///day_of_form_completion: 20///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 162///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: 80///month_of_form_completion: 3///performance_status_scale_timing: Pre-Adjuvant Therapy///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///unique_patient_ID: TCGA-13-1412///batch: 13///Extract.Name: TCGA-13-1412-01A-01R-0453-01
1
age_at_initial_pathologic_diagnosis: 42///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 02594e5e-8751-47c1-9245-90c66984b665///days_to_birth: -15650///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: ASHKENAZI///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 2051///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 9///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: YES///year_of_initial_pathologic_diagnosis: 2004///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: YES///bcr_followup_uuid: 94294882-49ef-4a27-9a2a-03646c87209d///chemo_therapy: YES///day_of_form_completion: 3///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: 875///days_to_death: NA///days_to_last_followup: 1919///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 583///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 11///performance_status_scale_timing: NA///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT; Other method Ca 125 rising///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///unique_patient_ID: TCGA-09-2051///batch: 24///Extract.Name: TCGA-09-2051-01A-01R-0709-01
1
age_at_initial_pathologic_diagnosis: 42///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 0aa020cb-69d2-4235-a609-c279a133d8bb///days_to_birth: -15514///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Cytology (e.g. Peritoneal or pleural fluid)///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 1737///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 61///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IV///tumor_tissue_site: OVARY///venous_invasion: YES///year_of_initial_pathologic_diagnosis: 2005///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 36c9e79e-9559-4eb1-bc79-7274be460b42///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 1364///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: YES///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///unique_patient_ID: TCGA-61-1737///batch: 19///Extract.Name: TCGA-61-1737-01A-01R-0582-01
1
age_at_initial_pathologic_diagnosis: 42///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 14c58def-60ee-48e0-a74b-da4eb77ef344///days_to_birth: -15669///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: ASHKENAZI///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 887///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2002///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: YES///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NO///bcr_followup_uuid: 5db4b8a6-caf0-4a60-9eb5-01711d0b7af9///chemo_therapy: YES///day_of_form_completion: 25///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 2027///days_to_last_followup: 2027///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 513///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: 80///month_of_form_completion: 2///performance_status_scale_timing: Pre-Adjuvant Therapy///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: Molecular marker///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///unique_patient_ID: TCGA-13-0887///batch: 11///Extract.Name: TCGA-13-0887-01A-01R-0404-01
1
age_at_initial_pathologic_diagnosis: 42///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 8783e4b0-2b62-45d5-8cd9-f5a71cc0138e///days_to_birth: -15705///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 903///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IV///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2004///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NO///bcr_followup_uuid: af4c2496-e373-4d64-bd57-acdf6bfe34ae///chemo_therapy: YES///day_of_form_completion: 25///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 1441///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: 80///month_of_form_completion: 2///performance_status_scale_timing: Pre-Adjuvant Therapy///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: YES///vital_status: LIVING///year_of_form_completion: 2009///unique_patient_ID: TCGA-13-0903///batch: 11///Extract.Name: TCGA-13-0903-01A-01R-0404-01
1
age_at_initial_pathologic_diagnosis: 42///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 8fe44099-b313-4bfd-a94a-27e72f2a818c///days_to_birth: -15570///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 766///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2006///additional_chemo_therapy: NA///additional_drug_therapy: NA///additional_immuno_therapy: NA///additional_pharmaceutical_therapy: NA///additional_radiation_therapy: NA///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NO///bcr_followup_uuid: 6f218d11-5224-464e-a2ee-d18e3eaf0dc5///chemo_therapy: YES///day_of_form_completion: 24///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 651///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 628///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 2///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Physical Examination///progression_determined_by_notes: Image study, loco-regional///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///unique_patient_ID: TCGA-13-0766///batch: 9///Extract.Name: TCGA-13-0766-01A-02R-0362-01
1
age_at_initial_pathologic_diagnosis: 42///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: a782352e-c4bb-4c3e-ba82-456a47c3689a///days_to_birth: -15599///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1845///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 24///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2009///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 589f82e0-f528-49ec-ab57-8efff59e192c///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 116///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: NA///primary_therapy_outcome_success: NA///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///unique_patient_ID: TCGA-24-1845///batch: 19///Extract.Name: TCGA-24-1845-01A-01R-0582-01
1
age_at_initial_pathologic_diagnosis: 42///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: f3cd0ca3-8e5d-481b-b28c-619a4123dcd0///days_to_birth: -15444///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 2545///pretreatment_history: NO///race: NA///residual_tumor: R0///tissue_source_site: 36///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IIIA///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2008///additional_chemo_therapy: NA///additional_drug_therapy: NA///additional_immuno_therapy: NA///additional_pharmaceutical_therapy: NA///additional_radiation_therapy: NA///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 9d76fdcd-128d-4287-8eb5-694eef3b5754///chemo_therapy: YES///day_of_form_completion: 18///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 557///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 8///performance_status_scale_timing: NA///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: NA///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2010///unique_patient_ID: TCGA-36-2545///batch: 40///Extract.Name: TCGA-36-2545-01A-01R-1048-01
1
age_at_initial_pathologic_diagnosis: 42///anatomic_organ_subdivision: NA///bcr_patient_uuid: 0b2ea4b7-98bb-4190-b682-2c75b447c90a///days_to_birth: -15462///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: NA///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1314///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 25///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IV///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2000///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: YES///additional_surgery_metastatic_procedure: NO///bcr_followup_uuid: fe94fad3-1f4c-4204-ad9b-d8a1ab9b75cc///chemo_therapy: YES///day_of_form_completion: 27///days_to_additional_surgery_locoregional_procedure: 273///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1003///days_to_last_followup: 973///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: 273///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 3///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Partial Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///unique_patient_ID: TCGA-25-1314///batch: 13///Extract.Name: TCGA-25-1314-01A-01R-0453-01
1
age_at_initial_pathologic_diagnosis: 42///anatomic_organ_subdivision: NA///bcr_patient_uuid: 9fb1ba57-2007-4477-b000-2d36f163efd2///days_to_birth: -15383///days_to_initial_pathologic_diagnosis: 0///ethnicity: HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: NA///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 1110///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 23///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: YES///year_of_initial_pathologic_diagnosis: 2003///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 412125d8-6e4b-4ece-9596-a1bb77f81e61///chemo_therapy: YES///day_of_form_completion: 23///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 1658///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 326///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 2///performance_status_scale_timing: NA///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CAT Scan///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///unique_patient_ID: TCGA-23-1110///batch: 12///Extract.Name: TCGA-23-1110-01A-01R-0434-01
1
age_at_initial_pathologic_diagnosis: 42///anatomic_organ_subdivision: NA///bcr_patient_uuid: a88b7e66-5f12-4023-a7e2-fcfbd1f25977///days_to_birth: -15690///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: NA///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 1117///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 23///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: YES///year_of_initial_pathologic_diagnosis: 1998///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: YES///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 7a1fbb0f-3052-4169-b736-a2ad807a71ec///chemo_therapy: NO///day_of_form_completion: 19///days_to_additional_surgery_locoregional_procedure: 438///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1013///days_to_last_followup: 1013///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 418///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 2///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Other Method: Specify In Notes///progression_determined_by_notes: Biopsy///radiation_therapy: YES///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///unique_patient_ID: TCGA-23-1117///batch: 12///Extract.Name: TCGA-23-1117-01A-02R-0434-01
1
age_at_initial_pathologic_diagnosis: 43///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 242da7d0-8c6a-4395-9a0d-aa36e7c25ce6///days_to_birth: -16021///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G2///patient_id: 1763///pretreatment_history: NO///race: BLACK OR AFRICAN AMERICAN///residual_tumor: NA///tissue_source_site: 29///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2004///additional_chemo_therapy: YES///additional_drug_therapy: YES///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: YES///additional_surgery_locoregional_procedure: YES///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 5ab2d1a0-ed91-44b1-97ec-51a9f633cbea///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: 1868///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 2031///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 428///eastern_cancer_oncology_group: 0///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: Other///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Other Method: Specify In Notes///progression_determined_by_notes: Biopsy///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: YES///vital_status: LIVING///year_of_form_completion: 2009///unique_patient_ID: TCGA-29-1763///batch: 18///Extract.Name: TCGA-29-1763-01A-02R-0564-01
1
age_at_initial_pathologic_diagnosis: 43///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 931738a7-4b5b-46dc-b69f-72600862d8af///days_to_birth: -16016///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 1995///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 61///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: YES///year_of_initial_pathologic_diagnosis: 2009///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 23cec1cb-18f5-4261-bb98-4a4260f7306c///chemo_therapy: YES///day_of_form_completion: 8///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 60///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 12///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Stable Disease///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///unique_patient_ID: TCGA-61-1995///batch: 22///Extract.Name: TCGA-61-1995-01A-01R-0668-01
1
age_at_initial_pathologic_diagnosis: 43///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: c8acee1b-6854-409b-86ab-bf69dbe22ab6///days_to_birth: -15948///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 1426///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 24///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2008///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: dcc9dd22-4227-46a6-b054-4b094b5f6718///chemo_therapy: YES///day_of_form_completion: 16///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 163///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 4///performance_status_scale_timing: NA///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: Per Notes:No recurrence///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///unique_patient_ID: TCGA-24-1426///batch: 14///Extract.Name: TCGA-24-1426-01A-01R-0477-01
1
age_at_initial_pathologic_diagnosis: 43///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: cce34351-1700-405b-818f-a598f63a33e8///days_to_birth: -15925///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NO///neoplasm_histologic_grade: G3///patient_id: 1955///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 31///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: YES///year_of_initial_pathologic_diagnosis: 2005///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: YES///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 7651c94b-9420-44da-afbc-a38c01e82d6d///chemo_therapy: YES///day_of_form_completion: 19///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 1293///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 918///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 10///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: NA///progression_determined_by: Physical Examination///progression_determined_by_notes: NA///radiation_therapy: YES///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///unique_patient_ID: TCGA-31-1955///batch: 21///Extract.Name: TCGA-31-1955-01A-01R-0653-01
1
age_at_initial_pathologic_diagnosis: 43///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: e294b940-2828-499c-be24-47ef6c2e9035///days_to_birth: -15803///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Cytology (e.g. Peritoneal or pleural fluid)///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G2///patient_id: 1577///pretreatment_history: NO///race: ASIAN///residual_tumor: NA///tissue_source_site: 36///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2007///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 210fbda1-7211-4d2b-9eea-f48f0d3f8567///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 783///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: YES///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///unique_patient_ID: TCGA-36-1577///batch: 17///Extract.Name: TCGA-36-1577-01A-01R-0538-01
1
age_at_initial_pathologic_diagnosis: 43///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: f50ee039-1da9-43d9-ac01-657ec77a7f32///days_to_birth: -15993///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Incisional Biopsy///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1494///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: NA///tumor_stage: IV///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2004///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: YES///bcr_followup_uuid: 0ddc7119-70bd-4d8b-985a-0fbe4758e999///chemo_therapy: YES///day_of_form_completion: 31///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: 767///days_to_death: NA///days_to_last_followup: 1161///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 693///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 3///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT scan///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///unique_patient_ID: TCGA-13-1494///batch: 14///Extract.Name: TCGA-13-1494-01A-01R-0477-01
1
age_at_initial_pathologic_diagnosis: 43///anatomic_organ_subdivision: NA///bcr_patient_uuid: df53c3c0-3605-4d2b-bdc7-96d9beab27ea///days_to_birth: -16018///days_to_initial_pathologic_diagnosis: 0///ethnicity: HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: NA///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 1028///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 23///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: YES///year_of_initial_pathologic_diagnosis: 2004///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: YES///bcr_followup_uuid: 775ea41c-8d7e-4dd1-af91-41ee25e480d1///chemo_therapy: YES///day_of_form_completion: 23///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 1503///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 133///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 2///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT scan///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///unique_patient_ID: TCGA-23-1028///batch: 12///Extract.Name: TCGA-23-1028-01A-01R-0434-01
1
age_at_initial_pathologic_diagnosis: 43///anatomic_organ_subdivision: Right///bcr_patient_uuid: 8a98a6e6-b763-4824-858b-fd2738e6c9a3///days_to_birth: -15818///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NO///neoplasm_histologic_grade: G2///patient_id: 1696///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 29///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2003///additional_chemo_therapy: YES///additional_drug_therapy: YES///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: YES///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 82bd749e-d9aa-4da7-bd7d-57255e9c7e2e///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: 454///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1032///days_to_last_followup: 1025///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 342///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Partial Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///unique_patient_ID: TCGA-29-1696///batch: 18///Extract.Name: TCGA-29-1696-01A-01R-0564-01
1
age_at_initial_pathologic_diagnosis: 44///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 15c84da3-16e5-4909-aea9-cb5894b0f8af///days_to_birth: -16303///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: GX///patient_id: 751///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 1999///additional_chemo_therapy: YES///additional_drug_therapy: YES///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: YES///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 830bb982-a48a-4d97-8836-251f0cd6440d///chemo_therapy: YES///day_of_form_completion: 24///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1678///days_to_last_followup: 1678///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 653///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 2///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: Molecular marker(s)///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///unique_patient_ID: TCGA-13-0751///batch: 9///Extract.Name: TCGA-13-0751-01A-01R-0362-01
1
age_at_initial_pathologic_diagnosis: 44///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 446ce2a3-d328-443c-a419-3344baad0e16///days_to_birth: -16086///days_to_initial_pathologic_diagnosis: 0///ethnicity: HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Cytology (e.g. Peritoneal or pleural fluid)///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 725///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2002///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 24a9120f-4794-4b42-8edf-6794e062f04d///chemo_therapy: YES///day_of_form_completion: 24///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 377///days_to_last_followup: 377///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 190///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 2///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: Molecular marker(s)///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///unique_patient_ID: TCGA-13-0725///batch: 9///Extract.Name: TCGA-13-0725-01A-01R-0362-01
1
age_at_initial_pathologic_diagnosis: 44///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: a5030259-cf9c-4a58-8710-b9da8ee59320///days_to_birth: -16221///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 937///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 10///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2005///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NO///bcr_followup_uuid: 33721cd1-5029-49c4-bc36-64ee90e76df1///chemo_therapy: YES///day_of_form_completion: 6///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 608///days_to_last_followup: 460///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 235///eastern_cancer_oncology_group: 0///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 3///performance_status_scale_timing: Pre-Operative///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT Scan of Abd; Other method-FNA///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///unique_patient_ID: TCGA-10-0937///batch: 11///Extract.Name: TCGA-10-0937-01A-02R-0404-01
1
age_at_initial_pathologic_diagnosis: 44///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: ad2939e6-b8b8-475a-90e2-6a369c3d3167///days_to_birth: -16400///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NO///neoplasm_histologic_grade: G3///patient_id: 1718///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 30///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NO///year_of_initial_pathologic_diagnosis: 2002///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 634effee-a1bd-4dd7-a813-4f04f2c4a872///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1579///days_to_last_followup: 1579///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 896///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: YES///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: NA///progression_determined_by: Imaging Study///progression_determined_by_notes: DECT; Other CA 125///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///unique_patient_ID: TCGA-30-1718///batch: 18///Extract.Name: TCGA-30-1718-01A-01R-0564-01
1
age_at_initial_pathologic_diagnosis: 44///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: b9418c6d-94f7-4db4-a1e4-f384b09d54cb///days_to_birth: -16170///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 799///pretreatment_history: NO///race: ASIAN///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2008///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 20105ff9-cc71-41ab-942d-44454c233406///chemo_therapy: YES///day_of_form_completion: 25///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 237///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: 80///month_of_form_completion: 2///performance_status_scale_timing: Pre-Adjuvant Therapy///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///unique_patient_ID: TCGA-13-0799///batch: 9///Extract.Name: TCGA-13-0799-01A-01R-0362-01
1
age_at_initial_pathologic_diagnosis: 44///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: e07a61e2-bcd2-4a96-80df-97e04aafbd32///days_to_birth: -16261///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 931///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 10///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NO///year_of_initial_pathologic_diagnosis: 2002///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: YES///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NO///bcr_followup_uuid: c2b9ac2e-f094-4664-81f1-ba7e9a64ca33///chemo_therapy: YES///day_of_form_completion: 6///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1000///days_to_last_followup: 982///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 300///eastern_cancer_oncology_group: 1///followup_case_report_form_submission_reason: NA///hormonal_therapy: YES///immuno_therapy: YES///karnofsky_performance_score: NA///month_of_form_completion: 3///performance_status_scale_timing: Pre-Operative///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT scan and CA125///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: YES///vital_status: DECEASED///year_of_form_completion: 2009///unique_patient_ID: TCGA-10-0931///batch: 11///Extract.Name: TCGA-10-0931-01A-01R-0404-01
1
age_at_initial_pathologic_diagnosis: 44///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: e978a457-92ff-4eab-b759-ec6e74d973e8///days_to_birth: [Completed]///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 2350///pretreatment_history: NO///race: NA///residual_tumor: NA///tissue_source_site: 59///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IV///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 1995///additional_chemo_therapy: NA///additional_drug_therapy: NA///additional_immuno_therapy: NA///additional_pharmaceutical_therapy: NA///additional_radiation_therapy: NA///additional_surgery_locoregional_procedure: YES///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 3623594b-c07c-40e0-9eba-0a95a662d146///chemo_therapy: NA///day_of_form_completion: 29///days_to_additional_surgery_locoregional_procedure: 211///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 679///days_to_last_followup: 679///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: 211///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NA///immuno_therapy: NA///karnofsky_performance_score: NA///month_of_form_completion: 1///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Partial Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NA///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NA///vital_status: DECEASED///year_of_form_completion: 2010///unique_patient_ID: TCGA-59-2350///batch: 24///Extract.Name: TCGA-59-2350-01A-01R-0709-01
1
age_at_initial_pathologic_diagnosis: 44///anatomic_organ_subdivision: NA///bcr_patient_uuid: f7752d6e-f9cd-4dc9-ab01-3ab87acb21e4///days_to_birth: -16236///days_to_initial_pathologic_diagnosis: 0///ethnicity: HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: NA///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 1348///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 4///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIB///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2004///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: YES///bcr_followup_uuid: 4bd91396-4007-4ff3-9673-58e37b089fe6///chemo_therapy: YES///day_of_form_completion: 26///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1483///days_to_last_followup: 1483///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 574///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 3///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Molecular Marker(S)///progression_determined_by_notes: CA125///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///unique_patient_ID: TCGA-04-1348///batch: 13///Extract.Name: TCGA-04-1348-01A-01R-0453-01
1
age_at_initial_pathologic_diagnosis: 45///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 0a2d29de-869a-4dc8-ad11-6ee0d0a3a895///days_to_birth: -16612///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Excisional Biopsy///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 1736///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 61///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: NA///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: YES///year_of_initial_pathologic_diagnosis: 2005///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: YES///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: dbee91e2-9410-4570-9c69-8e43beb8887d///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: 812///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1484///days_to_last_followup: 1484///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 764///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT Scan///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///unique_patient_ID: TCGA-61-1736///batch: 22///Extract.Name: TCGA-61-1736-01B-01R-0668-01
1
age_at_initial_pathologic_diagnosis: 45///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 1cc02c64-a34e-46ae-9bc7-5d50f2fefb31///days_to_birth: -16733///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1506///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: NA///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2008///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: c38894f1-b486-48fd-acc2-f53027cb3ffa///chemo_therapy: YES///day_of_form_completion: 31///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 134///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: 80///month_of_form_completion: 3///performance_status_scale_timing: Pre-Adjuvant Therapy///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///unique_patient_ID: TCGA-13-1506///batch: 14///Extract.Name: TCGA-13-1506-01A-01R-0477-01
1
age_at_initial_pathologic_diagnosis: 45///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 1db60f09-7f5a-4f21-8003-06a6abc781db///days_to_birth: -16522///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: GX///patient_id: 1694///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 29///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 11-20 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2002///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: YES///additional_radiation_therapy: YES///additional_surgery_locoregional_procedure: YES///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: a17e36f4-a75c-4d56-a8a4-f79d48e9513b///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: 206///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1187///days_to_last_followup: 1172///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: 1///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: Other///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Stable Disease///progression_determined_by: First Seen At Further Surgery///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///unique_patient_ID: TCGA-29-1694///batch: 18///Extract.Name: TCGA-29-1694-01A-01R-0564-01
1
age_at_initial_pathologic_diagnosis: 45///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 21966708-4e66-4211-add0-f1515b09e362///days_to_birth: -16529///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Excisional Biopsy///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 1847///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 24///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IV///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2009///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: a302ccb0-5b86-4a6a-8121-fdf54689c24c///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 343///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///unique_patient_ID: TCGA-24-1847///batch: 18///Extract.Name: TCGA-24-1847-01A-01R-0564-01
1
age_at_initial_pathologic_diagnosis: 45///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 3491d67a-4f83-4f67-8085-bbb9fe942be5///days_to_birth: -16689///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1918///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 61///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IV///tumor_tissue_site: OVARY///venous_invasion: YES///year_of_initial_pathologic_diagnosis: 2002///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: f5f189d5-ceda-430f-996d-dbd6cdbb24a2///chemo_therapy: YES///day_of_form_completion: 30///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 479///days_to_last_followup: 479///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 413///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 11///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT scan and CA 125 elevation///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///unique_patient_ID: TCGA-61-1918///batch: 21///Extract.Name: TCGA-61-1918-01A-01R-0653-01
1
age_at_initial_pathologic_diagnosis: 45///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 67f526f1-def5-43b4-bc89-154baae190fc///days_to_birth: -16533///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 1846///pretreatment_history: NO///race: NA///residual_tumor: NA///tissue_source_site: 24///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2009///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: e73b1ede-abff-4032-af69-0c538317414f///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 133///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: 1///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: Other///person_neoplasm_cancer_status: NA///primary_therapy_outcome_success: NA///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///unique_patient_ID: TCGA-24-1846///batch: 19///Extract.Name: TCGA-24-1846-01A-01R-0582-01
1
age_at_initial_pathologic_diagnosis: 45///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: b120b701-c194-43d7-a491-3206fac38ec1///days_to_birth: -16763///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1425///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 24///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2008///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 4a3aabd7-413a-42fe-a1dd-5af7e3935ec3///chemo_therapy: YES///day_of_form_completion: 12///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 181///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: 0///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 5///performance_status_scale_timing: Other///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///unique_patient_ID: TCGA-24-1425///batch: 15///Extract.Name: TCGA-24-1425-01A-02R-0502-01
1
age_at_initial_pathologic_diagnosis: 45///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: cbc5b936-ead5-4858-ab90-e639402789b0///days_to_birth: -16745///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NO///neoplasm_histologic_grade: G3///patient_id: 1685///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 20///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NO///year_of_initial_pathologic_diagnosis: 2008///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NO///bcr_followup_uuid: f74f942b-3336-4eab-b6f5-96ea2715a52e///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 507///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: 0///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: Post-Adjuvant Therapy///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///unique_patient_ID: TCGA-20-1685///batch: 18///Extract.Name: TCGA-20-1685-01A-01R-0564-01
1
age_at_initial_pathologic_diagnosis: 45///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: e9483296-cb91-497a-b955-39a3c3289dac///days_to_birth: -16724///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NO///neoplasm_histologic_grade: G2///patient_id: 1514///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 4///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IIIA///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2004///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: YES///bcr_followup_uuid: 5d6ed657-10c2-447e-bd5e-9a72631507ab///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: 1284///days_to_death: 1720///days_to_last_followup: 1720///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 1221///eastern_cancer_oncology_group: 1///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: Pre-Operative///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT Scan///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///unique_patient_ID: TCGA-04-1514///batch: 15///Extract.Name: TCGA-04-1514-01A-01R-0502-01
1
age_at_initial_pathologic_diagnosis: 45///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: f58e49fc-9641-4b46-be4c-766445ec70a3///days_to_birth: -16485///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G2///patient_id: 1711///pretreatment_history: NO///race: BLACK OR AFRICAN AMERICAN///residual_tumor: NA///tissue_source_site: 29///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2006///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 764f8125-40f5-4183-8365-5d97c30cbdf0///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 1053///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: 0///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: Post-Adjuvant Therapy///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: YES///vital_status: LIVING///year_of_form_completion: 2009///unique_patient_ID: TCGA-29-1711///batch: 18///Extract.Name: TCGA-29-1711-01A-01R-0564-01
1
age_at_initial_pathologic_diagnosis: 45///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: fbb45305-de8d-4baf-8bd0-047b29c2e9d9///days_to_birth: -16670///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Cytology (e.g. Peritoneal or pleural fluid)///jewish_origin: ASHKENAZI///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 924///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IV///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2008///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: fae23792-aeda-4037-82cf-b8d048036938///chemo_therapy: YES///day_of_form_completion: 25///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 185///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 2///performance_status_scale_timing: NA///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: YES///vital_status: LIVING///year_of_form_completion: 2009///unique_patient_ID: TCGA-13-0924///batch: 11///Extract.Name: TCGA-13-0924-01A-01R-0404-01
1
age_at_initial_pathologic_diagnosis: 45///anatomic_organ_subdivision: Left///bcr_patient_uuid: ef57bc45-858f-4d4e-8407-b7eadfa43be5///days_to_birth: -16551///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NO///neoplasm_histologic_grade: G3///patient_id: 2077///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 23///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: YES///year_of_initial_pathologic_diagnosis: 1999///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: YES///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: f560f5c0-882a-44ba-b631-892ccda55b7e///chemo_therapy: YES///day_of_form_completion: 20///days_to_additional_surgery_locoregional_procedure: 1345///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 3525///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 1232///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 11///performance_status_scale_timing: NA///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT Scan///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///unique_patient_ID: TCGA-23-2077///batch: 22///Extract.Name: TCGA-23-2077-01A-01R-0668-01
1
age_at_initial_pathologic_diagnosis: 45///anatomic_organ_subdivision: NA///bcr_patient_uuid: 700e91bb-d675-41b2-bbbd-935767c7b447///days_to_birth: -16470///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: NA///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 1118///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 23///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: >20 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: YES///year_of_initial_pathologic_diagnosis: 2001///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 2c2e8996-31a2-4d40-ae52-a14131eb9684///chemo_therapy: YES///day_of_form_completion: 20///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 2616///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 2///performance_status_scale_timing: NA///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///unique_patient_ID: TCGA-23-1118///batch: 12///Extract.Name: TCGA-23-1118-01A-01R-0434-01
1
age_at_initial_pathologic_diagnosis: 45///anatomic_organ_subdivision: NA///bcr_patient_uuid: b923ac70-70ea-4a82-8466-46350c5803bf///days_to_birth: -16483///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: NA///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 1021///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 23///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: >20 mm///tumor_stage: IV///tumor_tissue_site: OVARY///venous_invasion: YES///year_of_initial_pathologic_diagnosis: 2004///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: YES///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: deff0c2e-9b3e-4181-97d6-13ddfc9f115a///chemo_therapy: YES///day_of_form_completion: 24///days_to_additional_surgery_locoregional_procedure: 1181///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1446///days_to_last_followup: 1446///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 2///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Partial Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///unique_patient_ID: TCGA-23-1021///batch: 12///Extract.Name: TCGA-23-1021-01B-01R-0434-01
1
age_at_initial_pathologic_diagnosis: 45///anatomic_organ_subdivision: NA///bcr_patient_uuid: c6ede8ae-881c-47a0-a0ef-745ed4b7764a///days_to_birth: -16442///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: NA///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1026///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 23///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2004///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: YES///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: adc0c0f8-0f93-40af-862a-f2efc4dd6cf1///chemo_therapy: YES///day_of_form_completion: 23///days_to_additional_surgery_locoregional_procedure: 816///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 816///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 797///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 2///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///unique_patient_ID: TCGA-23-1026///batch: 12///Extract.Name: TCGA-23-1026-01B-01R-0434-01
1
age_at_initial_pathologic_diagnosis: 45///anatomic_organ_subdivision: Right///bcr_patient_uuid: 2cb82948-7cbe-4b6c-8414-c02f662de2d0///days_to_birth: -16493///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: ASHKENAZI///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 2084///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 23///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IV///tumor_tissue_site: OVARY///venous_invasion: YES///year_of_initial_pathologic_diagnosis: 2000///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: YES///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 64e0a5f8-5338-401d-9c5b-85d0b1c484d4///chemo_therapy: YES///day_of_form_completion: 18///days_to_additional_surgery_locoregional_procedure: 627///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1516///days_to_last_followup: 1516///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 619///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 11///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT Scan; Molecular marker- Ca 125///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///unique_patient_ID: TCGA-23-2084///batch: 22///Extract.Name: TCGA-23-2084-01A-02R-0668-01
1
age_at_initial_pathologic_diagnosis: 46///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 85bb4987-51e7-40fe-ad59-2aa56754eca9///days_to_birth: -17115///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 2002///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 61///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 11-20 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: YES///year_of_initial_pathologic_diagnosis: 2008///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 7707c515-3224-4835-89c6-76f1f0d0e875///chemo_therapy: YES///day_of_form_completion: 8///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 547///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 12///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Progressive Disease///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///unique_patient_ID: TCGA-61-2002///batch: 22///Extract.Name: TCGA-61-2002-01A-01R-0668-01
1
age_at_initial_pathologic_diagnosis: 46///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 9bf16a89-2fc7-4c08-93bc-3105eec5c3cc///days_to_birth: -16960///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Cytology (e.g. Peritoneal or pleural fluid)///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 1687///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 20///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IV///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2008///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: f16936bd-4107-4e50-bcd0-da8f76ba03eb///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 81///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///unique_patient_ID: TCGA-20-1687///batch: 18///Extract.Name: TCGA-20-1687-01A-01R-0564-01
1
age_at_initial_pathologic_diagnosis: 46///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 9e7d3dea-5d81-4f10-819c-1c2a68ddd150///days_to_birth: -17129///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1546///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 24///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 1997///additional_chemo_therapy: NA///additional_drug_therapy: NA///additional_immuno_therapy: NA///additional_pharmaceutical_therapy: NA///additional_radiation_therapy: NA///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 0b61178a-f8fb-4a88-8c08-54ae6e0ab3f0///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1955///days_to_last_followup: 1955///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NA///immuno_therapy: NA///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: NA///primary_therapy_outcome_success: NA///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NA///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NA///vital_status: DECEASED///year_of_form_completion: 2009///unique_patient_ID: TCGA-24-1546///batch: 17///Extract.Name: TCGA-24-1546-01A-01R-0538-01
1
age_at_initial_pathologic_diagnosis: 46///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: b8c3d99c-429b-42a3-b486-6fbcb90cc2e0///days_to_birth: -16811///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Cytology (e.g. Peritoneal or pleural fluid)///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 801///pretreatment_history: NO///race: BLACK OR AFRICAN AMERICAN///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2008///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NO///bcr_followup_uuid: 7198f423-8333-4349-8ee6-65e5a4322771///chemo_therapy: YES///day_of_form_completion: 25///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 252///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: 80///month_of_form_completion: 2///performance_status_scale_timing: Pre-Adjuvant Therapy///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///unique_patient_ID: TCGA-13-0801///batch: 9///Extract.Name: TCGA-13-0801-01A-01R-0362-01
1
age_at_initial_pathologic_diagnosis: 46///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: bbad2efe-e9c7-4f8f-924b-ebbbe4c181d4///days_to_birth: -17009///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 2019///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 24///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2009///additional_chemo_therapy: NA///additional_drug_therapy: NA///additional_immuno_therapy: NA///additional_pharmaceutical_therapy: NA///additional_radiation_therapy: NA///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 478f18ec-c7d2-485e-b83d-1b416c86ac20///chemo_therapy: YES///day_of_form_completion: 16///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 148///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: 1///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 3///performance_status_scale_timing: Other///person_neoplasm_cancer_status: NA///primary_therapy_outcome_success: NA///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2010///unique_patient_ID: TCGA-24-2019///batch: 22///Extract.Name: TCGA-24-2019-01A-02R-0668-01
1
age_at_initial_pathologic_diagnosis: 46///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: e3ea5137-76b8-4afc-9b80-ed74714e7172///days_to_birth: -17122///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: ASHKENAZI///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 2079///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 23///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: YES///year_of_initial_pathologic_diagnosis: 2001///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: YES///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 0b186b74-05f4-4e60-86de-30afe98b56e3///chemo_therapy: YES///day_of_form_completion: 20///days_to_additional_surgery_locoregional_procedure: 2488///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 2788///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 283///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 11///performance_status_scale_timing: NA///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT Scan///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///unique_patient_ID: TCGA-23-2079///batch: 22///Extract.Name: TCGA-23-2079-01A-01R-0668-01
1
age_at_initial_pathologic_diagnosis: 46///anatomic_organ_subdivision: NA///bcr_patient_uuid: 0f4a4ad1-e394-45c4-9aa9-aadf2bff0628///days_to_birth: -16941///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: NA///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1350///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 4///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: >20 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2003///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: YES///additional_pharmaceutical_therapy: YES///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 7b044c52-3464-4207-bbec-d65b1cc081f0///chemo_therapy: NO///day_of_form_completion: 26///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1946///days_to_last_followup: 1946///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 111///eastern_cancer_oncology_group: 0///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 3///performance_status_scale_timing: Pre-Operative///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Stable Disease///progression_determined_by: Imaging Study///progression_determined_by_notes: CT Scan///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///unique_patient_ID: TCGA-04-1350///batch: 13///Extract.Name: TCGA-04-1350-01A-01R-0453-01
1
age_at_initial_pathologic_diagnosis: 46///anatomic_organ_subdivision: NA///bcr_patient_uuid: f9824a6e-7a97-445c-8846-df8d8cddedaa///days_to_birth: -17159///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: GX///patient_id: 1867///pretreatment_history: NO///race: NA///residual_tumor: NA///tissue_source_site: 30///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: NA///tumor_stage: IV///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2004///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: b412d4a8-d468-4489-ad11-87d530725059///chemo_therapy: NO///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 36///days_to_last_followup: 36///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: NA///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///unique_patient_ID: TCGA-30-1867///batch: 21///Extract.Name: TCGA-30-1867-01A-01R-0653-01
1
age_at_initial_pathologic_diagnosis: 46///anatomic_organ_subdivision: Right///bcr_patient_uuid: 4d71dd15-cd01-4dae-ad70-6dc325140207///days_to_birth: -16889///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1029///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 23///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2007///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NO///bcr_followup_uuid: b21097d0-d714-4e0c-a8b9-fecac7ce4111///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 268///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///unique_patient_ID: TCGA-23-1029///batch: 19///Extract.Name: TCGA-23-1029-01B-01R-0582-01
1
age_at_initial_pathologic_diagnosis: 47///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 2ae65a06-df0f-4de1-a536-537cae0cc260///days_to_birth: -17168///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 1724///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 61///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: YES///year_of_initial_pathologic_diagnosis: 2007///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: YES///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 81734ce6-1983-4b83-a2ac-394d263fefb0///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: 186///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 637///days_to_last_followup: 637///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Progressive Disease///progression_determined_by: Imaging Study///progression_determined_by_notes: CT Abd///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///unique_patient_ID: TCGA-61-1724///batch: 21///Extract.Name: TCGA-61-1724-01A-01R-0653-01
1
age_at_initial_pathologic_diagnosis: 47///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 2bb96e1e-6992-434d-83e5-2f03713b3911///days_to_birth: -17469///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NO///neoplasm_histologic_grade: G3///patient_id: 1525///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 4///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NO///year_of_initial_pathologic_diagnosis: 2005///additional_chemo_therapy: NO///additional_drug_therapy: YES///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 375c3a71-0dc9-475a-bf5d-bea64f332b78///chemo_therapy: YES///day_of_form_completion: 3///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1167///days_to_last_followup: 1167///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 212///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: Spiral Scan///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///unique_patient_ID: TCGA-04-1525///batch: 17///Extract.Name: TCGA-04-1525-01A-01R-0538-01
1
age_at_initial_pathologic_diagnosis: 47///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 5ced5b58-fab4-4bcd-b706-d6e49ce0cfc5///days_to_birth: -17355///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G2///patient_id: 1777///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 29///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: >20 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2008///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 26534f1e-ae94-44af-8630-10166f59e9a1///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 374///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: 0///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: Post-Adjuvant Therapy///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Progressive Disease///progression_determined_by: Imaging Study///progression_determined_by_notes: CT; Molecular markers CA 125///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///unique_patient_ID: TCGA-29-1777///batch: 19///Extract.Name: TCGA-29-1777-01A-01R-0582-01
1
age_at_initial_pathologic_diagnosis: 47///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 6fee41dc-b8a9-4347-8085-b7e05f813ad0///days_to_birth: -17207///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 1944///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 31///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: YES///year_of_initial_pathologic_diagnosis: 2005///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: YES///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: YES///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: d1397f20-f35b-48a1-8d55-fdf484d16766///chemo_therapy: YES///day_of_form_completion: 19///days_to_additional_surgery_locoregional_procedure: 701///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 1386///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 678///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 10///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///unique_patient_ID: TCGA-31-1944///batch: 21///Extract.Name: TCGA-31-1944-01A-01R-0653-01
1
age_at_initial_pathologic_diagnosis: 47///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: ed21615c-0de3-421c-9e8d-8996026c4431///days_to_birth: -17257///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 1584///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 57///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: YES///year_of_initial_pathologic_diagnosis: 2007///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: YES///bcr_followup_uuid: aca7dfdd-2755-43e1-a775-1687dee80c72///chemo_therapy: NO///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: 532///days_to_death: NA///days_to_last_followup: 643///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 530///eastern_cancer_oncology_group: 0///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: Pre-Adjuvant Therapy///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: NA///progression_determined_by: Imaging Study///progression_determined_by_notes: CT of abdomen and pelvis with contrast///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///unique_patient_ID: TCGA-57-1584///batch: 17///Extract.Name: TCGA-57-1584-01A-01R-0538-01
1
age_at_initial_pathologic_diagnosis: 47///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: f9c835db-2ab6-4bf5-826f-48723493c0ec///days_to_birth: -17530///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G2///patient_id: 1705///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 29///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: >20 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2005///additional_chemo_therapy: YES///additional_drug_therapy: YES///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: YES///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 1fe3bcd4-e15d-4d28-a88d-81ce50f34996///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: 434///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 555///days_to_last_followup: 555///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 283///eastern_cancer_oncology_group: 0///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: Post-Adjuvant Therapy///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///unique_patient_ID: TCGA-29-1705///batch: 18///Extract.Name: TCGA-29-1705-01A-01R-0564-01
1
age_at_initial_pathologic_diagnosis: 47///anatomic_organ_subdivision: NA///bcr_patient_uuid: bc4bc342-20bf-40c3-af26-2c6f942da93d///days_to_birth: -17528///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Cytology (e.g. Peritoneal or pleural fluid)///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1497///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: NA///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2004///additional_chemo_therapy: YES///additional_drug_therapy: YES///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: YES///bcr_followup_uuid: d8a1710d-bba3-4b22-9c76-124568b7b543///chemo_therapy: YES///day_of_form_completion: 31///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: 861///days_to_death: NA///days_to_last_followup: 1652///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 813///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: 80///month_of_form_completion: 3///performance_status_scale_timing: Pre-Adjuvant Therapy///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT scan///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: YES///vital_status: LIVING///year_of_form_completion: 2009///unique_patient_ID: TCGA-13-1497///batch: 14///Extract.Name: TCGA-13-1497-01A-01R-0477-01
1
age_at_initial_pathologic_diagnosis: 47///anatomic_organ_subdivision: Right///bcr_patient_uuid: bdd792e7-d75f-4aa3-b38e-f0708e112075///days_to_birth: -17235///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C48.1///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 2293///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 24///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: >20 mm///tumor_stage: NA///tumor_tissue_site: OMENTUM///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 1995///additional_chemo_therapy: NA///additional_drug_therapy: NA///additional_immuno_therapy: NA///additional_pharmaceutical_therapy: NA///additional_radiation_therapy: NA///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 65ef94b1-f432-43af-b82b-79eda4ec62be///chemo_therapy: YES///day_of_form_completion: 26///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 506///days_to_last_followup: 506///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 2///performance_status_scale_timing: NA///person_neoplasm_cancer_status: NA///primary_therapy_outcome_success: Partial Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2010///unique_patient_ID: TCGA-24-2293///batch: 24///Extract.Name: TCGA-24-2293-01A-01R-0709-01
1
age_at_initial_pathologic_diagnosis: 48///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 0d23fa5b-95f8-4626-a4d2-c72ad3cc553b///days_to_birth: -17798///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 720///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2001///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 7da47e49-e807-4f7f-834c-1ade13aca50c///chemo_therapy: YES///day_of_form_completion: 24///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1355///days_to_last_followup: 1355///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 292///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: 80///month_of_form_completion: 2///performance_status_scale_timing: Pre-Adjuvant Therapy///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: Molecular marker///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///unique_patient_ID: TCGA-13-0720///batch: 9///Extract.Name: TCGA-13-0720-01A-01R-0362-01
1
age_at_initial_pathologic_diagnosis: 48///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 49bfd0fe-48ce-49db-9f76-ce2310410950///days_to_birth: -17641///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Incisional Biopsy///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G2///patient_id: 1485///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IV///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2001///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: c541cbcc-09ee-4152-b710-60d9f09f384d///chemo_therapy: YES///day_of_form_completion: 31///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 629///days_to_last_followup: 629///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: 170///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: 80///month_of_form_completion: 3///performance_status_scale_timing: Pre-Adjuvant Therapy///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Partial Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT scan///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///unique_patient_ID: TCGA-13-1485///batch: 14///Extract.Name: TCGA-13-1485-01A-02R-0477-01
1
age_at_initial_pathologic_diagnosis: 48///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 565d06a1-3640-4274-8fb3-8cad7e578876///days_to_birth: -17855///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 1998///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 61///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: YES///year_of_initial_pathologic_diagnosis: 2009///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 0d0da8b8-e9f8-4dbb-9a7f-ff76d2dc734f///chemo_therapy: YES///day_of_form_completion: 8///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 168///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 12///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: NA///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///unique_patient_ID: TCGA-61-1998///batch: 22///Extract.Name: TCGA-61-1998-01A-01R-0668-01
1
age_at_initial_pathologic_diagnosis: 48///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 6f592f17-e00b-4d04-a45b-d9d4cf4c3075///days_to_birth: -17724///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1644///pretreatment_history: NO///race: WHITE///residual_tumor: R1///tissue_source_site: 4///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: >20 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2002///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 28f1bf15-8aeb-478c-83b4-d19d4437ca7f///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1487///days_to_last_followup: 1487///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: 634///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: 1///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: Pre-Adjuvant Therapy///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Partial Response///progression_determined_by: Imaging Study///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///unique_patient_ID: TCGA-04-1644///batch: 40///Extract.Name: TCGA-04-1644-01B-01R-1048-01
1
age_at_initial_pathologic_diagnosis: 48///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: eeb9d147-608d-4692-8adf-2f601d23a8ff///days_to_birth: -17847///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1574///pretreatment_history: NO///race: ASIAN///residual_tumor: NA///tissue_source_site: 36///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: >20 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2007///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: a362d009-06b1-4ec1-a13b-762036f060a8///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 686///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 648///eastern_cancer_oncology_group: 0///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: Pre-Operative///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Complete Response///progression_determined_by: Imaging Study///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: Loco-Regional///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///unique_patient_ID: TCGA-36-1574///batch: 17///Extract.Name: TCGA-36-1574-01A-01R-0538-01
1
age_at_initial_pathologic_diagnosis: 48///anatomic_organ_subdivision: Left///bcr_patient_uuid: 1c86e4e5-ecc9-4f6d-a557-77bf396a653b///days_to_birth: -17767///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1516///pretreatment_history: NO///race: WHITE///residual_tumor: R0///tissue_source_site: 4///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IA///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2006///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 315cef90-6683-4c74-ae71-9888cc51cc33///chemo_therapy: YES///day_of_form_completion: 25///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 1265///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: 0///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: Post-Adjuvant Therapy///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2010///unique_patient_ID: TCGA-04-1516///batch: 40///Extract.Name: TCGA-04-1516-01A-01R-1048-01
1
age_at_initial_pathologic_diagnosis: 48///anatomic_organ_subdivision: Left///bcr_patient_uuid: 838778c3-0b33-4fc5-97fc-5da163475485///days_to_birth: -17545///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NO///neoplasm_histologic_grade: G3///patient_id: 2055///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 9///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: No Macroscopic disease///tumor_stage: IC///tumor_tissue_site: OVARY///venous_invasion: NO///year_of_initial_pathologic_diagnosis: 2007///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: fac2d6fc-13cf-49fc-9201-6997dd4cb7a0///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 819///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 11///performance_status_scale_timing: NA///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///unique_patient_ID: TCGA-09-2055///batch: 24///Extract.Name: TCGA-09-2055-01B-01R-0709-01
1
age_at_initial_pathologic_diagnosis: 48///anatomic_organ_subdivision: NA///bcr_patient_uuid: 0d5e232d-5aa2-4f6f-be58-ffd5f15ee0b8///days_to_birth: -17697///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: NA///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1403///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: NA///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2008///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 1b8ebf1f-79f6-4198-ad79-00cec38ef301///chemo_therapy: YES///day_of_form_completion: 20///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 331///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 3///performance_status_scale_timing: NA///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///unique_patient_ID: TCGA-13-1403///batch: 13///Extract.Name: TCGA-13-1403-01A-01R-0453-01
1
age_at_initial_pathologic_diagnosis: 48///anatomic_organ_subdivision: NA///bcr_patient_uuid: 15170c7f-5880-4fb6-82ce-68d3df0dfb68///days_to_birth: -17573///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: NA///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 893///pretreatment_history: NO///race: BLACK OR AFRICAN AMERICAN///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 11-20 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2003///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 2e198688-0234-4ff0-bae5-0472ce5af182///chemo_therapy: YES///day_of_form_completion: 20///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 1319///days_to_last_followup: 1319///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 461///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: YES///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 3///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Partial Response///progression_determined_by: Imaging Study///progression_determined_by_notes: CT scan; Molecular marker CA 125///radiation_therapy: NO///site_of_tumor_first_recurrence: Metastasis///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///unique_patient_ID: TCGA-13-0893///batch: 13///Extract.Name: TCGA-13-0893-01B-01R-0453-01
1
age_at_initial_pathologic_diagnosis: 48///anatomic_organ_subdivision: NA///bcr_patient_uuid: 6209e80d-a115-4f8e-bf0d-18461401a1c6///days_to_birth: -17791///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: NA///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 1113///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 23///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IV///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2002///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NO///bcr_followup_uuid: 8f74e7a1-1849-44b8-8387-31bff5e4bfb7///chemo_therapy: YES///day_of_form_completion: 19///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 949///days_to_last_followup: 949///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 2///performance_status_scale_timing: NA///person_neoplasm_cancer_status: WITH TUMOR///primary_therapy_outcome_success: Partial Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: DECEASED///year_of_form_completion: 2009///unique_patient_ID: TCGA-23-1113///batch: 12///Extract.Name: TCGA-23-1113-01A-01R-0434-01
1
age_at_initial_pathologic_diagnosis: 48///anatomic_organ_subdivision: NA///bcr_patient_uuid: 8e107f4b-1912-4d3e-814a-b863e2d65ed7///days_to_birth: -17783///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: NA///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1404///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 13///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2008///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: b605a929-f33e-4bfa-98c1-3bd3d2ce980a///chemo_therapy: YES///day_of_form_completion: 20///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 201///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: 60///month_of_form_completion: 3///performance_status_scale_timing: Pre-Adjuvant Therapy///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///unique_patient_ID: TCGA-13-1404///batch: 13///Extract.Name: TCGA-13-1404-01A-01R-0453-01
1
age_at_initial_pathologic_diagnosis: 48///anatomic_organ_subdivision: NA///bcr_patient_uuid: c9e58844-9d61-44a2-aee6-1760bc19711b///days_to_birth: -17588///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: NA///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 1027///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 23///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: YES///year_of_initial_pathologic_diagnosis: 2005///additional_chemo_therapy: YES///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NO///additional_surgery_metastatic_procedure: NO///bcr_followup_uuid: 517a109a-a6a8-4855-837c-b8d6a48412d3///chemo_therapy: YES///day_of_form_completion: 24///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: 975///days_to_last_followup: 965///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: 114///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 2///performance_status_scale_timing: NA///person_neoplasm_cancer_status: NA///primary_therapy_outcome_success: Progressive Disease///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: YES///vital_status: DECEASED///year_of_form_completion: 2009///unique_patient_ID: TCGA-23-1027///batch: 12///Extract.Name: TCGA-23-1027-01A-02R-0434-01
1
age_at_initial_pathologic_diagnosis: 48///anatomic_organ_subdivision: NA///bcr_patient_uuid: e9b5336e-d724-4e7d-8c81-1147abd0a80d///days_to_birth: -17670///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: NA///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1519///pretreatment_history: NO///race: NA///residual_tumor: NA///tissue_source_site: 4///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: NA///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2007///additional_chemo_therapy: NA///additional_drug_therapy: NA///additional_immuno_therapy: NA///additional_pharmaceutical_therapy: NA///additional_radiation_therapy: NA///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: NA///chemo_therapy: NA///day_of_form_completion: NA///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: NA///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NA///immuno_therapy: NA///karnofsky_performance_score: NA///month_of_form_completion: NA///performance_status_scale_timing: NA///person_neoplasm_cancer_status: NA///primary_therapy_outcome_success: NA///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NA///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NA///vital_status: NA///year_of_form_completion: NA///unique_patient_ID: TCGA-04-1519///batch: 17///Extract.Name: TCGA-04-1519-01A-01R-0538-01
1
age_at_initial_pathologic_diagnosis: 48///anatomic_organ_subdivision: Right///bcr_patient_uuid: 8516d4f2-0b98-4847-99c6-4d7269fa4af2///days_to_birth: -17574///days_to_initial_pathologic_diagnosis: 0///ethnicity: NOT HISPANIC OR LATINO///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: NA///neoplasm_histologic_grade: G3///patient_id: 1913///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 61///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIB///tumor_tissue_site: OVARY///venous_invasion: YES///year_of_initial_pathologic_diagnosis: 2005///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: 13bbd5c0-51bc-4d78-800b-adad5eaa8d38///chemo_therapy: YES///day_of_form_completion: 1///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 1488///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: NA///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 10///performance_status_scale_timing: NA///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: NO///vital_status: LIVING///year_of_form_completion: 2009///unique_patient_ID: TCGA-61-1913///batch: 19///Extract.Name: TCGA-61-1913-01A-01R-0582-01
1
age_at_initial_pathologic_diagnosis: 49///anatomic_organ_subdivision: Bilateral///bcr_patient_uuid: 09c77947-a333-4392-b18d-a6c1f08764a1///days_to_birth: -18227///days_to_initial_pathologic_diagnosis: 0///ethnicity: NA///gender: FEMALE///gynecologic_figo_staging_system: NA///histological_type: Serous Cystadenocarcinoma///icd_10: NA///icd_o_3_histology: 8441/3///icd_o_3_site: C56.9///informed_consent_verified: YES///initial_pathologic_diagnosis_method: Tumor resection///jewish_origin: NA///lymphatic_invasion: YES///neoplasm_histologic_grade: G3///patient_id: 1842///pretreatment_history: NO///race: WHITE///residual_tumor: NA///tissue_source_site: 24///tumor_histologic_subtype: Cystadenocarcinoma///tumor_residual_disease: 1-10 mm///tumor_stage: IIIC///tumor_tissue_site: OVARY///venous_invasion: NA///year_of_initial_pathologic_diagnosis: 2009///additional_chemo_therapy: NO///additional_drug_therapy: NO///additional_immuno_therapy: NO///additional_pharmaceutical_therapy: NO///additional_radiation_therapy: NO///additional_surgery_locoregional_procedure: NA///additional_surgery_metastatic_procedure: NA///bcr_followup_uuid: ea813aa8-df86-407b-aea1-092fb2c8608e///chemo_therapy: YES///day_of_form_completion: 2///days_to_additional_surgery_locoregional_procedure: NA///days_to_additional_surgery_metastatic_procedure: NA///days_to_death: NA///days_to_last_followup: 253///days_to_new_tumor_event_after_initial_treatment: NA///days_to_tumor_progression: NA///days_to_tumor_recurrence: NA///eastern_cancer_oncology_group: 0///followup_case_report_form_submission_reason: NA///hormonal_therapy: NO///immuno_therapy: NO///karnofsky_performance_score: NA///month_of_form_completion: 6///performance_status_scale_timing: Other///person_neoplasm_cancer_status: TUMOR FREE///primary_therapy_outcome_success: Complete Response///progression_determined_by: NA///progression_determined_by_notes: NA///radiation_therapy: NO///site_of_tumor_first_recurrence: NA///targeted_molecular_therapy: YES///vital_status: LIVING///year_of_form_completion: 2009///unique_patient_ID: TCGA-24-1842///batch: 19///Extract.Name: TCGA-24-1842-01A-01R-0582-01
1
(Other)
479
duplicates:
Length Class Mode
578 character character
An expression set
This is a note to inform package users that the days_to_death variable is also valid for living pateints. In this case, the value in days_to_death is the number of days since the last follow-up appointment.
A field included in various data files in the this package.
The object is a list where each element is a patient ID that is believed to be a duplicate of a patient in another dataset. Patients are designated as duplicated if they have Spearman correlations greater than or equal to 0.98 with other patient expression profiles
A list with 130 elements, each of which is a patient ID.
This function returns ovarian cancer datasets from the hub and a vector of patients from the datasets that are duplicates based on a spearman correlation > 0.98
loadOvarianDatasets( rescale = FALSE, minNumberGenes = 0, minNumberEvents = 0, minSampleSize = 0, keepCommonOnly = FALSE, imputeMissing = FALSE, removeDuplicates = FALSE )loadOvarianDatasets( rescale = FALSE, minNumberGenes = 0, minNumberEvents = 0, minSampleSize = 0, keepCommonOnly = FALSE, imputeMissing = FALSE, removeDuplicates = FALSE )
rescale |
apply centering and scaling to the expression sets (default FALSE) |
minNumberGenes |
an integer specifying to remove expression sets with less genes than this number (default 0) |
minNumberEvents |
an integer specifying how man survival events must be in the dataset to keep the dataset (default 0) |
minSampleSize |
an integer specifying the minimum number of patients required in a summarizedExperiment (default 0) |
keepCommonOnly |
remove entrezIDs not common to all datasets (default FALSE) |
imputeMissing |
remove patients from datasets with missing expression values |
removeDuplicates |
remove patients with a Spearman correlation greater than or equal to 0.98 with other patient expression profiles (default TRUE) |
a list with 2 elements. The First element named summarizedExperiments contains the datasets. The second element named duplicates contains a vector with patient IDs for the duplicate patients (those with Spearman correlation greater than or equal to 0.98 with other patient expression profiles).
experimentsAndDups = loadOvarianDatasets()experimentsAndDups = loadOvarianDatasets()
This function returns ovarian cancer datasets from the hub and a vector of patients from the datasets that are most likely duplicates
loadOvarianEsets( removeDuplicates = TRUE, quantileCutoff = 0, rescale = FALSE, minNumberGenes = 0, minNumberEvents = 0, minSampleSize = 0, removeRetracted = TRUE, removeSubsets = TRUE, keepCommonOnly = FALSE, imputeMissing = FALSE )loadOvarianEsets( removeDuplicates = TRUE, quantileCutoff = 0, rescale = FALSE, minNumberGenes = 0, minNumberEvents = 0, minSampleSize = 0, removeRetracted = TRUE, removeSubsets = TRUE, keepCommonOnly = FALSE, imputeMissing = FALSE )
removeDuplicates |
remove patients with a Spearman correlation greater than or equal to 0.98 with other patient expression profiles (default TRUE) |
quantileCutoff |
A nueric between 0 and 1 specifying to remove genes with standard deviation below the required quantile (default 0) |
rescale |
apply centering and scaling to the expression sets (default FALSE) |
minNumberGenes |
an integer specifying to remove expression sets with less genes than this number (default 0) |
minNumberEvents |
an integer specifying how man survival events must be in the dataset to keep the dataset (default 0) |
minSampleSize |
an integer specifying the minimum number of patients required in an eset (default 0) |
removeRetracted |
remove datasets from retracted papers (default TRUE, currently just PMID17290060 dataset) |
removeSubsets |
remove datasets that are a subset of other datasets (defeault TRUE, currently just PMID19318476) |
keepCommonOnly |
remove probes not common to all datasets (default FALSE) |
imputeMissing |
remove patients from datasets with missing expression values |
a list with 2 elements. The First element named esets contains the datasets. The second element named duplicates contains a vector with patient IDs for the duplicate patients (those with Spearman correlation greater than or equal to 0.98 with other patient expression profiles).
esetsAndDups = loadOvarianEsets()esetsAndDups = loadOvarianEsets()